Source Class, Target Class, Score
pathogen vector role,extended organism,0.6121621621621621
pathogen vector role,virus aggregate,0.5928571428571429
pathogen vector role,source of infection,0.6294871794871795
pathogen vector role,infectious disease mortality rate,0.619811320754717
pathogen vector role,infection incidence rate profile,0.6807692307692308
pathogen vector role,pathogen generative stage,0.7388888888888888
pathogen vector role,pathogen portal of entry,0.7681818181818181
pathogen vector role,subclinical coronavirus infection,0.6009433962264151
pathogen vector role,primary pathogen,0.6722222222222223
pathogen vector role,infection end temporal region,0.6744897959183673
pathogen vector role,drug-based immunosuppressed organism,0.575
pathogen vector role,vector control strategy,0.7058139534883722
pathogen vector role,infectious disease,0.6342105263157894
pathogen vector role,double-stranded DNA virus,0.5833333333333334
pathogen vector role,site of infection,0.6391891891891892
pathogen vector role,immunocompetent organism,0.609090909090909
pathogen vector role,pathogen portal of exit,0.7755813953488372
pathogen vector role,infectious disease incidence,0.5958333333333333
pathogen vector role,reservoir of pathogen role,0.7326086956521739
pathogen vector role,subclinical SARS-CoV-2 infection,0.5846153846153846
pathogen vector role,virus translation stage,0.6127906976744186
pathogen vector role,disease surveillance objective specification,0.590625
pathogen vector role,virus release stage,0.6038461538461539
pathogen vector role,infectious agent host role,0.7108695652173913
pathogen vector role,source of infection site,0.6545454545454545
pathogen vector role,virus,0.53
pathogen vector role,virus replication,0.5851351351351352
pathogen vector role,B cell receptor complex,0.7058139534883722
pathogen vector role,passive immunization against infectious agent,0.65
pathogen vector role,systematic infection,0.625
pathogen vector role,infection incidence rate,0.6545454545454545
pathogen vector role,virus host,0.5833333333333334
pathogen vector role,double-stranded RNA virus,0.6055555555555556
pathogen vector role,mechanical vector,0.6932432432432433
pathogen vector role,pathogen portal of entry role,0.7969387755102041
pathogen vector role,virus transcription stage,0.6055555555555556
pathogen vector role,infectious disease lifetime prevalence,0.6224137931034482
pathogen vector role,pathogen birth temporal region,0.75
pathogen vector role,lower respiratory tract disease,0.6460784313725491
pathogen vector role,infectious disease incidence proportion,0.6025423728813559
pathogen vector role,opportunistic pathogen,0.6404761904761905
pathogen vector role,virus generative stage,0.6166666666666667
pathogen vector role,acute infectious disease course,0.6656862745098039
pathogen vector role,cidal agent disposition,0.6127906976744186
pathogen vector role,role,0.6166666666666667
pathogen vector role,genetic resistance to pathogen,0.67
pathogen vector role,subclinical infection,0.5963414634146341
pathogen vector role,appearance of disorder,0.6404761904761905
pathogen vector role,simple infection,0.6444444444444444
pathogen vector role,droplet pathogen transmission process,0.7131578947368421
pathogen vector role,infectious disease sporadicity,0.59
pathogen vector role,mutualist role,0.6558823529411765
pathogen vector role,infection incidence proportion profile,0.6741379310344828
pathogen vector role,infectious agent colony,0.6593023255813953
pathogen vector role,pathogen transporter,0.775
pathogen vector role,infectious disease epidemic,0.598936170212766
pathogen vector role,infectious agent generative stage,0.6386792452830189
pathogen vector role,disease transmission model,0.6239130434782608
pathogen vector role,vector surveillance,0.7064102564102563
pathogen vector role,pathologically immunosuppressed organism,0.6333333333333333
pathogen vector role,negative-sense single-stranded RNA virus,0.6166666666666667
pathogen vector role,cidal agent,0.6112903225806451
pathogen vector role,infectious structure host role,0.67
pathogen vector role,pathogen vehicle,0.8388888888888889
pathogen vector role,community-acquired infection,0.5958333333333333
pathogen vector role,pathogen vector,0.8785714285714286
pathogen vector role,pathogen vehicle role,0.8646341463414635
pathogen vector role,chronic infectious disease course,0.6575471698113208
pathogen vector role,asymptomatic infectious agent carrier,0.6605263157894737
pathogen vector role,nursing-home acquired infection,0.6068627450980393
pathogen vector role,secondary infection,0.6294871794871795
pathogen vector role,mechanical vector role,0.7833333333333333
pathogen vector role,infection start temporal region,0.6460784313725491
pathogen vector role,infection incidence,0.6294871794871795
pathogen vector role,virus disorder,0.5970588235294118
pathogen vector role,sterilizing immunity to infectious agent,0.6166666666666667
pathogen vector role,primary infection,0.6391891891891892
pathogen vector role,process of establishing an infection,0.6285714285714286
pathogen vector role,dead-end host role,0.7131578947368421
pathogen vector role,pathogen death process boundary,0.7441176470588234
pathogen vector role,immunosuppressed organism,0.5611111111111111
pathogen vector role,definitive host role,0.7
pathogen vector role,innate immunity to infectious agent,0.65
pathogen vector role,virus adhesion susceptible cell,0.6264705882352941
pathogen vector role,infection,0.6224137931034482
pathogen vector role,static agent disposition,0.6318181818181818
pathogen vector role,T cell receptor complex,0.7290697674418604
pathogen vector role,asymptomatic carrier role,0.6944444444444444
pathogen vector role,infectious agent population,0.6414893617021277
pathogen vector role,respiratory system disease,0.6239130434782608
pathogen vector role,biological vector,0.6932432432432433
pathogen vector role,leukocyte-mediated immunity to infectious agent,0.6141791044776119
pathogen vector role,indirect pathogen transmission process,0.7086206896551723
pathogen vector role,organism population,0.6038461538461539
pathogen vector role,humoral immunity to infectious agent,0.6285714285714286
pathogen vector role,infectious disease control strategy,0.6318181818181818
pathogen vector role,parasite,0.5928571428571429
pathogen vector role,infectious disease pandemic,0.598936170212766
pathogen vector role,antibody reagent,0.6444444444444444
pathogen vector role,viral disease course,0.625
pathogen vector role,intracellular infection,0.6127906976744186
pathogen vector role,secondary infection role,0.7227272727272727
pathogen vector role,metastatic infection,0.625
pathogen vector role,passive immunity to infectious agent,0.6464285714285714
pathogen vector role,vaccination against infectious agent,0.6642857142857143
pathogen vector role,acute infection,0.6785714285714286
pathogen vector role,susceptibility to infectious agent,0.6351851851851852
pathogen vector role,epitope site,0.66875
pathogen vector role,immunity to pathogen,0.65
pathogen vector role,source of infection role,0.7227272727272727
pathogen vector role,pathogen host,0.7530303030303032
pathogen vector role,chronic infection,0.6662162162162162
pathogen vector role,disease course,0.6558823529411765
pathogen vector role,infectious disease course,0.6277777777777778
pathogen vector role,acquired immunity to infectious agent,0.6254385964912281
pathogen vector role,complex infection,0.6391891891891892
pathogen vector role,COVID-19 disease incidence proportion,0.5903508771929825
pathogen vector role,coronavirus disease course,0.6239130434782608
pathogen vector role,biological vehicle role,0.7058139534883722
pathogen vector role,infection incidence proportion,0.63
pathogen vector role,symptomatic infectious agent carrier,0.6642857142857143
pathogen vector role,respiratory droplet virus fomite,0.6615384615384616
pathogen vector role,symbiont role,0.6924242424242425
pathogen vector role,susceptible organism,0.6
pathogen vector role,parasite role,0.7227272727272727
pathogen vector role,pathogen vector role,0.95
pathogen vector role,pathogen portal of exit site,0.7416666666666667
pathogen vector role,infectious disease prevalence,0.6336734693877552
pathogen vector role,organism substance,0.6078947368421053
pathogen vector role,single-stranded DNA virus,0.5833333333333334
pathogen vector role,viral disease,0.5712121212121213
pathogen vector role,primary infection role,0.7357142857142857
pathogen vector role,biological role,0.6785714285714286
pathogen vector role,pathogen portal of entry site,0.7357142857142857
pathogen vector role,infection incidence profile,0.6840425531914894
pathogen vector role,disease,0.524074074074074
pathogen vector role,biological vector role,0.7833333333333333
pathogen vector role,site,0.5333333333333333
pathogen vector role,pathogen host role,0.8447368421052631
pathogen vector role,infection prevalence,0.675
pathogen vector role,symptomatic carrier role,0.7
pathogen vector role,infectious pathogen transmissibility,0.6642857142857143
pathogen vector role,intermediate host role,0.6880952380952381
pathogen vector role,pathogen surveillance,0.7670731707317073
pathogen vector role,immunodeficient organism,0.5863636363636363
pathogen vector role,host role,0.7258620689655172
pathogen vector role,pathogen,0.7357142857142857
pathogen vector role,pathogen birth process boundary,0.7245098039215686
pathogen vector role,infectious human pathogen,0.6277777777777778
pathogen vector role,subclinical virus infection,0.598936170212766
pathogen vector role,resistance to pathogen,0.6404761904761905
pathogen vector role,establishment of localization in virus host,0.6246031746031746
pathogen vector role,immunization against infectious agent,0.6605263157894737
pathogen vector role,virus attachment stage,0.6404761904761905
pathogen vector role,virus synthesis stage,0.5963414634146341
pathogen vector role,pathogen portal of exit role,0.7833333333333333
pathogen vector role,infectious agent host,0.6451219512195122
pathogen vector role,re-emerging pathogen,0.65
pathogen vector role,long-term non-progressing infectious disease course,0.6330985915492958
pathogen vector role,viral disease epidemic,0.569047619047619
pathogen vector role,commensal role,0.6852941176470588
pathogen vector role,epitope role,0.73125
pathogen vector role,viral disease pandemic,0.569047619047619
pathogen vector role,virus penetration stage,0.636046511627907
pathogen vector role,pathogen seroprevalence,0.7755813953488372
pathogen vector role,infectious disease endemicity,0.5928571428571429
pathogen vector role,contact pathogen transmission process,0.7131578947368421
pathogen vector role,function,0.5928571428571429
pathogen vector role,herd immunity to infectious organism,0.6285714285714286
pathogen vector role,extracellular infection,0.6127906976744186
pathogen vector role,pathogen transporter role,0.8277777777777777
pathogen vector role,infectious agent reservoir,0.6456521739130434
pathogen vector role,antigen role,0.7625
pathogen vector role,infection start process boundary,0.6423076923076922
pathogen vector role,action specification,0.675
pathogen vector role,infectious disease control objective specification,0.5928571428571429
pathogen vector role,symbiont host role,0.6868421052631578
pathogen vector role,fomite role,0.6758064516129032
pathogen vector role,process of establishing viral infection,0.6194915254237288
pathogen vector role,COVID-19 disease course,0.6127906976744186
pathogen vector role,infectious disease incidence rate,0.619811320754717
pathogen vector role,active immunization against infectious agent,0.6375
pathogen vector role,disordered virus,0.5888888888888889
pathogen vector role,reagent role,0.7625
pathogen vector role,viral load,0.5833333333333334
pathogen vector role,organism,0.5571428571428572
pathogen vector role,virus uncoating stage,0.5963414634146341
pathogen vector role,local infection,0.6214285714285714
pathogen vector role,infectious agent,0.6444444444444444
pathogen vector role,establishment of a clinically abnormal colony,0.6192307692307693
pathogen vector role,coronavirus disease,0.6038461538461539
pathogen vector role,positive-sense single-stranded RNA virus,0.6166666666666667
pathogen vector role,horizontal pathogen transmission process,0.7
pathogen vector role,hospital-acquired infection,0.6202127659574468
pathogen vector role,pathogen death temporal region,0.77
pathogen vector role,emerging pathogen,0.6662162162162162
pathogen vector role,drug susceptibility of infectious agent,0.6194915254237288
pathogen vector role,static agent,0.6375
pathogen vector role,pathogen transmission process,0.7561224489795919
infection end temporal region,virus aggregate,0.5863636363636363
infection end temporal region,source of infection,0.6375
infection end temporal region,virostatic disposition,0.6460784313725491
infection end temporal region,zoonotic disposition,0.6540816326530612
infection end temporal region,infectious disease mortality rate,0.7564516129032257
infection end temporal region,infection incidence rate profile,0.7614754098360657
infection end temporal region,communicability end temporal region,0.809375
infection end temporal region,subclinical coronavirus infection,0.6435483870967742
infection end temporal region,infection end temporal region,0.95
infection end temporal region,infectious disease,0.7265957446808511
infection end temporal region,SARS-CoV-2 incidence rate,0.6351851851851852
infection end temporal region,double-stranded DNA virus,0.6166666666666667
infection end temporal region,incubation end temporal region,0.9076271186440679
infection end temporal region,site of infection,0.6673913043478261
infection end temporal region,two-dimensional spatial region,0.7211864406779661
infection end temporal region,one-dimensional temporal region,0.8
infection end temporal region,virulence factor disposition,0.6780701754385965
infection end temporal region,viral adhesion disposition,0.6681818181818181
infection end temporal region,parasitostatic disposition,0.6318181818181818
infection end temporal region,temporal region,0.7909090909090909
infection end temporal region,infectious disease incidence,0.7131578947368421
infection end temporal region,reverse zoonotic disposition,0.6254385964912281
infection end temporal region,subclinical SARS-CoV-2 infection,0.630327868852459
infection end temporal region,virus translation stage,0.6423076923076922
infection end temporal region,disease surveillance objective specification,0.6280821917808219
infection end temporal region,virus release stage,0.5958333333333333
infection end temporal region,material entity,0.6318181818181818
infection end temporal region,source of infection site,0.6764150943396227
infection end temporal region,virus,0.5088235294117647
infection end temporal region,virus replication,0.6239130434782608
infection end temporal region,B cell receptor complex,0.6230769230769231
infection end temporal region,systematic infection,0.6336734693877552
infection end temporal region,infection incidence rate,0.7518867924528303
infection end temporal region,virus host,0.5525641025641026
infection end temporal region,double-stranded RNA virus,0.6351851851851852
infection end temporal region,virus transcription stage,0.6537037037037037
infection end temporal region,infectious disease lifetime prevalence,0.7335820895522389
infection end temporal region,toxin disposition,0.6673913043478261
infection end temporal region,pathogen birth temporal region,0.7889830508474576
infection end temporal region,lower respiratory tract disease,0.6166666666666667
infection end temporal region,infectious disease incidence proportion,0.7294117647058823
infection end temporal region,virus generative stage,0.6460784313725491
infection end temporal region,acute infectious disease course,0.7
infection end temporal region,cidal agent disposition,0.6615384615384616
infection end temporal region,infectious disorder,0.7208333333333333
infection end temporal region,subclinical infection,0.65
infection end temporal region,appearance of disorder,0.6068627450980393
infection end temporal region,simple infection,0.65
infection end temporal region,parasiticidal disposition,0.6351851851851852
infection end temporal region,infectious disease sporadicity,0.7211864406779661
infection end temporal region,communicability end process boundary,0.65
infection end temporal region,infection incidence proportion profile,0.7335820895522389
infection end temporal region,SARS-CoV-2 incidence proportion,0.6666666666666667
infection end temporal region,spatiotemporal region,0.81
infection end temporal region,transmissibility disposition,0.6078947368421053
infection end temporal region,latency end process boundary,0.6605263157894737
infection end temporal region,infectious disease epidemic,0.7178571428571427
infection end temporal region,disease transmission model,0.6318181818181818
infection end temporal region,endotoxin disposition,0.67
infection end temporal region,negative-sense single-stranded RNA virus,0.6528985507246376
infection end temporal region,COVID-19 incidence rate,0.6423076923076922
infection end temporal region,cytotoxin disposition,0.67
infection end temporal region,community-acquired infection,0.6254385964912281
infection end temporal region,zero-dimensional spatial region,0.7166666666666667
infection end temporal region,zero-dimensional temporal region,0.7942622950819671
infection end temporal region,chronic infectious disease course,0.6919354838709677
infection end temporal region,nursing-home acquired infection,0.65
infection end temporal region,COVID-19 epidemic,0.6239130434782608
infection end temporal region,secondary infection,0.6791666666666666
infection end temporal region,infection start temporal region,0.8833333333333334
infection end temporal region,infection incidence,0.7416666666666667
infection end temporal region,virus disorder,0.5895348837209302
infection end temporal region,establishment of localization in human host,0.6583333333333334
infection end temporal region,primary infection,0.6456521739130434
infection end temporal region,process of establishing an infection,0.6346153846153847
infection end temporal region,incubation end process boundary,0.7333333333333333
infection end temporal region,SARS-CoV-2 disorder,0.5958333333333333
infection end temporal region,collective pathogenic disposition,0.6596774193548387
infection end temporal region,neurotoxin disposition,0.6852941176470588
infection end temporal region,pathogen death process boundary,0.65
infection end temporal region,geographical region,0.7
infection end temporal region,latency end temporal region,0.8428571428571427
infection end temporal region,virus adhesion susceptible cell,0.6333333333333333
infection end temporal region,collective disposition,0.6656862745098039
infection end temporal region,infection,0.6868421052631578
infection end temporal region,static agent disposition,0.6575471698113208
infection end temporal region,T cell receptor complex,0.6423076923076922
infection end temporal region,respiratory system disease,0.6136363636363636
infection end temporal region,communicability interval,0.6386792452830189
infection end temporal region,infectious disease control strategy,0.73125
infection end temporal region,infectious disease pandemic,0.7178571428571427
infection end temporal region,immunosuppressive disposition,0.6396551724137931
infection end temporal region,pathogenic disposition,0.6460784313725491
infection end temporal region,viral disease course,0.6132653061224489
infection end temporal region,intracellular infection,0.6615384615384616
infection end temporal region,secondary infection role,0.6952830188679244
infection end temporal region,metastatic infection,0.6336734693877552
infection end temporal region,three-dimensional spatial region,0.7122950819672131
infection end temporal region,cell,0.5409090909090909
infection end temporal region,infectious disposition,0.7441176470588234
infection end temporal region,objective specification,0.6615384615384616
infection end temporal region,acute infection,0.6545454545454545
infection end temporal region,bacteriostatic disposition,0.65
infection end temporal region,bactericidal disposition,0.6386792452830189
infection end temporal region,country,0.5888888888888889
infection end temporal region,source of infection role,0.6952830188679244
infection end temporal region,chronic infection,0.6456521739130434
infection end temporal region,invasion disposition,0.6948979591836735
infection end temporal region,disease course,0.6127906976744186
infection end temporal region,infectious disease course,0.7277777777777777
infection end temporal region,viricidal disposition,0.65
infection end temporal region,complex infection,0.6673913043478261
infection end temporal region,COVID-19 disease incidence proportion,0.6469696969696969
infection end temporal region,coronavirus disease course,0.6318181818181818
infection end temporal region,infection incidence proportion,0.7720338983050847
infection end temporal region,respiratory droplet virus fomite,0.6139344262295081
infection end temporal region,infectious disease prevalence,0.743103448275862
infection end temporal region,disposition,0.6
infection end temporal region,single-stranded DNA virus,0.6537037037037037
infection end temporal region,COVID-19 mortality rate,0.6807692307692308
infection end temporal region,place closure control strategy,0.6533898305084747
infection end temporal region,viral disease,0.5928571428571429
infection end temporal region,primary infection role,0.7049019607843137
infection end temporal region,adhesion disposition,0.6744897959183673
infection end temporal region,infection incidence profile,0.7535714285714286
infection end temporal region,contagiousness,0.6593023255813953
infection end temporal region,disease,0.5611111111111111
infection end temporal region,primary infectious disposition,0.7042372881355932
infection end temporal region,infection prevalence,0.7765306122448979
infection end temporal region,coronavirus disorder,0.6132653061224489
infection end temporal region,SARS-COV-2 adhesion susceptible cell,0.6192307692307693
infection end temporal region,incubation start process boundary,0.6919354838709677
infection end temporal region,object,0.5357142857142857
infection end temporal region,pathogen birth process boundary,0.6333333333333333
infection end temporal region,infectious human pathogen,0.7277777777777777
infection end temporal region,subclinical virus infection,0.6464285714285714
infection end temporal region,colonization of human,0.65
infection end temporal region,establishment of localization in virus host,0.6444444444444444
infection end temporal region,virus attachment stage,0.6068627450980393
infection end temporal region,virus synthesis stage,0.61
infection end temporal region,SARS-COV-2 adhesion disposition,0.6333333333333333
infection end temporal region,object aggregate,0.6277777777777778
infection end temporal region,invasive disposition,0.6540816326530612
infection end temporal region,long-term non-progressing infectious disease course,0.6375
infection end temporal region,viral disease epidemic,0.6068627450980393
infection end temporal region,communicability start temporal region,0.7530303030303032
infection end temporal region,fungicidal disposition,0.6460784313725491
infection end temporal region,viral disease pandemic,0.6068627450980393
infection end temporal region,virus penetration stage,0.6615384615384616
infection end temporal region,acute respiratory distress syndrome,0.6375
infection end temporal region,geospatial region,0.7108695652173913
infection end temporal region,division of geopolitical entity,0.6833333333333332
infection end temporal region,infectious disease endemicity,0.7086206896551723
infection end temporal region,disorder,0.5851351351351352
infection end temporal region,communicability,0.5863636363636363
infection end temporal region,extracellular infection,0.6423076923076922
infection end temporal region,exotoxin disposition,0.6744897959183673
infection end temporal region,infection start process boundary,0.728688524590164
infection end temporal region,action specification,0.6744897959183673
infection end temporal region,processed material,0.6414893617021277
infection end temporal region,latency start process boundary,0.6364406779661017
infection end temporal region,infectious disease control objective specification,0.690506329113924
infection end temporal region,opportunistic infectious disposition,0.6807692307692308
infection end temporal region,process of establishing viral infection,0.6558823529411765
infection end temporal region,enterotoxin disposition,0.6807692307692308
infection end temporal region,COVID-19 disease course,0.6230769230769231
infection end temporal region,infectious disease incidence rate,0.7080645161290323
infection end temporal region,communicability start process boundary,0.6141791044776119
infection end temporal region,process that results in death,0.6224137931034482
infection end temporal region,single-stranded RNA retrovirus,0.6872881355932203
infection end temporal region,disordered virus,0.6055555555555556
infection end temporal region,collective resistance disposition,0.6596774193548387
infection end temporal region,fungistatic disposition,0.6423076923076922
infection end temporal region,virus uncoating stage,0.65
infection end temporal region,local infection,0.6545454545454545
infection end temporal region,establishment of a clinically abnormal colony,0.6527027027027027
infection end temporal region,process boundary,0.5833333333333334
infection end temporal region,coronavirus disease,0.6166666666666667
infection end temporal region,positive-sense single-stranded RNA virus,0.6384057971014493
infection end temporal region,one-dimensional spatial region,0.7211864406779661
infection end temporal region,hospital-acquired infection,0.6285714285714286
infection end temporal region,spatial region,0.7058139534883722
infection end temporal region,pathogen death temporal region,0.8059322033898306
infection end temporal region,cell space,0.6038461538461539
infection end temporal region,material processing,0.6583333333333334
virus translation stage,extended organism,0.6
virus translation stage,virus aggregate,0.7131578947368421
virus translation stage,source of infection,0.6166666666666667
virus translation stage,virostatic disposition,0.6944444444444444
virus translation stage,information content entity,0.6540816326530612
virus translation stage,zoonotic disposition,0.6127906976744186
virus translation stage,immune response,0.6868421052631578
virus translation stage,infectious disease mortality rate,0.6464285714285714
virus translation stage,infection incidence rate profile,0.6136363636363636
virus translation stage,communicability end temporal region,0.6051724137931035
virus translation stage,pathogen generative stage,0.6791666666666666
virus translation stage,pathogen portal of entry,0.6202127659574468
virus translation stage,subclinical coronavirus infection,0.6464285714285714
virus translation stage,primary pathogen,0.6551282051282051
virus translation stage,infection end temporal region,0.6423076923076922
virus translation stage,drug-based immunosuppressed organism,0.6025423728813559
virus translation stage,infectious disease,0.6695121951219513
virus translation stage,SARS-CoV-2 incidence rate,0.6375
virus translation stage,double-stranded DNA virus,0.6375
virus translation stage,incubation end temporal region,0.6575471698113208
virus translation stage,site of infection,0.625
virus translation stage,immunocompetent organism,0.6202127659574468
virus translation stage,virulence factor disposition,0.6852941176470588
virus translation stage,pathogen portal of exit,0.6239130434782608
virus translation stage,viral adhesion disposition,0.6948979591836735
virus translation stage,parasitostatic disposition,0.6540816326530612
virus translation stage,infectious disease incidence,0.6264705882352941
virus translation stage,reservoir of pathogen role,0.6540816326530612
virus translation stage,reverse zoonotic disposition,0.6460784313725491
virus translation stage,subclinical SARS-CoV-2 infection,0.6136363636363636
virus translation stage,virus translation stage,0.95
virus translation stage,disease surveillance objective specification,0.6291044776119403
virus translation stage,virus release stage,0.8071428571428573
virus translation stage,source of infection site,0.6840425531914894
virus translation stage,virus,0.6285714285714286
virus translation stage,virus replication,0.775
virus translation stage,B cell receptor complex,0.5804347826086956
virus translation stage,systematic infection,0.636046511627907
virus translation stage,infection incidence rate,0.6414893617021277
virus translation stage,virus host,0.7227272727272727
virus translation stage,double-stranded RNA virus,0.6375
virus translation stage,pathogen portal of entry role,0.6038461538461539
virus translation stage,virus transcription stage,0.8875
virus translation stage,infectious disease lifetime prevalence,0.6467213114754098
virus translation stage,toxin disposition,0.625
virus translation stage,pathogen birth temporal region,0.6386792452830189
virus translation stage,lower respiratory tract disease,0.6537037037037037
virus translation stage,infectious disease incidence proportion,0.6112903225806451
virus translation stage,opportunistic pathogen,0.6722222222222223
virus translation stage,virus generative stage,0.8055555555555556
virus translation stage,acute infectious disease course,0.6351851851851852
virus translation stage,cidal agent disposition,0.6456521739130434
virus translation stage,infectious disorder,0.6404761904761905
virus translation stage,genetic resistance to pathogen,0.6764150943396227
virus translation stage,subclinical infection,0.609090909090909
virus translation stage,appearance of disorder,0.6055555555555556
virus translation stage,simple infection,0.6294871794871795
virus translation stage,biological vehicle,0.5719512195121951
virus translation stage,droplet pathogen transmission process,0.65
virus translation stage,parasiticidal disposition,0.6375
virus translation stage,infectious disease sporadicity,0.619811320754717
virus translation stage,communicability end process boundary,0.5855932203389831
virus translation stage,directive information content entity,0.6533898305084747
virus translation stage,infection incidence proportion profile,0.5975409836065574
virus translation stage,pathogen transporter,0.6593023255813953
virus translation stage,transmissibility disposition,0.6656862745098039
virus translation stage,latency end process boundary,0.5872549019607843
virus translation stage,infectious disease epidemic,0.63
virus translation stage,infectious agent generative stage,0.7178571428571427
virus translation stage,disease transmission model,0.7153061224489795
virus translation stage,endotoxin disposition,0.609090909090909
virus translation stage,pathologically immunosuppressed organism,0.5928571428571429
virus translation stage,negative-sense single-stranded RNA virus,0.6087301587301588
virus translation stage,pathogen vehicle,0.6038461538461539
virus translation stage,COVID-19 incidence rate,0.6456521739130434
virus translation stage,cytotoxin disposition,0.609090909090909
virus translation stage,community-acquired infection,0.6068627450980393
virus translation stage,pathogen vector,0.6078947368421053
virus translation stage,pathogen vehicle role,0.5863636363636363
virus translation stage,chronic infectious disease course,0.6285714285714286
virus translation stage,nursing-home acquired infection,0.6166666666666667
virus translation stage,descriptive information content entity,0.630327868852459
virus translation stage,COVID-19 epidemic,0.575
virus translation stage,secondary infection,0.6166666666666667
virus translation stage,infection start temporal region,0.6537037037037037
virus translation stage,infection incidence,0.6404761904761905
virus translation stage,virus disorder,0.6932432432432433
virus translation stage,primary infection,0.65
virus translation stage,process of establishing an infection,0.6364406779661017
virus translation stage,incubation end process boundary,0.6351851851851852
virus translation stage,SARS-CoV-2 disorder,0.6166666666666667
virus translation stage,collective pathogenic disposition,0.6107142857142857
virus translation stage,neurotoxin disposition,0.6277777777777778
virus translation stage,SARS-CoV-2 uncoating stage,0.7357142857142857
virus translation stage,pathogen death process boundary,0.5796296296296296
virus translation stage,immunosuppressed organism,0.6375
virus translation stage,plan specification,0.6451219512195122
virus translation stage,latency end temporal region,0.61
virus translation stage,SARS-CoV-2 penetration stage,0.7637254901960785
virus translation stage,virus adhesion susceptible cell,0.7277777777777777
virus translation stage,collective disposition,0.6277777777777778
virus translation stage,infection,0.6375
virus translation stage,static agent disposition,0.6414893617021277
virus translation stage,T cell receptor complex,0.5804347826086956
virus translation stage,respiratory system disease,0.6744897959183673
virus translation stage,indirect pathogen transmission process,0.6631147540983606
virus translation stage,organism population,0.6880952380952381
virus translation stage,generative stage,0.7064102564102563
virus translation stage,infectious disease control strategy,0.6741379310344828
virus translation stage,SARS-CoV-2 attachment stage,0.71
virus translation stage,infectious disease pandemic,0.63
virus translation stage,infectious structure generative stage,0.7166666666666667
virus translation stage,immunosuppressive disposition,0.6230769230769231
virus translation stage,innate immune response,0.65
virus translation stage,pathogenic disposition,0.6055555555555556
virus translation stage,viral disease course,0.6593023255813953
virus translation stage,intracellular infection,0.6673913043478261
virus translation stage,secondary infection role,0.6414893617021277
virus translation stage,metastatic infection,0.636046511627907
virus translation stage,infectious disposition,0.65
virus translation stage,acute infection,0.6342105263157894
virus translation stage,bacteriostatic disposition,0.6336734693877552
virus translation stage,immunity to pathogen,0.6593023255813953
virus translation stage,bactericidal disposition,0.6202127659574468
virus translation stage,source of infection role,0.6414893617021277
virus translation stage,pathogen host,0.6444444444444444
virus translation stage,acquired immunodeficiency,0.575
virus translation stage,chronic infection,0.625
virus translation stage,invasion disposition,0.6593023255813953
virus translation stage,disease course,0.6391891891891892
virus translation stage,infectious disease course,0.6375
virus translation stage,viricidal disposition,0.6545454545454545
virus translation stage,acquired immunity to infectious agent,0.6666666666666667
virus translation stage,complex infection,0.6
virus translation stage,COVID-19 disease incidence proportion,0.6
virus translation stage,coronavirus disease course,0.6744897959183673
virus translation stage,biological vehicle role,0.5804347826086956
virus translation stage,infection incidence proportion,0.6009433962264151
virus translation stage,respiratory droplet virus fomite,0.6318181818181818
virus translation stage,susceptible organism,0.636046511627907
virus translation stage,pathogen vector role,0.6127906976744186
virus translation stage,pathogen portal of exit site,0.6264705882352941
virus translation stage,infectious disease prevalence,0.6230769230769231
virus translation stage,organism substance,0.6695121951219513
virus translation stage,SARS-CoV-2 genome replication stage,0.7258620689655172
virus translation stage,disposition,0.6558823529411765
virus translation stage,single-stranded DNA virus,0.6375
virus translation stage,COVID-19 mortality rate,0.6673913043478261
virus translation stage,place closure control strategy,0.6386792452830189
virus translation stage,viral disease,0.7
virus translation stage,primary infection role,0.6722222222222223
virus translation stage,adhesion disposition,0.636046511627907
virus translation stage,pathogen portal of entry site,0.6423076923076922
virus translation stage,infection incidence profile,0.61
virus translation stage,disease,0.6166666666666667
virus translation stage,primary infectious disposition,0.6386792452830189
virus translation stage,pathogen host role,0.6451219512195122
virus translation stage,infection prevalence,0.6593023255813953
virus translation stage,designative information content entity,0.630327868852459
virus translation stage,humoral immune response,0.6456521739130434
virus translation stage,coronavirus disorder,0.6593023255813953
virus translation stage,infectious pathogen transmissibility,0.6533898305084747
virus translation stage,pathogen surveillance,0.6318181818181818
virus translation stage,immunodeficient organism,0.6202127659574468
virus translation stage,pathogen,0.6112903225806451
virus translation stage,pathogen birth process boundary,0.5981481481481481
virus translation stage,infectious human pathogen,0.6791666666666666
virus translation stage,subclinical virus infection,0.67
virus translation stage,resistance to pathogen,0.6944444444444444
virus translation stage,establishment of localization in virus host,0.6469696969696969
virus translation stage,virus attachment stage,0.8055555555555556
virus translation stage,negative regulation of immune response,0.6467213114754098
virus translation stage,SARS-CoV-2 transcription stage,0.789622641509434
virus translation stage,virus synthesis stage,0.7909090909090909
virus translation stage,SARS-COV-2 adhesion disposition,0.6537037037037037
virus translation stage,pathogen portal of exit role,0.6068627450980393
virus translation stage,invasive disposition,0.636046511627907
virus translation stage,re-emerging pathogen,0.636046511627907
virus translation stage,long-term non-progressing infectious disease course,0.5986486486486486
virus translation stage,viral disease epidemic,0.65
virus translation stage,fungicidal disposition,0.6055555555555556
virus translation stage,viral disease pandemic,0.65
virus translation stage,virus penetration stage,0.8630434782608696
virus translation stage,pathogen seroprevalence,0.6239130434782608
virus translation stage,acute respiratory distress syndrome,0.6396551724137931
virus translation stage,division of geopolitical entity,0.6351851851851852
virus translation stage,infectious disease endemicity,0.6230769230769231
virus translation stage,contact pathogen transmission process,0.6333333333333333
virus translation stage,disorder,0.5790322580645162
virus translation stage,herd immunity to infectious organism,0.6194915254237288
virus translation stage,extracellular infection,0.6456521739130434
virus translation stage,pathogen transporter role,0.6375
virus translation stage,transmission interval,0.7
virus translation stage,exotoxin disposition,0.6127906976744186
virus translation stage,infection start process boundary,0.65
virus translation stage,SARS-CoV-2 synthesis stage,0.6948979591836735
virus translation stage,infectious disease control objective specification,0.6143835616438357
virus translation stage,immune population,0.675
virus translation stage,opportunistic infectious disposition,0.6364406779661017
virus translation stage,process of establishing viral infection,0.6274193548387097
virus translation stage,enterotoxin disposition,0.6239130434782608
virus translation stage,COVID-19 disease course,0.6239130434782608
virus translation stage,infectious disease incidence rate,0.6464285714285714
virus translation stage,disordered virus,0.5782051282051281
virus translation stage,collective resistance disposition,0.6464285714285714
virus translation stage,adaptive immune response,0.6627659574468084
virus translation stage,fungistatic disposition,0.6456521739130434
virus translation stage,organism,0.6112903225806451
virus translation stage,virus uncoating stage,0.8363636363636363
virus translation stage,local infection,0.6078947368421053
virus translation stage,establishment of a clinically abnormal colony,0.5823529411764706
virus translation stage,coronavirus disease,0.6880952380952381
virus translation stage,positive-sense single-stranded RNA virus,0.6087301587301588
virus translation stage,horizontal pathogen transmission process,0.6404761904761905
virus translation stage,hospital-acquired infection,0.63
virus translation stage,pathogen death temporal region,0.6009433962264151
virus translation stage,emerging pathogen,0.625
virus translation stage,SARS-CoV-2 release stage,0.7053191489361703
virus translation stage,pathogen transmission process,0.6615384615384616
asymptomatic carrier,infectious agent host role,0.6021739130434782
asymptomatic carrier,asymptomatic infectious structure carrier,0.7778688524590163
asymptomatic carrier,B cell receptor complex,0.5895348837209302
asymptomatic carrier,passive immunization against infectious agent,0.6346153846153847
asymptomatic carrier,acute infectious disease course,0.6068627450980393
asymptomatic carrier,cidal agent disposition,0.5895348837209302
asymptomatic carrier,infectious agent colony,0.5895348837209302
asymptomatic carrier,pathogen transporter,0.65
asymptomatic carrier,infectious agent generative stage,0.6009433962264151
asymptomatic carrier,cidal agent,0.5790322580645162
asymptomatic carrier,chronic infectious disease course,0.6009433962264151
asymptomatic carrier,asymptomatic infectious agent carrier,0.8008771929824562
asymptomatic carrier,sterilizing immunity to infectious agent,0.6
asymptomatic carrier,innate immunity to infectious agent,0.6136363636363636
asymptomatic carrier,static agent disposition,0.6545454545454545
asymptomatic carrier,T cell receptor complex,0.5895348837209302
asymptomatic carrier,asymptomatic carrier role,0.8944444444444444
asymptomatic carrier,infectious agent population,0.598936170212766
asymptomatic carrier,leukocyte-mediated immunity to infectious agent,0.5992537313432835
asymptomatic carrier,humoral immunity to infectious agent,0.6107142857142857
asymptomatic carrier,viral disease course,0.625
asymptomatic carrier,passive immunity to infectious agent,0.6285714285714286
asymptomatic carrier,vaccination against infectious agent,0.6285714285714286
asymptomatic carrier,susceptibility to infectious agent,0.6166666666666667
asymptomatic carrier,disease course,0.6264705882352941
asymptomatic carrier,infectious disease course,0.6055555555555556
asymptomatic carrier,acquired immunity to infectious agent,0.6078947368421053
asymptomatic carrier,coronavirus disease course,0.6021739130434782
asymptomatic carrier,asymptomatic carrier,0.95
asymptomatic carrier,symptomatic infectious agent carrier,0.7892857142857143
asymptomatic carrier,symptomatic infectious structure carrier,0.7666666666666666
asymptomatic carrier,symptomatic carrier role,0.8818181818181818
asymptomatic carrier,immunization against infectious agent,0.6254385964912281
asymptomatic carrier,infectious agent host,0.5719512195121951
asymptomatic carrier,long-term non-progressing infectious disease course,0.5767605633802817
asymptomatic carrier,symptomatic carrier,0.9371794871794872
asymptomatic carrier,pathogen transporter role,0.6277777777777778
asymptomatic carrier,infectious agent reservoir,0.6456521739130434
asymptomatic carrier,COVID-19 disease course,0.5895348837209302
asymptomatic carrier,active immunization against infectious agent,0.621875
asymptomatic carrier,symptom,0.7092592592592593
asymptomatic carrier,infectious agent,0.5888888888888889
asymptomatic carrier,establishment of a clinically abnormal colony,0.6192307692307693
asymptomatic carrier,drug susceptibility of infectious agent,0.6025423728813559
asymptomatic carrier,static agent,0.73125
simple infection,virus aggregate,0.5790322580645162
simple infection,source of infection,0.7928571428571428
simple infection,virostatic disposition,0.6605263157894737
simple infection,zoonotic disposition,0.6444444444444444
simple infection,infectious disease mortality rate,0.6132653061224489
simple infection,infection incidence rate profile,0.6375
simple infection,communicability end temporal region,0.6264705882352941
simple infection,subclinical coronavirus infection,0.7153061224489795
simple infection,infection end temporal region,0.65
simple infection,infectious disease,0.6852941176470588
simple infection,SARS-CoV-2 incidence rate,0.6207317073170732
simple infection,double-stranded DNA virus,0.5719512195121951
simple infection,incubation end temporal region,0.6456521739130434
simple infection,site of infection,0.8439393939393939
simple infection,virulence factor disposition,0.6772727272727272
simple infection,viral adhesion disposition,0.6642857142857143
simple infection,parasitostatic disposition,0.6404761904761905
simple infection,infectious disease incidence,0.6545454545454545
simple infection,reverse zoonotic disposition,0.6545454545454545
simple infection,subclinical SARS-CoV-2 infection,0.7208333333333333
simple infection,virus translation stage,0.6294871794871795
simple infection,disease surveillance objective specification,0.65
simple infection,virus release stage,0.5928571428571429
simple infection,macromolecular complex,0.6078947368421053
simple infection,source of infection site,0.75
simple infection,virus replication,0.7227272727272727
simple infection,B cell receptor complex,0.6038461538461539
simple infection,systematic infection,0.7833333333333333
simple infection,infection incidence rate,0.675
simple infection,virus host,0.5653846153846154
simple infection,double-stranded RNA virus,0.5719512195121951
simple infection,virus transcription stage,0.6451219512195122
simple infection,infectious disease lifetime prevalence,0.6351851851851852
simple infection,toxin disposition,0.6621212121212122
simple infection,lower respiratory tract disease,0.598936170212766
simple infection,infectious disease incidence proportion,0.6681818181818181
simple infection,virus generative stage,0.6078947368421053
simple infection,acute infectious disease course,0.6627659574468084
simple infection,cidal agent disposition,0.6807692307692308
simple infection,infectious disorder,0.6785714285714286
simple infection,subclinical infection,0.8013513513513513
simple infection,appearance of disorder,0.6078947368421053
simple infection,simple infection,0.95
simple infection,parasiticidal disposition,0.6695121951219513
simple infection,infectious disease sporadicity,0.6239130434782608
simple infection,communicability end process boundary,0.5846153846153846
simple infection,infection incidence proportion profile,0.6537037037037037
simple infection,transmissibility disposition,0.6545454545454545
simple infection,latency end process boundary,0.609090909090909
simple infection,infectious disease epidemic,0.636046511627907
simple infection,disease transmission model,0.6166666666666667
simple infection,endotoxin disposition,0.6391891891891892
simple infection,negative-sense single-stranded RNA virus,0.5928571428571429
simple infection,COVID-19 incidence rate,0.6294871794871795
simple infection,cytotoxin disposition,0.6391891891891892
simple infection,community-acquired infection,0.7227272727272727
simple infection,chronic infectious disease course,0.6540816326530612
simple infection,nursing-home acquired infection,0.747872340425532
simple infection,COVID-19 epidemic,0.6015151515151516
simple infection,secondary infection,0.7928571428571428
simple infection,infection start temporal region,0.6414893617021277
simple infection,infection incidence,0.7071428571428571
simple infection,virus disorder,0.5833333333333334
simple infection,primary infection,0.8136363636363637
simple infection,process of establishing an infection,0.6807692307692308
simple infection,incubation end process boundary,0.598936170212766
simple infection,SARS-CoV-2 disorder,0.5642857142857143
simple infection,collective pathogenic disposition,0.6336734693877552
simple infection,neurotoxin disposition,0.6342105263157894
simple infection,plan specification,0.7441176470588234
simple infection,latency end temporal region,0.636046511627907
simple infection,virus adhesion susceptible cell,0.598936170212766
simple infection,collective disposition,0.6605263157894737
simple infection,infection,0.81
simple infection,static agent disposition,0.675
simple infection,T cell receptor complex,0.6038461538461539
simple infection,respiratory system disease,0.5928571428571429
simple infection,communicability interval,0.6
simple infection,infectious disease control strategy,0.6264705882352941
simple infection,infectious disease pandemic,0.6593023255813953
simple infection,immunosuppressive disposition,0.6722222222222223
simple infection,pathogenic disposition,0.6605263157894737
simple infection,viral disease course,0.6444444444444444
simple infection,intracellular infection,0.7576923076923078
simple infection,secondary infection role,0.75
simple infection,metastatic infection,0.7833333333333333
simple infection,infectious disposition,0.6868421052631578
simple infection,acute infection,0.8048387096774193
simple infection,bacteriostatic disposition,0.6404761904761905
simple infection,bactericidal disposition,0.65
simple infection,country,0.5804347826086956
simple infection,source of infection role,0.75
simple infection,chronic infection,0.7833333333333333
simple infection,invasion disposition,0.6722222222222223
simple infection,disease course,0.6166666666666667
simple infection,infectious disease course,0.6451219512195122
simple infection,viricidal disposition,0.6662162162162162
simple infection,complex infection,0.8742424242424243
simple infection,COVID-19 disease incidence proportion,0.6575471698113208
simple infection,coronavirus disease course,0.5928571428571429
simple infection,infection incidence proportion,0.6891304347826087
simple infection,respiratory droplet virus fomite,0.6375
simple infection,infectious disease prevalence,0.65
simple infection,disposition,0.7092592592592593
simple infection,single-stranded DNA virus,0.6207317073170732
simple infection,COVID-19 mortality rate,0.5782051282051281
simple infection,viral disease,0.6224137931034482
simple infection,primary infection role,0.7657894736842106
simple infection,adhesion disposition,0.6722222222222223
simple infection,infection incidence profile,0.6593023255813953
simple infection,contagiousness,0.6166666666666667
simple infection,disease,0.5804347826086956
simple infection,primary infectious disposition,0.7108695652173913
simple infection,infection prevalence,0.7
simple infection,coronavirus disorder,0.5611111111111111
simple infection,subclinical virus infection,0.7523255813953489
simple infection,establishment of localization in virus host,0.6364406779661017
simple infection,virus attachment stage,0.581578947368421
simple infection,virus synthesis stage,0.5851351351351352
simple infection,SARS-COV-2 adhesion disposition,0.6202127659574468
simple infection,invasive disposition,0.7
simple infection,long-term non-progressing infectious disease course,0.6291044776119403
simple infection,viral disease epidemic,0.6342105263157894
simple infection,communicability start temporal region,0.619811320754717
simple infection,fungicidal disposition,0.6605263157894737
simple infection,viral disease pandemic,0.6342105263157894
simple infection,virus penetration stage,0.6807692307692308
simple infection,acute respiratory distress syndrome,0.5676470588235294
simple infection,infectious disease endemicity,0.65
simple infection,disorder,0.5333333333333333
simple infection,communicability,0.5790322580645162
simple infection,extracellular infection,0.732051282051282
simple infection,exotoxin disposition,0.6444444444444444
simple infection,immunoglobulin complex,0.6342105263157894
simple infection,infection start process boundary,0.6375
simple infection,action specification,0.7277777777777777
simple infection,infectious disease control objective specification,0.6318181818181818
simple infection,opportunistic infectious disposition,0.6807692307692308
simple infection,process of establishing viral infection,0.6863636363636364
simple infection,enterotoxin disposition,0.6294871794871795
simple infection,COVID-19 disease course,0.6038461538461539
simple infection,infectious disease incidence rate,0.6336734693877552
simple infection,communicability start process boundary,0.5611111111111111
simple infection,single-stranded RNA retrovirus,0.6456521739130434
simple infection,disordered virus,0.575
simple infection,collective resistance disposition,0.6540816326530612
simple infection,fungistatic disposition,0.6551282051282051
simple infection,virus uncoating stage,0.6391891891891892
simple infection,local infection,0.8048387096774193
simple infection,establishment of a clinically abnormal colony,0.6139344262295081
simple infection,coronavirus disease,0.5642857142857143
simple infection,positive-sense single-stranded RNA virus,0.6107142857142857
simple infection,hospital-acquired infection,0.7755813953488372
pathologically immunosuppressed organism,extended organism,0.6780701754385965
pathologically immunosuppressed organism,information content entity,0.5863636363636363
pathologically immunosuppressed organism,infectious structure aggregate,0.6214285714285714
pathologically immunosuppressed organism,geographical entity,0.6194915254237288
pathologically immunosuppressed organism,drug-based immunosuppressed organism,0.8184210526315789
pathologically immunosuppressed organism,resistant entity,0.575
pathologically immunosuppressed organism,immunocompetent organism,0.73125
pathologically immunosuppressed organism,virulence factor disposition,0.5970588235294118
pathologically immunosuppressed organism,case isolation control strategy,0.6049295774647887
pathologically immunosuppressed organism,material entity,0.6136363636363636
pathologically immunosuppressed organism,asymptomatic infectious structure carrier,0.6475308641975309
pathologically immunosuppressed organism,architectual structure,0.6274193548387097
pathologically immunosuppressed organism,B cell receptor complex,0.6087301587301588
pathologically immunosuppressed organism,entity,0.5152173913043478
pathologically immunosuppressed organism,directive information content entity,0.5947368421052631
pathologically immunosuppressed organism,acellular structure aggregate,0.6384057971014493
pathologically immunosuppressed organism,invasion factor,0.5772727272727273
pathologically immunosuppressed organism,realizable entity,0.6078947368421053
pathologically immunosuppressed organism,pathologically immunosuppressed organism,0.95
pathologically immunosuppressed organism,infectious structure host role,0.6071428571428572
pathologically immunosuppressed organism,descriptive information content entity,0.6038461538461539
pathologically immunosuppressed organism,establishment of localization in human host,0.6307228915662652
pathologically immunosuppressed organism,acellular structure,0.6025423728813559
pathologically immunosuppressed organism,virulence factor,0.575
pathologically immunosuppressed organism,molecular entity,0.5928571428571429
pathologically immunosuppressed organism,immunosuppressed organism,0.8346153846153846
pathologically immunosuppressed organism,plan specification,0.6051724137931035
pathologically immunosuppressed organism,infectious structure,0.5833333333333334
pathologically immunosuppressed organism,T cell receptor complex,0.6246031746031746
pathologically immunosuppressed organism,infectious structure host,0.6192307692307693
pathologically immunosuppressed organism,organism population,0.6025423728813559
pathologically immunosuppressed organism,infectious structure generative stage,0.6188311688311688
pathologically immunosuppressed organism,susceptible organism,0.6833333333333332
pathologically immunosuppressed organism,organism substance,0.6224137931034482
pathologically immunosuppressed organism,anatomical entity,0.6429824561403508
pathologically immunosuppressed organism,geopolitical entity,0.6364406779661017
pathologically immunosuppressed organism,symptomatic infectious structure carrier,0.65
pathologically immunosuppressed organism,designative information content entity,0.6038461538461539
pathologically immunosuppressed organism,immunodeficient organism,0.715625
pathologically immunosuppressed organism,infectious human pathogen,0.6038461538461539
pathologically immunosuppressed organism,colonization of human,0.630327868852459
pathologically immunosuppressed organism,immaterial entity,0.6078947368421053
pathologically immunosuppressed organism,blood,0.5388888888888889
pathologically immunosuppressed organism,division of geopolitical entity,0.6049295774647887
pathologically immunosuppressed organism,geographical feature,0.6166666666666667
pathologically immunosuppressed organism,herd immunity to infectious organism,0.7
pathologically immunosuppressed organism,pathologic immunosuppression,0.8470588235294118
pathologically immunosuppressed organism,action specification,0.6
pathologically immunosuppressed organism,processed material,0.6396551724137931
pathologically immunosuppressed organism,organism,0.6166666666666667
pathologically immunosuppressed organism,establishment of a clinically abnormal colony,0.65
pathologically immunosuppressed organism,adhesion factor,0.5772727272727273
pathologically immunosuppressed organism,material processing,0.6533898305084747
negative regulation of establishment of localization,virostatic disposition,0.6391891891891892
negative regulation of establishment of localization,zoonotic disposition,0.6166666666666667
negative regulation of establishment of localization,infectious disease mortality rate,0.65
negative regulation of establishment of localization,infection incidence rate profile,0.6285714285714286
negative regulation of establishment of localization,infectious structure aggregate,0.6085365853658536
negative regulation of establishment of localization,communicability end temporal region,0.6224137931034482
negative regulation of establishment of localization,biological regulation,0.6280821917808219
negative regulation of establishment of localization,surveillance process,0.5888888888888889
negative regulation of establishment of localization,infection end temporal region,0.6475308641975309
negative regulation of establishment of localization,geospatial location,0.6753521126760563
negative regulation of establishment of localization,vector control strategy,0.61
negative regulation of establishment of localization,SARS-CoV-2 incidence rate,0.5928571428571429
negative regulation of establishment of localization,incubation end temporal region,0.6573170731707317
negative regulation of establishment of localization,site of infection,0.6528985507246376
negative regulation of establishment of localization,virulence factor disposition,0.6625
negative regulation of establishment of localization,viral adhesion disposition,0.6551282051282051
negative regulation of establishment of localization,parasitostatic disposition,0.6551282051282051
negative regulation of establishment of localization,negative regulation of production,0.7911764705882354
negative regulation of establishment of localization,reverse zoonotic disposition,0.6625
negative regulation of establishment of localization,establishment of localization in host,0.7758426966292135
negative regulation of establishment of localization,disease surveillance objective specification,0.6895833333333334
negative regulation of establishment of localization,case isolation control strategy,0.6548192771084337
negative regulation of establishment of localization,asymptomatic infectious structure carrier,0.6220430107526882
negative regulation of establishment of localization,source of infection site,0.6342105263157894
negative regulation of establishment of localization,architectual structure,0.5986486486486486
negative regulation of establishment of localization,quarantine control strategy,0.6272151898734176
negative regulation of establishment of localization,B cell receptor complex,0.5966666666666667
negative regulation of establishment of localization,infection incidence rate,0.6210526315789474
negative regulation of establishment of localization,double-stranded RNA virus,0.5798701298701299
negative regulation of establishment of localization,toxin disposition,0.6239130434782608
negative regulation of establishment of localization,lower respiratory tract disease,0.6186746987951807
negative regulation of establishment of localization,cidal agent disposition,0.6366666666666667
negative regulation of establishment of localization,parasiticidal disposition,0.6448051948051949
negative regulation of establishment of localization,communicability end process boundary,0.609090909090909
negative regulation of establishment of localization,acellular structure aggregate,0.6104938271604938
negative regulation of establishment of localization,invasion factor,0.6291044776119403
negative regulation of establishment of localization,transmissibility disposition,0.65
negative regulation of establishment of localization,latency end process boundary,0.625
negative regulation of establishment of localization,endotoxin disposition,0.6280821917808219
negative regulation of establishment of localization,vector surveillance,0.6049295774647887
negative regulation of establishment of localization,negative regulation of establishment of localization,0.95
negative regulation of establishment of localization,negative-sense single-stranded RNA virus,0.6565217391304347
negative regulation of establishment of localization,infectious structure host role,0.6329268292682927
negative regulation of establishment of localization,establishment of localization,0.8080246913580247
negative regulation of establishment of localization,COVID-19 incidence rate,0.5833333333333334
negative regulation of establishment of localization,cytotoxin disposition,0.6280821917808219
negative regulation of establishment of localization,negative regulation of developmental process,0.7833333333333333
negative regulation of establishment of localization,negative regulation of replication,0.822093023255814
negative regulation of establishment of localization,establishment of localization in human host,0.7552631578947369
negative regulation of establishment of localization,acellular structure,0.5908450704225352
negative regulation of establishment of localization,virulence factor,0.6117647058823529
negative regulation of establishment of localization,incubation end process boundary,0.6307228915662652
negative regulation of establishment of localization,collective pathogenic disposition,0.6735294117647059
negative regulation of establishment of localization,neurotoxin disposition,0.6527027027027027
negative regulation of establishment of localization,plan specification,0.6357142857142857
negative regulation of establishment of localization,latency end temporal region,0.639873417721519
negative regulation of establishment of localization,infectious structure,0.5888888888888889
negative regulation of establishment of localization,collective disposition,0.6391891891891892
negative regulation of establishment of localization,static agent disposition,0.6605263157894737
negative regulation of establishment of localization,T cell receptor complex,0.61
negative regulation of establishment of localization,infectious structure host,0.6058441558441559
negative regulation of establishment of localization,respiratory system disease,0.6166666666666667
negative regulation of establishment of localization,infectious disease control strategy,0.6339080459770114
negative regulation of establishment of localization,infectious structure generative stage,0.6297752808988765
negative regulation of establishment of localization,immunosuppressive disposition,0.6351851851851852
negative regulation of establishment of localization,pathogenic disposition,0.6256756756756756
negative regulation of establishment of localization,infectious disposition,0.6391891891891892
negative regulation of establishment of localization,bacteriostatic disposition,0.6679487179487179
negative regulation of establishment of localization,epitope site,0.575
negative regulation of establishment of localization,bactericidal disposition,0.6473684210526315
negative regulation of establishment of localization,invasion disposition,0.6583333333333334
negative regulation of establishment of localization,viricidal disposition,0.6280821917808219
negative regulation of establishment of localization,pathogen portal of exit site,0.65
negative regulation of establishment of localization,disposition,0.5769841269841269
negative regulation of establishment of localization,COVID-19 mortality rate,0.61
negative regulation of establishment of localization,negative regulation of life-sustaining process,0.7765306122448979
negative regulation of establishment of localization,place closure control strategy,0.6085365853658536
negative regulation of establishment of localization,adhesion disposition,0.6444444444444444
negative regulation of establishment of localization,pathogen portal of entry site,0.6475308641975309
negative regulation of establishment of localization,symptomatic infectious structure carrier,0.6239130434782608
negative regulation of establishment of localization,site,0.5035714285714286
negative regulation of establishment of localization,primary infectious disposition,0.6451219512195122
negative regulation of establishment of localization,pathogen surveillance,0.6006849315068493
negative regulation of establishment of localization,establishment of localization in virus host,0.7552631578947369
negative regulation of establishment of localization,negative regulation of immune response,0.7722222222222223
negative regulation of establishment of localization,SARS-COV-2 adhesion disposition,0.6427710843373494
negative regulation of establishment of localization,invasive disposition,0.6444444444444444
negative regulation of establishment of localization,fungicidal disposition,0.6391891891891892
negative regulation of establishment of localization,division of geopolitical entity,0.6668674698795181
negative regulation of establishment of localization,negative regulation of viral process,0.7681818181818181
negative regulation of establishment of localization,exotoxin disposition,0.6305555555555555
negative regulation of establishment of localization,infectious disease control objective specification,0.6754901960784313
negative regulation of establishment of localization,opportunistic infectious disposition,0.6545454545454545
negative regulation of establishment of localization,negative regulation of biological process,0.7940860215053763
negative regulation of establishment of localization,enterotoxin disposition,0.6633333333333334
negative regulation of establishment of localization,infectious disease incidence rate,0.6264705882352941
negative regulation of establishment of localization,single-stranded RNA retrovirus,0.5963414634146341
negative regulation of establishment of localization,active immunization against infectious agent,0.7
negative regulation of establishment of localization,collective resistance disposition,0.6852941176470588
negative regulation of establishment of localization,fungistatic disposition,0.65
negative regulation of establishment of localization,local infection,0.6291044776119403
negative regulation of establishment of localization,establishment of a clinically abnormal colony,0.6974226804123711
negative regulation of establishment of localization,positive-sense single-stranded RNA virus,0.6130434782608696
negative regulation of establishment of localization,adhesion factor,0.6141791044776119
infectious disease endemicity,virus aggregate,0.609090909090909
infectious disease endemicity,source of infection,0.6375
infectious disease endemicity,virostatic disposition,0.6460784313725491
infectious disease endemicity,zoonotic disposition,0.6540816326530612
infectious disease endemicity,infectious disease mortality rate,0.8209677419354838
infectious disease endemicity,infection incidence rate profile,0.6959016393442623
infectious disease endemicity,infectious structure aggregate,0.7211864406779661
infectious disease endemicity,communicability end temporal region,0.6375
infectious disease endemicity,subclinical coronavirus infection,0.6435483870967742
infectious disease endemicity,infection end temporal region,0.7086206896551723
infectious disease endemicity,COVID-19 endemicity,0.7416666666666667
infectious disease endemicity,infectious disease,0.8329787234042553
infectious disease endemicity,double-stranded DNA virus,0.5981481481481481
infectious disease endemicity,incubation end temporal region,0.6703389830508475
infectious disease endemicity,site of infection,0.6456521739130434
infectious disease endemicity,virulence factor disposition,0.6780701754385965
infectious disease endemicity,viral adhesion disposition,0.65
infectious disease endemicity,parasitostatic disposition,0.65
infectious disease endemicity,infectious disease incidence,0.8535087719298246
infectious disease endemicity,reverse zoonotic disposition,0.6254385964912281
infectious disease endemicity,subclinical SARS-CoV-2 infection,0.6467213114754098
infectious disease endemicity,virus translation stage,0.6230769230769231
infectious disease endemicity,disease surveillance objective specification,0.6554794520547945
infectious disease endemicity,virus release stage,0.6583333333333334
infectious disease endemicity,infectious agent host role,0.7227272727272727
infectious disease endemicity,asymptomatic infectious structure carrier,0.6785714285714286
infectious disease endemicity,source of infection site,0.6764150943396227
infectious disease endemicity,virus,0.5382352941176471
infectious disease endemicity,virus replication,0.6239130434782608
infectious disease endemicity,B cell receptor complex,0.5653846153846154
infectious disease endemicity,passive immunization against infectious agent,0.6527027027027027
infectious disease endemicity,systematic infection,0.6336734693877552
infectious disease endemicity,infection incidence rate,0.7330188679245283
infectious disease endemicity,virus host,0.6038461538461539
infectious disease endemicity,double-stranded RNA virus,0.5981481481481481
infectious disease endemicity,virus transcription stage,0.6351851851851852
infectious disease endemicity,infectious disease lifetime prevalence,0.7783582089552239
infectious disease endemicity,toxin disposition,0.6456521739130434
infectious disease endemicity,lower respiratory tract disease,0.6333333333333333
infectious disease endemicity,infectious disease incidence proportion,0.8029411764705883
infectious disease endemicity,virus generative stage,0.6264705882352941
infectious disease endemicity,acute infectious disease course,0.7833333333333333
infectious disease endemicity,cidal agent disposition,0.6615384615384616
infectious disease endemicity,infectious disorder,0.7833333333333333
infectious disease endemicity,subclinical infection,0.63
infectious disease endemicity,appearance of disorder,0.6264705882352941
infectious disease endemicity,simple infection,0.65
infectious disease endemicity,parasiticidal disposition,0.6351851851851852
infectious disease endemicity,infectious disease sporadicity,0.8737288135593221
infectious disease endemicity,communicability end process boundary,0.6192307692307693
infectious disease endemicity,infection incidence proportion profile,0.6738805970149254
infectious disease endemicity,infectious agent colony,0.7576923076923078
infectious disease endemicity,transmissibility disposition,0.6254385964912281
infectious disease endemicity,latency end process boundary,0.6254385964912281
infectious disease endemicity,infectious disease epidemic,0.8964285714285714
infectious disease endemicity,infectious agent generative stage,0.7564516129032257
infectious disease endemicity,disease transmission model,0.6681818181818181
infectious disease endemicity,endotoxin disposition,0.65
infectious disease endemicity,negative-sense single-stranded RNA virus,0.6528985507246376
infectious disease endemicity,infectious structure host role,0.7211864406779661
infectious disease endemicity,cytotoxin disposition,0.65
infectious disease endemicity,community-acquired infection,0.6429824561403508
infectious disease endemicity,chronic infectious disease course,0.7725806451612902
infectious disease endemicity,asymptomatic infectious agent carrier,0.6924242424242425
infectious disease endemicity,nursing-home acquired infection,0.65
infectious disease endemicity,COVID-19 epidemic,0.6673913043478261
infectious disease endemicity,secondary infection,0.6583333333333334
infectious disease endemicity,infection start temporal region,0.7
infectious disease endemicity,infection incidence,0.7416666666666667
infectious disease endemicity,virus disorder,0.6593023255813953
infectious disease endemicity,sterilizing immunity to infectious agent,0.6673913043478261
infectious disease endemicity,diseased population,0.6375
infectious disease endemicity,primary infection,0.6456521739130434
infectious disease endemicity,process of establishing an infection,0.6346153846153847
infectious disease endemicity,incubation end process boundary,0.6833333333333332
infectious disease endemicity,SARS-CoV-2 disorder,0.6166666666666667
infectious disease endemicity,collective pathogenic disposition,0.6435483870967742
infectious disease endemicity,neurotoxin disposition,0.6656862745098039
infectious disease endemicity,latency end temporal region,0.6107142857142857
infectious disease endemicity,innate immunity to infectious agent,0.684375
infectious disease endemicity,infectious structure,0.7357142857142857
infectious disease endemicity,virus adhesion susceptible cell,0.6333333333333333
infectious disease endemicity,collective disposition,0.6656862745098039
infectious disease endemicity,infection,0.6868421052631578
infectious disease endemicity,static agent disposition,0.6386792452830189
infectious disease endemicity,T cell receptor complex,0.5846153846153846
infectious disease endemicity,infectious structure host,0.7277777777777777
infectious disease endemicity,infectious agent population,0.7178571428571427
infectious disease endemicity,respiratory system disease,0.6681818181818181
infectious disease endemicity,leukocyte-mediated immunity to infectious agent,0.6473684210526315
infectious disease endemicity,humoral immunity to infectious agent,0.6807692307692308
infectious disease endemicity,infectious disease control strategy,0.79375
infectious disease endemicity,infectious disease pandemic,0.8964285714285714
infectious disease endemicity,infectious structure generative stage,0.7378787878787878
infectious disease endemicity,immunosuppressive disposition,0.656896551724138
infectious disease endemicity,pathogenic disposition,0.6264705882352941
infectious disease endemicity,viral disease course,0.6744897959183673
infectious disease endemicity,intracellular infection,0.6423076923076922
infectious disease endemicity,secondary infection role,0.6386792452830189
infectious disease endemicity,metastatic infection,0.6336734693877552
infectious disease endemicity,passive immunity to infectious agent,0.6807692307692308
infectious disease endemicity,infectious disposition,0.7833333333333333
infectious disease endemicity,vaccination against infectious agent,0.6807692307692308
infectious disease endemicity,acute infection,0.6545454545454545
infectious disease endemicity,susceptibility to infectious agent,0.6880952380952381
infectious disease endemicity,bacteriostatic disposition,0.6681818181818181
infectious disease endemicity,bactericidal disposition,0.6386792452830189
infectious disease endemicity,source of infection role,0.6386792452830189
infectious disease endemicity,chronic infection,0.6456521739130434
infectious disease endemicity,invasion disposition,0.6744897959183673
infectious disease endemicity,disease course,0.6593023255813953
infectious disease endemicity,infectious disease course,0.8203703703703704
infectious disease endemicity,viricidal disposition,0.65
infectious disease endemicity,acquired immunity to infectious agent,0.6772727272727272
infectious disease endemicity,complex infection,0.6456521739130434
infectious disease endemicity,COVID-19 disease incidence proportion,0.6924242424242425
infectious disease endemicity,coronavirus disease course,0.7045454545454546
infectious disease endemicity,infection incidence proportion,0.7042372881355932
infectious disease endemicity,symptomatic infectious agent carrier,0.6961538461538461
infectious disease endemicity,respiratory droplet virus fomite,0.630327868852459
infectious disease endemicity,infectious disease prevalence,0.8293103448275861
infectious disease endemicity,disposition,0.6
infectious disease endemicity,single-stranded DNA virus,0.6166666666666667
infectious disease endemicity,infected population,0.6583333333333334
infectious disease endemicity,viral disease,0.6642857142857143
infectious disease endemicity,primary infection role,0.6460784313725491
infectious disease endemicity,adhesion disposition,0.6540816326530612
infectious disease endemicity,infection incidence profile,0.7178571428571427
infectious disease endemicity,disease,0.6444444444444444
infectious disease endemicity,symptomatic infectious structure carrier,0.6818840579710145
infectious disease endemicity,primary infectious disposition,0.738135593220339
infectious disease endemicity,infection prevalence,0.7357142857142857
infectious disease endemicity,coronavirus disorder,0.6540816326530612
infectious disease endemicity,infectious pathogen transmissibility,0.7576923076923078
infectious disease endemicity,infectious human pathogen,0.7277777777777777
infectious disease endemicity,subclinical virus infection,0.6642857142857143
infectious disease endemicity,establishment of localization in virus host,0.6166666666666667
infectious disease endemicity,immunization against infectious agent,0.6772727272727272
infectious disease endemicity,virus attachment stage,0.6068627450980393
infectious disease endemicity,virus synthesis stage,0.63
infectious disease endemicity,SARS-COV-2 adhesion disposition,0.6333333333333333
infectious disease endemicity,invasive disposition,0.6540816326530612
infectious disease endemicity,infectious agent host,0.75
infectious disease endemicity,long-term non-progressing infectious disease course,0.7
infectious disease endemicity,viral disease epidemic,0.7637254901960785
infectious disease endemicity,fungicidal disposition,0.6460784313725491
infectious disease endemicity,viral disease pandemic,0.7637254901960785
infectious disease endemicity,virus penetration stage,0.6423076923076922
infectious disease endemicity,acute respiratory distress syndrome,0.66875
infectious disease endemicity,infectious disease endemicity,0.95
infectious disease endemicity,disorder,0.5851351351351352
infectious disease endemicity,herd immunity to infectious organism,0.6653846153846155
infectious disease endemicity,extracellular infection,0.6230769230769231
infectious disease endemicity,exotoxin disposition,0.6540816326530612
infectious disease endemicity,infectious agent reservoir,0.759090909090909
infectious disease endemicity,COVID-19 pandemic,0.6673913043478261
infectious disease endemicity,infection start process boundary,0.7122950819672131
infectious disease endemicity,infectious disease control objective specification,0.7664556962025317
infectious disease endemicity,opportunistic infectious disposition,0.7115384615384616
infectious disease endemicity,process of establishing viral infection,0.6411764705882353
infectious disease endemicity,enterotoxin disposition,0.6615384615384616
infectious disease endemicity,COVID-19 disease course,0.6807692307692308
infectious disease endemicity,infectious disease incidence rate,0.8370967741935484
infectious disease endemicity,active immunization against infectious agent,0.6554794520547945
infectious disease endemicity,disordered virus,0.6055555555555556
infectious disease endemicity,collective resistance disposition,0.6758064516129032
infectious disease endemicity,fungistatic disposition,0.6423076923076922
infectious disease endemicity,virus uncoating stage,0.63
infectious disease endemicity,local infection,0.6545454545454545
infectious disease endemicity,infectious agent,0.7833333333333333
infectious disease endemicity,establishment of a clinically abnormal colony,0.6121621621621621
infectious disease endemicity,coronavirus disease,0.7
infectious disease endemicity,positive-sense single-stranded RNA virus,0.6384057971014493
infectious disease endemicity,hospital-acquired infection,0.6285714285714286
infectious disease endemicity,drug susceptibility of infectious agent,0.6705882352941177
pathogen transporter role,extended organism,0.6404761904761905
pathogen transporter role,virus aggregate,0.6
pathogen transporter role,source of infection,0.609090909090909
pathogen transporter role,infectious disease mortality rate,0.6396551724137931
pathogen transporter role,infection incidence rate profile,0.6956140350877194
pathogen transporter role,pathogen generative stage,0.75
pathogen transporter role,pathogen portal of entry,0.7765306122448979
pathogen transporter role,subclinical coronavirus infection,0.5706896551724138
pathogen transporter role,primary pathogen,0.6451219512195122
pathogen transporter role,infection end temporal region,0.6722222222222223
pathogen transporter role,drug-based immunosuppressed organism,0.6139344262295081
pathogen transporter role,infectious disease,0.5895348837209302
pathogen transporter role,double-stranded DNA virus,0.63
pathogen transporter role,site of infection,0.5928571428571429
pathogen transporter role,immunocompetent organism,0.6336734693877552
pathogen transporter role,pathogen portal of exit,0.7833333333333333
pathogen transporter role,infectious disease incidence,0.6009433962264151
pathogen transporter role,reservoir of pathogen role,0.7049019607843137
pathogen transporter role,subclinical SARS-CoV-2 infection,0.5728070175438597
pathogen transporter role,virus translation stage,0.6375
pathogen transporter role,disease surveillance objective specification,0.6094202898550725
pathogen transporter role,virus release stage,0.609090909090909
pathogen transporter role,infectious agent host role,0.7049019607843137
pathogen transporter role,asymptomatic infectious structure carrier,0.6318181818181818
pathogen transporter role,source of infection site,0.6132653061224489
pathogen transporter role,virus,0.5166666666666666
pathogen transporter role,virus replication,0.569047619047619
pathogen transporter role,B cell receptor complex,0.6583333333333334
pathogen transporter role,passive immunization against infectious agent,0.6357142857142857
pathogen transporter role,systematic infection,0.5833333333333334
pathogen transporter role,infection incidence rate,0.6336734693877552
pathogen transporter role,virus host,0.5642857142857143
pathogen transporter role,double-stranded RNA virus,0.65
pathogen transporter role,pathogen portal of entry role,0.8203703703703704
pathogen transporter role,virus transcription stage,0.65
pathogen transporter role,infectious disease lifetime prevalence,0.6246031746031746
pathogen transporter role,pathogen birth temporal region,0.740909090909091
pathogen transporter role,lower respiratory tract disease,0.6642857142857143
pathogen transporter role,infectious disease incidence proportion,0.621875
pathogen transporter role,opportunistic pathogen,0.6414893617021277
pathogen transporter role,virus generative stage,0.6414893617021277
pathogen transporter role,acute infectious disease course,0.6464285714285714
pathogen transporter role,cidal agent disposition,0.6583333333333334
pathogen transporter role,role,0.5879310344827586
pathogen transporter role,genetic resistance to pathogen,0.65
pathogen transporter role,subclinical infection,0.558695652173913
pathogen transporter role,appearance of disorder,0.6627659574468084
pathogen transporter role,simple infection,0.5963414634146341
pathogen transporter role,droplet pathogen transmission process,0.7564516129032257
pathogen transporter role,infectious disease sporadicity,0.6136363636363636
pathogen transporter role,mutualist role,0.6807692307692308
pathogen transporter role,infection incidence proportion profile,0.6880952380952381
pathogen transporter role,infectious agent colony,0.6375
pathogen transporter role,pathogen transporter,0.8944444444444444
pathogen transporter role,infectious disease epidemic,0.6038461538461539
pathogen transporter role,infectious agent generative stage,0.656896551724138
pathogen transporter role,disease transmission model,0.6852941176470588
pathogen transporter role,pathologically immunosuppressed organism,0.6653846153846155
pathogen transporter role,negative-sense single-stranded RNA virus,0.65
pathogen transporter role,cidal agent,0.5888888888888889
pathogen transporter role,infectious structure host role,0.6681818181818181
pathogen transporter role,pathogen vehicle,0.7426829268292683
pathogen transporter role,community-acquired infection,0.6009433962264151
pathogen transporter role,pathogen vector,0.75
pathogen transporter role,pathogen vehicle role,0.7760869565217391
pathogen transporter role,chronic infectious disease course,0.6396551724137931
pathogen transporter role,asymptomatic infectious agent carrier,0.6435483870967742
pathogen transporter role,nursing-home acquired infection,0.6107142857142857
pathogen transporter role,secondary infection,0.5863636363636363
pathogen transporter role,mechanical vector role,0.6840425531914894
pathogen transporter role,infection start temporal region,0.6821428571428573
pathogen transporter role,infection incidence,0.609090909090909
pathogen transporter role,virus disorder,0.6038461538461539
pathogen transporter role,sterilizing immunity to infectious agent,0.5884615384615385
pathogen transporter role,primary infection,0.5928571428571429
pathogen transporter role,process of establishing an infection,0.5975409836065574
pathogen transporter role,dead-end host role,0.7058139534883722
pathogen transporter role,pathogen death process boundary,0.7178571428571427
pathogen transporter role,immunosuppressed organism,0.59
pathogen transporter role,definitive host role,0.6722222222222223
pathogen transporter role,innate immunity to infectious agent,0.6166666666666667
pathogen transporter role,virus adhesion susceptible cell,0.6464285714285714
pathogen transporter role,infection,0.5382352941176471
pathogen transporter role,static agent disposition,0.6744897959183673
pathogen transporter role,T cell receptor complex,0.6791666666666666
pathogen transporter role,asymptomatic carrier role,0.71
pathogen transporter role,infectious agent population,0.6423076923076922
pathogen transporter role,respiratory system disease,0.6460784313725491
pathogen transporter role,leukocyte-mediated immunity to infectious agent,0.5888888888888889
pathogen transporter role,indirect pathogen transmission process,0.7515873015873015
pathogen transporter role,organism population,0.6545454545454545
pathogen transporter role,humoral immunity to infectious agent,0.5975409836065574
pathogen transporter role,infectious disease control strategy,0.6333333333333333
pathogen transporter role,parasite,0.6621212121212122
pathogen transporter role,infectious disease pandemic,0.6038461538461539
pathogen transporter role,antibody reagent,0.6451219512195122
pathogen transporter role,viral disease course,0.6277777777777778
pathogen transporter role,intracellular infection,0.6166666666666667
pathogen transporter role,secondary infection role,0.6540816326530612
pathogen transporter role,metastatic infection,0.6055555555555556
pathogen transporter role,passive immunity to infectious agent,0.6139344262295081
pathogen transporter role,vaccination against infectious agent,0.6467213114754098
pathogen transporter role,acute infection,0.625
pathogen transporter role,susceptibility to infectious agent,0.5855932203389831
pathogen transporter role,epitope site,0.6662162162162162
pathogen transporter role,immunity to pathogen,0.6277777777777778
pathogen transporter role,source of infection role,0.6540816326530612
pathogen transporter role,pathogen host,0.7394736842105263
pathogen transporter role,chronic infection,0.6166666666666667
pathogen transporter role,disease course,0.6294871794871795
pathogen transporter role,infectious disease course,0.63
pathogen transporter role,acquired immunity to infectious agent,0.5951612903225807
pathogen transporter role,complex infection,0.5928571428571429
pathogen transporter role,COVID-19 disease incidence proportion,0.6112903225806451
pathogen transporter role,coronavirus disease course,0.6264705882352941
pathogen transporter role,asymptomatic carrier,0.6277777777777778
pathogen transporter role,biological vehicle role,0.6375
pathogen transporter role,infection incidence proportion,0.65
pathogen transporter role,symptomatic infectious agent carrier,0.6467213114754098
pathogen transporter role,respiratory droplet virus fomite,0.6605263157894737
pathogen transporter role,symbiont role,0.6605263157894737
pathogen transporter role,susceptible organism,0.6277777777777778
pathogen transporter role,parasite role,0.7657894736842106
pathogen transporter role,pathogen vector role,0.8277777777777777
pathogen transporter role,pathogen portal of exit site,0.7518867924528303
pathogen transporter role,infectious disease prevalence,0.6351851851851852
pathogen transporter role,organism substance,0.636046511627907
pathogen transporter role,single-stranded DNA virus,0.63
pathogen transporter role,viral disease,0.581578947368421
pathogen transporter role,primary infection role,0.6627659574468084
pathogen transporter role,biological role,0.65
pathogen transporter role,pathogen portal of entry site,0.7648148148148148
pathogen transporter role,infection incidence profile,0.6615384615384616
pathogen transporter role,disease,0.575
pathogen transporter role,symptomatic infectious structure carrier,0.6346153846153847
pathogen transporter role,biological vector role,0.6840425531914894
pathogen transporter role,site,0.553448275862069
pathogen transporter role,pathogen host role,0.822093023255814
pathogen transporter role,infection prevalence,0.65
pathogen transporter role,symptomatic carrier role,0.7153061224489795
pathogen transporter role,infectious pathogen transmissibility,0.6959016393442623
pathogen transporter role,intermediate host role,0.6840425531914894
pathogen transporter role,pathogen surveillance,0.7543478260869566
pathogen transporter role,immunodeficient organism,0.6132653061224489
pathogen transporter role,host role,0.7147058823529412
pathogen transporter role,pathogen,0.6924242424242425
pathogen transporter role,pathogen birth process boundary,0.7178571428571427
pathogen transporter role,infectious human pathogen,0.63
pathogen transporter role,subclinical virus infection,0.5653846153846154
pathogen transporter role,resistance to pathogen,0.6202127659574468
pathogen transporter role,establishment of localization in virus host,0.5970588235294118
pathogen transporter role,immunization against infectious agent,0.6435483870967742
pathogen transporter role,virus attachment stage,0.6414893617021277
pathogen transporter role,virus synthesis stage,0.6021739130434782
pathogen transporter role,pathogen portal of exit role,0.808490566037736
pathogen transporter role,infectious agent host,0.6239130434782608
pathogen transporter role,re-emerging pathogen,0.6277777777777778
pathogen transporter role,long-term non-progressing infectious disease course,0.6210526315789474
pathogen transporter role,viral disease epidemic,0.598936170212766
pathogen transporter role,commensal role,0.6807692307692308
pathogen transporter role,epitope role,0.7202702702702704
pathogen transporter role,viral disease pandemic,0.598936170212766
pathogen transporter role,virus penetration stage,0.6583333333333334
pathogen transporter role,pathogen seroprevalence,0.7625
pathogen transporter role,symptomatic carrier,0.6318181818181818
pathogen transporter role,infectious disease endemicity,0.5981481481481481
pathogen transporter role,contact pathogen transmission process,0.7564516129032257
pathogen transporter role,function,0.5409090909090909
pathogen transporter role,herd immunity to infectious organism,0.5975409836065574
pathogen transporter role,extracellular infection,0.6166666666666667
pathogen transporter role,pathogen transporter role,0.95
pathogen transporter role,infectious agent reservoir,0.6656862745098039
pathogen transporter role,antigen role,0.7202702702702704
pathogen transporter role,infection start process boundary,0.6605263157894737
pathogen transporter role,action specification,0.65
pathogen transporter role,infectious disease control objective specification,0.5966666666666667
pathogen transporter role,symbiont host role,0.6825581395348838
pathogen transporter role,fomite role,0.6722222222222223
pathogen transporter role,process of establishing viral infection,0.621875
pathogen transporter role,COVID-19 disease course,0.6166666666666667
pathogen transporter role,infectious disease incidence rate,0.6051724137931035
pathogen transporter role,active immunization against infectious agent,0.6239130434782608
pathogen transporter role,disordered virus,0.6207317073170732
pathogen transporter role,reagent role,0.7202702702702704
pathogen transporter role,viral load,0.5642857142857143
pathogen transporter role,organism,0.6015151515151516
pathogen transporter role,virus uncoating stage,0.6021739130434782
pathogen transporter role,local infection,0.575
pathogen transporter role,infectious agent,0.5963414634146341
pathogen transporter role,establishment of a clinically abnormal colony,0.6214285714285714
pathogen transporter role,coronavirus disease,0.5863636363636363
pathogen transporter role,positive-sense single-stranded RNA virus,0.65
pathogen transporter role,horizontal pathogen transmission process,0.7423076923076922
pathogen transporter role,hospital-acquired infection,0.6038461538461539
pathogen transporter role,pathogen death temporal region,0.740909090909091
pathogen transporter role,emerging pathogen,0.6404761904761905
pathogen transporter role,drug susceptibility of infectious agent,0.575
pathogen transporter role,static agent,0.6121621621621621
pathogen transporter role,pathogen transmission process,0.8018518518518519
double-stranded RNA virus,extended organism,0.7119047619047619
double-stranded RNA virus,ribonucleic acid,0.6207317073170732
double-stranded RNA virus,virus aggregate,0.575
double-stranded RNA virus,source of infection,0.609090909090909
double-stranded RNA virus,virostatic disposition,0.598936170212766
double-stranded RNA virus,zoonotic disposition,0.5611111111111111
double-stranded RNA virus,immune response,0.625
double-stranded RNA virus,infectious disease mortality rate,0.6224137931034482
double-stranded RNA virus,infection incidence rate profile,0.6254385964912281
double-stranded RNA virus,communicability end temporal region,0.65
double-stranded RNA virus,pathogen generative stage,0.61
double-stranded RNA virus,pathogen portal of entry,0.6132653061224489
double-stranded RNA virus,subclinical coronavirus infection,0.6741379310344828
double-stranded RNA virus,primary pathogen,0.5475609756097561
double-stranded RNA virus,infection end temporal region,0.6351851851851852
double-stranded RNA virus,deoxyribonucleic acid,0.6239130434782608
double-stranded RNA virus,drug-based immunosuppressed organism,0.6631147540983606
double-stranded RNA virus,infectious disease,0.6127906976744186
double-stranded RNA virus,double-stranded DNA virus,0.93
double-stranded RNA virus,incubation end temporal region,0.65
double-stranded RNA virus,site of infection,0.5928571428571429
double-stranded RNA virus,double-stranded DNA,0.859090909090909
double-stranded RNA virus,immunocompetent organism,0.6336734693877552
double-stranded RNA virus,virulence factor disposition,0.6386792452830189
double-stranded RNA virus,pathogen portal of exit,0.6166666666666667
double-stranded RNA virus,viral adhesion disposition,0.6068627450980393
double-stranded RNA virus,parasitostatic disposition,0.5872549019607843
double-stranded RNA virus,infectious disease incidence,0.6009433962264151
double-stranded RNA virus,reservoir of pathogen role,0.6068627450980393
double-stranded RNA virus,reverse zoonotic disposition,0.6009433962264151
double-stranded RNA virus,subclinical SARS-CoV-2 infection,0.5903508771929825
double-stranded RNA virus,virus translation stage,0.6375
double-stranded RNA virus,disease surveillance objective specification,0.5949275362318841
double-stranded RNA virus,virus release stage,0.609090909090909
double-stranded RNA virus,source of infection site,0.6132653061224489
double-stranded RNA virus,virus,0.6166666666666667
double-stranded RNA virus,virus replication,0.5928571428571429
double-stranded RNA virus,B cell receptor complex,0.575
double-stranded RNA virus,systematic infection,0.5833333333333334
double-stranded RNA virus,infection incidence rate,0.6132653061224489
double-stranded RNA virus,virus host,0.5928571428571429
double-stranded RNA virus,double-stranded RNA virus,0.95
double-stranded RNA virus,pathogen portal of entry role,0.5981481481481481
double-stranded RNA virus,virus transcription stage,0.65
double-stranded RNA virus,infectious disease lifetime prevalence,0.5928571428571429
double-stranded RNA virus,toxin disposition,0.569047619047619
double-stranded RNA virus,pathogen birth temporal region,0.5954545454545455
double-stranded RNA virus,lower respiratory tract disease,0.6464285714285714
double-stranded RNA virus,infectious disease incidence proportion,0.60625
double-stranded RNA virus,opportunistic pathogen,0.598936170212766
double-stranded RNA virus,virus generative stage,0.6202127659574468
double-stranded RNA virus,acute infectious disease course,0.6107142857142857
double-stranded RNA virus,cidal agent disposition,0.6166666666666667
double-stranded RNA virus,infectious disorder,0.609090909090909
double-stranded RNA virus,genetic resistance to pathogen,0.5954545454545455
double-stranded RNA virus,subclinical infection,0.6021739130434782
double-stranded RNA virus,appearance of disorder,0.6414893617021277
double-stranded RNA virus,simple infection,0.5719512195121951
double-stranded RNA virus,droplet pathogen transmission process,0.6596774193548387
double-stranded RNA virus,parasiticidal disposition,0.59
double-stranded RNA virus,infectious disease sporadicity,0.6136363636363636
double-stranded RNA virus,communicability end process boundary,0.6467213114754098
double-stranded RNA virus,infection incidence proportion profile,0.6087301587301588
double-stranded RNA virus,pathogen transporter,0.6277777777777778
double-stranded RNA virus,transmissibility disposition,0.5820754716981132
double-stranded RNA virus,latency end process boundary,0.6386792452830189
double-stranded RNA virus,infectious disease epidemic,0.6038461538461539
double-stranded RNA virus,disease transmission model,0.6264705882352941
double-stranded RNA virus,endotoxin disposition,0.6021739130434782
double-stranded RNA virus,pathologically immunosuppressed organism,0.6192307692307693
double-stranded RNA virus,negative-sense single-stranded RNA virus,0.7730769230769231
double-stranded RNA virus,pathogen vehicle,0.5963414634146341
double-stranded RNA virus,cytotoxin disposition,0.5804347826086956
double-stranded RNA virus,community-acquired infection,0.619811320754717
double-stranded RNA virus,pathogen vector,0.6
double-stranded RNA virus,pathogen vehicle role,0.6021739130434782
double-stranded RNA virus,chronic infectious disease course,0.6051724137931035
double-stranded RNA virus,nursing-home acquired infection,0.5928571428571429
double-stranded RNA virus,COVID-19 epidemic,0.569047619047619
double-stranded RNA virus,secondary infection,0.5863636363636363
double-stranded RNA virus,nucleic acid,0.6121621621621621
double-stranded RNA virus,infection start temporal region,0.6107142857142857
double-stranded RNA virus,infection incidence,0.5863636363636363
double-stranded RNA virus,virus disorder,0.6038461538461539
double-stranded RNA virus,primary infection,0.569047619047619
double-stranded RNA virus,process of establishing an infection,0.6139344262295081
double-stranded RNA virus,incubation end process boundary,0.6464285714285714
double-stranded RNA virus,SARS-CoV-2 disorder,0.609090909090909
double-stranded RNA virus,collective pathogenic disposition,0.6224137931034482
double-stranded RNA virus,neurotoxin disposition,0.598936170212766
double-stranded RNA virus,pathogen death process boundary,0.6285714285714286
double-stranded RNA virus,immunosuppressed organism,0.67
double-stranded RNA virus,latency end temporal region,0.6423076923076922
double-stranded RNA virus,virus adhesion susceptible cell,0.6107142857142857
double-stranded RNA virus,collective disposition,0.6202127659574468
double-stranded RNA virus,infection,0.5382352941176471
double-stranded RNA virus,static agent disposition,0.6132653061224489
double-stranded RNA virus,T cell receptor complex,0.5541666666666667
double-stranded RNA virus,respiratory system disease,0.6068627450980393
double-stranded RNA virus,indirect pathogen transmission process,0.6246031746031746
double-stranded RNA virus,organism population,0.609090909090909
double-stranded RNA virus,infectious disease control strategy,0.6
double-stranded RNA virus,infectious disease pandemic,0.6230769230769231
double-stranded RNA virus,immunosuppressive disposition,0.5981481481481481
double-stranded RNA virus,innate immune response,0.598936170212766
double-stranded RNA virus,pathogenic disposition,0.5776595744680851
double-stranded RNA virus,viral disease course,0.6277777777777778
double-stranded RNA virus,intracellular infection,0.5958333333333333
double-stranded RNA virus,secondary infection role,0.5928571428571429
double-stranded RNA virus,metastatic infection,0.6055555555555556
double-stranded RNA virus,infectious disposition,0.5776595744680851
double-stranded RNA virus,acute infection,0.6
double-stranded RNA virus,bacteriostatic disposition,0.6068627450980393
double-stranded RNA virus,immunity to pathogen,0.5611111111111111
double-stranded RNA virus,bactericidal disposition,0.6132653061224489
double-stranded RNA virus,source of infection role,0.6132653061224489
double-stranded RNA virus,pathogen host,0.581578947368421
double-stranded RNA virus,acquired immunodeficiency,0.59
double-stranded RNA virus,chronic infection,0.569047619047619
double-stranded RNA virus,invasion disposition,0.5611111111111111
double-stranded RNA virus,disease course,0.6294871794871795
double-stranded RNA virus,infectious disease course,0.63
double-stranded RNA virus,viricidal disposition,0.5804347826086956
double-stranded RNA virus,acquired immunity to infectious agent,0.6112903225806451
double-stranded RNA virus,complex infection,0.5928571428571429
double-stranded RNA virus,COVID-19 disease incidence proportion,0.6112903225806451
double-stranded RNA virus,coronavirus disease course,0.6264705882352941
double-stranded RNA virus,infection incidence proportion,0.5954545454545455
double-stranded RNA virus,respiratory droplet virus fomite,0.6605263157894737
double-stranded RNA virus,susceptible organism,0.65
double-stranded RNA virus,pathogen vector role,0.6055555555555556
double-stranded RNA virus,pathogen portal of exit site,0.619811320754717
double-stranded RNA virus,infectious disease prevalence,0.5981481481481481
double-stranded RNA virus,organism substance,0.636046511627907
double-stranded RNA virus,disposition,0.5888888888888889
double-stranded RNA virus,single-stranded DNA virus,0.85
double-stranded RNA virus,viral disease,0.6078947368421053
double-stranded RNA virus,primary infection role,0.598936170212766
double-stranded RNA virus,adhesion disposition,0.6055555555555556
double-stranded RNA virus,pathogen portal of entry site,0.6166666666666667
double-stranded RNA virus,infection incidence profile,0.6038461538461539
double-stranded RNA virus,disease,0.60625
double-stranded RNA virus,primary infectious disposition,0.5772727272727273
double-stranded RNA virus,pathogen host role,0.5895348837209302
double-stranded RNA virus,infection prevalence,0.5833333333333334
double-stranded RNA virus,double-stranded DNA retrovirus,0.8863636363636362
double-stranded RNA virus,humoral immune response,0.6375
double-stranded RNA virus,coronavirus disorder,0.65
double-stranded RNA virus,infectious pathogen transmissibility,0.6139344262295081
double-stranded RNA virus,pathogen surveillance,0.6021739130434782
double-stranded RNA virus,immunodeficient organism,0.6336734693877552
double-stranded RNA virus,pathogen,0.5409090909090909
double-stranded RNA virus,pathogen birth process boundary,0.6107142857142857
double-stranded RNA virus,infectious human pathogen,0.59
double-stranded RNA virus,subclinical virus infection,0.6615384615384616
double-stranded RNA virus,resistance to pathogen,0.6202127659574468
double-stranded RNA virus,establishment of localization in virus host,0.6558823529411765
double-stranded RNA virus,virus attachment stage,0.6202127659574468
double-stranded RNA virus,negative regulation of immune response,0.6087301587301588
double-stranded RNA virus,virus synthesis stage,0.5804347826086956
double-stranded RNA virus,SARS-COV-2 adhesion disposition,0.6107142857142857
double-stranded RNA virus,pathogen portal of exit role,0.619811320754717
double-stranded RNA virus,invasive disposition,0.5611111111111111
double-stranded RNA virus,re-emerging pathogen,0.5833333333333334
double-stranded RNA virus,long-term non-progressing infectious disease course,0.6078947368421053
double-stranded RNA virus,viral disease epidemic,0.598936170212766
double-stranded RNA virus,fungicidal disposition,0.598936170212766
double-stranded RNA virus,viral disease pandemic,0.6202127659574468
double-stranded RNA virus,virus penetration stage,0.6166666666666667
double-stranded RNA virus,pathogen seroprevalence,0.5958333333333333
double-stranded RNA virus,acute respiratory distress syndrome,0.6166666666666667
double-stranded RNA virus,infectious disease endemicity,0.5981481481481481
double-stranded RNA virus,contact pathogen transmission process,0.6112903225806451
double-stranded RNA virus,disorder,0.6318181818181818
double-stranded RNA virus,herd immunity to infectious organism,0.6139344262295081
double-stranded RNA virus,extracellular infection,0.6166666666666667
double-stranded RNA virus,pathogen transporter role,0.65
double-stranded RNA virus,transmission interval,0.6239130434782608
double-stranded RNA virus,exotoxin disposition,0.5833333333333334
double-stranded RNA virus,infection start process boundary,0.6078947368421053
double-stranded RNA virus,infectious disease control objective specification,0.5833333333333334
double-stranded RNA virus,immune population,0.5928571428571429
double-stranded RNA virus,opportunistic infectious disposition,0.5975409836065574
double-stranded RNA virus,process of establishing viral infection,0.621875
double-stranded RNA virus,enterotoxin disposition,0.6166666666666667
double-stranded RNA virus,COVID-19 disease course,0.6166666666666667
double-stranded RNA virus,infectious disease incidence rate,0.6224137931034482
double-stranded RNA virus,single-stranded RNA retrovirus,0.8318181818181819
double-stranded RNA virus,disordered virus,0.7426829268292683
double-stranded RNA virus,collective resistance disposition,0.6396551724137931
double-stranded RNA virus,adaptive immune response,0.6132653061224489
double-stranded RNA virus,fungistatic disposition,0.5958333333333333
double-stranded RNA virus,organism,0.6318181818181818
double-stranded RNA virus,virus uncoating stage,0.6021739130434782
double-stranded RNA virus,local infection,0.575
double-stranded RNA virus,establishment of a clinically abnormal colony,0.5928571428571429
double-stranded RNA virus,coronavirus disease,0.6545454545454545
double-stranded RNA virus,positive-sense single-stranded RNA virus,0.7884615384615384
double-stranded RNA virus,horizontal pathogen transmission process,0.6192307692307693
double-stranded RNA virus,hospital-acquired infection,0.6230769230769231
double-stranded RNA virus,pathogen death temporal region,0.6318181818181818
double-stranded RNA virus,emerging pathogen,0.569047619047619
double-stranded RNA virus,pathogen transmission process,0.6351851851851852
infectious structure,virostatic disposition,0.5928571428571429
infectious structure,zoonotic disposition,0.6
infectious structure,infectious disease mortality rate,0.7518867924528303
infectious structure,infection incidence rate profile,0.7
infectious structure,infectious structure aggregate,0.85
infectious structure,communicability end temporal region,0.5954545454545455
infectious structure,infection end temporal region,0.7153061224489795
infectious structure,infectious disease,0.7921052631578948
infectious structure,SARS-CoV-2 incidence rate,0.6277777777777778
infectious structure,incubation end temporal region,0.67
infectious structure,virulence factor disposition,0.6375
infectious structure,viral adhesion disposition,0.6021739130434782
infectious structure,parasitostatic disposition,0.6021739130434782
infectious structure,infectious disease incidence,0.7416666666666667
infectious structure,reverse zoonotic disposition,0.575
infectious structure,disease surveillance objective specification,0.60625
infectious structure,infectious agent host role,0.7760869565217391
infectious structure,macromolecular complex,0.5928571428571429
infectious structure,asymptomatic infectious structure carrier,0.7778688524590163
infectious structure,architectual structure,0.8071428571428573
infectious structure,B cell receptor complex,0.6127906976744186
infectious structure,passive immunization against infectious agent,0.6346153846153847
infectious structure,infection incidence rate,0.7227272727272727
infectious structure,infectious disease lifetime prevalence,0.7258620689655172
infectious structure,toxin disposition,0.6121621621621621
infectious structure,lower respiratory tract disease,0.6264705882352941
infectious structure,infectious disease incidence proportion,0.6872881355932203
infectious structure,acute infectious disease course,0.7637254901960785
infectious structure,cidal agent disposition,0.6127906976744186
infectious structure,infectious disorder,0.808974358974359
infectious structure,parasiticidal disposition,0.5833333333333334
infectious structure,infectious disease sporadicity,0.75
infectious structure,communicability end process boundary,0.5928571428571429
infectious structure,acellular structure aggregate,0.6948979591836735
infectious structure,infectious agent colony,0.7523255813953489
infectious structure,transmissibility disposition,0.575
infectious structure,latency end process boundary,0.5958333333333333
infectious structure,infectious disease epidemic,0.7265957446808511
infectious structure,infectious agent generative stage,0.7330188679245283
infectious structure,disease transmission model,0.6021739130434782
infectious structure,endotoxin disposition,0.5963414634146341
infectious structure,infectious structure host role,0.85
infectious structure,COVID-19 incidence rate,0.636046511627907
infectious structure,cytotoxin disposition,0.5963414634146341
infectious structure,chronic infectious disease course,0.7518867924528303
infectious structure,asymptomatic infectious agent carrier,0.7131578947368421
infectious structure,COVID-19 epidemic,0.5581081081081081
infectious structure,sterilizing immunity to infectious agent,0.65
infectious structure,diseased population,0.6038461538461539
infectious structure,acellular structure,0.7576923076923078
infectious structure,incubation end process boundary,0.6656862745098039
infectious structure,collective pathogenic disposition,0.6009433962264151
infectious structure,neurotoxin disposition,0.6166666666666667
infectious structure,latency end temporal region,0.598936170212766
infectious structure,innate immunity to infectious agent,0.6681818181818181
infectious structure,infectious structure,0.95
infectious structure,collective disposition,0.6166666666666667
infectious structure,static agent disposition,0.609090909090909
infectious structure,T cell receptor complex,0.6127906976744186
infectious structure,infectious structure host,0.8944444444444444
infectious structure,infectious agent population,0.747872340425532
infectious structure,respiratory system disease,0.6021739130434782
infectious structure,leukocyte-mediated immunity to infectious agent,0.6291044776119403
infectious structure,humoral immunity to infectious agent,0.6642857142857143
infectious structure,infectious disease control strategy,0.759090909090909
infectious structure,infectious disease pandemic,0.7265957446808511
infectious structure,infectious structure generative stage,0.8008771929824562
infectious structure,immunosuppressive disposition,0.6132653061224489
infectious structure,pathogenic disposition,0.5928571428571429
infectious structure,viral disease course,0.65
infectious structure,passive immunity to infectious agent,0.6642857142857143
infectious structure,infectious disposition,0.7595238095238095
infectious structure,vaccination against infectious agent,0.6642857142857143
infectious structure,susceptibility to infectious agent,0.6722222222222223
infectious structure,bacteriostatic disposition,0.6239130434782608
infectious structure,bactericidal disposition,0.5863636363636363
infectious structure,invasion disposition,0.625
infectious structure,disease course,0.6852941176470588
infectious structure,infectious disease course,0.8055555555555556
infectious structure,viricidal disposition,0.5963414634146341
infectious structure,acquired immunity to infectious agent,0.6605263157894737
infectious structure,complex infection,0.6662162162162162
infectious structure,COVID-19 disease incidence proportion,0.5728070175438597
infectious structure,coronavirus disease course,0.6673913043478261
infectious structure,symptomatic infectious agent carrier,0.7178571428571427
infectious structure,infectious disease prevalence,0.7561224489795919
infectious structure,disposition,0.5790322580645162
infectious structure,infected population,0.6807692307692308
infectious structure,COVID-19 mortality rate,0.6127906976744186
infectious structure,viral disease,0.6015151515151516
infectious structure,adhesion disposition,0.6
infectious structure,disease,0.5981481481481481
infectious structure,symptomatic infectious structure carrier,0.7833333333333333
infectious structure,primary infectious disposition,0.71
infectious structure,infectious pathogen transmissibility,0.7
infectious structure,infectious human pathogen,0.7611111111111112
infectious structure,immunization against infectious agent,0.6605263157894737
infectious structure,virus synthesis stage,0.6695121951219513
infectious structure,SARS-COV-2 adhesion disposition,0.5676470588235294
infectious structure,invasive disposition,0.625
infectious structure,infectious agent host,0.7670731707317073
infectious structure,long-term non-progressing infectious disease course,0.6753521126760563
infectious structure,viral disease epidemic,0.569047619047619
infectious structure,fungicidal disposition,0.5928571428571429
infectious structure,viral disease pandemic,0.569047619047619
infectious structure,acute respiratory distress syndrome,0.6318181818181818
infectious structure,infectious disease endemicity,0.7357142857142857
infectious structure,herd immunity to infectious organism,0.6642857142857143
infectious structure,exotoxin disposition,0.6
infectious structure,infectious agent reservoir,0.7543478260869566
infectious structure,immunoglobulin complex,0.6166666666666667
infectious structure,COVID-19 pandemic,0.5851351351351352
infectious structure,SARS-CoV-2 synthesis stage,0.6239130434782608
infectious structure,infectious disease control objective specification,0.6928571428571427
infectious structure,opportunistic infectious disposition,0.6821428571428573
infectious structure,enterotoxin disposition,0.6127906976744186
infectious structure,polymerase chain reaction,0.6055555555555556
infectious structure,COVID-19 disease course,0.636046511627907
infectious structure,infectious disease incidence rate,0.7330188679245283
infectious structure,active immunization against infectious agent,0.6375
infectious structure,collective resistance disposition,0.619811320754717
infectious structure,fungistatic disposition,0.5895348837209302
infectious structure,infectious agent,0.7833333333333333
infectious structure,establishment of a clinically abnormal colony,0.573076923076923
infectious structure,coronavirus disease,0.6294871794871795
infectious structure,drug susceptibility of infectious agent,0.6533898305084747
colonization of host,virostatic disposition,0.6404761904761905
colonization of host,zoonotic disposition,0.675
colonization of host,geospatial location,0.6551282051282051
colonization of host,virulence factor disposition,0.6375
colonization of host,viral adhesion disposition,0.6456521739130434
colonization of host,parasitostatic disposition,0.6239130434782608
colonization of host,reverse zoonotic disposition,0.6375
colonization of host,establishment of localization in host,0.730701754385965
colonization of host,infectious agent host role,0.6673913043478261
colonization of host,B cell receptor complex,0.5895348837209302
colonization of host,colonized host,0.8029411764705883
colonization of host,virus host,0.65
colonization of host,toxin disposition,0.6391891891891892
colonization of host,cidal agent disposition,0.636046511627907
colonization of host,parasiticidal disposition,0.6277777777777778
colonization of host,infectious agent colony,0.636046511627907
colonization of host,transmissibility disposition,0.5958333333333333
colonization of host,colonization of host,0.95
colonization of host,endotoxin disposition,0.6451219512195122
colonization of host,negative regulation of establishment of localization,0.6444444444444444
colonization of host,infectious structure host role,0.65
colonization of host,establishment of localization,0.6540816326530612
colonization of host,cytotoxin disposition,0.6695121951219513
colonization of host,host,0.6166666666666667
colonization of host,establishment of localization in human host,0.7039682539682539
colonization of host,collective pathogenic disposition,0.6764150943396227
colonization of host,neurotoxin disposition,0.6404761904761905
colonization of host,dead-end host role,0.6342105263157894
colonization of host,plan specification,0.6605263157894737
colonization of host,definitive host role,0.675
colonization of host,collective disposition,0.6642857142857143
colonization of host,colony,0.6423076923076922
colonization of host,static agent disposition,0.6318181818181818
colonization of host,T cell receptor complex,0.5895348837209302
colonization of host,infectious structure host,0.6722222222222223
colonization of host,entry into host,0.7357142857142857
colonization of host,adhesion of symbiont to host,0.7
colonization of host,immunosuppressive disposition,0.5928571428571429
colonization of host,pathogenic disposition,0.6404761904761905
colonization of host,entry into host through host barriers,0.6429824561403508
colonization of host,infectious disposition,0.6404761904761905
colonization of host,bacteriostatic disposition,0.6456521739130434
colonization of host,bactericidal disposition,0.6318181818181818
colonization of host,pathogen host,0.7227272727272727
colonization of host,invasion disposition,0.675
colonization of host,viricidal disposition,0.6451219512195122
colonization of host,intermediate host,0.6932432432432433
colonization of host,disposition,0.6435483870967742
colonization of host,place closure control strategy,0.63
colonization of host,adhesion disposition,0.65
colonization of host,primary infectious disposition,0.63
colonization of host,pathogen host role,0.6868421052631578
colonization of host,intermediate host role,0.6642857142857143
colonization of host,dead-end host,0.6621212121212122
colonization of host,host role,0.5879310344827586
colonization of host,colonization of human,0.8646341463414635
colonization of host,establishment of localization in virus host,0.7039682539682539
colonization of host,SARS-COV-2 adhesion disposition,0.6460784313725491
colonization of host,invasive disposition,0.625
colonization of host,infectious agent host,0.6939024390243902
colonization of host,fungicidal disposition,0.6404761904761905
colonization of host,division of geopolitical entity,0.6460784313725491
colonization of host,exotoxin disposition,0.65
colonization of host,symbiont host role,0.6605263157894737
colonization of host,opportunistic infectious disposition,0.6642857142857143
colonization of host,enterotoxin disposition,0.636046511627907
colonization of host,collective resistance disposition,0.6386792452830189
colonization of host,fungistatic disposition,0.6593023255813953
colonization of host,establishment of a clinically abnormal colony,0.5884615384615385
colonization of host,definitive host,0.7071428571428571
virulence factor,infectious disease mortality rate,0.6132653061224489
virulence factor,infection incidence rate profile,0.6375
virulence factor,communicability end temporal region,0.6068627450980393
virulence factor,infection end temporal region,0.6277777777777778
virulence factor,SARS-CoV-2 incidence rate,0.6695121951219513
virulence factor,virulence,0.81
virulence factor,incubation end temporal region,0.6239130434782608
virulence factor,virulence factor disposition,0.8136363636363637
virulence factor,pathogen portal of exit,0.5782051282051281
virulence factor,infectious disease incidence,0.609090909090909
virulence factor,establishment of localization in host,0.6009433962264151
virulence factor,case isolation control strategy,0.6202127659574468
virulence factor,infectious agent host role,0.6404761904761905
virulence factor,macromolecular complex,0.6342105263157894
virulence factor,B cell receptor complex,0.6294871794871795
virulence factor,passive immunization against infectious agent,0.5975409836065574
virulence factor,infection incidence rate,0.65
virulence factor,colonized host,0.6166666666666667
virulence factor,virus host,0.6807692307692308
virulence factor,infectious disease incidence proportion,0.6136363636363636
virulence factor,cidal agent disposition,0.6294871794871795
virulence factor,biological vehicle,0.5970588235294118
virulence factor,communicability end process boundary,0.6230769230769231
virulence factor,infection incidence proportion profile,0.6166666666666667
virulence factor,infectious agent colony,0.6294871794871795
virulence factor,SARS-CoV-2 incidence proportion,0.6414893617021277
virulence factor,invasion factor,0.7725806451612902
virulence factor,latency end process boundary,0.6545454545454545
virulence factor,colonization of host,0.5888888888888889
virulence factor,infectious agent generative stage,0.5928571428571429
virulence factor,cidal agent,0.6351851851851852
virulence factor,infectious structure host role,0.6239130434782608
virulence factor,pathogen vehicle,0.575
virulence factor,SARS-CoV-2 virulence,0.7
virulence factor,COVID-19 incidence rate,0.6807692307692308
virulence factor,pathogen vehicle role,0.6121621621621621
virulence factor,host,0.5
virulence factor,asymptomatic infectious agent carrier,0.6009433962264151
virulence factor,infection incidence,0.6214285714285714
virulence factor,sterilizing immunity to infectious agent,0.5928571428571429
virulence factor,establishment of localization in human host,0.5855932203389831
virulence factor,virulence factor,0.95
virulence factor,incubation end process boundary,0.6414893617021277
virulence factor,dead-end host role,0.5970588235294118
virulence factor,COVID-19 incidence,0.6264705882352941
virulence factor,definitive host role,0.6166666666666667
virulence factor,latency end temporal region,0.6593023255813953
virulence factor,innate immunity to infectious agent,0.6068627450980393
virulence factor,static agent disposition,0.6
virulence factor,T cell receptor complex,0.6294871794871795
virulence factor,infectious structure host,0.6207317073170732
virulence factor,infectious agent population,0.636046511627907
virulence factor,entry into host,0.6112903225806451
virulence factor,leukocyte-mediated immunity to infectious agent,0.5928571428571429
virulence factor,adhesion of symbiont to host,0.5863636363636363
virulence factor,humoral immunity to infectious agent,0.6038461538461539
virulence factor,entry into host through host barriers,0.5632075471698114
virulence factor,passive immunity to infectious agent,0.6230769230769231
virulence factor,vaccination against infectious agent,0.6038461538461539
virulence factor,susceptibility to infectious agent,0.61
virulence factor,pathogen host,0.5879310344827586
virulence factor,acquired immunity to infectious agent,0.619811320754717
virulence factor,complex infection,0.6621212121212122
virulence factor,COVID-19 disease incidence proportion,0.619811320754717
virulence factor,biological vehicle role,0.6294871794871795
virulence factor,infection incidence proportion,0.6239130434782608
virulence factor,symptomatic infectious agent carrier,0.6038461538461539
virulence factor,intermediate host,0.6318181818181818
virulence factor,pathogen portal of exit site,0.5636363636363636
virulence factor,COVID-19 mortality rate,0.6294871794871795
virulence factor,place closure control strategy,0.6456521739130434
virulence factor,intervention,0.6642857142857143
virulence factor,infection incidence profile,0.6127906976744186
virulence factor,pathogen host role,0.5970588235294118
virulence factor,intermediate host role,0.6342105263157894
virulence factor,dead-end host,0.5879310344827586
virulence factor,host role,0.57
virulence factor,SARS-CoV-2 incidence,0.6166666666666667
virulence factor,establishment of localization in virus host,0.6025423728813559
virulence factor,immunization against infectious agent,0.6009433962264151
virulence factor,pathogen portal of exit role,0.5863636363636363
virulence factor,infectious agent host,0.6391891891891892
virulence factor,blood,0.5452380952380953
virulence factor,acute respiratory distress syndrome,0.5872549019607843
virulence factor,geographical feature,0.6444444444444444
virulence factor,infectious agent reservoir,0.6404761904761905
virulence factor,immunoglobulin complex,0.6342105263157894
virulence factor,action specification,0.6444444444444444
virulence factor,symbiont host role,0.5970588235294118
virulence factor,infectious disease incidence rate,0.6336734693877552
virulence factor,active immunization against infectious agent,0.6
virulence factor,infectious agent,0.6375
virulence factor,establishment of a clinically abnormal colony,0.5975409836065574
virulence factor,adhesion factor,0.7403225806451613
virulence factor,definitive host,0.6112903225806451
virulence factor,drug susceptibility of infectious agent,0.6136363636363636
virulence factor,static agent,0.6285714285714286
oncovirus,virus aggregate,0.6583333333333334
oncovirus,oncovirus,0.95
oncovirus,double-stranded DNA virus,0.6558823529411765
oncovirus,virus translation stage,0.60625
oncovirus,virus release stage,0.6285714285714286
oncovirus,virus,0.8071428571428573
oncovirus,virus replication,0.6423076923076922
oncovirus,virus host,0.7131578947368421
oncovirus,double-stranded RNA virus,0.6558823529411765
oncovirus,virus transcription stage,0.5970588235294118
oncovirus,virus generative stage,0.6112903225806451
oncovirus,negative-sense single-stranded RNA virus,0.5724489795918367
oncovirus,virus disorder,0.6673913043478261
oncovirus,virus adhesion susceptible cell,0.575
oncovirus,respiratory droplet virus fomite,0.6207317073170732
oncovirus,single-stranded DNA virus,0.6264705882352941
oncovirus,subclinical virus infection,0.6444444444444444
oncovirus,establishment of localization in virus host,0.6038461538461539
oncovirus,virus attachment stage,0.6112903225806451
oncovirus,virus synthesis stage,0.6166666666666667
oncovirus,virus penetration stage,0.60625
oncovirus,disordered virus,0.69
oncovirus,virus uncoating stage,0.6166666666666667
oncovirus,positive-sense single-stranded RNA virus,0.5928571428571429
symptomatic carrier role,communicability end temporal region,0.6364406779661017
symptomatic carrier role,infection end temporal region,0.6009433962264151
symptomatic carrier role,incubation end temporal region,0.6166666666666667
symptomatic carrier role,normal resident microbiota population,0.630327868852459
symptomatic carrier role,reservoir of pathogen role,0.67
symptomatic carrier role,infectious agent host role,0.65
symptomatic carrier role,asymptomatic infectious structure carrier,0.7423076923076922
symptomatic carrier role,B cell receptor complex,0.6414893617021277
symptomatic carrier role,passive immunization against infectious agent,0.6239130434782608
symptomatic carrier role,pathogen portal of entry role,0.6764150943396227
symptomatic carrier role,lower respiratory tract disease,0.6318181818181818
symptomatic carrier role,acute infectious disease course,0.6318181818181818
symptomatic carrier role,cidal agent disposition,0.5776595744680851
symptomatic carrier role,role,0.5928571428571429
symptomatic carrier role,appearance of disorder,0.6021739130434782
symptomatic carrier role,mutualist role,0.6868421052631578
symptomatic carrier role,communicability end process boundary,0.6333333333333333
symptomatic carrier role,infectious agent colony,0.6202127659574468
symptomatic carrier role,pathogen transporter,0.6318181818181818
symptomatic carrier role,latency end process boundary,0.6230769230769231
symptomatic carrier role,infectious agent generative stage,0.6254385964912281
symptomatic carrier role,cidal agent,0.5642857142857143
symptomatic carrier role,infectious structure host role,0.6537037037037037
symptomatic carrier role,pathogen vehicle role,0.6944444444444444
symptomatic carrier role,chronic infectious disease course,0.6254385964912281
symptomatic carrier role,asymptomatic infectious agent carrier,0.7614754098360657
symptomatic carrier role,mechanical vector role,0.7108695652173913
symptomatic carrier role,sterilizing immunity to infectious agent,0.590625
symptomatic carrier role,incubation end process boundary,0.6136363636363636
symptomatic carrier role,dead-end host role,0.6166666666666667
symptomatic carrier role,plan specification,0.6166666666666667
symptomatic carrier role,definitive host role,0.6318181818181818
symptomatic carrier role,latency end temporal region,0.6264705882352941
symptomatic carrier role,innate immunity to infectious agent,0.5855932203389831
symptomatic carrier role,static agent disposition,0.6791666666666666
symptomatic carrier role,T cell receptor complex,0.6627659574468084
symptomatic carrier role,asymptomatic carrier role,0.939795918367347
symptomatic carrier role,infectious agent population,0.6068627450980393
symptomatic carrier role,leukocyte-mediated immunity to infectious agent,0.6049295774647887
symptomatic carrier role,humoral immunity to infectious agent,0.6
symptomatic carrier role,innate immune response,0.6456521739130434
symptomatic carrier role,viral disease course,0.609090909090909
symptomatic carrier role,secondary infection role,0.6791666666666666
symptomatic carrier role,passive immunity to infectious agent,0.6
symptomatic carrier role,vaccination against infectious agent,0.6
symptomatic carrier role,susceptibility to infectious agent,0.6051724137931035
symptomatic carrier role,source of infection role,0.6791666666666666
symptomatic carrier role,disease course,0.6078947368421053
symptomatic carrier role,infectious disease course,0.6132653061224489
symptomatic carrier role,acquired immunity to infectious agent,0.5811475409836065
symptomatic carrier role,coronavirus disease course,0.63
symptomatic carrier role,asymptomatic carrier,0.8818181818181818
symptomatic carrier role,biological vehicle role,0.6840425531914894
symptomatic carrier role,symptomatic infectious agent carrier,0.7666666666666666
symptomatic carrier role,symbiont role,0.7202702702702704
symptomatic carrier role,parasite role,0.7202702702702704
symptomatic carrier role,pathogen vector role,0.7
symptomatic carrier role,primary infection role,0.6891304347826087
symptomatic carrier role,biological role,0.6807692307692308
symptomatic carrier role,symptomatic infectious structure carrier,0.746875
symptomatic carrier role,biological vector role,0.6891304347826087
symptomatic carrier role,pathogen host role,0.6642857142857143
symptomatic carrier role,designative information content entity,0.6435483870967742
symptomatic carrier role,symptomatic carrier role,0.95
symptomatic carrier role,intermediate host role,0.6673913043478261
symptomatic carrier role,host role,0.6621212121212122
symptomatic carrier role,immunization against infectious agent,0.630327868852459
symptomatic carrier role,pathogen portal of exit role,0.6615384615384616
symptomatic carrier role,infectious agent host,0.6055555555555556
symptomatic carrier role,long-term non-progressing infectious disease course,0.5966666666666667
symptomatic carrier role,commensal role,0.6605263157894737
symptomatic carrier role,epitope role,0.7
symptomatic carrier role,symptomatic carrier,0.891860465116279
symptomatic carrier role,function,0.54375
symptomatic carrier role,pathogen transporter role,0.7153061224489795
symptomatic carrier role,infectious agent reservoir,0.63
symptomatic carrier role,antigen role,0.7
symptomatic carrier role,action specification,0.6318181818181818
symptomatic carrier role,symbiont host role,0.7119047619047619
symptomatic carrier role,fomite role,0.7071428571428571
symptomatic carrier role,COVID-19 disease course,0.6202127659574468
symptomatic carrier role,active immunization against infectious agent,0.6117647058823529
symptomatic carrier role,symptom,0.6758064516129032
symptomatic carrier role,reagent role,0.6444444444444444
symptomatic carrier role,viral load,0.5676470588235294
symptomatic carrier role,local infection,0.6038461538461539
symptomatic carrier role,infectious agent,0.575
symptomatic carrier role,establishment of a clinically abnormal colony,0.6384057971014493
symptomatic carrier role,drug susceptibility of infectious agent,0.5928571428571429
symptomatic carrier role,static agent,0.7
antibiotic resistance,virostatic disposition,0.6825581395348838
antibiotic resistance,information content entity,0.6414893617021277
antibiotic resistance,zoonotic disposition,0.6939024390243902
antibiotic resistance,immune response,0.6444444444444444
antibiotic resistance,communicability end temporal region,0.6285714285714286
antibiotic resistance,infection end temporal region,0.65
antibiotic resistance,incubation end temporal region,0.6460784313725491
antibiotic resistance,virulence factor disposition,0.6132653061224489
antibiotic resistance,viral adhesion disposition,0.6202127659574468
antibiotic resistance,parasitostatic disposition,0.6840425531914894
antibiotic resistance,reverse zoonotic disposition,0.6540816326530612
antibiotic resistance,establishment of localization in host,0.6224137931034482
antibiotic resistance,infectious agent host role,0.6414893617021277
antibiotic resistance,B cell receptor complex,0.6318181818181818
antibiotic resistance,passive immunization against infectious agent,0.6318181818181818
antibiotic resistance,colonized host,0.5928571428571429
antibiotic resistance,virus host,0.6112903225806451
antibiotic resistance,drug susceptibility,0.6
antibiotic resistance,toxin disposition,0.6605263157894737
antibiotic resistance,cidal agent disposition,0.6545454545454545
antibiotic resistance,genetic resistance to pathogen,0.7441176470588234
antibiotic resistance,parasiticidal disposition,0.6673913043478261
antibiotic resistance,communicability end process boundary,0.6429824561403508
antibiotic resistance,directive information content entity,0.6429824561403508
antibiotic resistance,infectious agent colony,0.6318181818181818
antibiotic resistance,transmissibility disposition,0.6744897959183673
antibiotic resistance,latency end process boundary,0.6336734693877552
antibiotic resistance,colonization of host,0.6207317073170732
antibiotic resistance,infectious agent generative stage,0.6722222222222223
antibiotic resistance,endotoxin disposition,0.6642857142857143
antibiotic resistance,cidal agent,0.575
antibiotic resistance,infectious structure host role,0.6656862745098039
antibiotic resistance,cytotoxin disposition,0.6642857142857143
antibiotic resistance,antibiotic resistance,0.95
antibiotic resistance,host,0.57
antibiotic resistance,asymptomatic infectious agent carrier,0.6913793103448276
antibiotic resistance,descriptive information content entity,0.6364406779661017
antibiotic resistance,resistance to drug,0.7064102564102563
antibiotic resistance,sterilizing immunity to infectious agent,0.6139344262295081
antibiotic resistance,establishment of localization in human host,0.60625
antibiotic resistance,incubation end process boundary,0.6423076923076922
antibiotic resistance,collective pathogenic disposition,0.6351851851851852
antibiotic resistance,neurotoxin disposition,0.6593023255813953
antibiotic resistance,dead-end host role,0.6294871794871795
antibiotic resistance,definitive host role,0.6451219512195122
antibiotic resistance,latency end temporal region,0.6375
antibiotic resistance,innate immunity to infectious agent,0.6464285714285714
antibiotic resistance,collective disposition,0.636046511627907
antibiotic resistance,bactericidal,0.6318181818181818
antibiotic resistance,static agent disposition,0.6722222222222223
antibiotic resistance,T cell receptor complex,0.6318181818181818
antibiotic resistance,infectious structure host,0.6673913043478261
antibiotic resistance,infectious agent population,0.6375
antibiotic resistance,entry into host,0.6444444444444444
antibiotic resistance,leukocyte-mediated immunity to infectious agent,0.6117647058823529
antibiotic resistance,adhesion of symbiont to host,0.6336734693877552
antibiotic resistance,humoral immunity to infectious agent,0.6254385964912281
antibiotic resistance,antibody reagent,0.7472972972972972
antibiotic resistance,immunosuppressive disposition,0.63
antibiotic resistance,innate immune response,0.6593023255813953
antibiotic resistance,pathogenic disposition,0.6825581395348838
antibiotic resistance,toxin,0.6038461538461539
antibiotic resistance,entry into host through host barriers,0.6396551724137931
antibiotic resistance,passive immunity to infectious agent,0.6254385964912281
antibiotic resistance,infectious disposition,0.6593023255813953
antibiotic resistance,vaccination against infectious agent,0.6605263157894737
antibiotic resistance,susceptibility to infectious agent,0.65
antibiotic resistance,bacteriostatic disposition,0.7053191489361703
antibiotic resistance,immunity to pathogen,0.6207317073170732
antibiotic resistance,bactericidal disposition,0.65
antibiotic resistance,pathogen host,0.6264705882352941
antibiotic resistance,invasion disposition,0.6451219512195122
antibiotic resistance,viricidal disposition,0.6404761904761905
antibiotic resistance,acquired immunity to infectious agent,0.6224137931034482
antibiotic resistance,symptomatic infectious agent carrier,0.6780701754385965
antibiotic resistance,intermediate host,0.6342105263157894
antibiotic resistance,disposition,0.6375
antibiotic resistance,adhesion disposition,0.6451219512195122
antibiotic resistance,leukocyte mediated immunity,0.5958333333333333
antibiotic resistance,primary infectious disposition,0.6460784313725491
antibiotic resistance,pathogen host role,0.6294871794871795
antibiotic resistance,designative information content entity,0.6533898305084747
antibiotic resistance,humoral immune response,0.6318181818181818
antibiotic resistance,object,0.5611111111111111
antibiotic resistance,intermediate host role,0.636046511627907
antibiotic resistance,dead-end host,0.5970588235294118
antibiotic resistance,host role,0.6166666666666667
antibiotic resistance,resistance to pathogen,0.6825581395348838
antibiotic resistance,establishment of localization in virus host,0.6375
antibiotic resistance,immunization against infectious agent,0.6396551724137931
antibiotic resistance,negative regulation of immune response,0.6533898305084747
antibiotic resistance,SARS-COV-2 adhesion disposition,0.6230769230769231
antibiotic resistance,object aggregate,0.6391891891891892
antibiotic resistance,invasive disposition,0.6451219512195122
antibiotic resistance,infectious agent host,0.6404761904761905
antibiotic resistance,fungicidal disposition,0.636046511627907
antibiotic resistance,herd immunity to infectious organism,0.6078947368421053
antibiotic resistance,exotoxin disposition,0.6451219512195122
antibiotic resistance,infectious agent reservoir,0.6627659574468084
antibiotic resistance,action specification,0.6695121951219513
antibiotic resistance,protective resistance,0.7833333333333333
antibiotic resistance,symbiont host role,0.6551282051282051
antibiotic resistance,opportunistic infectious disposition,0.6605263157894737
antibiotic resistance,enterotoxin disposition,0.6772727272727272
antibiotic resistance,polymerase chain reaction,0.6021739130434782
antibiotic resistance,active immunization against infectious agent,0.65
antibiotic resistance,collective resistance disposition,0.7092592592592593
antibiotic resistance,adaptive immune response,0.6722222222222223
antibiotic resistance,fungistatic disposition,0.6772727272727272
antibiotic resistance,infectious agent,0.6391891891891892
antibiotic resistance,establishment of a clinically abnormal colony,0.6015151515151516
antibiotic resistance,definitive host,0.6444444444444444
antibiotic resistance,bacteria,0.6224137931034482
antibiotic resistance,drug susceptibility of infectious agent,0.6333333333333333
antibiotic resistance,static agent,0.6621212121212122
symbiont host role,virostatic disposition,0.65
symbiont host role,zoonotic disposition,0.6605263157894737
symbiont host role,virulence factor disposition,0.6239130434782608
symbiont host role,viral adhesion disposition,0.6545454545454545
symbiont host role,parasitostatic disposition,0.6545454545454545
symbiont host role,reservoir of pathogen role,0.7
symbiont host role,reverse zoonotic disposition,0.6456521739130434
symbiont host role,establishment of localization in host,0.6318181818181818
symbiont host role,infectious agent host role,0.7681818181818181
symbiont host role,B cell receptor complex,0.6207317073170732
symbiont host role,colonized host,0.66875
symbiont host role,virus host,0.6642857142857143
symbiont host role,pathogen portal of entry role,0.6840425531914894
symbiont host role,toxin disposition,0.65
symbiont host role,lower respiratory tract disease,0.5928571428571429
symbiont host role,acute infectious disease course,0.6132653061224489
symbiont host role,cidal agent disposition,0.6451219512195122
symbiont host role,role,0.6318181818181818
symbiont host role,appearance of disorder,0.6
symbiont host role,parasiticidal disposition,0.636046511627907
symbiont host role,mutualist role,0.73125
symbiont host role,transmissibility disposition,0.6673913043478261
symbiont host role,colonization of host,0.6605263157894737
symbiont host role,endotoxin disposition,0.6294871794871795
symbiont host role,infectious structure host role,0.7208333333333333
symbiont host role,cytotoxin disposition,0.6551282051282051
symbiont host role,pathogen vehicle role,0.6807692307692308
symbiont host role,host,0.6318181818181818
symbiont host role,chronic infectious disease course,0.6068627450980393
symbiont host role,mechanical vector role,0.675
symbiont host role,establishment of localization in human host,0.6139344262295081
symbiont host role,collective pathogenic disposition,0.6068627450980393
symbiont host role,neurotoxin disposition,0.625
symbiont host role,dead-end host role,0.7555555555555555
symbiont host role,definitive host role,0.7921052631578948
symbiont host role,collective disposition,0.625
symbiont host role,static agent disposition,0.6642857142857143
symbiont host role,T cell receptor complex,0.6207317073170732
symbiont host role,asymptomatic carrier role,0.7058139534883722
symbiont host role,infectious structure host,0.636046511627907
symbiont host role,entry into host,0.7227272727272727
symbiont host role,adhesion of symbiont to host,0.7326086956521739
symbiont host role,immunosuppressive disposition,0.598936170212766
symbiont host role,pathogenic disposition,0.625
symbiont host role,viral disease course,0.6078947368421053
symbiont host role,entry into host through host barriers,0.6863636363636364
symbiont host role,secondary infection role,0.7119047619047619
symbiont host role,infectious disposition,0.65
symbiont host role,bacteriostatic disposition,0.6545454545454545
symbiont host role,bactericidal disposition,0.6166666666666667
symbiont host role,source of infection role,0.6880952380952381
symbiont host role,pathogen host,0.6758064516129032
symbiont host role,invasion disposition,0.6868421052631578
symbiont host role,disease course,0.60625
symbiont host role,infectious disease course,0.636046511627907
symbiont host role,viricidal disposition,0.6038461538461539
symbiont host role,coronavirus disease course,0.609090909090909
symbiont host role,biological vehicle role,0.6939024390243902
symbiont host role,symbiont role,0.8693548387096774
symbiont host role,parasite role,0.7080645161290323
symbiont host role,intermediate host,0.6785714285714286
symbiont host role,pathogen vector role,0.6868421052631578
symbiont host role,disposition,0.6224137931034482
symbiont host role,primary infection role,0.7
symbiont host role,biological role,0.7227272727272727
symbiont host role,adhesion disposition,0.6868421052631578
symbiont host role,biological vector role,0.7
symbiont host role,primary infectious disposition,0.6375
symbiont host role,pathogen host role,0.7833333333333333
symbiont host role,symptomatic carrier role,0.7119047619047619
symbiont host role,intermediate host role,0.775
symbiont host role,dead-end host,0.6435483870967742
symbiont host role,host role,0.7833333333333333
symbiont host role,establishment of localization in virus host,0.630327868852459
symbiont host role,SARS-COV-2 adhesion disposition,0.6336734693877552
symbiont host role,pathogen portal of exit role,0.6891304347826087
symbiont host role,invasive disposition,0.6342105263157894
symbiont host role,infectious agent host,0.6807692307692308
symbiont host role,obligatory symbiont,0.6662162162162162
symbiont host role,long-term non-progressing infectious disease course,0.5949275362318841
symbiont host role,commensal role,0.7
symbiont host role,epitope role,0.7166666666666667
symbiont host role,fungicidal disposition,0.6
symbiont host role,division of geopolitical entity,0.6540816326530612
symbiont host role,function,0.5653846153846154
symbiont host role,pathogen transporter role,0.6825581395348838
symbiont host role,exotoxin disposition,0.6342105263157894
symbiont host role,antigen role,0.6833333333333332
symbiont host role,action specification,0.6342105263157894
symbiont host role,symbiont host role,0.95
symbiont host role,opportunistic infectious disposition,0.6166666666666667
symbiont host role,fomite role,0.7258620689655172
symbiont host role,symbiont,0.7576923076923078
symbiont host role,enterotoxin disposition,0.6207317073170732
symbiont host role,COVID-19 disease course,0.5963414634146341
symbiont host role,collective resistance disposition,0.6068627450980393
symbiont host role,reagent role,0.6833333333333332
symbiont host role,viral load,0.5571428571428572
symbiont host role,fungistatic disposition,0.6207317073170732
symbiont host role,establishment of a clinically abnormal colony,0.6246031746031746
symbiont host role,definitive host,0.6924242424242425
virus synthesis stage,extended organism,0.5552631578947369
virus synthesis stage,virus aggregate,0.7
virus synthesis stage,source of infection,0.575
virus synthesis stage,virostatic disposition,0.6593023255813953
virus synthesis stage,zoonotic disposition,0.5963414634146341
virus synthesis stage,immune response,0.6444444444444444
virus synthesis stage,infectious disease mortality rate,0.6537037037037037
virus synthesis stage,infection incidence rate profile,0.5820754716981132
virus synthesis stage,infectious structure aggregate,0.6656862745098039
virus synthesis stage,communicability end temporal region,0.5928571428571429
virus synthesis stage,pathogen generative stage,0.6673913043478261
virus synthesis stage,pathogen portal of entry,0.6055555555555556
virus synthesis stage,subclinical coronavirus infection,0.6166666666666667
virus synthesis stage,primary pathogen,0.6391891891891892
virus synthesis stage,infection end temporal region,0.61
virus synthesis stage,drug-based immunosuppressed organism,0.6254385964912281
virus synthesis stage,infectious disease,0.6807692307692308
virus synthesis stage,SARS-CoV-2 incidence rate,0.6239130434782608
virus synthesis stage,double-stranded DNA virus,0.5804347826086956
virus synthesis stage,incubation end temporal region,0.6068627450980393
virus synthesis stage,site of infection,0.581578947368421
virus synthesis stage,immunocompetent organism,0.6055555555555556
virus synthesis stage,virulence factor disposition,0.6540816326530612
virus synthesis stage,pathogen portal of exit,0.609090909090909
virus synthesis stage,viral adhesion disposition,0.6840425531914894
virus synthesis stage,parasitostatic disposition,0.6202127659574468
virus synthesis stage,infectious disease incidence,0.6336734693877552
virus synthesis stage,reservoir of pathogen role,0.6414893617021277
virus synthesis stage,reverse zoonotic disposition,0.6540816326530612
virus synthesis stage,subclinical SARS-CoV-2 infection,0.5820754716981132
virus synthesis stage,virus translation stage,0.7909090909090909
virus synthesis stage,disease surveillance objective specification,0.6038461538461539
virus synthesis stage,virus release stage,0.8
virus synthesis stage,macromolecular complex,0.5430232558139535
virus synthesis stage,SARS-CoV-2 aggregate,0.5963414634146341
virus synthesis stage,asymptomatic infectious structure carrier,0.6274193548387097
virus synthesis stage,source of infection site,0.65
virus synthesis stage,architectual structure,0.6127906976744186
virus synthesis stage,virus,0.6423076923076922
virus synthesis stage,virus replication,0.6868421052631578
virus synthesis stage,B cell receptor complex,0.5636363636363636
virus synthesis stage,systematic infection,0.6207317073170732
virus synthesis stage,infection incidence rate,0.6055555555555556
virus synthesis stage,virus host,0.7403225806451613
virus synthesis stage,double-stranded RNA virus,0.5804347826086956
virus synthesis stage,pathogen portal of entry role,0.59
virus synthesis stage,virus transcription stage,0.7760869565217391
virus synthesis stage,infectious disease lifetime prevalence,0.6364406779661017
virus synthesis stage,toxin disposition,0.6078947368421053
virus synthesis stage,pathogen birth temporal region,0.6068627450980393
virus synthesis stage,lower respiratory tract disease,0.6230769230769231
virus synthesis stage,infectious disease incidence proportion,0.6166666666666667
virus synthesis stage,opportunistic pathogen,0.6593023255813953
virus synthesis stage,virus generative stage,0.7988372093023256
virus synthesis stage,acute infectious disease course,0.6423076923076922
virus synthesis stage,cidal agent disposition,0.6318181818181818
virus synthesis stage,infectious disorder,0.65
virus synthesis stage,genetic resistance to pathogen,0.6656862745098039
virus synthesis stage,subclinical infection,0.569047619047619
virus synthesis stage,appearance of disorder,0.5895348837209302
virus synthesis stage,simple infection,0.5851351351351352
virus synthesis stage,biological vehicle,0.5782051282051281
virus synthesis stage,droplet pathogen transmission process,0.6224137931034482
virus synthesis stage,parasiticidal disposition,0.6021739130434782
virus synthesis stage,infectious disease sporadicity,0.6460784313725491
virus synthesis stage,communicability end process boundary,0.5903508771929825
virus synthesis stage,acellular structure aggregate,0.63
virus synthesis stage,infection incidence proportion profile,0.5686440677966101
virus synthesis stage,pathogen transporter,0.6207317073170732
virus synthesis stage,transmissibility disposition,0.6132653061224489
virus synthesis stage,latency end process boundary,0.5928571428571429
virus synthesis stage,infectious disease epidemic,0.6375
virus synthesis stage,infectious agent generative stage,0.7092592592592593
virus synthesis stage,disease transmission model,0.6414893617021277
virus synthesis stage,endotoxin disposition,0.5928571428571429
virus synthesis stage,pathologically immunosuppressed organism,0.5811475409836065
virus synthesis stage,negative-sense single-stranded RNA virus,0.6139344262295081
virus synthesis stage,infectious structure host role,0.6656862745098039
virus synthesis stage,pathogen vehicle,0.5851351351351352
virus synthesis stage,COVID-19 incidence rate,0.6318181818181818
virus synthesis stage,cytotoxin disposition,0.5928571428571429
virus synthesis stage,community-acquired infection,0.5724489795918367
virus synthesis stage,pathogen vector,0.5888888888888889
virus synthesis stage,pathogen vehicle role,0.5928571428571429
virus synthesis stage,chronic infectious disease course,0.6351851851851852
virus synthesis stage,nursing-home acquired infection,0.6038461538461539
virus synthesis stage,COVID-19 epidemic,0.6078947368421053
virus synthesis stage,secondary infection,0.575
virus synthesis stage,infection start temporal region,0.6230769230769231
virus synthesis stage,infection incidence,0.6
virus synthesis stage,virus disorder,0.7071428571428571
virus synthesis stage,acellular structure,0.6
virus synthesis stage,primary infection,0.6078947368421053
virus synthesis stage,process of establishing an infection,0.6254385964912281
virus synthesis stage,incubation end process boundary,0.6230769230769231
virus synthesis stage,SARS-CoV-2 disorder,0.6
virus synthesis stage,collective pathogenic disposition,0.6166666666666667
virus synthesis stage,neurotoxin disposition,0.5895348837209302
virus synthesis stage,SARS-CoV-2 uncoating stage,0.7053191489361703
virus synthesis stage,pathogen death process boundary,0.6038461538461539
virus synthesis stage,immunosuppressed organism,0.6239130434782608
virus synthesis stage,plan specification,0.5782051282051281
virus synthesis stage,latency end temporal region,0.575
virus synthesis stage,coronavirus aggregate,0.6642857142857143
virus synthesis stage,SARS-CoV-2 penetration stage,0.6948979591836735
virus synthesis stage,infectious structure,0.6695121951219513
virus synthesis stage,virus adhesion susceptible cell,0.7192307692307692
virus synthesis stage,collective disposition,0.5895348837209302
virus synthesis stage,infection,0.5833333333333334
virus synthesis stage,static agent disposition,0.6277777777777778
virus synthesis stage,T cell receptor complex,0.5636363636363636
virus synthesis stage,infectious structure host,0.6673913043478261
virus synthesis stage,respiratory system disease,0.6840425531914894
virus synthesis stage,indirect pathogen transmission process,0.6364406779661017
virus synthesis stage,organism population,0.6
virus synthesis stage,generative stage,0.6932432432432433
virus synthesis stage,infectious disease control strategy,0.6642857142857143
virus synthesis stage,SARS-CoV-2 attachment stage,0.7
virus synthesis stage,infectious disease pandemic,0.6583333333333334
virus synthesis stage,infectious structure generative stage,0.6913793103448276
virus synthesis stage,immunosuppressive disposition,0.63
virus synthesis stage,innate immune response,0.636046511627907
virus synthesis stage,pathogenic disposition,0.6127906976744186
virus synthesis stage,viral disease course,0.6939024390243902
virus synthesis stage,intracellular infection,0.609090909090909
virus synthesis stage,secondary infection role,0.6055555555555556
virus synthesis stage,metastatic infection,0.5719512195121951
virus synthesis stage,infectious disposition,0.636046511627907
virus synthesis stage,acute infection,0.5888888888888889
virus synthesis stage,bacteriostatic disposition,0.598936170212766
virus synthesis stage,epitope site,0.6621212121212122
virus synthesis stage,immunity to pathogen,0.6695121951219513
virus synthesis stage,bactericidal disposition,0.5833333333333334
virus synthesis stage,source of infection role,0.6055555555555556
virus synthesis stage,pathogen host,0.6264705882352941
virus synthesis stage,acquired immunodeficiency,0.6021739130434782
virus synthesis stage,chronic infection,0.581578947368421
virus synthesis stage,invasion disposition,0.6207317073170732
virus synthesis stage,disease course,0.65
virus synthesis stage,infectious disease course,0.6673913043478261
virus synthesis stage,viricidal disposition,0.6404761904761905
virus synthesis stage,acquired immunity to infectious agent,0.656896551724138
virus synthesis stage,complex infection,0.5552631578947369
virus synthesis stage,prion aggregate,0.6166666666666667
virus synthesis stage,COVID-19 disease incidence proportion,0.6051724137931035
virus synthesis stage,coronavirus disease course,0.7053191489361703
virus synthesis stage,biological vehicle role,0.5863636363636363
virus synthesis stage,infection incidence proportion,0.5676470588235294
virus synthesis stage,respiratory droplet virus fomite,0.619811320754717
virus synthesis stage,susceptible organism,0.5963414634146341
virus synthesis stage,pathogen vector role,0.5963414634146341
virus synthesis stage,pathogen portal of exit site,0.6132653061224489
virus synthesis stage,infectious disease prevalence,0.65
virus synthesis stage,organism substance,0.6807692307692308
virus synthesis stage,SARS-CoV-2 genome replication stage,0.6642857142857143
virus synthesis stage,disposition,0.60625
virus synthesis stage,single-stranded DNA virus,0.6021739130434782
virus synthesis stage,COVID-19 mortality rate,0.6318181818181818
virus synthesis stage,viral disease,0.6852941176470588
virus synthesis stage,primary infection role,0.636046511627907
virus synthesis stage,adhesion disposition,0.6207317073170732
virus synthesis stage,pathogen portal of entry site,0.61
virus synthesis stage,infection incidence profile,0.575
virus synthesis stage,viroid aggregate,0.6662162162162162
virus synthesis stage,disease,0.6285714285714286
virus synthesis stage,symptomatic infectious structure carrier,0.630327868852459
virus synthesis stage,site,0.61
virus synthesis stage,primary infectious disposition,0.6460784313725491
virus synthesis stage,pathogen host role,0.6294871794871795
virus synthesis stage,infection prevalence,0.6207317073170732
virus synthesis stage,humoral immune response,0.609090909090909
virus synthesis stage,coronavirus disorder,0.6695121951219513
virus synthesis stage,SARS-COV-2 adhesion susceptible cell,0.6429824561403508
virus synthesis stage,infectious pathogen transmissibility,0.6605263157894737
virus synthesis stage,pathogen surveillance,0.6166666666666667
virus synthesis stage,immunodeficient organism,0.6055555555555556
virus synthesis stage,pathogen,0.5879310344827586
virus synthesis stage,pathogen birth process boundary,0.6230769230769231
virus synthesis stage,infectious human pathogen,0.6456521739130434
virus synthesis stage,subclinical virus infection,0.6375
virus synthesis stage,resistance to pathogen,0.6825581395348838
virus synthesis stage,establishment of localization in virus host,0.590625
virus synthesis stage,virus attachment stage,0.7988372093023256
virus synthesis stage,negative regulation of immune response,0.6025423728813559
virus synthesis stage,SARS-CoV-2 transcription stage,0.6852941176470588
virus synthesis stage,virus synthesis stage,0.95
virus synthesis stage,SARS-COV-2 adhesion disposition,0.6423076923076922
virus synthesis stage,object aggregate,0.5851351351351352
virus synthesis stage,pathogen portal of exit role,0.5928571428571429
virus synthesis stage,invasive disposition,0.6207317073170732
virus synthesis stage,re-emerging pathogen,0.6207317073170732
virus synthesis stage,long-term non-progressing infectious disease course,0.6027777777777777
virus synthesis stage,viral disease epidemic,0.6593023255813953
virus synthesis stage,fungicidal disposition,0.5895348837209302
virus synthesis stage,viral disease pandemic,0.6825581395348838
virus synthesis stage,virus penetration stage,0.7909090909090909
virus synthesis stage,pathogen seroprevalence,0.609090909090909
virus synthesis stage,acute respiratory distress syndrome,0.6464285714285714
virus synthesis stage,division of geopolitical entity,0.6230769230769231
virus synthesis stage,infectious disease endemicity,0.63
virus synthesis stage,contact pathogen transmission process,0.6051724137931035
virus synthesis stage,disorder,0.553448275862069
virus synthesis stage,herd immunity to infectious organism,0.6078947368421053
virus synthesis stage,extracellular infection,0.5863636363636363
virus synthesis stage,pathogen transporter role,0.6021739130434782
virus synthesis stage,transmission interval,0.6404761904761905
virus synthesis stage,exotoxin disposition,0.5963414634146341
virus synthesis stage,immunoglobulin complex,0.5895348837209302
virus synthesis stage,infection start process boundary,0.619811320754717
virus synthesis stage,SARS-CoV-2 synthesis stage,0.8329787234042553
virus synthesis stage,infectious disease control objective specification,0.6190140845070422
virus synthesis stage,immune population,0.6078947368421053
virus synthesis stage,opportunistic infectious disposition,0.6429824561403508
virus synthesis stage,process of establishing viral infection,0.6166666666666667
virus synthesis stage,enterotoxin disposition,0.609090909090909
virus synthesis stage,COVID-19 disease course,0.6545454545454545
virus synthesis stage,infectious disease incidence rate,0.6537037037037037
virus synthesis stage,disordered virus,0.5851351351351352
virus synthesis stage,collective resistance disposition,0.6351851851851852
virus synthesis stage,adaptive immune response,0.6277777777777778
virus synthesis stage,fungistatic disposition,0.609090909090909
virus synthesis stage,organism,0.5879310344827586
virus synthesis stage,virus uncoating stage,0.8071428571428573
virus synthesis stage,local infection,0.5611111111111111
virus synthesis stage,establishment of a clinically abnormal colony,0.5560606060606061
virus synthesis stage,coronavirus disease,0.7
virus synthesis stage,positive-sense single-stranded RNA virus,0.6139344262295081
virus synthesis stage,horizontal pathogen transmission process,0.6139344262295081
virus synthesis stage,hospital-acquired infection,0.575
virus synthesis stage,pathogen death temporal region,0.5872549019607843
virus synthesis stage,emerging pathogen,0.6078947368421053
virus synthesis stage,SARS-CoV-2 release stage,0.6944444444444444
virus synthesis stage,pathogen transmission process,0.61
virus synthesis stage,cell space,0.6112903225806451
collective pathogenic disposition,virus aggregate,0.575
collective pathogenic disposition,virostatic disposition,0.7772727272727272
collective pathogenic disposition,information content entity,0.6194915254237288
collective pathogenic disposition,zoonotic disposition,0.7707547169811321
collective pathogenic disposition,infectious disease mortality rate,0.6318181818181818
collective pathogenic disposition,infection incidence rate profile,0.65
collective pathogenic disposition,infectious structure aggregate,0.6087301587301588
collective pathogenic disposition,communicability end temporal region,0.6411764705882353
collective pathogenic disposition,geographical entity,0.6038461538461539
collective pathogenic disposition,pathogen generative stage,0.656896551724138
collective pathogenic disposition,pathogen portal of entry,0.6956140350877194
collective pathogenic disposition,biological regulation,0.6537037037037037
collective pathogenic disposition,primary pathogen,0.6540816326530612
collective pathogenic disposition,surveillance process,0.6386792452830189
collective pathogenic disposition,infection end temporal region,0.6596774193548387
collective pathogenic disposition,vector control strategy,0.6107142857142857
collective pathogenic disposition,SARS-CoV-2 incidence rate,0.6051724137931035
collective pathogenic disposition,incubation end temporal region,0.6404761904761905
collective pathogenic disposition,site of infection,0.65
collective pathogenic disposition,resistant entity,0.6132653061224489
collective pathogenic disposition,virulence factor disposition,0.7778688524590163
collective pathogenic disposition,pathogen portal of exit,0.6821428571428573
collective pathogenic disposition,viral adhesion disposition,0.7550847457627118
collective pathogenic disposition,parasitostatic disposition,0.7550847457627118
collective pathogenic disposition,reservoir of pathogen role,0.6703389830508475
collective pathogenic disposition,negative regulation of production,0.7075757575757575
collective pathogenic disposition,reverse zoonotic disposition,0.7778688524590163
collective pathogenic disposition,establishment of localization in host,0.65
collective pathogenic disposition,disease surveillance objective specification,0.6837662337662337
collective pathogenic disposition,case isolation control strategy,0.621875
collective pathogenic disposition,infectious agent host role,0.6872881355932203
collective pathogenic disposition,macromolecular complex,0.5954545454545455
collective pathogenic disposition,material entity,0.5958333333333333
collective pathogenic disposition,SARS-CoV-2 aggregate,0.6009433962264151
collective pathogenic disposition,asymptomatic infectious structure carrier,0.5986486486486486
collective pathogenic disposition,source of infection site,0.6605263157894737
collective pathogenic disposition,architectual structure,0.5954545454545455
collective pathogenic disposition,quarantine control strategy,0.6
collective pathogenic disposition,B cell receptor complex,0.6464285714285714
collective pathogenic disposition,infection incidence rate,0.6254385964912281
collective pathogenic disposition,colonized host,0.6627659574468084
collective pathogenic disposition,virus host,0.5895348837209302
collective pathogenic disposition,entity,0.5525641025641026
collective pathogenic disposition,pathogen portal of entry role,0.6758064516129032
collective pathogenic disposition,toxin disposition,0.75
collective pathogenic disposition,pathogen birth temporal region,0.6880952380952381
collective pathogenic disposition,opportunistic pathogen,0.6681818181818181
collective pathogenic disposition,cidal agent disposition,0.7892857142857143
collective pathogenic disposition,genetic resistance to pathogen,0.6563492063492063
collective pathogenic disposition,droplet pathogen transmission process,0.7357142857142857
collective pathogenic disposition,parasiticidal disposition,0.743103448275862
collective pathogenic disposition,communicability end process boundary,0.6384057971014493
collective pathogenic disposition,directive information content entity,0.6673913043478261
collective pathogenic disposition,acellular structure aggregate,0.6274193548387097
collective pathogenic disposition,pathogen transporter,0.6952830188679244
collective pathogenic disposition,transmissibility disposition,0.7122950819672131
collective pathogenic disposition,latency end process boundary,0.6631147540983606
collective pathogenic disposition,colonization of host,0.6764150943396227
collective pathogenic disposition,realizable entity,0.61
collective pathogenic disposition,endotoxin disposition,0.7462962962962962
collective pathogenic disposition,vector surveillance,0.6038461538461539
collective pathogenic disposition,negative regulation of establishment of localization,0.6735294117647059
collective pathogenic disposition,infectious structure host role,0.6404761904761905
collective pathogenic disposition,pathogen vehicle,0.6540816326530612
collective pathogenic disposition,COVID-19 incidence rate,0.6107142857142857
collective pathogenic disposition,cytotoxin disposition,0.7648148148148148
collective pathogenic disposition,pathogen vector,0.6791666666666666
collective pathogenic disposition,negative regulation of developmental process,0.6448051948051949
collective pathogenic disposition,pathogen vehicle role,0.6722222222222223
collective pathogenic disposition,host,0.5581081081081081
collective pathogenic disposition,descriptive information content entity,0.6612676056338028
collective pathogenic disposition,negative regulation of replication,0.703731343283582
collective pathogenic disposition,establishment of localization in human host,0.6342105263157894
collective pathogenic disposition,acellular structure,0.5846153846153846
collective pathogenic disposition,incubation end process boundary,0.6375
collective pathogenic disposition,collective pathogenic disposition,0.95
collective pathogenic disposition,neurotoxin disposition,0.740909090909091
collective pathogenic disposition,dead-end host role,0.6264705882352941
collective pathogenic disposition,pathogen death process boundary,0.684375
collective pathogenic disposition,molecular entity,0.6336734693877552
collective pathogenic disposition,plan specification,0.6656862745098039
collective pathogenic disposition,definitive host role,0.6575471698113208
collective pathogenic disposition,latency end temporal region,0.6666666666666667
collective pathogenic disposition,coronavirus aggregate,0.5981481481481481
collective pathogenic disposition,infectious structure,0.6009433962264151
collective pathogenic disposition,collective disposition,0.85
collective pathogenic disposition,static agent disposition,0.7833333333333333
collective pathogenic disposition,T cell receptor complex,0.6464285714285714
collective pathogenic disposition,infectious structure host,0.6396551724137931
collective pathogenic disposition,respiratory system disease,0.6364406779661017
collective pathogenic disposition,entry into host,0.6375
collective pathogenic disposition,indirect pathogen transmission process,0.717605633802817
collective pathogenic disposition,adhesion of symbiont to host,0.6139344262295081
collective pathogenic disposition,infectious disease control strategy,0.6264705882352941
collective pathogenic disposition,infectious structure generative stage,0.6357142857142857
collective pathogenic disposition,immunosuppressive disposition,0.7241935483870968
collective pathogenic disposition,pathogenic disposition,0.85
collective pathogenic disposition,entry into host through host barriers,0.6357142857142857
collective pathogenic disposition,infectious disposition,0.759090909090909
collective pathogenic disposition,bacteriostatic disposition,0.7720338983050847
collective pathogenic disposition,epitope site,0.65
collective pathogenic disposition,immunity to pathogen,0.6386792452830189
collective pathogenic disposition,bactericidal disposition,0.7482456140350877
collective pathogenic disposition,pathogen host,0.7108695652173913
collective pathogenic disposition,invasion disposition,0.7707547169811321
collective pathogenic disposition,viricidal disposition,0.7277777777777777
collective pathogenic disposition,complex infection,0.67
collective pathogenic disposition,prion aggregate,0.575
collective pathogenic disposition,intermediate host,0.63
collective pathogenic disposition,pathogen vector role,0.6575471698113208
collective pathogenic disposition,pathogen portal of exit site,0.6795081967213115
collective pathogenic disposition,anatomical entity,0.61
collective pathogenic disposition,disposition,0.7
collective pathogenic disposition,COVID-19 mortality rate,0.5928571428571429
collective pathogenic disposition,negative regulation of life-sustaining process,0.6651898734177215
collective pathogenic disposition,place closure control strategy,0.6087301587301588
collective pathogenic disposition,geopolitical entity,0.6230769230769231
collective pathogenic disposition,adhesion disposition,0.7518867924528303
collective pathogenic disposition,pathogen portal of entry site,0.6758064516129032
collective pathogenic disposition,viroid aggregate,0.5928571428571429
collective pathogenic disposition,symptomatic infectious structure carrier,0.6006849315068493
collective pathogenic disposition,site,0.5310810810810811
collective pathogenic disposition,primary infectious disposition,0.7198412698412698
collective pathogenic disposition,pathogen host role,0.7049019607843137
collective pathogenic disposition,designative information content entity,0.6471830985915493
collective pathogenic disposition,infectious pathogen transmissibility,0.7253623188405797
collective pathogenic disposition,intermediate host role,0.6318181818181818
collective pathogenic disposition,dead-end host,0.6239130434782608
collective pathogenic disposition,pathogen surveillance,0.6722222222222223
collective pathogenic disposition,host role,0.569047619047619
collective pathogenic disposition,pathogen,0.6451219512195122
collective pathogenic disposition,pathogen birth process boundary,0.684375
collective pathogenic disposition,infectious human pathogen,0.6741379310344828
collective pathogenic disposition,resistance to pathogen,0.6681818181818181
collective pathogenic disposition,establishment of localization in virus host,0.6605263157894737
collective pathogenic disposition,negative regulation of immune response,0.6753521126760563
collective pathogenic disposition,immaterial entity,0.61
collective pathogenic disposition,SARS-COV-2 adhesion disposition,0.7625
collective pathogenic disposition,object aggregate,0.6336734693877552
collective pathogenic disposition,pathogen portal of exit role,0.6795081967213115
collective pathogenic disposition,invasive disposition,0.7518867924528303
collective pathogenic disposition,infectious agent host,0.6907407407407408
collective pathogenic disposition,re-emerging pathogen,0.6575471698113208
collective pathogenic disposition,fungicidal disposition,0.7227272727272727
collective pathogenic disposition,pathogen seroprevalence,0.6642857142857143
collective pathogenic disposition,division of geopolitical entity,0.6375
collective pathogenic disposition,negative regulation of viral process,0.6673913043478261
collective pathogenic disposition,contact pathogen transmission process,0.7357142857142857
collective pathogenic disposition,pathogen transporter role,0.6913793103448276
collective pathogenic disposition,exotoxin disposition,0.7518867924528303
collective pathogenic disposition,immunoglobulin complex,0.5772727272727273
collective pathogenic disposition,infectious disease control objective specification,0.6789156626506024
collective pathogenic disposition,symbiont host role,0.6068627450980393
collective pathogenic disposition,opportunistic infectious disposition,0.7108695652173913
collective pathogenic disposition,negative regulation of biological process,0.6662162162162162
collective pathogenic disposition,enterotoxin disposition,0.7714285714285714
collective pathogenic disposition,infectious disease incidence rate,0.6469696969696969
collective pathogenic disposition,collective resistance disposition,0.8439393939393939
collective pathogenic disposition,fungistatic disposition,0.7535714285714286
collective pathogenic disposition,establishment of a clinically abnormal colony,0.6166666666666667
collective pathogenic disposition,definitive host,0.6583333333333334
collective pathogenic disposition,horizontal pathogen transmission process,0.6965753424657534
collective pathogenic disposition,pathogen death temporal region,0.6880952380952381
collective pathogenic disposition,emerging pathogen,0.67
collective pathogenic disposition,pathogen transmission process,0.6919354838709677
communicability end temporal region,virus aggregate,0.57
communicability end temporal region,infectious disease mortality rate,0.6705882352941177
communicability end temporal region,infection incidence rate profile,0.6738805970149254
communicability end temporal region,communicability end temporal region,0.95
communicability end temporal region,infection end temporal region,0.809375
communicability end temporal region,infectious disease,0.6009433962264151
communicability end temporal region,SARS-CoV-2 incidence rate,0.6333333333333333
communicability end temporal region,double-stranded DNA virus,0.6333333333333333
communicability end temporal region,incubation end temporal region,0.8192307692307693
communicability end temporal region,two-dimensional spatial region,0.7115384615384616
communicability end temporal region,one-dimensional temporal region,0.7833333333333333
communicability end temporal region,temporal region,0.75
communicability end temporal region,infectious disease incidence,0.6087301587301588
communicability end temporal region,virus translation stage,0.6051724137931035
communicability end temporal region,disease surveillance objective specification,0.6145569620253164
communicability end temporal region,virus release stage,0.5796296296296296
communicability end temporal region,material entity,0.65
communicability end temporal region,virus,0.5
communicability end temporal region,virus replication,0.6038461538461539
communicability end temporal region,B cell receptor complex,0.6224137931034482
communicability end temporal region,infection incidence rate,0.6533898305084747
communicability end temporal region,virus host,0.5388888888888889
communicability end temporal region,double-stranded RNA virus,0.65
communicability end temporal region,virus transcription stage,0.6166666666666667
communicability end temporal region,infectious disease lifetime prevalence,0.6691780821917809
communicability end temporal region,pathogen birth temporal region,0.7730769230769231
communicability end temporal region,lower respiratory tract disease,0.6166666666666667
communicability end temporal region,infectious disease incidence proportion,0.6662162162162162
communicability end temporal region,virus generative stage,0.6078947368421053
communicability end temporal region,acute infectious disease course,0.6318181818181818
communicability end temporal region,infectious disease sporadicity,0.6346153846153847
communicability end temporal region,communicability end process boundary,0.802112676056338
communicability end temporal region,infection incidence proportion profile,0.6554794520547945
communicability end temporal region,SARS-CoV-2 incidence proportion,0.6621212121212122
communicability end temporal region,spatiotemporal region,0.7535714285714286
communicability end temporal region,latency end process boundary,0.6563492063492063
communicability end temporal region,infectious disease epidemic,0.6274193548387097
communicability end temporal region,disease transmission model,0.6139344262295081
communicability end temporal region,negative-sense single-stranded RNA virus,0.61
communicability end temporal region,COVID-19 incidence rate,0.6396551724137931
communicability end temporal region,zero-dimensional spatial region,0.7075757575757575
communicability end temporal region,zero-dimensional temporal region,0.7783582089552239
communicability end temporal region,chronic infectious disease course,0.6558823529411765
communicability end temporal region,COVID-19 epidemic,0.6230769230769231
communicability end temporal region,infection start temporal region,0.7681818181818181
communicability end temporal region,virus disorder,0.5724489795918367
communicability end temporal region,establishment of localization in human host,0.6294871794871795
communicability end temporal region,incubation end process boundary,0.6621212121212122
communicability end temporal region,pathogen death process boundary,0.6318181818181818
communicability end temporal region,geographical region,0.6722222222222223
communicability end temporal region,latency end temporal region,0.8209677419354838
communicability end temporal region,virus adhesion susceptible cell,0.6015151515151516
communicability end temporal region,T cell receptor complex,0.6224137931034482
communicability end temporal region,respiratory system disease,0.6139344262295081
communicability end temporal region,communicability interval,0.8228813559322035
communicability end temporal region,infectious disease control strategy,0.65
communicability end temporal region,infectious disease pandemic,0.6274193548387097
communicability end temporal region,viral disease course,0.6318181818181818
communicability end temporal region,three-dimensional spatial region,0.6888059701492537
communicability end temporal region,cell,0.5269230769230769
communicability end temporal region,objective specification,0.6224137931034482
communicability end temporal region,country,0.5928571428571429
communicability end temporal region,disease course,0.5928571428571429
communicability end temporal region,infectious disease course,0.6166666666666667
communicability end temporal region,COVID-19 disease incidence proportion,0.6583333333333334
communicability end temporal region,coronavirus disease course,0.6467213114754098
communicability end temporal region,infection incidence proportion,0.6807692307692308
communicability end temporal region,respiratory droplet virus fomite,0.6141791044776119
communicability end temporal region,infectious disease prevalence,0.653125
communicability end temporal region,single-stranded DNA virus,0.6
communicability end temporal region,COVID-19 mortality rate,0.6741379310344828
communicability end temporal region,place closure control strategy,0.6346153846153847
communicability end temporal region,viral disease,0.6166666666666667
communicability end temporal region,contagiousness,0.6336734693877552
communicability end temporal region,disease,0.5452380952380953
communicability end temporal region,SARS-COV-2 adhesion susceptible cell,0.6049295774647887
communicability end temporal region,incubation start process boundary,0.6411764705882353
communicability end temporal region,object,0.5475609756097561
communicability end temporal region,pathogen birth process boundary,0.6166666666666667
communicability end temporal region,infectious human pathogen,0.6166666666666667
communicability end temporal region,subclinical virus infection,0.6596774193548387
communicability end temporal region,colonization of human,0.6464285714285714
communicability end temporal region,establishment of localization in virus host,0.6166666666666667
communicability end temporal region,virus attachment stage,0.6078947368421053
communicability end temporal region,virus synthesis stage,0.5928571428571429
communicability end temporal region,object aggregate,0.6068627450980393
communicability end temporal region,long-term non-progressing infectious disease course,0.6011627906976744
communicability end temporal region,viral disease epidemic,0.6254385964912281
communicability end temporal region,communicability start temporal region,0.8944444444444444
communicability end temporal region,viral disease pandemic,0.6254385964912281
communicability end temporal region,virus penetration stage,0.6224137931034482
communicability end temporal region,geospatial region,0.6807692307692308
communicability end temporal region,division of geopolitical entity,0.6469696969696969
communicability end temporal region,infectious disease endemicity,0.6375
communicability end temporal region,communicability,0.75
communicability end temporal region,infection start process boundary,0.6291044776119403
communicability end temporal region,processed material,0.6386792452830189
communicability end temporal region,latency start process boundary,0.6346153846153847
communicability end temporal region,infectious disease control objective specification,0.6264705882352941
communicability end temporal region,COVID-19 disease course,0.6224137931034482
communicability end temporal region,infectious disease incidence rate,0.6411764705882353
communicability end temporal region,communicability start process boundary,0.7650684931506849
communicability end temporal region,process that results in death,0.621875
communicability end temporal region,single-stranded RNA retrovirus,0.6346153846153847
communicability end temporal region,disordered virus,0.5676470588235294
communicability end temporal region,virus uncoating stage,0.6285714285714286
communicability end temporal region,local infection,0.65
communicability end temporal region,establishment of a clinically abnormal colony,0.65
communicability end temporal region,process boundary,0.5872549019607843
communicability end temporal region,coronavirus disease,0.6351851851851852
communicability end temporal region,positive-sense single-stranded RNA virus,0.61
communicability end temporal region,one-dimensional spatial region,0.7115384615384616
communicability end temporal region,spatial region,0.6744897959183673
communicability end temporal region,pathogen death temporal region,0.7730769230769231
communicability end temporal region,cell space,0.5833333333333334
communicability end temporal region,material processing,0.6722222222222223
information content entity,extended organism,0.5895348837209302
information content entity,information content entity,0.95
information content entity,infectious disease mortality rate,0.6703389830508475
information content entity,infection incidence rate profile,0.6913793103448276
information content entity,infectious structure aggregate,0.6821428571428573
information content entity,communicability end temporal region,0.630327868852459
information content entity,geographical entity,0.7166666666666667
information content entity,infection end temporal region,0.7045454545454546
information content entity,drug-based immunosuppressed organism,0.5951612903225807
information content entity,SARS-CoV-2 incidence rate,0.6068627450980393
information content entity,incubation end temporal region,0.7
information content entity,resistant entity,0.7357142857142857
information content entity,immunocompetent organism,0.69
information content entity,virulence factor disposition,0.6351851851851852
information content entity,virus translation stage,0.6540816326530612
information content entity,case isolation control strategy,0.730701754385965
information content entity,material entity,0.7182926829268292
information content entity,asymptomatic infectious structure carrier,0.6291044776119403
information content entity,architectual structure,0.6166666666666667
information content entity,B cell receptor complex,0.5928571428571429
information content entity,infection incidence rate,0.71
information content entity,entity,0.6375
information content entity,communicability end process boundary,0.6274193548387097
information content entity,directive information content entity,0.8693548387096774
information content entity,acellular structure aggregate,0.5954545454545455
information content entity,invasion factor,0.6695121951219513
information content entity,latency end process boundary,0.6351851851851852
information content entity,realizable entity,0.7058139534883722
information content entity,pathologically immunosuppressed organism,0.5863636363636363
information content entity,infectious structure host role,0.6821428571428573
information content entity,COVID-19 incidence rate,0.6132653061224489
information content entity,descriptive information content entity,0.85625
information content entity,establishment of localization in human host,0.6528985507246376
information content entity,acellular structure,0.5833333333333334
information content entity,virulence factor,0.6166666666666667
information content entity,incubation end process boundary,0.6956140350877194
information content entity,molecular entity,0.6880952380952381
information content entity,immunosuppressed organism,0.6068627450980393
information content entity,latency end temporal region,0.6386792452830189
information content entity,infectious structure,0.6673913043478261
information content entity,T cell receptor complex,0.5928571428571429
information content entity,infectious structure host,0.6852941176470588
information content entity,respiratory system disease,0.6423076923076922
information content entity,organism population,0.6277777777777778
information content entity,infectious structure generative stage,0.7039682539682539
information content entity,susceptible organism,0.5804347826086956
information content entity,organism substance,0.6318181818181818
information content entity,anatomical entity,0.7290697674418604
information content entity,COVID-19 mortality rate,0.6132653061224489
information content entity,place closure control strategy,0.6464285714285714
information content entity,geopolitical entity,0.6944444444444444
information content entity,symptomatic infectious structure carrier,0.6318181818181818
information content entity,designative information content entity,0.85625
information content entity,immunodeficient organism,0.67
information content entity,infectious human pathogen,0.6656862745098039
information content entity,colonization of human,0.6627659574468084
information content entity,immaterial entity,0.7290697674418604
information content entity,blood,0.5145161290322581
information content entity,division of geopolitical entity,0.7131578947368421
information content entity,geographical feature,0.6239130434782608
information content entity,herd immunity to infectious organism,0.6274193548387097
information content entity,action specification,0.6456521739130434
information content entity,processed material,0.609090909090909
information content entity,quality,0.5712121212121213
information content entity,infectious disease incidence rate,0.6533898305084747
information content entity,viral load,0.5888888888888889
information content entity,organism,0.5970588235294118
information content entity,establishment of a clinically abnormal colony,0.6190140845070422
information content entity,adhesion factor,0.6207317073170732
information content entity,material processing,0.6277777777777778
object,information content entity,0.54375
object,infectious disease mortality rate,0.5269230769230769
object,infection incidence rate profile,0.5552631578947369
object,communicability end temporal region,0.5475609756097561
object,geographical entity,0.57
object,infection end temporal region,0.5357142857142857
object,SARS-CoV-2 incidence rate,0.5790322580645162
object,incubation end temporal region,0.5333333333333333
object,resistant entity,0.5409090909090909
object,disease surveillance objective specification,0.57
object,material entity,0.5452380952380953
object,B cell receptor complex,0.5879310344827586
object,infection incidence rate,0.5833333333333334
object,entity,0.6166666666666667
object,acute infectious disease course,0.5310810810810811
object,communicability end process boundary,0.5452380952380953
object,directive information content entity,0.5214285714285714
object,latency end process boundary,0.5088235294117647
object,realizable entity,0.5804347826086956
object,COVID-19 incidence rate,0.5879310344827586
object,chronic infectious disease course,0.5525641025641026
object,descriptive information content entity,0.5181818181818182
object,incubation end process boundary,0.5310810810810811
object,molecular entity,0.6318181818181818
object,plan specification,0.575
object,latency end temporal region,0.5409090909090909
object,T cell receptor complex,0.553448275862069
object,viral disease course,0.5269230769230769
object,objective specification,0.656896551724138
object,disease course,0.55
object,infectious disease course,0.5467741935483871
object,coronavirus disease course,0.54375
object,organism substance,0.575
object,anatomical entity,0.5804347826086956
object,COVID-19 mortality rate,0.5189655172413793
object,geopolitical entity,0.57
object,designative information content entity,0.5181818181818182
object,object,0.95
object,immaterial entity,0.5369565217391304
object,object aggregate,0.7227272727272727
object,long-term non-progressing infectious disease course,0.5201754385964912
object,division of geopolitical entity,0.5581081081081081
object,function,0.5928571428571429
object,infectious disease control objective specification,0.5571428571428572
object,COVID-19 disease course,0.553448275862069
object,infectious disease incidence rate,0.5525641025641026
object,establishment of a clinically abnormal colony,0.5088235294117647
healthcare facility,source of infection,0.6078947368421053
healthcare facility,communicability end temporal region,0.5981481481481481
healthcare facility,infection end temporal region,0.5958333333333333
healthcare facility,incubation end temporal region,0.5928571428571429
healthcare facility,material entity,0.6852941176470588
healthcare facility,source of infection site,0.636046511627907
healthcare facility,B cell receptor complex,0.6166666666666667
healthcare facility,communicability end process boundary,0.5954545454545455
healthcare facility,latency end process boundary,0.6202127659574468
healthcare facility,incubation end process boundary,0.59
healthcare facility,latency end temporal region,0.6239130434782608
healthcare facility,virus adhesion susceptible cell,0.59
healthcare facility,T cell receptor complex,0.6166666666666667
healthcare facility,facility,0.7462962962962962
healthcare facility,healthcare facility,0.95
healthcare facility,cell,0.5804347826086956
healthcare facility,source of infection role,0.6127906976744186
healthcare facility,hospital facility,0.7833333333333333
healthcare facility,SARS-COV-2 adhesion susceptible cell,0.5954545454545455
healthcare facility,processed material,0.6121621621621621
healthcare facility,quality,0.6423076923076922
healthcare facility,establishment of a clinically abnormal colony,0.6375
healthcare facility,cell space,0.6224137931034482
healthcare facility,material processing,0.6078947368421053
secondary infection,virus aggregate,0.5970588235294118
secondary infection,source of infection,0.7921052631578948
secondary infection,virostatic disposition,0.6451219512195122
secondary infection,zoonotic disposition,0.6551282051282051
secondary infection,infectious disease mortality rate,0.6230769230769231
secondary infection,infection incidence rate profile,0.6656862745098039
secondary infection,communicability end temporal region,0.6537037037037037
secondary infection,subclinical coronavirus infection,0.7576923076923078
secondary infection,infection end temporal region,0.6791666666666666
secondary infection,infectious disease,0.6662162162162162
secondary infection,SARS-CoV-2 incidence rate,0.6545454545454545
secondary infection,double-stranded DNA virus,0.5863636363636363
secondary infection,incubation end temporal region,0.6540816326530612
secondary infection,site of infection,0.8111111111111111
secondary infection,virulence factor disposition,0.6627659574468084
secondary infection,viral adhesion disposition,0.65
secondary infection,parasitostatic disposition,0.65
secondary infection,infectious disease incidence,0.6840425531914894
secondary infection,reverse zoonotic disposition,0.6627659574468084
secondary infection,subclinical SARS-CoV-2 infection,0.7441176470588234
secondary infection,virus translation stage,0.6166666666666667
secondary infection,disease surveillance objective specification,0.6404761904761905
secondary infection,virus release stage,0.581578947368421
secondary infection,source of infection site,0.7523255813953489
secondary infection,virus replication,0.6722222222222223
secondary infection,B cell receptor complex,0.6166666666666667
secondary infection,systematic infection,0.7833333333333333
secondary infection,infection incidence rate,0.6825581395348838
secondary infection,virus host,0.553448275862069
secondary infection,double-stranded RNA virus,0.5863636363636363
secondary infection,virus transcription stage,0.6318181818181818
secondary infection,infectious disease lifetime prevalence,0.6605263157894737
secondary infection,toxin disposition,0.6722222222222223
secondary infection,lower respiratory tract disease,0.61
secondary infection,infectious disease incidence proportion,0.6913793103448276
secondary infection,virus generative stage,0.6207317073170732
secondary infection,acute infectious disease course,0.65
secondary infection,cidal agent disposition,0.6642857142857143
secondary infection,infectious disorder,0.6605263157894737
secondary infection,subclinical infection,0.8
secondary infection,appearance of disorder,0.6207317073170732
secondary infection,simple infection,0.7928571428571428
secondary infection,parasiticidal disposition,0.6772727272727272
secondary infection,infectious disease sporadicity,0.6336734693877552
secondary infection,communicability end process boundary,0.6318181818181818
secondary infection,infection incidence proportion profile,0.6780701754385965
secondary infection,transmissibility disposition,0.6202127659574468
secondary infection,latency end process boundary,0.6202127659574468
secondary infection,infectious disease epidemic,0.6456521739130434
secondary infection,disease transmission model,0.6277777777777778
secondary infection,endotoxin disposition,0.675
secondary infection,negative-sense single-stranded RNA virus,0.6025423728813559
secondary infection,COVID-19 incidence rate,0.6642857142857143
secondary infection,cytotoxin disposition,0.675
secondary infection,community-acquired infection,0.7691489361702127
secondary infection,chronic infectious disease course,0.6807692307692308
secondary infection,nursing-home acquired infection,0.73
secondary infection,COVID-19 epidemic,0.6444444444444444
secondary infection,secondary infection,0.95
secondary infection,infection start temporal region,0.67
secondary infection,infection incidence,0.7131578947368421
secondary infection,virus disorder,0.5712121212121213
secondary infection,primary infection,0.8111111111111111
secondary infection,process of establishing an infection,0.7045454545454546
secondary infection,incubation end process boundary,0.61
secondary infection,SARS-CoV-2 disorder,0.6078947368421053
secondary infection,collective pathogenic disposition,0.6423076923076922
secondary infection,neurotoxin disposition,0.6695121951219513
secondary infection,latency end temporal region,0.6673913043478261
secondary infection,virus adhesion susceptible cell,0.61
secondary infection,collective disposition,0.6451219512195122
secondary infection,infection,0.7714285714285714
secondary infection,static agent disposition,0.6593023255813953
secondary infection,T cell receptor complex,0.6166666666666667
secondary infection,respiratory system disease,0.6055555555555556
secondary infection,indirect pathogen transmission process,0.6078947368421053
secondary infection,communicability interval,0.6593023255813953
secondary infection,infectious disease control strategy,0.6166666666666667
secondary infection,infectious disease pandemic,0.6456521739130434
secondary infection,immunosuppressive disposition,0.6166666666666667
secondary infection,pathogenic disposition,0.6451219512195122
secondary infection,viral disease course,0.6038461538461539
secondary infection,intracellular infection,0.7595238095238095
secondary infection,secondary infection role,0.891860465116279
secondary infection,metastatic infection,0.7576923076923078
secondary infection,infectious disposition,0.6695121951219513
secondary infection,acute infection,0.7735294117647058
secondary infection,bacteriostatic disposition,0.65
secondary infection,bactericidal disposition,0.6825581395348838
secondary infection,source of infection role,0.7523255813953489
secondary infection,acquired immunodeficiency,0.6545454545454545
secondary infection,chronic infection,0.8111111111111111
secondary infection,invasion disposition,0.6807692307692308
secondary infection,disease course,0.6318181818181818
secondary infection,infectious disease course,0.6318181818181818
secondary infection,viricidal disposition,0.675
secondary infection,acquired immunity to infectious agent,0.6821428571428573
secondary infection,complex infection,0.7833333333333333
secondary infection,COVID-19 disease incidence proportion,0.6821428571428573
secondary infection,coronavirus disease course,0.6722222222222223
secondary infection,infection incidence proportion,0.7153061224489795
secondary infection,respiratory droplet virus fomite,0.6264705882352941
secondary infection,generically dependent continuant,0.6656862745098039
secondary infection,infectious disease prevalence,0.6375
secondary infection,disposition,0.6833333333333332
secondary infection,single-stranded DNA virus,0.609090909090909
secondary infection,COVID-19 mortality rate,0.6166666666666667
secondary infection,viral disease,0.575
secondary infection,primary infection role,0.7670731707317073
secondary infection,adhesion disposition,0.6807692307692308
secondary infection,infection incidence profile,0.6673913043478261
secondary infection,contagiousness,0.6621212121212122
secondary infection,disease,0.6038461538461539
secondary infection,primary infectious disposition,0.7153061224489795
secondary infection,infection prevalence,0.6807692307692308
secondary infection,coronavirus disorder,0.6551282051282051
secondary infection,subclinical virus infection,0.7760869565217391
secondary infection,establishment of localization in virus host,0.6112903225806451
secondary infection,virus attachment stage,0.5719512195121951
secondary infection,specifically dependent continuant,0.6807692307692308
secondary infection,virus synthesis stage,0.575
secondary infection,SARS-COV-2 adhesion disposition,0.65
secondary infection,invasive disposition,0.6551282051282051
secondary infection,long-term non-progressing infectious disease course,0.6357142857142857
secondary infection,viral disease epidemic,0.6207317073170732
secondary infection,communicability start temporal region,0.6285714285714286
secondary infection,fungicidal disposition,0.6695121951219513
secondary infection,viral disease pandemic,0.6207317073170732
secondary infection,virus penetration stage,0.6404761904761905
secondary infection,acute respiratory distress syndrome,0.5981481481481481
secondary infection,infectious disease endemicity,0.6583333333333334
secondary infection,disorder,0.5981481481481481
secondary infection,communicability,0.6264705882352941
secondary infection,extracellular infection,0.7833333333333333
secondary infection,exotoxin disposition,0.6807692307692308
secondary infection,infection start process boundary,0.6460784313725491
secondary infection,action specification,0.732051282051282
secondary infection,infectious disease control objective specification,0.6528985507246376
secondary infection,opportunistic infectious disposition,0.6681818181818181
secondary infection,process of establishing viral infection,0.6913793103448276
secondary infection,enterotoxin disposition,0.6642857142857143
secondary infection,COVID-19 disease course,0.6404761904761905
secondary infection,infectious disease incidence rate,0.6615384615384616
secondary infection,communicability start process boundary,0.6078947368421053
secondary infection,single-stranded RNA retrovirus,0.6336734693877552
secondary infection,disordered virus,0.6214285714285714
secondary infection,collective resistance disposition,0.6423076923076922
secondary infection,fungistatic disposition,0.6404761904761905
secondary infection,virus uncoating stage,0.625
secondary infection,local infection,0.8029411764705883
secondary infection,establishment of a clinically abnormal colony,0.621875
secondary infection,coronavirus disease,0.6605263157894737
secondary infection,positive-sense single-stranded RNA virus,0.6025423728813559
secondary infection,hospital-acquired infection,0.7326086956521739
viral adhesion disposition,virostatic disposition,0.8041666666666667
viral adhesion disposition,information content entity,0.6423076923076922
viral adhesion disposition,zoonotic disposition,0.7543478260869566
viral adhesion disposition,infectious disease mortality rate,0.6364406779661017
viral adhesion disposition,infection incidence rate profile,0.6224137931034482
viral adhesion disposition,infectious structure aggregate,0.575
viral adhesion disposition,communicability end temporal region,0.6467213114754098
viral adhesion disposition,geographical entity,0.6277777777777778
viral adhesion disposition,biological regulation,0.6414893617021277
viral adhesion disposition,surveillance process,0.6456521739130434
viral adhesion disposition,infection end temporal region,0.6681818181818181
viral adhesion disposition,vector control strategy,0.6132653061224489
viral adhesion disposition,SARS-CoV-2 incidence rate,0.5872549019607843
viral adhesion disposition,incubation end temporal region,0.6642857142857143
viral adhesion disposition,resistant entity,0.6404761904761905
viral adhesion disposition,virulence factor disposition,0.8018518518518519
viral adhesion disposition,viral adhesion disposition,0.95
viral adhesion disposition,parasitostatic disposition,0.7769230769230769
viral adhesion disposition,negative regulation of production,0.6872881355932203
viral adhesion disposition,reverse zoonotic disposition,0.7648148148148148
viral adhesion disposition,establishment of localization in host,0.6404761904761905
viral adhesion disposition,disease surveillance objective specification,0.6642857142857143
viral adhesion disposition,case isolation control strategy,0.6254385964912281
viral adhesion disposition,infectious agent host role,0.6423076923076922
viral adhesion disposition,macromolecular complex,0.5541666666666667
viral adhesion disposition,material entity,0.6451219512195122
viral adhesion disposition,asymptomatic infectious structure carrier,0.5843283582089552
viral adhesion disposition,architectual structure,0.575
viral adhesion disposition,quarantine control strategy,0.6009433962264151
viral adhesion disposition,B cell receptor complex,0.5724489795918367
viral adhesion disposition,infection incidence rate,0.63
viral adhesion disposition,colonized host,0.625
viral adhesion disposition,virus host,0.6722222222222223
viral adhesion disposition,entity,0.575
viral adhesion disposition,toxin disposition,0.7755813953488372
viral adhesion disposition,lower respiratory tract disease,0.6429824561403508
viral adhesion disposition,cidal agent disposition,0.8377551020408163
viral adhesion disposition,parasiticidal disposition,0.7637254901960785
viral adhesion disposition,communicability end process boundary,0.6435483870967742
viral adhesion disposition,directive information content entity,0.6274193548387097
viral adhesion disposition,acellular structure aggregate,0.5590909090909091
viral adhesion disposition,transmissibility disposition,0.7462962962962962
viral adhesion disposition,latency end process boundary,0.6537037037037037
viral adhesion disposition,colonization of host,0.6456521739130434
viral adhesion disposition,realizable entity,0.636046511627907
viral adhesion disposition,endotoxin disposition,0.7691489361702127
viral adhesion disposition,vector surveillance,0.6055555555555556
viral adhesion disposition,negative regulation of establishment of localization,0.6551282051282051
viral adhesion disposition,infectious structure host role,0.6285714285714286
viral adhesion disposition,COVID-19 incidence rate,0.6132653061224489
viral adhesion disposition,viral plaque assay,0.7
viral adhesion disposition,cytotoxin disposition,0.747872340425532
viral adhesion disposition,negative regulation of developmental process,0.6214285714285714
viral adhesion disposition,host,0.5833333333333334
viral adhesion disposition,descriptive information content entity,0.621875
viral adhesion disposition,negative regulation of replication,0.6833333333333332
viral adhesion disposition,establishment of localization in human host,0.6239130434782608
viral adhesion disposition,acellular structure,0.5833333333333334
viral adhesion disposition,incubation end process boundary,0.6605263157894737
viral adhesion disposition,collective pathogenic disposition,0.7550847457627118
viral adhesion disposition,neurotoxin disposition,0.7625
viral adhesion disposition,dead-end host role,0.6545454545454545
viral adhesion disposition,molecular entity,0.5928571428571429
viral adhesion disposition,plan specification,0.7
viral adhesion disposition,definitive host role,0.6456521739130434
viral adhesion disposition,latency end temporal region,0.6575471698113208
viral adhesion disposition,infectious structure,0.6021739130434782
viral adhesion disposition,virus adhesion susceptible cell,0.7482456140350877
viral adhesion disposition,collective disposition,0.7625
viral adhesion disposition,static agent disposition,0.79
viral adhesion disposition,T cell receptor complex,0.5724489795918367
viral adhesion disposition,infectious structure host,0.6264705882352941
viral adhesion disposition,respiratory system disease,0.6423076923076922
viral adhesion disposition,entry into host,0.6451219512195122
viral adhesion disposition,adhesion of symbiont to host,0.7092592592592593
viral adhesion disposition,infectious disease control strategy,0.630327868852459
viral adhesion disposition,SARS-CoV-2 attachment stage,0.619811320754717
viral adhesion disposition,infectious structure generative stage,0.5769841269841269
viral adhesion disposition,immunosuppressive disposition,0.759090909090909
viral adhesion disposition,pathogenic disposition,0.7833333333333333
viral adhesion disposition,viral disease course,0.7108695652173913
viral adhesion disposition,entry into host through host barriers,0.6087301587301588
viral adhesion disposition,viral envelope,0.675
viral adhesion disposition,infectious disposition,0.7833333333333333
viral adhesion disposition,bacteriostatic disposition,0.7576923076923078
viral adhesion disposition,bactericidal disposition,0.75
viral adhesion disposition,pathogen host,0.6551282051282051
viral adhesion disposition,invasion disposition,0.8413043478260869
viral adhesion disposition,viricidal disposition,0.8117021276595744
viral adhesion disposition,complex infection,0.636046511627907
viral adhesion disposition,viral capsid,0.7131578947368421
viral adhesion disposition,intermediate host,0.636046511627907
viral adhesion disposition,anatomical entity,0.636046511627907
viral adhesion disposition,disposition,0.7472972972972972
viral adhesion disposition,COVID-19 mortality rate,0.6132653061224489
viral adhesion disposition,negative regulation of life-sustaining process,0.6444444444444444
viral adhesion disposition,place closure control strategy,0.6107142857142857
viral adhesion disposition,geopolitical entity,0.6277777777777778
viral adhesion disposition,viral disease,0.7064102564102563
viral adhesion disposition,adhesion disposition,0.8847826086956522
viral adhesion disposition,symptomatic infectious structure carrier,0.5863636363636363
viral adhesion disposition,primary infectious disposition,0.7714285714285714
viral adhesion disposition,pathogen host role,0.6545454545454545
viral adhesion disposition,designative information content entity,0.6375
viral adhesion disposition,SARS-COV-2 adhesion susceptible cell,0.6919354838709677
viral adhesion disposition,intermediate host role,0.6375
viral adhesion disposition,dead-end host,0.6551282051282051
viral adhesion disposition,pathogen surveillance,0.6202127659574468
viral adhesion disposition,host role,0.5928571428571429
viral adhesion disposition,establishment of localization in virus host,0.6384057971014493
viral adhesion disposition,virus attachment stage,0.6791666666666666
viral adhesion disposition,negative regulation of immune response,0.653125
viral adhesion disposition,immaterial entity,0.6593023255813953
viral adhesion disposition,SARS-COV-2 adhesion disposition,0.8359649122807017
viral adhesion disposition,invasive disposition,0.7978260869565217
viral adhesion disposition,infectious agent host,0.6414893617021277
viral adhesion disposition,viral disease epidemic,0.7208333333333333
viral adhesion disposition,fungicidal disposition,0.7625
viral adhesion disposition,viral disease pandemic,0.7
viral adhesion disposition,division of geopolitical entity,0.6780701754385965
viral adhesion disposition,negative regulation of viral process,0.6435483870967742
viral adhesion disposition,exotoxin disposition,0.7760869565217391
viral adhesion disposition,immunoglobulin complex,0.575
viral adhesion disposition,action specification,0.7108695652173913
viral adhesion disposition,infectious disease control objective specification,0.6605263157894737
viral adhesion disposition,symbiont host role,0.6545454545454545
viral adhesion disposition,opportunistic infectious disposition,0.7241935483870968
viral adhesion disposition,process of establishing viral infection,0.65
viral adhesion disposition,negative regulation of biological process,0.6291044776119403
viral adhesion disposition,enterotoxin disposition,0.7561224489795919
viral adhesion disposition,infectious disease incidence rate,0.6533898305084747
viral adhesion disposition,collective resistance disposition,0.7550847457627118
viral adhesion disposition,viral load,0.6722222222222223
viral adhesion disposition,fungistatic disposition,0.7561224489795919
viral adhesion disposition,establishment of a clinically abnormal colony,0.6049295774647887
viral adhesion disposition,adhesion factor,0.7182926829268292
viral adhesion disposition,definitive host,0.6451219512195122
viral adhesion disposition,viral pathogenesis,0.7227272727272727
fomite role,reservoir of pathogen role,0.6932432432432433
fomite role,infectious agent host role,0.6662162162162162
fomite role,B cell receptor complex,0.6264705882352941
fomite role,pathogen portal of entry role,0.65
fomite role,respiratory droplet coronavirus fomite,0.5928571428571429
fomite role,lower respiratory tract disease,0.5928571428571429
fomite role,acute infectious disease course,0.6166666666666667
fomite role,role,0.7166666666666667
fomite role,appearance of disorder,0.5712121212121213
fomite role,mutualist role,0.77
fomite role,infectious structure host role,0.6695121951219513
fomite role,respiratory droplet SARS-CoV-2 fomite,0.5958333333333333
fomite role,pathogen vehicle role,0.7
fomite role,fomite,0.8029411764705883
fomite role,chronic infectious disease course,0.609090909090909
fomite role,mechanical vector role,0.6924242424242425
fomite role,dead-end host role,0.6913793103448276
fomite role,definitive host role,0.7403225806451613
fomite role,T cell receptor complex,0.6558823529411765
fomite role,asymptomatic carrier role,0.7
fomite role,viral disease course,0.6112903225806451
fomite role,secondary infection role,0.6785714285714286
fomite role,source of infection role,0.6785714285714286
fomite role,disease course,0.65
fomite role,infectious disease course,0.6444444444444444
fomite role,coronavirus disease course,0.6121621621621621
fomite role,biological vehicle role,0.6852941176470588
fomite role,respiratory droplet virus fomite,0.6127906976744186
fomite role,symbiont role,0.7833333333333333
fomite role,parasite role,0.7833333333333333
fomite role,pathogen vector role,0.6758064516129032
fomite role,respiratory droplet fomite,0.6391891891891892
fomite role,primary infection role,0.6924242424242425
fomite role,biological role,0.7192307692307692
fomite role,biological vector role,0.6924242424242425
fomite role,pathogen host role,0.6913793103448276
fomite role,symptomatic carrier role,0.7071428571428571
fomite role,intermediate host role,0.7227272727272727
fomite role,host role,0.8
fomite role,pathogen portal of exit role,0.6551282051282051
fomite role,long-term non-progressing infectious disease course,0.5790322580645162
fomite role,commensal role,0.77
fomite role,epitope role,0.7978260869565217
fomite role,function,0.6078947368421053
fomite role,pathogen transporter role,0.6722222222222223
fomite role,antigen role,0.7543478260869566
fomite role,action specification,0.5790322580645162
fomite role,symbiont host role,0.7258620689655172
fomite role,fomite role,0.95
fomite role,COVID-19 disease course,0.6264705882352941
fomite role,reagent role,0.7108695652173913
fomite role,viral load,0.5928571428571429
fomite role,establishment of a clinically abnormal colony,0.5571428571428572
definitive host,virostatic disposition,0.6391891891891892
definitive host,zoonotic disposition,0.65
definitive host,infectious disease mortality rate,0.6166666666666667
definitive host,infection incidence rate profile,0.6202127659574468
definitive host,communicability end temporal region,0.57
definitive host,infection end temporal region,0.609090909090909
definitive host,SARS-CoV-2 incidence rate,0.6
definitive host,incubation end temporal region,0.6055555555555556
definitive host,virulence factor disposition,0.6127906976744186
definitive host,viral adhesion disposition,0.6451219512195122
definitive host,parasitostatic disposition,0.6207317073170732
definitive host,reverse zoonotic disposition,0.636046511627907
definitive host,establishment of localization in host,0.6615384615384616
definitive host,infectious agent host role,0.6939024390243902
definitive host,B cell receptor complex,0.5552631578947369
definitive host,infection incidence rate,0.6551282051282051
definitive host,colonized host,0.7258620689655172
definitive host,virus host,0.69
definitive host,toxin disposition,0.6375
definitive host,cidal agent disposition,0.6605263157894737
definitive host,parasiticidal disposition,0.625
definitive host,communicability end process boundary,0.5872549019607843
definitive host,transmissibility disposition,0.6127906976744186
definitive host,latency end process boundary,0.5895348837209302
definitive host,colonization of host,0.7071428571428571
definitive host,endotoxin disposition,0.6722222222222223
definitive host,infectious structure host role,0.6722222222222223
definitive host,COVID-19 incidence rate,0.6342105263157894
definitive host,cytotoxin disposition,0.6166666666666667
definitive host,host,0.6605263157894737
definitive host,establishment of localization in human host,0.6396551724137931
definitive host,incubation end process boundary,0.6239130434782608
definitive host,collective pathogenic disposition,0.6583333333333334
definitive host,neurotoxin disposition,0.6391891891891892
definitive host,dead-end host role,0.6924242424242425
definitive host,definitive host role,0.8785714285714286
definitive host,latency end temporal region,0.5928571428571429
definitive host,virus adhesion susceptible cell,0.6239130434782608
definitive host,collective disposition,0.6932432432432433
definitive host,static agent disposition,0.6294871794871795
definitive host,T cell receptor complex,0.5552631578947369
definitive host,infectious structure host,0.7
definitive host,entry into host,0.75
definitive host,adhesion of symbiont to host,0.7058139534883722
definitive host,immunosuppressive disposition,0.6545454545454545
definitive host,pathogenic disposition,0.6391891891891892
definitive host,entry into host through host barriers,0.6230769230769231
definitive host,cell,0.5026315789473684
definitive host,infectious disposition,0.6662162162162162
definitive host,bacteriostatic disposition,0.6451219512195122
definitive host,bactericidal disposition,0.6294871794871795
definitive host,pathogen host,0.7
definitive host,invasion disposition,0.65
definitive host,viricidal disposition,0.6444444444444444
definitive host,intermediate host,0.7625
definitive host,disposition,0.6807692307692308
definitive host,COVID-19 mortality rate,0.581578947368421
definitive host,adhesion disposition,0.6785714285714286
definitive host,primary infectious disposition,0.6277777777777778
definitive host,pathogen host role,0.6621212121212122
definitive host,SARS-COV-2 adhesion susceptible cell,0.6068627450980393
definitive host,intermediate host role,0.7202702702702704
definitive host,dead-end host,0.7357142857142857
definitive host,host role,0.6166666666666667
definitive host,establishment of localization in virus host,0.656896551724138
definitive host,SARS-COV-2 adhesion disposition,0.6239130434782608
definitive host,invasive disposition,0.7071428571428571
definitive host,infectious agent host,0.7277777777777777
definitive host,fungicidal disposition,0.6662162162162162
definitive host,division of geopolitical entity,0.6239130434782608
definitive host,exotoxin disposition,0.65
definitive host,symbiont host role,0.6924242424242425
definitive host,opportunistic infectious disposition,0.6264705882352941
definitive host,enterotoxin disposition,0.6605263157894737
definitive host,infectious disease incidence rate,0.6166666666666667
definitive host,collective resistance disposition,0.6375
definitive host,fungistatic disposition,0.6868421052631578
definitive host,establishment of a clinically abnormal colony,0.5666666666666667
definitive host,definitive host,0.95
definitive host,cell space,0.57
negative regulation of replication,virostatic disposition,0.6642857142857143
negative regulation of replication,zoonotic disposition,0.6537037037037037
negative regulation of replication,infectious disease mortality rate,0.658955223880597
negative regulation of replication,infection incidence rate profile,0.6469696969696969
negative regulation of replication,communicability end temporal region,0.6528985507246376
negative regulation of replication,biological regulation,0.6863636363636364
negative regulation of replication,surveillance process,0.5981481481481481
negative regulation of replication,infection end temporal region,0.6880952380952381
negative regulation of replication,coronavirus replication,0.7482456140350877
negative regulation of replication,geospatial location,0.6952830188679244
negative regulation of replication,vector control strategy,0.6254385964912281
negative regulation of replication,SARS-CoV-2 incidence rate,0.6025423728813559
negative regulation of replication,incubation end temporal region,0.684375
negative regulation of replication,site of infection,0.6852941176470588
negative regulation of replication,virulence factor disposition,0.6758064516129032
negative regulation of replication,viral adhesion disposition,0.6833333333333332
negative regulation of replication,parasitostatic disposition,0.65
negative regulation of replication,prion replication,0.7637254901960785
negative regulation of replication,negative regulation of production,0.8828358208955223
negative regulation of replication,reverse zoonotic disposition,0.6919354838709677
negative regulation of replication,disease surveillance objective specification,0.7064102564102563
negative regulation of replication,case isolation control strategy,0.6807692307692308
negative regulation of replication,source of infection site,0.656896551724138
negative regulation of replication,quarantine control strategy,0.6467213114754098
negative regulation of replication,virus replication,0.7441176470588234
negative regulation of replication,B cell receptor complex,0.6254385964912281
negative regulation of replication,infection incidence rate,0.6396551724137931
negative regulation of replication,double-stranded RNA virus,0.6025423728813559
negative regulation of replication,virus transcription stage,0.6364406779661017
negative regulation of replication,toxin disposition,0.6460784313725491
negative regulation of replication,lower respiratory tract disease,0.6346153846153847
negative regulation of replication,cidal agent disposition,0.6429824561403508
negative regulation of replication,appearance of disorder,0.6464285714285714
negative regulation of replication,parasiticidal disposition,0.6533898305084747
negative regulation of replication,communicability end process boundary,0.6071428571428572
negative regulation of replication,transmissibility disposition,0.6274193548387097
negative regulation of replication,latency end process boundary,0.6274193548387097
negative regulation of replication,disease transmission model,0.6666666666666667
negative regulation of replication,endotoxin disposition,0.65
negative regulation of replication,vector surveillance,0.6386792452830189
negative regulation of replication,negative regulation of establishment of localization,0.822093023255814
negative regulation of replication,negative-sense single-stranded RNA virus,0.6797297297297297
negative regulation of replication,COVID-19 incidence rate,0.5903508771929825
negative regulation of replication,cytotoxin disposition,0.65
negative regulation of replication,negative regulation of developmental process,0.7961538461538461
negative regulation of replication,negative regulation of replication,0.95
negative regulation of replication,PCR product,0.5611111111111111
negative regulation of replication,incubation end process boundary,0.65
negative regulation of replication,collective pathogenic disposition,0.703731343283582
negative regulation of replication,neurotoxin disposition,0.6821428571428573
negative regulation of replication,latency end temporal region,0.6795081967213115
negative regulation of replication,collective disposition,0.6821428571428573
negative regulation of replication,static agent disposition,0.6741379310344828
negative regulation of replication,T cell receptor complex,0.6429824561403508
negative regulation of replication,respiratory system disease,0.6166666666666667
negative regulation of replication,infectious disease control strategy,0.6528985507246376
negative regulation of replication,immunosuppressive disposition,0.6563492063492063
negative regulation of replication,SARS-CoV-2 replication,0.7178571428571427
negative regulation of replication,pathogenic disposition,0.6464285714285714
negative regulation of replication,infectious disposition,0.6642857142857143
negative regulation of replication,bacteriostatic disposition,0.6833333333333332
negative regulation of replication,epitope site,0.6021739130434782
negative regulation of replication,bactericidal disposition,0.656896551724138
negative regulation of replication,invasion disposition,0.6907407407407408
negative regulation of replication,viricidal disposition,0.6318181818181818
negative regulation of replication,pathogen portal of exit site,0.6758064516129032
negative regulation of replication,SARS-CoV-2 genome replication stage,0.7108695652173913
negative regulation of replication,production,0.609090909090909
negative regulation of replication,disposition,0.6055555555555556
negative regulation of replication,COVID-19 mortality rate,0.6078947368421053
negative regulation of replication,contact tracing,0.6336734693877552
negative regulation of replication,negative regulation of life-sustaining process,0.8
negative regulation of replication,place closure control strategy,0.6375
negative regulation of replication,adhesion disposition,0.6722222222222223
negative regulation of replication,pathogen portal of entry site,0.6563492063492063
negative regulation of replication,site,0.5289473684210526
negative regulation of replication,primary infectious disposition,0.653125
negative regulation of replication,replication,0.6944444444444444
negative regulation of replication,pathogen surveillance,0.6318181818181818
negative regulation of replication,negative regulation of immune response,0.8388888888888889
negative regulation of replication,SARS-CoV-2 transcription stage,0.6375
negative regulation of replication,SARS-COV-2 adhesion disposition,0.6653846153846155
negative regulation of replication,invasive disposition,0.6907407407407408
negative regulation of replication,fungicidal disposition,0.6464285714285714
negative regulation of replication,division of geopolitical entity,0.7115384615384616
negative regulation of replication,negative regulation of viral process,0.8214285714285714
negative regulation of replication,exotoxin disposition,0.6537037037037037
negative regulation of replication,infectious disease control objective specification,0.6880952380952381
negative regulation of replication,opportunistic infectious disposition,0.6642857142857143
negative regulation of replication,negative regulation of biological process,0.8233333333333335
negative regulation of replication,enterotoxin disposition,0.6956140350877194
negative regulation of replication,infectious disease incidence rate,0.6440298507462687
negative regulation of replication,single-stranded RNA retrovirus,0.6375
negative regulation of replication,active immunization against infectious agent,0.7064102564102563
negative regulation of replication,collective resistance disposition,0.703731343283582
negative regulation of replication,fungistatic disposition,0.6780701754385965
negative regulation of replication,establishment of a clinically abnormal colony,0.639873417721519
negative regulation of replication,positive-sense single-stranded RNA virus,0.6256756756756756
immunization against infectious agent,information content entity,0.7039682539682539
immunization against infectious agent,infectious disease mortality rate,0.65
immunization against infectious agent,infection incidence rate profile,0.6673913043478261
immunization against infectious agent,infectious structure aggregate,0.6888059701492537
immunization against infectious agent,communicability end temporal region,0.6722222222222223
immunization against infectious agent,infection end temporal region,0.6621212121212122
immunization against infectious agent,infectious disease,0.6863636363636364
immunization against infectious agent,SARS-CoV-2 incidence rate,0.6274193548387097
immunization against infectious agent,incubation end temporal region,0.6738805970149254
immunization against infectious agent,virulence factor disposition,0.6653846153846155
immunization against infectious agent,infectious disease incidence,0.6807692307692308
immunization against infectious agent,disease surveillance objective specification,0.6351851851851852
immunization against infectious agent,infectious agent host role,0.7039682539682539
immunization against infectious agent,asymptomatic infectious structure carrier,0.6935897435897437
immunization against infectious agent,B cell receptor complex,0.5833333333333334
immunization against infectious agent,passive immunization against infectious agent,0.901219512195122
immunization against infectious agent,infection incidence rate,0.6959016393442623
immunization against infectious agent,infectious disease lifetime prevalence,0.69
immunization against infectious agent,lower respiratory tract disease,0.6264705882352941
immunization against infectious agent,infectious disease incidence proportion,0.6736842105263158
immunization against infectious agent,acute infectious disease course,0.6852941176470588
immunization against infectious agent,cidal agent disposition,0.6666666666666667
immunization against infectious agent,infectious disorder,0.6642857142857143
immunization against infectious agent,biological vehicle,0.5954545454545455
immunization against infectious agent,infectious disease sporadicity,0.658955223880597
immunization against infectious agent,communicability end process boundary,0.6554794520547945
immunization against infectious agent,directive information content entity,0.6691780821917809
immunization against infectious agent,infectious agent colony,0.7166666666666667
immunization against infectious agent,pathogen transporter,0.6254385964912281
immunization against infectious agent,invasion factor,0.6615384615384616
immunization against infectious agent,latency end process boundary,0.6038461538461539
immunization against infectious agent,infectious disease epidemic,0.653125
immunization against infectious agent,infectious agent generative stage,0.7214285714285714
immunization against infectious agent,disease transmission model,0.6246031746031746
immunization against infectious agent,cidal agent,0.6166666666666667
immunization against infectious agent,infectious structure host role,0.658955223880597
immunization against infectious agent,pathogen vehicle,0.619811320754717
immunization against infectious agent,COVID-19 incidence rate,0.6166666666666667
immunization against infectious agent,pathogen vehicle role,0.6224137931034482
immunization against infectious agent,chronic infectious disease course,0.6928571428571427
immunization against infectious agent,asymptomatic infectious agent carrier,0.7472972972972972
immunization against infectious agent,descriptive information content entity,0.6633333333333334
immunization against infectious agent,COVID-19 epidemic,0.5611111111111111
immunization against infectious agent,sterilizing immunity to infectious agent,0.7876623376623377
immunization against infectious agent,diseased population,0.5928571428571429
immunization against infectious agent,virulence factor,0.6009433962264151
immunization against infectious agent,incubation end process boundary,0.6558823529411765
immunization against infectious agent,latency end temporal region,0.621875
immunization against infectious agent,innate immunity to infectious agent,0.8111111111111111
immunization against infectious agent,infectious structure,0.6605263157894737
immunization against infectious agent,static agent disposition,0.6795081967213115
immunization against infectious agent,T cell receptor complex,0.6
immunization against infectious agent,asymptomatic carrier role,0.6274193548387097
immunization against infectious agent,infectious structure host,0.6596774193548387
immunization against infectious agent,infectious agent population,0.7
immunization against infectious agent,respiratory system disease,0.6404761904761905
immunization against infectious agent,leukocyte-mediated immunity to infectious agent,0.7595238095238095
immunization against infectious agent,humoral immunity to infectious agent,0.8061643835616438
immunization against infectious agent,infectious disease control strategy,0.6583333333333334
immunization against infectious agent,infectious disease pandemic,0.66875
immunization against infectious agent,infectious structure generative stage,0.6797297297297297
immunization against infectious agent,viral disease course,0.6429824561403508
immunization against infectious agent,passive immunity to infectious agent,0.8061643835616438
immunization against infectious agent,infectious disposition,0.6703389830508475
immunization against infectious agent,vaccination against infectious agent,0.8883561643835617
immunization against infectious agent,susceptibility to infectious agent,0.7598591549295775
immunization against infectious agent,disease course,0.6264705882352941
immunization against infectious agent,infectious disease course,0.6758064516129032
immunization against infectious agent,acquired immunity to infectious agent,0.8013513513513513
immunization against infectious agent,COVID-19 disease incidence proportion,0.6256756756756756
immunization against infectious agent,coronavirus disease course,0.6563492063492063
immunization against infectious agent,asymptomatic carrier,0.6254385964912281
immunization against infectious agent,biological vehicle role,0.6
immunization against infectious agent,symptomatic infectious agent carrier,0.7513698630136986
immunization against infectious agent,intermediate host,0.6351851851851852
immunization against infectious agent,infectious disease prevalence,0.6621212121212122
immunization against infectious agent,infected population,0.6285714285714286
immunization against infectious agent,COVID-19 mortality rate,0.6
immunization against infectious agent,viral disease,0.61
immunization against infectious agent,disease,0.5636363636363636
immunization against infectious agent,symptomatic infectious structure carrier,0.6967532467532468
immunization against infectious agent,primary infectious disposition,0.6888059701492537
immunization against infectious agent,designative information content entity,0.6766666666666665
immunization against infectious agent,symptomatic carrier role,0.630327868852459
immunization against infectious agent,infectious pathogen transmissibility,0.6691780821917809
immunization against infectious agent,intermediate host role,0.6364406779661017
immunization against infectious agent,infectious human pathogen,0.6919354838709677
immunization against infectious agent,immunization against infectious agent,0.95
immunization against infectious agent,infectious agent host,0.7258620689655172
immunization against infectious agent,long-term non-progressing infectious disease course,0.6886363636363636
immunization against infectious agent,viral disease epidemic,0.6025423728813559
immunization against infectious agent,viral disease pandemic,0.6194915254237288
immunization against infectious agent,symptomatic carrier,0.6285714285714286
immunization against infectious agent,infectious disease endemicity,0.6772727272727272
immunization against infectious agent,function,0.6055555555555556
immunization against infectious agent,herd immunity to infectious organism,0.7650684931506849
immunization against infectious agent,pathogen transporter role,0.6435483870967742
immunization against infectious agent,infectious agent reservoir,0.7039682539682539
immunization against infectious agent,COVID-19 pandemic,0.5611111111111111
immunization against infectious agent,action specification,0.6956140350877194
immunization against infectious agent,infectious disease control objective specification,0.6454022988505748
immunization against infectious agent,opportunistic infectious disposition,0.6965753424657534
immunization against infectious agent,polymerase chain reaction,0.6596774193548387
immunization against infectious agent,COVID-19 disease course,0.6166666666666667
immunization against infectious agent,infectious disease incidence rate,0.6785714285714286
immunization against infectious agent,active immunization against infectious agent,0.9067901234567901
immunization against infectious agent,infectious agent,0.7518867924528303
immunization against infectious agent,establishment of a clinically abnormal colony,0.6207317073170732
immunization against infectious agent,coronavirus disease,0.6285714285714286
immunization against infectious agent,adhesion factor,0.6230769230769231
immunization against infectious agent,drug susceptibility of infectious agent,0.7394736842105263
immunization against infectious agent,static agent,0.6744897959183673
immunity to pathogen,extended organism,0.5851351351351352
immunity to pathogen,virus aggregate,0.6214285714285714
immunity to pathogen,source of infection,0.6294871794871795
immunity to pathogen,infectious disease mortality rate,0.619811320754717
immunity to pathogen,infection incidence rate profile,0.6230769230769231
immunity to pathogen,pathogen generative stage,0.6277777777777778
immunity to pathogen,pathogen portal of entry,0.6318181818181818
immunity to pathogen,subclinical coronavirus infection,0.619811320754717
immunity to pathogen,primary pathogen,0.7833333333333333
immunity to pathogen,infection end temporal region,0.6336734693877552
immunity to pathogen,drug-based immunosuppressed organism,0.6285714285714286
immunity to pathogen,infectious disease,0.6342105263157894
immunity to pathogen,double-stranded DNA virus,0.5611111111111111
immunity to pathogen,site of infection,0.6662162162162162
immunity to pathogen,immunocompetent organism,0.7
immunity to pathogen,pathogen portal of exit,0.636046511627907
immunity to pathogen,infectious disease incidence,0.6166666666666667
immunity to pathogen,reservoir of pathogen role,0.7108695652173913
immunity to pathogen,subclinical SARS-CoV-2 infection,0.6230769230769231
immunity to pathogen,virus translation stage,0.6593023255813953
immunity to pathogen,disease surveillance objective specification,0.621875
immunity to pathogen,virus release stage,0.6294871794871795
immunity to pathogen,infectious agent host role,0.6673913043478261
immunity to pathogen,source of infection site,0.609090909090909
immunity to pathogen,virus,0.53
immunity to pathogen,virus replication,0.6662162162162162
immunity to pathogen,B cell receptor complex,0.5895348837209302
immunity to pathogen,passive immunization against infectious agent,0.6807692307692308
immunity to pathogen,systematic infection,0.6
immunity to pathogen,infection incidence rate,0.6318181818181818
immunity to pathogen,virus host,0.6166666666666667
immunity to pathogen,double-stranded RNA virus,0.5611111111111111
immunity to pathogen,pathogen portal of entry role,0.6132653061224489
immunity to pathogen,virus transcription stage,0.6722222222222223
immunity to pathogen,infectious disease lifetime prevalence,0.6224137931034482
immunity to pathogen,pathogen birth temporal region,0.63
immunity to pathogen,lower respiratory tract disease,0.6068627450980393
immunity to pathogen,infectious disease incidence proportion,0.6194915254237288
immunity to pathogen,opportunistic pathogen,0.7595238095238095
immunity to pathogen,virus generative stage,0.6642857142857143
immunity to pathogen,acute infectious disease course,0.6264705882352941
immunity to pathogen,cidal agent disposition,0.636046511627907
immunity to pathogen,genetic resistance to pathogen,0.75
immunity to pathogen,subclinical infection,0.6207317073170732
immunity to pathogen,simple infection,0.6166666666666667
immunity to pathogen,droplet pathogen transmission process,0.6254385964912281
immunity to pathogen,infectious disease sporadicity,0.61
immunity to pathogen,infection incidence proportion profile,0.6224137931034482
immunity to pathogen,infectious agent colony,0.6593023255813953
immunity to pathogen,pathogen transporter,0.65
immunity to pathogen,infectious disease epidemic,0.598936170212766
immunity to pathogen,infectious agent generative stage,0.6386792452830189
immunity to pathogen,disease transmission model,0.6021739130434782
immunity to pathogen,pathologically immunosuppressed organism,0.6166666666666667
immunity to pathogen,negative-sense single-stranded RNA virus,0.5666666666666667
immunity to pathogen,cidal agent,0.6435483870967742
immunity to pathogen,pathogen vehicle,0.6722222222222223
immunity to pathogen,community-acquired infection,0.6791666666666666
immunity to pathogen,pathogen vector,0.6785714285714286
immunity to pathogen,antibiotic resistance,0.6207317073170732
immunity to pathogen,pathogen vehicle role,0.6451219512195122
immunity to pathogen,chronic infectious disease course,0.619811320754717
immunity to pathogen,asymptomatic infectious agent carrier,0.6429824561403508
immunity to pathogen,nursing-home acquired infection,0.6068627450980393
immunity to pathogen,secondary infection,0.6038461538461539
immunity to pathogen,infection start temporal region,0.6460784313725491
immunity to pathogen,infection incidence,0.6294871794871795
immunity to pathogen,virus disorder,0.5970588235294118
immunity to pathogen,resistance to drug,0.6342105263157894
immunity to pathogen,sterilizing immunity to infectious agent,0.7333333333333333
immunity to pathogen,primary infection,0.6391891891891892
immunity to pathogen,process of establishing an infection,0.5928571428571429
immunity to pathogen,pathogen death process boundary,0.6264705882352941
immunity to pathogen,immunosuppressed organism,0.6722222222222223
immunity to pathogen,innate immunity to infectious agent,0.759090909090909
immunity to pathogen,virus adhesion susceptible cell,0.6068627450980393
immunity to pathogen,infection,0.6224137931034482
immunity to pathogen,static agent disposition,0.6318181818181818
immunity to pathogen,T cell receptor complex,0.6127906976744186
immunity to pathogen,infectious agent population,0.6840425531914894
immunity to pathogen,respiratory system disease,0.6239130434782608
immunity to pathogen,leukocyte-mediated immunity to infectious agent,0.703731343283582
immunity to pathogen,indirect pathogen transmission process,0.6741379310344828
immunity to pathogen,organism population,0.6807692307692308
immunity to pathogen,humoral immunity to infectious agent,0.7535714285714286
immunity to pathogen,infectious disease control strategy,0.6318181818181818
immunity to pathogen,parasite,0.5928571428571429
immunity to pathogen,infectious disease pandemic,0.6202127659574468
immunity to pathogen,antibody reagent,0.6722222222222223
immunity to pathogen,viral disease course,0.575
immunity to pathogen,intracellular infection,0.6127906976744186
immunity to pathogen,secondary infection role,0.6318181818181818
immunity to pathogen,metastatic infection,0.625
immunity to pathogen,passive immunity to infectious agent,0.7535714285714286
immunity to pathogen,vaccination against infectious agent,0.6642857142857143
immunity to pathogen,acute infection,0.6214285714285714
immunity to pathogen,susceptibility to infectious agent,0.6907407407407408
immunity to pathogen,epitope site,0.6375
immunity to pathogen,immunity to pathogen,0.95
immunity to pathogen,source of infection role,0.609090909090909
immunity to pathogen,pathogen host,0.6924242424242425
immunity to pathogen,chronic infection,0.6121621621621621
immunity to pathogen,disease course,0.5676470588235294
immunity to pathogen,infectious disease course,0.6277777777777778
immunity to pathogen,acquired immunity to infectious agent,0.7482456140350877
immunity to pathogen,complex infection,0.5851351351351352
immunity to pathogen,COVID-19 disease incidence proportion,0.6078947368421053
immunity to pathogen,coronavirus disease course,0.5804347826086956
immunity to pathogen,infection incidence proportion,0.63
immunity to pathogen,symptomatic infectious agent carrier,0.6464285714285714
immunity to pathogen,respiratory droplet virus fomite,0.6230769230769231
immunity to pathogen,susceptible organism,0.6
immunity to pathogen,parasite role,0.6015151515151516
immunity to pathogen,pathogen vector role,0.65
immunity to pathogen,pathogen portal of exit site,0.6166666666666667
immunity to pathogen,infectious disease prevalence,0.6336734693877552
immunity to pathogen,organism substance,0.6078947368421053
immunity to pathogen,single-stranded DNA virus,0.5833333333333334
immunity to pathogen,viral disease,0.5712121212121213
immunity to pathogen,primary infection role,0.6642857142857143
immunity to pathogen,leukocyte mediated immunity,0.6202127659574468
immunity to pathogen,pathogen portal of entry site,0.6132653061224489
immunity to pathogen,infection incidence profile,0.6202127659574468
immunity to pathogen,disease,0.5611111111111111
immunity to pathogen,site,0.575
immunity to pathogen,pathogen host role,0.6605263157894737
immunity to pathogen,infection prevalence,0.675
immunity to pathogen,infectious pathogen transmissibility,0.6821428571428573
immunity to pathogen,pathogen surveillance,0.6451219512195122
immunity to pathogen,immunodeficient organism,0.7
immunity to pathogen,pathogen,0.7357142857142857
immunity to pathogen,pathogen birth process boundary,0.6068627450980393
immunity to pathogen,infectious human pathogen,0.7388888888888888
immunity to pathogen,subclinical virus infection,0.6202127659574468
immunity to pathogen,resistance to pathogen,0.7833333333333333
immunity to pathogen,establishment of localization in virus host,0.6246031746031746
immunity to pathogen,immunization against infectious agent,0.7131578947368421
immunity to pathogen,virus attachment stage,0.6642857142857143
immunity to pathogen,virus synthesis stage,0.6695121951219513
immunity to pathogen,pathogen portal of exit role,0.6166666666666667
immunity to pathogen,infectious agent host,0.6695121951219513
immunity to pathogen,re-emerging pathogen,0.725
immunity to pathogen,long-term non-progressing infectious disease course,0.5908450704225352
immunity to pathogen,viral disease epidemic,0.569047619047619
immunity to pathogen,viral disease pandemic,0.5928571428571429
immunity to pathogen,virus penetration stage,0.6825581395348838
immunity to pathogen,pathogen seroprevalence,0.636046511627907
immunity to pathogen,infectious disease endemicity,0.6132653061224489
immunity to pathogen,contact pathogen transmission process,0.6605263157894737
immunity to pathogen,herd immunity to infectious organism,0.7357142857142857
immunity to pathogen,extracellular infection,0.5662790697674418
immunity to pathogen,pathogen transporter role,0.6277777777777778
immunity to pathogen,infectious agent reservoir,0.6456521739130434
immunity to pathogen,infection start process boundary,0.6423076923076922
immunity to pathogen,protective resistance,0.5719512195121951
immunity to pathogen,infectious disease control objective specification,0.6214285714285714
immunity to pathogen,process of establishing viral infection,0.5855932203389831
immunity to pathogen,COVID-19 disease course,0.5662790697674418
immunity to pathogen,infectious disease incidence rate,0.6009433962264151
immunity to pathogen,active immunization against infectious agent,0.684375
immunity to pathogen,disordered virus,0.5333333333333333
immunity to pathogen,collective resistance disposition,0.6009433962264151
immunity to pathogen,organism,0.5571428571428572
immunity to pathogen,virus uncoating stage,0.6695121951219513
immunity to pathogen,local infection,0.5928571428571429
immunity to pathogen,infectious agent,0.7
immunity to pathogen,establishment of a clinically abnormal colony,0.6038461538461539
immunity to pathogen,coronavirus disease,0.5782051282051281
immunity to pathogen,positive-sense single-stranded RNA virus,0.5666666666666667
immunity to pathogen,horizontal pathogen transmission process,0.65
immunity to pathogen,hospital-acquired infection,0.598936170212766
immunity to pathogen,pathogen death temporal region,0.63
immunity to pathogen,emerging pathogen,0.7472972972972972
immunity to pathogen,drug susceptibility of infectious agent,0.6533898305084747
immunity to pathogen,SARS-CoV-2 release stage,0.5863636363636363
immunity to pathogen,static agent,0.66875
immunity to pathogen,pathogen transmission process,0.6132653061224489
processed material,information content entity,0.609090909090909
processed material,infectious disease mortality rate,0.6460784313725491
processed material,infection incidence rate profile,0.67
processed material,geographical entity,0.5851351351351352
processed material,primary pathogen,0.6264705882352941
processed material,surveillance process,0.6342105263157894
processed material,SARS-CoV-2 incidence rate,0.6593023255813953
processed material,double-stranded DNA virus,0.636046511627907
processed material,site of infection,0.5928571428571429
processed material,resistant entity,0.6852941176470588
processed material,double-stranded DNA,0.6391891891891892
processed material,disease surveillance objective specification,0.5951612903225807
processed material,material entity,0.6924242424242425
processed material,source of infection site,0.6166666666666667
processed material,B cell receptor complex,0.5963414634146341
processed material,infection incidence rate,0.6404761904761905
processed material,entity,0.575
processed material,double-stranded RNA virus,0.636046511627907
processed material,process,0.73
processed material,droplet pathogen transmission process,0.6136363636363636
processed material,communicability end process boundary,0.6351851851851852
processed material,directive information content entity,0.6166666666666667
processed material,latency end process boundary,0.6673913043478261
processed material,realizable entity,0.6214285714285714
processed material,negative-sense single-stranded RNA virus,0.6051724137931035
processed material,COVID-19 incidence rate,0.6451219512195122
processed material,negative regulation of developmental process,0.5790322580645162
processed material,descriptive information content entity,0.6107142857142857
processed material,primary infection,0.6214285714285714
processed material,process of establishing an infection,0.6722222222222223
processed material,incubation end process boundary,0.6540816326530612
processed material,pathogen death process boundary,0.6540816326530612
processed material,molecular entity,0.5970588235294118
processed material,plan specification,0.6166666666666667
processed material,T cell receptor complex,0.5963414634146341
processed material,respiratory system disease,0.6545454545454545
processed material,indirect pathogen transmission process,0.5928571428571429
processed material,planned process,0.6621212121212122
processed material,objective specification,0.6451219512195122
processed material,epitope site,0.65
processed material,pathogen portal of exit site,0.6021739130434782
processed material,organism substance,0.5888888888888889
processed material,anatomical entity,0.5928571428571429
processed material,single-stranded DNA virus,0.6127906976744186
processed material,COVID-19 mortality rate,0.6451219512195122
processed material,process profile,0.7833333333333333
processed material,negative regulation of life-sustaining process,0.559375
processed material,geopolitical entity,0.6121621621621621
processed material,primary infection role,0.625
processed material,primary immunodeficiency,0.5928571428571429
processed material,pathogen portal of entry site,0.6202127659574468
processed material,developmental process,0.6294871794871795
processed material,biological process,0.6444444444444444
processed material,site,0.5863636363636363
processed material,primary infectious disposition,0.5958333333333333
processed material,designative information content entity,0.6107142857142857
processed material,double-stranded DNA retrovirus,0.6583333333333334
processed material,incubation start process boundary,0.6460784313725491
processed material,object,0.575
processed material,pathogen birth process boundary,0.6540816326530612
processed material,immaterial entity,0.6785714285714286
processed material,object aggregate,0.6264705882352941
processed material,division of geopolitical entity,0.5724489795918367
processed material,negative regulation of viral process,0.5981481481481481
processed material,contact pathogen transmission process,0.5954545454545455
processed material,symbiotic process,0.65
processed material,infection start process boundary,0.65
processed material,processed material,0.95
processed material,latency start process boundary,0.6583333333333334
processed material,infectious disease control objective specification,0.5823529411764706
processed material,process of establishing viral infection,0.6605263157894737
processed material,negative regulation of biological process,0.5855932203389831
processed material,infectious disease incidence rate,0.6264705882352941
processed material,communicability start process boundary,0.6285714285714286
processed material,process that results in death,0.7265957446808511
processed material,single-stranded RNA retrovirus,0.6375
processed material,establishment of a clinically abnormal colony,0.5928571428571429
processed material,process boundary,0.7441176470588234
processed material,positive-sense single-stranded RNA virus,0.6396551724137931
processed material,horizontal pathogen transmission process,0.5879310344827586
processed material,pathogen transmission process,0.598936170212766
processed material,material processing,0.6662162162162162
reverse zoonotic disposition,virostatic disposition,0.81
reverse zoonotic disposition,information content entity,0.5981481481481481
reverse zoonotic disposition,zoonotic disposition,0.8666666666666667
reverse zoonotic disposition,infectious disease mortality rate,0.6139344262295081
reverse zoonotic disposition,infection incidence rate profile,0.6
reverse zoonotic disposition,infectious structure aggregate,0.5706896551724138
reverse zoonotic disposition,communicability end temporal region,0.6246031746031746
reverse zoonotic disposition,geographical entity,0.598936170212766
reverse zoonotic disposition,biological regulation,0.6336734693877552
reverse zoonotic disposition,surveillance process,0.6375
reverse zoonotic disposition,infection end temporal region,0.6254385964912281
reverse zoonotic disposition,vector control strategy,0.6460784313725491
reverse zoonotic disposition,SARS-CoV-2 incidence rate,0.6009433962264151
reverse zoonotic disposition,incubation end temporal region,0.6224137931034482
reverse zoonotic disposition,resistant entity,0.6318181818181818
reverse zoonotic disposition,virulence factor disposition,0.7535714285714286
reverse zoonotic disposition,viral adhesion disposition,0.7648148148148148
reverse zoonotic disposition,parasitostatic disposition,0.7833333333333333
reverse zoonotic disposition,negative regulation of production,0.6959016393442623
reverse zoonotic disposition,reverse zoonotic disposition,0.95
reverse zoonotic disposition,establishment of localization in host,0.65
reverse zoonotic disposition,disease surveillance objective specification,0.6722222222222223
reverse zoonotic disposition,case isolation control strategy,0.6364406779661017
reverse zoonotic disposition,infectious agent host role,0.6351851851851852
reverse zoonotic disposition,macromolecular complex,0.57
reverse zoonotic disposition,material entity,0.6127906976744186
reverse zoonotic disposition,asymptomatic infectious structure carrier,0.6094202898550725
reverse zoonotic disposition,architectual structure,0.57
reverse zoonotic disposition,quarantine control strategy,0.6136363636363636
reverse zoonotic disposition,B cell receptor complex,0.5872549019607843
reverse zoonotic disposition,infection incidence rate,0.5846153846153846
reverse zoonotic disposition,colonized host,0.6404761904761905
reverse zoonotic disposition,virus host,0.6342105263157894
reverse zoonotic disposition,entity,0.5970588235294118
reverse zoonotic disposition,double-stranded RNA virus,0.6009433962264151
reverse zoonotic disposition,toxin disposition,0.7611111111111112
reverse zoonotic disposition,lower respiratory tract disease,0.6364406779661017
reverse zoonotic disposition,cidal agent disposition,0.7441176470588234
reverse zoonotic disposition,parasiticidal disposition,0.7707547169811321
reverse zoonotic disposition,communicability end process boundary,0.621875
reverse zoonotic disposition,directive information content entity,0.653125
reverse zoonotic disposition,acellular structure aggregate,0.5728070175438597
reverse zoonotic disposition,transmissibility disposition,0.7178571428571427
reverse zoonotic disposition,latency end process boundary,0.6285714285714286
reverse zoonotic disposition,colonization of host,0.6375
reverse zoonotic disposition,realizable entity,0.6277777777777778
reverse zoonotic disposition,endotoxin disposition,0.7969387755102041
reverse zoonotic disposition,vector surveillance,0.598936170212766
reverse zoonotic disposition,negative regulation of establishment of localization,0.6625
reverse zoonotic disposition,negative-sense single-stranded RNA virus,0.6117647058823529
reverse zoonotic disposition,infectious structure host role,0.6224137931034482
reverse zoonotic disposition,COVID-19 incidence rate,0.5872549019607843
reverse zoonotic disposition,cytotoxin disposition,0.7561224489795919
reverse zoonotic disposition,negative regulation of developmental process,0.6444444444444444
reverse zoonotic disposition,host,0.54375
reverse zoonotic disposition,descriptive information content entity,0.6318181818181818
reverse zoonotic disposition,negative regulation of replication,0.6919354838709677
reverse zoonotic disposition,establishment of localization in human host,0.6330985915492958
reverse zoonotic disposition,acellular structure,0.5776595744680851
reverse zoonotic disposition,incubation end process boundary,0.6194915254237288
reverse zoonotic disposition,collective pathogenic disposition,0.7778688524590163
reverse zoonotic disposition,neurotoxin disposition,0.79
reverse zoonotic disposition,dead-end host role,0.6239130434782608
reverse zoonotic disposition,pathogen death process boundary,0.6025423728813559
reverse zoonotic disposition,molecular entity,0.609090909090909
reverse zoonotic disposition,plan specification,0.6456521739130434
reverse zoonotic disposition,definitive host role,0.6375
reverse zoonotic disposition,latency end temporal region,0.6318181818181818
reverse zoonotic disposition,infectious structure,0.575
reverse zoonotic disposition,collective disposition,0.75
reverse zoonotic disposition,static agent disposition,0.7576923076923078
reverse zoonotic disposition,T cell receptor complex,0.5872549019607843
reverse zoonotic disposition,infectious structure host,0.619811320754717
reverse zoonotic disposition,respiratory system disease,0.6351851851851852
reverse zoonotic disposition,entry into host,0.6593023255813953
reverse zoonotic disposition,adhesion of symbiont to host,0.6464285714285714
reverse zoonotic disposition,infectious disease control strategy,0.6246031746031746
reverse zoonotic disposition,infectious structure generative stage,0.6038461538461539
reverse zoonotic disposition,immunosuppressive disposition,0.730701754385965
reverse zoonotic disposition,reverse zoonosis,0.7909090909090909
reverse zoonotic disposition,pathogenic disposition,0.77
reverse zoonotic disposition,entry into host through host barriers,0.6192307692307693
reverse zoonotic disposition,infectious disposition,0.75
reverse zoonotic disposition,bacteriostatic disposition,0.7833333333333333
reverse zoonotic disposition,bactericidal disposition,0.7576923076923078
reverse zoonotic disposition,pathogen host,0.5963414634146341
reverse zoonotic disposition,invasion disposition,0.7833333333333333
reverse zoonotic disposition,viricidal disposition,0.7765306122448979
reverse zoonotic disposition,complex infection,0.6277777777777778
reverse zoonotic disposition,intermediate host,0.6277777777777778
reverse zoonotic disposition,anatomical entity,0.6055555555555556
reverse zoonotic disposition,disposition,0.732051282051282
reverse zoonotic disposition,COVID-19 mortality rate,0.5872549019607843
reverse zoonotic disposition,reverse transcribed PCR,0.6852941176470588
reverse zoonotic disposition,negative regulation of life-sustaining process,0.6527027027027027
reverse zoonotic disposition,place closure control strategy,0.6224137931034482
reverse zoonotic disposition,geopolitical entity,0.6414893617021277
reverse zoonotic disposition,adhesion disposition,0.7833333333333333
reverse zoonotic disposition,symptomatic infectious structure carrier,0.6117647058823529
reverse zoonotic disposition,primary infectious disposition,0.760344827586207
reverse zoonotic disposition,pathogen host role,0.6021739130434782
reverse zoonotic disposition,designative information content entity,0.6318181818181818
reverse zoonotic disposition,intermediate host role,0.63
reverse zoonotic disposition,dead-end host,0.6207317073170732
reverse zoonotic disposition,pathogen surveillance,0.5724489795918367
reverse zoonotic disposition,host role,0.5581081081081081
reverse zoonotic disposition,establishment of localization in virus host,0.6471830985915493
reverse zoonotic disposition,negative regulation of immune response,0.6621212121212122
reverse zoonotic disposition,immaterial entity,0.6055555555555556
reverse zoonotic disposition,SARS-COV-2 adhesion disposition,0.7550847457627118
reverse zoonotic disposition,invasive disposition,0.7625
reverse zoonotic disposition,infectious agent host,0.6336734693877552
reverse zoonotic disposition,fungicidal disposition,0.75
reverse zoonotic disposition,acute respiratory distress syndrome,0.6087301587301588
reverse zoonotic disposition,division of geopolitical entity,0.6533898305084747
reverse zoonotic disposition,negative regulation of viral process,0.653125
reverse zoonotic disposition,exotoxin disposition,0.7833333333333333
reverse zoonotic disposition,immunoglobulin complex,0.55
reverse zoonotic disposition,action specification,0.6583333333333334
reverse zoonotic disposition,infectious disease control objective specification,0.6807692307692308
reverse zoonotic disposition,symbiont host role,0.6456521739130434
reverse zoonotic disposition,opportunistic infectious disposition,0.73125
reverse zoonotic disposition,negative regulation of biological process,0.6673913043478261
reverse zoonotic disposition,enterotoxin disposition,0.8029411764705883
reverse zoonotic disposition,infectious disease incidence rate,0.630327868852459
reverse zoonotic disposition,process that results in death,0.6254385964912281
reverse zoonotic disposition,single-stranded RNA retrovirus,0.5879310344827586
reverse zoonotic disposition,collective resistance disposition,0.7614754098360657
reverse zoonotic disposition,fungistatic disposition,0.7637254901960785
reverse zoonotic disposition,establishment of a clinically abnormal colony,0.6143835616438357
reverse zoonotic disposition,positive-sense single-stranded RNA virus,0.5970588235294118
reverse zoonotic disposition,definitive host,0.636046511627907
reverse zoonotic disposition,pathogen death temporal region,0.6051724137931035
ribonucleic acid,ribonucleic acid,0.95
ribonucleic acid,infectious disease mortality rate,0.5928571428571429
ribonucleic acid,infection incidence rate profile,0.6375
ribonucleic acid,deoxyribonucleic acid,0.8824324324324324
ribonucleic acid,SARS-CoV-2 incidence rate,0.6451219512195122
ribonucleic acid,B cell receptor complex,0.6294871794871795
ribonucleic acid,infection incidence rate,0.65
ribonucleic acid,drug susceptibility,0.6214285714285714
ribonucleic acid,COVID-19 incidence rate,0.6294871794871795
ribonucleic acid,nucleic acid,0.8785714285714286
ribonucleic acid,resistance to drug,0.6558823529411765
ribonucleic acid,T cell receptor complex,0.6038461538461539
ribonucleic acid,COVID-19 mortality rate,0.6038461538461539
ribonucleic acid,infectious disease incidence rate,0.6336734693877552
ribonucleic acid,establishment of a clinically abnormal colony,0.5975409836065574
ribonucleic acid,drug susceptibility of infectious agent,0.6136363636363636
bacteriophage,B cell receptor complex,0.6444444444444444
bacteriophage,T cell receptor complex,0.6166666666666667
bacteriophage,bacteriophage,0.95
bacteriophage,establishment of a clinically abnormal colony,0.553448275862069
infectious disease course,virus aggregate,0.625
infectious disease course,source of infection,0.6318181818181818
infectious disease course,virostatic disposition,0.6414893617021277
infectious disease course,zoonotic disposition,0.65
infectious disease course,infectious disease mortality rate,0.8293103448275861
infectious disease course,infection incidence rate profile,0.730701754385965
infectious disease course,infectious structure aggregate,0.740909090909091
infectious disease course,communicability end temporal region,0.6166666666666667
infectious disease course,pathogen portal of entry,0.5928571428571429
infectious disease course,subclinical coronavirus infection,0.6396551724137931
infectious disease course,infection end temporal region,0.7277777777777777
infectious disease course,infectious disease,0.8686046511627907
infectious disease course,double-stranded DNA virus,0.63
infectious disease course,incubation end temporal region,0.6863636363636364
infectious disease course,site of infection,0.6404761904761905
infectious disease course,virulence factor disposition,0.6764150943396227
infectious disease course,viral adhesion disposition,0.6460784313725491
infectious disease course,parasitostatic disposition,0.6460784313725491
infectious disease course,infectious disease incidence,0.8462264150943396
infectious disease course,reverse zoonotic disposition,0.619811320754717
infectious disease course,subclinical SARS-CoV-2 infection,0.6254385964912281
infectious disease course,virus translation stage,0.6375
infectious disease course,disease surveillance objective specification,0.6239130434782608
infectious disease course,virus release stage,0.7
infectious disease course,infectious agent host role,0.7833333333333333
infectious disease course,asymptomatic infectious structure carrier,0.7075757575757575
infectious disease course,source of infection site,0.6744897959183673
infectious disease course,virus,0.55
infectious disease course,virus replication,0.6166666666666667
infectious disease course,B cell receptor complex,0.6166666666666667
infectious disease course,passive immunization against infectious agent,0.65
infectious disease course,systematic infection,0.6277777777777778
infectious disease course,infection incidence rate,0.7561224489795919
infectious disease course,virus host,0.6214285714285714
infectious disease course,double-stranded RNA virus,0.63
infectious disease course,pathogen portal of entry role,0.5981481481481481
infectious disease course,virus transcription stage,0.65
infectious disease course,infectious disease lifetime prevalence,0.7833333333333333
infectious disease course,toxin disposition,0.6404761904761905
infectious disease course,lower respiratory tract disease,0.6464285714285714
infectious disease course,infectious disease incidence proportion,0.79375
infectious disease course,virus generative stage,0.6627659574468084
infectious disease course,acute infectious disease course,0.8964285714285714
infectious disease course,cidal agent disposition,0.6375
infectious disease course,infectious disorder,0.8363636363636363
infectious disease course,subclinical infection,0.6239130434782608
infectious disease course,appearance of disorder,0.6627659574468084
infectious disease course,simple infection,0.6451219512195122
infectious disease course,parasiticidal disposition,0.63
infectious disease course,infectious disease sporadicity,0.8318181818181819
infectious disease course,communicability end process boundary,0.630327868852459
infectious disease course,infection incidence proportion profile,0.7039682539682539
infectious disease course,infectious agent colony,0.7833333333333333
infectious disease course,transmissibility disposition,0.619811320754717
infectious disease course,latency end process boundary,0.6386792452830189
infectious disease course,infectious disease epidemic,0.8346153846153846
infectious disease course,infectious agent generative stage,0.743103448275862
infectious disease course,disease transmission model,0.6656862745098039
infectious disease course,endotoxin disposition,0.6456521739130434
infectious disease course,negative-sense single-stranded RNA virus,0.65
infectious disease course,infectious structure host role,0.759090909090909
infectious disease course,cytotoxin disposition,0.6456521739130434
infectious disease course,community-acquired infection,0.619811320754717
infectious disease course,chronic infectious disease course,0.8810344827586206
infectious disease course,asymptomatic infectious agent carrier,0.7241935483870968
infectious disease course,nursing-home acquired infection,0.6285714285714286
infectious disease course,COVID-19 epidemic,0.5928571428571429
infectious disease course,secondary infection,0.6318181818181818
infectious disease course,infection start temporal region,0.7178571428571427
infectious disease course,infection incidence,0.7454545454545455
infectious disease course,virus disorder,0.7064102564102563
infectious disease course,sterilizing immunity to infectious agent,0.65
infectious disease course,diseased population,0.6772727272727272
infectious disease course,primary infection,0.6404761904761905
infectious disease course,process of establishing an infection,0.6139344262295081
infectious disease course,incubation end process boundary,0.7
infectious disease course,SARS-CoV-2 disorder,0.6545454545454545
infectious disease course,collective pathogenic disposition,0.6396551724137931
infectious disease course,neurotoxin disposition,0.6627659574468084
infectious disease course,plan specification,0.6127906976744186
infectious disease course,latency end temporal region,0.6230769230769231
infectious disease course,innate immunity to infectious agent,0.6666666666666667
infectious disease course,infectious structure,0.8055555555555556
infectious disease course,virus adhesion susceptible cell,0.6642857142857143
infectious disease course,collective disposition,0.6627659574468084
infectious disease course,infection,0.6852941176470588
infectious disease course,static agent disposition,0.6336734693877552
infectious disease course,T cell receptor complex,0.6166666666666667
infectious disease course,infectious structure host,0.77
infectious disease course,infectious agent population,0.7576923076923078
infectious disease course,respiratory system disease,0.6852941176470588
infectious disease course,entry into host,0.625
infectious disease course,leukocyte-mediated immunity to infectious agent,0.6305555555555555
infectious disease course,humoral immunity to infectious agent,0.6631147540983606
infectious disease course,infectious disease control strategy,0.85
infectious disease course,infectious disease pandemic,0.8346153846153846
infectious disease course,infectious structure generative stage,0.7403225806451613
infectious disease course,immunosuppressive disposition,0.6537037037037037
infectious disease course,pathogenic disposition,0.6202127659574468
infectious disease course,viral disease course,0.8055555555555556
infectious disease course,entry into host through host barriers,0.6274193548387097
infectious disease course,intracellular infection,0.6375
infectious disease course,secondary infection role,0.6744897959183673
infectious disease course,metastatic infection,0.6277777777777778
infectious disease course,passive immunity to infectious agent,0.6631147540983606
infectious disease course,infectious disposition,0.7904255319148936
infectious disease course,vaccination against infectious agent,0.6795081967213115
infectious disease course,objective specification,0.6375
infectious disease course,acute infection,0.65
infectious disease course,susceptibility to infectious agent,0.6703389830508475
infectious disease course,bacteriostatic disposition,0.6656862745098039
infectious disease course,bactericidal disposition,0.6336734693877552
infectious disease course,source of infection role,0.6744897959183673
infectious disease course,chronic infection,0.6404761904761905
infectious disease course,invasion disposition,0.6722222222222223
infectious disease course,disease course,0.808974358974359
infectious disease course,infectious disease course,0.95
infectious disease course,viricidal disposition,0.6456521739130434
infectious disease course,acquired immunity to infectious agent,0.6596774193548387
infectious disease course,complex infection,0.6404761904761905
infectious disease course,COVID-19 disease incidence proportion,0.6758064516129032
infectious disease course,coronavirus disease course,0.8225490196078431
infectious disease course,infection incidence proportion,0.7227272727272727
infectious disease course,symptomatic infectious agent carrier,0.728688524590164
infectious disease course,respiratory droplet virus fomite,0.6254385964912281
infectious disease course,infectious disease prevalence,0.8388888888888889
infectious disease course,disposition,0.5888888888888889
infectious disease course,single-stranded DNA virus,0.65
infectious disease course,infected population,0.6772727272727272
infectious disease course,contact tracing,0.6
infectious disease course,viral disease,0.6868421052631578
infectious disease course,primary infection role,0.6840425531914894
infectious disease course,adhesion disposition,0.65
infectious disease course,pathogen portal of entry site,0.6166666666666667
infectious disease course,infection incidence profile,0.7384615384615384
infectious disease course,disease,0.66875
infectious disease course,symptomatic infectious structure carrier,0.7115384615384616
infectious disease course,primary infectious disposition,0.740909090909091
infectious disease course,infection prevalence,0.7611111111111112
infectious disease course,coronavirus disorder,0.6944444444444444
infectious disease course,infectious pathogen transmissibility,0.7122950819672131
infectious disease course,object,0.5467741935483871
infectious disease course,infectious human pathogen,0.75
infectious disease course,subclinical virus infection,0.6615384615384616
infectious disease course,establishment of localization in virus host,0.6411764705882353
infectious disease course,immunization against infectious agent,0.6758064516129032
infectious disease course,virus attachment stage,0.6414893617021277
infectious disease course,virus synthesis stage,0.6673913043478261
infectious disease course,SARS-COV-2 adhesion disposition,0.6107142857142857
infectious disease course,object aggregate,0.6207317073170732
infectious disease course,invasive disposition,0.65
infectious disease course,infectious agent host,0.7978260869565217
infectious disease course,long-term non-progressing infectious disease course,0.7789473684210526
infectious disease course,viral disease epidemic,0.6840425531914894
infectious disease course,fungicidal disposition,0.6414893617021277
infectious disease course,viral disease pandemic,0.6840425531914894
infectious disease course,virus penetration stage,0.6583333333333334
infectious disease course,acute respiratory distress syndrome,0.6666666666666667
infectious disease course,infectious disease endemicity,0.8203703703703704
infectious disease course,contact pathogen transmission process,0.6274193548387097
infectious disease course,disorder,0.6318181818181818
infectious disease course,herd immunity to infectious organism,0.6795081967213115
infectious disease course,extracellular infection,0.6166666666666667
infectious disease course,exotoxin disposition,0.65
infectious disease course,infectious agent reservoir,0.7833333333333333
infectious disease course,COVID-19 pandemic,0.5928571428571429
infectious disease course,infection start process boundary,0.730701754385965
infectious disease course,infectious disease control objective specification,0.77
infectious disease course,opportunistic infectious disposition,0.7122950819672131
infectious disease course,process of establishing viral infection,0.621875
infectious disease course,enterotoxin disposition,0.6583333333333334
infectious disease course,polymerase chain reaction,0.63
infectious disease course,COVID-19 disease course,0.8041666666666667
infectious disease course,infectious disease incidence rate,0.8293103448275861
infectious disease course,active immunization against infectious agent,0.6528985507246376
infectious disease course,disordered virus,0.6451219512195122
infectious disease course,collective resistance disposition,0.656896551724138
infectious disease course,fungistatic disposition,0.6375
infectious disease course,virus uncoating stage,0.6456521739130434
infectious disease course,local infection,0.65
infectious disease course,infectious agent,0.7670731707317073
infectious disease course,establishment of a clinically abnormal colony,0.5928571428571429
infectious disease course,coronavirus disease,0.7227272727272727
infectious disease course,positive-sense single-stranded RNA virus,0.6346153846153847
infectious disease course,hospital-acquired infection,0.6038461538461539
infectious disease course,drug susceptibility of infectious agent,0.653125
immune population,angiotensin-converting enzyme 2,0.575
immune population,immune response,0.7625
immune population,infectious disease mortality rate,0.61
immune population,infection incidence rate profile,0.5928571428571429
immune population,communicability end temporal region,0.6807692307692308
immune population,infection end temporal region,0.6673913043478261
immune population,SARS-CoV-2 incidence rate,0.5928571428571429
immune population,incubation end temporal region,0.6840425531914894
immune population,resistant entity,0.6015151515151516
immune population,normal resident microbiota population,0.6907407407407408
immune population,reservoir of pathogen role,0.636046511627907
immune population,virus release stage,0.6166666666666667
immune population,infectious agent host role,0.636046511627907
immune population,B cell receptor complex,0.6
immune population,passive immunization against infectious agent,0.6274193548387097
immune population,infection incidence rate,0.6207317073170732
immune population,pathogen portal of entry role,0.6021739130434782
immune population,lower respiratory tract disease,0.5958333333333333
immune population,role,0.5452380952380953
immune population,mutualist role,0.6435483870967742
immune population,communicability end process boundary,0.6386792452830189
immune population,latency end process boundary,0.6055555555555556
immune population,infectious structure host role,0.598936170212766
immune population,susceptible population,0.7833333333333333
immune population,COVID-19 incidence rate,0.6
immune population,pathogen vehicle role,0.581578947368421
immune population,mechanical vector role,0.6038461538461539
immune population,establishment of localization in human host,0.6333333333333333
immune population,diseased population,0.8111111111111111
immune population,incubation end process boundary,0.6375
immune population,dead-end host role,0.5928571428571429
immune population,definitive host role,0.6391891891891892
immune population,latency end temporal region,0.6545454545454545
immune population,virus adhesion susceptible cell,0.5958333333333333
immune population,T cell receptor complex,0.6
immune population,asymptomatic carrier role,0.6166666666666667
immune population,infectious agent population,0.7681818181818181
immune population,organism population,0.8111111111111111
immune population,innate immune response,0.7064102564102563
immune population,secondary infection role,0.6207317073170732
immune population,passive immunity to infectious agent,0.6575471698113208
immune population,country,0.575
immune population,source of infection role,0.6451219512195122
immune population,biological vehicle role,0.6
immune population,symbiont role,0.6166666666666667
immune population,susceptible organism,0.6391891891891892
immune population,parasite role,0.6166666666666667
immune population,pathogen vector role,0.5851351351351352
immune population,infected population,0.8388888888888889
immune population,COVID-19 mortality rate,0.6
immune population,primary infection role,0.6551282051282051
immune population,biological role,0.60625
immune population,biological vector role,0.6038461538461539
immune population,pathogen host role,0.5928571428571429
immune population,symptomatic carrier role,0.6207317073170732
immune population,humoral immune response,0.7
immune population,SARS-COV-2 adhesion susceptible cell,0.5632075471698114
immune population,intermediate host role,0.6294871794871795
immune population,host role,0.5653846153846154
immune population,infectious human pathogen,0.6642857142857143
immune population,colonization of human,0.6342105263157894
immune population,negative regulation of immune response,0.6318181818181818
immune population,pathogen portal of exit role,0.6055555555555556
immune population,commensal role,0.6435483870967742
immune population,epitope role,0.6224137931034482
immune population,herd immunity to infectious organism,0.6575471698113208
immune population,pathogen transporter role,0.5928571428571429
immune population,antigen role,0.6224137931034482
immune population,symbiont host role,0.6214285714285714
immune population,immune population,0.95
immune population,fomite role,0.6285714285714286
immune population,infectious disease incidence rate,0.61
immune population,adaptive immune response,0.6939024390243902
immune population,reagent role,0.5879310344827586
immune population,establishment of a clinically abnormal colony,0.5951612903225807
immune population,SARS-CoV-2 release stage,0.5475609756097561
infectious agent host role,virostatic disposition,0.6583333333333334
infectious agent host role,information content entity,0.6807692307692308
infectious agent host role,zoonotic disposition,0.6239130434782608
infectious agent host role,infectious disease mortality rate,0.7720338983050847
infectious agent host role,infection incidence rate profile,0.760344827586207
infectious agent host role,infectious structure aggregate,0.7357142857142857
infectious agent host role,communicability end temporal region,0.630327868852459
infectious agent host role,infection end temporal region,0.740909090909091
infectious agent host role,infectious disease,0.7681818181818181
infectious agent host role,SARS-CoV-2 incidence rate,0.6264705882352941
infectious agent host role,incubation end temporal region,0.7
infectious agent host role,virulence factor disposition,0.6537037037037037
infectious agent host role,viral adhesion disposition,0.6423076923076922
infectious agent host role,parasitostatic disposition,0.6615384615384616
infectious agent host role,infectious disease incidence,0.7277777777777777
infectious agent host role,reservoir of pathogen role,0.7
infectious agent host role,reverse zoonotic disposition,0.6351851851851852
infectious agent host role,establishment of localization in host,0.6722222222222223
infectious agent host role,disease surveillance objective specification,0.6071428571428572
infectious agent host role,infectious agent host role,0.95
infectious agent host role,asymptomatic infectious structure carrier,0.6888059701492537
infectious agent host role,B cell receptor complex,0.6336734693877552
infectious agent host role,passive immunization against infectious agent,0.6753521126760563
infectious agent host role,infection incidence rate,0.73
infectious agent host role,colonized host,0.65
infectious agent host role,virus host,0.6722222222222223
infectious agent host role,pathogen portal of entry role,0.7045454545454546
infectious agent host role,infectious disease lifetime prevalence,0.746875
infectious agent host role,toxin disposition,0.636046511627907
infectious agent host role,lower respiratory tract disease,0.6078947368421053
infectious agent host role,infectious disease incidence proportion,0.7269230769230769
infectious agent host role,acute infectious disease course,0.7482456140350877
infectious agent host role,cidal agent disposition,0.7153061224489795
infectious agent host role,infectious disorder,0.7611111111111112
infectious agent host role,role,0.5833333333333334
infectious agent host role,appearance of disorder,0.6166666666666667
infectious agent host role,biological vehicle,0.609090909090909
infectious agent host role,parasiticidal disposition,0.6264705882352941
infectious agent host role,infectious disease sporadicity,0.7357142857142857
infectious agent host role,mutualist role,0.7
infectious agent host role,communicability end process boundary,0.6274193548387097
infectious agent host role,directive information content entity,0.6596774193548387
infectious agent host role,infectious agent colony,0.8377551020408163
infectious agent host role,pathogen transporter,0.6673913043478261
infectious agent host role,invasion factor,0.6695121951219513
infectious agent host role,transmissibility disposition,0.6166666666666667
infectious agent host role,latency end process boundary,0.6351851851851852
infectious agent host role,colonization of host,0.6673913043478261
infectious agent host role,infectious disease epidemic,0.7330188679245283
infectious agent host role,infectious agent generative stage,0.7889830508474576
infectious agent host role,disease transmission model,0.6423076923076922
infectious agent host role,endotoxin disposition,0.6414893617021277
infectious agent host role,cidal agent,0.6662162162162162
infectious agent host role,infectious structure host role,0.8428571428571427
infectious agent host role,pathogen vehicle,0.6642857142857143
infectious agent host role,COVID-19 incidence rate,0.6336734693877552
infectious agent host role,cytotoxin disposition,0.6414893617021277
infectious agent host role,pathogen vehicle role,0.7053191489361703
infectious agent host role,host,0.5833333333333334
infectious agent host role,chronic infectious disease course,0.738135593220339
infectious agent host role,asymptomatic infectious agent carrier,0.7515873015873015
infectious agent host role,descriptive information content entity,0.6375
infectious agent host role,COVID-19 epidemic,0.5662790697674418
infectious agent host role,mechanical vector role,0.7
infectious agent host role,sterilizing immunity to infectious agent,0.6924242424242425
infectious agent host role,establishment of localization in human host,0.6673913043478261
infectious agent host role,diseased population,0.6277777777777778
infectious agent host role,virulence factor,0.6404761904761905
infectious agent host role,incubation end process boundary,0.6956140350877194
infectious agent host role,collective pathogenic disposition,0.6872881355932203
infectious agent host role,neurotoxin disposition,0.6583333333333334
infectious agent host role,dead-end host role,0.7681818181818181
infectious agent host role,definitive host role,0.7760869565217391
infectious agent host role,latency end temporal region,0.6386792452830189
infectious agent host role,innate immunity to infectious agent,0.7122950819672131
infectious agent host role,infectious structure,0.7760869565217391
infectious agent host role,collective disposition,0.6583333333333334
infectious agent host role,static agent disposition,0.71
infectious agent host role,T cell receptor complex,0.6336734693877552
infectious agent host role,asymptomatic carrier role,0.6460784313725491
infectious agent host role,infectious structure host,0.7833333333333333
infectious agent host role,infectious agent population,0.8273584905660377
infectious agent host role,respiratory system disease,0.6230769230769231
infectious agent host role,entry into host,0.6939024390243902
infectious agent host role,leukocyte-mediated immunity to infectious agent,0.6691780821917809
infectious agent host role,adhesion of symbiont to host,0.6722222222222223
infectious agent host role,humoral immunity to infectious agent,0.7080645161290323
infectious agent host role,infectious disease control strategy,0.7778688524590163
infectious agent host role,infectious disease pandemic,0.7330188679245283
infectious agent host role,infectious structure generative stage,0.7515873015873015
infectious agent host role,immunosuppressive disposition,0.65
infectious agent host role,pathogenic disposition,0.6583333333333334
infectious agent host role,viral disease course,0.6456521739130434
infectious agent host role,entry into host through host barriers,0.6880952380952381
infectious agent host role,secondary infection role,0.73
infectious agent host role,passive immunity to infectious agent,0.7080645161290323
infectious agent host role,infectious disposition,0.7625
infectious agent host role,vaccination against infectious agent,0.7080645161290323
infectious agent host role,susceptibility to infectious agent,0.7166666666666667
infectious agent host role,bacteriostatic disposition,0.6807692307692308
infectious agent host role,bactericidal disposition,0.63
infectious agent host role,source of infection role,0.73
infectious agent host role,pathogen host,0.7064102564102563
infectious agent host role,invasion disposition,0.6673913043478261
infectious agent host role,disease course,0.65
infectious agent host role,infectious disease course,0.7833333333333333
infectious agent host role,viricidal disposition,0.6414893617021277
infectious agent host role,acquired immunity to infectious agent,0.7039682539682539
infectious agent host role,COVID-19 disease incidence proportion,0.6087301587301588
infectious agent host role,coronavirus disease course,0.6615384615384616
infectious agent host role,asymptomatic carrier,0.6021739130434782
infectious agent host role,biological vehicle role,0.6540816326530612
infectious agent host role,symptomatic infectious agent carrier,0.7564516129032257
infectious agent host role,symbiont role,0.6807692307692308
infectious agent host role,parasite role,0.6551282051282051
infectious agent host role,intermediate host,0.7058139534883722
infectious agent host role,pathogen vector role,0.7108695652173913
infectious agent host role,infectious disease prevalence,0.759090909090909
infectious agent host role,disposition,0.6121621621621621
infectious agent host role,infected population,0.6944444444444444
infectious agent host role,COVID-19 mortality rate,0.6132653061224489
infectious agent host role,viral disease,0.6038461538461539
infectious agent host role,primary infection role,0.7416666666666667
infectious agent host role,biological role,0.6451219512195122
infectious agent host role,adhesion disposition,0.6456521739130434
infectious agent host role,disease,0.6015151515151516
infectious agent host role,symptomatic infectious structure carrier,0.6924242424242425
infectious agent host role,biological vector role,0.6791666666666666
infectious agent host role,primary infectious disposition,0.7178571428571427
infectious agent host role,pathogen host role,0.7909090909090909
infectious agent host role,designative information content entity,0.6375
infectious agent host role,symptomatic carrier role,0.65
infectious agent host role,infectious pathogen transmissibility,0.7564516129032257
infectious agent host role,intermediate host role,0.7833333333333333
infectious agent host role,dead-end host,0.6807692307692308
infectious agent host role,host role,0.7071428571428571
infectious agent host role,infectious human pathogen,0.7833333333333333
infectious agent host role,establishment of localization in virus host,0.6528985507246376
infectious agent host role,immunization against infectious agent,0.7039682539682539
infectious agent host role,SARS-COV-2 adhesion disposition,0.6429824561403508
infectious agent host role,pathogen portal of exit role,0.7092592592592593
infectious agent host role,invasive disposition,0.6456521739130434
infectious agent host role,infectious agent host,0.8968085106382978
infectious agent host role,long-term non-progressing infectious disease course,0.6707792207792208
infectious agent host role,viral disease epidemic,0.5958333333333333
infectious agent host role,commensal role,0.7
infectious agent host role,epitope role,0.6868421052631578
infectious agent host role,fungicidal disposition,0.6375
infectious agent host role,viral disease pandemic,0.5958333333333333
infectious agent host role,division of geopolitical entity,0.6429824561403508
infectious agent host role,symptomatic carrier,0.6055555555555556
infectious agent host role,infectious disease endemicity,0.7227272727272727
infectious agent host role,function,0.6264705882352941
infectious agent host role,herd immunity to infectious organism,0.6758064516129032
infectious agent host role,pathogen transporter role,0.7049019607843137
infectious agent host role,exotoxin disposition,0.6456521739130434
infectious agent host role,infectious agent reservoir,0.8346153846153846
infectious agent host role,antigen role,0.7394736842105263
infectious agent host role,COVID-19 pandemic,0.5895348837209302
infectious agent host role,action specification,0.6456521739130434
infectious agent host role,infectious disease control objective specification,0.7131578947368421
infectious agent host role,symbiont host role,0.7681818181818181
infectious agent host role,opportunistic infectious disposition,0.6919354838709677
infectious agent host role,fomite role,0.6662162162162162
infectious agent host role,enterotoxin disposition,0.6540816326530612
infectious agent host role,polymerase chain reaction,0.6068627450980393
infectious agent host role,COVID-19 disease course,0.6336734693877552
infectious agent host role,infectious disease incidence rate,0.738135593220339
infectious agent host role,active immunization against infectious agent,0.6785714285714286
infectious agent host role,collective resistance disposition,0.6533898305084747
infectious agent host role,reagent role,0.7394736842105263
infectious agent host role,viral load,0.5611111111111111
infectious agent host role,fungistatic disposition,0.6540816326530612
infectious agent host role,infectious agent,0.830952380952381
infectious agent host role,establishment of a clinically abnormal colony,0.6330985915492958
infectious agent host role,coronavirus disease,0.6277777777777778
infectious agent host role,adhesion factor,0.6451219512195122
infectious agent host role,definitive host,0.6939024390243902
infectious agent host role,drug susceptibility of infectious agent,0.6961538461538461
infectious agent host role,static agent,0.6605263157894737
infection,virus aggregate,0.575
infection,source of infection,0.7714285714285714
infection,virostatic disposition,0.6435483870967742
infection,zoonotic disposition,0.656896551724138
infection,infectious disease mortality rate,0.6404761904761905
infection,infection incidence rate profile,0.6695121951219513
infection,communicability end temporal region,0.5863636363636363
infection,subclinical coronavirus infection,0.6642857142857143
infection,infection end temporal region,0.6868421052631578
infection,infectious disease,0.7462962962962962
infection,double-stranded DNA virus,0.5382352941176471
infection,incubation end temporal region,0.6294871794871795
infection,site of infection,0.7961538461538461
infection,virulence factor disposition,0.6662162162162162
infection,viral adhesion disposition,0.6214285714285714
infection,parasitostatic disposition,0.6214285714285714
infection,infectious disease incidence,0.6932432432432433
infection,reverse zoonotic disposition,0.6121621621621621
infection,subclinical SARS-CoV-2 infection,0.6695121951219513
infection,virus translation stage,0.6375
infection,disease surveillance objective specification,0.6009433962264151
infection,virus release stage,0.5571428571428572
infection,source of infection site,0.7227272727272727
infection,virus,0.5214285714285714
infection,virus replication,0.7192307692307692
infection,B cell receptor complex,0.575
infection,systematic infection,0.760344827586207
infection,infection incidence rate,0.7227272727272727
infection,virus host,0.5552631578947369
infection,double-stranded RNA virus,0.5382352941176471
infection,virus transcription stage,0.6558823529411765
infection,infectious disease lifetime prevalence,0.6414893617021277
infection,toxin disposition,0.6807692307692308
infection,lower respiratory tract disease,0.55
infection,infectious disease incidence proportion,0.6375
infection,virus generative stage,0.6112903225806451
infection,acute infectious disease course,0.65
infection,cidal agent disposition,0.6375
infection,infectious disorder,0.7357142857142857
infection,subclinical infection,0.75
infection,appearance of disorder,0.5790322580645162
infection,simple infection,0.81
infection,parasiticidal disposition,0.6264705882352941
infection,infectious disease sporadicity,0.6551282051282051
infection,communicability end process boundary,0.5611111111111111
infection,infection incidence proportion profile,0.6414893617021277
infection,transmissibility disposition,0.5851351351351352
infection,latency end process boundary,0.5851351351351352
infection,infectious disease epidemic,0.6722222222222223
infection,disease transmission model,0.6214285714285714
infection,endotoxin disposition,0.65
infection,negative-sense single-stranded RNA virus,0.5520408163265306
infection,cytotoxin disposition,0.65
infection,community-acquired infection,0.6932432432432433
infection,chronic infectious disease course,0.6404761904761905
infection,nursing-home acquired infection,0.675
infection,COVID-19 epidemic,0.5653846153846154
infection,secondary infection,0.7714285714285714
infection,infection start temporal region,0.675
infection,infection incidence,0.7714285714285714
infection,virus disorder,0.5804347826086956
infection,primary infection,0.7961538461538461
infection,process of establishing an infection,0.65
infection,incubation end process boundary,0.625
infection,SARS-CoV-2 disorder,0.5571428571428572
infection,collective pathogenic disposition,0.6166666666666667
infection,neurotoxin disposition,0.6435483870967742
infection,latency end temporal region,0.6166666666666667
infection,virus adhesion susceptible cell,0.575
infection,collective disposition,0.6435483870967742
infection,infection,0.95
infection,static agent disposition,0.6318181818181818
infection,T cell receptor complex,0.575
infection,respiratory system disease,0.5357142857142857
infection,communicability interval,0.6015151515151516
infection,infectious disease control strategy,0.6545454545454545
infection,infectious disease pandemic,0.7
infection,immunosuppressive disposition,0.6342105263157894
infection,pathogenic disposition,0.6435483870967742
infection,viral disease course,0.5879310344827586
infection,intracellular infection,0.73125
infection,secondary infection role,0.7227272727272727
infection,metastatic infection,0.760344827586207
infection,infectious disposition,0.7403225806451613
infection,acute infection,0.825
infection,bacteriostatic disposition,0.6214285714285714
infection,bactericidal disposition,0.6318181818181818
infection,source of infection role,0.7227272727272727
infection,chronic infection,0.7961538461538461
infection,invasion disposition,0.656896551724138
infection,disease course,0.6239130434782608
infection,infectious disease course,0.6852941176470588
infection,viricidal disposition,0.65
infection,complex infection,0.7961538461538461
infection,COVID-19 disease incidence proportion,0.6239130434782608
infection,coronavirus disease course,0.5642857142857143
infection,infection incidence proportion,0.6807692307692308
infection,respiratory droplet virus fomite,0.5719512195121951
infection,infectious disease prevalence,0.6868421052631578
infection,disposition,0.7
infection,single-stranded DNA virus,0.5970588235294118
infection,viral disease,0.5409090909090909
infection,primary infection role,0.7403225806451613
infection,adhesion disposition,0.656896551724138
infection,infection incidence profile,0.7
infection,contagiousness,0.6673913043478261
infection,disease,0.575
infection,primary infectious disposition,0.6807692307692308
infection,infection prevalence,0.760344827586207
infection,coronavirus disorder,0.553448275862069
infection,subclinical virus infection,0.7
infection,establishment of localization in virus host,0.6038461538461539
infection,virus attachment stage,0.5467741935483871
infection,virus synthesis stage,0.5833333333333334
infection,SARS-COV-2 adhesion disposition,0.6
infection,invasive disposition,0.6913793103448276
infection,long-term non-progressing infectious disease course,0.5833333333333334
infection,viral disease epidemic,0.5467741935483871
infection,communicability start temporal region,0.5804347826086956
infection,fungicidal disposition,0.6435483870967742
infection,viral disease pandemic,0.5790322580645162
infection,virus penetration stage,0.66875
infection,acute respiratory distress syndrome,0.5636363636363636
infection,infectious disease endemicity,0.6868421052631578
infection,disorder,0.5676470588235294
infection,communicability,0.575
infection,extracellular infection,0.73125
infection,exotoxin disposition,0.656896551724138
infection,infection start process boundary,0.6695121951219513
infection,action specification,0.7258620689655172
infection,infectious disease control objective specification,0.6025423728813559
infection,opportunistic infectious disposition,0.65
infection,process of establishing viral infection,0.6375
infection,enterotoxin disposition,0.6375
infection,COVID-19 disease course,0.575
infection,infectious disease incidence rate,0.6642857142857143
infection,communicability start process boundary,0.5563829787234043
infection,disordered virus,0.57
infection,collective resistance disposition,0.6166666666666667
infection,fungistatic disposition,0.6375
infection,virus uncoating stage,0.65
infection,local infection,0.825
infection,establishment of a clinically abnormal colony,0.5796296296296296
infection,coronavirus disease,0.5571428571428572
infection,positive-sense single-stranded RNA virus,0.5520408163265306
infection,hospital-acquired infection,0.7
viral pathogenesis,pathogen generative stage,0.7058139534883722
viral pathogenesis,pathogen portal of entry,0.6642857142857143
viral pathogenesis,primary pathogen,0.7735294117647058
viral pathogenesis,pathogen portal of exit,0.6939024390243902
viral pathogenesis,viral adhesion disposition,0.7227272727272727
viral pathogenesis,pathogenesis,0.85
viral pathogenesis,reservoir of pathogen role,0.7454545454545455
viral pathogenesis,B cell receptor complex,0.5963414634146341
viral pathogenesis,pathogen portal of entry role,0.6414893617021277
viral pathogenesis,pathogen birth temporal region,0.6583333333333334
viral pathogenesis,opportunistic pathogen,0.7
viral pathogenesis,genetic resistance to pathogen,0.7
viral pathogenesis,droplet pathogen transmission process,0.7045454545454546
viral pathogenesis,pathogen transporter,0.6868421052631578
viral pathogenesis,pathogen vehicle,0.7441176470588234
viral pathogenesis,viral plaque assay,0.7555555555555555
viral pathogenesis,pathogen vector,0.7227272727272727
viral pathogenesis,pathogen vehicle role,0.7064102564102563
viral pathogenesis,pathogen death process boundary,0.6744897959183673
viral pathogenesis,T cell receptor complex,0.5963414634146341
viral pathogenesis,indirect pathogen transmission process,0.7
viral pathogenesis,viral disease course,0.6868421052631578
viral pathogenesis,viral envelope,0.73125
viral pathogenesis,immunity to pathogen,0.7131578947368421
viral pathogenesis,pathogen host,0.7403225806451613
viral pathogenesis,viral capsid,0.75
viral pathogenesis,pathogen vector role,0.6868421052631578
viral pathogenesis,pathogen portal of exit site,0.6891304347826087
viral pathogenesis,viral disease,0.7080645161290323
viral pathogenesis,pathogen portal of entry site,0.6840425531914894
viral pathogenesis,SARS-CoV-2 pathogenesis,0.7914634146341464
viral pathogenesis,pathogen host role,0.7
viral pathogenesis,infectious pathogen transmissibility,0.6907407407407408
viral pathogenesis,pathogen surveillance,0.7064102564102563
viral pathogenesis,pathogen,0.7576923076923078
viral pathogenesis,pathogen birth process boundary,0.6744897959183673
viral pathogenesis,infectious human pathogen,0.7058139534883722
viral pathogenesis,resistance to pathogen,0.725
viral pathogenesis,pathogen portal of exit role,0.6673913043478261
viral pathogenesis,re-emerging pathogen,0.7131578947368421
viral pathogenesis,viral disease epidemic,0.7
viral pathogenesis,viral disease pandemic,0.725
viral pathogenesis,pathogen seroprevalence,0.6695121951219513
viral pathogenesis,negative regulation of viral process,0.6537037037037037
viral pathogenesis,contact pathogen transmission process,0.6863636363636364
viral pathogenesis,pathogen transporter role,0.6593023255813953
viral pathogenesis,coronavirus pathogenesis,0.830952380952381
viral pathogenesis,process of establishing viral infection,0.6078947368421053
viral pathogenesis,viral load,0.7
viral pathogenesis,establishment of a clinically abnormal colony,0.5611111111111111
viral pathogenesis,horizontal pathogen transmission process,0.7086206896551723
viral pathogenesis,viral pathogenesis,0.95
viral pathogenesis,pathogen death temporal region,0.6583333333333334
viral pathogenesis,emerging pathogen,0.7357142857142857
viral pathogenesis,pathogen transmission process,0.6840425531914894
immaterial entity,extended organism,0.6264705882352941
immaterial entity,information content entity,0.7290697674418604
immaterial entity,infectious disease mortality rate,0.63
immaterial entity,infection incidence rate profile,0.6132653061224489
immaterial entity,infectious structure aggregate,0.5776595744680851
immaterial entity,communicability end temporal region,0.6615384615384616
immaterial entity,geographical entity,0.7833333333333333
immaterial entity,infection end temporal region,0.6456521739130434
immaterial entity,drug-based immunosuppressed organism,0.6009433962264151
immaterial entity,SARS-CoV-2 incidence rate,0.5928571428571429
immaterial entity,incubation end temporal region,0.6627659574468084
immaterial entity,site of infection,0.6558823529411765
immaterial entity,resistant entity,0.7530303030303032
immaterial entity,immunocompetent organism,0.6695121951219513
immaterial entity,virulence factor disposition,0.6277777777777778
immaterial entity,establishment of localization in host,0.5981481481481481
immaterial entity,case isolation control strategy,0.6375
immaterial entity,infectious agent host role,0.636046511627907
immaterial entity,material entity,0.91875
immaterial entity,asymptomatic infectious structure carrier,0.6224137931034482
immaterial entity,source of infection site,0.5963414634146341
immaterial entity,architectual structure,0.6551282051282051
immaterial entity,B cell receptor complex,0.575
immaterial entity,infection incidence rate,0.6207317073170732
immaterial entity,colonized host,0.5790322580645162
immaterial entity,virus host,0.5981481481481481
immaterial entity,entity,0.7108695652173913
immaterial entity,double-stranded RNA virus,0.5928571428571429
immaterial entity,lower respiratory tract disease,0.5958333333333333
immaterial entity,communicability end process boundary,0.619811320754717
immaterial entity,directive information content entity,0.6764150943396227
immaterial entity,acellular structure aggregate,0.5804347826086956
immaterial entity,invasion factor,0.60625
immaterial entity,latency end process boundary,0.6055555555555556
immaterial entity,colonization of host,0.6121621621621621
immaterial entity,realizable entity,0.7735294117647058
immaterial entity,pathologically immunosuppressed organism,0.6078947368421053
immaterial entity,negative-sense single-stranded RNA virus,0.5903508771929825
immaterial entity,infectious structure host role,0.5776595744680851
immaterial entity,COVID-19 incidence rate,0.575
immaterial entity,descriptive information content entity,0.6681818181818181
immaterial entity,establishment of localization in human host,0.5833333333333334
immaterial entity,acellular structure,0.6166666666666667
immaterial entity,virulence factor,0.6318181818181818
immaterial entity,incubation end process boundary,0.6166666666666667
immaterial entity,dead-end host role,0.5928571428571429
immaterial entity,molecular entity,0.7530303030303032
immaterial entity,immunosuppressed organism,0.6404761904761905
immaterial entity,definitive host role,0.6121621621621621
immaterial entity,latency end temporal region,0.6545454545454545
immaterial entity,infectious structure,0.6121621621621621
immaterial entity,virus adhesion susceptible cell,0.6166666666666667
immaterial entity,T cell receptor complex,0.6
immaterial entity,infectious structure host,0.5928571428571429
immaterial entity,respiratory system disease,0.6127906976744186
immaterial entity,entry into host,0.6375
immaterial entity,adhesion of symbiont to host,0.6055555555555556
immaterial entity,organism population,0.6166666666666667
immaterial entity,infectious structure generative stage,0.6166666666666667
immaterial entity,entry into host through host barriers,0.5611111111111111
immaterial entity,cell,0.5452380952380953
immaterial entity,epitope site,0.656896551724138
immaterial entity,pathogen host,0.6166666666666667
immaterial entity,susceptible organism,0.6121621621621621
immaterial entity,intermediate host,0.6852941176470588
immaterial entity,pathogen portal of exit site,0.6944444444444444
immaterial entity,organism substance,0.5928571428571429
immaterial entity,anatomical entity,0.8029411764705883
immaterial entity,COVID-19 mortality rate,0.65
immaterial entity,geopolitical entity,0.7833333333333333
immaterial entity,pathogen portal of entry site,0.7108695652173913
immaterial entity,symptomatic infectious structure carrier,0.6254385964912281
immaterial entity,site,0.5928571428571429
immaterial entity,pathogen host role,0.6214285714285714
immaterial entity,designative information content entity,0.6863636363636364
immaterial entity,SARS-COV-2 adhesion susceptible cell,0.5820754716981132
immaterial entity,intermediate host role,0.6551282051282051
immaterial entity,dead-end host,0.6166666666666667
immaterial entity,immunodeficient organism,0.6695121951219513
immaterial entity,host role,0.6038461538461539
immaterial entity,infectious human pathogen,0.6166666666666667
immaterial entity,colonization of human,0.6078947368421053
immaterial entity,establishment of localization in virus host,0.6
immaterial entity,immaterial entity,0.95
immaterial entity,infectious agent host,0.6605263157894737
immaterial entity,division of geopolitical entity,0.7
immaterial entity,geographical feature,0.6662162162162162
immaterial entity,herd immunity to infectious organism,0.619811320754717
immaterial entity,action specification,0.6391891891891892
immaterial entity,processed material,0.6785714285714286
immaterial entity,symbiont host role,0.5928571428571429
immaterial entity,quality,0.6583333333333334
immaterial entity,infectious disease incidence rate,0.61
immaterial entity,single-stranded RNA retrovirus,0.6414893617021277
immaterial entity,organism,0.61
immaterial entity,establishment of a clinically abnormal colony,0.5951612903225807
immaterial entity,positive-sense single-stranded RNA virus,0.5903508771929825
immaterial entity,adhesion factor,0.60625
immaterial entity,definitive host,0.6375
immaterial entity,cell space,0.5981481481481481
immaterial entity,material processing,0.7555555555555555
positive-sense single-stranded RNA virus,extended organism,0.6429824561403508
positive-sense single-stranded RNA virus,ribonucleic acid,0.575
positive-sense single-stranded RNA virus,virus aggregate,0.5772727272727273
positive-sense single-stranded RNA virus,source of infection,0.5855932203389831
positive-sense single-stranded RNA virus,virostatic disposition,0.5951612903225807
positive-sense single-stranded RNA virus,zoonotic disposition,0.5833333333333334
positive-sense single-stranded RNA virus,immune response,0.5954545454545455
positive-sense single-stranded RNA virus,infectious disease mortality rate,0.6417808219178082
positive-sense single-stranded RNA virus,infection incidence rate profile,0.6583333333333334
positive-sense single-stranded RNA virus,communicability end temporal region,0.61
positive-sense single-stranded RNA virus,pathogen generative stage,0.65
positive-sense single-stranded RNA virus,pathogen portal of entry,0.60625
positive-sense single-stranded RNA virus,subclinical coronavirus infection,0.6417808219178082
positive-sense single-stranded RNA virus,primary pathogen,0.5571428571428572
positive-sense single-stranded RNA virus,infection end temporal region,0.6384057971014493
positive-sense single-stranded RNA virus,deoxyribonucleic acid,0.5811475409836065
positive-sense single-stranded RNA virus,drug-based immunosuppressed organism,0.6473684210526315
positive-sense single-stranded RNA virus,infectious disease,0.6224137931034482
positive-sense single-stranded RNA virus,double-stranded DNA virus,0.7730769230769231
positive-sense single-stranded RNA virus,incubation end temporal region,0.6357142857142857
positive-sense single-stranded RNA virus,site of infection,0.6254385964912281
positive-sense single-stranded RNA virus,immunocompetent organism,0.60625
positive-sense single-stranded RNA virus,virulence factor disposition,0.6117647058823529
positive-sense single-stranded RNA virus,pathogen portal of exit,0.6087301587301588
positive-sense single-stranded RNA virus,viral adhesion disposition,0.6015151515151516
positive-sense single-stranded RNA virus,parasitostatic disposition,0.6015151515151516
positive-sense single-stranded RNA virus,infectious disease incidence,0.6411764705882353
positive-sense single-stranded RNA virus,reservoir of pathogen role,0.6015151515151516
positive-sense single-stranded RNA virus,reverse zoonotic disposition,0.5970588235294118
positive-sense single-stranded RNA virus,subclinical SARS-CoV-2 infection,0.6027777777777777
positive-sense single-stranded RNA virus,virus translation stage,0.6087301587301588
positive-sense single-stranded RNA virus,disease surveillance objective specification,0.6285714285714286
positive-sense single-stranded RNA virus,virus release stage,0.6194915254237288
positive-sense single-stranded RNA virus,source of infection site,0.60625
positive-sense single-stranded RNA virus,virus,0.5611111111111111
positive-sense single-stranded RNA virus,virus replication,0.5728070175438597
positive-sense single-stranded RNA virus,B cell receptor complex,0.5452380952380953
positive-sense single-stranded RNA virus,systematic infection,0.6
positive-sense single-stranded RNA virus,infection incidence rate,0.653125
positive-sense single-stranded RNA virus,virus host,0.55
positive-sense single-stranded RNA virus,double-stranded RNA virus,0.7884615384615384
positive-sense single-stranded RNA virus,pathogen portal of entry role,0.6094202898550725
positive-sense single-stranded RNA virus,virus transcription stage,0.6192307692307693
positive-sense single-stranded RNA virus,infectious disease lifetime prevalence,0.6423076923076922
positive-sense single-stranded RNA virus,toxin disposition,0.5903508771929825
positive-sense single-stranded RNA virus,pathogen birth temporal region,0.6214285714285714
positive-sense single-stranded RNA virus,lower respiratory tract disease,0.6330985915492958
positive-sense single-stranded RNA virus,infectious disease incidence proportion,0.6525316455696202
positive-sense single-stranded RNA virus,opportunistic pathogen,0.6112903225806451
positive-sense single-stranded RNA virus,virus generative stage,0.6274193548387097
positive-sense single-stranded RNA virus,acute infectious disease course,0.6330985915492958
positive-sense single-stranded RNA virus,cidal agent disposition,0.5769841269841269
positive-sense single-stranded RNA virus,infectious disorder,0.6364406779661017
positive-sense single-stranded RNA virus,genetic resistance to pathogen,0.6357142857142857
positive-sense single-stranded RNA virus,subclinical infection,0.5975409836065574
positive-sense single-stranded RNA virus,appearance of disorder,0.6274193548387097
positive-sense single-stranded RNA virus,simple infection,0.6107142857142857
positive-sense single-stranded RNA virus,droplet pathogen transmission process,0.6188311688311688
positive-sense single-stranded RNA virus,parasiticidal disposition,0.6192307692307693
positive-sense single-stranded RNA virus,infectious disease sporadicity,0.6357142857142857
positive-sense single-stranded RNA virus,communicability end process boundary,0.6078947368421053
positive-sense single-stranded RNA virus,infection incidence proportion profile,0.6423076923076922
positive-sense single-stranded RNA virus,pathogen transporter,0.6333333333333333
positive-sense single-stranded RNA virus,transmissibility disposition,0.5970588235294118
positive-sense single-stranded RNA virus,latency end process boundary,0.6264705882352941
positive-sense single-stranded RNA virus,infectious disease epidemic,0.6291044776119403
positive-sense single-stranded RNA virus,disease transmission model,0.6318181818181818
positive-sense single-stranded RNA virus,endotoxin disposition,0.5975409836065574
positive-sense single-stranded RNA virus,pathologically immunosuppressed organism,0.65
positive-sense single-stranded RNA virus,negative-sense single-stranded RNA virus,0.9
positive-sense single-stranded RNA virus,pathogen vehicle,0.5928571428571429
positive-sense single-stranded RNA virus,cytotoxin disposition,0.5975409836065574
positive-sense single-stranded RNA virus,community-acquired infection,0.6117647058823529
positive-sense single-stranded RNA virus,pathogen vector,0.5954545454545455
positive-sense single-stranded RNA virus,pathogen vehicle role,0.6139344262295081
positive-sense single-stranded RNA virus,chronic infectious disease course,0.6280821917808219
positive-sense single-stranded RNA virus,nursing-home acquired infection,0.6190140845070422
positive-sense single-stranded RNA virus,COVID-19 epidemic,0.5903508771929825
positive-sense single-stranded RNA virus,secondary infection,0.6025423728813559
positive-sense single-stranded RNA virus,nucleic acid,0.5653846153846154
positive-sense single-stranded RNA virus,infection start temporal region,0.6330985915492958
positive-sense single-stranded RNA virus,infection incidence,0.6194915254237288
positive-sense single-stranded RNA virus,virus disorder,0.6166666666666667
positive-sense single-stranded RNA virus,primary infection,0.5903508771929825
positive-sense single-stranded RNA virus,process of establishing an infection,0.6473684210526315
positive-sense single-stranded RNA virus,incubation end process boundary,0.6330985915492958
positive-sense single-stranded RNA virus,SARS-CoV-2 disorder,0.6194915254237288
positive-sense single-stranded RNA virus,collective pathogenic disposition,0.6143835616438357
positive-sense single-stranded RNA virus,neurotoxin disposition,0.5951612903225807
positive-sense single-stranded RNA virus,pathogen death process boundary,0.6330985915492958
positive-sense single-stranded RNA virus,immunosuppressed organism,0.65
positive-sense single-stranded RNA virus,latency end temporal region,0.6291044776119403
positive-sense single-stranded RNA virus,virus adhesion susceptible cell,0.5908450704225352
positive-sense single-stranded RNA virus,collective disposition,0.6112903225806451
positive-sense single-stranded RNA virus,infection,0.5520408163265306
positive-sense single-stranded RNA virus,static agent disposition,0.60625
positive-sense single-stranded RNA virus,T cell receptor complex,0.5611111111111111
positive-sense single-stranded RNA virus,respiratory system disease,0.6318181818181818
positive-sense single-stranded RNA virus,indirect pathogen transmission process,0.6294871794871795
positive-sense single-stranded RNA virus,organism population,0.5686440677966101
positive-sense single-stranded RNA virus,infectious disease control strategy,0.65
positive-sense single-stranded RNA virus,infectious disease pandemic,0.6440298507462687
positive-sense single-stranded RNA virus,immunosuppressive disposition,0.6094202898550725
positive-sense single-stranded RNA virus,innate immune response,0.6274193548387097
positive-sense single-stranded RNA virus,pathogenic disposition,0.5951612903225807
positive-sense single-stranded RNA virus,viral disease course,0.6166666666666667
positive-sense single-stranded RNA virus,intracellular infection,0.5928571428571429
positive-sense single-stranded RNA virus,secondary infection role,0.621875
positive-sense single-stranded RNA virus,metastatic infection,0.6
positive-sense single-stranded RNA virus,infectious disposition,0.5951612903225807
positive-sense single-stranded RNA virus,acute infection,0.5954545454545455
positive-sense single-stranded RNA virus,bacteriostatic disposition,0.5863636363636363
positive-sense single-stranded RNA virus,immunity to pathogen,0.5666666666666667
positive-sense single-stranded RNA virus,bactericidal disposition,0.575
positive-sense single-stranded RNA virus,source of infection role,0.60625
positive-sense single-stranded RNA virus,pathogen host,0.5820754716981132
positive-sense single-stranded RNA virus,acquired immunodeficiency,0.573076923076923
positive-sense single-stranded RNA virus,chronic infection,0.5903508771929825
positive-sense single-stranded RNA virus,invasion disposition,0.6
positive-sense single-stranded RNA virus,disease course,0.5981481481481481
positive-sense single-stranded RNA virus,infectious disease course,0.6346153846153847
positive-sense single-stranded RNA virus,viricidal disposition,0.5811475409836065
positive-sense single-stranded RNA virus,acquired immunity to infectious agent,0.5928571428571429
positive-sense single-stranded RNA virus,complex infection,0.5903508771929825
positive-sense single-stranded RNA virus,COVID-19 disease incidence proportion,0.6577922077922078
positive-sense single-stranded RNA virus,coronavirus disease course,0.6166666666666667
positive-sense single-stranded RNA virus,infection incidence proportion,0.6357142857142857
positive-sense single-stranded RNA virus,respiratory droplet virus fomite,0.6305555555555555
positive-sense single-stranded RNA virus,susceptible organism,0.6333333333333333
positive-sense single-stranded RNA virus,pathogen vector role,0.6166666666666667
positive-sense single-stranded RNA virus,pathogen portal of exit site,0.6117647058823529
positive-sense single-stranded RNA virus,infectious disease prevalence,0.6239130434782608
positive-sense single-stranded RNA virus,organism substance,0.6224137931034482
positive-sense single-stranded RNA virus,disposition,0.5872549019607843
positive-sense single-stranded RNA virus,single-stranded DNA virus,0.8192307692307693
positive-sense single-stranded RNA virus,viral disease,0.6009433962264151
positive-sense single-stranded RNA virus,primary infection role,0.6112903225806451
positive-sense single-stranded RNA virus,adhesion disposition,0.5833333333333334
positive-sense single-stranded RNA virus,pathogen portal of entry site,0.6094202898550725
positive-sense single-stranded RNA virus,infection incidence profile,0.6440298507462687
positive-sense single-stranded RNA virus,disease,0.5563829787234043
positive-sense single-stranded RNA virus,primary infectious disposition,0.5928571428571429
positive-sense single-stranded RNA virus,pathogen host role,0.6051724137931035
positive-sense single-stranded RNA virus,infection prevalence,0.6
positive-sense single-stranded RNA virus,humoral immune response,0.5928571428571429
positive-sense single-stranded RNA virus,coronavirus disorder,0.6166666666666667
positive-sense single-stranded RNA virus,infectious pathogen transmissibility,0.6210526315789474
positive-sense single-stranded RNA virus,pathogen surveillance,0.630327868852459
positive-sense single-stranded RNA virus,immunodeficient organism,0.621875
positive-sense single-stranded RNA virus,pathogen,0.5541666666666667
positive-sense single-stranded RNA virus,pathogen birth process boundary,0.6330985915492958
positive-sense single-stranded RNA virus,infectious human pathogen,0.5884615384615385
positive-sense single-stranded RNA virus,subclinical virus infection,0.6141791044776119
positive-sense single-stranded RNA virus,resistance to pathogen,0.6112903225806451
positive-sense single-stranded RNA virus,establishment of localization in virus host,0.6668674698795181
positive-sense single-stranded RNA virus,virus attachment stage,0.5951612903225807
positive-sense single-stranded RNA virus,negative regulation of immune response,0.6294871794871795
positive-sense single-stranded RNA virus,virus synthesis stage,0.6139344262295081
positive-sense single-stranded RNA virus,SARS-COV-2 adhesion disposition,0.6049295774647887
positive-sense single-stranded RNA virus,pathogen portal of exit role,0.6117647058823529
positive-sense single-stranded RNA virus,invasive disposition,0.6
positive-sense single-stranded RNA virus,re-emerging pathogen,0.6166666666666667
positive-sense single-stranded RNA virus,long-term non-progressing infectious disease course,0.6478021978021978
positive-sense single-stranded RNA virus,viral disease epidemic,0.6274193548387097
positive-sense single-stranded RNA virus,fungicidal disposition,0.5629032258064516
positive-sense single-stranded RNA virus,viral disease pandemic,0.6435483870967742
positive-sense single-stranded RNA virus,virus penetration stage,0.6246031746031746
positive-sense single-stranded RNA virus,pathogen seroprevalence,0.6246031746031746
positive-sense single-stranded RNA virus,acute respiratory distress syndrome,0.6233333333333334
positive-sense single-stranded RNA virus,infectious disease endemicity,0.6384057971014493
positive-sense single-stranded RNA virus,contact pathogen transmission process,0.6188311688311688
positive-sense single-stranded RNA virus,disorder,0.575
positive-sense single-stranded RNA virus,herd immunity to infectious organism,0.6078947368421053
positive-sense single-stranded RNA virus,extracellular infection,0.5769841269841269
positive-sense single-stranded RNA virus,pathogen transporter role,0.65
positive-sense single-stranded RNA virus,transmission interval,0.630327868852459
positive-sense single-stranded RNA virus,exotoxin disposition,0.6
positive-sense single-stranded RNA virus,infection start process boundary,0.6305555555555555
positive-sense single-stranded RNA virus,infectious disease control objective specification,0.6277777777777778
positive-sense single-stranded RNA virus,immune population,0.5728070175438597
positive-sense single-stranded RNA virus,opportunistic infectious disposition,0.6210526315789474
positive-sense single-stranded RNA virus,process of establishing viral infection,0.6525316455696202
positive-sense single-stranded RNA virus,enterotoxin disposition,0.5928571428571429
positive-sense single-stranded RNA virus,COVID-19 disease course,0.6246031746031746
positive-sense single-stranded RNA virus,infectious disease incidence rate,0.6691780821917809
positive-sense single-stranded RNA virus,single-stranded RNA retrovirus,0.8071428571428573
positive-sense single-stranded RNA virus,disordered virus,0.6642857142857143
positive-sense single-stranded RNA virus,collective resistance disposition,0.6691780821917809
positive-sense single-stranded RNA virus,adaptive immune response,0.653125
positive-sense single-stranded RNA virus,fungistatic disposition,0.5769841269841269
positive-sense single-stranded RNA virus,organism,0.575
positive-sense single-stranded RNA virus,virus uncoating stage,0.6139344262295081
positive-sense single-stranded RNA virus,local infection,0.5772727272727273
positive-sense single-stranded RNA virus,establishment of a clinically abnormal colony,0.6264705882352941
positive-sense single-stranded RNA virus,coronavirus disease,0.6025423728813559
positive-sense single-stranded RNA virus,positive-sense single-stranded RNA virus,0.95
positive-sense single-stranded RNA virus,horizontal pathogen transmission process,0.625
positive-sense single-stranded RNA virus,hospital-acquired infection,0.6291044776119403
positive-sense single-stranded RNA virus,pathogen death temporal region,0.6214285714285714
positive-sense single-stranded RNA virus,emerging pathogen,0.5903508771929825
positive-sense single-stranded RNA virus,pathogen transmission process,0.6384057971014493
bacteriostatic disposition,virostatic disposition,0.8666666666666667
bacteriostatic disposition,information content entity,0.6230769230769231
bacteriostatic disposition,zoonotic disposition,0.7978260869565217
bacteriostatic disposition,infectious disease mortality rate,0.6533898305084747
bacteriostatic disposition,infection incidence rate profile,0.6224137931034482
bacteriostatic disposition,infectious structure aggregate,0.6107142857142857
bacteriostatic disposition,communicability end temporal region,0.630327868852459
bacteriostatic disposition,geographical entity,0.6277777777777778
bacteriostatic disposition,biological regulation,0.6627659574468084
bacteriostatic disposition,surveillance process,0.6239130434782608
bacteriostatic disposition,infection end temporal region,0.65
bacteriostatic disposition,vector control strategy,0.6132653061224489
bacteriostatic disposition,SARS-CoV-2 incidence rate,0.6068627450980393
bacteriostatic disposition,incubation end temporal region,0.6642857142857143
bacteriostatic disposition,resistant entity,0.6642857142857143
bacteriostatic disposition,virulence factor disposition,0.7462962962962962
bacteriostatic disposition,viral adhesion disposition,0.7576923076923078
bacteriostatic disposition,parasitostatic disposition,0.8730769230769231
bacteriostatic disposition,negative regulation of production,0.6872881355932203
bacteriostatic disposition,reverse zoonotic disposition,0.7833333333333333
bacteriostatic disposition,establishment of localization in host,0.6404761904761905
bacteriostatic disposition,disease surveillance objective specification,0.6642857142857143
bacteriostatic disposition,case isolation control strategy,0.6429824561403508
bacteriostatic disposition,infectious agent host role,0.6807692307692308
bacteriostatic disposition,macromolecular complex,0.5958333333333333
bacteriostatic disposition,material entity,0.6695121951219513
bacteriostatic disposition,asymptomatic infectious structure carrier,0.6440298507462687
bacteriostatic disposition,architectual structure,0.6375
bacteriostatic disposition,quarantine control strategy,0.619811320754717
bacteriostatic disposition,B cell receptor complex,0.6132653061224489
bacteriostatic disposition,infection incidence rate,0.61
bacteriostatic disposition,colonized host,0.625
bacteriostatic disposition,virus host,0.6166666666666667
bacteriostatic disposition,entity,0.575
bacteriostatic disposition,toxin disposition,0.7988372093023256
bacteriostatic disposition,cidal agent disposition,0.7765306122448979
bacteriostatic disposition,parasiticidal disposition,0.8029411764705883
bacteriostatic disposition,communicability end process boundary,0.6274193548387097
bacteriostatic disposition,directive information content entity,0.6435483870967742
bacteriostatic disposition,acellular structure aggregate,0.6136363636363636
bacteriostatic disposition,transmissibility disposition,0.7648148148148148
bacteriostatic disposition,latency end process boundary,0.6537037037037037
bacteriostatic disposition,colonization of host,0.6456521739130434
bacteriostatic disposition,realizable entity,0.5895348837209302
bacteriostatic disposition,endotoxin disposition,0.7904255319148936
bacteriostatic disposition,vector surveillance,0.6055555555555556
bacteriostatic disposition,negative regulation of establishment of localization,0.6679487179487179
bacteriostatic disposition,infectious structure host role,0.6642857142857143
bacteriostatic disposition,COVID-19 incidence rate,0.5928571428571429
bacteriostatic disposition,cytotoxin disposition,0.8117021276595744
bacteriostatic disposition,negative regulation of developmental process,0.6214285714285714
bacteriostatic disposition,host,0.55
bacteriostatic disposition,descriptive information content entity,0.6375
bacteriostatic disposition,negative regulation of replication,0.6833333333333332
bacteriostatic disposition,establishment of localization in human host,0.6239130434782608
bacteriostatic disposition,acellular structure,0.6277777777777778
bacteriostatic disposition,incubation end process boundary,0.6605263157894737
bacteriostatic disposition,collective pathogenic disposition,0.7720338983050847
bacteriostatic disposition,neurotoxin disposition,0.8041666666666667
bacteriostatic disposition,dead-end host role,0.609090909090909
bacteriostatic disposition,molecular entity,0.569047619047619
bacteriostatic disposition,plan specification,0.6545454545454545
bacteriostatic disposition,definitive host role,0.6456521739130434
bacteriostatic disposition,latency end temporal region,0.6575471698113208
bacteriostatic disposition,infectious structure,0.6239130434782608
bacteriostatic disposition,collective disposition,0.7833333333333333
bacteriostatic disposition,static agent disposition,0.81
bacteriostatic disposition,T cell receptor complex,0.5928571428571429
bacteriostatic disposition,infectious structure host,0.6656862745098039
bacteriostatic disposition,respiratory system disease,0.6423076923076922
bacteriostatic disposition,entry into host,0.6451219512195122
bacteriostatic disposition,adhesion of symbiont to host,0.6537037037037037
bacteriostatic disposition,infectious disease control strategy,0.6467213114754098
bacteriostatic disposition,infectious structure generative stage,0.6404761904761905
bacteriostatic disposition,immunosuppressive disposition,0.740909090909091
bacteriostatic disposition,bacteriostatic,0.8
bacteriostatic disposition,pathogenic disposition,0.8041666666666667
bacteriostatic disposition,entry into host through host barriers,0.6404761904761905
bacteriostatic disposition,infectious disposition,0.8041666666666667
bacteriostatic disposition,bacteriostatic disposition,0.95
bacteriostatic disposition,bactericidal disposition,0.85
bacteriostatic disposition,pathogen host,0.6294871794871795
bacteriostatic disposition,invasion disposition,0.7760869565217391
bacteriostatic disposition,viricidal disposition,0.7691489361702127
bacteriostatic disposition,complex infection,0.636046511627907
bacteriostatic disposition,intermediate host,0.6825581395348838
bacteriostatic disposition,anatomical entity,0.636046511627907
bacteriostatic disposition,disposition,0.7472972972972972
bacteriostatic disposition,COVID-19 mortality rate,0.6132653061224489
bacteriostatic disposition,negative regulation of life-sustaining process,0.6444444444444444
bacteriostatic disposition,place closure control strategy,0.6107142857142857
bacteriostatic disposition,geopolitical entity,0.6277777777777778
bacteriostatic disposition,adhesion disposition,0.7978260869565217
bacteriostatic disposition,symptomatic infectious structure carrier,0.6318181818181818
bacteriostatic disposition,primary infectious disposition,0.7714285714285714
bacteriostatic disposition,pathogen host role,0.6318181818181818
bacteriostatic disposition,designative information content entity,0.6375
bacteriostatic disposition,intermediate host role,0.6791666666666666
bacteriostatic disposition,dead-end host,0.6038461538461539
bacteriostatic disposition,pathogen surveillance,0.598936170212766
bacteriostatic disposition,host role,0.5928571428571429
bacteriostatic disposition,establishment of localization in virus host,0.6384057971014493
bacteriostatic disposition,negative regulation of immune response,0.653125
bacteriostatic disposition,immaterial entity,0.6593023255813953
bacteriostatic disposition,SARS-COV-2 adhesion disposition,0.7482456140350877
bacteriostatic disposition,invasive disposition,0.7760869565217391
bacteriostatic disposition,infectious agent host,0.6840425531914894
bacteriostatic disposition,fungicidal disposition,0.7625
bacteriostatic disposition,division of geopolitical entity,0.6254385964912281
bacteriostatic disposition,negative regulation of viral process,0.6435483870967742
bacteriostatic disposition,exotoxin disposition,0.7978260869565217
bacteriostatic disposition,immunoglobulin complex,0.5541666666666667
bacteriostatic disposition,infectious disease control objective specification,0.6605263157894737
bacteriostatic disposition,symbiont host role,0.6545454545454545
bacteriostatic disposition,opportunistic infectious disposition,0.7403225806451613
bacteriostatic disposition,negative regulation of biological process,0.6291044776119403
bacteriostatic disposition,enterotoxin disposition,0.8173469387755102
bacteriostatic disposition,infectious disease incidence rate,0.6703389830508475
bacteriostatic disposition,collective resistance disposition,0.8059322033898306
bacteriostatic disposition,fungistatic disposition,0.8377551020408163
bacteriostatic disposition,establishment of a clinically abnormal colony,0.6049295774647887
bacteriostatic disposition,definitive host,0.6451219512195122
bacteriostatic disposition,static agent,0.6605263157894737
communicability end process boundary,virus aggregate,0.5676470588235294
communicability end process boundary,immune response,0.6656862745098039
communicability end process boundary,infectious disease mortality rate,0.6239130434782608
communicability end process boundary,infection incidence rate profile,0.6411764705882353
communicability end process boundary,communicability end temporal region,0.802112676056338
communicability end process boundary,pathogen generative stage,0.5975409836065574
communicability end process boundary,surveillance process,0.6642857142857143
communicability end process boundary,infection end temporal region,0.65
communicability end process boundary,infectious disease,0.5981481481481481
communicability end process boundary,SARS-CoV-2 incidence rate,0.630327868852459
communicability end process boundary,double-stranded DNA virus,0.6467213114754098
communicability end process boundary,incubation end temporal region,0.6621212121212122
communicability end process boundary,infectious disease incidence,0.621875
communicability end process boundary,virus translation stage,0.5855932203389831
communicability end process boundary,disease surveillance objective specification,0.6
communicability end process boundary,case isolation control strategy,0.6291044776119403
communicability end process boundary,virus release stage,0.5772727272727273
communicability end process boundary,virus,0.523170731707317
communicability end process boundary,virus replication,0.5820754716981132
communicability end process boundary,B cell receptor complex,0.6025423728813559
communicability end process boundary,infection incidence rate,0.65
communicability end process boundary,virus host,0.558695652173913
communicability end process boundary,double-stranded RNA virus,0.6467213114754098
communicability end process boundary,virus transcription stage,0.5975409836065574
communicability end process boundary,infectious disease lifetime prevalence,0.6391891891891892
communicability end process boundary,lower respiratory tract disease,0.6141791044776119
communicability end process boundary,infectious disease incidence proportion,0.65
communicability end process boundary,virus generative stage,0.5879310344827586
communicability end process boundary,acute infectious disease course,0.6440298507462687
communicability end process boundary,process,0.6127906976744186
communicability end process boundary,droplet pathogen transmission process,0.6417808219178082
communicability end process boundary,infectious disease sporadicity,0.6166666666666667
communicability end process boundary,communicability end process boundary,0.95
communicability end process boundary,latency end process boundary,0.825
communicability end process boundary,infectious disease epidemic,0.5928571428571429
communicability end process boundary,infectious agent generative stage,0.6239130434782608
communicability end process boundary,disease transmission model,0.6112903225806451
communicability end process boundary,negative-sense single-stranded RNA virus,0.6078947368421053
communicability end process boundary,COVID-19 incidence rate,0.6364406779661017
communicability end process boundary,negative regulation of developmental process,0.65
communicability end process boundary,chronic infectious disease course,0.6673913043478261
communicability end process boundary,COVID-19 epidemic,0.5820754716981132
communicability end process boundary,virus disorder,0.59
communicability end process boundary,process of establishing an infection,0.6166666666666667
communicability end process boundary,incubation end process boundary,0.8231343283582089
communicability end process boundary,SARS-CoV-2 uncoating stage,0.6274193548387097
communicability end process boundary,pathogen death process boundary,0.7783582089552239
communicability end process boundary,plan specification,0.5796296296296296
communicability end process boundary,latency end temporal region,0.6563492063492063
communicability end process boundary,SARS-CoV-2 penetration stage,0.590625
communicability end process boundary,virus adhesion susceptible cell,0.5843283582089552
communicability end process boundary,anatomical space,0.6423076923076922
communicability end process boundary,T cell receptor complex,0.6025423728813559
communicability end process boundary,respiratory system disease,0.6112903225806451
communicability end process boundary,indirect pathogen transmission process,0.6527027027027027
communicability end process boundary,planned process,0.6656862745098039
communicability end process boundary,generative stage,0.5846153846153846
communicability end process boundary,communicability interval,0.7666666666666666
communicability end process boundary,infectious disease control strategy,0.6190140845070422
communicability end process boundary,SARS-CoV-2 attachment stage,0.5928571428571429
communicability end process boundary,infectious disease pandemic,0.6087301587301588
communicability end process boundary,infectious structure generative stage,0.6143835616438357
communicability end process boundary,innate immune response,0.6396551724137931
communicability end process boundary,viral disease course,0.6464285714285714
communicability end process boundary,cell,0.5
communicability end process boundary,objective specification,0.6025423728813559
communicability end process boundary,disease course,0.61
communicability end process boundary,infectious disease course,0.630327868852459
communicability end process boundary,COVID-19 disease incidence proportion,0.6417808219178082
communicability end process boundary,coronavirus disease course,0.6596774193548387
communicability end process boundary,respiratory droplet virus fomite,0.6264705882352941
communicability end process boundary,infectious disease prevalence,0.6192307692307693
communicability end process boundary,SARS-CoV-2 genome replication stage,0.6049295774647887
communicability end process boundary,single-stranded DNA virus,0.6139344262295081
communicability end process boundary,COVID-19 mortality rate,0.6364406779661017
communicability end process boundary,process profile,0.6264705882352941
communicability end process boundary,negative regulation of life-sustaining process,0.6451219512195122
communicability end process boundary,place closure control strategy,0.6015151515151516
communicability end process boundary,viral disease,0.5928571428571429
communicability end process boundary,developmental process,0.6780701754385965
communicability end process boundary,contagiousness,0.63
communicability end process boundary,disease,0.5197674418604651
communicability end process boundary,biological process,0.6907407407407408
communicability end process boundary,humoral immune response,0.6533898305084747
communicability end process boundary,SARS-COV-2 adhesion susceptible cell,0.5888888888888889
communicability end process boundary,incubation start process boundary,0.7688405797101449
communicability end process boundary,object,0.5452380952380953
communicability end process boundary,pathogen birth process boundary,0.7783582089552239
communicability end process boundary,subclinical virus infection,0.6404761904761905
communicability end process boundary,establishment of localization in virus host,0.6272151898734176
communicability end process boundary,virus attachment stage,0.5879310344827586
communicability end process boundary,negative regulation of immune response,0.6256756756756756
communicability end process boundary,SARS-CoV-2 transcription stage,0.6015151515151516
communicability end process boundary,virus synthesis stage,0.5903508771929825
communicability end process boundary,object aggregate,0.5846153846153846
communicability end process boundary,long-term non-progressing infectious disease course,0.6454022988505748
communicability end process boundary,viral disease epidemic,0.6051724137931035
communicability end process boundary,communicability start temporal region,0.7513698630136986
communicability end process boundary,viral disease pandemic,0.6224137931034482
communicability end process boundary,virus penetration stage,0.5855932203389831
communicability end process boundary,algorithm,0.5388888888888889
communicability end process boundary,infectious disease endemicity,0.6192307692307693
communicability end process boundary,negative regulation of viral process,0.6444444444444444
communicability end process boundary,contact pathogen transmission process,0.6691780821917809
communicability end process boundary,function,0.5863636363636363
communicability end process boundary,communicability,0.7441176470588234
communicability end process boundary,symbiotic process,0.6764150943396227
communicability end process boundary,infection start process boundary,0.7735294117647058
communicability end process boundary,action specification,0.6107142857142857
communicability end process boundary,SARS-CoV-2 synthesis stage,0.5951612903225807
communicability end process boundary,latency start process boundary,0.7681818181818181
communicability end process boundary,infectious disease control objective specification,0.6127906976744186
communicability end process boundary,process of establishing viral infection,0.61
communicability end process boundary,negative regulation of biological process,0.6448051948051949
communicability end process boundary,polymerase chain reaction,0.630327868852459
communicability end process boundary,COVID-19 disease course,0.6364406779661017
communicability end process boundary,infectious disease incidence rate,0.6384057971014493
communicability end process boundary,communicability start process boundary,0.895945945945946
communicability end process boundary,process that results in death,0.65
communicability end process boundary,disordered virus,0.5653846153846154
communicability end process boundary,adaptive immune response,0.6333333333333333
communicability end process boundary,virus uncoating stage,0.6078947368421053
communicability end process boundary,establishment of a clinically abnormal colony,0.6228395061728395
communicability end process boundary,process boundary,0.7576923076923078
communicability end process boundary,coronavirus disease,0.6318181818181818
communicability end process boundary,positive-sense single-stranded RNA virus,0.6078947368421053
communicability end process boundary,horizontal pathogen transmission process,0.6473684210526315
communicability end process boundary,pathogen death temporal region,0.6166666666666667
communicability end process boundary,SARS-CoV-2 release stage,0.5833333333333334
communicability end process boundary,pathogen transmission process,0.6653846153846155
communicability end process boundary,cell space,0.5804347826086956
infectious disease incidence proportion,virus aggregate,0.5796296296296296
infectious disease incidence proportion,source of infection,0.656896551724138
infectious disease incidence proportion,virostatic disposition,0.6631147540983606
infectious disease incidence proportion,zoonotic disposition,0.6703389830508475
infectious disease incidence proportion,infectious disease mortality rate,0.7694444444444444
infectious disease incidence proportion,infection incidence rate profile,0.7739436619718311
infectious disease incidence proportion,infectious structure aggregate,0.696376811594203
infectious disease incidence proportion,communicability end temporal region,0.6662162162162162
infectious disease incidence proportion,subclinical coronavirus infection,0.6583333333333334
infectious disease incidence proportion,infection end temporal region,0.7294117647058823
infectious disease incidence proportion,infectious disease,0.7657894736842106
infectious disease incidence proportion,SARS-CoV-2 incidence rate,0.7
infectious disease incidence proportion,double-stranded DNA virus,0.60625
infectious disease incidence proportion,incubation end temporal region,0.696376811594203
infectious disease incidence proportion,site of infection,0.6642857142857143
infectious disease incidence proportion,virulence factor disposition,0.6888059701492537
infectious disease incidence proportion,viral adhesion disposition,0.6653846153846155
infectious disease incidence proportion,parasitostatic disposition,0.6653846153846155
infectious disease incidence proportion,infectious disease incidence,0.8679104477611941
infectious disease incidence proportion,reverse zoonotic disposition,0.6738805970149254
infectious disease incidence proportion,subclinical SARS-CoV-2 infection,0.6753521126760563
infectious disease incidence proportion,virus translation stage,0.6112903225806451
infectious disease incidence proportion,disease surveillance objective specification,0.6909638554216868
infectious disease incidence proportion,virus release stage,0.6224137931034482
infectious disease incidence proportion,infectious agent host role,0.7269230769230769
infectious disease incidence proportion,material entity,0.5981481481481481
infectious disease incidence proportion,asymptomatic infectious structure carrier,0.675
infectious disease incidence proportion,source of infection site,0.6404761904761905
infectious disease incidence proportion,virus,0.5181818181818182
infectious disease incidence proportion,virus replication,0.6464285714285714
infectious disease incidence proportion,B cell receptor complex,0.6112903225806451
infectious disease incidence proportion,passive immunization against infectious agent,0.6523809523809524
infectious disease incidence proportion,systematic infection,0.6703389830508475
infectious disease incidence proportion,infection incidence rate,0.7833333333333333
infectious disease incidence proportion,virus host,0.5724489795918367
infectious disease incidence proportion,double-stranded RNA virus,0.60625
infectious disease incidence proportion,virus transcription stage,0.653125
infectious disease incidence proportion,infectious disease lifetime prevalence,0.7876623376623377
infectious disease incidence proportion,toxin disposition,0.6642857142857143
infectious disease incidence proportion,lower respiratory tract disease,0.6071428571428572
infectious disease incidence proportion,infectious disease incidence proportion,0.95
infectious disease incidence proportion,virus generative stage,0.6139344262295081
infectious disease incidence proportion,acute infectious disease course,0.7642857142857143
infectious disease incidence proportion,cidal agent disposition,0.6758064516129032
infectious disease incidence proportion,infectious disorder,0.743103448275862
infectious disease incidence proportion,subclinical infection,0.6666666666666667
infectious disease incidence proportion,appearance of disorder,0.6139344262295081
infectious disease incidence proportion,simple infection,0.6681818181818181
infectious disease incidence proportion,parasiticidal disposition,0.653125
infectious disease incidence proportion,infectious disease sporadicity,0.7833333333333333
infectious disease incidence proportion,communicability end process boundary,0.65
infectious disease incidence proportion,infection incidence proportion profile,0.8266233766233766
infectious disease incidence proportion,infectious agent colony,0.7403225806451613
infectious disease incidence proportion,SARS-CoV-2 incidence proportion,0.7928571428571428
infectious disease incidence proportion,transmissibility disposition,0.658955223880597
infectious disease incidence proportion,latency end process boundary,0.6291044776119403
infectious disease incidence proportion,infectious disease epidemic,0.7984848484848485
infectious disease incidence proportion,infectious agent generative stage,0.7277777777777777
infectious disease incidence proportion,disease transmission model,0.65
infectious disease incidence proportion,endotoxin disposition,0.6666666666666667
infectious disease incidence proportion,negative-sense single-stranded RNA virus,0.6651898734177215
infectious disease incidence proportion,infectious structure host role,0.7108695652173913
infectious disease incidence proportion,COVID-19 incidence rate,0.7080645161290323
infectious disease incidence proportion,cytotoxin disposition,0.6666666666666667
infectious disease incidence proportion,community-acquired infection,0.6738805970149254
infectious disease incidence proportion,chronic infectious disease course,0.7555555555555555
infectious disease incidence proportion,asymptomatic infectious agent carrier,0.6868421052631578
infectious disease incidence proportion,nursing-home acquired infection,0.6785714285714286
infectious disease incidence proportion,COVID-19 epidemic,0.5928571428571429
infectious disease incidence proportion,secondary infection,0.6913793103448276
infectious disease incidence proportion,infection start temporal region,0.7214285714285714
infectious disease incidence proportion,infection incidence,0.760344827586207
infectious disease incidence proportion,virus disorder,0.6386792452830189
infectious disease incidence proportion,sterilizing immunity to infectious agent,0.639873417721519
infectious disease incidence proportion,diseased population,0.7258620689655172
infectious disease incidence proportion,primary infection,0.6464285714285714
infectious disease incidence proportion,process of establishing an infection,0.6633333333333334
infectious disease incidence proportion,incubation end process boundary,0.6785714285714286
infectious disease incidence proportion,SARS-CoV-2 disorder,0.6051724137931035
infectious disease incidence proportion,collective pathogenic disposition,0.6861111111111111
infectious disease incidence proportion,neurotoxin disposition,0.6795081967213115
infectious disease incidence proportion,COVID-19 incidence,0.6780701754385965
infectious disease incidence proportion,latency end temporal region,0.6469696969696969
infectious disease incidence proportion,innate immunity to infectious agent,0.6527027027027027
infectious disease incidence proportion,infectious structure,0.6872881355932203
infectious disease incidence proportion,virus adhesion susceptible cell,0.65
infectious disease incidence proportion,collective disposition,0.6795081967213115
infectious disease incidence proportion,infection,0.6375
infectious disease incidence proportion,static agent disposition,0.6563492063492063
infectious disease incidence proportion,T cell receptor complex,0.6274193548387097
infectious disease incidence proportion,infectious structure host,0.715625
infectious disease incidence proportion,infectious agent population,0.7833333333333333
infectious disease incidence proportion,respiratory system disease,0.6346153846153847
infectious disease incidence proportion,leukocyte-mediated immunity to infectious agent,0.6476744186046511
infectious disease incidence proportion,humoral immunity to infectious agent,0.65
infectious disease incidence proportion,infectious disease control strategy,0.7878378378378378
infectious disease incidence proportion,infectious disease pandemic,0.7984848484848485
infectious disease incidence proportion,infectious structure generative stage,0.7131578947368421
infectious disease incidence proportion,immunosuppressive disposition,0.6705882352941177
infectious disease incidence proportion,pathogenic disposition,0.6631147540983606
infectious disease incidence proportion,viral disease course,0.6703389830508475
infectious disease incidence proportion,intracellular infection,0.6758064516129032
infectious disease incidence proportion,secondary infection role,0.6722222222222223
infectious disease incidence proportion,metastatic infection,0.6703389830508475
infectious disease incidence proportion,passive immunity to infectious agent,0.65
infectious disease incidence proportion,infectious disposition,0.7778688524590163
infectious disease incidence proportion,vaccination against infectious agent,0.6766666666666665
infectious disease incidence proportion,acute infection,0.6722222222222223
infectious disease incidence proportion,susceptibility to infectious agent,0.6554794520547945
infectious disease incidence proportion,bacteriostatic disposition,0.6807692307692308
infectious disease incidence proportion,bactericidal disposition,0.6722222222222223
infectious disease incidence proportion,source of infection role,0.6404761904761905
infectious disease incidence proportion,chronic infection,0.6642857142857143
infectious disease incidence proportion,invasion disposition,0.6872881355932203
infectious disease incidence proportion,disease course,0.6575471698113208
infectious disease incidence proportion,infectious disease course,0.79375
infectious disease incidence proportion,viricidal disposition,0.6666666666666667
infectious disease incidence proportion,acquired immunity to infectious agent,0.6473684210526315
infectious disease incidence proportion,complex infection,0.6642857142857143
infectious disease incidence proportion,COVID-19 disease incidence proportion,0.8578947368421052
infectious disease incidence proportion,coronavirus disease course,0.6961538461538461
infectious disease incidence proportion,infection incidence proportion,0.8702898550724637
infectious disease incidence proportion,symptomatic infectious agent carrier,0.69
infectious disease incidence proportion,respiratory droplet virus fomite,0.6190140845070422
infectious disease incidence proportion,infectious disease prevalence,0.7882352941176471
infectious disease incidence proportion,disposition,0.63
infectious disease incidence proportion,single-stranded DNA virus,0.621875
infectious disease incidence proportion,infected population,0.7258620689655172
infectious disease incidence proportion,COVID-19 mortality rate,0.5951612903225807
infectious disease incidence proportion,viral disease,0.6230769230769231
infectious disease incidence proportion,primary infection role,0.6467213114754098
infectious disease incidence proportion,adhesion disposition,0.6703389830508475
infectious disease incidence proportion,infection incidence profile,0.7984848484848485
infectious disease incidence proportion,disease,0.6021739130434782
infectious disease incidence proportion,symptomatic infectious structure carrier,0.6778481012658227
infectious disease incidence proportion,primary infectious disposition,0.7398550724637681
infectious disease incidence proportion,infection prevalence,0.7042372881355932
infectious disease incidence proportion,coronavirus disorder,0.6364406779661017
infectious disease incidence proportion,infectious pathogen transmissibility,0.6766666666666665
infectious disease incidence proportion,SARS-CoV-2 incidence,0.6703389830508475
infectious disease incidence proportion,infectious human pathogen,0.73125
infectious disease incidence proportion,subclinical virus infection,0.6772727272727272
infectious disease incidence proportion,establishment of localization in virus host,0.6329268292682927
infectious disease incidence proportion,immunization against infectious agent,0.6736842105263158
infectious disease incidence proportion,virus attachment stage,0.6139344262295081
infectious disease incidence proportion,virus synthesis stage,0.6166666666666667
infectious disease incidence proportion,SARS-COV-2 adhesion disposition,0.6642857142857143
infectious disease incidence proportion,invasive disposition,0.6703389830508475
infectious disease incidence proportion,infectious agent host,0.7333333333333333
infectious disease incidence proportion,long-term non-progressing infectious disease course,0.6944444444444444
infectious disease incidence proportion,viral disease epidemic,0.6795081967213115
infectious disease incidence proportion,fungicidal disposition,0.6631147540983606
infectious disease incidence proportion,viral disease pandemic,0.6795081967213115
infectious disease incidence proportion,virus penetration stage,0.6435483870967742
infectious disease incidence proportion,acute respiratory distress syndrome,0.6527027027027027
infectious disease incidence proportion,division of geopolitical entity,0.6214285714285714
infectious disease incidence proportion,infectious disease endemicity,0.8029411764705883
infectious disease incidence proportion,disorder,0.5776595744680851
infectious disease incidence proportion,herd immunity to infectious organism,0.6366666666666667
infectious disease incidence proportion,extracellular infection,0.6596774193548387
infectious disease incidence proportion,exotoxin disposition,0.6703389830508475
infectious disease incidence proportion,infectious agent reservoir,0.7423076923076922
infectious disease incidence proportion,COVID-19 pandemic,0.5928571428571429
infectious disease incidence proportion,infection start process boundary,0.6894366197183097
infectious disease incidence proportion,action specification,0.6872881355932203
infectious disease incidence proportion,processed material,0.5903508771929825
infectious disease incidence proportion,infectious disease control objective specification,0.7758426966292135
infectious disease incidence proportion,COVID-19 lifetime prevalence,0.6291044776119403
infectious disease incidence proportion,opportunistic infectious disposition,0.7166666666666667
infectious disease incidence proportion,process of establishing viral infection,0.6679487179487179
infectious disease incidence proportion,enterotoxin disposition,0.6758064516129032
infectious disease incidence proportion,COVID-19 disease course,0.6758064516129032
infectious disease incidence proportion,infectious disease incidence rate,0.8805555555555555
infectious disease incidence proportion,COVID-19 prevalence,0.6051724137931035
infectious disease incidence proportion,active immunization against infectious agent,0.6548192771084337
infectious disease incidence proportion,SARS-COV-2 prevalence,0.6
infectious disease incidence proportion,disordered virus,0.5954545454545455
infectious disease incidence proportion,collective resistance disposition,0.7
infectious disease incidence proportion,fungistatic disposition,0.6758064516129032
infectious disease incidence proportion,virus uncoating stage,0.6166666666666667
infectious disease incidence proportion,local infection,0.6537037037037037
infectious disease incidence proportion,infectious agent,0.7227272727272727
infectious disease incidence proportion,establishment of a clinically abnormal colony,0.6404761904761905
infectious disease incidence proportion,coronavirus disease,0.656896551724138
infectious disease incidence proportion,positive-sense single-stranded RNA virus,0.6525316455696202
infectious disease incidence proportion,hospital-acquired infection,0.6621212121212122
infectious disease incidence proportion,drug susceptibility of infectious agent,0.6423076923076922
infectious disease incidence proportion,material processing,0.6051724137931035
negative regulation of developmental process,virostatic disposition,0.6015151515151516
negative regulation of developmental process,zoonotic disposition,0.575
negative regulation of developmental process,immune response,0.6025423728813559
negative regulation of developmental process,infectious disease mortality rate,0.6577922077922078
negative regulation of developmental process,infection incidence rate profile,0.6605263157894737
negative regulation of developmental process,communicability end temporal region,0.6272151898734176
negative regulation of developmental process,pathogen generative stage,0.6384057971014493
negative regulation of developmental process,biological regulation,0.65
negative regulation of developmental process,primary pathogen,0.5833333333333334
negative regulation of developmental process,surveillance process,0.66875
negative regulation of developmental process,infection end temporal region,0.6554794520547945
negative regulation of developmental process,geospatial location,0.6246031746031746
negative regulation of developmental process,vector control strategy,0.6291044776119403
negative regulation of developmental process,SARS-CoV-2 incidence rate,0.6094202898550725
negative regulation of developmental process,incubation end temporal region,0.6662162162162162
negative regulation of developmental process,site of infection,0.5975409836065574
negative regulation of developmental process,virulence factor disposition,0.6166666666666667
negative regulation of developmental process,viral adhesion disposition,0.6214285714285714
negative regulation of developmental process,parasitostatic disposition,0.6071428571428572
negative regulation of developmental process,negative regulation of production,0.8006493506493507
negative regulation of developmental process,reverse zoonotic disposition,0.6444444444444444
negative regulation of developmental process,virus translation stage,0.6440298507462687
negative regulation of developmental process,disease surveillance objective specification,0.6545454545454545
negative regulation of developmental process,case isolation control strategy,0.6766666666666665
negative regulation of developmental process,physiologic immunosuppression,0.6143835616438357
negative regulation of developmental process,virus release stage,0.6087301587301588
negative regulation of developmental process,source of infection site,0.6117647058823529
negative regulation of developmental process,quarantine control strategy,0.6471830985915493
negative regulation of developmental process,B cell receptor complex,0.6141791044776119
negative regulation of developmental process,infection incidence rate,0.6411764705882353
negative regulation of developmental process,double-stranded RNA virus,0.6239130434782608
negative regulation of developmental process,virus transcription stage,0.6239130434782608
negative regulation of developmental process,toxin disposition,0.5811475409836065
negative regulation of developmental process,lower respiratory tract disease,0.6233333333333334
negative regulation of developmental process,virus generative stage,0.6166666666666667
negative regulation of developmental process,acute infectious disease course,0.65
negative regulation of developmental process,cidal agent disposition,0.5992537313432835
negative regulation of developmental process,process,0.5872549019607843
negative regulation of developmental process,droplet pathogen transmission process,0.6722222222222223
negative regulation of developmental process,parasiticidal disposition,0.6239130434782608
negative regulation of developmental process,communicability end process boundary,0.65
negative regulation of developmental process,transmissibility disposition,0.5888888888888889
negative regulation of developmental process,latency end process boundary,0.6583333333333334
negative regulation of developmental process,infectious agent generative stage,0.6448051948051949
negative regulation of developmental process,endotoxin disposition,0.5884615384615385
negative regulation of developmental process,vector surveillance,0.6246031746031746
negative regulation of developmental process,negative regulation of establishment of localization,0.7833333333333333
negative regulation of developmental process,negative-sense single-stranded RNA virus,0.6880952380952381
negative regulation of developmental process,susceptible population,0.6318181818181818
negative regulation of developmental process,COVID-19 incidence rate,0.5992537313432835
negative regulation of developmental process,cytotoxin disposition,0.5884615384615385
negative regulation of developmental process,negative regulation of developmental process,0.95
negative regulation of developmental process,chronic infectious disease course,0.6318181818181818
negative regulation of developmental process,negative regulation of replication,0.7961538461538461
negative regulation of developmental process,establishment of localization in human host,0.656896551724138
negative regulation of developmental process,primary infection,0.5811475409836065
negative regulation of developmental process,process of establishing an infection,0.6
negative regulation of developmental process,incubation end process boundary,0.69
negative regulation of developmental process,collective pathogenic disposition,0.6448051948051949
negative regulation of developmental process,neurotoxin disposition,0.6166666666666667
negative regulation of developmental process,SARS-CoV-2 uncoating stage,0.6214285714285714
negative regulation of developmental process,pathogen death process boundary,0.6633333333333334
negative regulation of developmental process,plan specification,0.5790322580645162
negative regulation of developmental process,latency end temporal region,0.6471830985915493
negative regulation of developmental process,SARS-CoV-2 penetration stage,0.6305555555555555
negative regulation of developmental process,virus adhesion susceptible cell,0.65
negative regulation of developmental process,collective disposition,0.6015151515151516
negative regulation of developmental process,static agent disposition,0.6264705882352941
negative regulation of developmental process,T cell receptor complex,0.6291044776119403
negative regulation of developmental process,respiratory system disease,0.6214285714285714
negative regulation of developmental process,indirect pathogen transmission process,0.6817073170731708
negative regulation of developmental process,planned process,0.6533898305084747
negative regulation of developmental process,generative stage,0.6333333333333333
negative regulation of developmental process,infectious disease control strategy,0.6525316455696202
negative regulation of developmental process,SARS-CoV-2 attachment stage,0.6049295774647887
negative regulation of developmental process,infectious structure generative stage,0.6475308641975309
negative regulation of developmental process,immunosuppressive disposition,0.6006849315068493
negative regulation of developmental process,innate immune response,0.6469696969696969
negative regulation of developmental process,pathogenic disposition,0.5863636363636363
negative regulation of developmental process,viral disease course,0.60625
negative regulation of developmental process,infectious disposition,0.6015151515151516
negative regulation of developmental process,bacteriostatic disposition,0.6214285714285714
negative regulation of developmental process,epitope site,0.5928571428571429
negative regulation of developmental process,bactericidal disposition,0.6264705882352941
negative regulation of developmental process,invasion disposition,0.621875
negative regulation of developmental process,disease course,0.5706896551724138
negative regulation of developmental process,infectious disease course,0.6239130434782608
negative regulation of developmental process,viricidal disposition,0.6038461538461539
negative regulation of developmental process,coronavirus disease course,0.6214285714285714
negative regulation of developmental process,susceptible organism,0.60625
negative regulation of developmental process,pathogen portal of exit site,0.6444444444444444
negative regulation of developmental process,SARS-CoV-2 genome replication stage,0.6525316455696202
negative regulation of developmental process,disposition,0.5409090909090909
negative regulation of developmental process,COVID-19 mortality rate,0.5992537313432835
negative regulation of developmental process,process profile,0.5855932203389831
negative regulation of developmental process,negative regulation of life-sustaining process,0.8388888888888889
negative regulation of developmental process,place closure control strategy,0.6256756756756756
negative regulation of developmental process,primary infection role,0.6318181818181818
negative regulation of developmental process,primary immunodeficiency,0.5970588235294118
negative regulation of developmental process,adhesion disposition,0.60625
negative regulation of developmental process,pathogen portal of entry site,0.6554794520547945
negative regulation of developmental process,developmental process,0.7730769230769231
negative regulation of developmental process,biological process,0.6758064516129032
negative regulation of developmental process,site,0.5125
negative regulation of developmental process,primary infectious disposition,0.5986486486486486
negative regulation of developmental process,humoral immune response,0.5992537313432835
negative regulation of developmental process,SARS-COV-2 adhesion susceptible cell,0.6375
negative regulation of developmental process,incubation start process boundary,0.6837662337662337
negative regulation of developmental process,pathogen surveillance,0.6192307692307693
negative regulation of developmental process,pathogen birth process boundary,0.6366666666666667
negative regulation of developmental process,infectious human pathogen,0.6384057971014493
negative regulation of developmental process,colonization of human,0.65
negative regulation of developmental process,virus attachment stage,0.6166666666666667
negative regulation of developmental process,negative regulation of immune response,0.8158536585365854
negative regulation of developmental process,SARS-CoV-2 transcription stage,0.6256756756756756
negative regulation of developmental process,virus synthesis stage,0.5884615384615385
negative regulation of developmental process,SARS-COV-2 adhesion disposition,0.61
negative regulation of developmental process,invasive disposition,0.60625
negative regulation of developmental process,long-term non-progressing infectious disease course,0.6394736842105263
negative regulation of developmental process,fungicidal disposition,0.6166666666666667
negative regulation of developmental process,virus penetration stage,0.6440298507462687
negative regulation of developmental process,algorithm,0.5254716981132076
negative regulation of developmental process,division of geopolitical entity,0.6766666666666665
negative regulation of developmental process,negative regulation of viral process,0.875
negative regulation of developmental process,contact pathogen transmission process,0.6845679012345678
negative regulation of developmental process,function,0.5461538461538461
negative regulation of developmental process,symbiotic process,0.630327868852459
negative regulation of developmental process,exotoxin disposition,0.590625
negative regulation of developmental process,infection start process boundary,0.6736842105263158
negative regulation of developmental process,action specification,0.60625
negative regulation of developmental process,SARS-CoV-2 synthesis stage,0.5785714285714285
negative regulation of developmental process,latency start process boundary,0.6527027027027027
negative regulation of developmental process,infectious disease control objective specification,0.6414893617021277
negative regulation of developmental process,opportunistic infectious disposition,0.6125
negative regulation of developmental process,process of establishing viral infection,0.6066265060240964
negative regulation of developmental process,negative regulation of biological process,0.8617647058823529
negative regulation of developmental process,enterotoxin disposition,0.6291044776119403
negative regulation of developmental process,polymerase chain reaction,0.6094202898550725
negative regulation of developmental process,COVID-19 disease course,0.5843283582089552
negative regulation of developmental process,infectious disease incidence rate,0.6448051948051949
negative regulation of developmental process,communicability start process boundary,0.6451219512195122
negative regulation of developmental process,process that results in death,0.6554794520547945
negative regulation of developmental process,single-stranded RNA retrovirus,0.6391891891891892
negative regulation of developmental process,active immunization against infectious agent,0.6659090909090909
negative regulation of developmental process,collective resistance disposition,0.6448051948051949
negative regulation of developmental process,adaptive immune response,0.6558823529411765
negative regulation of developmental process,fungistatic disposition,0.6141791044776119
negative regulation of developmental process,virus uncoating stage,0.6192307692307693
negative regulation of developmental process,establishment of a clinically abnormal colony,0.6297752808988765
negative regulation of developmental process,process boundary,0.5666666666666667
negative regulation of developmental process,positive-sense single-stranded RNA virus,0.6404761904761905
negative regulation of developmental process,horizontal pathogen transmission process,0.6642857142857143
negative regulation of developmental process,SARS-CoV-2 release stage,0.6117647058823529
negative regulation of developmental process,pathogen transmission process,0.682876712328767
assay,infectious disease mortality rate,0.5552631578947369
assay,SARS-CoV-2 incidence rate,0.55
assay,serology assay,0.7131578947368421
assay,viral plaque assay,0.6673913043478261
assay,COVID-19 mortality rate,0.5214285714285714
assay,assay,0.95
assay,division of geopolitical entity,0.5333333333333333
assay,infectious disease incidence rate,0.5289473684210526
assay,establishment of a clinically abnormal colony,0.53
collective resistance disposition,virus aggregate,0.575
collective resistance disposition,virostatic disposition,0.7772727272727272
collective resistance disposition,information content entity,0.6025423728813559
collective resistance disposition,zoonotic disposition,0.7518867924528303
collective resistance disposition,immune response,0.6375
collective resistance disposition,infectious disease mortality rate,0.6469696969696969
collective resistance disposition,infection incidence rate profile,0.65
collective resistance disposition,infectious structure aggregate,0.6246031746031746
collective resistance disposition,communicability end temporal region,0.6411764705882353
collective resistance disposition,geographical entity,0.5846153846153846
collective resistance disposition,biological regulation,0.6537037037037037
collective resistance disposition,surveillance process,0.6575471698113208
collective resistance disposition,infection end temporal region,0.6596774193548387
collective resistance disposition,vector control strategy,0.6107142857142857
collective resistance disposition,SARS-CoV-2 incidence rate,0.6224137931034482
collective resistance disposition,incubation end temporal region,0.6404761904761905
collective resistance disposition,site of infection,0.67
collective resistance disposition,resistant entity,0.6744897959183673
collective resistance disposition,virulence factor disposition,0.7614754098360657
collective resistance disposition,viral adhesion disposition,0.7550847457627118
collective resistance disposition,parasitostatic disposition,0.7720338983050847
collective resistance disposition,negative regulation of production,0.7075757575757575
collective resistance disposition,reverse zoonotic disposition,0.7614754098360657
collective resistance disposition,establishment of localization in host,0.6357142857142857
collective resistance disposition,disease surveillance objective specification,0.6967532467532468
collective resistance disposition,case isolation control strategy,0.621875
collective resistance disposition,infectious agent host role,0.6533898305084747
collective resistance disposition,macromolecular complex,0.5954545454545455
collective resistance disposition,material entity,0.6166666666666667
collective resistance disposition,SARS-CoV-2 aggregate,0.6009433962264151
collective resistance disposition,asymptomatic infectious structure carrier,0.6121621621621621
collective resistance disposition,source of infection site,0.6605263157894737
collective resistance disposition,architectual structure,0.6136363636363636
collective resistance disposition,quarantine control strategy,0.6
collective resistance disposition,B cell receptor complex,0.6464285714285714
collective resistance disposition,infection incidence rate,0.6429824561403508
collective resistance disposition,colonized host,0.6414893617021277
collective resistance disposition,virus host,0.6127906976744186
collective resistance disposition,entity,0.5525641025641026
collective resistance disposition,toxin disposition,0.75
collective resistance disposition,cidal agent disposition,0.7535714285714286
collective resistance disposition,genetic resistance to pathogen,0.7515873015873015
collective resistance disposition,parasiticidal disposition,0.743103448275862
collective resistance disposition,communicability end process boundary,0.6384057971014493
collective resistance disposition,directive information content entity,0.6673913043478261
collective resistance disposition,acellular structure aggregate,0.6274193548387097
collective resistance disposition,transmissibility disposition,0.7450819672131148
collective resistance disposition,latency end process boundary,0.6467213114754098
collective resistance disposition,colonization of host,0.6386792452830189
collective resistance disposition,realizable entity,0.61
collective resistance disposition,endotoxin disposition,0.7462962962962962
collective resistance disposition,vector surveillance,0.6615384615384616
collective resistance disposition,negative regulation of establishment of localization,0.6852941176470588
collective resistance disposition,infectious structure host role,0.6722222222222223
collective resistance disposition,COVID-19 incidence rate,0.6285714285714286
collective resistance disposition,cytotoxin disposition,0.7648148148148148
collective resistance disposition,negative regulation of developmental process,0.6448051948051949
collective resistance disposition,antibiotic resistance,0.7092592592592593
collective resistance disposition,host,0.5310810810810811
collective resistance disposition,descriptive information content entity,0.6612676056338028
collective resistance disposition,negative regulation of replication,0.703731343283582
collective resistance disposition,resistance to drug,0.7049019607843137
collective resistance disposition,sterilizing immunity to infectious agent,0.6280821917808219
collective resistance disposition,establishment of localization in human host,0.6210526315789474
collective resistance disposition,acellular structure,0.6038461538461539
collective resistance disposition,incubation end process boundary,0.6375
collective resistance disposition,collective pathogenic disposition,0.8439393939393939
collective resistance disposition,neurotoxin disposition,0.740909090909091
collective resistance disposition,dead-end host role,0.6068627450980393
collective resistance disposition,molecular entity,0.6336734693877552
collective resistance disposition,plan specification,0.6656862745098039
collective resistance disposition,definitive host role,0.6386792452830189
collective resistance disposition,latency end temporal region,0.65
collective resistance disposition,coronavirus aggregate,0.5981481481481481
collective resistance disposition,innate immunity to infectious agent,0.6264705882352941
collective resistance disposition,infectious structure,0.619811320754717
collective resistance disposition,collective disposition,0.85
collective resistance disposition,static agent disposition,0.7482456140350877
collective resistance disposition,T cell receptor complex,0.6464285714285714
collective resistance disposition,infectious structure host,0.6741379310344828
collective resistance disposition,respiratory system disease,0.6533898305084747
collective resistance disposition,entry into host,0.6375
collective resistance disposition,leukocyte-mediated immunity to infectious agent,0.6625
collective resistance disposition,adhesion of symbiont to host,0.6139344262295081
collective resistance disposition,humoral immunity to infectious agent,0.6239130434782608
collective resistance disposition,infectious disease control strategy,0.6411764705882353
collective resistance disposition,infectious structure generative stage,0.6357142857142857
collective resistance disposition,immunosuppressive disposition,0.7403225806451613
collective resistance disposition,innate immune response,0.65
collective resistance disposition,pathogenic disposition,0.740909090909091
collective resistance disposition,entry into host through host barriers,0.6071428571428572
collective resistance disposition,passive immunity to infectious agent,0.6384057971014493
collective resistance disposition,infectious disposition,0.759090909090909
collective resistance disposition,bacteriostatic disposition,0.8059322033898306
collective resistance disposition,epitope site,0.6277777777777778
collective resistance disposition,immunity to pathogen,0.6009433962264151
collective resistance disposition,bactericidal disposition,0.7657894736842106
collective resistance disposition,pathogen host,0.6021739130434782
collective resistance disposition,invasion disposition,0.7707547169811321
collective resistance disposition,viricidal disposition,0.7462962962962962
collective resistance disposition,acquired immunity to infectious agent,0.6357142857142857
collective resistance disposition,complex infection,0.69
collective resistance disposition,prion aggregate,0.575
collective resistance disposition,intermediate host,0.67
collective resistance disposition,pathogen portal of exit site,0.630327868852459
collective resistance disposition,anatomical entity,0.59
collective resistance disposition,disposition,0.7
collective resistance disposition,COVID-19 mortality rate,0.6107142857142857
collective resistance disposition,negative regulation of life-sustaining process,0.6651898734177215
collective resistance disposition,place closure control strategy,0.6087301587301588
collective resistance disposition,geopolitical entity,0.6230769230769231
collective resistance disposition,adhesion disposition,0.7518867924528303
collective resistance disposition,leukocyte mediated immunity,0.6833333333333332
collective resistance disposition,pathogen portal of entry site,0.6274193548387097
collective resistance disposition,viroid aggregate,0.5928571428571429
collective resistance disposition,symptomatic infectious structure carrier,0.6143835616438357
collective resistance disposition,site,0.5581081081081081
collective resistance disposition,primary infectious disposition,0.7198412698412698
collective resistance disposition,pathogen host role,0.6068627450980393
collective resistance disposition,designative information content entity,0.6471830985915493
collective resistance disposition,humoral immune response,0.6464285714285714
collective resistance disposition,object,0.5525641025641026
collective resistance disposition,intermediate host role,0.6681818181818181
collective resistance disposition,dead-end host,0.6021739130434782
collective resistance disposition,pathogen surveillance,0.6351851851851852
collective resistance disposition,host role,0.569047619047619
collective resistance disposition,resistance to pathogen,0.7227272727272727
collective resistance disposition,establishment of localization in virus host,0.6342105263157894
collective resistance disposition,negative regulation of immune response,0.6753521126760563
collective resistance disposition,immaterial entity,0.61
collective resistance disposition,SARS-COV-2 adhesion disposition,0.7625
collective resistance disposition,object aggregate,0.6336734693877552
collective resistance disposition,invasive disposition,0.7707547169811321
collective resistance disposition,infectious agent host,0.6537037037037037
collective resistance disposition,fungicidal disposition,0.7227272727272727
collective resistance disposition,division of geopolitical entity,0.6375
collective resistance disposition,negative regulation of viral process,0.6673913043478261
collective resistance disposition,herd immunity to infectious organism,0.6094202898550725
collective resistance disposition,exotoxin disposition,0.7518867924528303
collective resistance disposition,immunoglobulin complex,0.5772727272727273
collective resistance disposition,action specification,0.6764150943396227
collective resistance disposition,protective resistance,0.7833333333333333
collective resistance disposition,infectious disease control objective specification,0.6789156626506024
collective resistance disposition,symbiont host role,0.6068627450980393
collective resistance disposition,opportunistic infectious disposition,0.7253623188405797
collective resistance disposition,negative regulation of biological process,0.6527027027027027
collective resistance disposition,enterotoxin disposition,0.7714285714285714
collective resistance disposition,polymerase chain reaction,0.6913793103448276
collective resistance disposition,infectious disease incidence rate,0.6469696969696969
collective resistance disposition,collective resistance disposition,0.95
collective resistance disposition,adaptive immune response,0.6780701754385965
collective resistance disposition,fungistatic disposition,0.7535714285714286
collective resistance disposition,establishment of a clinically abnormal colony,0.6038461538461539
collective resistance disposition,definitive host,0.6375
establishment of localization in host,virostatic disposition,0.6364406779661017
establishment of localization in host,zoonotic disposition,0.6078947368421053
establishment of localization in host,infectious structure aggregate,0.5992537313432835
establishment of localization in host,communicability end temporal region,0.6305555555555555
establishment of localization in host,infection end temporal region,0.6318181818181818
establishment of localization in host,incubation end temporal region,0.6291044776119403
establishment of localization in host,virulence factor disposition,0.65
establishment of localization in host,viral adhesion disposition,0.6404761904761905
establishment of localization in host,parasitostatic disposition,0.6404761904761905
establishment of localization in host,reverse zoonotic disposition,0.65
establishment of localization in host,establishment of localization in host,0.95
establishment of localization in host,infectious agent host role,0.6722222222222223
establishment of localization in host,asymptomatic infectious structure carrier,0.6294871794871795
establishment of localization in host,architectual structure,0.6025423728813559
establishment of localization in host,B cell receptor complex,0.5833333333333334
establishment of localization in host,colonized host,0.6460784313725491
establishment of localization in host,virus host,0.598936170212766
establishment of localization in host,toxin disposition,0.6351851851851852
establishment of localization in host,cidal agent disposition,0.65
establishment of localization in host,parasiticidal disposition,0.6435483870967742
establishment of localization in host,communicability end process boundary,0.6143835616438357
establishment of localization in host,acellular structure aggregate,0.5712121212121213
establishment of localization in host,invasion factor,0.6038461538461539
establishment of localization in host,transmissibility disposition,0.65
establishment of localization in host,latency end process boundary,0.5884615384615385
establishment of localization in host,colonization of host,0.730701754385965
establishment of localization in host,endotoxin disposition,0.6396551724137931
establishment of localization in host,negative regulation of establishment of localization,0.7758426966292135
establishment of localization in host,infectious structure host role,0.6440298507462687
establishment of localization in host,establishment of localization,0.8893939393939394
establishment of localization in host,cytotoxin disposition,0.6224137931034482
establishment of localization in host,host,0.5475609756097561
establishment of localization in host,establishment of localization in human host,0.9125
establishment of localization in host,acellular structure,0.5928571428571429
establishment of localization in host,virulence factor,0.6009433962264151
establishment of localization in host,incubation end process boundary,0.6411764705882353
establishment of localization in host,collective pathogenic disposition,0.65
establishment of localization in host,neurotoxin disposition,0.6364406779661017
establishment of localization in host,dead-end host role,0.6136363636363636
establishment of localization in host,plan specification,0.6318181818181818
establishment of localization in host,definitive host role,0.6429824561403508
establishment of localization in host,latency end temporal region,0.621875
establishment of localization in host,infectious structure,0.6254385964912281
establishment of localization in host,collective disposition,0.6364406779661017
establishment of localization in host,static agent disposition,0.6795081967213115
establishment of localization in host,T cell receptor complex,0.5833333333333334
establishment of localization in host,infectious structure host,0.6596774193548387
establishment of localization in host,respiratory system disease,0.6087301587301588
establishment of localization in host,entry into host,0.6807692307692308
establishment of localization in host,adhesion of symbiont to host,0.7115384615384616
establishment of localization in host,infectious structure generative stage,0.6121621621621621
establishment of localization in host,immunosuppressive disposition,0.6166666666666667
establishment of localization in host,pathogenic disposition,0.6364406779661017
establishment of localization in host,entry into host through host barriers,0.6527027027027027
establishment of localization in host,infectious disposition,0.6533898305084747
establishment of localization in host,bacteriostatic disposition,0.6404761904761905
establishment of localization in host,bactericidal disposition,0.630327868852459
establishment of localization in host,pathogen host,0.63
establishment of localization in host,invasion disposition,0.6429824561403508
establishment of localization in host,viricidal disposition,0.6224137931034482
establishment of localization in host,intermediate host,0.6537037037037037
establishment of localization in host,disposition,0.6166666666666667
establishment of localization in host,place closure control strategy,0.6141791044776119
establishment of localization in host,adhesion disposition,0.6429824561403508
establishment of localization in host,symptomatic infectious structure carrier,0.6188311688311688
establishment of localization in host,primary infectious disposition,0.6440298507462687
establishment of localization in host,pathogen host role,0.6136363636363636
establishment of localization in host,intermediate host role,0.6364406779661017
establishment of localization in host,dead-end host,0.63
establishment of localization in host,host role,0.558695652173913
establishment of localization in host,establishment of localization in virus host,0.9125
establishment of localization in host,SARS-COV-2 adhesion disposition,0.6558823529411765
establishment of localization in host,invasive disposition,0.6254385964912281
establishment of localization in host,infectious agent host,0.6913793103448276
establishment of localization in host,fungicidal disposition,0.6194915254237288
establishment of localization in host,division of geopolitical entity,0.6705882352941177
establishment of localization in host,exotoxin disposition,0.6429824561403508
establishment of localization in host,symbiont host role,0.6318181818181818
establishment of localization in host,opportunistic infectious disposition,0.6554794520547945
establishment of localization in host,enterotoxin disposition,0.65
establishment of localization in host,collective resistance disposition,0.6357142857142857
establishment of localization in host,fungistatic disposition,0.6333333333333333
establishment of localization in host,local infection,0.6423076923076922
establishment of localization in host,establishment of a clinically abnormal colony,0.7548780487804878
establishment of localization in host,adhesion factor,0.6230769230769231
establishment of localization in host,definitive host,0.6615384615384616
negative regulation of life-sustaining process,virostatic disposition,0.6264705882352941
negative regulation of life-sustaining process,zoonotic disposition,0.6015151515151516
negative regulation of life-sustaining process,immune response,0.5975409836065574
negative regulation of life-sustaining process,infectious disease mortality rate,0.639873417721519
negative regulation of life-sustaining process,infection incidence rate profile,0.6551282051282051
negative regulation of life-sustaining process,communicability end temporal region,0.5981481481481481
negative regulation of life-sustaining process,pathogen generative stage,0.6471830985915493
negative regulation of life-sustaining process,biological regulation,0.6440298507462687
negative regulation of life-sustaining process,surveillance process,0.6621212121212122
negative regulation of life-sustaining process,infection end temporal region,0.6233333333333334
negative regulation of life-sustaining process,geospatial location,0.6192307692307693
negative regulation of life-sustaining process,vector control strategy,0.6094202898550725
negative regulation of life-sustaining process,SARS-CoV-2 incidence rate,0.6049295774647887
negative regulation of life-sustaining process,incubation end temporal region,0.6342105263157894
negative regulation of life-sustaining process,site of infection,0.6404761904761905
negative regulation of life-sustaining process,virulence factor disposition,0.6391891891891892
negative regulation of life-sustaining process,viral adhesion disposition,0.6444444444444444
negative regulation of life-sustaining process,parasitostatic disposition,0.6305555555555555
negative regulation of life-sustaining process,negative regulation of production,0.7917721518987341
negative regulation of life-sustaining process,reverse zoonotic disposition,0.6527027027027027
negative regulation of life-sustaining process,virus translation stage,0.6673913043478261
negative regulation of life-sustaining process,disease surveillance objective specification,0.6388888888888888
negative regulation of life-sustaining process,case isolation control strategy,0.6577922077922078
negative regulation of life-sustaining process,virus release stage,0.6346153846153847
negative regulation of life-sustaining process,source of infection site,0.65
negative regulation of life-sustaining process,quarantine control strategy,0.6280821917808219
negative regulation of life-sustaining process,B cell receptor complex,0.5949275362318841
negative regulation of life-sustaining process,infection incidence rate,0.65
negative regulation of life-sustaining process,double-stranded RNA virus,0.6190140845070422
negative regulation of life-sustaining process,virus transcription stage,0.6471830985915493
negative regulation of life-sustaining process,toxin disposition,0.6087301587301588
negative regulation of life-sustaining process,lower respiratory tract disease,0.6188311688311688
negative regulation of life-sustaining process,virus generative stage,0.6411764705882353
negative regulation of life-sustaining process,acute infectious disease course,0.6448051948051949
negative regulation of life-sustaining process,cidal agent disposition,0.6094202898550725
negative regulation of life-sustaining process,process,0.5820754716981132
negative regulation of life-sustaining process,droplet pathogen transmission process,0.7030120481927711
negative regulation of life-sustaining process,parasiticidal disposition,0.6190140845070422
negative regulation of life-sustaining process,communicability end process boundary,0.6451219512195122
negative regulation of life-sustaining process,transmissibility disposition,0.6256756756756756
negative regulation of life-sustaining process,latency end process boundary,0.6527027027027027
negative regulation of life-sustaining process,infectious agent generative stage,0.6525316455696202
negative regulation of life-sustaining process,endotoxin disposition,0.6141791044776119
negative regulation of life-sustaining process,vector surveillance,0.6192307692307693
negative regulation of life-sustaining process,negative regulation of establishment of localization,0.7765306122448979
negative regulation of life-sustaining process,negative-sense single-stranded RNA virus,0.7058139534883722
negative regulation of life-sustaining process,COVID-19 incidence rate,0.5949275362318841
negative regulation of life-sustaining process,cytotoxin disposition,0.6141791044776119
negative regulation of life-sustaining process,negative regulation of developmental process,0.8388888888888889
negative regulation of life-sustaining process,chronic infectious disease course,0.6272151898734176
negative regulation of life-sustaining process,negative regulation of replication,0.8
negative regulation of life-sustaining process,process of establishing an infection,0.6451219512195122
negative regulation of life-sustaining process,incubation end process boundary,0.6837662337662337
negative regulation of life-sustaining process,collective pathogenic disposition,0.6651898734177215
negative regulation of life-sustaining process,neurotoxin disposition,0.6411764705882353
negative regulation of life-sustaining process,SARS-CoV-2 uncoating stage,0.6444444444444444
negative regulation of life-sustaining process,pathogen death process boundary,0.6448051948051949
negative regulation of life-sustaining process,plan specification,0.590625
negative regulation of life-sustaining process,latency end temporal region,0.6143835616438357
negative regulation of life-sustaining process,SARS-CoV-2 penetration stage,0.6527027027027027
negative regulation of life-sustaining process,collective disposition,0.6264705882352941
negative regulation of life-sustaining process,static agent disposition,0.6357142857142857
negative regulation of life-sustaining process,T cell receptor complex,0.6094202898550725
negative regulation of life-sustaining process,respiratory system disease,0.6305555555555555
negative regulation of life-sustaining process,indirect pathogen transmission process,0.7119047619047619
negative regulation of life-sustaining process,planned process,0.6467213114754098
negative regulation of life-sustaining process,generative stage,0.6596774193548387
negative regulation of life-sustaining process,infectious disease control strategy,0.6351851851851852
negative regulation of life-sustaining process,SARS-CoV-2 attachment stage,0.6143835616438357
negative regulation of life-sustaining process,infectious structure generative stage,0.6548192771084337
negative regulation of life-sustaining process,immunosuppressive disposition,0.61
negative regulation of life-sustaining process,innate immune response,0.6411764705882353
negative regulation of life-sustaining process,pathogenic disposition,0.6117647058823529
negative regulation of life-sustaining process,viral disease course,0.6015151515151516
negative regulation of life-sustaining process,infectious disposition,0.6264705882352941
negative regulation of life-sustaining process,bacteriostatic disposition,0.6444444444444444
negative regulation of life-sustaining process,epitope site,0.5879310344827586
negative regulation of life-sustaining process,bactericidal disposition,0.6214285714285714
negative regulation of life-sustaining process,invasion disposition,0.6469696969696969
negative regulation of life-sustaining process,disease course,0.5833333333333334
negative regulation of life-sustaining process,infectious disease course,0.6190140845070422
negative regulation of life-sustaining process,viricidal disposition,0.5992537313432835
negative regulation of life-sustaining process,coronavirus disease course,0.6166666666666667
negative regulation of life-sustaining process,pathogen portal of exit site,0.6391891891891892
negative regulation of life-sustaining process,SARS-CoV-2 genome replication stage,0.6722222222222223
negative regulation of life-sustaining process,disposition,0.5552631578947369
negative regulation of life-sustaining process,COVID-19 mortality rate,0.5949275362318841
negative regulation of life-sustaining process,process profile,0.6139344262295081
negative regulation of life-sustaining process,negative regulation of life-sustaining process,0.95
negative regulation of life-sustaining process,place closure control strategy,0.6210526315789474
negative regulation of life-sustaining process,adhesion disposition,0.6318181818181818
negative regulation of life-sustaining process,pathogen portal of entry site,0.6366666666666667
negative regulation of life-sustaining process,developmental process,0.6888059701492537
negative regulation of life-sustaining process,biological process,0.653125
negative regulation of life-sustaining process,site,0.51
negative regulation of life-sustaining process,primary infectious disposition,0.6210526315789474
negative regulation of life-sustaining process,humoral immune response,0.6094202898550725
negative regulation of life-sustaining process,incubation start process boundary,0.690506329113924
negative regulation of life-sustaining process,pathogen surveillance,0.6291044776119403
negative regulation of life-sustaining process,pathogen birth process boundary,0.6448051948051949
negative regulation of life-sustaining process,virus attachment stage,0.6264705882352941
negative regulation of life-sustaining process,negative regulation of immune response,0.819047619047619
negative regulation of life-sustaining process,SARS-CoV-2 transcription stage,0.6473684210526315
negative regulation of life-sustaining process,virus synthesis stage,0.6141791044776119
negative regulation of life-sustaining process,SARS-COV-2 adhesion disposition,0.6318181818181818
negative regulation of life-sustaining process,invasive disposition,0.6318181818181818
negative regulation of life-sustaining process,long-term non-progressing infectious disease course,0.6458762886597939
negative regulation of life-sustaining process,fungicidal disposition,0.6117647058823529
negative regulation of life-sustaining process,virus penetration stage,0.6673913043478261
negative regulation of life-sustaining process,algorithm,0.5409090909090909
negative regulation of life-sustaining process,division of geopolitical entity,0.6448051948051949
negative regulation of life-sustaining process,negative regulation of viral process,0.852439024390244
negative regulation of life-sustaining process,contact pathogen transmission process,0.7150602409638555
negative regulation of life-sustaining process,function,0.5425925925925926
negative regulation of life-sustaining process,symbiotic process,0.6404761904761905
negative regulation of life-sustaining process,exotoxin disposition,0.6166666666666667
negative regulation of life-sustaining process,infection start process boundary,0.6807692307692308
negative regulation of life-sustaining process,action specification,0.6166666666666667
negative regulation of life-sustaining process,SARS-CoV-2 synthesis stage,0.6027777777777777
negative regulation of life-sustaining process,latency start process boundary,0.6605263157894737
negative regulation of life-sustaining process,infectious disease control objective specification,0.6270833333333333
negative regulation of life-sustaining process,opportunistic infectious disposition,0.6329268292682927
negative regulation of life-sustaining process,process of establishing viral infection,0.65
negative regulation of life-sustaining process,negative regulation of biological process,0.8408045977011495
negative regulation of life-sustaining process,enterotoxin disposition,0.6528985507246376
negative regulation of life-sustaining process,polymerase chain reaction,0.6190140845070422
negative regulation of life-sustaining process,COVID-19 disease course,0.5804347826086956
negative regulation of life-sustaining process,infectious disease incidence rate,0.6525316455696202
negative regulation of life-sustaining process,communicability start process boundary,0.6523809523809524
negative regulation of life-sustaining process,process that results in death,0.6366666666666667
negative regulation of life-sustaining process,single-stranded RNA retrovirus,0.6342105263157894
negative regulation of life-sustaining process,active immunization against infectious agent,0.6944444444444444
negative regulation of life-sustaining process,collective resistance disposition,0.6651898734177215
negative regulation of life-sustaining process,adaptive immune response,0.65
negative regulation of life-sustaining process,fungistatic disposition,0.6384057971014493
negative regulation of life-sustaining process,virus uncoating stage,0.6440298507462687
negative regulation of life-sustaining process,establishment of a clinically abnormal colony,0.6258241758241758
negative regulation of life-sustaining process,process boundary,0.5629032258064516
negative regulation of life-sustaining process,positive-sense single-stranded RNA virus,0.6593023255813953
negative regulation of life-sustaining process,horizontal pathogen transmission process,0.6941860465116279
negative regulation of life-sustaining process,SARS-CoV-2 release stage,0.6357142857142857
negative regulation of life-sustaining process,pathogen transmission process,0.7166666666666667
enzymatic amplification,B cell receptor complex,0.5804347826086956
enzymatic amplification,enzymatic amplification,0.95
enzymatic amplification,plan specification,0.7426829268292683
enzymatic amplification,anatomical space,0.6551282051282051
enzymatic amplification,T cell receptor complex,0.5804347826086956
enzymatic amplification,establishment of a clinically abnormal colony,0.6264705882352941
enzymatic amplification,cell space,0.5712121212121213
emerging pathogen,extended organism,0.6558823529411765
emerging pathogen,virus aggregate,0.6375
emerging pathogen,source of infection,0.6166666666666667
emerging pathogen,infectious disease mortality rate,0.61
emerging pathogen,infection incidence rate profile,0.6132653061224489
emerging pathogen,communicability end temporal region,0.6038461538461539
emerging pathogen,pathogen generative stage,0.6404761904761905
emerging pathogen,pathogen portal of entry,0.6451219512195122
emerging pathogen,subclinical coronavirus infection,0.59
emerging pathogen,primary pathogen,0.7833333333333333
emerging pathogen,infection end temporal region,0.6239130434782608
emerging pathogen,drug-based immunosuppressed organism,0.6009433962264151
emerging pathogen,infectious disease,0.5928571428571429
emerging pathogen,double-stranded DNA virus,0.569047619047619
emerging pathogen,incubation end temporal region,0.598936170212766
emerging pathogen,site of infection,0.6264705882352941
emerging pathogen,immunocompetent organism,0.6207317073170732
emerging pathogen,pathogen portal of exit,0.65
emerging pathogen,infectious disease incidence,0.5833333333333334
emerging pathogen,reservoir of pathogen role,0.7523255813953489
emerging pathogen,subclinical SARS-CoV-2 infection,0.5928571428571429
emerging pathogen,virus translation stage,0.625
emerging pathogen,disease surveillance objective specification,0.630327868852459
emerging pathogen,virus release stage,0.6166666666666667
emerging pathogen,infectious agent host role,0.636046511627907
emerging pathogen,material entity,0.66875
emerging pathogen,source of infection site,0.6207317073170732
emerging pathogen,virus replication,0.6558823529411765
emerging pathogen,B cell receptor complex,0.6
emerging pathogen,passive immunization against infectious agent,0.6274193548387097
emerging pathogen,systematic infection,0.6391891891891892
emerging pathogen,infection incidence rate,0.6207317073170732
emerging pathogen,virus host,0.5981481481481481
emerging pathogen,double-stranded RNA virus,0.569047619047619
emerging pathogen,pathogen portal of entry role,0.6239130434782608
emerging pathogen,virus transcription stage,0.6166666666666667
emerging pathogen,infectious disease lifetime prevalence,0.5954545454545455
emerging pathogen,pathogen birth temporal region,0.6202127659574468
emerging pathogen,lower respiratory tract disease,0.6166666666666667
emerging pathogen,infectious disease incidence proportion,0.6107142857142857
emerging pathogen,opportunistic pathogen,0.732051282051282
emerging pathogen,virus generative stage,0.6551282051282051
emerging pathogen,acute infectious disease course,0.5958333333333333
emerging pathogen,cidal agent disposition,0.625
emerging pathogen,genetic resistance to pathogen,0.747872340425532
emerging pathogen,subclinical infection,0.6078947368421053
emerging pathogen,appearance of disorder,0.6038461538461539
emerging pathogen,simple infection,0.6621212121212122
emerging pathogen,droplet pathogen transmission process,0.6351851851851852
emerging pathogen,infectious disease sporadicity,0.5776595744680851
emerging pathogen,communicability end process boundary,0.6009433962264151
emerging pathogen,infection incidence proportion profile,0.6136363636363636
emerging pathogen,infectious agent colony,0.625
emerging pathogen,pathogen transporter,0.6662162162162162
emerging pathogen,latency end process boundary,0.6277777777777778
emerging pathogen,infectious disease epidemic,0.5636363636363636
emerging pathogen,infectious agent generative stage,0.61
emerging pathogen,disease transmission model,0.636046511627907
emerging pathogen,pathologically immunosuppressed organism,0.5903508771929825
emerging pathogen,negative-sense single-stranded RNA virus,0.5903508771929825
emerging pathogen,cidal agent,0.6642857142857143
emerging pathogen,pathogen vehicle,0.6924242424242425
emerging pathogen,community-acquired infection,0.6055555555555556
emerging pathogen,pathogen vector,0.7
emerging pathogen,pathogen vehicle role,0.6605263157894737
emerging pathogen,chronic infectious disease course,0.59
emerging pathogen,asymptomatic infectious agent carrier,0.5981481481481481
emerging pathogen,nursing-home acquired infection,0.6375
emerging pathogen,secondary infection,0.6444444444444444
emerging pathogen,infection start temporal region,0.6375
emerging pathogen,infection incidence,0.6166666666666667
emerging pathogen,virus disorder,0.5790322580645162
emerging pathogen,sterilizing immunity to infectious agent,0.6429824561403508
emerging pathogen,primary infection,0.6558823529411765
emerging pathogen,process of establishing an infection,0.6386792452830189
emerging pathogen,incubation end process boundary,0.5958333333333333
emerging pathogen,pathogen death process boundary,0.6375
emerging pathogen,immunosuppressed organism,0.5928571428571429
emerging pathogen,latency end temporal region,0.6318181818181818
emerging pathogen,innate immunity to infectious agent,0.6230769230769231
emerging pathogen,virus adhesion susceptible cell,0.5958333333333333
emerging pathogen,infection,0.6423076923076922
emerging pathogen,static agent disposition,0.6207317073170732
emerging pathogen,T cell receptor complex,0.6
emerging pathogen,infectious agent population,0.6545454545454545
emerging pathogen,respiratory system disease,0.5895348837209302
emerging pathogen,leukocyte-mediated immunity to infectious agent,0.621875
emerging pathogen,indirect pathogen transmission process,0.65
emerging pathogen,organism population,0.7
emerging pathogen,humoral immunity to infectious agent,0.6386792452830189
emerging pathogen,infectious disease control strategy,0.5846153846153846
emerging pathogen,parasite,0.61
emerging pathogen,infectious disease pandemic,0.5863636363636363
emerging pathogen,antibody reagent,0.6318181818181818
emerging pathogen,viral disease course,0.5851351351351352
emerging pathogen,intracellular infection,0.625
emerging pathogen,secondary infection role,0.6207317073170732
emerging pathogen,metastatic infection,0.6391891891891892
emerging pathogen,passive immunity to infectious agent,0.619811320754717
emerging pathogen,vaccination against infectious agent,0.619811320754717
emerging pathogen,acute infection,0.6375
emerging pathogen,susceptibility to infectious agent,0.6068627450980393
emerging pathogen,epitope site,0.6224137931034482
emerging pathogen,immunity to pathogen,0.7472972972972972
emerging pathogen,source of infection role,0.6207317073170732
emerging pathogen,pathogen host,0.7166666666666667
emerging pathogen,chronic infection,0.6264705882352941
emerging pathogen,disease course,0.6112903225806451
emerging pathogen,infectious disease course,0.5928571428571429
emerging pathogen,acquired immunity to infectious agent,0.6166666666666667
emerging pathogen,complex infection,0.6558823529411765
emerging pathogen,COVID-19 disease incidence proportion,0.6166666666666667
emerging pathogen,coronavirus disease course,0.5895348837209302
emerging pathogen,infection incidence proportion,0.6202127659574468
emerging pathogen,symptomatic infectious agent carrier,0.6009433962264151
emerging pathogen,respiratory droplet virus fomite,0.5928571428571429
emerging pathogen,susceptible organism,0.6121621621621621
emerging pathogen,parasite role,0.6166666666666667
emerging pathogen,pathogen vector role,0.6662162162162162
emerging pathogen,pathogen portal of exit site,0.6277777777777778
emerging pathogen,infectious disease prevalence,0.6021739130434782
emerging pathogen,organism substance,0.6214285714285714
emerging pathogen,single-stranded DNA virus,0.5928571428571429
emerging pathogen,viral disease,0.5833333333333334
emerging pathogen,primary infection role,0.6294871794871795
emerging pathogen,pathogen portal of entry site,0.6239130434782608
emerging pathogen,infection incidence profile,0.609090909090909
emerging pathogen,disease,0.575
emerging pathogen,site,0.5928571428571429
emerging pathogen,pathogen host role,0.6785714285714286
emerging pathogen,infection prevalence,0.6662162162162162
emerging pathogen,infectious pathogen transmissibility,0.6575471698113208
emerging pathogen,pathogen surveillance,0.6605263157894737
emerging pathogen,immunodeficient organism,0.6451219512195122
emerging pathogen,pathogen,0.77
emerging pathogen,pathogen birth process boundary,0.6166666666666667
emerging pathogen,infectious human pathogen,0.7357142857142857
emerging pathogen,subclinical virus infection,0.5863636363636363
emerging pathogen,resistance to pathogen,0.7576923076923078
emerging pathogen,establishment of localization in virus host,0.6
emerging pathogen,immunization against infectious agent,0.6351851851851852
emerging pathogen,virus attachment stage,0.6294871794871795
emerging pathogen,virus synthesis stage,0.6078947368421053
emerging pathogen,pathogen portal of exit role,0.6277777777777778
emerging pathogen,infectious agent host,0.6342105263157894
emerging pathogen,re-emerging pathogen,0.9094594594594595
emerging pathogen,long-term non-progressing infectious disease course,0.6117647058823529
emerging pathogen,viral disease epidemic,0.5782051282051281
emerging pathogen,viral disease pandemic,0.6038461538461539
emerging pathogen,virus penetration stage,0.675
emerging pathogen,pathogen seroprevalence,0.65
emerging pathogen,infectious disease endemicity,0.5804347826086956
emerging pathogen,contact pathogen transmission process,0.6351851851851852
emerging pathogen,herd immunity to infectious organism,0.619811320754717
emerging pathogen,extracellular infection,0.65
emerging pathogen,pathogen transporter role,0.6404761904761905
emerging pathogen,infectious agent reservoir,0.6127906976744186
emerging pathogen,infection start process boundary,0.6336734693877552
emerging pathogen,processed material,0.6214285714285714
emerging pathogen,infectious disease control objective specification,0.5992537313432835
emerging pathogen,process of establishing viral infection,0.6285714285714286
emerging pathogen,COVID-19 disease course,0.575
emerging pathogen,infectious disease incidence rate,0.61
emerging pathogen,active immunization against infectious agent,0.630327868852459
emerging pathogen,disordered virus,0.5409090909090909
emerging pathogen,organism,0.61
emerging pathogen,virus uncoating stage,0.6605263157894737
emerging pathogen,local infection,0.60625
emerging pathogen,infectious agent,0.6621212121212122
emerging pathogen,establishment of a clinically abnormal colony,0.5951612903225807
emerging pathogen,coronavirus disease,0.5888888888888889
emerging pathogen,positive-sense single-stranded RNA virus,0.5903508771929825
emerging pathogen,horizontal pathogen transmission process,0.6605263157894737
emerging pathogen,hospital-acquired infection,0.5863636363636363
emerging pathogen,pathogen death temporal region,0.6414893617021277
emerging pathogen,emerging pathogen,0.95
emerging pathogen,drug susceptibility of infectious agent,0.6107142857142857
emerging pathogen,static agent,0.656896551724138
emerging pathogen,pathogen transmission process,0.6239130434782608
emerging pathogen,material processing,0.7
virus disorder,extended organism,0.5467741935483871
virus disorder,virus aggregate,0.7258620689655172
virus disorder,source of infection,0.5712121212121213
virus disorder,virostatic disposition,0.7
virus disorder,zoonotic disposition,0.6264705882352941
virus disorder,immune response,0.656896551724138
virus disorder,infectious disease mortality rate,0.6627659574468084
virus disorder,infection incidence rate profile,0.5804347826086956
virus disorder,communicability end temporal region,0.5724489795918367
virus disorder,pathogen generative stage,0.5525641025641026
virus disorder,pathogen portal of entry,0.581578947368421
virus disorder,subclinical coronavirus infection,0.6202127659574468
virus disorder,primary pathogen,0.6166666666666667
virus disorder,infection end temporal region,0.5895348837209302
virus disorder,drug-based immunosuppressed organism,0.63
virus disorder,infectious disease,0.7
virus disorder,double-stranded DNA virus,0.6038461538461539
virus disorder,incubation end temporal region,0.609090909090909
virus disorder,site of infection,0.5790322580645162
virus disorder,immunocompetent organism,0.581578947368421
virus disorder,virulence factor disposition,0.6642857142857143
virus disorder,pathogen portal of exit,0.5581081081081081
virus disorder,viral adhesion disposition,0.675
virus disorder,parasitostatic disposition,0.625
virus disorder,infectious disease incidence,0.6642857142857143
virus disorder,reservoir of pathogen role,0.625
virus disorder,reverse zoonotic disposition,0.6404761904761905
virus disorder,subclinical SARS-CoV-2 infection,0.5804347826086956
virus disorder,establishment of localization in host,0.5480392156862746
virus disorder,virus translation stage,0.6932432432432433
virus disorder,disease surveillance objective specification,0.553448275862069
virus disorder,virus release stage,0.6924242424242425
virus disorder,infectious agent host role,0.625
virus disorder,source of infection site,0.581578947368421
virus disorder,virus,0.7131578947368421
virus disorder,virus replication,0.7080645161290323
virus disorder,B cell receptor complex,0.5581081081081081
virus disorder,systematic infection,0.5676470588235294
virus disorder,infection incidence rate,0.6078947368421053
virus disorder,colonized host,0.5571428571428572
virus disorder,virus host,0.7416666666666667
virus disorder,double-stranded RNA virus,0.6038461538461539
virus disorder,pathogen portal of entry role,0.5662790697674418
virus disorder,virus transcription stage,0.6807692307692308
virus disorder,infectious disease lifetime prevalence,0.6230769230769231
virus disorder,toxin disposition,0.6435483870967742
virus disorder,pathogen birth temporal region,0.5863636363636363
virus disorder,lower respiratory tract disease,0.6055555555555556
virus disorder,infectious disease incidence proportion,0.6386792452830189
virus disorder,opportunistic pathogen,0.6166666666666667
virus disorder,virus generative stage,0.7
virus disorder,acute infectious disease course,0.6722222222222223
virus disorder,cidal agent disposition,0.6121621621621621
virus disorder,infectious disorder,0.8136363636363637
virus disorder,genetic resistance to pathogen,0.609090909090909
virus disorder,subclinical infection,0.5642857142857143
virus disorder,appearance of disorder,0.7277777777777777
virus disorder,simple infection,0.5833333333333334
virus disorder,droplet pathogen transmission process,0.5872549019607843
virus disorder,parasiticidal disposition,0.6294871794871795
virus disorder,infectious disease sporadicity,0.6772727272727272
virus disorder,communicability end process boundary,0.59
virus disorder,infection incidence proportion profile,0.5846153846153846
virus disorder,pathogen transporter,0.6264705882352941
virus disorder,transmissibility disposition,0.6166666666666667
virus disorder,latency end process boundary,0.5928571428571429
virus disorder,colonization of host,0.5382352941176471
virus disorder,infectious disease epidemic,0.6695121951219513
virus disorder,disease transmission model,0.65
virus disorder,endotoxin disposition,0.6214285714285714
virus disorder,pathologically immunosuppressed organism,0.5796296296296296
virus disorder,negative-sense single-stranded RNA virus,0.6166666666666667
virus disorder,infectious structure host role,0.6318181818181818
virus disorder,pathogen vehicle,0.55
virus disorder,cytotoxin disposition,0.6214285714285714
virus disorder,community-acquired infection,0.5928571428571429
virus disorder,pathogen vector,0.553448275862069
virus disorder,pathogen vehicle role,0.5928571428571429
virus disorder,host,0.5055555555555555
virus disorder,chronic infectious disease course,0.6627659574468084
virus disorder,nursing-home acquired infection,0.6055555555555556
virus disorder,COVID-19 epidemic,0.6435483870967742
virus disorder,secondary infection,0.5712121212121213
virus disorder,infection start temporal region,0.5833333333333334
virus disorder,infection incidence,0.6015151515151516
virus disorder,virus disorder,0.95
virus disorder,establishment of localization in human host,0.537719298245614
virus disorder,diseased population,0.6015151515151516
virus disorder,primary infection,0.6112903225806451
virus disorder,process of establishing an infection,0.57
virus disorder,incubation end process boundary,0.6277777777777778
virus disorder,SARS-CoV-2 disorder,0.7833333333333333
virus disorder,collective pathogenic disposition,0.598936170212766
virus disorder,neurotoxin disposition,0.6166666666666667
virus disorder,dead-end host role,0.575
virus disorder,pathogen death process boundary,0.5833333333333334
virus disorder,immunosuppressed organism,0.6038461538461539
virus disorder,definitive host role,0.5970588235294118
virus disorder,latency end temporal region,0.5719512195121951
virus disorder,virus adhesion susceptible cell,0.6722222222222223
virus disorder,collective disposition,0.6166666666666667
virus disorder,infection,0.5804347826086956
virus disorder,static agent disposition,0.6078947368421053
virus disorder,T cell receptor complex,0.5581081081081081
virus disorder,infectious structure host,0.6294871794871795
virus disorder,respiratory system disease,0.65
virus disorder,entry into host,0.5879310344827586
virus disorder,indirect pathogen transmission process,0.6038461538461539
virus disorder,adhesion of symbiont to host,0.5452380952380953
virus disorder,organism population,0.6015151515151516
virus disorder,infectious disease control strategy,0.6540816326530612
virus disorder,infectious disease pandemic,0.6695121951219513
virus disorder,immunosuppressive disposition,0.636046511627907
virus disorder,innate immune response,0.6166666666666667
virus disorder,pathogenic disposition,0.6166666666666667
virus disorder,viral disease course,0.7441176470588234
virus disorder,entry into host through host barriers,0.6068627450980393
virus disorder,intracellular infection,0.6121621621621621
virus disorder,secondary infection role,0.6078947368421053
virus disorder,metastatic infection,0.5676470588235294
virus disorder,infectious disposition,0.6722222222222223
virus disorder,acute infection,0.5879310344827586
virus disorder,bacteriostatic disposition,0.625
virus disorder,immunity to pathogen,0.5970588235294118
virus disorder,bactericidal disposition,0.6078947368421053
virus disorder,source of infection role,0.6078947368421053
virus disorder,pathogen host,0.524074074074074
virus disorder,acquired immunodeficiency,0.6294871794871795
virus disorder,chronic infection,0.5790322580645162
virus disorder,invasion disposition,0.6558823529411765
virus disorder,disease course,0.6642857142857143
virus disorder,infectious disease course,0.7064102564102563
virus disorder,viricidal disposition,0.6785714285714286
virus disorder,acquired immunity to infectious agent,0.5872549019607843
virus disorder,complex infection,0.5467741935483871
virus disorder,COVID-19 disease incidence proportion,0.6264705882352941
virus disorder,coronavirus disease course,0.75
virus disorder,infection incidence proportion,0.5863636363636363
virus disorder,respiratory droplet virus fomite,0.6239130434782608
virus disorder,susceptible organism,0.5970588235294118
virus disorder,intermediate host,0.6112903225806451
virus disorder,pathogen vector role,0.5970588235294118
virus disorder,pathogen portal of exit site,0.569047619047619
virus disorder,infectious disease prevalence,0.6593023255813953
virus disorder,organism substance,0.60625
virus disorder,disposition,0.61
virus disorder,single-stranded DNA virus,0.6294871794871795
virus disorder,viral disease,0.7462962962962962
virus disorder,primary infection role,0.6444444444444444
virus disorder,adhesion disposition,0.6264705882352941
virus disorder,pathogen portal of entry site,0.5662790697674418
virus disorder,infection incidence profile,0.5963414634146341
virus disorder,disease,0.6404761904761905
virus disorder,primary infectious disposition,0.6545454545454545
virus disorder,pathogen host role,0.575
virus disorder,infection prevalence,0.5970588235294118
virus disorder,humoral immune response,0.6121621621621621
virus disorder,coronavirus disorder,0.8617647058823529
virus disorder,infectious pathogen transmissibility,0.59
virus disorder,intermediate host role,0.6444444444444444
virus disorder,dead-end host,0.5611111111111111
virus disorder,pathogen surveillance,0.5642857142857143
virus disorder,immunodeficient organism,0.6078947368421053
virus disorder,host role,0.6239130434782608
virus disorder,pathogen,0.5409090909090909
virus disorder,pathogen birth process boundary,0.6055555555555556
virus disorder,infectious human pathogen,0.6038461538461539
virus disorder,subclinical virus infection,0.6451219512195122
virus disorder,resistance to pathogen,0.6166666666666667
virus disorder,establishment of localization in virus host,0.5728070175438597
virus disorder,virus attachment stage,0.6722222222222223
virus disorder,negative regulation of immune response,0.6038461538461539
virus disorder,virus synthesis stage,0.7071428571428571
virus disorder,SARS-COV-2 adhesion disposition,0.6055555555555556
virus disorder,pathogen portal of exit role,0.569047619047619
virus disorder,invasive disposition,0.6558823529411765
virus disorder,infectious agent host,0.5928571428571429
virus disorder,re-emerging pathogen,0.5676470588235294
virus disorder,long-term non-progressing infectious disease course,0.6038461538461539
virus disorder,viral disease epidemic,0.7
virus disorder,fungicidal disposition,0.6166666666666667
virus disorder,viral disease pandemic,0.7
virus disorder,virus penetration stage,0.6932432432432433
virus disorder,pathogen seroprevalence,0.5851351351351352
virus disorder,acute respiratory distress syndrome,0.6336734693877552
virus disorder,infectious disease endemicity,0.6593023255813953
virus disorder,contact pathogen transmission process,0.5872549019607843
virus disorder,disorder,0.8136363636363637
virus disorder,herd immunity to infectious organism,0.59
virus disorder,extracellular infection,0.5851351351351352
virus disorder,pathogen transporter role,0.6038461538461539
virus disorder,transmission interval,0.65
virus disorder,exotoxin disposition,0.6264705882352941
virus disorder,infection start process boundary,0.6021739130434782
virus disorder,infectious disease control objective specification,0.60625
virus disorder,symbiont host role,0.60625
virus disorder,immune population,0.6112903225806451
virus disorder,opportunistic infectious disposition,0.61
virus disorder,process of establishing viral infection,0.5820754716981132
virus disorder,enterotoxin disposition,0.6121621621621621
virus disorder,COVID-19 disease course,0.6932432432432433
virus disorder,infectious disease incidence rate,0.6627659574468084
virus disorder,disordered virus,0.7166666666666667
virus disorder,collective resistance disposition,0.6202127659574468
virus disorder,adaptive immune response,0.6342105263157894
virus disorder,fungistatic disposition,0.6391891891891892
virus disorder,organism,0.5863636363636363
virus disorder,virus uncoating stage,0.7071428571428571
virus disorder,local infection,0.553448275862069
virus disorder,establishment of a clinically abnormal colony,0.5516949152542373
virus disorder,coronavirus disease,0.7530303030303032
virus disorder,positive-sense single-stranded RNA virus,0.6166666666666667
virus disorder,definitive host,0.553448275862069
virus disorder,horizontal pathogen transmission process,0.5981481481481481
virus disorder,hospital-acquired infection,0.5963414634146341
virus disorder,pathogen death temporal region,0.5636363636363636
virus disorder,emerging pathogen,0.5790322580645162
virus disorder,static agent,0.5653846153846154
virus disorder,pathogen transmission process,0.6127906976744186
enterotoxin,enterotoxin,0.95
enterotoxin,toxin disposition,0.6285714285714286
enterotoxin,T cell receptor complex,0.6264705882352941
enterotoxin,toxin,0.7625
enterotoxin,enterotoxin disposition,0.7735294117647058
infectivity,SARS-CoV-2 infectivity,0.7833333333333333
infectivity,T cell receptor complex,0.5382352941176471
infectivity,infectivity,0.95
reverse transcribed PCR,infectious disease mortality rate,0.6285714285714286
reverse transcribed PCR,infection incidence rate profile,0.6318181818181818
reverse transcribed PCR,communicability end temporal region,0.5879310344827586
reverse transcribed PCR,infection end temporal region,0.6038461538461539
reverse transcribed PCR,SARS-CoV-2 incidence rate,0.6375
reverse transcribed PCR,incubation end temporal region,0.6009433962264151
reverse transcribed PCR,reverse zoonotic disposition,0.6852941176470588
reverse transcribed PCR,B cell receptor complex,0.6021739130434782
reverse transcribed PCR,infection incidence rate,0.6202127659574468
reverse transcribed PCR,double-stranded RNA virus,0.6583333333333334
reverse transcribed PCR,lower respiratory tract disease,0.6351851851851852
reverse transcribed PCR,communicability end process boundary,0.6025423728813559
reverse transcribed PCR,latency end process boundary,0.6264705882352941
reverse transcribed PCR,negative-sense single-stranded RNA virus,0.6722222222222223
reverse transcribed PCR,COVID-19 incidence rate,0.6239130434782608
reverse transcribed PCR,PCR product,0.5970588235294118
reverse transcribed PCR,incubation end process boundary,0.6166666666666667
reverse transcribed PCR,pathogen death process boundary,0.5981481481481481
reverse transcribed PCR,latency end temporal region,0.61
reverse transcribed PCR,T cell receptor complex,0.6021739130434782
reverse transcribed PCR,reverse zoonosis,0.732051282051282
reverse transcribed PCR,COVID-19 mortality rate,0.6021739130434782
reverse transcribed PCR,reverse transcribed PCR,0.95
reverse transcribed PCR,place closure control strategy,0.619811320754717
reverse transcribed PCR,acute respiratory distress syndrome,0.6224137931034482
reverse transcribed PCR,action specification,0.5895348837209302
reverse transcribed PCR,infectious disease incidence rate,0.6464285714285714
reverse transcribed PCR,process that results in death,0.6230769230769231
reverse transcribed PCR,single-stranded RNA retrovirus,0.6386792452830189
reverse transcribed PCR,establishment of a clinically abnormal colony,0.5970588235294118
reverse transcribed PCR,positive-sense single-stranded RNA virus,0.6563492063492063
reverse transcribed PCR,pathogen death temporal region,0.6009433962264151
horizontal pathogen transmission process,extended organism,0.6078947368421053
horizontal pathogen transmission process,virus aggregate,0.5772727272727273
horizontal pathogen transmission process,source of infection,0.6025423728813559
horizontal pathogen transmission process,immune response,0.6136363636363636
horizontal pathogen transmission process,infectious disease mortality rate,0.6280821917808219
horizontal pathogen transmission process,infection incidence rate profile,0.6444444444444444
horizontal pathogen transmission process,communicability end temporal region,0.6366666666666667
horizontal pathogen transmission process,pathogen generative stage,0.6653846153846155
horizontal pathogen transmission process,pathogen portal of entry,0.66875
horizontal pathogen transmission process,subclinical coronavirus infection,0.6280821917808219
horizontal pathogen transmission process,primary pathogen,0.6642857142857143
horizontal pathogen transmission process,surveillance process,0.6666666666666667
horizontal pathogen transmission process,infection end temporal region,0.6384057971014493
horizontal pathogen transmission process,drug-based immunosuppressed organism,0.5947368421052631
horizontal pathogen transmission process,infectious disease,0.6051724137931035
horizontal pathogen transmission process,SARS-CoV-2 incidence rate,0.5884615384615385
horizontal pathogen transmission process,double-stranded DNA virus,0.6192307692307693
horizontal pathogen transmission process,incubation end temporal region,0.65
horizontal pathogen transmission process,site of infection,0.6078947368421053
horizontal pathogen transmission process,immunocompetent organism,0.6375
horizontal pathogen transmission process,pathogen portal of exit,0.6722222222222223
horizontal pathogen transmission process,infectious disease incidence,0.6264705882352941
horizontal pathogen transmission process,reservoir of pathogen role,0.6924242424242425
horizontal pathogen transmission process,subclinical SARS-CoV-2 infection,0.6166666666666667
horizontal pathogen transmission process,virus translation stage,0.6404761904761905
horizontal pathogen transmission process,disease surveillance objective specification,0.5928571428571429
horizontal pathogen transmission process,case isolation control strategy,0.6471830985915493
horizontal pathogen transmission process,virus release stage,0.5855932203389831
horizontal pathogen transmission process,infectious agent host role,0.6621212121212122
horizontal pathogen transmission process,source of infection site,0.621875
horizontal pathogen transmission process,virus,0.5166666666666666
horizontal pathogen transmission process,virus replication,0.5903508771929825
horizontal pathogen transmission process,B cell receptor complex,0.5928571428571429
horizontal pathogen transmission process,passive immunization against infectious agent,0.6264705882352941
horizontal pathogen transmission process,systematic infection,0.5833333333333334
horizontal pathogen transmission process,infection incidence rate,0.6375
horizontal pathogen transmission process,virus host,0.57
horizontal pathogen transmission process,double-stranded RNA virus,0.6192307692307693
horizontal pathogen transmission process,pathogen portal of entry role,0.696376811594203
horizontal pathogen transmission process,virus transcription stage,0.65
horizontal pathogen transmission process,infectious disease lifetime prevalence,0.6294871794871795
horizontal pathogen transmission process,pathogen birth temporal region,0.6642857142857143
horizontal pathogen transmission process,lower respiratory tract disease,0.6612676056338028
horizontal pathogen transmission process,infectious disease incidence proportion,0.6272151898734176
horizontal pathogen transmission process,opportunistic pathogen,0.6596774193548387
horizontal pathogen transmission process,virus generative stage,0.6112903225806451
horizontal pathogen transmission process,acute infectious disease course,0.6190140845070422
horizontal pathogen transmission process,cidal agent disposition,0.6880952380952381
horizontal pathogen transmission process,genetic resistance to pathogen,0.6357142857142857
horizontal pathogen transmission process,subclinical infection,0.6139344262295081
horizontal pathogen transmission process,process,0.598936170212766
horizontal pathogen transmission process,simple infection,0.5928571428571429
horizontal pathogen transmission process,droplet pathogen transmission process,0.8785714285714286
horizontal pathogen transmission process,infectious disease sporadicity,0.6214285714285714
horizontal pathogen transmission process,communicability end process boundary,0.6473684210526315
horizontal pathogen transmission process,infection incidence proportion profile,0.6551282051282051
horizontal pathogen transmission process,infectious agent colony,0.6246031746031746
horizontal pathogen transmission process,SARS-CoV-2 incidence proportion,0.6049295774647887
horizontal pathogen transmission process,pathogen transporter,0.7333333333333333
horizontal pathogen transmission process,latency end process boundary,0.6705882352941177
horizontal pathogen transmission process,infectious disease epidemic,0.6141791044776119
horizontal pathogen transmission process,infectious agent generative stage,0.6417808219178082
horizontal pathogen transmission process,disease transmission model,0.7378787878787878
horizontal pathogen transmission process,pathologically immunosuppressed organism,0.625
horizontal pathogen transmission process,negative-sense single-stranded RNA virus,0.625
horizontal pathogen transmission process,cidal agent,0.6264705882352941
horizontal pathogen transmission process,pathogen vehicle,0.6642857142857143
horizontal pathogen transmission process,COVID-19 incidence rate,0.5928571428571429
horizontal pathogen transmission process,community-acquired infection,0.5970588235294118
horizontal pathogen transmission process,pathogen vector,0.6681818181818181
horizontal pathogen transmission process,negative regulation of developmental process,0.6642857142857143
horizontal pathogen transmission process,pathogen vehicle role,0.6795081967213115
horizontal pathogen transmission process,chronic infectious disease course,0.6417808219178082
horizontal pathogen transmission process,asymptomatic infectious agent carrier,0.6188311688311688
horizontal pathogen transmission process,nursing-home acquired infection,0.6190140845070422
horizontal pathogen transmission process,secondary infection,0.6025423728813559
horizontal pathogen transmission process,infection start temporal region,0.6330985915492958
horizontal pathogen transmission process,infection incidence,0.6364406779661017
horizontal pathogen transmission process,virus disorder,0.5981481481481481
horizontal pathogen transmission process,sterilizing immunity to infectious agent,0.625
horizontal pathogen transmission process,primary infection,0.6078947368421053
horizontal pathogen transmission process,process of establishing an infection,0.6342105263157894
horizontal pathogen transmission process,incubation end process boundary,0.6753521126760563
horizontal pathogen transmission process,SARS-CoV-2 uncoating stage,0.6015151515151516
horizontal pathogen transmission process,pathogen death process boundary,0.7035211267605633
horizontal pathogen transmission process,immunosuppressed organism,0.6038461538461539
horizontal pathogen transmission process,plan specification,0.6051724137931035
horizontal pathogen transmission process,latency end temporal region,0.6291044776119403
horizontal pathogen transmission process,innate immunity to infectious agent,0.6233333333333334
horizontal pathogen transmission process,SARS-CoV-2 penetration stage,0.6558823529411765
horizontal pathogen transmission process,virus adhesion susceptible cell,0.6330985915492958
horizontal pathogen transmission process,infection,0.5928571428571429
horizontal pathogen transmission process,static agent disposition,0.66875
horizontal pathogen transmission process,T cell receptor complex,0.6087301587301588
horizontal pathogen transmission process,infectious agent population,0.6440298507462687
horizontal pathogen transmission process,respiratory system disease,0.6318181818181818
horizontal pathogen transmission process,leukocyte-mediated immunity to infectious agent,0.5994252873563218
horizontal pathogen transmission process,indirect pathogen transmission process,0.8730769230769231
horizontal pathogen transmission process,organism population,0.6194915254237288
horizontal pathogen transmission process,planned process,0.6681818181818181
horizontal pathogen transmission process,generative stage,0.5928571428571429
horizontal pathogen transmission process,humoral immunity to infectious agent,0.6473684210526315
horizontal pathogen transmission process,infectious disease control strategy,0.6233333333333334
horizontal pathogen transmission process,SARS-CoV-2 attachment stage,0.6291044776119403
horizontal pathogen transmission process,parasite,0.5958333333333333
horizontal pathogen transmission process,infectious disease pandemic,0.6291044776119403
horizontal pathogen transmission process,antibody reagent,0.5928571428571429
horizontal pathogen transmission process,infectious structure generative stage,0.6188311688311688
horizontal pathogen transmission process,innate immune response,0.6596774193548387
horizontal pathogen transmission process,viral disease course,0.6166666666666667
horizontal pathogen transmission process,intracellular infection,0.6246031746031746
horizontal pathogen transmission process,secondary infection role,0.653125
horizontal pathogen transmission process,metastatic infection,0.6
horizontal pathogen transmission process,passive immunity to infectious agent,0.6078947368421053
horizontal pathogen transmission process,vaccination against infectious agent,0.6473684210526315
horizontal pathogen transmission process,acute infection,0.5954545454545455
horizontal pathogen transmission process,susceptibility to infectious agent,0.5986486486486486
horizontal pathogen transmission process,epitope site,0.6038461538461539
horizontal pathogen transmission process,immunity to pathogen,0.65
horizontal pathogen transmission process,source of infection role,0.653125
horizontal pathogen transmission process,pathogen host,0.6575471698113208
horizontal pathogen transmission process,chronic infection,0.6254385964912281
horizontal pathogen transmission process,disease course,0.5796296296296296
horizontal pathogen transmission process,infectious disease course,0.6192307692307693
horizontal pathogen transmission process,acquired immunity to infectious agent,0.6188311688311688
horizontal pathogen transmission process,complex infection,0.5903508771929825
horizontal pathogen transmission process,COVID-19 disease incidence proportion,0.6188311688311688
horizontal pathogen transmission process,coronavirus disease course,0.6469696969696969
horizontal pathogen transmission process,infection incidence proportion,0.6357142857142857
horizontal pathogen transmission process,symptomatic infectious agent carrier,0.6210526315789474
horizontal pathogen transmission process,respiratory droplet virus fomite,0.6166666666666667
horizontal pathogen transmission process,susceptible organism,0.6
horizontal pathogen transmission process,parasite role,0.6386792452830189
horizontal pathogen transmission process,pathogen vector role,0.7
horizontal pathogen transmission process,pathogen portal of exit site,0.6705882352941177
horizontal pathogen transmission process,infectious disease prevalence,0.6384057971014493
horizontal pathogen transmission process,organism substance,0.656896551724138
horizontal pathogen transmission process,SARS-CoV-2 genome replication stage,0.6366666666666667
horizontal pathogen transmission process,single-stranded DNA virus,0.6346153846153847
horizontal pathogen transmission process,COVID-19 mortality rate,0.6246031746031746
horizontal pathogen transmission process,contact tracing,0.65
horizontal pathogen transmission process,process profile,0.6318181818181818
horizontal pathogen transmission process,negative regulation of life-sustaining process,0.6941860465116279
horizontal pathogen transmission process,viral disease,0.6009433962264151
horizontal pathogen transmission process,primary infection role,0.6596774193548387
horizontal pathogen transmission process,pathogen portal of entry site,0.6673913043478261
horizontal pathogen transmission process,developmental process,0.6795081967213115
horizontal pathogen transmission process,infection incidence profile,0.658955223880597
horizontal pathogen transmission process,disease,0.5563829787234043
horizontal pathogen transmission process,biological process,0.6913793103448276
horizontal pathogen transmission process,homo sapiens,0.6038461538461539
horizontal pathogen transmission process,site,0.5181818181818182
horizontal pathogen transmission process,pathogen host role,0.6913793103448276
horizontal pathogen transmission process,infection prevalence,0.65
horizontal pathogen transmission process,humoral immune response,0.6563492063492063
horizontal pathogen transmission process,infectious pathogen transmissibility,0.7526315789473685
horizontal pathogen transmission process,incubation start process boundary,0.682876712328767
horizontal pathogen transmission process,pathogen surveillance,0.6795081967213115
horizontal pathogen transmission process,immunodeficient organism,0.621875
horizontal pathogen transmission process,pathogen,0.6166666666666667
horizontal pathogen transmission process,pathogen birth process boundary,0.7035211267605633
horizontal pathogen transmission process,infectious human pathogen,0.65
horizontal pathogen transmission process,subclinical virus infection,0.6141791044776119
horizontal pathogen transmission process,resistance to pathogen,0.6596774193548387
horizontal pathogen transmission process,establishment of localization in virus host,0.6427710843373494
horizontal pathogen transmission process,immunization against infectious agent,0.6448051948051949
horizontal pathogen transmission process,virus attachment stage,0.6274193548387097
horizontal pathogen transmission process,negative regulation of immune response,0.6423076923076922
horizontal pathogen transmission process,SARS-CoV-2 transcription stage,0.65
horizontal pathogen transmission process,virus synthesis stage,0.6139344262295081
horizontal pathogen transmission process,pathogen portal of exit role,0.6852941176470588
horizontal pathogen transmission process,infectious agent host,0.6467213114754098
horizontal pathogen transmission process,re-emerging pathogen,0.65
horizontal pathogen transmission process,long-term non-progressing infectious disease course,0.6478021978021978
horizontal pathogen transmission process,viral disease epidemic,0.6112903225806451
horizontal pathogen transmission process,viral disease pandemic,0.6435483870967742
horizontal pathogen transmission process,virus penetration stage,0.6563492063492063
horizontal pathogen transmission process,algorithm,0.5724489795918367
horizontal pathogen transmission process,pathogen seroprevalence,0.6880952380952381
horizontal pathogen transmission process,infectious disease endemicity,0.6094202898550725
horizontal pathogen transmission process,negative regulation of viral process,0.6868421052631578
horizontal pathogen transmission process,contact pathogen transmission process,0.8915584415584417
horizontal pathogen transmission process,function,0.5541666666666667
horizontal pathogen transmission process,herd immunity to infectious organism,0.6473684210526315
horizontal pathogen transmission process,extracellular infection,0.5928571428571429
horizontal pathogen transmission process,pathogen transporter role,0.7423076923076922
horizontal pathogen transmission process,symbiotic process,0.6605263157894737
horizontal pathogen transmission process,transmission interval,0.6795081967213115
horizontal pathogen transmission process,infectious agent reservoir,0.6469696969696969
horizontal pathogen transmission process,infection start process boundary,0.6722222222222223
horizontal pathogen transmission process,action specification,0.6166666666666667
horizontal pathogen transmission process,SARS-CoV-2 synthesis stage,0.6166666666666667
horizontal pathogen transmission process,latency start process boundary,0.6785714285714286
horizontal pathogen transmission process,infectious disease control objective specification,0.6166666666666667
horizontal pathogen transmission process,process of establishing viral infection,0.6272151898734176
horizontal pathogen transmission process,negative regulation of biological process,0.6722222222222223
horizontal pathogen transmission process,polymerase chain reaction,0.6346153846153847
horizontal pathogen transmission process,COVID-19 disease course,0.5928571428571429
horizontal pathogen transmission process,infectious disease incidence rate,0.6280821917808219
horizontal pathogen transmission process,communicability start process boundary,0.6551282051282051
horizontal pathogen transmission process,process that results in death,0.6384057971014493
horizontal pathogen transmission process,active immunization against infectious agent,0.6285714285714286
horizontal pathogen transmission process,disordered virus,0.575
horizontal pathogen transmission process,adaptive immune response,0.6375
horizontal pathogen transmission process,organism,0.5958333333333333
horizontal pathogen transmission process,virus uncoating stage,0.5975409836065574
horizontal pathogen transmission process,local infection,0.6136363636363636
horizontal pathogen transmission process,infectious agent,0.6107142857142857
horizontal pathogen transmission process,establishment of a clinically abnormal colony,0.6029411764705883
horizontal pathogen transmission process,process boundary,0.5928571428571429
horizontal pathogen transmission process,coronavirus disease,0.6364406779661017
horizontal pathogen transmission process,positive-sense single-stranded RNA virus,0.625
horizontal pathogen transmission process,horizontal pathogen transmission process,0.95
horizontal pathogen transmission process,hospital-acquired infection,0.6440298507462687
horizontal pathogen transmission process,pathogen death temporal region,0.6642857142857143
horizontal pathogen transmission process,emerging pathogen,0.6605263157894737
horizontal pathogen transmission process,drug susceptibility of infectious agent,0.5892405063291138
horizontal pathogen transmission process,SARS-CoV-2 release stage,0.590625
horizontal pathogen transmission process,static agent,0.6038461538461539
horizontal pathogen transmission process,pathogen transmission process,0.8702898550724637
communicability interval,virus aggregate,0.5525641025641026
communicability interval,infectious disease mortality rate,0.6605263157894737
communicability interval,communicability end temporal region,0.8228813559322035
communicability interval,infectious disease,0.6166666666666667
communicability interval,double-stranded DNA virus,0.6132653061224489
communicability interval,infectious disease incidence,0.6230769230769231
communicability interval,virus translation stage,0.6202127659574468
communicability interval,disease surveillance objective specification,0.5823529411764706
communicability interval,virus release stage,0.5662790697674418
communicability interval,virus,0.5189655172413793
communicability interval,virus replication,0.6207317073170732
communicability interval,B cell receptor complex,0.5776595744680851
communicability interval,virus host,0.5382352941176471
communicability interval,double-stranded RNA virus,0.6336734693877552
communicability interval,virus transcription stage,0.6336734693877552
communicability interval,infectious disease lifetime prevalence,0.6758064516129032
communicability interval,lower respiratory tract disease,0.6136363636363636
communicability interval,infectious disease incidence proportion,0.6087301587301588
communicability interval,virus generative stage,0.6021739130434782
communicability interval,acute infectious disease course,0.6136363636363636
communicability interval,infectious disease sporadicity,0.6166666666666667
communicability interval,communicability end process boundary,0.7666666666666666
communicability interval,infectious disease epidemic,0.6068627450980393
communicability interval,disease transmission model,0.59
communicability interval,negative-sense single-stranded RNA virus,0.60625
communicability interval,chronic infectious disease course,0.6429824561403508
communicability interval,latency interval,0.75
communicability interval,COVID-19 epidemic,0.5963414634146341
communicability interval,virus disorder,0.581578947368421
communicability interval,virus adhesion susceptible cell,0.5954545454545455
communicability interval,anatomical space,0.65
communicability interval,T cell receptor complex,0.5776595744680851
communicability interval,respiratory system disease,0.61
communicability interval,communicability interval,0.95
communicability interval,infectious disease control strategy,0.6194915254237288
communicability interval,infectious disease pandemic,0.6068627450980393
communicability interval,viral disease course,0.609090909090909
communicability interval,disease course,0.5552631578947369
communicability interval,infectious disease course,0.5928571428571429
communicability interval,COVID-19 disease incidence proportion,0.5975409836065574
communicability interval,coronavirus disease course,0.63
communicability interval,respiratory droplet virus fomite,0.5928571428571429
communicability interval,infectious disease prevalence,0.6386792452830189
communicability interval,incubation interval,0.7523255813953489
communicability interval,single-stranded DNA virus,0.5724489795918367
communicability interval,viral disease,0.6391891891891892
communicability interval,contagiousness,0.6342105263157894
communicability interval,disease,0.5467741935483871
communicability interval,eclipse interval,0.75
communicability interval,subclinical virus infection,0.6656862745098039
communicability interval,establishment of localization in virus host,0.6141791044776119
communicability interval,virus attachment stage,0.6021739130434782
communicability interval,virus synthesis stage,0.5833333333333334
communicability interval,long-term non-progressing infectious disease course,0.5833333333333334
communicability interval,viral disease epidemic,0.6021739130434782
communicability interval,communicability start temporal region,0.7942622950819671
communicability interval,viral disease pandemic,0.6021739130434782
communicability interval,virus penetration stage,0.6202127659574468
communicability interval,infectious disease endemicity,0.619811320754717
communicability interval,communicability,0.8346153846153846
communicability interval,transmission interval,0.7166666666666667
communicability interval,infectious disease control objective specification,0.5986486486486486
communicability interval,COVID-19 lifetime prevalence,0.6807692307692308
communicability interval,COVID-19 disease course,0.598936170212766
communicability interval,infectious disease incidence rate,0.6429824561403508
communicability interval,communicability start process boundary,0.7564516129032257
communicability interval,disordered virus,0.55
communicability interval,virus uncoating stage,0.65
communicability interval,establishment of a clinically abnormal colony,0.6239130434782608
communicability interval,coronavirus disease,0.6593023255813953
communicability interval,positive-sense single-stranded RNA virus,0.60625
communicability interval,cell space,0.5676470588235294
pathogen birth process boundary,extended organism,0.5958333333333333
pathogen birth process boundary,virus aggregate,0.5804347826086956
pathogen birth process boundary,source of infection,0.59
pathogen birth process boundary,immune response,0.6021739130434782
pathogen birth process boundary,infectious disease mortality rate,0.60625
pathogen birth process boundary,infection incidence rate profile,0.6404761904761905
pathogen birth process boundary,communicability end temporal region,0.6166666666666667
pathogen birth process boundary,pathogen generative stage,0.7
pathogen birth process boundary,pathogen portal of entry,0.759090909090909
pathogen birth process boundary,subclinical coronavirus infection,0.590625
pathogen birth process boundary,primary pathogen,0.6202127659574468
pathogen birth process boundary,surveillance process,0.6460784313725491
pathogen birth process boundary,infection end temporal region,0.6333333333333333
pathogen birth process boundary,drug-based immunosuppressed organism,0.6291044776119403
pathogen birth process boundary,infectious disease,0.5928571428571429
pathogen birth process boundary,SARS-CoV-2 incidence rate,0.5928571428571429
pathogen birth process boundary,double-stranded DNA virus,0.6107142857142857
pathogen birth process boundary,incubation end temporal region,0.6467213114754098
pathogen birth process boundary,site of infection,0.5958333333333333
pathogen birth process boundary,immunocompetent organism,0.5954545454545455
pathogen birth process boundary,pathogen portal of exit,0.7092592592592593
pathogen birth process boundary,infectious disease incidence,0.6025423728813559
pathogen birth process boundary,reservoir of pathogen role,0.6605263157894737
pathogen birth process boundary,subclinical SARS-CoV-2 infection,0.5769841269841269
pathogen birth process boundary,virus translation stage,0.5981481481481481
pathogen birth process boundary,disease surveillance objective specification,0.5966666666666667
pathogen birth process boundary,case isolation control strategy,0.6274193548387097
pathogen birth process boundary,virus release stage,0.61
pathogen birth process boundary,infectious agent host role,0.6429824561403508
pathogen birth process boundary,source of infection site,0.5772727272727273
pathogen birth process boundary,virus,0.5333333333333333
pathogen birth process boundary,virus replication,0.5958333333333333
pathogen birth process boundary,B cell receptor complex,0.5796296296296296
pathogen birth process boundary,passive immunization against infectious agent,0.6210526315789474
pathogen birth process boundary,systematic infection,0.5872549019607843
pathogen birth process boundary,infection incidence rate,0.6136363636363636
pathogen birth process boundary,virus host,0.5719512195121951
pathogen birth process boundary,double-stranded RNA virus,0.6107142857142857
pathogen birth process boundary,pathogen portal of entry role,0.7333333333333333
pathogen birth process boundary,virus transcription stage,0.5928571428571429
pathogen birth process boundary,infectious disease lifetime prevalence,0.6094202898550725
pathogen birth process boundary,pathogen birth temporal region,0.7778688524590163
pathogen birth process boundary,lower respiratory tract disease,0.6435483870967742
pathogen birth process boundary,infectious disease incidence proportion,0.6071428571428572
pathogen birth process boundary,opportunistic pathogen,0.6386792452830189
pathogen birth process boundary,virus generative stage,0.6009433962264151
pathogen birth process boundary,acute infectious disease course,0.6596774193548387
pathogen birth process boundary,cidal agent disposition,0.6537037037037037
pathogen birth process boundary,genetic resistance to pathogen,0.6467213114754098
pathogen birth process boundary,subclinical infection,0.5653846153846154
pathogen birth process boundary,process,0.6342105263157894
pathogen birth process boundary,simple infection,0.598936170212766
pathogen birth process boundary,droplet pathogen transmission process,0.7147058823529412
pathogen birth process boundary,infectious disease sporadicity,0.6139344262295081
pathogen birth process boundary,communicability end process boundary,0.7783582089552239
pathogen birth process boundary,infection incidence proportion profile,0.6239130434782608
pathogen birth process boundary,infectious agent colony,0.6537037037037037
pathogen birth process boundary,pathogen transporter,0.7245098039215686
pathogen birth process boundary,latency end process boundary,0.8228813559322035
pathogen birth process boundary,infectious disease epidemic,0.5879310344827586
pathogen birth process boundary,infectious agent generative stage,0.621875
pathogen birth process boundary,disease transmission model,0.6254385964912281
pathogen birth process boundary,pathologically immunosuppressed organism,0.6753521126760563
pathogen birth process boundary,negative-sense single-stranded RNA virus,0.6330985915492958
pathogen birth process boundary,cidal agent,0.569047619047619
pathogen birth process boundary,pathogen vehicle,0.7053191489361703
pathogen birth process boundary,COVID-19 incidence rate,0.5796296296296296
pathogen birth process boundary,community-acquired infection,0.6025423728813559
pathogen birth process boundary,pathogen vector,0.7108695652173913
pathogen birth process boundary,negative regulation of developmental process,0.6366666666666667
pathogen birth process boundary,pathogen vehicle role,0.7192307692307692
pathogen birth process boundary,chronic infectious disease course,0.653125
pathogen birth process boundary,asymptomatic infectious agent carrier,0.6264705882352941
pathogen birth process boundary,nursing-home acquired infection,0.6112903225806451
pathogen birth process boundary,secondary infection,0.61
pathogen birth process boundary,infection start temporal region,0.6435483870967742
pathogen birth process boundary,infection incidence,0.61
pathogen birth process boundary,virus disorder,0.6055555555555556
pathogen birth process boundary,sterilizing immunity to infectious agent,0.6190140845070422
pathogen birth process boundary,primary infection,0.5958333333333333
pathogen birth process boundary,process of establishing an infection,0.6141791044776119
pathogen birth process boundary,incubation end process boundary,0.8048387096774193
pathogen birth process boundary,SARS-CoV-2 uncoating stage,0.5728070175438597
pathogen birth process boundary,pathogen death process boundary,0.9016129032258065
pathogen birth process boundary,immunosuppressed organism,0.6107142857142857
pathogen birth process boundary,plan specification,0.6132653061224489
pathogen birth process boundary,latency end temporal region,0.6396551724137931
pathogen birth process boundary,innate immunity to infectious agent,0.6318181818181818
pathogen birth process boundary,SARS-CoV-2 penetration stage,0.6025423728813559
pathogen birth process boundary,virus adhesion susceptible cell,0.5951612903225807
pathogen birth process boundary,anatomical space,0.6202127659574468
pathogen birth process boundary,infection,0.55
pathogen birth process boundary,static agent disposition,0.6681818181818181
pathogen birth process boundary,T cell receptor complex,0.5981481481481481
pathogen birth process boundary,infectious agent population,0.6396551724137931
pathogen birth process boundary,respiratory system disease,0.6429824561403508
pathogen birth process boundary,leukocyte-mediated immunity to infectious agent,0.6038461538461539
pathogen birth process boundary,indirect pathogen transmission process,0.7108695652173913
pathogen birth process boundary,organism population,0.63
pathogen birth process boundary,planned process,0.6891304347826087
pathogen birth process boundary,generative stage,0.6202127659574468
pathogen birth process boundary,humoral immunity to infectious agent,0.6141791044776119
pathogen birth process boundary,infectious disease control strategy,0.6166666666666667
pathogen birth process boundary,SARS-CoV-2 attachment stage,0.6051724137931035
pathogen birth process boundary,parasite,0.5782051282051281
pathogen birth process boundary,infectious disease pandemic,0.6051724137931035
pathogen birth process boundary,antibody reagent,0.598936170212766
pathogen birth process boundary,infectious structure generative stage,0.5970588235294118
pathogen birth process boundary,innate immune response,0.6575471698113208
pathogen birth process boundary,viral disease course,0.6264705882352941
pathogen birth process boundary,intracellular infection,0.5981481481481481
pathogen birth process boundary,secondary infection role,0.6136363636363636
pathogen birth process boundary,metastatic infection,0.5872549019607843
pathogen birth process boundary,passive immunity to infectious agent,0.6291044776119403
pathogen birth process boundary,vaccination against infectious agent,0.6291044776119403
pathogen birth process boundary,acute infection,0.6239130434782608
pathogen birth process boundary,susceptibility to infectious agent,0.6192307692307693
pathogen birth process boundary,epitope site,0.636046511627907
pathogen birth process boundary,immunity to pathogen,0.6068627450980393
pathogen birth process boundary,source of infection role,0.6136363636363636
pathogen birth process boundary,pathogen host,0.7227272727272727
pathogen birth process boundary,chronic infection,0.6166666666666667
pathogen birth process boundary,disease course,0.6055555555555556
pathogen birth process boundary,infectious disease course,0.6285714285714286
pathogen birth process boundary,acquired immunity to infectious agent,0.6117647058823529
pathogen birth process boundary,complex infection,0.5958333333333333
pathogen birth process boundary,COVID-19 disease incidence proportion,0.5970588235294118
pathogen birth process boundary,coronavirus disease course,0.6429824561403508
pathogen birth process boundary,infection incidence proportion,0.630327868852459
pathogen birth process boundary,symptomatic infectious agent carrier,0.6291044776119403
pathogen birth process boundary,respiratory droplet virus fomite,0.6404761904761905
pathogen birth process boundary,susceptible organism,0.5872549019607843
pathogen birth process boundary,parasite role,0.6318181818181818
pathogen birth process boundary,pathogen vector role,0.7245098039215686
pathogen birth process boundary,pathogen portal of exit site,0.7042372881355932
pathogen birth process boundary,infectious disease prevalence,0.6
pathogen birth process boundary,organism substance,0.6132653061224489
pathogen birth process boundary,SARS-CoV-2 genome replication stage,0.6318181818181818
pathogen birth process boundary,single-stranded DNA virus,0.6107142857142857
pathogen birth process boundary,COVID-19 mortality rate,0.5796296296296296
pathogen birth process boundary,process profile,0.6456521739130434
pathogen birth process boundary,negative regulation of life-sustaining process,0.6448051948051949
pathogen birth process boundary,place closure control strategy,0.630327868852459
pathogen birth process boundary,viral disease,0.5636363636363636
pathogen birth process boundary,primary infection role,0.619811320754717
pathogen birth process boundary,pathogen portal of entry site,0.7333333333333333
pathogen birth process boundary,developmental process,0.6807692307692308
pathogen birth process boundary,infection incidence profile,0.6224137931034482
pathogen birth process boundary,disease,0.5289473684210526
pathogen birth process boundary,biological process,0.6744897959183673
pathogen birth process boundary,site,0.5357142857142857
pathogen birth process boundary,pathogen host role,0.7357142857142857
pathogen birth process boundary,infection prevalence,0.6068627450980393
pathogen birth process boundary,humoral immune response,0.6351851851851852
pathogen birth process boundary,infectious pathogen transmissibility,0.6738805970149254
pathogen birth process boundary,incubation start process boundary,0.825
pathogen birth process boundary,pathogen surveillance,0.6807692307692308
pathogen birth process boundary,immunodeficient organism,0.5954545454545455
pathogen birth process boundary,pathogen,0.6551282051282051
pathogen birth process boundary,pathogen birth process boundary,0.95
pathogen birth process boundary,infectious human pathogen,0.6107142857142857
pathogen birth process boundary,subclinical virus infection,0.5879310344827586
pathogen birth process boundary,resistance to pathogen,0.619811320754717
pathogen birth process boundary,establishment of localization in virus host,0.6121621621621621
pathogen birth process boundary,immunization against infectious agent,0.6264705882352941
pathogen birth process boundary,virus attachment stage,0.619811320754717
pathogen birth process boundary,negative regulation of immune response,0.6239130434782608
pathogen birth process boundary,SARS-CoV-2 transcription stage,0.5975409836065574
pathogen birth process boundary,virus synthesis stage,0.6230769230769231
pathogen birth process boundary,pathogen portal of exit role,0.7211864406779661
pathogen birth process boundary,infectious agent host,0.6230769230769231
pathogen birth process boundary,re-emerging pathogen,0.6068627450980393
pathogen birth process boundary,long-term non-progressing infectious disease course,0.6573170731707317
pathogen birth process boundary,viral disease epidemic,0.5820754716981132
pathogen birth process boundary,communicability start temporal region,0.6264705882352941
pathogen birth process boundary,blood,0.5611111111111111
pathogen birth process boundary,viral disease pandemic,0.6009433962264151
pathogen birth process boundary,virus penetration stage,0.5981481481481481
pathogen birth process boundary,algorithm,0.575
pathogen birth process boundary,pathogen seroprevalence,0.7092592592592593
pathogen birth process boundary,infectious disease endemicity,0.6166666666666667
pathogen birth process boundary,negative regulation of viral process,0.6738805970149254
pathogen birth process boundary,contact pathogen transmission process,0.7147058823529412
pathogen birth process boundary,function,0.5525641025641026
pathogen birth process boundary,herd immunity to infectious organism,0.6291044776119403
pathogen birth process boundary,extracellular infection,0.5981481481481481
pathogen birth process boundary,pathogen transporter role,0.7178571428571427
pathogen birth process boundary,symbiotic process,0.6791666666666666
pathogen birth process boundary,infectious agent reservoir,0.6605263157894737
pathogen birth process boundary,infection start process boundary,0.8150793650793651
pathogen birth process boundary,action specification,0.6264705882352941
pathogen birth process boundary,SARS-CoV-2 synthesis stage,0.6254385964912281
pathogen birth process boundary,latency start process boundary,0.8434426229508196
pathogen birth process boundary,infectious disease control objective specification,0.5981481481481481
pathogen birth process boundary,process of establishing viral infection,0.6214285714285714
pathogen birth process boundary,negative regulation of biological process,0.6583333333333334
pathogen birth process boundary,polymerase chain reaction,0.6285714285714286
pathogen birth process boundary,COVID-19 disease course,0.6166666666666667
pathogen birth process boundary,infectious disease incidence rate,0.60625
pathogen birth process boundary,communicability start process boundary,0.7833333333333333
pathogen birth process boundary,process that results in death,0.7
pathogen birth process boundary,active immunization against infectious agent,0.61
pathogen birth process boundary,disordered virus,0.5776595744680851
pathogen birth process boundary,adaptive immune response,0.65
pathogen birth process boundary,organism,0.5782051282051281
pathogen birth process boundary,virus uncoating stage,0.5846153846153846
pathogen birth process boundary,local infection,0.5804347826086956
pathogen birth process boundary,infectious agent,0.5776595744680851
pathogen birth process boundary,establishment of a clinically abnormal colony,0.6210526315789474
pathogen birth process boundary,process boundary,0.7904255319148936
pathogen birth process boundary,coronavirus disease,0.61
pathogen birth process boundary,positive-sense single-stranded RNA virus,0.6330985915492958
pathogen birth process boundary,horizontal pathogen transmission process,0.7035211267605633
pathogen birth process boundary,hospital-acquired infection,0.6051724137931035
pathogen birth process boundary,pathogen death temporal region,0.728688524590164
pathogen birth process boundary,emerging pathogen,0.6166666666666667
pathogen birth process boundary,drug susceptibility of infectious agent,0.6071428571428572
pathogen birth process boundary,SARS-CoV-2 release stage,0.5954545454545455
pathogen birth process boundary,static agent,0.5895348837209302
pathogen birth process boundary,pathogen transmission process,0.75
pathogen birth process boundary,cell space,0.5719512195121951
physiologic immunosuppression,physiologic immunosuppression,0.95
physiologic immunosuppression,immunosuppression,0.8195652173913044
physiologic immunosuppression,pathologic immunosuppression,0.9061403508771929
infectious agent colony,information content entity,0.7153061224489795
infectious agent colony,infectious disease mortality rate,0.7535714285714286
infectious agent colony,infection incidence rate profile,0.7227272727272727
infectious agent colony,infectious structure aggregate,0.7330188679245283
infectious agent colony,communicability end temporal region,0.6396551724137931
infectious agent colony,infection end temporal region,0.7576923076923078
infectious agent colony,infectious disease,0.7670731707317073
infectious agent colony,SARS-CoV-2 incidence rate,0.5958333333333333
infectious agent colony,incubation end temporal region,0.7141509433962264
infectious agent colony,normal resident microbiota population,0.65
infectious agent colony,virulence factor disposition,0.6656862745098039
infectious agent colony,infectious disease incidence,0.7637254901960785
infectious agent colony,establishment of localization in host,0.65
infectious agent colony,disease surveillance objective specification,0.6141791044776119
infectious agent colony,infectious agent host role,0.8377551020408163
infectious agent colony,asymptomatic infectious structure carrier,0.66875
infectious agent colony,B cell receptor complex,0.6239130434782608
infectious agent colony,passive immunization against infectious agent,0.6852941176470588
infectious agent colony,infection incidence rate,0.7053191489361703
infectious agent colony,colonized host,0.5851351351351352
infectious agent colony,virus host,0.6015151515151516
infectious agent colony,infectious disease lifetime prevalence,0.728688524590164
infectious agent colony,lower respiratory tract disease,0.5796296296296296
infectious agent colony,infectious disease incidence proportion,0.7403225806451613
infectious agent colony,acute infectious disease course,0.7462962962962962
infectious agent colony,cidal agent disposition,0.7108695652173913
infectious agent colony,infectious disorder,0.7357142857142857
infectious agent colony,biological vehicle,0.5963414634146341
infectious agent colony,infectious disease sporadicity,0.7518867924528303
infectious agent colony,communicability end process boundary,0.6364406779661017
infectious agent colony,directive information content entity,0.6703389830508475
infectious agent colony,infectious agent colony,0.95
infectious agent colony,pathogen transporter,0.6127906976744186
infectious agent colony,invasion factor,0.6605263157894737
infectious agent colony,latency end process boundary,0.6460784313725491
infectious agent colony,colonization of host,0.636046511627907
infectious agent colony,infectious disease epidemic,0.75
infectious agent colony,infectious agent generative stage,0.7714285714285714
infectious agent colony,disease transmission model,0.6336734693877552
infectious agent colony,cidal agent,0.6852941176470588
infectious agent colony,infectious structure host role,0.7518867924528303
infectious agent colony,pathogen vehicle,0.6551282051282051
infectious agent colony,COVID-19 incidence rate,0.6021739130434782
infectious agent colony,pathogen vehicle role,0.6545454545454545
infectious agent colony,host,0.5611111111111111
infectious agent colony,chronic infectious disease course,0.7357142857142857
infectious agent colony,asymptomatic infectious agent carrier,0.75
infectious agent colony,descriptive information content entity,0.6631147540983606
infectious agent colony,COVID-19 epidemic,0.575
infectious agent colony,sterilizing immunity to infectious agent,0.7039682539682539
infectious agent colony,establishment of localization in human host,0.6318181818181818
infectious agent colony,diseased population,0.6642857142857143
infectious agent colony,virulence factor,0.6294871794871795
infectious agent colony,incubation end process boundary,0.7092592592592593
infectious agent colony,dead-end host role,0.6451219512195122
infectious agent colony,definitive host role,0.6825581395348838
infectious agent colony,latency end temporal region,0.65
infectious agent colony,innate immunity to infectious agent,0.7258620689655172
infectious agent colony,infectious structure,0.7523255813953489
infectious agent colony,colony,0.656896551724138
infectious agent colony,static agent disposition,0.7053191489361703
infectious agent colony,T cell receptor complex,0.6239130434782608
infectious agent colony,asymptomatic carrier role,0.6166666666666667
infectious agent colony,infectious structure host,0.7416666666666667
infectious agent colony,infectious agent population,0.87
infectious agent colony,respiratory system disease,0.5928571428571429
infectious agent colony,entry into host,0.6342105263157894
infectious agent colony,leukocyte-mediated immunity to infectious agent,0.6785714285714286
infectious agent colony,adhesion of symbiont to host,0.6460784313725491
infectious agent colony,humoral immunity to infectious agent,0.7211864406779661
infectious agent colony,infectious disease control strategy,0.760344827586207
infectious agent colony,infectious disease pandemic,0.75
infectious agent colony,infectious structure generative stage,0.7166666666666667
infectious agent colony,viral disease course,0.636046511627907
infectious agent colony,entry into host through host barriers,0.6
infectious agent colony,passive immunity to infectious agent,0.7211864406779661
infectious agent colony,infectious disposition,0.7611111111111112
infectious agent colony,vaccination against infectious agent,0.7211864406779661
infectious agent colony,susceptibility to infectious agent,0.730701754385965
infectious agent colony,pathogen host,0.6444444444444444
infectious agent colony,disease course,0.6391891891891892
infectious agent colony,infectious disease course,0.7833333333333333
infectious agent colony,acquired immunity to infectious agent,0.7166666666666667
infectious agent colony,COVID-19 disease incidence proportion,0.6166666666666667
infectious agent colony,coronavirus disease course,0.6540816326530612
infectious agent colony,asymptomatic carrier,0.5895348837209302
infectious agent colony,biological vehicle role,0.6021739130434782
infectious agent colony,symptomatic infectious agent carrier,0.7550847457627118
infectious agent colony,intermediate host,0.65
infectious agent colony,infectious disease prevalence,0.7576923076923078
infectious agent colony,infected population,0.7357142857142857
infectious agent colony,COVID-19 mortality rate,0.5804347826086956
infectious agent colony,viral disease,0.5888888888888889
infectious agent colony,disease,0.5833333333333334
infectious agent colony,symptomatic infectious structure carrier,0.6722222222222223
infectious agent colony,primary infectious disposition,0.7141509433962264
infectious agent colony,pathogen host role,0.6695121951219513
infectious agent colony,designative information content entity,0.6631147540983606
infectious agent colony,symptomatic carrier role,0.6202127659574468
infectious agent colony,infectious pathogen transmissibility,0.7550847457627118
infectious agent colony,intermediate host role,0.6722222222222223
infectious agent colony,dead-end host,0.6166666666666667
infectious agent colony,host role,0.6375
infectious agent colony,infectious human pathogen,0.7833333333333333
infectious agent colony,establishment of localization in virus host,0.6318181818181818
infectious agent colony,immunization against infectious agent,0.7166666666666667
infectious agent colony,infectious agent host,0.859090909090909
infectious agent colony,long-term non-progressing infectious disease course,0.6662162162162162
infectious agent colony,viral disease epidemic,0.6055555555555556
infectious agent colony,viral disease pandemic,0.6055555555555556
infectious agent colony,symptomatic carrier,0.5928571428571429
infectious agent colony,infectious disease endemicity,0.7576923076923078
infectious agent colony,function,0.6435483870967742
infectious agent colony,herd immunity to infectious organism,0.6703389830508475
infectious agent colony,pathogen transporter role,0.6375
infectious agent colony,infectious agent reservoir,0.8173469387755102
infectious agent colony,COVID-19 pandemic,0.6
infectious agent colony,action specification,0.6593023255813953
infectious agent colony,infectious disease control objective specification,0.7102739726027397
infectious agent colony,symbiont host role,0.6695121951219513
infectious agent colony,opportunistic infectious disposition,0.6872881355932203
infectious agent colony,polymerase chain reaction,0.6375
infectious agent colony,COVID-19 disease course,0.6239130434782608
infectious agent colony,infectious disease incidence rate,0.7357142857142857
infectious agent colony,active immunization against infectious agent,0.6888059701492537
infectious agent colony,local infection,0.6868421052631578
infectious agent colony,infectious agent,0.8602564102564102
infectious agent colony,establishment of a clinically abnormal colony,0.6705882352941177
infectious agent colony,coronavirus disease,0.6166666666666667
infectious agent colony,adhesion factor,0.6342105263157894
infectious agent colony,definitive host,0.6342105263157894
infectious agent colony,drug susceptibility of infectious agent,0.7080645161290323
infectious agent colony,static agent,0.6785714285714286
drug-based immunosuppressed organism,extended organism,0.6952830188679244
drug-based immunosuppressed organism,information content entity,0.5951612903225807
drug-based immunosuppressed organism,infectious structure aggregate,0.6166666666666667
drug-based immunosuppressed organism,geographical entity,0.5772727272727273
drug-based immunosuppressed organism,drug-based immunosuppressed organism,0.95
drug-based immunosuppressed organism,resistant entity,0.5846153846153846
drug-based immunosuppressed organism,immunocompetent organism,0.75
drug-based immunosuppressed organism,virulence factor disposition,0.60625
drug-based immunosuppressed organism,case isolation control strategy,0.6141791044776119
drug-based immunosuppressed organism,material entity,0.5676470588235294
drug-based immunosuppressed organism,asymptomatic infectious structure carrier,0.6188311688311688
drug-based immunosuppressed organism,architectual structure,0.5879310344827586
drug-based immunosuppressed organism,B cell receptor complex,0.6025423728813559
drug-based immunosuppressed organism,entity,0.5214285714285714
drug-based immunosuppressed organism,drug susceptibility,0.6318181818181818
drug-based immunosuppressed organism,directive information content entity,0.6166666666666667
drug-based immunosuppressed organism,acellular structure aggregate,0.6192307692307693
drug-based immunosuppressed organism,invasion factor,0.5872549019607843
drug-based immunosuppressed organism,realizable entity,0.5820754716981132
drug-based immunosuppressed organism,pathologically immunosuppressed organism,0.8184210526315789
drug-based immunosuppressed organism,infectious structure host role,0.6015151515151516
drug-based immunosuppressed organism,descriptive information content entity,0.6121621621621621
drug-based immunosuppressed organism,resistance to drug,0.6166666666666667
drug-based immunosuppressed organism,establishment of localization in human host,0.5892405063291138
drug-based immunosuppressed organism,acellular structure,0.5772727272727273
drug-based immunosuppressed organism,virulence factor,0.6038461538461539
drug-based immunosuppressed organism,molecular entity,0.5846153846153846
drug-based immunosuppressed organism,immunosuppressed organism,0.8598360655737705
drug-based immunosuppressed organism,plan specification,0.5796296296296296
drug-based immunosuppressed organism,infectious structure,0.575
drug-based immunosuppressed organism,T cell receptor complex,0.5855932203389831
drug-based immunosuppressed organism,infectious structure host,0.6139344262295081
drug-based immunosuppressed organism,organism population,0.6136363636363636
drug-based immunosuppressed organism,infectious structure generative stage,0.6143835616438357
drug-based immunosuppressed organism,susceptible organism,0.7
drug-based immunosuppressed organism,organism substance,0.6351851851851852
drug-based immunosuppressed organism,anatomical entity,0.5632075471698114
drug-based immunosuppressed organism,geopolitical entity,0.5954545454545455
drug-based immunosuppressed organism,symptomatic infectious structure carrier,0.6078947368421053
drug-based immunosuppressed organism,designative information content entity,0.6256756756756756
drug-based immunosuppressed organism,immunodeficient organism,0.7333333333333333
drug-based immunosuppressed organism,infectious human pathogen,0.5975409836065574
drug-based immunosuppressed organism,colonization of human,0.5728070175438597
drug-based immunosuppressed organism,immaterial entity,0.6009433962264151
drug-based immunosuppressed organism,blood,0.523170731707317
drug-based immunosuppressed organism,division of geopolitical entity,0.5992537313432835
drug-based immunosuppressed organism,geographical feature,0.5571428571428572
drug-based immunosuppressed organism,herd immunity to infectious organism,0.7277777777777777
drug-based immunosuppressed organism,action specification,0.5928571428571429
drug-based immunosuppressed organism,processed material,0.6351851851851852
drug-based immunosuppressed organism,organism,0.6318181818181818
drug-based immunosuppressed organism,establishment of a clinically abnormal colony,0.5858024691358025
drug-based immunosuppressed organism,adhesion factor,0.5872549019607843
drug-based immunosuppressed organism,drug susceptibility of infectious agent,0.65
drug-based immunosuppressed organism,material processing,0.6136363636363636
extended organism,extended organism,0.95
extended organism,information content entity,0.5895348837209302
extended organism,infectious structure aggregate,0.598936170212766
extended organism,communicability end temporal region,0.6230769230769231
extended organism,geographical entity,0.6166666666666667
extended organism,infection end temporal region,0.6673913043478261
extended organism,drug-based immunosuppressed organism,0.6952830188679244
extended organism,incubation end temporal region,0.6414893617021277
extended organism,resistant entity,0.6318181818181818
extended organism,immunocompetent organism,0.7670731707317073
extended organism,virulence factor disposition,0.6277777777777778
extended organism,case isolation control strategy,0.5958333333333333
extended organism,material entity,0.6375
extended organism,asymptomatic infectious structure carrier,0.5706896551724138
extended organism,architectual structure,0.5525641025641026
extended organism,B cell receptor complex,0.6
extended organism,entity,0.5804347826086956
extended organism,lower respiratory tract disease,0.5958333333333333
extended organism,communicability end process boundary,0.6009433962264151
extended organism,directive information content entity,0.619811320754717
extended organism,acellular structure aggregate,0.6021739130434782
extended organism,invasion factor,0.575
extended organism,latency end process boundary,0.6277777777777778
extended organism,realizable entity,0.5970588235294118
extended organism,pathologically immunosuppressed organism,0.6780701754385965
extended organism,infectious structure host role,0.5776595744680851
extended organism,descriptive information content entity,0.6136363636363636
extended organism,establishment of localization in human host,0.6166666666666667
extended organism,acellular structure,0.5333333333333333
extended organism,virulence factor,0.6318181818181818
extended organism,incubation end process boundary,0.6166666666666667
extended organism,molecular entity,0.5712121212121213
extended organism,immunosuppressed organism,0.7357142857142857
extended organism,plan specification,0.5642857142857143
extended organism,latency end temporal region,0.6772727272727272
extended organism,infectious structure,0.5581081081081081
extended organism,T cell receptor complex,0.6
extended organism,infectious structure host,0.5928571428571429
extended organism,organism population,0.6722222222222223
extended organism,infectious structure generative stage,0.6166666666666667
extended organism,susceptible organism,0.7743243243243243
extended organism,organism substance,0.6785714285714286
extended organism,anatomical entity,0.5970588235294118
extended organism,geopolitical entity,0.5888888888888889
extended organism,symptomatic infectious structure carrier,0.5728070175438597
extended organism,designative information content entity,0.6136363636363636
extended organism,immunodeficient organism,0.7426829268292683
extended organism,infectious human pathogen,0.6166666666666667
extended organism,colonization of human,0.6078947368421053
extended organism,immaterial entity,0.6264705882352941
extended organism,division of geopolitical entity,0.5958333333333333
extended organism,geographical feature,0.5851351351351352
extended organism,herd immunity to infectious organism,0.6952830188679244
extended organism,action specification,0.5851351351351352
extended organism,processed material,0.6214285714285714
extended organism,organism,0.77
extended organism,establishment of a clinically abnormal colony,0.6112903225806451
extended organism,adhesion factor,0.60625
extended organism,material processing,0.5888888888888889
bacteriostatic,B cell receptor complex,0.6121621621621621
bacteriostatic,static agent disposition,0.6605263157894737
bacteriostatic,T cell receptor complex,0.5851351351351352
bacteriostatic,bacteriostatic,0.95
bacteriostatic,bacteriostatic disposition,0.8
bacteriostatic,establishment of a clinically abnormal colony,0.5686440677966101
bacteriostatic,static agent,0.6807692307692308
biological vector,biological regulation,0.8184210526315789
biological vector,primary pathogen,0.6015151515151516
biological vector,vector control strategy,0.6
biological vector,infectious agent host role,0.6127906976744186
biological vector,B cell receptor complex,0.675
biological vector,passive immunization against infectious agent,0.5951612903225807
biological vector,mechanical vector,0.7735294117647058
biological vector,acute infectious disease course,0.6166666666666667
biological vector,cidal agent disposition,0.625
biological vector,biological vehicle,0.85
biological vector,infectious agent colony,0.6
biological vector,infectious agent generative stage,0.59
biological vector,vector surveillance,0.6166666666666667
biological vector,cidal agent,0.6642857142857143
biological vector,pathogen vector,0.73125
biological vector,chronic infectious disease course,0.63
biological vector,asymptomatic infectious agent carrier,0.6166666666666667
biological vector,mechanical vector role,0.732051282051282
biological vector,sterilizing immunity to infectious agent,0.6078947368421053
biological vector,primary infection,0.6558823529411765
biological vector,innate immunity to infectious agent,0.5846153846153846
biological vector,virus adhesion susceptible cell,0.575
biological vector,anatomical space,0.6621212121212122
biological vector,static agent disposition,0.5963414634146341
biological vector,T cell receptor complex,0.65
biological vector,infectious agent population,0.5863636363636363
biological vector,biological vector,0.95
biological vector,leukocyte-mediated immunity to infectious agent,0.590625
biological vector,humoral immunity to infectious agent,0.6009433962264151
biological vector,innate immune response,0.5782051282051281
biological vector,viral disease course,0.6662162162162162
biological vector,cell,0.5452380952380953
biological vector,passive immunity to infectious agent,0.5820754716981132
biological vector,vaccination against infectious agent,0.619811320754717
biological vector,susceptibility to infectious agent,0.6264705882352941
biological vector,disease course,0.6435483870967742
biological vector,infectious disease course,0.6404761904761905
biological vector,acquired immunity to infectious agent,0.5796296296296296
biological vector,coronavirus disease course,0.636046511627907
biological vector,biological vehicle role,0.825
biological vector,symptomatic infectious agent carrier,0.619811320754717
biological vector,pathogen vector role,0.6932432432432433
biological vector,anatomical entity,0.6852941176470588
biological vector,primary infection role,0.6551282051282051
biological vector,primary immunodeficiency,0.5963414634146341
biological vector,biological role,0.825
biological vector,biological process,0.7928571428571428
biological vector,biological vector role,0.8858974358974359
biological vector,primary infectious disposition,0.598936170212766
biological vector,SARS-COV-2 adhesion susceptible cell,0.5632075471698114
biological vector,immunization against infectious agent,0.6166666666666667
biological vector,infectious agent host,0.6078947368421053
biological vector,long-term non-progressing infectious disease course,0.5970588235294118
biological vector,infectious agent reservoir,0.6127906976744186
biological vector,negative regulation of biological process,0.656896551724138
biological vector,COVID-19 disease course,0.625
biological vector,active immunization against infectious agent,0.5975409836065574
biological vector,infectious agent,0.6015151515151516
biological vector,establishment of a clinically abnormal colony,0.6274193548387097
biological vector,drug susceptibility of infectious agent,0.6107142857142857
biological vector,static agent,0.6224137931034482
biological vector,cell space,0.5981481481481481
static agent,information content entity,0.6605263157894737
static agent,infectious disease mortality rate,0.6055555555555556
static agent,infection incidence rate profile,0.5863636363636363
static agent,communicability end temporal region,0.5776595744680851
static agent,infection end temporal region,0.5963414634146341
static agent,SARS-CoV-2 incidence rate,0.6391891891891892
static agent,incubation end temporal region,0.6166666666666667
static agent,virulence factor disposition,0.575
static agent,establishment of localization in host,0.6132653061224489
static agent,infectious agent host role,0.6605263157894737
static agent,asymptomatic infectious structure carrier,0.619811320754717
static agent,B cell receptor complex,0.5642857142857143
static agent,passive immunization against infectious agent,0.6605263157894737
static agent,infection incidence rate,0.6166666666666667
static agent,colonized host,0.5653846153846154
static agent,virus host,0.5863636363636363
static agent,acute infectious disease course,0.6127906976744186
static agent,cidal agent disposition,0.65
static agent,biological vehicle,0.5833333333333334
static agent,communicability end process boundary,0.5541666666666667
static agent,directive information content entity,0.6375
static agent,infectious agent colony,0.6785714285714286
static agent,pathogen transporter,0.6375
static agent,invasion factor,0.6351851851851852
static agent,latency end process boundary,0.6
static agent,colonization of host,0.60625
static agent,infectious agent generative stage,0.65
static agent,cidal agent,0.7543478260869566
static agent,infectious structure host role,0.569047619047619
static agent,pathogen vehicle,0.6285714285714286
static agent,COVID-19 incidence rate,0.5928571428571429
static agent,pathogen vehicle role,0.6318181818181818
static agent,host,0.575
static agent,chronic infectious disease course,0.5611111111111111
static agent,asymptomatic infectious agent carrier,0.6948979591836735
static agent,descriptive information content entity,0.65
static agent,sterilizing immunity to infectious agent,0.6615384615384616
static agent,establishment of localization in human host,0.6136363636363636
static agent,virulence factor,0.6285714285714286
static agent,incubation end process boundary,0.5895348837209302
static agent,dead-end host role,0.5833333333333334
static agent,definitive host role,0.575
static agent,latency end temporal region,0.6294871794871795
static agent,innate immunity to infectious agent,0.6627659574468084
static agent,static agent disposition,0.7833333333333333
static agent,T cell receptor complex,0.5928571428571429
static agent,asymptomatic carrier role,0.6932432432432433
static agent,infectious structure host,0.5851351351351352
static agent,infectious agent population,0.6551282051282051
static agent,entry into host,0.5981481481481481
static agent,leukocyte-mediated immunity to infectious agent,0.6364406779661017
static agent,adhesion of symbiont to host,0.575
static agent,humoral immunity to infectious agent,0.6583333333333334
static agent,viral disease course,0.575
static agent,entry into host through host barriers,0.5724489795918367
static agent,passive immunity to infectious agent,0.6791666666666666
static agent,vaccination against infectious agent,0.6791666666666666
static agent,susceptibility to infectious agent,0.6891304347826087
static agent,pathogen host,0.69
static agent,disease course,0.6038461538461539
static agent,infectious disease course,0.5851351351351352
static agent,acquired immunity to infectious agent,0.6540816326530612
static agent,coronavirus disease course,0.581578947368421
static agent,asymptomatic carrier,0.73125
static agent,biological vehicle role,0.5928571428571429
static agent,symptomatic infectious agent carrier,0.7
static agent,intermediate host,0.6224137931034482
static agent,COVID-19 mortality rate,0.6214285714285714
static agent,symptomatic infectious structure carrier,0.6230769230769231
static agent,pathogen host role,0.65
static agent,designative information content entity,0.65
static agent,symptomatic carrier role,0.7
static agent,object,0.5611111111111111
static agent,intermediate host role,0.5970588235294118
static agent,dead-end host,0.61
static agent,host role,0.6404761904761905
static agent,establishment of localization in virus host,0.5954545454545455
static agent,immunization against infectious agent,0.6744897959183673
static agent,object aggregate,0.6642857142857143
static agent,infectious agent host,0.6924242424242425
static agent,long-term non-progressing infectious disease course,0.5452380952380953
static agent,symptomatic carrier,0.7403225806451613
static agent,function,0.6
static agent,pathogen transporter role,0.6121621621621621
static agent,infectious agent reservoir,0.6605263157894737
static agent,action specification,0.6375
static agent,symbiont host role,0.6166666666666667
static agent,polymerase chain reaction,0.6121621621621621
static agent,COVID-19 disease course,0.5642857142857143
static agent,infectious disease incidence rate,0.6055555555555556
static agent,active immunization against infectious agent,0.6464285714285714
static agent,infectious agent,0.7357142857142857
static agent,establishment of a clinically abnormal colony,0.6078947368421053
static agent,adhesion factor,0.6351851851851852
static agent,definitive host,0.5981481481481481
static agent,drug susceptibility of infectious agent,0.6656862745098039
static agent,static agent,0.95
local infection,virus aggregate,0.55
local infection,source of infection,0.8029411764705883
local infection,virostatic disposition,0.6662162162162162
local infection,zoonotic disposition,0.6785714285714286
local infection,infectious disease mortality rate,0.6166666666666667
local infection,infection incidence rate profile,0.6414893617021277
local infection,communicability end temporal region,0.65
local infection,geographical entity,0.6852941176470588
local infection,subclinical coronavirus infection,0.7416666666666667
local infection,infection end temporal region,0.6545454545454545
local infection,infectious disease,0.6924242424242425
local infection,double-stranded DNA virus,0.575
local infection,incubation end temporal region,0.65
local infection,site of infection,0.79375
local infection,two-dimensional spatial region,0.65
local infection,one-dimensional temporal region,0.6456521739130434
local infection,normal resident microbiota population,0.6615384615384616
local infection,virulence factor disposition,0.6593023255813953
local infection,viral adhesion disposition,0.6695121951219513
local infection,parasitostatic disposition,0.6451219512195122
local infection,temporal region,0.7166666666666667
local infection,infectious disease incidence,0.6593023255813953
local infection,reverse zoonotic disposition,0.636046511627907
local infection,subclinical SARS-CoV-2 infection,0.747872340425532
local infection,virus translation stage,0.6078947368421053
local infection,disease surveillance objective specification,0.6364406779661017
local infection,virus release stage,0.5676470588235294
local infection,source of infection site,0.7576923076923078
local infection,virus,0.5
local infection,virus replication,0.66875
local infection,B cell receptor complex,0.6342105263157894
local infection,systematic infection,0.7642857142857143
local infection,infection incidence rate,0.6807692307692308
local infection,virus host,0.53
local infection,double-stranded RNA virus,0.575
local infection,virus transcription stage,0.625
local infection,infectious disease lifetime prevalence,0.619811320754717
local infection,toxin disposition,0.66875
local infection,pathogen birth temporal region,0.6277777777777778
local infection,lower respiratory tract disease,0.6021739130434782
local infection,infectious disease incidence proportion,0.6537037037037037
local infection,virus generative stage,0.5851351351351352
local infection,acute infectious disease course,0.6673913043478261
local infection,cidal agent disposition,0.6868421052631578
local infection,infectious disorder,0.6852941176470588
local infection,subclinical infection,0.8388888888888889
local infection,appearance of disorder,0.5851351351351352
local infection,simple infection,0.8048387096774193
local infection,parasiticidal disposition,0.675
local infection,infectious disease sporadicity,0.6277777777777778
local infection,communicability end process boundary,0.6264705882352941
local infection,infection incidence proportion profile,0.6386792452830189
local infection,spatiotemporal region,0.6722222222222223
local infection,transmissibility disposition,0.636046511627907
local infection,latency end process boundary,0.6127906976744186
local infection,infectious disease epidemic,0.6404761904761905
local infection,disease transmission model,0.5963414634146341
local infection,endotoxin disposition,0.6444444444444444
local infection,negative-sense single-stranded RNA virus,0.5772727272727273
local infection,cytotoxin disposition,0.6444444444444444
local infection,community-acquired infection,0.7290697674418604
local infection,zero-dimensional spatial region,0.6456521739130434
local infection,zero-dimensional temporal region,0.6414893617021277
local infection,chronic infectious disease course,0.6791666666666666
local infection,nursing-home acquired infection,0.7108695652173913
local infection,COVID-19 epidemic,0.60625
local infection,secondary infection,0.8029411764705883
local infection,infection start temporal region,0.6456521739130434
local infection,infection incidence,0.7147058823529412
local infection,virus disorder,0.553448275862069
local infection,primary infection,0.79375
local infection,process of establishing an infection,0.7245098039215686
local infection,incubation end process boundary,0.6239130434782608
local infection,SARS-CoV-2 disorder,0.5676470588235294
local infection,collective pathogenic disposition,0.6375
local infection,neurotoxin disposition,0.6391891891891892
local infection,geographical region,0.7147058823529412
local infection,latency end temporal region,0.6642857142857143
local infection,innate immunity to infectious agent,0.67
local infection,virus adhesion susceptible cell,0.5804347826086956
local infection,collective disposition,0.6662162162162162
local infection,infection,0.825
local infection,static agent disposition,0.6551282051282051
local infection,T cell receptor complex,0.6342105263157894
local infection,respiratory system disease,0.5475609756097561
local infection,communicability interval,0.6551282051282051
local infection,infectious disease control strategy,0.63
local infection,infectious disease pandemic,0.6642857142857143
local infection,immunosuppressive disposition,0.609090909090909
local infection,innate immune response,0.6391891891891892
local infection,pathogenic disposition,0.6662162162162162
local infection,viral disease course,0.65
local infection,intracellular infection,0.7657894736842106
local infection,secondary infection role,0.7576923076923078
local infection,metastatic infection,0.7642857142857143
local infection,three-dimensional spatial region,0.6414893617021277
local infection,infectious disposition,0.6932432432432433
local infection,acute infection,0.8166666666666665
local infection,bacteriostatic disposition,0.6451219512195122
local infection,bactericidal disposition,0.6807692307692308
local infection,source of infection role,0.7576923076923078
local infection,chronic infection,0.825
local infection,invasion disposition,0.65
local infection,disease course,0.5879310344827586
local infection,infectious disease course,0.65
local infection,viricidal disposition,0.7
local infection,complex infection,0.825
local infection,COVID-19 disease incidence proportion,0.6615384615384616
local infection,coronavirus disease course,0.6207317073170732
local infection,infection incidence proportion,0.6722222222222223
local infection,symptomatic infectious agent carrier,0.6852941176470588
local infection,respiratory droplet virus fomite,0.5776595744680851
local infection,infectious disease prevalence,0.6545454545454545
local infection,disposition,0.6807692307692308
local infection,single-stranded DNA virus,0.575
local infection,viral disease,0.6285714285714286
local infection,primary infection role,0.7472972972972972
local infection,adhesion disposition,0.65
local infection,infection incidence profile,0.6642857142857143
local infection,contagiousness,0.656896551724138
local infection,disease,0.5409090909090909
local infection,symptomatic infectious structure carrier,0.65
local infection,primary infectious disposition,0.6944444444444444
local infection,infection prevalence,0.7071428571428571
local infection,symptomatic carrier role,0.6038461538461539
local infection,coronavirus disorder,0.5928571428571429
local infection,subclinical virus infection,0.7833333333333333
local infection,establishment of localization in virus host,0.6224137931034482
local infection,virus attachment stage,0.5310810810810811
local infection,virus synthesis stage,0.5611111111111111
local infection,SARS-COV-2 adhesion disposition,0.6239130434782608
local infection,invasive disposition,0.65
local infection,long-term non-progressing infectious disease course,0.6166666666666667
local infection,viral disease epidemic,0.6121621621621621
local infection,communicability start temporal region,0.6230769230769231
local infection,fungicidal disposition,0.6932432432432433
local infection,viral disease pandemic,0.6391891891891892
local infection,virus penetration stage,0.6342105263157894
local infection,acute respiratory distress syndrome,0.57
local infection,geospatial region,0.7
local infection,division of geopolitical entity,0.6239130434782608
local infection,symptomatic carrier,0.5970588235294118
local infection,geographical feature,0.6785714285714286
local infection,infectious disease endemicity,0.6545454545454545
local infection,disorder,0.5369565217391304
local infection,communicability,0.65
local infection,extracellular infection,0.7657894736842106
local infection,exotoxin disposition,0.65
local infection,infection start process boundary,0.6414893617021277
local infection,action specification,0.7071428571428571
local infection,infectious disease control objective specification,0.6192307692307693
local infection,opportunistic infectious disposition,0.6852941176470588
local infection,process of establishing viral infection,0.7092592592592593
local infection,enterotoxin disposition,0.6342105263157894
local infection,COVID-19 disease course,0.6078947368421053
local infection,infectious disease incidence rate,0.6375
local infection,communicability start process boundary,0.6009433962264151
local infection,single-stranded RNA retrovirus,0.6055555555555556
local infection,disordered virus,0.5467741935483871
local infection,collective resistance disposition,0.6583333333333334
local infection,symptom,0.5409090909090909
local infection,fungistatic disposition,0.6342105263157894
local infection,virus uncoating stage,0.6166666666666667
local infection,local infection,0.95
local infection,establishment of a clinically abnormal colony,0.6166666666666667
local infection,coronavirus disease,0.5970588235294118
local infection,positive-sense single-stranded RNA virus,0.5772727272727273
local infection,one-dimensional spatial region,0.65
local infection,hospital-acquired infection,0.7595238095238095
local infection,spatial region,0.6913793103448276
local infection,pathogen death temporal region,0.6277777777777778
infectious disease lifetime prevalence,virus aggregate,0.619811320754717
infectious disease lifetime prevalence,source of infection,0.6254385964912281
infectious disease lifetime prevalence,virostatic disposition,0.65
infectious disease lifetime prevalence,zoonotic disposition,0.656896551724138
infectious disease lifetime prevalence,infectious disease mortality rate,0.8161971830985917
infectious disease lifetime prevalence,infection incidence rate profile,0.7357142857142857
infectious disease lifetime prevalence,infectious structure aggregate,0.7294117647058823
infectious disease lifetime prevalence,communicability end temporal region,0.6691780821917809
infectious disease lifetime prevalence,subclinical coronavirus infection,0.6330985915492958
infectious disease lifetime prevalence,infection end temporal region,0.7335820895522389
infectious disease lifetime prevalence,vector control strategy,0.6139344262295081
infectious disease lifetime prevalence,infectious disease,0.7714285714285714
infectious disease lifetime prevalence,SARS-CoV-2 incidence rate,0.6246031746031746
infectious disease lifetime prevalence,double-stranded DNA virus,0.5928571428571429
infectious disease lifetime prevalence,incubation end temporal region,0.7
infectious disease lifetime prevalence,site of infection,0.6318181818181818
infectious disease lifetime prevalence,virulence factor disposition,0.6772727272727272
infectious disease lifetime prevalence,viral adhesion disposition,0.653125
infectious disease lifetime prevalence,parasitostatic disposition,0.653125
infectious disease lifetime prevalence,infectious disease incidence,0.8287878787878787
infectious disease lifetime prevalence,reverse zoonotic disposition,0.6318181818181818
infectious disease lifetime prevalence,subclinical SARS-CoV-2 infection,0.65
infectious disease lifetime prevalence,virus translation stage,0.6467213114754098
infectious disease lifetime prevalence,disease surveillance objective specification,0.6695121951219513
infectious disease lifetime prevalence,case isolation control strategy,0.6239130434782608
infectious disease lifetime prevalence,virus release stage,0.6605263157894737
infectious disease lifetime prevalence,infectious agent host role,0.746875
infectious disease lifetime prevalence,asymptomatic infectious structure carrier,0.6651898734177215
infectious disease lifetime prevalence,source of infection site,0.6596774193548387
infectious disease lifetime prevalence,virus,0.5197674418604651
infectious disease lifetime prevalence,quarantine control strategy,0.6346153846153847
infectious disease lifetime prevalence,virus replication,0.6318181818181818
infectious disease lifetime prevalence,B cell receptor complex,0.5975409836065574
infectious disease lifetime prevalence,passive immunization against infectious agent,0.6668674698795181
infectious disease lifetime prevalence,systematic infection,0.6396551724137931
infectious disease lifetime prevalence,infection incidence rate,0.7241935483870968
infectious disease lifetime prevalence,virus host,0.575
infectious disease lifetime prevalence,double-stranded RNA virus,0.5928571428571429
infectious disease lifetime prevalence,virus transcription stage,0.6404761904761905
infectious disease lifetime prevalence,infectious disease lifetime prevalence,0.95
infectious disease lifetime prevalence,toxin disposition,0.65
infectious disease lifetime prevalence,lower respiratory tract disease,0.6094202898550725
infectious disease lifetime prevalence,infectious disease incidence proportion,0.7876623376623377
infectious disease lifetime prevalence,virus generative stage,0.65
infectious disease lifetime prevalence,acute infectious disease course,0.7543478260869566
infectious disease lifetime prevalence,cidal agent disposition,0.6467213114754098
infectious disease lifetime prevalence,infectious disorder,0.730701754385965
infectious disease lifetime prevalence,subclinical infection,0.6364406779661017
infectious disease lifetime prevalence,appearance of disorder,0.6
infectious disease lifetime prevalence,simple infection,0.6351851851851852
infectious disease lifetime prevalence,parasiticidal disposition,0.6404761904761905
infectious disease lifetime prevalence,infectious disease sporadicity,0.7882352941176471
infectious disease lifetime prevalence,communicability end process boundary,0.6391891891891892
infectious disease lifetime prevalence,infection incidence proportion profile,0.7131578947368421
infectious disease lifetime prevalence,infectious agent colony,0.728688524590164
infectious disease lifetime prevalence,transmissibility disposition,0.6318181818181818
infectious disease lifetime prevalence,latency end process boundary,0.5863636363636363
infectious disease lifetime prevalence,infectious disease epidemic,0.8038461538461539
infectious disease lifetime prevalence,infectious agent generative stage,0.7457746478873238
infectious disease lifetime prevalence,disease transmission model,0.653125
infectious disease lifetime prevalence,endotoxin disposition,0.6533898305084747
infectious disease lifetime prevalence,negative-sense single-stranded RNA virus,0.6551282051282051
infectious disease lifetime prevalence,infectious structure host role,0.7294117647058823
infectious disease lifetime prevalence,COVID-19 incidence rate,0.630327868852459
infectious disease lifetime prevalence,cytotoxin disposition,0.6533898305084747
infectious disease lifetime prevalence,community-acquired infection,0.6469696969696969
infectious disease lifetime prevalence,chronic infectious disease course,0.7457746478873238
infectious disease lifetime prevalence,asymptomatic infectious agent carrier,0.6766666666666665
infectious disease lifetime prevalence,nursing-home acquired infection,0.6528985507246376
infectious disease lifetime prevalence,latency interval,0.6351851851851852
infectious disease lifetime prevalence,COVID-19 epidemic,0.5954545454545455
infectious disease lifetime prevalence,secondary infection,0.6605263157894737
infectious disease lifetime prevalence,infection start temporal region,0.7398550724637681
infectious disease lifetime prevalence,infection incidence,0.7131578947368421
infectious disease lifetime prevalence,virus disorder,0.6230769230769231
infectious disease lifetime prevalence,sterilizing immunity to infectious agent,0.6423076923076922
infectious disease lifetime prevalence,diseased population,0.6605263157894737
infectious disease lifetime prevalence,primary infection,0.6136363636363636
infectious disease lifetime prevalence,process of establishing an infection,0.6391891891891892
infectious disease lifetime prevalence,incubation end process boundary,0.6384057971014493
infectious disease lifetime prevalence,SARS-CoV-2 disorder,0.5903508771929825
infectious disease lifetime prevalence,collective pathogenic disposition,0.6471830985915493
infectious disease lifetime prevalence,neurotoxin disposition,0.6666666666666667
infectious disease lifetime prevalence,latency end temporal region,0.65
infectious disease lifetime prevalence,innate immunity to infectious agent,0.6691780821917809
infectious disease lifetime prevalence,infectious structure,0.7258620689655172
infectious disease lifetime prevalence,virus adhesion susceptible cell,0.6673913043478261
infectious disease lifetime prevalence,collective disposition,0.6666666666666667
infectious disease lifetime prevalence,infection,0.6414893617021277
infectious disease lifetime prevalence,static agent disposition,0.6435483870967742
infectious disease lifetime prevalence,T cell receptor complex,0.6139344262295081
infectious disease lifetime prevalence,infectious structure host,0.7039682539682539
infectious disease lifetime prevalence,infectious agent population,0.7269230769230769
infectious disease lifetime prevalence,respiratory system disease,0.6375
infectious disease lifetime prevalence,leukocyte-mediated immunity to infectious agent,0.65
infectious disease lifetime prevalence,communicability interval,0.6758064516129032
infectious disease lifetime prevalence,humoral immunity to infectious agent,0.6391891891891892
infectious disease lifetime prevalence,infectious disease control strategy,0.7787671232876713
infectious disease lifetime prevalence,infectious disease pandemic,0.8038461538461539
infectious disease lifetime prevalence,infectious structure generative stage,0.73
infectious disease lifetime prevalence,immunosuppressive disposition,0.658955223880597
infectious disease lifetime prevalence,pathogenic disposition,0.6333333333333333
infectious disease lifetime prevalence,viral disease course,0.656896551724138
infectious disease lifetime prevalence,intracellular infection,0.6467213114754098
infectious disease lifetime prevalence,secondary infection role,0.6919354838709677
infectious disease lifetime prevalence,metastatic infection,0.6396551724137931
infectious disease lifetime prevalence,passive immunity to infectious agent,0.6527027027027027
infectious disease lifetime prevalence,infectious disposition,0.7666666666666666
infectious disease lifetime prevalence,vaccination against infectious agent,0.6932432432432433
infectious disease lifetime prevalence,acute infection,0.6386792452830189
infectious disease lifetime prevalence,susceptibility to infectious agent,0.6444444444444444
infectious disease lifetime prevalence,bacteriostatic disposition,0.66875
infectious disease lifetime prevalence,bactericidal disposition,0.6435483870967742
infectious disease lifetime prevalence,source of infection role,0.6596774193548387
infectious disease lifetime prevalence,chronic infection,0.6318181818181818
infectious disease lifetime prevalence,invasion disposition,0.6741379310344828
infectious disease lifetime prevalence,disease course,0.6423076923076922
infectious disease lifetime prevalence,infectious disease course,0.7833333333333333
infectious disease lifetime prevalence,viricidal disposition,0.6533898305084747
infectious disease lifetime prevalence,acquired immunity to infectious agent,0.65
infectious disease lifetime prevalence,complex infection,0.6318181818181818
infectious disease lifetime prevalence,COVID-19 disease incidence proportion,0.69
infectious disease lifetime prevalence,coronavirus disease course,0.684375
infectious disease lifetime prevalence,infection incidence proportion,0.7
infectious disease lifetime prevalence,symptomatic infectious agent carrier,0.6797297297297297
infectious disease lifetime prevalence,respiratory droplet virus fomite,0.6071428571428572
infectious disease lifetime prevalence,infectious disease prevalence,0.8828358208955223
infectious disease lifetime prevalence,incubation interval,0.6956140350877194
infectious disease lifetime prevalence,disposition,0.6132653061224489
infectious disease lifetime prevalence,single-stranded DNA virus,0.6087301587301588
infectious disease lifetime prevalence,infected population,0.6605263157894737
infectious disease lifetime prevalence,COVID-19 mortality rate,0.630327868852459
infectious disease lifetime prevalence,place closure control strategy,0.6117647058823529
infectious disease lifetime prevalence,viral disease,0.6264705882352941
infectious disease lifetime prevalence,primary infection role,0.65
infectious disease lifetime prevalence,adhesion disposition,0.656896551724138
infectious disease lifetime prevalence,infection incidence profile,0.7269230769230769
infectious disease lifetime prevalence,disease,0.6055555555555556
infectious disease lifetime prevalence,symptomatic infectious structure carrier,0.6679487179487179
infectious disease lifetime prevalence,primary infectious disposition,0.7294117647058823
infectious disease lifetime prevalence,infection prevalence,0.7775862068965518
infectious disease lifetime prevalence,coronavirus disorder,0.6224137931034482
infectious disease lifetime prevalence,eclipse interval,0.6907407407407408
infectious disease lifetime prevalence,infectious pathogen transmissibility,0.6932432432432433
infectious disease lifetime prevalence,incubation start process boundary,0.6612676056338028
infectious disease lifetime prevalence,infectious human pathogen,0.7198412698412698
infectious disease lifetime prevalence,subclinical virus infection,0.65
infectious disease lifetime prevalence,establishment of localization in virus host,0.5981481481481481
infectious disease lifetime prevalence,immunization against infectious agent,0.69
infectious disease lifetime prevalence,virus attachment stage,0.6333333333333333
infectious disease lifetime prevalence,virus synthesis stage,0.6364406779661017
infectious disease lifetime prevalence,SARS-COV-2 adhesion disposition,0.6239130434782608
infectious disease lifetime prevalence,invasive disposition,0.656896551724138
infectious disease lifetime prevalence,infectious agent host,0.7042372881355932
infectious disease lifetime prevalence,long-term non-progressing infectious disease course,0.6859550561797753
infectious disease lifetime prevalence,viral disease epidemic,0.6833333333333332
infectious disease lifetime prevalence,communicability start temporal region,0.65
infectious disease lifetime prevalence,fungicidal disposition,0.65
infectious disease lifetime prevalence,viral disease pandemic,0.6833333333333332
infectious disease lifetime prevalence,virus penetration stage,0.630327868852459
infectious disease lifetime prevalence,acute respiratory distress syndrome,0.6280821917808219
infectious disease lifetime prevalence,infectious disease endemicity,0.7783582089552239
infectious disease lifetime prevalence,disorder,0.558695652173913
infectious disease lifetime prevalence,history,0.5388888888888889
infectious disease lifetime prevalence,herd immunity to infectious organism,0.6391891891891892
infectious disease lifetime prevalence,extracellular infection,0.630327868852459
infectious disease lifetime prevalence,transmission interval,0.6703389830508475
infectious disease lifetime prevalence,exotoxin disposition,0.656896551724138
infectious disease lifetime prevalence,infectious agent reservoir,0.73125
infectious disease lifetime prevalence,COVID-19 pandemic,0.5954545454545455
infectious disease lifetime prevalence,infection start process boundary,0.6928571428571427
infectious disease lifetime prevalence,latency start process boundary,0.6117647058823529
infectious disease lifetime prevalence,infectious disease control objective specification,0.7795454545454545
infectious disease lifetime prevalence,COVID-19 lifetime prevalence,0.7984848484848485
infectious disease lifetime prevalence,opportunistic infectious disposition,0.7067567567567568
infectious disease lifetime prevalence,process of establishing viral infection,0.6448051948051949
infectious disease lifetime prevalence,enterotoxin disposition,0.6631147540983606
infectious disease lifetime prevalence,COVID-19 disease course,0.6631147540983606
infectious disease lifetime prevalence,infectious disease incidence rate,0.8161971830985917
infectious disease lifetime prevalence,communicability start process boundary,0.6210526315789474
infectious disease lifetime prevalence,COVID-19 prevalence,0.6956140350877194
infectious disease lifetime prevalence,active immunization against infectious agent,0.6695121951219513
infectious disease lifetime prevalence,SARS-COV-2 prevalence,0.6872881355932203
infectious disease lifetime prevalence,disordered virus,0.5981481481481481
infectious disease lifetime prevalence,collective resistance disposition,0.6471830985915493
infectious disease lifetime prevalence,fungistatic disposition,0.6467213114754098
infectious disease lifetime prevalence,virus uncoating stage,0.6194915254237288
infectious disease lifetime prevalence,local infection,0.619811320754717
infectious disease lifetime prevalence,infectious agent,0.7092592592592593
infectious disease lifetime prevalence,establishment of a clinically abnormal colony,0.6307228915662652
infectious disease lifetime prevalence,coronavirus disease,0.6605263157894737
infectious disease lifetime prevalence,positive-sense single-stranded RNA virus,0.6423076923076922
infectious disease lifetime prevalence,hospital-acquired infection,0.6346153846153847
infectious disease lifetime prevalence,drug susceptibility of infectious agent,0.6448051948051949
intermediate host role,virostatic disposition,0.6545454545454545
intermediate host role,zoonotic disposition,0.6404761904761905
intermediate host role,infectious disease mortality rate,0.6863636363636364
intermediate host role,infection incidence rate profile,0.6907407407407408
intermediate host role,primary pathogen,0.6342105263157894
intermediate host role,SARS-CoV-2 incidence rate,0.598936170212766
intermediate host role,virulence factor disposition,0.65
intermediate host role,viral adhesion disposition,0.6375
intermediate host role,parasitostatic disposition,0.6375
intermediate host role,reservoir of pathogen role,0.7
intermediate host role,reverse zoonotic disposition,0.63
intermediate host role,establishment of localization in host,0.6364406779661017
intermediate host role,infectious agent host role,0.7833333333333333
intermediate host role,B cell receptor complex,0.65
intermediate host role,passive immunization against infectious agent,0.6291044776119403
intermediate host role,infection incidence rate,0.6239130434782608
intermediate host role,colonized host,0.6722222222222223
intermediate host role,virus host,0.66875
intermediate host role,double-stranded RNA virus,0.598936170212766
intermediate host role,pathogen portal of entry role,0.6852941176470588
intermediate host role,toxin disposition,0.6551282051282051
intermediate host role,lower respiratory tract disease,0.6386792452830189
intermediate host role,acute infectious disease course,0.6575471698113208
intermediate host role,cidal agent disposition,0.65
intermediate host role,role,0.6038461538461539
intermediate host role,appearance of disorder,0.6545454545454545
intermediate host role,parasiticidal disposition,0.6414893617021277
intermediate host role,mutualist role,0.7
intermediate host role,infectious agent colony,0.6722222222222223
intermediate host role,invasion factor,0.6391891891891892
intermediate host role,transmissibility disposition,0.65
intermediate host role,colonization of host,0.6642857142857143
intermediate host role,infectious agent generative stage,0.6681818181818181
intermediate host role,endotoxin disposition,0.636046511627907
intermediate host role,negative-sense single-stranded RNA virus,0.6112903225806451
intermediate host role,cidal agent,0.6015151515151516
intermediate host role,infectious structure host role,0.7576923076923078
intermediate host role,COVID-19 incidence rate,0.6055555555555556
intermediate host role,cytotoxin disposition,0.636046511627907
intermediate host role,pathogen vehicle role,0.6825581395348838
intermediate host role,host,0.6038461538461539
intermediate host role,chronic infectious disease course,0.65
intermediate host role,asymptomatic infectious agent carrier,0.6364406779661017
intermediate host role,mechanical vector role,0.7
intermediate host role,sterilizing immunity to infectious agent,0.6274193548387097
intermediate host role,establishment of localization in human host,0.6192307692307693
intermediate host role,primary infection,0.6038461538461539
intermediate host role,virulence factor,0.6342105263157894
intermediate host role,collective pathogenic disposition,0.6318181818181818
intermediate host role,neurotoxin disposition,0.6545454545454545
intermediate host role,dead-end host role,0.775
intermediate host role,definitive host role,0.8071428571428573
intermediate host role,innate immunity to infectious agent,0.6605263157894737
intermediate host role,collective disposition,0.6318181818181818
intermediate host role,static agent disposition,0.6456521739130434
intermediate host role,T cell receptor complex,0.6722222222222223
intermediate host role,asymptomatic carrier role,0.6627659574468084
intermediate host role,infectious structure host,0.6840425531914894
intermediate host role,infectious agent population,0.6540816326530612
intermediate host role,entry into host,0.7202702702702704
intermediate host role,leukocyte-mediated immunity to infectious agent,0.6528985507246376
intermediate host role,adhesion of symbiont to host,0.65
intermediate host role,humoral immunity to infectious agent,0.6051724137931035
intermediate host role,immunosuppressive disposition,0.6656862745098039
intermediate host role,pathogenic disposition,0.6318181818181818
intermediate host role,viral disease course,0.6880952380952381
intermediate host role,entry into host through host barriers,0.6872881355932203
intermediate host role,secondary infection role,0.6673913043478261
intermediate host role,passive immunity to infectious agent,0.6224137931034482
intermediate host role,infectious disposition,0.6545454545454545
intermediate host role,vaccination against infectious agent,0.6396551724137931
intermediate host role,susceptibility to infectious agent,0.5928571428571429
intermediate host role,bacteriostatic disposition,0.6791666666666666
intermediate host role,bactericidal disposition,0.6673913043478261
intermediate host role,source of infection role,0.6673913043478261
intermediate host role,pathogen host,0.6785714285714286
intermediate host role,invasion disposition,0.6404761904761905
intermediate host role,disease course,0.6722222222222223
intermediate host role,infectious disease course,0.6840425531914894
intermediate host role,viricidal disposition,0.6593023255813953
intermediate host role,acquired immunity to infectious agent,0.6364406779661017
intermediate host role,coronavirus disease course,0.6583333333333334
intermediate host role,biological vehicle role,0.6722222222222223
intermediate host role,symptomatic infectious agent carrier,0.6396551724137931
intermediate host role,symbiont role,0.7071428571428571
intermediate host role,parasite role,0.7071428571428571
intermediate host role,intermediate host,0.8858974358974359
intermediate host role,pathogen vector role,0.6880952380952381
intermediate host role,disposition,0.6318181818181818
intermediate host role,COVID-19 mortality rate,0.6277777777777778
intermediate host role,place closure control strategy,0.6423076923076922
intermediate host role,primary infection role,0.6772727272727272
intermediate host role,primary immunodeficiency,0.5804347826086956
intermediate host role,biological role,0.6662162162162162
intermediate host role,adhesion disposition,0.6404761904761905
intermediate host role,biological vector role,0.6772727272727272
intermediate host role,primary infectious disposition,0.6230769230769231
intermediate host role,pathogen host role,0.775
intermediate host role,symptomatic carrier role,0.6673913043478261
intermediate host role,intermediate host role,0.95
intermediate host role,dead-end host,0.6785714285714286
intermediate host role,host role,0.7403225806451613
intermediate host role,establishment of localization in virus host,0.6192307692307693
intermediate host role,immunization against infectious agent,0.6364406779661017
intermediate host role,SARS-COV-2 adhesion disposition,0.6009433962264151
intermediate host role,pathogen portal of exit role,0.69
intermediate host role,invasive disposition,0.6642857142857143
intermediate host role,infectious agent host,0.7058139534883722
intermediate host role,long-term non-progressing infectious disease course,0.6417808219178082
intermediate host role,commensal role,0.6722222222222223
intermediate host role,epitope role,0.7147058823529412
intermediate host role,fungicidal disposition,0.6318181818181818
intermediate host role,division of geopolitical entity,0.6009433962264151
intermediate host role,function,0.5833333333333334
intermediate host role,pathogen transporter role,0.6840425531914894
intermediate host role,exotoxin disposition,0.6404761904761905
intermediate host role,infectious agent reservoir,0.6583333333333334
intermediate host role,antigen role,0.7147058823529412
intermediate host role,action specification,0.6166666666666667
intermediate host role,symbiont host role,0.775
intermediate host role,opportunistic infectious disposition,0.6051724137931035
intermediate host role,fomite role,0.7227272727272727
intermediate host role,enterotoxin disposition,0.6722222222222223
intermediate host role,COVID-19 disease course,0.65
intermediate host role,infectious disease incidence rate,0.65
intermediate host role,single-stranded RNA retrovirus,0.6615384615384616
intermediate host role,active immunization against infectious agent,0.6318181818181818
intermediate host role,collective resistance disposition,0.6681818181818181
intermediate host role,reagent role,0.7441176470588234
intermediate host role,viral load,0.60625
intermediate host role,fungistatic disposition,0.65
intermediate host role,infectious agent,0.6605263157894737
intermediate host role,establishment of a clinically abnormal colony,0.5992537313432835
intermediate host role,positive-sense single-stranded RNA virus,0.6112903225806451
intermediate host role,adhesion factor,0.6121621621621621
intermediate host role,definitive host,0.7202702702702704
intermediate host role,drug susceptibility of infectious agent,0.5975409836065574
intermediate host role,static agent,0.5970588235294118
zero-dimensional spatial region,communicability end temporal region,0.7075757575757575
zero-dimensional spatial region,geographical entity,0.65
zero-dimensional spatial region,infection end temporal region,0.7166666666666667
zero-dimensional spatial region,incubation end temporal region,0.7122950819672131
zero-dimensional spatial region,two-dimensional spatial region,0.909016393442623
zero-dimensional spatial region,one-dimensional temporal region,0.8370967741935484
zero-dimensional spatial region,temporal region,0.7108695652173913
zero-dimensional spatial region,disease surveillance objective specification,0.6366666666666667
zero-dimensional spatial region,B cell receptor complex,0.5981481481481481
zero-dimensional spatial region,pathogen birth temporal region,0.6959016393442623
zero-dimensional spatial region,lower respiratory tract disease,0.6435483870967742
zero-dimensional spatial region,infectious disease incidence proportion,0.65
zero-dimensional spatial region,acute infectious disease course,0.6274193548387097
zero-dimensional spatial region,communicability end process boundary,0.6291044776119403
zero-dimensional spatial region,infection incidence proportion profile,0.6384057971014493
zero-dimensional spatial region,SARS-CoV-2 incidence proportion,0.6596774193548387
zero-dimensional spatial region,spatiotemporal region,0.7192307692307692
zero-dimensional spatial region,latency end process boundary,0.6025423728813559
zero-dimensional spatial region,zero-dimensional spatial region,0.95
zero-dimensional spatial region,zero-dimensional temporal region,0.8785714285714286
zero-dimensional spatial region,chronic infectious disease course,0.6375
zero-dimensional spatial region,infection start temporal region,0.7403225806451613
zero-dimensional spatial region,incubation end process boundary,0.6274193548387097
zero-dimensional spatial region,geographical region,0.73
zero-dimensional spatial region,latency end temporal region,0.6913793103448276
zero-dimensional spatial region,T cell receptor complex,0.5981481481481481
zero-dimensional spatial region,viral disease course,0.6264705882352941
zero-dimensional spatial region,three-dimensional spatial region,0.8944444444444444
zero-dimensional spatial region,objective specification,0.6537037037037037
zero-dimensional spatial region,country,0.5552631578947369
zero-dimensional spatial region,disease course,0.6277777777777778
zero-dimensional spatial region,infectious disease course,0.6285714285714286
zero-dimensional spatial region,COVID-19 disease incidence proportion,0.6558823529411765
zero-dimensional spatial region,coronavirus disease course,0.6254385964912281
zero-dimensional spatial region,infection incidence proportion,0.6467213114754098
zero-dimensional spatial region,place closure control strategy,0.6467213114754098
zero-dimensional spatial region,object,0.5310810810810811
zero-dimensional spatial region,object aggregate,0.598936170212766
zero-dimensional spatial region,long-term non-progressing infectious disease course,0.6329268292682927
zero-dimensional spatial region,communicability start temporal region,0.7294117647058823
zero-dimensional spatial region,geospatial region,0.7833333333333333
zero-dimensional spatial region,division of geopolitical entity,0.6919354838709677
zero-dimensional spatial region,geographical feature,0.6460784313725491
zero-dimensional spatial region,infectious disease control objective specification,0.6598765432098764
zero-dimensional spatial region,COVID-19 disease course,0.6351851851851852
zero-dimensional spatial region,local infection,0.6456521739130434
zero-dimensional spatial region,establishment of a clinically abnormal colony,0.6605263157894737
zero-dimensional spatial region,one-dimensional spatial region,0.909016393442623
zero-dimensional spatial region,spatial region,0.7611111111111112
zero-dimensional spatial region,pathogen death temporal region,0.6959016393442623
extracellular infection,virus aggregate,0.6078947368421053
extracellular infection,source of infection,0.7595238095238095
extracellular infection,virostatic disposition,0.65
extracellular infection,zoonotic disposition,0.636046511627907
extracellular infection,infectious disease mortality rate,0.5928571428571429
extracellular infection,infection incidence rate profile,0.6136363636363636
extracellular infection,communicability end temporal region,0.6224137931034482
extracellular infection,subclinical coronavirus infection,0.7178571428571427
extracellular infection,infection end temporal region,0.6423076923076922
extracellular infection,infectious disease,0.6451219512195122
extracellular infection,double-stranded DNA virus,0.6166666666666667
extracellular infection,incubation end temporal region,0.6386792452830189
extracellular infection,site of infection,0.75
extracellular infection,virulence factor disposition,0.6656862745098039
extracellular infection,viral adhesion disposition,0.6540816326530612
extracellular infection,parasitostatic disposition,0.6336734693877552
extracellular infection,infectious disease incidence,0.6460784313725491
extracellular infection,reverse zoonotic disposition,0.6460784313725491
extracellular infection,subclinical SARS-CoV-2 infection,0.7227272727272727
extracellular infection,virus translation stage,0.6456521739130434
extracellular infection,disease surveillance objective specification,0.658955223880597
extracellular infection,virus release stage,0.5928571428571429
extracellular infection,source of infection site,0.7265957446808511
extracellular infection,virus,0.5214285714285714
extracellular infection,virus replication,0.675
extracellular infection,B cell receptor complex,0.6456521739130434
extracellular infection,systematic infection,0.7523255813953489
extracellular infection,infection incidence rate,0.6414893617021277
extracellular infection,virus host,0.5712121212121213
extracellular infection,double-stranded RNA virus,0.6166666666666667
extracellular infection,virus transcription stage,0.6583333333333334
extracellular infection,infectious disease lifetime prevalence,0.630327868852459
extracellular infection,toxin disposition,0.625
extracellular infection,lower respiratory tract disease,0.6166666666666667
extracellular infection,infectious disease incidence proportion,0.6596774193548387
extracellular infection,virus generative stage,0.6055555555555556
extracellular infection,acute infectious disease course,0.6722222222222223
extracellular infection,cidal agent disposition,0.6456521739130434
extracellular infection,infectious disorder,0.6404761904761905
extracellular infection,subclinical infection,0.7454545454545455
extracellular infection,appearance of disorder,0.65
extracellular infection,simple infection,0.732051282051282
extracellular infection,parasiticidal disposition,0.6583333333333334
extracellular infection,infectious disease sporadicity,0.6009433962264151
extracellular infection,communicability end process boundary,0.5855932203389831
extracellular infection,acellular structure aggregate,0.6807692307692308
extracellular infection,infection incidence proportion profile,0.630327868852459
extracellular infection,transmissibility disposition,0.6460784313725491
extracellular infection,latency end process boundary,0.5872549019607843
extracellular infection,infectious disease epidemic,0.61
extracellular infection,disease transmission model,0.6132653061224489
extracellular infection,endotoxin disposition,0.6318181818181818
extracellular infection,negative-sense single-stranded RNA virus,0.5928571428571429
extracellular infection,cytotoxin disposition,0.609090909090909
extracellular infection,community-acquired infection,0.7441176470588234
extracellular infection,chronic infectious disease course,0.6464285714285714
extracellular infection,nursing-home acquired infection,0.7277777777777777
extracellular infection,COVID-19 epidemic,0.575
extracellular infection,secondary infection,0.7833333333333333
extracellular infection,infection start temporal region,0.6351851851851852
extracellular infection,infection incidence,0.6642857142857143
extracellular infection,virus disorder,0.5851351351351352
extracellular infection,acellular structure,0.7357142857142857
extracellular infection,primary infection,0.775
extracellular infection,process of establishing an infection,0.7042372881355932
extracellular infection,incubation end process boundary,0.6166666666666667
extracellular infection,SARS-CoV-2 disorder,0.569047619047619
extracellular infection,collective pathogenic disposition,0.6285714285714286
extracellular infection,neurotoxin disposition,0.65
extracellular infection,latency end temporal region,0.65
extracellular infection,virus adhesion susceptible cell,0.5981481481481481
extracellular infection,collective disposition,0.65
extracellular infection,infection,0.73125
extracellular infection,static agent disposition,0.6627659574468084
extracellular infection,T cell receptor complex,0.6673913043478261
extracellular infection,respiratory system disease,0.5928571428571429
extracellular infection,communicability interval,0.598936170212766
extracellular infection,infectious disease control strategy,0.6051724137931035
extracellular infection,infectious disease pandemic,0.63
extracellular infection,immunosuppressive disposition,0.6038461538461539
extracellular infection,pathogenic disposition,0.6277777777777778
extracellular infection,viral disease course,0.636046511627907
extracellular infection,intracellular infection,0.9065217391304347
extracellular infection,secondary infection role,0.747872340425532
extracellular infection,metastatic infection,0.7755813953488372
extracellular infection,cell,0.5981481481481481
extracellular infection,infectious disposition,0.65
extracellular infection,acute infection,0.7921052631578948
extracellular infection,bacteriostatic disposition,0.6540816326530612
extracellular infection,bactericidal disposition,0.6627659574468084
extracellular infection,source of infection role,0.7265957446808511
extracellular infection,chronic infection,0.75
extracellular infection,invasion disposition,0.6127906976744186
extracellular infection,disease course,0.6121621621621621
extracellular infection,infectious disease course,0.6166666666666667
extracellular infection,viricidal disposition,0.6545454545454545
extracellular infection,complex infection,0.75
extracellular infection,COVID-19 disease incidence proportion,0.65
extracellular infection,coronavirus disease course,0.6132653061224489
extracellular infection,infection incidence proportion,0.6575471698113208
extracellular infection,respiratory droplet virus fomite,0.6136363636363636
extracellular infection,infectious disease prevalence,0.6230769230769231
extracellular infection,disposition,0.5970588235294118
extracellular infection,single-stranded DNA virus,0.6166666666666667
extracellular infection,viral disease,0.6166666666666667
extracellular infection,primary infection role,0.7388888888888888
extracellular infection,adhesion disposition,0.636046511627907
extracellular infection,infection incidence profile,0.63
extracellular infection,contagiousness,0.6121621621621621
extracellular infection,disease,0.55
extracellular infection,primary infectious disposition,0.6952830188679244
extracellular infection,infection prevalence,0.6593023255813953
extracellular infection,coronavirus disorder,0.5895348837209302
extracellular infection,SARS-COV-2 adhesion susceptible cell,0.5855932203389831
extracellular infection,subclinical virus infection,0.73
extracellular infection,establishment of localization in virus host,0.6318181818181818
extracellular infection,virus attachment stage,0.5833333333333334
extracellular infection,virus synthesis stage,0.5863636363636363
extracellular infection,SARS-COV-2 adhesion disposition,0.6166666666666667
extracellular infection,invasive disposition,0.636046511627907
extracellular infection,long-term non-progressing infectious disease course,0.6121621621621621
extracellular infection,viral disease epidemic,0.6277777777777778
extracellular infection,communicability start temporal region,0.6166666666666667
extracellular infection,fungicidal disposition,0.6277777777777778
extracellular infection,viral disease pandemic,0.6277777777777778
extracellular infection,virus penetration stage,0.6456521739130434
extracellular infection,acute respiratory distress syndrome,0.6051724137931035
extracellular infection,infectious disease endemicity,0.6230769230769231
extracellular infection,disorder,0.5467741935483871
extracellular infection,communicability,0.581578947368421
extracellular infection,extracellular infection,0.95
extracellular infection,exotoxin disposition,0.6593023255813953
extracellular infection,infection start process boundary,0.6136363636363636
extracellular infection,action specification,0.6825581395348838
extracellular infection,infectious disease control objective specification,0.6280821917808219
extracellular infection,opportunistic infectious disposition,0.6533898305084747
extracellular infection,process of establishing viral infection,0.6919354838709677
extracellular infection,enterotoxin disposition,0.6673913043478261
extracellular infection,COVID-19 disease course,0.5804347826086956
extracellular infection,infectious disease incidence rate,0.6285714285714286
extracellular infection,communicability start process boundary,0.5975409836065574
extracellular infection,disordered virus,0.5782051282051281
extracellular infection,collective resistance disposition,0.6642857142857143
extracellular infection,fungistatic disposition,0.6456521739130434
extracellular infection,virus uncoating stage,0.6318181818181818
extracellular infection,local infection,0.7657894736842106
extracellular infection,establishment of a clinically abnormal colony,0.6411764705882353
extracellular infection,coronavirus disease,0.5928571428571429
extracellular infection,positive-sense single-stranded RNA virus,0.5769841269841269
extracellular infection,hospital-acquired infection,0.75
extracellular infection,cell space,0.6318181818181818
designative information content entity,extended organism,0.6136363636363636
designative information content entity,information content entity,0.85625
designative information content entity,infectious disease mortality rate,0.6330985915492958
designative information content entity,infection incidence rate profile,0.65
designative information content entity,infectious structure aggregate,0.6411764705882353
designative information content entity,communicability end temporal region,0.6143835616438357
designative information content entity,geographical entity,0.6956140350877194
designative information content entity,infection end temporal region,0.658955223880597
designative information content entity,drug-based immunosuppressed organism,0.6256756756756756
designative information content entity,SARS-CoV-2 incidence rate,0.6404761904761905
designative information content entity,incubation end temporal region,0.6558823529411765
designative information content entity,resistant entity,0.7092592592592593
designative information content entity,immunocompetent organism,0.6435483870967742
designative information content entity,virulence factor disposition,0.6318181818181818
designative information content entity,virus translation stage,0.630327868852459
designative information content entity,case isolation control strategy,0.7253623188405797
designative information content entity,material entity,0.6764150943396227
designative information content entity,asymptomatic infectious structure carrier,0.6651898734177215
designative information content entity,architectual structure,0.6
designative information content entity,B cell receptor complex,0.5975409836065574
designative information content entity,infection incidence rate,0.6596774193548387
designative information content entity,entity,0.5863636363636363
designative information content entity,communicability end process boundary,0.6121621621621621
designative information content entity,directive information content entity,0.895945945945946
designative information content entity,acellular structure aggregate,0.5992537313432835
designative information content entity,invasion factor,0.6386792452830189
designative information content entity,latency end process boundary,0.6318181818181818
designative information content entity,realizable entity,0.6681818181818181
designative information content entity,pathologically immunosuppressed organism,0.6038461538461539
designative information content entity,infectious structure host role,0.6411764705882353
designative information content entity,COVID-19 incidence rate,0.6139344262295081
designative information content entity,descriptive information content entity,0.9105263157894737
designative information content entity,establishment of localization in human host,0.6722222222222223
designative information content entity,acellular structure,0.5728070175438597
designative information content entity,virulence factor,0.5981481481481481
designative information content entity,incubation end process boundary,0.6528985507246376
designative information content entity,molecular entity,0.6351851851851852
designative information content entity,immunosuppressed organism,0.5928571428571429
designative information content entity,latency end temporal region,0.6192307692307693
designative information content entity,infectious structure,0.6224137931034482
designative information content entity,T cell receptor complex,0.6139344262295081
designative information content entity,infectious structure host,0.6404761904761905
designative information content entity,respiratory system disease,0.6375
designative information content entity,organism population,0.6254385964912281
designative information content entity,infectious structure generative stage,0.6633333333333334
designative information content entity,symptomatic infectious agent carrier,0.6797297297297297
designative information content entity,susceptible organism,0.6224137931034482
designative information content entity,organism substance,0.5928571428571429
designative information content entity,anatomical entity,0.7045454545454546
designative information content entity,COVID-19 mortality rate,0.5975409836065574
designative information content entity,place closure control strategy,0.6558823529411765
designative information content entity,geopolitical entity,0.6780701754385965
designative information content entity,symptomatic infectious structure carrier,0.6679487179487179
designative information content entity,designative information content entity,0.95
designative information content entity,symptomatic carrier role,0.6435483870967742
designative information content entity,immunodeficient organism,0.6435483870967742
designative information content entity,infectious human pathogen,0.6404761904761905
designative information content entity,colonization of human,0.6364406779661017
designative information content entity,immaterial entity,0.6863636363636364
designative information content entity,division of geopolitical entity,0.7108695652173913
designative information content entity,symptomatic carrier,0.6254385964912281
designative information content entity,geographical feature,0.6224137931034482
designative information content entity,herd immunity to infectious organism,0.6527027027027027
designative information content entity,action specification,0.6396551724137931
designative information content entity,processed material,0.6107142857142857
designative information content entity,quality,0.5388888888888889
designative information content entity,infectious disease incidence rate,0.6471830985915493
designative information content entity,symptom,0.5388888888888889
designative information content entity,viral load,0.575
designative information content entity,organism,0.558695652173913
designative information content entity,establishment of a clinically abnormal colony,0.6548192771084337
designative information content entity,adhesion factor,0.6386792452830189
designative information content entity,material processing,0.6078947368421053
biological regulation,virostatic disposition,0.6593023255813953
biological regulation,zoonotic disposition,0.6695121951219513
biological regulation,infectious disease mortality rate,0.6166666666666667
biological regulation,infection incidence rate profile,0.619811320754717
biological regulation,communicability end temporal region,0.6821428571428573
biological regulation,biological regulation,0.95
biological regulation,primary pathogen,0.6391891891891892
biological regulation,surveillance process,0.5963414634146341
biological regulation,infection end temporal region,0.69
biological regulation,geospatial location,0.725
biological regulation,vector control strategy,0.609090909090909
biological regulation,SARS-CoV-2 incidence rate,0.6021739130434782
biological regulation,incubation end temporal region,0.7049019607843137
biological regulation,virulence factor disposition,0.6336734693877552
biological regulation,viral adhesion disposition,0.6414893617021277
biological regulation,parasitostatic disposition,0.6414893617021277
biological regulation,negative regulation of production,0.6907407407407408
biological regulation,reverse zoonotic disposition,0.6336734693877552
biological regulation,disease surveillance objective specification,0.6192307692307693
biological regulation,case isolation control strategy,0.6423076923076922
biological regulation,quarantine control strategy,0.6166666666666667
biological regulation,B cell receptor complex,0.6318181818181818
biological regulation,infection incidence rate,0.6277777777777778
biological regulation,double-stranded RNA virus,0.6021739130434782
biological regulation,toxin disposition,0.6342105263157894
biological regulation,cidal agent disposition,0.6545454545454545
biological regulation,biological vehicle,0.7833333333333333
biological regulation,parasiticidal disposition,0.6673913043478261
biological regulation,communicability end process boundary,0.6254385964912281
biological regulation,transmissibility disposition,0.6336734693877552
biological regulation,latency end process boundary,0.5928571428571429
biological regulation,endotoxin disposition,0.6404761904761905
biological regulation,vector surveillance,0.625
biological regulation,negative regulation of establishment of localization,0.6280821917808219
biological regulation,negative-sense single-stranded RNA virus,0.5647540983606557
biological regulation,COVID-19 incidence rate,0.609090909090909
biological regulation,cytotoxin disposition,0.6404761904761905
biological regulation,negative regulation of developmental process,0.65
biological regulation,negative regulation of replication,0.6863636363636364
biological regulation,primary infection,0.6605263157894737
biological regulation,incubation end process boundary,0.6038461538461539
biological regulation,collective pathogenic disposition,0.6537037037037037
biological regulation,neurotoxin disposition,0.636046511627907
biological regulation,latency end temporal region,0.6791666666666666
biological regulation,innate immunity to infectious agent,0.5928571428571429
biological regulation,virus adhesion susceptible cell,0.5846153846153846
biological regulation,anatomical space,0.6391891891891892
biological regulation,collective disposition,0.636046511627907
biological regulation,static agent disposition,0.6277777777777778
biological regulation,T cell receptor complex,0.609090909090909
biological regulation,respiratory system disease,0.5563829787234043
biological regulation,biological vector,0.8184210526315789
biological regulation,infectious disease control strategy,0.6107142857142857
biological regulation,immunosuppressive disposition,0.61
biological regulation,innate immune response,0.6127906976744186
biological regulation,pathogenic disposition,0.6593023255813953
biological regulation,cell,0.57
biological regulation,infectious disposition,0.636046511627907
biological regulation,bacteriostatic disposition,0.6627659574468084
biological regulation,bactericidal disposition,0.6722222222222223
biological regulation,invasion disposition,0.6451219512195122
biological regulation,viricidal disposition,0.6880952380952381
biological regulation,biological vehicle role,0.7681818181818181
biological regulation,anatomical entity,0.6868421052631578
biological regulation,disposition,0.66875
biological regulation,COVID-19 mortality rate,0.6318181818181818
biological regulation,negative regulation of life-sustaining process,0.6440298507462687
biological regulation,place closure control strategy,0.6068627450980393
biological regulation,primary infection role,0.636046511627907
biological regulation,primary immunodeficiency,0.5833333333333334
biological regulation,biological role,0.8111111111111111
biological regulation,adhesion disposition,0.6451219512195122
biological regulation,biological process,0.7833333333333333
biological regulation,biological vector role,0.7755813953488372
biological regulation,primary infectious disposition,0.6264705882352941
biological regulation,SARS-COV-2 adhesion susceptible cell,0.5728070175438597
biological regulation,pathogen surveillance,0.6404761904761905
biological regulation,negative regulation of immune response,0.6703389830508475
biological regulation,SARS-COV-2 adhesion disposition,0.6038461538461539
biological regulation,invasive disposition,0.6207317073170732
biological regulation,fungicidal disposition,0.6825581395348838
biological regulation,division of geopolitical entity,0.6807692307692308
biological regulation,negative regulation of viral process,0.6780701754385965
biological regulation,exotoxin disposition,0.6451219512195122
biological regulation,infectious disease control objective specification,0.6190140845070422
biological regulation,opportunistic infectious disposition,0.6429824561403508
biological regulation,negative regulation of biological process,0.6596774193548387
biological regulation,enterotoxin disposition,0.6318181818181818
biological regulation,infectious disease incidence rate,0.5981481481481481
biological regulation,single-stranded RNA retrovirus,0.6068627450980393
biological regulation,collective resistance disposition,0.6537037037037037
biological regulation,fungistatic disposition,0.6318181818181818
biological regulation,establishment of a clinically abnormal colony,0.6469696969696969
biological regulation,positive-sense single-stranded RNA virus,0.5647540983606557
biological regulation,cell space,0.5790322580645162
mechanical vector,infectious disease mortality rate,0.59
mechanical vector,infection incidence rate profile,0.6336734693877552
mechanical vector,vector control strategy,0.625
mechanical vector,SARS-CoV-2 incidence rate,0.5928571428571429
mechanical vector,normal resident microbiota population,0.6166666666666667
mechanical vector,virulence factor disposition,0.6277777777777778
mechanical vector,infectious agent host role,0.636046511627907
mechanical vector,B cell receptor complex,0.65
mechanical vector,passive immunization against infectious agent,0.5951612903225807
mechanical vector,systematic infection,0.6932432432432433
mechanical vector,infection incidence rate,0.6451219512195122
mechanical vector,mechanical vector,0.95
mechanical vector,acute infectious disease course,0.6166666666666667
mechanical vector,cidal agent disposition,0.65
mechanical vector,genetic resistance to pathogen,0.6414893617021277
mechanical vector,infectious agent colony,0.625
mechanical vector,invasion factor,0.66875
mechanical vector,infectious agent generative stage,0.61
mechanical vector,vector surveillance,0.6166666666666667
mechanical vector,cidal agent,0.7
mechanical vector,COVID-19 incidence rate,0.6
mechanical vector,pathogen vector,0.73125
mechanical vector,chronic infectious disease course,0.67
mechanical vector,asymptomatic infectious agent carrier,0.6351851851851852
mechanical vector,mechanical vector role,0.8858974358974359
mechanical vector,sterilizing immunity to infectious agent,0.5903508771929825
mechanical vector,virulence factor,0.6924242424242425
mechanical vector,innate immunity to infectious agent,0.6038461538461539
mechanical vector,static agent disposition,0.6207317073170732
mechanical vector,T cell receptor complex,0.65
mechanical vector,infectious agent population,0.609090909090909
mechanical vector,respiratory system disease,0.5895348837209302
mechanical vector,biological vector,0.7735294117647058
mechanical vector,leukocyte-mediated immunity to infectious agent,0.60625
mechanical vector,humoral immunity to infectious agent,0.619811320754717
mechanical vector,innate immune response,0.5782051282051281
mechanical vector,viral disease course,0.6662162162162162
mechanical vector,passive immunity to infectious agent,0.6009433962264151
mechanical vector,vaccination against infectious agent,0.619811320754717
mechanical vector,susceptibility to infectious agent,0.6068627450980393
mechanical vector,chronic infection,0.7441176470588234
mechanical vector,disease course,0.6435483870967742
mechanical vector,infectious disease course,0.6404761904761905
mechanical vector,acquired immunity to infectious agent,0.5981481481481481
mechanical vector,coronavirus disease course,0.636046511627907
mechanical vector,symptomatic infectious agent carrier,0.6386792452830189
mechanical vector,pathogen vector role,0.6932432432432433
mechanical vector,COVID-19 mortality rate,0.6
mechanical vector,place closure control strategy,0.6202127659574468
mechanical vector,biological vector role,0.732051282051282
mechanical vector,immunization against infectious agent,0.6166666666666667
mechanical vector,infectious agent host,0.6342105263157894
mechanical vector,long-term non-progressing infectious disease course,0.5970588235294118
mechanical vector,infectious agent reservoir,0.636046511627907
mechanical vector,COVID-19 disease course,0.625
mechanical vector,infectious disease incidence rate,0.61
mechanical vector,active immunization against infectious agent,0.5975409836065574
mechanical vector,infectious agent,0.6318181818181818
mechanical vector,establishment of a clinically abnormal colony,0.6274193548387097
mechanical vector,adhesion factor,0.66875
mechanical vector,drug susceptibility of infectious agent,0.5928571428571429
mechanical vector,static agent,0.656896551724138
toxin,virus aggregate,0.5
toxin,source of infection,0.575
toxin,infection incidence rate profile,0.5581081081081081
toxin,subclinical coronavirus infection,0.5289473684210526
toxin,infection end temporal region,0.5676470588235294
toxin,double-stranded DNA virus,0.5166666666666666
toxin,site of infection,0.6318181818181818
toxin,subclinical SARS-CoV-2 infection,0.5310810810810811
toxin,virus translation stage,0.5571428571428572
toxin,source of infection site,0.553448275862069
toxin,virus,0.55
toxin,virus replication,0.5863636363636363
toxin,B cell receptor complex,0.5571428571428572
toxin,systematic infection,0.57
toxin,infection incidence rate,0.5879310344827586
toxin,virus host,0.5166666666666666
toxin,double-stranded RNA virus,0.5166666666666666
toxin,virus transcription stage,0.55
toxin,toxin disposition,0.6772727272727272
toxin,virus generative stage,0.524074074074074
toxin,subclinical infection,0.5653846153846154
toxin,simple infection,0.5928571428571429
toxin,infection incidence proportion profile,0.5430232558139535
toxin,negative-sense single-stranded RNA virus,0.5166666666666666
toxin,community-acquired infection,0.5409090909090909
toxin,nursing-home acquired infection,0.5333333333333333
toxin,secondary infection,0.575
toxin,infection start temporal region,0.5611111111111111
toxin,infection incidence,0.6166666666666667
toxin,virus disorder,0.5026315789473684
toxin,primary infection,0.5863636363636363
toxin,process of establishing an infection,0.523170731707317
toxin,virus adhesion susceptible cell,0.5055555555555555
toxin,infection,0.6642857142857143
toxin,T cell receptor complex,0.5571428571428572
toxin,toxin,0.95
toxin,intracellular infection,0.5571428571428572
toxin,secondary infection role,0.553448275862069
toxin,metastatic infection,0.57
toxin,acute infection,0.6
toxin,source of infection role,0.553448275862069
toxin,chronic infection,0.5863636363636363
toxin,complex infection,0.6318181818181818
toxin,infection incidence proportion,0.5642857142857143
toxin,respiratory droplet virus fomite,0.5310810810810811
toxin,organism substance,0.5804347826086956
toxin,single-stranded DNA virus,0.5166666666666666
toxin,primary infection role,0.5611111111111111
toxin,infection incidence profile,0.575
toxin,infection prevalence,0.57
toxin,subclinical virus infection,0.54375
toxin,establishment of localization in virus host,0.5333333333333333
toxin,virus attachment stage,0.524074074074074
toxin,virus synthesis stage,0.5269230769230769
toxin,virus penetration stage,0.5571428571428572
toxin,extracellular infection,0.5571428571428572
toxin,infection start process boundary,0.5310810810810811
toxin,process of establishing viral infection,0.5181818181818182
toxin,disordered virus,0.5452380952380953
toxin,virus uncoating stage,0.5653846153846154
toxin,local infection,0.6
toxin,establishment of a clinically abnormal colony,0.53
toxin,positive-sense single-stranded RNA virus,0.5166666666666666
toxin,hospital-acquired infection,0.54375
toxin,bacteria,0.6038461538461539
infectious human pathogen,extended organism,0.6166666666666667
infectious human pathogen,virus aggregate,0.65
infectious human pathogen,source of infection,0.6545454545454545
infectious human pathogen,information content entity,0.6656862745098039
infectious human pathogen,infectious disease mortality rate,0.743103448275862
infectious human pathogen,infection incidence rate profile,0.7131578947368421
infectious human pathogen,infectious structure aggregate,0.740909090909091
infectious human pathogen,communicability end temporal region,0.6166666666666667
infectious human pathogen,geographical entity,0.609090909090909
infectious human pathogen,pathogen generative stage,0.61
infectious human pathogen,pathogen portal of entry,0.6336734693877552
infectious human pathogen,subclinical coronavirus infection,0.6396551724137931
infectious human pathogen,primary pathogen,0.7426829268292683
infectious human pathogen,infection end temporal region,0.7277777777777777
infectious human pathogen,drug-based immunosuppressed organism,0.5975409836065574
infectious human pathogen,infectious disease,0.7523255813953489
infectious human pathogen,SARS-CoV-2 incidence rate,0.63
infectious human pathogen,double-stranded DNA virus,0.59
infectious human pathogen,incubation end temporal region,0.6863636363636364
infectious human pathogen,site of infection,0.6642857142857143
infectious human pathogen,resistant entity,0.6451219512195122
infectious human pathogen,normal resident microbiota population,0.6435483870967742
infectious human pathogen,immunocompetent organism,0.6540816326530612
infectious human pathogen,pathogen portal of exit,0.6166666666666667
infectious human pathogen,infectious disease incidence,0.7330188679245283
infectious human pathogen,reservoir of pathogen role,0.6852941176470588
infectious human pathogen,subclinical SARS-CoV-2 infection,0.6078947368421053
infectious human pathogen,virus translation stage,0.6791666666666666
infectious human pathogen,disease surveillance objective specification,0.6384057971014493
infectious human pathogen,virus release stage,0.6545454545454545
infectious human pathogen,infectious agent host role,0.7833333333333333
infectious human pathogen,material entity,0.6
infectious human pathogen,asymptomatic infectious structure carrier,0.6772727272727272
infectious human pathogen,source of infection site,0.6948979591836735
infectious human pathogen,virus,0.55
infectious human pathogen,virus replication,0.6642857142857143
infectious human pathogen,B cell receptor complex,0.6166666666666667
infectious human pathogen,passive immunization against infectious agent,0.6642857142857143
infectious human pathogen,systematic infection,0.65
infectious human pathogen,infection incidence rate,0.7357142857142857
infectious human pathogen,virus host,0.6214285714285714
infectious human pathogen,entity,0.5790322580645162
infectious human pathogen,double-stranded RNA virus,0.59
infectious human pathogen,pathogen portal of entry role,0.6166666666666667
infectious human pathogen,virus transcription stage,0.67
infectious human pathogen,infectious disease lifetime prevalence,0.7198412698412698
infectious human pathogen,pathogen birth temporal region,0.6136363636363636
infectious human pathogen,lower respiratory tract disease,0.5928571428571429
infectious human pathogen,infectious disease incidence proportion,0.73125
infectious human pathogen,opportunistic pathogen,0.7053191489361703
infectious human pathogen,virus generative stage,0.6414893617021277
infectious human pathogen,acute infectious disease course,0.7178571428571427
infectious human pathogen,cidal agent disposition,0.6583333333333334
infectious human pathogen,infectious disorder,0.7454545454545455
infectious human pathogen,genetic resistance to pathogen,0.740909090909091
infectious human pathogen,subclinical infection,0.6456521739130434
infectious human pathogen,simple infection,0.6695121951219513
infectious human pathogen,droplet pathogen transmission process,0.6274193548387097
infectious human pathogen,infectious disease sporadicity,0.740909090909091
infectious human pathogen,communicability end process boundary,0.6139344262295081
infectious human pathogen,directive information content entity,0.6631147540983606
infectious human pathogen,infection incidence proportion profile,0.6880952380952381
infectious human pathogen,infectious agent colony,0.7833333333333333
infectious human pathogen,pathogen transporter,0.6277777777777778
infectious human pathogen,latency end process boundary,0.619811320754717
infectious human pathogen,infectious disease epidemic,0.7384615384615384
infectious human pathogen,infectious agent generative stage,0.760344827586207
infectious human pathogen,disease transmission model,0.6264705882352941
infectious human pathogen,realizable entity,0.5928571428571429
infectious human pathogen,pathologically immunosuppressed organism,0.6038461538461539
infectious human pathogen,negative-sense single-stranded RNA virus,0.6038461538461539
infectious human pathogen,cidal agent,0.6722222222222223
infectious human pathogen,infectious structure host role,0.740909090909091
infectious human pathogen,pathogen vehicle,0.6451219512195122
infectious human pathogen,COVID-19 incidence rate,0.6375
infectious human pathogen,community-acquired infection,0.619811320754717
infectious human pathogen,pathogen vector,0.65
infectious human pathogen,pathogen vehicle role,0.6239130434782608
infectious human pathogen,chronic infectious disease course,0.7086206896551723
infectious human pathogen,asymptomatic infectious agent carrier,0.7080645161290323
infectious human pathogen,nursing-home acquired infection,0.6285714285714286
infectious human pathogen,descriptive information content entity,0.6404761904761905
infectious human pathogen,COVID-19 epidemic,0.569047619047619
infectious human pathogen,secondary infection,0.6545454545454545
infectious human pathogen,infection start temporal region,0.7178571428571427
infectious human pathogen,infection incidence,0.7227272727272727
infectious human pathogen,virus disorder,0.6038461538461539
infectious human pathogen,sterilizing immunity to infectious agent,0.6807692307692308
infectious human pathogen,establishment of localization in human host,0.6852941176470588
infectious human pathogen,diseased population,0.6545454545454545
infectious human pathogen,primary infection,0.6642857142857143
infectious human pathogen,process of establishing an infection,0.6467213114754098
infectious human pathogen,incubation end process boundary,0.6821428571428573
infectious human pathogen,pathogen death process boundary,0.6285714285714286
infectious human pathogen,molecular entity,0.6207317073170732
infectious human pathogen,immunosuppressed organism,0.63
infectious human pathogen,latency end temporal region,0.6230769230769231
infectious human pathogen,innate immunity to infectious agent,0.7
infectious human pathogen,infectious structure,0.7611111111111112
infectious human pathogen,virus adhesion susceptible cell,0.6285714285714286
infectious human pathogen,infection,0.7147058823529412
infectious human pathogen,static agent disposition,0.6540816326530612
infectious human pathogen,T cell receptor complex,0.6166666666666667
infectious human pathogen,infectious structure host,0.75
infectious human pathogen,infectious agent population,0.8153846153846154
infectious human pathogen,respiratory system disease,0.6068627450980393
infectious human pathogen,leukocyte-mediated immunity to infectious agent,0.6583333333333334
infectious human pathogen,indirect pathogen transmission process,0.6722222222222223
infectious human pathogen,organism population,0.6772727272727272
infectious human pathogen,humoral immunity to infectious agent,0.6959016393442623
infectious human pathogen,infectious disease control strategy,0.7333333333333333
infectious human pathogen,parasite,0.5712121212121213
infectious human pathogen,infectious disease pandemic,0.7576923076923078
infectious human pathogen,antibody reagent,0.6695121951219513
infectious human pathogen,infectious structure generative stage,0.7241935483870968
infectious human pathogen,viral disease course,0.6055555555555556
infectious human pathogen,intracellular infection,0.6375
infectious human pathogen,secondary infection role,0.6948979591836735
infectious human pathogen,metastatic infection,0.65
infectious human pathogen,passive immunity to infectious agent,0.6959016393442623
infectious human pathogen,infectious disposition,0.7691489361702127
infectious human pathogen,vaccination against infectious agent,0.6959016393442623
infectious human pathogen,acute infection,0.675
infectious human pathogen,susceptibility to infectious agent,0.7042372881355932
infectious human pathogen,epitope site,0.6121621621621621
infectious human pathogen,immunity to pathogen,0.7388888888888888
infectious human pathogen,source of infection role,0.6948979591836735
infectious human pathogen,pathogen host,0.6605263157894737
infectious human pathogen,chronic infection,0.6642857142857143
infectious human pathogen,disease course,0.6294871794871795
infectious human pathogen,infectious disease course,0.75
infectious human pathogen,acquired immunity to infectious agent,0.6919354838709677
infectious human pathogen,complex infection,0.6642857142857143
infectious human pathogen,COVID-19 disease incidence proportion,0.6112903225806451
infectious human pathogen,coronavirus disease course,0.6264705882352941
infectious human pathogen,infection incidence proportion,0.7227272727272727
infectious human pathogen,symptomatic infectious agent carrier,0.7122950819672131
infectious human pathogen,respiratory droplet virus fomite,0.6254385964912281
infectious human pathogen,susceptible organism,0.6055555555555556
infectious human pathogen,parasite role,0.581578947368421
infectious human pathogen,pathogen vector role,0.6277777777777778
infectious human pathogen,pathogen portal of exit site,0.6009433962264151
infectious human pathogen,infectious disease prevalence,0.7648148148148148
infectious human pathogen,organism substance,0.636046511627907
infectious human pathogen,anatomical entity,0.6404761904761905
infectious human pathogen,single-stranded DNA virus,0.61
infectious human pathogen,infected population,0.7227272727272727
infectious human pathogen,COVID-19 mortality rate,0.6375
infectious human pathogen,geopolitical entity,0.609090909090909
infectious human pathogen,viral disease,0.581578947368421
infectious human pathogen,primary infection role,0.7053191489361703
infectious human pathogen,pathogen portal of entry site,0.6166666666666667
infectious human pathogen,infection incidence profile,0.7192307692307692
infectious human pathogen,disease,0.575
infectious human pathogen,symptomatic infectious structure carrier,0.6807692307692308
infectious human pathogen,homo sapiens,0.6121621621621621
infectious human pathogen,site,0.553448275862069
infectious human pathogen,primary infectious disposition,0.7227272727272727
infectious human pathogen,pathogen host role,0.636046511627907
infectious human pathogen,infection prevalence,0.7611111111111112
infectious human pathogen,designative information content entity,0.6404761904761905
infectious human pathogen,infectious pathogen transmissibility,0.7614754098360657
infectious human pathogen,pathogen surveillance,0.6239130434782608
infectious human pathogen,immunodeficient organism,0.6540816326530612
infectious human pathogen,pathogen,0.6924242424242425
infectious human pathogen,pathogen birth process boundary,0.6107142857142857
infectious human pathogen,infectious human pathogen,0.95
infectious human pathogen,subclinical virus infection,0.6615384615384616
infectious human pathogen,resistance to pathogen,0.747872340425532
infectious human pathogen,colonization of human,0.6673913043478261
infectious human pathogen,establishment of localization in virus host,0.6264705882352941
infectious human pathogen,immunization against infectious agent,0.6919354838709677
infectious human pathogen,virus attachment stage,0.6840425531914894
infectious human pathogen,virus synthesis stage,0.6456521739130434
infectious human pathogen,immaterial entity,0.6166666666666667
infectious human pathogen,pathogen portal of exit role,0.619811320754717
infectious human pathogen,infectious agent host,0.7978260869565217
infectious human pathogen,re-emerging pathogen,0.7166666666666667
infectious human pathogen,long-term non-progressing infectious disease course,0.6473684210526315
infectious human pathogen,viral disease epidemic,0.598936170212766
infectious human pathogen,viral disease pandemic,0.6202127659574468
infectious human pathogen,virus penetration stage,0.6791666666666666
infectious human pathogen,pathogen seroprevalence,0.6166666666666667
infectious human pathogen,division of geopolitical entity,0.6285714285714286
infectious human pathogen,infectious disease endemicity,0.7277777777777777
infectious human pathogen,contact pathogen transmission process,0.6435483870967742
infectious human pathogen,herd immunity to infectious organism,0.6795081967213115
infectious human pathogen,extracellular infection,0.6375
infectious human pathogen,pathogen transporter role,0.63
infectious human pathogen,infectious agent reservoir,0.7441176470588234
infectious human pathogen,COVID-19 pandemic,0.5928571428571429
infectious human pathogen,infection start process boundary,0.7131578947368421
infectious human pathogen,processed material,0.6127906976744186
infectious human pathogen,infectious disease control objective specification,0.7033333333333335
infectious human pathogen,opportunistic infectious disposition,0.6959016393442623
infectious human pathogen,process of establishing viral infection,0.6375
infectious human pathogen,COVID-19 disease course,0.5958333333333333
infectious human pathogen,infectious disease incidence rate,0.743103448275862
infectious human pathogen,single-stranded RNA retrovirus,0.6318181818181818
infectious human pathogen,active immunization against infectious agent,0.6673913043478261
infectious human pathogen,disordered virus,0.5719512195121951
infectious human pathogen,organism,0.5712121212121213
infectious human pathogen,virus uncoating stage,0.6891304347826087
infectious human pathogen,local infection,0.675
infectious human pathogen,infectious agent,0.8158536585365854
infectious human pathogen,establishment of a clinically abnormal colony,0.6214285714285714
infectious human pathogen,coronavirus disease,0.609090909090909
infectious human pathogen,positive-sense single-stranded RNA virus,0.5884615384615385
infectious human pathogen,horizontal pathogen transmission process,0.65
infectious human pathogen,hospital-acquired infection,0.6230769230769231
infectious human pathogen,pathogen death temporal region,0.6318181818181818
infectious human pathogen,emerging pathogen,0.7357142857142857
infectious human pathogen,drug susceptibility of infectious agent,0.684375
infectious human pathogen,static agent,0.6391891891891892
infectious human pathogen,pathogen transmission process,0.6166666666666667
infectious human pathogen,material processing,0.6318181818181818
invasion disposition,virostatic disposition,0.8071428571428573
invasion disposition,information content entity,0.6673913043478261
invasion disposition,zoonotic disposition,0.8
invasion disposition,infectious disease mortality rate,0.6575471698113208
invasion disposition,infection incidence rate profile,0.6423076923076922
invasion disposition,infectious structure aggregate,0.59
invasion disposition,communicability end temporal region,0.6318181818181818
invasion disposition,geographical entity,0.5782051282051281
invasion disposition,biological regulation,0.6451219512195122
invasion disposition,surveillance process,0.625
invasion disposition,infection end temporal region,0.6948979591836735
invasion disposition,vector control strategy,0.5895348837209302
invasion disposition,SARS-CoV-2 incidence rate,0.6055555555555556
invasion disposition,incubation end temporal region,0.71
invasion disposition,resistant entity,0.6166666666666667
invasion disposition,virulence factor disposition,0.7833333333333333
invasion disposition,viral adhesion disposition,0.8413043478260869
invasion disposition,parasitostatic disposition,0.7978260869565217
invasion disposition,negative regulation of production,0.6952830188679244
invasion disposition,reverse zoonotic disposition,0.7833333333333333
invasion disposition,establishment of localization in host,0.6429824561403508
invasion disposition,disease surveillance objective specification,0.66875
invasion disposition,case isolation control strategy,0.6460784313725491
invasion disposition,infectious agent host role,0.6673913043478261
invasion disposition,macromolecular complex,0.5452380952380953
invasion disposition,material entity,0.5928571428571429
invasion disposition,asymptomatic infectious structure carrier,0.5975409836065574
invasion disposition,architectual structure,0.569047619047619
invasion disposition,quarantine control strategy,0.598936170212766
invasion disposition,B cell receptor complex,0.5430232558139535
invasion disposition,infection incidence rate,0.6545454545454545
invasion disposition,colonized host,0.6264705882352941
invasion disposition,virus host,0.65
invasion disposition,entity,0.5653846153846154
invasion disposition,toxin disposition,0.8283783783783784
invasion disposition,cidal agent disposition,0.7988372093023256
invasion disposition,parasiticidal disposition,0.7833333333333333
invasion disposition,communicability end process boundary,0.6285714285714286
invasion disposition,directive information content entity,0.6285714285714286
invasion disposition,acellular structure aggregate,0.5316326530612244
invasion disposition,invasion factor,0.7642857142857143
invasion disposition,transmissibility disposition,0.7625
invasion disposition,latency end process boundary,0.6375
invasion disposition,colonization of host,0.675
invasion disposition,realizable entity,0.5851351351351352
invasion disposition,endotoxin disposition,0.8158536585365854
invasion disposition,vector surveillance,0.6038461538461539
invasion disposition,negative regulation of establishment of localization,0.6583333333333334
invasion disposition,infectious structure host role,0.65
invasion disposition,COVID-19 incidence rate,0.5895348837209302
invasion disposition,cytotoxin disposition,0.7914634146341464
invasion disposition,negative regulation of developmental process,0.621875
invasion disposition,host,0.575
invasion disposition,descriptive information content entity,0.6224137931034482
invasion disposition,negative regulation of replication,0.6907407407407408
invasion disposition,establishment of localization in human host,0.6246031746031746
invasion disposition,acellular structure,0.5525641025641026
invasion disposition,incubation end process boundary,0.7049019607843137
invasion disposition,collective pathogenic disposition,0.7707547169811321
invasion disposition,neurotoxin disposition,0.8071428571428573
invasion disposition,dead-end host role,0.6342105263157894
invasion disposition,molecular entity,0.5611111111111111
invasion disposition,plan specification,0.7131578947368421
invasion disposition,definitive host role,0.65
invasion disposition,latency end temporal region,0.6414893617021277
invasion disposition,infectious structure,0.625
invasion disposition,collective disposition,0.7833333333333333
invasion disposition,static agent disposition,0.7909090909090909
invasion disposition,T cell receptor complex,0.5430232558139535
invasion disposition,infectious structure host,0.65
invasion disposition,respiratory system disease,0.6239130434782608
invasion disposition,entry into host,0.65
invasion disposition,adhesion of symbiont to host,0.6791666666666666
invasion disposition,infectious disease control strategy,0.65
invasion disposition,infectious structure generative stage,0.5903508771929825
invasion disposition,immunosuppressive disposition,0.7765306122448979
invasion disposition,pathogenic disposition,0.8071428571428573
invasion disposition,entry into host through host barriers,0.6078947368421053
invasion disposition,infectious disposition,0.830952380952381
invasion disposition,bacteriostatic disposition,0.7760869565217391
invasion disposition,bactericidal disposition,0.7681818181818181
invasion disposition,pathogen host,0.6621212121212122
invasion disposition,invasion disposition,0.95
invasion disposition,viricidal disposition,0.7914634146341464
invasion disposition,complex infection,0.6391891891891892
invasion disposition,intermediate host,0.6391891891891892
invasion disposition,anatomical entity,0.6121621621621621
invasion disposition,disposition,0.8048387096774193
invasion disposition,COVID-19 mortality rate,0.5895348837209302
invasion disposition,negative regulation of life-sustaining process,0.6469696969696969
invasion disposition,place closure control strategy,0.59
invasion disposition,geopolitical entity,0.6294871794871795
invasion disposition,intervention,0.7
invasion disposition,adhesion disposition,0.875
invasion disposition,symptomatic infectious structure carrier,0.5833333333333334
invasion disposition,primary infectious disposition,0.77
invasion disposition,pathogen host role,0.6605263157894737
invasion disposition,designative information content entity,0.6396551724137931
invasion disposition,intermediate host role,0.6404761904761905
invasion disposition,dead-end host,0.6318181818181818
invasion disposition,pathogen surveillance,0.6207317073170732
invasion disposition,host role,0.5879310344827586
invasion disposition,establishment of localization in virus host,0.6404761904761905
invasion disposition,negative regulation of immune response,0.656896551724138
invasion disposition,immaterial entity,0.6121621621621621
invasion disposition,SARS-COV-2 adhesion disposition,0.8029411764705883
invasion disposition,invasive disposition,0.9
invasion disposition,infectious agent host,0.6695121951219513
invasion disposition,fungicidal disposition,0.7833333333333333
invasion disposition,division of geopolitical entity,0.7049019607843137
invasion disposition,negative regulation of viral process,0.6464285714285714
invasion disposition,exotoxin disposition,0.8
invasion disposition,immunoglobulin complex,0.5928571428571429
invasion disposition,action specification,0.75
invasion disposition,infectious disease control objective specification,0.6642857142857143
invasion disposition,symbiont host role,0.6868421052631578
invasion disposition,opportunistic infectious disposition,0.7357142857142857
invasion disposition,negative regulation of biological process,0.630327868852459
invasion disposition,enterotoxin disposition,0.7988372093023256
invasion disposition,infectious disease incidence rate,0.6764150943396227
invasion disposition,collective resistance disposition,0.7707547169811321
invasion disposition,fungistatic disposition,0.7988372093023256
invasion disposition,establishment of a clinically abnormal colony,0.5884615384615385
invasion disposition,definitive host,0.65
viral disease pandemic,virus aggregate,0.6662162162162162
viral disease pandemic,source of infection,0.5963414634146341
viral disease pandemic,virostatic disposition,0.6772727272727272
viral disease pandemic,zoonotic disposition,0.6166666666666667
viral disease pandemic,infectious disease mortality rate,0.6681818181818181
viral disease pandemic,infection incidence rate profile,0.6166666666666667
viral disease pandemic,infectious structure aggregate,0.6038461538461539
viral disease pandemic,communicability end temporal region,0.6254385964912281
viral disease pandemic,subclinical coronavirus infection,0.6318181818181818
viral disease pandemic,infection end temporal region,0.6068627450980393
viral disease pandemic,infectious disease,0.675
viral disease pandemic,double-stranded DNA virus,0.6202127659574468
viral disease pandemic,incubation end temporal region,0.6230769230769231
viral disease pandemic,site of infection,0.6038461538461539
viral disease pandemic,virulence factor disposition,0.65
viral disease pandemic,viral adhesion disposition,0.7
viral disease pandemic,parasitostatic disposition,0.6166666666666667
viral disease pandemic,infectious disease incidence,0.73
viral disease pandemic,reverse zoonotic disposition,0.61
viral disease pandemic,subclinical SARS-CoV-2 infection,0.6537037037037037
viral disease pandemic,virus translation stage,0.65
viral disease pandemic,disease surveillance objective specification,0.6469696969696969
viral disease pandemic,virus release stage,0.7182926829268292
viral disease pandemic,infectious agent host role,0.5958333333333333
viral disease pandemic,asymptomatic infectious structure carrier,0.5928571428571429
viral disease pandemic,source of infection site,0.5804347826086956
viral disease pandemic,virus,0.5981481481481481
viral disease pandemic,virus replication,0.6551282051282051
viral disease pandemic,B cell receptor complex,0.6055555555555556
viral disease pandemic,passive immunization against infectious agent,0.6141791044776119
viral disease pandemic,systematic infection,0.6166666666666667
viral disease pandemic,infection incidence rate,0.6239130434782608
viral disease pandemic,virus host,0.60625
viral disease pandemic,double-stranded RNA virus,0.6202127659574468
viral disease pandemic,virus transcription stage,0.6414893617021277
viral disease pandemic,infectious disease lifetime prevalence,0.6833333333333332
viral disease pandemic,toxin disposition,0.6294871794871795
viral disease pandemic,lower respiratory tract disease,0.6575471698113208
viral disease pandemic,infectious disease incidence proportion,0.6795081967213115
viral disease pandemic,virus generative stage,0.6772727272727272
viral disease pandemic,acute infectious disease course,0.6575471698113208
viral disease pandemic,cidal agent disposition,0.65
viral disease pandemic,infectious disorder,0.6207317073170732
viral disease pandemic,subclinical infection,0.636046511627907
viral disease pandemic,appearance of disorder,0.6318181818181818
viral disease pandemic,simple infection,0.6342105263157894
viral disease pandemic,parasiticidal disposition,0.6414893617021277
viral disease pandemic,infectious disease sporadicity,0.7384615384615384
viral disease pandemic,communicability end process boundary,0.6224137931034482
viral disease pandemic,infection incidence proportion profile,0.6
viral disease pandemic,infectious agent colony,0.6055555555555556
viral disease pandemic,invasion factor,0.6121621621621621
viral disease pandemic,transmissibility disposition,0.63
viral disease pandemic,latency end process boundary,0.61
viral disease pandemic,infectious disease epidemic,0.7765306122448979
viral disease pandemic,infectious agent generative stage,0.6136363636363636
viral disease pandemic,disease transmission model,0.7
viral disease pandemic,endotoxin disposition,0.6127906976744186
viral disease pandemic,negative-sense single-stranded RNA virus,0.6435483870967742
viral disease pandemic,infectious structure host role,0.5846153846153846
viral disease pandemic,viral plaque assay,0.7
viral disease pandemic,cytotoxin disposition,0.6127906976744186
viral disease pandemic,community-acquired infection,0.61
viral disease pandemic,chronic infectious disease course,0.65
viral disease pandemic,asymptomatic infectious agent carrier,0.6025423728813559
viral disease pandemic,nursing-home acquired infection,0.619811320754717
viral disease pandemic,COVID-19 epidemic,0.7064102564102563
viral disease pandemic,secondary infection,0.6207317073170732
viral disease pandemic,infection start temporal region,0.619811320754717
viral disease pandemic,infection incidence,0.6207317073170732
viral disease pandemic,virus disorder,0.7
viral disease pandemic,sterilizing immunity to infectious agent,0.5951612903225807
viral disease pandemic,primary infection,0.6294871794871795
viral disease pandemic,process of establishing an infection,0.6224137931034482
viral disease pandemic,incubation end process boundary,0.619811320754717
viral disease pandemic,SARS-CoV-2 disorder,0.6207317073170732
viral disease pandemic,collective pathogenic disposition,0.6136363636363636
viral disease pandemic,neurotoxin disposition,0.609090909090909
viral disease pandemic,plan specification,0.625
viral disease pandemic,latency end temporal region,0.6336734693877552
viral disease pandemic,innate immunity to infectious agent,0.6078947368421053
viral disease pandemic,infectious structure,0.569047619047619
viral disease pandemic,virus adhesion susceptible cell,0.6764150943396227
viral disease pandemic,collective disposition,0.609090909090909
viral disease pandemic,infection,0.5790322580645162
viral disease pandemic,static agent disposition,0.6239130434782608
viral disease pandemic,T cell receptor complex,0.6055555555555556
viral disease pandemic,infectious structure host,0.5776595744680851
viral disease pandemic,infectious agent population,0.6336734693877552
viral disease pandemic,respiratory system disease,0.6791666666666666
viral disease pandemic,leukocyte-mediated immunity to infectious agent,0.5804347826086956
viral disease pandemic,humoral immunity to infectious agent,0.6224137931034482
viral disease pandemic,infectious disease control strategy,0.6605263157894737
viral disease pandemic,infectious disease pandemic,0.8173469387755102
viral disease pandemic,infectious structure generative stage,0.6025423728813559
viral disease pandemic,immunosuppressive disposition,0.6068627450980393
viral disease pandemic,pathogenic disposition,0.609090909090909
viral disease pandemic,viral disease course,0.8071428571428573
viral disease pandemic,intracellular infection,0.65
viral disease pandemic,secondary infection role,0.6021739130434782
viral disease pandemic,metastatic infection,0.6166666666666667
viral disease pandemic,viral envelope,0.7277777777777777
viral disease pandemic,passive immunity to infectious agent,0.6051724137931035
viral disease pandemic,infectious disposition,0.609090909090909
viral disease pandemic,vaccination against infectious agent,0.6396551724137931
viral disease pandemic,acute infection,0.6121621621621621
viral disease pandemic,susceptibility to infectious agent,0.6107142857142857
viral disease pandemic,bacteriostatic disposition,0.6166666666666667
viral disease pandemic,bactericidal disposition,0.6456521739130434
viral disease pandemic,source of infection role,0.5804347826086956
viral disease pandemic,chronic infection,0.6038461538461539
viral disease pandemic,invasion disposition,0.6404761904761905
viral disease pandemic,disease course,0.7
viral disease pandemic,infectious disease course,0.6840425531914894
viral disease pandemic,viricidal disposition,0.7058139534883722
viral disease pandemic,acquired immunity to infectious agent,0.6025423728813559
viral disease pandemic,complex infection,0.6038461538461539
viral disease pandemic,COVID-19 disease incidence proportion,0.7042372881355932
viral disease pandemic,coronavirus disease course,0.7208333333333333
viral disease pandemic,infection incidence proportion,0.6038461538461539
viral disease pandemic,symptomatic infectious agent carrier,0.6051724137931035
viral disease pandemic,viral capsid,0.7147058823529412
viral disease pandemic,respiratory droplet virus fomite,0.6351851851851852
viral disease pandemic,infectious disease prevalence,0.7245098039215686
viral disease pandemic,disposition,0.6015151515151516
viral disease pandemic,single-stranded DNA virus,0.6414893617021277
viral disease pandemic,place closure control strategy,0.5846153846153846
viral disease pandemic,viral disease,0.8214285714285714
viral disease pandemic,primary infection role,0.609090909090909
viral disease pandemic,adhesion disposition,0.6166666666666667
viral disease pandemic,infection incidence profile,0.6132653061224489
viral disease pandemic,disease,0.6913793103448276
viral disease pandemic,symptomatic infectious structure carrier,0.5951612903225807
viral disease pandemic,primary infectious disposition,0.6230769230769231
viral disease pandemic,infection prevalence,0.6166666666666667
viral disease pandemic,coronavirus disorder,0.6642857142857143
viral disease pandemic,infectious pathogen transmissibility,0.6224137931034482
viral disease pandemic,infectious human pathogen,0.6202127659574468
viral disease pandemic,subclinical virus infection,0.6540816326530612
viral disease pandemic,establishment of localization in virus host,0.5884615384615385
viral disease pandemic,immunization against infectious agent,0.6194915254237288
viral disease pandemic,virus attachment stage,0.6545454545454545
viral disease pandemic,virus synthesis stage,0.6825581395348838
viral disease pandemic,SARS-COV-2 adhesion disposition,0.6009433962264151
viral disease pandemic,invasive disposition,0.6404761904761905
viral disease pandemic,infectious agent host,0.5895348837209302
viral disease pandemic,long-term non-progressing infectious disease course,0.6006849315068493
viral disease pandemic,viral disease epidemic,0.9045454545454545
viral disease pandemic,fungicidal disposition,0.6545454545454545
viral disease pandemic,viral disease pandemic,0.95
viral disease pandemic,virus penetration stage,0.65
viral disease pandemic,acute respiratory distress syndrome,0.6780701754385965
viral disease pandemic,infectious disease endemicity,0.7637254901960785
viral disease pandemic,negative regulation of viral process,0.6051724137931035
viral disease pandemic,disorder,0.6166666666666667
viral disease pandemic,herd immunity to infectious organism,0.6051724137931035
viral disease pandemic,extracellular infection,0.6277777777777778
viral disease pandemic,exotoxin disposition,0.6166666666666667
viral disease pandemic,infectious agent reservoir,0.6166666666666667
viral disease pandemic,COVID-19 pandemic,0.7576923076923078
viral disease pandemic,infection start process boundary,0.5981481481481481
viral disease pandemic,infectious disease control objective specification,0.6444444444444444
viral disease pandemic,opportunistic infectious disposition,0.5879310344827586
viral disease pandemic,process of establishing viral infection,0.6139344262295081
viral disease pandemic,enterotoxin disposition,0.6055555555555556
viral disease pandemic,COVID-19 disease course,0.7166666666666667
viral disease pandemic,infectious disease incidence rate,0.7045454545454546
viral disease pandemic,single-stranded RNA retrovirus,0.6230769230769231
viral disease pandemic,active immunization against infectious agent,0.6166666666666667
viral disease pandemic,disordered virus,0.6342105263157894
viral disease pandemic,collective resistance disposition,0.6136363636363636
viral disease pandemic,viral load,0.7
viral disease pandemic,fungistatic disposition,0.6277777777777778
viral disease pandemic,virus uncoating stage,0.636046511627907
viral disease pandemic,local infection,0.6391891891891892
viral disease pandemic,infectious agent,0.6078947368421053
viral disease pandemic,establishment of a clinically abnormal colony,0.6141791044776119
viral disease pandemic,coronavirus disease,0.7182926829268292
viral disease pandemic,positive-sense single-stranded RNA virus,0.6435483870967742
viral disease pandemic,hospital-acquired infection,0.6336734693877552
viral disease pandemic,viral pathogenesis,0.725
viral disease pandemic,drug susceptibility of infectious agent,0.5975409836065574
infectious structure host,virostatic disposition,0.6414893617021277
infectious structure host,zoonotic disposition,0.6277777777777778
infectious structure host,infectious disease mortality rate,0.7258620689655172
infectious structure host,infection incidence rate profile,0.6956140350877194
infectious structure host,infectious structure aggregate,0.85
infectious structure host,communicability end temporal region,0.6
infectious structure host,infection end temporal region,0.7092592592592593
infectious structure host,infectious disease,0.7755813953488372
infectious structure host,SARS-CoV-2 incidence rate,0.61
infectious structure host,incubation end temporal region,0.6681818181818181
infectious structure host,virulence factor disposition,0.6575471698113208
infectious structure host,viral adhesion disposition,0.6264705882352941
infectious structure host,parasitostatic disposition,0.6460784313725491
infectious structure host,infectious disease incidence,0.7141509433962264
infectious structure host,reverse zoonotic disposition,0.619811320754717
infectious structure host,establishment of localization in host,0.6596774193548387
infectious structure host,disease surveillance objective specification,0.6239130434782608
infectious structure host,infectious agent host role,0.7833333333333333
infectious structure host,macromolecular complex,0.598936170212766
infectious structure host,asymptomatic infectious structure carrier,0.7681818181818181
infectious structure host,architectual structure,0.7691489361702127
infectious structure host,B cell receptor complex,0.6166666666666667
infectious structure host,passive immunization against infectious agent,0.6357142857142857
infectious structure host,infection incidence rate,0.7153061224489795
infectious structure host,colonized host,0.6551282051282051
infectious structure host,virus host,0.6785714285714286
infectious structure host,infectious disease lifetime prevalence,0.7039682539682539
infectious structure host,toxin disposition,0.6166666666666667
infectious structure host,lower respiratory tract disease,0.6285714285714286
infectious structure host,infectious disease incidence proportion,0.715625
infectious structure host,acute infectious disease course,0.7357142857142857
infectious structure host,cidal agent disposition,0.6166666666666667
infectious structure host,infectious disorder,0.7681818181818181
infectious structure host,parasiticidal disposition,0.61
infectious structure host,infectious disease sporadicity,0.740909090909091
infectious structure host,communicability end process boundary,0.5975409836065574
infectious structure host,acellular structure aggregate,0.7092592592592593
infectious structure host,infectious agent colony,0.7416666666666667
infectious structure host,transmissibility disposition,0.619811320754717
infectious structure host,latency end process boundary,0.6009433962264151
infectious structure host,colonization of host,0.6722222222222223
infectious structure host,infectious disease epidemic,0.7192307692307692
infectious structure host,infectious agent generative stage,0.760344827586207
infectious structure host,disease transmission model,0.6068627450980393
infectious structure host,endotoxin disposition,0.6239130434782608
infectious structure host,infectious structure host role,0.9045454545454545
infectious structure host,COVID-19 incidence rate,0.6166666666666667
infectious structure host,cytotoxin disposition,0.6239130434782608
infectious structure host,host,0.5879310344827586
infectious structure host,chronic infectious disease course,0.7258620689655172
infectious structure host,asymptomatic infectious agent carrier,0.6919354838709677
infectious structure host,COVID-19 epidemic,0.5452380952380953
infectious structure host,sterilizing immunity to infectious agent,0.65
infectious structure host,establishment of localization in human host,0.6558823529411765
infectious structure host,diseased population,0.609090909090909
infectious structure host,acellular structure,0.7227272727272727
infectious structure host,incubation end process boundary,0.6642857142857143
infectious structure host,collective pathogenic disposition,0.6396551724137931
infectious structure host,neurotoxin disposition,0.6414893617021277
infectious structure host,dead-end host role,0.6127906976744186
infectious structure host,definitive host role,0.6722222222222223
infectious structure host,latency end temporal region,0.6038461538461539
infectious structure host,innate immunity to infectious agent,0.6666666666666667
infectious structure host,infectious structure,0.8944444444444444
infectious structure host,collective disposition,0.6414893617021277
infectious structure host,static agent disposition,0.6132653061224489
infectious structure host,T cell receptor complex,0.6166666666666667
infectious structure host,infectious structure host,0.95
infectious structure host,infectious agent population,0.7384615384615384
infectious structure host,respiratory system disease,0.6264705882352941
infectious structure host,entry into host,0.675
infectious structure host,leukocyte-mediated immunity to infectious agent,0.6305555555555555
infectious structure host,adhesion of symbiont to host,0.6764150943396227
infectious structure host,humoral immunity to infectious agent,0.6631147540983606
infectious structure host,infectious disease control strategy,0.75
infectious structure host,infectious disease pandemic,0.7192307692307692
infectious structure host,infectious structure generative stage,0.8209677419354838
infectious structure host,immunosuppressive disposition,0.6537037037037037
infectious structure host,pathogenic disposition,0.598936170212766
infectious structure host,viral disease course,0.6277777777777778
infectious structure host,entry into host through host barriers,0.6758064516129032
infectious structure host,passive immunity to infectious agent,0.6631147540983606
infectious structure host,infectious disposition,0.7691489361702127
infectious structure host,vaccination against infectious agent,0.6631147540983606
infectious structure host,susceptibility to infectious agent,0.6703389830508475
infectious structure host,bacteriostatic disposition,0.6656862745098039
infectious structure host,bactericidal disposition,0.6132653061224489
infectious structure host,pathogen host,0.6605263157894737
infectious structure host,invasion disposition,0.65
infectious structure host,disease course,0.6551282051282051
infectious structure host,infectious disease course,0.77
infectious structure host,viricidal disposition,0.6239130434782608
infectious structure host,acquired immunity to infectious agent,0.6596774193548387
infectious structure host,complex infection,0.6404761904761905
infectious structure host,COVID-19 disease incidence proportion,0.5951612903225807
infectious structure host,coronavirus disease course,0.6460784313725491
infectious structure host,symptomatic infectious agent carrier,0.6959016393442623
infectious structure host,intermediate host,0.7119047619047619
infectious structure host,infectious disease prevalence,0.7277777777777777
infectious structure host,disposition,0.5888888888888889
infectious structure host,infected population,0.6772727272727272
infectious structure host,COVID-19 mortality rate,0.5958333333333333
infectious structure host,viral disease,0.581578947368421
infectious structure host,adhesion disposition,0.6277777777777778
infectious structure host,disease,0.575
infectious structure host,symptomatic infectious structure carrier,0.7730769230769231
infectious structure host,primary infectious disposition,0.7227272727272727
infectious structure host,pathogen host role,0.636046511627907
infectious structure host,infectious pathogen transmissibility,0.7122950819672131
infectious structure host,intermediate host role,0.6840425531914894
infectious structure host,dead-end host,0.6342105263157894
infectious structure host,host role,0.5970588235294118
infectious structure host,infectious human pathogen,0.75
infectious structure host,establishment of localization in virus host,0.6705882352941177
infectious structure host,immunization against infectious agent,0.6596774193548387
infectious structure host,virus synthesis stage,0.6673913043478261
infectious structure host,SARS-COV-2 adhesion disposition,0.5928571428571429
infectious structure host,invasive disposition,0.6277777777777778
infectious structure host,infectious agent host,0.8195652173913044
infectious structure host,long-term non-progressing infectious disease course,0.6605263157894737
infectious structure host,viral disease epidemic,0.5776595744680851
infectious structure host,fungicidal disposition,0.6202127659574468
infectious structure host,viral disease pandemic,0.5776595744680851
infectious structure host,acute respiratory distress syndrome,0.6333333333333333
infectious structure host,division of geopolitical entity,0.6107142857142857
infectious structure host,infectious disease endemicity,0.7277777777777777
infectious structure host,herd immunity to infectious organism,0.6631147540983606
infectious structure host,exotoxin disposition,0.6277777777777778
infectious structure host,infectious agent reservoir,0.7441176470588234
infectious structure host,immunoglobulin complex,0.598936170212766
infectious structure host,COVID-19 pandemic,0.569047619047619
infectious structure host,SARS-CoV-2 synthesis stage,0.6264705882352941
infectious structure host,infectious disease control objective specification,0.7166666666666667
infectious structure host,symbiont host role,0.636046511627907
infectious structure host,opportunistic infectious disposition,0.6959016393442623
infectious structure host,enterotoxin disposition,0.6375
infectious structure host,polymerase chain reaction,0.61
infectious structure host,COVID-19 disease course,0.6166666666666667
infectious structure host,infectious disease incidence rate,0.7258620689655172
infectious structure host,active immunization against infectious agent,0.6384057971014493
infectious structure host,collective resistance disposition,0.6741379310344828
infectious structure host,fungistatic disposition,0.6375
infectious structure host,infectious agent,0.7670731707317073
infectious structure host,establishment of a clinically abnormal colony,0.5785714285714285
infectious structure host,coronavirus disease,0.6318181818181818
infectious structure host,definitive host,0.7
infectious structure host,drug susceptibility of infectious agent,0.653125
process that results in death,immune response,0.609090909090909
process that results in death,infectious disease mortality rate,0.6274193548387097
process that results in death,infection incidence rate profile,0.6139344262295081
process that results in death,communicability end temporal region,0.621875
process that results in death,pathogen generative stage,0.6351851851851852
process that results in death,surveillance process,0.6132653061224489
process that results in death,infection end temporal region,0.6224137931034482
process that results in death,SARS-CoV-2 incidence rate,0.6537037037037037
process that results in death,incubation end temporal region,0.6194915254237288
process that results in death,pathogen portal of exit,0.6615384615384616
process that results in death,negative regulation of production,0.6758064516129032
process that results in death,virus translation stage,0.6807692307692308
process that results in death,case isolation control strategy,0.6333333333333333
process that results in death,virus release stage,0.6375
process that results in death,material entity,0.609090909090909
process that results in death,B cell receptor complex,0.6038461538461539
process that results in death,infection incidence rate,0.619811320754717
process that results in death,double-stranded RNA virus,0.6166666666666667
process that results in death,virus transcription stage,0.6537037037037037
process that results in death,lower respiratory tract disease,0.65
process that results in death,virus generative stage,0.6264705882352941
process that results in death,acute infectious disease course,0.6166666666666667
process that results in death,process,0.6444444444444444
process that results in death,droplet pathogen transmission process,0.6621212121212122
process that results in death,communicability end process boundary,0.65
process that results in death,latency end process boundary,0.6605263157894737
process that results in death,infectious agent generative stage,0.6274193548387097
process that results in death,negative-sense single-stranded RNA virus,0.6239130434782608
process that results in death,COVID-19 incidence rate,0.6038461538461539
process that results in death,negative regulation of developmental process,0.6554794520547945
process that results in death,chronic infectious disease course,0.6274193548387097
process that results in death,PCR product,0.6
process that results in death,process of establishing an infection,0.7269230769230769
process that results in death,incubation end process boundary,0.65
process that results in death,SARS-CoV-2 uncoating stage,0.6318181818181818
process that results in death,pathogen death process boundary,0.7
process that results in death,plan specification,0.598936170212766
process that results in death,latency end temporal region,0.6285714285714286
process that results in death,SARS-CoV-2 penetration stage,0.6254385964912281
process that results in death,T cell receptor complex,0.6038461538461539
process that results in death,respiratory system disease,0.6681818181818181
process that results in death,indirect pathogen transmission process,0.6440298507462687
process that results in death,planned process,0.609090909090909
process that results in death,generative stage,0.6055555555555556
process that results in death,SARS-CoV-2 attachment stage,0.6285714285714286
process that results in death,infectious structure generative stage,0.6318181818181818
process that results in death,innate immune response,0.6068627450980393
process that results in death,viral disease course,0.6132653061224489
process that results in death,disease course,0.5895348837209302
process that results in death,infectious disease course,0.5981481481481481
process that results in death,coronavirus disease course,0.6318181818181818
process that results in death,pathogen portal of exit site,0.6605263157894737
process that results in death,SARS-CoV-2 genome replication stage,0.6375
process that results in death,production,0.6294871794871795
process that results in death,COVID-19 mortality rate,0.6230769230769231
process that results in death,process profile,0.7
process that results in death,negative regulation of life-sustaining process,0.6366666666666667
process that results in death,developmental process,0.63
process that results in death,biological process,0.6202127659574468
process that results in death,humoral immune response,0.6038461538461539
process that results in death,incubation start process boundary,0.6758064516129032
process that results in death,pathogen birth process boundary,0.7
process that results in death,virus attachment stage,0.6460784313725491
process that results in death,negative regulation of immune response,0.658955223880597
process that results in death,SARS-CoV-2 transcription stage,0.6364406779661017
process that results in death,virus synthesis stage,0.65
process that results in death,pathogen portal of exit role,0.6429824561403508
process that results in death,long-term non-progressing infectious disease course,0.625
process that results in death,virus penetration stage,0.6423076923076922
process that results in death,algorithm,0.581578947368421
process that results in death,negative regulation of viral process,0.65
process that results in death,contact pathogen transmission process,0.6469696969696969
process that results in death,function,0.5581081081081081
process that results in death,symbiotic process,0.6021739130434782
process that results in death,infection start process boundary,0.6795081967213115
process that results in death,action specification,0.6132653061224489
process that results in death,SARS-CoV-2 synthesis stage,0.6318181818181818
process that results in death,processed material,0.7265957446808511
process that results in death,latency start process boundary,0.6872881355932203
process that results in death,process of establishing viral infection,0.7147058823529412
process that results in death,negative regulation of biological process,0.6357142857142857
process that results in death,polymerase chain reaction,0.6907407407407408
process that results in death,COVID-19 disease course,0.5846153846153846
process that results in death,infectious disease incidence rate,0.6435483870967742
process that results in death,communicability start process boundary,0.6738805970149254
process that results in death,process that results in death,0.95
process that results in death,single-stranded RNA retrovirus,0.6194915254237288
process that results in death,adaptive immune response,0.619811320754717
process that results in death,virus uncoating stage,0.63
process that results in death,establishment of a clinically abnormal colony,0.5986486486486486
process that results in death,process boundary,0.7166666666666667
process that results in death,positive-sense single-stranded RNA virus,0.6384057971014493
process that results in death,horizontal pathogen transmission process,0.6384057971014493
process that results in death,pathogen death temporal region,0.6533898305084747
process that results in death,SARS-CoV-2 release stage,0.619811320754717
process that results in death,pathogen transmission process,0.656896551724138
process that results in death,material processing,0.6375
geographical entity,extended organism,0.6166666666666667
geographical entity,information content entity,0.7166666666666667
geographical entity,infectious disease mortality rate,0.6230769230769231
geographical entity,infection incidence rate profile,0.6068627450980393
geographical entity,infectious structure aggregate,0.5928571428571429
geographical entity,communicability end temporal region,0.6351851851851852
geographical entity,geographical entity,0.95
geographical entity,infection end temporal region,0.6166666666666667
geographical entity,drug-based immunosuppressed organism,0.5772727272727273
geographical entity,SARS-CoV-2 incidence rate,0.5863636363636363
geographical entity,incubation end temporal region,0.6132653061224489
geographical entity,resistant entity,0.7357142857142857
geographical entity,two-dimensional spatial region,0.6540816326530612
geographical entity,one-dimensional temporal region,0.63
geographical entity,immunocompetent organism,0.5895348837209302
geographical entity,virulence factor disposition,0.598936170212766
geographical entity,temporal region,0.6852941176470588
geographical entity,case isolation control strategy,0.65
geographical entity,material entity,0.8029411764705883
geographical entity,asymptomatic infectious structure carrier,0.6
geographical entity,architectual structure,0.6695121951219513
geographical entity,B cell receptor complex,0.5928571428571429
geographical entity,infection incidence rate,0.6127906976744186
geographical entity,entity,0.69
geographical entity,double-stranded RNA virus,0.5863636363636363
geographical entity,pathogen birth temporal region,0.6336734693877552
geographical entity,communicability end process boundary,0.6136363636363636
geographical entity,directive information content entity,0.6863636363636364
geographical entity,acellular structure aggregate,0.575
geographical entity,spatiotemporal region,0.65
geographical entity,invasion factor,0.5676470588235294
geographical entity,latency end process boundary,0.5776595744680851
geographical entity,realizable entity,0.7833333333333333
geographical entity,pathologically immunosuppressed organism,0.6194915254237288
geographical entity,negative-sense single-stranded RNA virus,0.5855932203389831
geographical entity,infectious structure host role,0.5724489795918367
geographical entity,COVID-19 incidence rate,0.5928571428571429
geographical entity,zero-dimensional spatial region,0.65
geographical entity,zero-dimensional temporal region,0.6264705882352941
geographical entity,descriptive information content entity,0.6780701754385965
geographical entity,infection start temporal region,0.63
geographical entity,establishment of localization in human host,0.5951612903225807
geographical entity,acellular structure,0.6078947368421053
geographical entity,virulence factor,0.5928571428571429
geographical entity,incubation end process boundary,0.59
geographical entity,geographical region,0.8447368421052631
geographical entity,molecular entity,0.7357142857142857
geographical entity,immunosuppressed organism,0.5863636363636363
geographical entity,latency end temporal region,0.6239130434782608
geographical entity,infectious structure,0.5782051282051281
geographical entity,T cell receptor complex,0.5928571428571429
geographical entity,infectious structure host,0.5863636363636363
geographical entity,respiratory system disease,0.6055555555555556
geographical entity,organism population,0.6342105263157894
geographical entity,infectious structure generative stage,0.6285714285714286
geographical entity,three-dimensional spatial region,0.6460784313725491
geographical entity,susceptible organism,0.6294871794871795
geographical entity,organism substance,0.6121621621621621
geographical entity,anatomical entity,0.7833333333333333
geographical entity,COVID-19 mortality rate,0.6166666666666667
geographical entity,geopolitical entity,0.8447368421052631
geographical entity,symptomatic infectious structure carrier,0.6025423728813559
geographical entity,designative information content entity,0.6956140350877194
geographical entity,immunodeficient organism,0.6127906976744186
geographical entity,infectious human pathogen,0.609090909090909
geographical entity,colonization of human,0.575
geographical entity,immaterial entity,0.7833333333333333
geographical entity,communicability start temporal region,0.5928571428571429
geographical entity,geospatial region,0.7277777777777777
geographical entity,division of geopolitical entity,0.75
geographical entity,geographical feature,0.8346153846153846
geographical entity,herd immunity to infectious organism,0.5772727272727273
geographical entity,action specification,0.6294871794871795
geographical entity,processed material,0.5851351351351352
geographical entity,quality,0.6423076923076922
geographical entity,infectious disease incidence rate,0.6038461538461539
geographical entity,single-stranded RNA retrovirus,0.6336734693877552
geographical entity,organism,0.6351851851851852
geographical entity,establishment of a clinically abnormal colony,0.60625
geographical entity,positive-sense single-stranded RNA virus,0.5686440677966101
geographical entity,adhesion factor,0.5970588235294118
geographical entity,one-dimensional spatial region,0.6540816326530612
geographical entity,spatial region,0.6621212121212122
geographical entity,pathogen death temporal region,0.6336734693877552
geographical entity,material processing,0.6605263157894737
acquired immunodeficiency,communicability end temporal region,0.6333333333333333
acquired immunodeficiency,infection end temporal region,0.6351851851851852
acquired immunodeficiency,incubation end temporal region,0.65
acquired immunodeficiency,B cell receptor complex,0.5958333333333333
acquired immunodeficiency,double-stranded RNA virus,0.59
acquired immunodeficiency,lower respiratory tract disease,0.575
acquired immunodeficiency,communicability end process boundary,0.6467213114754098
acquired immunodeficiency,latency end process boundary,0.6386792452830189
acquired immunodeficiency,negative-sense single-stranded RNA virus,0.5884615384615385
acquired immunodeficiency,nursing-home acquired infection,0.7178571428571427
acquired immunodeficiency,secondary infection,0.6545454545454545
acquired immunodeficiency,incubation end process boundary,0.6464285714285714
acquired immunodeficiency,immunodeficiency,0.8402439024390245
acquired immunodeficiency,latency end temporal region,0.6423076923076922
acquired immunodeficiency,T cell receptor complex,0.5958333333333333
acquired immunodeficiency,secondary infection role,0.6336734693877552
acquired immunodeficiency,acquired immunodeficiency,0.95
acquired immunodeficiency,acquired immunity to infectious agent,0.7725806451612902
acquired immunodeficiency,primary immunodeficiency,0.8377551020408163
acquired immunodeficiency,single-stranded RNA retrovirus,0.5954545454545455
acquired immunodeficiency,establishment of a clinically abnormal colony,0.6071428571428572
acquired immunodeficiency,positive-sense single-stranded RNA virus,0.573076923076923
pathogenic disposition,virostatic disposition,0.8136363636363637
pathogenic disposition,information content entity,0.6166666666666667
pathogenic disposition,zoonotic disposition,0.830952380952381
pathogenic disposition,infectious disease mortality rate,0.6136363636363636
pathogenic disposition,infection incidence rate profile,0.6166666666666667
pathogenic disposition,infectious structure aggregate,0.5653846153846154
pathogenic disposition,communicability end temporal region,0.6429824561403508
pathogenic disposition,geographical entity,0.6207317073170732
pathogenic disposition,pathogen generative stage,0.7053191489361703
pathogenic disposition,pathogen portal of entry,0.7543478260869566
pathogenic disposition,biological regulation,0.6593023255813953
pathogenic disposition,primary pathogen,0.6605263157894737
pathogenic disposition,surveillance process,0.6166666666666667
pathogenic disposition,infection end temporal region,0.6460784313725491
pathogenic disposition,vector control strategy,0.5833333333333334
pathogenic disposition,SARS-CoV-2 incidence rate,0.598936170212766
pathogenic disposition,incubation end temporal region,0.6615384615384616
pathogenic disposition,resistant entity,0.6078947368421053
pathogenic disposition,virulence factor disposition,0.75
pathogenic disposition,pathogen portal of exit,0.7388888888888888
pathogenic disposition,viral adhesion disposition,0.7833333333333333
pathogenic disposition,parasitostatic disposition,0.825
pathogenic disposition,reservoir of pathogen role,0.6583333333333334
pathogenic disposition,negative regulation of production,0.65
pathogenic disposition,reverse zoonotic disposition,0.77
pathogenic disposition,establishment of localization in host,0.6364406779661017
pathogenic disposition,disease surveillance objective specification,0.6469696969696969
pathogenic disposition,case isolation control strategy,0.6386792452830189
pathogenic disposition,infectious agent host role,0.6583333333333334
pathogenic disposition,macromolecular complex,0.5863636363636363
pathogenic disposition,material entity,0.6391891891891892
pathogenic disposition,asymptomatic infectious structure carrier,0.6246031746031746
pathogenic disposition,architectual structure,0.609090909090909
pathogenic disposition,quarantine control strategy,0.5928571428571429
pathogenic disposition,B cell receptor complex,0.5611111111111111
pathogenic disposition,infection incidence rate,0.6021739130434782
pathogenic disposition,colonized host,0.6444444444444444
pathogenic disposition,virus host,0.60625
pathogenic disposition,entity,0.5928571428571429
pathogenic disposition,pathogen portal of entry role,0.7245098039215686
pathogenic disposition,toxin disposition,0.8346153846153846
pathogenic disposition,pathogen birth temporal region,0.7384615384615384
pathogenic disposition,opportunistic pathogen,0.6772727272727272
pathogenic disposition,cidal agent disposition,0.8055555555555556
pathogenic disposition,genetic resistance to pathogen,0.6807692307692308
pathogenic disposition,droplet pathogen transmission process,0.7042372881355932
pathogenic disposition,parasiticidal disposition,0.8117021276595744
pathogenic disposition,communicability end process boundary,0.6396551724137931
pathogenic disposition,directive information content entity,0.6051724137931035
pathogenic disposition,acellular structure aggregate,0.5480392156862746
pathogenic disposition,pathogen transporter,0.7595238095238095
pathogenic disposition,transmissibility disposition,0.75
pathogenic disposition,latency end process boundary,0.69
pathogenic disposition,colonization of host,0.6404761904761905
pathogenic disposition,realizable entity,0.5782051282051281
pathogenic disposition,endotoxin disposition,0.7988372093023256
pathogenic disposition,vector surveillance,0.5963414634146341
pathogenic disposition,negative regulation of establishment of localization,0.6256756756756756
pathogenic disposition,infectious structure host role,0.6038461538461539
pathogenic disposition,pathogen vehicle,0.7131578947368421
pathogenic disposition,COVID-19 incidence rate,0.5833333333333334
pathogenic disposition,cytotoxin disposition,0.7988372093023256
pathogenic disposition,pathogen vector,0.7472972972972972
pathogenic disposition,negative regulation of developmental process,0.5863636363636363
pathogenic disposition,pathogen vehicle role,0.7290697674418604
pathogenic disposition,host,0.6038461538461539
pathogenic disposition,descriptive information content entity,0.6166666666666667
pathogenic disposition,negative regulation of replication,0.6464285714285714
pathogenic disposition,establishment of localization in human host,0.6192307692307693
pathogenic disposition,acellular structure,0.5719512195121951
pathogenic disposition,incubation end process boundary,0.6575471698113208
pathogenic disposition,collective pathogenic disposition,0.85
pathogenic disposition,neurotoxin disposition,0.7909090909090909
pathogenic disposition,dead-end host role,0.65
pathogenic disposition,pathogen death process boundary,0.7330188679245283
pathogenic disposition,molecular entity,0.6078947368421053
pathogenic disposition,plan specification,0.725
pathogenic disposition,definitive host role,0.6404761904761905
pathogenic disposition,latency end temporal region,0.6948979591836735
pathogenic disposition,infectious structure,0.5928571428571429
pathogenic disposition,collective disposition,0.7909090909090909
pathogenic disposition,static agent disposition,0.8195652173913044
pathogenic disposition,T cell receptor complex,0.5833333333333334
pathogenic disposition,infectious structure host,0.598936170212766
pathogenic disposition,respiratory system disease,0.6583333333333334
pathogenic disposition,entry into host,0.6391891891891892
pathogenic disposition,indirect pathogen transmission process,0.7
pathogenic disposition,adhesion of symbiont to host,0.65
pathogenic disposition,infectious disease control strategy,0.6078947368421053
pathogenic disposition,infectious structure generative stage,0.6025423728813559
pathogenic disposition,immunosuppressive disposition,0.7441176470588234
pathogenic disposition,pathogenic disposition,0.95
pathogenic disposition,entry into host through host barriers,0.6025423728813559
pathogenic disposition,infectious disposition,0.7681818181818181
pathogenic disposition,bacteriostatic disposition,0.8041666666666667
pathogenic disposition,immunity to pathogen,0.6404761904761905
pathogenic disposition,bactericidal disposition,0.8195652173913044
pathogenic disposition,pathogen host,0.7928571428571428
pathogenic disposition,invasion disposition,0.8071428571428573
pathogenic disposition,viricidal disposition,0.7755813953488372
pathogenic disposition,complex infection,0.6551282051282051
pathogenic disposition,intermediate host,0.6294871794871795
pathogenic disposition,pathogen vector role,0.7119047619047619
pathogenic disposition,pathogen portal of exit site,0.73
pathogenic disposition,anatomical entity,0.6551282051282051
pathogenic disposition,disposition,0.7833333333333333
pathogenic disposition,COVID-19 mortality rate,0.5833333333333334
pathogenic disposition,negative regulation of life-sustaining process,0.6117647058823529
pathogenic disposition,place closure control strategy,0.6038461538461539
pathogenic disposition,geopolitical entity,0.6451219512195122
pathogenic disposition,adhesion disposition,0.830952380952381
pathogenic disposition,pathogen portal of entry site,0.7245098039215686
pathogenic disposition,symptomatic infectious structure carrier,0.6274193548387097
pathogenic disposition,primary infectious disposition,0.7576923076923078
pathogenic disposition,pathogen host role,0.775
pathogenic disposition,designative information content entity,0.6166666666666667
pathogenic disposition,infectious pathogen transmissibility,0.6913793103448276
pathogenic disposition,intermediate host role,0.6318181818181818
pathogenic disposition,dead-end host,0.65
pathogenic disposition,pathogen surveillance,0.7290697674418604
pathogenic disposition,host role,0.6112903225806451
pathogenic disposition,pathogen,0.7166666666666667
pathogenic disposition,pathogen birth process boundary,0.7330188679245283
pathogenic disposition,infectious human pathogen,0.6202127659574468
pathogenic disposition,resistance to pathogen,0.6318181818181818
pathogenic disposition,establishment of localization in virus host,0.6192307692307693
pathogenic disposition,negative regulation of immune response,0.6166666666666667
pathogenic disposition,immaterial entity,0.6294871794871795
pathogenic disposition,SARS-COV-2 adhesion disposition,0.7518867924528303
pathogenic disposition,pathogen portal of exit role,0.73
pathogenic disposition,invasive disposition,0.7833333333333333
pathogenic disposition,infectious agent host,0.6593023255813953
pathogenic disposition,re-emerging pathogen,0.6404761904761905
pathogenic disposition,fungicidal disposition,0.7909090909090909
pathogenic disposition,pathogen seroprevalence,0.7166666666666667
pathogenic disposition,division of geopolitical entity,0.619811320754717
pathogenic disposition,negative regulation of viral process,0.6051724137931035
pathogenic disposition,contact pathogen transmission process,0.7042372881355932
pathogenic disposition,pathogen transporter role,0.747872340425532
pathogenic disposition,exotoxin disposition,0.8071428571428573
pathogenic disposition,immunoglobulin complex,0.5636363636363636
pathogenic disposition,infectious disease control objective specification,0.6305555555555555
pathogenic disposition,symbiont host role,0.625
pathogenic disposition,opportunistic infectious disposition,0.743103448275862
pathogenic disposition,negative regulation of biological process,0.6087301587301588
pathogenic disposition,enterotoxin disposition,0.7833333333333333
pathogenic disposition,infectious disease incidence rate,0.6318181818181818
pathogenic disposition,collective resistance disposition,0.740909090909091
pathogenic disposition,fungistatic disposition,0.8055555555555556
pathogenic disposition,establishment of a clinically abnormal colony,0.5992537313432835
pathogenic disposition,definitive host,0.6391891891891892
pathogenic disposition,horizontal pathogen transmission process,0.6919354838709677
pathogenic disposition,pathogen death temporal region,0.7384615384615384
pathogenic disposition,emerging pathogen,0.6551282051282051
pathogenic disposition,pathogen transmission process,0.7441176470588234
surveillance process,virostatic disposition,0.6404761904761905
surveillance process,zoonotic disposition,0.6
surveillance process,immune response,0.6785714285714286
surveillance process,infectious disease mortality rate,0.5820754716981132
surveillance process,infection incidence rate profile,0.6423076923076922
surveillance process,communicability end temporal region,0.5954545454545455
surveillance process,pathogen generative stage,0.5833333333333334
surveillance process,pathogen portal of entry,0.609090909090909
surveillance process,biological regulation,0.5963414634146341
surveillance process,surveillance process,0.95
surveillance process,infection end temporal region,0.6132653061224489
surveillance process,vector control strategy,0.6127906976744186
surveillance process,SARS-CoV-2 incidence rate,0.6722222222222223
surveillance process,incubation end temporal region,0.61
surveillance process,virulence factor disposition,0.6583333333333334
surveillance process,viral adhesion disposition,0.6456521739130434
surveillance process,parasitostatic disposition,0.6239130434782608
surveillance process,negative regulation of production,0.6386792452830189
surveillance process,reverse zoonotic disposition,0.6375
surveillance process,virus translation stage,0.6127906976744186
surveillance process,disease surveillance objective specification,0.715625
surveillance process,case isolation control strategy,0.6460784313725491
surveillance process,virus release stage,0.6551282051282051
surveillance process,quarantine control strategy,0.6414893617021277
surveillance process,B cell receptor complex,0.6593023255813953
surveillance process,infection incidence rate,0.6318181818181818
surveillance process,pathogen portal of entry role,0.5928571428571429
surveillance process,virus transcription stage,0.6277777777777778
surveillance process,toxin disposition,0.6121621621621621
surveillance process,virus generative stage,0.6166666666666667
surveillance process,acute infectious disease course,0.6264705882352941
surveillance process,cidal agent disposition,0.636046511627907
surveillance process,process,0.7092592592592593
surveillance process,droplet pathogen transmission process,0.6605263157894737
surveillance process,parasiticidal disposition,0.6055555555555556
surveillance process,communicability end process boundary,0.6642857142857143
surveillance process,transmissibility disposition,0.5958333333333333
surveillance process,latency end process boundary,0.7208333333333333
surveillance process,infectious agent generative stage,0.6009433962264151
surveillance process,endotoxin disposition,0.6207317073170732
surveillance process,vector surveillance,0.7576923076923078
surveillance process,negative regulation of establishment of localization,0.5888888888888889
surveillance process,COVID-19 incidence rate,0.636046511627907
surveillance process,cytotoxin disposition,0.5963414634146341
surveillance process,negative regulation of developmental process,0.66875
surveillance process,chronic infectious disease course,0.6009433962264151
surveillance process,negative regulation of replication,0.5981481481481481
surveillance process,process of establishing an infection,0.5928571428571429
surveillance process,incubation end process boundary,0.6852941176470588
surveillance process,collective pathogenic disposition,0.6386792452830189
surveillance process,neurotoxin disposition,0.6404761904761905
surveillance process,SARS-CoV-2 uncoating stage,0.6021739130434782
surveillance process,pathogen death process boundary,0.6656862745098039
surveillance process,plan specification,0.6078947368421053
surveillance process,latency end temporal region,0.6414893617021277
surveillance process,SARS-CoV-2 penetration stage,0.6375
surveillance process,collective disposition,0.6404761904761905
surveillance process,static agent disposition,0.6318181818181818
surveillance process,T cell receptor complex,0.6593023255813953
surveillance process,respiratory system disease,0.6239130434782608
surveillance process,entry into host,0.6214285714285714
surveillance process,indirect pathogen transmission process,0.656896551724138
surveillance process,planned process,0.7928571428571428
surveillance process,generative stage,0.6166666666666667
surveillance process,infectious disease control strategy,0.5954545454545455
surveillance process,SARS-CoV-2 attachment stage,0.6202127659574468
surveillance process,infectious structure generative stage,0.6078947368421053
surveillance process,immunosuppressive disposition,0.6540816326530612
surveillance process,innate immune response,0.6642857142857143
surveillance process,pathogenic disposition,0.6166666666666667
surveillance process,viral disease course,0.65
surveillance process,entry into host through host barriers,0.5903508771929825
surveillance process,infectious disposition,0.6166666666666667
surveillance process,bacteriostatic disposition,0.6239130434782608
surveillance process,bactericidal disposition,0.609090909090909
surveillance process,invasion disposition,0.625
surveillance process,disease course,0.6558823529411765
surveillance process,infectious disease course,0.6055555555555556
surveillance process,viricidal disposition,0.6207317073170732
surveillance process,coronavirus disease course,0.6239130434782608
surveillance process,SARS-CoV-2 genome replication stage,0.6318181818181818
surveillance process,disposition,0.5790322580645162
surveillance process,COVID-19 mortality rate,0.5895348837209302
surveillance process,process profile,0.6785714285714286
surveillance process,negative regulation of life-sustaining process,0.6621212121212122
surveillance process,place closure control strategy,0.61
surveillance process,adhesion disposition,0.625
surveillance process,pathogen portal of entry site,0.6132653061224489
surveillance process,developmental process,0.7426829268292683
surveillance process,biological process,0.7394736842105263
surveillance process,primary infectious disposition,0.63
surveillance process,humoral immune response,0.6825581395348838
surveillance process,incubation start process boundary,0.6575471698113208
surveillance process,pathogen surveillance,0.7426829268292683
surveillance process,pathogen birth process boundary,0.6460784313725491
surveillance process,virus attachment stage,0.6166666666666667
surveillance process,negative regulation of immune response,0.6396551724137931
surveillance process,SARS-CoV-2 transcription stage,0.63
surveillance process,virus synthesis stage,0.5963414634146341
surveillance process,SARS-COV-2 adhesion disposition,0.6460784313725491
surveillance process,invasive disposition,0.625
surveillance process,long-term non-progressing infectious disease course,0.6049295774647887
surveillance process,fungicidal disposition,0.6166666666666667
surveillance process,virus penetration stage,0.6127906976744186
surveillance process,algorithm,0.5189655172413793
surveillance process,negative regulation of viral process,0.6821428571428573
surveillance process,contact pathogen transmission process,0.6429824561403508
surveillance process,function,0.5928571428571429
surveillance process,symbiotic process,0.7472972972972972
surveillance process,exotoxin disposition,0.625
surveillance process,infection start process boundary,0.6615384615384616
surveillance process,action specification,0.575
surveillance process,SARS-CoV-2 synthesis stage,0.6021739130434782
surveillance process,latency start process boundary,0.69
surveillance process,infectious disease control objective specification,0.5928571428571429
surveillance process,opportunistic infectious disposition,0.5928571428571429
surveillance process,process of establishing viral infection,0.5855932203389831
surveillance process,negative regulation of biological process,0.6795081967213115
surveillance process,enterotoxin disposition,0.6127906976744186
surveillance process,polymerase chain reaction,0.6055555555555556
surveillance process,COVID-19 disease course,0.6127906976744186
surveillance process,infectious disease incidence rate,0.619811320754717
surveillance process,communicability start process boundary,0.656896551724138
surveillance process,process that results in death,0.6132653061224489
surveillance process,collective resistance disposition,0.6575471698113208
surveillance process,adaptive immune response,0.6772727272727272
surveillance process,fungistatic disposition,0.636046511627907
surveillance process,virus uncoating stage,0.5963414634146341
surveillance process,establishment of a clinically abnormal colony,0.5884615384615385
surveillance process,process boundary,0.6444444444444444
surveillance process,horizontal pathogen transmission process,0.6666666666666667
surveillance process,SARS-CoV-2 release stage,0.6545454545454545
surveillance process,pathogen transmission process,0.6744897959183673
incubation interval,infectious structure aggregate,0.6744897959183673
incubation interval,incubation end temporal region,0.7969387755102041
incubation interval,negative regulation of production,0.6423076923076922
incubation interval,establishment of localization in host,0.6642857142857143
incubation interval,asymptomatic infectious structure carrier,0.6166666666666667
incubation interval,architectual structure,0.6207317073170732
incubation interval,B cell receptor complex,0.569047619047619
incubation interval,infectious disease lifetime prevalence,0.6956140350877194
incubation interval,acellular structure aggregate,0.6166666666666667
incubation interval,negative regulation of establishment of localization,0.6330985915492958
incubation interval,infectious structure host role,0.6744897959183673
incubation interval,establishment of localization,0.6166666666666667
incubation interval,latency interval,0.7928571428571428
incubation interval,PCR product,0.55
incubation interval,establishment of localization in human host,0.6435483870967742
incubation interval,acellular structure,0.6078947368421053
incubation interval,incubation end process boundary,0.73
incubation interval,plan specification,0.6391891891891892
incubation interval,infectious structure,0.6807692307692308
incubation interval,anatomical space,0.65
incubation interval,T cell receptor complex,0.569047619047619
incubation interval,infectious structure host,0.6545454545454545
incubation interval,communicability interval,0.7523255813953489
incubation interval,infectious structure generative stage,0.6642857142857143
incubation interval,incubation interval,0.95
incubation interval,production,0.6224137931034482
incubation interval,symptomatic infectious structure carrier,0.6194915254237288
incubation interval,eclipse interval,0.7642857142857143
incubation interval,incubation start process boundary,0.7192307692307692
incubation interval,establishment of localization in virus host,0.6435483870967742
incubation interval,transmission interval,0.775
incubation interval,COVID-19 lifetime prevalence,0.6627659574468084
incubation interval,establishment of a clinically abnormal colony,0.60625
incubation interval,cell space,0.553448275862069
acellular structure aggregate,virus aggregate,0.7227272727272727
acellular structure aggregate,virostatic disposition,0.5676470588235294
acellular structure aggregate,zoonotic disposition,0.5316326530612244
acellular structure aggregate,infectious disease mortality rate,0.6274193548387097
acellular structure aggregate,infection incidence rate profile,0.5975409836065574
acellular structure aggregate,infectious structure aggregate,0.8228813559322035
acellular structure aggregate,SARS-CoV-2 incidence rate,0.6351851851851852
acellular structure aggregate,site of infection,0.5804347826086956
acellular structure aggregate,virulence factor disposition,0.5903508771929825
acellular structure aggregate,viral adhesion disposition,0.5590909090909091
acellular structure aggregate,parasitostatic disposition,0.5772727272727273
acellular structure aggregate,reverse zoonotic disposition,0.5728070175438597
acellular structure aggregate,macromolecular complex,0.6460784313725491
acellular structure aggregate,SARS-CoV-2 aggregate,0.7357142857142857
acellular structure aggregate,asymptomatic infectious structure carrier,0.7071428571428571
acellular structure aggregate,source of infection site,0.6009433962264151
acellular structure aggregate,architectual structure,0.7441176470588234
acellular structure aggregate,B cell receptor complex,0.6615384615384616
acellular structure aggregate,infection incidence rate,0.619811320754717
acellular structure aggregate,toxin disposition,0.5152173913043478
acellular structure aggregate,cidal agent disposition,0.5846153846153846
acellular structure aggregate,parasiticidal disposition,0.5796296296296296
acellular structure aggregate,acellular structure aggregate,0.95
acellular structure aggregate,transmissibility disposition,0.537719298245614
acellular structure aggregate,endotoxin disposition,0.53
acellular structure aggregate,infectious structure host role,0.7042372881355932
acellular structure aggregate,COVID-19 incidence rate,0.6230769230769231
acellular structure aggregate,cytotoxin disposition,0.55
acellular structure aggregate,acellular structure,0.8458333333333333
acellular structure aggregate,collective pathogenic disposition,0.6274193548387097
acellular structure aggregate,neurotoxin disposition,0.5676470588235294
acellular structure aggregate,coronavirus aggregate,0.73
acellular structure aggregate,infectious structure,0.6948979591836735
acellular structure aggregate,virus adhesion susceptible cell,0.6166666666666667
acellular structure aggregate,collective disposition,0.6068627450980393
acellular structure aggregate,static agent disposition,0.6009433962264151
acellular structure aggregate,T cell receptor complex,0.6615384615384616
acellular structure aggregate,infectious structure host,0.7092592592592593
acellular structure aggregate,respiratory system disease,0.65
acellular structure aggregate,infectious structure generative stage,0.7227272727272727
acellular structure aggregate,immunosuppressive disposition,0.5706896551724138
acellular structure aggregate,pathogenic disposition,0.5480392156862746
acellular structure aggregate,cell,0.5712121212121213
acellular structure aggregate,infectious disposition,0.5676470588235294
acellular structure aggregate,bacteriostatic disposition,0.6136363636363636
acellular structure aggregate,epitope site,0.5963414634146341
acellular structure aggregate,bactericidal disposition,0.5820754716981132
acellular structure aggregate,invasion disposition,0.5316326530612244
acellular structure aggregate,viricidal disposition,0.55
acellular structure aggregate,complex infection,0.5804347826086956
acellular structure aggregate,prion aggregate,0.7
acellular structure aggregate,pathogen portal of exit site,0.6078947368421053
acellular structure aggregate,disposition,0.5
acellular structure aggregate,COVID-19 mortality rate,0.6230769230769231
acellular structure aggregate,adhesion disposition,0.5520408163265306
acellular structure aggregate,pathogen portal of entry site,0.6051724137931035
acellular structure aggregate,viroid aggregate,0.6944444444444444
acellular structure aggregate,symptomatic infectious structure carrier,0.7108695652173913
acellular structure aggregate,site,0.5409090909090909
acellular structure aggregate,primary infectious disposition,0.5855932203389831
acellular structure aggregate,SARS-COV-2 adhesion susceptible cell,0.6192307692307693
acellular structure aggregate,virus synthesis stage,0.63
acellular structure aggregate,SARS-COV-2 adhesion disposition,0.5833333333333334
acellular structure aggregate,object aggregate,0.7388888888888888
acellular structure aggregate,invasive disposition,0.5520408163265306
acellular structure aggregate,fungicidal disposition,0.5480392156862746
acellular structure aggregate,acute respiratory distress syndrome,0.653125
acellular structure aggregate,exotoxin disposition,0.5316326530612244
acellular structure aggregate,immunoglobulin complex,0.5676470588235294
acellular structure aggregate,SARS-CoV-2 synthesis stage,0.6318181818181818
acellular structure aggregate,opportunistic infectious disposition,0.573076923076923
acellular structure aggregate,enterotoxin disposition,0.5653846153846154
acellular structure aggregate,polymerase chain reaction,0.6351851851851852
acellular structure aggregate,infectious disease incidence rate,0.6274193548387097
acellular structure aggregate,collective resistance disposition,0.6274193548387097
acellular structure aggregate,viral load,0.5525641025641026
acellular structure aggregate,fungistatic disposition,0.5653846153846154
acellular structure aggregate,establishment of a clinically abnormal colony,0.5716216216216217
acellular structure aggregate,cell space,0.6551282051282051
pathogenesis,pathogen generative stage,0.7472972972972972
pathogenesis,pathogen portal of entry,0.7
pathogenesis,primary pathogen,0.7357142857142857
pathogenesis,pathogen portal of exit,0.7357142857142857
pathogenesis,pathogenesis,0.95
pathogenesis,reservoir of pathogen role,0.6868421052631578
pathogenesis,pathogen portal of entry role,0.6695121951219513
pathogenesis,pathogen birth temporal region,0.6880952380952381
pathogenesis,opportunistic pathogen,0.6852941176470588
pathogenesis,genetic resistance to pathogen,0.6404761904761905
pathogenesis,droplet pathogen transmission process,0.6744897959183673
pathogenesis,pathogen transporter,0.73125
pathogenesis,pathogen vehicle,0.8071428571428573
pathogenesis,pathogen vector,0.7833333333333333
pathogenesis,pathogen vehicle role,0.7530303030303032
pathogenesis,pathogen death process boundary,0.7058139534883722
pathogenesis,T cell receptor complex,0.5642857142857143
pathogenesis,indirect pathogen transmission process,0.67
pathogenesis,immunity to pathogen,0.7
pathogenesis,pathogen host,0.81
pathogenesis,pathogen vector role,0.73125
pathogenesis,pathogen portal of exit site,0.725
pathogenesis,pathogen portal of entry site,0.7182926829268292
pathogenesis,SARS-CoV-2 pathogenesis,0.7928571428571428
pathogenesis,pathogen host role,0.75
pathogenesis,infectious pathogen transmissibility,0.6791666666666666
pathogenesis,pathogen surveillance,0.7530303030303032
pathogenesis,pathogen,0.85
pathogenesis,pathogen birth process boundary,0.7058139534883722
pathogenesis,infectious human pathogen,0.6662162162162162
pathogenesis,resistance to pathogen,0.6852941176470588
pathogenesis,pathogen portal of exit role,0.7
pathogenesis,re-emerging pathogen,0.7
pathogenesis,pathogen seroprevalence,0.7071428571428571
pathogenesis,contact pathogen transmission process,0.6744897959183673
pathogenesis,pathogen transporter role,0.6932432432432433
pathogenesis,coronavirus pathogenesis,0.7833333333333333
pathogenesis,establishment of a clinically abnormal colony,0.537719298245614
pathogenesis,horizontal pathogen transmission process,0.6615384615384616
pathogenesis,viral pathogenesis,0.85
pathogenesis,pathogen death temporal region,0.6880952380952381
pathogenesis,emerging pathogen,0.7258620689655172
pathogenesis,pathogen transmission process,0.7182926829268292
descriptive information content entity,extended organism,0.6136363636363636
descriptive information content entity,information content entity,0.85625
descriptive information content entity,infectious disease mortality rate,0.6330985915492958
descriptive information content entity,infection incidence rate profile,0.65
descriptive information content entity,infectious structure aggregate,0.6411764705882353
descriptive information content entity,communicability end temporal region,0.6143835616438357
descriptive information content entity,geographical entity,0.6780701754385965
descriptive information content entity,infection end temporal region,0.658955223880597
descriptive information content entity,drug-based immunosuppressed organism,0.6121621621621621
descriptive information content entity,SARS-CoV-2 incidence rate,0.6404761904761905
descriptive information content entity,incubation end temporal region,0.6558823529411765
descriptive information content entity,resistant entity,0.7092592592592593
descriptive information content entity,immunocompetent organism,0.6435483870967742
descriptive information content entity,virulence factor disposition,0.6318181818181818
descriptive information content entity,virus translation stage,0.630327868852459
descriptive information content entity,disease surveillance objective specification,0.6573170731707317
descriptive information content entity,case isolation control strategy,0.7253623188405797
descriptive information content entity,material entity,0.6575471698113208
descriptive information content entity,asymptomatic infectious structure carrier,0.6651898734177215
descriptive information content entity,architectual structure,0.6
descriptive information content entity,B cell receptor complex,0.6139344262295081
descriptive information content entity,infection incidence rate,0.6596774193548387
descriptive information content entity,entity,0.5863636363636363
descriptive information content entity,double-stranded RNA virus,0.6246031746031746
descriptive information content entity,lower respiratory tract disease,0.6384057971014493
descriptive information content entity,communicability end process boundary,0.6121621621621621
descriptive information content entity,directive information content entity,0.9094594594594595
descriptive information content entity,acellular structure aggregate,0.5992537313432835
descriptive information content entity,invasion factor,0.619811320754717
descriptive information content entity,latency end process boundary,0.6166666666666667
descriptive information content entity,realizable entity,0.6681818181818181
descriptive information content entity,pathologically immunosuppressed organism,0.6038461538461539
descriptive information content entity,negative-sense single-stranded RNA virus,0.6423076923076922
descriptive information content entity,infectious structure host role,0.6411764705882353
descriptive information content entity,COVID-19 incidence rate,0.630327868852459
descriptive information content entity,descriptive information content entity,0.95
descriptive information content entity,establishment of localization in human host,0.6722222222222223
descriptive information content entity,acellular structure,0.5728070175438597
descriptive information content entity,virulence factor,0.5981481481481481
descriptive information content entity,incubation end process boundary,0.6528985507246376
descriptive information content entity,molecular entity,0.6351851851851852
descriptive information content entity,immunosuppressed organism,0.5928571428571429
descriptive information content entity,plan specification,0.6285714285714286
descriptive information content entity,definitive host role,0.6741379310344828
descriptive information content entity,latency end temporal region,0.6038461538461539
descriptive information content entity,infectious structure,0.6224137931034482
descriptive information content entity,T cell receptor complex,0.6139344262295081
descriptive information content entity,infectious structure host,0.6404761904761905
descriptive information content entity,respiratory system disease,0.653125
descriptive information content entity,organism population,0.6078947368421053
descriptive information content entity,infectious structure generative stage,0.6633333333333334
descriptive information content entity,objective specification,0.6795081967213115
descriptive information content entity,susceptible organism,0.656896551724138
descriptive information content entity,generically dependent continuant,0.6642857142857143
descriptive information content entity,organism substance,0.5928571428571429
descriptive information content entity,anatomical entity,0.6681818181818181
descriptive information content entity,COVID-19 mortality rate,0.6139344262295081
descriptive information content entity,place closure control strategy,0.6558823529411765
descriptive information content entity,geopolitical entity,0.6780701754385965
descriptive information content entity,symptomatic infectious structure carrier,0.6679487179487179
descriptive information content entity,designative information content entity,0.9105263157894737
descriptive information content entity,object,0.5181818181818182
descriptive information content entity,immunodeficient organism,0.6274193548387097
descriptive information content entity,infectious human pathogen,0.6404761904761905
descriptive information content entity,colonization of human,0.6364406779661017
descriptive information content entity,specifically dependent continuant,0.6753521126760563
descriptive information content entity,immaterial entity,0.6681818181818181
descriptive information content entity,object aggregate,0.5981481481481481
descriptive information content entity,division of geopolitical entity,0.7108695652173913
descriptive information content entity,geographical feature,0.6051724137931035
descriptive information content entity,herd immunity to infectious organism,0.6527027027027027
descriptive information content entity,action specification,0.6396551724137931
descriptive information content entity,processed material,0.6107142857142857
descriptive information content entity,infectious disease control objective specification,0.6545454545454545
descriptive information content entity,quality,0.5388888888888889
descriptive information content entity,infectious disease incidence rate,0.6471830985915493
descriptive information content entity,single-stranded RNA retrovirus,0.6264705882352941
descriptive information content entity,viral load,0.575
descriptive information content entity,organism,0.558695652173913
descriptive information content entity,establishment of a clinically abnormal colony,0.6548192771084337
descriptive information content entity,positive-sense single-stranded RNA virus,0.6551282051282051
descriptive information content entity,adhesion factor,0.619811320754717
descriptive information content entity,definitive host,0.6386792452830189
descriptive information content entity,material processing,0.6078947368421053
deoxyribonucleic acid,ribonucleic acid,0.8824324324324324
deoxyribonucleic acid,infectious disease mortality rate,0.5981481481481481
deoxyribonucleic acid,infection incidence rate profile,0.6386792452830189
deoxyribonucleic acid,deoxyribonucleic acid,0.95
deoxyribonucleic acid,SARS-CoV-2 incidence rate,0.6239130434782608
deoxyribonucleic acid,B cell receptor complex,0.609090909090909
deoxyribonucleic acid,infection incidence rate,0.65
deoxyribonucleic acid,drug susceptibility,0.625
deoxyribonucleic acid,COVID-19 incidence rate,0.6318181818181818
deoxyribonucleic acid,nucleic acid,0.8136363636363637
deoxyribonucleic acid,resistance to drug,0.6294871794871795
deoxyribonucleic acid,T cell receptor complex,0.5863636363636363
deoxyribonucleic acid,COVID-19 mortality rate,0.609090909090909
deoxyribonucleic acid,infectious disease incidence rate,0.6166666666666667
deoxyribonucleic acid,establishment of a clinically abnormal colony,0.6015151515151516
deoxyribonucleic acid,drug susceptibility of infectious agent,0.6166666666666667
virulence factor disposition,virostatic disposition,0.79
virulence factor disposition,information content entity,0.6351851851851852
virulence factor disposition,zoonotic disposition,0.7416666666666667
virulence factor disposition,infectious disease mortality rate,0.6631147540983606
virulence factor disposition,infection incidence rate profile,0.65
virulence factor disposition,infectious structure aggregate,0.6051724137931035
virulence factor disposition,communicability end temporal region,0.6404761904761905
virulence factor disposition,geographical entity,0.598936170212766
virulence factor disposition,biological regulation,0.6336734693877552
virulence factor disposition,surveillance process,0.6583333333333334
virulence factor disposition,infection end temporal region,0.6780701754385965
virulence factor disposition,vector control strategy,0.6460784313725491
virulence factor disposition,SARS-CoV-2 incidence rate,0.619811320754717
virulence factor disposition,virulence,0.6932432432432433
virulence factor disposition,incubation end temporal region,0.6741379310344828
virulence factor disposition,resistant entity,0.609090909090909
virulence factor disposition,virulence factor disposition,0.95
virulence factor disposition,pathogen portal of exit,0.6264705882352941
virulence factor disposition,viral adhesion disposition,0.8018518518518519
virulence factor disposition,parasitostatic disposition,0.7462962962962962
virulence factor disposition,infectious disease incidence,0.7
virulence factor disposition,negative regulation of production,0.6795081967213115
virulence factor disposition,reverse zoonotic disposition,0.7535714285714286
virulence factor disposition,establishment of localization in host,0.65
virulence factor disposition,disease surveillance objective specification,0.6861111111111111
virulence factor disposition,case isolation control strategy,0.6194915254237288
virulence factor disposition,infectious agent host role,0.6537037037037037
virulence factor disposition,macromolecular complex,0.61
virulence factor disposition,material entity,0.6127906976744186
virulence factor disposition,asymptomatic infectious structure carrier,0.6094202898550725
virulence factor disposition,architectual structure,0.61
virulence factor disposition,quarantine control strategy,0.6318181818181818
virulence factor disposition,B cell receptor complex,0.6264705882352941
virulence factor disposition,passive immunization against infectious agent,0.6554794520547945
virulence factor disposition,infection incidence rate,0.6423076923076922
virulence factor disposition,colonized host,0.6166666666666667
virulence factor disposition,virus host,0.6605263157894737
virulence factor disposition,entity,0.5970588235294118
virulence factor disposition,toxin disposition,0.7611111111111112
virulence factor disposition,infectious disease incidence proportion,0.6888059701492537
virulence factor disposition,cidal agent disposition,0.7833333333333333
virulence factor disposition,biological vehicle,0.5804347826086956
virulence factor disposition,parasiticidal disposition,0.7330188679245283
virulence factor disposition,communicability end process boundary,0.6375
virulence factor disposition,directive information content entity,0.66875
virulence factor disposition,acellular structure aggregate,0.5903508771929825
virulence factor disposition,infection incidence proportion profile,0.6621212121212122
virulence factor disposition,infectious agent colony,0.6656862745098039
virulence factor disposition,SARS-CoV-2 incidence proportion,0.6872881355932203
virulence factor disposition,invasion factor,0.6825581395348838
virulence factor disposition,transmissibility disposition,0.7178571428571427
virulence factor disposition,latency end process boundary,0.6464285714285714
virulence factor disposition,colonization of host,0.6375
virulence factor disposition,infectious agent generative stage,0.6139344262295081
virulence factor disposition,realizable entity,0.6055555555555556
virulence factor disposition,endotoxin disposition,0.7765306122448979
virulence factor disposition,vector surveillance,0.6627659574468084
virulence factor disposition,negative regulation of establishment of localization,0.6625
virulence factor disposition,cidal agent,0.5782051282051281
virulence factor disposition,infectious structure host role,0.656896551724138
virulence factor disposition,pathogen vehicle,0.5636363636363636
virulence factor disposition,SARS-CoV-2 virulence,0.6375
virulence factor disposition,COVID-19 incidence rate,0.6264705882352941
virulence factor disposition,cytotoxin disposition,0.7561224489795919
virulence factor disposition,negative regulation of developmental process,0.6166666666666667
virulence factor disposition,pathogen vehicle role,0.5928571428571429
virulence factor disposition,host,0.54375
virulence factor disposition,asymptomatic infectious agent carrier,0.6192307692307693
virulence factor disposition,descriptive information content entity,0.6318181818181818
virulence factor disposition,negative regulation of replication,0.6758064516129032
virulence factor disposition,infection incidence,0.6627659574468084
virulence factor disposition,sterilizing immunity to infectious agent,0.6264705882352941
virulence factor disposition,establishment of localization in human host,0.6330985915492958
virulence factor disposition,acellular structure,0.598936170212766
virulence factor disposition,virulence factor,0.8136363636363637
virulence factor disposition,incubation end process boundary,0.6703389830508475
virulence factor disposition,collective pathogenic disposition,0.7778688524590163
virulence factor disposition,neurotoxin disposition,0.77
virulence factor disposition,dead-end host role,0.6021739130434782
virulence factor disposition,molecular entity,0.6318181818181818
virulence factor disposition,COVID-19 incidence,0.5804347826086956
virulence factor disposition,plan specification,0.6673913043478261
virulence factor disposition,definitive host role,0.6166666666666667
virulence factor disposition,latency end temporal region,0.6863636363636364
virulence factor disposition,innate immunity to infectious agent,0.6404761904761905
virulence factor disposition,infectious structure,0.6375
virulence factor disposition,collective disposition,0.77
virulence factor disposition,static agent disposition,0.7769230769230769
virulence factor disposition,T cell receptor complex,0.6264705882352941
virulence factor disposition,infectious structure host,0.6575471698113208
virulence factor disposition,infectious agent population,0.6863636363636364
virulence factor disposition,respiratory system disease,0.6537037037037037
virulence factor disposition,entry into host,0.6593023255813953
virulence factor disposition,leukocyte-mediated immunity to infectious agent,0.6366666666666667
virulence factor disposition,adhesion of symbiont to host,0.6285714285714286
virulence factor disposition,humoral immunity to infectious agent,0.6375
virulence factor disposition,infectious disease control strategy,0.6563492063492063
virulence factor disposition,infectious structure generative stage,0.6192307692307693
virulence factor disposition,immunosuppressive disposition,0.7482456140350877
virulence factor disposition,pathogenic disposition,0.75
virulence factor disposition,entry into host through host barriers,0.6192307692307693
virulence factor disposition,passive immunity to infectious agent,0.653125
virulence factor disposition,infectious disposition,0.81
virulence factor disposition,vaccination against infectious agent,0.66875
virulence factor disposition,susceptibility to infectious agent,0.6435483870967742
virulence factor disposition,bacteriostatic disposition,0.7462962962962962
virulence factor disposition,bactericidal disposition,0.7576923076923078
virulence factor disposition,pathogen host,0.6207317073170732
virulence factor disposition,invasion disposition,0.7833333333333333
virulence factor disposition,viricidal disposition,0.7969387755102041
virulence factor disposition,acquired immunity to infectious agent,0.65
virulence factor disposition,complex infection,0.65
virulence factor disposition,COVID-19 disease incidence proportion,0.6653846153846155
virulence factor disposition,biological vehicle role,0.6068627450980393
virulence factor disposition,infection incidence proportion,0.6913793103448276
virulence factor disposition,symptomatic infectious agent carrier,0.621875
virulence factor disposition,intermediate host,0.65
virulence factor disposition,pathogen portal of exit site,0.6285714285714286
virulence factor disposition,anatomical entity,0.6055555555555556
virulence factor disposition,disposition,0.732051282051282
virulence factor disposition,COVID-19 mortality rate,0.5872549019607843
virulence factor disposition,negative regulation of life-sustaining process,0.6391891891891892
virulence factor disposition,place closure control strategy,0.6396551724137931
virulence factor disposition,geopolitical entity,0.6202127659574468
virulence factor disposition,intervention,0.65
virulence factor disposition,adhesion disposition,0.7416666666666667
virulence factor disposition,infection incidence profile,0.65
virulence factor disposition,symptomatic infectious structure carrier,0.6117647058823529
virulence factor disposition,primary infectious disposition,0.7775862068965518
virulence factor disposition,pathogen host role,0.6239130434782608
virulence factor disposition,designative information content entity,0.6318181818181818
virulence factor disposition,intermediate host role,0.65
virulence factor disposition,dead-end host,0.5963414634146341
virulence factor disposition,pathogen surveillance,0.5928571428571429
virulence factor disposition,host role,0.5581081081081081
virulence factor disposition,SARS-CoV-2 incidence,0.5958333333333333
virulence factor disposition,establishment of localization in virus host,0.6471830985915493
virulence factor disposition,immunization against infectious agent,0.6653846153846155
virulence factor disposition,negative regulation of immune response,0.6469696969696969
virulence factor disposition,immaterial entity,0.6277777777777778
virulence factor disposition,SARS-COV-2 adhesion disposition,0.738135593220339
virulence factor disposition,pathogen portal of exit role,0.6285714285714286
virulence factor disposition,invasive disposition,0.7625
virulence factor disposition,infectious agent host,0.6540816326530612
virulence factor disposition,fungicidal disposition,0.77
virulence factor disposition,blood,0.5409090909090909
virulence factor disposition,acute respiratory distress syndrome,0.6563492063492063
virulence factor disposition,division of geopolitical entity,0.6533898305084747
virulence factor disposition,geographical feature,0.5958333333333333
virulence factor disposition,negative regulation of viral process,0.6375
virulence factor disposition,exotoxin disposition,0.7625
virulence factor disposition,infectious agent reservoir,0.6351851851851852
virulence factor disposition,immunoglobulin complex,0.61
virulence factor disposition,action specification,0.7
virulence factor disposition,infectious disease control objective specification,0.6679487179487179
virulence factor disposition,symbiont host role,0.6239130434782608
virulence factor disposition,opportunistic infectious disposition,0.778125
virulence factor disposition,negative regulation of biological process,0.6239130434782608
virulence factor disposition,enterotoxin disposition,0.7833333333333333
virulence factor disposition,infectious disease incidence rate,0.6795081967213115
virulence factor disposition,active immunization against infectious agent,0.6583333333333334
virulence factor disposition,collective resistance disposition,0.7614754098360657
virulence factor disposition,fungistatic disposition,0.7637254901960785
virulence factor disposition,infectious agent,0.6545454545454545
virulence factor disposition,establishment of a clinically abnormal colony,0.6280821917808219
virulence factor disposition,adhesion factor,0.6593023255813953
virulence factor disposition,definitive host,0.6127906976744186
virulence factor disposition,drug susceptibility of infectious agent,0.6291044776119403
virulence factor disposition,static agent,0.575
architectual structure,virostatic disposition,0.5863636363636363
architectual structure,zoonotic disposition,0.569047619047619
architectual structure,infectious disease mortality rate,0.65
architectual structure,infection incidence rate profile,0.6166666666666667
architectual structure,infectious structure aggregate,0.7384615384615384
architectual structure,SARS-CoV-2 incidence rate,0.6627659574468084
architectual structure,virulence factor disposition,0.61
architectual structure,viral adhesion disposition,0.575
architectual structure,parasitostatic disposition,0.6375
architectual structure,reverse zoonotic disposition,0.57
architectual structure,macromolecular complex,0.6545454545454545
architectual structure,asymptomatic infectious structure carrier,0.7198412698412698
architectual structure,architectual structure,0.95
architectual structure,B cell receptor complex,0.65
architectual structure,infection incidence rate,0.6239130434782608
architectual structure,toxin disposition,0.5525641025641026
architectual structure,cidal agent disposition,0.6055555555555556
architectual structure,parasiticidal disposition,0.6627659574468084
architectual structure,acellular structure aggregate,0.7441176470588234
architectual structure,transmissibility disposition,0.57
architectual structure,endotoxin disposition,0.5662790697674418
architectual structure,infectious structure host role,0.7384615384615384
architectual structure,COVID-19 incidence rate,0.6277777777777778
architectual structure,cytotoxin disposition,0.5895348837209302
architectual structure,acellular structure,0.8158536585365854
architectual structure,collective pathogenic disposition,0.5954545454545455
architectual structure,neurotoxin disposition,0.5636363636363636
architectual structure,infectious structure,0.8071428571428573
architectual structure,collective disposition,0.609090909090909
architectual structure,static agent disposition,0.6021739130434782
architectual structure,T cell receptor complex,0.65
architectual structure,infectious structure host,0.7691489361702127
architectual structure,respiratory system disease,0.5958333333333333
architectual structure,infectious structure generative stage,0.7042372881355932
architectual structure,immunosuppressive disposition,0.5676470588235294
architectual structure,pathogenic disposition,0.609090909090909
architectual structure,infectious disposition,0.6318181818181818
architectual structure,bacteriostatic disposition,0.6375
architectual structure,bactericidal disposition,0.6673913043478261
architectual structure,invasion disposition,0.569047619047619
architectual structure,viricidal disposition,0.636046511627907
architectual structure,complex infection,0.5782051282051281
architectual structure,disposition,0.5409090909090909
architectual structure,COVID-19 mortality rate,0.65
architectual structure,adhesion disposition,0.5928571428571429
architectual structure,symptomatic infectious structure carrier,0.7241935483870968
architectual structure,primary infectious disposition,0.6423076923076922
architectual structure,virus synthesis stage,0.6127906976744186
architectual structure,SARS-COV-2 adhesion disposition,0.6009433962264151
architectual structure,invasive disposition,0.5928571428571429
architectual structure,fungicidal disposition,0.609090909090909
architectual structure,acute respiratory distress syndrome,0.6429824561403508
architectual structure,exotoxin disposition,0.569047619047619
architectual structure,immunoglobulin complex,0.5863636363636363
architectual structure,SARS-CoV-2 synthesis stage,0.6375
architectual structure,opportunistic infectious disposition,0.6224137931034482
architectual structure,enterotoxin disposition,0.5833333333333334
architectual structure,polymerase chain reaction,0.6202127659574468
architectual structure,infectious disease incidence rate,0.6318181818181818
architectual structure,collective resistance disposition,0.6136363636363636
architectual structure,fungistatic disposition,0.5833333333333334
architectual structure,establishment of a clinically abnormal colony,0.5843283582089552
negative-sense single-stranded RNA virus,extended organism,0.6605263157894737
negative-sense single-stranded RNA virus,ribonucleic acid,0.575
negative-sense single-stranded RNA virus,virus aggregate,0.5772727272727273
negative-sense single-stranded RNA virus,source of infection,0.5855932203389831
negative-sense single-stranded RNA virus,virostatic disposition,0.5790322580645162
negative-sense single-stranded RNA virus,zoonotic disposition,0.5833333333333334
negative-sense single-stranded RNA virus,immune response,0.5954545454545455
negative-sense single-stranded RNA virus,infectious disease mortality rate,0.6554794520547945
negative-sense single-stranded RNA virus,infection incidence rate profile,0.6722222222222223
negative-sense single-stranded RNA virus,communicability end temporal region,0.61
negative-sense single-stranded RNA virus,pathogen generative stage,0.65
negative-sense single-stranded RNA virus,pathogen portal of entry,0.60625
negative-sense single-stranded RNA virus,subclinical coronavirus infection,0.6280821917808219
negative-sense single-stranded RNA virus,primary pathogen,0.5392857142857143
negative-sense single-stranded RNA virus,infection end temporal region,0.6528985507246376
negative-sense single-stranded RNA virus,deoxyribonucleic acid,0.5811475409836065
negative-sense single-stranded RNA virus,drug-based immunosuppressed organism,0.6605263157894737
negative-sense single-stranded RNA virus,infectious disease,0.6396551724137931
negative-sense single-stranded RNA virus,double-stranded DNA virus,0.7576923076923078
negative-sense single-stranded RNA virus,incubation end temporal region,0.65
negative-sense single-stranded RNA virus,site of infection,0.5903508771929825
negative-sense single-stranded RNA virus,immunocompetent organism,0.621875
negative-sense single-stranded RNA virus,virulence factor disposition,0.6117647058823529
negative-sense single-stranded RNA virus,pathogen portal of exit,0.6087301587301588
negative-sense single-stranded RNA virus,viral adhesion disposition,0.6015151515151516
negative-sense single-stranded RNA virus,parasitostatic disposition,0.5863636363636363
negative-sense single-stranded RNA virus,infectious disease incidence,0.6558823529411765
negative-sense single-stranded RNA virus,reservoir of pathogen role,0.6015151515151516
negative-sense single-stranded RNA virus,negative regulation of production,0.682876712328767
negative-sense single-stranded RNA virus,reverse zoonotic disposition,0.6117647058823529
negative-sense single-stranded RNA virus,subclinical SARS-CoV-2 infection,0.5888888888888889
negative-sense single-stranded RNA virus,virus translation stage,0.6087301587301588
negative-sense single-stranded RNA virus,disease surveillance objective specification,0.6285714285714286
negative-sense single-stranded RNA virus,virus release stage,0.6194915254237288
negative-sense single-stranded RNA virus,source of infection site,0.60625
negative-sense single-stranded RNA virus,virus,0.5611111111111111
negative-sense single-stranded RNA virus,virus replication,0.5728070175438597
negative-sense single-stranded RNA virus,B cell receptor complex,0.5452380952380953
negative-sense single-stranded RNA virus,systematic infection,0.6166666666666667
negative-sense single-stranded RNA virus,infection incidence rate,0.66875
negative-sense single-stranded RNA virus,virus host,0.55
negative-sense single-stranded RNA virus,double-stranded RNA virus,0.7730769230769231
negative-sense single-stranded RNA virus,pathogen portal of entry role,0.6094202898550725
negative-sense single-stranded RNA virus,virus transcription stage,0.6192307692307693
negative-sense single-stranded RNA virus,infectious disease lifetime prevalence,0.6551282051282051
negative-sense single-stranded RNA virus,toxin disposition,0.5903508771929825
negative-sense single-stranded RNA virus,pathogen birth temporal region,0.6214285714285714
negative-sense single-stranded RNA virus,lower respiratory tract disease,0.6190140845070422
negative-sense single-stranded RNA virus,infectious disease incidence proportion,0.6651898734177215
negative-sense single-stranded RNA virus,opportunistic pathogen,0.5790322580645162
negative-sense single-stranded RNA virus,virus generative stage,0.6435483870967742
negative-sense single-stranded RNA virus,acute infectious disease course,0.6471830985915493
negative-sense single-stranded RNA virus,cidal agent disposition,0.5769841269841269
negative-sense single-stranded RNA virus,infectious disorder,0.6533898305084747
negative-sense single-stranded RNA virus,genetic resistance to pathogen,0.65
negative-sense single-stranded RNA virus,subclinical infection,0.5811475409836065
negative-sense single-stranded RNA virus,appearance of disorder,0.6274193548387097
negative-sense single-stranded RNA virus,simple infection,0.5928571428571429
negative-sense single-stranded RNA virus,droplet pathogen transmission process,0.6318181818181818
negative-sense single-stranded RNA virus,parasiticidal disposition,0.5884615384615385
negative-sense single-stranded RNA virus,infectious disease sporadicity,0.65
negative-sense single-stranded RNA virus,communicability end process boundary,0.6078947368421053
negative-sense single-stranded RNA virus,infection incidence proportion profile,0.6551282051282051
negative-sense single-stranded RNA virus,pathogen transporter,0.6333333333333333
negative-sense single-stranded RNA virus,transmissibility disposition,0.5970588235294118
negative-sense single-stranded RNA virus,latency end process boundary,0.6411764705882353
negative-sense single-stranded RNA virus,infectious disease epidemic,0.6440298507462687
negative-sense single-stranded RNA virus,disease transmission model,0.6318181818181818
negative-sense single-stranded RNA virus,endotoxin disposition,0.5975409836065574
negative-sense single-stranded RNA virus,negative regulation of establishment of localization,0.6565217391304347
negative-sense single-stranded RNA virus,pathologically immunosuppressed organism,0.6375
negative-sense single-stranded RNA virus,negative-sense single-stranded RNA virus,0.95
negative-sense single-stranded RNA virus,pathogen vehicle,0.5928571428571429
negative-sense single-stranded RNA virus,cytotoxin disposition,0.5811475409836065
negative-sense single-stranded RNA virus,community-acquired infection,0.5970588235294118
negative-sense single-stranded RNA virus,pathogen vector,0.5954545454545455
negative-sense single-stranded RNA virus,negative regulation of developmental process,0.6880952380952381
negative-sense single-stranded RNA virus,pathogen vehicle role,0.6139344262295081
negative-sense single-stranded RNA virus,chronic infectious disease course,0.6280821917808219
negative-sense single-stranded RNA virus,nursing-home acquired infection,0.6190140845070422
negative-sense single-stranded RNA virus,COVID-19 epidemic,0.5728070175438597
negative-sense single-stranded RNA virus,negative regulation of replication,0.6797297297297297
negative-sense single-stranded RNA virus,secondary infection,0.6025423728813559
negative-sense single-stranded RNA virus,nucleic acid,0.5653846153846154
negative-sense single-stranded RNA virus,infection start temporal region,0.6471830985915493
negative-sense single-stranded RNA virus,infection incidence,0.6364406779661017
negative-sense single-stranded RNA virus,virus disorder,0.6166666666666667
negative-sense single-stranded RNA virus,primary infection,0.5728070175438597
negative-sense single-stranded RNA virus,process of establishing an infection,0.6210526315789474
negative-sense single-stranded RNA virus,incubation end process boundary,0.6471830985915493
negative-sense single-stranded RNA virus,SARS-CoV-2 disorder,0.6194915254237288
negative-sense single-stranded RNA virus,collective pathogenic disposition,0.6143835616438357
negative-sense single-stranded RNA virus,neurotoxin disposition,0.6112903225806451
negative-sense single-stranded RNA virus,pathogen death process boundary,0.6330985915492958
negative-sense single-stranded RNA virus,immunosuppressed organism,0.65
negative-sense single-stranded RNA virus,latency end temporal region,0.6440298507462687
negative-sense single-stranded RNA virus,virus adhesion susceptible cell,0.5908450704225352
negative-sense single-stranded RNA virus,collective disposition,0.6112903225806451
negative-sense single-stranded RNA virus,infection,0.5520408163265306
negative-sense single-stranded RNA virus,static agent disposition,0.60625
negative-sense single-stranded RNA virus,T cell receptor complex,0.5611111111111111
negative-sense single-stranded RNA virus,respiratory system disease,0.6318181818181818
negative-sense single-stranded RNA virus,indirect pathogen transmission process,0.6423076923076922
negative-sense single-stranded RNA virus,organism population,0.5855932203389831
negative-sense single-stranded RNA virus,infectious disease control strategy,0.6633333333333334
negative-sense single-stranded RNA virus,infectious disease pandemic,0.658955223880597
negative-sense single-stranded RNA virus,immunosuppressive disposition,0.5949275362318841
negative-sense single-stranded RNA virus,innate immune response,0.6435483870967742
negative-sense single-stranded RNA virus,pathogenic disposition,0.5951612903225807
negative-sense single-stranded RNA virus,viral disease course,0.6166666666666667
negative-sense single-stranded RNA virus,intracellular infection,0.5928571428571429
negative-sense single-stranded RNA virus,secondary infection role,0.621875
negative-sense single-stranded RNA virus,metastatic infection,0.6166666666666667
negative-sense single-stranded RNA virus,infectious disposition,0.6112903225806451
negative-sense single-stranded RNA virus,acute infection,0.6136363636363636
negative-sense single-stranded RNA virus,bacteriostatic disposition,0.6015151515151516
negative-sense single-stranded RNA virus,immunity to pathogen,0.5666666666666667
negative-sense single-stranded RNA virus,bactericidal disposition,0.590625
negative-sense single-stranded RNA virus,source of infection role,0.60625
negative-sense single-stranded RNA virus,pathogen host,0.5820754716981132
negative-sense single-stranded RNA virus,acquired immunodeficiency,0.5884615384615385
negative-sense single-stranded RNA virus,chronic infection,0.5903508771929825
negative-sense single-stranded RNA virus,invasion disposition,0.6
negative-sense single-stranded RNA virus,disease course,0.5981481481481481
negative-sense single-stranded RNA virus,infectious disease course,0.65
negative-sense single-stranded RNA virus,viricidal disposition,0.5811475409836065
negative-sense single-stranded RNA virus,acquired immunity to infectious agent,0.6058441558441559
negative-sense single-stranded RNA virus,complex infection,0.5728070175438597
negative-sense single-stranded RNA virus,COVID-19 disease incidence proportion,0.6448051948051949
negative-sense single-stranded RNA virus,coronavirus disease course,0.6318181818181818
negative-sense single-stranded RNA virus,infection incidence proportion,0.65
negative-sense single-stranded RNA virus,respiratory droplet virus fomite,0.6305555555555555
negative-sense single-stranded RNA virus,susceptible organism,0.6333333333333333
negative-sense single-stranded RNA virus,pathogen vector role,0.6166666666666667
negative-sense single-stranded RNA virus,pathogen portal of exit site,0.6117647058823529
negative-sense single-stranded RNA virus,infectious disease prevalence,0.6384057971014493
negative-sense single-stranded RNA virus,organism substance,0.6396551724137931
negative-sense single-stranded RNA virus,disposition,0.5676470588235294
negative-sense single-stranded RNA virus,single-stranded DNA virus,0.8192307692307693
negative-sense single-stranded RNA virus,negative regulation of life-sustaining process,0.7058139534883722
negative-sense single-stranded RNA virus,viral disease,0.6009433962264151
negative-sense single-stranded RNA virus,primary infection role,0.5951612903225807
negative-sense single-stranded RNA virus,adhesion disposition,0.6
negative-sense single-stranded RNA virus,pathogen portal of entry site,0.6094202898550725
negative-sense single-stranded RNA virus,infection incidence profile,0.658955223880597
negative-sense single-stranded RNA virus,disease,0.5563829787234043
negative-sense single-stranded RNA virus,primary infectious disposition,0.5928571428571429
negative-sense single-stranded RNA virus,pathogen host role,0.6051724137931035
negative-sense single-stranded RNA virus,infection prevalence,0.6166666666666667
negative-sense single-stranded RNA virus,humoral immune response,0.5928571428571429
negative-sense single-stranded RNA virus,coronavirus disorder,0.6333333333333333
negative-sense single-stranded RNA virus,infectious pathogen transmissibility,0.6342105263157894
negative-sense single-stranded RNA virus,pathogen surveillance,0.630327868852459
negative-sense single-stranded RNA virus,immunodeficient organism,0.621875
negative-sense single-stranded RNA virus,pathogen,0.5541666666666667
negative-sense single-stranded RNA virus,pathogen birth process boundary,0.6330985915492958
negative-sense single-stranded RNA virus,infectious human pathogen,0.6038461538461539
negative-sense single-stranded RNA virus,subclinical virus infection,0.5992537313432835
negative-sense single-stranded RNA virus,resistance to pathogen,0.6112903225806451
negative-sense single-stranded RNA virus,establishment of localization in virus host,0.6668674698795181
negative-sense single-stranded RNA virus,virus attachment stage,0.5951612903225807
negative-sense single-stranded RNA virus,negative regulation of immune response,0.6807692307692308
negative-sense single-stranded RNA virus,virus synthesis stage,0.6139344262295081
negative-sense single-stranded RNA virus,SARS-COV-2 adhesion disposition,0.6049295774647887
negative-sense single-stranded RNA virus,pathogen portal of exit role,0.6117647058823529
negative-sense single-stranded RNA virus,invasive disposition,0.6166666666666667
negative-sense single-stranded RNA virus,re-emerging pathogen,0.6166666666666667
negative-sense single-stranded RNA virus,long-term non-progressing infectious disease course,0.6587912087912088
negative-sense single-stranded RNA virus,viral disease epidemic,0.6274193548387097
negative-sense single-stranded RNA virus,fungicidal disposition,0.5951612903225807
negative-sense single-stranded RNA virus,viral disease pandemic,0.6435483870967742
negative-sense single-stranded RNA virus,virus penetration stage,0.6246031746031746
negative-sense single-stranded RNA virus,pathogen seroprevalence,0.6246031746031746
negative-sense single-stranded RNA virus,acute respiratory distress syndrome,0.6366666666666667
negative-sense single-stranded RNA virus,infectious disease endemicity,0.6528985507246376
negative-sense single-stranded RNA virus,negative regulation of viral process,0.7
negative-sense single-stranded RNA virus,contact pathogen transmission process,0.6318181818181818
negative-sense single-stranded RNA virus,disorder,0.575
negative-sense single-stranded RNA virus,herd immunity to infectious organism,0.6210526315789474
negative-sense single-stranded RNA virus,extracellular infection,0.5928571428571429
negative-sense single-stranded RNA virus,pathogen transporter role,0.65
negative-sense single-stranded RNA virus,transmission interval,0.630327868852459
negative-sense single-stranded RNA virus,exotoxin disposition,0.6
negative-sense single-stranded RNA virus,infection start process boundary,0.6444444444444444
negative-sense single-stranded RNA virus,infectious disease control objective specification,0.6388888888888888
negative-sense single-stranded RNA virus,immune population,0.5728070175438597
negative-sense single-stranded RNA virus,opportunistic infectious disposition,0.5947368421052631
negative-sense single-stranded RNA virus,process of establishing viral infection,0.6272151898734176
negative-sense single-stranded RNA virus,negative regulation of biological process,0.6722222222222223
negative-sense single-stranded RNA virus,enterotoxin disposition,0.6087301587301588
negative-sense single-stranded RNA virus,COVID-19 disease course,0.6087301587301588
negative-sense single-stranded RNA virus,infectious disease incidence rate,0.682876712328767
negative-sense single-stranded RNA virus,single-stranded RNA retrovirus,0.8071428571428573
negative-sense single-stranded RNA virus,disordered virus,0.6642857142857143
negative-sense single-stranded RNA virus,collective resistance disposition,0.6691780821917809
negative-sense single-stranded RNA virus,adaptive immune response,0.653125
negative-sense single-stranded RNA virus,fungistatic disposition,0.6087301587301588
negative-sense single-stranded RNA virus,organism,0.5541666666666667
negative-sense single-stranded RNA virus,virus uncoating stage,0.6139344262295081
negative-sense single-stranded RNA virus,local infection,0.5772727272727273
negative-sense single-stranded RNA virus,establishment of a clinically abnormal colony,0.6264705882352941
negative-sense single-stranded RNA virus,coronavirus disease,0.6194915254237288
negative-sense single-stranded RNA virus,positive-sense single-stranded RNA virus,0.9
negative-sense single-stranded RNA virus,horizontal pathogen transmission process,0.625
negative-sense single-stranded RNA virus,hospital-acquired infection,0.5992537313432835
negative-sense single-stranded RNA virus,pathogen death temporal region,0.6214285714285714
negative-sense single-stranded RNA virus,emerging pathogen,0.5903508771929825
negative-sense single-stranded RNA virus,pathogen transmission process,0.6384057971014493
bactericidal,B cell receptor complex,0.6214285714285714
bactericidal,cidal agent disposition,0.5928571428571429
bactericidal,cidal agent,0.6673913043478261
bactericidal,antibiotic resistance,0.6318181818181818
bactericidal,sterilizing immunity to infectious agent,0.5846153846153846
bactericidal,bactericidal,0.95
bactericidal,T cell receptor complex,0.5928571428571429
bactericidal,bactericidal disposition,0.7833333333333333
bactericidal,establishment of a clinically abnormal colony,0.5728070175438597
bactericidal,bacteria,0.85
immunosuppressive disposition,virostatic disposition,0.7637254901960785
immunosuppressive disposition,information content entity,0.6136363636363636
immunosuppressive disposition,zoonotic disposition,0.7561224489795919
immunosuppressive disposition,infectious disease mortality rate,0.6435483870967742
immunosuppressive disposition,infection incidence rate profile,0.5975409836065574
immunosuppressive disposition,infectious structure aggregate,0.6025423728813559
immunosuppressive disposition,communicability end temporal region,0.6375
immunosuppressive disposition,geographical entity,0.575
immunosuppressive disposition,biological regulation,0.61
immunosuppressive disposition,surveillance process,0.6540816326530612
immunosuppressive disposition,infection end temporal region,0.6396551724137931
immunosuppressive disposition,vector control strategy,0.5653846153846154
immunosuppressive disposition,SARS-CoV-2 incidence rate,0.5981481481481481
immunosuppressive disposition,incubation end temporal region,0.6364406779661017
immunosuppressive disposition,resistant entity,0.6055555555555556
immunosuppressive disposition,virulence factor disposition,0.7482456140350877
immunosuppressive disposition,viral adhesion disposition,0.759090909090909
immunosuppressive disposition,parasitostatic disposition,0.759090909090909
immunosuppressive disposition,negative regulation of production,0.6596774193548387
immunosuppressive disposition,reverse zoonotic disposition,0.730701754385965
immunosuppressive disposition,establishment of localization in host,0.6166666666666667
immunosuppressive disposition,disease surveillance objective specification,0.6691780821917809
immunosuppressive disposition,case isolation control strategy,0.6166666666666667
immunosuppressive disposition,infectious agent host role,0.65
immunosuppressive disposition,macromolecular complex,0.5872549019607843
immunosuppressive disposition,material entity,0.5863636363636363
immunosuppressive disposition,asymptomatic infectious structure carrier,0.5928571428571429
immunosuppressive disposition,architectual structure,0.5676470588235294
immunosuppressive disposition,quarantine control strategy,0.5928571428571429
immunosuppressive disposition,B cell receptor complex,0.5653846153846154
immunosuppressive disposition,infection incidence rate,0.6009433962264151
immunosuppressive disposition,colonized host,0.6127906976744186
immunosuppressive disposition,virus host,0.6294871794871795
immunosuppressive disposition,entity,0.5357142857142857
immunosuppressive disposition,toxin disposition,0.7543478260869566
immunosuppressive disposition,cidal agent disposition,0.7192307692307692
immunosuppressive disposition,parasiticidal disposition,0.7462962962962962
immunosuppressive disposition,communicability end process boundary,0.6346153846153847
immunosuppressive disposition,directive information content entity,0.65
immunosuppressive disposition,acellular structure aggregate,0.5706896551724138
immunosuppressive disposition,transmissibility disposition,0.7482456140350877
immunosuppressive disposition,latency end process boundary,0.6078947368421053
immunosuppressive disposition,colonization of host,0.5928571428571429
immunosuppressive disposition,realizable entity,0.6021739130434782
immunosuppressive disposition,endotoxin disposition,0.75
immunosuppressive disposition,vector surveillance,0.6166666666666667
immunosuppressive disposition,negative regulation of establishment of localization,0.6351851851851852
immunosuppressive disposition,infectious structure host role,0.6533898305084747
immunosuppressive disposition,COVID-19 incidence rate,0.5653846153846154
immunosuppressive disposition,cytotoxin disposition,0.73
immunosuppressive disposition,negative regulation of developmental process,0.6006849315068493
immunosuppressive disposition,host,0.5409090909090909
immunosuppressive disposition,descriptive information content entity,0.6291044776119403
immunosuppressive disposition,negative regulation of replication,0.6563492063492063
immunosuppressive disposition,establishment of localization in human host,0.6027777777777777
immunosuppressive disposition,acellular structure,0.5541666666666667
immunosuppressive disposition,incubation end process boundary,0.6333333333333333
immunosuppressive disposition,collective pathogenic disposition,0.7241935483870968
immunosuppressive disposition,neurotoxin disposition,0.7637254901960785
immunosuppressive disposition,dead-end host role,0.598936170212766
immunosuppressive disposition,molecular entity,0.6055555555555556
immunosuppressive disposition,plan specification,0.6627659574468084
immunosuppressive disposition,definitive host role,0.6540816326530612
immunosuppressive disposition,latency end temporal region,0.5928571428571429
immunosuppressive disposition,infectious structure,0.6132653061224489
immunosuppressive disposition,collective disposition,0.7833333333333333
immunosuppressive disposition,static agent disposition,0.7330188679245283
immunosuppressive disposition,T cell receptor complex,0.5653846153846154
immunosuppressive disposition,infectious structure host,0.6537037037037037
immunosuppressive disposition,respiratory system disease,0.65
immunosuppressive disposition,entry into host,0.609090909090909
immunosuppressive disposition,adhesion of symbiont to host,0.6078947368421053
immunosuppressive disposition,infectious disease control strategy,0.6375
immunosuppressive disposition,infectious structure generative stage,0.6469696969696969
immunosuppressive disposition,immunosuppressive disposition,0.95
immunosuppressive disposition,pathogenic disposition,0.7441176470588234
immunosuppressive disposition,entry into host through host barriers,0.6015151515151516
immunosuppressive disposition,infectious disposition,0.7833333333333333
immunosuppressive disposition,bacteriostatic disposition,0.740909090909091
immunosuppressive disposition,bactericidal disposition,0.7141509433962264
immunosuppressive disposition,pathogen host,0.5928571428571429
immunosuppressive disposition,invasion disposition,0.7765306122448979
immunosuppressive disposition,viricidal disposition,0.75
immunosuppressive disposition,complex infection,0.6456521739130434
immunosuppressive disposition,intermediate host,0.6673913043478261
immunosuppressive disposition,anatomical entity,0.5804347826086956
immunosuppressive disposition,disposition,0.725
immunosuppressive disposition,COVID-19 mortality rate,0.5846153846153846
immunosuppressive disposition,negative regulation of life-sustaining process,0.61
immunosuppressive disposition,place closure control strategy,0.6025423728813559
immunosuppressive disposition,geopolitical entity,0.5958333333333333
immunosuppressive disposition,adhesion disposition,0.7561224489795919
immunosuppressive disposition,symptomatic infectious structure carrier,0.5949275362318841
immunosuppressive disposition,primary infectious disposition,0.7550847457627118
immunosuppressive disposition,pathogen host role,0.598936170212766
immunosuppressive disposition,designative information content entity,0.6291044776119403
immunosuppressive disposition,intermediate host role,0.6656862745098039
immunosuppressive disposition,dead-end host,0.5928571428571429
immunosuppressive disposition,pathogen surveillance,0.61
immunosuppressive disposition,host role,0.5552631578947369
immunosuppressive disposition,establishment of localization in virus host,0.6027777777777777
immunosuppressive disposition,negative regulation of immune response,0.6141791044776119
immunosuppressive disposition,immaterial entity,0.6239130434782608
immunosuppressive disposition,SARS-COV-2 adhesion disposition,0.7333333333333333
immunosuppressive disposition,invasive disposition,0.8173469387755102
immunosuppressive disposition,infectious agent host,0.65
immunosuppressive disposition,fungicidal disposition,0.7441176470588234
immunosuppressive disposition,division of geopolitical entity,0.6166666666666667
immunosuppressive disposition,negative regulation of viral process,0.6038461538461539
immunosuppressive disposition,exotoxin disposition,0.7357142857142857
immunosuppressive disposition,immunoglobulin complex,0.6460784313725491
immunosuppressive disposition,infectious disease control objective specification,0.6651898734177215
immunosuppressive disposition,symbiont host role,0.598936170212766
immunosuppressive disposition,opportunistic infectious disposition,0.7423076923076922
immunosuppressive disposition,negative regulation of biological process,0.6071428571428572
immunosuppressive disposition,enterotoxin disposition,0.7384615384615384
immunosuppressive disposition,infectious disease incidence rate,0.6596774193548387
immunosuppressive disposition,collective resistance disposition,0.7403225806451613
immunosuppressive disposition,fungistatic disposition,0.7576923076923078
immunosuppressive disposition,establishment of a clinically abnormal colony,0.5851351351351352
immunosuppressive disposition,definitive host,0.6545454545454545
eukaryota,eukaryota,0.95
eukaryota,T cell receptor complex,0.54375
eukaryota,establishment of a clinically abnormal colony,0.5425925925925926
viral capsid,viral adhesion disposition,0.7131578947368421
viral capsid,B cell receptor complex,0.5642857142857143
viral capsid,viral plaque assay,0.7166666666666667
viral capsid,T cell receptor complex,0.5642857142857143
viral capsid,viral disease course,0.7
viral capsid,viral envelope,0.7192307692307692
viral capsid,viral capsid,0.95
viral capsid,viral disease,0.77
viral capsid,viral disease epidemic,0.7441176470588234
viral capsid,viral disease pandemic,0.7147058823529412
viral capsid,negative regulation of viral process,0.6166666666666667
viral capsid,process of establishing viral infection,0.6068627450980393
viral capsid,viral load,0.8136363636363637
viral capsid,establishment of a clinically abnormal colony,0.5552631578947369
viral capsid,viral pathogenesis,0.75
capsomere,capsomere,0.95
capsomere,establishment of a clinically abnormal colony,0.5425925925925926
negative regulation of biological process,virostatic disposition,0.6087301587301588
negative regulation of biological process,zoonotic disposition,0.5975409836065574
negative regulation of biological process,immune response,0.5928571428571429
negative regulation of biological process,infectious disease mortality rate,0.6391891891891892
negative regulation of biological process,infection incidence rate profile,0.6691780821917809
negative regulation of biological process,communicability end temporal region,0.6210526315789474
negative regulation of biological process,pathogen generative stage,0.6166666666666667
negative regulation of biological process,biological regulation,0.6596774193548387
negative regulation of biological process,primary pathogen,0.5728070175438597
negative regulation of biological process,surveillance process,0.6795081967213115
negative regulation of biological process,infection end temporal region,0.65
negative regulation of biological process,geospatial location,0.6333333333333333
negative regulation of biological process,vector control strategy,0.621875
negative regulation of biological process,SARS-CoV-2 incidence rate,0.6015151515151516
negative regulation of biological process,incubation end temporal region,0.6612676056338028
negative regulation of biological process,site of infection,0.6051724137931035
negative regulation of biological process,virulence factor disposition,0.6239130434782608
negative regulation of biological process,viral adhesion disposition,0.6291044776119403
negative regulation of biological process,parasitostatic disposition,0.6141791044776119
negative regulation of biological process,negative regulation of production,0.8148648648648649
negative regulation of biological process,reverse zoonotic disposition,0.6673913043478261
negative regulation of biological process,virus translation stage,0.6375
negative regulation of biological process,disease surveillance objective specification,0.65
negative regulation of biological process,case isolation control strategy,0.6722222222222223
negative regulation of biological process,virus release stage,0.6
negative regulation of biological process,source of infection site,0.6038461538461539
negative regulation of biological process,quarantine control strategy,0.6411764705882353
negative regulation of biological process,B cell receptor complex,0.60625
negative regulation of biological process,infection incidence rate,0.65
negative regulation of biological process,double-stranded RNA virus,0.6015151515151516
negative regulation of biological process,virus transcription stage,0.6166666666666667
negative regulation of biological process,toxin disposition,0.5879310344827586
negative regulation of biological process,lower respiratory tract disease,0.6166666666666667
negative regulation of biological process,virus generative stage,0.6246031746031746
negative regulation of biological process,acute infectious disease course,0.6444444444444444
negative regulation of biological process,cidal agent disposition,0.590625
negative regulation of biological process,process,0.5958333333333333
negative regulation of biological process,biological vehicle,0.6703389830508475
negative regulation of biological process,droplet pathogen transmission process,0.6807692307692308
negative regulation of biological process,parasiticidal disposition,0.6318181818181818
negative regulation of biological process,communicability end process boundary,0.6448051948051949
negative regulation of biological process,transmissibility disposition,0.6239130434782608
negative regulation of biological process,latency end process boundary,0.6528985507246376
negative regulation of biological process,infectious agent generative stage,0.6256756756756756
negative regulation of biological process,endotoxin disposition,0.5951612903225807
negative regulation of biological process,vector surveillance,0.6166666666666667
negative regulation of biological process,negative regulation of establishment of localization,0.7940860215053763
negative regulation of biological process,negative-sense single-stranded RNA virus,0.6722222222222223
negative regulation of biological process,COVID-19 incidence rate,0.590625
negative regulation of biological process,cytotoxin disposition,0.5951612903225807
negative regulation of biological process,negative regulation of developmental process,0.8617647058823529
negative regulation of biological process,chronic infectious disease course,0.6256756756756756
negative regulation of biological process,negative regulation of replication,0.8233333333333335
negative regulation of biological process,primary infection,0.5706896551724138
negative regulation of biological process,process of establishing an infection,0.6058441558441559
negative regulation of biological process,incubation end process boundary,0.6722222222222223
negative regulation of biological process,collective pathogenic disposition,0.6662162162162162
negative regulation of biological process,neurotoxin disposition,0.6246031746031746
negative regulation of biological process,SARS-CoV-2 uncoating stage,0.6141791044776119
negative regulation of biological process,pathogen death process boundary,0.6583333333333334
negative regulation of biological process,plan specification,0.6025423728813559
negative regulation of biological process,latency end temporal region,0.6411764705882353
negative regulation of biological process,innate immunity to infectious agent,0.6342105263157894
negative regulation of biological process,SARS-CoV-2 penetration stage,0.6239130434782608
negative regulation of biological process,virus adhesion susceptible cell,0.6305555555555555
negative regulation of biological process,anatomical space,0.6605263157894737
negative regulation of biological process,collective disposition,0.6246031746031746
negative regulation of biological process,static agent disposition,0.6192307692307693
negative regulation of biological process,T cell receptor complex,0.621875
negative regulation of biological process,respiratory system disease,0.6141791044776119
negative regulation of biological process,biological vector,0.656896551724138
negative regulation of biological process,indirect pathogen transmission process,0.690506329113924
negative regulation of biological process,planned process,0.6464285714285714
negative regulation of biological process,generative stage,0.6429824561403508
negative regulation of biological process,infectious disease control strategy,0.6342105263157894
negative regulation of biological process,SARS-CoV-2 attachment stage,0.5823529411764706
negative regulation of biological process,infectious structure generative stage,0.6294871794871795
negative regulation of biological process,immunosuppressive disposition,0.6071428571428572
negative regulation of biological process,innate immune response,0.6404761904761905
negative regulation of biological process,pathogenic disposition,0.6087301587301588
negative regulation of biological process,viral disease course,0.5975409836065574
negative regulation of biological process,cell,0.5166666666666666
negative regulation of biological process,infectious disposition,0.6087301587301588
negative regulation of biological process,bacteriostatic disposition,0.6291044776119403
negative regulation of biological process,epitope site,0.5820754716981132
negative regulation of biological process,bactericidal disposition,0.6346153846153847
negative regulation of biological process,invasion disposition,0.630327868852459
negative regulation of biological process,disease course,0.5772727272727273
negative regulation of biological process,infectious disease course,0.6166666666666667
negative regulation of biological process,viricidal disposition,0.6112903225806451
negative regulation of biological process,coronavirus disease course,0.6141791044776119
negative regulation of biological process,biological vehicle role,0.66875
negative regulation of biological process,pathogen portal of exit site,0.6384057971014493
negative regulation of biological process,anatomical entity,0.6224137931034482
negative regulation of biological process,SARS-CoV-2 genome replication stage,0.6473684210526315
negative regulation of biological process,disposition,0.5461538461538461
negative regulation of biological process,COVID-19 mortality rate,0.590625
negative regulation of biological process,process profile,0.5928571428571429
negative regulation of biological process,negative regulation of life-sustaining process,0.8408045977011495
negative regulation of biological process,place closure control strategy,0.6190140845070422
negative regulation of biological process,primary infection role,0.6246031746031746
negative regulation of biological process,primary immunodeficiency,0.5884615384615385
negative regulation of biological process,biological role,0.7
negative regulation of biological process,adhesion disposition,0.6139344262295081
negative regulation of biological process,pathogen portal of entry site,0.6214285714285714
negative regulation of biological process,developmental process,0.7080645161290323
negative regulation of biological process,biological process,0.7550847457627118
negative regulation of biological process,biological vector role,0.6722222222222223
negative regulation of biological process,site,0.5166666666666666
negative regulation of biological process,primary infectious disposition,0.6049295774647887
negative regulation of biological process,humoral immune response,0.590625
negative regulation of biological process,SARS-COV-2 adhesion susceptible cell,0.6188311688311688
negative regulation of biological process,incubation start process boundary,0.6797297297297297
negative regulation of biological process,pathogen surveillance,0.6274193548387097
negative regulation of biological process,pathogen birth process boundary,0.6583333333333334
negative regulation of biological process,virus attachment stage,0.5928571428571429
negative regulation of biological process,negative regulation of immune response,0.8170886075949367
negative regulation of biological process,SARS-CoV-2 transcription stage,0.6190140845070422
negative regulation of biological process,virus synthesis stage,0.5790322580645162
negative regulation of biological process,SARS-COV-2 adhesion disposition,0.6166666666666667
negative regulation of biological process,invasive disposition,0.630327868852459
negative regulation of biological process,long-term non-progressing infectious disease course,0.6456521739130434
negative regulation of biological process,fungicidal disposition,0.6246031746031746
negative regulation of biological process,virus penetration stage,0.6375
negative regulation of biological process,algorithm,0.53
negative regulation of biological process,division of geopolitical entity,0.6861111111111111
negative regulation of biological process,negative regulation of viral process,0.8915584415584417
negative regulation of biological process,contact pathogen transmission process,0.6935897435897437
negative regulation of biological process,function,0.5520408163265306
negative regulation of biological process,symbiotic process,0.6741379310344828
negative regulation of biological process,exotoxin disposition,0.5975409836065574
negative regulation of biological process,infection start process boundary,0.6691780821917809
negative regulation of biological process,action specification,0.630327868852459
negative regulation of biological process,SARS-CoV-2 synthesis stage,0.5694029850746268
negative regulation of biological process,latency start process boundary,0.6471830985915493
negative regulation of biological process,infectious disease control objective specification,0.6368131868131869
negative regulation of biological process,opportunistic infectious disposition,0.6188311688311688
negative regulation of biological process,process of establishing viral infection,0.625
negative regulation of biological process,negative regulation of biological process,0.95
negative regulation of biological process,enterotoxin disposition,0.6375
negative regulation of biological process,polymerase chain reaction,0.6166666666666667
negative regulation of biological process,COVID-19 disease course,0.575
negative regulation of biological process,infectious disease incidence rate,0.6391891891891892
negative regulation of biological process,communicability start process boundary,0.6525316455696202
negative regulation of biological process,process that results in death,0.6357142857142857
negative regulation of biological process,single-stranded RNA retrovirus,0.6190140845070422
negative regulation of biological process,active immunization against infectious agent,0.6617647058823529
negative regulation of biological process,collective resistance disposition,0.6527027027027027
negative regulation of biological process,adaptive immune response,0.65
negative regulation of biological process,fungistatic disposition,0.621875
negative regulation of biological process,virus uncoating stage,0.6112903225806451
negative regulation of biological process,establishment of a clinically abnormal colony,0.6476744186046511
negative regulation of biological process,process boundary,0.5728070175438597
negative regulation of biological process,positive-sense single-stranded RNA virus,0.6228395061728395
negative regulation of biological process,horizontal pathogen transmission process,0.6722222222222223
negative regulation of biological process,SARS-CoV-2 release stage,0.6038461538461539
negative regulation of biological process,pathogen transmission process,0.6928571428571427
negative regulation of biological process,cell space,0.5872549019607843
biological vector role,biological regulation,0.7755813953488372
biological vector role,primary pathogen,0.6078947368421053
biological vector role,vector control strategy,0.6944444444444444
biological vector role,reservoir of pathogen role,0.6583333333333334
biological vector role,infectious agent host role,0.6791666666666666
biological vector role,B cell receptor complex,0.7388888888888888
biological vector role,passive immunization against infectious agent,0.6141791044776119
biological vector role,mechanical vector,0.732051282051282
biological vector role,pathogen portal of entry role,0.7049019607843137
biological vector role,lower respiratory tract disease,0.6386792452830189
biological vector role,acute infectious disease course,0.619811320754717
biological vector role,cidal agent disposition,0.6277777777777778
biological vector role,role,0.6038461538461539
biological vector role,appearance of disorder,0.609090909090909
biological vector role,biological vehicle,0.85
biological vector role,mutualist role,0.6722222222222223
biological vector role,infectious agent colony,0.6277777777777778
biological vector role,infectious agent generative stage,0.5954545454545455
biological vector role,vector surveillance,0.6939024390243902
biological vector role,cidal agent,0.6318181818181818
biological vector role,infectious structure host role,0.6615384615384616
biological vector role,pathogen vector,0.6932432432432433
biological vector role,pathogen vehicle role,0.7058139534883722
biological vector role,chronic infectious disease course,0.65
biological vector role,asymptomatic infectious agent carrier,0.6364406779661017
biological vector role,mechanical vector role,0.8136363636363637
biological vector role,sterilizing immunity to infectious agent,0.6274193548387097
biological vector role,primary infection,0.6294871794871795
biological vector role,dead-end host role,0.65
biological vector role,definitive host role,0.6880952380952381
biological vector role,innate immunity to infectious agent,0.6078947368421053
biological vector role,virus adhesion susceptible cell,0.5820754716981132
biological vector role,anatomical space,0.6605263157894737
biological vector role,static agent disposition,0.6021739130434782
biological vector role,T cell receptor complex,0.7166666666666667
biological vector role,asymptomatic carrier role,0.6840425531914894
biological vector role,infectious agent population,0.6132653061224489
biological vector role,biological vector,0.8858974358974359
biological vector role,leukocyte-mediated immunity to infectious agent,0.6094202898550725
biological vector role,humoral immunity to infectious agent,0.6224137931034482
biological vector role,innate immune response,0.6318181818181818
biological vector role,viral disease course,0.6642857142857143
biological vector role,secondary infection role,0.7108695652173913
biological vector role,cell,0.5653846153846154
biological vector role,passive immunity to infectious agent,0.6051724137931035
biological vector role,vaccination against infectious agent,0.6396551724137931
biological vector role,susceptibility to infectious agent,0.6464285714285714
biological vector role,source of infection role,0.7108695652173913
biological vector role,disease course,0.6444444444444444
biological vector role,infectious disease course,0.6414893617021277
biological vector role,acquired immunity to infectious agent,0.6025423728813559
biological vector role,coronavirus disease course,0.6375
biological vector role,biological vehicle role,0.8722222222222222
biological vector role,symptomatic infectious agent carrier,0.6396551724137931
biological vector role,symbiont role,0.7071428571428571
biological vector role,parasite role,0.65
biological vector role,pathogen vector role,0.7833333333333333
biological vector role,anatomical entity,0.6551282051282051
biological vector role,primary infection role,0.7227272727272727
biological vector role,primary immunodeficiency,0.5804347826086956
biological vector role,biological role,0.8554054054054054
biological vector role,biological process,0.8
biological vector role,biological vector role,0.95
biological vector role,primary infectious disposition,0.6230769230769231
biological vector role,pathogen host role,0.675
biological vector role,symptomatic carrier role,0.6891304347826087
biological vector role,SARS-COV-2 adhesion susceptible cell,0.5706896551724138
biological vector role,intermediate host role,0.6772727272727272
biological vector role,host role,0.6758064516129032
biological vector role,immunization against infectious agent,0.6364406779661017
biological vector role,pathogen portal of exit role,0.69
biological vector role,infectious agent host,0.6127906976744186
biological vector role,long-term non-progressing infectious disease course,0.6143835616438357
biological vector role,commensal role,0.6722222222222223
biological vector role,epitope role,0.6852941176470588
biological vector role,function,0.55
biological vector role,pathogen transporter role,0.6840425531914894
biological vector role,infectious agent reservoir,0.6166666666666667
biological vector role,antigen role,0.6852941176470588
biological vector role,action specification,0.6166666666666667
biological vector role,symbiont host role,0.7
biological vector role,fomite role,0.6924242424242425
biological vector role,negative regulation of biological process,0.6722222222222223
biological vector role,COVID-19 disease course,0.6277777777777778
biological vector role,active immunization against infectious agent,0.6166666666666667
biological vector role,reagent role,0.6852941176470588
biological vector role,viral load,0.60625
biological vector role,infectious agent,0.6342105263157894
biological vector role,establishment of a clinically abnormal colony,0.658955223880597
biological vector role,drug susceptibility of infectious agent,0.630327868852459
biological vector role,static agent,0.5970588235294118
biological vector role,cell space,0.60625
infectious pathogen transmissibility,extended organism,0.6386792452830189
infectious pathogen transmissibility,virus aggregate,0.6264705882352941
infectious pathogen transmissibility,source of infection,0.6136363636363636
infectious pathogen transmissibility,infectious disease mortality rate,0.7398550724637681
infectious pathogen transmissibility,infection incidence rate profile,0.6852941176470588
infectious pathogen transmissibility,infectious structure aggregate,0.7075757575757575
infectious pathogen transmissibility,communicability end temporal region,0.6330985915492958
infectious pathogen transmissibility,pathogen generative stage,0.6795081967213115
infectious pathogen transmissibility,pathogen portal of entry,0.6833333333333332
infectious pathogen transmissibility,subclinical coronavirus infection,0.6094202898550725
infectious pathogen transmissibility,primary pathogen,0.6423076923076922
infectious pathogen transmissibility,infection end temporal region,0.7115384615384616
infectious pathogen transmissibility,drug-based immunosuppressed organism,0.6166666666666667
infectious pathogen transmissibility,infectious disease,0.7092592592592593
infectious pathogen transmissibility,double-stranded DNA virus,0.5975409836065574
infectious pathogen transmissibility,incubation end temporal region,0.6772727272727272
infectious pathogen transmissibility,site of infection,0.619811320754717
infectious pathogen transmissibility,immunocompetent organism,0.6833333333333332
infectious pathogen transmissibility,pathogen portal of exit,0.6872881355932203
infectious pathogen transmissibility,infectious disease incidence,0.7
infectious pathogen transmissibility,reservoir of pathogen role,0.6919354838709677
infectious pathogen transmissibility,subclinical SARS-CoV-2 infection,0.5823529411764706
infectious pathogen transmissibility,virus translation stage,0.6533898305084747
infectious pathogen transmissibility,disease surveillance objective specification,0.6125
infectious pathogen transmissibility,virus release stage,0.6136363636363636
infectious pathogen transmissibility,infectious agent host role,0.7564516129032257
infectious pathogen transmissibility,asymptomatic infectious structure carrier,0.6577922077922078
infectious pathogen transmissibility,source of infection site,0.6666666666666667
infectious pathogen transmissibility,virus,0.523170731707317
infectious pathogen transmissibility,virus replication,0.619811320754717
infectious pathogen transmissibility,B cell receptor complex,0.5855932203389831
infectious pathogen transmissibility,passive immunization against infectious agent,0.6475308641975309
infectious pathogen transmissibility,systematic infection,0.6107142857142857
infectious pathogen transmissibility,infection incidence rate,0.7
infectious pathogen transmissibility,virus host,0.6239130434782608
infectious pathogen transmissibility,double-stranded RNA virus,0.6139344262295081
infectious pathogen transmissibility,pathogen portal of entry role,0.6653846153846155
infectious pathogen transmissibility,virus transcription stage,0.6467213114754098
infectious pathogen transmissibility,infectious disease lifetime prevalence,0.6932432432432433
infectious pathogen transmissibility,pathogen birth temporal region,0.6621212121212122
infectious pathogen transmissibility,lower respiratory tract disease,0.6440298507462687
infectious pathogen transmissibility,infectious disease incidence proportion,0.6766666666666665
infectious pathogen transmissibility,opportunistic pathogen,0.656896551724138
infectious pathogen transmissibility,virus generative stage,0.656896551724138
infectious pathogen transmissibility,acute infectious disease course,0.6888059701492537
infectious pathogen transmissibility,cidal agent disposition,0.6703389830508475
infectious pathogen transmissibility,infectious disorder,0.7045454545454546
infectious pathogen transmissibility,genetic resistance to pathogen,0.6621212121212122
infectious pathogen transmissibility,subclinical infection,0.6078947368421053
infectious pathogen transmissibility,simple infection,0.6230769230769231
infectious pathogen transmissibility,droplet pathogen transmission process,0.7513698630136986
infectious pathogen transmissibility,infectious disease sporadicity,0.7530303030303032
infectious pathogen transmissibility,communicability end process boundary,0.6305555555555555
infectious pathogen transmissibility,infection incidence proportion profile,0.6797297297297297
infectious pathogen transmissibility,infectious agent colony,0.7550847457627118
infectious pathogen transmissibility,pathogen transporter,0.7178571428571427
infectious pathogen transmissibility,transmissibility disposition,0.7
infectious pathogen transmissibility,latency end process boundary,0.621875
infectious pathogen transmissibility,infectious disease epidemic,0.7039682539682539
infectious pathogen transmissibility,infectious agent generative stage,0.7543478260869566
infectious pathogen transmissibility,disease transmission model,0.7080645161290323
infectious pathogen transmissibility,pathologically immunosuppressed organism,0.6210526315789474
infectious pathogen transmissibility,negative-sense single-stranded RNA virus,0.6342105263157894
infectious pathogen transmissibility,cidal agent,0.6202127659574468
infectious pathogen transmissibility,infectious structure host role,0.7075757575757575
infectious pathogen transmissibility,pathogen vehicle,0.6615384615384616
infectious pathogen transmissibility,community-acquired infection,0.590625
infectious pathogen transmissibility,pathogen vector,0.6656862745098039
infectious pathogen transmissibility,pathogen vehicle role,0.6429824561403508
infectious pathogen transmissibility,chronic infectious disease course,0.6818840579710145
infectious pathogen transmissibility,asymptomatic infectious agent carrier,0.6965753424657534
infectious pathogen transmissibility,nursing-home acquired infection,0.6141791044776119
infectious pathogen transmissibility,COVID-19 epidemic,0.5820754716981132
infectious pathogen transmissibility,secondary infection,0.6136363636363636
infectious pathogen transmissibility,infection start temporal region,0.703731343283582
infectious pathogen transmissibility,infection incidence,0.6681818181818181
infectious pathogen transmissibility,virus disorder,0.59
infectious pathogen transmissibility,sterilizing immunity to infectious agent,0.6605263157894737
infectious pathogen transmissibility,diseased population,0.6136363636363636
infectious pathogen transmissibility,primary infection,0.619811320754717
infectious pathogen transmissibility,process of establishing an infection,0.6166666666666667
infectious pathogen transmissibility,incubation end process boundary,0.6738805970149254
infectious pathogen transmissibility,pathogen death process boundary,0.6738805970149254
infectious pathogen transmissibility,immunosuppressed organism,0.6467213114754098
infectious pathogen transmissibility,latency end temporal region,0.6246031746031746
infectious pathogen transmissibility,innate immunity to infectious agent,0.6753521126760563
infectious pathogen transmissibility,infectious structure,0.7
infectious pathogen transmissibility,virus adhesion susceptible cell,0.658955223880597
infectious pathogen transmissibility,infection,0.65
infectious pathogen transmissibility,static agent disposition,0.6666666666666667
infectious pathogen transmissibility,T cell receptor complex,0.5855932203389831
infectious pathogen transmissibility,infectious structure host,0.7122950819672131
infectious pathogen transmissibility,infectious agent population,0.7357142857142857
infectious pathogen transmissibility,respiratory system disease,0.6435483870967742
infectious pathogen transmissibility,leukocyte-mediated immunity to infectious agent,0.6427710843373494
infectious pathogen transmissibility,indirect pathogen transmission process,0.7878378378378378
infectious pathogen transmissibility,organism population,0.6136363636363636
infectious pathogen transmissibility,humoral immunity to infectious agent,0.6722222222222223
infectious pathogen transmissibility,infectious disease control strategy,0.7316901408450704
infectious pathogen transmissibility,parasite,0.609090909090909
infectious pathogen transmissibility,infectious disease pandemic,0.7357142857142857
infectious pathogen transmissibility,antibody reagent,0.6423076923076922
infectious pathogen transmissibility,infectious structure generative stage,0.7239726027397261
infectious pathogen transmissibility,viral disease course,0.5928571428571429
infectious pathogen transmissibility,intracellular infection,0.6025423728813559
infectious pathogen transmissibility,secondary infection role,0.65
infectious pathogen transmissibility,metastatic infection,0.6107142857142857
infectious pathogen transmissibility,passive immunity to infectious agent,0.6722222222222223
infectious pathogen transmissibility,infectious disposition,0.7258620689655172
infectious pathogen transmissibility,vaccination against infectious agent,0.6722222222222223
infectious pathogen transmissibility,acute infection,0.6264705882352941
infectious pathogen transmissibility,susceptibility to infectious agent,0.6785714285714286
infectious pathogen transmissibility,epitope site,0.6375
infectious pathogen transmissibility,immunity to pathogen,0.6821428571428573
infectious pathogen transmissibility,source of infection role,0.65
infectious pathogen transmissibility,pathogen host,0.6744897959183673
infectious pathogen transmissibility,chronic infection,0.619811320754717
infectious pathogen transmissibility,disease course,0.59
infectious pathogen transmissibility,infectious disease course,0.7122950819672131
infectious pathogen transmissibility,acquired immunity to infectious agent,0.6691780821917809
infectious pathogen transmissibility,complex infection,0.619811320754717
infectious pathogen transmissibility,COVID-19 disease incidence proportion,0.5732876712328767
infectious pathogen transmissibility,coronavirus disease course,0.6112903225806451
infectious pathogen transmissibility,infection incidence proportion,0.6621212121212122
infectious pathogen transmissibility,symptomatic infectious agent carrier,0.7
infectious pathogen transmissibility,respiratory droplet virus fomite,0.6411764705882353
infectious pathogen transmissibility,susceptible organism,0.6464285714285714
infectious pathogen transmissibility,parasite role,0.5928571428571429
infectious pathogen transmissibility,SARS-CoV-2 transmissibility,0.7674603174603175
infectious pathogen transmissibility,pathogen vector role,0.6642857142857143
infectious pathogen transmissibility,pathogen portal of exit site,0.684375
infectious pathogen transmissibility,infectious disease prevalence,0.7115384615384616
infectious pathogen transmissibility,organism substance,0.6166666666666667
infectious pathogen transmissibility,single-stranded DNA virus,0.6139344262295081
infectious pathogen transmissibility,infected population,0.6681818181818181
infectious pathogen transmissibility,viral disease,0.5724489795918367
infectious pathogen transmissibility,primary infection role,0.656896551724138
infectious pathogen transmissibility,pathogen portal of entry site,0.6807692307692308
infectious pathogen transmissibility,infection incidence profile,0.6880952380952381
infectious pathogen transmissibility,disease,0.5662790697674418
infectious pathogen transmissibility,symptomatic infectious structure carrier,0.6605263157894737
infectious pathogen transmissibility,site,0.525
infectious pathogen transmissibility,primary infectious disposition,0.6924242424242425
infectious pathogen transmissibility,pathogen host role,0.6722222222222223
infectious pathogen transmissibility,infection prevalence,0.6821428571428573
infectious pathogen transmissibility,infectious pathogen transmissibility,0.95
infectious pathogen transmissibility,pathogen surveillance,0.6605263157894737
infectious pathogen transmissibility,immunodeficient organism,0.6666666666666667
infectious pathogen transmissibility,pathogen,0.6318181818181818
infectious pathogen transmissibility,pathogen birth process boundary,0.6738805970149254
infectious pathogen transmissibility,infectious human pathogen,0.7614754098360657
infectious pathogen transmissibility,subclinical virus infection,0.6087301587301588
infectious pathogen transmissibility,resistance to pathogen,0.6913793103448276
infectious pathogen transmissibility,establishment of localization in virus host,0.639873417721519
infectious pathogen transmissibility,immunization against infectious agent,0.6691780821917809
infectious pathogen transmissibility,virus attachment stage,0.656896551724138
infectious pathogen transmissibility,virus synthesis stage,0.6605263157894737
infectious pathogen transmissibility,pathogen portal of exit role,0.66875
infectious pathogen transmissibility,infectious agent host,0.7657894736842106
infectious pathogen transmissibility,re-emerging pathogen,0.6464285714285714
infectious pathogen transmissibility,long-term non-progressing infectious disease course,0.6339080459770114
infectious pathogen transmissibility,viral disease epidemic,0.5879310344827586
infectious pathogen transmissibility,viral disease pandemic,0.6224137931034482
infectious pathogen transmissibility,virus penetration stage,0.6703389830508475
infectious pathogen transmissibility,pathogen seroprevalence,0.6533898305084747
infectious pathogen transmissibility,infectious disease endemicity,0.7576923076923078
infectious pathogen transmissibility,contact pathogen transmission process,0.7650684931506849
infectious pathogen transmissibility,herd immunity to infectious organism,0.6861111111111111
infectious pathogen transmissibility,extracellular infection,0.6025423728813559
infectious pathogen transmissibility,pathogen transporter role,0.6959016393442623
infectious pathogen transmissibility,infectious agent reservoir,0.7564516129032257
infectious pathogen transmissibility,COVID-19 pandemic,0.6009433962264151
infectious pathogen transmissibility,infection start process boundary,0.7
infectious pathogen transmissibility,infectious disease control objective specification,0.6941860465116279
infectious pathogen transmissibility,opportunistic infectious disposition,0.6722222222222223
infectious pathogen transmissibility,process of establishing viral infection,0.6366666666666667
infectious pathogen transmissibility,COVID-19 disease course,0.5855932203389831
infectious pathogen transmissibility,infectious disease incidence rate,0.7108695652173913
infectious pathogen transmissibility,active immunization against infectious agent,0.65
infectious pathogen transmissibility,disordered virus,0.5846153846153846
infectious pathogen transmissibility,organism,0.5863636363636363
infectious pathogen transmissibility,virus uncoating stage,0.6254385964912281
infectious pathogen transmissibility,local infection,0.6264705882352941
infectious pathogen transmissibility,infectious agent,0.7576923076923078
infectious pathogen transmissibility,establishment of a clinically abnormal colony,0.6228395061728395
infectious pathogen transmissibility,coronavirus disease,0.6136363636363636
infectious pathogen transmissibility,positive-sense single-stranded RNA virus,0.6210526315789474
infectious pathogen transmissibility,horizontal pathogen transmission process,0.7526315789473685
infectious pathogen transmissibility,hospital-acquired infection,0.5928571428571429
infectious pathogen transmissibility,pathogen death temporal region,0.6621212121212122
infectious pathogen transmissibility,emerging pathogen,0.6575471698113208
infectious pathogen transmissibility,drug susceptibility of infectious agent,0.6633333333333334
infectious pathogen transmissibility,static agent,0.6166666666666667
infectious pathogen transmissibility,pathogen transmission process,0.7423076923076922
commensal,commensal,0.95
commensal,commensal role,0.8413043478260869
commensal,establishment of a clinically abnormal colony,0.5425925925925926
zoonotic disposition,virostatic disposition,0.830952380952381
zoonotic disposition,information content entity,0.6239130434782608
zoonotic disposition,zoonotic disposition,0.95
zoonotic disposition,infectious disease mortality rate,0.6386792452830189
zoonotic disposition,infection incidence rate profile,0.6038461538461539
zoonotic disposition,infectious structure aggregate,0.57
zoonotic disposition,communicability end temporal region,0.65
zoonotic disposition,geographical entity,0.6038461538461539
zoonotic disposition,biological regulation,0.6695121951219513
zoonotic disposition,surveillance process,0.6
zoonotic disposition,infection end temporal region,0.6540816326530612
zoonotic disposition,vector control strategy,0.6127906976744186
zoonotic disposition,SARS-CoV-2 incidence rate,0.5833333333333334
zoonotic disposition,incubation end temporal region,0.65
zoonotic disposition,resistant entity,0.5888888888888889
zoonotic disposition,virulence factor disposition,0.7416666666666667
zoonotic disposition,viral adhesion disposition,0.7543478260869566
zoonotic disposition,parasitostatic disposition,0.7978260869565217
zoonotic disposition,negative regulation of production,0.6575471698113208
zoonotic disposition,reverse zoonotic disposition,0.8666666666666667
zoonotic disposition,establishment of localization in host,0.6078947368421053
zoonotic disposition,disease surveillance objective specification,0.6375
zoonotic disposition,case isolation control strategy,0.6264705882352941
zoonotic disposition,infectious agent host role,0.6239130434782608
zoonotic disposition,macromolecular complex,0.569047619047619
zoonotic disposition,material entity,0.5928571428571429
zoonotic disposition,asymptomatic infectious structure carrier,0.6139344262295081
zoonotic disposition,architectual structure,0.569047619047619
zoonotic disposition,quarantine control strategy,0.598936170212766
zoonotic disposition,B cell receptor complex,0.5662790697674418
zoonotic disposition,infection incidence rate,0.609090909090909
zoonotic disposition,colonized host,0.6852941176470588
zoonotic disposition,virus host,0.6166666666666667
zoonotic disposition,entity,0.6038461538461539
zoonotic disposition,toxin disposition,0.8283783783783784
zoonotic disposition,cidal agent disposition,0.7755813953488372
zoonotic disposition,parasiticidal disposition,0.7833333333333333
zoonotic disposition,communicability end process boundary,0.6464285714285714
zoonotic disposition,directive information content entity,0.6107142857142857
zoonotic disposition,acellular structure aggregate,0.5316326530612244
zoonotic disposition,transmissibility disposition,0.7416666666666667
zoonotic disposition,latency end process boundary,0.6375
zoonotic disposition,colonization of host,0.675
zoonotic disposition,realizable entity,0.5851351351351352
zoonotic disposition,endotoxin disposition,0.8402439024390245
zoonotic disposition,vector surveillance,0.5782051282051281
zoonotic disposition,negative regulation of establishment of localization,0.6166666666666667
zoonotic disposition,infectious structure host role,0.63
zoonotic disposition,COVID-19 incidence rate,0.5895348837209302
zoonotic disposition,cytotoxin disposition,0.8158536585365854
zoonotic disposition,negative regulation of developmental process,0.575
zoonotic disposition,host,0.575
zoonotic disposition,descriptive information content entity,0.6051724137931035
zoonotic disposition,negative regulation of replication,0.6537037037037037
zoonotic disposition,establishment of localization in human host,0.5928571428571429
zoonotic disposition,acellular structure,0.5525641025641026
zoonotic disposition,incubation end process boundary,0.6460784313725491
zoonotic disposition,collective pathogenic disposition,0.7707547169811321
zoonotic disposition,neurotoxin disposition,0.830952380952381
zoonotic disposition,dead-end host role,0.6078947368421053
zoonotic disposition,molecular entity,0.5888888888888889
zoonotic disposition,plan specification,0.6868421052631578
zoonotic disposition,definitive host role,0.65
zoonotic disposition,latency end temporal region,0.6414893617021277
zoonotic disposition,infectious structure,0.6
zoonotic disposition,collective disposition,0.8071428571428573
zoonotic disposition,static agent disposition,0.7909090909090909
zoonotic disposition,T cell receptor complex,0.5895348837209302
zoonotic disposition,infectious structure host,0.6277777777777778
zoonotic disposition,respiratory system disease,0.6021739130434782
zoonotic disposition,entry into host,0.65
zoonotic disposition,adhesion of symbiont to host,0.6166666666666667
zoonotic disposition,infectious disease control strategy,0.6318181818181818
zoonotic disposition,infectious structure generative stage,0.5903508771929825
zoonotic disposition,immunosuppressive disposition,0.7561224489795919
zoonotic disposition,pathogenic disposition,0.830952380952381
zoonotic disposition,entry into host through host barriers,0.6078947368421053
zoonotic disposition,infectious disposition,0.8071428571428573
zoonotic disposition,bacteriostatic disposition,0.7978260869565217
zoonotic disposition,bactericidal disposition,0.7909090909090909
zoonotic disposition,pathogen host,0.6318181818181818
zoonotic disposition,invasion disposition,0.8
zoonotic disposition,viricidal disposition,0.7914634146341464
zoonotic disposition,complex infection,0.6391891891891892
zoonotic disposition,intermediate host,0.6391891891891892
zoonotic disposition,anatomical entity,0.6391891891891892
zoonotic disposition,disposition,0.8048387096774193
zoonotic disposition,COVID-19 mortality rate,0.5895348837209302
zoonotic disposition,negative regulation of life-sustaining process,0.6015151515151516
zoonotic disposition,place closure control strategy,0.59
zoonotic disposition,geopolitical entity,0.6551282051282051
zoonotic disposition,adhesion disposition,0.8
zoonotic disposition,symptomatic infectious structure carrier,0.6166666666666667
zoonotic disposition,primary infectious disposition,0.75
zoonotic disposition,pathogen host role,0.6342105263157894
zoonotic disposition,designative information content entity,0.6224137931034482
zoonotic disposition,intermediate host role,0.6404761904761905
zoonotic disposition,dead-end host,0.6015151515151516
zoonotic disposition,pathogen surveillance,0.5963414634146341
zoonotic disposition,host role,0.5879310344827586
zoonotic disposition,establishment of localization in virus host,0.6087301587301588
zoonotic disposition,negative regulation of immune response,0.6051724137931035
zoonotic disposition,immaterial entity,0.5851351351351352
zoonotic disposition,SARS-COV-2 adhesion disposition,0.7441176470588234
zoonotic disposition,invasive disposition,0.8
zoonotic disposition,infectious agent host,0.6207317073170732
zoonotic disposition,fungicidal disposition,0.8071428571428573
zoonotic disposition,division of geopolitical entity,0.6460784313725491
zoonotic disposition,negative regulation of viral process,0.5928571428571429
zoonotic disposition,exotoxin disposition,0.825
zoonotic disposition,immunoglobulin complex,0.569047619047619
zoonotic disposition,infectious disease control objective specification,0.65
zoonotic disposition,symbiont host role,0.6605263157894737
zoonotic disposition,opportunistic infectious disposition,0.7714285714285714
zoonotic disposition,negative regulation of biological process,0.5975409836065574
zoonotic disposition,enterotoxin disposition,0.822093023255814
zoonotic disposition,infectious disease incidence rate,0.6575471698113208
zoonotic disposition,collective resistance disposition,0.7518867924528303
zoonotic disposition,fungistatic disposition,0.822093023255814
zoonotic disposition,establishment of a clinically abnormal colony,0.573076923076923
zoonotic disposition,definitive host,0.65
epitope role,epitope,0.8184210526315789
epitope role,reservoir of pathogen role,0.7131578947368421
epitope role,infectious agent host role,0.6868421052631578
epitope role,B cell receptor complex,0.6785714285714286
epitope role,pathogen portal of entry role,0.6939024390243902
epitope role,lower respiratory tract disease,0.636046511627907
epitope role,acute infectious disease course,0.636046511627907
epitope role,role,0.7
epitope role,appearance of disorder,0.6264705882352941
epitope role,mutualist role,0.7192307692307692
epitope role,infectious structure host role,0.6642857142857143
epitope role,pathogen vehicle role,0.7227272727272727
epitope role,chronic infectious disease course,0.6055555555555556
epitope role,mechanical vector role,0.7147058823529412
epitope role,dead-end host role,0.6833333333333332
epitope role,definitive host role,0.73125
epitope role,T cell receptor complex,0.6785714285714286
epitope role,asymptomatic carrier role,0.6932432432432433
epitope role,viral disease course,0.60625
epitope role,secondary infection role,0.7
epitope role,epitope site,0.825
epitope role,source of infection role,0.7
epitope role,disease course,0.6423076923076922
epitope role,infectious disease course,0.6391891891891892
epitope role,coronavirus disease course,0.581578947368421
epitope role,biological vehicle role,0.6785714285714286
epitope role,symbiont role,0.73
epitope role,parasite role,0.81
epitope role,pathogen vector role,0.73125
epitope role,primary infection role,0.7147058823529412
epitope role,biological role,0.7092592592592593
epitope role,biological vector role,0.6852941176470588
epitope role,pathogen host role,0.75
epitope role,symptomatic carrier role,0.7
epitope role,intermediate host role,0.7147058823529412
epitope role,host role,0.7357142857142857
epitope role,pathogen portal of exit role,0.7
epitope role,long-term non-progressing infectious disease course,0.5928571428571429
epitope role,commensal role,0.7192307692307692
epitope role,epitope role,0.95
epitope role,function,0.55
epitope role,pathogen transporter role,0.7202702702702704
epitope role,antigen role,0.7416666666666667
epitope role,action specification,0.60625
epitope role,symbiont host role,0.7166666666666667
epitope role,fomite role,0.7978260869565217
epitope role,COVID-19 disease course,0.5928571428571429
epitope role,reagent role,0.7416666666666667
epitope role,viral load,0.5863636363636363
epitope role,establishment of a clinically abnormal colony,0.5903508771929825
generically dependent continuant,communicability end temporal region,0.658955223880597
generically dependent continuant,infection end temporal region,0.630327868852459
generically dependent continuant,vector control strategy,0.6318181818181818
generically dependent continuant,incubation end temporal region,0.6274193548387097
generically dependent continuant,case isolation control strategy,0.6246031746031746
generically dependent continuant,quarantine control strategy,0.6364406779661017
generically dependent continuant,B cell receptor complex,0.6318181818181818
generically dependent continuant,lower respiratory tract disease,0.6246031746031746
generically dependent continuant,communicability end process boundary,0.6705882352941177
generically dependent continuant,latency end process boundary,0.6666666666666667
generically dependent continuant,susceptible population,0.6166666666666667
generically dependent continuant,descriptive information content entity,0.6642857142857143
generically dependent continuant,secondary infection,0.6656862745098039
generically dependent continuant,incubation end process boundary,0.6404761904761905
generically dependent continuant,latency end temporal region,0.6533898305084747
generically dependent continuant,virus adhesion susceptible cell,0.5928571428571429
generically dependent continuant,anatomical space,0.6166666666666667
generically dependent continuant,T cell receptor complex,0.6318181818181818
generically dependent continuant,infectious disease control strategy,0.658955223880597
generically dependent continuant,secondary infection role,0.6464285714285714
generically dependent continuant,susceptible organism,0.6038461538461539
generically dependent continuant,generically dependent continuant,0.95
generically dependent continuant,place closure control strategy,0.6274193548387097
generically dependent continuant,continuant,0.6880952380952381
generically dependent continuant,SARS-COV-2 adhesion susceptible cell,0.5970588235294118
generically dependent continuant,specifically dependent continuant,0.8807692307692307
generically dependent continuant,independent continuant,0.8388888888888889
generically dependent continuant,infectious disease control objective specification,0.6329268292682927
generically dependent continuant,establishment of a clinically abnormal colony,0.6318181818181818
generically dependent continuant,cell space,0.5928571428571429
sterilizing immunity to infectious agent,information content entity,0.6469696969696969
sterilizing immunity to infectious agent,infectious disease mortality rate,0.6417808219178082
sterilizing immunity to infectious agent,infection incidence rate profile,0.6305555555555555
sterilizing immunity to infectious agent,infectious structure aggregate,0.6642857142857143
sterilizing immunity to infectious agent,communicability end temporal region,0.65
sterilizing immunity to infectious agent,infection end temporal region,0.6384057971014493
sterilizing immunity to infectious agent,vector control strategy,0.6087301587301588
sterilizing immunity to infectious agent,infectious disease,0.6741379310344828
sterilizing immunity to infectious agent,SARS-CoV-2 incidence rate,0.6192307692307693
sterilizing immunity to infectious agent,incubation end temporal region,0.6357142857142857
sterilizing immunity to infectious agent,virulence factor disposition,0.6264705882352941
sterilizing immunity to infectious agent,infectious disease incidence,0.6558823529411765
sterilizing immunity to infectious agent,disease surveillance objective specification,0.6404761904761905
sterilizing immunity to infectious agent,case isolation control strategy,0.6471830985915493
sterilizing immunity to infectious agent,virus release stage,0.6025423728813559
sterilizing immunity to infectious agent,infectious agent host role,0.6924242424242425
sterilizing immunity to infectious agent,asymptomatic infectious structure carrier,0.6722222222222223
sterilizing immunity to infectious agent,quarantine control strategy,0.6291044776119403
sterilizing immunity to infectious agent,B cell receptor complex,0.5928571428571429
sterilizing immunity to infectious agent,passive immunization against infectious agent,0.7911764705882354
sterilizing immunity to infectious agent,infection incidence rate,0.6375
sterilizing immunity to infectious agent,infectious disease lifetime prevalence,0.6423076923076922
sterilizing immunity to infectious agent,lower respiratory tract disease,0.6471830985915493
sterilizing immunity to infectious agent,infectious disease incidence proportion,0.639873417721519
sterilizing immunity to infectious agent,acute infectious disease course,0.6753521126760563
sterilizing immunity to infectious agent,cidal agent disposition,0.6404761904761905
sterilizing immunity to infectious agent,infectious disorder,0.6533898305084747
sterilizing immunity to infectious agent,genetic resistance to pathogen,0.65
sterilizing immunity to infectious agent,biological vehicle,0.5879310344827586
sterilizing immunity to infectious agent,droplet pathogen transmission process,0.6058441558441559
sterilizing immunity to infectious agent,infectious disease sporadicity,0.65
sterilizing immunity to infectious agent,communicability end process boundary,0.6210526315789474
sterilizing immunity to infectious agent,directive information content entity,0.6473684210526315
sterilizing immunity to infectious agent,infectious agent colony,0.7039682539682539
sterilizing immunity to infectious agent,pathogen transporter,0.5833333333333334
sterilizing immunity to infectious agent,invasion factor,0.6136363636363636
sterilizing immunity to infectious agent,latency end process boundary,0.6117647058823529
sterilizing immunity to infectious agent,infectious disease epidemic,0.6440298507462687
sterilizing immunity to infectious agent,infectious agent generative stage,0.6691780821917809
sterilizing immunity to infectious agent,disease transmission model,0.6015151515151516
sterilizing immunity to infectious agent,cidal agent,0.6068627450980393
sterilizing immunity to infectious agent,infectious structure host role,0.6357142857142857
sterilizing immunity to infectious agent,pathogen vehicle,0.575
sterilizing immunity to infectious agent,COVID-19 incidence rate,0.6087301587301588
sterilizing immunity to infectious agent,antibiotic resistance,0.6139344262295081
sterilizing immunity to infectious agent,pathogen vehicle role,0.5811475409836065
sterilizing immunity to infectious agent,chronic infectious disease course,0.682876712328767
sterilizing immunity to infectious agent,asymptomatic infectious agent carrier,0.7227272727272727
sterilizing immunity to infectious agent,descriptive information content entity,0.6679487179487179
sterilizing immunity to infectious agent,COVID-19 epidemic,0.5552631578947369
sterilizing immunity to infectious agent,resistance to drug,0.6051724137931035
sterilizing immunity to infectious agent,sterilizing immunity to infectious agent,0.95
sterilizing immunity to infectious agent,diseased population,0.5855932203389831
sterilizing immunity to infectious agent,virulence factor,0.5928571428571429
sterilizing immunity to infectious agent,incubation end process boundary,0.6049295774647887
sterilizing immunity to infectious agent,latency end temporal region,0.6440298507462687
sterilizing immunity to infectious agent,innate immunity to infectious agent,0.8633333333333334
sterilizing immunity to infectious agent,infectious structure,0.65
sterilizing immunity to infectious agent,static agent disposition,0.653125
sterilizing immunity to infectious agent,T cell receptor complex,0.6087301587301588
sterilizing immunity to infectious agent,asymptomatic carrier role,0.5884615384615385
sterilizing immunity to infectious agent,infectious structure host,0.65
sterilizing immunity to infectious agent,infectious agent population,0.6888059701492537
sterilizing immunity to infectious agent,respiratory system disease,0.6166666666666667
sterilizing immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.8178160919540229
sterilizing immunity to infectious agent,indirect pathogen transmission process,0.6166666666666667
sterilizing immunity to infectious agent,humoral immunity to infectious agent,0.8578947368421052
sterilizing immunity to infectious agent,infectious disease control strategy,0.65
sterilizing immunity to infectious agent,infectious disease pandemic,0.658955223880597
sterilizing immunity to infectious agent,infectious structure generative stage,0.6448051948051949
sterilizing immunity to infectious agent,viral disease course,0.6166666666666667
sterilizing immunity to infectious agent,passive immunity to infectious agent,0.8578947368421052
sterilizing immunity to infectious agent,infectious disposition,0.6435483870967742
sterilizing immunity to infectious agent,vaccination against infectious agent,0.7657894736842106
sterilizing immunity to infectious agent,susceptibility to infectious agent,0.8148648648648649
sterilizing immunity to infectious agent,immunity to pathogen,0.7333333333333333
sterilizing immunity to infectious agent,disease course,0.5981481481481481
sterilizing immunity to infectious agent,infectious disease course,0.65
sterilizing immunity to infectious agent,acquired immunity to infectious agent,0.8396103896103897
sterilizing immunity to infectious agent,COVID-19 disease incidence proportion,0.6058441558441559
sterilizing immunity to infectious agent,coronavirus disease course,0.6318181818181818
sterilizing immunity to infectious agent,asymptomatic carrier,0.6
sterilizing immunity to infectious agent,biological vehicle role,0.5928571428571429
sterilizing immunity to infectious agent,symptomatic infectious agent carrier,0.7263157894736842
sterilizing immunity to infectious agent,intermediate host,0.6254385964912281
sterilizing immunity to infectious agent,infectious disease prevalence,0.6528985507246376
sterilizing immunity to infectious agent,infected population,0.6194915254237288
sterilizing immunity to infectious agent,COVID-19 mortality rate,0.5928571428571429
sterilizing immunity to infectious agent,place closure control strategy,0.6071428571428572
sterilizing immunity to infectious agent,viral disease,0.5820754716981132
sterilizing immunity to infectious agent,leukocyte mediated immunity,0.6291044776119403
sterilizing immunity to infectious agent,disease,0.5351063829787234
sterilizing immunity to infectious agent,symptomatic infectious structure carrier,0.675
sterilizing immunity to infectious agent,primary infectious disposition,0.6928571428571427
sterilizing immunity to infectious agent,designative information content entity,0.6551282051282051
sterilizing immunity to infectious agent,symptomatic carrier role,0.590625
sterilizing immunity to infectious agent,infectious pathogen transmissibility,0.6605263157894737
sterilizing immunity to infectious agent,intermediate host role,0.6274193548387097
sterilizing immunity to infectious agent,infectious human pathogen,0.6807692307692308
sterilizing immunity to infectious agent,resistance to pathogen,0.6435483870967742
sterilizing immunity to infectious agent,immunization against infectious agent,0.7876623376623377
sterilizing immunity to infectious agent,infectious agent host,0.7122950819672131
sterilizing immunity to infectious agent,long-term non-progressing infectious disease course,0.6807692307692308
sterilizing immunity to infectious agent,viral disease epidemic,0.5790322580645162
sterilizing immunity to infectious agent,viral disease pandemic,0.5951612903225807
sterilizing immunity to infectious agent,symptomatic carrier,0.6025423728813559
sterilizing immunity to infectious agent,infectious disease endemicity,0.6673913043478261
sterilizing immunity to infectious agent,contact pathogen transmission process,0.5928571428571429
sterilizing immunity to infectious agent,function,0.5958333333333333
sterilizing immunity to infectious agent,herd immunity to infectious organism,0.8184210526315789
sterilizing immunity to infectious agent,pathogen transporter role,0.5884615384615385
sterilizing immunity to infectious agent,transmission interval,0.630327868852459
sterilizing immunity to infectious agent,infectious agent reservoir,0.6924242424242425
sterilizing immunity to infectious agent,COVID-19 pandemic,0.537719298245614
sterilizing immunity to infectious agent,action specification,0.6333333333333333
sterilizing immunity to infectious agent,protective resistance,0.5975409836065574
sterilizing immunity to infectious agent,infectious disease control objective specification,0.6277777777777778
sterilizing immunity to infectious agent,opportunistic infectious disposition,0.6868421052631578
sterilizing immunity to infectious agent,polymerase chain reaction,0.6346153846153847
sterilizing immunity to infectious agent,COVID-19 disease course,0.5928571428571429
sterilizing immunity to infectious agent,infectious disease incidence rate,0.6554794520547945
sterilizing immunity to infectious agent,active immunization against infectious agent,0.7952380952380952
sterilizing immunity to infectious agent,collective resistance disposition,0.6280821917808219
sterilizing immunity to infectious agent,infectious agent,0.7357142857142857
sterilizing immunity to infectious agent,establishment of a clinically abnormal colony,0.6382352941176471
sterilizing immunity to infectious agent,coronavirus disease,0.6025423728813559
sterilizing immunity to infectious agent,adhesion factor,0.5954545454545455
sterilizing immunity to infectious agent,horizontal pathogen transmission process,0.625
sterilizing immunity to infectious agent,drug susceptibility of infectious agent,0.7791139240506328
sterilizing immunity to infectious agent,SARS-CoV-2 release stage,0.60625
sterilizing immunity to infectious agent,static agent,0.6615384615384616
sterilizing immunity to infectious agent,pathogen transmission process,0.5949275362318841
generative stage,source of infection,0.5928571428571429
generative stage,infectious disease mortality rate,0.6336734693877552
generative stage,infection incidence rate profile,0.6375
generative stage,pathogen generative stage,0.8402439024390245
generative stage,SARS-CoV-2 incidence rate,0.6207317073170732
generative stage,virus translation stage,0.7064102564102563
generative stage,virus release stage,0.7357142857142857
generative stage,source of infection site,0.675
generative stage,B cell receptor complex,0.5782051282051281
generative stage,infection incidence rate,0.65
generative stage,double-stranded RNA virus,0.6207317073170732
generative stage,virus transcription stage,0.6939024390243902
generative stage,lower respiratory tract disease,0.6414893617021277
generative stage,virus generative stage,0.8710526315789474
generative stage,acute infectious disease course,0.6414893617021277
generative stage,biological vehicle,0.5970588235294118
generative stage,infectious agent generative stage,0.7765306122448979
generative stage,negative-sense single-stranded RNA virus,0.6642857142857143
generative stage,pathogen vehicle,0.6375
generative stage,COVID-19 incidence rate,0.6294871794871795
generative stage,negative regulation of developmental process,0.6333333333333333
generative stage,pathogen vehicle role,0.6662162162162162
generative stage,chronic infectious disease course,0.6132653061224489
generative stage,PCR product,0.5611111111111111
generative stage,SARS-CoV-2 uncoating stage,0.6880952380952381
generative stage,plan specification,0.5970588235294118
generative stage,SARS-CoV-2 penetration stage,0.7454545454545455
generative stage,T cell receptor complex,0.5782051282051281
generative stage,respiratory system disease,0.6642857142857143
generative stage,generative stage,0.95
generative stage,SARS-CoV-2 attachment stage,0.6825581395348838
generative stage,infectious structure generative stage,0.7518867924528303
generative stage,viral disease course,0.6444444444444444
generative stage,source of infection role,0.625
generative stage,disease course,0.65
generative stage,infectious disease course,0.6451219512195122
generative stage,coronavirus disease course,0.6166666666666667
generative stage,biological vehicle role,0.6038461538461539
generative stage,SARS-CoV-2 genome replication stage,0.7245098039215686
generative stage,COVID-19 mortality rate,0.6038461538461539
generative stage,developmental process,0.6121621621621621
generative stage,virus attachment stage,0.7131578947368421
generative stage,SARS-CoV-2 transcription stage,0.6673913043478261
generative stage,virus synthesis stage,0.6932432432432433
generative stage,long-term non-progressing infectious disease course,0.5992537313432835
generative stage,virus penetration stage,0.7833333333333333
generative stage,division of geopolitical entity,0.5776595744680851
generative stage,SARS-CoV-2 synthesis stage,0.6642857142857143
generative stage,COVID-19 disease course,0.6038461538461539
generative stage,infectious disease incidence rate,0.6132653061224489
generative stage,single-stranded RNA retrovirus,0.6456521739130434
generative stage,virus uncoating stage,0.7202702702702704
generative stage,establishment of a clinically abnormal colony,0.5483606557377049
generative stage,positive-sense single-stranded RNA virus,0.6107142857142857
generative stage,SARS-CoV-2 release stage,0.7
immunoglobulin complex,virostatic disposition,0.5636363636363636
immunoglobulin complex,zoonotic disposition,0.569047619047619
immunoglobulin complex,infectious disease mortality rate,0.6136363636363636
immunoglobulin complex,infection incidence rate profile,0.6166666666666667
immunoglobulin complex,infectious structure aggregate,0.5846153846153846
immunoglobulin complex,communicability end temporal region,0.6780701754385965
immunoglobulin complex,infection end temporal region,0.6264705882352941
immunoglobulin complex,SARS-CoV-2 incidence rate,0.5776595744680851
immunoglobulin complex,incubation end temporal region,0.6423076923076922
immunoglobulin complex,site of infection,0.6038461538461539
immunoglobulin complex,virulence factor disposition,0.61
immunoglobulin complex,viral adhesion disposition,0.575
immunoglobulin complex,parasitostatic disposition,0.5541666666666667
immunoglobulin complex,reverse zoonotic disposition,0.55
immunoglobulin complex,macromolecular complex,0.7681818181818181
immunoglobulin complex,asymptomatic infectious structure carrier,0.5769841269841269
immunoglobulin complex,source of infection site,0.6021739130434782
immunoglobulin complex,architectual structure,0.5863636363636363
immunoglobulin complex,B cell receptor complex,0.6722222222222223
immunoglobulin complex,infection incidence rate,0.6021739130434782
immunoglobulin complex,toxin disposition,0.5782051282051281
immunoglobulin complex,lower respiratory tract disease,0.5632075471698114
immunoglobulin complex,cidal agent disposition,0.5611111111111111
immunoglobulin complex,infectious disorder,0.6207317073170732
immunoglobulin complex,appearance of disorder,0.5636363636363636
immunoglobulin complex,parasiticidal disposition,0.5563829787234043
immunoglobulin complex,communicability end process boundary,0.6396551724137931
immunoglobulin complex,acellular structure aggregate,0.5676470588235294
immunoglobulin complex,transmissibility disposition,0.57
immunoglobulin complex,latency end process boundary,0.55
immunoglobulin complex,endotoxin disposition,0.6127906976744186
immunoglobulin complex,infectious structure host role,0.6230769230769231
immunoglobulin complex,COVID-19 incidence rate,0.5833333333333334
immunoglobulin complex,cytotoxin disposition,0.5895348837209302
immunoglobulin complex,virus disorder,0.5888888888888889
immunoglobulin complex,acellular structure,0.5963414634146341
immunoglobulin complex,incubation end process boundary,0.6009433962264151
immunoglobulin complex,SARS-CoV-2 disorder,0.5475609756097561
immunoglobulin complex,collective pathogenic disposition,0.5772727272727273
immunoglobulin complex,neurotoxin disposition,0.609090909090909
immunoglobulin complex,latency end temporal region,0.5928571428571429
immunoglobulin complex,infectious structure,0.6166666666666667
immunoglobulin complex,virus adhesion susceptible cell,0.619811320754717
immunoglobulin complex,collective disposition,0.5863636363636363
immunoglobulin complex,static agent disposition,0.558695652173913
immunoglobulin complex,T cell receptor complex,0.6722222222222223
immunoglobulin complex,infectious structure host,0.598936170212766
immunoglobulin complex,respiratory system disease,0.5541666666666667
immunoglobulin complex,infectious structure generative stage,0.5686440677966101
immunoglobulin complex,immunosuppressive disposition,0.6460784313725491
immunoglobulin complex,disordered prion,0.5552631578947369
immunoglobulin complex,pathogenic disposition,0.5636363636363636
immunoglobulin complex,cell,0.5269230769230769
immunoglobulin complex,infectious disposition,0.5863636363636363
immunoglobulin complex,bacteriostatic disposition,0.5541666666666667
immunoglobulin complex,epitope site,0.5676470588235294
immunoglobulin complex,bactericidal disposition,0.558695652173913
immunoglobulin complex,invasion disposition,0.5928571428571429
immunoglobulin complex,viricidal disposition,0.5662790697674418
immunoglobulin complex,complex infection,0.6294871794871795
immunoglobulin complex,pathogen portal of exit site,0.61
immunoglobulin complex,disposition,0.5712121212121213
immunoglobulin complex,COVID-19 mortality rate,0.6055555555555556
immunoglobulin complex,adhesion disposition,0.569047619047619
immunoglobulin complex,pathogen portal of entry site,0.5872549019607843
immunoglobulin complex,symptomatic infectious structure carrier,0.5790322580645162
immunoglobulin complex,site,0.5269230769230769
immunoglobulin complex,primary infectious disposition,0.5846153846153846
immunoglobulin complex,coronavirus disorder,0.5928571428571429
immunoglobulin complex,SARS-COV-2 adhesion susceptible cell,0.5879310344827586
immunoglobulin complex,virus synthesis stage,0.5895348837209302
immunoglobulin complex,SARS-COV-2 adhesion disposition,0.5443396226415094
immunoglobulin complex,invasive disposition,0.569047619047619
immunoglobulin complex,fungicidal disposition,0.609090909090909
immunoglobulin complex,acute respiratory distress syndrome,0.5728070175438597
immunoglobulin complex,disorder,0.55
immunoglobulin complex,exotoxin disposition,0.5928571428571429
immunoglobulin complex,immunoglobulin complex,0.95
immunoglobulin complex,action specification,0.5928571428571429
immunoglobulin complex,SARS-CoV-2 synthesis stage,0.5333333333333333
immunoglobulin complex,opportunistic infectious disposition,0.5879310344827586
immunoglobulin complex,quality,0.553448275862069
immunoglobulin complex,enterotoxin disposition,0.6055555555555556
immunoglobulin complex,polymerase chain reaction,0.598936170212766
immunoglobulin complex,infectious disease incidence rate,0.5954545454545455
immunoglobulin complex,disordered virus,0.5289473684210526
immunoglobulin complex,collective resistance disposition,0.5772727272727273
immunoglobulin complex,fungistatic disposition,0.5833333333333334
immunoglobulin complex,establishment of a clinically abnormal colony,0.6141791044776119
immunoglobulin complex,cell space,0.60625
systematic infection,virus aggregate,0.5928571428571429
systematic infection,source of infection,0.7576923076923078
systematic infection,virostatic disposition,0.7357142857142857
systematic infection,zoonotic disposition,0.675
systematic infection,infectious disease mortality rate,0.6009433962264151
systematic infection,infection incidence rate profile,0.6423076923076922
systematic infection,communicability end temporal region,0.6318181818181818
systematic infection,subclinical coronavirus infection,0.6952830188679244
systematic infection,infection end temporal region,0.6336734693877552
systematic infection,infectious disease,0.6605263157894737
systematic infection,SARS-CoV-2 incidence rate,0.65
systematic infection,double-stranded DNA virus,0.5833333333333334
systematic infection,incubation end temporal region,0.63
systematic infection,site of infection,0.8013513513513513
systematic infection,virulence factor disposition,0.6375
systematic infection,viral adhesion disposition,0.6239130434782608
systematic infection,parasitostatic disposition,0.7326086956521739
systematic infection,infectious disease incidence,0.6583333333333334
systematic infection,reverse zoonotic disposition,0.6791666666666666
systematic infection,subclinical SARS-CoV-2 infection,0.7192307692307692
systematic infection,virus translation stage,0.636046511627907
systematic infection,disease surveillance objective specification,0.66875
systematic infection,virus release stage,0.5782051282051281
systematic infection,source of infection site,0.7227272727272727
systematic infection,virus replication,0.6662162162162162
systematic infection,B cell receptor complex,0.5895348837209302
systematic infection,systematic infection,0.95
systematic infection,infection incidence rate,0.6545454545454545
systematic infection,virus host,0.55
systematic infection,double-stranded RNA virus,0.5833333333333334
systematic infection,virus transcription stage,0.65
systematic infection,infectious disease lifetime prevalence,0.6396551724137931
systematic infection,toxin disposition,0.6662162162162162
systematic infection,lower respiratory tract disease,0.6068627450980393
systematic infection,infectious disease incidence proportion,0.6703389830508475
systematic infection,virus generative stage,0.6166666666666667
systematic infection,acute infectious disease course,0.6656862745098039
systematic infection,cidal agent disposition,0.636046511627907
systematic infection,infectious disorder,0.6551282051282051
systematic infection,subclinical infection,0.7670731707317073
systematic infection,appearance of disorder,0.6166666666666667
systematic infection,simple infection,0.7833333333333333
systematic infection,parasiticidal disposition,0.6722222222222223
systematic infection,infectious disease sporadicity,0.61
systematic infection,communicability end process boundary,0.5928571428571429
systematic infection,infection incidence proportion profile,0.656896551724138
systematic infection,transmissibility disposition,0.6375
systematic infection,latency end process boundary,0.6166666666666667
systematic infection,infectious disease epidemic,0.6202127659574468
systematic infection,disease transmission model,0.6239130434782608
systematic infection,endotoxin disposition,0.6695121951219513
systematic infection,negative-sense single-stranded RNA virus,0.6166666666666667
systematic infection,COVID-19 incidence rate,0.6127906976744186
systematic infection,cytotoxin disposition,0.6939024390243902
systematic infection,community-acquired infection,0.7208333333333333
systematic infection,chronic infectious disease course,0.6575471698113208
systematic infection,nursing-home acquired infection,0.7245098039215686
systematic infection,COVID-19 epidemic,0.5851351351351352
systematic infection,secondary infection,0.7833333333333333
systematic infection,infection start temporal region,0.6460784313725491
systematic infection,infection incidence,0.6807692307692308
systematic infection,virus disorder,0.5676470588235294
systematic infection,primary infection,0.7743243243243243
systematic infection,process of establishing an infection,0.7178571428571427
systematic infection,incubation end process boundary,0.6068627450980393
systematic infection,SARS-CoV-2 disorder,0.6038461538461539
systematic infection,collective pathogenic disposition,0.6764150943396227
systematic infection,neurotoxin disposition,0.6642857142857143
systematic infection,plan specification,0.7131578947368421
systematic infection,latency end temporal region,0.6627659574468084
systematic infection,virus adhesion susceptible cell,0.5872549019607843
systematic infection,collective disposition,0.6642857142857143
systematic infection,infection,0.760344827586207
systematic infection,static agent disposition,0.7227272727272727
systematic infection,T cell receptor complex,0.6127906976744186
systematic infection,respiratory system disease,0.6456521739130434
systematic infection,communicability interval,0.609090909090909
systematic infection,infectious disease control strategy,0.6136363636363636
systematic infection,infectious disease pandemic,0.6414893617021277
systematic infection,immunosuppressive disposition,0.6336734693877552
systematic infection,pathogenic disposition,0.6880952380952381
systematic infection,viral disease course,0.6
systematic infection,intracellular infection,0.7523255813953489
systematic infection,secondary infection role,0.7454545454545455
systematic infection,metastatic infection,0.85
systematic infection,infectious disposition,0.6642857142857143
systematic infection,acute infection,0.7928571428571428
systematic infection,bacteriostatic disposition,0.7108695652173913
systematic infection,bactericidal disposition,0.6772727272727272
systematic infection,source of infection role,0.7227272727272727
systematic infection,chronic infection,0.7743243243243243
systematic infection,invasion disposition,0.65
systematic infection,disease course,0.6264705882352941
systematic infection,infectious disease course,0.6277777777777778
systematic infection,viricidal disposition,0.6451219512195122
systematic infection,complex infection,0.7472972972972972
systematic infection,COVID-19 disease incidence proportion,0.6605263157894737
systematic infection,coronavirus disease course,0.6021739130434782
systematic infection,infection incidence proportion,0.69
systematic infection,respiratory droplet virus fomite,0.6038461538461539
systematic infection,infectious disease prevalence,0.6336734693877552
systematic infection,disposition,0.6758064516129032
systematic infection,single-stranded DNA virus,0.6055555555555556
systematic infection,COVID-19 mortality rate,0.5662790697674418
systematic infection,viral disease,0.5712121212121213
systematic infection,primary infection role,0.7357142857142857
systematic infection,adhesion disposition,0.65
systematic infection,infection incidence profile,0.6414893617021277
systematic infection,contagiousness,0.6264705882352941
systematic infection,disease,0.5981481481481481
systematic infection,primary infectious disposition,0.69
systematic infection,infection prevalence,0.675
systematic infection,coronavirus disorder,0.575
systematic infection,subclinical virus infection,0.7265957446808511
systematic infection,establishment of localization in virus host,0.6246031746031746
systematic infection,virus attachment stage,0.5928571428571429
systematic infection,virus synthesis stage,0.6207317073170732
systematic infection,SARS-COV-2 adhesion disposition,0.6460784313725491
systematic infection,invasive disposition,0.65
systematic infection,long-term non-progressing infectious disease course,0.6330985915492958
systematic infection,viral disease epidemic,0.6166666666666667
systematic infection,communicability start temporal region,0.6429824561403508
systematic infection,fungicidal disposition,0.6404761904761905
systematic infection,viral disease pandemic,0.6166666666666667
systematic infection,virus penetration stage,0.636046511627907
systematic infection,acute respiratory distress syndrome,0.5954545454545455
systematic infection,infectious disease endemicity,0.6336734693877552
systematic infection,disorder,0.5214285714285714
systematic infection,communicability,0.5928571428571429
systematic infection,extracellular infection,0.7523255813953489
systematic infection,exotoxin disposition,0.675
systematic infection,infection start process boundary,0.6230769230769231
systematic infection,action specification,0.725
systematic infection,infectious disease control objective specification,0.65
systematic infection,opportunistic infectious disposition,0.7
systematic infection,process of establishing viral infection,0.7042372881355932
systematic infection,enterotoxin disposition,0.6825581395348838
systematic infection,COVID-19 disease course,0.5895348837209302
systematic infection,infectious disease incidence rate,0.6386792452830189
systematic infection,communicability start process boundary,0.6051724137931035
systematic infection,disordered virus,0.5611111111111111
systematic infection,collective resistance disposition,0.6575471698113208
systematic infection,fungistatic disposition,0.7290697674418604
systematic infection,virus uncoating stage,0.6207317073170732
systematic infection,local infection,0.7642857142857143
systematic infection,establishment of a clinically abnormal colony,0.6192307692307693
systematic infection,coronavirus disease,0.5782051282051281
systematic infection,positive-sense single-stranded RNA virus,0.6
systematic infection,hospital-acquired infection,0.747872340425532
chronic infection,virus aggregate,0.575
chronic infection,source of infection,0.7833333333333333
chronic infection,virostatic disposition,0.7064102564102563
chronic infection,zoonotic disposition,0.7202702702702704
chronic infection,infectious disease mortality rate,0.61
chronic infection,infection incidence rate profile,0.6540816326530612
chronic infection,communicability end temporal region,0.6615384615384616
chronic infection,biological regulation,0.6868421052631578
chronic infection,subclinical coronavirus infection,0.75
chronic infection,infection end temporal region,0.6456521739130434
chronic infection,infectious disease,0.6785714285714286
chronic infection,SARS-CoV-2 incidence rate,0.6404761904761905
chronic infection,double-stranded DNA virus,0.569047619047619
chronic infection,incubation end temporal region,0.6414893617021277
chronic infection,site of infection,0.7735294117647058
chronic infection,normal resident microbiota population,0.6166666666666667
chronic infection,virulence factor disposition,0.6722222222222223
chronic infection,viral adhesion disposition,0.6593023255813953
chronic infection,parasitostatic disposition,0.6825581395348838
chronic infection,infectious disease incidence,0.65
chronic infection,negative regulation of production,0.67
chronic infection,reverse zoonotic disposition,0.6944444444444444
chronic infection,subclinical SARS-CoV-2 infection,0.7357142857142857
chronic infection,virus translation stage,0.625
chronic infection,disease surveillance objective specification,0.630327868852459
chronic infection,virus release stage,0.5611111111111111
chronic infection,source of infection site,0.7426829268292683
chronic infection,virus replication,0.6852941176470588
chronic infection,B cell receptor complex,0.6
chronic infection,systematic infection,0.7743243243243243
chronic infection,infection incidence rate,0.6695121951219513
chronic infection,virus host,0.5611111111111111
chronic infection,double-stranded RNA virus,0.569047619047619
chronic infection,virus transcription stage,0.6404761904761905
chronic infection,infectious disease lifetime prevalence,0.6318181818181818
chronic infection,toxin disposition,0.6852941176470588
chronic infection,lower respiratory tract disease,0.575
chronic infection,infectious disease incidence proportion,0.6642857142857143
chronic infection,virus generative stage,0.6038461538461539
chronic infection,acute infectious disease course,0.6583333333333334
chronic infection,cidal agent disposition,0.65
chronic infection,infectious disorder,0.6722222222222223
chronic infection,subclinical infection,0.8184210526315789
chronic infection,appearance of disorder,0.6294871794871795
chronic infection,simple infection,0.7833333333333333
chronic infection,parasiticidal disposition,0.6642857142857143
chronic infection,infectious disease sporadicity,0.6202127659574468
chronic infection,communicability end process boundary,0.6386792452830189
chronic infection,infection incidence proportion profile,0.6681818181818181
chronic infection,transmissibility disposition,0.65
chronic infection,latency end process boundary,0.6055555555555556
chronic infection,infectious disease epidemic,0.6318181818181818
chronic infection,disease transmission model,0.5895348837209302
chronic infection,endotoxin disposition,0.6605263157894737
chronic infection,negative regulation of establishment of localization,0.6239130434782608
chronic infection,negative-sense single-stranded RNA virus,0.5903508771929825
chronic infection,COVID-19 incidence rate,0.675
chronic infection,cytotoxin disposition,0.6868421052631578
chronic infection,community-acquired infection,0.7833333333333333
chronic infection,negative regulation of developmental process,0.5975409836065574
chronic infection,chronic infectious disease course,0.77
chronic infection,nursing-home acquired infection,0.7208333333333333
chronic infection,COVID-19 epidemic,0.6558823529411765
chronic infection,negative regulation of replication,0.6852941176470588
chronic infection,secondary infection,0.8111111111111111
chronic infection,infection start temporal region,0.6375
chronic infection,infection incidence,0.7
chronic infection,virus disorder,0.5790322580645162
chronic infection,primary infection,0.8029411764705883
chronic infection,process of establishing an infection,0.6952830188679244
chronic infection,incubation end process boundary,0.6166666666666667
chronic infection,SARS-CoV-2 disorder,0.5888888888888889
chronic infection,collective pathogenic disposition,0.69
chronic infection,neurotoxin disposition,0.6807692307692308
chronic infection,latency end temporal region,0.6318181818181818
chronic infection,virus adhesion susceptible cell,0.5958333333333333
chronic infection,collective disposition,0.6807692307692308
chronic infection,infection,0.7961538461538461
chronic infection,static agent disposition,0.6451219512195122
chronic infection,T cell receptor complex,0.6
chronic infection,respiratory system disease,0.5662790697674418
chronic infection,communicability interval,0.6695121951219513
chronic infection,infectious disease control strategy,0.6230769230769231
chronic infection,infectious disease pandemic,0.6545454545454545
chronic infection,immunosuppressive disposition,0.6239130434782608
chronic infection,pathogenic disposition,0.732051282051282
chronic infection,viral disease course,0.6121621621621621
chronic infection,intracellular infection,0.75
chronic infection,secondary infection role,0.7670731707317073
chronic infection,metastatic infection,0.7743243243243243
chronic infection,infectious disposition,0.6807692307692308
chronic infection,acute infection,0.79375
chronic infection,bacteriostatic disposition,0.7058139534883722
chronic infection,bactericidal disposition,0.6939024390243902
chronic infection,source of infection role,0.7426829268292683
chronic infection,chronic infection,0.95
chronic infection,invasion disposition,0.6662162162162162
chronic infection,disease course,0.5790322580645162
chronic infection,infectious disease course,0.6404761904761905
chronic infection,viricidal disposition,0.6868421052631578
chronic infection,complex infection,0.8029411764705883
chronic infection,COVID-19 disease incidence proportion,0.6722222222222223
chronic infection,coronavirus disease course,0.6825581395348838
chronic infection,infection incidence proportion,0.7053191489361703
chronic infection,respiratory droplet virus fomite,0.5928571428571429
chronic infection,infectious disease prevalence,0.6456521739130434
chronic infection,disposition,0.6642857142857143
chronic infection,single-stranded DNA virus,0.569047619047619
chronic infection,COVID-19 mortality rate,0.6
chronic infection,negative regulation of life-sustaining process,0.6087301587301588
chronic infection,viral disease,0.5833333333333334
chronic infection,primary infection role,0.7576923076923078
chronic infection,adhesion disposition,0.6932432432432433
chronic infection,infection incidence profile,0.6545454545454545
chronic infection,contagiousness,0.6758064516129032
chronic infection,disease,0.5333333333333333
chronic infection,primary infectious disposition,0.7053191489361703
chronic infection,infection prevalence,0.6932432432432433
chronic infection,coronavirus disorder,0.6662162162162162
chronic infection,subclinical virus infection,0.7681818181818181
chronic infection,establishment of localization in virus host,0.6
chronic infection,virus attachment stage,0.5782051282051281
chronic infection,negative regulation of immune response,0.6136363636363636
chronic infection,virus synthesis stage,0.581578947368421
chronic infection,SARS-COV-2 adhesion disposition,0.6583333333333334
chronic infection,invasive disposition,0.6662162162162162
chronic infection,long-term non-progressing infectious disease course,0.6411764705882353
chronic infection,viral disease epidemic,0.6038461538461539
chronic infection,communicability start temporal region,0.6351851851851852
chronic infection,fungicidal disposition,0.6807692307692308
chronic infection,viral disease pandemic,0.6038461538461539
chronic infection,virus penetration stage,0.65
chronic infection,acute respiratory distress syndrome,0.5846153846153846
chronic infection,infectious disease endemicity,0.6456521739130434
chronic infection,negative regulation of viral process,0.6009433962264151
chronic infection,disorder,0.53
chronic infection,communicability,0.66875
chronic infection,extracellular infection,0.75
chronic infection,exotoxin disposition,0.6662162162162162
chronic infection,infection start process boundary,0.6336734693877552
chronic infection,action specification,0.7472972972972972
chronic infection,infectious disease control objective specification,0.6291044776119403
chronic infection,opportunistic infectious disposition,0.7141509433962264
chronic infection,process of establishing viral infection,0.7
chronic infection,negative regulation of biological process,0.5879310344827586
chronic infection,enterotoxin disposition,0.675
chronic infection,COVID-19 disease course,0.65
chronic infection,infectious disease incidence rate,0.63
chronic infection,communicability start process boundary,0.6136363636363636
chronic infection,single-stranded RNA retrovirus,0.598936170212766
chronic infection,disordered virus,0.5409090909090909
chronic infection,collective resistance disposition,0.67
chronic infection,fungistatic disposition,0.675
chronic infection,virus uncoating stage,0.6342105263157894
chronic infection,local infection,0.825
chronic infection,establishment of a clinically abnormal colony,0.6112903225806451
chronic infection,coronavirus disease,0.6722222222222223
chronic infection,positive-sense single-stranded RNA virus,0.5903508771929825
chronic infection,hospital-acquired infection,0.7681818181818181
virus aggregate,extended organism,0.575
virus aggregate,virus aggregate,0.95
virus aggregate,source of infection,0.5676470588235294
virus aggregate,virostatic disposition,0.6121621621621621
virus aggregate,zoonotic disposition,0.5357142857142857
virus aggregate,immune response,0.65
virus aggregate,infectious disease mortality rate,0.6375
virus aggregate,infection incidence rate profile,0.5776595744680851
virus aggregate,infectious structure aggregate,0.7388888888888888
virus aggregate,communicability end temporal region,0.57
virus aggregate,pathogen generative stage,0.625
virus aggregate,pathogen portal of entry,0.5782051282051281
virus aggregate,subclinical coronavirus infection,0.6166666666666667
virus aggregate,primary pathogen,0.6435483870967742
virus aggregate,infection end temporal region,0.5863636363636363
virus aggregate,drug-based immunosuppressed organism,0.6068627450980393
virus aggregate,infectious disease,0.6621212121212122
virus aggregate,SARS-CoV-2 incidence rate,0.625
virus aggregate,double-stranded DNA virus,0.575
virus aggregate,incubation end temporal region,0.6055555555555556
virus aggregate,site of infection,0.575
virus aggregate,immunocompetent organism,0.6038461538461539
virus aggregate,virulence factor disposition,0.636046511627907
virus aggregate,pathogen portal of exit,0.581578947368421
virus aggregate,viral adhesion disposition,0.6207317073170732
virus aggregate,parasitostatic disposition,0.5475609756097561
virus aggregate,infectious disease incidence,0.6127906976744186
virus aggregate,reservoir of pathogen role,0.6451219512195122
virus aggregate,reverse zoonotic disposition,0.5662790697674418
virus aggregate,subclinical SARS-CoV-2 infection,0.5776595744680851
virus aggregate,virus translation stage,0.7131578947368421
virus aggregate,disease surveillance objective specification,0.5855932203389831
virus aggregate,virus release stage,0.7735294117647058
virus aggregate,SARS-CoV-2 aggregate,0.7928571428571428
virus aggregate,source of infection site,0.5782051282051281
virus aggregate,virus,0.7
virus aggregate,virus replication,0.7625
virus aggregate,B cell receptor complex,0.581578947368421
virus aggregate,systematic infection,0.5928571428571429
virus aggregate,infection incidence rate,0.6038461538461539
virus aggregate,virus host,0.73
virus aggregate,double-stranded RNA virus,0.575
virus aggregate,pathogen portal of entry role,0.5863636363636363
virus aggregate,virus transcription stage,0.7
virus aggregate,infectious disease lifetime prevalence,0.619811320754717
virus aggregate,toxin disposition,0.54375
virus aggregate,pathogen birth temporal region,0.6055555555555556
virus aggregate,lower respiratory tract disease,0.6021739130434782
virus aggregate,infectious disease incidence proportion,0.5796296296296296
virus aggregate,opportunistic pathogen,0.6391891891891892
virus aggregate,virus generative stage,0.7472972972972972
virus aggregate,acute infectious disease course,0.6021739130434782
virus aggregate,cidal agent disposition,0.6078947368421053
virus aggregate,infectious disorder,0.6264705882352941
virus aggregate,genetic resistance to pathogen,0.6277777777777778
virus aggregate,subclinical infection,0.5611111111111111
virus aggregate,appearance of disorder,0.5581081081081081
virus aggregate,simple infection,0.5790322580645162
virus aggregate,droplet pathogen transmission process,0.5846153846153846
virus aggregate,parasiticidal disposition,0.55
virus aggregate,infectious disease sporadicity,0.6277777777777778
virus aggregate,communicability end process boundary,0.5676470588235294
virus aggregate,acellular structure aggregate,0.7227272727272727
virus aggregate,infection incidence proportion profile,0.5443396226415094
virus aggregate,pathogen transporter,0.6214285714285714
virus aggregate,transmissibility disposition,0.5430232558139535
virus aggregate,latency end process boundary,0.5662790697674418
virus aggregate,infectious disease epidemic,0.6166666666666667
virus aggregate,disease transmission model,0.5963414634146341
virus aggregate,endotoxin disposition,0.5333333333333333
virus aggregate,pathologically immunosuppressed organism,0.5772727272727273
virus aggregate,negative-sense single-stranded RNA virus,0.5772727272727273
virus aggregate,pathogen vehicle,0.5790322580645162
virus aggregate,COVID-19 incidence rate,0.6342105263157894
virus aggregate,cytotoxin disposition,0.5333333333333333
virus aggregate,community-acquired infection,0.5662790697674418
virus aggregate,pathogen vector,0.5833333333333334
virus aggregate,pathogen vehicle role,0.5888888888888889
virus aggregate,chronic infectious disease course,0.5958333333333333
virus aggregate,nursing-home acquired infection,0.6021739130434782
virus aggregate,COVID-19 epidemic,0.60625
virus aggregate,secondary infection,0.5970588235294118
virus aggregate,infection start temporal region,0.6021739130434782
virus aggregate,infection incidence,0.5676470588235294
virus aggregate,virus disorder,0.7258620689655172
virus aggregate,primary infection,0.60625
virus aggregate,process of establishing an infection,0.5872549019607843
virus aggregate,incubation end process boundary,0.5804347826086956
virus aggregate,SARS-CoV-2 disorder,0.5970588235294118
virus aggregate,collective pathogenic disposition,0.575
virus aggregate,neurotoxin disposition,0.5310810810810811
virus aggregate,pathogen death process boundary,0.5804347826086956
virus aggregate,immunosuppressed organism,0.625
virus aggregate,latency end temporal region,0.569047619047619
virus aggregate,coronavirus aggregate,0.8666666666666667
virus aggregate,virus adhesion susceptible cell,0.6673913043478261
virus aggregate,collective disposition,0.5581081081081081
virus aggregate,infection,0.575
virus aggregate,static agent disposition,0.6038461538461539
virus aggregate,T cell receptor complex,0.581578947368421
virus aggregate,respiratory system disease,0.6207317073170732
virus aggregate,indirect pathogen transmission process,0.6009433962264151
virus aggregate,organism population,0.5970588235294118
virus aggregate,infectious disease control strategy,0.63
virus aggregate,infectious disease pandemic,0.6404761904761905
virus aggregate,immunosuppressive disposition,0.5863636363636363
virus aggregate,innate immune response,0.6121621621621621
virus aggregate,pathogenic disposition,0.5581081081081081
virus aggregate,viral disease course,0.65
virus aggregate,intracellular infection,0.6342105263157894
virus aggregate,secondary infection role,0.6038461538461539
virus aggregate,metastatic infection,0.5642857142857143
virus aggregate,infectious disposition,0.5851351351351352
virus aggregate,acute infection,0.5833333333333334
virus aggregate,bacteriostatic disposition,0.5475609756097561
virus aggregate,epitope site,0.5981481481481481
virus aggregate,immunity to pathogen,0.6214285714285714
virus aggregate,bactericidal disposition,0.5525641025641026
virus aggregate,source of infection role,0.5782051282051281
virus aggregate,pathogen host,0.5928571428571429
virus aggregate,acquired immunodeficiency,0.575
virus aggregate,chronic infection,0.575
virus aggregate,invasion disposition,0.5642857142857143
virus aggregate,disease course,0.6224137931034482
virus aggregate,infectious disease course,0.625
virus aggregate,viricidal disposition,0.5888888888888889
virus aggregate,acquired immunity to infectious agent,0.6230769230769231
virus aggregate,complex infection,0.54375
virus aggregate,prion aggregate,0.8166666666666665
virus aggregate,COVID-19 disease incidence proportion,0.5653846153846154
virus aggregate,coronavirus disease course,0.6695121951219513
virus aggregate,infection incidence proportion,0.5388888888888889
virus aggregate,respiratory droplet virus fomite,0.6202127659574468
virus aggregate,susceptible organism,0.6214285714285714
virus aggregate,pathogen vector role,0.5928571428571429
virus aggregate,pathogen portal of exit site,0.5895348837209302
virus aggregate,infectious disease prevalence,0.6545454545454545
virus aggregate,organism substance,0.6015151515151516
virus aggregate,disposition,0.5653846153846154
virus aggregate,single-stranded DNA virus,0.575
virus aggregate,COVID-19 mortality rate,0.6605263157894737
virus aggregate,viral disease,0.7
virus aggregate,primary infection role,0.6121621621621621
virus aggregate,adhesion disposition,0.5357142857142857
virus aggregate,pathogen portal of entry site,0.5863636363636363
virus aggregate,infection incidence profile,0.5452380952380953
virus aggregate,viroid aggregate,0.8693548387096774
virus aggregate,disease,0.6772727272727272
virus aggregate,site,0.6078947368421053
virus aggregate,primary infectious disposition,0.5833333333333334
virus aggregate,pathogen host role,0.6015151515151516
virus aggregate,infection prevalence,0.6214285714285714
virus aggregate,humoral immune response,0.6078947368421053
virus aggregate,coronavirus disorder,0.6785714285714286
virus aggregate,infectious pathogen transmissibility,0.6264705882352941
virus aggregate,pathogen surveillance,0.6166666666666667
virus aggregate,immunodeficient organism,0.6038461538461539
virus aggregate,pathogen,0.5804347826086956
virus aggregate,pathogen birth process boundary,0.5804347826086956
virus aggregate,infectious human pathogen,0.65
virus aggregate,subclinical virus infection,0.6404761904761905
virus aggregate,resistance to pathogen,0.6391891891891892
virus aggregate,establishment of localization in virus host,0.5706896551724138
virus aggregate,virus attachment stage,0.7202702702702704
virus aggregate,negative regulation of immune response,0.6009433962264151
virus aggregate,virus synthesis stage,0.7
virus aggregate,SARS-COV-2 adhesion disposition,0.5804347826086956
virus aggregate,object aggregate,0.7725806451612902
virus aggregate,pathogen portal of exit role,0.5895348837209302
virus aggregate,invasive disposition,0.5642857142857143
virus aggregate,re-emerging pathogen,0.6214285714285714
virus aggregate,long-term non-progressing infectious disease course,0.5712121212121213
virus aggregate,viral disease epidemic,0.6391891891891892
virus aggregate,fungicidal disposition,0.5581081081081081
virus aggregate,viral disease pandemic,0.6662162162162162
virus aggregate,virus penetration stage,0.7131578947368421
virus aggregate,pathogen seroprevalence,0.6078947368421053
virus aggregate,acute respiratory distress syndrome,0.59
virus aggregate,infectious disease endemicity,0.609090909090909
virus aggregate,contact pathogen transmission process,0.5653846153846154
virus aggregate,disorder,0.6239130434782608
virus aggregate,herd immunity to infectious organism,0.5872549019607843
virus aggregate,extracellular infection,0.6078947368421053
virus aggregate,pathogen transporter role,0.6
virus aggregate,transmission interval,0.5888888888888889
virus aggregate,exotoxin disposition,0.5357142857142857
virus aggregate,infection start process boundary,0.5776595744680851
virus aggregate,infectious disease control objective specification,0.5884615384615385
virus aggregate,immune population,0.60625
virus aggregate,opportunistic infectious disposition,0.5676470588235294
virus aggregate,process of establishing viral infection,0.5981481481481481
virus aggregate,enterotoxin disposition,0.5289473684210526
virus aggregate,COVID-19 disease course,0.6078947368421053
virus aggregate,infectious disease incidence rate,0.6375
virus aggregate,disordered virus,0.6112903225806451
virus aggregate,collective resistance disposition,0.575
virus aggregate,adaptive immune response,0.6294871794871795
virus aggregate,viral load,0.65
virus aggregate,fungistatic disposition,0.5552631578947369
virus aggregate,organism,0.5804347826086956
virus aggregate,virus uncoating stage,0.7277777777777777
virus aggregate,local infection,0.55
virus aggregate,establishment of a clinically abnormal colony,0.55
virus aggregate,coronavirus disease,0.7147058823529412
virus aggregate,positive-sense single-stranded RNA virus,0.5772727272727273
virus aggregate,horizontal pathogen transmission process,0.5772727272727273
virus aggregate,hospital-acquired infection,0.569047619047619
virus aggregate,pathogen death temporal region,0.5833333333333334
virus aggregate,emerging pathogen,0.6375
virus aggregate,pathogen transmission process,0.5636363636363636
bactericidal disposition,virostatic disposition,0.7978260869565217
bactericidal disposition,information content entity,0.59
bactericidal disposition,zoonotic disposition,0.7909090909090909
bactericidal disposition,infectious disease mortality rate,0.6254385964912281
bactericidal disposition,infection incidence rate profile,0.6464285714285714
bactericidal disposition,infectious structure aggregate,0.5611111111111111
bactericidal disposition,communicability end temporal region,0.6533898305084747
bactericidal disposition,geographical entity,0.6593023255813953
bactericidal disposition,biological regulation,0.6722222222222223
bactericidal disposition,surveillance process,0.609090909090909
bactericidal disposition,infection end temporal region,0.6386792452830189
bactericidal disposition,vector control strategy,0.6202127659574468
bactericidal disposition,SARS-CoV-2 incidence rate,0.6132653061224489
bactericidal disposition,incubation end temporal region,0.6537037037037037
bactericidal disposition,resistant entity,0.6
bactericidal disposition,virulence factor disposition,0.7576923076923078
bactericidal disposition,viral adhesion disposition,0.75
bactericidal disposition,parasitostatic disposition,0.77
bactericidal disposition,negative regulation of production,0.6605263157894737
bactericidal disposition,reverse zoonotic disposition,0.7576923076923078
bactericidal disposition,establishment of localization in host,0.630327868852459
bactericidal disposition,disease surveillance objective specification,0.6558823529411765
bactericidal disposition,case isolation control strategy,0.6318181818181818
bactericidal disposition,infectious agent host role,0.63
bactericidal disposition,macromolecular complex,0.6021739130434782
bactericidal disposition,material entity,0.7064102564102563
bactericidal disposition,asymptomatic infectious structure carrier,0.6038461538461539
bactericidal disposition,architectual structure,0.6673913043478261
bactericidal disposition,quarantine control strategy,0.6068627450980393
bactericidal disposition,B cell receptor complex,0.6202127659574468
bactericidal disposition,infection incidence rate,0.6166666666666667
bactericidal disposition,colonized host,0.6342105263157894
bactericidal disposition,virus host,0.5970588235294118
bactericidal disposition,entity,0.55
bactericidal disposition,toxin disposition,0.7914634146341464
bactericidal disposition,cidal agent disposition,0.8117021276595744
bactericidal disposition,parasiticidal disposition,0.8581632653061224
bactericidal disposition,communicability end process boundary,0.65
bactericidal disposition,directive information content entity,0.6166666666666667
bactericidal disposition,acellular structure aggregate,0.5820754716981132
bactericidal disposition,transmissibility disposition,0.7769230769230769
bactericidal disposition,latency end process boundary,0.6615384615384616
bactericidal disposition,colonization of host,0.6318181818181818
bactericidal disposition,realizable entity,0.6207317073170732
bactericidal disposition,endotoxin disposition,0.7611111111111112
bactericidal disposition,vector surveillance,0.6127906976744186
bactericidal disposition,negative regulation of establishment of localization,0.6473684210526315
bactericidal disposition,cidal agent,0.65
bactericidal disposition,infectious structure host role,0.6166666666666667
bactericidal disposition,COVID-19 incidence rate,0.598936170212766
bactericidal disposition,cytotoxin disposition,0.7833333333333333
bactericidal disposition,negative regulation of developmental process,0.6264705882352941
bactericidal disposition,antibiotic resistance,0.65
bactericidal disposition,host,0.5571428571428572
bactericidal disposition,descriptive information content entity,0.6274193548387097
bactericidal disposition,negative regulation of replication,0.656896551724138
bactericidal disposition,sterilizing immunity to infectious agent,0.653125
bactericidal disposition,establishment of localization in human host,0.6141791044776119
bactericidal disposition,acellular structure,0.6127906976744186
bactericidal disposition,incubation end process boundary,0.65
bactericidal disposition,collective pathogenic disposition,0.7482456140350877
bactericidal disposition,neurotoxin disposition,0.7760869565217391
bactericidal disposition,dead-end host role,0.6404761904761905
bactericidal disposition,molecular entity,0.6
bactericidal disposition,plan specification,0.6642857142857143
bactericidal disposition,definitive host role,0.6318181818181818
bactericidal disposition,latency end temporal region,0.6656862745098039
bactericidal disposition,infectious structure,0.5863636363636363
bactericidal disposition,collective disposition,0.7978260869565217
bactericidal disposition,bactericidal,0.7833333333333333
bactericidal disposition,static agent disposition,0.8041666666666667
bactericidal disposition,T cell receptor complex,0.598936170212766
bactericidal disposition,infectious structure host,0.6132653061224489
bactericidal disposition,respiratory system disease,0.61
bactericidal disposition,entry into host,0.6294871794871795
bactericidal disposition,adhesion of symbiont to host,0.6230769230769231
bactericidal disposition,infectious disease control strategy,0.6194915254237288
bactericidal disposition,infectious structure generative stage,0.5811475409836065
bactericidal disposition,immunosuppressive disposition,0.7141509433962264
bactericidal disposition,pathogenic disposition,0.8195652173913044
bactericidal disposition,entry into host through host barriers,0.5975409836065574
bactericidal disposition,infectious disposition,0.7760869565217391
bactericidal disposition,bacteriostatic disposition,0.85
bactericidal disposition,bactericidal disposition,0.95
bactericidal disposition,pathogen host,0.6391891891891892
bactericidal disposition,invasion disposition,0.7681818181818181
bactericidal disposition,viricidal disposition,0.8722222222222222
bactericidal disposition,complex infection,0.6451219512195122
bactericidal disposition,intermediate host,0.6695121951219513
bactericidal disposition,anatomical entity,0.6695121951219513
bactericidal disposition,disposition,0.7642857142857143
bactericidal disposition,COVID-19 mortality rate,0.598936170212766
bactericidal disposition,negative regulation of life-sustaining process,0.6214285714285714
bactericidal disposition,place closure control strategy,0.6166666666666667
bactericidal disposition,geopolitical entity,0.636046511627907
bactericidal disposition,adhesion disposition,0.7909090909090909
bactericidal disposition,symptomatic infectious structure carrier,0.60625
bactericidal disposition,primary infectious disposition,0.7648148148148148
bactericidal disposition,pathogen host role,0.6404761904761905
bactericidal disposition,designative information content entity,0.6112903225806451
bactericidal disposition,intermediate host role,0.6673913043478261
bactericidal disposition,dead-end host,0.6391891891891892
bactericidal disposition,pathogen surveillance,0.6055555555555556
bactericidal disposition,host role,0.5712121212121213
bactericidal disposition,establishment of localization in virus host,0.6141791044776119
bactericidal disposition,negative regulation of immune response,0.6274193548387097
bactericidal disposition,immaterial entity,0.6939024390243902
bactericidal disposition,SARS-COV-2 adhesion disposition,0.740909090909091
bactericidal disposition,invasive disposition,0.7681818181818181
bactericidal disposition,infectious agent host,0.6277777777777778
bactericidal disposition,fungicidal disposition,0.8413043478260869
bactericidal disposition,division of geopolitical entity,0.6136363636363636
bactericidal disposition,negative regulation of viral process,0.65
bactericidal disposition,exotoxin disposition,0.7681818181818181
bactericidal disposition,immunoglobulin complex,0.558695652173913
bactericidal disposition,infectious disease control objective specification,0.6527027027027027
bactericidal disposition,symbiont host role,0.6166666666666667
bactericidal disposition,opportunistic infectious disposition,0.7166666666666667
bactericidal disposition,negative regulation of biological process,0.6346153846153847
bactericidal disposition,enterotoxin disposition,0.7904255319148936
bactericidal disposition,infectious disease incidence rate,0.6429824561403508
bactericidal disposition,collective resistance disposition,0.7657894736842106
bactericidal disposition,fungistatic disposition,0.7904255319148936
bactericidal disposition,establishment of a clinically abnormal colony,0.6094202898550725
bactericidal disposition,definitive host,0.6294871794871795
bactericidal disposition,bacteria,0.7
establishment of localization in virus host,extended organism,0.6166666666666667
establishment of localization in virus host,virus aggregate,0.5706896551724138
establishment of localization in virus host,source of infection,0.6274193548387097
establishment of localization in virus host,virostatic disposition,0.6346153846153847
establishment of localization in virus host,zoonotic disposition,0.6087301587301588
establishment of localization in virus host,immune response,0.5879310344827586
establishment of localization in virus host,infectious disease mortality rate,0.6342105263157894
establishment of localization in virus host,infection incidence rate profile,0.65
establishment of localization in virus host,infectious structure aggregate,0.6143835616438357
establishment of localization in virus host,communicability end temporal region,0.6166666666666667
establishment of localization in virus host,pathogen generative stage,0.6264705882352941
establishment of localization in virus host,pathogen portal of entry,0.6291044776119403
establishment of localization in virus host,subclinical coronavirus infection,0.6736842105263158
establishment of localization in virus host,primary pathogen,0.5686440677966101
establishment of localization in virus host,infection end temporal region,0.6444444444444444
establishment of localization in virus host,drug-based immunosuppressed organism,0.5892405063291138
establishment of localization in virus host,infectious disease,0.630327868852459
establishment of localization in virus host,double-stranded DNA virus,0.6558823529411765
establishment of localization in virus host,incubation end temporal region,0.6417808219178082
establishment of localization in virus host,site of infection,0.65
establishment of localization in virus host,immunocompetent organism,0.6141791044776119
establishment of localization in virus host,virulence factor disposition,0.6471830985915493
establishment of localization in virus host,pathogen portal of exit,0.6318181818181818
establishment of localization in virus host,viral adhesion disposition,0.6384057971014493
establishment of localization in virus host,parasitostatic disposition,0.6384057971014493
establishment of localization in virus host,infectious disease incidence,0.6049295774647887
establishment of localization in virus host,reservoir of pathogen role,0.6528985507246376
establishment of localization in virus host,reverse zoonotic disposition,0.6471830985915493
establishment of localization in virus host,subclinical SARS-CoV-2 infection,0.65
establishment of localization in virus host,establishment of localization in host,0.9125
establishment of localization in virus host,virus translation stage,0.6469696969696969
establishment of localization in virus host,disease surveillance objective specification,0.6224137931034482
establishment of localization in virus host,virus release stage,0.5951612903225807
establishment of localization in virus host,infectious agent host role,0.6528985507246376
establishment of localization in virus host,asymptomatic infectious structure carrier,0.6523809523809524
establishment of localization in virus host,source of infection site,0.658955223880597
establishment of localization in virus host,architectual structure,0.6038461538461539
establishment of localization in virus host,virus,0.5541666666666667
establishment of localization in virus host,virus replication,0.6166666666666667
establishment of localization in virus host,B cell receptor complex,0.5863636363636363
establishment of localization in virus host,systematic infection,0.6246031746031746
establishment of localization in virus host,infection incidence rate,0.658955223880597
establishment of localization in virus host,colonized host,0.6254385964912281
establishment of localization in virus host,virus host,0.6386792452830189
establishment of localization in virus host,double-stranded RNA virus,0.6558823529411765
establishment of localization in virus host,pathogen portal of entry role,0.6444444444444444
establishment of localization in virus host,virus transcription stage,0.6411764705882353
establishment of localization in virus host,infectious disease lifetime prevalence,0.5981481481481481
establishment of localization in virus host,toxin disposition,0.6166666666666667
establishment of localization in virus host,pathogen birth temporal region,0.6143835616438357
establishment of localization in virus host,lower respiratory tract disease,0.6121621621621621
establishment of localization in virus host,infectious disease incidence proportion,0.6329268292682927
establishment of localization in virus host,opportunistic pathogen,0.5884615384615385
establishment of localization in virus host,virus generative stage,0.6192307692307693
establishment of localization in virus host,acute infectious disease course,0.6391891891891892
establishment of localization in virus host,cidal agent disposition,0.6318181818181818
establishment of localization in virus host,infectious disorder,0.6274193548387097
establishment of localization in virus host,genetic resistance to pathogen,0.6143835616438357
establishment of localization in virus host,subclinical infection,0.653125
establishment of localization in virus host,appearance of disorder,0.6038461538461539
establishment of localization in virus host,simple infection,0.6364406779661017
establishment of localization in virus host,droplet pathogen transmission process,0.65
establishment of localization in virus host,parasiticidal disposition,0.6264705882352941
establishment of localization in virus host,infectious disease sporadicity,0.6280821917808219
establishment of localization in virus host,communicability end process boundary,0.6272151898734176
establishment of localization in virus host,acellular structure aggregate,0.5888888888888889
establishment of localization in virus host,infection incidence proportion profile,0.6351851851851852
establishment of localization in virus host,pathogen transporter,0.6087301587301588
establishment of localization in virus host,invasion factor,0.6051724137931035
establishment of localization in virus host,transmissibility disposition,0.6330985915492958
establishment of localization in virus host,latency end process boundary,0.6049295774647887
establishment of localization in virus host,colonization of host,0.7039682539682539
establishment of localization in virus host,infectious disease epidemic,0.6071428571428572
establishment of localization in virus host,disease transmission model,0.6239130434782608
establishment of localization in virus host,endotoxin disposition,0.653125
establishment of localization in virus host,negative regulation of establishment of localization,0.7552631578947369
establishment of localization in virus host,pathologically immunosuppressed organism,0.6427710843373494
establishment of localization in virus host,negative-sense single-stranded RNA virus,0.6668674698795181
establishment of localization in virus host,infectious structure host role,0.6554794520547945
establishment of localization in virus host,pathogen vehicle,0.5686440677966101
establishment of localization in virus host,establishment of localization,0.8527777777777777
establishment of localization in virus host,cytotoxin disposition,0.6375
establishment of localization in virus host,community-acquired infection,0.6049295774647887
establishment of localization in virus host,pathogen vector,0.6051724137931035
establishment of localization in virus host,pathogen vehicle role,0.60625
establishment of localization in virus host,host,0.5351063829787234
establishment of localization in virus host,chronic infectious disease course,0.6342105263157894
establishment of localization in virus host,nursing-home acquired infection,0.6256756756756756
establishment of localization in virus host,COVID-19 epidemic,0.5333333333333333
establishment of localization in virus host,secondary infection,0.6112903225806451
establishment of localization in virus host,infection start temporal region,0.6256756756756756
establishment of localization in virus host,infection incidence,0.6435483870967742
establishment of localization in virus host,virus disorder,0.5728070175438597
establishment of localization in virus host,establishment of localization in human host,0.9034883720930234
establishment of localization in virus host,acellular structure,0.5951612903225807
establishment of localization in virus host,primary infection,0.6
establishment of localization in virus host,virulence factor,0.6025423728813559
establishment of localization in virus host,process of establishing an infection,0.6778481012658227
establishment of localization in virus host,incubation end process boundary,0.6527027027027027
establishment of localization in virus host,SARS-CoV-2 disorder,0.5951612903225807
establishment of localization in virus host,collective pathogenic disposition,0.6605263157894737
establishment of localization in virus host,neurotoxin disposition,0.6346153846153847
establishment of localization in virus host,dead-end host role,0.6139344262295081
establishment of localization in virus host,pathogen death process boundary,0.6121621621621621
establishment of localization in virus host,immunosuppressed organism,0.5970588235294118
establishment of localization in virus host,plan specification,0.6139344262295081
establishment of localization in virus host,definitive host role,0.6404761904761905
establishment of localization in virus host,latency end temporal region,0.6071428571428572
establishment of localization in virus host,infectious structure,0.6404761904761905
establishment of localization in virus host,virus adhesion susceptible cell,0.5986486486486486
establishment of localization in virus host,collective disposition,0.6192307692307693
establishment of localization in virus host,infection,0.6038461538461539
establishment of localization in virus host,static agent disposition,0.658955223880597
establishment of localization in virus host,T cell receptor complex,0.5863636363636363
establishment of localization in virus host,infectious structure host,0.6705882352941177
establishment of localization in virus host,respiratory system disease,0.6094202898550725
establishment of localization in virus host,entry into host,0.656896551724138
establishment of localization in virus host,indirect pathogen transmission process,0.6475308641975309
establishment of localization in virus host,adhesion of symbiont to host,0.6894366197183097
establishment of localization in virus host,organism population,0.6435483870967742
establishment of localization in virus host,infectious disease control strategy,0.6294871794871795
establishment of localization in virus host,infectious disease pandemic,0.6071428571428572
establishment of localization in virus host,infectious structure generative stage,0.6125
establishment of localization in virus host,immunosuppressive disposition,0.6027777777777777
establishment of localization in virus host,innate immune response,0.6346153846153847
establishment of localization in virus host,pathogenic disposition,0.6192307692307693
establishment of localization in virus host,viral disease course,0.6087301587301588
establishment of localization in virus host,entry into host through host barriers,0.6625
establishment of localization in virus host,intracellular infection,0.6166666666666667
establishment of localization in virus host,secondary infection role,0.6440298507462687
establishment of localization in virus host,metastatic infection,0.6563492063492063
establishment of localization in virus host,infectious disposition,0.65
establishment of localization in virus host,acute infection,0.6051724137931035
establishment of localization in virus host,bacteriostatic disposition,0.6384057971014493
establishment of localization in virus host,immunity to pathogen,0.6246031746031746
establishment of localization in virus host,bactericidal disposition,0.6141791044776119
establishment of localization in virus host,source of infection role,0.658955223880597
establishment of localization in virus host,pathogen host,0.6107142857142857
establishment of localization in virus host,acquired immunodeficiency,0.5823529411764706
establishment of localization in virus host,chronic infection,0.6
establishment of localization in virus host,invasion disposition,0.6404761904761905
establishment of localization in virus host,disease course,0.6078947368421053
establishment of localization in virus host,infectious disease course,0.6411764705882353
establishment of localization in virus host,viricidal disposition,0.60625
establishment of localization in virus host,acquired immunity to infectious agent,0.65
establishment of localization in virus host,complex infection,0.6
establishment of localization in virus host,COVID-19 disease incidence proportion,0.6125
establishment of localization in virus host,coronavirus disease course,0.6094202898550725
establishment of localization in virus host,infection incidence proportion,0.6554794520547945
establishment of localization in virus host,respiratory droplet virus fomite,0.69
establishment of localization in virus host,susceptible organism,0.6246031746031746
establishment of localization in virus host,intermediate host,0.6333333333333333
establishment of localization in virus host,pathogen vector role,0.6246031746031746
establishment of localization in virus host,pathogen portal of exit site,0.6471830985915493
establishment of localization in virus host,infectious disease prevalence,0.6027777777777777
establishment of localization in virus host,organism substance,0.5811475409836065
establishment of localization in virus host,disposition,0.5981481481481481
establishment of localization in virus host,single-stranded DNA virus,0.6558823529411765
establishment of localization in virus host,place closure control strategy,0.6143835616438357
establishment of localization in virus host,viral disease,0.575
establishment of localization in virus host,primary infection role,0.6346153846153847
establishment of localization in virus host,adhesion disposition,0.6404761904761905
establishment of localization in virus host,pathogen portal of entry site,0.6583333333333334
establishment of localization in virus host,infection incidence profile,0.65
establishment of localization in virus host,disease,0.55
establishment of localization in virus host,symptomatic infectious structure carrier,0.6427710843373494
establishment of localization in virus host,primary infectious disposition,0.6417808219178082
establishment of localization in virus host,pathogen host role,0.6139344262295081
establishment of localization in virus host,infection prevalence,0.6087301587301588
establishment of localization in virus host,humoral immune response,0.6469696969696969
establishment of localization in virus host,coronavirus disorder,0.6087301587301588
establishment of localization in virus host,infectious pathogen transmissibility,0.639873417721519
establishment of localization in virus host,intermediate host role,0.6192307692307693
establishment of localization in virus host,dead-end host,0.6107142857142857
establishment of localization in virus host,pathogen surveillance,0.590625
establishment of localization in virus host,immunodeficient organism,0.6291044776119403
establishment of localization in virus host,host role,0.5653846153846154
establishment of localization in virus host,pathogen,0.5284313725490196
establishment of localization in virus host,pathogen birth process boundary,0.6121621621621621
establishment of localization in virus host,infectious human pathogen,0.6264705882352941
establishment of localization in virus host,subclinical virus infection,0.6785714285714286
establishment of localization in virus host,resistance to pathogen,0.6346153846153847
establishment of localization in virus host,establishment of localization in virus host,0.95
establishment of localization in virus host,virus attachment stage,0.6192307692307693
establishment of localization in virus host,negative regulation of immune response,0.6845679012345678
establishment of localization in virus host,virus synthesis stage,0.590625
establishment of localization in virus host,SARS-COV-2 adhesion disposition,0.6527027027027027
establishment of localization in virus host,pathogen portal of exit role,0.6471830985915493
establishment of localization in virus host,invasive disposition,0.6087301587301588
establishment of localization in virus host,infectious agent host,0.66875
establishment of localization in virus host,re-emerging pathogen,0.5928571428571429
establishment of localization in virus host,long-term non-progressing infectious disease course,0.6308510638297872
establishment of localization in virus host,viral disease epidemic,0.5884615384615385
establishment of localization in virus host,fungicidal disposition,0.6038461538461539
establishment of localization in virus host,viral disease pandemic,0.5884615384615385
establishment of localization in virus host,virus penetration stage,0.6469696969696969
establishment of localization in virus host,pathogen seroprevalence,0.5863636363636363
establishment of localization in virus host,acute respiratory distress syndrome,0.6166666666666667
establishment of localization in virus host,division of geopolitical entity,0.6662162162162162
establishment of localization in virus host,infectious disease endemicity,0.6166666666666667
establishment of localization in virus host,contact pathogen transmission process,0.6375
establishment of localization in virus host,disorder,0.5284313725490196
establishment of localization in virus host,herd immunity to infectious organism,0.6651898734177215
establishment of localization in virus host,extracellular infection,0.6318181818181818
establishment of localization in virus host,pathogen transporter role,0.5970588235294118
establishment of localization in virus host,transmission interval,0.6375
establishment of localization in virus host,exotoxin disposition,0.6404761904761905
establishment of localization in virus host,infection start process boundary,0.6366666666666667
establishment of localization in virus host,infectious disease control objective specification,0.6327956989247312
establishment of localization in virus host,symbiont host role,0.630327868852459
establishment of localization in virus host,immune population,0.6333333333333333
establishment of localization in virus host,opportunistic infectious disposition,0.6525316455696202
establishment of localization in virus host,process of establishing viral infection,0.6695121951219513
establishment of localization in virus host,enterotoxin disposition,0.6621212121212122
establishment of localization in virus host,COVID-19 disease course,0.5863636363636363
establishment of localization in virus host,infectious disease incidence rate,0.6342105263157894
establishment of localization in virus host,disordered virus,0.6025423728813559
establishment of localization in virus host,collective resistance disposition,0.6342105263157894
establishment of localization in virus host,adaptive immune response,0.6291044776119403
establishment of localization in virus host,fungistatic disposition,0.6318181818181818
establishment of localization in virus host,organism,0.5480392156862746
establishment of localization in virus host,virus uncoating stage,0.621875
establishment of localization in virus host,local infection,0.6224137931034482
establishment of localization in virus host,establishment of a clinically abnormal colony,0.7454545454545455
establishment of localization in virus host,coronavirus disease,0.6112903225806451
establishment of localization in virus host,positive-sense single-stranded RNA virus,0.6668674698795181
establishment of localization in virus host,adhesion factor,0.6224137931034482
establishment of localization in virus host,definitive host,0.656896551724138
establishment of localization in virus host,horizontal pathogen transmission process,0.6427710843373494
establishment of localization in virus host,hospital-acquired infection,0.6357142857142857
establishment of localization in virus host,pathogen death temporal region,0.6143835616438357
establishment of localization in virus host,emerging pathogen,0.6
establishment of localization in virus host,pathogen transmission process,0.6444444444444444
virus release stage,extended organism,0.5888888888888889
virus release stage,virus aggregate,0.7735294117647058
virus release stage,source of infection,0.581578947368421
virus release stage,virostatic disposition,0.6451219512195122
virus release stage,zoonotic disposition,0.5782051282051281
virus release stage,immune response,0.6852941176470588
virus release stage,infectious disease mortality rate,0.6807692307692308
virus release stage,infection incidence rate profile,0.6068627450980393
virus release stage,communicability end temporal region,0.5796296296296296
virus release stage,pathogen generative stage,0.7
virus release stage,pathogen portal of entry,0.5895348837209302
virus release stage,subclinical coronavirus infection,0.6038461538461539
virus release stage,primary pathogen,0.65
virus release stage,infection end temporal region,0.5958333333333333
virus release stage,drug-based immunosuppressed organism,0.6318181818181818
virus release stage,infectious disease,0.6662162162162162
virus release stage,SARS-CoV-2 incidence rate,0.6318181818181818
virus release stage,double-stranded DNA virus,0.609090909090909
virus release stage,incubation end temporal region,0.6132653061224489
virus release stage,site of infection,0.5611111111111111
virus release stage,immunocompetent organism,0.5895348837209302
virus release stage,virulence factor disposition,0.6627659574468084
virus release stage,pathogen portal of exit,0.5928571428571429
virus release stage,viral adhesion disposition,0.65
virus release stage,parasitostatic disposition,0.5833333333333334
virus release stage,infectious disease incidence,0.6627659574468084
virus release stage,reservoir of pathogen role,0.6277777777777778
virus release stage,reverse zoonotic disposition,0.6202127659574468
virus release stage,subclinical SARS-CoV-2 infection,0.5872549019607843
virus release stage,virus translation stage,0.8071428571428573
virus release stage,disease surveillance objective specification,0.6246031746031746
virus release stage,virus release stage,0.95
virus release stage,source of infection site,0.636046511627907
virus release stage,virus,0.6583333333333334
virus release stage,virus replication,0.7555555555555555
virus release stage,B cell receptor complex,0.6166666666666667
virus release stage,systematic infection,0.5782051282051281
virus release stage,infection incidence rate,0.6127906976744186
virus release stage,virus host,0.7258620689655172
virus release stage,double-stranded RNA virus,0.609090909090909
virus release stage,pathogen portal of entry role,0.575
virus release stage,virus transcription stage,0.7909090909090909
virus release stage,infectious disease lifetime prevalence,0.6605263157894737
virus release stage,toxin disposition,0.5888888888888889
virus release stage,pathogen birth temporal region,0.5928571428571429
virus release stage,lower respiratory tract disease,0.63
virus release stage,infectious disease incidence proportion,0.6224137931034482
virus release stage,opportunistic pathogen,0.6451219512195122
virus release stage,virus generative stage,0.8402439024390245
virus release stage,acute infectious disease course,0.67
virus release stage,cidal agent disposition,0.6166666666666667
virus release stage,infectious disorder,0.6078947368421053
virus release stage,genetic resistance to pathogen,0.6744897959183673
virus release stage,subclinical infection,0.575
virus release stage,appearance of disorder,0.5963414634146341
virus release stage,simple infection,0.5928571428571429
virus release stage,biological vehicle,0.5851351351351352
virus release stage,droplet pathogen transmission process,0.6107142857142857
virus release stage,parasiticidal disposition,0.5863636363636363
virus release stage,infectious disease sporadicity,0.6744897959183673
virus release stage,communicability end process boundary,0.5772727272727273
virus release stage,infection incidence proportion profile,0.5728070175438597
virus release stage,pathogen transporter,0.6038461538461539
virus release stage,transmissibility disposition,0.5776595744680851
virus release stage,latency end process boundary,0.5776595744680851
virus release stage,infectious disease epidemic,0.6673913043478261
virus release stage,infectious agent generative stage,0.7192307692307692
virus release stage,disease transmission model,0.6722222222222223
virus release stage,endotoxin disposition,0.575
virus release stage,pathologically immunosuppressed organism,0.6025423728813559
virus release stage,negative-sense single-stranded RNA virus,0.6194915254237288
virus release stage,pathogen vehicle,0.5642857142857143
virus release stage,COVID-19 incidence rate,0.6404761904761905
virus release stage,cytotoxin disposition,0.575
virus release stage,community-acquired infection,0.5776595744680851
virus release stage,pathogen vector,0.5676470588235294
virus release stage,pathogen vehicle role,0.6
virus release stage,chronic infectious disease course,0.6615384615384616
virus release stage,nursing-home acquired infection,0.59
virus release stage,COVID-19 epidemic,0.5888888888888889
virus release stage,secondary infection,0.581578947368421
virus release stage,infection start temporal region,0.59
virus release stage,infection incidence,0.5552631578947369
virus release stage,virus disorder,0.6924242424242425
virus release stage,primary infection,0.5888888888888889
virus release stage,process of establishing an infection,0.6136363636363636
virus release stage,incubation end process boundary,0.61
virus release stage,SARS-CoV-2 disorder,0.6078947368421053
virus release stage,collective pathogenic disposition,0.5846153846153846
virus release stage,neurotoxin disposition,0.5719512195121951
virus release stage,SARS-CoV-2 uncoating stage,0.6722222222222223
virus release stage,pathogen death process boundary,0.57
virus release stage,immunosuppressed organism,0.6545454545454545
virus release stage,plan specification,0.5851351351351352
virus release stage,latency end temporal region,0.6021739130434782
virus release stage,SARS-CoV-2 penetration stage,0.7053191489361703
virus release stage,virus adhesion susceptible cell,0.69
virus release stage,collective disposition,0.5963414634146341
virus release stage,infection,0.5571428571428572
virus release stage,static agent disposition,0.6127906976744186
virus release stage,T cell receptor complex,0.6166666666666667
virus release stage,respiratory system disease,0.6722222222222223
virus release stage,indirect pathogen transmission process,0.6078947368421053
virus release stage,organism population,0.6078947368421053
virus release stage,generative stage,0.7357142857142857
virus release stage,infectious disease control strategy,0.6907407407407408
virus release stage,SARS-CoV-2 attachment stage,0.6891304347826087
virus release stage,infectious disease pandemic,0.6891304347826087
virus release stage,infectious structure generative stage,0.7178571428571427
virus release stage,immunosuppressive disposition,0.6583333333333334
virus release stage,innate immune response,0.6451219512195122
virus release stage,pathogenic disposition,0.5719512195121951
virus release stage,viral disease course,0.732051282051282
virus release stage,intracellular infection,0.6166666666666667
virus release stage,secondary infection role,0.5895348837209302
virus release stage,metastatic infection,0.6038461538461539
virus release stage,infectious disposition,0.6207317073170732
virus release stage,acute infection,0.5676470588235294
virus release stage,bacteriostatic disposition,0.5833333333333334
virus release stage,immunity to pathogen,0.6294871794871795
virus release stage,bactericidal disposition,0.5662790697674418
virus release stage,source of infection role,0.5895348837209302
virus release stage,pathogen host,0.60625
virus release stage,acquired immunodeficiency,0.5636363636363636
virus release stage,chronic infection,0.5611111111111111
virus release stage,invasion disposition,0.6038461538461539
virus release stage,disease course,0.7227272727272727
virus release stage,infectious disease course,0.7
virus release stage,viricidal disposition,0.625
virus release stage,acquired immunity to infectious agent,0.6285714285714286
virus release stage,complex infection,0.5611111111111111
virus release stage,COVID-19 disease incidence proportion,0.6107142857142857
virus release stage,coronavirus disease course,0.7388888888888888
virus release stage,biological vehicle role,0.6166666666666667
virus release stage,infection incidence proportion,0.5724489795918367
virus release stage,respiratory droplet virus fomite,0.6460784313725491
virus release stage,susceptible organism,0.6294871794871795
virus release stage,pathogen vector role,0.6038461538461539
virus release stage,pathogen portal of exit site,0.6202127659574468
virus release stage,infectious disease prevalence,0.6791666666666666
virus release stage,organism substance,0.6662162162162162
virus release stage,SARS-CoV-2 genome replication stage,0.6907407407407408
virus release stage,disposition,0.5833333333333334
virus release stage,single-stranded DNA virus,0.609090909090909
virus release stage,COVID-19 mortality rate,0.6404761904761905
virus release stage,viral disease,0.7
virus release stage,primary infection role,0.5963414634146341
virus release stage,adhesion disposition,0.5782051282051281
virus release stage,pathogen portal of entry site,0.6166666666666667
virus release stage,infection incidence profile,0.5804347826086956
virus release stage,disease,0.6807692307692308
virus release stage,primary infectious disposition,0.6132653061224489
virus release stage,pathogen host role,0.6121621621621621
virus release stage,infection prevalence,0.6294871794871795
virus release stage,humoral immune response,0.6404761904761905
virus release stage,coronavirus disorder,0.6551282051282051
virus release stage,infectious pathogen transmissibility,0.6136363636363636
virus release stage,pathogen surveillance,0.6
virus release stage,immunodeficient organism,0.5895348837209302
virus release stage,pathogen,0.5981481481481481
virus release stage,pathogen birth process boundary,0.61
virus release stage,infectious human pathogen,0.6545454545454545
virus release stage,subclinical virus infection,0.6239130434782608
virus release stage,resistance to pathogen,0.6695121951219513
virus release stage,establishment of localization in virus host,0.5951612903225807
virus release stage,virus attachment stage,0.7914634146341464
virus release stage,negative regulation of immune response,0.6254385964912281
virus release stage,SARS-CoV-2 transcription stage,0.6948979591836735
virus release stage,virus synthesis stage,0.8
virus release stage,SARS-COV-2 adhesion disposition,0.61
virus release stage,pathogen portal of exit role,0.5776595744680851
virus release stage,invasive disposition,0.6294871794871795
virus release stage,re-emerging pathogen,0.6551282051282051
virus release stage,long-term non-progressing infectious disease course,0.6071428571428572
virus release stage,viral disease epidemic,0.6939024390243902
virus release stage,fungicidal disposition,0.5719512195121951
virus release stage,viral disease pandemic,0.7182926829268292
virus release stage,virus penetration stage,0.8071428571428573
virus release stage,pathogen seroprevalence,0.5928571428571429
virus release stage,acute respiratory distress syndrome,0.6351851851851852
virus release stage,division of geopolitical entity,0.63
virus release stage,infectious disease endemicity,0.6583333333333334
virus release stage,contact pathogen transmission process,0.575
virus release stage,disorder,0.5981481481481481
virus release stage,herd immunity to infectious organism,0.5772727272727273
virus release stage,extracellular infection,0.5928571428571429
virus release stage,pathogen transporter role,0.609090909090909
virus release stage,transmission interval,0.6
virus release stage,exotoxin disposition,0.5782051282051281
virus release stage,infection start process boundary,0.6068627450980393
virus release stage,SARS-CoV-2 synthesis stage,0.6944444444444444
virus release stage,infectious disease control objective specification,0.6094202898550725
virus release stage,immune population,0.6166666666666667
virus release stage,opportunistic infectious disposition,0.6136363636363636
virus release stage,process of establishing viral infection,0.6051724137931035
virus release stage,enterotoxin disposition,0.569047619047619
virus release stage,polymerase chain reaction,0.6318181818181818
virus release stage,COVID-19 disease course,0.6880952380952381
virus release stage,infectious disease incidence rate,0.6615384615384616
virus release stage,disordered virus,0.65
virus release stage,collective resistance disposition,0.6230769230769231
virus release stage,adaptive immune response,0.6593023255813953
virus release stage,fungistatic disposition,0.5928571428571429
virus release stage,organism,0.5611111111111111
virus release stage,virus uncoating stage,0.775
virus release stage,local infection,0.5676470588235294
virus release stage,establishment of a clinically abnormal colony,0.559375
virus release stage,coronavirus disease,0.7131578947368421
virus release stage,positive-sense single-stranded RNA virus,0.6194915254237288
virus release stage,horizontal pathogen transmission process,0.5855932203389831
virus release stage,hospital-acquired infection,0.5804347826086956
virus release stage,pathogen death temporal region,0.5928571428571429
virus release stage,emerging pathogen,0.6166666666666667
virus release stage,SARS-CoV-2 release stage,0.822093023255814
virus release stage,pathogen transmission process,0.5958333333333333
immunosuppression,physiologic immunosuppression,0.8195652173913044
immunosuppression,immunosuppression,0.95
immunosuppression,pathologic immunosuppression,0.8277777777777777
establishment of a clinically abnormal colony,infectious disease mortality rate,0.6294871794871795
establishment of a clinically abnormal colony,infection incidence rate profile,0.6448051948051949
establishment of a clinically abnormal colony,infectious structure aggregate,0.5833333333333334
establishment of a clinically abnormal colony,communicability end temporal region,0.65
establishment of a clinically abnormal colony,infection end temporal region,0.6527027027027027
establishment of a clinically abnormal colony,SARS-CoV-2 incidence rate,0.6214285714285714
establishment of a clinically abnormal colony,incubation end temporal region,0.6366666666666667
establishment of a clinically abnormal colony,site of infection,0.6435483870967742
establishment of a clinically abnormal colony,normal resident microbiota population,0.6573170731707317
establishment of a clinically abnormal colony,virulence factor disposition,0.6280821917808219
establishment of a clinically abnormal colony,establishment of localization in host,0.7548780487804878
establishment of a clinically abnormal colony,infectious agent host role,0.6330985915492958
establishment of a clinically abnormal colony,asymptomatic infectious structure carrier,0.6127906976744186
establishment of a clinically abnormal colony,source of infection site,0.6094202898550725
establishment of a clinically abnormal colony,architectual structure,0.5843283582089552
establishment of a clinically abnormal colony,B cell receptor complex,0.6264705882352941
establishment of a clinically abnormal colony,infection incidence rate,0.6239130434782608
establishment of a clinically abnormal colony,colonized host,0.5516949152542373
establishment of a clinically abnormal colony,virus host,0.5227272727272727
establishment of a clinically abnormal colony,double-stranded RNA virus,0.5928571428571429
establishment of a clinically abnormal colony,communicability end process boundary,0.6228395061728395
establishment of a clinically abnormal colony,acellular structure aggregate,0.5716216216216217
establishment of a clinically abnormal colony,infectious agent colony,0.6705882352941177
establishment of a clinically abnormal colony,invasion factor,0.6
establishment of a clinically abnormal colony,latency end process boundary,0.6143835616438357
establishment of a clinically abnormal colony,colonization of host,0.5884615384615385
establishment of a clinically abnormal colony,negative regulation of establishment of localization,0.6974226804123711
establishment of a clinically abnormal colony,negative-sense single-stranded RNA virus,0.6264705882352941
establishment of a clinically abnormal colony,infectious structure host role,0.5966666666666667
establishment of a clinically abnormal colony,establishment of localization,0.7743243243243243
establishment of a clinically abnormal colony,COVID-19 incidence rate,0.5823529411764706
establishment of a clinically abnormal colony,establishment of localization in human host,0.7568181818181818
establishment of a clinically abnormal colony,acellular structure,0.590625
establishment of a clinically abnormal colony,virulence factor,0.5975409836065574
establishment of a clinically abnormal colony,incubation end process boundary,0.6078947368421053
establishment of a clinically abnormal colony,dead-end host role,0.6087301587301588
establishment of a clinically abnormal colony,plan specification,0.6087301587301588
establishment of a clinically abnormal colony,definitive host role,0.6038461538461539
establishment of a clinically abnormal colony,latency end temporal region,0.6444444444444444
establishment of a clinically abnormal colony,infectious structure,0.573076923076923
establishment of a clinically abnormal colony,colony,0.5676470588235294
establishment of a clinically abnormal colony,T cell receptor complex,0.6264705882352941
establishment of a clinically abnormal colony,infectious structure host,0.5785714285714285
establishment of a clinically abnormal colony,respiratory system disease,0.5767605633802817
establishment of a clinically abnormal colony,entry into host,0.6
establishment of a clinically abnormal colony,adhesion of symbiont to host,0.6417808219178082
establishment of a clinically abnormal colony,infectious structure generative stage,0.5841463414634146
establishment of a clinically abnormal colony,entry into host through host barriers,0.5963414634146341
establishment of a clinically abnormal colony,epitope site,0.5552631578947369
establishment of a clinically abnormal colony,pathogen host,0.553448275862069
establishment of a clinically abnormal colony,intermediate host,0.5790322580645162
establishment of a clinically abnormal colony,pathogen portal of exit site,0.6006849315068493
establishment of a clinically abnormal colony,COVID-19 mortality rate,0.5970588235294118
establishment of a clinically abnormal colony,place closure control strategy,0.61
establishment of a clinically abnormal colony,pathogen portal of entry site,0.6256756756756756
establishment of a clinically abnormal colony,symptomatic infectious structure carrier,0.6029411764705883
establishment of a clinically abnormal colony,site,0.5112244897959184
establishment of a clinically abnormal colony,pathogen host role,0.6087301587301588
establishment of a clinically abnormal colony,intermediate host role,0.5992537313432835
establishment of a clinically abnormal colony,dead-end host,0.553448275862069
establishment of a clinically abnormal colony,host role,0.5611111111111111
establishment of a clinically abnormal colony,establishment of localization in virus host,0.7454545454545455
establishment of a clinically abnormal colony,infectious agent host,0.6015151515151516
establishment of a clinically abnormal colony,herd immunity to infectious organism,0.6475308641975309
establishment of a clinically abnormal colony,action specification,0.6192307692307693
establishment of a clinically abnormal colony,symbiont host role,0.6246031746031746
establishment of a clinically abnormal colony,infectious disease incidence rate,0.6294871794871795
establishment of a clinically abnormal colony,single-stranded RNA retrovirus,0.5966666666666667
establishment of a clinically abnormal colony,local infection,0.6166666666666667
establishment of a clinically abnormal colony,establishment of a clinically abnormal colony,0.95
establishment of a clinically abnormal colony,positive-sense single-stranded RNA virus,0.6264705882352941
establishment of a clinically abnormal colony,adhesion factor,0.6166666666666667
establishment of a clinically abnormal colony,definitive host,0.5666666666666667
B cell receptor complex,extended organism,0.6
B cell receptor complex,virostatic disposition,0.5611111111111111
B cell receptor complex,zoonotic disposition,0.5662790697674418
B cell receptor complex,infectious disease mortality rate,0.5928571428571429
B cell receptor complex,infection incidence rate profile,0.65
B cell receptor complex,infectious structure aggregate,0.6009433962264151
B cell receptor complex,communicability end temporal region,0.6224137931034482
B cell receptor complex,infection end temporal region,0.6230769230769231
B cell receptor complex,drug-based immunosuppressed organism,0.6025423728813559
B cell receptor complex,SARS-CoV-2 incidence rate,0.5958333333333333
B cell receptor complex,incubation end temporal region,0.6386792452830189
B cell receptor complex,site of infection,0.6
B cell receptor complex,immunocompetent organism,0.598936170212766
B cell receptor complex,virulence factor disposition,0.6264705882352941
B cell receptor complex,viral adhesion disposition,0.5724489795918367
B cell receptor complex,parasitostatic disposition,0.5520408163265306
B cell receptor complex,reverse zoonotic disposition,0.5872549019607843
B cell receptor complex,case isolation control strategy,0.6351851851851852
B cell receptor complex,macromolecular complex,0.7388888888888888
B cell receptor complex,asymptomatic infectious structure carrier,0.60625
B cell receptor complex,source of infection site,0.6414893617021277
B cell receptor complex,architectual structure,0.65
B cell receptor complex,B cell receptor complex,0.95
B cell receptor complex,infection incidence rate,0.598936170212766
B cell receptor complex,toxin disposition,0.55
B cell receptor complex,lower respiratory tract disease,0.6537037037037037
B cell receptor complex,cidal agent disposition,0.6021739130434782
B cell receptor complex,infectious disorder,0.6166666666666667
B cell receptor complex,appearance of disorder,0.6277777777777778
B cell receptor complex,parasiticidal disposition,0.575
B cell receptor complex,communicability end process boundary,0.6025423728813559
B cell receptor complex,acellular structure aggregate,0.6615384615384616
B cell receptor complex,transmissibility disposition,0.5676470588235294
B cell receptor complex,latency end process boundary,0.6068627450980393
B cell receptor complex,endotoxin disposition,0.5636363636363636
B cell receptor complex,pathologically immunosuppressed organism,0.6087301587301588
B cell receptor complex,infectious structure host role,0.6386792452830189
B cell receptor complex,COVID-19 incidence rate,0.6021739130434782
B cell receptor complex,cytotoxin disposition,0.5636363636363636
B cell receptor complex,virus disorder,0.5581081081081081
B cell receptor complex,acellular structure,0.6880952380952381
B cell receptor complex,incubation end process boundary,0.6166666666666667
B cell receptor complex,SARS-CoV-2 disorder,0.5928571428571429
B cell receptor complex,collective pathogenic disposition,0.6464285714285714
B cell receptor complex,neurotoxin disposition,0.5833333333333334
B cell receptor complex,immunosuppressed organism,0.575
B cell receptor complex,latency end temporal region,0.63
B cell receptor complex,infectious structure,0.6127906976744186
B cell receptor complex,virus adhesion susceptible cell,0.6351851851851852
B cell receptor complex,collective disposition,0.65
B cell receptor complex,static agent disposition,0.5776595744680851
B cell receptor complex,T cell receptor complex,0.9282608695652175
B cell receptor complex,infectious structure host,0.6166666666666667
B cell receptor complex,respiratory system disease,0.6336734693877552
B cell receptor complex,organism population,0.5928571428571429
B cell receptor complex,infectious structure generative stage,0.6
B cell receptor complex,immunosuppressive disposition,0.5653846153846154
B cell receptor complex,disordered prion,0.6038461538461539
B cell receptor complex,pathogenic disposition,0.5611111111111111
B cell receptor complex,cell,0.5981481481481481
B cell receptor complex,infectious disposition,0.5833333333333334
B cell receptor complex,bacteriostatic disposition,0.6132653061224489
B cell receptor complex,epitope site,0.6214285714285714
B cell receptor complex,bactericidal disposition,0.6202127659574468
B cell receptor complex,invasion disposition,0.5430232558139535
B cell receptor complex,viricidal disposition,0.5863636363636363
B cell receptor complex,complex infection,0.625
B cell receptor complex,susceptible organism,0.6127906976744186
B cell receptor complex,pathogen portal of exit site,0.6264705882352941
B cell receptor complex,organism substance,0.5719512195121951
B cell receptor complex,disposition,0.5382352941176471
B cell receptor complex,COVID-19 mortality rate,0.5804347826086956
B cell receptor complex,place closure control strategy,0.6575471698113208
B cell receptor complex,adhesion disposition,0.5662790697674418
B cell receptor complex,pathogen portal of entry site,0.6038461538461539
B cell receptor complex,symptomatic infectious structure carrier,0.6087301587301588
B cell receptor complex,site,0.524074074074074
B cell receptor complex,primary infectious disposition,0.5820754716981132
B cell receptor complex,coronavirus disorder,0.6127906976744186
B cell receptor complex,SARS-COV-2 adhesion susceptible cell,0.6194915254237288
B cell receptor complex,immunodeficient organism,0.598936170212766
B cell receptor complex,virus synthesis stage,0.5636363636363636
B cell receptor complex,SARS-COV-2 adhesion disposition,0.5611111111111111
B cell receptor complex,invasive disposition,0.5662790697674418
B cell receptor complex,fungicidal disposition,0.5833333333333334
B cell receptor complex,acute respiratory distress syndrome,0.6741379310344828
B cell receptor complex,division of geopolitical entity,0.5981481481481481
B cell receptor complex,disorder,0.5467741935483871
B cell receptor complex,herd immunity to infectious organism,0.6025423728813559
B cell receptor complex,exotoxin disposition,0.5662790697674418
B cell receptor complex,immunoglobulin complex,0.6722222222222223
B cell receptor complex,action specification,0.5895348837209302
B cell receptor complex,SARS-CoV-2 synthesis stage,0.5520408163265306
B cell receptor complex,opportunistic infectious disposition,0.5855932203389831
B cell receptor complex,quality,0.5166666666666666
B cell receptor complex,enterotoxin disposition,0.5804347826086956
B cell receptor complex,polymerase chain reaction,0.6166666666666667
B cell receptor complex,infectious disease incidence rate,0.5928571428571429
B cell receptor complex,disordered virus,0.5525641025641026
B cell receptor complex,collective resistance disposition,0.6464285714285714
B cell receptor complex,fungistatic disposition,0.558695652173913
B cell receptor complex,organism,0.5467741935483871
B cell receptor complex,establishment of a clinically abnormal colony,0.6264705882352941
B cell receptor complex,cell space,0.6924242424242425
latency start process boundary,source of infection,0.5928571428571429
latency start process boundary,immune response,0.6055555555555556
latency start process boundary,infectious disease mortality rate,0.6087301587301588
latency start process boundary,infection incidence rate profile,0.6435483870967742
latency start process boundary,communicability end temporal region,0.6346153846153847
latency start process boundary,pathogen generative stage,0.6318181818181818
latency start process boundary,surveillance process,0.69
latency start process boundary,infection end temporal region,0.6364406779661017
latency start process boundary,SARS-CoV-2 incidence rate,0.5954545454545455
latency start process boundary,incubation end temporal region,0.65
latency start process boundary,pathogen portal of exit,0.6386792452830189
latency start process boundary,virus translation stage,0.619811320754717
latency start process boundary,case isolation control strategy,0.6467213114754098
latency start process boundary,virus release stage,0.6132653061224489
latency start process boundary,source of infection site,0.5796296296296296
latency start process boundary,B cell receptor complex,0.6009433962264151
latency start process boundary,infection incidence rate,0.5981481481481481
latency start process boundary,virus transcription stage,0.5954545454545455
latency start process boundary,pathogen birth temporal region,0.6666666666666667
latency start process boundary,virus generative stage,0.6038461538461539
latency start process boundary,acute infectious disease course,0.6631147540983606
latency start process boundary,process,0.6391891891891892
latency start process boundary,droplet pathogen transmission process,0.6888059701492537
latency start process boundary,communicability end process boundary,0.7681818181818181
latency start process boundary,latency end process boundary,0.8810344827586206
latency start process boundary,infectious agent generative stage,0.6087301587301588
latency start process boundary,COVID-19 incidence rate,0.5820754716981132
latency start process boundary,negative regulation of developmental process,0.6527027027027027
latency start process boundary,chronic infectious disease course,0.6246031746031746
latency start process boundary,latency interval,0.6891304347826087
latency start process boundary,infection start temporal region,0.6795081967213115
latency start process boundary,process of establishing an infection,0.6166666666666667
latency start process boundary,incubation end process boundary,0.7942622950819671
latency start process boundary,SARS-CoV-2 uncoating stage,0.5928571428571429
latency start process boundary,pathogen death process boundary,0.8434426229508196
latency start process boundary,plan specification,0.6375
latency start process boundary,latency end temporal region,0.7131578947368421
latency start process boundary,SARS-CoV-2 penetration stage,0.6051724137931035
latency start process boundary,anatomical space,0.6239130434782608
latency start process boundary,T cell receptor complex,0.6009433962264151
latency start process boundary,respiratory system disease,0.6285714285714286
latency start process boundary,indirect pathogen transmission process,0.6705882352941177
latency start process boundary,planned process,0.6944444444444444
latency start process boundary,generative stage,0.6239130434782608
latency start process boundary,communicability interval,0.5796296296296296
latency start process boundary,SARS-CoV-2 attachment stage,0.6078947368421053
latency start process boundary,infectious structure generative stage,0.6291044776119403
latency start process boundary,innate immune response,0.6423076923076922
latency start process boundary,viral disease course,0.63
latency start process boundary,source of infection role,0.5981481481481481
latency start process boundary,disease course,0.609090909090909
latency start process boundary,infectious disease course,0.6318181818181818
latency start process boundary,coronavirus disease course,0.6285714285714286
latency start process boundary,pathogen portal of exit site,0.6396551724137931
latency start process boundary,incubation interval,0.6132653061224489
latency start process boundary,SARS-CoV-2 genome replication stage,0.6038461538461539
latency start process boundary,COVID-19 mortality rate,0.6009433962264151
latency start process boundary,process profile,0.65
latency start process boundary,negative regulation of life-sustaining process,0.6605263157894737
latency start process boundary,place closure control strategy,0.65
latency start process boundary,developmental process,0.7049019607843137
latency start process boundary,biological process,0.6791666666666666
latency start process boundary,humoral immune response,0.6009433962264151
latency start process boundary,eclipse interval,0.6021739130434782
latency start process boundary,incubation start process boundary,0.8626984126984126
latency start process boundary,pathogen birth process boundary,0.8434426229508196
latency start process boundary,virus attachment stage,0.6230769230769231
latency start process boundary,negative regulation of immune response,0.6264705882352941
latency start process boundary,SARS-CoV-2 transcription stage,0.6166666666666667
latency start process boundary,virus synthesis stage,0.6068627450980393
latency start process boundary,pathogen portal of exit role,0.656896551724138
latency start process boundary,long-term non-progressing infectious disease course,0.6598765432098764
latency start process boundary,communicability start temporal region,0.6738805970149254
latency start process boundary,virus penetration stage,0.6009433962264151
latency start process boundary,algorithm,0.5269230769230769
latency start process boundary,division of geopolitical entity,0.5975409836065574
latency start process boundary,negative regulation of viral process,0.6621212121212122
latency start process boundary,contact pathogen transmission process,0.6738805970149254
latency start process boundary,function,0.581578947368421
latency start process boundary,symbiotic process,0.6627659574468084
latency start process boundary,transmission interval,0.6068627450980393
latency start process boundary,infection start process boundary,0.8532258064516128
latency start process boundary,action specification,0.63
latency start process boundary,SARS-CoV-2 synthesis stage,0.6285714285714286
latency start process boundary,latency start process boundary,0.95
latency start process boundary,process of establishing viral infection,0.6094202898550725
latency start process boundary,negative regulation of biological process,0.6471830985915493
latency start process boundary,polymerase chain reaction,0.6318181818181818
latency start process boundary,COVID-19 disease course,0.619811320754717
latency start process boundary,infectious disease incidence rate,0.6087301587301588
latency start process boundary,communicability start process boundary,0.8323529411764706
latency start process boundary,process that results in death,0.6872881355932203
latency start process boundary,adaptive immune response,0.6351851851851852
latency start process boundary,virus uncoating stage,0.6068627450980393
latency start process boundary,establishment of a clinically abnormal colony,0.6233333333333334
latency start process boundary,process boundary,0.7978260869565217
latency start process boundary,horizontal pathogen transmission process,0.6785714285714286
latency start process boundary,SARS-CoV-2 release stage,0.6166666666666667
latency start process boundary,pathogen transmission process,0.7042372881355932
latency start process boundary,cell space,0.6
communicability start temporal region,virus aggregate,0.5846153846153846
communicability start temporal region,source of infection,0.6285714285714286
communicability start temporal region,infectious disease mortality rate,0.6642857142857143
communicability start temporal region,infection incidence rate profile,0.6528985507246376
communicability start temporal region,communicability end temporal region,0.8944444444444444
communicability start temporal region,infection end temporal region,0.7530303030303032
communicability start temporal region,infectious disease,0.5954545454545455
communicability start temporal region,SARS-CoV-2 incidence rate,0.5951612903225807
communicability start temporal region,double-stranded DNA virus,0.6274193548387097
communicability start temporal region,incubation end temporal region,0.7634328358208955
communicability start temporal region,two-dimensional spatial region,0.7335820895522389
communicability start temporal region,one-dimensional temporal region,0.7735294117647058
communicability start temporal region,pathogen portal of exit,0.6333333333333333
communicability start temporal region,temporal region,0.7384615384615384
communicability start temporal region,infectious disease incidence,0.6038461538461539
communicability start temporal region,virus translation stage,0.6166666666666667
communicability start temporal region,disease surveillance objective specification,0.6104938271604938
communicability start temporal region,virus release stage,0.575
communicability start temporal region,material entity,0.6423076923076922
communicability start temporal region,source of infection site,0.6139344262295081
communicability start temporal region,virus replication,0.6166666666666667
communicability start temporal region,B cell receptor complex,0.6166666666666667
communicability start temporal region,infection incidence rate,0.6139344262295081
communicability start temporal region,virus host,0.5351063829787234
communicability start temporal region,double-stranded RNA virus,0.6435483870967742
communicability start temporal region,virus transcription stage,0.6112903225806451
communicability start temporal region,infectious disease lifetime prevalence,0.65
communicability start temporal region,pathogen birth temporal region,0.7783582089552239
communicability start temporal region,lower respiratory tract disease,0.6411764705882353
communicability start temporal region,infectious disease incidence proportion,0.6473684210526315
communicability start temporal region,virus generative stage,0.6025423728813559
communicability start temporal region,acute infectious disease course,0.6264705882352941
communicability start temporal region,infectious disease sporadicity,0.6291044776119403
communicability start temporal region,communicability end process boundary,0.7513698630136986
communicability start temporal region,infection incidence proportion profile,0.6366666666666667
communicability start temporal region,SARS-CoV-2 incidence proportion,0.6411764705882353
communicability start temporal region,spatiotemporal region,0.760344827586207
communicability start temporal region,latency end process boundary,0.6038461538461539
communicability start temporal region,infectious disease epidemic,0.621875
communicability start temporal region,disease transmission model,0.6087301587301588
communicability start temporal region,negative-sense single-stranded RNA virus,0.6058441558441559
communicability start temporal region,COVID-19 incidence rate,0.6
communicability start temporal region,zero-dimensional spatial region,0.7294117647058823
communicability start temporal region,zero-dimensional temporal region,0.7688405797101449
communicability start temporal region,chronic infectious disease course,0.65
communicability start temporal region,COVID-19 epidemic,0.5981481481481481
communicability start temporal region,infection start temporal region,0.8176470588235294
communicability start temporal region,virus disorder,0.5676470588235294
communicability start temporal region,establishment of localization in human host,0.6125
communicability start temporal region,incubation end process boundary,0.6264705882352941
communicability start temporal region,geographical region,0.6642857142857143
communicability start temporal region,latency end temporal region,0.7625
communicability start temporal region,virus adhesion susceptible cell,0.5970588235294118
communicability start temporal region,T cell receptor complex,0.6166666666666667
communicability start temporal region,respiratory system disease,0.6246031746031746
communicability start temporal region,communicability interval,0.7942622950819671
communicability start temporal region,infectious disease control strategy,0.6444444444444444
communicability start temporal region,infectious disease pandemic,0.621875
communicability start temporal region,viral disease course,0.6254385964912281
communicability start temporal region,three-dimensional spatial region,0.7108695652173913
communicability start temporal region,objective specification,0.6166666666666667
communicability start temporal region,country,0.5863636363636363
communicability start temporal region,source of infection role,0.6139344262295081
communicability start temporal region,disease course,0.5872549019607843
communicability start temporal region,infectious disease course,0.6112903225806451
communicability start temporal region,COVID-19 disease incidence proportion,0.6391891891891892
communicability start temporal region,coronavirus disease course,0.6404761904761905
communicability start temporal region,infection incidence proportion,0.658955223880597
communicability start temporal region,respiratory droplet virus fomite,0.6094202898550725
communicability start temporal region,pathogen portal of exit site,0.6192307692307693
communicability start temporal region,infectious disease prevalence,0.6469696969696969
communicability start temporal region,single-stranded DNA virus,0.5951612903225807
communicability start temporal region,COVID-19 mortality rate,0.65
communicability start temporal region,place closure control strategy,0.6440298507462687
communicability start temporal region,viral disease,0.61
communicability start temporal region,contagiousness,0.6264705882352941
communicability start temporal region,disease,0.5636363636363636
communicability start temporal region,incubation start process boundary,0.6785714285714286
communicability start temporal region,object,0.5197674418604651
communicability start temporal region,pathogen birth process boundary,0.6264705882352941
communicability start temporal region,infectious human pathogen,0.6112903225806451
communicability start temporal region,subclinical virus infection,0.653125
communicability start temporal region,colonization of human,0.6396551724137931
communicability start temporal region,establishment of localization in virus host,0.6125
communicability start temporal region,virus attachment stage,0.6194915254237288
communicability start temporal region,virus synthesis stage,0.5879310344827586
communicability start temporal region,object aggregate,0.619811320754717
communicability start temporal region,pathogen portal of exit role,0.6346153846153847
communicability start temporal region,long-term non-progressing infectious disease course,0.5977272727272728
communicability start temporal region,viral disease epidemic,0.6364406779661017
communicability start temporal region,communicability start temporal region,0.95
communicability start temporal region,viral disease pandemic,0.6364406779661017
communicability start temporal region,virus penetration stage,0.6
communicability start temporal region,geospatial region,0.6907407407407408
communicability start temporal region,division of geopolitical entity,0.6411764705882353
communicability start temporal region,infectious disease endemicity,0.6015151515151516
communicability start temporal region,communicability,0.7384615384615384
communicability start temporal region,infection start process boundary,0.6673913043478261
communicability start temporal region,processed material,0.6136363636363636
communicability start temporal region,latency start process boundary,0.6738805970149254
communicability start temporal region,infectious disease control objective specification,0.6339080459770114
communicability start temporal region,COVID-19 disease course,0.6166666666666667
communicability start temporal region,infectious disease incidence rate,0.6071428571428572
communicability start temporal region,communicability start process boundary,0.81
communicability start temporal region,single-stranded RNA retrovirus,0.6291044776119403
communicability start temporal region,disordered virus,0.5820754716981132
communicability start temporal region,virus uncoating stage,0.6224137931034482
communicability start temporal region,local infection,0.6230769230769231
communicability start temporal region,establishment of a clinically abnormal colony,0.6451219512195122
communicability start temporal region,coronavirus disease,0.6285714285714286
communicability start temporal region,positive-sense single-stranded RNA virus,0.6058441558441559
communicability start temporal region,one-dimensional spatial region,0.7335820895522389
communicability start temporal region,spatial region,0.6852941176470588
communicability start temporal region,pathogen death temporal region,0.7634328358208955
communicability start temporal region,material processing,0.6642857142857143
reagent,infectious agent host role,0.6318181818181818
reagent,passive immunization against infectious agent,0.5653846153846154
reagent,cidal agent disposition,0.6166666666666667
reagent,infectious agent colony,0.65
reagent,infectious agent generative stage,0.6
reagent,cidal agent,0.7277777777777777
reagent,asymptomatic infectious agent carrier,0.5863636363636363
reagent,sterilizing immunity to infectious agent,0.598936170212766
reagent,innate immunity to infectious agent,0.5928571428571429
reagent,static agent disposition,0.6112903225806451
reagent,T cell receptor complex,0.5833333333333334
reagent,infectious agent population,0.6264705882352941
reagent,leukocyte-mediated immunity to infectious agent,0.5611111111111111
reagent,humoral immunity to infectious agent,0.6127906976744186
reagent,antibody reagent,0.7543478260869566
reagent,passive immunity to infectious agent,0.5895348837209302
reagent,vaccination against infectious agent,0.5895348837209302
reagent,susceptibility to infectious agent,0.5963414634146341
reagent,acquired immunity to infectious agent,0.609090909090909
reagent,symptomatic infectious agent carrier,0.5895348837209302
reagent,reagent,0.95
reagent,immunization against infectious agent,0.5863636363636363
reagent,infectious agent host,0.6642857142857143
reagent,infectious agent reservoir,0.6318181818181818
reagent,active immunization against infectious agent,0.5676470588235294
reagent,reagent role,0.8184210526315789
reagent,infectious agent,0.7108695652173913
reagent,establishment of a clinically abnormal colony,0.5461538461538461
reagent,drug susceptibility of infectious agent,0.6021739130434782
reagent,static agent,0.7131578947368421
case isolation control strategy,virostatic disposition,0.619811320754717
case isolation control strategy,information content entity,0.730701754385965
case isolation control strategy,zoonotic disposition,0.6264705882352941
case isolation control strategy,infectious disease mortality rate,0.684375
case isolation control strategy,infection incidence rate profile,0.6563492063492063
case isolation control strategy,communicability end temporal region,0.6621212121212122
case isolation control strategy,biological regulation,0.6423076923076922
case isolation control strategy,surveillance process,0.6460784313725491
case isolation control strategy,infection end temporal region,0.6833333333333332
case isolation control strategy,vector control strategy,0.8203703703703704
case isolation control strategy,SARS-CoV-2 incidence rate,0.6642857142857143
case isolation control strategy,incubation end temporal region,0.6959016393442623
case isolation control strategy,virulence factor disposition,0.6194915254237288
case isolation control strategy,viral adhesion disposition,0.6254385964912281
case isolation control strategy,parasitostatic disposition,0.6429824561403508
case isolation control strategy,negative regulation of production,0.66875
case isolation control strategy,reverse zoonotic disposition,0.6364406779661017
case isolation control strategy,disease surveillance objective specification,0.65
case isolation control strategy,case isolation control strategy,0.95
case isolation control strategy,quarantine control strategy,0.8293103448275861
case isolation control strategy,B cell receptor complex,0.6351851851851852
case isolation control strategy,infection incidence rate,0.6863636363636364
case isolation control strategy,infectious disease lifetime prevalence,0.6239130434782608
case isolation control strategy,toxin disposition,0.6166666666666667
case isolation control strategy,cidal agent disposition,0.6537037037037037
case isolation control strategy,process,0.5552631578947369
case isolation control strategy,droplet pathogen transmission process,0.6411764705882353
case isolation control strategy,parasiticidal disposition,0.6285714285714286
case isolation control strategy,communicability end process boundary,0.6291044776119403
case isolation control strategy,directive information content entity,0.7335820895522389
case isolation control strategy,transmissibility disposition,0.6194915254237288
case isolation control strategy,latency end process boundary,0.6364406779661017
case isolation control strategy,endotoxin disposition,0.6230769230769231
case isolation control strategy,vector surveillance,0.63
case isolation control strategy,negative regulation of establishment of localization,0.6548192771084337
case isolation control strategy,COVID-19 incidence rate,0.6537037037037037
case isolation control strategy,cytotoxin disposition,0.6230769230769231
case isolation control strategy,negative regulation of developmental process,0.6766666666666665
case isolation control strategy,descriptive information content entity,0.7253623188405797
case isolation control strategy,negative regulation of replication,0.6807692307692308
case isolation control strategy,process of establishing an infection,0.6141791044776119
case isolation control strategy,incubation end process boundary,0.6596774193548387
case isolation control strategy,collective pathogenic disposition,0.621875
case isolation control strategy,neurotoxin disposition,0.619811320754717
case isolation control strategy,pathogen death process boundary,0.6274193548387097
case isolation control strategy,plan specification,0.6336734693877552
case isolation control strategy,latency end temporal region,0.6741379310344828
case isolation control strategy,collective disposition,0.6386792452830189
case isolation control strategy,static agent disposition,0.65
case isolation control strategy,T cell receptor complex,0.6351851851851852
case isolation control strategy,respiratory system disease,0.6429824561403508
case isolation control strategy,indirect pathogen transmission process,0.6384057971014493
case isolation control strategy,planned process,0.6021739130434782
case isolation control strategy,infectious disease control strategy,0.7984848484848485
case isolation control strategy,SARS-CoV-2 attachment stage,0.6741379310344828
case isolation control strategy,immunosuppressive disposition,0.6166666666666667
case isolation control strategy,pathogenic disposition,0.6386792452830189
case isolation control strategy,viral envelope,0.5833333333333334
case isolation control strategy,infectious disposition,0.6386792452830189
case isolation control strategy,bacteriostatic disposition,0.6429824561403508
case isolation control strategy,bactericidal disposition,0.6318181818181818
case isolation control strategy,country,0.6078947368421053
case isolation control strategy,invasion disposition,0.6460784313725491
case isolation control strategy,viricidal disposition,0.6423076923076922
case isolation control strategy,infectious disease prevalence,0.6166666666666667
case isolation control strategy,disposition,0.6166666666666667
case isolation control strategy,COVID-19 mortality rate,0.6722222222222223
case isolation control strategy,process profile,0.6239130434782608
case isolation control strategy,negative regulation of life-sustaining process,0.6577922077922078
case isolation control strategy,place closure control strategy,0.810655737704918
case isolation control strategy,adhesion disposition,0.6460784313725491
case isolation control strategy,developmental process,0.6230769230769231
case isolation control strategy,biological process,0.6336734693877552
case isolation control strategy,primary infectious disposition,0.6139344262295081
case isolation control strategy,infection prevalence,0.6264705882352941
case isolation control strategy,designative information content entity,0.7253623188405797
case isolation control strategy,incubation start process boundary,0.653125
case isolation control strategy,pathogen surveillance,0.6230769230769231
case isolation control strategy,pathogen birth process boundary,0.6274193548387097
case isolation control strategy,virus attachment stage,0.6764150943396227
case isolation control strategy,negative regulation of immune response,0.6818840579710145
case isolation control strategy,SARS-COV-2 adhesion disposition,0.6274193548387097
case isolation control strategy,invasive disposition,0.6656862745098039
case isolation control strategy,fungicidal disposition,0.6386792452830189
case isolation control strategy,division of geopolitical entity,0.6596774193548387
case isolation control strategy,negative regulation of viral process,0.6888059701492537
case isolation control strategy,contact pathogen transmission process,0.6558823529411765
case isolation control strategy,history,0.6078947368421053
case isolation control strategy,function,0.5782051282051281
case isolation control strategy,herd immunity to infectious organism,0.6291044776119403
case isolation control strategy,symbiotic process,0.6375
case isolation control strategy,exotoxin disposition,0.6264705882352941
case isolation control strategy,infection start process boundary,0.6404761904761905
case isolation control strategy,action specification,0.6264705882352941
case isolation control strategy,latency start process boundary,0.6467213114754098
case isolation control strategy,infectious disease control objective specification,0.6722222222222223
case isolation control strategy,COVID-19 lifetime prevalence,0.6025423728813559
case isolation control strategy,opportunistic infectious disposition,0.6141791044776119
case isolation control strategy,process of establishing viral infection,0.6214285714285714
case isolation control strategy,negative regulation of biological process,0.6722222222222223
case isolation control strategy,enterotoxin disposition,0.6166666666666667
case isolation control strategy,infectious disease incidence rate,0.684375
case isolation control strategy,communicability start process boundary,0.6384057971014493
case isolation control strategy,process that results in death,0.6333333333333333
case isolation control strategy,COVID-19 prevalence,0.59
case isolation control strategy,SARS-COV-2 prevalence,0.6038461538461539
case isolation control strategy,collective resistance disposition,0.621875
case isolation control strategy,fungistatic disposition,0.6166666666666667
case isolation control strategy,establishment of a clinically abnormal colony,0.6342105263157894
case isolation control strategy,process boundary,0.6202127659574468
case isolation control strategy,horizontal pathogen transmission process,0.6471830985915493
case isolation control strategy,pathogen transmission process,0.65
place closure control strategy,virostatic disposition,0.5846153846153846
place closure control strategy,zoonotic disposition,0.59
place closure control strategy,infectious disease mortality rate,0.6722222222222223
place closure control strategy,infection incidence rate profile,0.6274193548387097
place closure control strategy,communicability end temporal region,0.6346153846153847
place closure control strategy,biological regulation,0.6068627450980393
place closure control strategy,surveillance process,0.61
place closure control strategy,infection end temporal region,0.6533898305084747
place closure control strategy,vector control strategy,0.8462264150943396
place closure control strategy,SARS-CoV-2 incidence rate,0.65
place closure control strategy,incubation end temporal region,0.6333333333333333
place closure control strategy,site of infection,0.598936170212766
place closure control strategy,two-dimensional spatial region,0.6333333333333333
place closure control strategy,one-dimensional temporal region,0.630327868852459
place closure control strategy,virulence factor disposition,0.6396551724137931
place closure control strategy,viral adhesion disposition,0.6107142857142857
place closure control strategy,parasitostatic disposition,0.6107142857142857
place closure control strategy,temporal region,0.6277777777777778
place closure control strategy,negative regulation of production,0.6246031746031746
place closure control strategy,reverse zoonotic disposition,0.6224137931034482
place closure control strategy,disease surveillance objective specification,0.6391891891891892
place closure control strategy,case isolation control strategy,0.810655737704918
place closure control strategy,source of infection site,0.6907407407407408
place closure control strategy,quarantine control strategy,0.8008771929824562
place closure control strategy,B cell receptor complex,0.6575471698113208
place closure control strategy,infection incidence rate,0.6537037037037037
place closure control strategy,infectious disease lifetime prevalence,0.6117647058823529
place closure control strategy,toxin disposition,0.5563829787234043
place closure control strategy,pathogen birth temporal region,0.6666666666666667
place closure control strategy,cidal agent disposition,0.6009433962264151
place closure control strategy,parasiticidal disposition,0.5954545454545455
place closure control strategy,communicability end process boundary,0.6015151515151516
place closure control strategy,spatiotemporal region,0.6656862745098039
place closure control strategy,transmissibility disposition,0.553448275862069
place closure control strategy,latency end process boundary,0.656896551724138
place closure control strategy,endotoxin disposition,0.5872549019607843
place closure control strategy,vector surveillance,0.6540816326530612
place closure control strategy,negative regulation of establishment of localization,0.6085365853658536
place closure control strategy,COVID-19 incidence rate,0.6386792452830189
place closure control strategy,cytotoxin disposition,0.5872549019607843
place closure control strategy,negative regulation of developmental process,0.6256756756756756
place closure control strategy,zero-dimensional spatial region,0.6467213114754098
place closure control strategy,zero-dimensional temporal region,0.6435483870967742
place closure control strategy,negative regulation of replication,0.6375
place closure control strategy,infection start temporal region,0.6631147540983606
place closure control strategy,incubation end process boundary,0.6139344262295081
place closure control strategy,collective pathogenic disposition,0.6087301587301588
place closure control strategy,neurotoxin disposition,0.6230769230769231
place closure control strategy,geographical region,0.6336734693877552
place closure control strategy,plan specification,0.6375
place closure control strategy,latency end temporal region,0.6780701754385965
place closure control strategy,anatomical space,0.6456521739130434
place closure control strategy,collective disposition,0.6038461538461539
place closure control strategy,static agent disposition,0.6166666666666667
place closure control strategy,T cell receptor complex,0.6575471698113208
place closure control strategy,respiratory system disease,0.6285714285714286
place closure control strategy,infectious disease control strategy,0.7884615384615384
place closure control strategy,immunosuppressive disposition,0.6025423728813559
place closure control strategy,pathogenic disposition,0.6038461538461539
place closure control strategy,three-dimensional spatial region,0.6274193548387097
place closure control strategy,infectious disposition,0.6038461538461539
place closure control strategy,bacteriostatic disposition,0.6107142857142857
place closure control strategy,epitope site,0.6166666666666667
place closure control strategy,bactericidal disposition,0.6166666666666667
place closure control strategy,country,0.6391891891891892
place closure control strategy,invasion disposition,0.59
place closure control strategy,viricidal disposition,0.5676470588235294
place closure control strategy,pathogen portal of exit site,0.6741379310344828
place closure control strategy,infectious disease prevalence,0.6025423728813559
place closure control strategy,disposition,0.5719512195121951
place closure control strategy,COVID-19 mortality rate,0.6575471698113208
place closure control strategy,negative regulation of life-sustaining process,0.6210526315789474
place closure control strategy,place closure control strategy,0.95
place closure control strategy,adhesion disposition,0.61
place closure control strategy,pathogen portal of entry site,0.7042372881355932
place closure control strategy,site,0.5382352941176471
place closure control strategy,primary infectious disposition,0.6166666666666667
place closure control strategy,infection prevalence,0.61
place closure control strategy,pathogen surveillance,0.6656862745098039
place closure control strategy,negative regulation of immune response,0.6264705882352941
place closure control strategy,SARS-COV-2 adhesion disposition,0.5975409836065574
place closure control strategy,invasive disposition,0.59
place closure control strategy,communicability start temporal region,0.6440298507462687
place closure control strategy,fungicidal disposition,0.5653846153846154
place closure control strategy,geospatial region,0.6414893617021277
place closure control strategy,negative regulation of viral process,0.6318181818181818
place closure control strategy,function,0.5552631578947369
place closure control strategy,herd immunity to infectious organism,0.6166666666666667
place closure control strategy,exotoxin disposition,0.59
place closure control strategy,action specification,0.61
place closure control strategy,infectious disease control objective specification,0.6625
place closure control strategy,COVID-19 lifetime prevalence,0.6051724137931035
place closure control strategy,opportunistic infectious disposition,0.6015151515151516
place closure control strategy,quality,0.5581081081081081
place closure control strategy,negative regulation of biological process,0.6190140845070422
place closure control strategy,enterotoxin disposition,0.6009433962264151
place closure control strategy,infectious disease incidence rate,0.6563492063492063
place closure control strategy,COVID-19 prevalence,0.5724489795918367
place closure control strategy,SARS-COV-2 prevalence,0.6068627450980393
place closure control strategy,collective resistance disposition,0.6087301587301588
place closure control strategy,fungistatic disposition,0.5820754716981132
place closure control strategy,local infection,0.6055555555555556
place closure control strategy,establishment of a clinically abnormal colony,0.61
place closure control strategy,one-dimensional spatial region,0.6333333333333333
place closure control strategy,spatial region,0.6318181818181818
place closure control strategy,pathogen death temporal region,0.6666666666666667
place closure control strategy,cell space,0.65
pathogen host,extended organism,0.65
pathogen host,virus aggregate,0.5928571428571429
pathogen host,source of infection,0.60625
pathogen host,virostatic disposition,0.6214285714285714
pathogen host,zoonotic disposition,0.6318181818181818
pathogen host,infectious disease mortality rate,0.5804347826086956
pathogen host,infection incidence rate profile,0.5833333333333334
pathogen host,pathogen generative stage,0.7394736842105263
pathogen host,pathogen portal of entry,0.7472972972972972
pathogen host,subclinical coronavirus infection,0.558695652173913
pathogen host,primary pathogen,0.7258620689655172
pathogen host,infection end temporal region,0.5928571428571429
pathogen host,drug-based immunosuppressed organism,0.5724489795918367
pathogen host,infectious disease,0.5790322580645162
pathogen host,double-stranded DNA virus,0.581578947368421
pathogen host,site of infection,0.6166666666666667
pathogen host,immunocompetent organism,0.6391891891891892
pathogen host,virulence factor disposition,0.6207317073170732
pathogen host,pathogen portal of exit,0.7555555555555555
pathogen host,viral adhesion disposition,0.6551282051282051
pathogen host,parasitostatic disposition,0.6551282051282051
pathogen host,infectious disease incidence,0.5475609756097561
pathogen host,reservoir of pathogen role,0.7064102564102563
pathogen host,reverse zoonotic disposition,0.5963414634146341
pathogen host,subclinical SARS-CoV-2 infection,0.5388888888888889
pathogen host,establishment of localization in host,0.63
pathogen host,virus translation stage,0.6444444444444444
pathogen host,disease surveillance objective specification,0.5728070175438597
pathogen host,virus release stage,0.60625
pathogen host,infectious agent host role,0.7064102564102563
pathogen host,source of infection site,0.6121621621621621
pathogen host,virus,0.5055555555555555
pathogen host,virus replication,0.6166666666666667
pathogen host,B cell receptor complex,0.5888888888888889
pathogen host,passive immunization against infectious agent,0.6224137931034482
pathogen host,systematic infection,0.5712121212121213
pathogen host,infection incidence rate,0.6121621621621621
pathogen host,colonized host,0.7092592592592593
pathogen host,virus host,0.6673913043478261
pathogen host,double-stranded RNA virus,0.581578947368421
pathogen host,pathogen portal of entry role,0.7119047619047619
pathogen host,virus transcription stage,0.6342105263157894
pathogen host,infectious disease lifetime prevalence,0.5480392156862746
pathogen host,toxin disposition,0.6833333333333332
pathogen host,pathogen birth temporal region,0.7058139534883722
pathogen host,lower respiratory tract disease,0.5863636363636363
pathogen host,infectious disease incidence proportion,0.5846153846153846
pathogen host,opportunistic pathogen,0.6785714285714286
pathogen host,virus generative stage,0.6214285714285714
pathogen host,acute infectious disease course,0.609090909090909
pathogen host,cidal agent disposition,0.6722222222222223
pathogen host,genetic resistance to pathogen,0.636046511627907
pathogen host,subclinical infection,0.5676470588235294
pathogen host,simple infection,0.5879310344827586
pathogen host,droplet pathogen transmission process,0.67
pathogen host,parasiticidal disposition,0.6342105263157894
pathogen host,infectious disease sporadicity,0.5895348837209302
pathogen host,infection incidence proportion profile,0.5872549019607843
pathogen host,infectious agent colony,0.6444444444444444
pathogen host,pathogen transporter,0.7833333333333333
pathogen host,transmissibility disposition,0.5963414634146341
pathogen host,colonization of host,0.7227272727272727
pathogen host,infectious disease epidemic,0.55
pathogen host,infectious agent generative stage,0.6239130434782608
pathogen host,disease transmission model,0.6038461538461539
pathogen host,endotoxin disposition,0.6558823529411765
pathogen host,pathologically immunosuppressed organism,0.6386792452830189
pathogen host,negative-sense single-stranded RNA virus,0.5820754716981132
pathogen host,cidal agent,0.6583333333333334
pathogen host,infectious structure host role,0.636046511627907
pathogen host,pathogen vehicle,0.7948275862068965
pathogen host,cytotoxin disposition,0.6558823529411765
pathogen host,community-acquired infection,0.5475609756097561
pathogen host,pathogen vector,0.8071428571428573
pathogen host,pathogen vehicle role,0.7735294117647058
pathogen host,host,0.6852941176470588
pathogen host,chronic infectious disease course,0.5804347826086956
pathogen host,asymptomatic infectious agent carrier,0.61
pathogen host,nursing-home acquired infection,0.5636363636363636
pathogen host,secondary infection,0.575
pathogen host,infection start temporal region,0.5863636363636363
pathogen host,infection incidence,0.575
pathogen host,virus disorder,0.524074074074074
pathogen host,sterilizing immunity to infectious agent,0.5820754716981132
pathogen host,establishment of localization in human host,0.6107142857142857
pathogen host,primary infection,0.6166666666666667
pathogen host,process of establishing an infection,0.5928571428571429
pathogen host,collective pathogenic disposition,0.7108695652173913
pathogen host,neurotoxin disposition,0.65
pathogen host,dead-end host role,0.7080645161290323
pathogen host,pathogen death process boundary,0.7227272727272727
pathogen host,immunosuppressed organism,0.581578947368421
pathogen host,definitive host role,0.6621212121212122
pathogen host,innate immunity to infectious agent,0.6166666666666667
pathogen host,virus adhesion susceptible cell,0.609090909090909
pathogen host,collective disposition,0.6214285714285714
pathogen host,infection,0.5863636363636363
pathogen host,static agent disposition,0.6932432432432433
pathogen host,T cell receptor complex,0.5888888888888889
pathogen host,infectious structure host,0.6605263157894737
pathogen host,infectious agent population,0.65
pathogen host,respiratory system disease,0.6294871794871795
pathogen host,entry into host,0.7
pathogen host,leukocyte-mediated immunity to infectious agent,0.5833333333333334
pathogen host,indirect pathogen transmission process,0.6656862745098039
pathogen host,adhesion of symbiont to host,0.6695121951219513
pathogen host,organism population,0.6375
pathogen host,humoral immunity to infectious agent,0.5928571428571429
pathogen host,infectious disease control strategy,0.5958333333333333
pathogen host,parasite,0.6404761904761905
pathogen host,infectious disease pandemic,0.55
pathogen host,antibody reagent,0.6913793103448276
pathogen host,immunosuppressive disposition,0.5928571428571429
pathogen host,pathogenic disposition,0.7928571428571428
pathogen host,viral disease course,0.6015151515151516
pathogen host,entry into host through host barriers,0.63
pathogen host,intracellular infection,0.5611111111111111
pathogen host,secondary infection role,0.6121621621621621
pathogen host,metastatic infection,0.5712121212121213
pathogen host,passive immunity to infectious agent,0.6132653061224489
pathogen host,infectious disposition,0.6214285714285714
pathogen host,vaccination against infectious agent,0.6336734693877552
pathogen host,acute infection,0.6285714285714286
pathogen host,susceptibility to infectious agent,0.598936170212766
pathogen host,bacteriostatic disposition,0.6294871794871795
pathogen host,epitope site,0.73
pathogen host,immunity to pathogen,0.6924242424242425
pathogen host,bactericidal disposition,0.6391891891891892
pathogen host,source of infection role,0.5851351351351352
pathogen host,pathogen host,0.95
pathogen host,chronic infection,0.6166666666666667
pathogen host,invasion disposition,0.6621212121212122
pathogen host,disease course,0.6351851851851852
pathogen host,infectious disease course,0.6078947368421053
pathogen host,viricidal disposition,0.5970588235294118
pathogen host,acquired immunity to infectious agent,0.59
pathogen host,complex infection,0.5833333333333334
pathogen host,COVID-19 disease incidence proportion,0.57
pathogen host,coronavirus disease course,0.5782051282051281
pathogen host,infection incidence proportion,0.6127906976744186
pathogen host,symptomatic infectious agent carrier,0.6132653061224489
pathogen host,respiratory droplet virus fomite,0.6277777777777778
pathogen host,susceptible organism,0.6318181818181818
pathogen host,parasite role,0.6807692307692308
pathogen host,intermediate host,0.7166666666666667
pathogen host,pathogen vector role,0.7530303030303032
pathogen host,pathogen portal of exit site,0.7426829268292683
pathogen host,infectious disease prevalence,0.5452380952380953
pathogen host,organism substance,0.6435483870967742
pathogen host,disposition,0.6166666666666667
pathogen host,single-stranded DNA virus,0.581578947368421
pathogen host,viral disease,0.5653846153846154
pathogen host,primary infection role,0.65
pathogen host,adhesion disposition,0.6924242424242425
pathogen host,pathogen portal of entry site,0.7357142857142857
pathogen host,infection incidence profile,0.6
pathogen host,disease,0.55
pathogen host,site,0.5676470588235294
pathogen host,primary infectious disposition,0.636046511627907
pathogen host,pathogen host role,0.8693548387096774
pathogen host,infection prevalence,0.5712121212121213
pathogen host,infectious pathogen transmissibility,0.6744897959183673
pathogen host,intermediate host role,0.6785714285714286
pathogen host,dead-end host,0.7576923076923078
pathogen host,pathogen surveillance,0.7441176470588234
pathogen host,immunodeficient organism,0.6121621621621621
pathogen host,host role,0.6318181818181818
pathogen host,pathogen,0.830952380952381
pathogen host,pathogen birth process boundary,0.7227272727272727
pathogen host,infectious human pathogen,0.6605263157894737
pathogen host,subclinical virus infection,0.55
pathogen host,resistance to pathogen,0.6785714285714286
pathogen host,establishment of localization in virus host,0.6107142857142857
pathogen host,immunization against infectious agent,0.63
pathogen host,virus attachment stage,0.6785714285714286
pathogen host,virus synthesis stage,0.6264705882352941
pathogen host,SARS-COV-2 adhesion disposition,0.6318181818181818
pathogen host,pathogen portal of exit role,0.7182926829268292
pathogen host,invasive disposition,0.6318181818181818
pathogen host,infectious agent host,0.7441176470588234
pathogen host,re-emerging pathogen,0.6924242424242425
pathogen host,long-term non-progressing infectious disease course,0.575
pathogen host,viral disease epidemic,0.5357142857142857
pathogen host,fungicidal disposition,0.5928571428571429
pathogen host,viral disease pandemic,0.5357142857142857
pathogen host,virus penetration stage,0.6722222222222223
pathogen host,pathogen seroprevalence,0.7277777777777777
pathogen host,division of geopolitical entity,0.5636363636363636
pathogen host,infectious disease endemicity,0.569047619047619
pathogen host,contact pathogen transmission process,0.67
pathogen host,herd immunity to infectious organism,0.5724489795918367
pathogen host,extracellular infection,0.5611111111111111
pathogen host,pathogen transporter role,0.7394736842105263
pathogen host,exotoxin disposition,0.6621212121212122
pathogen host,infectious agent reservoir,0.6294871794871795
pathogen host,infection start process boundary,0.5833333333333334
pathogen host,infectious disease control objective specification,0.5769841269841269
pathogen host,symbiont host role,0.6758064516129032
pathogen host,opportunistic infectious disposition,0.5928571428571429
pathogen host,process of establishing viral infection,0.5846153846153846
pathogen host,enterotoxin disposition,0.6444444444444444
pathogen host,COVID-19 disease course,0.5888888888888889
pathogen host,infectious disease incidence rate,0.5804347826086956
pathogen host,active immunization against infectious agent,0.6078947368421053
pathogen host,disordered virus,0.5879310344827586
pathogen host,collective resistance disposition,0.6021739130434782
pathogen host,fungistatic disposition,0.6166666666666667
pathogen host,organism,0.6404761904761905
pathogen host,virus uncoating stage,0.6264705882352941
pathogen host,local infection,0.5928571428571429
pathogen host,infectious agent,0.656896551724138
pathogen host,establishment of a clinically abnormal colony,0.553448275862069
pathogen host,coronavirus disease,0.575
pathogen host,positive-sense single-stranded RNA virus,0.5820754716981132
pathogen host,definitive host,0.7
pathogen host,horizontal pathogen transmission process,0.6575471698113208
pathogen host,hospital-acquired infection,0.575
pathogen host,pathogen death temporal region,0.7058139534883722
pathogen host,emerging pathogen,0.7166666666666667
pathogen host,drug susceptibility of infectious agent,0.5846153846153846
pathogen host,static agent,0.69
pathogen host,pathogen transmission process,0.7119047619047619
asymptomatic infectious agent carrier,information content entity,0.6722222222222223
asymptomatic infectious agent carrier,infectious disease mortality rate,0.6928571428571427
asymptomatic infectious agent carrier,infection incidence rate profile,0.6818840579710145
asymptomatic infectious agent carrier,infectious structure aggregate,0.6888059701492537
asymptomatic infectious agent carrier,communicability end temporal region,0.6305555555555555
asymptomatic infectious agent carrier,infection end temporal region,0.6772727272727272
asymptomatic infectious agent carrier,infectious disease,0.7045454545454546
asymptomatic infectious agent carrier,SARS-CoV-2 incidence rate,0.6596774193548387
asymptomatic infectious agent carrier,incubation end temporal region,0.6440298507462687
asymptomatic infectious agent carrier,virulence factor disposition,0.6192307692307693
asymptomatic infectious agent carrier,infectious disease incidence,0.7115384615384616
asymptomatic infectious agent carrier,disease surveillance objective specification,0.6228395061728395
asymptomatic infectious agent carrier,infectious agent host role,0.7515873015873015
asymptomatic infectious agent carrier,asymptomatic infectious structure carrier,0.8730769230769231
asymptomatic infectious agent carrier,B cell receptor complex,0.6
asymptomatic infectious agent carrier,passive immunization against infectious agent,0.7426829268292683
asymptomatic infectious agent carrier,infection incidence rate,0.6795081967213115
asymptomatic infectious agent carrier,infectious disease lifetime prevalence,0.6766666666666665
asymptomatic infectious agent carrier,lower respiratory tract disease,0.6264705882352941
asymptomatic infectious agent carrier,infectious disease incidence proportion,0.6868421052631578
asymptomatic infectious agent carrier,acute infectious disease course,0.7441176470588234
asymptomatic infectious agent carrier,cidal agent disposition,0.6166666666666667
asymptomatic infectious agent carrier,infectious disorder,0.7
asymptomatic infectious agent carrier,biological vehicle,0.5954545454545455
asymptomatic infectious agent carrier,infectious disease sporadicity,0.6888059701492537
asymptomatic infectious agent carrier,communicability end process boundary,0.6280821917808219
asymptomatic infectious agent carrier,directive information content entity,0.6554794520547945
asymptomatic infectious agent carrier,infectious agent colony,0.75
asymptomatic infectious agent carrier,pathogen transporter,0.6605263157894737
asymptomatic infectious agent carrier,invasion factor,0.6230769230769231
asymptomatic infectious agent carrier,latency end process boundary,0.6192307692307693
asymptomatic infectious agent carrier,infectious disease epidemic,0.7
asymptomatic infectious agent carrier,infectious agent generative stage,0.7357142857142857
asymptomatic infectious agent carrier,disease transmission model,0.6087301587301588
asymptomatic infectious agent carrier,cidal agent,0.6166666666666667
asymptomatic infectious agent carrier,infectious structure host role,0.6888059701492537
asymptomatic infectious agent carrier,pathogen vehicle,0.6386792452830189
asymptomatic infectious agent carrier,COVID-19 incidence rate,0.65
asymptomatic infectious agent carrier,pathogen vehicle role,0.6396551724137931
asymptomatic infectious agent carrier,chronic infectious disease course,0.75
asymptomatic infectious agent carrier,asymptomatic infectious agent carrier,0.95
asymptomatic infectious agent carrier,descriptive information content entity,0.6766666666666665
asymptomatic infectious agent carrier,COVID-19 epidemic,0.5796296296296296
asymptomatic infectious agent carrier,sterilizing immunity to infectious agent,0.7227272727272727
asymptomatic infectious agent carrier,diseased population,0.6107142857142857
asymptomatic infectious agent carrier,virulence factor,0.6009433962264151
asymptomatic infectious agent carrier,incubation end process boundary,0.6411764705882353
asymptomatic infectious agent carrier,latency end temporal region,0.621875
asymptomatic infectious agent carrier,innate immunity to infectious agent,0.7416666666666667
asymptomatic infectious agent carrier,infectious structure,0.7131578947368421
asymptomatic infectious agent carrier,static agent disposition,0.6795081967213115
asymptomatic infectious agent carrier,T cell receptor complex,0.6166666666666667
asymptomatic infectious agent carrier,asymptomatic carrier role,0.7725806451612902
asymptomatic infectious agent carrier,infectious structure host,0.6919354838709677
asymptomatic infectious agent carrier,infectious agent population,0.746875
asymptomatic infectious agent carrier,respiratory system disease,0.6246031746031746
asymptomatic infectious agent carrier,leukocyte-mediated immunity to infectious agent,0.7238095238095238
asymptomatic infectious agent carrier,humoral immunity to infectious agent,0.7376712328767124
asymptomatic infectious agent carrier,infectious disease control strategy,0.7
asymptomatic infectious agent carrier,infectious disease pandemic,0.7
asymptomatic infectious agent carrier,infectious structure generative stage,0.6932432432432433
asymptomatic infectious agent carrier,viral disease course,0.6254385964912281
asymptomatic infectious agent carrier,passive immunity to infectious agent,0.7513698630136986
asymptomatic infectious agent carrier,infectious disposition,0.6703389830508475
asymptomatic infectious agent carrier,vaccination against infectious agent,0.7513698630136986
asymptomatic infectious agent carrier,susceptibility to infectious agent,0.7457746478873238
asymptomatic infectious agent carrier,disease course,0.6068627450980393
asymptomatic infectious agent carrier,infectious disease course,0.7241935483870968
asymptomatic infectious agent carrier,acquired immunity to infectious agent,0.7337837837837838
asymptomatic infectious agent carrier,COVID-19 disease incidence proportion,0.6256756756756756
asymptomatic infectious agent carrier,coronavirus disease course,0.6404761904761905
asymptomatic infectious agent carrier,asymptomatic carrier,0.8008771929824562
asymptomatic infectious agent carrier,biological vehicle role,0.6166666666666667
asymptomatic infectious agent carrier,symptomatic infectious agent carrier,0.9431506849315068
asymptomatic infectious agent carrier,intermediate host,0.5981481481481481
asymptomatic infectious agent carrier,infectious disease prevalence,0.6924242424242425
asymptomatic infectious agent carrier,infected population,0.6464285714285714
asymptomatic infectious agent carrier,COVID-19 mortality rate,0.6
asymptomatic infectious agent carrier,viral disease,0.59
asymptomatic infectious agent carrier,disease,0.5636363636363636
asymptomatic infectious agent carrier,symptomatic infectious structure carrier,0.8655844155844156
asymptomatic infectious agent carrier,primary infectious disposition,0.703731343283582
asymptomatic infectious agent carrier,designative information content entity,0.6766666666666665
asymptomatic infectious agent carrier,symptomatic carrier role,0.7614754098360657
asymptomatic infectious agent carrier,infectious pathogen transmissibility,0.6965753424657534
asymptomatic infectious agent carrier,intermediate host role,0.6364406779661017
asymptomatic infectious agent carrier,infectious human pathogen,0.7080645161290323
asymptomatic infectious agent carrier,immunization against infectious agent,0.7472972972972972
asymptomatic infectious agent carrier,infectious agent host,0.743103448275862
asymptomatic infectious agent carrier,long-term non-progressing infectious disease course,0.7
asymptomatic infectious agent carrier,viral disease epidemic,0.6025423728813559
asymptomatic infectious agent carrier,viral disease pandemic,0.6025423728813559
asymptomatic infectious agent carrier,symptomatic carrier,0.7892857142857143
asymptomatic infectious agent carrier,infectious disease endemicity,0.6924242424242425
asymptomatic infectious agent carrier,function,0.5833333333333334
asymptomatic infectious agent carrier,herd immunity to infectious organism,0.6965753424657534
asymptomatic infectious agent carrier,pathogen transporter role,0.6435483870967742
asymptomatic infectious agent carrier,infectious agent reservoir,0.7833333333333333
asymptomatic infectious agent carrier,COVID-19 pandemic,0.5796296296296296
asymptomatic infectious agent carrier,action specification,0.6429824561403508
asymptomatic infectious agent carrier,infectious disease control objective specification,0.6683908045977012
asymptomatic infectious agent carrier,opportunistic infectious disposition,0.7102739726027397
asymptomatic infectious agent carrier,polymerase chain reaction,0.6596774193548387
asymptomatic infectious agent carrier,COVID-19 disease course,0.6333333333333333
asymptomatic infectious agent carrier,infectious disease incidence rate,0.7071428571428571
asymptomatic infectious agent carrier,active immunization against infectious agent,0.7339506172839506
asymptomatic infectious agent carrier,symptom,0.609090909090909
asymptomatic infectious agent carrier,infectious agent,0.7518867924528303
asymptomatic infectious agent carrier,establishment of a clinically abnormal colony,0.6329268292682927
asymptomatic infectious agent carrier,coronavirus disease,0.6107142857142857
asymptomatic infectious agent carrier,adhesion factor,0.6230769230769231
asymptomatic infectious agent carrier,drug susceptibility of infectious agent,0.7263157894736842
asymptomatic infectious agent carrier,static agent,0.6948979591836735
one-dimensional spatial region,communicability end temporal region,0.7115384615384616
one-dimensional spatial region,geographical entity,0.6540816326530612
one-dimensional spatial region,infection end temporal region,0.7211864406779661
one-dimensional spatial region,incubation end temporal region,0.7166666666666667
one-dimensional spatial region,two-dimensional spatial region,0.9166666666666665
one-dimensional spatial region,one-dimensional temporal region,0.8762295081967213
one-dimensional spatial region,temporal region,0.7166666666666667
one-dimensional spatial region,disease surveillance objective specification,0.6391891891891892
one-dimensional spatial region,B cell receptor complex,0.5820754716981132
one-dimensional spatial region,double-stranded RNA virus,0.6318181818181818
one-dimensional spatial region,pathogen birth temporal region,0.7
one-dimensional spatial region,lower respiratory tract disease,0.6467213114754098
one-dimensional spatial region,infectious disease incidence proportion,0.6528985507246376
one-dimensional spatial region,acute infectious disease course,0.630327868852459
one-dimensional spatial region,communicability end process boundary,0.6318181818181818
one-dimensional spatial region,infection incidence proportion profile,0.6411764705882353
one-dimensional spatial region,SARS-CoV-2 incidence proportion,0.6467213114754098
one-dimensional spatial region,spatiotemporal region,0.7245098039215686
one-dimensional spatial region,latency end process boundary,0.6051724137931035
one-dimensional spatial region,negative-sense single-stranded RNA virus,0.6642857142857143
one-dimensional spatial region,zero-dimensional spatial region,0.909016393442623
one-dimensional spatial region,zero-dimensional temporal region,0.8370967741935484
one-dimensional spatial region,chronic infectious disease course,0.6404761904761905
one-dimensional spatial region,infection start temporal region,0.7450819672131148
one-dimensional spatial region,incubation end process boundary,0.630327868852459
one-dimensional spatial region,geographical region,0.7357142857142857
one-dimensional spatial region,latency end temporal region,0.6956140350877194
one-dimensional spatial region,T cell receptor complex,0.5820754716981132
one-dimensional spatial region,viral disease course,0.63
one-dimensional spatial region,three-dimensional spatial region,0.9016129032258065
one-dimensional spatial region,objective specification,0.6764150943396227
one-dimensional spatial region,country,0.5581081081081081
one-dimensional spatial region,disease course,0.6318181818181818
one-dimensional spatial region,infectious disease course,0.6318181818181818
one-dimensional spatial region,COVID-19 disease incidence proportion,0.658955223880597
one-dimensional spatial region,coronavirus disease course,0.6285714285714286
one-dimensional spatial region,infection incidence proportion,0.65
one-dimensional spatial region,place closure control strategy,0.6333333333333333
one-dimensional spatial region,object,0.5333333333333333
one-dimensional spatial region,object aggregate,0.6021739130434782
one-dimensional spatial region,long-term non-progressing infectious disease course,0.6351851851851852
one-dimensional spatial region,communicability start temporal region,0.7335820895522389
one-dimensional spatial region,geospatial region,0.7904255319148936
one-dimensional spatial region,division of geopolitical entity,0.6959016393442623
one-dimensional spatial region,geographical feature,0.65
one-dimensional spatial region,infectious disease control objective specification,0.6625
one-dimensional spatial region,COVID-19 disease course,0.6386792452830189
one-dimensional spatial region,single-stranded RNA retrovirus,0.6333333333333333
one-dimensional spatial region,local infection,0.65
one-dimensional spatial region,establishment of a clinically abnormal colony,0.6633333333333334
one-dimensional spatial region,positive-sense single-stranded RNA virus,0.6642857142857143
one-dimensional spatial region,one-dimensional spatial region,0.95
one-dimensional spatial region,spatial region,0.7681818181818181
one-dimensional spatial region,pathogen death temporal region,0.7166666666666667
mycovirus,virus aggregate,0.6583333333333334
mycovirus,double-stranded DNA virus,0.6264705882352941
mycovirus,virus translation stage,0.60625
mycovirus,virus release stage,0.6285714285714286
mycovirus,virus,0.8071428571428573
mycovirus,virus replication,0.6423076923076922
mycovirus,virus host,0.7131578947368421
mycovirus,double-stranded RNA virus,0.6264705882352941
mycovirus,virus transcription stage,0.5970588235294118
mycovirus,virus generative stage,0.6112903225806451
mycovirus,negative-sense single-stranded RNA virus,0.5520408163265306
mycovirus,virus disorder,0.6673913043478261
mycovirus,virus adhesion susceptible cell,0.575
mycovirus,respiratory droplet virus fomite,0.6207317073170732
mycovirus,single-stranded DNA virus,0.5970588235294118
mycovirus,subclinical virus infection,0.6166666666666667
mycovirus,establishment of localization in virus host,0.6038461538461539
mycovirus,virus attachment stage,0.6112903225806451
mycovirus,virus synthesis stage,0.6166666666666667
mycovirus,virus penetration stage,0.60625
mycovirus,mycovirus,0.95
mycovirus,disordered virus,0.69
mycovirus,virus uncoating stage,0.6166666666666667
mycovirus,positive-sense single-stranded RNA virus,0.5724489795918367
viral disease epidemic,virus aggregate,0.6391891891891892
viral disease epidemic,source of infection,0.5963414634146341
viral disease epidemic,virostatic disposition,0.7
viral disease epidemic,zoonotic disposition,0.6404761904761905
viral disease epidemic,infectious disease mortality rate,0.6681818181818181
viral disease epidemic,infection incidence rate profile,0.6351851851851852
viral disease epidemic,infectious structure aggregate,0.6038461538461539
viral disease epidemic,communicability end temporal region,0.6254385964912281
viral disease epidemic,subclinical coronavirus infection,0.6318181818181818
viral disease epidemic,infection end temporal region,0.6068627450980393
viral disease epidemic,infectious disease,0.675
viral disease epidemic,double-stranded DNA virus,0.598936170212766
viral disease epidemic,incubation end temporal region,0.6230769230769231
viral disease epidemic,site of infection,0.6038461538461539
viral disease epidemic,virulence factor disposition,0.67
viral disease epidemic,viral adhesion disposition,0.7208333333333333
viral disease epidemic,parasitostatic disposition,0.6375
viral disease epidemic,infectious disease incidence,0.73
viral disease epidemic,reverse zoonotic disposition,0.63
viral disease epidemic,subclinical SARS-CoV-2 infection,0.6537037037037037
viral disease epidemic,virus translation stage,0.65
viral disease epidemic,disease surveillance objective specification,0.6469696969696969
viral disease epidemic,virus release stage,0.6939024390243902
viral disease epidemic,infectious agent host role,0.5958333333333333
viral disease epidemic,asymptomatic infectious structure carrier,0.5928571428571429
viral disease epidemic,source of infection site,0.6021739130434782
viral disease epidemic,virus,0.5981481481481481
viral disease epidemic,virus replication,0.6807692307692308
viral disease epidemic,B cell receptor complex,0.6055555555555556
viral disease epidemic,passive immunization against infectious agent,0.5992537313432835
viral disease epidemic,systematic infection,0.6166666666666667
viral disease epidemic,infection incidence rate,0.6021739130434782
viral disease epidemic,virus host,0.60625
viral disease epidemic,double-stranded RNA virus,0.598936170212766
viral disease epidemic,virus transcription stage,0.6414893617021277
viral disease epidemic,infectious disease lifetime prevalence,0.6833333333333332
viral disease epidemic,toxin disposition,0.6551282051282051
viral disease epidemic,lower respiratory tract disease,0.6575471698113208
viral disease epidemic,infectious disease incidence proportion,0.6795081967213115
viral disease epidemic,virus generative stage,0.6545454545454545
viral disease epidemic,acute infectious disease course,0.6575471698113208
viral disease epidemic,cidal agent disposition,0.6722222222222223
viral disease epidemic,infectious disorder,0.6207317073170732
viral disease epidemic,subclinical infection,0.6127906976744186
viral disease epidemic,appearance of disorder,0.6318181818181818
viral disease epidemic,simple infection,0.6342105263157894
viral disease epidemic,parasiticidal disposition,0.6627659574468084
viral disease epidemic,infectious disease sporadicity,0.7192307692307692
viral disease epidemic,communicability end process boundary,0.6051724137931035
viral disease epidemic,infection incidence proportion profile,0.6
viral disease epidemic,infectious agent colony,0.6055555555555556
viral disease epidemic,transmissibility disposition,0.65
viral disease epidemic,latency end process boundary,0.59
viral disease epidemic,infectious disease epidemic,0.8173469387755102
viral disease epidemic,infectious agent generative stage,0.6136363636363636
viral disease epidemic,disease transmission model,0.6791666666666666
viral disease epidemic,endotoxin disposition,0.636046511627907
viral disease epidemic,negative-sense single-stranded RNA virus,0.6274193548387097
viral disease epidemic,infectious structure host role,0.5846153846153846
viral disease epidemic,viral plaque assay,0.675
viral disease epidemic,cytotoxin disposition,0.636046511627907
viral disease epidemic,community-acquired infection,0.61
viral disease epidemic,chronic infectious disease course,0.65
viral disease epidemic,asymptomatic infectious agent carrier,0.6025423728813559
viral disease epidemic,nursing-home acquired infection,0.619811320754717
viral disease epidemic,COVID-19 epidemic,0.7576923076923078
viral disease epidemic,secondary infection,0.6207317073170732
viral disease epidemic,infection start temporal region,0.619811320754717
viral disease epidemic,infection incidence,0.6207317073170732
viral disease epidemic,virus disorder,0.7
viral disease epidemic,sterilizing immunity to infectious agent,0.5790322580645162
viral disease epidemic,primary infection,0.6294871794871795
viral disease epidemic,process of establishing an infection,0.6224137931034482
viral disease epidemic,incubation end process boundary,0.6009433962264151
viral disease epidemic,SARS-CoV-2 disorder,0.6207317073170732
viral disease epidemic,collective pathogenic disposition,0.6136363636363636
viral disease epidemic,neurotoxin disposition,0.6318181818181818
viral disease epidemic,latency end temporal region,0.6336734693877552
viral disease epidemic,innate immunity to infectious agent,0.5903508771929825
viral disease epidemic,infectious structure,0.569047619047619
viral disease epidemic,virus adhesion susceptible cell,0.6952830188679244
viral disease epidemic,collective disposition,0.6318181818181818
viral disease epidemic,infection,0.5467741935483871
viral disease epidemic,static agent disposition,0.6456521739130434
viral disease epidemic,T cell receptor complex,0.6055555555555556
viral disease epidemic,infectious structure host,0.5776595744680851
viral disease epidemic,infectious agent population,0.6132653061224489
viral disease epidemic,respiratory system disease,0.6791666666666666
viral disease epidemic,leukocyte-mediated immunity to infectious agent,0.5949275362318841
viral disease epidemic,humoral immunity to infectious agent,0.6051724137931035
viral disease epidemic,infectious disease control strategy,0.6429824561403508
viral disease epidemic,infectious disease pandemic,0.7765306122448979
viral disease epidemic,infectious structure generative stage,0.6025423728813559
viral disease epidemic,immunosuppressive disposition,0.6264705882352941
viral disease epidemic,pathogenic disposition,0.6318181818181818
viral disease epidemic,viral disease course,0.8071428571428573
viral disease epidemic,intracellular infection,0.65
viral disease epidemic,secondary infection role,0.6021739130434782
viral disease epidemic,metastatic infection,0.6166666666666667
viral disease epidemic,viral envelope,0.7277777777777777
viral disease epidemic,passive immunity to infectious agent,0.6051724137931035
viral disease epidemic,infectious disposition,0.6318181818181818
viral disease epidemic,vaccination against infectious agent,0.6224137931034482
viral disease epidemic,acute infection,0.6121621621621621
viral disease epidemic,susceptibility to infectious agent,0.5928571428571429
viral disease epidemic,bacteriostatic disposition,0.6375
viral disease epidemic,bactericidal disposition,0.6673913043478261
viral disease epidemic,source of infection role,0.5804347826086956
viral disease epidemic,chronic infection,0.6038461538461539
viral disease epidemic,invasion disposition,0.6642857142857143
viral disease epidemic,disease course,0.7
viral disease epidemic,infectious disease course,0.6840425531914894
viral disease epidemic,viricidal disposition,0.7290697674418604
viral disease epidemic,acquired immunity to infectious agent,0.5855932203389831
viral disease epidemic,complex infection,0.6038461538461539
viral disease epidemic,COVID-19 disease incidence proportion,0.7042372881355932
viral disease epidemic,coronavirus disease course,0.7208333333333333
viral disease epidemic,infection incidence proportion,0.6038461538461539
viral disease epidemic,symptomatic infectious agent carrier,0.6051724137931035
viral disease epidemic,viral capsid,0.7441176470588234
viral disease epidemic,respiratory droplet virus fomite,0.6351851851851852
viral disease epidemic,infectious disease prevalence,0.7049019607843137
viral disease epidemic,disposition,0.6318181818181818
viral disease epidemic,single-stranded DNA virus,0.6202127659574468
viral disease epidemic,viral disease,0.8214285714285714
viral disease epidemic,primary infection role,0.609090909090909
viral disease epidemic,adhesion disposition,0.6404761904761905
viral disease epidemic,infection incidence profile,0.6336734693877552
viral disease epidemic,disease,0.6913793103448276
viral disease epidemic,symptomatic infectious structure carrier,0.5951612903225807
viral disease epidemic,primary infectious disposition,0.6423076923076922
viral disease epidemic,infection prevalence,0.5928571428571429
viral disease epidemic,coronavirus disorder,0.6642857142857143
viral disease epidemic,infectious pathogen transmissibility,0.5879310344827586
viral disease epidemic,infectious human pathogen,0.598936170212766
viral disease epidemic,subclinical virus infection,0.6540816326530612
viral disease epidemic,establishment of localization in virus host,0.5884615384615385
viral disease epidemic,immunization against infectious agent,0.6025423728813559
viral disease epidemic,virus attachment stage,0.6318181818181818
viral disease epidemic,virus synthesis stage,0.6593023255813953
viral disease epidemic,SARS-COV-2 adhesion disposition,0.619811320754717
viral disease epidemic,invasive disposition,0.6642857142857143
viral disease epidemic,infectious agent host,0.5895348837209302
viral disease epidemic,long-term non-progressing infectious disease course,0.6006849315068493
viral disease epidemic,viral disease epidemic,0.95
viral disease epidemic,fungicidal disposition,0.6772727272727272
viral disease epidemic,viral disease pandemic,0.9045454545454545
viral disease epidemic,virus penetration stage,0.6277777777777778
viral disease epidemic,acute respiratory distress syndrome,0.6605263157894737
viral disease epidemic,infectious disease endemicity,0.7637254901960785
viral disease epidemic,negative regulation of viral process,0.6051724137931035
viral disease epidemic,disorder,0.6166666666666667
viral disease epidemic,herd immunity to infectious organism,0.5879310344827586
viral disease epidemic,extracellular infection,0.6277777777777778
viral disease epidemic,exotoxin disposition,0.6404761904761905
viral disease epidemic,infectious agent reservoir,0.6375
viral disease epidemic,COVID-19 pandemic,0.7064102564102563
viral disease epidemic,infection start process boundary,0.5796296296296296
viral disease epidemic,infectious disease control objective specification,0.6583333333333334
viral disease epidemic,opportunistic infectious disposition,0.6051724137931035
viral disease epidemic,process of establishing viral infection,0.6139344262295081
viral disease epidemic,enterotoxin disposition,0.6277777777777778
viral disease epidemic,COVID-19 disease course,0.7166666666666667
viral disease epidemic,infectious disease incidence rate,0.7045454545454546
viral disease epidemic,active immunization against infectious agent,0.6015151515151516
viral disease epidemic,disordered virus,0.6342105263157894
viral disease epidemic,collective resistance disposition,0.6318181818181818
viral disease epidemic,viral load,0.7
viral disease epidemic,fungistatic disposition,0.65
viral disease epidemic,virus uncoating stage,0.636046511627907
viral disease epidemic,local infection,0.6121621621621621
viral disease epidemic,infectious agent,0.581578947368421
viral disease epidemic,establishment of a clinically abnormal colony,0.5992537313432835
viral disease epidemic,coronavirus disease,0.7182926829268292
viral disease epidemic,positive-sense single-stranded RNA virus,0.6274193548387097
viral disease epidemic,hospital-acquired infection,0.6336734693877552
viral disease epidemic,viral pathogenesis,0.7
viral disease epidemic,drug susceptibility of infectious agent,0.5975409836065574
hospital facility,source of infection,0.5888888888888889
hospital facility,communicability end temporal region,0.6038461538461539
hospital facility,infection end temporal region,0.5804347826086956
hospital facility,incubation end temporal region,0.5776595744680851
hospital facility,establishment of localization in host,0.6351851851851852
hospital facility,material entity,0.66875
hospital facility,source of infection site,0.6207317073170732
hospital facility,B cell receptor complex,0.575
hospital facility,communicability end process boundary,0.6009433962264151
hospital facility,latency end process boundary,0.5611111111111111
hospital facility,negative regulation of establishment of localization,0.6094202898550725
hospital facility,establishment of localization,0.6673913043478261
hospital facility,establishment of localization in human host,0.6166666666666667
hospital facility,incubation end process boundary,0.5541666666666667
hospital facility,latency end temporal region,0.5636363636363636
hospital facility,virus adhesion susceptible cell,0.6375
hospital facility,T cell receptor complex,0.575
hospital facility,facility,0.77
hospital facility,respiratory system disease,0.5895348837209302
hospital facility,healthcare facility,0.7833333333333333
hospital facility,cell,0.5452380952380953
hospital facility,source of infection role,0.5963414634146341
hospital facility,hospital facility,0.95
hospital facility,place closure control strategy,0.6202127659574468
hospital facility,SARS-COV-2 adhesion susceptible cell,0.619811320754717
hospital facility,establishment of localization in virus host,0.6166666666666667
hospital facility,processed material,0.6214285714285714
hospital facility,quality,0.6583333333333334
hospital facility,establishment of a clinically abnormal colony,0.6274193548387097
hospital facility,cell space,0.5981481481481481
hospital facility,material processing,0.6166666666666667
polymerase chain reaction,virostatic disposition,0.6414893617021277
polymerase chain reaction,zoonotic disposition,0.6277777777777778
polymerase chain reaction,immune response,0.625
polymerase chain reaction,infectious disease mortality rate,0.656896551724138
polymerase chain reaction,infection incidence rate profile,0.6254385964912281
polymerase chain reaction,communicability end temporal region,0.65
polymerase chain reaction,surveillance process,0.6055555555555556
polymerase chain reaction,infection end temporal region,0.6351851851851852
polymerase chain reaction,SARS-CoV-2 incidence rate,0.65
polymerase chain reaction,incubation end temporal region,0.6318181818181818
polymerase chain reaction,virulence factor disposition,0.6386792452830189
polymerase chain reaction,viral adhesion disposition,0.6656862745098039
polymerase chain reaction,parasitostatic disposition,0.6656862745098039
polymerase chain reaction,reverse zoonotic disposition,0.6575471698113208
polymerase chain reaction,case isolation control strategy,0.6464285714285714
polymerase chain reaction,B cell receptor complex,0.6166666666666667
polymerase chain reaction,infection incidence rate,0.6336734693877552
polymerase chain reaction,double-stranded RNA virus,0.65
polymerase chain reaction,toxin disposition,0.6404761904761905
polymerase chain reaction,lower respiratory tract disease,0.6464285714285714
polymerase chain reaction,cidal agent disposition,0.6375
polymerase chain reaction,genetic resistance to pathogen,0.65
polymerase chain reaction,process,0.575
polymerase chain reaction,droplet pathogen transmission process,0.6435483870967742
polymerase chain reaction,parasiticidal disposition,0.67
polymerase chain reaction,communicability end process boundary,0.630327868852459
polymerase chain reaction,transmissibility disposition,0.619811320754717
polymerase chain reaction,latency end process boundary,0.6386792452830189
polymerase chain reaction,endotoxin disposition,0.6239130434782608
polymerase chain reaction,negative-sense single-stranded RNA virus,0.6192307692307693
polymerase chain reaction,COVID-19 incidence rate,0.6375
polymerase chain reaction,cytotoxin disposition,0.6239130434782608
polymerase chain reaction,negative regulation of developmental process,0.6094202898550725
polymerase chain reaction,antibiotic resistance,0.6021739130434782
polymerase chain reaction,resistance to drug,0.6127906976744186
polymerase chain reaction,process of establishing an infection,0.6959016393442623
polymerase chain reaction,incubation end process boundary,0.6107142857142857
polymerase chain reaction,collective pathogenic disposition,0.656896551724138
polymerase chain reaction,neurotoxin disposition,0.6414893617021277
polymerase chain reaction,pathogen death process boundary,0.6285714285714286
polymerase chain reaction,plan specification,0.7290697674418604
polymerase chain reaction,latency end temporal region,0.6615384615384616
polymerase chain reaction,collective disposition,0.6627659574468084
polymerase chain reaction,static agent disposition,0.6336734693877552
polymerase chain reaction,T cell receptor complex,0.6166666666666667
polymerase chain reaction,indirect pathogen transmission process,0.6246031746031746
polymerase chain reaction,planned process,0.625
polymerase chain reaction,immunosuppressive disposition,0.6351851851851852
polymerase chain reaction,innate immune response,0.6627659574468084
polymerase chain reaction,pathogenic disposition,0.6414893617021277
polymerase chain reaction,infectious disposition,0.6202127659574468
polymerase chain reaction,bacteriostatic disposition,0.6460784313725491
polymerase chain reaction,bactericidal disposition,0.6336734693877552
polymerase chain reaction,invasion disposition,0.65
polymerase chain reaction,viricidal disposition,0.6239130434782608
polymerase chain reaction,disposition,0.6722222222222223
polymerase chain reaction,COVID-19 mortality rate,0.6375
polymerase chain reaction,process profile,0.625
polymerase chain reaction,negative regulation of life-sustaining process,0.6190140845070422
polymerase chain reaction,adhesion disposition,0.65
polymerase chain reaction,developmental process,0.6021739130434782
polymerase chain reaction,biological process,0.6127906976744186
polymerase chain reaction,primary infectious disposition,0.6681818181818181
polymerase chain reaction,humoral immune response,0.6791666666666666
polymerase chain reaction,incubation start process boundary,0.6051724137931035
polymerase chain reaction,pathogen birth process boundary,0.6285714285714286
polymerase chain reaction,resistance to pathogen,0.6414893617021277
polymerase chain reaction,negative regulation of immune response,0.6404761904761905
polymerase chain reaction,SARS-COV-2 adhesion disposition,0.6464285714285714
polymerase chain reaction,invasive disposition,0.65
polymerase chain reaction,fungicidal disposition,0.6202127659574468
polymerase chain reaction,negative regulation of viral process,0.630327868852459
polymerase chain reaction,contact pathogen transmission process,0.6274193548387097
polymerase chain reaction,function,0.6318181818181818
polymerase chain reaction,symbiotic process,0.5928571428571429
polymerase chain reaction,exotoxin disposition,0.6277777777777778
polymerase chain reaction,infection start process boundary,0.6078947368421053
polymerase chain reaction,action specification,0.6944444444444444
polymerase chain reaction,protective resistance,0.6673913043478261
polymerase chain reaction,latency start process boundary,0.6318181818181818
polymerase chain reaction,opportunistic infectious disposition,0.6631147540983606
polymerase chain reaction,process of establishing viral infection,0.7
polymerase chain reaction,negative regulation of biological process,0.6166666666666667
polymerase chain reaction,enterotoxin disposition,0.6375
polymerase chain reaction,polymerase chain reaction,0.95
polymerase chain reaction,infectious disease incidence rate,0.6741379310344828
polymerase chain reaction,communicability start process boundary,0.6087301587301588
polymerase chain reaction,process that results in death,0.6907407407407408
polymerase chain reaction,single-stranded RNA retrovirus,0.6681818181818181
polymerase chain reaction,collective resistance disposition,0.6913793103448276
polymerase chain reaction,adaptive immune response,0.6540816326530612
polymerase chain reaction,fungistatic disposition,0.6166666666666667
polymerase chain reaction,establishment of a clinically abnormal colony,0.65
polymerase chain reaction,process boundary,0.6207317073170732
polymerase chain reaction,positive-sense single-stranded RNA virus,0.6346153846153847
polymerase chain reaction,horizontal pathogen transmission process,0.6346153846153847
polymerase chain reaction,pathogen transmission process,0.6537037037037037
latency end process boundary,immune response,0.636046511627907
latency end process boundary,infectious disease mortality rate,0.6139344262295081
latency end process boundary,infection incidence rate profile,0.6333333333333333
latency end process boundary,communicability end temporal region,0.6563492063492063
latency end process boundary,pathogen generative stage,0.6575471698113208
latency end process boundary,surveillance process,0.7208333333333333
latency end process boundary,infection end temporal region,0.6605263157894737
latency end process boundary,SARS-CoV-2 incidence rate,0.619811320754717
latency end process boundary,incubation end temporal region,0.6741379310344828
latency end process boundary,virus translation stage,0.5872549019607843
latency end process boundary,disease surveillance objective specification,0.6166666666666667
latency end process boundary,case isolation control strategy,0.6364406779661017
latency end process boundary,virus release stage,0.5776595744680851
latency end process boundary,B cell receptor complex,0.6068627450980393
latency end process boundary,infection incidence rate,0.6230769230769231
latency end process boundary,virus transcription stage,0.5820754716981132
latency end process boundary,lower respiratory tract disease,0.6364406779661017
latency end process boundary,virus generative stage,0.59
latency end process boundary,acute infectious disease course,0.6703389830508475
latency end process boundary,process,0.65
latency end process boundary,droplet pathogen transmission process,0.6807692307692308
latency end process boundary,communicability end process boundary,0.825
latency end process boundary,latency end process boundary,0.95
latency end process boundary,infectious agent generative stage,0.6139344262295081
latency end process boundary,COVID-19 incidence rate,0.6068627450980393
latency end process boundary,negative regulation of developmental process,0.6583333333333334
latency end process boundary,chronic infectious disease course,0.630327868852459
latency end process boundary,latency interval,0.7
latency end process boundary,process of establishing an infection,0.621875
latency end process boundary,incubation end process boundary,0.8567796610169492
latency end process boundary,SARS-CoV-2 uncoating stage,0.5981481481481481
latency end process boundary,pathogen death process boundary,0.8398305084745763
latency end process boundary,plan specification,0.6239130434782608
latency end process boundary,latency end temporal region,0.759090909090909
latency end process boundary,SARS-CoV-2 penetration stage,0.6107142857142857
latency end process boundary,virus adhesion susceptible cell,0.5855932203389831
latency end process boundary,anatomical space,0.609090909090909
latency end process boundary,T cell receptor complex,0.6264705882352941
latency end process boundary,respiratory system disease,0.6166666666666667
latency end process boundary,indirect pathogen transmission process,0.6621212121212122
latency end process boundary,planned process,0.7523255813953489
latency end process boundary,generative stage,0.609090909090909
latency end process boundary,communicability interval,0.5846153846153846
latency end process boundary,SARS-CoV-2 attachment stage,0.5954545454545455
latency end process boundary,infectious structure generative stage,0.5884615384615385
latency end process boundary,innate immune response,0.67
latency end process boundary,viral disease course,0.6375
latency end process boundary,cell,0.5125
latency end process boundary,objective specification,0.6068627450980393
latency end process boundary,disease course,0.6166666666666667
latency end process boundary,infectious disease course,0.6386792452830189
latency end process boundary,coronavirus disease course,0.6166666666666667
latency end process boundary,incubation interval,0.598936170212766
latency end process boundary,SARS-CoV-2 genome replication stage,0.6246031746031746
latency end process boundary,COVID-19 mortality rate,0.5676470588235294
latency end process boundary,process profile,0.6593023255813953
latency end process boundary,negative regulation of life-sustaining process,0.6527027027027027
latency end process boundary,place closure control strategy,0.656896551724138
latency end process boundary,developmental process,0.6744897959183673
latency end process boundary,biological process,0.6673913043478261
latency end process boundary,humoral immune response,0.6264705882352941
latency end process boundary,SARS-COV-2 adhesion susceptible cell,0.590625
latency end process boundary,eclipse interval,0.609090909090909
latency end process boundary,incubation start process boundary,0.7942622950819671
latency end process boundary,object,0.5088235294117647
latency end process boundary,pathogen birth process boundary,0.8228813559322035
latency end process boundary,virus attachment stage,0.61
latency end process boundary,negative regulation of immune response,0.6318181818181818
latency end process boundary,SARS-CoV-2 transcription stage,0.5879310344827586
latency end process boundary,virus synthesis stage,0.5928571428571429
latency end process boundary,object aggregate,0.5863636363636363
latency end process boundary,long-term non-progressing infectious disease course,0.6651898734177215
latency end process boundary,virus penetration stage,0.5872549019607843
latency end process boundary,algorithm,0.5310810810810811
latency end process boundary,division of geopolitical entity,0.6025423728813559
latency end process boundary,negative regulation of viral process,0.66875
latency end process boundary,contact pathogen transmission process,0.6653846153846155
latency end process boundary,function,0.5611111111111111
latency end process boundary,symbiotic process,0.6722222222222223
latency end process boundary,transmission interval,0.5928571428571429
latency end process boundary,infection start process boundary,0.7833333333333333
latency end process boundary,action specification,0.6166666666666667
latency end process boundary,SARS-CoV-2 synthesis stage,0.6166666666666667
latency end process boundary,latency start process boundary,0.8810344827586206
latency end process boundary,infectious disease control objective specification,0.6038461538461539
latency end process boundary,process of establishing viral infection,0.6141791044776119
latency end process boundary,negative regulation of biological process,0.6528985507246376
latency end process boundary,polymerase chain reaction,0.6386792452830189
latency end process boundary,COVID-19 disease course,0.6264705882352941
latency end process boundary,infectious disease incidence rate,0.6139344262295081
latency end process boundary,communicability start process boundary,0.7681818181818181
latency end process boundary,process that results in death,0.6605263157894737
latency end process boundary,adaptive immune response,0.6615384615384616
latency end process boundary,virus uncoating stage,0.5724489795918367
latency end process boundary,establishment of a clinically abnormal colony,0.6143835616438357
latency end process boundary,process boundary,0.8136363636363637
latency end process boundary,horizontal pathogen transmission process,0.6705882352941177
latency end process boundary,pathogen death temporal region,0.656896551724138
latency end process boundary,SARS-CoV-2 release stage,0.6038461538461539
latency end process boundary,pathogen transmission process,0.6956140350877194
latency end process boundary,cell space,0.6078947368421053
anatomical entity,extended organism,0.5970588235294118
anatomical entity,information content entity,0.7290697674418604
anatomical entity,infectious disease mortality rate,0.65
anatomical entity,infection incidence rate profile,0.6336734693877552
anatomical entity,infectious structure aggregate,0.598936170212766
anatomical entity,communicability end temporal region,0.6615384615384616
anatomical entity,geographical entity,0.7833333333333333
anatomical entity,biological regulation,0.6868421052631578
anatomical entity,primary pathogen,0.6318181818181818
anatomical entity,infection end temporal region,0.6456521739130434
anatomical entity,drug-based immunosuppressed organism,0.5632075471698114
anatomical entity,SARS-CoV-2 incidence rate,0.6166666666666667
anatomical entity,incubation end temporal region,0.6627659574468084
anatomical entity,resistant entity,0.7530303030303032
anatomical entity,immunocompetent organism,0.6207317073170732
anatomical entity,virulence factor disposition,0.6055555555555556
anatomical entity,disease surveillance objective specification,0.5811475409836065
anatomical entity,case isolation control strategy,0.6583333333333334
anatomical entity,physiologic immunosuppression,0.5804347826086956
anatomical entity,material entity,0.825
anatomical entity,asymptomatic infectious structure carrier,0.6396551724137931
anatomical entity,architectual structure,0.6551282051282051
anatomical entity,B cell receptor complex,0.575
anatomical entity,infection incidence rate,0.6451219512195122
anatomical entity,entity,0.7108695652173913
anatomical entity,double-stranded RNA virus,0.569047619047619
anatomical entity,biological vehicle,0.6785714285714286
anatomical entity,communicability end process boundary,0.6386792452830189
anatomical entity,directive information content entity,0.6764150943396227
anatomical entity,acellular structure aggregate,0.6021739130434782
anatomical entity,invasion factor,0.60625
anatomical entity,latency end process boundary,0.6055555555555556
anatomical entity,realizable entity,0.7735294117647058
anatomical entity,pathologically immunosuppressed organism,0.6429824561403508
anatomical entity,negative-sense single-stranded RNA virus,0.5903508771929825
anatomical entity,infectious structure host role,0.5776595744680851
anatomical entity,COVID-19 incidence rate,0.6
anatomical entity,descriptive information content entity,0.6681818181818181
anatomical entity,establishment of localization in human host,0.6166666666666667
anatomical entity,acellular structure,0.6166666666666667
anatomical entity,primary infection,0.6264705882352941
anatomical entity,virulence factor,0.6015151515151516
anatomical entity,incubation end process boundary,0.6166666666666667
anatomical entity,molecular entity,0.7530303030303032
anatomical entity,immunosuppressed organism,0.569047619047619
anatomical entity,latency end temporal region,0.6545454545454545
anatomical entity,innate immunity to infectious agent,0.6423076923076922
anatomical entity,infectious structure,0.6121621621621621
anatomical entity,virus adhesion susceptible cell,0.5958333333333333
anatomical entity,anatomical space,0.8136363636363637
anatomical entity,T cell receptor complex,0.6
anatomical entity,infectious structure host,0.5928571428571429
anatomical entity,respiratory system disease,0.6127906976744186
anatomical entity,biological vector,0.6852941176470588
anatomical entity,organism population,0.6166666666666667
anatomical entity,infectious structure generative stage,0.6351851851851852
anatomical entity,innate immune response,0.6294871794871795
anatomical entity,cell,0.5452380952380953
anatomical entity,objective specification,0.6
anatomical entity,biological vehicle role,0.65
anatomical entity,susceptible organism,0.6121621621621621
anatomical entity,organism substance,0.5928571428571429
anatomical entity,anatomical entity,0.95
anatomical entity,COVID-19 mortality rate,0.625
anatomical entity,geopolitical entity,0.7833333333333333
anatomical entity,primary infection role,0.6038461538461539
anatomical entity,primary immunodeficiency,0.6451219512195122
anatomical entity,biological role,0.66875
anatomical entity,biological process,0.65
anatomical entity,symptomatic infectious structure carrier,0.6254385964912281
anatomical entity,biological vector role,0.6551282051282051
anatomical entity,primary infectious disposition,0.598936170212766
anatomical entity,designative information content entity,0.7045454545454546
anatomical entity,SARS-COV-2 adhesion susceptible cell,0.5820754716981132
anatomical entity,object,0.5804347826086956
anatomical entity,immunodeficient organism,0.6451219512195122
anatomical entity,infectious human pathogen,0.6404761904761905
anatomical entity,colonization of human,0.6342105263157894
anatomical entity,immaterial entity,0.8029411764705883
anatomical entity,object aggregate,0.6015151515151516
anatomical entity,division of geopolitical entity,0.7208333333333333
anatomical entity,geographical feature,0.6662162162162162
anatomical entity,herd immunity to infectious organism,0.6009433962264151
anatomical entity,action specification,0.6662162162162162
anatomical entity,processed material,0.5928571428571429
anatomical entity,infectious disease control objective specification,0.6141791044776119
anatomical entity,quality,0.6583333333333334
anatomical entity,negative regulation of biological process,0.6224137931034482
anatomical entity,infectious disease incidence rate,0.63
anatomical entity,single-stranded RNA retrovirus,0.598936170212766
anatomical entity,organism,0.61
anatomical entity,establishment of a clinically abnormal colony,0.6274193548387097
anatomical entity,positive-sense single-stranded RNA virus,0.5552631578947369
anatomical entity,adhesion factor,0.60625
anatomical entity,cell space,0.5981481481481481
anatomical entity,material processing,0.6722222222222223
organism,extended organism,0.77
organism,information content entity,0.5970588235294118
organism,infectious structure aggregate,0.5552631578947369
organism,geographical entity,0.6351851851851852
organism,drug-based immunosuppressed organism,0.6318181818181818
organism,resistant entity,0.6166666666666667
organism,immunocompetent organism,0.7
organism,virulence factor disposition,0.5611111111111111
organism,case isolation control strategy,0.5525641025641026
organism,material entity,0.6239130434782608
organism,asymptomatic infectious structure carrier,0.5520408163265306
organism,architectual structure,0.55
organism,B cell receptor complex,0.5467741935483871
organism,entity,0.5928571428571429
organism,directive information content entity,0.5636363636363636
organism,acellular structure aggregate,0.5310810810810811
organism,invasion factor,0.5369565217391304
organism,realizable entity,0.61
organism,pathologically immunosuppressed organism,0.6166666666666667
organism,infectious structure host role,0.5289473684210526
organism,descriptive information content entity,0.558695652173913
organism,establishment of localization in human host,0.5480392156862746
organism,acellular structure,0.524074074074074
organism,virulence factor,0.5333333333333333
organism,molecular entity,0.6166666666666667
organism,immunosuppressed organism,0.6924242424242425
organism,plan specification,0.5653846153846154
organism,infectious structure,0.5571428571428572
organism,T cell receptor complex,0.5467741935483871
organism,infectious structure host,0.5409090909090909
organism,organism population,0.7462962962962962
organism,infectious structure generative stage,0.5833333333333334
organism,susceptible organism,0.7357142857142857
organism,organism substance,0.7576923076923078
organism,anatomical entity,0.61
organism,geopolitical entity,0.5981481481481481
organism,symptomatic infectious structure carrier,0.5541666666666667
organism,designative information content entity,0.558695652173913
organism,immunodeficient organism,0.7
organism,infectious human pathogen,0.5712121212121213
organism,colonization of human,0.5879310344827586
organism,immaterial entity,0.61
organism,blood,0.5269230769230769
organism,division of geopolitical entity,0.5782051282051281
organism,geographical feature,0.5928571428571429
organism,herd immunity to infectious organism,0.6318181818181818
organism,action specification,0.5571428571428572
organism,processed material,0.5653846153846154
organism,organism,0.95
organism,establishment of a clinically abnormal colony,0.5443396226415094
organism,adhesion factor,0.5369565217391304
organism,material processing,0.5611111111111111
contagiousness,virus aggregate,0.5879310344827586
contagiousness,infectious disease mortality rate,0.6202127659574468
contagiousness,communicability end temporal region,0.6336734693877552
contagiousness,infectious disease,0.7
contagiousness,double-stranded DNA virus,0.6038461538461539
contagiousness,infectious disease incidence,0.6404761904761905
contagiousness,virus translation stage,0.6121621621621621
contagiousness,disease surveillance objective specification,0.5706896551724138
contagiousness,virus release stage,0.6318181818181818
contagiousness,virus,0.6078947368421053
contagiousness,virus replication,0.6112903225806451
contagiousness,B cell receptor complex,0.5581081081081081
contagiousness,virus host,0.6166666666666667
contagiousness,double-stranded RNA virus,0.6038461538461539
contagiousness,virus transcription stage,0.6294871794871795
contagiousness,infectious disease lifetime prevalence,0.6038461538461539
contagiousness,lower respiratory tract disease,0.6055555555555556
contagiousness,infectious disease incidence proportion,0.6009433962264151
contagiousness,virus generative stage,0.6166666666666667
contagiousness,acute infectious disease course,0.6722222222222223
contagiousness,infectious disease sporadicity,0.6545454545454545
contagiousness,communicability end process boundary,0.63
contagiousness,infectious disease epidemic,0.6451219512195122
contagiousness,disease transmission model,0.6
contagiousness,negative-sense single-stranded RNA virus,0.5981481481481481
contagiousness,chronic infectious disease course,0.6840425531914894
contagiousness,COVID-19 epidemic,0.5790322580645162
contagiousness,virus disorder,0.5928571428571429
contagiousness,virus adhesion susceptible cell,0.5833333333333334
contagiousness,T cell receptor complex,0.5581081081081081
contagiousness,respiratory system disease,0.6
contagiousness,communicability interval,0.6342105263157894
contagiousness,infectious disease control strategy,0.6336734693877552
contagiousness,infectious disease pandemic,0.6451219512195122
contagiousness,viral disease course,0.6264705882352941
contagiousness,disease course,0.6285714285714286
contagiousness,infectious disease course,0.6807692307692308
contagiousness,COVID-19 disease incidence proportion,0.5872549019607843
contagiousness,coronavirus disease course,0.7
contagiousness,respiratory droplet virus fomite,0.5804347826086956
contagiousness,infectious disease prevalence,0.636046511627907
contagiousness,single-stranded DNA virus,0.6038461538461539
contagiousness,viral disease,0.6351851851851852
contagiousness,contagiousness,0.95
contagiousness,disease,0.6404761904761905
contagiousness,subclinical virus infection,0.6451219512195122
contagiousness,establishment of localization in virus host,0.5903508771929825
contagiousness,virus attachment stage,0.6166666666666667
contagiousness,virus synthesis stage,0.65
contagiousness,long-term non-progressing infectious disease course,0.6192307692307693
contagiousness,viral disease epidemic,0.5888888888888889
contagiousness,communicability start temporal region,0.6264705882352941
contagiousness,viral disease pandemic,0.5888888888888889
contagiousness,virus penetration stage,0.6391891891891892
contagiousness,infectious disease endemicity,0.636046511627907
contagiousness,communicability,0.6224137931034482
contagiousness,infectious disease control objective specification,0.590625
contagiousness,COVID-19 disease course,0.6391891891891892
contagiousness,infectious disease incidence rate,0.6202127659574468
contagiousness,communicability start process boundary,0.6230769230769231
contagiousness,disordered virus,0.5833333333333334
contagiousness,virus uncoating stage,0.65
contagiousness,establishment of a clinically abnormal colony,0.5516949152542373
contagiousness,coronavirus disease,0.7227272727272727
contagiousness,positive-sense single-stranded RNA virus,0.5981481481481481
adhesion disposition,virostatic disposition,0.7833333333333333
adhesion disposition,information content entity,0.6239130434782608
adhesion disposition,zoonotic disposition,0.8
adhesion disposition,infectious disease mortality rate,0.6386792452830189
adhesion disposition,infection incidence rate profile,0.6230769230769231
adhesion disposition,infectious structure aggregate,0.57
adhesion disposition,communicability end temporal region,0.6136363636363636
adhesion disposition,geographical entity,0.6038461538461539
adhesion disposition,biological regulation,0.6451219512195122
adhesion disposition,surveillance process,0.625
adhesion disposition,infection end temporal region,0.6744897959183673
adhesion disposition,vector control strategy,0.5895348837209302
adhesion disposition,SARS-CoV-2 incidence rate,0.6055555555555556
adhesion disposition,incubation end temporal region,0.67
adhesion disposition,resistant entity,0.6444444444444444
adhesion disposition,virulence factor disposition,0.7416666666666667
adhesion disposition,viral adhesion disposition,0.8847826086956522
adhesion disposition,parasitostatic disposition,0.7978260869565217
adhesion disposition,negative regulation of production,0.6764150943396227
adhesion disposition,reverse zoonotic disposition,0.7833333333333333
adhesion disposition,establishment of localization in host,0.6429824561403508
adhesion disposition,disease surveillance objective specification,0.66875
adhesion disposition,case isolation control strategy,0.6460784313725491
adhesion disposition,infectious agent host role,0.6456521739130434
adhesion disposition,macromolecular complex,0.5452380952380953
adhesion disposition,material entity,0.6214285714285714
adhesion disposition,asymptomatic infectious structure carrier,0.5975409836065574
adhesion disposition,architectual structure,0.5928571428571429
adhesion disposition,quarantine control strategy,0.598936170212766
adhesion disposition,B cell receptor complex,0.5662790697674418
adhesion disposition,infection incidence rate,0.6318181818181818
adhesion disposition,colonized host,0.6264705882352941
adhesion disposition,virus host,0.6166666666666667
adhesion disposition,entity,0.6038461538461539
adhesion disposition,toxin disposition,0.8283783783783784
adhesion disposition,lower respiratory tract disease,0.6264705882352941
adhesion disposition,cidal agent disposition,0.7988372093023256
adhesion disposition,parasiticidal disposition,0.7833333333333333
adhesion disposition,communicability end process boundary,0.6107142857142857
adhesion disposition,directive information content entity,0.6285714285714286
adhesion disposition,acellular structure aggregate,0.5520408163265306
adhesion disposition,transmissibility disposition,0.7625
adhesion disposition,latency end process boundary,0.6583333333333334
adhesion disposition,colonization of host,0.65
adhesion disposition,realizable entity,0.5851351351351352
adhesion disposition,endotoxin disposition,0.8158536585365854
adhesion disposition,vector surveillance,0.6038461538461539
adhesion disposition,negative regulation of establishment of localization,0.6444444444444444
adhesion disposition,infectious structure host role,0.63
adhesion disposition,COVID-19 incidence rate,0.5662790697674418
adhesion disposition,cytotoxin disposition,0.7914634146341464
adhesion disposition,negative regulation of developmental process,0.60625
adhesion disposition,host,0.6166666666666667
adhesion disposition,descriptive information content entity,0.6396551724137931
adhesion disposition,negative regulation of replication,0.6722222222222223
adhesion disposition,establishment of localization in human host,0.6246031746031746
adhesion disposition,acellular structure,0.5782051282051281
adhesion disposition,incubation end process boundary,0.6656862745098039
adhesion disposition,collective pathogenic disposition,0.7518867924528303
adhesion disposition,neurotoxin disposition,0.8071428571428573
adhesion disposition,dead-end host role,0.6868421052631578
adhesion disposition,molecular entity,0.5888888888888889
adhesion disposition,plan specification,0.7131578947368421
adhesion disposition,definitive host role,0.675
adhesion disposition,latency end temporal region,0.6627659574468084
adhesion disposition,infectious structure,0.6
adhesion disposition,virus adhesion susceptible cell,0.7049019607843137
adhesion disposition,collective disposition,0.7833333333333333
adhesion disposition,static agent disposition,0.7909090909090909
adhesion disposition,T cell receptor complex,0.5662790697674418
adhesion disposition,infectious structure host,0.6277777777777778
adhesion disposition,respiratory system disease,0.6456521739130434
adhesion disposition,entry into host,0.65
adhesion disposition,adhesion of symbiont to host,0.7416666666666667
adhesion disposition,infectious disease control strategy,0.6318181818181818
adhesion disposition,SARS-CoV-2 attachment stage,0.598936170212766
adhesion disposition,infectious structure generative stage,0.5728070175438597
adhesion disposition,immunosuppressive disposition,0.7561224489795919
adhesion disposition,pathogenic disposition,0.830952380952381
adhesion disposition,entry into host through host barriers,0.6078947368421053
adhesion disposition,infectious disposition,0.8071428571428573
adhesion disposition,bacteriostatic disposition,0.7978260869565217
adhesion disposition,bactericidal disposition,0.7909090909090909
adhesion disposition,pathogen host,0.6924242424242425
adhesion disposition,invasion disposition,0.875
adhesion disposition,viricidal disposition,0.7670731707317073
adhesion disposition,complex infection,0.6391891891891892
adhesion disposition,intermediate host,0.6391891891891892
adhesion disposition,anatomical entity,0.6121621621621621
adhesion disposition,disposition,0.8048387096774193
adhesion disposition,COVID-19 mortality rate,0.5662790697674418
adhesion disposition,negative regulation of life-sustaining process,0.6318181818181818
adhesion disposition,place closure control strategy,0.61
adhesion disposition,geopolitical entity,0.6551282051282051
adhesion disposition,adhesion disposition,0.95
adhesion disposition,symptomatic infectious structure carrier,0.5833333333333334
adhesion disposition,primary infectious disposition,0.77
adhesion disposition,pathogen host role,0.6868421052631578
adhesion disposition,designative information content entity,0.656896551724138
adhesion disposition,SARS-COV-2 adhesion susceptible cell,0.6821428571428573
adhesion disposition,intermediate host role,0.6404761904761905
adhesion disposition,dead-end host,0.6924242424242425
adhesion disposition,pathogen surveillance,0.6451219512195122
adhesion disposition,host role,0.6224137931034482
adhesion disposition,establishment of localization in virus host,0.6404761904761905
adhesion disposition,virus attachment stage,0.6166666666666667
adhesion disposition,negative regulation of immune response,0.6396551724137931
adhesion disposition,immaterial entity,0.6121621621621621
adhesion disposition,SARS-COV-2 adhesion disposition,0.842156862745098
adhesion disposition,invasive disposition,0.825
adhesion disposition,infectious agent host,0.6451219512195122
adhesion disposition,fungicidal disposition,0.7595238095238095
adhesion disposition,division of geopolitical entity,0.6852941176470588
adhesion disposition,negative regulation of viral process,0.6285714285714286
adhesion disposition,exotoxin disposition,0.825
adhesion disposition,immunoglobulin complex,0.569047619047619
adhesion disposition,action specification,0.75
adhesion disposition,infectious disease control objective specification,0.65
adhesion disposition,symbiont host role,0.6868421052631578
adhesion disposition,opportunistic infectious disposition,0.7178571428571427
adhesion disposition,negative regulation of biological process,0.6139344262295081
adhesion disposition,enterotoxin disposition,0.7988372093023256
adhesion disposition,infectious disease incidence rate,0.6575471698113208
adhesion disposition,collective resistance disposition,0.7518867924528303
adhesion disposition,fungistatic disposition,0.7755813953488372
adhesion disposition,establishment of a clinically abnormal colony,0.6038461538461539
adhesion disposition,adhesion factor,0.7642857142857143
adhesion disposition,definitive host,0.6785714285714286
process,immune response,0.6318181818181818
process,infectious disease mortality rate,0.525
process,infection incidence rate profile,0.5525641025641026
process,communicability end temporal region,0.5214285714285714
process,pathogen generative stage,0.575
process,surveillance process,0.7092592592592593
process,infection end temporal region,0.5333333333333333
process,SARS-CoV-2 incidence rate,0.575
process,incubation end temporal region,0.5310810810810811
process,virus translation stage,0.55
process,case isolation control strategy,0.5552631578947369
process,virus release stage,0.6038461538461539
process,B cell receptor complex,0.5833333333333334
process,infection incidence rate,0.5467741935483871
process,virus transcription stage,0.54375
process,virus generative stage,0.553448275862069
process,acute infectious disease course,0.5552631578947369
process,process,0.95
process,droplet pathogen transmission process,0.609090909090909
process,communicability end process boundary,0.6127906976744186
process,latency end process boundary,0.65
process,infectious agent generative stage,0.525
process,COVID-19 incidence rate,0.55
process,negative regulation of developmental process,0.5872549019607843
process,chronic infectious disease course,0.6
process,process of establishing an infection,0.6127906976744186
process,incubation end process boundary,0.6342105263157894
process,SARS-CoV-2 uncoating stage,0.5712121212121213
process,pathogen death process boundary,0.6342105263157894
process,plan specification,0.53
process,latency end temporal region,0.5382352941176471
process,SARS-CoV-2 penetration stage,0.5642857142857143
process,T cell receptor complex,0.5833333333333334
process,respiratory system disease,0.6318181818181818
process,indirect pathogen transmission process,0.6055555555555556
process,planned process,0.7681818181818181
process,generative stage,0.5804347826086956
process,SARS-CoV-2 attachment stage,0.5970588235294118
process,infectious structure generative stage,0.5409090909090909
process,innate immune response,0.5879310344827586
process,viral disease course,0.5981481481481481
process,disease course,0.5928571428571429
process,infectious disease course,0.575
process,coronavirus disease course,0.6015151515151516
process,SARS-CoV-2 genome replication stage,0.5452380952380953
process,COVID-19 mortality rate,0.5166666666666666
process,process profile,0.7681818181818181
process,negative regulation of life-sustaining process,0.5820754716981132
process,developmental process,0.7
process,biological process,0.73
process,humoral immune response,0.5833333333333334
process,incubation start process boundary,0.625
process,pathogen birth process boundary,0.6342105263157894
process,virus attachment stage,0.5879310344827586
process,negative regulation of immune response,0.5611111111111111
process,SARS-CoV-2 transcription stage,0.5581081081081081
process,virus synthesis stage,0.5928571428571429
process,long-term non-progressing infectious disease course,0.5706896551724138
process,virus penetration stage,0.5833333333333334
process,algorithm,0.5125
process,negative regulation of viral process,0.6127906976744186
process,contact pathogen transmission process,0.609090909090909
process,function,0.5166666666666666
process,symbiotic process,0.7416666666666667
process,infection start process boundary,0.6294871794871795
process,action specification,0.524074074074074
process,SARS-CoV-2 synthesis stage,0.6015151515151516
process,latency start process boundary,0.6391891891891892
process,process of establishing viral infection,0.6021739130434782
process,negative regulation of biological process,0.5958333333333333
process,polymerase chain reaction,0.575
process,COVID-19 disease course,0.5833333333333334
process,infectious disease incidence rate,0.525
process,communicability start process boundary,0.6055555555555556
process,process that results in death,0.6444444444444444
process,adaptive immune response,0.6112903225806451
process,virus uncoating stage,0.5571428571428572
process,establishment of a clinically abnormal colony,0.5076923076923077
process,process boundary,0.7543478260869566
process,horizontal pathogen transmission process,0.598936170212766
process,SARS-CoV-2 release stage,0.6112903225806451
process,pathogen transmission process,0.6444444444444444
cytotoxin,toxin disposition,0.6423076923076922
cytotoxin,cytotoxin disposition,0.75
cytotoxin,T cell receptor complex,0.60625
cytotoxin,toxin,0.8071428571428573
cytotoxin,cytotoxin,0.95
leukocyte mediated immunity,infectious disease mortality rate,0.6666666666666667
leukocyte mediated immunity,infection incidence rate profile,0.6194915254237288
leukocyte mediated immunity,SARS-CoV-2 incidence rate,0.5846153846153846
leukocyte mediated immunity,virus release stage,0.6021739130434782
leukocyte mediated immunity,B cell receptor complex,0.59
leukocyte mediated immunity,infection incidence rate,0.6264705882352941
leukocyte mediated immunity,genetic resistance to pathogen,0.6078947368421053
leukocyte mediated immunity,COVID-19 incidence rate,0.61
leukocyte mediated immunity,antibiotic resistance,0.5958333333333333
leukocyte mediated immunity,resistance to drug,0.6055555555555556
leukocyte mediated immunity,sterilizing immunity to infectious agent,0.6291044776119403
leukocyte mediated immunity,innate immunity to infectious agent,0.6596774193548387
leukocyte mediated immunity,virus adhesion susceptible cell,0.5706896551724138
leukocyte mediated immunity,T cell receptor complex,0.59
leukocyte mediated immunity,leukocyte-mediated immunity to infectious agent,0.8013513513513513
leukocyte mediated immunity,humoral immunity to infectious agent,0.6404761904761905
leukocyte mediated immunity,cell,0.5145161290322581
leukocyte mediated immunity,passive immunity to infectious agent,0.6246031746031746
leukocyte mediated immunity,immunity to pathogen,0.6202127659574468
leukocyte mediated immunity,acquired immunity to infectious agent,0.653125
leukocyte mediated immunity,intermediate host,0.7
leukocyte mediated immunity,COVID-19 mortality rate,0.61
leukocyte mediated immunity,leukocyte mediated immunity,0.95
leukocyte mediated immunity,SARS-COV-2 adhesion susceptible cell,0.5611111111111111
leukocyte mediated immunity,intermediate host role,0.6744897959183673
leukocyte mediated immunity,resistance to pathogen,0.6132653061224489
leukocyte mediated immunity,blood,0.54375
leukocyte mediated immunity,herd immunity to infectious organism,0.6246031746031746
leukocyte mediated immunity,protective resistance,0.6375
leukocyte mediated immunity,infectious disease incidence rate,0.6666666666666667
leukocyte mediated immunity,collective resistance disposition,0.6833333333333332
leukocyte mediated immunity,establishment of a clinically abnormal colony,0.6027777777777777
leukocyte mediated immunity,SARS-CoV-2 release stage,0.5872549019607843
leukocyte mediated immunity,cell space,0.5851351351351352
pathogen transmission process,extended organism,0.6456521739130434
pathogen transmission process,virus aggregate,0.5636363636363636
pathogen transmission process,source of infection,0.5958333333333333
pathogen transmission process,immune response,0.609090909090909
pathogen transmission process,infectious disease mortality rate,0.6112903225806451
pathogen transmission process,infection incidence rate profile,0.6467213114754098
pathogen transmission process,communicability end temporal region,0.621875
pathogen transmission process,pathogen generative stage,0.7092592592592593
pathogen transmission process,pathogen portal of entry,0.7141509433962264
pathogen transmission process,subclinical coronavirus infection,0.5951612903225807
pathogen transmission process,primary pathogen,0.6277777777777778
pathogen transmission process,surveillance process,0.6744897959183673
pathogen transmission process,infection end temporal region,0.6396551724137931
pathogen transmission process,drug-based immunosuppressed organism,0.6038461538461539
pathogen transmission process,infectious disease,0.598936170212766
pathogen transmission process,SARS-CoV-2 incidence rate,0.6166666666666667
pathogen transmission process,double-stranded DNA virus,0.6351851851851852
pathogen transmission process,incubation end temporal region,0.6533898305084747
pathogen transmission process,site of infection,0.6021739130434782
pathogen transmission process,immunocompetent organism,0.6386792452830189
pathogen transmission process,pathogen portal of exit,0.7192307692307692
pathogen transmission process,infectious disease incidence,0.6254385964912281
pathogen transmission process,reservoir of pathogen role,0.6681818181818181
pathogen transmission process,subclinical SARS-CoV-2 infection,0.5811475409836065
pathogen transmission process,virus translation stage,0.6615384615384616
pathogen transmission process,disease surveillance objective specification,0.6006849315068493
pathogen transmission process,case isolation control strategy,0.65
pathogen transmission process,virus release stage,0.5958333333333333
pathogen transmission process,infectious agent host role,0.65
pathogen transmission process,source of infection site,0.619811320754717
pathogen transmission process,virus,0.5382352941176471
pathogen transmission process,virus replication,0.5804347826086956
pathogen transmission process,B cell receptor complex,0.5846153846153846
pathogen transmission process,passive immunization against infectious agent,0.6391891891891892
pathogen transmission process,systematic infection,0.5928571428571429
pathogen transmission process,infection incidence rate,0.6386792452830189
pathogen transmission process,virus host,0.5782051282051281
pathogen transmission process,double-stranded RNA virus,0.6351851851851852
pathogen transmission process,pathogen portal of entry role,0.743103448275862
pathogen transmission process,virus transcription stage,0.6722222222222223
pathogen transmission process,infectious disease lifetime prevalence,0.6291044776119403
pathogen transmission process,pathogen birth temporal region,0.7042372881355932
pathogen transmission process,lower respiratory tract disease,0.65
pathogen transmission process,infectious disease incidence proportion,0.6264705882352941
pathogen transmission process,opportunistic pathogen,0.6656862745098039
pathogen transmission process,virus generative stage,0.6068627450980393
pathogen transmission process,acute infectious disease course,0.65
pathogen transmission process,cidal agent disposition,0.6615384615384616
pathogen transmission process,genetic resistance to pathogen,0.6703389830508475
pathogen transmission process,subclinical infection,0.57
pathogen transmission process,process,0.6444444444444444
pathogen transmission process,simple infection,0.6055555555555556
pathogen transmission process,droplet pathogen transmission process,0.8893939393939394
pathogen transmission process,infectious disease sporadicity,0.6194915254237288
pathogen transmission process,communicability end process boundary,0.6653846153846155
pathogen transmission process,infection incidence proportion profile,0.658955223880597
pathogen transmission process,infectious agent colony,0.6038461538461539
pathogen transmission process,pathogen transporter,0.7969387755102041
pathogen transmission process,latency end process boundary,0.6956140350877194
pathogen transmission process,infectious disease epidemic,0.6107142857142857
pathogen transmission process,infectious agent generative stage,0.6274193548387097
pathogen transmission process,disease transmission model,0.7772727272727272
pathogen transmission process,pathologically immunosuppressed organism,0.6528985507246376
pathogen transmission process,negative-sense single-stranded RNA virus,0.6384057971014493
pathogen transmission process,cidal agent,0.575
pathogen transmission process,pathogen vehicle,0.7166666666666667
pathogen transmission process,COVID-19 incidence rate,0.6038461538461539
pathogen transmission process,community-acquired infection,0.5903508771929825
pathogen transmission process,pathogen vector,0.7227272727272727
pathogen transmission process,negative regulation of developmental process,0.682876712328767
pathogen transmission process,pathogen vehicle role,0.73
pathogen transmission process,chronic infectious disease course,0.6435483870967742
pathogen transmission process,asymptomatic infectious agent carrier,0.6166666666666667
pathogen transmission process,nursing-home acquired infection,0.6
pathogen transmission process,secondary infection,0.5958333333333333
pathogen transmission process,infection start temporal region,0.6333333333333333
pathogen transmission process,infection incidence,0.6375
pathogen transmission process,virus disorder,0.6127906976744186
pathogen transmission process,sterilizing immunity to infectious agent,0.5949275362318841
pathogen transmission process,primary infection,0.6021739130434782
pathogen transmission process,process of establishing an infection,0.6346153846153847
pathogen transmission process,incubation end process boundary,0.6833333333333332
pathogen transmission process,SARS-CoV-2 uncoating stage,0.5954545454545455
pathogen transmission process,pathogen death process boundary,0.75
pathogen transmission process,immunosuppressed organism,0.5981481481481481
pathogen transmission process,plan specification,0.6414893617021277
pathogen transmission process,latency end temporal region,0.6464285714285714
pathogen transmission process,innate immunity to infectious agent,0.621875
pathogen transmission process,SARS-CoV-2 penetration stage,0.6605263157894737
pathogen transmission process,virus adhesion susceptible cell,0.6333333333333333
pathogen transmission process,infection,0.581578947368421
pathogen transmission process,static agent disposition,0.6764150943396227
pathogen transmission process,T cell receptor complex,0.6038461538461539
pathogen transmission process,infectious agent population,0.6285714285714286
pathogen transmission process,respiratory system disease,0.65
pathogen transmission process,leukocyte-mediated immunity to infectious agent,0.5947368421052631
pathogen transmission process,indirect pathogen transmission process,0.8828358208955223
pathogen transmission process,organism population,0.6375
pathogen transmission process,planned process,0.7227272727272727
pathogen transmission process,generative stage,0.6277777777777778
pathogen transmission process,humoral immunity to infectious agent,0.6038461538461539
pathogen transmission process,infectious disease control strategy,0.621875
pathogen transmission process,SARS-CoV-2 attachment stage,0.6107142857142857
pathogen transmission process,parasite,0.6391891891891892
pathogen transmission process,infectious disease pandemic,0.6107142857142857
pathogen transmission process,antibody reagent,0.6277777777777778
pathogen transmission process,infectious structure generative stage,0.6015151515151516
pathogen transmission process,innate immune response,0.6656862745098039
pathogen transmission process,viral disease course,0.6132653061224489
pathogen transmission process,intracellular infection,0.6038461538461539
pathogen transmission process,secondary infection role,0.6575471698113208
pathogen transmission process,metastatic infection,0.6132653061224489
pathogen transmission process,passive immunity to infectious agent,0.6192307692307693
pathogen transmission process,vaccination against infectious agent,0.65
pathogen transmission process,acute infection,0.6318181818181818
pathogen transmission process,susceptibility to infectious agent,0.5928571428571429
pathogen transmission process,epitope site,0.6451219512195122
pathogen transmission process,immunity to pathogen,0.6132653061224489
pathogen transmission process,source of infection role,0.6575471698113208
pathogen transmission process,pathogen host,0.7119047619047619
pathogen transmission process,chronic infection,0.6239130434782608
pathogen transmission process,disease course,0.5895348837209302
pathogen transmission process,infectious disease course,0.6166666666666667
pathogen transmission process,acquired immunity to infectious agent,0.6015151515151516
pathogen transmission process,complex infection,0.6021739130434782
pathogen transmission process,COVID-19 disease incidence proportion,0.6166666666666667
pathogen transmission process,coronavirus disease course,0.6318181818181818
pathogen transmission process,infection incidence proportion,0.6364406779661017
pathogen transmission process,symptomatic infectious agent carrier,0.6192307692307693
pathogen transmission process,respiratory droplet virus fomite,0.630327868852459
pathogen transmission process,susceptible organism,0.6336734693877552
pathogen transmission process,parasite role,0.6880952380952381
pathogen transmission process,pathogen vector role,0.7561224489795919
pathogen transmission process,pathogen portal of exit site,0.7131578947368421
pathogen transmission process,infectious disease prevalence,0.6396551724137931
pathogen transmission process,organism substance,0.6840425531914894
pathogen transmission process,SARS-CoV-2 genome replication stage,0.653125
pathogen transmission process,single-stranded DNA virus,0.6351851851851852
pathogen transmission process,COVID-19 mortality rate,0.6038461538461539
pathogen transmission process,contact tracing,0.6318181818181818
pathogen transmission process,process profile,0.6772727272727272
pathogen transmission process,negative regulation of life-sustaining process,0.7166666666666667
pathogen transmission process,viral disease,0.5928571428571429
pathogen transmission process,primary infection role,0.6656862745098039
pathogen transmission process,pathogen portal of entry site,0.7086206896551723
pathogen transmission process,developmental process,0.71
pathogen transmission process,infection incidence profile,0.6642857142857143
pathogen transmission process,disease,0.5611111111111111
pathogen transmission process,biological process,0.6840425531914894
pathogen transmission process,site,0.5409090909090909
pathogen transmission process,pathogen host role,0.747872340425532
pathogen transmission process,infection prevalence,0.6540816326530612
pathogen transmission process,humoral immune response,0.6615384615384616
pathogen transmission process,infectious pathogen transmissibility,0.7423076923076922
pathogen transmission process,incubation start process boundary,0.6919354838709677
pathogen transmission process,pathogen surveillance,0.73
pathogen transmission process,immunodeficient organism,0.619811320754717
pathogen transmission process,pathogen,0.6662162162162162
pathogen transmission process,pathogen birth process boundary,0.75
pathogen transmission process,infectious human pathogen,0.6166666666666667
pathogen transmission process,subclinical virus infection,0.5928571428571429
pathogen transmission process,resistance to pathogen,0.6264705882352941
pathogen transmission process,establishment of localization in virus host,0.6444444444444444
pathogen transmission process,immunization against infectious agent,0.6469696969696969
pathogen transmission process,virus attachment stage,0.6264705882352941
pathogen transmission process,negative regulation of immune response,0.658955223880597
pathogen transmission process,SARS-CoV-2 transcription stage,0.6872881355932203
pathogen transmission process,virus synthesis stage,0.61
pathogen transmission process,pathogen portal of exit role,0.730701754385965
pathogen transmission process,infectious agent host,0.63
pathogen transmission process,re-emerging pathogen,0.6132653061224489
pathogen transmission process,long-term non-progressing infectious disease course,0.625
pathogen transmission process,viral disease epidemic,0.6068627450980393
pathogen transmission process,viral disease pandemic,0.6068627450980393
pathogen transmission process,virus penetration stage,0.6615384615384616
pathogen transmission process,algorithm,0.5552631578947369
pathogen transmission process,pathogen seroprevalence,0.7384615384615384
pathogen transmission process,infectious disease endemicity,0.5879310344827586
pathogen transmission process,negative regulation of viral process,0.7115384615384616
pathogen transmission process,contact pathogen transmission process,0.8893939393939394
pathogen transmission process,function,0.5851351351351352
pathogen transmission process,herd immunity to infectious organism,0.6192307692307693
pathogen transmission process,extracellular infection,0.6038461538461539
pathogen transmission process,pathogen transporter role,0.8018518518518519
pathogen transmission process,symbiotic process,0.7108695652173913
pathogen transmission process,transmission interval,0.73
pathogen transmission process,infectious agent reservoir,0.6318181818181818
pathogen transmission process,infection start process boundary,0.6795081967213115
pathogen transmission process,action specification,0.6540816326530612
pathogen transmission process,SARS-CoV-2 synthesis stage,0.6136363636363636
pathogen transmission process,latency start process boundary,0.7042372881355932
pathogen transmission process,infectious disease control objective specification,0.6145569620253164
pathogen transmission process,process of establishing viral infection,0.6411764705882353
pathogen transmission process,negative regulation of biological process,0.6928571428571427
pathogen transmission process,polymerase chain reaction,0.6537037037037037
pathogen transmission process,COVID-19 disease course,0.6038461538461539
pathogen transmission process,infectious disease incidence rate,0.6274193548387097
pathogen transmission process,communicability start process boundary,0.6440298507462687
pathogen transmission process,process that results in death,0.656896551724138
pathogen transmission process,active immunization against infectious agent,0.6280821917808219
pathogen transmission process,disordered virus,0.5833333333333334
pathogen transmission process,adaptive immune response,0.6575471698113208
pathogen transmission process,organism,0.6121621621621621
pathogen transmission process,virus uncoating stage,0.59
pathogen transmission process,local infection,0.5863636363636363
pathogen transmission process,infectious agent,0.5833333333333334
pathogen transmission process,establishment of a clinically abnormal colony,0.5986486486486486
pathogen transmission process,process boundary,0.6277777777777778
pathogen transmission process,coronavirus disease,0.6166666666666667
pathogen transmission process,positive-sense single-stranded RNA virus,0.6384057971014493
pathogen transmission process,horizontal pathogen transmission process,0.8702898550724637
pathogen transmission process,hospital-acquired infection,0.5928571428571429
pathogen transmission process,pathogen death temporal region,0.7042372881355932
pathogen transmission process,emerging pathogen,0.6239130434782608
pathogen transmission process,drug susceptibility of infectious agent,0.5823529411764706
pathogen transmission process,SARS-CoV-2 release stage,0.619811320754717
pathogen transmission process,static agent,0.5963414634146341
pathogen transmission process,pathogen transmission process,0.95
one-dimensional temporal region,communicability end temporal region,0.7833333333333333
one-dimensional temporal region,infection end temporal region,0.8
one-dimensional temporal region,incubation end temporal region,0.7942622950819671
one-dimensional temporal region,two-dimensional spatial region,0.8434426229508196
one-dimensional temporal region,one-dimensional temporal region,0.95
one-dimensional temporal region,temporal region,0.7760869565217391
one-dimensional temporal region,disease surveillance objective specification,0.6366666666666667
one-dimensional temporal region,material entity,0.6673913043478261
one-dimensional temporal region,B cell receptor complex,0.6166666666666667
one-dimensional temporal region,double-stranded RNA virus,0.6285714285714286
one-dimensional temporal region,pathogen birth temporal region,0.7778688524590163
one-dimensional temporal region,lower respiratory tract disease,0.6435483870967742
one-dimensional temporal region,infectious disease incidence proportion,0.6642857142857143
one-dimensional temporal region,acute infectious disease course,0.6274193548387097
one-dimensional temporal region,communicability end process boundary,0.6440298507462687
one-dimensional temporal region,infection incidence proportion profile,0.6384057971014493
one-dimensional temporal region,SARS-CoV-2 incidence proportion,0.6596774193548387
one-dimensional temporal region,spatiotemporal region,0.7961538461538461
one-dimensional temporal region,latency end process boundary,0.6025423728813559
one-dimensional temporal region,negative-sense single-stranded RNA virus,0.6612676056338028
one-dimensional temporal region,zero-dimensional spatial region,0.8370967741935484
one-dimensional temporal region,zero-dimensional temporal region,0.9103174603174602
one-dimensional temporal region,chronic infectious disease course,0.6375
one-dimensional temporal region,infection start temporal region,0.8048387096774193
one-dimensional temporal region,establishment of localization in human host,0.6256756756756756
one-dimensional temporal region,incubation end process boundary,0.6435483870967742
one-dimensional temporal region,geographical region,0.71
one-dimensional temporal region,latency end temporal region,0.7775862068965518
one-dimensional temporal region,T cell receptor complex,0.6166666666666667
one-dimensional temporal region,viral disease course,0.6264705882352941
one-dimensional temporal region,three-dimensional spatial region,0.830952380952381
one-dimensional temporal region,objective specification,0.6537037037037037
one-dimensional temporal region,country,0.5552631578947369
one-dimensional temporal region,disease course,0.6277777777777778
one-dimensional temporal region,infectious disease course,0.6285714285714286
one-dimensional temporal region,COVID-19 disease incidence proportion,0.6705882352941177
one-dimensional temporal region,coronavirus disease course,0.6254385964912281
one-dimensional temporal region,infection incidence proportion,0.6631147540983606
one-dimensional temporal region,place closure control strategy,0.630327868852459
one-dimensional temporal region,object,0.5310810810810811
one-dimensional temporal region,infectious human pathogen,0.6285714285714286
one-dimensional temporal region,colonization of human,0.6423076923076922
one-dimensional temporal region,object aggregate,0.598936170212766
one-dimensional temporal region,long-term non-progressing infectious disease course,0.6329268292682927
one-dimensional temporal region,communicability start temporal region,0.7735294117647058
one-dimensional temporal region,geospatial region,0.7208333333333333
one-dimensional temporal region,division of geopolitical entity,0.6919354838709677
one-dimensional temporal region,processed material,0.6540816326530612
one-dimensional temporal region,infectious disease control objective specification,0.6598765432098764
one-dimensional temporal region,COVID-19 disease course,0.6351851851851852
one-dimensional temporal region,single-stranded RNA retrovirus,0.6467213114754098
one-dimensional temporal region,local infection,0.6456521739130434
one-dimensional temporal region,establishment of a clinically abnormal colony,0.6736842105263158
one-dimensional temporal region,positive-sense single-stranded RNA virus,0.6612676056338028
one-dimensional temporal region,one-dimensional spatial region,0.8762295081967213
one-dimensional temporal region,spatial region,0.7166666666666667
one-dimensional temporal region,pathogen death temporal region,0.7942622950819671
one-dimensional temporal region,material processing,0.69
humoral immunity to infectious agent,information content entity,0.6758064516129032
humoral immunity to infectious agent,infectious disease mortality rate,0.6528985507246376
humoral immunity to infectious agent,infection incidence rate profile,0.6264705882352941
humoral immunity to infectious agent,infectious structure aggregate,0.6772727272727272
humoral immunity to infectious agent,communicability end temporal region,0.6753521126760563
humoral immunity to infectious agent,infection end temporal region,0.6346153846153847
humoral immunity to infectious agent,infectious disease,0.6907407407407408
humoral immunity to infectious agent,SARS-CoV-2 incidence rate,0.6139344262295081
humoral immunity to infectious agent,incubation end temporal region,0.6318181818181818
humoral immunity to infectious agent,virulence factor disposition,0.6375
humoral immunity to infectious agent,infectious disease incidence,0.66875
humoral immunity to infectious agent,disease surveillance objective specification,0.625
humoral immunity to infectious agent,virus release stage,0.6136363636363636
humoral immunity to infectious agent,infectious agent host role,0.7080645161290323
humoral immunity to infectious agent,asymptomatic infectious structure carrier,0.6837662337662337
humoral immunity to infectious agent,B cell receptor complex,0.5855932203389831
humoral immunity to infectious agent,passive immunization against infectious agent,0.795679012345679
humoral immunity to infectious agent,infection incidence rate,0.65
humoral immunity to infectious agent,infectious disease lifetime prevalence,0.6391891891891892
humoral immunity to infectious agent,lower respiratory tract disease,0.658955223880597
humoral immunity to infectious agent,infectious disease incidence proportion,0.65
humoral immunity to infectious agent,acute infectious disease course,0.703731343283582
humoral immunity to infectious agent,cidal agent disposition,0.6533898305084747
humoral immunity to infectious agent,infectious disorder,0.6681818181818181
humoral immunity to infectious agent,genetic resistance to pathogen,0.6469696969696969
humoral immunity to infectious agent,biological vehicle,0.5796296296296296
humoral immunity to infectious agent,infectious disease sporadicity,0.6621212121212122
humoral immunity to infectious agent,communicability end process boundary,0.6444444444444444
humoral immunity to infectious agent,directive information content entity,0.6444444444444444
humoral immunity to infectious agent,infectious agent colony,0.7211864406779661
humoral immunity to infectious agent,pathogen transporter,0.5928571428571429
humoral immunity to infectious agent,invasion factor,0.6264705882352941
humoral immunity to infectious agent,latency end process boundary,0.590625
humoral immunity to infectious agent,infectious disease epidemic,0.6563492063492063
humoral immunity to infectious agent,infectious agent generative stage,0.6818840579710145
humoral immunity to infectious agent,disease transmission model,0.5790322580645162
humoral immunity to infectious agent,cidal agent,0.6202127659574468
humoral immunity to infectious agent,infectious structure host role,0.6469696969696969
humoral immunity to infectious agent,pathogen vehicle,0.5846153846153846
humoral immunity to infectious agent,COVID-19 incidence rate,0.6194915254237288
humoral immunity to infectious agent,antibiotic resistance,0.6254385964912281
humoral immunity to infectious agent,pathogen vehicle role,0.5903508771929825
humoral immunity to infectious agent,chronic infectious disease course,0.7108695652173913
humoral immunity to infectious agent,asymptomatic infectious agent carrier,0.7376712328767124
humoral immunity to infectious agent,descriptive information content entity,0.6391891891891892
humoral immunity to infectious agent,COVID-19 epidemic,0.5632075471698114
humoral immunity to infectious agent,resistance to drug,0.6166666666666667
humoral immunity to infectious agent,sterilizing immunity to infectious agent,0.8578947368421052
humoral immunity to infectious agent,diseased population,0.5772727272727273
humoral immunity to infectious agent,virulence factor,0.6038461538461539
humoral immunity to infectious agent,incubation end process boundary,0.5992537313432835
humoral immunity to infectious agent,latency end temporal region,0.6246031746031746
humoral immunity to infectious agent,innate immunity to infectious agent,0.8725352112676056
humoral immunity to infectious agent,infectious structure,0.6642857142857143
humoral immunity to infectious agent,static agent disposition,0.6333333333333333
humoral immunity to infectious agent,T cell receptor complex,0.6025423728813559
humoral immunity to infectious agent,asymptomatic carrier role,0.5975409836065574
humoral immunity to infectious agent,infectious structure host,0.6631147540983606
humoral immunity to infectious agent,infectious agent population,0.7039682539682539
humoral immunity to infectious agent,respiratory system disease,0.6274193548387097
humoral immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.8355421686746988
humoral immunity to infectious agent,humoral immunity to infectious agent,0.95
humoral immunity to infectious agent,infectious disease control strategy,0.6612676056338028
humoral immunity to infectious agent,infectious disease pandemic,0.6722222222222223
humoral immunity to infectious agent,infectious structure generative stage,0.6554794520547945
humoral immunity to infectious agent,viral disease course,0.6464285714285714
humoral immunity to infectious agent,passive immunity to infectious agent,0.8666666666666667
humoral immunity to infectious agent,infectious disposition,0.656896551724138
humoral immunity to infectious agent,vaccination against infectious agent,0.7694444444444444
humoral immunity to infectious agent,susceptibility to infectious agent,0.8071428571428573
humoral immunity to infectious agent,immunity to pathogen,0.7535714285714286
humoral immunity to infectious agent,disease course,0.59
humoral immunity to infectious agent,infectious disease course,0.6631147540983606
humoral immunity to infectious agent,acquired immunity to infectious agent,0.8746575342465753
humoral immunity to infectious agent,COVID-19 disease incidence proportion,0.6143835616438357
humoral immunity to infectious agent,coronavirus disease course,0.6596774193548387
humoral immunity to infectious agent,asymptomatic carrier,0.6107142857142857
humoral immunity to infectious agent,biological vehicle role,0.5855932203389831
humoral immunity to infectious agent,symptomatic infectious agent carrier,0.7416666666666667
humoral immunity to infectious agent,intermediate host,0.6009433962264151
humoral immunity to infectious agent,infectious disease prevalence,0.6653846153846155
humoral immunity to infectious agent,infected population,0.6318181818181818
humoral immunity to infectious agent,COVID-19 mortality rate,0.6364406779661017
humoral immunity to infectious agent,viral disease,0.6132653061224489
humoral immunity to infectious agent,leukocyte mediated immunity,0.6404761904761905
humoral immunity to infectious agent,disease,0.5430232558139535
humoral immunity to infectious agent,symptomatic infectious structure carrier,0.6868421052631578
humoral immunity to infectious agent,primary infectious disposition,0.7075757575757575
humoral immunity to infectious agent,designative information content entity,0.6391891891891892
humoral immunity to infectious agent,symptomatic carrier role,0.6
humoral immunity to infectious agent,humoral immune response,0.7550847457627118
humoral immunity to infectious agent,infectious pathogen transmissibility,0.6722222222222223
humoral immunity to infectious agent,intermediate host role,0.6051724137931035
humoral immunity to infectious agent,infectious human pathogen,0.6959016393442623
humoral immunity to infectious agent,resistance to pathogen,0.656896551724138
humoral immunity to infectious agent,immunization against infectious agent,0.8061643835616438
humoral immunity to infectious agent,infectious agent host,0.730701754385965
humoral immunity to infectious agent,long-term non-progressing infectious disease course,0.6683908045977012
humoral immunity to infectious agent,viral disease epidemic,0.6051724137931035
humoral immunity to infectious agent,viral disease pandemic,0.6224137931034482
humoral immunity to infectious agent,symptomatic carrier,0.6136363636363636
humoral immunity to infectious agent,infectious disease endemicity,0.6807692307692308
humoral immunity to infectious agent,function,0.609090909090909
humoral immunity to infectious agent,herd immunity to infectious organism,0.8388888888888889
humoral immunity to infectious agent,pathogen transporter role,0.5975409836065574
humoral immunity to infectious agent,infectious agent reservoir,0.7080645161290323
humoral immunity to infectious agent,COVID-19 pandemic,0.5632075471698114
humoral immunity to infectious agent,action specification,0.6464285714285714
humoral immunity to infectious agent,protective resistance,0.6078947368421053
humoral immunity to infectious agent,infectious disease control objective specification,0.6244186046511628
humoral immunity to infectious agent,opportunistic infectious disposition,0.7138888888888889
humoral immunity to infectious agent,polymerase chain reaction,0.6631147540983606
humoral immunity to infectious agent,COVID-19 disease course,0.6194915254237288
humoral immunity to infectious agent,infectious disease incidence rate,0.6673913043478261
humoral immunity to infectious agent,active immunization against infectious agent,0.8
humoral immunity to infectious agent,collective resistance disposition,0.6239130434782608
humoral immunity to infectious agent,infectious agent,0.7576923076923078
humoral immunity to infectious agent,establishment of a clinically abnormal colony,0.6351851851851852
humoral immunity to infectious agent,coronavirus disease,0.6318181818181818
humoral immunity to infectious agent,adhesion factor,0.6068627450980393
humoral immunity to infectious agent,drug susceptibility of infectious agent,0.7833333333333333
humoral immunity to infectious agent,SARS-CoV-2 release stage,0.6
humoral immunity to infectious agent,static agent,0.6583333333333334
host role,virostatic disposition,0.6112903225806451
host role,zoonotic disposition,0.5879310344827586
host role,virulence factor disposition,0.5581081081081081
host role,viral adhesion disposition,0.5928571428571429
host role,parasitostatic disposition,0.5928571428571429
host role,reservoir of pathogen role,0.65
host role,reverse zoonotic disposition,0.5581081081081081
host role,establishment of localization in host,0.558695652173913
host role,infectious agent host role,0.7071428571428571
host role,B cell receptor complex,0.60625
host role,colonized host,0.6239130434782608
host role,virus host,0.6605263157894737
host role,pathogen portal of entry role,0.6605263157894737
host role,toxin disposition,0.6038461538461539
host role,lower respiratory tract disease,0.6
host role,acute infectious disease course,0.575
host role,cidal agent disposition,0.575
host role,role,0.7576923076923078
host role,appearance of disorder,0.5790322580645162
host role,parasiticidal disposition,0.5676470588235294
host role,mutualist role,0.7543478260869566
host role,transmissibility disposition,0.5581081081081081
host role,colonization of host,0.5879310344827586
host role,endotoxin disposition,0.5833333333333334
host role,infectious structure host role,0.6807692307692308
host role,cytotoxin disposition,0.5833333333333334
host role,pathogen vehicle role,0.6833333333333332
host role,host,0.7576923076923078
host role,chronic infectious disease course,0.5928571428571429
host role,mechanical vector role,0.6758064516129032
host role,establishment of localization in human host,0.5461538461538461
host role,collective pathogenic disposition,0.569047619047619
host role,neurotoxin disposition,0.5790322580645162
host role,dead-end host role,0.7833333333333333
host role,definitive host role,0.760344827586207
host role,collective disposition,0.5790322580645162
host role,static agent disposition,0.5712121212121213
host role,T cell receptor complex,0.6375
host role,asymptomatic carrier role,0.6558823529411765
host role,infectious structure host,0.5970588235294118
host role,entry into host,0.6166666666666667
host role,adhesion of symbiont to host,0.6121621621621621
host role,immunosuppressive disposition,0.5552631578947369
host role,pathogenic disposition,0.6112903225806451
host role,viral disease course,0.5879310344827586
host role,entry into host through host barriers,0.6239130434782608
host role,secondary infection role,0.6621212121212122
host role,infectious disposition,0.5790322580645162
host role,bacteriostatic disposition,0.5928571428571429
host role,bactericidal disposition,0.5712121212121213
host role,source of infection role,0.6621212121212122
host role,pathogen host,0.6318181818181818
host role,invasion disposition,0.5879310344827586
host role,disease course,0.6239130434782608
host role,infectious disease course,0.5970588235294118
host role,viricidal disposition,0.5833333333333334
host role,coronavirus disease course,0.5928571428571429
host role,biological vehicle role,0.6375
host role,symbiont role,0.7681818181818181
host role,parasite role,0.7681818181818181
host role,intermediate host,0.6038461538461539
host role,pathogen vector role,0.7258620689655172
host role,disposition,0.65
host role,primary infection role,0.6435483870967742
host role,biological role,0.7
host role,adhesion disposition,0.6224137931034482
host role,biological vector role,0.6758064516129032
host role,primary infectious disposition,0.5525641025641026
host role,pathogen host role,0.7833333333333333
host role,symptomatic carrier role,0.6621212121212122
host role,intermediate host role,0.7403225806451613
host role,dead-end host,0.6318181818181818
host role,host role,0.95
host role,establishment of localization in virus host,0.5653846153846154
host role,SARS-COV-2 adhesion disposition,0.575
host role,pathogen portal of exit role,0.6662162162162162
host role,invasive disposition,0.5879310344827586
host role,infectious agent host,0.6166666666666667
host role,long-term non-progressing infectious disease course,0.55
host role,commensal role,0.7543478260869566
host role,epitope role,0.7357142857142857
host role,fungicidal disposition,0.5790322580645162
host role,division of geopolitical entity,0.575
host role,function,0.5676470588235294
host role,pathogen transporter role,0.7147058823529412
host role,exotoxin disposition,0.5879310344827586
host role,antigen role,0.7357142857142857
host role,action specification,0.5879310344827586
host role,symbiont host role,0.7833333333333333
host role,opportunistic infectious disposition,0.5611111111111111
host role,fomite role,0.8
host role,enterotoxin disposition,0.575
host role,COVID-19 disease course,0.60625
host role,collective resistance disposition,0.569047619047619
host role,reagent role,0.7357142857142857
host role,viral load,0.5552631578947369
host role,fungistatic disposition,0.575
host role,establishment of a clinically abnormal colony,0.5611111111111111
host role,definitive host,0.6166666666666667
endotoxin,communicability end temporal region,0.609090909090909
endotoxin,infection end temporal region,0.6342105263157894
endotoxin,incubation end temporal region,0.6294871794871795
endotoxin,toxin disposition,0.6807692307692308
endotoxin,communicability end process boundary,0.5833333333333334
endotoxin,latency end process boundary,0.6121621621621621
endotoxin,endotoxin disposition,0.75
endotoxin,incubation end process boundary,0.6
endotoxin,latency end temporal region,0.6444444444444444
endotoxin,T cell receptor complex,0.575
endotoxin,toxin,0.8071428571428573
endotoxin,endotoxin,0.95
double-stranded DNA,ribonucleic acid,0.6214285714285714
double-stranded DNA,deoxyribonucleic acid,0.625
double-stranded DNA,double-stranded DNA virus,0.8818181818181818
double-stranded DNA,double-stranded DNA,0.95
double-stranded DNA,B cell receptor complex,0.5928571428571429
double-stranded DNA,double-stranded RNA virus,0.859090909090909
double-stranded DNA,genetic resistance to pathogen,0.6132653061224489
double-stranded DNA,nucleic acid,0.6112903225806451
double-stranded DNA,T cell receptor complex,0.569047619047619
double-stranded DNA,single-stranded DNA virus,0.7909090909090909
double-stranded DNA,double-stranded DNA retrovirus,0.8377551020408163
double-stranded DNA,establishment of a clinically abnormal colony,0.590625
virulence,infectious disease mortality rate,0.5452380952380953
virulence,communicability end temporal region,0.5636363636363636
virulence,infection end temporal region,0.581578947368421
virulence,virulence,0.95
virulence,incubation end temporal region,0.5782051282051281
virulence,virulence factor disposition,0.6932432432432433
virulence,establishment of localization in host,0.5369565217391304
virulence,infectious agent host role,0.5928571428571429
virulence,B cell receptor complex,0.575
virulence,colonized host,0.5804347826086956
virulence,virus host,0.6605263157894737
virulence,communicability end process boundary,0.5833333333333334
virulence,latency end process boundary,0.5851351351351352
virulence,colonization of host,0.5189655172413793
virulence,infectious structure host role,0.5782051282051281
virulence,SARS-CoV-2 virulence,0.760344827586207
virulence,establishment of localization in human host,0.5269230769230769
virulence,virulence factor,0.81
virulence,incubation end process boundary,0.6
virulence,dead-end host role,0.5611111111111111
virulence,definitive host role,0.5879310344827586
virulence,latency end temporal region,0.5888888888888889
virulence,T cell receptor complex,0.575
virulence,infectious structure host,0.5970588235294118
virulence,entry into host,0.5333333333333333
virulence,adhesion of symbiont to host,0.504054054054054
virulence,entry into host through host barriers,0.5369565217391304
virulence,pathogen host,0.5409090909090909
virulence,intermediate host,0.6038461538461539
virulence,COVID-19 mortality rate,0.60625
virulence,pathogen host role,0.5611111111111111
virulence,intermediate host role,0.5790322580645162
virulence,dead-end host,0.5409090909090909
virulence,host role,0.6166666666666667
virulence,establishment of localization in virus host,0.5269230769230769
virulence,infectious agent host,0.5833333333333334
virulence,blood,0.5214285714285714
virulence,acute respiratory distress syndrome,0.5636363636363636
virulence,symbiont host role,0.5981481481481481
virulence,establishment of a clinically abnormal colony,0.524074074074074
virulence,definitive host,0.575
infectious agent generative stage,source of infection,0.6230769230769231
infectious agent generative stage,information content entity,0.7211864406779661
infectious agent generative stage,infectious disease mortality rate,0.7530303030303032
infectious agent generative stage,infection incidence rate profile,0.7423076923076922
infectious agent generative stage,infectious structure aggregate,0.7515873015873015
infectious agent generative stage,communicability end temporal region,0.6411764705882353
infectious agent generative stage,pathogen generative stage,0.8293103448275861
infectious agent generative stage,infection end temporal region,0.7241935483870968
infectious agent generative stage,infectious disease,0.7441176470588234
infectious agent generative stage,SARS-CoV-2 incidence rate,0.6396551724137931
infectious agent generative stage,incubation end temporal region,0.6880952380952381
infectious agent generative stage,virulence factor disposition,0.6139344262295081
infectious agent generative stage,infectious disease incidence,0.7450819672131148
infectious agent generative stage,virus translation stage,0.7178571428571427
infectious agent generative stage,disease surveillance objective specification,0.6448051948051949
infectious agent generative stage,virus release stage,0.7192307692307692
infectious agent generative stage,infectious agent host role,0.7889830508474576
infectious agent generative stage,asymptomatic infectious structure carrier,0.6932432432432433
infectious agent generative stage,source of infection site,0.6780701754385965
infectious agent generative stage,B cell receptor complex,0.5928571428571429
infectious agent generative stage,passive immunization against infectious agent,0.6935897435897437
infectious agent generative stage,infection incidence rate,0.7482456140350877
infectious agent generative stage,double-stranded RNA virus,0.6224137931034482
infectious agent generative stage,virus transcription stage,0.7086206896551723
infectious agent generative stage,infectious disease lifetime prevalence,0.7457746478873238
infectious agent generative stage,lower respiratory tract disease,0.6375
infectious agent generative stage,infectious disease incidence proportion,0.7277777777777777
infectious agent generative stage,virus generative stage,0.8136363636363637
infectious agent generative stage,acute infectious disease course,0.715625
infectious agent generative stage,cidal agent disposition,0.6642857142857143
infectious agent generative stage,infectious disorder,0.7192307692307692
infectious agent generative stage,biological vehicle,0.5872549019607843
infectious agent generative stage,infectious disease sporadicity,0.7357142857142857
infectious agent generative stage,communicability end process boundary,0.6239130434782608
infectious agent generative stage,directive information content entity,0.6818840579710145
infectious agent generative stage,infectious agent colony,0.7714285714285714
infectious agent generative stage,pathogen transporter,0.6575471698113208
infectious agent generative stage,invasion factor,0.6166666666666667
infectious agent generative stage,latency end process boundary,0.6139344262295081
infectious agent generative stage,infectious disease epidemic,0.7333333333333333
infectious agent generative stage,infectious agent generative stage,0.95
infectious agent generative stage,disease transmission model,0.6194915254237288
infectious agent generative stage,negative-sense single-stranded RNA virus,0.6691780821917809
infectious agent generative stage,cidal agent,0.6318181818181818
infectious agent generative stage,infectious structure host role,0.7515873015873015
infectious agent generative stage,pathogen vehicle,0.6336734693877552
infectious agent generative stage,COVID-19 incidence rate,0.6464285714285714
infectious agent generative stage,negative regulation of developmental process,0.6448051948051949
infectious agent generative stage,pathogen vehicle role,0.6537037037037037
infectious agent generative stage,chronic infectious disease course,0.7075757575757575
infectious agent generative stage,asymptomatic infectious agent carrier,0.7357142857142857
infectious agent generative stage,descriptive information content entity,0.6753521126760563
infectious agent generative stage,COVID-19 epidemic,0.57
infectious agent generative stage,PCR product,0.5409090909090909
infectious agent generative stage,sterilizing immunity to infectious agent,0.6691780821917809
infectious agent generative stage,diseased population,0.6038461538461539
infectious agent generative stage,virulence factor,0.5928571428571429
infectious agent generative stage,incubation end process boundary,0.66875
infectious agent generative stage,SARS-CoV-2 uncoating stage,0.6703389830508475
infectious agent generative stage,plan specification,0.5872549019607843
infectious agent generative stage,latency end temporal region,0.6333333333333333
infectious agent generative stage,innate immunity to infectious agent,0.6852941176470588
infectious agent generative stage,SARS-CoV-2 penetration stage,0.7122950819672131
infectious agent generative stage,infectious structure,0.7330188679245283
infectious agent generative stage,static agent disposition,0.6605263157894737
infectious agent generative stage,T cell receptor complex,0.6107142857142857
infectious agent generative stage,asymptomatic carrier role,0.6224137931034482
infectious agent generative stage,infectious structure host,0.760344827586207
infectious agent generative stage,infectious agent population,0.7833333333333333
infectious agent generative stage,respiratory system disease,0.6364406779661017
infectious agent generative stage,leukocyte-mediated immunity to infectious agent,0.6625
infectious agent generative stage,generative stage,0.7765306122448979
infectious agent generative stage,humoral immunity to infectious agent,0.6818840579710145
infectious agent generative stage,infectious disease control strategy,0.7588235294117647
infectious agent generative stage,SARS-CoV-2 attachment stage,0.6833333333333332
infectious agent generative stage,infectious disease pandemic,0.7333333333333333
infectious agent generative stage,infectious structure generative stage,0.8642857142857143
infectious agent generative stage,viral disease course,0.619811320754717
infectious agent generative stage,passive immunity to infectious agent,0.6818840579710145
infectious agent generative stage,infectious disposition,0.7045454545454546
infectious agent generative stage,vaccination against infectious agent,0.7253623188405797
infectious agent generative stage,susceptibility to infectious agent,0.6888059701492537
infectious agent generative stage,source of infection role,0.6605263157894737
infectious agent generative stage,disease course,0.6202127659574468
infectious agent generative stage,infectious disease course,0.743103448275862
infectious agent generative stage,acquired immunity to infectious agent,0.6785714285714286
infectious agent generative stage,COVID-19 disease incidence proportion,0.6214285714285714
infectious agent generative stage,coronavirus disease course,0.6364406779661017
infectious agent generative stage,asymptomatic carrier,0.6009433962264151
infectious agent generative stage,biological vehicle role,0.6107142857142857
infectious agent generative stage,symptomatic infectious agent carrier,0.7398550724637681
infectious agent generative stage,intermediate host,0.67
infectious agent generative stage,infectious disease prevalence,0.7403225806451613
infectious agent generative stage,SARS-CoV-2 genome replication stage,0.7
infectious agent generative stage,infected population,0.6615384615384616
infectious agent generative stage,COVID-19 mortality rate,0.6285714285714286
infectious agent generative stage,viral disease,0.6021739130434782
infectious agent generative stage,developmental process,0.6166666666666667
infectious agent generative stage,disease,0.6
infectious agent generative stage,symptomatic infectious structure carrier,0.6965753424657534
infectious agent generative stage,primary infectious disposition,0.6722222222222223
infectious agent generative stage,designative information content entity,0.6753521126760563
infectious agent generative stage,symptomatic carrier role,0.6254385964912281
infectious agent generative stage,infectious pathogen transmissibility,0.7543478260869566
infectious agent generative stage,intermediate host role,0.6681818181818181
infectious agent generative stage,infectious human pathogen,0.760344827586207
infectious agent generative stage,immunization against infectious agent,0.7214285714285714
infectious agent generative stage,virus attachment stage,0.7227272727272727
infectious agent generative stage,SARS-CoV-2 transcription stage,0.6722222222222223
infectious agent generative stage,virus synthesis stage,0.7092592592592593
infectious agent generative stage,infectious agent host,0.8018518518518519
infectious agent generative stage,long-term non-progressing infectious disease course,0.6523809523809524
infectious agent generative stage,viral disease epidemic,0.6136363636363636
infectious agent generative stage,viral disease pandemic,0.6136363636363636
infectious agent generative stage,virus penetration stage,0.7535714285714286
infectious agent generative stage,division of geopolitical entity,0.653125
infectious agent generative stage,symptomatic carrier,0.6038461538461539
infectious agent generative stage,infectious disease endemicity,0.7564516129032257
infectious agent generative stage,function,0.5963414634146341
infectious agent generative stage,herd immunity to infectious organism,0.6673913043478261
infectious agent generative stage,pathogen transporter role,0.656896551724138
infectious agent generative stage,infectious agent reservoir,0.8059322033898306
infectious agent generative stage,COVID-19 pandemic,0.59
infectious agent generative stage,action specification,0.6386792452830189
infectious agent generative stage,SARS-CoV-2 synthesis stage,0.6703389830508475
infectious agent generative stage,infectious disease control objective specification,0.739156626506024
infectious agent generative stage,opportunistic infectious disposition,0.6528985507246376
infectious agent generative stage,polymerase chain reaction,0.6224137931034482
infectious agent generative stage,COVID-19 disease course,0.6107142857142857
infectious agent generative stage,infectious disease incidence rate,0.7681818181818181
infectious agent generative stage,single-stranded RNA retrovirus,0.6404761904761905
infectious agent generative stage,active immunization against infectious agent,0.6967532467532468
infectious agent generative stage,virus uncoating stage,0.7092592592592593
infectious agent generative stage,infectious agent,0.7765306122448979
infectious agent generative stage,establishment of a clinically abnormal colony,0.6038461538461539
infectious agent generative stage,coronavirus disease,0.6230769230769231
infectious agent generative stage,positive-sense single-stranded RNA virus,0.6554794520547945
infectious agent generative stage,adhesion factor,0.5958333333333333
infectious agent generative stage,drug susceptibility of infectious agent,0.6722222222222223
infectious agent generative stage,SARS-CoV-2 release stage,0.6780701754385965
infectious agent generative stage,static agent,0.65
infectious disease control objective specification,virus aggregate,0.5884615384615385
infectious disease control objective specification,source of infection,0.6384057971014493
infectious disease control objective specification,virostatic disposition,0.6444444444444444
infectious disease control objective specification,zoonotic disposition,0.65
infectious disease control objective specification,infectious disease mortality rate,0.7632530120481928
infectious disease control objective specification,infection incidence rate profile,0.6939024390243902
infectious disease control objective specification,infectious structure aggregate,0.7125
infectious disease control objective specification,communicability end temporal region,0.6264705882352941
infectious disease control objective specification,biological regulation,0.6190140845070422
infectious disease control objective specification,subclinical coronavirus infection,0.6668674698795181
infectious disease control objective specification,surveillance process,0.5928571428571429
infectious disease control objective specification,infection end temporal region,0.690506329113924
infectious disease control objective specification,geospatial location,0.6528985507246376
infectious disease control objective specification,vector control strategy,0.6691780821917809
infectious disease control objective specification,infectious disease,0.7147058823529412
infectious disease control objective specification,SARS-CoV-2 incidence rate,0.61
infectious disease control objective specification,double-stranded DNA virus,0.5833333333333334
infectious disease control objective specification,incubation end temporal region,0.6625
infectious disease control objective specification,site of infection,0.6440298507462687
infectious disease control objective specification,virulence factor disposition,0.6679487179487179
infectious disease control objective specification,viral adhesion disposition,0.6605263157894737
infectious disease control objective specification,parasitostatic disposition,0.6473684210526315
infectious disease control objective specification,infectious disease incidence,0.7576923076923078
infectious disease control objective specification,negative regulation of production,0.6668674698795181
infectious disease control objective specification,reverse zoonotic disposition,0.6807692307692308
infectious disease control objective specification,subclinical SARS-CoV-2 infection,0.6695121951219513
infectious disease control objective specification,virus translation stage,0.6143835616438357
infectious disease control objective specification,disease surveillance objective specification,0.8117021276595744
infectious disease control objective specification,case isolation control strategy,0.6722222222222223
infectious disease control objective specification,virus release stage,0.6094202898550725
infectious disease control objective specification,infectious agent host role,0.7131578947368421
infectious disease control objective specification,asymptomatic infectious structure carrier,0.6807692307692308
infectious disease control objective specification,source of infection site,0.6391891891891892
infectious disease control objective specification,virus,0.5045454545454545
infectious disease control objective specification,quarantine control strategy,0.6577922077922078
infectious disease control objective specification,virus replication,0.658955223880597
infectious disease control objective specification,B cell receptor complex,0.5869863013698631
infectious disease control objective specification,passive immunization against infectious agent,0.6394736842105263
infectious disease control objective specification,systematic infection,0.65
infectious disease control objective specification,infection incidence rate,0.6797297297297297
infectious disease control objective specification,virus host,0.5666666666666667
infectious disease control objective specification,double-stranded RNA virus,0.5833333333333334
infectious disease control objective specification,virus transcription stage,0.6366666666666667
infectious disease control objective specification,infectious disease lifetime prevalence,0.7795454545454545
infectious disease control objective specification,toxin disposition,0.6440298507462687
infectious disease control objective specification,lower respiratory tract disease,0.6104938271604938
infectious disease control objective specification,infectious disease incidence proportion,0.7758426966292135
infectious disease control objective specification,virus generative stage,0.6444444444444444
infectious disease control objective specification,acute infectious disease course,0.7462962962962962
infectious disease control objective specification,cidal agent disposition,0.6691780821917809
infectious disease control objective specification,infectious disorder,0.696376811594203
infectious disease control objective specification,subclinical infection,0.6330985915492958
infectious disease control objective specification,appearance of disorder,0.5888888888888889
infectious disease control objective specification,simple infection,0.6318181818181818
infectious disease control objective specification,parasiticidal disposition,0.65
infectious disease control objective specification,infectious disease sporadicity,0.7625
infectious disease control objective specification,communicability end process boundary,0.6127906976744186
infectious disease control objective specification,infection incidence proportion profile,0.7
infectious disease control objective specification,infectious agent colony,0.7102739726027397
infectious disease control objective specification,transmissibility disposition,0.6423076923076922
infectious disease control objective specification,latency end process boundary,0.6038461538461539
infectious disease control objective specification,infectious disease epidemic,0.7616883116883116
infectious disease control objective specification,infectious agent generative stage,0.739156626506024
infectious disease control objective specification,disease transmission model,0.6473684210526315
infectious disease control objective specification,endotoxin disposition,0.6471830985915493
infectious disease control objective specification,vector surveillance,0.6239130434782608
infectious disease control objective specification,negative regulation of establishment of localization,0.6754901960784313
infectious disease control objective specification,negative-sense single-stranded RNA virus,0.6388888888888888
infectious disease control objective specification,infectious structure host role,0.7125
infectious disease control objective specification,COVID-19 incidence rate,0.6143835616438357
infectious disease control objective specification,cytotoxin disposition,0.6471830985915493
infectious disease control objective specification,community-acquired infection,0.6551282051282051
infectious disease control objective specification,negative regulation of developmental process,0.6414893617021277
infectious disease control objective specification,chronic infectious disease course,0.739156626506024
infectious disease control objective specification,asymptomatic infectious agent carrier,0.6683908045977012
infectious disease control objective specification,nursing-home acquired infection,0.6722222222222223
infectious disease control objective specification,COVID-19 epidemic,0.5843283582089552
infectious disease control objective specification,negative regulation of replication,0.6880952380952381
infectious disease control objective specification,secondary infection,0.6528985507246376
infectious disease control objective specification,infection start temporal region,0.6969135802469135
infectious disease control objective specification,infection incidence,0.6673913043478261
infectious disease control objective specification,virus disorder,0.60625
infectious disease control objective specification,sterilizing immunity to infectious agent,0.6277777777777778
infectious disease control objective specification,diseased population,0.6673913043478261
infectious disease control objective specification,primary infection,0.6141791044776119
infectious disease control objective specification,process of establishing an infection,0.6476744186046511
infectious disease control objective specification,incubation end process boundary,0.6475308641975309
infectious disease control objective specification,SARS-CoV-2 disorder,0.5804347826086956
infectious disease control objective specification,collective pathogenic disposition,0.6789156626506024
infectious disease control objective specification,neurotoxin disposition,0.6583333333333334
infectious disease control objective specification,plan specification,0.6852941176470588
infectious disease control objective specification,latency end temporal region,0.6188311688311688
infectious disease control objective specification,innate immunity to infectious agent,0.65
infectious disease control objective specification,infectious structure,0.6928571428571427
infectious disease control objective specification,virus adhesion susceptible cell,0.6475308641975309
infectious disease control objective specification,collective disposition,0.6861111111111111
infectious disease control objective specification,infection,0.6025423728813559
infectious disease control objective specification,static agent disposition,0.6662162162162162
infectious disease control objective specification,T cell receptor complex,0.6006849315068493
infectious disease control objective specification,infectious structure host,0.7166666666666667
infectious disease control objective specification,infectious agent population,0.7487012987012988
infectious disease control objective specification,respiratory system disease,0.6210526315789474
infectious disease control objective specification,leukocyte-mediated immunity to infectious agent,0.6561855670103093
infectious disease control objective specification,humoral immunity to infectious agent,0.6244186046511628
infectious disease control objective specification,infectious disease control strategy,0.8029411764705883
infectious disease control objective specification,infectious disease pandemic,0.7487012987012988
infectious disease control objective specification,infectious structure generative stage,0.7258620689655172
infectious disease control objective specification,immunosuppressive disposition,0.6651898734177215
infectious disease control objective specification,pathogenic disposition,0.6305555555555555
infectious disease control objective specification,viral disease course,0.6642857142857143
infectious disease control objective specification,intracellular infection,0.6417808219178082
infectious disease control objective specification,secondary infection role,0.6391891891891892
infectious disease control objective specification,metastatic infection,0.6642857142857143
infectious disease control objective specification,passive immunity to infectious agent,0.636046511627907
infectious disease control objective specification,infectious disposition,0.7416666666666667
infectious disease control objective specification,vaccination against infectious agent,0.6476744186046511
infectious disease control objective specification,objective specification,0.7650684931506849
infectious disease control objective specification,acute infection,0.6346153846153847
infectious disease control objective specification,susceptibility to infectious agent,0.6285714285714286
infectious disease control objective specification,bacteriostatic disposition,0.6605263157894737
infectious disease control objective specification,bactericidal disposition,0.6527027027027027
infectious disease control objective specification,source of infection role,0.6256756756756756
infectious disease control objective specification,chronic infection,0.6291044776119403
infectious disease control objective specification,invasion disposition,0.6642857142857143
infectious disease control objective specification,disease course,0.653125
infectious disease control objective specification,infectious disease course,0.77
infectious disease control objective specification,viricidal disposition,0.6612676056338028
infectious disease control objective specification,acquired immunity to infectious agent,0.6454022988505748
infectious disease control objective specification,complex infection,0.6291044776119403
infectious disease control objective specification,COVID-19 disease incidence proportion,0.6913793103448276
infectious disease control objective specification,coronavirus disease course,0.6868421052631578
infectious disease control objective specification,infection incidence proportion,0.7
infectious disease control objective specification,symptomatic infectious agent carrier,0.6709302325581397
infectious disease control objective specification,respiratory droplet virus fomite,0.6329268292682927
infectious disease control objective specification,infectious disease prevalence,0.7537974683544304
infectious disease control objective specification,disposition,0.6139344262295081
infectious disease control objective specification,single-stranded DNA virus,0.5966666666666667
infectious disease control objective specification,infected population,0.6673913043478261
infectious disease control objective specification,COVID-19 mortality rate,0.6006849315068493
infectious disease control objective specification,negative regulation of life-sustaining process,0.6270833333333333
infectious disease control objective specification,place closure control strategy,0.6625
infectious disease control objective specification,viral disease,0.5928571428571429
infectious disease control objective specification,primary infection role,0.6305555555555555
infectious disease control objective specification,adhesion disposition,0.65
infectious disease control objective specification,infection incidence profile,0.6837662337662337
infectious disease control objective specification,disease,0.5728070175438597
infectious disease control objective specification,symptomatic infectious structure carrier,0.6833333333333332
infectious disease control objective specification,primary infectious disposition,0.7125
infectious disease control objective specification,infection prevalence,0.6642857142857143
infectious disease control objective specification,coronavirus disorder,0.6071428571428572
infectious disease control objective specification,infectious pathogen transmissibility,0.6941860465116279
infectious disease control objective specification,object,0.5571428571428572
infectious disease control objective specification,pathogen surveillance,0.5908450704225352
infectious disease control objective specification,infectious human pathogen,0.7033333333333335
infectious disease control objective specification,subclinical virus infection,0.6448051948051949
infectious disease control objective specification,establishment of localization in virus host,0.6327956989247312
infectious disease control objective specification,immunization against infectious agent,0.6454022988505748
infectious disease control objective specification,virus attachment stage,0.6027777777777777
infectious disease control objective specification,negative regulation of immune response,0.6545454545454545
infectious disease control objective specification,virus synthesis stage,0.6190140845070422
infectious disease control objective specification,SARS-COV-2 adhesion disposition,0.6598765432098764
infectious disease control objective specification,object aggregate,0.6015151515151516
infectious disease control objective specification,invasive disposition,0.6642857142857143
infectious disease control objective specification,infectious agent host,0.717605633802817
infectious disease control objective specification,long-term non-progressing infectious disease course,0.6876237623762376
infectious disease control objective specification,viral disease epidemic,0.6583333333333334
infectious disease control objective specification,fungicidal disposition,0.6583333333333334
infectious disease control objective specification,viral disease pandemic,0.6444444444444444
infectious disease control objective specification,virus penetration stage,0.6280821917808219
infectious disease control objective specification,acute respiratory distress syndrome,0.6264705882352941
infectious disease control objective specification,infectious disease endemicity,0.7664556962025317
infectious disease control objective specification,negative regulation of viral process,0.636046511627907
infectious disease control objective specification,disorder,0.553448275862069
infectious disease control objective specification,herd immunity to infectious organism,0.6244186046511628
infectious disease control objective specification,extracellular infection,0.6280821917808219
infectious disease control objective specification,exotoxin disposition,0.65
infectious disease control objective specification,infectious agent reservoir,0.7131578947368421
infectious disease control objective specification,COVID-19 pandemic,0.5694029850746268
infectious disease control objective specification,infection start process boundary,0.6817073170731708
infectious disease control objective specification,action specification,0.7214285714285714
infectious disease control objective specification,infectious disease control objective specification,0.95
infectious disease control objective specification,COVID-19 lifetime prevalence,0.6294871794871795
infectious disease control objective specification,opportunistic infectious disposition,0.6941860465116279
infectious disease control objective specification,process of establishing viral infection,0.652247191011236
infectious disease control objective specification,negative regulation of biological process,0.6368131868131869
infectious disease control objective specification,enterotoxin disposition,0.6554794520547945
infectious disease control objective specification,COVID-19 disease course,0.6691780821917809
infectious disease control objective specification,infectious disease incidence rate,0.7632530120481928
infectious disease control objective specification,COVID-19 prevalence,0.5804347826086956
infectious disease control objective specification,active immunization against infectious agent,0.6414893617021277
infectious disease control objective specification,SARS-COV-2 prevalence,0.6049295774647887
infectious disease control objective specification,disordered virus,0.5863636363636363
infectious disease control objective specification,collective resistance disposition,0.6789156626506024
infectious disease control objective specification,fungistatic disposition,0.6554794520547945
infectious disease control objective specification,virus uncoating stage,0.6049295774647887
infectious disease control objective specification,local infection,0.6192307692307693
infectious disease control objective specification,infectious agent,0.6772727272727272
infectious disease control objective specification,establishment of a clinically abnormal colony,0.6289473684210526
infectious disease control objective specification,coronavirus disease,0.6239130434782608
infectious disease control objective specification,positive-sense single-stranded RNA virus,0.6277777777777778
infectious disease control objective specification,hospital-acquired infection,0.6577922077922078
infectious disease control objective specification,drug susceptibility of infectious agent,0.6410112359550562
disease course,virus aggregate,0.6224137931034482
disease course,source of infection,0.6015151515151516
disease course,virostatic disposition,0.6166666666666667
disease course,zoonotic disposition,0.5970588235294118
disease course,infectious disease mortality rate,0.6840425531914894
disease course,infection incidence rate profile,0.6021739130434782
disease course,communicability end temporal region,0.5928571428571429
disease course,pathogen portal of entry,0.6078947368421053
disease course,subclinical coronavirus infection,0.6202127659574468
disease course,infection end temporal region,0.6127906976744186
disease course,infectious disease,0.66875
disease course,double-stranded DNA virus,0.6294871794871795
disease course,incubation end temporal region,0.609090909090909
disease course,site of infection,0.6112903225806451
disease course,virulence factor disposition,0.6404761904761905
disease course,viral adhesion disposition,0.6
disease course,parasitostatic disposition,0.6
disease course,infectious disease incidence,0.6880952380952381
disease course,reverse zoonotic disposition,0.6166666666666667
disease course,subclinical SARS-CoV-2 infection,0.6021739130434782
disease course,virus translation stage,0.6391891891891892
disease course,disease surveillance objective specification,0.656896551724138
disease course,virus release stage,0.7227272727272727
disease course,source of infection site,0.6342105263157894
disease course,virus,0.6078947368421053
disease course,virus replication,0.6112903225806451
disease course,B cell receptor complex,0.6121621621621621
disease course,systematic infection,0.6264705882352941
disease course,infection incidence rate,0.6078947368421053
disease course,virus host,0.6583333333333334
disease course,double-stranded RNA virus,0.6294871794871795
disease course,pathogen portal of entry role,0.5895348837209302
disease course,virus transcription stage,0.6551282051282051
disease course,infectious disease lifetime prevalence,0.6423076923076922
disease course,toxin disposition,0.6112903225806451
disease course,lower respiratory tract disease,0.6055555555555556
disease course,infectious disease incidence proportion,0.6575471698113208
disease course,virus generative stage,0.6722222222222223
disease course,acute infectious disease course,0.7611111111111112
disease course,cidal agent disposition,0.6121621621621621
disease course,infectious disorder,0.6621212121212122
disease course,subclinical infection,0.5928571428571429
disease course,appearance of disorder,0.6444444444444444
disease course,simple infection,0.6166666666666667
disease course,parasiticidal disposition,0.5782051282051281
disease course,infectious disease sporadicity,0.6772727272727272
disease course,communicability end process boundary,0.61
disease course,infection incidence proportion profile,0.5846153846153846
disease course,transmissibility disposition,0.5928571428571429
disease course,latency end process boundary,0.6166666666666667
disease course,infectious disease epidemic,0.6695121951219513
disease course,disease transmission model,0.725
disease course,endotoxin disposition,0.5928571428571429
disease course,negative-sense single-stranded RNA virus,0.5981481481481481
disease course,cytotoxin disposition,0.5928571428571429
disease course,community-acquired infection,0.5928571428571429
disease course,chronic infectious disease course,0.747872340425532
disease course,nursing-home acquired infection,0.6055555555555556
disease course,COVID-19 epidemic,0.5790322580645162
disease course,secondary infection,0.6318181818181818
disease course,infection start temporal region,0.6055555555555556
disease course,infection incidence,0.6015151515151516
disease course,virus disorder,0.6642857142857143
disease course,primary infection,0.6112903225806451
disease course,process of establishing an infection,0.59
disease course,incubation end process boundary,0.6277777777777778
disease course,SARS-CoV-2 disorder,0.6621212121212122
disease course,collective pathogenic disposition,0.598936170212766
disease course,neurotoxin disposition,0.5888888888888889
disease course,plan specification,0.60625
disease course,latency end temporal region,0.5963414634146341
disease course,virus adhesion susceptible cell,0.6277777777777778
disease course,collective disposition,0.5888888888888889
disease course,infection,0.6239130434782608
disease course,static agent disposition,0.6078947368421053
disease course,T cell receptor complex,0.6121621621621621
disease course,respiratory system disease,0.625
disease course,entry into host,0.5879310344827586
disease course,infectious disease control strategy,0.7153061224489795
disease course,infectious disease pandemic,0.6695121951219513
disease course,immunosuppressive disposition,0.636046511627907
disease course,pathogenic disposition,0.5888888888888889
disease course,viral disease course,0.8617647058823529
disease course,entry into host through host barriers,0.5872549019607843
disease course,intracellular infection,0.6121621621621621
disease course,secondary infection role,0.6605263157894737
disease course,metastatic infection,0.6264705882352941
disease course,infectious disposition,0.6166666666666667
disease course,objective specification,0.6121621621621621
disease course,acute infection,0.6224137931034482
disease course,bacteriostatic disposition,0.6
disease course,bactericidal disposition,0.581578947368421
disease course,source of infection role,0.6342105263157894
disease course,chronic infection,0.5790322580645162
disease course,invasion disposition,0.6264705882352941
disease course,disease course,0.95
disease course,infectious disease course,0.808974358974359
disease course,viricidal disposition,0.5928571428571429
disease course,complex infection,0.5790322580645162
disease course,COVID-19 disease incidence proportion,0.6656862745098039
disease course,coronavirus disease course,0.8
disease course,infection incidence proportion,0.5863636363636363
disease course,respiratory droplet virus fomite,0.6021739130434782
disease course,infectious disease prevalence,0.6825581395348838
disease course,disposition,0.65
disease course,single-stranded DNA virus,0.6294871794871795
disease course,contact tracing,0.553448275862069
disease course,viral disease,0.7092592592592593
disease course,primary infection role,0.6444444444444444
disease course,adhesion disposition,0.6264705882352941
disease course,pathogen portal of entry site,0.6127906976744186
disease course,infection incidence profile,0.5963414634146341
disease course,disease,0.7833333333333333
disease course,primary infectious disposition,0.609090909090909
disease course,infection prevalence,0.6264705882352941
disease course,coronavirus disorder,0.6264705882352941
disease course,object,0.55
disease course,subclinical virus infection,0.5963414634146341
disease course,establishment of localization in virus host,0.6078947368421053
disease course,virus attachment stage,0.6444444444444444
disease course,virus synthesis stage,0.65
disease course,SARS-COV-2 adhesion disposition,0.6055555555555556
disease course,object aggregate,0.5833333333333334
disease course,invasive disposition,0.6558823529411765
disease course,long-term non-progressing infectious disease course,0.6653846153846155
disease course,viral disease epidemic,0.7
disease course,fungicidal disposition,0.5888888888888889
disease course,viral disease pandemic,0.7
disease course,virus penetration stage,0.6391891891891892
disease course,acute respiratory distress syndrome,0.6132653061224489
disease course,infectious disease endemicity,0.6593023255813953
disease course,contact pathogen transmission process,0.5676470588235294
disease course,disorder,0.7227272727272727
disease course,extracellular infection,0.6121621621621621
disease course,exotoxin disposition,0.5970588235294118
disease course,infection start process boundary,0.6239130434782608
disease course,infectious disease control objective specification,0.653125
disease course,opportunistic infectious disposition,0.59
disease course,process of establishing viral infection,0.5820754716981132
disease course,enterotoxin disposition,0.5851351351351352
disease course,polymerase chain reaction,0.6551282051282051
disease course,COVID-19 disease course,0.8283783783783784
disease course,infectious disease incidence rate,0.6840425531914894
disease course,disordered virus,0.7166666666666667
disease course,collective resistance disposition,0.598936170212766
disease course,fungistatic disposition,0.6121621621621621
disease course,virus uncoating stage,0.65
disease course,local infection,0.5879310344827586
disease course,establishment of a clinically abnormal colony,0.5855932203389831
disease course,coronavirus disease,0.6621212121212122
disease course,positive-sense single-stranded RNA virus,0.5981481481481481
disease course,hospital-acquired infection,0.5963414634146341
independent continuant,infectious disease mortality rate,0.65
independent continuant,infection incidence rate profile,0.6537037037037037
independent continuant,communicability end temporal region,0.5903508771929825
independent continuant,infection end temporal region,0.6460784313725491
independent continuant,vector control strategy,0.65
independent continuant,SARS-CoV-2 incidence rate,0.6414893617021277
independent continuant,incubation end temporal region,0.6230769230769231
independent continuant,case isolation control strategy,0.619811320754717
independent continuant,quarantine control strategy,0.6540816326530612
independent continuant,B cell receptor complex,0.6055555555555556
independent continuant,infection incidence rate,0.6673913043478261
independent continuant,communicability end process boundary,0.6051724137931035
independent continuant,latency end process boundary,0.63
independent continuant,COVID-19 incidence rate,0.65
independent continuant,incubation end process boundary,0.6386792452830189
independent continuant,latency end temporal region,0.6132653061224489
independent continuant,T cell receptor complex,0.6055555555555556
independent continuant,infectious disease control strategy,0.6605263157894737
independent continuant,country,0.6224137931034482
independent continuant,generically dependent continuant,0.8388888888888889
independent continuant,COVID-19 mortality rate,0.6277777777777778
independent continuant,place closure control strategy,0.6423076923076922
independent continuant,continuant,0.7625
independent continuant,specifically dependent continuant,0.8318181818181819
independent continuant,independent continuant,0.95
independent continuant,infectious disease control objective specification,0.6305555555555555
independent continuant,infectious disease incidence rate,0.6681818181818181
independent continuant,establishment of a clinically abnormal colony,0.6141791044776119
biological vehicle role,infectious disease mortality rate,0.6107142857142857
biological vehicle role,infection incidence rate profile,0.6681818181818181
biological vehicle role,biological regulation,0.7681818181818181
biological vehicle role,primary pathogen,0.6038461538461539
biological vehicle role,vector control strategy,0.6239130434782608
biological vehicle role,SARS-CoV-2 incidence rate,0.6375
biological vehicle role,virulence factor disposition,0.6068627450980393
biological vehicle role,reservoir of pathogen role,0.6540816326530612
biological vehicle role,infectious agent host role,0.6540816326530612
biological vehicle role,asymptomatic infectious structure carrier,0.621875
biological vehicle role,B cell receptor complex,0.6891304347826087
biological vehicle role,passive immunization against infectious agent,0.5823529411764706
biological vehicle role,infection incidence rate,0.6627659574468084
biological vehicle role,mechanical vector,0.675
biological vehicle role,pathogen portal of entry role,0.6615384615384616
biological vehicle role,lower respiratory tract disease,0.5981481481481481
biological vehicle role,acute infectious disease course,0.5981481481481481
biological vehicle role,cidal agent disposition,0.6021739130434782
biological vehicle role,role,0.5981481481481481
biological vehicle role,appearance of disorder,0.6055555555555556
biological vehicle role,biological vehicle,0.8890243902439025
biological vehicle role,mutualist role,0.6662162162162162
biological vehicle role,infectious agent colony,0.6021739130434782
biological vehicle role,invasion factor,0.581578947368421
biological vehicle role,infectious agent generative stage,0.6107142857142857
biological vehicle role,vector surveillance,0.6404761904761905
biological vehicle role,cidal agent,0.5970588235294118
biological vehicle role,infectious structure host role,0.6386792452830189
biological vehicle role,pathogen vehicle,0.7064102564102563
biological vehicle role,COVID-19 incidence rate,0.6456521739130434
biological vehicle role,pathogen vector,0.6342105263157894
biological vehicle role,pathogen vehicle role,0.7909090909090909
biological vehicle role,chronic infectious disease course,0.6285714285714286
biological vehicle role,asymptomatic infectious agent carrier,0.6166666666666667
biological vehicle role,mechanical vector role,0.7388888888888888
biological vehicle role,sterilizing immunity to infectious agent,0.5928571428571429
biological vehicle role,primary infection,0.6
biological vehicle role,virulence factor,0.6294871794871795
biological vehicle role,dead-end host role,0.6451219512195122
biological vehicle role,definitive host role,0.6825581395348838
biological vehicle role,innate immunity to infectious agent,0.5706896551724138
biological vehicle role,virus adhesion susceptible cell,0.6166666666666667
biological vehicle role,anatomical space,0.6551282051282051
biological vehicle role,static agent disposition,0.5776595744680851
biological vehicle role,T cell receptor complex,0.6673913043478261
biological vehicle role,asymptomatic carrier role,0.6791666666666666
biological vehicle role,infectious agent population,0.59
biological vehicle role,biological vector,0.825
biological vehicle role,leukocyte-mediated immunity to infectious agent,0.5785714285714285
biological vehicle role,humoral immunity to infectious agent,0.5855932203389831
biological vehicle role,innate immune response,0.65
biological vehicle role,viral disease course,0.6593023255813953
biological vehicle role,secondary infection role,0.6627659574468084
biological vehicle role,cell,0.5981481481481481
biological vehicle role,passive immunity to infectious agent,0.5686440677966101
biological vehicle role,vaccination against infectious agent,0.6025423728813559
biological vehicle role,susceptibility to infectious agent,0.6078947368421053
biological vehicle role,source of infection role,0.6627659574468084
biological vehicle role,disease course,0.6121621621621621
biological vehicle role,infectious disease course,0.6166666666666667
biological vehicle role,acquired immunity to infectious agent,0.5666666666666667
biological vehicle role,coronavirus disease course,0.6336734693877552
biological vehicle role,asymptomatic carrier,0.6127906976744186
biological vehicle role,biological vehicle role,0.95
biological vehicle role,symptomatic infectious agent carrier,0.6194915254237288
biological vehicle role,symbiont role,0.6722222222222223
biological vehicle role,parasite role,0.6722222222222223
biological vehicle role,pathogen vector role,0.7058139534883722
biological vehicle role,anatomical entity,0.65
biological vehicle role,COVID-19 mortality rate,0.6239130434782608
biological vehicle role,primary infection role,0.6722222222222223
biological vehicle role,intervention,0.5928571428571429
biological vehicle role,primary immunodeficiency,0.598936170212766
biological vehicle role,biological role,0.8447368421052631
biological vehicle role,biological process,0.7914634146341464
biological vehicle role,symptomatic infectious structure carrier,0.6246031746031746
biological vehicle role,biological vector role,0.8722222222222222
biological vehicle role,primary infectious disposition,0.5820754716981132
biological vehicle role,pathogen host role,0.6695121951219513
biological vehicle role,symptomatic carrier role,0.6840425531914894
biological vehicle role,SARS-COV-2 adhesion susceptible cell,0.6025423728813559
biological vehicle role,intermediate host role,0.6722222222222223
biological vehicle role,host role,0.6375
biological vehicle role,immunization against infectious agent,0.6
biological vehicle role,pathogen portal of exit role,0.6852941176470588
biological vehicle role,infectious agent host,0.5863636363636363
biological vehicle role,long-term non-progressing infectious disease course,0.5986486486486486
biological vehicle role,commensal role,0.6662162162162162
biological vehicle role,epitope role,0.6785714285714286
biological vehicle role,symptomatic carrier,0.6166666666666667
biological vehicle role,function,0.5467741935483871
biological vehicle role,pathogen transporter role,0.6375
biological vehicle role,infectious agent reservoir,0.6132653061224489
biological vehicle role,antigen role,0.6785714285714286
biological vehicle role,action specification,0.6127906976744186
biological vehicle role,symbiont host role,0.6939024390243902
biological vehicle role,fomite role,0.6852941176470588
biological vehicle role,negative regulation of biological process,0.66875
biological vehicle role,COVID-19 disease course,0.6239130434782608
biological vehicle role,infectious disease incidence rate,0.6464285714285714
biological vehicle role,active immunization against infectious agent,0.5843283582089552
biological vehicle role,reagent role,0.65
biological vehicle role,viral load,0.6318181818181818
biological vehicle role,infectious agent,0.5782051282051281
biological vehicle role,establishment of a clinically abnormal colony,0.6411764705882353
biological vehicle role,adhesion factor,0.581578947368421
biological vehicle role,drug susceptibility of infectious agent,0.5951612903225807
biological vehicle role,static agent,0.5928571428571429
biological vehicle role,cell space,0.6015151515151516
establishment of localization in human host,extended organism,0.6166666666666667
establishment of localization in human host,virostatic disposition,0.6192307692307693
establishment of localization in human host,information content entity,0.6528985507246376
establishment of localization in human host,zoonotic disposition,0.5928571428571429
establishment of localization in human host,infectious disease mortality rate,0.6342105263157894
establishment of localization in human host,infection incidence rate profile,0.65
establishment of localization in human host,infectious structure aggregate,0.6006849315068493
establishment of localization in human host,communicability end temporal region,0.6294871794871795
establishment of localization in human host,geographical entity,0.5951612903225807
establishment of localization in human host,infection end temporal region,0.6583333333333334
establishment of localization in human host,drug-based immunosuppressed organism,0.5892405063291138
establishment of localization in human host,SARS-CoV-2 incidence rate,0.6264705882352941
establishment of localization in human host,incubation end temporal region,0.6554794520547945
establishment of localization in human host,resistant entity,0.6194915254237288
establishment of localization in human host,normal resident microbiota population,0.65
establishment of localization in human host,immunocompetent organism,0.6141791044776119
establishment of localization in human host,virulence factor disposition,0.6330985915492958
establishment of localization in human host,viral adhesion disposition,0.6239130434782608
establishment of localization in human host,parasitostatic disposition,0.6239130434782608
establishment of localization in human host,reverse zoonotic disposition,0.6330985915492958
establishment of localization in human host,establishment of localization in host,0.9125
establishment of localization in human host,infectious agent host role,0.6673913043478261
establishment of localization in human host,material entity,0.5879310344827586
establishment of localization in human host,asymptomatic infectious structure carrier,0.6285714285714286
establishment of localization in human host,architectual structure,0.6038461538461539
establishment of localization in human host,B cell receptor complex,0.5863636363636363
establishment of localization in human host,infection incidence rate,0.658955223880597
establishment of localization in human host,colonized host,0.6254385964912281
establishment of localization in human host,virus host,0.5820754716981132
establishment of localization in human host,entity,0.5520408163265306
establishment of localization in human host,double-stranded RNA virus,0.6117647058823529
establishment of localization in human host,toxin disposition,0.6166666666666667
establishment of localization in human host,cidal agent disposition,0.6318181818181818
establishment of localization in human host,parasiticidal disposition,0.6264705882352941
establishment of localization in human host,communicability end process boundary,0.6018987341772152
establishment of localization in human host,directive information content entity,0.6651898734177215
establishment of localization in human host,acellular structure aggregate,0.575
establishment of localization in human host,invasion factor,0.6051724137931035
establishment of localization in human host,transmissibility disposition,0.6330985915492958
establishment of localization in human host,latency end process boundary,0.5908450704225352
establishment of localization in human host,colonization of host,0.7039682539682539
establishment of localization in human host,realizable entity,0.6
establishment of localization in human host,endotoxin disposition,0.621875
establishment of localization in human host,negative regulation of establishment of localization,0.7552631578947369
establishment of localization in human host,pathologically immunosuppressed organism,0.6307228915662652
establishment of localization in human host,negative-sense single-stranded RNA virus,0.6307228915662652
establishment of localization in human host,infectious structure host role,0.6417808219178082
establishment of localization in human host,establishment of localization,0.8527777777777777
establishment of localization in human host,COVID-19 incidence rate,0.5863636363636363
establishment of localization in human host,cytotoxin disposition,0.60625
establishment of localization in human host,host,0.5351063829787234
establishment of localization in human host,descriptive information content entity,0.6722222222222223
establishment of localization in human host,establishment of localization in human host,0.95
establishment of localization in human host,acellular structure,0.5951612903225807
establishment of localization in human host,virulence factor,0.5855932203389831
establishment of localization in human host,incubation end process boundary,0.6256756756756756
establishment of localization in human host,collective pathogenic disposition,0.6342105263157894
establishment of localization in human host,neurotoxin disposition,0.6192307692307693
establishment of localization in human host,dead-end host role,0.5975409836065574
establishment of localization in human host,molecular entity,0.6025423728813559
establishment of localization in human host,immunosuppressed organism,0.5970588235294118
establishment of localization in human host,plan specification,0.6139344262295081
establishment of localization in human host,definitive host role,0.6246031746031746
establishment of localization in human host,latency end temporal region,0.6071428571428572
establishment of localization in human host,infectious structure,0.6246031746031746
establishment of localization in human host,collective disposition,0.6192307692307693
establishment of localization in human host,static agent disposition,0.658955223880597
establishment of localization in human host,T cell receptor complex,0.5863636363636363
establishment of localization in human host,infectious structure host,0.6558823529411765
establishment of localization in human host,respiratory system disease,0.6094202898550725
establishment of localization in human host,entry into host,0.656896551724138
establishment of localization in human host,adhesion of symbiont to host,0.6894366197183097
establishment of localization in human host,organism population,0.6435483870967742
establishment of localization in human host,infectious structure generative stage,0.6125
establishment of localization in human host,immunosuppressive disposition,0.6027777777777777
establishment of localization in human host,pathogenic disposition,0.6192307692307693
establishment of localization in human host,entry into host through host barriers,0.6625
establishment of localization in human host,infectious disposition,0.6346153846153847
establishment of localization in human host,bacteriostatic disposition,0.6239130434782608
establishment of localization in human host,bactericidal disposition,0.6141791044776119
establishment of localization in human host,pathogen host,0.6107142857142857
establishment of localization in human host,invasion disposition,0.6246031746031746
establishment of localization in human host,viricidal disposition,0.60625
establishment of localization in human host,susceptible organism,0.6246031746031746
establishment of localization in human host,intermediate host,0.6333333333333333
establishment of localization in human host,organism substance,0.5811475409836065
establishment of localization in human host,anatomical entity,0.6166666666666667
establishment of localization in human host,disposition,0.5981481481481481
establishment of localization in human host,COVID-19 mortality rate,0.6015151515151516
establishment of localization in human host,place closure control strategy,0.6006849315068493
establishment of localization in human host,geopolitical entity,0.6112903225806451
establishment of localization in human host,adhesion disposition,0.6246031746031746
establishment of localization in human host,symptomatic infectious structure carrier,0.6186746987951807
establishment of localization in human host,homo sapiens,0.5954545454545455
establishment of localization in human host,primary infectious disposition,0.6280821917808219
establishment of localization in human host,pathogen host role,0.5975409836065574
establishment of localization in human host,designative information content entity,0.6722222222222223
establishment of localization in human host,intermediate host role,0.6192307692307693
establishment of localization in human host,dead-end host,0.6107142857142857
establishment of localization in human host,immunodeficient organism,0.6291044776119403
establishment of localization in human host,host role,0.5461538461538461
establishment of localization in human host,infectious human pathogen,0.6852941176470588
establishment of localization in human host,colonization of human,0.715625
establishment of localization in human host,establishment of localization in virus host,0.9034883720930234
establishment of localization in human host,immaterial entity,0.5833333333333334
establishment of localization in human host,SARS-COV-2 adhesion disposition,0.6391891891891892
establishment of localization in human host,invasive disposition,0.6087301587301588
establishment of localization in human host,infectious agent host,0.684375
establishment of localization in human host,fungicidal disposition,0.6038461538461539
establishment of localization in human host,division of geopolitical entity,0.6527027027027027
establishment of localization in human host,herd immunity to infectious organism,0.6525316455696202
establishment of localization in human host,exotoxin disposition,0.6246031746031746
establishment of localization in human host,processed material,0.5975409836065574
establishment of localization in human host,symbiont host role,0.6139344262295081
establishment of localization in human host,opportunistic infectious disposition,0.639873417721519
establishment of localization in human host,enterotoxin disposition,0.6318181818181818
establishment of localization in human host,infectious disease incidence rate,0.6342105263157894
establishment of localization in human host,single-stranded RNA retrovirus,0.6143835616438357
establishment of localization in human host,collective resistance disposition,0.6210526315789474
establishment of localization in human host,fungistatic disposition,0.6166666666666667
establishment of localization in human host,organism,0.5480392156862746
establishment of localization in human host,local infection,0.6224137931034482
establishment of localization in human host,establishment of a clinically abnormal colony,0.7568181818181818
establishment of localization in human host,positive-sense single-stranded RNA virus,0.6307228915662652
establishment of localization in human host,adhesion factor,0.6051724137931035
establishment of localization in human host,definitive host,0.6396551724137931
establishment of localization in human host,material processing,0.5790322580645162
viral plaque assay,infectious disease mortality rate,0.5872549019607843
viral plaque assay,infection incidence rate profile,0.59
viral plaque assay,SARS-CoV-2 incidence rate,0.5662790697674418
viral plaque assay,viral adhesion disposition,0.7
viral plaque assay,B cell receptor complex,0.5719512195121951
viral plaque assay,infection incidence rate,0.569047619047619
viral plaque assay,double-stranded RNA virus,0.5895348837209302
viral plaque assay,serology assay,0.7
viral plaque assay,negative-sense single-stranded RNA virus,0.5879310344827586
viral plaque assay,COVID-19 incidence rate,0.5963414634146341
viral plaque assay,viral plaque assay,0.95
viral plaque assay,T cell receptor complex,0.5719512195121951
viral plaque assay,viral disease course,0.7131578947368421
viral plaque assay,viral envelope,0.7
viral plaque assay,viral capsid,0.7166666666666667
viral plaque assay,COVID-19 mortality rate,0.6451219512195122
viral plaque assay,viral disease,0.7403225806451613
viral plaque assay,assay,0.6673913043478261
viral plaque assay,viral disease epidemic,0.675
viral plaque assay,viral disease pandemic,0.7
viral plaque assay,division of geopolitical entity,0.6132653061224489
viral plaque assay,negative regulation of viral process,0.6351851851851852
viral plaque assay,process of establishing viral infection,0.5728070175438597
viral plaque assay,infectious disease incidence rate,0.5676470588235294
viral plaque assay,single-stranded RNA retrovirus,0.5958333333333333
viral plaque assay,viral load,0.7357142857142857
viral plaque assay,establishment of a clinically abnormal colony,0.5928571428571429
viral plaque assay,positive-sense single-stranded RNA virus,0.5879310344827586
viral plaque assay,viral pathogenesis,0.7555555555555555
enterotoxin disposition,virostatic disposition,0.8055555555555556
enterotoxin disposition,information content entity,0.6336734693877552
enterotoxin disposition,zoonotic disposition,0.822093023255814
enterotoxin disposition,infectious disease mortality rate,0.6464285714285714
enterotoxin disposition,infection incidence rate profile,0.6318181818181818
enterotoxin disposition,infectious structure aggregate,0.5820754716981132
enterotoxin disposition,communicability end temporal region,0.6224137931034482
enterotoxin disposition,geographical entity,0.5928571428571429
enterotoxin disposition,biological regulation,0.6318181818181818
enterotoxin disposition,surveillance process,0.6127906976744186
enterotoxin disposition,infection end temporal region,0.6807692307692308
enterotoxin disposition,vector control strategy,0.6456521739130434
enterotoxin disposition,SARS-CoV-2 incidence rate,0.575
enterotoxin disposition,incubation end temporal region,0.6575471698113208
enterotoxin disposition,resistant entity,0.6294871794871795
enterotoxin disposition,virulence factor disposition,0.7833333333333333
enterotoxin disposition,viral adhesion disposition,0.7561224489795919
enterotoxin disposition,parasitostatic disposition,0.7765306122448979
enterotoxin disposition,negative regulation of production,0.7
enterotoxin disposition,reverse zoonotic disposition,0.8029411764705883
enterotoxin disposition,establishment of localization in host,0.65
enterotoxin disposition,disease surveillance objective specification,0.658955223880597
enterotoxin disposition,case isolation control strategy,0.6166666666666667
enterotoxin disposition,infectious agent host role,0.6540816326530612
enterotoxin disposition,macromolecular complex,0.5611111111111111
enterotoxin disposition,material entity,0.6342105263157894
enterotoxin disposition,asymptomatic infectious structure carrier,0.60625
enterotoxin disposition,architectual structure,0.5833333333333334
enterotoxin disposition,quarantine control strategy,0.63
enterotoxin disposition,B cell receptor complex,0.5804347826086956
enterotoxin disposition,infection incidence rate,0.6414893617021277
enterotoxin disposition,colonized host,0.6391891891891892
enterotoxin disposition,virus host,0.6015151515151516
enterotoxin disposition,entity,0.6224137931034482
enterotoxin disposition,enterotoxin,0.7735294117647058
enterotoxin disposition,toxin disposition,0.875
enterotoxin disposition,cidal agent disposition,0.7760869565217391
enterotoxin disposition,parasiticidal disposition,0.7625
enterotoxin disposition,communicability end process boundary,0.6194915254237288
enterotoxin disposition,directive information content entity,0.6364406779661017
enterotoxin disposition,acellular structure aggregate,0.5653846153846154
enterotoxin disposition,transmissibility disposition,0.7441176470588234
enterotoxin disposition,latency end process boundary,0.6460784313725491
enterotoxin disposition,colonization of host,0.636046511627907
enterotoxin disposition,realizable entity,0.575
enterotoxin disposition,endotoxin disposition,0.9045454545454545
enterotoxin disposition,vector surveillance,0.6166666666666667
enterotoxin disposition,negative regulation of establishment of localization,0.6633333333333334
enterotoxin disposition,infectious structure host role,0.6386792452830189
enterotoxin disposition,COVID-19 incidence rate,0.5804347826086956
enterotoxin disposition,cytotoxin disposition,0.8818181818181818
enterotoxin disposition,negative regulation of developmental process,0.6291044776119403
enterotoxin disposition,host,0.5611111111111111
enterotoxin disposition,descriptive information content entity,0.630327868852459
enterotoxin disposition,negative regulation of replication,0.6956140350877194
enterotoxin disposition,establishment of localization in human host,0.6318181818181818
enterotoxin disposition,acellular structure,0.569047619047619
enterotoxin disposition,incubation end process boundary,0.6537037037037037
enterotoxin disposition,collective pathogenic disposition,0.7714285714285714
enterotoxin disposition,neurotoxin disposition,0.9166666666666665
enterotoxin disposition,dead-end host role,0.6451219512195122
enterotoxin disposition,molecular entity,0.5782051282051281
enterotoxin disposition,plan specification,0.6695121951219513
enterotoxin disposition,definitive host role,0.6593023255813953
enterotoxin disposition,latency end temporal region,0.65
enterotoxin disposition,infectious structure,0.6127906976744186
enterotoxin disposition,collective disposition,0.7833333333333333
enterotoxin disposition,static agent disposition,0.7904255319148936
enterotoxin disposition,T cell receptor complex,0.6021739130434782
enterotoxin disposition,infectious structure host,0.6375
enterotoxin disposition,respiratory system disease,0.6336734693877552
enterotoxin disposition,entry into host,0.7131578947368421
enterotoxin disposition,adhesion of symbiont to host,0.6264705882352941
enterotoxin disposition,infectious disease control strategy,0.6396551724137931
enterotoxin disposition,infectious structure generative stage,0.6
enterotoxin disposition,immunosuppressive disposition,0.7384615384615384
enterotoxin disposition,pathogenic disposition,0.7833333333333333
enterotoxin disposition,toxin,0.6285714285714286
enterotoxin disposition,entry into host through host barriers,0.65
enterotoxin disposition,infectious disposition,0.8055555555555556
enterotoxin disposition,bacteriostatic disposition,0.8173469387755102
enterotoxin disposition,bactericidal disposition,0.7904255319148936
enterotoxin disposition,pathogen host,0.6444444444444444
enterotoxin disposition,invasion disposition,0.7988372093023256
enterotoxin disposition,viricidal disposition,0.7681818181818181
enterotoxin disposition,complex infection,0.65
enterotoxin disposition,intermediate host,0.675
enterotoxin disposition,anatomical entity,0.625
enterotoxin disposition,disposition,0.7735294117647058
enterotoxin disposition,COVID-19 mortality rate,0.5804347826086956
enterotoxin disposition,negative regulation of life-sustaining process,0.6528985507246376
enterotoxin disposition,place closure control strategy,0.6009433962264151
enterotoxin disposition,geopolitical entity,0.6404761904761905
enterotoxin disposition,adhesion disposition,0.7988372093023256
enterotoxin disposition,symptomatic infectious structure carrier,0.6087301587301588
enterotoxin disposition,primary infectious disposition,0.7518867924528303
enterotoxin disposition,pathogen host role,0.6451219512195122
enterotoxin disposition,designative information content entity,0.6467213114754098
enterotoxin disposition,intermediate host role,0.6722222222222223
enterotoxin disposition,dead-end host,0.6444444444444444
enterotoxin disposition,pathogen surveillance,0.609090909090909
enterotoxin disposition,host role,0.575
enterotoxin disposition,establishment of localization in virus host,0.6621212121212122
enterotoxin disposition,negative regulation of immune response,0.6631147540983606
enterotoxin disposition,immaterial entity,0.625
enterotoxin disposition,SARS-COV-2 adhesion disposition,0.7462962962962962
enterotoxin disposition,invasive disposition,0.7755813953488372
enterotoxin disposition,infectious agent host,0.6545454545454545
enterotoxin disposition,fungicidal disposition,0.7611111111111112
enterotoxin disposition,division of geopolitical entity,0.6166666666666667
enterotoxin disposition,negative regulation of viral process,0.6533898305084747
enterotoxin disposition,exotoxin disposition,0.891860465116279
enterotoxin disposition,immunoglobulin complex,0.6055555555555556
enterotoxin disposition,infectious disease control objective specification,0.6554794520547945
enterotoxin disposition,symbiont host role,0.6207317073170732
enterotoxin disposition,opportunistic infectious disposition,0.738135593220339
enterotoxin disposition,negative regulation of biological process,0.6375
enterotoxin disposition,enterotoxin disposition,0.95
enterotoxin disposition,infectious disease incidence rate,0.6642857142857143
enterotoxin disposition,collective resistance disposition,0.7714285714285714
enterotoxin disposition,fungistatic disposition,0.7978260869565217
enterotoxin disposition,establishment of a clinically abnormal colony,0.6117647058823529
enterotoxin disposition,definitive host,0.6605263157894737
infectious disease incidence,virus aggregate,0.6127906976744186
infectious disease incidence,source of infection,0.6414893617021277
infectious disease incidence,virostatic disposition,0.67
infectious disease incidence,zoonotic disposition,0.6791666666666666
infectious disease incidence,infectious disease mortality rate,0.7942622950819671
infectious disease incidence,infection incidence rate profile,0.75
infectious disease incidence,infectious structure aggregate,0.7258620689655172
infectious disease incidence,communicability end temporal region,0.6087301587301588
infectious disease incidence,subclinical coronavirus infection,0.6467213114754098
infectious disease incidence,infection end temporal region,0.7131578947368421
infectious disease incidence,infectious disease,0.8413043478260869
infectious disease incidence,SARS-CoV-2 incidence rate,0.6952830188679244
infectious disease incidence,double-stranded DNA virus,0.6009433962264151
infectious disease incidence,incubation end temporal region,0.6741379310344828
infectious disease incidence,site of infection,0.65
infectious disease incidence,virulence factor disposition,0.7
infectious disease incidence,viral adhesion disposition,0.6722222222222223
infectious disease incidence,parasitostatic disposition,0.6722222222222223
infectious disease incidence,infectious disease incidence,0.95
infectious disease incidence,reverse zoonotic disposition,0.6464285714285714
infectious disease incidence,subclinical SARS-CoV-2 infection,0.6666666666666667
infectious disease incidence,virus translation stage,0.6264705882352941
infectious disease incidence,disease surveillance objective specification,0.6444444444444444
infectious disease incidence,virus release stage,0.6627659574468084
infectious disease incidence,infectious agent host role,0.7277777777777777
infectious disease incidence,material entity,0.5895348837209302
infectious disease incidence,asymptomatic infectious structure carrier,0.696376811594203
infectious disease incidence,source of infection site,0.6807692307692308
infectious disease incidence,virus,0.5409090909090909
infectious disease incidence,virus replication,0.65
infectious disease incidence,B cell receptor complex,0.5872549019607843
infectious disease incidence,passive immunization against infectious agent,0.6554794520547945
infectious disease incidence,systematic infection,0.6583333333333334
infectious disease incidence,infection incidence rate,0.7961538461538461
infectious disease incidence,virus host,0.581578947368421
infectious disease incidence,double-stranded RNA virus,0.6009433962264151
infectious disease incidence,virus transcription stage,0.6386792452830189
infectious disease incidence,infectious disease lifetime prevalence,0.8287878787878787
infectious disease incidence,toxin disposition,0.6722222222222223
infectious disease incidence,lower respiratory tract disease,0.6364406779661017
infectious disease incidence,infectious disease incidence proportion,0.8679104477611941
infectious disease incidence,virus generative stage,0.63
infectious disease incidence,acute infectious disease course,0.8059322033898306
infectious disease incidence,cidal agent disposition,0.6656862745098039
infectious disease incidence,infectious disorder,0.7904255319148936
infectious disease incidence,subclinical infection,0.6540816326530612
infectious disease incidence,appearance of disorder,0.63
infectious disease incidence,simple infection,0.6545454545454545
infectious disease incidence,parasiticidal disposition,0.6575471698113208
infectious disease incidence,infectious disease sporadicity,0.8293103448275861
infectious disease incidence,communicability end process boundary,0.621875
infectious disease incidence,infection incidence proportion profile,0.7227272727272727
infectious disease incidence,infectious agent colony,0.7637254901960785
infectious disease incidence,SARS-CoV-2 incidence proportion,0.6703389830508475
infectious disease incidence,transmissibility disposition,0.6464285714285714
infectious disease incidence,latency end process boundary,0.6107142857142857
infectious disease incidence,infectious disease epidemic,0.8681818181818182
infectious disease incidence,infectious agent generative stage,0.7450819672131148
infectious disease incidence,disease transmission model,0.6722222222222223
infectious disease incidence,endotoxin disposition,0.6744897959183673
infectious disease incidence,negative-sense single-stranded RNA virus,0.6558823529411765
infectious disease incidence,infectious structure host role,0.7258620689655172
infectious disease incidence,COVID-19 incidence rate,0.7049019607843137
infectious disease incidence,cytotoxin disposition,0.6744897959183673
infectious disease incidence,community-acquired infection,0.6642857142857143
infectious disease incidence,chronic infectious disease course,0.7942622950819671
infectious disease incidence,asymptomatic infectious agent carrier,0.7115384615384616
infectious disease incidence,nursing-home acquired infection,0.6703389830508475
infectious disease incidence,COVID-19 epidemic,0.6277777777777778
infectious disease incidence,secondary infection,0.6840425531914894
infectious disease incidence,infection start temporal region,0.7042372881355932
infectious disease incidence,infection incidence,0.8329787234042553
infectious disease incidence,virus disorder,0.6642857142857143
infectious disease incidence,sterilizing immunity to infectious agent,0.6558823529411765
infectious disease incidence,diseased population,0.6627659574468084
infectious disease incidence,primary infection,0.65
infectious disease incidence,process of establishing an infection,0.653125
infectious disease incidence,incubation end process boundary,0.6703389830508475
infectious disease incidence,SARS-CoV-2 disorder,0.6202127659574468
infectious disease incidence,collective pathogenic disposition,0.6631147540983606
infectious disease incidence,neurotoxin disposition,0.69
infectious disease incidence,COVID-19 incidence,0.7326086956521739
infectious disease incidence,latency end temporal region,0.6136363636363636
infectious disease incidence,innate immunity to infectious agent,0.6722222222222223
infectious disease incidence,infectious structure,0.7416666666666667
infectious disease incidence,virus adhesion susceptible cell,0.6872881355932203
infectious disease incidence,collective disposition,0.69
infectious disease incidence,infection,0.6932432432432433
infectious disease incidence,static agent disposition,0.6615384615384616
infectious disease incidence,T cell receptor complex,0.6068627450980393
infectious disease incidence,infectious structure host,0.7141509433962264
infectious disease incidence,infectious agent population,0.740909090909091
infectious disease incidence,respiratory system disease,0.6722222222222223
infectious disease incidence,leukocyte-mediated immunity to infectious agent,0.6366666666666667
infectious disease incidence,humoral immunity to infectious agent,0.66875
infectious disease incidence,infectious disease control strategy,0.7992063492063491
infectious disease incidence,infectious disease pandemic,0.8681818181818182
infectious disease incidence,infectious structure generative stage,0.7269230769230769
infectious disease incidence,immunosuppressive disposition,0.6780701754385965
infectious disease incidence,pathogenic disposition,0.65
infectious disease incidence,viral disease course,0.7
infectious disease incidence,intracellular infection,0.6656862745098039
infectious disease incidence,secondary infection role,0.6807692307692308
infectious disease incidence,metastatic infection,0.6583333333333334
infectious disease incidence,passive immunity to infectious agent,0.66875
infectious disease incidence,infectious disposition,0.81
infectious disease incidence,vaccination against infectious agent,0.684375
infectious disease incidence,acute infection,0.6593023255813953
infectious disease incidence,susceptibility to infectious agent,0.6758064516129032
infectious disease incidence,bacteriostatic disposition,0.6907407407407408
infectious disease incidence,bactericidal disposition,0.6615384615384616
infectious disease incidence,source of infection role,0.6423076923076922
infectious disease incidence,chronic infection,0.65
infectious disease incidence,invasion disposition,0.7
infectious disease incidence,disease course,0.6880952380952381
infectious disease incidence,infectious disease course,0.8462264150943396
infectious disease incidence,viricidal disposition,0.6744897959183673
infectious disease incidence,acquired immunity to infectious agent,0.6653846153846155
infectious disease incidence,complex infection,0.65
infectious disease incidence,COVID-19 disease incidence proportion,0.7576923076923078
infectious disease incidence,coronavirus disease course,0.7277777777777777
infectious disease incidence,infection incidence proportion,0.760344827586207
infectious disease incidence,symptomatic infectious agent carrier,0.715625
infectious disease incidence,respiratory droplet virus fomite,0.6166666666666667
infectious disease incidence,infectious disease prevalence,0.8535087719298246
infectious disease incidence,disposition,0.6294871794871795
infectious disease incidence,single-stranded DNA virus,0.619811320754717
infectious disease incidence,infected population,0.6840425531914894
infectious disease incidence,COVID-19 mortality rate,0.5676470588235294
infectious disease incidence,viral disease,0.6695121951219513
infectious disease incidence,primary infection role,0.65
infectious disease incidence,adhesion disposition,0.6791666666666666
infectious disease incidence,infection incidence profile,0.7772727272727272
infectious disease incidence,disease,0.65
infectious disease incidence,symptomatic infectious structure carrier,0.7
infectious disease incidence,primary infectious disposition,0.760344827586207
infectious disease incidence,infection prevalence,0.7625
infectious disease incidence,coronavirus disorder,0.6583333333333334
infectious disease incidence,infectious pathogen transmissibility,0.7
infectious disease incidence,SARS-CoV-2 incidence,0.7208333333333333
infectious disease incidence,infectious human pathogen,0.7330188679245283
infectious disease incidence,subclinical virus infection,0.6681818181818181
infectious disease incidence,establishment of localization in virus host,0.6049295774647887
infectious disease incidence,immunization against infectious agent,0.6807692307692308
infectious disease incidence,virus attachment stage,0.63
infectious disease incidence,virus synthesis stage,0.6336734693877552
infectious disease incidence,SARS-COV-2 adhesion disposition,0.6364406779661017
infectious disease incidence,invasive disposition,0.6791666666666666
infectious disease incidence,infectious agent host,0.7357142857142857
infectious disease incidence,long-term non-progressing infectious disease course,0.7158227848101265
infectious disease incidence,viral disease epidemic,0.73
infectious disease incidence,fungicidal disposition,0.67
infectious disease incidence,viral disease pandemic,0.73
infectious disease incidence,virus penetration stage,0.6460784313725491
infectious disease incidence,acute respiratory distress syndrome,0.6722222222222223
infectious disease incidence,infectious disease endemicity,0.8535087719298246
infectious disease incidence,disorder,0.5888888888888889
infectious disease incidence,herd immunity to infectious organism,0.66875
infectious disease incidence,extracellular infection,0.6460784313725491
infectious disease incidence,exotoxin disposition,0.6791666666666666
infectious disease incidence,infectious agent reservoir,0.7462962962962962
infectious disease incidence,COVID-19 pandemic,0.6277777777777778
infectious disease incidence,infection start process boundary,0.7
infectious disease incidence,action specification,0.6791666666666666
infectious disease incidence,processed material,0.6021739130434782
infectious disease incidence,infectious disease control objective specification,0.7576923076923078
infectious disease incidence,COVID-19 lifetime prevalence,0.6642857142857143
infectious disease incidence,opportunistic infectious disposition,0.73125
infectious disease incidence,process of establishing viral infection,0.658955223880597
infectious disease incidence,enterotoxin disposition,0.6852941176470588
infectious disease incidence,COVID-19 disease course,0.7049019607843137
infectious disease incidence,infectious disease incidence rate,0.909016393442623
infectious disease incidence,COVID-19 prevalence,0.6414893617021277
infectious disease incidence,active immunization against infectious agent,0.6583333333333334
infectious disease incidence,SARS-COV-2 prevalence,0.6336734693877552
infectious disease incidence,disordered virus,0.609090909090909
infectious disease incidence,collective resistance disposition,0.6631147540983606
infectious disease incidence,fungistatic disposition,0.6656862745098039
infectious disease incidence,virus uncoating stage,0.6336734693877552
infectious disease incidence,local infection,0.6593023255813953
infectious disease incidence,infectious agent,0.7681818181818181
infectious disease incidence,establishment of a clinically abnormal colony,0.6143835616438357
infectious disease incidence,coronavirus disease,0.7053191489361703
infectious disease incidence,positive-sense single-stranded RNA virus,0.6411764705882353
infectious disease incidence,hospital-acquired infection,0.65
infectious disease incidence,drug susceptibility of infectious agent,0.658955223880597
infectious disease incidence,material processing,0.598936170212766
biological vehicle,infectious disease mortality rate,0.5872549019607843
biological vehicle,infection incidence rate profile,0.63
biological vehicle,biological regulation,0.7833333333333333
biological vehicle,primary pathogen,0.5970588235294118
biological vehicle,vector control strategy,0.5719512195121951
biological vehicle,SARS-CoV-2 incidence rate,0.5895348837209302
biological vehicle,virulence factor disposition,0.5804347826086956
biological vehicle,infectious agent host role,0.609090909090909
biological vehicle,asymptomatic infectious structure carrier,0.5855932203389831
biological vehicle,B cell receptor complex,0.6451219512195122
biological vehicle,passive immunization against infectious agent,0.5769841269841269
biological vehicle,infection incidence rate,0.6166666666666667
biological vehicle,mechanical vector,0.6785714285714286
biological vehicle,cidal agent disposition,0.5963414634146341
biological vehicle,biological vehicle,0.95
biological vehicle,infectious agent colony,0.5963414634146341
biological vehicle,invasion factor,0.5712121212121213
biological vehicle,infectious agent generative stage,0.5872549019607843
biological vehicle,vector surveillance,0.6391891891891892
biological vehicle,cidal agent,0.6224137931034482
biological vehicle,pathogen vehicle,0.7441176470588234
biological vehicle,COVID-19 incidence rate,0.5963414634146341
biological vehicle,pathogen vector,0.6318181818181818
biological vehicle,pathogen vehicle role,0.7064102564102563
biological vehicle,asymptomatic infectious agent carrier,0.5954545454545455
biological vehicle,mechanical vector role,0.7
biological vehicle,sterilizing immunity to infectious agent,0.5879310344827586
biological vehicle,primary infection,0.5928571428571429
biological vehicle,virulence factor,0.5970588235294118
biological vehicle,innate immunity to infectious agent,0.5632075471698114
biological vehicle,virus adhesion susceptible cell,0.5928571428571429
biological vehicle,anatomical space,0.6852941176470588
biological vehicle,static agent disposition,0.569047619047619
biological vehicle,T cell receptor complex,0.6207317073170732
biological vehicle,asymptomatic carrier role,0.6127906976744186
biological vehicle,infectious agent population,0.5611111111111111
biological vehicle,biological vector,0.85
biological vehicle,leukocyte-mediated immunity to infectious agent,0.573076923076923
biological vehicle,humoral immunity to infectious agent,0.5796296296296296
biological vehicle,innate immune response,0.575
biological vehicle,cell,0.5863636363636363
biological vehicle,passive immunity to infectious agent,0.5611111111111111
biological vehicle,vaccination against infectious agent,0.5981481481481481
biological vehicle,susceptibility to infectious agent,0.6038461538461539
biological vehicle,acquired immunity to infectious agent,0.5590909090909091
biological vehicle,asymptomatic carrier,0.6078947368421053
biological vehicle,biological vehicle role,0.8890243902439025
biological vehicle,symptomatic infectious agent carrier,0.5981481481481481
biological vehicle,pathogen vector role,0.6605263157894737
biological vehicle,anatomical entity,0.6785714285714286
biological vehicle,COVID-19 mortality rate,0.5963414634146341
biological vehicle,primary infection role,0.625
biological vehicle,intervention,0.5833333333333334
biological vehicle,primary immunodeficiency,0.6166666666666667
biological vehicle,biological role,0.8439393939393939
biological vehicle,biological process,0.8111111111111111
biological vehicle,symptomatic infectious structure carrier,0.5879310344827586
biological vehicle,biological vector role,0.85
biological vehicle,primary infectious disposition,0.5541666666666667
biological vehicle,symptomatic carrier role,0.6166666666666667
biological vehicle,SARS-COV-2 adhesion susceptible cell,0.5796296296296296
biological vehicle,immunization against infectious agent,0.5954545454545455
biological vehicle,infectious agent host,0.5782051282051281
biological vehicle,symptomatic carrier,0.6121621621621621
biological vehicle,infectious agent reservoir,0.5863636363636363
biological vehicle,action specification,0.6078947368421053
biological vehicle,negative regulation of biological process,0.6703389830508475
biological vehicle,infectious disease incidence rate,0.6068627450980393
biological vehicle,active immunization against infectious agent,0.5790322580645162
biological vehicle,infectious agent,0.5676470588235294
biological vehicle,establishment of a clinically abnormal colony,0.6246031746031746
biological vehicle,adhesion factor,0.5712121212121213
biological vehicle,drug susceptibility of infectious agent,0.5903508771929825
biological vehicle,static agent,0.5833333333333334
biological vehicle,cell space,0.6285714285714286
neurotoxin disposition,virostatic disposition,0.8136363636363637
neurotoxin disposition,information content entity,0.6375
neurotoxin disposition,zoonotic disposition,0.830952380952381
neurotoxin disposition,infectious disease mortality rate,0.65
neurotoxin disposition,infection incidence rate profile,0.6351851851851852
neurotoxin disposition,infectious structure aggregate,0.5846153846153846
neurotoxin disposition,communicability end temporal region,0.6078947368421053
neurotoxin disposition,geographical entity,0.5963414634146341
neurotoxin disposition,biological regulation,0.636046511627907
neurotoxin disposition,surveillance process,0.6404761904761905
neurotoxin disposition,infection end temporal region,0.6852941176470588
neurotoxin disposition,vector control strategy,0.6277777777777778
neurotoxin disposition,SARS-CoV-2 incidence rate,0.5776595744680851
neurotoxin disposition,incubation end temporal region,0.6807692307692308
neurotoxin disposition,resistant entity,0.6078947368421053
neurotoxin disposition,virulence factor disposition,0.77
neurotoxin disposition,viral adhesion disposition,0.7625
neurotoxin disposition,parasitostatic disposition,0.7833333333333333
neurotoxin disposition,negative regulation of production,0.6863636363636364
neurotoxin disposition,reverse zoonotic disposition,0.79
neurotoxin disposition,establishment of localization in host,0.6364406779661017
neurotoxin disposition,disease surveillance objective specification,0.6621212121212122
neurotoxin disposition,case isolation control strategy,0.619811320754717
neurotoxin disposition,infectious agent host role,0.6583333333333334
neurotoxin disposition,macromolecular complex,0.5636363636363636
neurotoxin disposition,material entity,0.6121621621621621
neurotoxin disposition,asymptomatic infectious structure carrier,0.5928571428571429
neurotoxin disposition,architectual structure,0.5636363636363636
neurotoxin disposition,quarantine control strategy,0.6336734693877552
neurotoxin disposition,B cell receptor complex,0.5833333333333334
neurotoxin disposition,infection incidence rate,0.6456521739130434
neurotoxin disposition,colonized host,0.6444444444444444
neurotoxin disposition,virus host,0.60625
neurotoxin disposition,entity,0.5928571428571429
neurotoxin disposition,toxin disposition,0.8858974358974359
neurotoxin disposition,cidal agent disposition,0.7611111111111112
neurotoxin disposition,parasiticidal disposition,0.7691489361702127
neurotoxin disposition,communicability end process boundary,0.6051724137931035
neurotoxin disposition,directive information content entity,0.6224137931034482
neurotoxin disposition,acellular structure aggregate,0.5676470588235294
neurotoxin disposition,transmissibility disposition,0.73
neurotoxin disposition,latency end process boundary,0.63
neurotoxin disposition,colonization of host,0.6404761904761905
neurotoxin disposition,neurotoxin,0.7625
neurotoxin disposition,realizable entity,0.5782051282051281
neurotoxin disposition,endotoxin disposition,0.891860465116279
neurotoxin disposition,vector surveillance,0.6207317073170732
neurotoxin disposition,negative regulation of establishment of localization,0.6527027027027027
neurotoxin disposition,infectious structure host role,0.6423076923076922
neurotoxin disposition,COVID-19 incidence rate,0.5833333333333334
neurotoxin disposition,cytotoxin disposition,0.8686046511627907
neurotoxin disposition,negative regulation of developmental process,0.6166666666666667
neurotoxin disposition,host,0.5653846153846154
neurotoxin disposition,descriptive information content entity,0.6333333333333333
neurotoxin disposition,negative regulation of replication,0.6821428571428573
neurotoxin disposition,establishment of localization in human host,0.6192307692307693
neurotoxin disposition,acellular structure,0.5963414634146341
neurotoxin disposition,incubation end process boundary,0.6764150943396227
neurotoxin disposition,collective pathogenic disposition,0.740909090909091
neurotoxin disposition,neurotoxin disposition,0.95
neurotoxin disposition,dead-end host role,0.625
neurotoxin disposition,molecular entity,0.6078947368421053
neurotoxin disposition,plan specification,0.675
neurotoxin disposition,definitive host role,0.6404761904761905
neurotoxin disposition,latency end temporal region,0.6336734693877552
neurotoxin disposition,infectious structure,0.6166666666666667
neurotoxin disposition,collective disposition,0.7909090909090909
neurotoxin disposition,static agent disposition,0.7760869565217391
neurotoxin disposition,T cell receptor complex,0.5833333333333334
neurotoxin disposition,infectious structure host,0.6414893617021277
neurotoxin disposition,respiratory system disease,0.6375
neurotoxin disposition,entry into host,0.6662162162162162
neurotoxin disposition,adhesion of symbiont to host,0.63
neurotoxin disposition,infectious disease control strategy,0.6429824561403508
neurotoxin disposition,infectious structure generative stage,0.6025423728813559
neurotoxin disposition,immunosuppressive disposition,0.7637254901960785
neurotoxin disposition,pathogenic disposition,0.7909090909090909
neurotoxin disposition,toxin,0.6351851851851852
neurotoxin disposition,entry into host through host barriers,0.6194915254237288
neurotoxin disposition,infectious disposition,0.8136363636363637
neurotoxin disposition,bacteriostatic disposition,0.8041666666666667
neurotoxin disposition,bactericidal disposition,0.7760869565217391
neurotoxin disposition,pathogen host,0.65
neurotoxin disposition,invasion disposition,0.8071428571428573
neurotoxin disposition,viricidal disposition,0.7755813953488372
neurotoxin disposition,complex infection,0.6551282051282051
neurotoxin disposition,intermediate host,0.6551282051282051
neurotoxin disposition,anatomical entity,0.6294871794871795
neurotoxin disposition,disposition,0.7833333333333333
neurotoxin disposition,COVID-19 mortality rate,0.5833333333333334
neurotoxin disposition,negative regulation of life-sustaining process,0.6411764705882353
neurotoxin disposition,place closure control strategy,0.6230769230769231
neurotoxin disposition,geopolitical entity,0.6451219512195122
neurotoxin disposition,adhesion disposition,0.8071428571428573
neurotoxin disposition,symptomatic infectious structure carrier,0.5951612903225807
neurotoxin disposition,primary infectious disposition,0.7576923076923078
neurotoxin disposition,pathogen host role,0.65
neurotoxin disposition,designative information content entity,0.6166666666666667
neurotoxin disposition,intermediate host role,0.6545454545454545
neurotoxin disposition,dead-end host,0.6214285714285714
neurotoxin disposition,pathogen surveillance,0.6127906976744186
neurotoxin disposition,host role,0.5790322580645162
neurotoxin disposition,establishment of localization in virus host,0.6346153846153847
neurotoxin disposition,negative regulation of immune response,0.65
neurotoxin disposition,immaterial entity,0.6038461538461539
neurotoxin disposition,SARS-COV-2 adhesion disposition,0.7518867924528303
neurotoxin disposition,invasive disposition,0.7833333333333333
neurotoxin disposition,infectious agent host,0.6593023255813953
neurotoxin disposition,fungicidal disposition,0.7681818181818181
neurotoxin disposition,division of geopolitical entity,0.619811320754717
neurotoxin disposition,negative regulation of viral process,0.6396551724137931
neurotoxin disposition,exotoxin disposition,0.9023809523809524
neurotoxin disposition,immunoglobulin complex,0.609090909090909
neurotoxin disposition,infectious disease control objective specification,0.6583333333333334
neurotoxin disposition,symbiont host role,0.625
neurotoxin disposition,opportunistic infectious disposition,0.7258620689655172
neurotoxin disposition,negative regulation of biological process,0.6246031746031746
neurotoxin disposition,enterotoxin disposition,0.9166666666666665
neurotoxin disposition,infectious disease incidence rate,0.6681818181818181
neurotoxin disposition,collective resistance disposition,0.740909090909091
neurotoxin disposition,fungistatic disposition,0.7833333333333333
neurotoxin disposition,establishment of a clinically abnormal colony,0.5992537313432835
neurotoxin disposition,definitive host,0.6391891891891892
geospatial location,virostatic disposition,0.7182926829268292
geospatial location,zoonotic disposition,0.6807692307692308
geospatial location,communicability end temporal region,0.6351851851851852
geospatial location,infection end temporal region,0.6375
geospatial location,geospatial location,0.95
geospatial location,incubation end temporal region,0.6336734693877552
geospatial location,site of infection,0.7
geospatial location,two-dimensional spatial region,0.7153061224489795
geospatial location,one-dimensional temporal region,0.67
geospatial location,virulence factor disposition,0.6414893617021277
geospatial location,viral adhesion disposition,0.65
geospatial location,parasitostatic disposition,0.6944444444444444
geospatial location,temporal region,0.6852941176470588
geospatial location,reverse zoonotic disposition,0.6627659574468084
geospatial location,source of infection site,0.636046511627907
geospatial location,B cell receptor complex,0.5928571428571429
geospatial location,toxin disposition,0.6722222222222223
geospatial location,pathogen birth temporal region,0.6540816326530612
geospatial location,lower respiratory tract disease,0.63
geospatial location,acute infectious disease course,0.61
geospatial location,cidal agent disposition,0.6642857142857143
geospatial location,parasiticidal disposition,0.7227272727272727
geospatial location,spatiotemporal region,0.725
geospatial location,transmissibility disposition,0.6414893617021277
geospatial location,endotoxin disposition,0.7
geospatial location,cytotoxin disposition,0.675
geospatial location,zero-dimensional spatial region,0.71
geospatial location,zero-dimensional temporal region,0.6852941176470588
geospatial location,chronic infectious disease course,0.6038461538461539
geospatial location,infection start temporal region,0.67
geospatial location,collective pathogenic disposition,0.6615384615384616
geospatial location,neurotoxin disposition,0.6939024390243902
geospatial location,geographical region,0.7394736842105263
geospatial location,latency end temporal region,0.6239130434782608
geospatial location,collective disposition,0.6695121951219513
geospatial location,static agent disposition,0.7058139534883722
geospatial location,T cell receptor complex,0.5928571428571429
geospatial location,immunosuppressive disposition,0.6583333333333334
geospatial location,pathogenic disposition,0.6939024390243902
geospatial location,viral disease course,0.6038461538461539
geospatial location,three-dimensional spatial region,0.7049019607843137
geospatial location,infectious disposition,0.6695121951219513
geospatial location,bacteriostatic disposition,0.7166666666666667
geospatial location,epitope site,0.6112903225806451
geospatial location,bactericidal disposition,0.7058139534883722
geospatial location,invasion disposition,0.6551282051282051
geospatial location,disease course,0.6015151515151516
geospatial location,infectious disease course,0.6318181818181818
geospatial location,viricidal disposition,0.675
geospatial location,coronavirus disease course,0.6055555555555556
geospatial location,pathogen portal of exit site,0.6627659574468084
geospatial location,disposition,0.6833333333333332
geospatial location,place closure control strategy,0.6132653061224489
geospatial location,adhesion disposition,0.6807692307692308
geospatial location,pathogen portal of entry site,0.6583333333333334
geospatial location,site,0.5804347826086956
geospatial location,primary infectious disposition,0.6540816326530612
geospatial location,SARS-COV-2 adhesion disposition,0.63
geospatial location,invasive disposition,0.6551282051282051
geospatial location,long-term non-progressing infectious disease course,0.5928571428571429
geospatial location,communicability start temporal region,0.6285714285714286
geospatial location,fungicidal disposition,0.6939024390243902
geospatial location,geospatial region,0.8388888888888889
geospatial location,exotoxin disposition,0.7064102564102563
geospatial location,opportunistic infectious disposition,0.6318181818181818
geospatial location,enterotoxin disposition,0.6880952380952381
geospatial location,COVID-19 disease course,0.5928571428571429
geospatial location,collective resistance disposition,0.6423076923076922
geospatial location,fungistatic disposition,0.7119047619047619
geospatial location,local infection,0.7147058823529412
geospatial location,establishment of a clinically abnormal colony,0.6375
geospatial location,one-dimensional spatial region,0.7153061224489795
geospatial location,spatial region,0.7833333333333333
geospatial location,pathogen death temporal region,0.6540816326530612
susceptible population,angiotensin-converting enzyme 2,0.5820754716981132
susceptible population,immune response,0.6121621621621621
susceptible population,infectious disease mortality rate,0.6136363636363636
susceptible population,infection incidence rate profile,0.5981481481481481
susceptible population,communicability end temporal region,0.6605263157894737
susceptible population,infection end temporal region,0.6656862745098039
susceptible population,SARS-CoV-2 incidence rate,0.6202127659574468
susceptible population,incubation end temporal region,0.6615384615384616
susceptible population,resistant entity,0.6078947368421053
susceptible population,normal resident microbiota population,0.7211864406779661
susceptible population,reservoir of pathogen role,0.6583333333333334
susceptible population,infectious agent host role,0.6166666666666667
susceptible population,B cell receptor complex,0.6277777777777778
susceptible population,infection incidence rate,0.6021739130434782
susceptible population,pathogen portal of entry role,0.6264705882352941
susceptible population,lower respiratory tract disease,0.6009433962264151
susceptible population,role,0.5269230769230769
susceptible population,mutualist role,0.6166666666666667
susceptible population,communicability end process boundary,0.6224137931034482
susceptible population,latency end process boundary,0.61
susceptible population,infectious structure host role,0.6230769230769231
susceptible population,susceptible population,0.95
susceptible population,COVID-19 incidence rate,0.5833333333333334
susceptible population,pathogen vehicle role,0.636046511627907
susceptible population,mechanical vector role,0.609090909090909
susceptible population,establishment of localization in human host,0.65
susceptible population,diseased population,0.7914634146341464
susceptible population,incubation end process boundary,0.619811320754717
susceptible population,dead-end host role,0.6
susceptible population,definitive host role,0.6404761904761905
susceptible population,latency end temporal region,0.6540816326530612
susceptible population,virus adhesion susceptible cell,0.6952830188679244
susceptible population,T cell receptor complex,0.6277777777777778
susceptible population,asymptomatic carrier role,0.6202127659574468
susceptible population,infectious agent population,0.7561224489795919
susceptible population,organism population,0.7426829268292683
susceptible population,innate immune response,0.609090909090909
susceptible population,secondary infection role,0.6239130434782608
susceptible population,country,0.5879310344827586
susceptible population,source of infection role,0.6673913043478261
susceptible population,biological vehicle role,0.6277777777777778
susceptible population,symbiont role,0.5928571428571429
susceptible population,susceptible organism,0.8071428571428573
susceptible population,parasite role,0.6214285714285714
susceptible population,pathogen vector role,0.5928571428571429
susceptible population,infected population,0.7914634146341464
susceptible population,COVID-19 mortality rate,0.6055555555555556
susceptible population,primary infection role,0.609090909090909
susceptible population,biological role,0.5851351351351352
susceptible population,biological vector role,0.5863636363636363
susceptible population,pathogen host role,0.625
susceptible population,symptomatic carrier role,0.6239130434782608
susceptible population,humoral immune response,0.6055555555555556
susceptible population,SARS-COV-2 adhesion susceptible cell,0.6741379310344828
susceptible population,intermediate host role,0.609090909090909
susceptible population,host role,0.6112903225806451
susceptible population,infectious human pathogen,0.6414893617021277
susceptible population,colonization of human,0.636046511627907
susceptible population,negative regulation of immune response,0.65
susceptible population,pathogen portal of exit role,0.63
susceptible population,commensal role,0.6166666666666667
susceptible population,epitope role,0.6558823529411765
susceptible population,herd immunity to infectious organism,0.5879310344827586
susceptible population,pathogen transporter role,0.6202127659574468
susceptible population,antigen role,0.6264705882352941
susceptible population,symbiont host role,0.6
susceptible population,immune population,0.7833333333333333
susceptible population,fomite role,0.6015151515151516
susceptible population,infectious disease incidence rate,0.5954545454545455
susceptible population,adaptive immune response,0.6239130434782608
susceptible population,reagent role,0.5970588235294118
susceptible population,establishment of a clinically abnormal colony,0.6291044776119403
role,reservoir of pathogen role,0.5833333333333334
role,infectious agent host role,0.5833333333333334
role,B cell receptor complex,0.5981481481481481
role,pathogen portal of entry role,0.5712121212121213
role,lower respiratory tract disease,0.5357142857142857
role,acute infectious disease course,0.5071428571428571
role,role,0.95
role,appearance of disorder,0.5653846153846154
role,mutualist role,0.6722222222222223
role,infectious structure host role,0.5676470588235294
role,pathogen vehicle role,0.61
role,chronic infectious disease course,0.5310810810810811
role,mechanical vector role,0.6038461538461539
role,dead-end host role,0.6318181818181818
role,definitive host role,0.6166666666666667
role,T cell receptor complex,0.5981481481481481
role,asymptomatic carrier role,0.5879310344827586
role,viral disease course,0.575
role,secondary infection role,0.5928571428571429
role,source of infection role,0.5928571428571429
role,disease course,0.5611111111111111
role,infectious disease course,0.5189655172413793
role,coronavirus disease course,0.55
role,biological vehicle role,0.5981481481481481
role,symbiont role,0.6852941176470588
role,parasite role,0.6852941176470588
role,pathogen vector role,0.6166666666666667
role,primary infection role,0.6038461538461539
role,biological role,0.6605263157894737
role,biological vector role,0.6038461538461539
role,pathogen host role,0.6318181818181818
role,symptomatic carrier role,0.5928571428571429
role,intermediate host role,0.6038461538461539
role,host role,0.7576923076923078
role,pathogen portal of exit role,0.575
role,long-term non-progressing infectious disease course,0.5045454545454545
role,commensal role,0.6722222222222223
role,epitope role,0.7
role,function,0.5333333333333333
role,pathogen transporter role,0.5879310344827586
role,antigen role,0.7
role,action specification,0.5333333333333333
role,symbiont host role,0.6318181818181818
role,fomite role,0.7166666666666667
role,COVID-19 disease course,0.524074074074074
role,reagent role,0.7
role,viral load,0.5928571428571429
role,establishment of a clinically abnormal colony,0.5112244897959184
mutualist role,reservoir of pathogen role,0.625
mutualist role,infectious agent host role,0.7
mutualist role,B cell receptor complex,0.6121621621621621
mutualist role,pathogen portal of entry role,0.6593023255813953
mutualist role,lower respiratory tract disease,0.5833333333333334
mutualist role,mutualist,0.8413043478260869
mutualist role,acute infectious disease course,0.6277777777777778
mutualist role,role,0.6722222222222223
mutualist role,appearance of disorder,0.5888888888888889
mutualist role,mutualist role,0.95
mutualist role,infectious structure host role,0.6772727272727272
mutualist role,pathogen vehicle role,0.65
mutualist role,chronic infectious disease course,0.598936170212766
mutualist role,mechanical vector role,0.7
mutualist role,dead-end host role,0.7
mutualist role,definitive host role,0.7147058823529412
mutualist role,T cell receptor complex,0.6391891891891892
mutualist role,asymptomatic carrier role,0.6807692307692308
mutualist role,viral disease course,0.6558823529411765
mutualist role,secondary infection role,0.6605263157894737
mutualist role,source of infection role,0.6605263157894737
mutualist role,disease course,0.6285714285714286
mutualist role,infectious disease course,0.6294871794871795
mutualist role,coronavirus disease course,0.6
mutualist role,biological vehicle role,0.6662162162162162
mutualist role,symbiont role,0.7462962962962962
mutualist role,parasite role,0.7462962962962962
mutualist role,pathogen vector role,0.6558823529411765
mutualist role,primary infection role,0.7
mutualist role,biological role,0.6913793103448276
mutualist role,biological vector role,0.6722222222222223
mutualist role,pathogen host role,0.7
mutualist role,symptomatic carrier role,0.6868421052631578
mutualist role,intermediate host role,0.7
mutualist role,host role,0.7543478260869566
mutualist role,pathogen portal of exit role,0.6880952380952381
mutualist role,long-term non-progressing infectious disease course,0.573076923076923
mutualist role,commensal role,0.7357142857142857
mutualist role,epitope role,0.7192307692307692
mutualist role,function,0.6318181818181818
mutualist role,pathogen transporter role,0.6807692307692308
mutualist role,antigen role,0.7192307692307692
mutualist role,action specification,0.5970588235294118
mutualist role,symbiont host role,0.73125
mutualist role,fomite role,0.77
mutualist role,COVID-19 disease course,0.5851351351351352
mutualist role,reagent role,0.7192307692307692
mutualist role,viral load,0.6166666666666667
mutualist role,establishment of a clinically abnormal colony,0.6194915254237288
community-acquired infection,virus aggregate,0.5662790697674418
community-acquired infection,source of infection,0.747872340425532
community-acquired infection,virostatic disposition,0.65
community-acquired infection,zoonotic disposition,0.6583333333333334
community-acquired infection,infectious disease mortality rate,0.5975409836065574
community-acquired infection,infection incidence rate profile,0.6333333333333333
community-acquired infection,communicability end temporal region,0.7039682539682539
community-acquired infection,subclinical coronavirus infection,0.728688524590164
community-acquired infection,infection end temporal region,0.6254385964912281
community-acquired infection,infectious disease,0.6239130434782608
community-acquired infection,double-stranded DNA virus,0.619811320754717
community-acquired infection,incubation end temporal region,0.6396551724137931
community-acquired infection,site of infection,0.7388888888888888
community-acquired infection,virulence factor disposition,0.6464285714285714
community-acquired infection,viral adhesion disposition,0.6166666666666667
community-acquired infection,parasitostatic disposition,0.6351851851851852
community-acquired infection,infectious disease incidence,0.6642857142857143
community-acquired infection,reverse zoonotic disposition,0.6285714285714286
community-acquired infection,subclinical SARS-CoV-2 infection,0.7
community-acquired infection,virus translation stage,0.6068627450980393
community-acquired infection,disease surveillance objective specification,0.6444444444444444
community-acquired infection,virus release stage,0.5776595744680851
community-acquired infection,source of infection site,0.7192307692307692
community-acquired infection,virus,0.5106060606060606
community-acquired infection,virus replication,0.6722222222222223
community-acquired infection,B cell receptor complex,0.5872549019607843
community-acquired infection,systematic infection,0.7208333333333333
community-acquired infection,infection incidence rate,0.6423076923076922
community-acquired infection,virus host,0.5552631578947369
community-acquired infection,double-stranded RNA virus,0.619811320754717
community-acquired infection,virus transcription stage,0.6386792452830189
community-acquired infection,infectious disease lifetime prevalence,0.6469696969696969
community-acquired infection,toxin disposition,0.6277777777777778
community-acquired infection,lower respiratory tract disease,0.6025423728813559
community-acquired infection,infectious disease incidence proportion,0.6738805970149254
community-acquired infection,virus generative stage,0.59
community-acquired infection,acute infectious disease course,0.6703389830508475
community-acquired infection,cidal agent disposition,0.6460784313725491
community-acquired infection,infectious disorder,0.6202127659574468
community-acquired infection,subclinical infection,0.7357142857142857
community-acquired infection,appearance of disorder,0.59
community-acquired infection,simple infection,0.7227272727272727
community-acquired infection,parasiticidal disposition,0.6575471698113208
community-acquired infection,infectious disease sporadicity,0.6224137931034482
community-acquired infection,communicability end process boundary,0.684375
community-acquired infection,infection incidence proportion profile,0.6469696969696969
community-acquired infection,transmissibility disposition,0.6285714285714286
community-acquired infection,latency end process boundary,0.5928571428571429
community-acquired infection,infectious disease epidemic,0.6318181818181818
community-acquired infection,disease transmission model,0.5981481481481481
community-acquired infection,endotoxin disposition,0.6336734693877552
community-acquired infection,negative-sense single-stranded RNA virus,0.5970588235294118
community-acquired infection,cytotoxin disposition,0.6540816326530612
community-acquired infection,community-acquired infection,0.95
community-acquired infection,chronic infectious disease course,0.6795081967213115
community-acquired infection,nursing-home acquired infection,0.8059322033898306
community-acquired infection,COVID-19 epidemic,0.6277777777777778
community-acquired infection,secondary infection,0.7691489361702127
community-acquired infection,infection start temporal region,0.6533898305084747
community-acquired infection,infection incidence,0.6414893617021277
community-acquired infection,virus disorder,0.5928571428571429
community-acquired infection,primary infection,0.7388888888888888
community-acquired infection,process of establishing an infection,0.684375
community-acquired infection,incubation end process boundary,0.6194915254237288
community-acquired infection,SARS-CoV-2 disorder,0.598936170212766
community-acquired infection,collective pathogenic disposition,0.6467213114754098
community-acquired infection,neurotoxin disposition,0.63
community-acquired infection,latency end temporal region,0.6136363636363636
community-acquired infection,virus adhesion susceptible cell,0.5855932203389831
community-acquired infection,collective disposition,0.67
community-acquired infection,infection,0.6932432432432433
community-acquired infection,static agent disposition,0.6423076923076922
community-acquired infection,T cell receptor complex,0.6068627450980393
community-acquired infection,respiratory system disease,0.5796296296296296
community-acquired infection,communicability interval,0.7
community-acquired infection,infectious disease control strategy,0.6087301587301588
community-acquired infection,infectious disease pandemic,0.6318181818181818
community-acquired infection,immunosuppressive disposition,0.6780701754385965
community-acquired infection,pathogenic disposition,0.65
community-acquired infection,viral disease course,0.5958333333333333
community-acquired infection,intracellular infection,0.7637254901960785
community-acquired infection,secondary infection role,0.7384615384615384
community-acquired infection,metastatic infection,0.7416666666666667
community-acquired infection,infectious disposition,0.63
community-acquired infection,acute infection,0.7755813953488372
community-acquired infection,bacteriostatic disposition,0.6537037037037037
community-acquired infection,bactericidal disposition,0.6615384615384616
community-acquired infection,source of infection role,0.7192307692307692
community-acquired infection,acquired immunodeficiency,0.7330188679245283
community-acquired infection,chronic infection,0.7833333333333333
community-acquired infection,invasion disposition,0.6375
community-acquired infection,disease course,0.5928571428571429
community-acquired infection,infectious disease course,0.619811320754717
community-acquired infection,viricidal disposition,0.6540816326530612
community-acquired infection,acquired immunity to infectious agent,0.7269230769230769
community-acquired infection,complex infection,0.7611111111111112
community-acquired infection,COVID-19 disease incidence proportion,0.6807692307692308
community-acquired infection,coronavirus disease course,0.6537037037037037
community-acquired infection,infection incidence proportion,0.6741379310344828
community-acquired infection,respiratory droplet virus fomite,0.6
community-acquired infection,infectious disease prevalence,0.6078947368421053
community-acquired infection,disposition,0.6038461538461539
community-acquired infection,single-stranded DNA virus,0.6009433962264151
community-acquired infection,viral disease,0.5719512195121951
community-acquired infection,primary infection role,0.71
community-acquired infection,adhesion disposition,0.6166666666666667
community-acquired infection,infection incidence profile,0.6318181818181818
community-acquired infection,contagiousness,0.6404761904761905
community-acquired infection,disease,0.5357142857142857
community-acquired infection,primary infectious disposition,0.6741379310344828
community-acquired infection,infection prevalence,0.6375
community-acquired infection,coronavirus disorder,0.6375
community-acquired infection,subclinical virus infection,0.740909090909091
community-acquired infection,establishment of localization in virus host,0.6049295774647887
community-acquired infection,virus attachment stage,0.59
community-acquired infection,virus synthesis stage,0.5724489795918367
community-acquired infection,SARS-COV-2 adhesion disposition,0.6364406779661017
community-acquired infection,invasive disposition,0.6583333333333334
community-acquired infection,long-term non-progressing infectious disease course,0.639873417721519
community-acquired infection,viral disease epidemic,0.61
community-acquired infection,communicability start temporal region,0.7115384615384616
community-acquired infection,fungicidal disposition,0.69
community-acquired infection,viral disease pandemic,0.61
community-acquired infection,virus penetration stage,0.6264705882352941
community-acquired infection,acute respiratory distress syndrome,0.6246031746031746
community-acquired infection,infectious disease endemicity,0.6429824561403508
community-acquired infection,disorder,0.5611111111111111
community-acquired infection,communicability,0.7058139534883722
community-acquired infection,extracellular infection,0.7441176470588234
community-acquired infection,exotoxin disposition,0.6375
community-acquired infection,infection start process boundary,0.6166666666666667
community-acquired infection,action specification,0.6791666666666666
community-acquired infection,infectious disease control objective specification,0.6551282051282051
community-acquired infection,opportunistic infectious disposition,0.7
community-acquired infection,process of establishing viral infection,0.6888059701492537
community-acquired infection,enterotoxin disposition,0.6264705882352941
community-acquired infection,COVID-19 disease course,0.6264705882352941
community-acquired infection,infectious disease incidence rate,0.6467213114754098
community-acquired infection,communicability start process boundary,0.6772727272727272
community-acquired infection,disordered virus,0.5863636363636363
community-acquired infection,collective resistance disposition,0.6631147540983606
community-acquired infection,fungistatic disposition,0.6852941176470588
community-acquired infection,virus uncoating stage,0.6132653061224489
community-acquired infection,local infection,0.7290697674418604
community-acquired infection,establishment of a clinically abnormal colony,0.6006849315068493
community-acquired infection,coronavirus disease,0.6414893617021277
community-acquired infection,positive-sense single-stranded RNA virus,0.6117647058823529
community-acquired infection,hospital-acquired infection,0.85
virostatic,virostatic disposition,0.7625
virostatic,virostatic,0.95
virostatic,static agent disposition,0.6264705882352941
virostatic,T cell receptor complex,0.5409090909090909
virostatic,establishment of a clinically abnormal colony,0.5590909090909091
virostatic,static agent,0.7227272727272727
molecular entity,extended organism,0.5712121212121213
molecular entity,information content entity,0.6880952380952381
molecular entity,infectious disease mortality rate,0.6336734693877552
molecular entity,infection incidence rate profile,0.5958333333333333
molecular entity,infectious structure aggregate,0.6021739130434782
molecular entity,communicability end temporal region,0.6068627450980393
molecular entity,geographical entity,0.7357142857142857
molecular entity,pathogen portal of entry,0.65
molecular entity,infection end temporal region,0.6055555555555556
molecular entity,drug-based immunosuppressed organism,0.5846153846153846
molecular entity,SARS-CoV-2 incidence rate,0.5963414634146341
molecular entity,incubation end temporal region,0.6239130434782608
molecular entity,resistant entity,0.73125
molecular entity,immunocompetent organism,0.625
molecular entity,virulence factor disposition,0.6318181818181818
molecular entity,case isolation control strategy,0.6202127659574468
molecular entity,material entity,0.7725806451612902
molecular entity,asymptomatic infectious structure carrier,0.5903508771929825
molecular entity,architectual structure,0.6342105263157894
molecular entity,B cell receptor complex,0.6038461538461539
molecular entity,infection incidence rate,0.6
molecular entity,entity,0.7227272727272727
molecular entity,pathogen portal of entry role,0.6277777777777778
molecular entity,communicability end process boundary,0.6038461538461539
molecular entity,directive information content entity,0.6423076923076922
molecular entity,acellular structure aggregate,0.6277777777777778
molecular entity,invasion factor,0.5467741935483871
molecular entity,latency end process boundary,0.609090909090909
molecular entity,realizable entity,0.7530303030303032
molecular entity,pathologically immunosuppressed organism,0.5928571428571429
molecular entity,infectious structure host role,0.5804347826086956
molecular entity,COVID-19 incidence rate,0.5782051282051281
molecular entity,descriptive information content entity,0.6351851851851852
molecular entity,establishment of localization in human host,0.6025423728813559
molecular entity,acellular structure,0.6785714285714286
molecular entity,virulence factor,0.60625
molecular entity,incubation end process boundary,0.598936170212766
molecular entity,molecular entity,0.95
molecular entity,immunosuppressed organism,0.6207317073170732
molecular entity,latency end temporal region,0.636046511627907
molecular entity,infectious structure,0.6166666666666667
molecular entity,T cell receptor complex,0.6038461538461539
molecular entity,infectious structure host,0.5963414634146341
molecular entity,respiratory system disease,0.5928571428571429
molecular entity,entry into host,0.6435483870967742
molecular entity,organism population,0.65
molecular entity,infectious structure generative stage,0.6386792452830189
molecular entity,entry into host through host barriers,0.5632075471698114
molecular entity,susceptible organism,0.5888888888888889
molecular entity,organism substance,0.5970588235294118
molecular entity,anatomical entity,0.7530303030303032
molecular entity,COVID-19 mortality rate,0.6294871794871795
molecular entity,geopolitical entity,0.7642857142857143
molecular entity,pathogen portal of entry site,0.65
molecular entity,symptomatic infectious structure carrier,0.5928571428571429
molecular entity,designative information content entity,0.6351851851851852
molecular entity,immunodeficient organism,0.65
molecular entity,infectious human pathogen,0.6207317073170732
molecular entity,colonization of human,0.5851351351351352
molecular entity,immaterial entity,0.7530303030303032
molecular entity,division of geopolitical entity,0.6840425531914894
molecular entity,geographical feature,0.6166666666666667
molecular entity,herd immunity to infectious organism,0.6038461538461539
molecular entity,action specification,0.6166666666666667
molecular entity,processed material,0.5970588235294118
molecular entity,quality,0.6673913043478261
molecular entity,infectious disease incidence rate,0.6132653061224489
molecular entity,organism,0.6166666666666667
molecular entity,establishment of a clinically abnormal colony,0.6139344262295081
molecular entity,adhesion factor,0.5790322580645162
molecular entity,material processing,0.6214285714285714
epitope site,epitope,0.8184210526315789
epitope site,geospatial location,0.6112903225806451
epitope site,site of infection,0.656896551724138
epitope site,source of infection site,0.7
epitope site,B cell receptor complex,0.6214285714285714
epitope site,double-stranded RNA virus,0.5851351351351352
epitope site,negative-sense single-stranded RNA virus,0.6038461538461539
epitope site,infection start temporal region,0.6127906976744186
epitope site,anatomical space,0.6285714285714286
epitope site,T cell receptor complex,0.6214285714285714
epitope site,epitope site,0.95
epitope site,pathogen portal of exit site,0.7
epitope site,place closure control strategy,0.6166666666666667
epitope site,pathogen portal of entry site,0.6939024390243902
epitope site,site,0.7
epitope site,incubation start process boundary,0.6055555555555556
epitope site,communicability start temporal region,0.5724489795918367
epitope site,epitope role,0.825
epitope site,infection start process boundary,0.609090909090909
epitope site,latency start process boundary,0.5928571428571429
epitope site,communicability start process boundary,0.57
epitope site,single-stranded RNA retrovirus,0.569047619047619
epitope site,local infection,0.5981481481481481
epitope site,establishment of a clinically abnormal colony,0.5552631578947369
epitope site,positive-sense single-stranded RNA virus,0.6230769230769231
epitope site,cell space,0.6318181818181818
entry into host,virostatic disposition,0.6121621621621621
entry into host,zoonotic disposition,0.65
entry into host,pathogen portal of entry,0.6294871794871795
entry into host,virulence factor disposition,0.6593023255813953
entry into host,pathogen portal of exit,0.6342105263157894
entry into host,viral adhesion disposition,0.6451219512195122
entry into host,parasitostatic disposition,0.6451219512195122
entry into host,reverse zoonotic disposition,0.6593023255813953
entry into host,establishment of localization in host,0.6807692307692308
entry into host,infectious agent host role,0.6939024390243902
entry into host,B cell receptor complex,0.6078947368421053
entry into host,colonized host,0.6913793103448276
entry into host,virus host,0.69
entry into host,pathogen portal of entry role,0.6318181818181818
entry into host,toxin disposition,0.66875
entry into host,acute infectious disease course,0.6456521739130434
entry into host,cidal agent disposition,0.6605263157894737
entry into host,appearance of disorder,0.6121621621621621
entry into host,parasiticidal disposition,0.625
entry into host,transmissibility disposition,0.636046511627907
entry into host,colonization of host,0.7357142857142857
entry into host,endotoxin disposition,0.7
entry into host,infectious structure host role,0.65
entry into host,cytotoxin disposition,0.6444444444444444
entry into host,host,0.6605263157894737
entry into host,chronic infectious disease course,0.6375
entry into host,establishment of localization in human host,0.656896551724138
entry into host,collective pathogenic disposition,0.6375
entry into host,neurotoxin disposition,0.6662162162162162
entry into host,dead-end host role,0.6621212121212122
entry into host,definitive host role,0.7071428571428571
entry into host,collective disposition,0.6391891891891892
entry into host,static agent disposition,0.6551282051282051
entry into host,T cell receptor complex,0.6078947368421053
entry into host,infectious structure host,0.675
entry into host,entry into host,0.95
entry into host,adhesion of symbiont to host,0.7290697674418604
entry into host,immunosuppressive disposition,0.609090909090909
entry into host,pathogenic disposition,0.6391891891891892
entry into host,viral disease course,0.6214285714285714
entry into host,entry into host through host barriers,0.7384615384615384
entry into host,infectious disposition,0.6662162162162162
entry into host,bacteriostatic disposition,0.6451219512195122
entry into host,bactericidal disposition,0.6294871794871795
entry into host,pathogen host,0.7
entry into host,invasion disposition,0.65
entry into host,disease course,0.5879310344827586
entry into host,infectious disease course,0.625
entry into host,viricidal disposition,0.6166666666666667
entry into host,coronavirus disease course,0.6207317073170732
entry into host,intermediate host,0.7625
entry into host,pathogen portal of exit site,0.6593023255813953
entry into host,disposition,0.6038461538461539
entry into host,contact tracing,0.6166666666666667
entry into host,adhesion disposition,0.65
entry into host,pathogen portal of entry site,0.6545454545454545
entry into host,primary infectious disposition,0.6944444444444444
entry into host,pathogen host role,0.6621212121212122
entry into host,intermediate host role,0.7202702702702704
entry into host,dead-end host,0.7
entry into host,host role,0.6166666666666667
entry into host,establishment of localization in virus host,0.656896551724138
entry into host,SARS-COV-2 adhesion disposition,0.6239130434782608
entry into host,pathogen portal of exit role,0.636046511627907
entry into host,invasive disposition,0.6214285714285714
entry into host,infectious agent host,0.7277777777777777
entry into host,long-term non-progressing infectious disease course,0.6166666666666667
entry into host,fungicidal disposition,0.6121621621621621
entry into host,division of geopolitical entity,0.5804347826086956
entry into host,contact pathogen transmission process,0.6230769230769231
entry into host,exotoxin disposition,0.6785714285714286
entry into host,symbiont host role,0.7227272727272727
entry into host,opportunistic infectious disposition,0.6656862745098039
entry into host,enterotoxin disposition,0.7131578947368421
entry into host,COVID-19 disease course,0.581578947368421
entry into host,collective resistance disposition,0.6375
entry into host,fungistatic disposition,0.6342105263157894
entry into host,establishment of a clinically abnormal colony,0.6
entry into host,definitive host,0.75
viral envelope,infectious disease mortality rate,0.5776595744680851
viral envelope,infection incidence rate profile,0.6021739130434782
viral envelope,SARS-CoV-2 incidence rate,0.6038461538461539
viral envelope,site of infection,0.6112903225806451
viral envelope,viral adhesion disposition,0.675
viral envelope,case isolation control strategy,0.5833333333333334
viral envelope,source of infection site,0.6078947368421053
viral envelope,B cell receptor complex,0.6391891891891892
viral envelope,infection incidence rate,0.6078947368421053
viral envelope,lower respiratory tract disease,0.5833333333333334
viral envelope,COVID-19 incidence rate,0.6391891891891892
viral envelope,viral plaque assay,0.7
viral envelope,T cell receptor complex,0.6391891891891892
viral envelope,viral disease course,0.7441176470588234
viral envelope,viral envelope,0.95
viral envelope,epitope site,0.6038461538461539
viral envelope,viral capsid,0.7192307692307692
viral envelope,pathogen portal of exit site,0.5928571428571429
viral envelope,COVID-19 mortality rate,0.6391891891891892
viral envelope,place closure control strategy,0.5863636363636363
viral envelope,viral disease,0.7462962962962962
viral envelope,pathogen portal of entry site,0.6127906976744186
viral envelope,site,0.5611111111111111
viral envelope,viral disease epidemic,0.7277777777777777
viral envelope,viral disease pandemic,0.7277777777777777
viral envelope,negative regulation of viral process,0.61
viral envelope,process of establishing viral infection,0.619811320754717
viral envelope,infectious disease incidence rate,0.598936170212766
viral envelope,viral load,0.7833333333333333
viral envelope,establishment of a clinically abnormal colony,0.5686440677966101
viral envelope,viral pathogenesis,0.73125
disposition,virostatic disposition,0.7833333333333333
disposition,information content entity,0.6121621621621621
disposition,zoonotic disposition,0.8048387096774193
disposition,infectious disease mortality rate,0.5863636363636363
disposition,infection incidence rate profile,0.5662790697674418
disposition,infectious structure aggregate,0.5475609756097561
disposition,communicability end temporal region,0.5804347826086956
disposition,geographical entity,0.5833333333333334
disposition,biological regulation,0.66875
disposition,surveillance process,0.5790322580645162
disposition,infection end temporal region,0.6
disposition,vector control strategy,0.5382352941176471
disposition,SARS-CoV-2 incidence rate,0.5888888888888889
disposition,incubation end temporal region,0.5963414634146341
disposition,resistant entity,0.5981481481481481
disposition,virulence factor disposition,0.732051282051282
disposition,viral adhesion disposition,0.7472972972972972
disposition,parasitostatic disposition,0.7472972972972972
disposition,negative regulation of production,0.609090909090909
disposition,reverse zoonotic disposition,0.732051282051282
disposition,establishment of localization in host,0.6166666666666667
disposition,disease surveillance objective specification,0.6318181818181818
disposition,case isolation control strategy,0.6166666666666667
disposition,infectious agent host role,0.6121621621621621
disposition,macromolecular complex,0.5106060606060606
disposition,material entity,0.5653846153846154
disposition,asymptomatic infectious structure carrier,0.5846153846153846
disposition,architectual structure,0.5409090909090909
disposition,quarantine control strategy,0.5552631578947369
disposition,B cell receptor complex,0.5382352941176471
disposition,infection incidence rate,0.5928571428571429
disposition,colonized host,0.61
disposition,virus host,0.6880952380952381
disposition,entity,0.5676470588235294
disposition,toxin disposition,0.8428571428571427
disposition,cidal agent disposition,0.7735294117647058
disposition,parasiticidal disposition,0.7555555555555555
disposition,communicability end process boundary,0.5776595744680851
disposition,directive information content entity,0.598936170212766
disposition,acellular structure aggregate,0.5
disposition,transmissibility disposition,0.732051282051282
disposition,latency end process boundary,0.6038461538461539
disposition,colonization of host,0.6435483870967742
disposition,realizable entity,0.5571428571428572
disposition,endotoxin disposition,0.79375
disposition,vector surveillance,0.5833333333333334
disposition,negative regulation of establishment of localization,0.5769841269841269
disposition,infectious structure host role,0.5963414634146341
disposition,COVID-19 incidence rate,0.5676470588235294
disposition,cytotoxin disposition,0.79375
disposition,negative regulation of developmental process,0.5409090909090909
disposition,host,0.65
disposition,descriptive information content entity,0.6132653061224489
disposition,negative regulation of replication,0.6055555555555556
disposition,establishment of localization in human host,0.5981481481481481
disposition,acellular structure,0.5166666666666666
disposition,incubation end process boundary,0.5928571428571429
disposition,collective pathogenic disposition,0.7
disposition,neurotoxin disposition,0.7833333333333333
disposition,dead-end host role,0.6224137931034482
disposition,molecular entity,0.5611111111111111
disposition,plan specification,0.6913793103448276
disposition,definitive host role,0.6435483870967742
disposition,latency end temporal region,0.6078947368421053
disposition,infectious structure,0.5790322580645162
disposition,collective disposition,0.7833333333333333
disposition,static agent disposition,0.7642857142857143
disposition,T cell receptor complex,0.5382352941176471
disposition,infectious structure host,0.5888888888888889
disposition,respiratory system disease,0.6121621621621621
disposition,entry into host,0.6038461538461539
disposition,adhesion of symbiont to host,0.6294871794871795
disposition,infectious disease control strategy,0.5804347826086956
disposition,infectious structure generative stage,0.5541666666666667
disposition,immunosuppressive disposition,0.725
disposition,pathogenic disposition,0.7833333333333333
disposition,entry into host through host barriers,0.575
disposition,infectious disposition,0.7833333333333333
disposition,bacteriostatic disposition,0.7472972972972972
disposition,bactericidal disposition,0.7642857142857143
disposition,pathogen host,0.6166666666666667
disposition,invasion disposition,0.8048387096774193
disposition,viricidal disposition,0.79375
disposition,complex infection,0.6642857142857143
disposition,intermediate host,0.6285714285714286
disposition,anatomical entity,0.5928571428571429
disposition,disposition,0.95
disposition,COVID-19 mortality rate,0.5676470588235294
disposition,negative regulation of life-sustaining process,0.5552631578947369
disposition,place closure control strategy,0.5719512195121951
disposition,geopolitical entity,0.65
disposition,adhesion disposition,0.8048387096774193
disposition,symptomatic infectious structure carrier,0.5872549019607843
disposition,primary infectious disposition,0.7182926829268292
disposition,pathogen host role,0.6224137931034482
disposition,designative information content entity,0.5928571428571429
disposition,intermediate host role,0.6318181818181818
disposition,dead-end host,0.6166666666666667
disposition,pathogen surveillance,0.60625
disposition,host role,0.65
disposition,establishment of localization in virus host,0.5981481481481481
disposition,negative regulation of immune response,0.5520408163265306
disposition,immaterial entity,0.5928571428571429
disposition,SARS-COV-2 adhesion disposition,0.7119047619047619
disposition,invasive disposition,0.8048387096774193
disposition,infectious agent host,0.60625
disposition,fungicidal disposition,0.7833333333333333
disposition,division of geopolitical entity,0.6642857142857143
disposition,negative regulation of viral process,0.5563829787234043
disposition,exotoxin disposition,0.8048387096774193
disposition,immunoglobulin complex,0.5712121212121213
disposition,infectious disease control objective specification,0.6139344262295081
disposition,symbiont host role,0.6224137931034482
disposition,opportunistic infectious disposition,0.6840425531914894
disposition,negative regulation of biological process,0.5461538461538461
disposition,enterotoxin disposition,0.7735294117647058
disposition,infectious disease incidence rate,0.609090909090909
disposition,collective resistance disposition,0.7
disposition,fungistatic disposition,0.7735294117647058
disposition,establishment of a clinically abnormal colony,0.575
disposition,definitive host,0.6807692307692308
pathogen portal of exit site,extended organism,0.65
pathogen portal of exit site,virus aggregate,0.5895348837209302
pathogen portal of exit site,source of infection,0.6414893617021277
pathogen portal of exit site,infectious disease mortality rate,0.6795081967213115
pathogen portal of exit site,infection incidence rate profile,0.65
pathogen portal of exit site,communicability end temporal region,0.6563492063492063
pathogen portal of exit site,pathogen generative stage,0.7518867924528303
pathogen portal of exit site,pathogen portal of entry,0.8538461538461539
pathogen portal of exit site,subclinical coronavirus infection,0.6139344262295081
pathogen portal of exit site,primary pathogen,0.6318181818181818
pathogen portal of exit site,infection end temporal region,0.6780701754385965
pathogen portal of exit site,drug-based immunosuppressed organism,0.590625
pathogen portal of exit site,geospatial location,0.6627659574468084
pathogen portal of exit site,infectious disease,0.6021739130434782
pathogen portal of exit site,double-stranded DNA virus,0.6009433962264151
pathogen portal of exit site,incubation end temporal region,0.6913793103448276
pathogen portal of exit site,site of infection,0.65
pathogen portal of exit site,immunocompetent organism,0.6423076923076922
pathogen portal of exit site,pathogen portal of exit,0.9009803921568627
pathogen portal of exit site,infectious disease incidence,0.5928571428571429
pathogen portal of exit site,reservoir of pathogen role,0.6722222222222223
pathogen portal of exit site,subclinical SARS-CoV-2 infection,0.6
pathogen portal of exit site,virus translation stage,0.6264705882352941
pathogen portal of exit site,disease surveillance objective specification,0.6305555555555555
pathogen portal of exit site,case isolation control strategy,0.6533898305084747
pathogen portal of exit site,virus release stage,0.6202127659574468
pathogen portal of exit site,infectious agent host role,0.6537037037037037
pathogen portal of exit site,source of infection site,0.7
pathogen portal of exit site,virus,0.5106060606060606
pathogen portal of exit site,virus replication,0.5833333333333334
pathogen portal of exit site,B cell receptor complex,0.6264705882352941
pathogen portal of exit site,passive immunization against infectious agent,0.6280821917808219
pathogen portal of exit site,systematic infection,0.6166666666666667
pathogen portal of exit site,infection incidence rate,0.6230769230769231
pathogen portal of exit site,virus host,0.581578947368421
pathogen portal of exit site,double-stranded RNA virus,0.619811320754717
pathogen portal of exit site,pathogen portal of entry role,0.8535087719298246
pathogen portal of exit site,virus transcription stage,0.619811320754717
pathogen portal of exit site,infectious disease lifetime prevalence,0.6015151515151516
pathogen portal of exit site,pathogen birth temporal region,0.743103448275862
pathogen portal of exit site,lower respiratory tract disease,0.6533898305084747
pathogen portal of exit site,infectious disease incidence proportion,0.5992537313432835
pathogen portal of exit site,opportunistic pathogen,0.65
pathogen portal of exit site,virus generative stage,0.65
pathogen portal of exit site,acute infectious disease course,0.6364406779661017
pathogen portal of exit site,cidal agent disposition,0.6460784313725491
pathogen portal of exit site,genetic resistance to pathogen,0.656896551724138
pathogen portal of exit site,subclinical infection,0.6132653061224489
pathogen portal of exit site,simple infection,0.609090909090909
pathogen portal of exit site,droplet pathogen transmission process,0.6807692307692308
pathogen portal of exit site,infectious disease sporadicity,0.6396551724137931
pathogen portal of exit site,communicability end process boundary,0.60625
pathogen portal of exit site,infection incidence proportion profile,0.6621212121212122
pathogen portal of exit site,infectious agent colony,0.6264705882352941
pathogen portal of exit site,pathogen transporter,0.7416666666666667
pathogen portal of exit site,latency end process boundary,0.6285714285714286
pathogen portal of exit site,infectious disease epidemic,0.5954545454545455
pathogen portal of exit site,infectious agent generative stage,0.6631147540983606
pathogen portal of exit site,disease transmission model,0.6166666666666667
pathogen portal of exit site,pathologically immunosuppressed organism,0.6411764705882353
pathogen portal of exit site,negative-sense single-stranded RNA virus,0.6117647058823529
pathogen portal of exit site,cidal agent,0.5782051282051281
pathogen portal of exit site,pathogen vehicle,0.7227272727272727
pathogen portal of exit site,community-acquired infection,0.6107142857142857
pathogen portal of exit site,pathogen vector,0.7058139534883722
pathogen portal of exit site,pathogen vehicle role,0.7153061224489795
pathogen portal of exit site,chronic infectious disease course,0.630327868852459
pathogen portal of exit site,asymptomatic infectious agent carrier,0.6346153846153847
pathogen portal of exit site,nursing-home acquired infection,0.6194915254237288
pathogen portal of exit site,secondary infection,0.6202127659574468
pathogen portal of exit site,infection start temporal region,0.6533898305084747
pathogen portal of exit site,infection incidence,0.598936170212766
pathogen portal of exit site,virus disorder,0.569047619047619
pathogen portal of exit site,sterilizing immunity to infectious agent,0.6264705882352941
pathogen portal of exit site,primary infection,0.6277777777777778
pathogen portal of exit site,process of establishing an infection,0.653125
pathogen portal of exit site,incubation end process boundary,0.6364406779661017
pathogen portal of exit site,pathogen death process boundary,0.6872881355932203
pathogen portal of exit site,immunosuppressed organism,0.6009433962264151
pathogen portal of exit site,latency end temporal region,0.6863636363636364
pathogen portal of exit site,innate immunity to infectious agent,0.6404761904761905
pathogen portal of exit site,virus adhesion susceptible cell,0.6364406779661017
pathogen portal of exit site,anatomical space,0.6318181818181818
pathogen portal of exit site,infection,0.5851351351351352
pathogen portal of exit site,static agent disposition,0.6615384615384616
pathogen portal of exit site,T cell receptor complex,0.6460784313725491
pathogen portal of exit site,infectious agent population,0.65
pathogen portal of exit site,respiratory system disease,0.6351851851851852
pathogen portal of exit site,entry into host,0.6593023255813953
pathogen portal of exit site,leukocyte-mediated immunity to infectious agent,0.61
pathogen portal of exit site,indirect pathogen transmission process,0.6772727272727272
pathogen portal of exit site,organism population,0.6414893617021277
pathogen portal of exit site,humoral immunity to infectious agent,0.6375
pathogen portal of exit site,infectious disease control strategy,0.6246031746031746
pathogen portal of exit site,parasite,0.6722222222222223
pathogen portal of exit site,infectious disease pandemic,0.5954545454545455
pathogen portal of exit site,antibody reagent,0.6318181818181818
pathogen portal of exit site,viral disease course,0.6166666666666667
pathogen portal of exit site,entry into host through host barriers,0.6346153846153847
pathogen portal of exit site,intracellular infection,0.6264705882352941
pathogen portal of exit site,secondary infection role,0.6230769230769231
pathogen portal of exit site,metastatic infection,0.6166666666666667
pathogen portal of exit site,passive immunity to infectious agent,0.6375
pathogen portal of exit site,vaccination against infectious agent,0.6375
pathogen portal of exit site,acute infection,0.636046511627907
pathogen portal of exit site,susceptibility to infectious agent,0.6274193548387097
pathogen portal of exit site,epitope site,0.7
pathogen portal of exit site,immunity to pathogen,0.6166666666666667
pathogen portal of exit site,source of infection role,0.6423076923076922
pathogen portal of exit site,pathogen host,0.7426829268292683
pathogen portal of exit site,chronic infection,0.6277777777777778
pathogen portal of exit site,disease course,0.6166666666666667
pathogen portal of exit site,infectious disease course,0.6009433962264151
pathogen portal of exit site,acquired immunity to infectious agent,0.6192307692307693
pathogen portal of exit site,complex infection,0.6277777777777778
pathogen portal of exit site,COVID-19 disease incidence proportion,0.5884615384615385
pathogen portal of exit site,coronavirus disease course,0.5981481481481481
pathogen portal of exit site,infection incidence proportion,0.6224137931034482
pathogen portal of exit site,symptomatic infectious agent carrier,0.6375
pathogen portal of exit site,respiratory droplet virus fomite,0.6833333333333332
pathogen portal of exit site,susceptible organism,0.6375
pathogen portal of exit site,parasite role,0.6451219512195122
pathogen portal of exit site,pathogen vector role,0.7416666666666667
pathogen portal of exit site,pathogen portal of exit site,0.95
pathogen portal of exit site,infectious disease prevalence,0.6254385964912281
pathogen portal of exit site,organism substance,0.6239130434782608
pathogen portal of exit site,single-stranded DNA virus,0.6009433962264151
pathogen portal of exit site,COVID-19 mortality rate,0.6852941176470588
pathogen portal of exit site,place closure control strategy,0.6741379310344828
pathogen portal of exit site,viral disease,0.6207317073170732
pathogen portal of exit site,primary infection role,0.63
pathogen portal of exit site,pathogen portal of entry site,0.9061403508771929
pathogen portal of exit site,infection incidence profile,0.65
pathogen portal of exit site,disease,0.5642857142857143
pathogen portal of exit site,site,0.575
pathogen portal of exit site,pathogen host role,0.7543478260869566
pathogen portal of exit site,infection prevalence,0.6583333333333334
pathogen portal of exit site,infectious pathogen transmissibility,0.684375
pathogen portal of exit site,incubation start process boundary,0.630327868852459
pathogen portal of exit site,pathogen surveillance,0.7153061224489795
pathogen portal of exit site,immunodeficient organism,0.6230769230769231
pathogen portal of exit site,pathogen,0.6722222222222223
pathogen portal of exit site,pathogen birth process boundary,0.7042372881355932
pathogen portal of exit site,infectious human pathogen,0.6009433962264151
pathogen portal of exit site,subclinical virus infection,0.5954545454545455
pathogen portal of exit site,resistance to pathogen,0.61
pathogen portal of exit site,establishment of localization in virus host,0.6471830985915493
pathogen portal of exit site,immunization against infectious agent,0.6346153846153847
pathogen portal of exit site,virus attachment stage,0.65
pathogen portal of exit site,virus synthesis stage,0.6132653061224489
pathogen portal of exit site,pathogen portal of exit role,0.8964285714285714
pathogen portal of exit site,infectious agent host,0.6540816326530612
pathogen portal of exit site,re-emerging pathogen,0.6166666666666667
pathogen portal of exit site,long-term non-progressing infectious disease course,0.6272151898734176
pathogen portal of exit site,viral disease epidemic,0.61
pathogen portal of exit site,communicability start temporal region,0.6192307692307693
pathogen portal of exit site,viral disease pandemic,0.59
pathogen portal of exit site,virus penetration stage,0.6460784313725491
pathogen portal of exit site,pathogen seroprevalence,0.7441176470588234
pathogen portal of exit site,infectious disease endemicity,0.6078947368421053
pathogen portal of exit site,contact pathogen transmission process,0.6807692307692308
pathogen portal of exit site,herd immunity to infectious organism,0.621875
pathogen portal of exit site,extracellular infection,0.6264705882352941
pathogen portal of exit site,pathogen transporter role,0.7518867924528303
pathogen portal of exit site,infectious agent reservoir,0.6351851851851852
pathogen portal of exit site,infection start process boundary,0.6166666666666667
pathogen portal of exit site,latency start process boundary,0.6396551724137931
pathogen portal of exit site,infectious disease control objective specification,0.6423076923076922
pathogen portal of exit site,process of establishing viral infection,0.6440298507462687
pathogen portal of exit site,COVID-19 disease course,0.5872549019607843
pathogen portal of exit site,infectious disease incidence rate,0.5975409836065574
pathogen portal of exit site,communicability start process boundary,0.6015151515151516
pathogen portal of exit site,process that results in death,0.6605263157894737
pathogen portal of exit site,single-stranded RNA retrovirus,0.6224137931034482
pathogen portal of exit site,active immunization against infectious agent,0.6305555555555555
pathogen portal of exit site,disordered virus,0.5863636363636363
pathogen portal of exit site,organism,0.5888888888888889
pathogen portal of exit site,virus uncoating stage,0.6132653061224489
pathogen portal of exit site,local infection,0.636046511627907
pathogen portal of exit site,infectious agent,0.5863636363636363
pathogen portal of exit site,establishment of a clinically abnormal colony,0.6006849315068493
pathogen portal of exit site,process boundary,0.5863636363636363
pathogen portal of exit site,coronavirus disease,0.598936170212766
pathogen portal of exit site,positive-sense single-stranded RNA virus,0.6117647058823529
pathogen portal of exit site,horizontal pathogen transmission process,0.6705882352941177
pathogen portal of exit site,hospital-acquired infection,0.65
pathogen portal of exit site,pathogen death temporal region,0.743103448275862
pathogen portal of exit site,emerging pathogen,0.6277777777777778
pathogen portal of exit site,drug susceptibility of infectious agent,0.6440298507462687
pathogen portal of exit site,SARS-CoV-2 release stage,0.6423076923076922
pathogen portal of exit site,static agent,0.6
pathogen portal of exit site,pathogen transmission process,0.7131578947368421
pathogen portal of exit site,cell space,0.581578947368421
infectious disease control strategy,virus aggregate,0.63
infectious disease control strategy,source of infection,0.6166666666666667
infectious disease control strategy,virostatic disposition,0.6254385964912281
infectious disease control strategy,zoonotic disposition,0.6318181818181818
infectious disease control strategy,infectious disease mortality rate,0.8470588235294118
infectious disease control strategy,infection incidence rate profile,0.7186567164179104
infectious disease control strategy,infectious structure aggregate,0.7576923076923078
infectious disease control strategy,communicability end temporal region,0.65
infectious disease control strategy,biological regulation,0.6107142857142857
infectious disease control strategy,subclinical coronavirus infection,0.6264705882352941
infectious disease control strategy,surveillance process,0.5954545454545455
infectious disease control strategy,infection end temporal region,0.73125
infectious disease control strategy,vector control strategy,0.8120689655172413
infectious disease control strategy,infectious disease,0.789622641509434
infectious disease control strategy,SARS-CoV-2 incidence rate,0.65
infectious disease control strategy,double-stranded DNA virus,0.6
infectious disease control strategy,incubation end temporal region,0.6961538461538461
infectious disease control strategy,site of infection,0.6230769230769231
infectious disease control strategy,virulence factor disposition,0.6563492063492063
infectious disease control strategy,viral adhesion disposition,0.630327868852459
infectious disease control strategy,parasitostatic disposition,0.630327868852459
infectious disease control strategy,infectious disease incidence,0.7992063492063491
infectious disease control strategy,negative regulation of production,0.6411764705882353
infectious disease control strategy,reverse zoonotic disposition,0.6246031746031746
infectious disease control strategy,subclinical SARS-CoV-2 infection,0.6291044776119403
infectious disease control strategy,virus translation stage,0.6741379310344828
infectious disease control strategy,disease surveillance objective specification,0.639873417721519
infectious disease control strategy,case isolation control strategy,0.7984848484848485
infectious disease control strategy,virus release stage,0.6907407407407408
infectious disease control strategy,infectious agent host role,0.7778688524590163
infectious disease control strategy,asymptomatic infectious structure carrier,0.6868421052631578
infectious disease control strategy,source of infection site,0.6703389830508475
infectious disease control strategy,virus,0.525
infectious disease control strategy,quarantine control strategy,0.7887096774193548
infectious disease control strategy,virus replication,0.6038461538461539
infectious disease control strategy,B cell receptor complex,0.6051724137931035
infectious disease control strategy,passive immunization against infectious agent,0.6375
infectious disease control strategy,systematic infection,0.6136363636363636
infectious disease control strategy,infection incidence rate,0.738135593220339
infectious disease control strategy,virus host,0.6055555555555556
infectious disease control strategy,double-stranded RNA virus,0.6
infectious disease control strategy,virus transcription stage,0.6833333333333332
infectious disease control strategy,infectious disease lifetime prevalence,0.7787671232876713
infectious disease control strategy,toxin disposition,0.6230769230769231
infectious disease control strategy,lower respiratory tract disease,0.6318181818181818
infectious disease control strategy,infectious disease incidence proportion,0.7878378378378378
infectious disease control strategy,virus generative stage,0.6605263157894737
infectious disease control strategy,acute infectious disease course,0.8136363636363637
infectious disease control strategy,cidal agent disposition,0.6224137931034482
infectious disease control strategy,infectious disorder,0.7648148148148148
infectious disease control strategy,subclinical infection,0.6107142857142857
infectious disease control strategy,appearance of disorder,0.6254385964912281
infectious disease control strategy,simple infection,0.6264705882352941
infectious disease control strategy,parasiticidal disposition,0.6166666666666667
infectious disease control strategy,infectious disease sporadicity,0.8192307692307693
infectious disease control strategy,communicability end process boundary,0.6190140845070422
infectious disease control strategy,infection incidence proportion profile,0.7102739726027397
infectious disease control strategy,infectious agent colony,0.760344827586207
infectious disease control strategy,transmissibility disposition,0.6087301587301588
infectious disease control strategy,latency end process boundary,0.6246031746031746
infectious disease control strategy,infectious disease epidemic,0.7725806451612902
infectious disease control strategy,infectious agent generative stage,0.7588235294117647
infectious disease control strategy,disease transmission model,0.6631147540983606
infectious disease control strategy,endotoxin disposition,0.6285714285714286
infectious disease control strategy,vector surveillance,0.6351851851851852
infectious disease control strategy,negative regulation of establishment of localization,0.6339080459770114
infectious disease control strategy,negative-sense single-stranded RNA virus,0.6633333333333334
infectious disease control strategy,infectious structure host role,0.7576923076923078
infectious disease control strategy,COVID-19 incidence rate,0.656896551724138
infectious disease control strategy,cytotoxin disposition,0.6285714285714286
infectious disease control strategy,community-acquired infection,0.6087301587301588
infectious disease control strategy,negative regulation of developmental process,0.6525316455696202
infectious disease control strategy,chronic infectious disease course,0.8029411764705883
infectious disease control strategy,asymptomatic infectious agent carrier,0.7
infectious disease control strategy,nursing-home acquired infection,0.6166666666666667
infectious disease control strategy,COVID-19 epidemic,0.5653846153846154
infectious disease control strategy,negative regulation of replication,0.6528985507246376
infectious disease control strategy,secondary infection,0.6166666666666667
infectious disease control strategy,infection start temporal region,0.7378787878787878
infectious disease control strategy,infection incidence,0.6907407407407408
infectious disease control strategy,virus disorder,0.6540816326530612
infectious disease control strategy,sterilizing immunity to infectious agent,0.65
infectious disease control strategy,diseased population,0.6722222222222223
infectious disease control strategy,primary infection,0.6230769230769231
infectious disease control strategy,process of establishing an infection,0.6049295774647887
infectious disease control strategy,incubation end process boundary,0.6772727272727272
infectious disease control strategy,SARS-CoV-2 disorder,0.6166666666666667
infectious disease control strategy,collective pathogenic disposition,0.6264705882352941
infectious disease control strategy,neurotoxin disposition,0.6429824561403508
infectious disease control strategy,plan specification,0.6009433962264151
infectious disease control strategy,latency end temporal region,0.6435483870967742
infectious disease control strategy,innate immunity to infectious agent,0.6642857142857143
infectious disease control strategy,infectious structure,0.759090909090909
infectious disease control strategy,virus adhesion susceptible cell,0.6469696969696969
infectious disease control strategy,collective disposition,0.6429824561403508
infectious disease control strategy,infection,0.6545454545454545
infectious disease control strategy,static agent disposition,0.6194915254237288
infectious disease control strategy,T cell receptor complex,0.6224137931034482
infectious disease control strategy,infectious structure host,0.75
infectious disease control strategy,infectious agent population,0.7564516129032257
infectious disease control strategy,respiratory system disease,0.6467213114754098
infectious disease control strategy,leukocyte-mediated immunity to infectious agent,0.6329268292682927
infectious disease control strategy,humoral immunity to infectious agent,0.6612676056338028
infectious disease control strategy,infectious disease control strategy,0.95
infectious disease control strategy,infectious disease pandemic,0.7887096774193548
infectious disease control strategy,infectious structure generative stage,0.7416666666666667
infectious disease control strategy,immunosuppressive disposition,0.6375
infectious disease control strategy,pathogenic disposition,0.6078947368421053
infectious disease control strategy,viral disease course,0.7227272727272727
infectious disease control strategy,intracellular infection,0.6224137931034482
infectious disease control strategy,secondary infection role,0.6703389830508475
infectious disease control strategy,metastatic infection,0.6136363636363636
infectious disease control strategy,passive immunity to infectious agent,0.6612676056338028
infectious disease control strategy,infectious disposition,0.7482456140350877
infectious disease control strategy,vaccination against infectious agent,0.6612676056338028
infectious disease control strategy,acute infection,0.63
infectious disease control strategy,susceptibility to infectious agent,0.6673913043478261
infectious disease control strategy,bacteriostatic disposition,0.6467213114754098
infectious disease control strategy,bactericidal disposition,0.6194915254237288
infectious disease control strategy,source of infection role,0.6703389830508475
infectious disease control strategy,chronic infection,0.6230769230769231
infectious disease control strategy,invasion disposition,0.65
infectious disease control strategy,disease course,0.7153061224489795
infectious disease control strategy,infectious disease course,0.85
infectious disease control strategy,viricidal disposition,0.6285714285714286
infectious disease control strategy,acquired immunity to infectious agent,0.6583333333333334
infectious disease control strategy,complex infection,0.6230769230769231
infectious disease control strategy,COVID-19 disease incidence proportion,0.6861111111111111
infectious disease control strategy,coronavirus disease course,0.7450819672131148
infectious disease control strategy,infection incidence proportion,0.7115384615384616
infectious disease control strategy,symptomatic infectious agent carrier,0.7035211267605633
infectious disease control strategy,respiratory droplet virus fomite,0.6291044776119403
infectious disease control strategy,infectious disease prevalence,0.79375
infectious disease control strategy,disposition,0.5804347826086956
infectious disease control strategy,single-stranded DNA virus,0.6166666666666667
infectious disease control strategy,infected population,0.6722222222222223
infectious disease control strategy,COVID-19 mortality rate,0.656896551724138
infectious disease control strategy,negative regulation of life-sustaining process,0.6351851851851852
infectious disease control strategy,place closure control strategy,0.7884615384615384
infectious disease control strategy,viral disease,0.6375
infectious disease control strategy,primary infection role,0.6780701754385965
infectious disease control strategy,adhesion disposition,0.6318181818181818
infectious disease control strategy,infection incidence profile,0.7241935483870968
infectious disease control strategy,disease,0.6166666666666667
infectious disease control strategy,symptomatic infectious structure carrier,0.69
infectious disease control strategy,primary infectious disposition,0.7115384615384616
infectious disease control strategy,infection prevalence,0.7045454545454546
infectious disease control strategy,coronavirus disorder,0.65
infectious disease control strategy,infectious pathogen transmissibility,0.7316901408450704
infectious disease control strategy,pathogen surveillance,0.6107142857142857
infectious disease control strategy,infectious human pathogen,0.7333333333333333
infectious disease control strategy,subclinical virus infection,0.6435483870967742
infectious disease control strategy,establishment of localization in virus host,0.6294871794871795
infectious disease control strategy,immunization against infectious agent,0.6583333333333334
infectious disease control strategy,virus attachment stage,0.6780701754385965
infectious disease control strategy,negative regulation of immune response,0.6417808219178082
infectious disease control strategy,virus synthesis stage,0.6642857142857143
infectious disease control strategy,SARS-COV-2 adhesion disposition,0.6166666666666667
infectious disease control strategy,invasive disposition,0.6318181818181818
infectious disease control strategy,infectious agent host,0.7714285714285714
infectious disease control strategy,long-term non-progressing infectious disease course,0.7290697674418604
infectious disease control strategy,viral disease epidemic,0.6429824561403508
infectious disease control strategy,fungicidal disposition,0.6254385964912281
infectious disease control strategy,viral disease pandemic,0.6605263157894737
infectious disease control strategy,virus penetration stage,0.6913793103448276
infectious disease control strategy,acute respiratory distress syndrome,0.6642857142857143
infectious disease control strategy,infectious disease endemicity,0.79375
infectious disease control strategy,negative regulation of viral process,0.6471830985915493
infectious disease control strategy,disorder,0.5895348837209302
infectious disease control strategy,herd immunity to infectious organism,0.6471830985915493
infectious disease control strategy,extracellular infection,0.6051724137931035
infectious disease control strategy,exotoxin disposition,0.6318181818181818
infectious disease control strategy,infectious agent reservoir,0.7450819672131148
infectious disease control strategy,COVID-19 pandemic,0.5653846153846154
infectious disease control strategy,infection start process boundary,0.703731343283582
infectious disease control strategy,action specification,0.6318181818181818
infectious disease control strategy,infectious disease control objective specification,0.8029411764705883
infectious disease control strategy,COVID-19 lifetime prevalence,0.6246031746031746
infectious disease control strategy,opportunistic infectious disposition,0.6894366197183097
infectious disease control strategy,process of establishing viral infection,0.6121621621621621
infectious disease control strategy,negative regulation of biological process,0.6342105263157894
infectious disease control strategy,enterotoxin disposition,0.6396551724137931
infectious disease control strategy,COVID-19 disease course,0.7258620689655172
infectious disease control strategy,infectious disease incidence rate,0.8323529411764706
infectious disease control strategy,COVID-19 prevalence,0.5981481481481481
infectious disease control strategy,active immunization against infectious agent,0.639873417721519
infectious disease control strategy,SARS-COV-2 prevalence,0.6107142857142857
infectious disease control strategy,disordered virus,0.6068627450980393
infectious disease control strategy,collective resistance disposition,0.6411764705882353
infectious disease control strategy,fungistatic disposition,0.6224137931034482
infectious disease control strategy,virus uncoating stage,0.6642857142857143
infectious disease control strategy,local infection,0.63
infectious disease control strategy,infectious agent,0.7441176470588234
infectious disease control strategy,establishment of a clinically abnormal colony,0.625
infectious disease control strategy,coronavirus disease,0.6722222222222223
infectious disease control strategy,positive-sense single-stranded RNA virus,0.65
infectious disease control strategy,hospital-acquired infection,0.5951612903225807
infectious disease control strategy,drug susceptibility of infectious agent,0.6527027027027027
division of geopolitical entity,extended organism,0.5958333333333333
division of geopolitical entity,information content entity,0.7131578947368421
division of geopolitical entity,infectious disease mortality rate,0.6375
division of geopolitical entity,infection incidence rate profile,0.6404761904761905
division of geopolitical entity,infectious structure aggregate,0.6139344262295081
division of geopolitical entity,communicability end temporal region,0.6469696969696969
division of geopolitical entity,geographical entity,0.75
division of geopolitical entity,infection end temporal region,0.6833333333333332
division of geopolitical entity,drug-based immunosuppressed organism,0.5992537313432835
division of geopolitical entity,geospatial location,0.67
division of geopolitical entity,SARS-CoV-2 incidence rate,0.5928571428571429
division of geopolitical entity,incubation end temporal region,0.6795081967213115
division of geopolitical entity,resistant entity,0.6840425531914894
division of geopolitical entity,immunocompetent organism,0.6318181818181818
division of geopolitical entity,virulence factor disposition,0.6533898305084747
division of geopolitical entity,case isolation control strategy,0.6596774193548387
division of geopolitical entity,material entity,0.6891304347826087
division of geopolitical entity,asymptomatic infectious structure carrier,0.6027777777777777
division of geopolitical entity,architectual structure,0.6009433962264151
division of geopolitical entity,B cell receptor complex,0.5981481481481481
division of geopolitical entity,infection incidence rate,0.6318181818181818
division of geopolitical entity,entity,0.6121621621621621
division of geopolitical entity,serology assay,0.5833333333333334
division of geopolitical entity,genetic resistance to pathogen,0.630327868852459
division of geopolitical entity,communicability end process boundary,0.6141791044776119
division of geopolitical entity,directive information content entity,0.7186567164179104
division of geopolitical entity,acellular structure aggregate,0.5666666666666667
division of geopolitical entity,invasion factor,0.6673913043478261
division of geopolitical entity,latency end process boundary,0.6025423728813559
division of geopolitical entity,realizable entity,0.7
division of geopolitical entity,pathologically immunosuppressed organism,0.6049295774647887
division of geopolitical entity,infectious structure host role,0.5975409836065574
division of geopolitical entity,COVID-19 incidence rate,0.5981481481481481
division of geopolitical entity,viral plaque assay,0.6132653061224489
division of geopolitical entity,descriptive information content entity,0.7108695652173913
division of geopolitical entity,establishment of localization in human host,0.6527027027027027
division of geopolitical entity,acellular structure,0.57
division of geopolitical entity,virulence factor,0.598936170212766
division of geopolitical entity,incubation end process boundary,0.6435483870967742
division of geopolitical entity,pathogen death process boundary,0.6112903225806451
division of geopolitical entity,molecular entity,0.6840425531914894
division of geopolitical entity,immunosuppressed organism,0.5928571428571429
division of geopolitical entity,latency end temporal region,0.6396551724137931
division of geopolitical entity,infectious structure,0.6264705882352941
division of geopolitical entity,T cell receptor complex,0.5981481481481481
division of geopolitical entity,infectious structure host,0.6107142857142857
division of geopolitical entity,respiratory system disease,0.5903508771929825
division of geopolitical entity,organism population,0.63
division of geopolitical entity,infectious structure generative stage,0.6411764705882353
division of geopolitical entity,susceptible organism,0.6264705882352941
division of geopolitical entity,organism substance,0.5724489795918367
division of geopolitical entity,anatomical entity,0.7208333333333333
division of geopolitical entity,COVID-19 mortality rate,0.6351851851851852
division of geopolitical entity,geopolitical entity,0.83
division of geopolitical entity,symptomatic infectious structure carrier,0.6049295774647887
division of geopolitical entity,designative information content entity,0.7108695652173913
division of geopolitical entity,incubation start process boundary,0.6375
division of geopolitical entity,immunodeficient organism,0.6318181818181818
division of geopolitical entity,pathogen birth process boundary,0.6112903225806451
division of geopolitical entity,infectious human pathogen,0.6285714285714286
division of geopolitical entity,colonization of human,0.6423076923076922
division of geopolitical entity,assay,0.5333333333333333
division of geopolitical entity,immaterial entity,0.7
division of geopolitical entity,blood,0.5055555555555555
division of geopolitical entity,division of geopolitical entity,0.95
division of geopolitical entity,geographical feature,0.6656862745098039
division of geopolitical entity,herd immunity to infectious organism,0.6291044776119403
division of geopolitical entity,infection start process boundary,0.6404761904761905
division of geopolitical entity,action specification,0.6656862745098039
division of geopolitical entity,processed material,0.5724489795918367
division of geopolitical entity,latency start process boundary,0.5975409836065574
division of geopolitical entity,quality,0.581578947368421
division of geopolitical entity,infectious disease incidence rate,0.621875
division of geopolitical entity,communicability start process boundary,0.6094202898550725
division of geopolitical entity,organism,0.5782051282051281
division of geopolitical entity,establishment of a clinically abnormal colony,0.6605263157894737
division of geopolitical entity,process boundary,0.5776595744680851
division of geopolitical entity,adhesion factor,0.6456521739130434
division of geopolitical entity,material processing,0.59
infectious structure generative stage,source of infection,0.6285714285714286
infectious structure generative stage,virostatic disposition,0.6194915254237288
infectious structure generative stage,zoonotic disposition,0.5903508771929825
infectious structure generative stage,infectious disease mortality rate,0.7357142857142857
infectious structure generative stage,infection incidence rate profile,0.7253623188405797
infectious structure generative stage,infectious structure aggregate,0.8380597014925374
infectious structure generative stage,communicability end temporal region,0.6305555555555555
infectious structure generative stage,pathogen generative stage,0.7725806451612902
infectious structure generative stage,infection end temporal region,0.6924242424242425
infectious structure generative stage,infectious disease,0.740909090909091
infectious structure generative stage,SARS-CoV-2 incidence rate,0.6274193548387097
infectious structure generative stage,incubation end temporal region,0.658955223880597
infectious structure generative stage,virulence factor disposition,0.6192307692307693
infectious structure generative stage,viral adhesion disposition,0.5769841269841269
infectious structure generative stage,parasitostatic disposition,0.6246031746031746
infectious structure generative stage,infectious disease incidence,0.7269230769230769
infectious structure generative stage,reverse zoonotic disposition,0.6038461538461539
infectious structure generative stage,virus translation stage,0.7166666666666667
infectious structure generative stage,disease surveillance objective specification,0.6598765432098764
infectious structure generative stage,virus release stage,0.7178571428571427
infectious structure generative stage,infectious agent host role,0.7515873015873015
infectious structure generative stage,macromolecular complex,0.5686440677966101
infectious structure generative stage,asymptomatic infectious structure carrier,0.7576923076923078
infectious structure generative stage,source of infection site,0.6795081967213115
infectious structure generative stage,architectual structure,0.7042372881355932
infectious structure generative stage,B cell receptor complex,0.6
infectious structure generative stage,passive immunization against infectious agent,0.6573170731707317
infectious structure generative stage,infection incidence rate,0.728688524590164
infectious structure generative stage,double-stranded RNA virus,0.6274193548387097
infectious structure generative stage,virus transcription stage,0.7080645161290323
infectious structure generative stage,infectious disease lifetime prevalence,0.73
infectious structure generative stage,toxin disposition,0.5796296296296296
infectious structure generative stage,lower respiratory tract disease,0.6558823529411765
infectious structure generative stage,infectious disease incidence proportion,0.7131578947368421
infectious structure generative stage,virus generative stage,0.7889830508474576
infectious structure generative stage,acute infectious disease course,0.7147058823529412
infectious structure generative stage,cidal agent disposition,0.6166666666666667
infectious structure generative stage,infectious disorder,0.7178571428571427
infectious structure generative stage,biological vehicle,0.5772727272727273
infectious structure generative stage,parasiticidal disposition,0.5790322580645162
infectious structure generative stage,infectious disease sporadicity,0.7186567164179104
infectious structure generative stage,communicability end process boundary,0.6143835616438357
infectious structure generative stage,acellular structure aggregate,0.7227272727272727
infectious structure generative stage,infectious agent colony,0.7166666666666667
infectious structure generative stage,transmissibility disposition,0.5884615384615385
infectious structure generative stage,latency end process boundary,0.5884615384615385
infectious structure generative stage,infectious disease epidemic,0.715625
infectious structure generative stage,infectious agent generative stage,0.8642857142857143
infectious structure generative stage,disease transmission model,0.6087301587301588
infectious structure generative stage,endotoxin disposition,0.5706896551724138
infectious structure generative stage,negative-sense single-stranded RNA virus,0.6577922077922078
infectious structure generative stage,infectious structure host role,0.8082089552238806
infectious structure generative stage,pathogen vehicle,0.6009433962264151
infectious structure generative stage,COVID-19 incidence rate,0.6333333333333333
infectious structure generative stage,cytotoxin disposition,0.5879310344827586
infectious structure generative stage,negative regulation of developmental process,0.6475308641975309
infectious structure generative stage,pathogen vehicle role,0.6224137931034482
infectious structure generative stage,chronic infectious disease course,0.7071428571428571
infectious structure generative stage,asymptomatic infectious agent carrier,0.6932432432432433
infectious structure generative stage,COVID-19 epidemic,0.5611111111111111
infectious structure generative stage,PCR product,0.575
infectious structure generative stage,sterilizing immunity to infectious agent,0.6448051948051949
infectious structure generative stage,diseased population,0.5928571428571429
infectious structure generative stage,acellular structure,0.6642857142857143
infectious structure generative stage,incubation end process boundary,0.6411764705882353
infectious structure generative stage,collective pathogenic disposition,0.6357142857142857
infectious structure generative stage,neurotoxin disposition,0.6025423728813559
infectious structure generative stage,SARS-CoV-2 uncoating stage,0.6722222222222223
infectious structure generative stage,plan specification,0.5954545454545455
infectious structure generative stage,latency end temporal region,0.60625
infectious structure generative stage,innate immunity to infectious agent,0.6722222222222223
infectious structure generative stage,SARS-CoV-2 penetration stage,0.7115384615384616
infectious structure generative stage,infectious structure,0.8008771929824562
infectious structure generative stage,collective disposition,0.6194915254237288
infectious structure generative stage,static agent disposition,0.630327868852459
infectious structure generative stage,T cell receptor complex,0.6166666666666667
infectious structure generative stage,infectious structure host,0.8209677419354838
infectious structure generative stage,infectious agent population,0.715625
infectious structure generative stage,respiratory system disease,0.6404761904761905
infectious structure generative stage,leukocyte-mediated immunity to infectious agent,0.6404761904761905
infectious structure generative stage,generative stage,0.7518867924528303
infectious structure generative stage,humoral immunity to infectious agent,0.6554794520547945
infectious structure generative stage,infectious disease control strategy,0.7416666666666667
infectious structure generative stage,SARS-CoV-2 attachment stage,0.66875
infectious structure generative stage,infectious disease pandemic,0.73125
infectious structure generative stage,infectious structure generative stage,0.95
infectious structure generative stage,immunosuppressive disposition,0.6469696969696969
infectious structure generative stage,pathogenic disposition,0.6025423728813559
infectious structure generative stage,viral disease course,0.6078947368421053
infectious structure generative stage,passive immunity to infectious agent,0.6554794520547945
infectious structure generative stage,infectious disposition,0.6872881355932203
infectious structure generative stage,vaccination against infectious agent,0.682876712328767
infectious structure generative stage,susceptibility to infectious agent,0.6612676056338028
infectious structure generative stage,bacteriostatic disposition,0.6404761904761905
infectious structure generative stage,bactericidal disposition,0.5811475409836065
infectious structure generative stage,source of infection role,0.6467213114754098
infectious structure generative stage,invasion disposition,0.5903508771929825
infectious structure generative stage,disease course,0.6264705882352941
infectious structure generative stage,infectious disease course,0.7403225806451613
infectious structure generative stage,viricidal disposition,0.5706896551724138
infectious structure generative stage,acquired immunity to infectious agent,0.6527027027027027
infectious structure generative stage,complex infection,0.6166666666666667
infectious structure generative stage,COVID-19 disease incidence proportion,0.6121621621621621
infectious structure generative stage,coronavirus disease course,0.6404761904761905
infectious structure generative stage,biological vehicle role,0.6
infectious structure generative stage,symptomatic infectious agent carrier,0.6965753424657534
infectious structure generative stage,infectious disease prevalence,0.7227272727272727
infectious structure generative stage,SARS-CoV-2 genome replication stage,0.7
infectious structure generative stage,disposition,0.5541666666666667
infectious structure generative stage,infected population,0.6464285714285714
infectious structure generative stage,COVID-19 mortality rate,0.6166666666666667
infectious structure generative stage,viral disease,0.59
infectious structure generative stage,adhesion disposition,0.5728070175438597
infectious structure generative stage,developmental process,0.5706896551724138
infectious structure generative stage,disease,0.5863636363636363
infectious structure generative stage,symptomatic infectious structure carrier,0.7616883116883116
infectious structure generative stage,primary infectious disposition,0.658955223880597
infectious structure generative stage,infectious pathogen transmissibility,0.7239726027397261
infectious structure generative stage,infectious human pathogen,0.7241935483870968
infectious structure generative stage,immunization against infectious agent,0.6797297297297297
infectious structure generative stage,virus attachment stage,0.7042372881355932
infectious structure generative stage,SARS-CoV-2 transcription stage,0.6738805970149254
infectious structure generative stage,virus synthesis stage,0.6913793103448276
infectious structure generative stage,SARS-COV-2 adhesion disposition,0.5823529411764706
infectious structure generative stage,invasive disposition,0.6078947368421053
infectious structure generative stage,infectious agent host,0.760344827586207
infectious structure generative stage,long-term non-progressing infectious disease course,0.6545454545454545
infectious structure generative stage,viral disease epidemic,0.6025423728813559
infectious structure generative stage,fungicidal disposition,0.5686440677966101
infectious structure generative stage,viral disease pandemic,0.6025423728813559
infectious structure generative stage,virus penetration stage,0.7333333333333333
infectious structure generative stage,acute respiratory distress syndrome,0.6444444444444444
infectious structure generative stage,division of geopolitical entity,0.6411764705882353
infectious structure generative stage,infectious disease endemicity,0.7378787878787878
infectious structure generative stage,herd immunity to infectious organism,0.6691780821917809
infectious structure generative stage,exotoxin disposition,0.5728070175438597
infectious structure generative stage,infectious agent reservoir,0.7357142857142857
infectious structure generative stage,immunoglobulin complex,0.5686440677966101
infectious structure generative stage,COVID-19 pandemic,0.5611111111111111
infectious structure generative stage,SARS-CoV-2 synthesis stage,0.6563492063492063
infectious structure generative stage,infectious disease control objective specification,0.7258620689655172
infectious structure generative stage,opportunistic infectious disposition,0.6417808219178082
infectious structure generative stage,enterotoxin disposition,0.6
infectious structure generative stage,polymerase chain reaction,0.5951612903225807
infectious structure generative stage,COVID-19 disease course,0.6166666666666667
infectious structure generative stage,infectious disease incidence rate,0.75
infectious structure generative stage,single-stranded RNA retrovirus,0.6440298507462687
infectious structure generative stage,active immunization against infectious agent,0.6598765432098764
infectious structure generative stage,collective resistance disposition,0.6357142857142857
infectious structure generative stage,fungistatic disposition,0.6166666666666667
infectious structure generative stage,virus uncoating stage,0.7086206896551723
infectious structure generative stage,infectious agent,0.7330188679245283
infectious structure generative stage,establishment of a clinically abnormal colony,0.5841463414634146
infectious structure generative stage,coronavirus disease,0.6285714285714286
infectious structure generative stage,positive-sense single-stranded RNA virus,0.6448051948051949
infectious structure generative stage,drug susceptibility of infectious agent,0.6473684210526315
infectious structure generative stage,SARS-CoV-2 release stage,0.6795081967213115
geospatial region,communicability end temporal region,0.6807692307692308
geospatial region,infection end temporal region,0.7108695652173913
geospatial region,geospatial location,0.8388888888888889
geospatial region,incubation end temporal region,0.7053191489361703
geospatial region,two-dimensional spatial region,0.7904255319148936
geospatial region,one-dimensional temporal region,0.7208333333333333
geospatial region,temporal region,0.79375
geospatial region,disease surveillance objective specification,0.6139344262295081
geospatial region,B cell receptor complex,0.6
geospatial region,pathogen birth temporal region,0.7265957446808511
geospatial region,lower respiratory tract disease,0.6166666666666667
geospatial region,infectious disease incidence proportion,0.6285714285714286
geospatial region,acute infectious disease course,0.6166666666666667
geospatial region,communicability end process boundary,0.619811320754717
geospatial region,infection incidence proportion profile,0.5954545454545455
geospatial region,SARS-CoV-2 incidence proportion,0.6166666666666667
geospatial region,spatiotemporal region,0.8184210526315789
geospatial region,latency end process boundary,0.6055555555555556
geospatial region,zero-dimensional spatial region,0.7833333333333333
geospatial region,zero-dimensional temporal region,0.7357142857142857
geospatial region,chronic infectious disease course,0.61
geospatial region,infection start temporal region,0.7416666666666667
geospatial region,incubation end process boundary,0.6166666666666667
geospatial region,geographical region,0.8388888888888889
geospatial region,latency end temporal region,0.7
geospatial region,T cell receptor complex,0.6
geospatial region,viral disease course,0.6121621621621621
geospatial region,three-dimensional spatial region,0.7765306122448979
geospatial region,objective specification,0.65
geospatial region,country,0.575
geospatial region,disease course,0.6112903225806451
geospatial region,infectious disease course,0.6404761904761905
geospatial region,COVID-19 disease incidence proportion,0.6166666666666667
geospatial region,coronavirus disease course,0.6127906976744186
geospatial region,infection incidence proportion,0.6202127659574468
geospatial region,place closure control strategy,0.6414893617021277
geospatial region,object,0.5369565217391304
geospatial region,object aggregate,0.6318181818181818
geospatial region,long-term non-progressing infectious disease course,0.5970588235294118
geospatial region,communicability start temporal region,0.6907407407407408
geospatial region,geospatial region,0.95
geospatial region,division of geopolitical entity,0.6791666666666666
geospatial region,infectious disease control objective specification,0.6141791044776119
geospatial region,COVID-19 disease course,0.6
geospatial region,local infection,0.7
geospatial region,establishment of a clinically abnormal colony,0.6274193548387097
geospatial region,one-dimensional spatial region,0.7904255319148936
geospatial region,spatial region,0.9016129032258065
geospatial region,pathogen death temporal region,0.7265957446808511
intervention,infection incidence rate profile,0.609090909090909
intervention,SARS-CoV-2 incidence rate,0.5851351351351352
intervention,virulence factor disposition,0.65
intervention,infectious disease incidence,0.65
intervention,case isolation control strategy,0.5662790697674418
intervention,B cell receptor complex,0.5928571428571429
intervention,infection incidence rate,0.6444444444444444
intervention,infectious disease incidence proportion,0.6460784313725491
intervention,biological vehicle,0.5833333333333334
intervention,infection incidence proportion profile,0.63
intervention,SARS-CoV-2 incidence proportion,0.636046511627907
intervention,invasion factor,0.6722222222222223
intervention,pathogen vehicle,0.6285714285714286
intervention,COVID-19 incidence rate,0.5928571428571429
intervention,pathogen vehicle role,0.6318181818181818
intervention,infection incidence,0.6758064516129032
intervention,virulence factor,0.6642857142857143
intervention,COVID-19 incidence,0.5833333333333334
intervention,T cell receptor complex,0.6214285714285714
intervention,invasion disposition,0.7
intervention,COVID-19 disease incidence proportion,0.6132653061224489
intervention,biological vehicle role,0.5928571428571429
intervention,infection incidence proportion,0.6642857142857143
intervention,place closure control strategy,0.5928571428571429
intervention,intervention,0.95
intervention,infection incidence profile,0.6294871794871795
intervention,SARS-CoV-2 incidence,0.60625
intervention,geographical feature,0.575
intervention,action specification,0.66875
intervention,infectious disease incidence rate,0.6277777777777778
intervention,establishment of a clinically abnormal colony,0.5728070175438597
intervention,adhesion factor,0.5981481481481481
protein,SARS-CoV-2 membrane protein,0.6558823529411765
protein,T cell receptor complex,0.5833333333333334
protein,SARS-CoV-2 nucleoside protein,0.6444444444444444
protein,protein,0.95
latency interval,B cell receptor complex,0.6038461538461539
latency interval,infectious disease lifetime prevalence,0.6351851851851852
latency interval,latency end process boundary,0.7
latency interval,latency interval,0.95
latency interval,latency end temporal region,0.7755813953488372
latency interval,anatomical space,0.60625
latency interval,T cell receptor complex,0.6038461538461539
latency interval,communicability interval,0.75
latency interval,incubation interval,0.7928571428571428
latency interval,eclipse interval,0.79375
latency interval,division of geopolitical entity,0.5776595744680851
latency interval,transmission interval,0.7472972972972972
latency interval,action specification,0.6166666666666667
latency interval,latency start process boundary,0.6891304347826087
latency interval,COVID-19 lifetime prevalence,0.6545454545454545
latency interval,establishment of a clinically abnormal colony,0.6139344262295081
latency interval,cell space,0.6038461538461539
parasite,communicability end temporal region,0.5430232558139535
parasite,infection end temporal region,0.5581081081081081
parasite,incubation end temporal region,0.5552631578947369
parasite,site of infection,0.61
parasite,source of infection site,0.60625
parasite,B cell receptor complex,0.5467741935483871
parasite,double-stranded RNA virus,0.5712121212121213
parasite,communicability end process boundary,0.5409090909090909
parasite,latency end process boundary,0.5333333333333333
parasite,negative-sense single-stranded RNA virus,0.5541666666666667
parasite,incubation end process boundary,0.5269230769230769
parasite,latency end temporal region,0.5642857142857143
parasite,T cell receptor complex,0.5467741935483871
parasite,parasite,0.95
parasite,epitope site,0.7
parasite,parasite role,0.830952380952381
parasite,generically dependent continuant,0.55
parasite,pathogen portal of exit site,0.6722222222222223
parasite,pathogen portal of entry site,0.6662162162162162
parasite,site,0.7833333333333333
parasite,specifically dependent continuant,0.5475609756097561
parasite,single-stranded RNA retrovirus,0.5552631578947369
parasite,viral load,0.5611111111111111
parasite,establishment of a clinically abnormal colony,0.5066037735849056
parasite,positive-sense single-stranded RNA virus,0.5541666666666667
symptomatic infectious structure carrier,virostatic disposition,0.6435483870967742
symptomatic infectious structure carrier,zoonotic disposition,0.6166666666666667
symptomatic infectious structure carrier,infectious disease mortality rate,0.682876712328767
symptomatic infectious structure carrier,infection incidence rate profile,0.6722222222222223
symptomatic infectious structure carrier,infectious structure aggregate,0.7928571428571428
symptomatic infectious structure carrier,communicability end temporal region,0.61
symptomatic infectious structure carrier,infection end temporal region,0.6528985507246376
symptomatic infectious structure carrier,infectious disease,0.7086206896551723
symptomatic infectious structure carrier,SARS-CoV-2 incidence rate,0.65
symptomatic infectious structure carrier,incubation end temporal region,0.6214285714285714
symptomatic infectious structure carrier,normal resident microbiota population,0.6188311688311688
symptomatic infectious structure carrier,virulence factor disposition,0.6117647058823529
symptomatic infectious structure carrier,viral adhesion disposition,0.5863636363636363
symptomatic infectious structure carrier,parasitostatic disposition,0.6469696969696969
symptomatic infectious structure carrier,infectious disease incidence,0.7
symptomatic infectious structure carrier,reverse zoonotic disposition,0.6117647058823529
symptomatic infectious structure carrier,disease surveillance objective specification,0.6285714285714286
symptomatic infectious structure carrier,infectious agent host role,0.6924242424242425
symptomatic infectious structure carrier,macromolecular complex,0.6112903225806451
symptomatic infectious structure carrier,asymptomatic infectious structure carrier,0.9438271604938271
symptomatic infectious structure carrier,architectual structure,0.7241935483870968
symptomatic infectious structure carrier,B cell receptor complex,0.6087301587301588
symptomatic infectious structure carrier,passive immunization against infectious agent,0.6852941176470588
symptomatic infectious structure carrier,infection incidence rate,0.66875
symptomatic infectious structure carrier,infectious disease lifetime prevalence,0.6679487179487179
symptomatic infectious structure carrier,toxin disposition,0.6078947368421053
symptomatic infectious structure carrier,lower respiratory tract disease,0.6330985915492958
symptomatic infectious structure carrier,infectious disease incidence proportion,0.6778481012658227
symptomatic infectious structure carrier,acute infectious disease course,0.7316901408450704
symptomatic infectious structure carrier,cidal agent disposition,0.5928571428571429
symptomatic infectious structure carrier,infectious disorder,0.7042372881355932
symptomatic infectious structure carrier,parasiticidal disposition,0.6192307692307693
symptomatic infectious structure carrier,infectious disease sporadicity,0.6785714285714286
symptomatic infectious structure carrier,communicability end process boundary,0.6210526315789474
symptomatic infectious structure carrier,acellular structure aggregate,0.7108695652173913
symptomatic infectious structure carrier,infectious agent colony,0.6722222222222223
symptomatic infectious structure carrier,pathogen transporter,0.6333333333333333
symptomatic infectious structure carrier,transmissibility disposition,0.5970588235294118
symptomatic infectious structure carrier,latency end process boundary,0.6264705882352941
symptomatic infectious structure carrier,infectious disease epidemic,0.6888059701492537
symptomatic infectious structure carrier,infectious agent generative stage,0.6965753424657534
symptomatic infectious structure carrier,disease transmission model,0.5863636363636363
symptomatic infectious structure carrier,endotoxin disposition,0.5975409836065574
symptomatic infectious structure carrier,cidal agent,0.5480392156862746
symptomatic infectious structure carrier,infectious structure host role,0.7785714285714286
symptomatic infectious structure carrier,COVID-19 incidence rate,0.6404761904761905
symptomatic infectious structure carrier,cytotoxin disposition,0.630327868852459
symptomatic infectious structure carrier,chronic infectious disease course,0.7376712328767124
symptomatic infectious structure carrier,asymptomatic infectious agent carrier,0.8655844155844156
symptomatic infectious structure carrier,COVID-19 epidemic,0.5728070175438597
symptomatic infectious structure carrier,sterilizing immunity to infectious agent,0.675
symptomatic infectious structure carrier,diseased population,0.5686440677966101
symptomatic infectious structure carrier,acellular structure,0.6872881355932203
symptomatic infectious structure carrier,incubation end process boundary,0.6330985915492958
symptomatic infectious structure carrier,collective pathogenic disposition,0.6006849315068493
symptomatic infectious structure carrier,neurotoxin disposition,0.5951612903225807
symptomatic infectious structure carrier,plan specification,0.6051724137931035
symptomatic infectious structure carrier,latency end temporal region,0.6141791044776119
symptomatic infectious structure carrier,innate immunity to infectious agent,0.6766666666666665
symptomatic infectious structure carrier,infectious structure,0.7833333333333333
symptomatic infectious structure carrier,collective disposition,0.5951612903225807
symptomatic infectious structure carrier,static agent disposition,0.66875
symptomatic infectious structure carrier,T cell receptor complex,0.6246031746031746
symptomatic infectious structure carrier,asymptomatic carrier role,0.7423076923076922
symptomatic infectious structure carrier,infectious structure host,0.7730769230769231
symptomatic infectious structure carrier,infectious agent population,0.6738805970149254
symptomatic infectious structure carrier,respiratory system disease,0.6318181818181818
symptomatic infectious structure carrier,leukocyte-mediated immunity to infectious agent,0.6798850574712644
symptomatic infectious structure carrier,humoral immunity to infectious agent,0.6868421052631578
symptomatic infectious structure carrier,infectious disease control strategy,0.69
symptomatic infectious structure carrier,infectious disease pandemic,0.6888059701492537
symptomatic infectious structure carrier,infectious structure generative stage,0.7616883116883116
symptomatic infectious structure carrier,immunosuppressive disposition,0.5949275362318841
symptomatic infectious structure carrier,innate immune response,0.6112903225806451
symptomatic infectious structure carrier,pathogenic disposition,0.6274193548387097
symptomatic infectious structure carrier,viral disease course,0.6166666666666667
symptomatic infectious structure carrier,passive immunity to infectious agent,0.6868421052631578
symptomatic infectious structure carrier,infectious disposition,0.6758064516129032
symptomatic infectious structure carrier,vaccination against infectious agent,0.6868421052631578
symptomatic infectious structure carrier,susceptibility to infectious agent,0.6932432432432433
symptomatic infectious structure carrier,bacteriostatic disposition,0.6318181818181818
symptomatic infectious structure carrier,bactericidal disposition,0.60625
symptomatic infectious structure carrier,invasion disposition,0.5833333333333334
symptomatic infectious structure carrier,disease course,0.5981481481481481
symptomatic infectious structure carrier,infectious disease course,0.7115384615384616
symptomatic infectious structure carrier,viricidal disposition,0.5811475409836065
symptomatic infectious structure carrier,acquired immunity to infectious agent,0.6707792207792208
symptomatic infectious structure carrier,complex infection,0.6429824561403508
symptomatic infectious structure carrier,COVID-19 disease incidence proportion,0.6188311688311688
symptomatic infectious structure carrier,coronavirus disease course,0.6318181818181818
symptomatic infectious structure carrier,asymptomatic carrier,0.7666666666666666
symptomatic infectious structure carrier,symptomatic infectious agent carrier,0.8710526315789474
symptomatic infectious structure carrier,infectious disease prevalence,0.6818840579710145
symptomatic infectious structure carrier,disposition,0.5872549019607843
symptomatic infectious structure carrier,infected population,0.6194915254237288
symptomatic infectious structure carrier,COVID-19 mortality rate,0.5928571428571429
symptomatic infectious structure carrier,viral disease,0.5820754716981132
symptomatic infectious structure carrier,adhesion disposition,0.5833333333333334
symptomatic infectious structure carrier,disease,0.5563829787234043
symptomatic infectious structure carrier,symptomatic infectious structure carrier,0.95
symptomatic infectious structure carrier,primary infectious disposition,0.7071428571428571
symptomatic infectious structure carrier,designative information content entity,0.6679487179487179
symptomatic infectious structure carrier,symptomatic carrier role,0.746875
symptomatic infectious structure carrier,infectious pathogen transmissibility,0.6605263157894737
symptomatic infectious structure carrier,infectious human pathogen,0.6807692307692308
symptomatic infectious structure carrier,immunization against infectious agent,0.6967532467532468
symptomatic infectious structure carrier,virus synthesis stage,0.630327868852459
symptomatic infectious structure carrier,SARS-COV-2 adhesion disposition,0.6049295774647887
symptomatic infectious structure carrier,invasive disposition,0.5833333333333334
symptomatic infectious structure carrier,infectious agent host,0.6631147540983606
symptomatic infectious structure carrier,long-term non-progressing infectious disease course,0.6917582417582417
symptomatic infectious structure carrier,viral disease epidemic,0.5951612903225807
symptomatic infectious structure carrier,fungicidal disposition,0.5790322580645162
symptomatic infectious structure carrier,viral disease pandemic,0.5951612903225807
symptomatic infectious structure carrier,acute respiratory distress syndrome,0.6366666666666667
symptomatic infectious structure carrier,symptomatic carrier,0.7720338983050847
symptomatic infectious structure carrier,infectious disease endemicity,0.6818840579710145
symptomatic infectious structure carrier,herd immunity to infectious organism,0.6868421052631578
symptomatic infectious structure carrier,pathogen transporter role,0.6346153846153847
symptomatic infectious structure carrier,exotoxin disposition,0.6
symptomatic infectious structure carrier,infectious agent reservoir,0.7075757575757575
symptomatic infectious structure carrier,immunoglobulin complex,0.5790322580645162
symptomatic infectious structure carrier,COVID-19 pandemic,0.5728070175438597
symptomatic infectious structure carrier,SARS-CoV-2 synthesis stage,0.6469696969696969
symptomatic infectious structure carrier,infectious disease control objective specification,0.6833333333333332
symptomatic infectious structure carrier,opportunistic infectious disposition,0.7131578947368421
symptomatic infectious structure carrier,enterotoxin disposition,0.6087301587301588
symptomatic infectious structure carrier,polymerase chain reaction,0.6346153846153847
symptomatic infectious structure carrier,COVID-19 disease course,0.6246031746031746
symptomatic infectious structure carrier,infectious disease incidence rate,0.6965753424657534
symptomatic infectious structure carrier,active immunization against infectious agent,0.6761904761904762
symptomatic infectious structure carrier,collective resistance disposition,0.6143835616438357
symptomatic infectious structure carrier,symptom,0.598936170212766
symptomatic infectious structure carrier,fungistatic disposition,0.6404761904761905
symptomatic infectious structure carrier,local infection,0.65
symptomatic infectious structure carrier,infectious agent,0.6821428571428573
symptomatic infectious structure carrier,establishment of a clinically abnormal colony,0.6029411764705883
symptomatic infectious structure carrier,coronavirus disease,0.6194915254237288
symptomatic infectious structure carrier,drug susceptibility of infectious agent,0.6778481012658227
symptomatic infectious structure carrier,static agent,0.6230769230769231
adaptive immune response,immune response,0.8346153846153846
adaptive immune response,infectious disease mortality rate,0.6078947368421053
adaptive immune response,infection incidence rate profile,0.6642857142857143
adaptive immune response,communicability end temporal region,0.6194915254237288
adaptive immune response,surveillance process,0.6772727272727272
adaptive immune response,infection end temporal region,0.6386792452830189
adaptive immune response,SARS-CoV-2 incidence rate,0.6336734693877552
adaptive immune response,incubation end temporal region,0.6537037037037037
adaptive immune response,resistant entity,0.6
adaptive immune response,virus release stage,0.6593023255813953
adaptive immune response,B cell receptor complex,0.6202127659574468
adaptive immune response,passive immunization against infectious agent,0.6673913043478261
adaptive immune response,infection incidence rate,0.6375
adaptive immune response,lower respiratory tract disease,0.6136363636363636
adaptive immune response,genetic resistance to pathogen,0.6351851851851852
adaptive immune response,process,0.6112903225806451
adaptive immune response,droplet pathogen transmission process,0.6467213114754098
adaptive immune response,communicability end process boundary,0.6333333333333333
adaptive immune response,latency end process boundary,0.6615384615384616
adaptive immune response,susceptible population,0.6239130434782608
adaptive immune response,COVID-19 incidence rate,0.6202127659574468
adaptive immune response,negative regulation of developmental process,0.6558823529411765
adaptive immune response,antibiotic resistance,0.6722222222222223
adaptive immune response,resistance to drug,0.5928571428571429
adaptive immune response,process of establishing an infection,0.6
adaptive immune response,incubation end process boundary,0.65
adaptive immune response,pathogen death process boundary,0.65
adaptive immune response,plan specification,0.6166666666666667
adaptive immune response,latency end temporal region,0.6656862745098039
adaptive immune response,virus adhesion susceptible cell,0.6318181818181818
adaptive immune response,T cell receptor complex,0.6414893617021277
adaptive immune response,indirect pathogen transmission process,0.6435483870967742
adaptive immune response,planned process,0.6551282051282051
adaptive immune response,innate immune response,0.8630434782608696
adaptive immune response,passive immunity to infectious agent,0.7
adaptive immune response,susceptible organism,0.6318181818181818
adaptive immune response,COVID-19 mortality rate,0.5776595744680851
adaptive immune response,process profile,0.6294871794871795
adaptive immune response,negative regulation of life-sustaining process,0.65
adaptive immune response,place closure control strategy,0.6351851851851852
adaptive immune response,developmental process,0.6722222222222223
adaptive immune response,biological process,0.6166666666666667
adaptive immune response,humoral immune response,0.8117021276595744
adaptive immune response,SARS-COV-2 adhesion susceptible cell,0.6
adaptive immune response,incubation start process boundary,0.6254385964912281
adaptive immune response,pathogen birth process boundary,0.65
adaptive immune response,resistance to pathogen,0.6239130434782608
adaptive immune response,negative regulation of immune response,0.7887096774193548
adaptive immune response,negative regulation of viral process,0.6666666666666667
adaptive immune response,contact pathogen transmission process,0.6467213114754098
adaptive immune response,function,0.575
adaptive immune response,symbiotic process,0.6207317073170732
adaptive immune response,infection start process boundary,0.6285714285714286
adaptive immune response,action specification,0.6545454545454545
adaptive immune response,protective resistance,0.6944444444444444
adaptive immune response,latency start process boundary,0.6351851851851852
adaptive immune response,immune population,0.6939024390243902
adaptive immune response,process of establishing viral infection,0.6087301587301588
adaptive immune response,negative regulation of biological process,0.65
adaptive immune response,polymerase chain reaction,0.6540816326530612
adaptive immune response,infectious disease incidence rate,0.6254385964912281
adaptive immune response,communicability start process boundary,0.6112903225806451
adaptive immune response,process that results in death,0.619811320754717
adaptive immune response,collective resistance disposition,0.6780701754385965
adaptive immune response,adaptive immune response,0.95
adaptive immune response,establishment of a clinically abnormal colony,0.5949275362318841
adaptive immune response,process boundary,0.6
adaptive immune response,horizontal pathogen transmission process,0.6375
adaptive immune response,SARS-CoV-2 release stage,0.6166666666666667
adaptive immune response,pathogen transmission process,0.6575471698113208
serology assay,infectious disease mortality rate,0.598936170212766
serology assay,infection incidence rate profile,0.5369565217391304
serology assay,SARS-CoV-2 incidence rate,0.5782051282051281
serology assay,B cell receptor complex,0.5581081081081081
serology assay,infection incidence rate,0.5552631578947369
serology assay,serology assay,0.95
serology assay,COVID-19 incidence rate,0.5310810810810811
serology assay,viral plaque assay,0.7
serology assay,T cell receptor complex,0.5581081081081081
serology assay,COVID-19 mortality rate,0.5851351351351352
serology assay,assay,0.7131578947368421
serology assay,division of geopolitical entity,0.5833333333333334
serology assay,infectious disease incidence rate,0.5776595744680851
serology assay,establishment of a clinically abnormal colony,0.6025423728813559
immunodeficient organism,extended organism,0.7426829268292683
immunodeficient organism,information content entity,0.67
immunodeficient organism,infectious structure aggregate,0.6351851851851852
immunodeficient organism,geographical entity,0.6127906976744186
immunodeficient organism,drug-based immunosuppressed organism,0.7333333333333333
immunodeficient organism,resistant entity,0.625
immunodeficient organism,immunocompetent organism,0.8458333333333333
immunodeficient organism,virulence factor disposition,0.6615384615384616
immunodeficient organism,case isolation control strategy,0.6136363636363636
immunodeficient organism,material entity,0.6294871794871795
immunodeficient organism,asymptomatic infectious structure carrier,0.6192307692307693
immunodeficient organism,architectual structure,0.5804347826086956
immunodeficient organism,B cell receptor complex,0.598936170212766
immunodeficient organism,entity,0.5833333333333334
immunodeficient organism,directive information content entity,0.6333333333333333
immunodeficient organism,acellular structure aggregate,0.5820754716981132
immunodeficient organism,invasion factor,0.6551282051282051
immunodeficient organism,realizable entity,0.5963414634146341
immunodeficient organism,pathologically immunosuppressed organism,0.715625
immunodeficient organism,infectious structure host role,0.6166666666666667
immunodeficient organism,descriptive information content entity,0.6274193548387097
immunodeficient organism,establishment of localization in human host,0.6291044776119403
immunodeficient organism,acellular structure,0.5430232558139535
immunodeficient organism,virulence factor,0.675
immunodeficient organism,molecular entity,0.65
immunodeficient organism,immunosuppressed organism,0.7969387755102041
immunodeficient organism,plan specification,0.6404761904761905
immunodeficient organism,infectious structure,0.609090909090909
immunodeficient organism,T cell receptor complex,0.598936170212766
immunodeficient organism,infectious structure host,0.6336734693877552
immunodeficient organism,organism population,0.636046511627907
immunodeficient organism,infectious structure generative stage,0.630327868852459
immunodeficient organism,susceptible organism,0.7454545454545455
immunodeficient organism,organism substance,0.6404761904761905
immunodeficient organism,anatomical entity,0.6451219512195122
immunodeficient organism,geopolitical entity,0.6127906976744186
immunodeficient organism,symptomatic infectious structure carrier,0.621875
immunodeficient organism,designative information content entity,0.6435483870967742
immunodeficient organism,immunodeficient organism,0.95
immunodeficient organism,infectious human pathogen,0.6540816326530612
immunodeficient organism,colonization of human,0.6277777777777778
immunodeficient organism,immaterial entity,0.6695121951219513
immunodeficient organism,blood,0.5189655172413793
immunodeficient organism,division of geopolitical entity,0.6318181818181818
immunodeficient organism,geographical feature,0.5863636363636363
immunodeficient organism,herd immunity to infectious organism,0.75
immunodeficient organism,action specification,0.6545454545454545
immunodeficient organism,processed material,0.5928571428571429
immunodeficient organism,organism,0.7
immunodeficient organism,establishment of a clinically abnormal colony,0.6384057971014493
immunodeficient organism,adhesion factor,0.6294871794871795
immunodeficient organism,material processing,0.6127906976744186
prion aggregate,virus aggregate,0.8166666666666665
prion aggregate,infectious disease mortality rate,0.6166666666666667
prion aggregate,infection incidence rate profile,0.6202127659574468
prion aggregate,infectious structure aggregate,0.7166666666666667
prion aggregate,SARS-CoV-2 incidence rate,0.65
prion aggregate,site of infection,0.60625
prion aggregate,prion replication,0.7625
prion aggregate,SARS-CoV-2 aggregate,0.7928571428571428
prion aggregate,source of infection site,0.6294871794871795
prion aggregate,B cell receptor complex,0.581578947368421
prion aggregate,infection incidence rate,0.6551282051282051
prion aggregate,acellular structure aggregate,0.7
prion aggregate,COVID-19 incidence rate,0.6342105263157894
prion aggregate,collective pathogenic disposition,0.575
prion aggregate,coronavirus aggregate,0.8111111111111111
prion aggregate,collective disposition,0.5581081081081081
prion aggregate,T cell receptor complex,0.581578947368421
prion aggregate,disordered prion,0.6112903225806451
prion aggregate,epitope site,0.6722222222222223
prion aggregate,prion aggregate,0.95
prion aggregate,pathogen portal of exit site,0.636046511627907
prion aggregate,COVID-19 mortality rate,0.6342105263157894
prion aggregate,pathogen portal of entry site,0.6318181818181818
prion aggregate,viroid aggregate,0.8370967741935484
prion aggregate,site,0.6078947368421053
prion aggregate,object aggregate,0.8048387096774193
prion aggregate,infectious disease incidence rate,0.6166666666666667
prion aggregate,collective resistance disposition,0.575
prion aggregate,viral load,0.57
prion aggregate,establishment of a clinically abnormal colony,0.5666666666666667
prion aggregate,prion,0.7
appearance of disorder,virostatic disposition,0.6318181818181818
appearance of disorder,zoonotic disposition,0.6166666666666667
appearance of disorder,infectious disease mortality rate,0.6318181818181818
appearance of disorder,infectious disease,0.65
appearance of disorder,virulence factor disposition,0.67
appearance of disorder,viral adhesion disposition,0.6375
appearance of disorder,parasitostatic disposition,0.6583333333333334
appearance of disorder,infectious disease incidence,0.63
appearance of disorder,reverse zoonotic disposition,0.65
appearance of disorder,establishment of localization in host,0.6025423728813559
appearance of disorder,disease surveillance objective specification,0.6318181818181818
appearance of disorder,infectious agent host role,0.6166666666666667
appearance of disorder,material entity,0.6121621621621621
appearance of disorder,B cell receptor complex,0.6277777777777778
appearance of disorder,colonized host,0.5888888888888889
appearance of disorder,virus host,0.575
appearance of disorder,infectious disease lifetime prevalence,0.6
appearance of disorder,toxin disposition,0.6038461538461539
appearance of disorder,lower respiratory tract disease,0.6386792452830189
appearance of disorder,infectious disease incidence proportion,0.6139344262295081
appearance of disorder,acute infectious disease course,0.6764150943396227
appearance of disorder,cidal agent disposition,0.6277777777777778
appearance of disorder,infectious disorder,0.7426829268292683
appearance of disorder,appearance of disorder,0.95
appearance of disorder,parasiticidal disposition,0.6627659574468084
appearance of disorder,infectious disease sporadicity,0.6423076923076922
appearance of disorder,transmissibility disposition,0.61
appearance of disorder,colonization of host,0.6166666666666667
appearance of disorder,infectious disease epidemic,0.6336734693877552
appearance of disorder,disease transmission model,0.6583333333333334
appearance of disorder,endotoxin disposition,0.636046511627907
appearance of disorder,infectious structure host role,0.6230769230769231
appearance of disorder,cytotoxin disposition,0.6127906976744186
appearance of disorder,host,0.5269230769230769
appearance of disorder,chronic infectious disease course,0.6681818181818181
appearance of disorder,virus disorder,0.7277777777777777
appearance of disorder,establishment of localization in human host,0.5884615384615385
appearance of disorder,diseased population,0.6207317073170732
appearance of disorder,SARS-CoV-2 disorder,0.7670731707317073
appearance of disorder,collective pathogenic disposition,0.6318181818181818
appearance of disorder,neurotoxin disposition,0.6318181818181818
appearance of disorder,dead-end host role,0.65
appearance of disorder,definitive host role,0.6404761904761905
appearance of disorder,collective disposition,0.6318181818181818
appearance of disorder,static agent disposition,0.6239130434782608
appearance of disorder,T cell receptor complex,0.6277777777777778
appearance of disorder,infectious structure host,0.598936170212766
appearance of disorder,respiratory system disease,0.6375
appearance of disorder,entry into host,0.6121621621621621
appearance of disorder,adhesion of symbiont to host,0.63
appearance of disorder,infectious disease control strategy,0.6254385964912281
appearance of disorder,infectious disease pandemic,0.6336734693877552
appearance of disorder,immunosuppressive disposition,0.6264705882352941
appearance of disorder,pathogenic disposition,0.6545454545454545
appearance of disorder,viral disease course,0.6642857142857143
appearance of disorder,entry into host through host barriers,0.6194915254237288
appearance of disorder,infectious disposition,0.6318181818181818
appearance of disorder,bacteriostatic disposition,0.6583333333333334
appearance of disorder,bactericidal disposition,0.6456521739130434
appearance of disorder,pathogen host,0.6214285714285714
appearance of disorder,invasion disposition,0.6166666666666667
appearance of disorder,disease course,0.6444444444444444
appearance of disorder,infectious disease course,0.6627659574468084
appearance of disorder,viricidal disposition,0.6127906976744186
appearance of disorder,COVID-19 disease incidence proportion,0.6025423728813559
appearance of disorder,coronavirus disease course,0.6375
appearance of disorder,intermediate host,0.6294871794871795
appearance of disorder,infectious disease prevalence,0.6264705882352941
appearance of disorder,disposition,0.5712121212121213
appearance of disorder,viral disease,0.65
appearance of disorder,adhesion disposition,0.6404761904761905
appearance of disorder,disease,0.5879310344827586
appearance of disorder,primary infectious disposition,0.6615384615384616
appearance of disorder,pathogen host role,0.65
appearance of disorder,coronavirus disorder,0.7119047619047619
appearance of disorder,intermediate host role,0.6545454545454545
appearance of disorder,dead-end host,0.6214285714285714
appearance of disorder,host role,0.5790322580645162
appearance of disorder,establishment of localization in virus host,0.6038461538461539
appearance of disorder,SARS-COV-2 adhesion disposition,0.6386792452830189
appearance of disorder,invasive disposition,0.6166666666666667
appearance of disorder,infectious agent host,0.5895348837209302
appearance of disorder,long-term non-progressing infectious disease course,0.6280821917808219
appearance of disorder,viral disease epidemic,0.6318181818181818
appearance of disorder,fungicidal disposition,0.609090909090909
appearance of disorder,viral disease pandemic,0.6318181818181818
appearance of disorder,acute respiratory distress syndrome,0.6605263157894737
appearance of disorder,geographical feature,0.6404761904761905
appearance of disorder,infectious disease endemicity,0.6264705882352941
appearance of disorder,disorder,0.7166666666666667
appearance of disorder,exotoxin disposition,0.6166666666666667
appearance of disorder,processed material,0.65
appearance of disorder,infectious disease control objective specification,0.5888888888888889
appearance of disorder,symbiont host role,0.6
appearance of disorder,opportunistic infectious disposition,0.656896551724138
appearance of disorder,quality,0.5189655172413793
appearance of disorder,enterotoxin disposition,0.65
appearance of disorder,COVID-19 disease course,0.65
appearance of disorder,infectious disease incidence rate,0.6318181818181818
appearance of disorder,collective resistance disposition,0.65
appearance of disorder,fungistatic disposition,0.6055555555555556
appearance of disorder,establishment of a clinically abnormal colony,0.5992537313432835
appearance of disorder,coronavirus disease,0.6207317073170732
appearance of disorder,definitive host,0.6121621621621621
appearance of disorder,static agent,0.5676470588235294
appearance of disorder,material processing,0.6207317073170732
infectious structure host role,virostatic disposition,0.6423076923076922
infectious structure host role,zoonotic disposition,0.63
infectious structure host role,infectious disease mortality rate,0.7515873015873015
infectious structure host role,infection incidence rate profile,0.7403225806451613
infectious structure host role,infectious structure aggregate,0.8333333333333335
infectious structure host role,communicability end temporal region,0.6192307692307693
infectious structure host role,infection end temporal region,0.7042372881355932
infectious structure host role,infectious disease,0.7625
infectious structure host role,SARS-CoV-2 incidence rate,0.6136363636363636
infectious structure host role,incubation end temporal region,0.6666666666666667
infectious structure host role,virulence factor disposition,0.656896551724138
infectious structure host role,viral adhesion disposition,0.6285714285714286
infectious structure host role,parasitostatic disposition,0.6464285714285714
infectious structure host role,infectious disease incidence,0.7258620689655172
infectious structure host role,reservoir of pathogen role,0.6642857142857143
infectious structure host role,reverse zoonotic disposition,0.6224137931034482
infectious structure host role,establishment of localization in host,0.6440298507462687
infectious structure host role,disease surveillance objective specification,0.6256756756756756
infectious structure host role,infectious agent host role,0.8428571428571427
infectious structure host role,macromolecular complex,0.6230769230769231
infectious structure host role,asymptomatic infectious structure carrier,0.7739436619718311
infectious structure host role,architectual structure,0.7384615384615384
infectious structure host role,B cell receptor complex,0.6386792452830189
infectious structure host role,passive immunization against infectious agent,0.6366666666666667
infectious structure host role,infection incidence rate,0.7092592592592593
infectious structure host role,colonized host,0.6318181818181818
infectious structure host role,virus host,0.65
infectious structure host role,pathogen portal of entry role,0.6703389830508475
infectious structure host role,infectious disease lifetime prevalence,0.7294117647058823
infectious structure host role,toxin disposition,0.6202127659574468
infectious structure host role,lower respiratory tract disease,0.630327868852459
infectious structure host role,infectious disease incidence proportion,0.7108695652173913
infectious structure host role,acute infectious disease course,0.728688524590164
infectious structure host role,cidal agent disposition,0.619811320754717
infectious structure host role,infectious disorder,0.7561224489795919
infectious structure host role,role,0.5676470588235294
infectious structure host role,appearance of disorder,0.6230769230769231
infectious structure host role,parasiticidal disposition,0.6136363636363636
infectious structure host role,infectious disease sporadicity,0.7166666666666667
infectious structure host role,mutualist role,0.6772727272727272
infectious structure host role,communicability end process boundary,0.6166666666666667
infectious structure host role,acellular structure aggregate,0.7042372881355932
infectious structure host role,infectious agent colony,0.7518867924528303
infectious structure host role,transmissibility disposition,0.6224137931034482
infectious structure host role,latency end process boundary,0.6051724137931035
infectious structure host role,colonization of host,0.65
infectious structure host role,infectious disease epidemic,0.730701754385965
infectious structure host role,infectious agent generative stage,0.7515873015873015
infectious structure host role,disease transmission model,0.6285714285714286
infectious structure host role,endotoxin disposition,0.6264705882352941
infectious structure host role,infectious structure host role,0.95
infectious structure host role,COVID-19 incidence rate,0.619811320754717
infectious structure host role,cytotoxin disposition,0.6264705882352941
infectious structure host role,pathogen vehicle role,0.6460784313725491
infectious structure host role,host,0.5676470588235294
infectious structure host role,chronic infectious disease course,0.7198412698412698
infectious structure host role,asymptomatic infectious agent carrier,0.6888059701492537
infectious structure host role,COVID-19 epidemic,0.5563829787234043
infectious structure host role,mechanical vector role,0.6807692307692308
infectious structure host role,sterilizing immunity to infectious agent,0.6357142857142857
infectious structure host role,establishment of localization in human host,0.6417808219178082
infectious structure host role,diseased population,0.6132653061224489
infectious structure host role,acellular structure,0.6948979591836735
infectious structure host role,incubation end process boundary,0.6631147540983606
infectious structure host role,collective pathogenic disposition,0.6404761904761905
infectious structure host role,neurotoxin disposition,0.6423076923076922
infectious structure host role,dead-end host role,0.7
infectious structure host role,definitive host role,0.75
infectious structure host role,latency end temporal region,0.6078947368421053
infectious structure host role,innate immunity to infectious agent,0.65
infectious structure host role,infectious structure,0.85
infectious structure host role,collective disposition,0.6423076923076922
infectious structure host role,static agent disposition,0.6166666666666667
infectious structure host role,T cell receptor complex,0.6386792452830189
infectious structure host role,asymptomatic carrier role,0.65
infectious structure host role,infectious structure host,0.9045454545454545
infectious structure host role,infectious agent population,0.730701754385965
infectious structure host role,respiratory system disease,0.6285714285714286
infectious structure host role,entry into host,0.65
infectious structure host role,leukocyte-mediated immunity to infectious agent,0.6188311688311688
infectious structure host role,adhesion of symbiont to host,0.656896551724138
infectious structure host role,humoral immunity to infectious agent,0.6469696969696969
infectious structure host role,infectious disease control strategy,0.7576923076923078
infectious structure host role,infectious disease pandemic,0.730701754385965
infectious structure host role,infectious structure generative stage,0.8082089552238806
infectious structure host role,immunosuppressive disposition,0.6533898305084747
infectious structure host role,pathogenic disposition,0.6038461538461539
infectious structure host role,viral disease course,0.63
infectious structure host role,entry into host through host barriers,0.703731343283582
infectious structure host role,secondary infection role,0.6907407407407408
infectious structure host role,passive immunity to infectious agent,0.6469696969696969
infectious structure host role,infectious disposition,0.7576923076923078
infectious structure host role,vaccination against infectious agent,0.6621212121212122
infectious structure host role,susceptibility to infectious agent,0.653125
infectious structure host role,bacteriostatic disposition,0.6642857142857143
infectious structure host role,bactericidal disposition,0.6166666666666667
infectious structure host role,source of infection role,0.6907407407407408
infectious structure host role,pathogen host,0.636046511627907
infectious structure host role,invasion disposition,0.65
infectious structure host role,disease course,0.6545454545454545
infectious structure host role,infectious disease course,0.759090909090909
infectious structure host role,viricidal disposition,0.6264705882352941
infectious structure host role,acquired immunity to infectious agent,0.6440298507462687
infectious structure host role,complex infection,0.6202127659574468
infectious structure host role,COVID-19 disease incidence proportion,0.5992537313432835
infectious structure host role,coronavirus disease course,0.6464285714285714
infectious structure host role,biological vehicle role,0.6386792452830189
infectious structure host role,symptomatic infectious agent carrier,0.6924242424242425
infectious structure host role,symbiont role,0.636046511627907
infectious structure host role,parasite role,0.636046511627907
infectious structure host role,intermediate host,0.6840425531914894
infectious structure host role,pathogen vector role,0.67
infectious structure host role,infectious disease prevalence,0.7550847457627118
infectious structure host role,disposition,0.5963414634146341
infectious structure host role,infected population,0.6744897959183673
infectious structure host role,COVID-19 mortality rate,0.619811320754717
infectious structure host role,viral disease,0.5895348837209302
infectious structure host role,primary infection role,0.7
infectious structure host role,biological role,0.6277777777777778
infectious structure host role,adhesion disposition,0.63
infectious structure host role,disease,0.5851351351351352
infectious structure host role,symptomatic infectious structure carrier,0.7785714285714286
infectious structure host role,biological vector role,0.6615384615384616
infectious structure host role,primary infectious disposition,0.7166666666666667
infectious structure host role,pathogen host role,0.7208333333333333
infectious structure host role,symptomatic carrier role,0.6537037037037037
infectious structure host role,infectious pathogen transmissibility,0.7075757575757575
infectious structure host role,intermediate host role,0.7576923076923078
infectious structure host role,dead-end host,0.6127906976744186
infectious structure host role,host role,0.6807692307692308
infectious structure host role,infectious human pathogen,0.740909090909091
infectious structure host role,establishment of localization in virus host,0.6554794520547945
infectious structure host role,immunization against infectious agent,0.658955223880597
infectious structure host role,virus synthesis stage,0.6656862745098039
infectious structure host role,SARS-COV-2 adhesion disposition,0.5975409836065574
infectious structure host role,pathogen portal of exit role,0.6741379310344828
infectious structure host role,invasive disposition,0.63
infectious structure host role,infectious agent host,0.7833333333333333
infectious structure host role,long-term non-progressing infectious disease course,0.6598765432098764
infectious structure host role,viral disease epidemic,0.5846153846153846
infectious structure host role,commensal role,0.6545454545454545
infectious structure host role,epitope role,0.6642857142857143
infectious structure host role,fungicidal disposition,0.6230769230769231
infectious structure host role,viral disease pandemic,0.5846153846153846
infectious structure host role,acute respiratory distress syndrome,0.6653846153846155
infectious structure host role,division of geopolitical entity,0.5975409836065574
infectious structure host role,infectious disease endemicity,0.7211864406779661
infectious structure host role,function,0.581578947368421
infectious structure host role,herd immunity to infectious organism,0.6469696969696969
infectious structure host role,pathogen transporter role,0.6681818181818181
infectious structure host role,exotoxin disposition,0.63
infectious structure host role,infectious agent reservoir,0.7535714285714286
infectious structure host role,antigen role,0.6642857142857143
infectious structure host role,immunoglobulin complex,0.6230769230769231
infectious structure host role,COVID-19 pandemic,0.5563829787234043
infectious structure host role,action specification,0.63
infectious structure host role,SARS-CoV-2 synthesis stage,0.6285714285714286
infectious structure host role,infectious disease control objective specification,0.7125
infectious structure host role,symbiont host role,0.7208333333333333
infectious structure host role,opportunistic infectious disposition,0.6924242424242425
infectious structure host role,fomite role,0.6695121951219513
infectious structure host role,enterotoxin disposition,0.6386792452830189
infectious structure host role,polymerase chain reaction,0.5954545454545455
infectious structure host role,COVID-19 disease course,0.619811320754717
infectious structure host role,infectious disease incidence rate,0.7198412698412698
infectious structure host role,active immunization against infectious agent,0.6391891891891892
infectious structure host role,collective resistance disposition,0.6722222222222223
infectious structure host role,reagent role,0.6404761904761905
infectious structure host role,viral load,0.55
infectious structure host role,fungistatic disposition,0.6386792452830189
infectious structure host role,infectious agent,0.7326086956521739
infectious structure host role,establishment of a clinically abnormal colony,0.5966666666666667
infectious structure host role,coronavirus disease,0.6336734693877552
infectious structure host role,definitive host,0.6722222222222223
infectious structure host role,drug susceptibility of infectious agent,0.6384057971014493
symptomatic infectious agent carrier,information content entity,0.6758064516129032
symptomatic infectious agent carrier,infectious disease mortality rate,0.696376811594203
symptomatic infectious agent carrier,infection incidence rate profile,0.6852941176470588
symptomatic infectious agent carrier,infectious structure aggregate,0.6924242424242425
symptomatic infectious agent carrier,communicability end temporal region,0.6330985915492958
symptomatic infectious agent carrier,infection end temporal region,0.6807692307692308
symptomatic infectious agent carrier,infectious disease,0.7092592592592593
symptomatic infectious agent carrier,SARS-CoV-2 incidence rate,0.6631147540983606
symptomatic infectious agent carrier,incubation end temporal region,0.6469696969696969
symptomatic infectious agent carrier,normal resident microbiota population,0.6280821917808219
symptomatic infectious agent carrier,virulence factor disposition,0.621875
symptomatic infectious agent carrier,infectious disease incidence,0.715625
symptomatic infectious agent carrier,disease surveillance objective specification,0.625
symptomatic infectious agent carrier,infectious agent host role,0.7564516129032257
symptomatic infectious agent carrier,asymptomatic infectious structure carrier,0.8655844155844156
symptomatic infectious agent carrier,B cell receptor complex,0.6025423728813559
symptomatic infectious agent carrier,passive immunization against infectious agent,0.7339506172839506
symptomatic infectious agent carrier,infection incidence rate,0.6833333333333332
symptomatic infectious agent carrier,infectious disease lifetime prevalence,0.6797297297297297
symptomatic infectious agent carrier,lower respiratory tract disease,0.6291044776119403
symptomatic infectious agent carrier,infectious disease incidence proportion,0.69
symptomatic infectious agent carrier,acute infectious disease course,0.7485074626865671
symptomatic infectious agent carrier,cidal agent disposition,0.6194915254237288
symptomatic infectious agent carrier,infectious disorder,0.7045454545454546
symptomatic infectious agent carrier,biological vehicle,0.5981481481481481
symptomatic infectious agent carrier,infectious disease sporadicity,0.6924242424242425
symptomatic infectious agent carrier,communicability end process boundary,0.6305555555555555
symptomatic infectious agent carrier,directive information content entity,0.6583333333333334
symptomatic infectious agent carrier,infectious agent colony,0.7550847457627118
symptomatic infectious agent carrier,pathogen transporter,0.6642857142857143
symptomatic infectious agent carrier,invasion factor,0.6068627450980393
symptomatic infectious agent carrier,latency end process boundary,0.621875
symptomatic infectious agent carrier,infectious disease epidemic,0.7039682539682539
symptomatic infectious agent carrier,infectious agent generative stage,0.7398550724637681
symptomatic infectious agent carrier,disease transmission model,0.5951612903225807
symptomatic infectious agent carrier,cidal agent,0.6202127659574468
symptomatic infectious agent carrier,infectious structure host role,0.6924242424242425
symptomatic infectious agent carrier,pathogen vehicle,0.6423076923076922
symptomatic infectious agent carrier,COVID-19 incidence rate,0.6533898305084747
symptomatic infectious agent carrier,pathogen vehicle role,0.6429824561403508
symptomatic infectious agent carrier,chronic infectious disease course,0.7543478260869566
symptomatic infectious agent carrier,asymptomatic infectious agent carrier,0.9431506849315068
symptomatic infectious agent carrier,descriptive information content entity,0.6797297297297297
symptomatic infectious agent carrier,COVID-19 epidemic,0.5820754716981132
symptomatic infectious agent carrier,sterilizing immunity to infectious agent,0.7263157894736842
symptomatic infectious agent carrier,diseased population,0.5954545454545455
symptomatic infectious agent carrier,virulence factor,0.6038461538461539
symptomatic infectious agent carrier,incubation end process boundary,0.6440298507462687
symptomatic infectious agent carrier,plan specification,0.6351851851851852
symptomatic infectious agent carrier,latency end temporal region,0.6246031746031746
symptomatic infectious agent carrier,innate immunity to infectious agent,0.7316901408450704
symptomatic infectious agent carrier,infectious structure,0.7178571428571427
symptomatic infectious agent carrier,static agent disposition,0.6833333333333332
symptomatic infectious agent carrier,T cell receptor complex,0.6194915254237288
symptomatic infectious agent carrier,asymptomatic carrier role,0.7614754098360657
symptomatic infectious agent carrier,infectious structure host,0.6959016393442623
symptomatic infectious agent carrier,infectious agent population,0.7515873015873015
symptomatic infectious agent carrier,respiratory system disease,0.6274193548387097
symptomatic infectious agent carrier,leukocyte-mediated immunity to infectious agent,0.7271084337349397
symptomatic infectious agent carrier,humoral immunity to infectious agent,0.7416666666666667
symptomatic infectious agent carrier,infectious disease control strategy,0.7035211267605633
symptomatic infectious agent carrier,infectious disease pandemic,0.7039682539682539
symptomatic infectious agent carrier,infectious structure generative stage,0.6965753424657534
symptomatic infectious agent carrier,innate immune response,0.6224137931034482
symptomatic infectious agent carrier,viral disease course,0.6285714285714286
symptomatic infectious agent carrier,passive immunity to infectious agent,0.7416666666666667
symptomatic infectious agent carrier,infectious disposition,0.6741379310344828
symptomatic infectious agent carrier,vaccination against infectious agent,0.7416666666666667
symptomatic infectious agent carrier,susceptibility to infectious agent,0.75
symptomatic infectious agent carrier,disease course,0.61
symptomatic infectious agent carrier,infectious disease course,0.728688524590164
symptomatic infectious agent carrier,acquired immunity to infectious agent,0.7239726027397261
symptomatic infectious agent carrier,COVID-19 disease incidence proportion,0.6280821917808219
symptomatic infectious agent carrier,coronavirus disease course,0.6435483870967742
symptomatic infectious agent carrier,asymptomatic carrier,0.7892857142857143
symptomatic infectious agent carrier,biological vehicle role,0.6194915254237288
symptomatic infectious agent carrier,symptomatic infectious agent carrier,0.95
symptomatic infectious agent carrier,intermediate host,0.6009433962264151
symptomatic infectious agent carrier,infectious disease prevalence,0.6961538461538461
symptomatic infectious agent carrier,infected population,0.65
symptomatic infectious agent carrier,COVID-19 mortality rate,0.6025423728813559
symptomatic infectious agent carrier,viral disease,0.5928571428571429
symptomatic infectious agent carrier,disease,0.5662790697674418
symptomatic infectious agent carrier,symptomatic infectious structure carrier,0.8710526315789474
symptomatic infectious agent carrier,primary infectious disposition,0.7075757575757575
symptomatic infectious agent carrier,designative information content entity,0.6797297297297297
symptomatic infectious agent carrier,symptomatic carrier role,0.7666666666666666
symptomatic infectious agent carrier,infectious pathogen transmissibility,0.7
symptomatic infectious agent carrier,intermediate host role,0.6396551724137931
symptomatic infectious agent carrier,infectious human pathogen,0.7122950819672131
symptomatic infectious agent carrier,immunization against infectious agent,0.7513698630136986
symptomatic infectious agent carrier,infectious agent host,0.7482456140350877
symptomatic infectious agent carrier,long-term non-progressing infectious disease course,0.7028735632183909
symptomatic infectious agent carrier,viral disease epidemic,0.6051724137931035
symptomatic infectious agent carrier,viral disease pandemic,0.6051724137931035
symptomatic infectious agent carrier,symptomatic carrier,0.7954545454545454
symptomatic infectious agent carrier,infectious disease endemicity,0.6961538461538461
symptomatic infectious agent carrier,function,0.5863636363636363
symptomatic infectious agent carrier,herd immunity to infectious organism,0.7
symptomatic infectious agent carrier,pathogen transporter role,0.6467213114754098
symptomatic infectious agent carrier,infectious agent reservoir,0.7887096774193548
symptomatic infectious agent carrier,COVID-19 pandemic,0.5820754716981132
symptomatic infectious agent carrier,action specification,0.6464285714285714
symptomatic infectious agent carrier,infectious disease control objective specification,0.6709302325581397
symptomatic infectious agent carrier,opportunistic infectious disposition,0.7138888888888889
symptomatic infectious agent carrier,polymerase chain reaction,0.6631147540983606
symptomatic infectious agent carrier,COVID-19 disease course,0.6364406779661017
symptomatic infectious agent carrier,infectious disease incidence rate,0.7108695652173913
symptomatic infectious agent carrier,active immunization against infectious agent,0.725
symptomatic infectious agent carrier,symptom,0.6127906976744186
symptomatic infectious agent carrier,local infection,0.6852941176470588
symptomatic infectious agent carrier,infectious agent,0.7576923076923078
symptomatic infectious agent carrier,establishment of a clinically abnormal colony,0.6228395061728395
symptomatic infectious agent carrier,coronavirus disease,0.6136363636363636
symptomatic infectious agent carrier,adhesion factor,0.6068627450980393
symptomatic infectious agent carrier,drug susceptibility of infectious agent,0.73
symptomatic infectious agent carrier,static agent,0.7
mechanical vector role,infectious disease mortality rate,0.6318181818181818
mechanical vector role,infection incidence rate profile,0.6907407407407408
mechanical vector role,vector control strategy,0.6944444444444444
mechanical vector role,SARS-CoV-2 incidence rate,0.6202127659574468
mechanical vector role,normal resident microbiota population,0.6194915254237288
mechanical vector role,virulence factor disposition,0.65
mechanical vector role,reservoir of pathogen role,0.6583333333333334
mechanical vector role,infectious agent host role,0.7
mechanical vector role,B cell receptor complex,0.7166666666666667
mechanical vector role,passive immunization against infectious agent,0.6141791044776119
mechanical vector role,systematic infection,0.6642857142857143
mechanical vector role,infection incidence rate,0.6673913043478261
mechanical vector role,mechanical vector,0.8858974358974359
mechanical vector role,pathogen portal of entry role,0.7049019607843137
mechanical vector role,lower respiratory tract disease,0.619811320754717
mechanical vector role,acute infectious disease course,0.6386792452830189
mechanical vector role,cidal agent disposition,0.65
mechanical vector role,role,0.6038461538461539
mechanical vector role,genetic resistance to pathogen,0.6807692307692308
mechanical vector role,appearance of disorder,0.6545454545454545
mechanical vector role,mutualist role,0.7
mechanical vector role,infectious agent colony,0.65
mechanical vector role,invasion factor,0.6391891891891892
mechanical vector role,infectious agent generative stage,0.6136363636363636
mechanical vector role,vector surveillance,0.6939024390243902
mechanical vector role,cidal agent,0.6621212121212122
mechanical vector role,infectious structure host role,0.6807692307692308
mechanical vector role,COVID-19 incidence rate,0.6277777777777778
mechanical vector role,pathogen vector,0.6932432432432433
mechanical vector role,pathogen vehicle role,0.7058139534883722
mechanical vector role,chronic infectious disease course,0.6863636363636364
mechanical vector role,asymptomatic infectious agent carrier,0.6533898305084747
mechanical vector role,mechanical vector role,0.95
mechanical vector role,sterilizing immunity to infectious agent,0.6112903225806451
mechanical vector role,virulence factor,0.6605263157894737
mechanical vector role,dead-end host role,0.7
mechanical vector role,definitive host role,0.7119047619047619
mechanical vector role,innate immunity to infectious agent,0.6254385964912281
mechanical vector role,static agent disposition,0.6239130434782608
mechanical vector role,T cell receptor complex,0.7166666666666667
mechanical vector role,asymptomatic carrier role,0.7053191489361703
mechanical vector role,infectious agent population,0.6336734693877552
mechanical vector role,respiratory system disease,0.6166666666666667
mechanical vector role,biological vector,0.732051282051282
mechanical vector role,leukocyte-mediated immunity to infectious agent,0.6239130434782608
mechanical vector role,humoral immunity to infectious agent,0.6396551724137931
mechanical vector role,innate immune response,0.6318181818181818
mechanical vector role,viral disease course,0.6642857142857143
mechanical vector role,secondary infection role,0.7543478260869566
mechanical vector role,passive immunity to infectious agent,0.6224137931034482
mechanical vector role,vaccination against infectious agent,0.6396551724137931
mechanical vector role,susceptibility to infectious agent,0.6285714285714286
mechanical vector role,source of infection role,0.6891304347826087
mechanical vector role,chronic infection,0.7064102564102563
mechanical vector role,disease course,0.6444444444444444
mechanical vector role,infectious disease course,0.6414893617021277
mechanical vector role,acquired immunity to infectious agent,0.6194915254237288
mechanical vector role,coronavirus disease course,0.6375
mechanical vector role,biological vehicle role,0.7388888888888888
mechanical vector role,symptomatic infectious agent carrier,0.656896551724138
mechanical vector role,symbiont role,0.6785714285714286
mechanical vector role,parasite role,0.6785714285714286
mechanical vector role,pathogen vector role,0.7833333333333333
mechanical vector role,COVID-19 mortality rate,0.6277777777777778
mechanical vector role,place closure control strategy,0.6615384615384616
mechanical vector role,primary infection role,0.7227272727272727
mechanical vector role,biological role,0.6932432432432433
mechanical vector role,biological vector role,0.8136363636363637
mechanical vector role,pathogen host role,0.675
mechanical vector role,symptomatic carrier role,0.7108695652173913
mechanical vector role,intermediate host role,0.7
mechanical vector role,host role,0.6758064516129032
mechanical vector role,immunization against infectious agent,0.6364406779661017
mechanical vector role,pathogen portal of exit role,0.69
mechanical vector role,infectious agent host,0.636046511627907
mechanical vector role,long-term non-progressing infectious disease course,0.6006849315068493
mechanical vector role,commensal role,0.7277777777777777
mechanical vector role,epitope role,0.7147058823529412
mechanical vector role,function,0.5833333333333334
mechanical vector role,pathogen transporter role,0.6840425531914894
mechanical vector role,infectious agent reservoir,0.6375
mechanical vector role,antigen role,0.7147058823529412
mechanical vector role,action specification,0.6166666666666667
mechanical vector role,symbiont host role,0.675
mechanical vector role,fomite role,0.6924242424242425
mechanical vector role,COVID-19 disease course,0.6277777777777778
mechanical vector role,infectious disease incidence rate,0.6318181818181818
mechanical vector role,active immunization against infectious agent,0.6166666666666667
mechanical vector role,reagent role,0.7147058823529412
mechanical vector role,viral load,0.60625
mechanical vector role,infectious agent,0.6342105263157894
mechanical vector role,establishment of a clinically abnormal colony,0.658955223880597
mechanical vector role,adhesion factor,0.6391891891891892
mechanical vector role,drug susceptibility of infectious agent,0.6139344262295081
mechanical vector role,static agent,0.6264705882352941
material processing,information content entity,0.6277777777777778
material processing,infectious disease mortality rate,0.6038461538461539
material processing,infection incidence rate profile,0.6264705882352941
material processing,geographical entity,0.6605263157894737
material processing,primary pathogen,0.6785714285714286
material processing,surveillance process,0.732051282051282
material processing,vector control strategy,0.6166666666666667
material processing,SARS-CoV-2 incidence rate,0.5863636363636363
material processing,double-stranded DNA virus,0.5863636363636363
material processing,site of infection,0.6444444444444444
material processing,resistant entity,0.6214285714285714
material processing,double-stranded DNA,0.581578947368421
material processing,disease surveillance objective specification,0.6404761904761905
material processing,case isolation control strategy,0.63
material processing,material entity,0.7735294117647058
material processing,source of infection site,0.5895348837209302
material processing,quarantine control strategy,0.6456521739130434
material processing,B cell receptor complex,0.6166666666666667
material processing,infection incidence rate,0.5895348837209302
material processing,entity,0.53
material processing,double-stranded RNA virus,0.609090909090909
material processing,process,0.7192307692307692
material processing,droplet pathogen transmission process,0.6821428571428573
material processing,communicability end process boundary,0.6863636363636364
material processing,directive information content entity,0.5954545454545455
material processing,latency end process boundary,0.7053191489361703
material processing,realizable entity,0.6444444444444444
material processing,negative-sense single-stranded RNA virus,0.6025423728813559
material processing,COVID-19 incidence rate,0.569047619047619
material processing,negative regulation of developmental process,0.6880952380952381
material processing,descriptive information content entity,0.6078947368421053
material processing,primary infection,0.6444444444444444
material processing,process of establishing an infection,0.6318181818181818
material processing,incubation end process boundary,0.69
material processing,pathogen death process boundary,0.71
material processing,molecular entity,0.6214285714285714
material processing,T cell receptor complex,0.6404761904761905
material processing,indirect pathogen transmission process,0.6780701754385965
material processing,planned process,0.7441176470588234
material processing,infectious disease control strategy,0.5981481481481481
material processing,objective specification,0.6166666666666667
material processing,epitope site,0.6435483870967742
material processing,pathogen portal of exit site,0.6840425531914894
material processing,organism substance,0.6121621621621621
material processing,anatomical entity,0.6722222222222223
material processing,single-stranded DNA virus,0.5863636363636363
material processing,COVID-19 mortality rate,0.6166666666666667
material processing,process profile,0.6852941176470588
material processing,negative regulation of life-sustaining process,0.6653846153846155
material processing,place closure control strategy,0.6132653061224489
material processing,geopolitical entity,0.6342105263157894
material processing,primary infection role,0.6451219512195122
material processing,primary immunodeficiency,0.636046511627907
material processing,pathogen portal of entry site,0.6791666666666666
material processing,developmental process,0.75
material processing,biological process,0.7472972972972972
material processing,site,0.5369565217391304
material processing,primary infectious disposition,0.6540816326530612
material processing,designative information content entity,0.6078947368421053
material processing,double-stranded DNA retrovirus,0.5928571428571429
material processing,incubation start process boundary,0.7
material processing,object,0.53
material processing,pathogen birth process boundary,0.71
material processing,immaterial entity,0.7555555555555555
material processing,object aggregate,0.5928571428571429
material processing,division of geopolitical entity,0.59
material processing,negative regulation of viral process,0.7227272727272727
material processing,contact pathogen transmission process,0.6821428571428573
material processing,symbiotic process,0.7555555555555555
material processing,infection start process boundary,0.6852941176470588
material processing,action specification,0.6551282051282051
material processing,processed material,0.6662162162162162
material processing,latency start process boundary,0.7153061224489795
material processing,infectious disease control objective specification,0.6094202898550725
material processing,process of establishing viral infection,0.6224137931034482
material processing,negative regulation of biological process,0.7
material processing,infectious disease incidence rate,0.5846153846153846
material processing,communicability start process boundary,0.6780701754385965
material processing,process that results in death,0.6375
material processing,single-stranded RNA retrovirus,0.6132653061224489
material processing,establishment of a clinically abnormal colony,0.590625
material processing,process boundary,0.6785714285714286
material processing,positive-sense single-stranded RNA virus,0.5855932203389831
material processing,horizontal pathogen transmission process,0.6703389830508475
material processing,pathogen transmission process,0.7208333333333333
material processing,material processing,0.95
infection incidence,virus aggregate,0.5676470588235294
infection incidence,source of infection,0.6868421052631578
infection incidence,virostatic disposition,0.6207317073170732
infection incidence,zoonotic disposition,0.6294871794871795
infection incidence,infectious disease mortality rate,0.6807692307692308
infection incidence,infection incidence rate profile,0.8225490196078431
infection incidence,communicability end temporal region,0.6166666666666667
infection incidence,subclinical coronavirus infection,0.6615384615384616
infection incidence,infection end temporal region,0.7416666666666667
infection incidence,infectious disease,0.7743243243243243
infection incidence,SARS-CoV-2 incidence rate,0.7227272727272727
infection incidence,double-stranded DNA virus,0.5863636363636363
infection incidence,incubation end temporal region,0.6948979591836735
infection incidence,site of infection,0.7
infection incidence,virulence factor disposition,0.6627659574468084
infection incidence,viral adhesion disposition,0.65
infection incidence,parasitostatic disposition,0.6055555555555556
infection incidence,infectious disease incidence,0.8329787234042553
infection incidence,reverse zoonotic disposition,0.598936170212766
infection incidence,subclinical SARS-CoV-2 infection,0.6460784313725491
infection incidence,virus translation stage,0.6404761904761905
infection incidence,disease surveillance objective specification,0.6246031746031746
infection incidence,virus release stage,0.5552631578947369
infection incidence,material entity,0.5970588235294118
infection incidence,source of infection site,0.7290697674418604
infection incidence,virus replication,0.6444444444444444
infection incidence,B cell receptor complex,0.6166666666666667
infection incidence,systematic infection,0.6807692307692308
infection incidence,infection incidence rate,0.891860465116279
infection incidence,virus host,0.5189655172413793
infection incidence,double-stranded RNA virus,0.5863636363636363
infection incidence,virus transcription stage,0.6545454545454545
infection incidence,infectious disease lifetime prevalence,0.7131578947368421
infection incidence,toxin disposition,0.6444444444444444
infection incidence,lower respiratory tract disease,0.61
infection incidence,infectious disease incidence proportion,0.760344827586207
infection incidence,virus generative stage,0.6207317073170732
infection incidence,acute infectious disease course,0.71
infection incidence,cidal agent disposition,0.6404761904761905
infection incidence,infectious disorder,0.7657894736842106
infection incidence,subclinical infection,0.675
infection incidence,appearance of disorder,0.6207317073170732
infection incidence,simple infection,0.7071428571428571
infection incidence,parasiticidal disposition,0.609090909090909
infection incidence,infectious disease sporadicity,0.6948979591836735
infection incidence,communicability end process boundary,0.6318181818181818
infection incidence,infection incidence proportion profile,0.7833333333333333
infection incidence,SARS-CoV-2 incidence proportion,0.69
infection incidence,transmissibility disposition,0.598936170212766
infection incidence,latency end process boundary,0.598936170212766
infection incidence,infectious disease epidemic,0.7543478260869566
infection incidence,disease transmission model,0.65
infection incidence,endotoxin disposition,0.65
infection incidence,negative-sense single-stranded RNA virus,0.6364406779661017
infection incidence,COVID-19 incidence rate,0.7357142857142857
infection incidence,cytotoxin disposition,0.65
infection incidence,community-acquired infection,0.6414893617021277
infection incidence,chronic infectious disease course,0.7
infection incidence,nursing-home acquired infection,0.67
infection incidence,COVID-19 epidemic,0.6444444444444444
infection incidence,secondary infection,0.7131578947368421
infection incidence,infection start temporal region,0.69
infection incidence,infection incidence,0.95
infection incidence,virus disorder,0.6015151515151516
infection incidence,primary infection,0.7
infection incidence,process of establishing an infection,0.65
infection incidence,incubation end process boundary,0.69
infection incidence,SARS-CoV-2 disorder,0.6078947368421053
infection incidence,collective pathogenic disposition,0.6423076923076922
infection incidence,neurotoxin disposition,0.6695121951219513
infection incidence,COVID-19 incidence,0.7743243243243243
infection incidence,latency end temporal region,0.6021739130434782
infection incidence,virus adhesion susceptible cell,0.67
infection incidence,collective disposition,0.6451219512195122
infection incidence,infection,0.7714285714285714
infection incidence,static agent disposition,0.636046511627907
infection incidence,T cell receptor complex,0.6166666666666667
infection incidence,respiratory system disease,0.6055555555555556
infection incidence,communicability interval,0.636046511627907
infection incidence,infectious disease control strategy,0.6907407407407408
infection incidence,infectious disease pandemic,0.7543478260869566
infection incidence,immunosuppressive disposition,0.6166666666666667
infection incidence,pathogenic disposition,0.6207317073170732
infection incidence,viral disease course,0.6038461538461539
infection incidence,intracellular infection,0.6642857142857143
infection incidence,secondary infection role,0.7058139534883722
infection incidence,metastatic infection,0.6807692307692308
infection incidence,infectious disposition,0.7426829268292683
infection incidence,acute infection,0.7147058823529412
infection incidence,bacteriostatic disposition,0.6277777777777778
infection incidence,bactericidal disposition,0.6127906976744186
infection incidence,source of infection role,0.7058139534883722
infection incidence,chronic infection,0.7
infection incidence,invasion disposition,0.6807692307692308
infection incidence,disease course,0.6015151515151516
infection incidence,infectious disease course,0.7454545454545455
infection incidence,viricidal disposition,0.625
infection incidence,complex infection,0.7
infection incidence,COVID-19 disease incidence proportion,0.6642857142857143
infection incidence,coronavirus disease course,0.6277777777777778
infection incidence,infection incidence proportion,0.8377551020408163
infection incidence,respiratory droplet virus fomite,0.5872549019607843
infection incidence,infectious disease prevalence,0.7416666666666667
infection incidence,disposition,0.6166666666666667
infection incidence,single-stranded DNA virus,0.6318181818181818
infection incidence,COVID-19 mortality rate,0.569047619047619
infection incidence,viral disease,0.60625
infection incidence,primary infection role,0.7182926829268292
infection incidence,adhesion disposition,0.6551282051282051
infection incidence,infection incidence profile,0.8630434782608696
infection incidence,contagiousness,0.6318181818181818
infection incidence,disease,0.5653846153846154
infection incidence,primary infectious disposition,0.6948979591836735
infection incidence,infection prevalence,0.808974358974359
infection incidence,coronavirus disorder,0.6294871794871795
infection incidence,SARS-CoV-2 incidence,0.7576923076923078
infection incidence,subclinical virus infection,0.6673913043478261
infection incidence,establishment of localization in virus host,0.6435483870967742
infection incidence,virus attachment stage,0.5963414634146341
infection incidence,virus synthesis stage,0.6
infection incidence,SARS-COV-2 adhesion disposition,0.61
infection incidence,invasive disposition,0.6551282051282051
infection incidence,long-term non-progressing infectious disease course,0.6357142857142857
infection incidence,viral disease epidemic,0.6207317073170732
infection incidence,communicability start temporal region,0.5928571428571429
infection incidence,fungicidal disposition,0.6207317073170732
infection incidence,viral disease pandemic,0.6207317073170732
infection incidence,virus penetration stage,0.6642857142857143
infection incidence,acute respiratory distress syndrome,0.6166666666666667
infection incidence,infectious disease endemicity,0.7416666666666667
infection incidence,disorder,0.5981481481481481
infection incidence,communicability,0.6264705882352941
infection incidence,extracellular infection,0.6642857142857143
infection incidence,exotoxin disposition,0.6551282051282051
infection incidence,infection start process boundary,0.7049019607843137
infection incidence,action specification,0.7064102564102563
infection incidence,processed material,0.5581081081081081
infection incidence,infectious disease control objective specification,0.6673913043478261
infection incidence,COVID-19 lifetime prevalence,0.6627659574468084
infection incidence,opportunistic infectious disposition,0.6681818181818181
infection incidence,process of establishing viral infection,0.6396551724137931
infection incidence,enterotoxin disposition,0.6642857142857143
infection incidence,COVID-19 disease course,0.6166666666666667
infection incidence,infectious disease incidence rate,0.7961538461538461
infection incidence,communicability start process boundary,0.5903508771929825
infection incidence,COVID-19 prevalence,0.6605263157894737
infection incidence,SARS-COV-2 prevalence,0.625
infection incidence,disordered virus,0.5928571428571429
infection incidence,collective resistance disposition,0.6423076923076922
infection incidence,fungistatic disposition,0.6166666666666667
infection incidence,virus uncoating stage,0.65
infection incidence,local infection,0.7147058823529412
infection incidence,establishment of a clinically abnormal colony,0.60625
infection incidence,coronavirus disease,0.6342105263157894
infection incidence,positive-sense single-stranded RNA virus,0.6194915254237288
infection incidence,hospital-acquired infection,0.6456521739130434
infection incidence,material processing,0.6078947368421053
T cell receptor complex,extended organism,0.6
T cell receptor complex,virostatic disposition,0.5833333333333334
T cell receptor complex,zoonotic disposition,0.5895348837209302
T cell receptor complex,infectious disease mortality rate,0.5928571428571429
T cell receptor complex,infection incidence rate profile,0.6681818181818181
T cell receptor complex,infectious structure aggregate,0.619811320754717
T cell receptor complex,communicability end temporal region,0.6224137931034482
T cell receptor complex,infection end temporal region,0.6423076923076922
T cell receptor complex,drug-based immunosuppressed organism,0.5855932203389831
T cell receptor complex,SARS-CoV-2 incidence rate,0.5958333333333333
T cell receptor complex,incubation end temporal region,0.6386792452830189
T cell receptor complex,site of infection,0.625
T cell receptor complex,immunocompetent organism,0.598936170212766
T cell receptor complex,virulence factor disposition,0.6264705882352941
T cell receptor complex,viral adhesion disposition,0.5724489795918367
T cell receptor complex,parasitostatic disposition,0.5724489795918367
T cell receptor complex,reverse zoonotic disposition,0.5872549019607843
T cell receptor complex,case isolation control strategy,0.6351851851851852
T cell receptor complex,macromolecular complex,0.7388888888888888
T cell receptor complex,asymptomatic infectious structure carrier,0.621875
T cell receptor complex,source of infection site,0.6414893617021277
T cell receptor complex,architectual structure,0.65
T cell receptor complex,B cell receptor complex,0.9282608695652175
T cell receptor complex,infection incidence rate,0.6202127659574468
T cell receptor complex,toxin disposition,0.575
T cell receptor complex,lower respiratory tract disease,0.6537037037037037
T cell receptor complex,cidal agent disposition,0.6021739130434782
T cell receptor complex,infectious disorder,0.6166666666666667
T cell receptor complex,appearance of disorder,0.6277777777777778
T cell receptor complex,parasiticidal disposition,0.5958333333333333
T cell receptor complex,communicability end process boundary,0.6025423728813559
T cell receptor complex,acellular structure aggregate,0.6615384615384616
T cell receptor complex,transmissibility disposition,0.5676470588235294
T cell receptor complex,latency end process boundary,0.6264705882352941
T cell receptor complex,endotoxin disposition,0.5636363636363636
T cell receptor complex,pathologically immunosuppressed organism,0.6246031746031746
T cell receptor complex,infectious structure host role,0.6386792452830189
T cell receptor complex,COVID-19 incidence rate,0.6021739130434782
T cell receptor complex,cytotoxin disposition,0.5636363636363636
T cell receptor complex,virus disorder,0.5581081081081081
T cell receptor complex,establishment of localization in human host,0.5863636363636363
T cell receptor complex,acellular structure,0.6880952380952381
T cell receptor complex,incubation end process boundary,0.6166666666666667
T cell receptor complex,SARS-CoV-2 disorder,0.5928571428571429
T cell receptor complex,collective pathogenic disposition,0.6464285714285714
T cell receptor complex,neurotoxin disposition,0.5833333333333334
T cell receptor complex,immunosuppressed organism,0.575
T cell receptor complex,latency end temporal region,0.65
T cell receptor complex,infectious structure,0.6127906976744186
T cell receptor complex,virus adhesion susceptible cell,0.6351851851851852
T cell receptor complex,collective disposition,0.65
T cell receptor complex,static agent disposition,0.598936170212766
T cell receptor complex,T cell receptor complex,0.95
T cell receptor complex,infectious structure host,0.6166666666666667
T cell receptor complex,respiratory system disease,0.6336734693877552
T cell receptor complex,organism population,0.5928571428571429
T cell receptor complex,infectious structure generative stage,0.6166666666666667
T cell receptor complex,immunosuppressive disposition,0.5653846153846154
T cell receptor complex,disordered prion,0.6038461538461539
T cell receptor complex,pathogenic disposition,0.5833333333333334
T cell receptor complex,cell,0.5981481481481481
T cell receptor complex,infectious disposition,0.5833333333333334
T cell receptor complex,bacteriostatic disposition,0.5928571428571429
T cell receptor complex,epitope site,0.6214285714285714
T cell receptor complex,bactericidal disposition,0.598936170212766
T cell receptor complex,invasion disposition,0.5430232558139535
T cell receptor complex,viricidal disposition,0.5863636363636363
T cell receptor complex,complex infection,0.625
T cell receptor complex,susceptible organism,0.6127906976744186
T cell receptor complex,pathogen portal of exit site,0.6460784313725491
T cell receptor complex,organism substance,0.5719512195121951
T cell receptor complex,disposition,0.5382352941176471
T cell receptor complex,COVID-19 mortality rate,0.5804347826086956
T cell receptor complex,place closure control strategy,0.6575471698113208
T cell receptor complex,adhesion disposition,0.5662790697674418
T cell receptor complex,pathogen portal of entry site,0.6230769230769231
T cell receptor complex,symptomatic infectious structure carrier,0.6246031746031746
T cell receptor complex,site,0.524074074074074
T cell receptor complex,primary infectious disposition,0.5820754716981132
T cell receptor complex,coronavirus disorder,0.6127906976744186
T cell receptor complex,SARS-COV-2 adhesion susceptible cell,0.6194915254237288
T cell receptor complex,immunodeficient organism,0.598936170212766
T cell receptor complex,infectious human pathogen,0.6166666666666667
T cell receptor complex,colonization of human,0.609090909090909
T cell receptor complex,virus synthesis stage,0.5636363636363636
T cell receptor complex,SARS-COV-2 adhesion disposition,0.5611111111111111
T cell receptor complex,invasive disposition,0.5662790697674418
T cell receptor complex,fungicidal disposition,0.5833333333333334
T cell receptor complex,acute respiratory distress syndrome,0.6741379310344828
T cell receptor complex,division of geopolitical entity,0.5981481481481481
T cell receptor complex,disorder,0.5467741935483871
T cell receptor complex,herd immunity to infectious organism,0.6194915254237288
T cell receptor complex,exotoxin disposition,0.5662790697674418
T cell receptor complex,immunoglobulin complex,0.6722222222222223
T cell receptor complex,action specification,0.5895348837209302
T cell receptor complex,SARS-CoV-2 synthesis stage,0.5520408163265306
T cell receptor complex,opportunistic infectious disposition,0.6025423728813559
T cell receptor complex,quality,0.5166666666666666
T cell receptor complex,enterotoxin disposition,0.6021739130434782
T cell receptor complex,polymerase chain reaction,0.6166666666666667
T cell receptor complex,infectious disease incidence rate,0.6107142857142857
T cell receptor complex,disordered virus,0.5525641025641026
T cell receptor complex,collective resistance disposition,0.6464285714285714
T cell receptor complex,fungistatic disposition,0.5804347826086956
T cell receptor complex,organism,0.5467741935483871
T cell receptor complex,establishment of a clinically abnormal colony,0.6264705882352941
T cell receptor complex,cell space,0.6924242424242425
primary infectious disposition,virostatic disposition,0.7576923076923078
primary infectious disposition,information content entity,0.6285714285714286
primary infectious disposition,zoonotic disposition,0.75
primary infectious disposition,infectious disease mortality rate,0.7198412698412698
primary infectious disposition,infection incidence rate profile,0.6596774193548387
primary infectious disposition,infectious structure aggregate,0.6666666666666667
primary infectious disposition,communicability end temporal region,0.6192307692307693
primary infectious disposition,geographical entity,0.6132653061224489
primary infectious disposition,biological regulation,0.6264705882352941
primary infectious disposition,primary pathogen,0.7108695652173913
primary infectious disposition,surveillance process,0.63
primary infectious disposition,infection end temporal region,0.7042372881355932
primary infectious disposition,vector control strategy,0.6009433962264151
primary infectious disposition,infectious disease,0.7625
primary infectious disposition,SARS-CoV-2 incidence rate,0.6136363636363636
primary infectious disposition,incubation end temporal region,0.6666666666666667
primary infectious disposition,resistant entity,0.6239130434782608
primary infectious disposition,virulence factor disposition,0.7775862068965518
primary infectious disposition,viral adhesion disposition,0.7714285714285714
primary infectious disposition,parasitostatic disposition,0.7892857142857143
primary infectious disposition,infectious disease incidence,0.760344827586207
primary infectious disposition,negative regulation of production,0.6563492063492063
primary infectious disposition,reverse zoonotic disposition,0.760344827586207
primary infectious disposition,establishment of localization in host,0.6440298507462687
primary infectious disposition,disease surveillance objective specification,0.6797297297297297
primary infectious disposition,case isolation control strategy,0.6139344262295081
primary infectious disposition,infectious agent host role,0.7178571428571427
primary infectious disposition,macromolecular complex,0.6038461538461539
primary infectious disposition,material entity,0.6277777777777778
primary infectious disposition,asymptomatic infectious structure carrier,0.7035211267605633
primary infectious disposition,architectual structure,0.6423076923076922
primary infectious disposition,quarantine control strategy,0.6429824561403508
primary infectious disposition,B cell receptor complex,0.5820754716981132
primary infectious disposition,passive immunization against infectious agent,0.6766666666666665
primary infectious disposition,infection incidence rate,0.6722222222222223
primary infectious disposition,colonized host,0.5863636363636363
primary infectious disposition,virus host,0.65
primary infectious disposition,entity,0.5611111111111111
primary infectious disposition,infectious disease lifetime prevalence,0.7294117647058823
primary infectious disposition,toxin disposition,0.747872340425532
primary infectious disposition,lower respiratory tract disease,0.6631147540983606
primary infectious disposition,infectious disease incidence proportion,0.7398550724637681
primary infectious disposition,acute infectious disease course,0.7450819672131148
primary infectious disposition,cidal agent disposition,0.7707547169811321
primary infectious disposition,infectious disorder,0.7561224489795919
primary infectious disposition,simple infection,0.7108695652173913
primary infectious disposition,parasiticidal disposition,0.7772727272727272
primary infectious disposition,infectious disease sporadicity,0.75
primary infectious disposition,communicability end process boundary,0.6166666666666667
primary infectious disposition,directive information content entity,0.6469696969696969
primary infectious disposition,acellular structure aggregate,0.5855932203389831
primary infectious disposition,infectious agent colony,0.7141509433962264
primary infectious disposition,transmissibility disposition,0.743103448275862
primary infectious disposition,latency end process boundary,0.6224137931034482
primary infectious disposition,colonization of host,0.63
primary infectious disposition,infectious disease epidemic,0.7482456140350877
primary infectious disposition,infectious agent generative stage,0.6722222222222223
primary infectious disposition,disease transmission model,0.6464285714285714
primary infectious disposition,realizable entity,0.6202127659574468
primary infectious disposition,endotoxin disposition,0.7441176470588234
primary infectious disposition,vector surveillance,0.6132653061224489
primary infectious disposition,negative regulation of establishment of localization,0.6451219512195122
primary infectious disposition,infectious structure host role,0.7166666666666667
primary infectious disposition,COVID-19 incidence rate,0.6009433962264151
primary infectious disposition,cytotoxin disposition,0.7441176470588234
primary infectious disposition,negative regulation of developmental process,0.5986486486486486
primary infectious disposition,host,0.5382352941176471
primary infectious disposition,chronic infectious disease course,0.7515873015873015
primary infectious disposition,asymptomatic infectious agent carrier,0.703731343283582
primary infectious disposition,descriptive information content entity,0.6411764705882353
primary infectious disposition,COVID-19 epidemic,0.5776595744680851
primary infectious disposition,negative regulation of replication,0.653125
primary infectious disposition,sterilizing immunity to infectious agent,0.6928571428571427
primary infectious disposition,establishment of localization in human host,0.6280821917808219
primary infectious disposition,diseased population,0.6540816326530612
primary infectious disposition,acellular structure,0.5724489795918367
primary infectious disposition,primary infection,0.8117021276595744
primary infectious disposition,incubation end process boundary,0.6631147540983606
primary infectious disposition,collective pathogenic disposition,0.7198412698412698
primary infectious disposition,neurotoxin disposition,0.7576923076923078
primary infectious disposition,dead-end host role,0.5958333333333333
primary infectious disposition,molecular entity,0.6239130434782608
primary infectious disposition,plan specification,0.6791666666666666
primary infectious disposition,definitive host role,0.63
primary infectious disposition,latency end temporal region,0.6254385964912281
primary infectious disposition,innate immunity to infectious agent,0.6961538461538461
primary infectious disposition,infectious structure,0.71
primary infectious disposition,collective disposition,0.7576923076923078
primary infectious disposition,static agent disposition,0.7462962962962962
primary infectious disposition,T cell receptor complex,0.5820754716981132
primary infectious disposition,infectious structure host,0.7227272727272727
primary infectious disposition,infectious agent population,0.7482456140350877
primary infectious disposition,respiratory system disease,0.6642857142857143
primary infectious disposition,entry into host,0.6944444444444444
primary infectious disposition,leukocyte-mediated immunity to infectious agent,0.6577922077922078
primary infectious disposition,adhesion of symbiont to host,0.6224137931034482
primary infectious disposition,humoral immunity to infectious agent,0.7075757575757575
primary infectious disposition,infectious disease control strategy,0.7115384615384616
primary infectious disposition,infectious disease pandemic,0.730701754385965
primary infectious disposition,infectious structure generative stage,0.658955223880597
primary infectious disposition,immunosuppressive disposition,0.7550847457627118
primary infectious disposition,pathogenic disposition,0.7576923076923078
primary infectious disposition,viral disease course,0.63
primary infectious disposition,entry into host through host barriers,0.6440298507462687
primary infectious disposition,passive immunity to infectious agent,0.7075757575757575
primary infectious disposition,infectious disposition,0.8730769230769231
primary infectious disposition,vaccination against infectious agent,0.6772727272727272
primary infectious disposition,susceptibility to infectious agent,0.7
primary infectious disposition,bacteriostatic disposition,0.7714285714285714
primary infectious disposition,bactericidal disposition,0.7648148148148148
primary infectious disposition,pathogen host,0.636046511627907
primary infectious disposition,invasion disposition,0.77
primary infectious disposition,disease course,0.609090909090909
primary infectious disposition,infectious disease course,0.740909090909091
primary infectious disposition,viricidal disposition,0.7833333333333333
primary infectious disposition,acquired immunity to infectious agent,0.703731343283582
primary infectious disposition,complex infection,0.6840425531914894
primary infectious disposition,COVID-19 disease incidence proportion,0.658955223880597
primary infectious disposition,coronavirus disease course,0.6464285714285714
primary infectious disposition,symptomatic infectious agent carrier,0.7075757575757575
primary infectious disposition,intermediate host,0.6202127659574468
primary infectious disposition,infectious disease prevalence,0.7211864406779661
primary infectious disposition,anatomical entity,0.598936170212766
primary infectious disposition,disposition,0.7182926829268292
primary infectious disposition,infected population,0.7153061224489795
primary infectious disposition,COVID-19 mortality rate,0.5820754716981132
primary infectious disposition,negative regulation of life-sustaining process,0.6210526315789474
primary infectious disposition,place closure control strategy,0.6166666666666667
primary infectious disposition,geopolitical entity,0.6132653061224489
primary infectious disposition,viral disease,0.6127906976744186
primary infectious disposition,primary infection role,0.7961538461538461
primary infectious disposition,primary immunodeficiency,0.7277777777777777
primary infectious disposition,adhesion disposition,0.77
primary infectious disposition,disease,0.5581081081081081
primary infectious disposition,symptomatic infectious structure carrier,0.7071428571428571
primary infectious disposition,primary infectious disposition,0.95
primary infectious disposition,pathogen host role,0.6375
primary infectious disposition,designative information content entity,0.6411764705882353
primary infectious disposition,infectious pathogen transmissibility,0.6924242424242425
primary infectious disposition,intermediate host role,0.6230769230769231
primary infectious disposition,dead-end host,0.5895348837209302
primary infectious disposition,pathogen surveillance,0.6068627450980393
primary infectious disposition,host role,0.5525641025641026
primary infectious disposition,infectious human pathogen,0.7227272727272727
primary infectious disposition,establishment of localization in virus host,0.6417808219178082
primary infectious disposition,immunization against infectious agent,0.6888059701492537
primary infectious disposition,negative regulation of immune response,0.6264705882352941
primary infectious disposition,immaterial entity,0.6414893617021277
primary infectious disposition,SARS-COV-2 adhesion disposition,0.7450819672131148
primary infectious disposition,invasive disposition,0.77
primary infectious disposition,infectious agent host,0.7245098039215686
primary infectious disposition,long-term non-progressing infectious disease course,0.6969135802469135
primary infectious disposition,viral disease epidemic,0.6423076923076922
primary infectious disposition,fungicidal disposition,0.7384615384615384
primary infectious disposition,viral disease pandemic,0.6230769230769231
primary infectious disposition,division of geopolitical entity,0.6467213114754098
primary infectious disposition,infectious disease endemicity,0.738135593220339
primary infectious disposition,negative regulation of viral process,0.6166666666666667
primary infectious disposition,herd immunity to infectious organism,0.7227272727272727
primary infectious disposition,exotoxin disposition,0.75
primary infectious disposition,infectious agent reservoir,0.7
primary infectious disposition,immunoglobulin complex,0.5846153846153846
primary infectious disposition,COVID-19 pandemic,0.5563829787234043
primary infectious disposition,infectious disease control objective specification,0.7125
primary infectious disposition,symbiont host role,0.6375
primary infectious disposition,opportunistic infectious disposition,0.8439393939393939
primary infectious disposition,negative regulation of biological process,0.6049295774647887
primary infectious disposition,enterotoxin disposition,0.7518867924528303
primary infectious disposition,COVID-19 disease course,0.6009433962264151
primary infectious disposition,infectious disease incidence rate,0.7357142857142857
primary infectious disposition,active immunization against infectious agent,0.6662162162162162
primary infectious disposition,collective resistance disposition,0.7198412698412698
primary infectious disposition,fungistatic disposition,0.7518867924528303
primary infectious disposition,infectious agent,0.7108695652173913
primary infectious disposition,establishment of a clinically abnormal colony,0.61
primary infectious disposition,coronavirus disease,0.6540816326530612
primary infectious disposition,definitive host,0.6277777777777778
primary infectious disposition,drug susceptibility of infectious agent,0.6818840579710145
resistance to pathogen,extended organism,0.6551282051282051
resistance to pathogen,virus aggregate,0.6391891891891892
resistance to pathogen,source of infection,0.6695121951219513
resistance to pathogen,virostatic disposition,0.6772727272727272
resistance to pathogen,information content entity,0.6375
resistance to pathogen,zoonotic disposition,0.6166666666666667
resistance to pathogen,immune response,0.6391891891891892
resistance to pathogen,infectious disease mortality rate,0.6681818181818181
resistance to pathogen,infection incidence rate profile,0.6537037037037037
resistance to pathogen,communicability end temporal region,0.6078947368421053
resistance to pathogen,pathogen generative stage,0.6202127659574468
resistance to pathogen,pathogen portal of entry,0.6456521739130434
resistance to pathogen,subclinical coronavirus infection,0.6318181818181818
resistance to pathogen,primary pathogen,0.7657894736842106
resistance to pathogen,infection end temporal region,0.6460784313725491
resistance to pathogen,drug-based immunosuppressed organism,0.6051724137931035
resistance to pathogen,infectious disease,0.65
resistance to pathogen,double-stranded DNA virus,0.6202127659574468
resistance to pathogen,incubation end temporal region,0.6423076923076922
resistance to pathogen,site of infection,0.7064102564102563
resistance to pathogen,immunocompetent organism,0.6456521739130434
resistance to pathogen,virulence factor disposition,0.71
resistance to pathogen,pathogen portal of exit,0.6277777777777778
resistance to pathogen,viral adhesion disposition,0.6583333333333334
resistance to pathogen,parasitostatic disposition,0.7
resistance to pathogen,infectious disease incidence,0.63
resistance to pathogen,reservoir of pathogen role,0.7625
resistance to pathogen,reverse zoonotic disposition,0.67
resistance to pathogen,subclinical SARS-CoV-2 infection,0.6351851851851852
resistance to pathogen,establishment of localization in host,0.6533898305084747
resistance to pathogen,virus translation stage,0.6944444444444444
resistance to pathogen,disease surveillance objective specification,0.6772727272727272
resistance to pathogen,virus release stage,0.6695121951219513
resistance to pathogen,infectious agent host role,0.6791666666666666
resistance to pathogen,source of infection site,0.6673913043478261
resistance to pathogen,virus,0.524074074074074
resistance to pathogen,virus replication,0.6551282051282051
resistance to pathogen,B cell receptor complex,0.65
resistance to pathogen,passive immunization against infectious agent,0.6440298507462687
resistance to pathogen,systematic infection,0.6642857142857143
resistance to pathogen,infection incidence rate,0.6456521739130434
resistance to pathogen,colonized host,0.5888888888888889
resistance to pathogen,virus host,0.60625
resistance to pathogen,double-stranded RNA virus,0.6202127659574468
resistance to pathogen,pathogen portal of entry role,0.6264705882352941
resistance to pathogen,virus transcription stage,0.7053191489361703
resistance to pathogen,infectious disease lifetime prevalence,0.6666666666666667
resistance to pathogen,toxin disposition,0.6294871794871795
resistance to pathogen,pathogen birth temporal region,0.6230769230769231
resistance to pathogen,lower respiratory tract disease,0.6575471698113208
resistance to pathogen,infectious disease incidence proportion,0.6795081967213115
resistance to pathogen,opportunistic pathogen,0.7681818181818181
resistance to pathogen,virus generative stage,0.6545454545454545
resistance to pathogen,acute infectious disease course,0.6386792452830189
resistance to pathogen,cidal agent disposition,0.65
resistance to pathogen,genetic resistance to pathogen,0.8730769230769231
resistance to pathogen,subclinical infection,0.636046511627907
resistance to pathogen,simple infection,0.6342105263157894
resistance to pathogen,droplet pathogen transmission process,0.6533898305084747
resistance to pathogen,parasiticidal disposition,0.6627659574468084
resistance to pathogen,infectious disease sporadicity,0.6423076923076922
resistance to pathogen,communicability end process boundary,0.5879310344827586
resistance to pathogen,directive information content entity,0.6396551724137931
resistance to pathogen,infection incidence proportion profile,0.65
resistance to pathogen,infectious agent colony,0.6722222222222223
resistance to pathogen,pathogen transporter,0.6404761904761905
resistance to pathogen,transmissibility disposition,0.65
resistance to pathogen,latency end process boundary,0.63
resistance to pathogen,colonization of host,0.6404761904761905
resistance to pathogen,infectious disease epidemic,0.6336734693877552
resistance to pathogen,infectious agent generative stage,0.65
resistance to pathogen,disease transmission model,0.6583333333333334
resistance to pathogen,endotoxin disposition,0.6593023255813953
resistance to pathogen,pathologically immunosuppressed organism,0.5951612903225807
resistance to pathogen,negative-sense single-stranded RNA virus,0.6112903225806451
resistance to pathogen,cidal agent,0.6621212121212122
resistance to pathogen,infectious structure host role,0.6615384615384616
resistance to pathogen,pathogen vehicle,0.6605263157894737
resistance to pathogen,cytotoxin disposition,0.636046511627907
resistance to pathogen,community-acquired infection,0.63
resistance to pathogen,pathogen vector,0.6662162162162162
resistance to pathogen,antibiotic resistance,0.6825581395348838
resistance to pathogen,pathogen vehicle role,0.636046511627907
resistance to pathogen,host,0.5269230769230769
resistance to pathogen,chronic infectious disease course,0.6318181818181818
resistance to pathogen,asymptomatic infectious agent carrier,0.6533898305084747
resistance to pathogen,nursing-home acquired infection,0.6386792452830189
resistance to pathogen,descriptive information content entity,0.65
resistance to pathogen,secondary infection,0.6207317073170732
resistance to pathogen,infection start temporal region,0.6575471698113208
resistance to pathogen,infection incidence,0.6451219512195122
resistance to pathogen,virus disorder,0.6166666666666667
resistance to pathogen,resistance to drug,0.825
resistance to pathogen,sterilizing immunity to infectious agent,0.6435483870967742
resistance to pathogen,establishment of localization in human host,0.6346153846153847
resistance to pathogen,primary infection,0.6551282051282051
resistance to pathogen,process of establishing an infection,0.656896551724138
resistance to pathogen,incubation end process boundary,0.6386792452830189
resistance to pathogen,collective pathogenic disposition,0.6681818181818181
resistance to pathogen,neurotoxin disposition,0.6545454545454545
resistance to pathogen,dead-end host role,0.65
resistance to pathogen,pathogen death process boundary,0.6386792452830189
resistance to pathogen,immunosuppressed organism,0.6414893617021277
resistance to pathogen,definitive host role,0.6642857142857143
resistance to pathogen,latency end temporal region,0.6540816326530612
resistance to pathogen,innate immunity to infectious agent,0.6605263157894737
resistance to pathogen,virus adhesion susceptible cell,0.6386792452830189
resistance to pathogen,collective disposition,0.6318181818181818
resistance to pathogen,infection,0.6435483870967742
resistance to pathogen,static agent disposition,0.6891304347826087
resistance to pathogen,T cell receptor complex,0.65
resistance to pathogen,infectious structure host,0.6414893617021277
resistance to pathogen,infectious agent population,0.6948979591836735
resistance to pathogen,respiratory system disease,0.6583333333333334
resistance to pathogen,entry into host,0.6662162162162162
resistance to pathogen,leukocyte-mediated immunity to infectious agent,0.6384057971014493
resistance to pathogen,indirect pathogen transmission process,0.6666666666666667
resistance to pathogen,adhesion of symbiont to host,0.67
resistance to pathogen,organism population,0.6939024390243902
resistance to pathogen,humoral immunity to infectious agent,0.656896551724138
resistance to pathogen,infectious disease control strategy,0.6780701754385965
resistance to pathogen,parasite,0.6166666666666667
resistance to pathogen,infectious disease pandemic,0.6540816326530612
resistance to pathogen,antibody reagent,0.6868421052631578
resistance to pathogen,immunosuppressive disposition,0.6460784313725491
resistance to pathogen,innate immune response,0.6318181818181818
resistance to pathogen,pathogenic disposition,0.6318181818181818
resistance to pathogen,viral disease course,0.6404761904761905
resistance to pathogen,entry into host through host barriers,0.6364406779661017
resistance to pathogen,intracellular infection,0.65
resistance to pathogen,secondary infection role,0.6456521739130434
resistance to pathogen,metastatic infection,0.6642857142857143
resistance to pathogen,passive immunity to infectious agent,0.656896551724138
resistance to pathogen,infectious disposition,0.6772727272727272
resistance to pathogen,vaccination against infectious agent,0.656896551724138
resistance to pathogen,acute infection,0.6391891891891892
resistance to pathogen,susceptibility to infectious agent,0.6821428571428573
resistance to pathogen,bacteriostatic disposition,0.6791666666666666
resistance to pathogen,epitope site,0.6558823529411765
resistance to pathogen,immunity to pathogen,0.7833333333333333
resistance to pathogen,bactericidal disposition,0.6239130434782608
resistance to pathogen,source of infection role,0.6673913043478261
resistance to pathogen,pathogen host,0.6785714285714286
resistance to pathogen,chronic infection,0.6294871794871795
resistance to pathogen,invasion disposition,0.6404761904761905
resistance to pathogen,disease course,0.6444444444444444
resistance to pathogen,infectious disease course,0.6414893617021277
resistance to pathogen,viricidal disposition,0.636046511627907
resistance to pathogen,acquired immunity to infectious agent,0.6703389830508475
resistance to pathogen,complex infection,0.6294871794871795
resistance to pathogen,COVID-19 disease incidence proportion,0.6533898305084747
resistance to pathogen,coronavirus disease course,0.6375
resistance to pathogen,infection incidence proportion,0.6615384615384616
resistance to pathogen,symptomatic infectious agent carrier,0.656896551724138
resistance to pathogen,respiratory droplet virus fomite,0.6722222222222223
resistance to pathogen,susceptible organism,0.6642857142857143
resistance to pathogen,parasite role,0.6785714285714286
resistance to pathogen,intermediate host,0.6551282051282051
resistance to pathogen,pathogen vector role,0.6404761904761905
resistance to pathogen,pathogen portal of exit site,0.61
resistance to pathogen,infectious disease prevalence,0.6656862745098039
resistance to pathogen,organism substance,0.65
resistance to pathogen,disposition,0.6318181818181818
resistance to pathogen,single-stranded DNA virus,0.6414893617021277
resistance to pathogen,viral disease,0.6214285714285714
resistance to pathogen,primary infection role,0.6772727272727272
resistance to pathogen,adhesion disposition,0.6642857142857143
resistance to pathogen,leukocyte mediated immunity,0.6132653061224489
resistance to pathogen,pathogen portal of entry site,0.6264705882352941
resistance to pathogen,infection incidence profile,0.6336734693877552
resistance to pathogen,disease,0.6224137931034482
resistance to pathogen,site,0.6038461538461539
resistance to pathogen,primary infectious disposition,0.6807692307692308
resistance to pathogen,pathogen host role,0.65
resistance to pathogen,infection prevalence,0.6880952380952381
resistance to pathogen,designative information content entity,0.65
resistance to pathogen,humoral immune response,0.6277777777777778
resistance to pathogen,infectious pathogen transmissibility,0.6913793103448276
resistance to pathogen,object,0.5571428571428572
resistance to pathogen,intermediate host role,0.6772727272727272
resistance to pathogen,dead-end host,0.6214285714285714
resistance to pathogen,pathogen surveillance,0.636046511627907
resistance to pathogen,immunodeficient organism,0.6456521739130434
resistance to pathogen,host role,0.6112903225806451
resistance to pathogen,pathogen,0.7166666666666667
resistance to pathogen,pathogen birth process boundary,0.619811320754717
resistance to pathogen,infectious human pathogen,0.747872340425532
resistance to pathogen,subclinical virus infection,0.6336734693877552
resistance to pathogen,resistance to pathogen,0.95
resistance to pathogen,establishment of localization in virus host,0.6346153846153847
resistance to pathogen,immunization against infectious agent,0.6533898305084747
resistance to pathogen,virus attachment stage,0.7
resistance to pathogen,negative regulation of immune response,0.6166666666666667
resistance to pathogen,virus synthesis stage,0.6825581395348838
resistance to pathogen,SARS-COV-2 adhesion disposition,0.6386792452830189
resistance to pathogen,object aggregate,0.6342105263157894
resistance to pathogen,pathogen portal of exit role,0.63
resistance to pathogen,invasive disposition,0.6404761904761905
resistance to pathogen,infectious agent host,0.6825581395348838
resistance to pathogen,re-emerging pathogen,0.7595238095238095
resistance to pathogen,long-term non-progressing infectious disease course,0.6143835616438357
resistance to pathogen,viral disease epidemic,0.6318181818181818
resistance to pathogen,fungicidal disposition,0.609090909090909
resistance to pathogen,viral disease pandemic,0.6545454545454545
resistance to pathogen,virus penetration stage,0.6722222222222223
resistance to pathogen,pathogen seroprevalence,0.6277777777777778
resistance to pathogen,infectious disease endemicity,0.6264705882352941
resistance to pathogen,contact pathogen transmission process,0.6703389830508475
resistance to pathogen,herd immunity to infectious organism,0.6396551724137931
resistance to pathogen,extracellular infection,0.65
resistance to pathogen,pathogen transporter role,0.6202127659574468
resistance to pathogen,exotoxin disposition,0.6404761904761905
resistance to pathogen,infectious agent reservoir,0.6583333333333334
resistance to pathogen,infection start process boundary,0.6537037037037037
resistance to pathogen,action specification,0.6880952380952381
resistance to pathogen,protective resistance,0.6825581395348838
resistance to pathogen,infectious disease control objective specification,0.6583333333333334
resistance to pathogen,symbiont host role,0.65
resistance to pathogen,opportunistic infectious disposition,0.6741379310344828
resistance to pathogen,process of establishing viral infection,0.6467213114754098
resistance to pathogen,enterotoxin disposition,0.6722222222222223
resistance to pathogen,polymerase chain reaction,0.6414893617021277
resistance to pathogen,COVID-19 disease course,0.6055555555555556
resistance to pathogen,infectious disease incidence rate,0.6681818181818181
resistance to pathogen,active immunization against infectious agent,0.6469696969696969
resistance to pathogen,disordered virus,0.5552631578947369
resistance to pathogen,collective resistance disposition,0.7227272727272727
resistance to pathogen,adaptive immune response,0.6239130434782608
resistance to pathogen,fungistatic disposition,0.6722222222222223
resistance to pathogen,organism,0.55
resistance to pathogen,virus uncoating stage,0.6593023255813953
resistance to pathogen,local infection,0.6121621621621621
resistance to pathogen,infectious agent,0.7131578947368421
resistance to pathogen,establishment of a clinically abnormal colony,0.6440298507462687
resistance to pathogen,coronavirus disease,0.6207317073170732
resistance to pathogen,positive-sense single-stranded RNA virus,0.6112903225806451
resistance to pathogen,definitive host,0.6391891891891892
resistance to pathogen,horizontal pathogen transmission process,0.6596774193548387
resistance to pathogen,hospital-acquired infection,0.6540816326530612
resistance to pathogen,pathogen death temporal region,0.6423076923076922
resistance to pathogen,emerging pathogen,0.7576923076923078
resistance to pathogen,drug susceptibility of infectious agent,0.6631147540983606
resistance to pathogen,static agent,0.7147058823529412
resistance to pathogen,pathogen transmission process,0.6264705882352941
developmental process,immune response,0.6444444444444444
developmental process,infectious disease mortality rate,0.6351851851851852
developmental process,infection incidence rate profile,0.6386792452830189
developmental process,communicability end temporal region,0.6285714285714286
developmental process,pathogen generative stage,0.6021739130434782
developmental process,primary pathogen,0.6391891891891892
developmental process,surveillance process,0.7426829268292683
developmental process,infection end temporal region,0.65
developmental process,SARS-CoV-2 incidence rate,0.5804347826086956
developmental process,incubation end temporal region,0.6264705882352941
developmental process,virus translation stage,0.609090909090909
developmental process,case isolation control strategy,0.6230769230769231
developmental process,physiologic immunosuppression,0.63
developmental process,virus release stage,0.625
developmental process,B cell receptor complex,0.6318181818181818
developmental process,infection incidence rate,0.6055555555555556
developmental process,double-stranded RNA virus,0.6239130434782608
developmental process,virus transcription stage,0.5804347826086956
developmental process,virus generative stage,0.5895348837209302
developmental process,acute infectious disease course,0.6038461538461539
developmental process,process,0.7
developmental process,droplet pathogen transmission process,0.7086206896551723
developmental process,communicability end process boundary,0.6780701754385965
developmental process,latency end process boundary,0.6744897959183673
developmental process,infectious agent generative stage,0.6166666666666667
developmental process,negative-sense single-stranded RNA virus,0.6139344262295081
developmental process,susceptible population,0.6127906976744186
developmental process,COVID-19 incidence rate,0.5863636363636363
developmental process,negative regulation of developmental process,0.7730769230769231
developmental process,chronic infectious disease course,0.5796296296296296
developmental process,establishment of localization in human host,0.621875
developmental process,primary infection,0.581578947368421
developmental process,process of establishing an infection,0.5903508771929825
developmental process,incubation end process boundary,0.6615384615384616
developmental process,SARS-CoV-2 uncoating stage,0.5776595744680851
developmental process,pathogen death process boundary,0.6807692307692308
developmental process,plan specification,0.5782051282051281
developmental process,latency end temporal region,0.6375
developmental process,SARS-CoV-2 penetration stage,0.6132653061224489
developmental process,virus adhesion susceptible cell,0.6230769230769231
developmental process,T cell receptor complex,0.6318181818181818
developmental process,respiratory system disease,0.598936170212766
developmental process,indirect pathogen transmission process,0.7042372881355932
developmental process,planned process,0.7277777777777777
developmental process,generative stage,0.6121621621621621
developmental process,SARS-CoV-2 attachment stage,0.5958333333333333
developmental process,infectious structure generative stage,0.5706896551724138
developmental process,innate immune response,0.636046511627907
developmental process,viral disease course,0.6207317073170732
developmental process,disease course,0.6214285714285714
developmental process,infectious disease course,0.6021739130434782
developmental process,coronavirus disease course,0.598936170212766
developmental process,susceptible organism,0.6207317073170732
developmental process,SARS-CoV-2 genome replication stage,0.6107142857142857
developmental process,COVID-19 mortality rate,0.6318181818181818
developmental process,process profile,0.6444444444444444
developmental process,negative regulation of life-sustaining process,0.6888059701492537
developmental process,primary infection role,0.636046511627907
developmental process,primary immunodeficiency,0.6055555555555556
developmental process,developmental process,0.95
developmental process,biological process,0.7576923076923078
developmental process,primary infectious disposition,0.6068627450980393
developmental process,humoral immune response,0.6318181818181818
developmental process,SARS-COV-2 adhesion susceptible cell,0.6078947368421053
developmental process,incubation start process boundary,0.6722222222222223
developmental process,pathogen birth process boundary,0.6807692307692308
developmental process,infectious human pathogen,0.6239130434782608
developmental process,colonization of human,0.5928571428571429
developmental process,virus attachment stage,0.6127906976744186
developmental process,negative regulation of immune response,0.6533898305084747
developmental process,SARS-CoV-2 transcription stage,0.5676470588235294
developmental process,virus synthesis stage,0.5928571428571429
developmental process,long-term non-progressing infectious disease course,0.6166666666666667
developmental process,virus penetration stage,0.6318181818181818
developmental process,algorithm,0.55
developmental process,negative regulation of viral process,0.730701754385965
developmental process,contact pathogen transmission process,0.6913793103448276
developmental process,function,0.553448275862069
developmental process,symbiotic process,0.7131578947368421
developmental process,infection start process boundary,0.6952830188679244
developmental process,action specification,0.5719512195121951
developmental process,SARS-CoV-2 synthesis stage,0.5776595744680851
developmental process,latency start process boundary,0.7049019607843137
developmental process,process of establishing viral infection,0.6
developmental process,negative regulation of biological process,0.7080645161290323
developmental process,polymerase chain reaction,0.6021739130434782
developmental process,COVID-19 disease course,0.5863636363636363
developmental process,infectious disease incidence rate,0.5981481481481481
developmental process,communicability start process boundary,0.6703389830508475
developmental process,process that results in death,0.63
developmental process,single-stranded RNA retrovirus,0.6068627450980393
developmental process,adaptive immune response,0.6722222222222223
developmental process,virus uncoating stage,0.5928571428571429
developmental process,establishment of a clinically abnormal colony,0.6166666666666667
developmental process,process boundary,0.6391891891891892
developmental process,positive-sense single-stranded RNA virus,0.5975409836065574
developmental process,horizontal pathogen transmission process,0.6795081967213115
developmental process,SARS-CoV-2 release stage,0.6055555555555556
developmental process,pathogen transmission process,0.71
infectious agent population,angiotensin-converting enzyme 2,0.6051724137931035
infectious agent population,information content entity,0.6952830188679244
infectious agent population,infectious disease mortality rate,0.75
infectious agent population,infection incidence rate profile,0.7211864406779661
infectious agent population,infectious structure aggregate,0.730701754385965
infectious agent population,communicability end temporal region,0.6596774193548387
infectious agent population,infection end temporal region,0.7714285714285714
infectious agent population,infectious disease,0.7388888888888888
infectious agent population,SARS-CoV-2 incidence rate,0.6230769230769231
infectious agent population,incubation end temporal region,0.730701754385965
infectious agent population,normal resident microbiota population,0.715625
infectious agent population,virulence factor disposition,0.6863636363636364
infectious agent population,infectious disease incidence,0.740909090909091
infectious agent population,reservoir of pathogen role,0.6575471698113208
infectious agent population,disease surveillance objective specification,0.6471830985915493
infectious agent population,infectious agent host role,0.8273584905660377
infectious agent population,asymptomatic infectious structure carrier,0.6705882352941177
infectious agent population,B cell receptor complex,0.61
infectious agent population,passive immunization against infectious agent,0.6722222222222223
infectious agent population,infection incidence rate,0.7245098039215686
infectious agent population,pathogen portal of entry role,0.6464285714285714
infectious agent population,infectious disease lifetime prevalence,0.7269230769230769
infectious agent population,lower respiratory tract disease,0.5879310344827586
infectious agent population,infectious disease incidence proportion,0.7833333333333333
infectious agent population,acute infectious disease course,0.7258620689655172
infectious agent population,cidal agent disposition,0.75
infectious agent population,infectious disorder,0.7326086956521739
infectious agent population,role,0.5145161290322581
infectious agent population,biological vehicle,0.5611111111111111
infectious agent population,infectious disease sporadicity,0.7657894736842106
infectious agent population,mutualist role,0.6207317073170732
infectious agent population,communicability end process boundary,0.6246031746031746
infectious agent population,directive information content entity,0.6563492063492063
infectious agent population,infectious agent colony,0.87
infectious agent population,pathogen transporter,0.6414893617021277
infectious agent population,invasion factor,0.6642857142857143
infectious agent population,latency end process boundary,0.6318181818181818
infectious agent population,infectious disease epidemic,0.7462962962962962
infectious agent population,infectious agent generative stage,0.7833333333333333
infectious agent population,disease transmission model,0.619811320754717
infectious agent population,cidal agent,0.6605263157894737
infectious agent population,infectious structure host role,0.730701754385965
infectious agent population,pathogen vehicle,0.6127906976744186
infectious agent population,susceptible population,0.7561224489795919
infectious agent population,COVID-19 incidence rate,0.63
infectious agent population,pathogen vehicle role,0.6166666666666667
infectious agent population,chronic infectious disease course,0.7166666666666667
infectious agent population,asymptomatic infectious agent carrier,0.746875
infectious agent population,descriptive information content entity,0.65
infectious agent population,COVID-19 epidemic,0.5863636363636363
infectious agent population,mechanical vector role,0.6336734693877552
infectious agent population,sterilizing immunity to infectious agent,0.6888059701492537
infectious agent population,establishment of localization in human host,0.6642857142857143
infectious agent population,diseased population,0.7760869565217391
infectious agent population,virulence factor,0.636046511627907
infectious agent population,incubation end process boundary,0.6913793103448276
infectious agent population,dead-end host role,0.6277777777777778
infectious agent population,definitive host role,0.6627659574468084
infectious agent population,latency end temporal region,0.6722222222222223
infectious agent population,innate immunity to infectious agent,0.7080645161290323
infectious agent population,infectious structure,0.747872340425532
infectious agent population,static agent disposition,0.7441176470588234
infectious agent population,T cell receptor complex,0.61
infectious agent population,asymptomatic carrier role,0.6038461538461539
infectious agent population,infectious structure host,0.7384615384615384
infectious agent population,infectious agent population,0.95
infectious agent population,respiratory system disease,0.5820754716981132
infectious agent population,leukocyte-mediated immunity to infectious agent,0.6662162162162162
infectious agent population,organism population,0.7543478260869566
infectious agent population,humoral immunity to infectious agent,0.7039682539682539
infectious agent population,infectious disease control strategy,0.7564516129032257
infectious agent population,infectious disease pandemic,0.7648148148148148
infectious agent population,infectious structure generative stage,0.715625
infectious agent population,viral disease course,0.6202127659574468
infectious agent population,secondary infection role,0.6852941176470588
infectious agent population,passive immunity to infectious agent,0.7039682539682539
infectious agent population,infectious disposition,0.7969387755102041
infectious agent population,vaccination against infectious agent,0.7039682539682539
infectious agent population,susceptibility to infectious agent,0.7122950819672131
infectious agent population,country,0.5970588235294118
infectious agent population,source of infection role,0.6852941176470588
infectious agent population,disease course,0.6207317073170732
infectious agent population,infectious disease course,0.7576923076923078
infectious agent population,acquired immunity to infectious agent,0.7
infectious agent population,COVID-19 disease incidence proportion,0.66875
infectious agent population,coronavirus disease course,0.6386792452830189
infectious agent population,asymptomatic carrier,0.598936170212766
infectious agent population,biological vehicle role,0.59
infectious agent population,symptomatic infectious agent carrier,0.7515873015873015
infectious agent population,symbiont role,0.625
infectious agent population,parasite role,0.6
infectious agent population,intermediate host,0.6545454545454545
infectious agent population,pathogen vector role,0.6414893617021277
infectious agent population,infectious disease prevalence,0.7535714285714286
infectious agent population,infected population,0.8413043478260869
infectious agent population,COVID-19 mortality rate,0.61
infectious agent population,viral disease,0.575
infectious agent population,primary infection role,0.6948979591836735
infectious agent population,biological role,0.5928571428571429
infectious agent population,disease,0.5676470588235294
infectious agent population,symptomatic infectious structure carrier,0.6738805970149254
infectious agent population,biological vector role,0.6132653061224489
infectious agent population,primary infectious disposition,0.7482456140350877
infectious agent population,pathogen host role,0.65
infectious agent population,designative information content entity,0.65
infectious agent population,symptomatic carrier role,0.6068627450980393
infectious agent population,infectious pathogen transmissibility,0.7357142857142857
infectious agent population,intermediate host role,0.6540816326530612
infectious agent population,host role,0.6166666666666667
infectious agent population,infectious human pathogen,0.8153846153846154
infectious agent population,colonization of human,0.6583333333333334
infectious agent population,immunization against infectious agent,0.7
infectious agent population,pathogen portal of exit role,0.65
infectious agent population,infectious agent host,0.8458333333333333
infectious agent population,long-term non-progressing infectious disease course,0.6551282051282051
infectious agent population,viral disease epidemic,0.6132653061224489
infectious agent population,commensal role,0.6207317073170732
infectious agent population,epitope role,0.6294871794871795
infectious agent population,viral disease pandemic,0.6336734693877552
infectious agent population,symptomatic carrier,0.6021739130434782
infectious agent population,infectious disease endemicity,0.7178571428571427
infectious agent population,function,0.65
infectious agent population,herd immunity to infectious organism,0.6722222222222223
infectious agent population,pathogen transporter role,0.6423076923076922
infectious agent population,infectious agent reservoir,0.808490566037736
infectious agent population,antigen role,0.6807692307692308
infectious agent population,COVID-19 pandemic,0.5863636363636363
infectious agent population,action specification,0.7053191489361703
infectious agent population,infectious disease control objective specification,0.7487012987012988
infectious agent population,symbiont host role,0.65
infectious agent population,immune population,0.7681818181818181
infectious agent population,opportunistic infectious disposition,0.7198412698412698
infectious agent population,fomite role,0.6078947368421053
infectious agent population,polymerase chain reaction,0.6615384615384616
infectious agent population,COVID-19 disease course,0.61
infectious agent population,infectious disease incidence rate,0.7333333333333333
infectious agent population,active immunization against infectious agent,0.6753521126760563
infectious agent population,reagent role,0.6807692307692308
infectious agent population,infectious agent,0.822093023255814
infectious agent population,establishment of a clinically abnormal colony,0.6305555555555555
infectious agent population,coronavirus disease,0.6021739130434782
infectious agent population,adhesion factor,0.6404761904761905
infectious agent population,drug susceptibility of infectious agent,0.6924242424242425
infectious agent population,static agent,0.6551282051282051
country,infectious disease mortality rate,0.575
country,infection incidence rate profile,0.5782051282051281
country,communicability end temporal region,0.5928571428571429
country,infection end temporal region,0.5888888888888889
country,SARS-CoV-2 incidence rate,0.575
country,incubation end temporal region,0.5851351351351352
country,two-dimensional spatial region,0.5581081081081081
country,one-dimensional temporal region,0.5552631578947369
country,temporal region,0.5409090909090909
country,B cell receptor complex,0.55
country,infection incidence rate,0.5790322580645162
country,pathogen birth temporal region,0.5581081081081081
country,infectious disease incidence proportion,0.558695652173913
country,simple infection,0.5804347826086956
country,communicability end process boundary,0.6127906976744186
country,infection incidence proportion profile,0.5611111111111111
country,SARS-CoV-2 incidence proportion,0.5552631578947369
country,spatiotemporal region,0.5571428571428572
country,latency end process boundary,0.6214285714285714
country,COVID-19 incidence rate,0.5833333333333334
country,zero-dimensional spatial region,0.5552631578947369
country,zero-dimensional temporal region,0.5525641025641026
country,infection start temporal region,0.581578947368421
country,incubation end process boundary,0.6078947368421053
country,geographical region,0.5653846153846154
country,latency end temporal region,0.5676470588235294
country,anatomical space,0.5369565217391304
country,T cell receptor complex,0.55
country,three-dimensional spatial region,0.5525641025641026
country,country,0.95
country,COVID-19 disease incidence proportion,0.5409090909090909
country,infection incidence proportion,0.5581081081081081
country,COVID-19 mortality rate,0.5833333333333334
country,communicability start temporal region,0.5863636363636363
country,geospatial region,0.575
country,infectious disease incidence rate,0.575
country,establishment of a clinically abnormal colony,0.5269230769230769
country,one-dimensional spatial region,0.5581081081081081
country,spatial region,0.5452380952380953
country,pathogen death temporal region,0.5581081081081081
country,cell space,0.5088235294117647
virus penetration stage,extended organism,0.625
virus penetration stage,virus aggregate,0.7131578947368421
virus penetration stage,source of infection,0.6404761904761905
virus penetration stage,virostatic disposition,0.6944444444444444
virus penetration stage,zoonotic disposition,0.6127906976744186
virus penetration stage,immune response,0.6868421052631578
virus penetration stage,infectious disease mortality rate,0.6642857142857143
virus penetration stage,infection incidence rate profile,0.6318181818181818
virus penetration stage,communicability end temporal region,0.6224137931034482
virus penetration stage,pathogen generative stage,0.7416666666666667
virus penetration stage,pathogen portal of entry,0.6414893617021277
virus penetration stage,subclinical coronavirus infection,0.6642857142857143
virus penetration stage,primary pathogen,0.6807692307692308
virus penetration stage,infection end temporal region,0.6615384615384616
virus penetration stage,drug-based immunosuppressed organism,0.6364406779661017
virus penetration stage,infectious disease,0.6939024390243902
virus penetration stage,SARS-CoV-2 incidence rate,0.6583333333333334
virus penetration stage,double-stranded DNA virus,0.6166666666666667
virus penetration stage,incubation end temporal region,0.6575471698113208
virus penetration stage,site of infection,0.65
virus penetration stage,immunocompetent organism,0.6627659574468084
virus penetration stage,virulence factor disposition,0.7049019607843137
virus penetration stage,pathogen portal of exit,0.6456521739130434
virus penetration stage,viral adhesion disposition,0.6744897959183673
virus penetration stage,parasitostatic disposition,0.6336734693877552
virus penetration stage,infectious disease incidence,0.6460784313725491
virus penetration stage,reservoir of pathogen role,0.6744897959183673
virus penetration stage,reverse zoonotic disposition,0.6460784313725491
virus penetration stage,subclinical SARS-CoV-2 infection,0.6318181818181818
virus penetration stage,virus translation stage,0.8630434782608696
virus penetration stage,disease surveillance objective specification,0.6291044776119403
virus penetration stage,virus release stage,0.8071428571428573
virus penetration stage,source of infection site,0.7053191489361703
virus penetration stage,virus,0.6285714285714286
virus penetration stage,virus replication,0.75
virus penetration stage,B cell receptor complex,0.6021739130434782
virus penetration stage,systematic infection,0.636046511627907
virus penetration stage,infection incidence rate,0.6627659574468084
virus penetration stage,virus host,0.7227272727272727
virus penetration stage,double-stranded RNA virus,0.6166666666666667
virus penetration stage,pathogen portal of entry role,0.6230769230769231
virus penetration stage,virus transcription stage,0.8458333333333333
virus penetration stage,infectious disease lifetime prevalence,0.630327868852459
virus penetration stage,toxin disposition,0.625
virus penetration stage,pathogen birth temporal region,0.619811320754717
virus penetration stage,lower respiratory tract disease,0.6537037037037037
virus penetration stage,infectious disease incidence proportion,0.6435483870967742
virus penetration stage,opportunistic pathogen,0.6722222222222223
virus penetration stage,virus generative stage,0.8722222222222222
virus penetration stage,acute infectious disease course,0.6537037037037037
virus penetration stage,cidal agent disposition,0.6456521739130434
virus penetration stage,infectious disorder,0.6642857142857143
virus penetration stage,genetic resistance to pathogen,0.6764150943396227
virus penetration stage,subclinical infection,0.6318181818181818
virus penetration stage,appearance of disorder,0.6277777777777778
virus penetration stage,simple infection,0.6807692307692308
virus penetration stage,biological vehicle,0.5719512195121951
virus penetration stage,droplet pathogen transmission process,0.6666666666666667
virus penetration stage,parasiticidal disposition,0.6166666666666667
virus penetration stage,infectious disease sporadicity,0.6386792452830189
virus penetration stage,communicability end process boundary,0.5855932203389831
virus penetration stage,infection incidence proportion profile,0.6467213114754098
virus penetration stage,pathogen transporter,0.6825581395348838
virus penetration stage,invasion factor,0.6605263157894737
virus penetration stage,transmissibility disposition,0.6068627450980393
virus penetration stage,latency end process boundary,0.5872549019607843
virus penetration stage,infectious disease epidemic,0.65
virus penetration stage,infectious agent generative stage,0.7535714285714286
virus penetration stage,disease transmission model,0.6948979591836735
virus penetration stage,endotoxin disposition,0.6318181818181818
virus penetration stage,pathologically immunosuppressed organism,0.6087301587301588
virus penetration stage,negative-sense single-stranded RNA virus,0.6246031746031746
virus penetration stage,pathogen vehicle,0.6294871794871795
virus penetration stage,COVID-19 incidence rate,0.6673913043478261
virus penetration stage,cytotoxin disposition,0.609090909090909
virus penetration stage,community-acquired infection,0.6264705882352941
virus penetration stage,pathogen vector,0.6342105263157894
virus penetration stage,pathogen vehicle role,0.609090909090909
virus penetration stage,chronic infectious disease course,0.6464285714285714
virus penetration stage,nursing-home acquired infection,0.6351851851851852
virus penetration stage,COVID-19 epidemic,0.6
virus penetration stage,secondary infection,0.6404761904761905
virus penetration stage,infection start temporal region,0.6722222222222223
virus penetration stage,infection incidence,0.6642857142857143
virus penetration stage,virus disorder,0.6932432432432433
virus penetration stage,primary infection,0.675
virus penetration stage,process of establishing an infection,0.6364406779661017
virus penetration stage,incubation end process boundary,0.6351851851851852
virus penetration stage,SARS-CoV-2 disorder,0.5928571428571429
virus penetration stage,collective pathogenic disposition,0.6285714285714286
virus penetration stage,neurotoxin disposition,0.65
virus penetration stage,SARS-CoV-2 uncoating stage,0.7357142857142857
virus penetration stage,pathogen death process boundary,0.6166666666666667
virus penetration stage,immunosuppressed organism,0.6583333333333334
virus penetration stage,plan specification,0.6451219512195122
virus penetration stage,latency end temporal region,0.63
virus penetration stage,SARS-CoV-2 penetration stage,0.842156862745098
virus penetration stage,virus adhesion susceptible cell,0.7092592592592593
virus penetration stage,collective disposition,0.6277777777777778
virus penetration stage,infection,0.66875
virus penetration stage,static agent disposition,0.6414893617021277
virus penetration stage,T cell receptor complex,0.6021739130434782
virus penetration stage,respiratory system disease,0.6948979591836735
virus penetration stage,indirect pathogen transmission process,0.6795081967213115
virus penetration stage,organism population,0.6642857142857143
virus penetration stage,generative stage,0.7833333333333333
virus penetration stage,infectious disease control strategy,0.6913793103448276
virus penetration stage,SARS-CoV-2 attachment stage,0.69
virus penetration stage,infectious disease pandemic,0.65
virus penetration stage,infectious structure generative stage,0.7333333333333333
virus penetration stage,immunosuppressive disposition,0.6423076923076922
virus penetration stage,innate immune response,0.65
virus penetration stage,pathogenic disposition,0.6277777777777778
virus penetration stage,viral disease course,0.6593023255813953
virus penetration stage,intracellular infection,0.6673913043478261
virus penetration stage,secondary infection role,0.6627659574468084
virus penetration stage,metastatic infection,0.636046511627907
virus penetration stage,infectious disposition,0.65
virus penetration stage,acute infection,0.6605263157894737
virus penetration stage,bacteriostatic disposition,0.6336734693877552
virus penetration stage,immunity to pathogen,0.6825581395348838
virus penetration stage,bactericidal disposition,0.598936170212766
virus penetration stage,source of infection role,0.6627659574468084
virus penetration stage,pathogen host,0.6722222222222223
virus penetration stage,acquired immunodeficiency,0.5958333333333333
virus penetration stage,chronic infection,0.65
virus penetration stage,invasion disposition,0.6593023255813953
virus penetration stage,disease course,0.6391891891891892
virus penetration stage,infectious disease course,0.6583333333333334
virus penetration stage,viricidal disposition,0.6545454545454545
virus penetration stage,acquired immunity to infectious agent,0.6666666666666667
virus penetration stage,complex infection,0.65
virus penetration stage,COVID-19 disease incidence proportion,0.65
virus penetration stage,coronavirus disease course,0.6744897959183673
virus penetration stage,biological vehicle role,0.6021739130434782
virus penetration stage,infection incidence proportion,0.6386792452830189
virus penetration stage,respiratory droplet virus fomite,0.65
virus penetration stage,susceptible organism,0.636046511627907
virus penetration stage,pathogen vector role,0.636046511627907
virus penetration stage,pathogen portal of exit site,0.6460784313725491
virus penetration stage,infectious disease prevalence,0.6423076923076922
virus penetration stage,organism substance,0.6451219512195122
virus penetration stage,SARS-CoV-2 genome replication stage,0.760344827586207
virus penetration stage,disposition,0.6558823529411765
virus penetration stage,single-stranded DNA virus,0.6375
virus penetration stage,COVID-19 mortality rate,0.6456521739130434
virus penetration stage,viral disease,0.6722222222222223
virus penetration stage,primary infection role,0.6944444444444444
virus penetration stage,adhesion disposition,0.6127906976744186
virus penetration stage,pathogen portal of entry site,0.6615384615384616
virus penetration stage,infection incidence profile,0.63
virus penetration stage,disease,0.65
virus penetration stage,primary infectious disposition,0.6575471698113208
virus penetration stage,pathogen host role,0.6695121951219513
virus penetration stage,infection prevalence,0.6825581395348838
virus penetration stage,humoral immune response,0.6456521739130434
virus penetration stage,coronavirus disorder,0.6593023255813953
virus penetration stage,infectious pathogen transmissibility,0.6703389830508475
virus penetration stage,pathogen surveillance,0.6545454545454545
virus penetration stage,immunodeficient organism,0.6414893617021277
virus penetration stage,pathogen,0.6435483870967742
virus penetration stage,pathogen birth process boundary,0.5981481481481481
virus penetration stage,infectious human pathogen,0.6791666666666666
virus penetration stage,subclinical virus infection,0.69
virus penetration stage,resistance to pathogen,0.6722222222222223
virus penetration stage,establishment of localization in virus host,0.6469696969696969
virus penetration stage,virus attachment stage,0.7833333333333333
virus penetration stage,negative regulation of immune response,0.6467213114754098
virus penetration stage,SARS-CoV-2 transcription stage,0.7518867924528303
virus penetration stage,virus synthesis stage,0.7909090909090909
virus penetration stage,SARS-COV-2 adhesion disposition,0.6351851851851852
virus penetration stage,pathogen portal of exit role,0.6264705882352941
virus penetration stage,invasive disposition,0.636046511627907
virus penetration stage,re-emerging pathogen,0.6825581395348838
virus penetration stage,long-term non-progressing infectious disease course,0.6256756756756756
virus penetration stage,viral disease epidemic,0.6277777777777778
virus penetration stage,fungicidal disposition,0.6055555555555556
virus penetration stage,viral disease pandemic,0.65
virus penetration stage,virus penetration stage,0.95
virus penetration stage,pathogen seroprevalence,0.6456521739130434
virus penetration stage,acute respiratory distress syndrome,0.6396551724137931
virus penetration stage,division of geopolitical entity,0.6351851851851852
virus penetration stage,infectious disease endemicity,0.6423076923076922
virus penetration stage,contact pathogen transmission process,0.65
virus penetration stage,disorder,0.5790322580645162
virus penetration stage,herd immunity to infectious organism,0.6194915254237288
virus penetration stage,extracellular infection,0.6456521739130434
virus penetration stage,pathogen transporter role,0.6583333333333334
virus penetration stage,transmission interval,0.6545454545454545
virus penetration stage,exotoxin disposition,0.6127906976744186
virus penetration stage,infection start process boundary,0.6681818181818181
virus penetration stage,SARS-CoV-2 synthesis stage,0.6948979591836735
virus penetration stage,infectious disease control objective specification,0.6280821917808219
virus penetration stage,immune population,0.675
virus penetration stage,opportunistic infectious disposition,0.6533898305084747
virus penetration stage,process of establishing viral infection,0.6274193548387097
virus penetration stage,enterotoxin disposition,0.6673913043478261
virus penetration stage,COVID-19 disease course,0.6239130434782608
virus penetration stage,infectious disease incidence rate,0.6464285714285714
virus penetration stage,disordered virus,0.6038461538461539
virus penetration stage,collective resistance disposition,0.6107142857142857
virus penetration stage,adaptive immune response,0.6627659574468084
virus penetration stage,fungistatic disposition,0.6456521739130434
virus penetration stage,organism,0.5790322580645162
virus penetration stage,virus uncoating stage,0.8363636363636363
virus penetration stage,local infection,0.6342105263157894
virus penetration stage,establishment of a clinically abnormal colony,0.5970588235294118
virus penetration stage,coronavirus disease,0.6880952380952381
virus penetration stage,positive-sense single-stranded RNA virus,0.6246031746031746
virus penetration stage,horizontal pathogen transmission process,0.6563492063492063
virus penetration stage,hospital-acquired infection,0.63
virus penetration stage,pathogen death temporal region,0.6386792452830189
virus penetration stage,emerging pathogen,0.675
virus penetration stage,SARS-CoV-2 release stage,0.7053191489361703
virus penetration stage,pathogen transmission process,0.6615384615384616
resistance to drug,ribonucleic acid,0.6558823529411765
resistance to drug,virostatic disposition,0.65
resistance to drug,information content entity,0.609090909090909
resistance to drug,zoonotic disposition,0.581578947368421
resistance to drug,immune response,0.6015151515151516
resistance to drug,communicability end temporal region,0.619811320754717
resistance to drug,infection end temporal region,0.6627659574468084
resistance to drug,deoxyribonucleic acid,0.6294871794871795
resistance to drug,incubation end temporal region,0.6583333333333334
resistance to drug,virulence factor disposition,0.6673913043478261
resistance to drug,viral adhesion disposition,0.6318181818181818
resistance to drug,parasitostatic disposition,0.6772727272727272
resistance to drug,reverse zoonotic disposition,0.6239130434782608
resistance to drug,establishment of localization in host,0.6136363636363636
resistance to drug,infectious agent host role,0.6545454545454545
resistance to drug,B cell receptor complex,0.6207317073170732
resistance to drug,passive immunization against infectious agent,0.6087301587301588
resistance to drug,colonized host,0.575
resistance to drug,virus host,0.5928571428571429
resistance to drug,drug susceptibility,0.6121621621621621
resistance to drug,toxin disposition,0.5928571428571429
resistance to drug,lower respiratory tract disease,0.6540816326530612
resistance to drug,cidal agent disposition,0.5963414634146341
resistance to drug,genetic resistance to pathogen,0.7625
resistance to drug,parasiticidal disposition,0.636046511627907
resistance to drug,communicability end process boundary,0.6166666666666667
resistance to drug,directive information content entity,0.6166666666666667
resistance to drug,infectious agent colony,0.6207317073170732
resistance to drug,transmissibility disposition,0.6239130434782608
resistance to drug,latency end process boundary,0.6456521739130434
resistance to drug,colonization of host,0.6078947368421053
resistance to drug,infectious agent generative stage,0.6264705882352941
resistance to drug,endotoxin disposition,0.6038461538461539
resistance to drug,cidal agent,0.5879310344827586
resistance to drug,infectious structure host role,0.6583333333333334
resistance to drug,cytotoxin disposition,0.5782051282051281
resistance to drug,antibiotic resistance,0.7064102564102563
resistance to drug,host,0.5409090909090909
resistance to drug,asymptomatic infectious agent carrier,0.6136363636363636
resistance to drug,descriptive information content entity,0.6285714285714286
resistance to drug,nucleic acid,0.6166666666666667
resistance to drug,resistance to drug,0.95
resistance to drug,sterilizing immunity to infectious agent,0.6051724137931035
resistance to drug,establishment of localization in human host,0.6139344262295081
resistance to drug,incubation end process boundary,0.6336734693877552
resistance to drug,collective pathogenic disposition,0.6068627450980393
resistance to drug,neurotoxin disposition,0.6
resistance to drug,dead-end host role,0.6444444444444444
resistance to drug,definitive host role,0.6605263157894737
resistance to drug,latency end temporal region,0.6722222222222223
resistance to drug,innate immunity to infectious agent,0.619811320754717
resistance to drug,collective disposition,0.6
resistance to drug,static agent disposition,0.6404761904761905
resistance to drug,T cell receptor complex,0.6207317073170732
resistance to drug,infectious structure host,0.636046511627907
resistance to drug,infectious agent population,0.6277777777777778
resistance to drug,entry into host,0.6318181818181818
resistance to drug,leukocyte-mediated immunity to infectious agent,0.6038461538461539
resistance to drug,adhesion of symbiont to host,0.6456521739130434
resistance to drug,humoral immunity to infectious agent,0.6166666666666667
resistance to drug,immunosuppressive disposition,0.6202127659574468
resistance to drug,innate immune response,0.6
resistance to drug,pathogenic disposition,0.6
resistance to drug,entry into host through host barriers,0.6136363636363636
resistance to drug,passive immunity to infectious agent,0.6166666666666667
resistance to drug,infectious disposition,0.625
resistance to drug,vaccination against infectious agent,0.6166666666666667
resistance to drug,susceptibility to infectious agent,0.6423076923076922
resistance to drug,bacteriostatic disposition,0.6545454545454545
resistance to drug,immunity to pathogen,0.6342105263157894
resistance to drug,bactericidal disposition,0.5928571428571429
resistance to drug,pathogen host,0.5790322580645162
resistance to drug,invasion disposition,0.6078947368421053
resistance to drug,viricidal disposition,0.6038461538461539
resistance to drug,acquired immunity to infectious agent,0.6318181818181818
resistance to drug,symptomatic infectious agent carrier,0.6166666666666667
resistance to drug,intermediate host,0.65
resistance to drug,organism substance,0.6722222222222223
resistance to drug,disposition,0.5879310344827586
resistance to drug,place closure control strategy,0.6375
resistance to drug,adhesion disposition,0.6342105263157894
resistance to drug,leukocyte mediated immunity,0.6055555555555556
resistance to drug,primary infectious disposition,0.6375
resistance to drug,pathogen host role,0.6166666666666667
resistance to drug,designative information content entity,0.6285714285714286
resistance to drug,humoral immune response,0.5963414634146341
resistance to drug,object,0.575
resistance to drug,intermediate host role,0.675
resistance to drug,dead-end host,0.6112903225806451
resistance to drug,host role,0.5981481481481481
resistance to drug,resistance to pathogen,0.825
resistance to drug,establishment of localization in virus host,0.630327868852459
resistance to drug,immunization against infectious agent,0.6136363636363636
resistance to drug,negative regulation of immune response,0.5928571428571429
resistance to drug,SARS-COV-2 adhesion disposition,0.6132653061224489
resistance to drug,object aggregate,0.6264705882352941
resistance to drug,invasive disposition,0.6078947368421053
resistance to drug,infectious agent host,0.6294871794871795
resistance to drug,fungicidal disposition,0.575
resistance to drug,herd immunity to infectious organism,0.6351851851851852
resistance to drug,exotoxin disposition,0.6078947368421053
resistance to drug,infectious agent reservoir,0.6318181818181818
resistance to drug,action specification,0.581578947368421
resistance to drug,protective resistance,0.7064102564102563
resistance to drug,symbiont host role,0.6444444444444444
resistance to drug,opportunistic infectious disposition,0.6351851851851852
resistance to drug,enterotoxin disposition,0.6207317073170732
resistance to drug,polymerase chain reaction,0.6127906976744186
resistance to drug,active immunization against infectious agent,0.6112903225806451
resistance to drug,collective resistance disposition,0.7049019607843137
resistance to drug,adaptive immune response,0.5928571428571429
resistance to drug,fungistatic disposition,0.6451219512195122
resistance to drug,infectious agent,0.6558823529411765
resistance to drug,establishment of a clinically abnormal colony,0.6246031746031746
resistance to drug,definitive host,0.6318181818181818
resistance to drug,drug susceptibility of infectious agent,0.6254385964912281
resistance to drug,static agent,0.65
infectious disease pandemic,virus aggregate,0.6404761904761905
infectious disease pandemic,source of infection,0.6456521739130434
infectious disease pandemic,virostatic disposition,0.6336734693877552
infectious disease pandemic,zoonotic disposition,0.6414893617021277
infectious disease pandemic,infectious disease mortality rate,0.8
infectious disease pandemic,infection incidence rate profile,0.7211864406779661
infectious disease pandemic,infectious structure aggregate,0.7482456140350877
infectious disease pandemic,communicability end temporal region,0.6274193548387097
infectious disease pandemic,subclinical coronavirus infection,0.6333333333333333
infectious disease pandemic,infection end temporal region,0.7178571428571427
infectious disease pandemic,infectious disease,0.85
infectious disease pandemic,double-stranded DNA virus,0.6230769230769231
infectious disease pandemic,incubation end temporal region,0.6780701754385965
infectious disease pandemic,site of infection,0.6545454545454545
infectious disease pandemic,virulence factor disposition,0.6681818181818181
infectious disease pandemic,viral adhesion disposition,0.6386792452830189
infectious disease pandemic,parasitostatic disposition,0.6386792452830189
infectious disease pandemic,infectious disease incidence,0.8681818181818182
infectious disease pandemic,reverse zoonotic disposition,0.6136363636363636
infectious disease pandemic,subclinical SARS-CoV-2 infection,0.6364406779661017
infectious disease pandemic,virus translation stage,0.63
infectious disease pandemic,disease surveillance objective specification,0.6330985915492958
infectious disease pandemic,virus release stage,0.6891304347826087
infectious disease pandemic,infectious agent host role,0.7330188679245283
infectious disease pandemic,asymptomatic infectious structure carrier,0.6852941176470588
infectious disease pandemic,source of infection site,0.6656862745098039
infectious disease pandemic,virus,0.54375
infectious disease pandemic,virus replication,0.6318181818181818
infectious disease pandemic,B cell receptor complex,0.59
infectious disease pandemic,passive immunization against infectious agent,0.6444444444444444
infectious disease pandemic,systematic infection,0.6414893617021277
infectious disease pandemic,infection incidence rate,0.7441176470588234
infectious disease pandemic,virus host,0.5851351351351352
infectious disease pandemic,double-stranded RNA virus,0.6230769230769231
infectious disease pandemic,virus transcription stage,0.6423076923076922
infectious disease pandemic,infectious disease lifetime prevalence,0.8038461538461539
infectious disease pandemic,toxin disposition,0.6318181818181818
infectious disease pandemic,lower respiratory tract disease,0.6396551724137931
infectious disease pandemic,infectious disease incidence proportion,0.7984848484848485
infectious disease pandemic,virus generative stage,0.6540816326530612
infectious disease pandemic,acute infectious disease course,0.7948275862068965
infectious disease pandemic,cidal agent disposition,0.63
infectious disease pandemic,infectious disorder,0.7978260869565217
infectious disease pandemic,subclinical infection,0.6375
infectious disease pandemic,appearance of disorder,0.6336734693877552
infectious disease pandemic,simple infection,0.6593023255813953
infectious disease pandemic,parasiticidal disposition,0.6230769230769231
infectious disease pandemic,infectious disease sporadicity,0.8710526315789474
infectious disease pandemic,communicability end process boundary,0.6087301587301588
infectious disease pandemic,infection incidence proportion profile,0.6961538461538461
infectious disease pandemic,infectious agent colony,0.75
infectious disease pandemic,invasion factor,0.6166666666666667
infectious disease pandemic,transmissibility disposition,0.6136363636363636
infectious disease pandemic,latency end process boundary,0.6136363636363636
infectious disease pandemic,infectious disease epidemic,0.9129629629629631
infectious disease pandemic,infectious agent generative stage,0.7333333333333333
infectious disease pandemic,disease transmission model,0.6764150943396227
infectious disease pandemic,endotoxin disposition,0.6375
infectious disease pandemic,negative-sense single-stranded RNA virus,0.658955223880597
infectious disease pandemic,infectious structure host role,0.730701754385965
infectious disease pandemic,cytotoxin disposition,0.6375
infectious disease pandemic,community-acquired infection,0.6318181818181818
infectious disease pandemic,chronic infectious disease course,0.7833333333333333
infectious disease pandemic,asymptomatic infectious agent carrier,0.7
infectious disease pandemic,nursing-home acquired infection,0.6396551724137931
infectious disease pandemic,COVID-19 epidemic,0.6772727272727272
infectious disease pandemic,secondary infection,0.6456521739130434
infectious disease pandemic,infection start temporal region,0.7258620689655172
infectious disease pandemic,infection incidence,0.7543478260869566
infectious disease pandemic,virus disorder,0.6695121951219513
infectious disease pandemic,sterilizing immunity to infectious agent,0.658955223880597
infectious disease pandemic,diseased population,0.6891304347826087
infectious disease pandemic,primary infection,0.6545454545454545
infectious disease pandemic,process of establishing an infection,0.6246031746031746
infectious disease pandemic,incubation end process boundary,0.6741379310344828
infectious disease pandemic,SARS-CoV-2 disorder,0.6239130434782608
infectious disease pandemic,collective pathogenic disposition,0.6333333333333333
infectious disease pandemic,neurotoxin disposition,0.6540816326530612
infectious disease pandemic,plan specification,0.6055555555555556
infectious disease pandemic,latency end temporal region,0.6166666666666667
infectious disease pandemic,innate immunity to infectious agent,0.6758064516129032
infectious disease pandemic,infectious structure,0.7265957446808511
infectious disease pandemic,virus adhesion susceptible cell,0.656896551724138
infectious disease pandemic,collective disposition,0.6540816326530612
infectious disease pandemic,infection,0.7
infectious disease pandemic,static agent disposition,0.6264705882352941
infectious disease pandemic,T cell receptor complex,0.59
infectious disease pandemic,infectious structure host,0.7192307692307692
infectious disease pandemic,infectious agent population,0.7648148148148148
infectious disease pandemic,respiratory system disease,0.6764150943396227
infectious disease pandemic,leukocyte-mediated immunity to infectious agent,0.6391891891891892
infectious disease pandemic,humoral immunity to infectious agent,0.6722222222222223
infectious disease pandemic,infectious disease control strategy,0.7887096774193548
infectious disease pandemic,infectious disease pandemic,0.95
infectious disease pandemic,infectious structure generative stage,0.73125
infectious disease pandemic,immunosuppressive disposition,0.6464285714285714
infectious disease pandemic,pathogenic disposition,0.6132653061224489
infectious disease pandemic,viral disease course,0.6840425531914894
infectious disease pandemic,intracellular infection,0.63
infectious disease pandemic,secondary infection role,0.6460784313725491
infectious disease pandemic,metastatic infection,0.6414893617021277
infectious disease pandemic,passive immunity to infectious agent,0.6722222222222223
infectious disease pandemic,infectious disposition,0.7765306122448979
infectious disease pandemic,vaccination against infectious agent,0.6722222222222223
infectious disease pandemic,acute infection,0.6642857142857143
infectious disease pandemic,susceptibility to infectious agent,0.6795081967213115
infectious disease pandemic,bacteriostatic disposition,0.6575471698113208
infectious disease pandemic,bactericidal disposition,0.6264705882352941
infectious disease pandemic,source of infection role,0.6460784313725491
infectious disease pandemic,chronic infection,0.6545454545454545
infectious disease pandemic,invasion disposition,0.6627659574468084
infectious disease pandemic,disease course,0.6695121951219513
infectious disease pandemic,infectious disease course,0.8346153846153846
infectious disease pandemic,viricidal disposition,0.6375
infectious disease pandemic,acquired immunity to infectious agent,0.66875
infectious disease pandemic,complex infection,0.6545454545454545
infectious disease pandemic,COVID-19 disease incidence proportion,0.684375
infectious disease pandemic,coronavirus disease course,0.7141509433962264
infectious disease pandemic,infection incidence proportion,0.7131578947368421
infectious disease pandemic,symptomatic infectious agent carrier,0.7039682539682539
infectious disease pandemic,respiratory droplet virus fomite,0.6194915254237288
infectious disease pandemic,infectious disease prevalence,0.8607142857142857
infectious disease pandemic,disposition,0.581578947368421
infectious disease pandemic,single-stranded DNA virus,0.6230769230769231
infectious disease pandemic,infected population,0.6891304347826087
infectious disease pandemic,place closure control strategy,0.5903508771929825
infectious disease pandemic,viral disease,0.675
infectious disease pandemic,primary infection role,0.6540816326530612
infectious disease pandemic,adhesion disposition,0.6414893617021277
infectious disease pandemic,infection incidence profile,0.7277777777777777
infectious disease pandemic,disease,0.6558823529411765
infectious disease pandemic,symptomatic infectious structure carrier,0.6888059701492537
infectious disease pandemic,primary infectious disposition,0.730701754385965
infectious disease pandemic,infection prevalence,0.747872340425532
infectious disease pandemic,coronavirus disorder,0.6627659574468084
infectious disease pandemic,infectious pathogen transmissibility,0.7357142857142857
infectious disease pandemic,infectious human pathogen,0.7576923076923078
infectious disease pandemic,subclinical virus infection,0.6537037037037037
infectious disease pandemic,establishment of localization in virus host,0.6071428571428572
infectious disease pandemic,immunization against infectious agent,0.66875
infectious disease pandemic,virus attachment stage,0.6336734693877552
infectious disease pandemic,virus synthesis stage,0.6583333333333334
infectious disease pandemic,SARS-COV-2 adhesion disposition,0.6051724137931035
infectious disease pandemic,invasive disposition,0.6414893617021277
infectious disease pandemic,infectious agent host,0.7416666666666667
infectious disease pandemic,long-term non-progressing infectious disease course,0.7064102564102563
infectious disease pandemic,viral disease epidemic,0.7765306122448979
infectious disease pandemic,fungicidal disposition,0.6336734693877552
infectious disease pandemic,viral disease pandemic,0.8173469387755102
infectious disease pandemic,virus penetration stage,0.65
infectious disease pandemic,acute respiratory distress syndrome,0.6758064516129032
infectious disease pandemic,infectious disease endemicity,0.8964285714285714
infectious disease pandemic,disorder,0.5928571428571429
infectious disease pandemic,herd immunity to infectious organism,0.6722222222222223
infectious disease pandemic,extracellular infection,0.63
infectious disease pandemic,exotoxin disposition,0.6414893617021277
infectious disease pandemic,infectious agent reservoir,0.7518867924528303
infectious disease pandemic,COVID-19 pandemic,0.7227272727272727
infectious disease pandemic,infection start process boundary,0.7042372881355932
infectious disease pandemic,infectious disease control objective specification,0.7487012987012988
infectious disease pandemic,opportunistic infectious disposition,0.7039682539682539
infectious disease pandemic,process of establishing viral infection,0.6318181818181818
infectious disease pandemic,enterotoxin disposition,0.65
infectious disease pandemic,COVID-19 disease course,0.69
infectious disease pandemic,infectious disease incidence rate,0.8333333333333335
infectious disease pandemic,single-stranded RNA retrovirus,0.6254385964912281
infectious disease pandemic,active immunization against infectious agent,0.6471830985915493
infectious disease pandemic,disordered virus,0.6127906976744186
infectious disease pandemic,collective resistance disposition,0.65
infectious disease pandemic,fungistatic disposition,0.63
infectious disease pandemic,virus uncoating stage,0.6375
infectious disease pandemic,local infection,0.6642857142857143
infectious disease pandemic,infectious agent,0.7755813953488372
infectious disease pandemic,establishment of a clinically abnormal colony,0.6166666666666667
infectious disease pandemic,coronavirus disease,0.7108695652173913
infectious disease pandemic,positive-sense single-stranded RNA virus,0.6440298507462687
infectious disease pandemic,hospital-acquired infection,0.6166666666666667
infectious disease pandemic,drug susceptibility of infectious agent,0.6621212121212122
dead-end host role,angiotensin-converting enzyme 2,0.5928571428571429
dead-end host role,virostatic disposition,0.6
dead-end host role,zoonotic disposition,0.6078947368421053
dead-end host role,communicability end temporal region,0.619811320754717
dead-end host role,infection end temporal region,0.6414893617021277
dead-end host role,incubation end temporal region,0.6375
dead-end host role,virulence factor disposition,0.6021739130434782
dead-end host role,pathogen portal of exit,0.6695121951219513
dead-end host role,viral adhesion disposition,0.6545454545454545
dead-end host role,parasitostatic disposition,0.5863636363636363
dead-end host role,reservoir of pathogen role,0.6772727272727272
dead-end host role,reverse zoonotic disposition,0.6239130434782608
dead-end host role,establishment of localization in host,0.6136363636363636
dead-end host role,infectious agent host role,0.7681818181818181
dead-end host role,B cell receptor complex,0.6207317073170732
dead-end host role,colonized host,0.66875
dead-end host role,virus host,0.6285714285714286
dead-end host role,pathogen portal of entry role,0.6840425531914894
dead-end host role,toxin disposition,0.6214285714285714
dead-end host role,lower respiratory tract disease,0.5928571428571429
dead-end host role,acute infectious disease course,0.6132653061224489
dead-end host role,cidal agent disposition,0.6695121951219513
dead-end host role,role,0.6318181818181818
dead-end host role,appearance of disorder,0.65
dead-end host role,parasiticidal disposition,0.6127906976744186
dead-end host role,mutualist role,0.7
dead-end host role,communicability end process boundary,0.6166666666666667
dead-end host role,transmissibility disposition,0.6021739130434782
dead-end host role,latency end process boundary,0.6456521739130434
dead-end host role,colonization of host,0.6342105263157894
dead-end host role,endotoxin disposition,0.6551282051282051
dead-end host role,infectious structure host role,0.7
dead-end host role,cytotoxin disposition,0.6038461538461539
dead-end host role,pathogen vehicle role,0.7064102564102563
dead-end host role,host,0.6318181818181818
dead-end host role,chronic infectious disease course,0.6068627450980393
dead-end host role,mechanical vector role,0.7
dead-end host role,establishment of localization in human host,0.5975409836065574
dead-end host role,incubation end process boundary,0.6336734693877552
dead-end host role,collective pathogenic disposition,0.6264705882352941
dead-end host role,neurotoxin disposition,0.625
dead-end host role,dead-end host role,0.95
dead-end host role,definitive host role,0.7921052631578948
dead-end host role,latency end temporal region,0.65
dead-end host role,collective disposition,0.625
dead-end host role,static agent disposition,0.6404761904761905
dead-end host role,T cell receptor complex,0.6207317073170732
dead-end host role,asymptomatic carrier role,0.636046511627907
dead-end host role,infectious structure host,0.6127906976744186
dead-end host role,entry into host,0.6621212121212122
dead-end host role,adhesion of symbiont to host,0.6673913043478261
dead-end host role,immunosuppressive disposition,0.598936170212766
dead-end host role,pathogenic disposition,0.65
dead-end host role,viral disease course,0.6605263157894737
dead-end host role,entry into host through host barriers,0.65
dead-end host role,secondary infection role,0.6880952380952381
dead-end host role,infectious disposition,0.6
dead-end host role,bacteriostatic disposition,0.609090909090909
dead-end host role,bactericidal disposition,0.6404761904761905
dead-end host role,source of infection role,0.6642857142857143
dead-end host role,pathogen host,0.7080645161290323
dead-end host role,invasion disposition,0.6342105263157894
dead-end host role,disease course,0.7
dead-end host role,infectious disease course,0.636046511627907
dead-end host role,viricidal disposition,0.6294871794871795
dead-end host role,coronavirus disease course,0.6318181818181818
dead-end host role,biological vehicle role,0.6451219512195122
dead-end host role,symbiont role,0.6758064516129032
dead-end host role,parasite role,0.7080645161290323
dead-end host role,intermediate host,0.6785714285714286
dead-end host role,pathogen vector role,0.7131578947368421
dead-end host role,pathogen portal of exit site,0.6456521739130434
dead-end host role,disposition,0.6224137931034482
dead-end host role,primary infection role,0.65
dead-end host role,biological role,0.6318181818181818
dead-end host role,adhesion disposition,0.6868421052631578
dead-end host role,biological vector role,0.65
dead-end host role,primary infectious disposition,0.5958333333333333
dead-end host role,pathogen host role,0.8111111111111111
dead-end host role,symptomatic carrier role,0.6166666666666667
dead-end host role,intermediate host role,0.775
dead-end host role,dead-end host,0.8693548387096774
dead-end host role,host role,0.7833333333333333
dead-end host role,establishment of localization in virus host,0.6139344262295081
dead-end host role,SARS-COV-2 adhesion disposition,0.6336734693877552
dead-end host role,pathogen portal of exit role,0.6891304347826087
dead-end host role,invasive disposition,0.6342105263157894
dead-end host role,infectious agent host,0.6807692307692308
dead-end host role,long-term non-progressing infectious disease course,0.5949275362318841
dead-end host role,commensal role,0.7
dead-end host role,epitope role,0.6833333333333332
dead-end host role,fungicidal disposition,0.625
dead-end host role,division of geopolitical entity,0.6132653061224489
dead-end host role,function,0.5653846153846154
dead-end host role,pathogen transporter role,0.7058139534883722
dead-end host role,exotoxin disposition,0.6342105263157894
dead-end host role,antigen role,0.7166666666666667
dead-end host role,action specification,0.6078947368421053
dead-end host role,symbiont host role,0.7555555555555555
dead-end host role,opportunistic infectious disposition,0.5611111111111111
dead-end host role,fomite role,0.6913793103448276
dead-end host role,enterotoxin disposition,0.6451219512195122
dead-end host role,COVID-19 disease course,0.6451219512195122
dead-end host role,collective resistance disposition,0.6068627450980393
dead-end host role,reagent role,0.7833333333333333
dead-end host role,viral load,0.5571428571428572
dead-end host role,fungistatic disposition,0.5963414634146341
dead-end host role,establishment of a clinically abnormal colony,0.6087301587301588
dead-end host role,definitive host,0.6924242424242425
pathogen seroprevalence,extended organism,0.65
pathogen seroprevalence,virus aggregate,0.6078947368421053
pathogen seroprevalence,source of infection,0.5928571428571429
pathogen seroprevalence,infectious disease mortality rate,0.6285714285714286
pathogen seroprevalence,infection incidence rate profile,0.6318181818181818
pathogen seroprevalence,pathogen generative stage,0.7416666666666667
pathogen seroprevalence,pathogen portal of entry,0.7691489361702127
pathogen seroprevalence,subclinical coronavirus infection,0.575
pathogen seroprevalence,primary pathogen,0.6551282051282051
pathogen seroprevalence,infection end temporal region,0.6807692307692308
pathogen seroprevalence,drug-based immunosuppressed organism,0.6025423728813559
pathogen seroprevalence,infectious disease,0.6207317073170732
pathogen seroprevalence,double-stranded DNA virus,0.5958333333333333
pathogen seroprevalence,site of infection,0.6
pathogen seroprevalence,immunocompetent organism,0.6414893617021277
pathogen seroprevalence,pathogen portal of exit,0.7543478260869566
pathogen seroprevalence,infectious disease incidence,0.6460784313725491
pathogen seroprevalence,reservoir of pathogen role,0.7153061224489795
pathogen seroprevalence,subclinical SARS-CoV-2 infection,0.5954545454545455
pathogen seroprevalence,virus translation stage,0.6239130434782608
pathogen seroprevalence,disease surveillance objective specification,0.5992537313432835
pathogen seroprevalence,virus release stage,0.5928571428571429
pathogen seroprevalence,infectious agent host role,0.6744897959183673
pathogen seroprevalence,source of infection site,0.598936170212766
pathogen seroprevalence,virus replication,0.575
pathogen seroprevalence,B cell receptor complex,0.6239130434782608
pathogen seroprevalence,passive immunization against infectious agent,0.6264705882352941
pathogen seroprevalence,systematic infection,0.5895348837209302
pathogen seroprevalence,infection incidence rate,0.6202127659574468
pathogen seroprevalence,virus host,0.5409090909090909
pathogen seroprevalence,double-stranded RNA virus,0.5958333333333333
pathogen seroprevalence,pathogen portal of entry role,0.7576923076923078
pathogen seroprevalence,virus transcription stage,0.6166666666666667
pathogen seroprevalence,infectious disease lifetime prevalence,0.6959016393442623
pathogen seroprevalence,pathogen birth temporal region,0.7518867924528303
pathogen seroprevalence,lower respiratory tract disease,0.6351851851851852
pathogen seroprevalence,infectious disease incidence proportion,0.6112903225806451
pathogen seroprevalence,opportunistic pathogen,0.6277777777777778
pathogen seroprevalence,virus generative stage,0.6277777777777778
pathogen seroprevalence,acute infectious disease course,0.6537037037037037
pathogen seroprevalence,cidal agent disposition,0.6239130434782608
pathogen seroprevalence,genetic resistance to pathogen,0.6575471698113208
pathogen seroprevalence,subclinical infection,0.5636363636363636
pathogen seroprevalence,simple infection,0.6038461538461539
pathogen seroprevalence,droplet pathogen transmission process,0.7
pathogen seroprevalence,infectious disease sporadicity,0.619811320754717
pathogen seroprevalence,infection incidence proportion profile,0.630327868852459
pathogen seroprevalence,infectious agent colony,0.6456521739130434
pathogen seroprevalence,pathogen transporter,0.7523255813953489
pathogen seroprevalence,infectious disease epidemic,0.61
pathogen seroprevalence,infectious agent generative stage,0.6464285714285714
pathogen seroprevalence,disease transmission model,0.6132653061224489
pathogen seroprevalence,pathologically immunosuppressed organism,0.6563492063492063
pathogen seroprevalence,negative-sense single-stranded RNA virus,0.6246031746031746
pathogen seroprevalence,cidal agent,0.5970588235294118
pathogen seroprevalence,pathogen vehicle,0.7833333333333333
pathogen seroprevalence,community-acquired infection,0.5676470588235294
pathogen seroprevalence,pathogen vector,0.7657894736842106
pathogen seroprevalence,pathogen vehicle role,0.7681818181818181
pathogen seroprevalence,chronic infectious disease course,0.6464285714285714
pathogen seroprevalence,asymptomatic infectious agent carrier,0.6333333333333333
pathogen seroprevalence,nursing-home acquired infection,0.5981481481481481
pathogen seroprevalence,secondary infection,0.5928571428571429
pathogen seroprevalence,infection start temporal region,0.6722222222222223
pathogen seroprevalence,infection incidence,0.6404761904761905
pathogen seroprevalence,virus disorder,0.5851351351351352
pathogen seroprevalence,sterilizing immunity to infectious agent,0.5928571428571429
pathogen seroprevalence,primary infection,0.6
pathogen seroprevalence,process of establishing an infection,0.6194915254237288
pathogen seroprevalence,pathogen death process boundary,0.7092592592592593
pathogen seroprevalence,immunosuppressed organism,0.6166666666666667
pathogen seroprevalence,innate immunity to infectious agent,0.6224137931034482
pathogen seroprevalence,virus adhesion susceptible cell,0.6722222222222223
pathogen seroprevalence,infection,0.575
pathogen seroprevalence,static agent disposition,0.6414893617021277
pathogen seroprevalence,T cell receptor complex,0.6456521739130434
pathogen seroprevalence,infectious agent population,0.65
pathogen seroprevalence,respiratory system disease,0.6540816326530612
pathogen seroprevalence,leukocyte-mediated immunity to infectious agent,0.5928571428571429
pathogen seroprevalence,indirect pathogen transmission process,0.6959016393442623
pathogen seroprevalence,organism population,0.6404761904761905
pathogen seroprevalence,humoral immunity to infectious agent,0.6025423728813559
pathogen seroprevalence,infectious disease control strategy,0.6224137931034482
pathogen seroprevalence,parasite,0.6112903225806451
pathogen seroprevalence,infectious disease pandemic,0.63
pathogen seroprevalence,antibody reagent,0.6807692307692308
pathogen seroprevalence,viral disease course,0.636046511627907
pathogen seroprevalence,intracellular infection,0.5804347826086956
pathogen seroprevalence,secondary infection role,0.6414893617021277
pathogen seroprevalence,metastatic infection,0.5895348837209302
pathogen seroprevalence,passive immunity to infectious agent,0.6194915254237288
pathogen seroprevalence,vaccination against infectious agent,0.6364406779661017
pathogen seroprevalence,acute infection,0.6342105263157894
pathogen seroprevalence,susceptibility to infectious agent,0.6078947368421053
pathogen seroprevalence,epitope site,0.65
pathogen seroprevalence,immunity to pathogen,0.636046511627907
pathogen seroprevalence,source of infection role,0.6202127659574468
pathogen seroprevalence,pathogen host,0.7277777777777777
pathogen seroprevalence,chronic infection,0.625
pathogen seroprevalence,disease course,0.6121621621621621
pathogen seroprevalence,infectious disease course,0.6375
pathogen seroprevalence,acquired immunity to infectious agent,0.6
pathogen seroprevalence,complex infection,0.6
pathogen seroprevalence,COVID-19 disease incidence proportion,0.6
pathogen seroprevalence,coronavirus disease course,0.6336734693877552
pathogen seroprevalence,infection incidence proportion,0.6386792452830189
pathogen seroprevalence,symptomatic infectious agent carrier,0.6364406779661017
pathogen seroprevalence,respiratory droplet virus fomite,0.65
pathogen seroprevalence,susceptible organism,0.636046511627907
pathogen seroprevalence,parasite role,0.7
pathogen seroprevalence,pathogen vector role,0.7755813953488372
pathogen seroprevalence,pathogen portal of exit site,0.7441176470588234
pathogen seroprevalence,infectious disease prevalence,0.7384615384615384
pathogen seroprevalence,organism substance,0.6695121951219513
pathogen seroprevalence,single-stranded DNA virus,0.5958333333333333
pathogen seroprevalence,viral disease,0.6166666666666667
pathogen seroprevalence,primary infection role,0.6722222222222223
pathogen seroprevalence,pathogen portal of entry site,0.7576923076923078
pathogen seroprevalence,infection incidence profile,0.63
pathogen seroprevalence,disease,0.5833333333333334
pathogen seroprevalence,site,0.524074074074074
pathogen seroprevalence,pathogen host role,0.7914634146341464
pathogen seroprevalence,infection prevalence,0.7755813953488372
pathogen seroprevalence,infectious pathogen transmissibility,0.6533898305084747
pathogen seroprevalence,pathogen surveillance,0.8136363636363637
pathogen seroprevalence,immunodeficient organism,0.6202127659574468
pathogen seroprevalence,pathogen,0.7080645161290323
pathogen seroprevalence,pathogen birth process boundary,0.7092592592592593
pathogen seroprevalence,infectious human pathogen,0.6166666666666667
pathogen seroprevalence,subclinical virus infection,0.57
pathogen seroprevalence,resistance to pathogen,0.6277777777777778
pathogen seroprevalence,establishment of localization in virus host,0.5863636363636363
pathogen seroprevalence,immunization against infectious agent,0.6333333333333333
pathogen seroprevalence,virus attachment stage,0.65
pathogen seroprevalence,virus synthesis stage,0.609090909090909
pathogen seroprevalence,pathogen portal of exit role,0.7441176470588234
pathogen seroprevalence,infectious agent host,0.609090909090909
pathogen seroprevalence,re-emerging pathogen,0.636046511627907
pathogen seroprevalence,long-term non-progressing infectious disease course,0.6256756756756756
pathogen seroprevalence,viral disease epidemic,0.6055555555555556
pathogen seroprevalence,viral disease pandemic,0.6277777777777778
pathogen seroprevalence,virus penetration stage,0.6456521739130434
pathogen seroprevalence,pathogen seroprevalence,0.95
pathogen seroprevalence,infectious disease endemicity,0.6230769230769231
pathogen seroprevalence,contact pathogen transmission process,0.7
pathogen seroprevalence,herd immunity to infectious organism,0.6025423728813559
pathogen seroprevalence,extracellular infection,0.5804347826086956
pathogen seroprevalence,pathogen transporter role,0.7625
pathogen seroprevalence,infectious agent reservoir,0.6744897959183673
pathogen seroprevalence,infection start process boundary,0.6318181818181818
pathogen seroprevalence,infectious disease control objective specification,0.6006849315068493
pathogen seroprevalence,COVID-19 lifetime prevalence,0.7049019607843137
pathogen seroprevalence,process of establishing viral infection,0.6274193548387097
pathogen seroprevalence,COVID-19 disease course,0.6239130434782608
pathogen seroprevalence,infectious disease incidence rate,0.6285714285714286
pathogen seroprevalence,COVID-19 prevalence,0.7357142857142857
pathogen seroprevalence,active immunization against infectious agent,0.6141791044776119
pathogen seroprevalence,SARS-COV-2 prevalence,0.7454545454545455
pathogen seroprevalence,disordered virus,0.5782051282051281
pathogen seroprevalence,organism,0.5790322580645162
pathogen seroprevalence,virus uncoating stage,0.609090909090909
pathogen seroprevalence,local infection,0.581578947368421
pathogen seroprevalence,infectious agent,0.6038461538461539
pathogen seroprevalence,establishment of a clinically abnormal colony,0.5970588235294118
pathogen seroprevalence,coronavirus disease,0.6166666666666667
pathogen seroprevalence,positive-sense single-stranded RNA virus,0.6246031746031746
pathogen seroprevalence,horizontal pathogen transmission process,0.6880952380952381
pathogen seroprevalence,hospital-acquired infection,0.63
pathogen seroprevalence,SARS-CoV-2 seroprevalence,0.8041666666666667
pathogen seroprevalence,pathogen death temporal region,0.7518867924528303
pathogen seroprevalence,emerging pathogen,0.65
pathogen seroprevalence,drug susceptibility of infectious agent,0.5951612903225807
pathogen seroprevalence,static agent,0.6214285714285714
pathogen seroprevalence,pathogen transmission process,0.7384615384615384
hospital-acquired infection,virus aggregate,0.569047619047619
hospital-acquired infection,source of infection,0.7543478260869566
hospital-acquired infection,virostatic disposition,0.6744897959183673
hospital-acquired infection,zoonotic disposition,0.6414893617021277
hospital-acquired infection,infectious disease mortality rate,0.6
hospital-acquired infection,infection incidence rate profile,0.6194915254237288
hospital-acquired infection,communicability end temporal region,0.6435483870967742
hospital-acquired infection,subclinical coronavirus infection,0.7333333333333333
hospital-acquired infection,infection end temporal region,0.6285714285714286
hospital-acquired infection,infectious disease,0.6277777777777778
hospital-acquired infection,double-stranded DNA virus,0.6230769230769231
hospital-acquired infection,incubation end temporal region,0.6429824561403508
hospital-acquired infection,site of infection,0.7681818181818181
hospital-acquired infection,virulence factor disposition,0.65
hospital-acquired infection,viral adhesion disposition,0.6575471698113208
hospital-acquired infection,parasitostatic disposition,0.6575471698113208
hospital-acquired infection,infectious disease incidence,0.65
hospital-acquired infection,reverse zoonotic disposition,0.6136363636363636
hospital-acquired infection,subclinical SARS-CoV-2 infection,0.7211864406779661
hospital-acquired infection,virus translation stage,0.63
hospital-acquired infection,disease surveillance objective specification,0.6612676056338028
hospital-acquired infection,virus release stage,0.5804347826086956
hospital-acquired infection,source of infection site,0.7245098039215686
hospital-acquired infection,virus,0.5125
hospital-acquired infection,virus replication,0.6772727272727272
hospital-acquired infection,B cell receptor complex,0.59
hospital-acquired infection,systematic infection,0.747872340425532
hospital-acquired infection,infection incidence rate,0.6264705882352941
hospital-acquired infection,virus host,0.5581081081081081
hospital-acquired infection,double-stranded RNA virus,0.6230769230769231
hospital-acquired infection,virus transcription stage,0.6423076923076922
hospital-acquired infection,infectious disease lifetime prevalence,0.6346153846153847
hospital-acquired infection,toxin disposition,0.6318181818181818
hospital-acquired infection,lower respiratory tract disease,0.6224137931034482
hospital-acquired infection,infectious disease incidence proportion,0.6621212121212122
hospital-acquired infection,virus generative stage,0.5928571428571429
hospital-acquired infection,acute infectious disease course,0.6741379310344828
hospital-acquired infection,cidal agent disposition,0.67
hospital-acquired infection,infectious disorder,0.6239130434782608
hospital-acquired infection,subclinical infection,0.7416666666666667
hospital-acquired infection,appearance of disorder,0.6336734693877552
hospital-acquired infection,simple infection,0.7755813953488372
hospital-acquired infection,parasiticidal disposition,0.6807692307692308
hospital-acquired infection,infectious disease sporadicity,0.6078947368421053
hospital-acquired infection,communicability end process boundary,0.6246031746031746
hospital-acquired infection,infection incidence proportion profile,0.6346153846153847
hospital-acquired infection,transmissibility disposition,0.6318181818181818
hospital-acquired infection,latency end process boundary,0.6136363636363636
hospital-acquired infection,infectious disease epidemic,0.6166666666666667
hospital-acquired infection,disease transmission model,0.6009433962264151
hospital-acquired infection,endotoxin disposition,0.6375
hospital-acquired infection,negative-sense single-stranded RNA virus,0.5992537313432835
hospital-acquired infection,cytotoxin disposition,0.6375
hospital-acquired infection,community-acquired infection,0.85
hospital-acquired infection,chronic infectious disease course,0.6666666666666667
hospital-acquired infection,nursing-home acquired infection,0.8120689655172413
hospital-acquired infection,COVID-19 epidemic,0.609090909090909
hospital-acquired infection,secondary infection,0.7326086956521739
hospital-acquired infection,infection start temporal region,0.6396551724137931
hospital-acquired infection,infection incidence,0.6456521739130434
hospital-acquired infection,virus disorder,0.5963414634146341
hospital-acquired infection,primary infection,0.7681818181818181
hospital-acquired infection,process of establishing an infection,0.7039682539682539
hospital-acquired infection,incubation end process boundary,0.6224137931034482
hospital-acquired infection,SARS-CoV-2 disorder,0.6239130434782608
hospital-acquired infection,collective pathogenic disposition,0.65
hospital-acquired infection,neurotoxin disposition,0.6336734693877552
hospital-acquired infection,latency end temporal region,0.6351851851851852
hospital-acquired infection,virus adhesion susceptible cell,0.6051724137931035
hospital-acquired infection,collective disposition,0.6744897959183673
hospital-acquired infection,infection,0.7
hospital-acquired infection,static agent disposition,0.6656862745098039
hospital-acquired infection,T cell receptor complex,0.61
hospital-acquired infection,respiratory system disease,0.619811320754717
hospital-acquired infection,communicability interval,0.6264705882352941
hospital-acquired infection,infectious disease control strategy,0.5951612903225807
hospital-acquired infection,infectious disease pandemic,0.6166666666666667
hospital-acquired infection,immunosuppressive disposition,0.6464285714285714
hospital-acquired infection,pathogenic disposition,0.6540816326530612
hospital-acquired infection,viral disease course,0.6202127659574468
hospital-acquired infection,intracellular infection,0.77
hospital-acquired infection,secondary infection role,0.7049019607843137
hospital-acquired infection,metastatic infection,0.747872340425532
hospital-acquired infection,infectious disposition,0.6336734693877552
hospital-acquired infection,acute infection,0.7833333333333333
hospital-acquired infection,bacteriostatic disposition,0.6575471698113208
hospital-acquired infection,bactericidal disposition,0.6460784313725491
hospital-acquired infection,source of infection role,0.7245098039215686
hospital-acquired infection,acquired immunodeficiency,0.7384615384615384
hospital-acquired infection,chronic infection,0.7681818181818181
hospital-acquired infection,invasion disposition,0.6414893617021277
hospital-acquired infection,disease course,0.5963414634146341
hospital-acquired infection,infectious disease course,0.6038461538461539
hospital-acquired infection,viricidal disposition,0.6583333333333334
hospital-acquired infection,acquired immunity to infectious agent,0.73125
hospital-acquired infection,complex infection,0.7681818181818181
hospital-acquired infection,COVID-19 disease incidence proportion,0.66875
hospital-acquired infection,coronavirus disease course,0.619811320754717
hospital-acquired infection,infection incidence proportion,0.6605263157894737
hospital-acquired infection,respiratory droplet virus fomite,0.6194915254237288
hospital-acquired infection,infectious disease prevalence,0.6107142857142857
hospital-acquired infection,disposition,0.6342105263157894
hospital-acquired infection,single-stranded DNA virus,0.6423076923076922
hospital-acquired infection,hospital facility,0.7454545454545455
hospital-acquired infection,viral disease,0.6
hospital-acquired infection,primary infection role,0.7357142857142857
hospital-acquired infection,adhesion disposition,0.6414893617021277
hospital-acquired infection,infection incidence profile,0.6166666666666667
hospital-acquired infection,contagiousness,0.5963414634146341
hospital-acquired infection,disease,0.5382352941176471
hospital-acquired infection,primary infectious disposition,0.6956140350877194
hospital-acquired infection,infection prevalence,0.6414893617021277
hospital-acquired infection,coronavirus disorder,0.598936170212766
hospital-acquired infection,subclinical virus infection,0.7462962962962962
hospital-acquired infection,establishment of localization in virus host,0.6357142857142857
hospital-acquired infection,virus attachment stage,0.5928571428571429
hospital-acquired infection,virus synthesis stage,0.575
hospital-acquired infection,SARS-COV-2 adhesion disposition,0.6396551724137931
hospital-acquired infection,invasive disposition,0.6627659574468084
hospital-acquired infection,long-term non-progressing infectious disease course,0.6294871794871795
hospital-acquired infection,viral disease epidemic,0.6336734693877552
hospital-acquired infection,communicability start temporal region,0.6375
hospital-acquired infection,fungicidal disposition,0.6540816326530612
hospital-acquired infection,viral disease pandemic,0.6336734693877552
hospital-acquired infection,virus penetration stage,0.63
hospital-acquired infection,acute respiratory distress syndrome,0.6112903225806451
hospital-acquired infection,infectious disease endemicity,0.6285714285714286
hospital-acquired infection,disorder,0.5642857142857143
hospital-acquired infection,communicability,0.5928571428571429
hospital-acquired infection,extracellular infection,0.75
hospital-acquired infection,exotoxin disposition,0.6414893617021277
hospital-acquired infection,infection start process boundary,0.6025423728813559
hospital-acquired infection,action specification,0.6840425531914894
hospital-acquired infection,infectious disease control objective specification,0.6577922077922078
hospital-acquired infection,opportunistic infectious disposition,0.6880952380952381
hospital-acquired infection,process of establishing viral infection,0.7075757575757575
hospital-acquired infection,enterotoxin disposition,0.63
hospital-acquired infection,COVID-19 disease course,0.61
hospital-acquired infection,infectious disease incidence rate,0.6333333333333333
hospital-acquired infection,communicability start process boundary,0.6038461538461539
hospital-acquired infection,disordered virus,0.5895348837209302
hospital-acquired infection,collective resistance disposition,0.6666666666666667
hospital-acquired infection,fungistatic disposition,0.65
hospital-acquired infection,virus uncoating stage,0.6166666666666667
hospital-acquired infection,local infection,0.7595238095238095
hospital-acquired infection,establishment of a clinically abnormal colony,0.6166666666666667
hospital-acquired infection,coronavirus disease,0.6021739130434782
hospital-acquired infection,positive-sense single-stranded RNA virus,0.6291044776119403
hospital-acquired infection,hospital-acquired infection,0.95
symbiont,B cell receptor complex,0.5145161290322581
symbiont,adhesion of symbiont to host,0.6722222222222223
symbiont,symbiont role,0.830952380952381
symbiont,obligatory symbiont,0.7462962962962962
symbiont,symbiont host role,0.7576923076923078
symbiont,symbiont,0.95
continuant,T cell receptor complex,0.5106060606060606
continuant,generically dependent continuant,0.6880952380952381
continuant,continuant,0.95
continuant,specifically dependent continuant,0.6825581395348838
continuant,independent continuant,0.7625
continuant,establishment of a clinically abnormal colony,0.5590909090909091
genetic resistance to pathogen,extended organism,0.6414893617021277
genetic resistance to pathogen,virus aggregate,0.6277777777777778
genetic resistance to pathogen,source of infection,0.6336734693877552
genetic resistance to pathogen,virostatic disposition,0.6615384615384616
genetic resistance to pathogen,information content entity,0.6285714285714286
genetic resistance to pathogen,zoonotic disposition,0.67
genetic resistance to pathogen,immune response,0.65
genetic resistance to pathogen,infectious disease mortality rate,0.6880952380952381
genetic resistance to pathogen,infection incidence rate profile,0.6919354838709677
genetic resistance to pathogen,communicability end temporal region,0.6346153846153847
genetic resistance to pathogen,pathogen generative stage,0.6681818181818181
genetic resistance to pathogen,pathogen portal of entry,0.6722222222222223
genetic resistance to pathogen,subclinical coronavirus infection,0.6404761904761905
genetic resistance to pathogen,primary pathogen,0.7108695652173913
genetic resistance to pathogen,infection end temporal region,0.6703389830508475
genetic resistance to pathogen,drug-based immunosuppressed organism,0.6318181818181818
genetic resistance to pathogen,infectious disease,0.6583333333333334
genetic resistance to pathogen,SARS-CoV-2 incidence rate,0.6318181818181818
genetic resistance to pathogen,double-stranded DNA virus,0.5954545454545455
genetic resistance to pathogen,incubation end temporal region,0.65
genetic resistance to pathogen,site of infection,0.6627659574468084
genetic resistance to pathogen,normal resident microbiota population,0.6888059701492537
genetic resistance to pathogen,immunocompetent organism,0.6351851851851852
genetic resistance to pathogen,virulence factor disposition,0.6913793103448276
genetic resistance to pathogen,pathogen portal of exit,0.6575471698113208
genetic resistance to pathogen,viral adhesion disposition,0.6464285714285714
genetic resistance to pathogen,parasitostatic disposition,0.6642857142857143
genetic resistance to pathogen,infectious disease incidence,0.656896551724138
genetic resistance to pathogen,reservoir of pathogen role,0.7178571428571427
genetic resistance to pathogen,reverse zoonotic disposition,0.656896551724138
genetic resistance to pathogen,subclinical SARS-CoV-2 infection,0.6435483870967742
genetic resistance to pathogen,establishment of localization in host,0.6291044776119403
genetic resistance to pathogen,virus translation stage,0.6764150943396227
genetic resistance to pathogen,disease surveillance objective specification,0.6932432432432433
genetic resistance to pathogen,virus release stage,0.6744897959183673
genetic resistance to pathogen,infectious agent host role,0.6642857142857143
genetic resistance to pathogen,source of infection site,0.6351851851851852
genetic resistance to pathogen,virus,0.5357142857142857
genetic resistance to pathogen,virus replication,0.6627659574468084
genetic resistance to pathogen,B cell receptor complex,0.6575471698113208
genetic resistance to pathogen,passive immunization against infectious agent,0.6766666666666665
genetic resistance to pathogen,systematic infection,0.67
genetic resistance to pathogen,infection incidence rate,0.6907407407407408
genetic resistance to pathogen,colonized host,0.5863636363636363
genetic resistance to pathogen,virus host,0.6
genetic resistance to pathogen,double-stranded RNA virus,0.5954545454545455
genetic resistance to pathogen,pathogen portal of entry role,0.6703389830508475
genetic resistance to pathogen,virus transcription stage,0.6863636363636364
genetic resistance to pathogen,infectious disease lifetime prevalence,0.6852941176470588
genetic resistance to pathogen,toxin disposition,0.6414893617021277
genetic resistance to pathogen,pathogen birth temporal region,0.65
genetic resistance to pathogen,lower respiratory tract disease,0.6631147540983606
genetic resistance to pathogen,infectious disease incidence proportion,0.696376811594203
genetic resistance to pathogen,opportunistic pathogen,0.7192307692307692
genetic resistance to pathogen,virus generative stage,0.6807692307692308
genetic resistance to pathogen,acute infectious disease course,0.6631147540983606
genetic resistance to pathogen,cidal agent disposition,0.6575471698113208
genetic resistance to pathogen,genetic resistance to pathogen,0.95
genetic resistance to pathogen,subclinical infection,0.6460784313725491
genetic resistance to pathogen,simple infection,0.6239130434782608
genetic resistance to pathogen,droplet pathogen transmission process,0.6440298507462687
genetic resistance to pathogen,parasiticidal disposition,0.6318181818181818
genetic resistance to pathogen,infectious disease sporadicity,0.6666666666666667
genetic resistance to pathogen,communicability end process boundary,0.6166666666666667
genetic resistance to pathogen,directive information content entity,0.6469696969696969
genetic resistance to pathogen,infection incidence proportion profile,0.6852941176470588
genetic resistance to pathogen,infectious agent colony,0.6575471698113208
genetic resistance to pathogen,pathogen transporter,0.65
genetic resistance to pathogen,transmissibility disposition,0.6396551724137931
genetic resistance to pathogen,latency end process boundary,0.6396551724137931
genetic resistance to pathogen,colonization of host,0.63
genetic resistance to pathogen,infectious disease epidemic,0.6605263157894737
genetic resistance to pathogen,infectious agent generative stage,0.6722222222222223
genetic resistance to pathogen,disease transmission model,0.6464285714285714
genetic resistance to pathogen,endotoxin disposition,0.6656862745098039
genetic resistance to pathogen,pathologically immunosuppressed organism,0.6357142857142857
genetic resistance to pathogen,negative-sense single-stranded RNA virus,0.65
genetic resistance to pathogen,cidal agent,0.6451219512195122
genetic resistance to pathogen,infectious structure host role,0.6833333333333332
genetic resistance to pathogen,pathogen vehicle,0.6239130434782608
genetic resistance to pathogen,COVID-19 incidence rate,0.6386792452830189
genetic resistance to pathogen,cytotoxin disposition,0.6264705882352941
genetic resistance to pathogen,community-acquired infection,0.6396551724137931
genetic resistance to pathogen,pathogen vector,0.6277777777777778
genetic resistance to pathogen,antibiotic resistance,0.7441176470588234
genetic resistance to pathogen,pathogen vehicle role,0.6656862745098039
genetic resistance to pathogen,host,0.5088235294117647
genetic resistance to pathogen,chronic infectious disease course,0.6563492063492063
genetic resistance to pathogen,asymptomatic infectious agent carrier,0.658955223880597
genetic resistance to pathogen,nursing-home acquired infection,0.630327868852459
genetic resistance to pathogen,descriptive information content entity,0.6411764705882353
genetic resistance to pathogen,secondary infection,0.6336734693877552
genetic resistance to pathogen,infection start temporal region,0.6795081967213115
genetic resistance to pathogen,infection incidence,0.6540816326530612
genetic resistance to pathogen,virus disorder,0.609090909090909
genetic resistance to pathogen,resistance to drug,0.7625
genetic resistance to pathogen,sterilizing immunity to infectious agent,0.65
genetic resistance to pathogen,establishment of localization in human host,0.6143835616438357
genetic resistance to pathogen,primary infection,0.6202127659574468
genetic resistance to pathogen,process of establishing an infection,0.6318181818181818
genetic resistance to pathogen,incubation end process boundary,0.630327868852459
genetic resistance to pathogen,collective pathogenic disposition,0.6563492063492063
genetic resistance to pathogen,neurotoxin disposition,0.6615384615384616
genetic resistance to pathogen,dead-end host role,0.6166666666666667
genetic resistance to pathogen,pathogen death process boundary,0.6631147540983606
genetic resistance to pathogen,immunosuppressed organism,0.6318181818181818
genetic resistance to pathogen,definitive host role,0.65
genetic resistance to pathogen,latency end temporal region,0.6605263157894737
genetic resistance to pathogen,innate immunity to infectious agent,0.6653846153846155
genetic resistance to pathogen,virus adhesion susceptible cell,0.630327868852459
genetic resistance to pathogen,collective disposition,0.6423076923076922
genetic resistance to pathogen,infection,0.6038461538461539
genetic resistance to pathogen,static agent disposition,0.6722222222222223
genetic resistance to pathogen,T cell receptor complex,0.6764150943396227
genetic resistance to pathogen,infectious structure host,0.6681818181818181
genetic resistance to pathogen,infectious agent population,0.6956140350877194
genetic resistance to pathogen,respiratory system disease,0.6285714285714286
genetic resistance to pathogen,entry into host,0.6944444444444444
genetic resistance to pathogen,leukocyte-mediated immunity to infectious agent,0.6448051948051949
genetic resistance to pathogen,indirect pathogen transmission process,0.6705882352941177
genetic resistance to pathogen,adhesion of symbiont to host,0.656896551724138
genetic resistance to pathogen,organism population,0.6744897959183673
genetic resistance to pathogen,humoral immunity to infectious agent,0.6469696969696969
genetic resistance to pathogen,infectious disease control strategy,0.6961538461538461
genetic resistance to pathogen,parasite,0.581578947368421
genetic resistance to pathogen,infectious disease pandemic,0.6780701754385965
genetic resistance to pathogen,antibody reagent,0.6673913043478261
genetic resistance to pathogen,immunosuppressive disposition,0.6364406779661017
genetic resistance to pathogen,innate immune response,0.6423076923076922
genetic resistance to pathogen,pathogenic disposition,0.6807692307692308
genetic resistance to pathogen,viral disease course,0.63
genetic resistance to pathogen,entry into host through host barriers,0.658955223880597
genetic resistance to pathogen,intracellular infection,0.6386792452830189
genetic resistance to pathogen,secondary infection role,0.6537037037037037
genetic resistance to pathogen,metastatic infection,0.67
genetic resistance to pathogen,passive immunity to infectious agent,0.6621212121212122
genetic resistance to pathogen,infectious disposition,0.6615384615384616
genetic resistance to pathogen,vaccination against infectious agent,0.6924242424242425
genetic resistance to pathogen,acute infection,0.6277777777777778
genetic resistance to pathogen,susceptibility to infectious agent,0.66875
genetic resistance to pathogen,bacteriostatic disposition,0.6642857142857143
genetic resistance to pathogen,epitope site,0.6166666666666667
genetic resistance to pathogen,immunity to pathogen,0.75
genetic resistance to pathogen,bactericidal disposition,0.6351851851851852
genetic resistance to pathogen,source of infection role,0.6351851851851852
genetic resistance to pathogen,pathogen host,0.636046511627907
genetic resistance to pathogen,chronic infection,0.6627659574468084
genetic resistance to pathogen,invasion disposition,0.63
genetic resistance to pathogen,disease course,0.609090909090909
genetic resistance to pathogen,infectious disease course,0.6681818181818181
genetic resistance to pathogen,viricidal disposition,0.6264705882352941
genetic resistance to pathogen,acquired immunity to infectious agent,0.658955223880597
genetic resistance to pathogen,complex infection,0.6202127659574468
genetic resistance to pathogen,COVID-19 disease incidence proportion,0.658955223880597
genetic resistance to pathogen,coronavirus disease course,0.6464285714285714
genetic resistance to pathogen,infection incidence proportion,0.7
genetic resistance to pathogen,symptomatic infectious agent carrier,0.6621212121212122
genetic resistance to pathogen,respiratory droplet virus fomite,0.6435483870967742
genetic resistance to pathogen,susceptible organism,0.63
genetic resistance to pathogen,parasite role,0.636046511627907
genetic resistance to pathogen,intermediate host,0.6627659574468084
genetic resistance to pathogen,pathogen vector role,0.67
genetic resistance to pathogen,pathogen portal of exit site,0.656896551724138
genetic resistance to pathogen,infectious disease prevalence,0.6872881355932203
genetic resistance to pathogen,organism substance,0.6791666666666666
genetic resistance to pathogen,disposition,0.5963414634146341
genetic resistance to pathogen,single-stranded DNA virus,0.6136363636363636
genetic resistance to pathogen,COVID-19 mortality rate,0.6386792452830189
genetic resistance to pathogen,viral disease,0.6127906976744186
genetic resistance to pathogen,primary infection role,0.6423076923076922
genetic resistance to pathogen,adhesion disposition,0.63
genetic resistance to pathogen,leukocyte mediated immunity,0.6078947368421053
genetic resistance to pathogen,pathogen portal of entry site,0.6533898305084747
genetic resistance to pathogen,infection incidence profile,0.6780701754385965
genetic resistance to pathogen,disease,0.5851351351351352
genetic resistance to pathogen,site,0.5676470588235294
genetic resistance to pathogen,primary infectious disposition,0.65
genetic resistance to pathogen,pathogen host role,0.6375
genetic resistance to pathogen,infection prevalence,0.67
genetic resistance to pathogen,designative information content entity,0.6558823529411765
genetic resistance to pathogen,humoral immune response,0.619811320754717
genetic resistance to pathogen,infectious pathogen transmissibility,0.6621212121212122
genetic resistance to pathogen,object,0.5333333333333333
genetic resistance to pathogen,intermediate host role,0.6807692307692308
genetic resistance to pathogen,dead-end host,0.5895348837209302
genetic resistance to pathogen,pathogen surveillance,0.6656862745098039
genetic resistance to pathogen,immunodeficient organism,0.6537037037037037
genetic resistance to pathogen,host role,0.5782051282051281
genetic resistance to pathogen,pathogen,0.6605263157894737
genetic resistance to pathogen,pathogen birth process boundary,0.6467213114754098
genetic resistance to pathogen,infectious human pathogen,0.740909090909091
genetic resistance to pathogen,subclinical virus infection,0.6605263157894737
genetic resistance to pathogen,resistance to pathogen,0.8730769230769231
genetic resistance to pathogen,establishment of localization in virus host,0.6143835616438357
genetic resistance to pathogen,immunization against infectious agent,0.6888059701492537
genetic resistance to pathogen,virus attachment stage,0.6807692307692308
genetic resistance to pathogen,negative regulation of immune response,0.6705882352941177
genetic resistance to pathogen,virus synthesis stage,0.6656862745098039
genetic resistance to pathogen,SARS-COV-2 adhesion disposition,0.630327868852459
genetic resistance to pathogen,object aggregate,0.6239130434782608
genetic resistance to pathogen,pathogen portal of exit role,0.6741379310344828
genetic resistance to pathogen,invasive disposition,0.63
genetic resistance to pathogen,infectious agent host,0.6656862745098039
genetic resistance to pathogen,re-emerging pathogen,0.73
genetic resistance to pathogen,long-term non-progressing infectious disease course,0.6351851851851852
genetic resistance to pathogen,viral disease epidemic,0.6230769230769231
genetic resistance to pathogen,fungicidal disposition,0.6423076923076922
genetic resistance to pathogen,blood,0.5071428571428571
genetic resistance to pathogen,viral disease pandemic,0.6423076923076922
genetic resistance to pathogen,virus penetration stage,0.6764150943396227
genetic resistance to pathogen,pathogen seroprevalence,0.6575471698113208
genetic resistance to pathogen,infectious disease endemicity,0.6533898305084747
genetic resistance to pathogen,contact pathogen transmission process,0.658955223880597
genetic resistance to pathogen,herd immunity to infectious organism,0.6469696969696969
genetic resistance to pathogen,extracellular infection,0.6386792452830189
genetic resistance to pathogen,pathogen transporter role,0.65
genetic resistance to pathogen,exotoxin disposition,0.65
genetic resistance to pathogen,infectious agent reservoir,0.6285714285714286
genetic resistance to pathogen,infection start process boundary,0.6758064516129032
genetic resistance to pathogen,action specification,0.65
genetic resistance to pathogen,protective resistance,0.7245098039215686
genetic resistance to pathogen,infectious disease control objective specification,0.675
genetic resistance to pathogen,symbiont host role,0.6166666666666667
genetic resistance to pathogen,opportunistic infectious disposition,0.6772727272727272
genetic resistance to pathogen,process of establishing viral infection,0.6239130434782608
genetic resistance to pathogen,enterotoxin disposition,0.6764150943396227
genetic resistance to pathogen,polymerase chain reaction,0.65
genetic resistance to pathogen,COVID-19 disease course,0.619811320754717
genetic resistance to pathogen,infectious disease incidence rate,0.6880952380952381
genetic resistance to pathogen,single-stranded RNA retrovirus,0.6333333333333333
genetic resistance to pathogen,active immunization against infectious agent,0.6797297297297297
genetic resistance to pathogen,disordered virus,0.558695652173913
genetic resistance to pathogen,collective resistance disposition,0.7515873015873015
genetic resistance to pathogen,adaptive immune response,0.6351851851851852
genetic resistance to pathogen,fungistatic disposition,0.6575471698113208
genetic resistance to pathogen,organism,0.5552631578947369
genetic resistance to pathogen,virus uncoating stage,0.6460784313725491
genetic resistance to pathogen,local infection,0.6277777777777778
genetic resistance to pathogen,infectious agent,0.6673913043478261
genetic resistance to pathogen,establishment of a clinically abnormal colony,0.6233333333333334
genetic resistance to pathogen,coronavirus disease,0.6336734693877552
genetic resistance to pathogen,positive-sense single-stranded RNA virus,0.6357142857142857
genetic resistance to pathogen,definitive host,0.6277777777777778
genetic resistance to pathogen,horizontal pathogen transmission process,0.6357142857142857
genetic resistance to pathogen,hospital-acquired infection,0.6254385964912281
genetic resistance to pathogen,pathogen death temporal region,0.65
genetic resistance to pathogen,emerging pathogen,0.747872340425532
genetic resistance to pathogen,drug susceptibility of infectious agent,0.6673913043478261
genetic resistance to pathogen,static agent,0.6642857142857143
genetic resistance to pathogen,pathogen transmission process,0.6703389830508475
vector surveillance,virostatic disposition,0.5963414634146341
vector surveillance,zoonotic disposition,0.5782051282051281
vector surveillance,infectious disease mortality rate,0.6423076923076922
vector surveillance,infection incidence rate profile,0.6460784313725491
vector surveillance,communicability end temporal region,0.6166666666666667
vector surveillance,pathogen portal of entry,0.5895348837209302
vector surveillance,biological regulation,0.625
vector surveillance,surveillance process,0.7576923076923078
vector surveillance,infection end temporal region,0.6583333333333334
vector surveillance,vector control strategy,0.7119047619047619
vector surveillance,SARS-CoV-2 incidence rate,0.609090909090909
vector surveillance,incubation end temporal region,0.6336734693877552
vector surveillance,virulence factor disposition,0.6627659574468084
vector surveillance,viral adhesion disposition,0.6055555555555556
vector surveillance,parasitostatic disposition,0.5833333333333334
vector surveillance,negative regulation of production,0.6230769230769231
vector surveillance,reverse zoonotic disposition,0.598936170212766
vector surveillance,disease surveillance objective specification,0.6722222222222223
vector surveillance,case isolation control strategy,0.63
vector surveillance,infectious agent host role,0.65
vector surveillance,quarantine control strategy,0.6456521739130434
vector surveillance,B cell receptor complex,0.6404761904761905
vector surveillance,passive immunization against infectious agent,0.60625
vector surveillance,infection incidence rate,0.6593023255813953
vector surveillance,mechanical vector,0.6166666666666667
vector surveillance,pathogen portal of entry role,0.6166666666666667
vector surveillance,toxin disposition,0.6166666666666667
vector surveillance,acute infectious disease course,0.65
vector surveillance,cidal agent disposition,0.5928571428571429
vector surveillance,parasiticidal disposition,0.5636363636363636
vector surveillance,communicability end process boundary,0.5954545454545455
vector surveillance,infectious agent colony,0.6404761904761905
vector surveillance,transmissibility disposition,0.5776595744680851
vector surveillance,latency end process boundary,0.598936170212766
vector surveillance,infectious agent generative stage,0.6423076923076922
vector surveillance,endotoxin disposition,0.625
vector surveillance,vector surveillance,0.95
vector surveillance,negative regulation of establishment of localization,0.6049295774647887
vector surveillance,cidal agent,0.6166666666666667
vector surveillance,COVID-19 incidence rate,0.6166666666666667
vector surveillance,cytotoxin disposition,0.625
vector surveillance,pathogen vector,0.6264705882352941
vector surveillance,negative regulation of developmental process,0.6246031746031746
vector surveillance,chronic infectious disease course,0.6423076923076922
vector surveillance,asymptomatic infectious agent carrier,0.6107142857142857
vector surveillance,negative regulation of replication,0.6386792452830189
vector surveillance,mechanical vector role,0.6939024390243902
vector surveillance,sterilizing immunity to infectious agent,0.5855932203389831
vector surveillance,incubation end process boundary,0.61
vector surveillance,collective pathogenic disposition,0.6038461538461539
vector surveillance,neurotoxin disposition,0.6207317073170732
vector surveillance,latency end temporal region,0.6673913043478261
vector surveillance,innate immunity to infectious agent,0.5981481481481481
vector surveillance,collective disposition,0.6207317073170732
vector surveillance,static agent disposition,0.5895348837209302
vector surveillance,T cell receptor complex,0.6404761904761905
vector surveillance,infectious agent population,0.6456521739130434
vector surveillance,biological vector,0.6166666666666667
vector surveillance,entry into host,0.6264705882352941
vector surveillance,leukocyte-mediated immunity to infectious agent,0.5863636363636363
vector surveillance,humoral immunity to infectious agent,0.5954545454545455
vector surveillance,infectious disease control strategy,0.6351851851851852
vector surveillance,immunosuppressive disposition,0.6166666666666667
vector surveillance,pathogenic disposition,0.5963414634146341
vector surveillance,viral disease course,0.6551282051282051
vector surveillance,entry into host through host barriers,0.6107142857142857
vector surveillance,passive immunity to infectious agent,0.6136363636363636
vector surveillance,infectious disposition,0.6451219512195122
vector surveillance,vaccination against infectious agent,0.6318181818181818
vector surveillance,susceptibility to infectious agent,0.6009433962264151
vector surveillance,bacteriostatic disposition,0.6055555555555556
vector surveillance,bactericidal disposition,0.6127906976744186
vector surveillance,invasion disposition,0.6038461538461539
vector surveillance,disease course,0.6318181818181818
vector surveillance,infectious disease course,0.6772727272727272
vector surveillance,viricidal disposition,0.6
vector surveillance,acquired immunity to infectious agent,0.5928571428571429
vector surveillance,coronavirus disease course,0.65
vector surveillance,symptomatic infectious agent carrier,0.6136363636363636
vector surveillance,pathogen vector role,0.7064102564102563
vector surveillance,disposition,0.5833333333333334
vector surveillance,COVID-19 mortality rate,0.6166666666666667
vector surveillance,negative regulation of life-sustaining process,0.6192307692307693
vector surveillance,place closure control strategy,0.6540816326530612
vector surveillance,adhesion disposition,0.6038461538461539
vector surveillance,pathogen portal of entry site,0.6166666666666667
vector surveillance,biological vector role,0.6939024390243902
vector surveillance,primary infectious disposition,0.6132653061224489
vector surveillance,pathogen surveillance,0.825
vector surveillance,immunization against infectious agent,0.5928571428571429
vector surveillance,negative regulation of immune response,0.6254385964912281
vector surveillance,SARS-COV-2 adhesion disposition,0.59
vector surveillance,invasive disposition,0.6038461538461539
vector surveillance,infectious agent host,0.625
vector surveillance,long-term non-progressing infectious disease course,0.5928571428571429
vector surveillance,fungicidal disposition,0.5719512195121951
vector surveillance,negative regulation of viral process,0.6318181818181818
vector surveillance,exotoxin disposition,0.6294871794871795
vector surveillance,infectious agent reservoir,0.65
vector surveillance,infectious disease control objective specification,0.6239130434782608
vector surveillance,opportunistic infectious disposition,0.5954545454545455
vector surveillance,negative regulation of biological process,0.6166666666666667
vector surveillance,enterotoxin disposition,0.6166666666666667
vector surveillance,COVID-19 disease course,0.6404761904761905
vector surveillance,infectious disease incidence rate,0.6615384615384616
vector surveillance,active immunization against infectious agent,0.6087301587301588
vector surveillance,collective resistance disposition,0.6615384615384616
vector surveillance,fungistatic disposition,0.569047619047619
vector surveillance,infectious agent,0.65
vector surveillance,establishment of a clinically abnormal colony,0.60625
vector surveillance,drug susceptibility of infectious agent,0.6224137931034482
vector surveillance,static agent,0.5790322580645162
pathogen vehicle,extended organism,0.6015151515151516
pathogen vehicle,virus aggregate,0.5790322580645162
pathogen vehicle,source of infection,0.5928571428571429
pathogen vehicle,infectious disease mortality rate,0.5724489795918367
pathogen vehicle,infection incidence rate profile,0.6375
pathogen vehicle,pathogen generative stage,0.7426829268292683
pathogen vehicle,pathogen portal of entry,0.725
pathogen vehicle,subclinical coronavirus infection,0.5724489795918367
pathogen vehicle,primary pathogen,0.7
pathogen vehicle,infection end temporal region,0.6277777777777778
pathogen vehicle,drug-based immunosuppressed organism,0.5461538461538461
pathogen vehicle,vector control strategy,0.6038461538461539
pathogen vehicle,infectious disease,0.5970588235294118
pathogen vehicle,SARS-CoV-2 incidence rate,0.5963414634146341
pathogen vehicle,double-stranded DNA virus,0.5963414634146341
pathogen vehicle,site of infection,0.6015151515151516
pathogen vehicle,immunocompetent organism,0.6
pathogen vehicle,virulence factor disposition,0.5636363636363636
pathogen vehicle,pathogen portal of exit,0.732051282051282
pathogen vehicle,infectious disease incidence,0.609090909090909
pathogen vehicle,reservoir of pathogen role,0.7119047619047619
pathogen vehicle,subclinical SARS-CoV-2 infection,0.5541666666666667
pathogen vehicle,virus translation stage,0.6038461538461539
pathogen vehicle,disease surveillance objective specification,0.5833333333333334
pathogen vehicle,virus release stage,0.5642857142857143
pathogen vehicle,infectious agent host role,0.6642857142857143
pathogen vehicle,asymptomatic infectious structure carrier,0.5903508771929825
pathogen vehicle,source of infection site,0.6
pathogen vehicle,virus,0.5452380952380953
pathogen vehicle,virus replication,0.6015151515151516
pathogen vehicle,B cell receptor complex,0.6294871794871795
pathogen vehicle,passive immunization against infectious agent,0.6139344262295081
pathogen vehicle,systematic infection,0.5888888888888889
pathogen vehicle,infection incidence rate,0.625
pathogen vehicle,virus host,0.5269230769230769
pathogen vehicle,double-stranded RNA virus,0.5963414634146341
pathogen vehicle,mechanical vector,0.6318181818181818
pathogen vehicle,pathogen portal of entry role,0.7166666666666667
pathogen vehicle,virus transcription stage,0.5963414634146341
pathogen vehicle,infectious disease lifetime prevalence,0.5981481481481481
pathogen vehicle,pathogen birth temporal region,0.7108695652173913
pathogen vehicle,lower respiratory tract disease,0.598936170212766
pathogen vehicle,infectious disease incidence proportion,0.5772727272727273
pathogen vehicle,opportunistic pathogen,0.6605263157894737
pathogen vehicle,virus generative stage,0.6078947368421053
pathogen vehicle,acute infectious disease course,0.6202127659574468
pathogen vehicle,cidal agent disposition,0.6038461538461539
pathogen vehicle,genetic resistance to pathogen,0.6239130434782608
pathogen vehicle,subclinical infection,0.5851351351351352
pathogen vehicle,simple infection,0.60625
pathogen vehicle,biological vehicle,0.7441176470588234
pathogen vehicle,droplet pathogen transmission process,0.6764150943396227
pathogen vehicle,infectious disease sporadicity,0.5804347826086956
pathogen vehicle,infection incidence proportion profile,0.5981481481481481
pathogen vehicle,infectious agent colony,0.6551282051282051
pathogen vehicle,pathogen transporter,0.7277777777777777
pathogen vehicle,invasion factor,0.6112903225806451
pathogen vehicle,infectious disease epidemic,0.6127906976744186
pathogen vehicle,infectious agent generative stage,0.6336734693877552
pathogen vehicle,disease transmission model,0.6166666666666667
pathogen vehicle,vector surveillance,0.6785714285714286
pathogen vehicle,pathologically immunosuppressed organism,0.6285714285714286
pathogen vehicle,negative-sense single-stranded RNA virus,0.5928571428571429
pathogen vehicle,cidal agent,0.5981481481481481
pathogen vehicle,pathogen vehicle,0.95
pathogen vehicle,COVID-19 incidence rate,0.5782051282051281
pathogen vehicle,community-acquired infection,0.5636363636363636
pathogen vehicle,pathogen vector,0.8370967741935484
pathogen vehicle,pathogen vehicle role,0.8824324324324324
pathogen vehicle,chronic infectious disease course,0.6132653061224489
pathogen vehicle,asymptomatic infectious agent carrier,0.6386792452830189
pathogen vehicle,nursing-home acquired infection,0.598936170212766
pathogen vehicle,secondary infection,0.5928571428571429
pathogen vehicle,mechanical vector role,0.6605263157894737
pathogen vehicle,infection start temporal region,0.598936170212766
pathogen vehicle,infection incidence,0.65
pathogen vehicle,virus disorder,0.55
pathogen vehicle,sterilizing immunity to infectious agent,0.575
pathogen vehicle,primary infection,0.6015151515151516
pathogen vehicle,virulence factor,0.575
pathogen vehicle,process of establishing an infection,0.6038461538461539
pathogen vehicle,pathogen death process boundary,0.7265957446808511
pathogen vehicle,immunosuppressed organism,0.5719512195121951
pathogen vehicle,innate immunity to infectious agent,0.6068627450980393
pathogen vehicle,virus adhesion susceptible cell,0.6414893617021277
pathogen vehicle,infection,0.57
pathogen vehicle,static agent disposition,0.625
pathogen vehicle,T cell receptor complex,0.6294871794871795
pathogen vehicle,asymptomatic carrier role,0.6207317073170732
pathogen vehicle,infectious agent population,0.6127906976744186
pathogen vehicle,respiratory system disease,0.6404761904761905
pathogen vehicle,biological vector,0.6318181818181818
pathogen vehicle,leukocyte-mediated immunity to infectious agent,0.5769841269841269
pathogen vehicle,indirect pathogen transmission process,0.6722222222222223
pathogen vehicle,organism population,0.5928571428571429
pathogen vehicle,humoral immunity to infectious agent,0.5846153846153846
pathogen vehicle,infectious disease control strategy,0.5872549019607843
pathogen vehicle,parasite,0.6166666666666667
pathogen vehicle,infectious disease pandemic,0.6127906976744186
pathogen vehicle,antibody reagent,0.6375
pathogen vehicle,viral disease course,0.5888888888888889
pathogen vehicle,intracellular infection,0.5782051282051281
pathogen vehicle,secondary infection role,0.625
pathogen vehicle,metastatic infection,0.5888888888888889
pathogen vehicle,passive immunity to infectious agent,0.6038461538461539
pathogen vehicle,vaccination against infectious agent,0.6230769230769231
pathogen vehicle,acute infection,0.6435483870967742
pathogen vehicle,susceptibility to infectious agent,0.59
pathogen vehicle,epitope site,0.7
pathogen vehicle,immunity to pathogen,0.6722222222222223
pathogen vehicle,source of infection role,0.625
pathogen vehicle,pathogen host,0.7948275862068965
pathogen vehicle,chronic infection,0.6318181818181818
pathogen vehicle,disease course,0.6166666666666667
pathogen vehicle,infectious disease course,0.5963414634146341
pathogen vehicle,acquired immunity to infectious agent,0.5820754716981132
pathogen vehicle,complex infection,0.6015151515151516
pathogen vehicle,COVID-19 disease incidence proportion,0.5632075471698114
pathogen vehicle,coronavirus disease course,0.5928571428571429
pathogen vehicle,asymptomatic carrier,0.6166666666666667
pathogen vehicle,biological vehicle role,0.7064102564102563
pathogen vehicle,infection incidence proportion,0.6021739130434782
pathogen vehicle,symptomatic infectious agent carrier,0.6423076923076922
pathogen vehicle,respiratory droplet virus fomite,0.6375
pathogen vehicle,susceptible organism,0.6166666666666667
pathogen vehicle,parasite role,0.6913793103448276
pathogen vehicle,pathogen vector role,0.8388888888888889
pathogen vehicle,pathogen portal of exit site,0.7227272727272727
pathogen vehicle,infectious disease prevalence,0.6277777777777778
pathogen vehicle,organism substance,0.6264705882352941
pathogen vehicle,single-stranded DNA virus,0.5963414634146341
pathogen vehicle,COVID-19 mortality rate,0.5782051282051281
pathogen vehicle,viral disease,0.5879310344827586
pathogen vehicle,primary infection role,0.6605263157894737
pathogen vehicle,intervention,0.6285714285714286
pathogen vehicle,pathogen portal of entry site,0.7166666666666667
pathogen vehicle,infection incidence profile,0.636046511627907
pathogen vehicle,disease,0.5369565217391304
pathogen vehicle,symptomatic infectious structure carrier,0.5928571428571429
pathogen vehicle,biological vector role,0.6605263157894737
pathogen vehicle,site,0.55
pathogen vehicle,pathogen host role,0.8029411764705883
pathogen vehicle,infection prevalence,0.6722222222222223
pathogen vehicle,symptomatic carrier role,0.625
pathogen vehicle,infectious pathogen transmissibility,0.6615384615384616
pathogen vehicle,pathogen surveillance,0.8283783783783784
pathogen vehicle,immunodeficient organism,0.575
pathogen vehicle,pathogen,0.7833333333333333
pathogen vehicle,pathogen birth process boundary,0.7053191489361703
pathogen vehicle,infectious human pathogen,0.6451219512195122
pathogen vehicle,subclinical virus infection,0.5662790697674418
pathogen vehicle,resistance to pathogen,0.6605263157894737
pathogen vehicle,establishment of localization in virus host,0.5686440677966101
pathogen vehicle,immunization against infectious agent,0.619811320754717
pathogen vehicle,virus attachment stage,0.6342105263157894
pathogen vehicle,virus synthesis stage,0.5851351351351352
pathogen vehicle,pathogen portal of exit role,0.7454545454545455
pathogen vehicle,infectious agent host,0.6391891891891892
pathogen vehicle,re-emerging pathogen,0.6722222222222223
pathogen vehicle,long-term non-progressing infectious disease course,0.5992537313432835
pathogen vehicle,viral disease epidemic,0.6078947368421053
pathogen vehicle,viral disease pandemic,0.6078947368421053
pathogen vehicle,virus penetration stage,0.6294871794871795
pathogen vehicle,pathogen seroprevalence,0.7833333333333333
pathogen vehicle,symptomatic carrier,0.6214285714285714
pathogen vehicle,infectious disease endemicity,0.6055555555555556
pathogen vehicle,contact pathogen transmission process,0.6764150943396227
pathogen vehicle,herd immunity to infectious organism,0.5653846153846154
pathogen vehicle,extracellular infection,0.5782051282051281
pathogen vehicle,pathogen transporter role,0.7426829268292683
pathogen vehicle,infectious agent reservoir,0.6404761904761905
pathogen vehicle,infection start process boundary,0.575
pathogen vehicle,action specification,0.6722222222222223
pathogen vehicle,infectious disease control objective specification,0.5863636363636363
pathogen vehicle,process of establishing viral infection,0.6136363636363636
pathogen vehicle,COVID-19 disease course,0.5782051282051281
pathogen vehicle,infectious disease incidence rate,0.5928571428571429
pathogen vehicle,active immunization against infectious agent,0.6
pathogen vehicle,disordered virus,0.60625
pathogen vehicle,organism,0.6166666666666667
pathogen vehicle,virus uncoating stage,0.5851351351351352
pathogen vehicle,local infection,0.5790322580645162
pathogen vehicle,infectious agent,0.60625
pathogen vehicle,establishment of a clinically abnormal colony,0.5811475409836065
pathogen vehicle,coronavirus disease,0.5928571428571429
pathogen vehicle,positive-sense single-stranded RNA virus,0.5928571428571429
pathogen vehicle,adhesion factor,0.6435483870967742
pathogen vehicle,horizontal pathogen transmission process,0.6642857142857143
pathogen vehicle,hospital-acquired infection,0.5895348837209302
pathogen vehicle,pathogen death temporal region,0.7326086956521739
pathogen vehicle,emerging pathogen,0.6924242424242425
pathogen vehicle,drug susceptibility of infectious agent,0.5772727272727273
pathogen vehicle,static agent,0.6285714285714286
pathogen vehicle,pathogen transmission process,0.7166666666666667
respiratory secretion,respiratory droplet,0.825
respiratory secretion,B cell receptor complex,0.6545454545454545
respiratory secretion,respiratory droplet coronavirus fomite,0.738135593220339
respiratory secretion,lower respiratory tract disease,0.7384615384615384
respiratory secretion,respiratory droplet SARS-CoV-2 fomite,0.7258620689655172
respiratory secretion,T cell receptor complex,0.6545454545454545
respiratory secretion,respiratory system disease,0.7691489361702127
respiratory secretion,respiratory secretion,0.95
respiratory secretion,respiratory droplet virus fomite,0.7707547169811321
respiratory secretion,respiratory droplet fomite,0.7904255319148936
respiratory secretion,acute respiratory distress syndrome,0.7357142857142857
respiratory secretion,establishment of a clinically abnormal colony,0.6015151515151516
plan specification,virostatic disposition,0.675
plan specification,zoonotic disposition,0.6868421052631578
plan specification,immune response,0.6318181818181818
plan specification,infectious disease mortality rate,0.6068627450980393
plan specification,infection incidence rate profile,0.63
plan specification,communicability end temporal region,0.6009433962264151
plan specification,surveillance process,0.6078947368421053
plan specification,infection end temporal region,0.6202127659574468
plan specification,geospatial location,0.6932432432432433
plan specification,vector control strategy,0.5719512195121951
plan specification,SARS-CoV-2 incidence rate,0.636046511627907
plan specification,incubation end temporal region,0.6166666666666667
plan specification,virulence factor disposition,0.6673913043478261
plan specification,viral adhesion disposition,0.7
plan specification,parasitostatic disposition,0.6772727272727272
plan specification,reverse zoonotic disposition,0.6456521739130434
plan specification,disease surveillance objective specification,0.7241935483870968
plan specification,case isolation control strategy,0.6336734693877552
plan specification,quarantine control strategy,0.5833333333333334
plan specification,B cell receptor complex,0.5963414634146341
plan specification,infection incidence rate,0.6404761904761905
plan specification,toxin disposition,0.7071428571428571
plan specification,acute infectious disease course,0.6132653061224489
plan specification,cidal agent disposition,0.7182926829268292
plan specification,process,0.53
plan specification,droplet pathogen transmission process,0.6318181818181818
plan specification,parasiticidal disposition,0.7058139534883722
plan specification,communicability end process boundary,0.5796296296296296
plan specification,transmissibility disposition,0.6673913043478261
plan specification,latency end process boundary,0.6239130434782608
plan specification,endotoxin disposition,0.6807692307692308
plan specification,COVID-19 incidence rate,0.5963414634146341
plan specification,cytotoxin disposition,0.6807692307692308
plan specification,negative regulation of developmental process,0.5790322580645162
plan specification,chronic infectious disease course,0.6068627450980393
plan specification,process of establishing an infection,0.6722222222222223
plan specification,incubation end process boundary,0.5928571428571429
plan specification,collective pathogenic disposition,0.6656862745098039
plan specification,neurotoxin disposition,0.675
plan specification,pathogen death process boundary,0.6336734693877552
plan specification,plan specification,0.95
plan specification,latency end temporal region,0.65
plan specification,collective disposition,0.675
plan specification,static agent disposition,0.6880952380952381
plan specification,T cell receptor complex,0.5963414634146341
plan specification,respiratory system disease,0.609090909090909
plan specification,indirect pathogen transmission process,0.6107142857142857
plan specification,planned process,0.6621212121212122
plan specification,infectious disease control strategy,0.6009433962264151
plan specification,immunosuppressive disposition,0.6627659574468084
plan specification,innate immune response,0.625
plan specification,pathogenic disposition,0.725
plan specification,viral disease course,0.6078947368421053
plan specification,infectious disposition,0.675
plan specification,objective specification,0.7914634146341464
plan specification,bacteriostatic disposition,0.6545454545454545
plan specification,bactericidal disposition,0.6642857142857143
plan specification,invasion disposition,0.7131578947368421
plan specification,disease course,0.60625
plan specification,infectious disease course,0.6127906976744186
plan specification,viricidal disposition,0.6807692307692308
plan specification,coronavirus disease course,0.5863636363636363
plan specification,disposition,0.6913793103448276
plan specification,COVID-19 mortality rate,0.5719512195121951
plan specification,process profile,0.6015151515151516
plan specification,negative regulation of life-sustaining process,0.590625
plan specification,place closure control strategy,0.6375
plan specification,adhesion disposition,0.7131578947368421
plan specification,developmental process,0.5782051282051281
plan specification,biological process,0.5888888888888889
plan specification,primary infectious disposition,0.6791666666666666
plan specification,humoral immune response,0.6207317073170732
plan specification,incubation start process boundary,0.6068627450980393
plan specification,object,0.575
plan specification,pathogen birth process boundary,0.6132653061224489
plan specification,negative regulation of immune response,0.5928571428571429
plan specification,SARS-COV-2 adhesion disposition,0.6540816326530612
plan specification,object aggregate,0.5676470588235294
plan specification,invasive disposition,0.6868421052631578
plan specification,long-term non-progressing infectious disease course,0.6094202898550725
plan specification,fungicidal disposition,0.675
plan specification,negative regulation of viral process,0.5981481481481481
plan specification,contact pathogen transmission process,0.6136363636363636
plan specification,function,0.6807692307692308
plan specification,symbiotic process,0.5928571428571429
plan specification,exotoxin disposition,0.6868421052631578
plan specification,infection start process boundary,0.61
plan specification,action specification,0.8710526315789474
plan specification,latency start process boundary,0.6375
plan specification,infectious disease control objective specification,0.6852941176470588
plan specification,opportunistic infectious disposition,0.6537037037037037
plan specification,process of establishing viral infection,0.6429824561403508
plan specification,negative regulation of biological process,0.6025423728813559
plan specification,enterotoxin disposition,0.6695121951219513
plan specification,polymerase chain reaction,0.7290697674418604
plan specification,COVID-19 disease course,0.5719512195121951
plan specification,infectious disease incidence rate,0.6264705882352941
plan specification,communicability start process boundary,0.5928571428571429
plan specification,process that results in death,0.598936170212766
plan specification,collective resistance disposition,0.6656862745098039
plan specification,adaptive immune response,0.6166666666666667
plan specification,fungistatic disposition,0.6695121951219513
plan specification,establishment of a clinically abnormal colony,0.6087301587301588
plan specification,process boundary,0.5676470588235294
plan specification,horizontal pathogen transmission process,0.6051724137931035
plan specification,pathogen transmission process,0.6414893617021277
commensal role,reservoir of pathogen role,0.65
commensal role,infectious agent host role,0.7
commensal role,B cell receptor complex,0.6662162162162162
commensal role,pathogen portal of entry role,0.6825581395348838
commensal role,lower respiratory tract disease,0.6055555555555556
commensal role,acute infectious disease course,0.6277777777777778
commensal role,role,0.6722222222222223
commensal role,appearance of disorder,0.5888888888888889
commensal role,mutualist role,0.7357142857142857
commensal role,infectious structure host role,0.6545454545454545
commensal role,pathogen vehicle role,0.7071428571428571
commensal role,chronic infectious disease course,0.6202127659574468
commensal role,mechanical vector role,0.7277777777777777
commensal role,dead-end host role,0.7
commensal role,commensal,0.8413043478260869
commensal role,definitive host role,0.6852941176470588
commensal role,T cell receptor complex,0.6662162162162162
commensal role,asymptomatic carrier role,0.6551282051282051
commensal role,viral disease course,0.5970588235294118
commensal role,secondary infection role,0.6868421052631578
commensal role,source of infection role,0.6868421052631578
commensal role,disease course,0.6285714285714286
commensal role,infectious disease course,0.6294871794871795
commensal role,coronavirus disease course,0.65
commensal role,biological vehicle role,0.6662162162162162
commensal role,symbiont role,0.7092592592592593
commensal role,parasite role,0.6722222222222223
commensal role,pathogen vector role,0.6852941176470588
commensal role,primary infection role,0.6722222222222223
commensal role,biological role,0.7258620689655172
commensal role,biological vector role,0.6722222222222223
commensal role,pathogen host role,0.73125
commensal role,symptomatic carrier role,0.6605263157894737
commensal role,intermediate host role,0.6722222222222223
commensal role,host role,0.7543478260869566
commensal role,pathogen portal of exit role,0.6880952380952381
commensal role,long-term non-progressing infectious disease course,0.5884615384615385
commensal role,commensal role,0.95
commensal role,epitope role,0.7192307692307692
commensal role,function,0.5863636363636363
commensal role,pathogen transporter role,0.6807692307692308
commensal role,antigen role,0.7192307692307692
commensal role,action specification,0.6264705882352941
commensal role,symbiont host role,0.7
commensal role,fomite role,0.77
commensal role,COVID-19 disease course,0.6391891891891892
commensal role,reagent role,0.7192307692307692
commensal role,viral load,0.6166666666666667
commensal role,establishment of a clinically abnormal colony,0.6025423728813559
contact pathogen transmission process,extended organism,0.6166666666666667
contact pathogen transmission process,virus aggregate,0.5653846153846154
contact pathogen transmission process,source of infection,0.6107142857142857
contact pathogen transmission process,immune response,0.6038461538461539
contact pathogen transmission process,infectious disease mortality rate,0.6357142857142857
contact pathogen transmission process,infection incidence rate profile,0.6528985507246376
contact pathogen transmission process,communicability end temporal region,0.6583333333333334
contact pathogen transmission process,pathogen generative stage,0.6758064516129032
contact pathogen transmission process,pathogen portal of entry,0.6795081967213115
contact pathogen transmission process,subclinical coronavirus infection,0.6214285714285714
contact pathogen transmission process,primary pathogen,0.6386792452830189
contact pathogen transmission process,surveillance process,0.6429824561403508
contact pathogen transmission process,infection end temporal region,0.6469696969696969
contact pathogen transmission process,drug-based immunosuppressed organism,0.5869863013698631
contact pathogen transmission process,infectious disease,0.6136363636363636
contact pathogen transmission process,SARS-CoV-2 incidence rate,0.6112903225806451
contact pathogen transmission process,double-stranded DNA virus,0.6112903225806451
contact pathogen transmission process,incubation end temporal region,0.658955223880597
contact pathogen transmission process,site of infection,0.5981481481481481
contact pathogen transmission process,immunocompetent organism,0.6467213114754098
contact pathogen transmission process,pathogen portal of exit,0.6833333333333332
contact pathogen transmission process,infectious disease incidence,0.6346153846153847
contact pathogen transmission process,reservoir of pathogen role,0.6722222222222223
contact pathogen transmission process,subclinical SARS-CoV-2 infection,0.6094202898550725
contact pathogen transmission process,virus translation stage,0.6333333333333333
contact pathogen transmission process,disease surveillance objective specification,0.5858024691358025
contact pathogen transmission process,case isolation control strategy,0.6558823529411765
contact pathogen transmission process,virus release stage,0.575
contact pathogen transmission process,infectious agent host role,0.6722222222222223
contact pathogen transmission process,source of infection site,0.630327868852459
contact pathogen transmission process,virus,0.5214285714285714
contact pathogen transmission process,virus replication,0.5796296296296296
contact pathogen transmission process,B cell receptor complex,0.6
contact pathogen transmission process,passive immunization against infectious agent,0.6329268292682927
contact pathogen transmission process,systematic infection,0.6078947368421053
contact pathogen transmission process,infection incidence rate,0.6467213114754098
contact pathogen transmission process,virus host,0.5563829787234043
contact pathogen transmission process,double-stranded RNA virus,0.6112903225806451
contact pathogen transmission process,pathogen portal of entry role,0.7075757575757575
contact pathogen transmission process,virus transcription stage,0.6435483870967742
contact pathogen transmission process,infectious disease lifetime prevalence,0.6366666666666667
contact pathogen transmission process,pathogen birth temporal region,0.6738805970149254
contact pathogen transmission process,lower respiratory tract disease,0.6558823529411765
contact pathogen transmission process,infectious disease incidence proportion,0.6342105263157894
contact pathogen transmission process,opportunistic pathogen,0.6703389830508475
contact pathogen transmission process,virus generative stage,0.6025423728813559
contact pathogen transmission process,acute infectious disease course,0.6411764705882353
contact pathogen transmission process,cidal agent disposition,0.6833333333333332
contact pathogen transmission process,genetic resistance to pathogen,0.658955223880597
contact pathogen transmission process,subclinical infection,0.6051724137931035
contact pathogen transmission process,process,0.609090909090909
contact pathogen transmission process,simple infection,0.5820754716981132
contact pathogen transmission process,droplet pathogen transmission process,0.8824324324324324
contact pathogen transmission process,infectious disease sporadicity,0.6291044776119403
contact pathogen transmission process,communicability end process boundary,0.6691780821917809
contact pathogen transmission process,infection incidence proportion profile,0.6633333333333334
contact pathogen transmission process,infectious agent colony,0.6333333333333333
contact pathogen transmission process,pathogen transporter,0.7482456140350877
contact pathogen transmission process,latency end process boundary,0.6653846153846155
contact pathogen transmission process,infectious disease epidemic,0.621875
contact pathogen transmission process,infectious agent generative stage,0.65
contact pathogen transmission process,disease transmission model,0.7357142857142857
contact pathogen transmission process,pathologically immunosuppressed organism,0.6318181818181818
contact pathogen transmission process,negative-sense single-stranded RNA virus,0.6318181818181818
contact pathogen transmission process,cidal agent,0.6166666666666667
contact pathogen transmission process,pathogen vehicle,0.6764150943396227
contact pathogen transmission process,COVID-19 incidence rate,0.6166666666666667
contact pathogen transmission process,community-acquired infection,0.6346153846153847
contact pathogen transmission process,pathogen vector,0.6807692307692308
contact pathogen transmission process,negative regulation of developmental process,0.6845679012345678
contact pathogen transmission process,pathogen vehicle role,0.6913793103448276
contact pathogen transmission process,chronic infectious disease course,0.65
contact pathogen transmission process,asymptomatic infectious agent carrier,0.6256756756756756
contact pathogen transmission process,nursing-home acquired infection,0.5970588235294118
contact pathogen transmission process,secondary infection,0.6285714285714286
contact pathogen transmission process,infection start temporal region,0.6558823529411765
contact pathogen transmission process,infection incidence,0.6464285714285714
contact pathogen transmission process,virus disorder,0.5872549019607843
contact pathogen transmission process,sterilizing immunity to infectious agent,0.5928571428571429
contact pathogen transmission process,primary infection,0.5796296296296296
contact pathogen transmission process,process of establishing an infection,0.6280821917808219
contact pathogen transmission process,incubation end process boundary,0.6852941176470588
contact pathogen transmission process,SARS-CoV-2 uncoating stage,0.6246031746031746
contact pathogen transmission process,pathogen death process boundary,0.7147058823529412
contact pathogen transmission process,immunosuppressed organism,0.5951612903225807
contact pathogen transmission process,plan specification,0.6136363636363636
contact pathogen transmission process,latency end temporal region,0.6375
contact pathogen transmission process,innate immunity to infectious agent,0.6166666666666667
contact pathogen transmission process,SARS-CoV-2 penetration stage,0.6653846153846155
contact pathogen transmission process,virus adhesion susceptible cell,0.6264705882352941
contact pathogen transmission process,infection,0.5804347826086956
contact pathogen transmission process,static agent disposition,0.6959016393442623
contact pathogen transmission process,T cell receptor complex,0.6166666666666667
contact pathogen transmission process,infectious agent population,0.653125
contact pathogen transmission process,respiratory system disease,0.6246031746031746
contact pathogen transmission process,entry into host,0.6230769230769231
contact pathogen transmission process,leukocyte-mediated immunity to infectious agent,0.6166666666666667
contact pathogen transmission process,indirect pathogen transmission process,0.89
contact pathogen transmission process,organism population,0.6107142857142857
contact pathogen transmission process,planned process,0.6807692307692308
contact pathogen transmission process,generative stage,0.6009433962264151
contact pathogen transmission process,humoral immunity to infectious agent,0.6143835616438357
contact pathogen transmission process,infectious disease control strategy,0.6305555555555555
contact pathogen transmission process,SARS-CoV-2 attachment stage,0.6375
contact pathogen transmission process,parasite,0.6055555555555556
contact pathogen transmission process,infectious disease pandemic,0.6375
contact pathogen transmission process,antibody reagent,0.6009433962264151
contact pathogen transmission process,infectious structure generative stage,0.6391891891891892
contact pathogen transmission process,innate immune response,0.6533898305084747
contact pathogen transmission process,viral disease course,0.5903508771929825
contact pathogen transmission process,entry into host through host barriers,0.6391891891891892
contact pathogen transmission process,intracellular infection,0.6166666666666667
contact pathogen transmission process,secondary infection role,0.6795081967213115
contact pathogen transmission process,metastatic infection,0.6254385964912281
contact pathogen transmission process,passive immunity to infectious agent,0.6006849315068493
contact pathogen transmission process,vaccination against infectious agent,0.6554794520547945
contact pathogen transmission process,acute infection,0.6230769230769231
contact pathogen transmission process,susceptibility to infectious agent,0.6190140845070422
contact pathogen transmission process,epitope site,0.6132653061224489
contact pathogen transmission process,immunity to pathogen,0.6605263157894737
contact pathogen transmission process,source of infection role,0.6631147540983606
contact pathogen transmission process,pathogen host,0.67
contact pathogen transmission process,chronic infection,0.6351851851851852
contact pathogen transmission process,disease course,0.5676470588235294
contact pathogen transmission process,infectious disease course,0.6274193548387097
contact pathogen transmission process,acquired immunity to infectious agent,0.6121621621621621
contact pathogen transmission process,complex infection,0.6166666666666667
contact pathogen transmission process,COVID-19 disease incidence proportion,0.6256756756756756
contact pathogen transmission process,coronavirus disease course,0.6404761904761905
contact pathogen transmission process,infection incidence proportion,0.6440298507462687
contact pathogen transmission process,symptomatic infectious agent carrier,0.6280821917808219
contact pathogen transmission process,respiratory droplet virus fomite,0.6094202898550725
contact pathogen transmission process,susceptible organism,0.6254385964912281
contact pathogen transmission process,parasite role,0.65
contact pathogen transmission process,pathogen vector role,0.7131578947368421
contact pathogen transmission process,pathogen portal of exit site,0.6807692307692308
contact pathogen transmission process,infectious disease prevalence,0.6469696969696969
contact pathogen transmission process,organism substance,0.65
contact pathogen transmission process,SARS-CoV-2 genome replication stage,0.6444444444444444
contact pathogen transmission process,single-stranded DNA virus,0.6274193548387097
contact pathogen transmission process,COVID-19 mortality rate,0.6166666666666667
contact pathogen transmission process,contact tracing,0.7
contact pathogen transmission process,process profile,0.6423076923076922
contact pathogen transmission process,negative regulation of life-sustaining process,0.7150602409638555
contact pathogen transmission process,viral disease,0.57
contact pathogen transmission process,primary infection role,0.6364406779661017
contact pathogen transmission process,pathogen portal of entry site,0.6772727272727272
contact pathogen transmission process,developmental process,0.6913793103448276
contact pathogen transmission process,infection incidence profile,0.66875
contact pathogen transmission process,disease,0.5409090909090909
contact pathogen transmission process,biological process,0.6681818181818181
contact pathogen transmission process,site,0.523170731707317
contact pathogen transmission process,pathogen host role,0.7045454545454546
contact pathogen transmission process,infection prevalence,0.6429824561403508
contact pathogen transmission process,humoral immune response,0.6333333333333333
contact pathogen transmission process,infectious pathogen transmissibility,0.7650684931506849
contact pathogen transmission process,incubation start process boundary,0.6928571428571427
contact pathogen transmission process,pathogen surveillance,0.6913793103448276
contact pathogen transmission process,immunodeficient organism,0.6139344262295081
contact pathogen transmission process,pathogen,0.6277777777777778
contact pathogen transmission process,pathogen birth process boundary,0.7147058823529412
contact pathogen transmission process,infectious human pathogen,0.6435483870967742
contact pathogen transmission process,subclinical virus infection,0.621875
contact pathogen transmission process,resistance to pathogen,0.6703389830508475
contact pathogen transmission process,establishment of localization in virus host,0.6375
contact pathogen transmission process,immunization against infectious agent,0.6391891891891892
contact pathogen transmission process,virus attachment stage,0.6194915254237288
contact pathogen transmission process,negative regulation of immune response,0.6633333333333334
contact pathogen transmission process,SARS-CoV-2 transcription stage,0.6738805970149254
contact pathogen transmission process,virus synthesis stage,0.6051724137931035
contact pathogen transmission process,pathogen portal of exit role,0.6961538461538461
contact pathogen transmission process,infectious agent host,0.656896551724138
contact pathogen transmission process,re-emerging pathogen,0.6254385964912281
contact pathogen transmission process,long-term non-progressing infectious disease course,0.6545454545454545
contact pathogen transmission process,viral disease epidemic,0.5855932203389831
contact pathogen transmission process,viral disease pandemic,0.6194915254237288
contact pathogen transmission process,virus penetration stage,0.65
contact pathogen transmission process,algorithm,0.5369565217391304
contact pathogen transmission process,pathogen seroprevalence,0.7
contact pathogen transmission process,infectious disease endemicity,0.6166666666666667
contact pathogen transmission process,negative regulation of viral process,0.7102739726027397
contact pathogen transmission process,contact pathogen transmission process,0.95
contact pathogen transmission process,function,0.5833333333333334
contact pathogen transmission process,herd immunity to infectious organism,0.6143835616438357
contact pathogen transmission process,extracellular infection,0.6
contact pathogen transmission process,pathogen transporter role,0.7564516129032257
contact pathogen transmission process,symbiotic process,0.6722222222222223
contact pathogen transmission process,transmission interval,0.6913793103448276
contact pathogen transmission process,infectious agent reservoir,0.6563492063492063
contact pathogen transmission process,infection start process boundary,0.6818840579710145
contact pathogen transmission process,action specification,0.6429824561403508
contact pathogen transmission process,SARS-CoV-2 synthesis stage,0.6246031746031746
contact pathogen transmission process,latency start process boundary,0.6738805970149254
contact pathogen transmission process,infectious disease control objective specification,0.6224137931034482
contact pathogen transmission process,process of establishing viral infection,0.6342105263157894
contact pathogen transmission process,negative regulation of biological process,0.6935897435897437
contact pathogen transmission process,polymerase chain reaction,0.6274193548387097
contact pathogen transmission process,COVID-19 disease course,0.6
contact pathogen transmission process,infectious disease incidence rate,0.6357142857142857
contact pathogen transmission process,communicability start process boundary,0.6766666666666665
contact pathogen transmission process,process that results in death,0.6469696969696969
contact pathogen transmission process,active immunization against infectious agent,0.6598765432098764
contact pathogen transmission process,disordered virus,0.5632075471698114
contact pathogen transmission process,adaptive immune response,0.6467213114754098
contact pathogen transmission process,organism,0.5833333333333334
contact pathogen transmission process,virus uncoating stage,0.6051724137931035
contact pathogen transmission process,local infection,0.6038461538461539
contact pathogen transmission process,infectious agent,0.619811320754717
contact pathogen transmission process,establishment of a clinically abnormal colony,0.5963414634146341
contact pathogen transmission process,process boundary,0.6009433962264151
contact pathogen transmission process,coronavirus disease,0.6285714285714286
contact pathogen transmission process,positive-sense single-stranded RNA virus,0.6188311688311688
contact pathogen transmission process,horizontal pathogen transmission process,0.8915584415584417
contact pathogen transmission process,hospital-acquired infection,0.60625
contact pathogen transmission process,pathogen death temporal region,0.6738805970149254
contact pathogen transmission process,emerging pathogen,0.6351851851851852
contact pathogen transmission process,drug susceptibility of infectious agent,0.5947368421052631
contact pathogen transmission process,SARS-CoV-2 release stage,0.5975409836065574
contact pathogen transmission process,static agent,0.6336734693877552
contact pathogen transmission process,pathogen transmission process,0.8893939393939394
virus host,extended organism,0.5611111111111111
virus host,virus aggregate,0.73
virus host,source of infection,0.5879310344827586
virus host,virostatic disposition,0.7
virus host,zoonotic disposition,0.6166666666666667
virus host,immune response,0.65
virus host,infectious disease mortality rate,0.5895348837209302
virus host,infection incidence rate profile,0.5452380952380953
virus host,communicability end temporal region,0.5388888888888889
virus host,pathogen generative stage,0.5642857142857143
virus host,pathogen portal of entry,0.5676470588235294
virus host,subclinical coronavirus infection,0.6127906976744186
virus host,primary pathogen,0.6423076923076922
virus host,infection end temporal region,0.5525641025641026
virus host,drug-based immunosuppressed organism,0.5804347826086956
virus host,infectious disease,0.6285714285714286
virus host,double-stranded DNA virus,0.5928571428571429
virus host,incubation end temporal region,0.55
virus host,site of infection,0.5981481481481481
virus host,immunocompetent organism,0.5970588235294118
virus host,virulence factor disposition,0.6605263157894737
virus host,pathogen portal of exit,0.5712121212121213
virus host,viral adhesion disposition,0.6722222222222223
virus host,parasitostatic disposition,0.6166666666666667
virus host,infectious disease incidence,0.581578947368421
virus host,reservoir of pathogen role,0.6166666666666667
virus host,reverse zoonotic disposition,0.6342105263157894
virus host,subclinical SARS-CoV-2 infection,0.569047619047619
virus host,establishment of localization in host,0.598936170212766
virus host,virus translation stage,0.7227272727272727
virus host,disease surveillance objective specification,0.5611111111111111
virus host,virus release stage,0.7258620689655172
virus host,infectious agent host role,0.6722222222222223
virus host,source of infection site,0.5970588235294118
virus host,virus,0.7833333333333333
virus host,virus replication,0.7092592592592593
virus host,B cell receptor complex,0.5409090909090909
virus host,systematic infection,0.55
virus host,infection incidence rate,0.5382352941176471
virus host,colonized host,0.7
virus host,virus host,0.95
virus host,double-stranded RNA virus,0.5928571428571429
virus host,pathogen portal of entry role,0.5525641025641026
virus host,virus transcription stage,0.7071428571428571
virus host,infectious disease lifetime prevalence,0.575
virus host,toxin disposition,0.6351851851851852
virus host,pathogen birth temporal region,0.55
virus host,lower respiratory tract disease,0.5475609756097561
virus host,infectious disease incidence proportion,0.5724489795918367
virus host,opportunistic pathogen,0.6375
virus host,virus generative stage,0.7
virus host,acute infectious disease course,0.5963414634146341
virus host,cidal agent disposition,0.6015151515151516
virus host,infectious disorder,0.6224137931034482
virus host,genetic resistance to pathogen,0.6
virus host,subclinical infection,0.5467741935483871
virus host,appearance of disorder,0.575
virus host,simple infection,0.5653846153846154
virus host,droplet pathogen transmission process,0.5563829787234043
virus host,parasiticidal disposition,0.6214285714285714
virus host,infectious disease sporadicity,0.6
virus host,communicability end process boundary,0.558695652173913
virus host,infection incidence proportion profile,0.5333333333333333
virus host,pathogen transporter,0.5833333333333334
virus host,transmissibility disposition,0.6078947368421053
virus host,latency end process boundary,0.5552631578947369
virus host,colonization of host,0.65
virus host,infectious disease epidemic,0.5851351351351352
virus host,disease transmission model,0.5888888888888889
virus host,endotoxin disposition,0.6112903225806451
virus host,pathologically immunosuppressed organism,0.57
virus host,negative-sense single-stranded RNA virus,0.55
virus host,infectious structure host role,0.65
virus host,pathogen vehicle,0.5269230769230769
virus host,cytotoxin disposition,0.6112903225806451
virus host,community-acquired infection,0.5552631578947369
virus host,pathogen vector,0.57
virus host,pathogen vehicle role,0.5790322580645162
virus host,host,0.7357142857142857
virus host,chronic infectious disease course,0.5895348837209302
virus host,nursing-home acquired infection,0.5719512195121951
virus host,COVID-19 epidemic,0.5611111111111111
virus host,secondary infection,0.553448275862069
virus host,infection start temporal region,0.5475609756097561
virus host,infection incidence,0.5189655172413793
virus host,virus disorder,0.7416666666666667
virus host,establishment of localization in human host,0.5820754716981132
virus host,primary infection,0.5981481481481481
virus host,process of establishing an infection,0.5804347826086956
virus host,incubation end process boundary,0.5719512195121951
virus host,SARS-CoV-2 disorder,0.5879310344827586
virus host,collective pathogenic disposition,0.5895348837209302
virus host,neurotoxin disposition,0.60625
virus host,dead-end host role,0.6285714285714286
virus host,pathogen death process boundary,0.5475609756097561
virus host,immunosuppressed organism,0.6214285714285714
virus host,definitive host role,0.65
virus host,latency end temporal region,0.5310810810810811
virus host,virus adhesion susceptible cell,0.6939024390243902
virus host,collective disposition,0.6375
virus host,infection,0.5552631578947369
virus host,static agent disposition,0.5970588235294118
virus host,T cell receptor complex,0.5409090909090909
virus host,infectious structure host,0.6785714285714286
virus host,respiratory system disease,0.5888888888888889
virus host,entry into host,0.69
virus host,indirect pathogen transmission process,0.575
virus host,adhesion of symbiont to host,0.6342105263157894
virus host,organism population,0.6224137931034482
virus host,infectious disease control strategy,0.6055555555555556
virus host,infectious disease pandemic,0.5851351351351352
virus host,immunosuppressive disposition,0.6294871794871795
virus host,innate immune response,0.60625
virus host,pathogenic disposition,0.60625
virus host,viral disease course,0.6833333333333332
virus host,entry into host through host barriers,0.6202127659574468
virus host,intracellular infection,0.6015151515151516
virus host,secondary infection role,0.5382352941176471
virus host,metastatic infection,0.55
virus host,infectious disposition,0.66875
virus host,acute infection,0.57
virus host,bacteriostatic disposition,0.6166666666666667
virus host,immunity to pathogen,0.6166666666666667
virus host,bactericidal disposition,0.5970588235294118
virus host,source of infection role,0.5676470588235294
virus host,pathogen host,0.6673913043478261
virus host,acquired immunodeficiency,0.5642857142857143
virus host,chronic infection,0.5611111111111111
virus host,invasion disposition,0.65
virus host,disease course,0.6583333333333334
virus host,infectious disease course,0.6214285714285714
virus host,viricidal disposition,0.6758064516129032
virus host,acquired immunity to infectious agent,0.598936170212766
virus host,complex infection,0.524074074074074
virus host,COVID-19 disease incidence proportion,0.5776595744680851
virus host,coronavirus disease course,0.6722222222222223
virus host,infection incidence proportion,0.55
virus host,respiratory droplet virus fomite,0.6404761904761905
virus host,susceptible organism,0.6166666666666667
virus host,intermediate host,0.7092592592592593
virus host,pathogen vector role,0.5833333333333334
virus host,pathogen portal of exit site,0.581578947368421
virus host,infectious disease prevalence,0.5782051282051281
virus host,organism substance,0.6285714285714286
virus host,disposition,0.6880952380952381
virus host,single-stranded DNA virus,0.5928571428571429
virus host,viral disease,0.6673913043478261
virus host,primary infection role,0.575
virus host,adhesion disposition,0.6166666666666667
virus host,pathogen portal of entry site,0.5782051282051281
virus host,infection incidence profile,0.5310810810810811
virus host,disease,0.6264705882352941
virus host,primary infectious disposition,0.65
virus host,pathogen host role,0.6285714285714286
virus host,infection prevalence,0.5166666666666666
virus host,humoral immune response,0.6015151515151516
virus host,coronavirus disorder,0.6833333333333332
virus host,infectious pathogen transmissibility,0.6239130434782608
virus host,intermediate host role,0.66875
virus host,dead-end host,0.6673913043478261
virus host,pathogen surveillance,0.5467741935483871
virus host,immunodeficient organism,0.5970588235294118
virus host,host role,0.6605263157894737
virus host,pathogen,0.5611111111111111
virus host,pathogen birth process boundary,0.5719512195121951
virus host,infectious human pathogen,0.6214285714285714
virus host,subclinical virus infection,0.6391891891891892
virus host,resistance to pathogen,0.60625
virus host,establishment of localization in virus host,0.6386792452830189
virus host,virus attachment stage,0.73125
virus host,negative regulation of immune response,0.575
virus host,virus synthesis stage,0.7403225806451613
virus host,SARS-COV-2 adhesion disposition,0.6207317073170732
virus host,pathogen portal of exit role,0.5552631578947369
virus host,invasive disposition,0.65
virus host,infectious agent host,0.7080645161290323
virus host,re-emerging pathogen,0.5833333333333334
virus host,long-term non-progressing infectious disease course,0.5483606557377049
virus host,viral disease epidemic,0.60625
virus host,fungicidal disposition,0.60625
virus host,viral disease pandemic,0.60625
virus host,virus penetration stage,0.7227272727272727
virus host,pathogen seroprevalence,0.5409090909090909
virus host,acute respiratory distress syndrome,0.5611111111111111
virus host,division of geopolitical entity,0.5963414634146341
virus host,infectious disease endemicity,0.6038461538461539
virus host,contact pathogen transmission process,0.5563829787234043
virus host,disorder,0.6166666666666667
virus host,herd immunity to infectious organism,0.5804347826086956
virus host,extracellular infection,0.5712121212121213
virus host,pathogen transporter role,0.5642857142857143
virus host,transmission interval,0.5790322580645162
virus host,exotoxin disposition,0.6166666666666667
virus host,infection start process boundary,0.569047619047619
virus host,infectious disease control objective specification,0.5666666666666667
virus host,symbiont host role,0.6642857142857143
virus host,immune population,0.6351851851851852
virus host,opportunistic infectious disposition,0.6021739130434782
virus host,process of establishing viral infection,0.5724489795918367
virus host,enterotoxin disposition,0.6015151515151516
virus host,COVID-19 disease course,0.6318181818181818
virus host,infectious disease incidence rate,0.5895348837209302
virus host,disordered virus,0.6423076923076922
virus host,collective resistance disposition,0.6127906976744186
virus host,adaptive immune response,0.6264705882352941
virus host,fungistatic disposition,0.6318181818181818
virus host,organism,0.5611111111111111
virus host,virus uncoating stage,0.7403225806451613
virus host,local infection,0.53
virus host,establishment of a clinically abnormal colony,0.5227272727272727
virus host,coronavirus disease,0.6913793103448276
virus host,positive-sense single-stranded RNA virus,0.55
virus host,definitive host,0.69
virus host,horizontal pathogen transmission process,0.57
virus host,hospital-acquired infection,0.5581081081081081
virus host,pathogen death temporal region,0.525
virus host,emerging pathogen,0.5981481481481481
virus host,pathogen transmission process,0.5782051282051281
pathogen host role,extended organism,0.6214285714285714
pathogen host role,virus aggregate,0.6015151515151516
pathogen host role,source of infection,0.6121621621621621
pathogen host role,virostatic disposition,0.625
pathogen host role,zoonotic disposition,0.6342105263157894
pathogen host role,infectious disease mortality rate,0.6264705882352941
pathogen host role,infection incidence rate profile,0.67
pathogen host role,pathogen generative stage,0.7290697674418604
pathogen host role,pathogen portal of entry,0.7833333333333333
pathogen host role,subclinical coronavirus infection,0.5676470588235294
pathogen host role,primary pathogen,0.6852941176470588
pathogen host role,infection end temporal region,0.6414893617021277
pathogen host role,drug-based immunosuppressed organism,0.5796296296296296
pathogen host role,infectious disease,0.5888888888888889
pathogen host role,double-stranded DNA virus,0.5895348837209302
pathogen host role,site of infection,0.6214285714285714
pathogen host role,immunocompetent organism,0.6166666666666667
pathogen host role,virulence factor disposition,0.6239130434782608
pathogen host role,pathogen portal of exit,0.7914634146341464
pathogen host role,viral adhesion disposition,0.6545454545454545
pathogen host role,parasitostatic disposition,0.6545454545454545
pathogen host role,infectious disease incidence,0.5804347826086956
pathogen host role,reservoir of pathogen role,0.7454545454545455
pathogen host role,reverse zoonotic disposition,0.6021739130434782
pathogen host role,subclinical SARS-CoV-2 infection,0.57
pathogen host role,establishment of localization in host,0.6136363636363636
pathogen host role,virus translation stage,0.6451219512195122
pathogen host role,disease surveillance objective specification,0.5790322580645162
pathogen host role,virus release stage,0.6121621621621621
pathogen host role,infectious agent host role,0.7909090909090909
pathogen host role,source of infection site,0.6166666666666667
pathogen host role,virus replication,0.5928571428571429
pathogen host role,B cell receptor complex,0.6207317073170732
pathogen host role,passive immunization against infectious agent,0.6246031746031746
pathogen host role,systematic infection,0.581578947368421
pathogen host role,infection incidence rate,0.6166666666666667
pathogen host role,colonized host,0.66875
pathogen host role,virus host,0.6285714285714286
pathogen host role,double-stranded RNA virus,0.5895348837209302
pathogen host role,pathogen portal of entry role,0.7904255319148936
pathogen host role,virus transcription stage,0.636046511627907
pathogen host role,infectious disease lifetime prevalence,0.6107142857142857
pathogen host role,toxin disposition,0.6785714285714286
pathogen host role,pathogen birth temporal region,0.7416666666666667
pathogen host role,lower respiratory tract disease,0.6132653061224489
pathogen host role,infectious disease incidence proportion,0.5903508771929825
pathogen host role,opportunistic pathogen,0.65
pathogen host role,virus generative stage,0.625
pathogen host role,acute infectious disease course,0.6336734693877552
pathogen host role,cidal agent disposition,0.6695121951219513
pathogen host role,role,0.6318181818181818
pathogen host role,genetic resistance to pathogen,0.6375
pathogen host role,subclinical infection,0.5525641025641026
pathogen host role,appearance of disorder,0.65
pathogen host role,simple infection,0.5970588235294118
pathogen host role,droplet pathogen transmission process,0.7045454545454546
pathogen host role,parasiticidal disposition,0.636046511627907
pathogen host role,infectious disease sporadicity,0.575
pathogen host role,mutualist role,0.7
pathogen host role,infection incidence proportion profile,0.6642857142857143
pathogen host role,infectious agent colony,0.6695121951219513
pathogen host role,pathogen transporter,0.7921052631578948
pathogen host role,transmissibility disposition,0.6021739130434782
pathogen host role,colonization of host,0.6868421052631578
pathogen host role,infectious disease epidemic,0.5833333333333334
pathogen host role,infectious agent generative stage,0.6264705882352941
pathogen host role,disease transmission model,0.609090909090909
pathogen host role,endotoxin disposition,0.6551282051282051
pathogen host role,pathologically immunosuppressed organism,0.6396551724137931
pathogen host role,negative-sense single-stranded RNA virus,0.6051724137931035
pathogen host role,cidal agent,0.6224137931034482
pathogen host role,infectious structure host role,0.7208333333333333
pathogen host role,pathogen vehicle,0.8029411764705883
pathogen host role,cytotoxin disposition,0.6551282051282051
pathogen host role,community-acquired infection,0.558695652173913
pathogen host role,pathogen vector,0.7833333333333333
pathogen host role,pathogen vehicle role,0.8346153846153846
pathogen host role,host,0.6318181818181818
pathogen host role,chronic infectious disease course,0.6264705882352941
pathogen host role,asymptomatic infectious agent carrier,0.65
pathogen host role,nursing-home acquired infection,0.5724489795918367
pathogen host role,secondary infection,0.5851351351351352
pathogen host role,mechanical vector role,0.675
pathogen host role,infection start temporal region,0.6540816326530612
pathogen host role,infection incidence,0.5851351351351352
pathogen host role,virus disorder,0.575
pathogen host role,sterilizing immunity to infectious agent,0.5879310344827586
pathogen host role,establishment of localization in human host,0.5975409836065574
pathogen host role,primary infection,0.5928571428571429
pathogen host role,process of establishing an infection,0.6166666666666667
pathogen host role,collective pathogenic disposition,0.7049019607843137
pathogen host role,neurotoxin disposition,0.65
pathogen host role,dead-end host role,0.8111111111111111
pathogen host role,pathogen death process boundary,0.7357142857142857
pathogen host role,immunosuppressed organism,0.5662790697674418
pathogen host role,definitive host role,0.7657894736842106
pathogen host role,innate immunity to infectious agent,0.619811320754717
pathogen host role,virus adhesion susceptible cell,0.6336734693877552
pathogen host role,collective disposition,0.625
pathogen host role,infection,0.5611111111111111
pathogen host role,static agent disposition,0.6880952380952381
pathogen host role,T cell receptor complex,0.6451219512195122
pathogen host role,asymptomatic carrier role,0.6593023255813953
pathogen host role,infectious structure host,0.636046511627907
pathogen host role,infectious agent population,0.65
pathogen host role,respiratory system disease,0.6545454545454545
pathogen host role,entry into host,0.6621212121212122
pathogen host role,leukocyte-mediated immunity to infectious agent,0.5884615384615385
pathogen host role,indirect pathogen transmission process,0.7
pathogen host role,adhesion of symbiont to host,0.6673913043478261
pathogen host role,organism population,0.6391891891891892
pathogen host role,humoral immunity to infectious agent,0.5981481481481481
pathogen host role,infectious disease control strategy,0.6386792452830189
pathogen host role,parasite,0.6423076923076922
pathogen host role,infectious disease pandemic,0.5833333333333334
pathogen host role,antibody reagent,0.6558823529411765
pathogen host role,immunosuppressive disposition,0.598936170212766
pathogen host role,pathogenic disposition,0.775
pathogen host role,viral disease course,0.6078947368421053
pathogen host role,entry into host through host barriers,0.6681818181818181
pathogen host role,intracellular infection,0.5719512195121951
pathogen host role,secondary infection role,0.6642857142857143
pathogen host role,metastatic infection,0.581578947368421
pathogen host role,passive immunity to infectious agent,0.6166666666666667
pathogen host role,infectious disposition,0.625
pathogen host role,vaccination against infectious agent,0.6351851851851852
pathogen host role,acute infection,0.6318181818181818
pathogen host role,susceptibility to infectious agent,0.6038461538461539
pathogen host role,bacteriostatic disposition,0.6318181818181818
pathogen host role,epitope site,0.7166666666666667
pathogen host role,immunity to pathogen,0.6605263157894737
pathogen host role,bactericidal disposition,0.6404761904761905
pathogen host role,source of infection role,0.6880952380952381
pathogen host role,pathogen host,0.8693548387096774
pathogen host role,chronic infection,0.6214285714285714
pathogen host role,invasion disposition,0.6605263157894737
pathogen host role,disease course,0.6375
pathogen host role,infectious disease course,0.6127906976744186
pathogen host role,viricidal disposition,0.6038461538461539
pathogen host role,acquired immunity to infectious agent,0.5954545454545455
pathogen host role,complex infection,0.5928571428571429
pathogen host role,COVID-19 disease incidence proportion,0.5772727272727273
pathogen host role,coronavirus disease course,0.609090909090909
pathogen host role,biological vehicle role,0.6695121951219513
pathogen host role,infection incidence proportion,0.6166666666666667
pathogen host role,symptomatic infectious agent carrier,0.6537037037037037
pathogen host role,respiratory droplet virus fomite,0.67
pathogen host role,symbiont role,0.7080645161290323
pathogen host role,susceptible organism,0.6078947368421053
pathogen host role,parasite role,0.7403225806451613
pathogen host role,intermediate host,0.6785714285714286
pathogen host role,pathogen vector role,0.8447368421052631
pathogen host role,pathogen portal of exit site,0.7543478260869566
pathogen host role,infectious disease prevalence,0.6202127659574468
pathogen host role,organism substance,0.6444444444444444
pathogen host role,disposition,0.6224137931034482
pathogen host role,single-stranded DNA virus,0.5895348837209302
pathogen host role,viral disease,0.5790322580645162
pathogen host role,primary infection role,0.7
pathogen host role,biological role,0.6621212121212122
pathogen host role,adhesion disposition,0.6868421052631578
pathogen host role,pathogen portal of entry site,0.747872340425532
pathogen host role,infection incidence profile,0.65
pathogen host role,disease,0.57
pathogen host role,biological vector role,0.675
pathogen host role,site,0.5863636363636363
pathogen host role,primary infectious disposition,0.6375
pathogen host role,pathogen host role,0.95
pathogen host role,infection prevalence,0.6342105263157894
pathogen host role,symptomatic carrier role,0.6642857142857143
pathogen host role,infectious pathogen transmissibility,0.6722222222222223
pathogen host role,intermediate host role,0.775
pathogen host role,dead-end host,0.7080645161290323
pathogen host role,pathogen surveillance,0.7833333333333333
pathogen host role,immunodeficient organism,0.5928571428571429
pathogen host role,host role,0.7833333333333333
pathogen host role,pathogen,0.7576923076923078
pathogen host role,pathogen birth process boundary,0.7357142857142857
pathogen host role,infectious human pathogen,0.636046511627907
pathogen host role,subclinical virus infection,0.5611111111111111
pathogen host role,resistance to pathogen,0.65
pathogen host role,establishment of localization in virus host,0.6139344262295081
pathogen host role,immunization against infectious agent,0.6318181818181818
pathogen host role,virus attachment stage,0.675
pathogen host role,virus synthesis stage,0.6294871794871795
pathogen host role,SARS-COV-2 adhesion disposition,0.6336734693877552
pathogen host role,pathogen portal of exit role,0.7978260869565217
pathogen host role,invasive disposition,0.6342105263157894
pathogen host role,infectious agent host,0.7064102564102563
pathogen host role,re-emerging pathogen,0.6605263157894737
pathogen host role,long-term non-progressing infectious disease course,0.6094202898550725
pathogen host role,viral disease epidemic,0.575
pathogen host role,commensal role,0.73125
pathogen host role,epitope role,0.75
pathogen host role,fungicidal disposition,0.6
pathogen host role,viral disease pandemic,0.575
pathogen host role,virus penetration stage,0.6695121951219513
pathogen host role,pathogen seroprevalence,0.7914634146341464
pathogen host role,division of geopolitical entity,0.6132653061224489
pathogen host role,infectious disease endemicity,0.5776595744680851
pathogen host role,contact pathogen transmission process,0.7045454545454546
pathogen host role,function,0.5653846153846154
pathogen host role,herd immunity to infectious organism,0.5981481481481481
pathogen host role,extracellular infection,0.5719512195121951
pathogen host role,pathogen transporter role,0.822093023255814
pathogen host role,exotoxin disposition,0.6605263157894737
pathogen host role,infectious agent reservoir,0.6545454545454545
pathogen host role,antigen role,0.7833333333333333
pathogen host role,infection start process boundary,0.65
pathogen host role,action specification,0.6605263157894737
pathogen host role,infectious disease control objective specification,0.5970588235294118
pathogen host role,symbiont host role,0.7833333333333333
pathogen host role,opportunistic infectious disposition,0.5981481481481481
pathogen host role,fomite role,0.6913793103448276
pathogen host role,process of establishing viral infection,0.6429824561403508
pathogen host role,enterotoxin disposition,0.6451219512195122
pathogen host role,COVID-19 disease course,0.5963414634146341
pathogen host role,infectious disease incidence rate,0.5872549019607843
pathogen host role,active immunization against infectious agent,0.6112903225806451
pathogen host role,disordered virus,0.5676470588235294
pathogen host role,collective resistance disposition,0.6068627450980393
pathogen host role,reagent role,0.7833333333333333
pathogen host role,viral load,0.5571428571428572
pathogen host role,fungistatic disposition,0.6207317073170732
pathogen host role,organism,0.6038461538461539
pathogen host role,virus uncoating stage,0.6294871794871795
pathogen host role,local infection,0.5712121212121213
pathogen host role,infectious agent,0.6264705882352941
pathogen host role,establishment of a clinically abnormal colony,0.6087301587301588
pathogen host role,coronavirus disease,0.5851351351351352
pathogen host role,positive-sense single-stranded RNA virus,0.6051724137931035
pathogen host role,definitive host,0.6621212121212122
pathogen host role,horizontal pathogen transmission process,0.6913793103448276
pathogen host role,hospital-acquired infection,0.5833333333333334
pathogen host role,pathogen death temporal region,0.7416666666666667
pathogen host role,emerging pathogen,0.6785714285714286
pathogen host role,drug susceptibility of infectious agent,0.5903508771929825
pathogen host role,static agent,0.65
pathogen host role,pathogen transmission process,0.747872340425532
infectious disorder,virostatic disposition,0.6451219512195122
infectious disorder,zoonotic disposition,0.6551282051282051
infectious disorder,infectious disease mortality rate,0.7769230769230769
infectious disorder,infectious structure aggregate,0.7561224489795919
infectious disorder,communicability end temporal region,0.5981481481481481
infectious disorder,infection end temporal region,0.7208333333333333
infectious disorder,infectious disease,0.8554054054054054
infectious disorder,incubation end temporal region,0.6744897959183673
infectious disorder,virulence factor disposition,0.6840425531914894
infectious disorder,viral adhesion disposition,0.65
infectious disorder,parasitostatic disposition,0.65
infectious disorder,infectious disease incidence,0.7904255319148936
infectious disorder,reverse zoonotic disposition,0.6202127659574468
infectious disorder,establishment of localization in host,0.6285714285714286
infectious disorder,disease surveillance objective specification,0.5928571428571429
infectious disorder,infectious agent host role,0.7611111111111112
infectious disorder,asymptomatic infectious structure carrier,0.7
infectious disorder,B cell receptor complex,0.6166666666666667
infectious disorder,passive immunization against infectious agent,0.6375
infectious disorder,colonized host,0.5712121212121213
infectious disorder,virus host,0.6224137931034482
infectious disorder,infectious disease lifetime prevalence,0.730701754385965
infectious disorder,toxin disposition,0.6444444444444444
infectious disorder,lower respiratory tract disease,0.61
infectious disorder,infectious disease incidence proportion,0.743103448275862
infectious disorder,acute infectious disease course,0.79
infectious disorder,cidal agent disposition,0.6404761904761905
infectious disorder,infectious disorder,0.95
infectious disorder,appearance of disorder,0.7426829268292683
infectious disorder,parasiticidal disposition,0.6318181818181818
infectious disorder,infectious disease sporadicity,0.7969387755102041
infectious disorder,communicability end process boundary,0.6136363636363636
infectious disorder,infectious agent colony,0.7357142857142857
infectious disorder,transmissibility disposition,0.6202127659574468
infectious disorder,latency end process boundary,0.6202127659574468
infectious disorder,colonization of host,0.6038461538461539
infectious disorder,infectious disease epidemic,0.7978260869565217
infectious disorder,infectious agent generative stage,0.7192307692307692
infectious disorder,disease transmission model,0.65
infectious disorder,endotoxin disposition,0.65
infectious disorder,infectious structure host role,0.7561224489795919
infectious disorder,cytotoxin disposition,0.65
infectious disorder,host,0.5369565217391304
infectious disorder,chronic infectious disease course,0.7769230769230769
infectious disorder,asymptomatic infectious agent carrier,0.7
infectious disorder,COVID-19 epidemic,0.6166666666666667
infectious disorder,virus disorder,0.8136363636363637
infectious disorder,sterilizing immunity to infectious agent,0.6533898305084747
infectious disorder,establishment of localization in human host,0.6112903225806451
infectious disorder,diseased population,0.6078947368421053
infectious disorder,incubation end process boundary,0.69
infectious disorder,SARS-CoV-2 disorder,0.7394736842105263
infectious disorder,collective pathogenic disposition,0.6423076923076922
infectious disorder,neurotoxin disposition,0.6695121951219513
infectious disorder,dead-end host role,0.6121621621621621
infectious disorder,definitive host role,0.6807692307692308
infectious disorder,latency end temporal region,0.6021739130434782
infectious disorder,innate immunity to infectious agent,0.6722222222222223
infectious disorder,infectious structure,0.808974358974359
infectious disorder,collective disposition,0.6695121951219513
infectious disorder,static agent disposition,0.636046511627907
infectious disorder,T cell receptor complex,0.6166666666666667
infectious disorder,infectious structure host,0.7681818181818181
infectious disorder,infectious agent population,0.7326086956521739
infectious disorder,respiratory system disease,0.65
infectious disorder,entry into host,0.6264705882352941
infectious disorder,leukocyte-mediated immunity to infectious agent,0.6318181818181818
infectious disorder,adhesion of symbiont to host,0.598936170212766
infectious disorder,humoral immunity to infectious agent,0.6681818181818181
infectious disorder,infectious disease control strategy,0.7648148148148148
infectious disorder,infectious disease pandemic,0.7978260869565217
infectious disorder,infectious structure generative stage,0.7178571428571427
infectious disorder,immunosuppressive disposition,0.6583333333333334
infectious disorder,pathogenic disposition,0.6207317073170732
infectious disorder,viral disease course,0.6551282051282051
infectious disorder,entry into host through host barriers,0.6285714285714286
infectious disorder,passive immunity to infectious agent,0.6681818181818181
infectious disorder,infectious disposition,0.8158536585365854
infectious disorder,vaccination against infectious agent,0.6681818181818181
infectious disorder,susceptibility to infectious agent,0.6764150943396227
infectious disorder,bacteriostatic disposition,0.6722222222222223
infectious disorder,bactericidal disposition,0.636046511627907
infectious disorder,pathogen host,0.575
infectious disorder,invasion disposition,0.6807692307692308
infectious disorder,disease course,0.6621212121212122
infectious disorder,infectious disease course,0.8363636363636363
infectious disorder,viricidal disposition,0.65
infectious disorder,acquired immunity to infectious agent,0.6642857142857143
infectious disorder,COVID-19 disease incidence proportion,0.6107142857142857
infectious disorder,coronavirus disease course,0.6944444444444444
infectious disorder,symptomatic infectious agent carrier,0.7045454545454546
infectious disorder,intermediate host,0.6166666666666667
infectious disorder,infectious disease prevalence,0.7833333333333333
infectious disorder,disposition,0.6166666666666667
infectious disorder,infected population,0.7131578947368421
infectious disorder,viral disease,0.6375
infectious disorder,adhesion disposition,0.6551282051282051
infectious disorder,disease,0.6038461538461539
infectious disorder,symptomatic infectious structure carrier,0.7042372881355932
infectious disorder,primary infectious disposition,0.7561224489795919
infectious disorder,pathogen host role,0.6121621621621621
infectious disorder,coronavirus disorder,0.7833333333333333
infectious disorder,infectious pathogen transmissibility,0.7045454545454546
infectious disorder,intermediate host role,0.6695121951219513
infectious disorder,dead-end host,0.54375
infectious disorder,host role,0.6285714285714286
infectious disorder,infectious human pathogen,0.7454545454545455
infectious disorder,establishment of localization in virus host,0.6274193548387097
infectious disorder,immunization against infectious agent,0.6642857142857143
infectious disorder,SARS-COV-2 adhesion disposition,0.61
infectious disorder,invasive disposition,0.6551282051282051
infectious disorder,infectious agent host,0.75
infectious disorder,long-term non-progressing infectious disease course,0.6928571428571427
infectious disorder,viral disease epidemic,0.6207317073170732
infectious disorder,fungicidal disposition,0.6451219512195122
infectious disorder,viral disease pandemic,0.6207317073170732
infectious disorder,acute respiratory distress syndrome,0.6537037037037037
infectious disorder,infectious disease endemicity,0.7833333333333333
infectious disorder,disorder,0.7462962962962962
infectious disorder,herd immunity to infectious organism,0.6863636363636364
infectious disorder,exotoxin disposition,0.6551282051282051
infectious disorder,infectious agent reservoir,0.7611111111111112
infectious disorder,COVID-19 pandemic,0.5888888888888889
infectious disorder,infectious disease control objective specification,0.696376811594203
infectious disorder,symbiont host role,0.6662162162162162
infectious disorder,opportunistic infectious disposition,0.7227272727272727
infectious disorder,enterotoxin disposition,0.6642857142857143
infectious disorder,COVID-19 disease course,0.6642857142857143
infectious disorder,infectious disease incidence rate,0.7769230769230769
infectious disorder,active immunization against infectious agent,0.6404761904761905
infectious disorder,collective resistance disposition,0.6423076923076922
infectious disorder,fungistatic disposition,0.6404761904761905
infectious disorder,infectious agent,0.7928571428571428
infectious disorder,establishment of a clinically abnormal colony,0.575
infectious disorder,coronavirus disease,0.6868421052631578
infectious disorder,definitive host,0.6264705882352941
infectious disorder,drug susceptibility of infectious agent,0.656896551724138
infectious disorder,static agent,0.5790322580645162
collective disposition,virus aggregate,0.5581081081081081
collective disposition,virostatic disposition,0.7909090909090909
collective disposition,information content entity,0.5958333333333333
collective disposition,zoonotic disposition,0.8071428571428573
collective disposition,infectious disease mortality rate,0.65
collective disposition,infection incidence rate profile,0.6351851851851852
collective disposition,infectious structure aggregate,0.5846153846153846
collective disposition,communicability end temporal region,0.6429824561403508
collective disposition,geographical entity,0.5963414634146341
collective disposition,biological regulation,0.636046511627907
collective disposition,surveillance process,0.6404761904761905
collective disposition,infection end temporal region,0.6656862745098039
collective disposition,vector control strategy,0.6055555555555556
collective disposition,SARS-CoV-2 incidence rate,0.598936170212766
collective disposition,incubation end temporal region,0.6423076923076922
collective disposition,site of infection,0.6807692307692308
collective disposition,resistant entity,0.581578947368421
collective disposition,virulence factor disposition,0.77
collective disposition,viral adhesion disposition,0.7625
collective disposition,parasitostatic disposition,0.7625
collective disposition,negative regulation of production,0.6863636363636364
collective disposition,reverse zoonotic disposition,0.75
collective disposition,establishment of localization in host,0.6364406779661017
collective disposition,disease surveillance objective specification,0.6924242424242425
collective disposition,case isolation control strategy,0.6386792452830189
collective disposition,infectious agent host role,0.6583333333333334
collective disposition,macromolecular complex,0.609090909090909
collective disposition,material entity,0.5851351351351352
collective disposition,SARS-CoV-2 aggregate,0.569047619047619
collective disposition,asymptomatic infectious structure carrier,0.5928571428571429
collective disposition,source of infection site,0.6673913043478261
collective disposition,architectual structure,0.609090909090909
collective disposition,quarantine control strategy,0.5928571428571429
collective disposition,B cell receptor complex,0.65
collective disposition,infection incidence rate,0.6239130434782608
collective disposition,colonized host,0.7
collective disposition,virus host,0.6375
collective disposition,entity,0.5928571428571429
collective disposition,toxin disposition,0.808974358974359
collective disposition,cidal agent disposition,0.8055555555555556
collective disposition,parasiticidal disposition,0.747872340425532
collective disposition,communicability end process boundary,0.6396551724137931
collective disposition,directive information content entity,0.6741379310344828
collective disposition,acellular structure aggregate,0.6068627450980393
collective disposition,transmissibility disposition,0.73
collective disposition,latency end process boundary,0.65
collective disposition,colonization of host,0.6642857142857143
collective disposition,realizable entity,0.6038461538461539
collective disposition,endotoxin disposition,0.7988372093023256
collective disposition,vector surveillance,0.6207317073170732
collective disposition,negative regulation of establishment of localization,0.6391891891891892
collective disposition,infectious structure host role,0.6423076923076922
collective disposition,COVID-19 incidence rate,0.6055555555555556
collective disposition,cytotoxin disposition,0.822093023255814
collective disposition,negative regulation of developmental process,0.6015151515151516
collective disposition,host,0.5653846153846154
collective disposition,descriptive information content entity,0.6666666666666667
collective disposition,negative regulation of replication,0.6821428571428573
collective disposition,establishment of localization in human host,0.6192307692307693
collective disposition,acellular structure,0.5963414634146341
collective disposition,incubation end process boundary,0.6386792452830189
collective disposition,collective pathogenic disposition,0.85
collective disposition,neurotoxin disposition,0.7909090909090909
collective disposition,dead-end host role,0.625
collective disposition,molecular entity,0.6342105263157894
collective disposition,plan specification,0.675
collective disposition,definitive host role,0.6880952380952381
collective disposition,latency end temporal region,0.6540816326530612
collective disposition,coronavirus aggregate,0.5895348837209302
collective disposition,infectious structure,0.6166666666666667
collective disposition,collective disposition,0.95
collective disposition,static agent disposition,0.7760869565217391
collective disposition,T cell receptor complex,0.65
collective disposition,infectious structure host,0.6414893617021277
collective disposition,respiratory system disease,0.6166666666666667
collective disposition,entry into host,0.6391891891891892
collective disposition,adhesion of symbiont to host,0.61
collective disposition,infectious disease control strategy,0.6429824561403508
collective disposition,infectious structure generative stage,0.6194915254237288
collective disposition,immunosuppressive disposition,0.7833333333333333
collective disposition,pathogenic disposition,0.7909090909090909
collective disposition,entry into host through host barriers,0.6025423728813559
collective disposition,infectious disposition,0.8136363636363637
collective disposition,bacteriostatic disposition,0.7833333333333333
collective disposition,epitope site,0.6558823529411765
collective disposition,bactericidal disposition,0.7978260869565217
collective disposition,pathogen host,0.6214285714285714
collective disposition,invasion disposition,0.7833333333333333
collective disposition,viricidal disposition,0.7755813953488372
collective disposition,complex infection,0.7064102564102563
collective disposition,prion aggregate,0.5581081081081081
collective disposition,intermediate host,0.6294871794871795
collective disposition,pathogen portal of exit site,0.61
collective disposition,anatomical entity,0.6038461538461539
collective disposition,disposition,0.7833333333333333
collective disposition,COVID-19 mortality rate,0.6055555555555556
collective disposition,negative regulation of life-sustaining process,0.6264705882352941
collective disposition,place closure control strategy,0.6038461538461539
collective disposition,geopolitical entity,0.6207317073170732
collective disposition,adhesion disposition,0.7833333333333333
collective disposition,pathogen portal of entry site,0.6068627450980393
collective disposition,viroid aggregate,0.581578947368421
collective disposition,symptomatic infectious structure carrier,0.5951612903225807
collective disposition,site,0.5653846153846154
collective disposition,primary infectious disposition,0.7576923076923078
collective disposition,pathogen host role,0.625
collective disposition,designative information content entity,0.65
collective disposition,intermediate host role,0.6318181818181818
collective disposition,dead-end host,0.6214285714285714
collective disposition,pathogen surveillance,0.5895348837209302
collective disposition,host role,0.5790322580645162
collective disposition,establishment of localization in virus host,0.6192307692307693
collective disposition,negative regulation of immune response,0.6333333333333333
collective disposition,immaterial entity,0.5782051282051281
collective disposition,SARS-COV-2 adhesion disposition,0.7518867924528303
collective disposition,object aggregate,0.6078947368421053
collective disposition,invasive disposition,0.8071428571428573
collective disposition,infectious agent host,0.6593023255813953
collective disposition,fungicidal disposition,0.7681818181818181
collective disposition,division of geopolitical entity,0.6386792452830189
collective disposition,negative regulation of viral process,0.6224137931034482
collective disposition,exotoxin disposition,0.8071428571428573
collective disposition,immunoglobulin complex,0.5863636363636363
collective disposition,infectious disease control objective specification,0.6861111111111111
collective disposition,symbiont host role,0.625
collective disposition,opportunistic infectious disposition,0.743103448275862
collective disposition,negative regulation of biological process,0.6246031746031746
collective disposition,enterotoxin disposition,0.7833333333333333
collective disposition,infectious disease incidence rate,0.6681818181818181
collective disposition,collective resistance disposition,0.85
collective disposition,fungistatic disposition,0.7611111111111112
collective disposition,establishment of a clinically abnormal colony,0.5992537313432835
collective disposition,definitive host,0.6932432432432433
geopolitical entity,extended organism,0.5888888888888889
geopolitical entity,information content entity,0.6944444444444444
geopolitical entity,infectious disease mortality rate,0.6230769230769231
geopolitical entity,infection incidence rate profile,0.6068627450980393
geopolitical entity,infectious structure aggregate,0.5928571428571429
geopolitical entity,communicability end temporal region,0.6351851851851852
geopolitical entity,geographical entity,0.8447368421052631
geopolitical entity,infection end temporal region,0.6375
geopolitical entity,drug-based immunosuppressed organism,0.5954545454545455
geopolitical entity,SARS-CoV-2 incidence rate,0.5863636363636363
geopolitical entity,incubation end temporal region,0.6132653061224489
geopolitical entity,resistant entity,0.7642857142857143
geopolitical entity,immunocompetent organism,0.6127906976744186
geopolitical entity,virulence factor disposition,0.6202127659574468
geopolitical entity,case isolation control strategy,0.67
geopolitical entity,material entity,0.7735294117647058
geopolitical entity,asymptomatic infectious structure carrier,0.6166666666666667
geopolitical entity,architectual structure,0.6451219512195122
geopolitical entity,B cell receptor complex,0.5928571428571429
geopolitical entity,infection incidence rate,0.6127906976744186
geopolitical entity,entity,0.69
geopolitical entity,communicability end process boundary,0.6136363636363636
geopolitical entity,directive information content entity,0.6681818181818181
geopolitical entity,acellular structure aggregate,0.5958333333333333
geopolitical entity,invasion factor,0.5676470588235294
geopolitical entity,latency end process boundary,0.598936170212766
geopolitical entity,realizable entity,0.7833333333333333
geopolitical entity,pathologically immunosuppressed organism,0.6364406779661017
geopolitical entity,infectious structure host role,0.5724489795918367
geopolitical entity,COVID-19 incidence rate,0.6166666666666667
geopolitical entity,descriptive information content entity,0.6780701754385965
geopolitical entity,establishment of localization in human host,0.6112903225806451
geopolitical entity,acellular structure,0.6078947368421053
geopolitical entity,virulence factor,0.5928571428571429
geopolitical entity,incubation end process boundary,0.59
geopolitical entity,molecular entity,0.7642857142857143
geopolitical entity,immunosuppressed organism,0.5863636363636363
geopolitical entity,latency end temporal region,0.6239130434782608
geopolitical entity,infectious structure,0.6038461538461539
geopolitical entity,T cell receptor complex,0.5928571428571429
geopolitical entity,infectious structure host,0.5863636363636363
geopolitical entity,respiratory system disease,0.6055555555555556
geopolitical entity,organism population,0.6342105263157894
geopolitical entity,infectious structure generative stage,0.6285714285714286
geopolitical entity,susceptible organism,0.6551282051282051
geopolitical entity,organism substance,0.5851351351351352
geopolitical entity,anatomical entity,0.7833333333333333
geopolitical entity,COVID-19 mortality rate,0.6404761904761905
geopolitical entity,geopolitical entity,0.95
geopolitical entity,symptomatic infectious structure carrier,0.6194915254237288
geopolitical entity,designative information content entity,0.6780701754385965
geopolitical entity,immunodeficient organism,0.6127906976744186
geopolitical entity,infectious human pathogen,0.609090909090909
geopolitical entity,colonization of human,0.625
geopolitical entity,immaterial entity,0.7833333333333333
geopolitical entity,blood,0.5333333333333333
geopolitical entity,division of geopolitical entity,0.83
geopolitical entity,geographical feature,0.732051282051282
geopolitical entity,herd immunity to infectious organism,0.5954545454545455
geopolitical entity,action specification,0.6551282051282051
geopolitical entity,processed material,0.6121621621621621
geopolitical entity,quality,0.6423076923076922
geopolitical entity,infectious disease incidence rate,0.6038461538461539
geopolitical entity,organism,0.5981481481481481
geopolitical entity,establishment of a clinically abnormal colony,0.621875
geopolitical entity,adhesion factor,0.5676470588235294
geopolitical entity,material processing,0.6342105263157894
invasion factor,infection incidence rate profile,0.6414893617021277
invasion factor,SARS-CoV-2 incidence rate,0.625
invasion factor,virulence factor disposition,0.6825581395348838
invasion factor,pathogen portal of exit,0.6078947368421053
invasion factor,infectious disease incidence,0.6127906976744186
invasion factor,case isolation control strategy,0.6673913043478261
invasion factor,infectious agent host role,0.6695121951219513
invasion factor,macromolecular complex,0.5851351351351352
invasion factor,B cell receptor complex,0.581578947368421
invasion factor,passive immunization against infectious agent,0.6333333333333333
invasion factor,infection incidence rate,0.6551282051282051
invasion factor,infectious disease incidence proportion,0.6166666666666667
invasion factor,cidal agent disposition,0.6078947368421053
invasion factor,biological vehicle,0.5712121212121213
invasion factor,infection incidence proportion profile,0.6386792452830189
invasion factor,infectious agent colony,0.6605263157894737
invasion factor,SARS-CoV-2 incidence proportion,0.6021739130434782
invasion factor,invasion factor,0.95
invasion factor,infectious agent generative stage,0.6166666666666667
invasion factor,cidal agent,0.6423076923076922
invasion factor,pathogen vehicle,0.6112903225806451
invasion factor,COVID-19 incidence rate,0.6342105263157894
invasion factor,pathogen vehicle role,0.6166666666666667
invasion factor,asymptomatic infectious agent carrier,0.6230769230769231
invasion factor,infection incidence,0.6558823529411765
invasion factor,sterilizing immunity to infectious agent,0.6136363636363636
invasion factor,virulence factor,0.7725806451612902
invasion factor,COVID-19 incidence,0.6015151515151516
invasion factor,innate immunity to infectious agent,0.65
invasion factor,static agent disposition,0.6038461538461539
invasion factor,T cell receptor complex,0.581578947368421
invasion factor,infectious agent population,0.6642857142857143
invasion factor,leukocyte-mediated immunity to infectious agent,0.5951612903225807
invasion factor,humoral immunity to infectious agent,0.6264705882352941
invasion factor,passive immunity to infectious agent,0.6264705882352941
invasion factor,vaccination against infectious agent,0.6656862745098039
invasion factor,susceptibility to infectious agent,0.6132653061224489
invasion factor,invasion disposition,0.7642857142857143
invasion factor,acquired immunity to infectious agent,0.6230769230769231
invasion factor,complex infection,0.6375
invasion factor,COVID-19 disease incidence proportion,0.6038461538461539
invasion factor,biological vehicle role,0.581578947368421
invasion factor,infection incidence proportion,0.65
invasion factor,symptomatic infectious agent carrier,0.6068627450980393
invasion factor,intermediate host,0.6375
invasion factor,pathogen portal of exit site,0.5895348837209302
invasion factor,place closure control strategy,0.6055555555555556
invasion factor,intervention,0.6722222222222223
invasion factor,infection incidence profile,0.6404761904761905
invasion factor,intermediate host role,0.6391891891891892
invasion factor,SARS-CoV-2 incidence,0.5928571428571429
invasion factor,immunization against infectious agent,0.6615384615384616
invasion factor,pathogen portal of exit role,0.6127906976744186
invasion factor,infectious agent host,0.6722222222222223
invasion factor,geographical feature,0.65
invasion factor,infectious agent reservoir,0.6695121951219513
invasion factor,immunoglobulin complex,0.6391891891891892
invasion factor,action specification,0.7071428571428571
invasion factor,infectious disease incidence rate,0.6375
invasion factor,active immunization against infectious agent,0.6364406779661017
invasion factor,infectious agent,0.6758064516129032
invasion factor,establishment of a clinically abnormal colony,0.6
invasion factor,adhesion factor,0.85
invasion factor,drug susceptibility of infectious agent,0.5981481481481481
invasion factor,static agent,0.6351851851851852
endotoxin disposition,virostatic disposition,0.7988372093023256
endotoxin disposition,information content entity,0.6414893617021277
endotoxin disposition,zoonotic disposition,0.8402439024390245
endotoxin disposition,infectious disease mortality rate,0.6351851851851852
endotoxin disposition,infection incidence rate profile,0.619811320754717
endotoxin disposition,infectious structure aggregate,0.5676470588235294
endotoxin disposition,communicability end temporal region,0.6107142857142857
endotoxin disposition,geographical entity,0.6
endotoxin disposition,biological regulation,0.6404761904761905
endotoxin disposition,surveillance process,0.6207317073170732
endotoxin disposition,infection end temporal region,0.67
endotoxin disposition,vector control strategy,0.609090909090909
endotoxin disposition,SARS-CoV-2 incidence rate,0.558695652173913
endotoxin disposition,incubation end temporal region,0.6656862745098039
endotoxin disposition,resistant entity,0.6121621621621621
endotoxin disposition,virulence factor disposition,0.7765306122448979
endotoxin disposition,viral adhesion disposition,0.7691489361702127
endotoxin disposition,parasitostatic disposition,0.7691489361702127
endotoxin disposition,negative regulation of production,0.6537037037037037
endotoxin disposition,reverse zoonotic disposition,0.7969387755102041
endotoxin disposition,establishment of localization in host,0.6396551724137931
endotoxin disposition,disease surveillance objective specification,0.65
endotoxin disposition,case isolation control strategy,0.6230769230769231
endotoxin disposition,infectious agent host role,0.6414893617021277
endotoxin disposition,macromolecular complex,0.5430232558139535
endotoxin disposition,material entity,0.5888888888888889
endotoxin disposition,asymptomatic infectious structure carrier,0.5951612903225807
endotoxin disposition,architectual structure,0.5662790697674418
endotoxin disposition,quarantine control strategy,0.6166666666666667
endotoxin disposition,B cell receptor complex,0.5636363636363636
endotoxin disposition,infection incidence rate,0.6277777777777778
endotoxin disposition,colonized host,0.65
endotoxin disposition,virus host,0.6112903225806451
endotoxin disposition,entity,0.6351851851851852
endotoxin disposition,toxin disposition,0.8973684210526315
endotoxin disposition,cidal agent disposition,0.7909090909090909
endotoxin disposition,parasiticidal disposition,0.7543478260869566
endotoxin disposition,communicability end process boundary,0.6078947368421053
endotoxin disposition,directive information content entity,0.6254385964912281
endotoxin disposition,acellular structure aggregate,0.53
endotoxin disposition,transmissibility disposition,0.7357142857142857
endotoxin disposition,latency end process boundary,0.6336734693877552
endotoxin disposition,colonization of host,0.6451219512195122
endotoxin disposition,realizable entity,0.581578947368421
endotoxin disposition,endotoxin disposition,0.95
endotoxin disposition,vector surveillance,0.625
endotoxin disposition,negative regulation of establishment of localization,0.6280821917808219
endotoxin disposition,infectious structure host role,0.6264705882352941
endotoxin disposition,COVID-19 incidence rate,0.5863636363636363
endotoxin disposition,cytotoxin disposition,0.8785714285714286
endotoxin disposition,negative regulation of developmental process,0.5884615384615385
endotoxin disposition,host,0.57
endotoxin disposition,descriptive information content entity,0.6194915254237288
endotoxin disposition,negative regulation of replication,0.65
endotoxin disposition,establishment of localization in human host,0.621875
endotoxin disposition,acellular structure,0.55
endotoxin disposition,incubation end process boundary,0.6615384615384616
endotoxin disposition,collective pathogenic disposition,0.7462962962962962
endotoxin disposition,neurotoxin disposition,0.891860465116279
endotoxin disposition,dead-end host role,0.6551282051282051
endotoxin disposition,molecular entity,0.5851351351351352
endotoxin disposition,plan specification,0.6807692307692308
endotoxin disposition,definitive host role,0.6695121951219513
endotoxin disposition,latency end temporal region,0.6375
endotoxin disposition,infectious structure,0.5963414634146341
endotoxin disposition,collective disposition,0.7988372093023256
endotoxin disposition,static agent disposition,0.7833333333333333
endotoxin disposition,T cell receptor complex,0.5636363636363636
endotoxin disposition,infectious structure host,0.6239130434782608
endotoxin disposition,respiratory system disease,0.6202127659574468
endotoxin disposition,entry into host,0.7
endotoxin disposition,adhesion of symbiont to host,0.6336734693877552
endotoxin disposition,infectious disease control strategy,0.6285714285714286
endotoxin disposition,infectious structure generative stage,0.5706896551724138
endotoxin disposition,immunosuppressive disposition,0.75
endotoxin disposition,pathogenic disposition,0.7988372093023256
endotoxin disposition,toxin,0.6423076923076922
endotoxin disposition,entry into host through host barriers,0.6396551724137931
endotoxin disposition,infectious disposition,0.7988372093023256
endotoxin disposition,endotoxin,0.75
endotoxin disposition,bacteriostatic disposition,0.7904255319148936
endotoxin disposition,bactericidal disposition,0.7611111111111112
endotoxin disposition,pathogen host,0.6558823529411765
endotoxin disposition,invasion disposition,0.8158536585365854
endotoxin disposition,viricidal disposition,0.7595238095238095
endotoxin disposition,complex infection,0.6605263157894737
endotoxin disposition,intermediate host,0.6342105263157894
endotoxin disposition,anatomical entity,0.6342105263157894
endotoxin disposition,disposition,0.79375
endotoxin disposition,COVID-19 mortality rate,0.5863636363636363
endotoxin disposition,negative regulation of life-sustaining process,0.6141791044776119
endotoxin disposition,place closure control strategy,0.5872549019607843
endotoxin disposition,geopolitical entity,0.65
endotoxin disposition,adhesion disposition,0.8158536585365854
endotoxin disposition,symptomatic infectious structure carrier,0.5975409836065574
endotoxin disposition,primary infectious disposition,0.7441176470588234
endotoxin disposition,pathogen host role,0.6551282051282051
endotoxin disposition,designative information content entity,0.6364406779661017
endotoxin disposition,intermediate host role,0.636046511627907
endotoxin disposition,dead-end host,0.6558823529411765
endotoxin disposition,pathogen surveillance,0.6166666666666667
endotoxin disposition,host role,0.5833333333333334
endotoxin disposition,establishment of localization in virus host,0.653125
endotoxin disposition,negative regulation of immune response,0.6194915254237288
endotoxin disposition,immaterial entity,0.581578947368421
endotoxin disposition,SARS-COV-2 adhesion disposition,0.7384615384615384
endotoxin disposition,invasive disposition,0.7914634146341464
endotoxin disposition,infectious agent host,0.6404761904761905
endotoxin disposition,fungicidal disposition,0.7755813953488372
endotoxin disposition,division of geopolitical entity,0.6423076923076922
endotoxin disposition,negative regulation of viral process,0.6078947368421053
endotoxin disposition,exotoxin disposition,0.9134146341463415
endotoxin disposition,immunoglobulin complex,0.6127906976744186
endotoxin disposition,infectious disease control objective specification,0.6471830985915493
endotoxin disposition,symbiont host role,0.6294871794871795
endotoxin disposition,opportunistic infectious disposition,0.730701754385965
endotoxin disposition,negative regulation of biological process,0.5951612903225807
endotoxin disposition,enterotoxin disposition,0.9045454545454545
endotoxin disposition,infectious disease incidence rate,0.6537037037037037
endotoxin disposition,collective resistance disposition,0.7462962962962962
endotoxin disposition,fungistatic disposition,0.7909090909090909
endotoxin disposition,establishment of a clinically abnormal colony,0.6015151515151516
endotoxin disposition,definitive host,0.6722222222222223
disordered prion,vector control strategy,0.5782051282051281
disordered prion,prion replication,0.6924242424242425
disordered prion,case isolation control strategy,0.5776595744680851
disordered prion,quarantine control strategy,0.5662790697674418
disordered prion,B cell receptor complex,0.6038461538461539
disordered prion,lower respiratory tract disease,0.598936170212766
disordered prion,infectious disorder,0.6785714285714286
disordered prion,appearance of disorder,0.6605263157894737
disordered prion,virus disorder,0.7166666666666667
disordered prion,SARS-CoV-2 disorder,0.6785714285714286
disordered prion,T cell receptor complex,0.6038461538461539
disordered prion,infectious disease control strategy,0.6068627450980393
disordered prion,disordered prion,0.95
disordered prion,prion aggregate,0.6112903225806451
disordered prion,place closure control strategy,0.5804347826086956
disordered prion,coronavirus disorder,0.6722222222222223
disordered prion,disorder,0.7833333333333333
disordered prion,infectious disease control objective specification,0.6318181818181818
disordered prion,disordered virus,0.825
disordered prion,establishment of a clinically abnormal colony,0.5647540983606557
disordered prion,prion,0.6880952380952381
reservoir of pathogen role,extended organism,0.5895348837209302
reservoir of pathogen role,virus aggregate,0.6451219512195122
reservoir of pathogen role,source of infection,0.6722222222222223
reservoir of pathogen role,infectious disease mortality rate,0.6194915254237288
reservoir of pathogen role,infection incidence rate profile,0.656896551724138
reservoir of pathogen role,communicability end temporal region,0.6139344262295081
reservoir of pathogen role,pathogen generative stage,0.6656862745098039
reservoir of pathogen role,pathogen portal of entry,0.69
reservoir of pathogen role,subclinical coronavirus infection,0.6194915254237288
reservoir of pathogen role,primary pathogen,0.7357142857142857
reservoir of pathogen role,infection end temporal region,0.6318181818181818
reservoir of pathogen role,drug-based immunosuppressed organism,0.5951612903225807
reservoir of pathogen role,infectious disease,0.5863636363636363
reservoir of pathogen role,double-stranded DNA virus,0.6068627450980393
reservoir of pathogen role,incubation end temporal region,0.6285714285714286
reservoir of pathogen role,site of infection,0.6593023255813953
reservoir of pathogen role,immunocompetent organism,0.61
reservoir of pathogen role,pathogen portal of exit,0.6948979591836735
reservoir of pathogen role,infectious disease incidence,0.5981481481481481
reservoir of pathogen role,reservoir of pathogen role,0.95
reservoir of pathogen role,subclinical SARS-CoV-2 infection,0.5879310344827586
reservoir of pathogen role,virus translation stage,0.6540816326530612
reservoir of pathogen role,disease surveillance objective specification,0.65
reservoir of pathogen role,virus release stage,0.6277777777777778
reservoir of pathogen role,infectious agent host role,0.7
reservoir of pathogen role,source of infection site,0.69
reservoir of pathogen role,virus,0.5467741935483871
reservoir of pathogen role,virus replication,0.6593023255813953
reservoir of pathogen role,B cell receptor complex,0.6540816326530612
reservoir of pathogen role,passive immunization against infectious agent,0.6049295774647887
reservoir of pathogen role,systematic infection,0.6239130434782608
reservoir of pathogen role,infection incidence rate,0.63
reservoir of pathogen role,virus host,0.6166666666666667
reservoir of pathogen role,double-stranded RNA virus,0.6068627450980393
reservoir of pathogen role,pathogen portal of entry role,0.7045454545454546
reservoir of pathogen role,virus transcription stage,0.6460784313725491
reservoir of pathogen role,infectious disease lifetime prevalence,0.621875
reservoir of pathogen role,pathogen birth temporal region,0.6821428571428573
reservoir of pathogen role,lower respiratory tract disease,0.6429824561403508
reservoir of pathogen role,infectious disease incidence proportion,0.6038461538461539
reservoir of pathogen role,opportunistic pathogen,0.7
reservoir of pathogen role,virus generative stage,0.6375
reservoir of pathogen role,acute infectious disease course,0.6254385964912281
reservoir of pathogen role,cidal agent disposition,0.6132653061224489
reservoir of pathogen role,role,0.5833333333333334
reservoir of pathogen role,genetic resistance to pathogen,0.7178571428571427
reservoir of pathogen role,subclinical infection,0.598936170212766
reservoir of pathogen role,appearance of disorder,0.6375
reservoir of pathogen role,simple infection,0.6166666666666667
reservoir of pathogen role,droplet pathogen transmission process,0.6880952380952381
reservoir of pathogen role,infectious disease sporadicity,0.5928571428571429
reservoir of pathogen role,mutualist role,0.625
reservoir of pathogen role,communicability end process boundary,0.6112903225806451
reservoir of pathogen role,infection incidence proportion profile,0.66875
reservoir of pathogen role,infectious agent colony,0.6744897959183673
reservoir of pathogen role,pathogen transporter,0.7108695652173913
reservoir of pathogen role,latency end process boundary,0.5981481481481481
reservoir of pathogen role,infectious disease epidemic,0.6009433962264151
reservoir of pathogen role,infectious agent generative stage,0.6364406779661017
reservoir of pathogen role,disease transmission model,0.6423076923076922
reservoir of pathogen role,pathologically immunosuppressed organism,0.5863636363636363
reservoir of pathogen role,negative-sense single-stranded RNA virus,0.6015151515151516
reservoir of pathogen role,cidal agent,0.6121621621621621
reservoir of pathogen role,infectious structure host role,0.6642857142857143
reservoir of pathogen role,pathogen vehicle,0.7119047619047619
reservoir of pathogen role,community-acquired infection,0.5981481481481481
reservoir of pathogen role,pathogen vector,0.6939024390243902
reservoir of pathogen role,pathogen vehicle role,0.7265957446808511
reservoir of pathogen role,chronic infectious disease course,0.6364406779661017
reservoir of pathogen role,asymptomatic infectious agent carrier,0.6563492063492063
reservoir of pathogen role,nursing-home acquired infection,0.6254385964912281
reservoir of pathogen role,secondary infection,0.65
reservoir of pathogen role,mechanical vector role,0.6583333333333334
reservoir of pathogen role,infection start temporal region,0.6254385964912281
reservoir of pathogen role,infection incidence,0.6055555555555556
reservoir of pathogen role,virus disorder,0.625
reservoir of pathogen role,sterilizing immunity to infectious agent,0.6318181818181818
reservoir of pathogen role,primary infection,0.636046511627907
reservoir of pathogen role,process of establishing an infection,0.6596774193548387
reservoir of pathogen role,incubation end process boundary,0.6254385964912281
reservoir of pathogen role,dead-end host role,0.6772727272727272
reservoir of pathogen role,pathogen death process boundary,0.6605263157894737
reservoir of pathogen role,immunosuppressed organism,0.6068627450980393
reservoir of pathogen role,definitive host role,0.6673913043478261
reservoir of pathogen role,latency end temporal region,0.6009433962264151
reservoir of pathogen role,innate immunity to infectious agent,0.6139344262295081
reservoir of pathogen role,virus adhesion susceptible cell,0.6429824561403508
reservoir of pathogen role,infection,0.5928571428571429
reservoir of pathogen role,static agent disposition,0.63
reservoir of pathogen role,T cell receptor complex,0.6540816326530612
reservoir of pathogen role,asymptomatic carrier role,0.6656862745098039
reservoir of pathogen role,infectious agent population,0.6575471698113208
reservoir of pathogen role,respiratory system disease,0.6615384615384616
reservoir of pathogen role,leukocyte-mediated immunity to infectious agent,0.6006849315068493
reservoir of pathogen role,indirect pathogen transmission process,0.684375
reservoir of pathogen role,organism population,0.65
reservoir of pathogen role,humoral immunity to infectious agent,0.6112903225806451
reservoir of pathogen role,infectious disease control strategy,0.630327868852459
reservoir of pathogen role,parasite,0.5970588235294118
reservoir of pathogen role,infectious disease pandemic,0.6009433962264151
reservoir of pathogen role,antibody reagent,0.6166666666666667
reservoir of pathogen role,viral disease course,0.6456521739130434
reservoir of pathogen role,intracellular infection,0.6132653061224489
reservoir of pathogen role,secondary infection role,0.73
reservoir of pathogen role,metastatic infection,0.6239130434782608
reservoir of pathogen role,passive immunity to infectious agent,0.6274193548387097
reservoir of pathogen role,vaccination against infectious agent,0.6112903225806451
reservoir of pathogen role,acute infection,0.5963414634146341
reservoir of pathogen role,susceptibility to infectious agent,0.6333333333333333
reservoir of pathogen role,epitope site,0.6342105263157894
reservoir of pathogen role,immunity to pathogen,0.7108695652173913
reservoir of pathogen role,source of infection role,0.75
reservoir of pathogen role,pathogen host,0.7064102564102563
reservoir of pathogen role,chronic infection,0.636046511627907
reservoir of pathogen role,disease course,0.625
reservoir of pathogen role,infectious disease course,0.6264705882352941
reservoir of pathogen role,acquired immunity to infectious agent,0.6246031746031746
reservoir of pathogen role,complex infection,0.5895348837209302
reservoir of pathogen role,COVID-19 disease incidence proportion,0.6087301587301588
reservoir of pathogen role,coronavirus disease course,0.6423076923076922
reservoir of pathogen role,biological vehicle role,0.6540816326530612
reservoir of pathogen role,infection incidence proportion,0.6107142857142857
reservoir of pathogen role,symptomatic infectious agent carrier,0.6596774193548387
reservoir of pathogen role,respiratory droplet virus fomite,0.6913793103448276
reservoir of pathogen role,symbiont role,0.6807692307692308
reservoir of pathogen role,susceptible organism,0.6021739130434782
reservoir of pathogen role,parasite role,0.7064102564102563
reservoir of pathogen role,pathogen vector role,0.7326086956521739
reservoir of pathogen role,pathogen portal of exit site,0.6722222222222223
reservoir of pathogen role,infectious disease prevalence,0.6318181818181818
reservoir of pathogen role,organism substance,0.5863636363636363
reservoir of pathogen role,single-stranded DNA virus,0.6068627450980393
reservoir of pathogen role,viral disease,0.6038461538461539
reservoir of pathogen role,primary infection role,0.7208333333333333
reservoir of pathogen role,biological role,0.6695121951219513
reservoir of pathogen role,pathogen portal of entry site,0.6681818181818181
reservoir of pathogen role,infection incidence profile,0.6575471698113208
reservoir of pathogen role,disease,0.5712121212121213
reservoir of pathogen role,biological vector role,0.6583333333333334
reservoir of pathogen role,site,0.5833333333333334
reservoir of pathogen role,pathogen host role,0.7454545454545455
reservoir of pathogen role,infection prevalence,0.6456521739130434
reservoir of pathogen role,symptomatic carrier role,0.67
reservoir of pathogen role,infectious pathogen transmissibility,0.6919354838709677
reservoir of pathogen role,intermediate host role,0.7
reservoir of pathogen role,pathogen surveillance,0.7053191489361703
reservoir of pathogen role,immunodeficient organism,0.59
reservoir of pathogen role,host role,0.65
reservoir of pathogen role,pathogen,0.6852941176470588
reservoir of pathogen role,pathogen birth process boundary,0.6605263157894737
reservoir of pathogen role,infectious human pathogen,0.6852941176470588
reservoir of pathogen role,subclinical virus infection,0.619811320754717
reservoir of pathogen role,resistance to pathogen,0.7625
reservoir of pathogen role,establishment of localization in virus host,0.6528985507246376
reservoir of pathogen role,immunization against infectious agent,0.5928571428571429
reservoir of pathogen role,virus attachment stage,0.6791666666666666
reservoir of pathogen role,virus synthesis stage,0.6414893617021277
reservoir of pathogen role,pathogen portal of exit role,0.6907407407407408
reservoir of pathogen role,infectious agent host,0.6627659574468084
reservoir of pathogen role,re-emerging pathogen,0.7543478260869566
reservoir of pathogen role,long-term non-progressing infectious disease course,0.6058441558441559
reservoir of pathogen role,viral disease epidemic,0.6166666666666667
reservoir of pathogen role,commensal role,0.65
reservoir of pathogen role,epitope role,0.7131578947368421
reservoir of pathogen role,viral disease pandemic,0.6375
reservoir of pathogen role,virus penetration stage,0.6744897959183673
reservoir of pathogen role,pathogen seroprevalence,0.7153061224489795
reservoir of pathogen role,infectious disease endemicity,0.5954545454545455
reservoir of pathogen role,contact pathogen transmission process,0.6722222222222223
reservoir of pathogen role,function,0.5676470588235294
reservoir of pathogen role,herd immunity to infectious organism,0.6112903225806451
reservoir of pathogen role,extracellular infection,0.6132653061224489
reservoir of pathogen role,pathogen transporter role,0.7049019607843137
reservoir of pathogen role,infectious agent reservoir,0.6615384615384616
reservoir of pathogen role,antigen role,0.7131578947368421
reservoir of pathogen role,infection start process boundary,0.6224137931034482
reservoir of pathogen role,action specification,0.6239130434782608
reservoir of pathogen role,infectious disease control objective specification,0.6210526315789474
reservoir of pathogen role,symbiont host role,0.7
reservoir of pathogen role,fomite role,0.6932432432432433
reservoir of pathogen role,process of establishing viral infection,0.6653846153846155
reservoir of pathogen role,COVID-19 disease course,0.6132653061224489
reservoir of pathogen role,infectious disease incidence rate,0.6194915254237288
reservoir of pathogen role,active immunization against infectious agent,0.5928571428571429
reservoir of pathogen role,disordered virus,0.5928571428571429
reservoir of pathogen role,reagent role,0.7394736842105263
reservoir of pathogen role,viral load,0.6166666666666667
reservoir of pathogen role,organism,0.5676470588235294
reservoir of pathogen role,virus uncoating stage,0.6627659574468084
reservoir of pathogen role,local infection,0.5963414634146341
reservoir of pathogen role,infectious agent,0.6404761904761905
reservoir of pathogen role,establishment of a clinically abnormal colony,0.6330985915492958
reservoir of pathogen role,coronavirus disease,0.6055555555555556
reservoir of pathogen role,positive-sense single-stranded RNA virus,0.6015151515151516
reservoir of pathogen role,horizontal pathogen transmission process,0.6924242424242425
reservoir of pathogen role,hospital-acquired infection,0.6009433962264151
reservoir of pathogen role,pathogen death temporal region,0.6642857142857143
reservoir of pathogen role,emerging pathogen,0.7523255813953489
reservoir of pathogen role,drug susceptibility of infectious agent,0.65
reservoir of pathogen role,static agent,0.6342105263157894
reservoir of pathogen role,pathogen transmission process,0.6681818181818181
active immunization against infectious agent,information content entity,0.6785714285714286
active immunization against infectious agent,infectious disease mortality rate,0.6318181818181818
active immunization against infectious agent,infection incidence rate profile,0.6473684210526315
active immunization against infectious agent,infectious structure aggregate,0.6662162162162162
active immunization against infectious agent,communicability end temporal region,0.6651898734177215
active immunization against infectious agent,surveillance process,0.575
active immunization against infectious agent,infection end temporal region,0.6417808219178082
active immunization against infectious agent,infectious disease,0.6596774193548387
active immunization against infectious agent,SARS-CoV-2 incidence rate,0.6239130434782608
active immunization against infectious agent,incubation end temporal region,0.6527027027027027
active immunization against infectious agent,virulence factor disposition,0.6583333333333334
active immunization against infectious agent,infectious disease incidence,0.6583333333333334
active immunization against infectious agent,disease surveillance objective specification,0.6431818181818181
active immunization against infectious agent,infectious agent host role,0.6785714285714286
active immunization against infectious agent,asymptomatic infectious structure carrier,0.6852941176470588
active immunization against infectious agent,B cell receptor complex,0.5843283582089552
active immunization against infectious agent,passive immunization against infectious agent,0.9219101123595504
active immunization against infectious agent,infection incidence rate,0.6705882352941177
active immunization against infectious agent,infectious disease lifetime prevalence,0.6695121951219513
active immunization against infectious agent,lower respiratory tract disease,0.6366666666666667
active immunization against infectious agent,infectious disease incidence proportion,0.6548192771084337
active immunization against infectious agent,acute infectious disease course,0.7033333333333335
active immunization against infectious agent,cidal agent disposition,0.658955223880597
active immunization against infectious agent,infectious disorder,0.6404761904761905
active immunization against infectious agent,process,0.5284313725490196
active immunization against infectious agent,biological vehicle,0.5790322580645162
active immunization against infectious agent,droplet pathogen transmission process,0.6351851851851852
active immunization against infectious agent,infectious disease sporadicity,0.6391891891891892
active immunization against infectious agent,communicability end process boundary,0.65
active immunization against infectious agent,directive information content entity,0.725
active immunization against infectious agent,infectious agent colony,0.6888059701492537
active immunization against infectious agent,pathogen transporter,0.60625
active immunization against infectious agent,invasion factor,0.6364406779661017
active immunization against infectious agent,latency end process boundary,0.6027777777777777
active immunization against infectious agent,infectious disease epidemic,0.6330985915492958
active immunization against infectious agent,infectious agent generative stage,0.6967532467532468
active immunization against infectious agent,disease transmission model,0.6214285714285714
active immunization against infectious agent,cidal agent,0.6136363636363636
active immunization against infectious agent,infectious structure host role,0.6391891891891892
active immunization against infectious agent,pathogen vehicle,0.6
active immunization against infectious agent,COVID-19 incidence rate,0.6291044776119403
active immunization against infectious agent,negative regulation of developmental process,0.6659090909090909
active immunization against infectious agent,pathogen vehicle role,0.6038461538461539
active immunization against infectious agent,chronic infectious disease course,0.6837662337662337
active immunization against infectious agent,asymptomatic infectious agent carrier,0.7339506172839506
active immunization against infectious agent,descriptive information content entity,0.7182926829268292
active immunization against infectious agent,COVID-19 epidemic,0.5647540983606557
active immunization against infectious agent,sterilizing immunity to infectious agent,0.7952380952380952
active immunization against infectious agent,diseased population,0.5928571428571429
active immunization against infectious agent,virulence factor,0.6
active immunization against infectious agent,process of establishing an infection,0.6875
active immunization against infectious agent,incubation end process boundary,0.6366666666666667
active immunization against infectious agent,pathogen death process boundary,0.61
active immunization against infectious agent,latency end temporal region,0.6330985915492958
active immunization against infectious agent,innate immunity to infectious agent,0.829746835443038
active immunization against infectious agent,infectious structure,0.6375
active immunization against infectious agent,static agent disposition,0.6705882352941177
active immunization against infectious agent,T cell receptor complex,0.5843283582089552
active immunization against infectious agent,asymptomatic carrier role,0.6239130434782608
active immunization against infectious agent,infectious structure host,0.6384057971014493
active immunization against infectious agent,infectious agent population,0.6753521126760563
active immunization against infectious agent,respiratory system disease,0.6357142857142857
active immunization against infectious agent,leukocyte-mediated immunity to infectious agent,0.7906593406593407
active immunization against infectious agent,indirect pathogen transmission process,0.6451219512195122
active immunization against infectious agent,planned process,0.5516949152542373
active immunization against infectious agent,humoral immunity to infectious agent,0.8
active immunization against infectious agent,infectious disease control strategy,0.639873417721519
active immunization against infectious agent,infectious disease pandemic,0.6471830985915493
active immunization against infectious agent,infectious structure generative stage,0.6598765432098764
active immunization against infectious agent,viral disease course,0.6375
active immunization against infectious agent,passive immunity to infectious agent,0.8375
active immunization against infectious agent,infectious disposition,0.6469696969696969
active immunization against infectious agent,vaccination against infectious agent,0.875
active immunization against infectious agent,acute infection,0.6872881355932203
active immunization against infectious agent,susceptibility to infectious agent,0.7705128205128204
active immunization against infectious agent,disease course,0.6224137931034482
active immunization against infectious agent,infectious disease course,0.6528985507246376
active immunization against infectious agent,acquired immunity to infectious agent,0.8327160493827159
active immunization against infectious agent,COVID-19 disease incidence proportion,0.6351851851851852
active immunization against infectious agent,coronavirus disease course,0.65
active immunization against infectious agent,asymptomatic carrier,0.621875
active immunization against infectious agent,biological vehicle role,0.5843283582089552
active immunization against infectious agent,symptomatic infectious agent carrier,0.725
active immunization against infectious agent,intermediate host,0.6139344262295081
active immunization against infectious agent,infectious disease prevalence,0.6417808219178082
active immunization against infectious agent,infected population,0.6087301587301588
active immunization against infectious agent,COVID-19 mortality rate,0.6141791044776119
active immunization against infectious agent,process profile,0.5686440677966101
active immunization against infectious agent,negative regulation of life-sustaining process,0.6944444444444444
active immunization against infectious agent,viral disease,0.6078947368421053
active immunization against infectious agent,developmental process,0.5884615384615385
active immunization against infectious agent,disease,0.5480392156862746
active immunization against infectious agent,biological process,0.5629032258064516
active immunization against infectious agent,symptomatic infectious structure carrier,0.6761904761904762
active immunization against infectious agent,primary infectious disposition,0.6662162162162162
active immunization against infectious agent,designative information content entity,0.7182926829268292
active immunization against infectious agent,symptomatic carrier role,0.6117647058823529
active immunization against infectious agent,infectious pathogen transmissibility,0.65
active immunization against infectious agent,incubation start process boundary,0.6448051948051949
active immunization against infectious agent,intermediate host role,0.6318181818181818
active immunization against infectious agent,pathogen birth process boundary,0.61
active immunization against infectious agent,infectious human pathogen,0.6673913043478261
active immunization against infectious agent,immunization against infectious agent,0.9067901234567901
active immunization against infectious agent,infectious agent host,0.6961538461538461
active immunization against infectious agent,long-term non-progressing infectious disease course,0.6921052631578948
active immunization against infectious agent,viral disease epidemic,0.6015151515151516
active immunization against infectious agent,viral disease pandemic,0.6166666666666667
active immunization against infectious agent,acute respiratory distress syndrome,0.6651898734177215
active immunization against infectious agent,symptomatic carrier,0.6087301587301588
active immunization against infectious agent,infectious disease endemicity,0.6554794520547945
active immunization against infectious agent,negative regulation of viral process,0.6625
active immunization against infectious agent,contact pathogen transmission process,0.6598765432098764
active immunization against infectious agent,function,0.5846153846153846
active immunization against infectious agent,herd immunity to infectious organism,0.7625
active immunization against infectious agent,pathogen transporter role,0.6239130434782608
active immunization against infectious agent,symbiotic process,0.5811475409836065
active immunization against infectious agent,infectious agent reservoir,0.6785714285714286
active immunization against infectious agent,COVID-19 pandemic,0.5811475409836065
active immunization against infectious agent,infection start process boundary,0.6342105263157894
active immunization against infectious agent,action specification,0.684375
active immunization against infectious agent,latency start process boundary,0.6121621621621621
active immunization against infectious agent,infectious disease control objective specification,0.6414893617021277
active immunization against infectious agent,opportunistic infectious disposition,0.6875
active immunization against infectious agent,process of establishing viral infection,0.6668674698795181
active immunization against infectious agent,negative regulation of biological process,0.6617647058823529
active immunization against infectious agent,polymerase chain reaction,0.6384057971014493
active immunization against infectious agent,COVID-19 disease course,0.6291044776119403
active immunization against infectious agent,infectious disease incidence rate,0.6577922077922078
active immunization against infectious agent,communicability start process boundary,0.6451219512195122
active immunization against infectious agent,process that results in death,0.6417808219178082
active immunization against infectious agent,active immunization against infectious agent,0.95
active immunization against infectious agent,infectious agent,0.7166666666666667
active immunization against infectious agent,establishment of a clinically abnormal colony,0.6185393258426967
active immunization against infectious agent,process boundary,0.5666666666666667
active immunization against infectious agent,coronavirus disease,0.6246031746031746
active immunization against infectious agent,adhesion factor,0.6194915254237288
active immunization against infectious agent,horizontal pathogen transmission process,0.6285714285714286
active immunization against infectious agent,drug susceptibility of infectious agent,0.739156626506024
active immunization against infectious agent,static agent,0.6464285714285714
active immunization against infectious agent,pathogen transmission process,0.6280821917808219
immunocompetent organism,extended organism,0.7670731707317073
immunocompetent organism,information content entity,0.69
immunocompetent organism,infectious structure aggregate,0.6351851851851852
immunocompetent organism,geographical entity,0.5895348837209302
immunocompetent organism,drug-based immunosuppressed organism,0.75
immunocompetent organism,resistant entity,0.625
immunocompetent organism,immunocompetent organism,0.95
immunocompetent organism,virulence factor disposition,0.6423076923076922
immunocompetent organism,case isolation control strategy,0.6136363636363636
immunocompetent organism,material entity,0.6294871794871795
immunocompetent organism,asymptomatic infectious structure carrier,0.6038461538461539
immunocompetent organism,architectual structure,0.5804347826086956
immunocompetent organism,B cell receptor complex,0.598936170212766
immunocompetent organism,entity,0.5833333333333334
immunocompetent organism,directive information content entity,0.65
immunocompetent organism,acellular structure aggregate,0.6009433962264151
immunocompetent organism,invasion factor,0.6294871794871795
immunocompetent organism,realizable entity,0.5963414634146341
immunocompetent organism,pathologically immunosuppressed organism,0.73125
immunocompetent organism,infectious structure host role,0.6166666666666667
immunocompetent organism,descriptive information content entity,0.6435483870967742
immunocompetent organism,establishment of localization in human host,0.6141791044776119
immunocompetent organism,acellular structure,0.5662790697674418
immunocompetent organism,virulence factor,0.65
immunocompetent organism,molecular entity,0.625
immunocompetent organism,immunosuppressed organism,0.8173469387755102
immunocompetent organism,plan specification,0.5928571428571429
immunocompetent organism,infectious structure,0.609090909090909
immunocompetent organism,T cell receptor complex,0.598936170212766
immunocompetent organism,infectious structure host,0.6336734693877552
immunocompetent organism,organism population,0.636046511627907
immunocompetent organism,infectious structure generative stage,0.630327868852459
immunocompetent organism,susceptible organism,0.7681818181818181
immunocompetent organism,organism substance,0.6404761904761905
immunocompetent organism,anatomical entity,0.6207317073170732
immunocompetent organism,geopolitical entity,0.6127906976744186
immunocompetent organism,symptomatic infectious structure carrier,0.60625
immunocompetent organism,designative information content entity,0.6435483870967742
immunocompetent organism,immunodeficient organism,0.8458333333333333
immunocompetent organism,infectious human pathogen,0.6540816326530612
immunocompetent organism,colonization of human,0.6277777777777778
immunocompetent organism,immaterial entity,0.6695121951219513
immunocompetent organism,blood,0.5189655172413793
immunocompetent organism,division of geopolitical entity,0.6318181818181818
immunocompetent organism,geographical feature,0.5636363636363636
immunocompetent organism,herd immunity to infectious organism,0.7333333333333333
immunocompetent organism,action specification,0.609090909090909
immunocompetent organism,processed material,0.6166666666666667
immunocompetent organism,organism,0.7
immunocompetent organism,establishment of a clinically abnormal colony,0.6094202898550725
immunocompetent organism,adhesion factor,0.6038461538461539
immunocompetent organism,material processing,0.5895348837209302
normal resident microbiota population,angiotensin-converting enzyme 2,0.6117647058823529
normal resident microbiota population,infectious disease mortality rate,0.65
normal resident microbiota population,infection incidence rate profile,0.6528985507246376
normal resident microbiota population,communicability end temporal region,0.6583333333333334
normal resident microbiota population,biological regulation,0.6741379310344828
normal resident microbiota population,infection end temporal region,0.6469696969696969
normal resident microbiota population,SARS-CoV-2 incidence rate,0.6274193548387097
normal resident microbiota population,incubation end temporal region,0.6440298507462687
normal resident microbiota population,normal resident microbiota population,0.95
normal resident microbiota population,reservoir of pathogen role,0.6722222222222223
normal resident microbiota population,negative regulation of production,0.6928571428571427
normal resident microbiota population,infectious agent host role,0.6404761904761905
normal resident microbiota population,material entity,0.6230769230769231
normal resident microbiota population,B cell receptor complex,0.6333333333333333
normal resident microbiota population,infection incidence rate,0.630327868852459
normal resident microbiota population,double-stranded RNA virus,0.6274193548387097
normal resident microbiota population,pathogen portal of entry role,0.6469696969696969
normal resident microbiota population,lower respiratory tract disease,0.6411764705882353
normal resident microbiota population,acute infectious disease course,0.6264705882352941
normal resident microbiota population,role,0.523170731707317
normal resident microbiota population,genetic resistance to pathogen,0.6888059701492537
normal resident microbiota population,mutualist role,0.6264705882352941
normal resident microbiota population,communicability end process boundary,0.6417808219178082
normal resident microbiota population,latency end process boundary,0.6192307692307693
normal resident microbiota population,negative regulation of establishment of localization,0.6747191011235956
normal resident microbiota population,negative-sense single-stranded RNA virus,0.6188311688311688
normal resident microbiota population,infectious structure host role,0.6291044776119403
normal resident microbiota population,susceptible population,0.7211864406779661
normal resident microbiota population,COVID-19 incidence rate,0.6166666666666667
normal resident microbiota population,negative regulation of developmental process,0.6351851851851852
normal resident microbiota population,pathogen vehicle role,0.6051724137931035
normal resident microbiota population,chronic infectious disease course,0.6214285714285714
normal resident microbiota population,negative regulation of replication,0.6894366197183097
normal resident microbiota population,mechanical vector role,0.6194915254237288
normal resident microbiota population,establishment of localization in human host,0.65
normal resident microbiota population,diseased population,0.7
normal resident microbiota population,incubation end process boundary,0.6264705882352941
normal resident microbiota population,dead-end host role,0.6318181818181818
normal resident microbiota population,definitive host role,0.6254385964912281
normal resident microbiota population,latency end temporal region,0.6375
normal resident microbiota population,innate immunity to infectious agent,0.6444444444444444
normal resident microbiota population,T cell receptor complex,0.6333333333333333
normal resident microbiota population,asymptomatic carrier role,0.6274193548387097
normal resident microbiota population,infectious agent population,0.715625
normal resident microbiota population,organism population,0.7357142857142857
normal resident microbiota population,innate immune response,0.6194915254237288
normal resident microbiota population,viral disease course,0.6429824561403508
normal resident microbiota population,secondary infection role,0.630327868852459
normal resident microbiota population,country,0.5409090909090909
normal resident microbiota population,source of infection role,0.630327868852459
normal resident microbiota population,chronic infection,0.6166666666666667
normal resident microbiota population,disease course,0.5872549019607843
normal resident microbiota population,infectious disease course,0.6112903225806451
normal resident microbiota population,coronavirus disease course,0.6246031746031746
normal resident microbiota population,biological vehicle role,0.6333333333333333
normal resident microbiota population,symptomatic infectious agent carrier,0.6280821917808219
normal resident microbiota population,symbiont role,0.63
normal resident microbiota population,parasite role,0.63
normal resident microbiota population,pathogen vector role,0.6078947368421053
normal resident microbiota population,infected population,0.7178571428571427
normal resident microbiota population,COVID-19 mortality rate,0.6333333333333333
normal resident microbiota population,negative regulation of life-sustaining process,0.6307228915662652
normal resident microbiota population,place closure control strategy,0.6291044776119403
normal resident microbiota population,primary infection role,0.6533898305084747
normal resident microbiota population,biological role,0.6038461538461539
normal resident microbiota population,symptomatic infectious structure carrier,0.6188311688311688
normal resident microbiota population,biological vector role,0.6194915254237288
normal resident microbiota population,pathogen host role,0.6136363636363636
normal resident microbiota population,symptomatic carrier role,0.630327868852459
normal resident microbiota population,intermediate host role,0.6533898305084747
normal resident microbiota population,host role,0.6021739130434782
normal resident microbiota population,infectious human pathogen,0.6435483870967742
normal resident microbiota population,colonization of human,0.6396551724137931
normal resident microbiota population,negative regulation of immune response,0.6366666666666667
normal resident microbiota population,pathogen portal of exit role,0.65
normal resident microbiota population,long-term non-progressing infectious disease course,0.6545454545454545
normal resident microbiota population,commensal role,0.6068627450980393
normal resident microbiota population,epitope role,0.5928571428571429
normal resident microbiota population,symptomatic carrier,0.6107142857142857
normal resident microbiota population,negative regulation of viral process,0.6417808219178082
normal resident microbiota population,herd immunity to infectious organism,0.6417808219178082
normal resident microbiota population,pathogen transporter role,0.6112903225806451
normal resident microbiota population,antigen role,0.6132653061224489
normal resident microbiota population,processed material,0.6318181818181818
normal resident microbiota population,symbiont host role,0.6318181818181818
normal resident microbiota population,immune population,0.6907407407407408
normal resident microbiota population,fomite role,0.6166666666666667
normal resident microbiota population,negative regulation of biological process,0.6551282051282051
normal resident microbiota population,COVID-19 disease course,0.6
normal resident microbiota population,infectious disease incidence rate,0.6357142857142857
normal resident microbiota population,single-stranded RNA retrovirus,0.6291044776119403
normal resident microbiota population,symptom,0.5636363636363636
normal resident microbiota population,reagent role,0.6336734693877552
normal resident microbiota population,local infection,0.6615384615384616
normal resident microbiota population,establishment of a clinically abnormal colony,0.6573170731707317
normal resident microbiota population,positive-sense single-stranded RNA virus,0.6058441558441559
normal resident microbiota population,material processing,0.6464285714285714
sputum,B cell receptor complex,0.553448275862069
sputum,T cell receptor complex,0.553448275862069
sputum,sputum,0.95
sputum,establishment of a clinically abnormal colony,0.5088235294117647
virion,virion,0.95
algorithm,communicability end temporal region,0.5636363636363636
algorithm,surveillance process,0.5189655172413793
algorithm,infection end temporal region,0.5552631578947369
algorithm,incubation end temporal region,0.5525641025641026
algorithm,B cell receptor complex,0.575
algorithm,process,0.5125
algorithm,droplet pathogen transmission process,0.5369565217391304
algorithm,communicability end process boundary,0.5388888888888889
algorithm,latency end process boundary,0.5310810810810811
algorithm,negative regulation of developmental process,0.5254716981132076
algorithm,process of establishing an infection,0.5611111111111111
algorithm,incubation end process boundary,0.525
algorithm,pathogen death process boundary,0.55
algorithm,latency end temporal region,0.5611111111111111
algorithm,T cell receptor complex,0.575
algorithm,indirect pathogen transmission process,0.5351063829787234
algorithm,planned process,0.5333333333333333
algorithm,process profile,0.575
algorithm,negative regulation of life-sustaining process,0.5409090909090909
algorithm,developmental process,0.55
algorithm,biological process,0.5611111111111111
algorithm,incubation start process boundary,0.5452380952380953
algorithm,pathogen birth process boundary,0.575
algorithm,algorithm,0.95
algorithm,negative regulation of viral process,0.5388888888888889
algorithm,contact pathogen transmission process,0.5369565217391304
algorithm,symbiotic process,0.5269230769230769
algorithm,infection start process boundary,0.523170731707317
algorithm,latency start process boundary,0.5269230769230769
algorithm,process of establishing viral infection,0.575
algorithm,negative regulation of biological process,0.53
algorithm,communicability start process boundary,0.5351063829787234
algorithm,process that results in death,0.581578947368421
algorithm,establishment of a clinically abnormal colony,0.5425925925925926
algorithm,process boundary,0.53
algorithm,horizontal pathogen transmission process,0.5724489795918367
algorithm,pathogen transmission process,0.5552631578947369
reverse zoonosis,infectious disease mortality rate,0.5928571428571429
reverse zoonosis,infection incidence rate profile,0.5958333333333333
reverse zoonosis,communicability end temporal region,0.5676470588235294
reverse zoonosis,infection end temporal region,0.5833333333333334
reverse zoonosis,SARS-CoV-2 incidence rate,0.5719512195121951
reverse zoonosis,incubation end temporal region,0.5804347826086956
reverse zoonosis,reverse zoonotic disposition,0.7909090909090909
reverse zoonosis,B cell receptor complex,0.6038461538461539
reverse zoonosis,infection incidence rate,0.55
reverse zoonosis,double-stranded RNA virus,0.6207317073170732
reverse zoonosis,lower respiratory tract disease,0.5776595744680851
reverse zoonosis,communicability end process boundary,0.5653846153846154
reverse zoonosis,latency end process boundary,0.609090909090909
reverse zoonosis,negative-sense single-stranded RNA virus,0.6285714285714286
reverse zoonosis,COVID-19 incidence rate,0.5525641025641026
reverse zoonosis,zoonosis,0.7833333333333333
reverse zoonosis,incubation end process boundary,0.5776595744680851
reverse zoonosis,pathogen death process boundary,0.598936170212766
reverse zoonosis,latency end temporal region,0.5895348837209302
reverse zoonosis,T cell receptor complex,0.6038461538461539
reverse zoonosis,reverse zoonosis,0.95
reverse zoonosis,COVID-19 mortality rate,0.5525641025641026
reverse zoonosis,reverse transcribed PCR,0.732051282051282
reverse zoonosis,place closure control strategy,0.6239130434782608
reverse zoonosis,acute respiratory distress syndrome,0.6068627450980393
reverse zoonosis,action specification,0.5611111111111111
reverse zoonosis,infectious disease incidence rate,0.5928571428571429
reverse zoonosis,process that results in death,0.5833333333333334
reverse zoonosis,single-stranded RNA retrovirus,0.6239130434782608
reverse zoonosis,establishment of a clinically abnormal colony,0.5647540983606557
reverse zoonosis,positive-sense single-stranded RNA virus,0.6107142857142857
reverse zoonosis,pathogen death temporal region,0.5804347826086956
facility,source of infection,0.5611111111111111
facility,communicability end temporal region,0.5895348837209302
facility,infection end temporal region,0.5851351351351352
facility,incubation end temporal region,0.5552631578947369
facility,material entity,0.7108695652173913
facility,source of infection site,0.60625
facility,B cell receptor complex,0.5467741935483871
facility,communicability end process boundary,0.5863636363636363
facility,latency end process boundary,0.5333333333333333
facility,incubation end process boundary,0.5269230769230769
facility,latency end temporal region,0.5642857142857143
facility,virus adhesion susceptible cell,0.5525641025641026
facility,T cell receptor complex,0.5467741935483871
facility,facility,0.95
facility,healthcare facility,0.7462962962962962
facility,cell,0.6166666666666667
facility,source of infection role,0.575
facility,hospital facility,0.77
facility,SARS-COV-2 adhesion susceptible cell,0.5409090909090909
facility,processed material,0.5653846153846154
facility,quality,0.7833333333333333
facility,establishment of a clinically abnormal colony,0.5632075471698114
facility,cell space,0.5611111111111111
facility,material processing,0.5981481481481481
incubation end temporal region,infectious disease mortality rate,0.7198412698412698
incubation end temporal region,infection incidence rate profile,0.7241935483870968
incubation end temporal region,infectious structure aggregate,0.6666666666666667
incubation end temporal region,communicability end temporal region,0.8192307692307693
incubation end temporal region,infection end temporal region,0.9076271186440679
incubation end temporal region,SARS-CoV-2 incidence rate,0.6318181818181818
incubation end temporal region,incubation end temporal region,0.95
incubation end temporal region,two-dimensional spatial region,0.7166666666666667
incubation end temporal region,one-dimensional temporal region,0.7942622950819671
incubation end temporal region,temporal region,0.7833333333333333
incubation end temporal region,negative regulation of production,0.6722222222222223
incubation end temporal region,establishment of localization in host,0.6291044776119403
incubation end temporal region,disease surveillance objective specification,0.6256756756756756
incubation end temporal region,material entity,0.65
incubation end temporal region,asymptomatic infectious structure carrier,0.6190140845070422
incubation end temporal region,architectual structure,0.6230769230769231
incubation end temporal region,B cell receptor complex,0.6386792452830189
incubation end temporal region,infection incidence rate,0.7092592592592593
incubation end temporal region,double-stranded RNA virus,0.65
incubation end temporal region,pathogen birth temporal region,0.8
incubation end temporal region,lower respiratory tract disease,0.6139344262295081
incubation end temporal region,infectious disease incidence proportion,0.696376811594203
incubation end temporal region,acute infectious disease course,0.6631147540983606
incubation end temporal region,communicability end process boundary,0.6621212121212122
incubation end temporal region,acellular structure aggregate,0.6194915254237288
incubation end temporal region,infection incidence proportion profile,0.7
incubation end temporal region,SARS-CoV-2 incidence proportion,0.6631147540983606
incubation end temporal region,spatiotemporal region,0.8225490196078431
incubation end temporal region,latency end process boundary,0.6741379310344828
incubation end temporal region,negative regulation of establishment of localization,0.6573170731707317
incubation end temporal region,negative-sense single-stranded RNA virus,0.65
incubation end temporal region,infectious structure host role,0.6666666666666667
incubation end temporal region,establishment of localization,0.6364406779661017
incubation end temporal region,COVID-19 incidence rate,0.6386792452830189
incubation end temporal region,zero-dimensional spatial region,0.7122950819672131
incubation end temporal region,zero-dimensional temporal region,0.7887096774193548
incubation end temporal region,chronic infectious disease course,0.6563492063492063
incubation end temporal region,PCR product,0.5719512195121951
incubation end temporal region,infection start temporal region,0.8434426229508196
incubation end temporal region,establishment of localization in human host,0.6554794520547945
incubation end temporal region,acellular structure,0.6132653061224489
incubation end temporal region,incubation end process boundary,0.7778688524590163
incubation end temporal region,pathogen death process boundary,0.6631147540983606
incubation end temporal region,geographical region,0.6948979591836735
incubation end temporal region,plan specification,0.6166666666666667
incubation end temporal region,latency end temporal region,0.8535087719298246
incubation end temporal region,infectious structure,0.67
incubation end temporal region,virus adhesion susceptible cell,0.6467213114754098
incubation end temporal region,T cell receptor complex,0.6386792452830189
incubation end temporal region,infectious structure host,0.6681818181818181
incubation end temporal region,infectious structure generative stage,0.658955223880597
incubation end temporal region,viral disease course,0.63
incubation end temporal region,three-dimensional spatial region,0.7080645161290323
incubation end temporal region,cell,0.5382352941176471
incubation end temporal region,objective specification,0.6386792452830189
incubation end temporal region,country,0.5851351351351352
incubation end temporal region,disease course,0.609090909090909
incubation end temporal region,infectious disease course,0.6863636363636364
incubation end temporal region,COVID-19 disease incidence proportion,0.6440298507462687
incubation end temporal region,coronavirus disease course,0.6285714285714286
incubation end temporal region,infection incidence proportion,0.7333333333333333
incubation end temporal region,incubation interval,0.7969387755102041
incubation end temporal region,production,0.6
incubation end temporal region,COVID-19 mortality rate,0.6764150943396227
incubation end temporal region,place closure control strategy,0.6333333333333333
incubation end temporal region,symptomatic infectious structure carrier,0.6214285714285714
incubation end temporal region,SARS-COV-2 adhesion susceptible cell,0.6166666666666667
incubation end temporal region,incubation start process boundary,0.7357142857142857
incubation end temporal region,object,0.5333333333333333
incubation end temporal region,pathogen birth process boundary,0.6467213114754098
incubation end temporal region,infectious human pathogen,0.6863636363636364
incubation end temporal region,colonization of human,0.6656862745098039
incubation end temporal region,establishment of localization in virus host,0.6417808219178082
incubation end temporal region,object aggregate,0.6021739130434782
incubation end temporal region,long-term non-progressing infectious disease course,0.6104938271604938
incubation end temporal region,communicability start temporal region,0.7634328358208955
incubation end temporal region,geospatial region,0.7053191489361703
incubation end temporal region,division of geopolitical entity,0.6795081967213115
incubation end temporal region,infection start process boundary,0.6919354838709677
incubation end temporal region,processed material,0.6375
incubation end temporal region,latency start process boundary,0.65
incubation end temporal region,infectious disease control objective specification,0.6625
incubation end temporal region,COVID-19 disease course,0.619811320754717
incubation end temporal region,infectious disease incidence rate,0.6722222222222223
incubation end temporal region,communicability start process boundary,0.6264705882352941
incubation end temporal region,process that results in death,0.6194915254237288
incubation end temporal region,single-stranded RNA retrovirus,0.6666666666666667
incubation end temporal region,local infection,0.65
incubation end temporal region,establishment of a clinically abnormal colony,0.6366666666666667
incubation end temporal region,process boundary,0.6021739130434782
incubation end temporal region,positive-sense single-stranded RNA virus,0.6357142857142857
incubation end temporal region,one-dimensional spatial region,0.7166666666666667
incubation end temporal region,spatial region,0.7227272727272727
incubation end temporal region,pathogen death temporal region,0.8166666666666665
incubation end temporal region,cell space,0.6
incubation end temporal region,material processing,0.6744897959183673
antigen role,immune response,0.6722222222222223
antigen role,virulence factor disposition,0.6
antigen role,reservoir of pathogen role,0.7131578947368421
antigen role,negative regulation of production,0.6277777777777778
antigen role,infectious agent host role,0.7394736842105263
antigen role,B cell receptor complex,0.6214285714285714
antigen role,pathogen portal of entry role,0.6939024390243902
antigen role,toxin disposition,0.6224137931034482
antigen role,lower respiratory tract disease,0.5662790697674418
antigen role,acute infectious disease course,0.636046511627907
antigen role,role,0.7
antigen role,appearance of disorder,0.6264705882352941
antigen role,mutualist role,0.7192307692307692
antigen role,invasion factor,0.6351851851851852
antigen role,negative regulation of establishment of localization,0.590625
antigen role,infectious structure host role,0.6642857142857143
antigen role,negative regulation of developmental process,0.6285714285714286
antigen role,pathogen vehicle role,0.7530303030303032
antigen role,chronic infectious disease course,0.6055555555555556
antigen role,negative regulation of replication,0.6239130434782608
antigen role,mechanical vector role,0.7147058823529412
antigen role,virulence factor,0.6285714285714286
antigen role,dead-end host role,0.7166666666666667
antigen role,definitive host role,0.73125
antigen role,T cell receptor complex,0.65
antigen role,asymptomatic carrier role,0.6932432432432433
antigen role,antibody reagent,0.7
antigen role,innate immune response,0.6852941176470588
antigen role,viral disease course,0.6375
antigen role,toxin,0.6264705882352941
antigen role,secondary infection role,0.7277777777777777
antigen role,source of infection role,0.7
antigen role,disease course,0.6423076923076922
antigen role,infectious disease course,0.6391891891891892
antigen role,coronavirus disease course,0.6078947368421053
antigen role,biological vehicle role,0.6785714285714286
antigen role,symbiont role,0.73
antigen role,parasite role,0.77
antigen role,pathogen vector role,0.7625
antigen role,organism substance,0.6166666666666667
antigen role,negative regulation of life-sustaining process,0.6224137931034482
antigen role,primary infection role,0.7441176470588234
antigen role,biological role,0.7092592592592593
antigen role,biological vector role,0.6852941176470588
antigen role,pathogen host role,0.7833333333333333
antigen role,symptomatic carrier role,0.7
antigen role,humoral immune response,0.65
antigen role,intermediate host role,0.7147058823529412
antigen role,host role,0.7357142857142857
antigen role,negative regulation of immune response,0.63
antigen role,pathogen portal of exit role,0.7
antigen role,long-term non-progressing infectious disease course,0.5769841269841269
antigen role,commensal role,0.7192307692307692
antigen role,epitope role,0.7416666666666667
antigen role,blood,0.5088235294117647
antigen role,negative regulation of viral process,0.6375
antigen role,function,0.65
antigen role,pathogen transporter role,0.7202702702702704
antigen role,antigen,0.8184210526315789
antigen role,antigen role,0.95
antigen role,action specification,0.6375
antigen role,symbiont host role,0.6833333333333332
antigen role,immune population,0.6224137931034482
antigen role,fomite role,0.7543478260869566
antigen role,negative regulation of biological process,0.619811320754717
antigen role,COVID-19 disease course,0.5928571428571429
antigen role,adaptive immune response,0.7
antigen role,reagent role,0.825
antigen role,viral load,0.5863636363636363
antigen role,establishment of a clinically abnormal colony,0.6078947368421053
antigen role,adhesion factor,0.6351851851851852
process of establishing an infection,virus aggregate,0.5872549019607843
process of establishing an infection,source of infection,0.740909090909091
process of establishing an infection,virostatic disposition,0.656896551724138
process of establishing an infection,zoonotic disposition,0.6285714285714286
process of establishing an infection,immune response,0.5676470588235294
process of establishing an infection,infectious disease mortality rate,0.6239130434782608
process of establishing an infection,infection incidence rate profile,0.6264705882352941
process of establishing an infection,communicability end temporal region,0.6471830985915493
process of establishing an infection,pathogen generative stage,0.6139344262295081
process of establishing an infection,subclinical coronavirus infection,0.696376811594203
process of establishing an infection,surveillance process,0.5928571428571429
process of establishing an infection,infection end temporal region,0.6346153846153847
process of establishing an infection,infectious disease,0.5981481481481481
process of establishing an infection,SARS-CoV-2 incidence rate,0.6139344262295081
process of establishing an infection,double-stranded DNA virus,0.6139344262295081
process of establishing an infection,incubation end temporal region,0.6318181818181818
process of establishing an infection,site of infection,0.7141509433962264
process of establishing an infection,virulence factor disposition,0.653125
process of establishing an infection,viral adhesion disposition,0.6435483870967742
process of establishing an infection,parasitostatic disposition,0.6758064516129032
process of establishing an infection,infectious disease incidence,0.653125
process of establishing an infection,reverse zoonotic disposition,0.653125
process of establishing an infection,subclinical SARS-CoV-2 infection,0.7
process of establishing an infection,virus translation stage,0.6364406779661017
process of establishing an infection,disease surveillance objective specification,0.65
process of establishing an infection,case isolation control strategy,0.6141791044776119
process of establishing an infection,virus release stage,0.6136363636363636
process of establishing an infection,source of infection site,0.7166666666666667
process of establishing an infection,virus replication,0.6575471698113208
process of establishing an infection,B cell receptor complex,0.5855932203389831
process of establishing an infection,systematic infection,0.7178571428571427
process of establishing an infection,infection incidence rate,0.6333333333333333
process of establishing an infection,virus host,0.5804347826086956
process of establishing an infection,double-stranded RNA virus,0.6139344262295081
process of establishing an infection,virus transcription stage,0.630327868852459
process of establishing an infection,infectious disease lifetime prevalence,0.6391891891891892
process of establishing an infection,toxin disposition,0.619811320754717
process of establishing an infection,lower respiratory tract disease,0.6141791044776119
process of establishing an infection,infectious disease incidence proportion,0.6633333333333334
process of establishing an infection,virus generative stage,0.6051724137931035
process of establishing an infection,acute infectious disease course,0.6440298507462687
process of establishing an infection,cidal agent disposition,0.6533898305084747
process of establishing an infection,infectious disorder,0.5954545454545455
process of establishing an infection,subclinical infection,0.730701754385965
process of establishing an infection,process,0.6127906976744186
process of establishing an infection,appearance of disorder,0.6396551724137931
process of establishing an infection,simple infection,0.6807692307692308
process of establishing an infection,droplet pathogen transmission process,0.6417808219178082
process of establishing an infection,parasiticidal disposition,0.6631147540983606
process of establishing an infection,infectious disease sporadicity,0.6166666666666667
process of establishing an infection,communicability end process boundary,0.6166666666666667
process of establishing an infection,infection incidence proportion profile,0.6391891891891892
process of establishing an infection,transmissibility disposition,0.653125
process of establishing an infection,latency end process boundary,0.621875
process of establishing an infection,infectious disease epidemic,0.6246031746031746
process of establishing an infection,infectious agent generative stage,0.6384057971014493
process of establishing an infection,disease transmission model,0.6274193548387097
process of establishing an infection,endotoxin disposition,0.6429824561403508
process of establishing an infection,negative-sense single-stranded RNA virus,0.6210526315789474
process of establishing an infection,COVID-19 incidence rate,0.6025423728813559
process of establishing an infection,cytotoxin disposition,0.6429824561403508
process of establishing an infection,community-acquired infection,0.684375
process of establishing an infection,negative regulation of developmental process,0.6
process of establishing an infection,chronic infectious disease course,0.6528985507246376
process of establishing an infection,nursing-home acquired infection,0.703731343283582
process of establishing an infection,COVID-19 epidemic,0.5820754716981132
process of establishing an infection,secondary infection,0.7045454545454546
process of establishing an infection,infection start temporal region,0.6440298507462687
process of establishing an infection,infection incidence,0.65
process of establishing an infection,virus disorder,0.57
process of establishing an infection,primary infection,0.7141509433962264
process of establishing an infection,process of establishing an infection,0.95
process of establishing an infection,incubation end process boundary,0.6141791044776119
process of establishing an infection,SARS-CoV-2 disorder,0.5772727272727273
process of establishing an infection,collective pathogenic disposition,0.6528985507246376
process of establishing an infection,neurotoxin disposition,0.6396551724137931
process of establishing an infection,SARS-CoV-2 uncoating stage,0.6274193548387097
process of establishing an infection,pathogen death process boundary,0.6141791044776119
process of establishing an infection,plan specification,0.6722222222222223
process of establishing an infection,latency end temporal region,0.6246031746031746
process of establishing an infection,SARS-CoV-2 penetration stage,0.6375
process of establishing an infection,virus adhesion susceptible cell,0.6141791044776119
process of establishing an infection,collective disposition,0.6396551724137931
process of establishing an infection,infection,0.65
process of establishing an infection,static agent disposition,0.6666666666666667
process of establishing an infection,T cell receptor complex,0.5855932203389831
process of establishing an infection,respiratory system disease,0.6274193548387097
process of establishing an infection,indirect pathogen transmission process,0.6256756756756756
process of establishing an infection,planned process,0.5872549019607843
process of establishing an infection,generative stage,0.6038461538461539
process of establishing an infection,communicability interval,0.6166666666666667
process of establishing an infection,infectious disease control strategy,0.6049295774647887
process of establishing an infection,SARS-CoV-2 attachment stage,0.6246031746031746
process of establishing an infection,infectious disease pandemic,0.6246031746031746
process of establishing an infection,infectious structure generative stage,0.6006849315068493
process of establishing an infection,immunosuppressive disposition,0.65
process of establishing an infection,innate immune response,0.6051724137931035
process of establishing an infection,pathogenic disposition,0.6396551724137931
process of establishing an infection,viral disease course,0.6107142857142857
process of establishing an infection,intracellular infection,0.7042372881355932
process of establishing an infection,secondary infection role,0.6833333333333332
process of establishing an infection,metastatic infection,0.7178571428571427
process of establishing an infection,infectious disposition,0.6396551724137931
process of establishing an infection,acute infection,0.6852941176470588
process of establishing an infection,bacteriostatic disposition,0.6596774193548387
process of establishing an infection,bactericidal disposition,0.6333333333333333
process of establishing an infection,source of infection role,0.7166666666666667
process of establishing an infection,chronic infection,0.6952830188679244
process of establishing an infection,invasion disposition,0.6285714285714286
process of establishing an infection,disease course,0.59
process of establishing an infection,infectious disease course,0.6139344262295081
process of establishing an infection,viricidal disposition,0.6429824561403508
process of establishing an infection,complex infection,0.6952830188679244
process of establishing an infection,COVID-19 disease incidence proportion,0.6554794520547945
process of establishing an infection,coronavirus disease course,0.6112903225806451
process of establishing an infection,infection incidence proportion,0.6621212121212122
process of establishing an infection,respiratory droplet virus fomite,0.6264705882352941
process of establishing an infection,infectious disease prevalence,0.6038461538461539
process of establishing an infection,SARS-CoV-2 genome replication stage,0.6330985915492958
process of establishing an infection,disposition,0.6202127659574468
process of establishing an infection,single-stranded DNA virus,0.6139344262295081
process of establishing an infection,COVID-19 mortality rate,0.6194915254237288
process of establishing an infection,process profile,0.6852941176470588
process of establishing an infection,negative regulation of life-sustaining process,0.6451219512195122
process of establishing an infection,place closure control strategy,0.6166666666666667
process of establishing an infection,viral disease,0.5928571428571429
process of establishing an infection,primary infection role,0.6913793103448276
process of establishing an infection,adhesion disposition,0.6464285714285714
process of establishing an infection,developmental process,0.5903508771929825
process of establishing an infection,infection incidence profile,0.6246031746031746
process of establishing an infection,contagiousness,0.61
process of establishing an infection,disease,0.5662790697674418
process of establishing an infection,biological process,0.5796296296296296
process of establishing an infection,primary infectious disposition,0.6621212121212122
process of establishing an infection,infection prevalence,0.6107142857142857
process of establishing an infection,humoral immune response,0.6025423728813559
process of establishing an infection,coronavirus disorder,0.5928571428571429
process of establishing an infection,incubation start process boundary,0.6094202898550725
process of establishing an infection,pathogen birth process boundary,0.6141791044776119
process of establishing an infection,subclinical virus infection,0.7039682539682539
process of establishing an infection,establishment of localization in virus host,0.6778481012658227
process of establishing an infection,virus attachment stage,0.6224137931034482
process of establishing an infection,negative regulation of immune response,0.6256756756756756
process of establishing an infection,SARS-CoV-2 transcription stage,0.6318181818181818
process of establishing an infection,virus synthesis stage,0.6254385964912281
process of establishing an infection,SARS-COV-2 adhesion disposition,0.658955223880597
process of establishing an infection,invasive disposition,0.6107142857142857
process of establishing an infection,long-term non-progressing infectious disease course,0.6683908045977012
process of establishing an infection,viral disease epidemic,0.6224137931034482
process of establishing an infection,communicability start temporal region,0.6417808219178082
process of establishing an infection,fungicidal disposition,0.6224137931034482
process of establishing an infection,viral disease pandemic,0.6224137931034482
process of establishing an infection,virus penetration stage,0.6364406779661017
process of establishing an infection,algorithm,0.5611111111111111
process of establishing an infection,acute respiratory distress syndrome,0.6049295774647887
process of establishing an infection,infectious disease endemicity,0.6346153846153847
process of establishing an infection,negative regulation of viral process,0.5888888888888889
process of establishing an infection,contact pathogen transmission process,0.6280821917808219
process of establishing an infection,disorder,0.5181818181818182
process of establishing an infection,function,0.609090909090909
process of establishing an infection,communicability,0.5872549019607843
process of establishing an infection,extracellular infection,0.7042372881355932
process of establishing an infection,symbiotic process,0.5820754716981132
process of establishing an infection,exotoxin disposition,0.6464285714285714
process of establishing an infection,infection start process boundary,0.6117647058823529
process of establishing an infection,action specification,0.6642857142857143
process of establishing an infection,SARS-CoV-2 synthesis stage,0.6274193548387097
process of establishing an infection,latency start process boundary,0.6166666666666667
process of establishing an infection,infectious disease control objective specification,0.6476744186046511
process of establishing an infection,opportunistic infectious disposition,0.6722222222222223
process of establishing an infection,process of establishing viral infection,0.9166666666666665
process of establishing an infection,negative regulation of biological process,0.6058441558441559
process of establishing an infection,enterotoxin disposition,0.6364406779661017
process of establishing an infection,polymerase chain reaction,0.6959016393442623
process of establishing an infection,COVID-19 disease course,0.6025423728813559
process of establishing an infection,infectious disease incidence rate,0.6384057971014493
process of establishing an infection,communicability start process boundary,0.6121621621621621
process of establishing an infection,process that results in death,0.7269230769230769
process of establishing an infection,disordered virus,0.5461538461538461
process of establishing an infection,collective resistance disposition,0.6818840579710145
process of establishing an infection,adaptive immune response,0.6
process of establishing an infection,fungistatic disposition,0.6364406779661017
process of establishing an infection,virus uncoating stage,0.6429824561403508
process of establishing an infection,local infection,0.7245098039215686
process of establishing an infection,establishment of a clinically abnormal colony,0.6722222222222223
process of establishing an infection,process boundary,0.6615384615384616
process of establishing an infection,coronavirus disease,0.5954545454545455
process of establishing an infection,positive-sense single-stranded RNA virus,0.6473684210526315
process of establishing an infection,horizontal pathogen transmission process,0.6342105263157894
process of establishing an infection,hospital-acquired infection,0.7039682539682539
process of establishing an infection,SARS-CoV-2 release stage,0.6166666666666667
process of establishing an infection,pathogen transmission process,0.6346153846153847
dead-end host,angiotensin-converting enzyme 2,0.5636363636363636
dead-end host,virostatic disposition,0.5928571428571429
dead-end host,zoonotic disposition,0.6015151515151516
dead-end host,communicability end temporal region,0.575
dead-end host,infection end temporal region,0.5928571428571429
dead-end host,incubation end temporal region,0.5895348837209302
dead-end host,virulence factor disposition,0.5963414634146341
dead-end host,pathogen portal of exit,0.6166666666666667
dead-end host,viral adhesion disposition,0.6551282051282051
dead-end host,parasitostatic disposition,0.5782051282051281
dead-end host,reverse zoonotic disposition,0.6207317073170732
dead-end host,establishment of localization in host,0.63
dead-end host,infectious agent host role,0.6807692307692308
dead-end host,B cell receptor complex,0.5611111111111111
dead-end host,colonized host,0.7092592592592593
dead-end host,virus host,0.6673913043478261
dead-end host,toxin disposition,0.6166666666666667
dead-end host,cidal agent disposition,0.6722222222222223
dead-end host,parasiticidal disposition,0.6078947368421053
dead-end host,communicability end process boundary,0.5928571428571429
dead-end host,transmissibility disposition,0.5963414634146341
dead-end host,latency end process boundary,0.6207317073170732
dead-end host,colonization of host,0.6621212121212122
dead-end host,endotoxin disposition,0.6558823529411765
dead-end host,infectious structure host role,0.6127906976744186
dead-end host,cytotoxin disposition,0.5970588235294118
dead-end host,host,0.6852941176470588
dead-end host,establishment of localization in human host,0.6107142857142857
dead-end host,incubation end process boundary,0.609090909090909
dead-end host,collective pathogenic disposition,0.6239130434782608
dead-end host,neurotoxin disposition,0.6214285714285714
dead-end host,dead-end host role,0.8693548387096774
dead-end host,definitive host role,0.6924242424242425
dead-end host,latency end temporal region,0.6
dead-end host,collective disposition,0.6214285714285714
dead-end host,static agent disposition,0.6391891891891892
dead-end host,T cell receptor complex,0.5611111111111111
dead-end host,infectious structure host,0.6342105263157894
dead-end host,entry into host,0.7
dead-end host,adhesion of symbiont to host,0.6695121951219513
dead-end host,immunosuppressive disposition,0.5928571428571429
dead-end host,pathogenic disposition,0.65
dead-end host,entry into host through host barriers,0.59
dead-end host,infectious disposition,0.5928571428571429
dead-end host,bacteriostatic disposition,0.6038461538461539
dead-end host,bactericidal disposition,0.6391891891891892
dead-end host,pathogen host,0.7576923076923078
dead-end host,invasion disposition,0.6318181818181818
dead-end host,viricidal disposition,0.6264705882352941
dead-end host,intermediate host,0.7166666666666667
dead-end host,pathogen portal of exit site,0.6207317073170732
dead-end host,disposition,0.6166666666666667
dead-end host,adhesion disposition,0.6924242424242425
dead-end host,primary infectious disposition,0.5895348837209302
dead-end host,pathogen host role,0.7080645161290323
dead-end host,intermediate host role,0.6785714285714286
dead-end host,dead-end host,0.95
dead-end host,host role,0.6318181818181818
dead-end host,establishment of localization in virus host,0.6107142857142857
dead-end host,SARS-COV-2 adhesion disposition,0.6318181818181818
dead-end host,pathogen portal of exit role,0.5963414634146341
dead-end host,invasive disposition,0.6318181818181818
dead-end host,infectious agent host,0.7147058823529412
dead-end host,fungicidal disposition,0.6214285714285714
dead-end host,division of geopolitical entity,0.5863636363636363
dead-end host,exotoxin disposition,0.6318181818181818
dead-end host,symbiont host role,0.6435483870967742
dead-end host,opportunistic infectious disposition,0.5520408163265306
dead-end host,enterotoxin disposition,0.6444444444444444
dead-end host,collective resistance disposition,0.6021739130434782
dead-end host,fungistatic disposition,0.5888888888888889
dead-end host,establishment of a clinically abnormal colony,0.553448275862069
dead-end host,definitive host,0.7357142857142857
drug susceptibility of infectious agent,ribonucleic acid,0.6136363636363636
drug susceptibility of infectious agent,information content entity,0.6346153846153847
drug susceptibility of infectious agent,infectious disease mortality rate,0.6444444444444444
drug susceptibility of infectious agent,infection incidence rate profile,0.6190140845070422
drug susceptibility of infectious agent,infectious structure aggregate,0.6673913043478261
drug susceptibility of infectious agent,communicability end temporal region,0.6527027027027027
drug susceptibility of infectious agent,infection end temporal region,0.6264705882352941
drug susceptibility of infectious agent,deoxyribonucleic acid,0.6166666666666667
drug susceptibility of infectious agent,infectious disease,0.6780701754385965
drug susceptibility of infectious agent,SARS-CoV-2 incidence rate,0.6375
drug susceptibility of infectious agent,incubation end temporal region,0.6094202898550725
drug susceptibility of infectious agent,virulence factor disposition,0.6291044776119403
drug susceptibility of infectious agent,infectious disease incidence,0.658955223880597
drug susceptibility of infectious agent,disease surveillance objective specification,0.6548192771084337
drug susceptibility of infectious agent,infectious agent host role,0.6961538461538461
drug susceptibility of infectious agent,asymptomatic infectious structure carrier,0.675
drug susceptibility of infectious agent,B cell receptor complex,0.6274193548387097
drug susceptibility of infectious agent,passive immunization against infectious agent,0.7357142857142857
drug susceptibility of infectious agent,infection incidence rate,0.6404761904761905
drug susceptibility of infectious agent,drug susceptibility,0.7775862068965518
drug susceptibility of infectious agent,infectious disease lifetime prevalence,0.6448051948051949
drug susceptibility of infectious agent,lower respiratory tract disease,0.65
drug susceptibility of infectious agent,infectious disease incidence proportion,0.6423076923076922
drug susceptibility of infectious agent,acute infectious disease course,0.6785714285714286
drug susceptibility of infectious agent,cidal agent disposition,0.6274193548387097
drug susceptibility of infectious agent,infectious disorder,0.656896551724138
drug susceptibility of infectious agent,biological vehicle,0.5903508771929825
drug susceptibility of infectious agent,infectious disease sporadicity,0.6528985507246376
drug susceptibility of infectious agent,communicability end process boundary,0.6366666666666667
drug susceptibility of infectious agent,directive information content entity,0.6633333333333334
drug susceptibility of infectious agent,infectious agent colony,0.7080645161290323
drug susceptibility of infectious agent,pathogen transporter,0.5855932203389831
drug susceptibility of infectious agent,invasion factor,0.5981481481481481
drug susceptibility of infectious agent,latency end process boundary,0.5843283582089552
drug susceptibility of infectious agent,infectious disease epidemic,0.6469696969696969
drug susceptibility of infectious agent,infectious agent generative stage,0.6722222222222223
drug susceptibility of infectious agent,disease transmission model,0.6192307692307693
drug susceptibility of infectious agent,cidal agent,0.63
drug susceptibility of infectious agent,infectious structure host role,0.6384057971014493
drug susceptibility of infectious agent,pathogen vehicle,0.5772727272727273
drug susceptibility of infectious agent,COVID-19 incidence rate,0.6112903225806451
drug susceptibility of infectious agent,pathogen vehicle role,0.5833333333333334
drug susceptibility of infectious agent,chronic infectious disease course,0.6722222222222223
drug susceptibility of infectious agent,asymptomatic infectious agent carrier,0.7263157894736842
drug susceptibility of infectious agent,descriptive information content entity,0.6707792207792208
drug susceptibility of infectious agent,COVID-19 epidemic,0.575
drug susceptibility of infectious agent,nucleic acid,0.5872549019607843
drug susceptibility of infectious agent,resistance to drug,0.6254385964912281
drug susceptibility of infectious agent,sterilizing immunity to infectious agent,0.7791139240506328
drug susceptibility of infectious agent,diseased population,0.6224137931034482
drug susceptibility of infectious agent,virulence factor,0.6136363636363636
drug susceptibility of infectious agent,incubation end process boundary,0.5928571428571429
drug susceptibility of infectious agent,latency end temporal region,0.6015151515151516
drug susceptibility of infectious agent,innate immunity to infectious agent,0.7743243243243243
drug susceptibility of infectious agent,infectious structure,0.6533898305084747
drug susceptibility of infectious agent,static agent disposition,0.6246031746031746
drug susceptibility of infectious agent,T cell receptor complex,0.6274193548387097
drug susceptibility of infectious agent,asymptomatic carrier role,0.590625
drug susceptibility of infectious agent,infectious structure host,0.653125
drug susceptibility of infectious agent,infectious agent population,0.6924242424242425
drug susceptibility of infectious agent,respiratory system disease,0.6346153846153847
drug susceptibility of infectious agent,leukocyte-mediated immunity to infectious agent,0.763953488372093
drug susceptibility of infectious agent,humoral immunity to infectious agent,0.7833333333333333
drug susceptibility of infectious agent,infectious disease control strategy,0.6527027027027027
drug susceptibility of infectious agent,SARS-CoV-2 attachment stage,0.6166666666666667
drug susceptibility of infectious agent,infectious disease pandemic,0.6621212121212122
drug susceptibility of infectious agent,infectious structure generative stage,0.6473684210526315
drug susceptibility of infectious agent,viral disease course,0.6364406779661017
drug susceptibility of infectious agent,passive immunity to infectious agent,0.7966666666666667
drug susceptibility of infectious agent,infectious disposition,0.6467213114754098
drug susceptibility of infectious agent,vaccination against infectious agent,0.7433333333333333
drug susceptibility of infectious agent,susceptibility,0.7141509433962264
drug susceptibility of infectious agent,susceptibility to infectious agent,0.9020547945205479
drug susceptibility of infectious agent,disease course,0.6386792452830189
drug susceptibility of infectious agent,infectious disease course,0.653125
drug susceptibility of infectious agent,acquired immunity to infectious agent,0.7789473684210526
drug susceptibility of infectious agent,COVID-19 disease incidence proportion,0.6342105263157894
drug susceptibility of infectious agent,coronavirus disease course,0.6346153846153847
drug susceptibility of infectious agent,asymptomatic carrier,0.6025423728813559
drug susceptibility of infectious agent,biological vehicle role,0.5951612903225807
drug susceptibility of infectious agent,symptomatic infectious agent carrier,0.73
drug susceptibility of infectious agent,intermediate host,0.5928571428571429
drug susceptibility of infectious agent,infectious disease prevalence,0.6558823529411765
drug susceptibility of infectious agent,organism substance,0.6254385964912281
drug susceptibility of infectious agent,infected population,0.6224137931034482
drug susceptibility of infectious agent,COVID-19 mortality rate,0.6112903225806451
drug susceptibility of infectious agent,place closure control strategy,0.6239130434782608
drug susceptibility of infectious agent,viral disease,0.5846153846153846
drug susceptibility of infectious agent,disease,0.558695652173913
drug susceptibility of infectious agent,symptomatic infectious structure carrier,0.6778481012658227
drug susceptibility of infectious agent,primary infectious disposition,0.6818840579710145
drug susceptibility of infectious agent,designative information content entity,0.6448051948051949
drug susceptibility of infectious agent,symptomatic carrier role,0.5928571428571429
drug susceptibility of infectious agent,infectious pathogen transmissibility,0.6633333333333334
drug susceptibility of infectious agent,intermediate host role,0.5975409836065574
drug susceptibility of infectious agent,infectious human pathogen,0.684375
drug susceptibility of infectious agent,immunization against infectious agent,0.7394736842105263
drug susceptibility of infectious agent,virus attachment stage,0.630327868852459
drug susceptibility of infectious agent,infectious agent host,0.7166666666666667
drug susceptibility of infectious agent,long-term non-progressing infectious disease course,0.6611111111111111
drug susceptibility of infectious agent,viral disease epidemic,0.5975409836065574
drug susceptibility of infectious agent,viral disease pandemic,0.5975409836065574
drug susceptibility of infectious agent,symptomatic carrier,0.6051724137931035
drug susceptibility of infectious agent,infectious disease endemicity,0.6705882352941177
drug susceptibility of infectious agent,function,0.598936170212766
drug susceptibility of infectious agent,herd immunity to infectious organism,0.7433333333333333
drug susceptibility of infectious agent,pathogen transporter role,0.575
drug susceptibility of infectious agent,infectious agent reservoir,0.6961538461538461
drug susceptibility of infectious agent,COVID-19 pandemic,0.5571428571428572
drug susceptibility of infectious agent,action specification,0.6533898305084747
drug susceptibility of infectious agent,infectious disease control objective specification,0.6410112359550562
drug susceptibility of infectious agent,opportunistic infectious disposition,0.69
drug susceptibility of infectious agent,polymerase chain reaction,0.6375
drug susceptibility of infectious agent,COVID-19 disease course,0.6274193548387097
drug susceptibility of infectious agent,infectious disease incidence rate,0.6583333333333334
drug susceptibility of infectious agent,active immunization against infectious agent,0.739156626506024
drug susceptibility of infectious agent,infectious agent,0.740909090909091
drug susceptibility of infectious agent,establishment of a clinically abnormal colony,0.6404761904761905
drug susceptibility of infectious agent,coronavirus disease,0.6051724137931035
drug susceptibility of infectious agent,adhesion factor,0.6166666666666667
drug susceptibility of infectious agent,drug susceptibility of infectious agent,0.95
drug susceptibility of infectious agent,static agent,0.6656862745098039
infection incidence rate profile,virus aggregate,0.5776595744680851
infection incidence rate profile,source of infection,0.6264705882352941
infection incidence rate profile,virostatic disposition,0.5981481481481481
infection incidence rate profile,information content entity,0.6913793103448276
infection incidence rate profile,zoonotic disposition,0.6038461538461539
infection incidence rate profile,infectious disease mortality rate,0.7423076923076922
infection incidence rate profile,infection incidence rate profile,0.95
infection incidence rate profile,communicability end temporal region,0.6738805970149254
infection incidence rate profile,subclinical coronavirus infection,0.6346153846153847
infection incidence rate profile,infection end temporal region,0.7614754098360657
infection incidence rate profile,infectious disease,0.71
infection incidence rate profile,SARS-CoV-2 incidence rate,0.7482456140350877
infection incidence rate profile,double-stranded DNA virus,0.6078947368421053
infection incidence rate profile,incubation end temporal region,0.7241935483870968
infection incidence rate profile,site of infection,0.6540816326530612
infection incidence rate profile,virulence factor disposition,0.65
infection incidence rate profile,viral adhesion disposition,0.6224137931034482
infection incidence rate profile,parasitostatic disposition,0.6051724137931035
infection incidence rate profile,infectious disease incidence,0.75
infection incidence rate profile,reverse zoonotic disposition,0.6
infection incidence rate profile,subclinical SARS-CoV-2 infection,0.621875
infection incidence rate profile,virus translation stage,0.6136363636363636
infection incidence rate profile,disease surveillance objective specification,0.6342105263157894
infection incidence rate profile,virus release stage,0.6068627450980393
infection incidence rate profile,material entity,0.598936170212766
infection incidence rate profile,source of infection site,0.6821428571428573
infection incidence rate profile,virus,0.504054054054054
infection incidence rate profile,virus replication,0.5928571428571429
infection incidence rate profile,B cell receptor complex,0.65
infection incidence rate profile,systematic infection,0.6423076923076922
infection incidence rate profile,infection incidence rate,0.8785714285714286
infection incidence rate profile,virus host,0.5452380952380953
infection incidence rate profile,double-stranded RNA virus,0.6254385964912281
infection incidence rate profile,virus transcription stage,0.6254385964912281
infection incidence rate profile,infectious disease lifetime prevalence,0.7357142857142857
infection incidence rate profile,toxin disposition,0.6132653061224489
infection incidence rate profile,serology assay,0.5369565217391304
infection incidence rate profile,lower respiratory tract disease,0.6087301587301588
infection incidence rate profile,infectious disease incidence proportion,0.7739436619718311
infection incidence rate profile,virus generative stage,0.6537037037037037
infection incidence rate profile,acute infectious disease course,0.7039682539682539
infection incidence rate profile,cidal agent disposition,0.6318181818181818
infection incidence rate profile,infectious disorder,0.7049019607843137
infection incidence rate profile,subclinical infection,0.6386792452830189
infection incidence rate profile,appearance of disorder,0.6166666666666667
infection incidence rate profile,simple infection,0.6375
infection incidence rate profile,parasiticidal disposition,0.6429824561403508
infection incidence rate profile,infectious disease sporadicity,0.7241935483870968
infection incidence rate profile,communicability end process boundary,0.6411764705882353
infection incidence rate profile,directive information content entity,0.6705882352941177
infection incidence rate profile,infection incidence proportion profile,0.8785714285714286
infection incidence rate profile,SARS-CoV-2 incidence proportion,0.7198412698412698
infection incidence rate profile,transmissibility disposition,0.6
infection incidence rate profile,latency end process boundary,0.6333333333333333
infection incidence rate profile,infectious disease epidemic,0.738135593220339
infection incidence rate profile,disease transmission model,0.6224137931034482
infection incidence rate profile,endotoxin disposition,0.619811320754717
infection incidence rate profile,negative-sense single-stranded RNA virus,0.6722222222222223
infection incidence rate profile,COVID-19 incidence rate,0.759090909090909
infection incidence rate profile,viral plaque assay,0.59
infection incidence rate profile,cytotoxin disposition,0.619811320754717
infection incidence rate profile,community-acquired infection,0.6333333333333333
infection incidence rate profile,chronic infectious disease course,0.6961538461538461
infection incidence rate profile,nursing-home acquired infection,0.6404761904761905
infection incidence rate profile,descriptive information content entity,0.65
infection incidence rate profile,COVID-19 epidemic,0.6336734693877552
infection incidence rate profile,secondary infection,0.6656862745098039
infection incidence rate profile,infection start temporal region,0.7198412698412698
infection incidence rate profile,infection incidence,0.8225490196078431
infection incidence rate profile,virus disorder,0.5804347826086956
infection incidence rate profile,primary infection,0.6336734693877552
infection incidence rate profile,process of establishing an infection,0.6264705882352941
infection incidence rate profile,incubation end process boundary,0.6880952380952381
infection incidence rate profile,SARS-CoV-2 disorder,0.5872549019607843
infection incidence rate profile,collective pathogenic disposition,0.65
infection incidence rate profile,neurotoxin disposition,0.6351851851851852
infection incidence rate profile,COVID-19 incidence,0.69
infection incidence rate profile,latency end temporal region,0.6533898305084747
infection incidence rate profile,virus adhesion susceptible cell,0.6404761904761905
infection incidence rate profile,collective disposition,0.6351851851851852
infection incidence rate profile,infection,0.6695121951219513
infection incidence rate profile,static agent disposition,0.6285714285714286
infection incidence rate profile,T cell receptor complex,0.6681818181818181
infection incidence rate profile,respiratory system disease,0.6051724137931035
infection incidence rate profile,communicability interval,0.6464285714285714
infection incidence rate profile,infectious disease control strategy,0.7186567164179104
infection incidence rate profile,infectious disease pandemic,0.7211864406779661
infection incidence rate profile,immunosuppressive disposition,0.5975409836065574
infection incidence rate profile,pathogenic disposition,0.6166666666666667
infection incidence rate profile,viral disease course,0.6230769230769231
infection incidence rate profile,intracellular infection,0.6318181818181818
infection incidence rate profile,secondary infection role,0.7178571428571427
infection incidence rate profile,metastatic infection,0.6423076923076922
infection incidence rate profile,infectious disposition,0.6907407407407408
infection incidence rate profile,acute infection,0.6414893617021277
infection incidence rate profile,bacteriostatic disposition,0.6224137931034482
infection incidence rate profile,bactericidal disposition,0.6464285714285714
infection incidence rate profile,source of infection role,0.7
infection incidence rate profile,chronic infection,0.6540816326530612
infection incidence rate profile,invasion disposition,0.6423076923076922
infection incidence rate profile,disease course,0.6021739130434782
infection incidence rate profile,infectious disease course,0.730701754385965
infection incidence rate profile,viricidal disposition,0.6386792452830189
infection incidence rate profile,complex infection,0.6336734693877552
infection incidence rate profile,COVID-19 disease incidence proportion,0.696376811594203
infection incidence rate profile,coronavirus disease course,0.6396551724137931
infection incidence rate profile,infection incidence proportion,0.8370967741935484
infection incidence rate profile,respiratory droplet virus fomite,0.6375
infection incidence rate profile,infectious disease prevalence,0.7450819672131148
infection incidence rate profile,disposition,0.5662790697674418
infection incidence rate profile,single-stranded DNA virus,0.6429824561403508
infection incidence rate profile,COVID-19 mortality rate,0.65
infection incidence rate profile,process profile,0.6840425531914894
infection incidence rate profile,viral disease,0.5833333333333334
infection incidence rate profile,primary infection role,0.7092592592592593
infection incidence rate profile,adhesion disposition,0.6230769230769231
infection incidence rate profile,infection incidence profile,0.9076271186440679
infection incidence rate profile,contagiousness,0.5804347826086956
infection incidence rate profile,disease,0.5525641025641026
infection incidence rate profile,primary infectious disposition,0.6596774193548387
infection incidence rate profile,infection prevalence,0.7192307692307692
infection incidence rate profile,designative information content entity,0.65
infection incidence rate profile,coronavirus disorder,0.6038461538461539
infection incidence rate profile,SARS-CoV-2 incidence,0.6807692307692308
infection incidence rate profile,subclinical virus infection,0.6364406779661017
infection incidence rate profile,establishment of localization in virus host,0.65
infection incidence rate profile,virus attachment stage,0.5981481481481481
infection incidence rate profile,virus synthesis stage,0.5820754716981132
infection incidence rate profile,SARS-COV-2 adhesion disposition,0.6087301587301588
infection incidence rate profile,invasive disposition,0.6038461538461539
infection incidence rate profile,long-term non-progressing infectious disease course,0.6427710843373494
infection incidence rate profile,viral disease epidemic,0.6351851851851852
infection incidence rate profile,communicability start temporal region,0.6528985507246376
infection incidence rate profile,fungicidal disposition,0.6537037037037037
infection incidence rate profile,viral disease pandemic,0.6166666666666667
infection incidence rate profile,virus penetration stage,0.6318181818181818
infection incidence rate profile,acute respiratory distress syndrome,0.6291044776119403
infection incidence rate profile,geographical feature,0.6230769230769231
infection incidence rate profile,infectious disease endemicity,0.6959016393442623
infection incidence rate profile,disorder,0.575
infection incidence rate profile,history,0.5525641025641026
infection incidence rate profile,communicability,0.6202127659574468
infection incidence rate profile,extracellular infection,0.6136363636363636
infection incidence rate profile,exotoxin disposition,0.6230769230769231
infection incidence rate profile,infection start process boundary,0.715625
infection incidence rate profile,action specification,0.6807692307692308
infection incidence rate profile,processed material,0.67
infection incidence rate profile,infectious disease control objective specification,0.6939024390243902
infection incidence rate profile,COVID-19 lifetime prevalence,0.65
infection incidence rate profile,opportunistic infectious disposition,0.6411764705882353
infection incidence rate profile,process of establishing viral infection,0.6190140845070422
infection incidence rate profile,enterotoxin disposition,0.6318181818181818
infection incidence rate profile,COVID-19 disease course,0.6318181818181818
infection incidence rate profile,infectious disease incidence rate,0.8038461538461539
infection incidence rate profile,communicability start process boundary,0.65
infection incidence rate profile,COVID-19 prevalence,0.6264705882352941
infection incidence rate profile,single-stranded RNA retrovirus,0.6758064516129032
infection incidence rate profile,SARS-COV-2 prevalence,0.5820754716981132
infection incidence rate profile,disordered virus,0.6166666666666667
infection incidence rate profile,collective resistance disposition,0.65
infection incidence rate profile,fungistatic disposition,0.6136363636363636
infection incidence rate profile,virus uncoating stage,0.619811320754717
infection incidence rate profile,local infection,0.6414893617021277
infection incidence rate profile,establishment of a clinically abnormal colony,0.6448051948051949
infection incidence rate profile,coronavirus disease,0.6068627450980393
infection incidence rate profile,positive-sense single-stranded RNA virus,0.6583333333333334
infection incidence rate profile,hospital-acquired infection,0.6194915254237288
infection incidence rate profile,material processing,0.6264705882352941
spatial region,communicability end temporal region,0.6744897959183673
spatial region,geographical entity,0.6621212121212122
spatial region,infection end temporal region,0.7058139534883722
spatial region,incubation end temporal region,0.7227272727272727
spatial region,two-dimensional spatial region,0.7681818181818181
spatial region,one-dimensional temporal region,0.7166666666666667
spatial region,temporal region,0.7948275862068965
spatial region,disease surveillance objective specification,0.6051724137931035
spatial region,B cell receptor complex,0.5851351351351352
spatial region,pathogen birth temporal region,0.7454545454545455
spatial region,lower respiratory tract disease,0.6055555555555556
spatial region,infectious disease incidence proportion,0.6009433962264151
spatial region,acute infectious disease course,0.6055555555555556
spatial region,communicability end process boundary,0.61
spatial region,infection incidence proportion profile,0.5846153846153846
spatial region,SARS-CoV-2 incidence proportion,0.6277777777777778
spatial region,spatiotemporal region,0.85
spatial region,latency end process boundary,0.6166666666666667
spatial region,zero-dimensional spatial region,0.7611111111111112
spatial region,zero-dimensional temporal region,0.7108695652173913
spatial region,chronic infectious disease course,0.5776595744680851
spatial region,infection start temporal region,0.7166666666666667
spatial region,incubation end process boundary,0.6277777777777778
spatial region,geographical region,0.7833333333333333
spatial region,latency end temporal region,0.7182926829268292
spatial region,T cell receptor complex,0.6121621621621621
spatial region,viral disease course,0.6264705882352941
spatial region,three-dimensional spatial region,0.7543478260869566
spatial region,objective specification,0.6391891891891892
spatial region,country,0.5452380952380953
spatial region,disease course,0.6285714285714286
spatial region,infectious disease course,0.6038461538461539
spatial region,COVID-19 disease incidence proportion,0.6068627450980393
spatial region,coronavirus disease course,0.6
spatial region,infection incidence proportion,0.609090909090909
spatial region,place closure control strategy,0.6318181818181818
spatial region,object,0.5
spatial region,object aggregate,0.6166666666666667
spatial region,long-term non-progressing infectious disease course,0.5576923076923077
spatial region,communicability start temporal region,0.6852941176470588
spatial region,geospatial region,0.9016129032258065
spatial region,division of geopolitical entity,0.65
spatial region,geographical feature,0.6558823529411765
spatial region,infectious disease control objective specification,0.590625
spatial region,COVID-19 disease course,0.5851351351351352
spatial region,local infection,0.6913793103448276
spatial region,establishment of a clinically abnormal colony,0.6194915254237288
spatial region,one-dimensional spatial region,0.7681818181818181
spatial region,spatial region,0.95
spatial region,pathogen death temporal region,0.7227272727272727
macromolecule,macromolecule,0.95
macromolecule,establishment of a clinically abnormal colony,0.5879310344827586
virus attachment stage,extended organism,0.5782051282051281
virus attachment stage,virus aggregate,0.7202702702702704
virus attachment stage,source of infection,0.5719512195121951
virus attachment stage,virostatic disposition,0.6772727272727272
virus attachment stage,zoonotic disposition,0.569047619047619
virus attachment stage,immune response,0.6391891891891892
virus attachment stage,infectious disease mortality rate,0.65
virus attachment stage,infection incidence rate profile,0.5981481481481481
virus attachment stage,communicability end temporal region,0.6078947368421053
virus attachment stage,pathogen generative stage,0.7053191489361703
virus attachment stage,pathogen portal of entry,0.6456521739130434
virus attachment stage,subclinical coronavirus infection,0.5954545454545455
virus attachment stage,primary pathogen,0.6605263157894737
virus attachment stage,infection end temporal region,0.6068627450980393
virus attachment stage,drug-based immunosuppressed organism,0.5879310344827586
virus attachment stage,infectious disease,0.625
virus attachment stage,SARS-CoV-2 incidence rate,0.6414893617021277
virus attachment stage,double-stranded DNA virus,0.6202127659574468
virus attachment stage,incubation end temporal region,0.6423076923076922
virus attachment stage,site of infection,0.5782051282051281
virus attachment stage,immunocompetent organism,0.6456521739130434
virus attachment stage,virulence factor disposition,0.67
virus attachment stage,pathogen portal of exit,0.65
virus attachment stage,viral adhesion disposition,0.6791666666666666
virus attachment stage,parasitostatic disposition,0.6375
virus attachment stage,infectious disease incidence,0.63
virus attachment stage,reservoir of pathogen role,0.6791666666666666
virus attachment stage,reverse zoonotic disposition,0.63
virus attachment stage,subclinical SARS-CoV-2 infection,0.5796296296296296
virus attachment stage,virus translation stage,0.8055555555555556
virus attachment stage,disease surveillance objective specification,0.6015151515151516
virus attachment stage,case isolation control strategy,0.6764150943396227
virus attachment stage,virus release stage,0.7914634146341464
virus attachment stage,source of infection site,0.6456521739130434
virus attachment stage,virus,0.6351851851851852
virus attachment stage,virus replication,0.6807692307692308
virus attachment stage,B cell receptor complex,0.5833333333333334
virus attachment stage,systematic infection,0.5928571428571429
virus attachment stage,infection incidence rate,0.6239130434782608
virus attachment stage,virus host,0.73125
virus attachment stage,double-stranded RNA virus,0.6202127659574468
virus attachment stage,pathogen portal of entry role,0.6264705882352941
virus attachment stage,virus transcription stage,0.7904255319148936
virus attachment stage,infectious disease lifetime prevalence,0.6333333333333333
virus attachment stage,toxin disposition,0.5782051282051281
virus attachment stage,pathogen birth temporal region,0.6423076923076922
virus attachment stage,lower respiratory tract disease,0.6764150943396227
virus attachment stage,infectious disease incidence proportion,0.6139344262295081
virus attachment stage,opportunistic pathogen,0.6545454545454545
virus attachment stage,virus generative stage,0.7909090909090909
virus attachment stage,acute infectious disease course,0.619811320754717
virus attachment stage,cidal agent disposition,0.65
virus attachment stage,infectious disorder,0.5963414634146341
virus attachment stage,genetic resistance to pathogen,0.6807692307692308
virus attachment stage,subclinical infection,0.5662790697674418
virus attachment stage,appearance of disorder,0.609090909090909
virus attachment stage,simple infection,0.581578947368421
virus attachment stage,biological vehicle,0.55
virus attachment stage,droplet pathogen transmission process,0.6364406779661017
virus attachment stage,parasiticidal disposition,0.598936170212766
virus attachment stage,infectious disease sporadicity,0.6230769230769231
virus attachment stage,communicability end process boundary,0.5879310344827586
virus attachment stage,infection incidence proportion profile,0.5833333333333334
virus attachment stage,pathogen transporter,0.6642857142857143
virus attachment stage,transmissibility disposition,0.59
virus attachment stage,latency end process boundary,0.61
virus attachment stage,infectious disease epidemic,0.6132653061224489
virus attachment stage,infectious agent generative stage,0.7227272727272727
virus attachment stage,disease transmission model,0.6375
virus attachment stage,endotoxin disposition,0.5895348837209302
virus attachment stage,pathologically immunosuppressed organism,0.5629032258064516
virus attachment stage,negative-sense single-stranded RNA virus,0.5951612903225807
virus attachment stage,pathogen vehicle,0.6342105263157894
virus attachment stage,COVID-19 incidence rate,0.65
virus attachment stage,cytotoxin disposition,0.5895348837209302
virus attachment stage,community-acquired infection,0.59
virus attachment stage,pathogen vector,0.6391891891891892
virus attachment stage,pathogen vehicle role,0.6127906976744186
virus attachment stage,chronic infectious disease course,0.6136363636363636
virus attachment stage,nursing-home acquired infection,0.6009433962264151
virus attachment stage,COVID-19 epidemic,0.5782051282051281
virus attachment stage,secondary infection,0.5719512195121951
virus attachment stage,infection start temporal region,0.619811320754717
virus attachment stage,infection incidence,0.5963414634146341
virus attachment stage,virus disorder,0.6722222222222223
virus attachment stage,primary infection,0.5782051282051281
virus attachment stage,process of establishing an infection,0.6224137931034482
virus attachment stage,incubation end process boundary,0.619811320754717
virus attachment stage,SARS-CoV-2 disorder,0.5963414634146341
virus attachment stage,collective pathogenic disposition,0.6318181818181818
virus attachment stage,neurotoxin disposition,0.5863636363636363
virus attachment stage,SARS-CoV-2 uncoating stage,0.7
virus attachment stage,pathogen death process boundary,0.619811320754717
virus attachment stage,immunosuppressed organism,0.598936170212766
virus attachment stage,plan specification,0.575
virus attachment stage,latency end temporal region,0.6336734693877552
virus attachment stage,SARS-CoV-2 penetration stage,0.69
virus attachment stage,virus adhesion susceptible cell,0.7141509433962264
virus attachment stage,collective disposition,0.5863636363636363
virus attachment stage,infection,0.5467741935483871
virus attachment stage,static agent disposition,0.6673913043478261
virus attachment stage,T cell receptor complex,0.5833333333333334
virus attachment stage,respiratory system disease,0.6583333333333334
virus attachment stage,indirect pathogen transmission process,0.65
virus attachment stage,organism population,0.5963414634146341
virus attachment stage,generative stage,0.7131578947368421
virus attachment stage,infectious disease control strategy,0.6780701754385965
virus attachment stage,SARS-CoV-2 attachment stage,0.8377551020408163
virus attachment stage,infectious disease pandemic,0.6336734693877552
virus attachment stage,infectious structure generative stage,0.7042372881355932
virus attachment stage,immunosuppressive disposition,0.5872549019607843
virus attachment stage,innate immune response,0.6318181818181818
virus attachment stage,pathogenic disposition,0.6318181818181818
virus attachment stage,viral disease course,0.6642857142857143
virus attachment stage,intracellular infection,0.6055555555555556
virus attachment stage,secondary infection role,0.5804347826086956
virus attachment stage,metastatic infection,0.6166666666666667
virus attachment stage,infectious disposition,0.5863636363636363
virus attachment stage,acute infection,0.5851351351351352
virus attachment stage,bacteriostatic disposition,0.6166666666666667
virus attachment stage,immunity to pathogen,0.6642857142857143
virus attachment stage,bactericidal disposition,0.5804347826086956
virus attachment stage,source of infection role,0.6021739130434782
virus attachment stage,pathogen host,0.6785714285714286
virus attachment stage,acquired immunodeficiency,0.5776595744680851
virus attachment stage,chronic infection,0.5782051282051281
virus attachment stage,invasion disposition,0.5928571428571429
virus attachment stage,disease course,0.6444444444444444
virus attachment stage,infectious disease course,0.6414893617021277
virus attachment stage,viricidal disposition,0.6127906976744186
virus attachment stage,acquired immunity to infectious agent,0.6364406779661017
virus attachment stage,complex infection,0.5782051282051281
virus attachment stage,COVID-19 disease incidence proportion,0.6025423728813559
virus attachment stage,coronavirus disease course,0.6791666666666666
virus attachment stage,biological vehicle role,0.5833333333333334
virus attachment stage,infection incidence proportion,0.5846153846153846
virus attachment stage,respiratory droplet virus fomite,0.6351851851851852
virus attachment stage,susceptible organism,0.6166666666666667
virus attachment stage,pathogen vector role,0.6404761904761905
virus attachment stage,pathogen portal of exit site,0.65
virus attachment stage,infectious disease prevalence,0.6264705882352941
virus attachment stage,organism substance,0.65
virus attachment stage,SARS-CoV-2 genome replication stage,0.6605263157894737
virus attachment stage,disposition,0.5712121212121213
virus attachment stage,single-stranded DNA virus,0.6202127659574468
virus attachment stage,COVID-19 mortality rate,0.65
virus attachment stage,viral disease,0.6785714285714286
virus attachment stage,primary infection role,0.609090909090909
virus attachment stage,adhesion disposition,0.6166666666666667
virus attachment stage,pathogen portal of entry site,0.6656862745098039
virus attachment stage,infection incidence profile,0.5928571428571429
virus attachment stage,disease,0.6224137931034482
virus attachment stage,primary infectious disposition,0.6038461538461539
virus attachment stage,pathogen host role,0.675
virus attachment stage,infection prevalence,0.5928571428571429
virus attachment stage,humoral immune response,0.6055555555555556
virus attachment stage,coronavirus disorder,0.6404761904761905
virus attachment stage,infectious pathogen transmissibility,0.656896551724138
virus attachment stage,pathogen surveillance,0.6593023255813953
virus attachment stage,immunodeficient organism,0.6239130434782608
virus attachment stage,pathogen,0.6166666666666667
virus attachment stage,pathogen birth process boundary,0.619811320754717
virus attachment stage,infectious human pathogen,0.6840425531914894
virus attachment stage,subclinical virus infection,0.6132653061224489
virus attachment stage,resistance to pathogen,0.7
virus attachment stage,establishment of localization in virus host,0.6192307692307693
virus attachment stage,virus attachment stage,0.95
virus attachment stage,negative regulation of immune response,0.6166666666666667
virus attachment stage,SARS-CoV-2 transcription stage,0.7
virus attachment stage,virus synthesis stage,0.7988372093023256
virus attachment stage,SARS-COV-2 adhesion disposition,0.6386792452830189
virus attachment stage,pathogen portal of exit role,0.63
virus attachment stage,invasive disposition,0.5928571428571429
virus attachment stage,re-emerging pathogen,0.6404761904761905
virus attachment stage,long-term non-progressing infectious disease course,0.5732876712328767
virus attachment stage,viral disease epidemic,0.6318181818181818
virus attachment stage,fungicidal disposition,0.5636363636363636
virus attachment stage,viral disease pandemic,0.6545454545454545
virus attachment stage,virus penetration stage,0.7833333333333333
virus attachment stage,pathogen seroprevalence,0.65
virus attachment stage,acute respiratory distress syndrome,0.6078947368421053
virus attachment stage,division of geopolitical entity,0.6386792452830189
virus attachment stage,infectious disease endemicity,0.6068627450980393
virus attachment stage,contact pathogen transmission process,0.6194915254237288
virus attachment stage,disorder,0.55
virus attachment stage,herd immunity to infectious organism,0.5879310344827586
virus attachment stage,extracellular infection,0.5833333333333334
virus attachment stage,pathogen transporter role,0.6414893617021277
virus attachment stage,transmission interval,0.6127906976744186
virus attachment stage,exotoxin disposition,0.569047619047619
virus attachment stage,infection start process boundary,0.5981481481481481
virus attachment stage,action specification,0.5928571428571429
virus attachment stage,SARS-CoV-2 synthesis stage,0.7
virus attachment stage,infectious disease control objective specification,0.6027777777777777
virus attachment stage,immune population,0.6038461538461539
virus attachment stage,opportunistic infectious disposition,0.6224137931034482
virus attachment stage,process of establishing viral infection,0.6139344262295081
virus attachment stage,enterotoxin disposition,0.5833333333333334
virus attachment stage,COVID-19 disease course,0.6277777777777778
virus attachment stage,infectious disease incidence rate,0.65
virus attachment stage,disordered virus,0.581578947368421
virus attachment stage,collective resistance disposition,0.6318181818181818
virus attachment stage,adaptive immune response,0.6239130434782608
virus attachment stage,fungistatic disposition,0.6277777777777778
virus attachment stage,organism,0.5833333333333334
virus attachment stage,virus uncoating stage,0.7988372093023256
virus attachment stage,local infection,0.5310810810810811
virus attachment stage,establishment of a clinically abnormal colony,0.5992537313432835
virus attachment stage,coronavirus disease,0.6695121951219513
virus attachment stage,positive-sense single-stranded RNA virus,0.5951612903225807
virus attachment stage,horizontal pathogen transmission process,0.6274193548387097
virus attachment stage,hospital-acquired infection,0.5928571428571429
virus attachment stage,pathogen death temporal region,0.6423076923076922
virus attachment stage,emerging pathogen,0.6294871794871795
virus attachment stage,SARS-CoV-2 release stage,0.6891304347826087
virus attachment stage,pathogen transmission process,0.6264705882352941
immunosuppressed organism,extended organism,0.7357142857142857
immunosuppressed organism,information content entity,0.6068627450980393
immunosuppressed organism,infectious structure aggregate,0.65
immunosuppressed organism,geographical entity,0.5863636363636363
immunosuppressed organism,drug-based immunosuppressed organism,0.8598360655737705
immunosuppressed organism,resistant entity,0.6207317073170732
immunosuppressed organism,immunocompetent organism,0.8173469387755102
immunosuppressed organism,virulence factor disposition,0.619811320754717
immunosuppressed organism,case isolation control strategy,0.575
immunosuppressed organism,material entity,0.6
immunosuppressed organism,asymptomatic infectious structure carrier,0.6166666666666667
immunosuppressed organism,architectual structure,0.5776595744680851
immunosuppressed organism,B cell receptor complex,0.575
immunosuppressed organism,entity,0.5467741935483871
immunosuppressed organism,directive information content entity,0.6139344262295081
immunosuppressed organism,acellular structure aggregate,0.6166666666666667
immunosuppressed organism,invasion factor,0.6
immunosuppressed organism,realizable entity,0.5928571428571429
immunosuppressed organism,pathologically immunosuppressed organism,0.8346153846153846
immunosuppressed organism,infectious structure host role,0.6318181818181818
immunosuppressed organism,descriptive information content entity,0.5928571428571429
immunosuppressed organism,establishment of localization in human host,0.5970588235294118
immunosuppressed organism,acellular structure,0.5636363636363636
immunosuppressed organism,virulence factor,0.6207317073170732
immunosuppressed organism,molecular entity,0.6207317073170732
immunosuppressed organism,immunosuppressed organism,0.95
immunosuppressed organism,plan specification,0.5895348837209302
immunosuppressed organism,infectious structure,0.6055555555555556
immunosuppressed organism,T cell receptor complex,0.575
immunosuppressed organism,infectious structure host,0.65
immunosuppressed organism,organism population,0.6318181818181818
immunosuppressed organism,infectious structure generative stage,0.6435483870967742
immunosuppressed organism,susceptible organism,0.7388888888888888
immunosuppressed organism,organism substance,0.636046511627907
immunosuppressed organism,anatomical entity,0.569047619047619
immunosuppressed organism,geopolitical entity,0.5863636363636363
immunosuppressed organism,symptomatic infectious structure carrier,0.6192307692307693
immunosuppressed organism,designative information content entity,0.5928571428571429
immunosuppressed organism,immunodeficient organism,0.7969387755102041
immunosuppressed organism,infectious human pathogen,0.63
immunosuppressed organism,colonization of human,0.5804347826086956
immunosuppressed organism,immaterial entity,0.6404761904761905
immunosuppressed organism,blood,0.5166666666666666
immunosuppressed organism,division of geopolitical entity,0.5928571428571429
immunosuppressed organism,geographical feature,0.5611111111111111
immunosuppressed organism,herd immunity to infectious organism,0.728688524590164
immunosuppressed organism,action specification,0.6055555555555556
immunosuppressed organism,processed material,0.6825581395348838
immunosuppressed organism,organism,0.6924242424242425
immunosuppressed organism,establishment of a clinically abnormal colony,0.5928571428571429
immunosuppressed organism,adhesion factor,0.575
immunosuppressed organism,material processing,0.609090909090909
neurotoxin,toxin disposition,0.6351851851851852
neurotoxin,neurotoxin,0.95
neurotoxin,neurotoxin disposition,0.7625
neurotoxin,T cell receptor complex,0.6015151515151516
neurotoxin,toxin,0.7833333333333333
mutualist,mutualist,0.95
mutualist,mutualist role,0.8413043478260869
mutualist,T cell receptor complex,0.54375
mutualist,establishment of a clinically abnormal colony,0.5611111111111111
static agent disposition,virostatic disposition,0.8413043478260869
static agent disposition,information content entity,0.65
static agent disposition,zoonotic disposition,0.7909090909090909
static agent disposition,infectious disease mortality rate,0.6254385964912281
static agent disposition,infection incidence rate profile,0.6285714285714286
static agent disposition,infectious structure aggregate,0.5981481481481481
static agent disposition,communicability end temporal region,0.6364406779661017
static agent disposition,geographical entity,0.6593023255813953
static agent disposition,biological regulation,0.6277777777777778
static agent disposition,surveillance process,0.6318181818181818
static agent disposition,infection end temporal region,0.6575471698113208
static agent disposition,vector control strategy,0.598936170212766
static agent disposition,SARS-CoV-2 incidence rate,0.6132653061224489
static agent disposition,incubation end temporal region,0.6722222222222223
static agent disposition,resistant entity,0.7
static agent disposition,virulence factor disposition,0.7769230769230769
static agent disposition,viral adhesion disposition,0.79
static agent disposition,parasitostatic disposition,0.81
static agent disposition,negative regulation of production,0.6780701754385965
static agent disposition,reverse zoonotic disposition,0.7576923076923078
static agent disposition,establishment of localization in host,0.6795081967213115
static agent disposition,disease surveillance objective specification,0.6705882352941177
static agent disposition,case isolation control strategy,0.65
static agent disposition,infectious agent host role,0.71
static agent disposition,macromolecular complex,0.558695652173913
static agent disposition,material entity,0.6807692307692308
static agent disposition,asymptomatic infectious structure carrier,0.6653846153846155
static agent disposition,architectual structure,0.6021739130434782
static agent disposition,quarantine control strategy,0.6264705882352941
static agent disposition,B cell receptor complex,0.5776595744680851
static agent disposition,passive immunization against infectious agent,0.6673913043478261
static agent disposition,infection incidence rate,0.6166666666666667
static agent disposition,colonized host,0.6078947368421053
static agent disposition,virus host,0.5970588235294118
static agent disposition,entity,0.6166666666666667
static agent disposition,toxin disposition,0.8158536585365854
static agent disposition,acute infectious disease course,0.65
static agent disposition,cidal agent disposition,0.8542553191489362
static agent disposition,biological vehicle,0.569047619047619
static agent disposition,parasiticidal disposition,0.7969387755102041
static agent disposition,communicability end process boundary,0.6333333333333333
static agent disposition,directive information content entity,0.6333333333333333
static agent disposition,acellular structure aggregate,0.6009433962264151
static agent disposition,infectious agent colony,0.7053191489361703
static agent disposition,pathogen transporter,0.6772727272727272
static agent disposition,invasion factor,0.6038461538461539
static agent disposition,transmissibility disposition,0.7576923076923078
static agent disposition,latency end process boundary,0.6807692307692308
static agent disposition,colonization of host,0.6318181818181818
static agent disposition,infectious agent generative stage,0.6605263157894737
static agent disposition,realizable entity,0.6451219512195122
static agent disposition,endotoxin disposition,0.7833333333333333
static agent disposition,vector surveillance,0.5895348837209302
static agent disposition,negative regulation of establishment of localization,0.6605263157894737
static agent disposition,cidal agent,0.65
static agent disposition,infectious structure host role,0.6166666666666667
static agent disposition,pathogen vehicle,0.625
static agent disposition,COVID-19 incidence rate,0.5776595744680851
static agent disposition,cytotoxin disposition,0.8055555555555556
static agent disposition,negative regulation of developmental process,0.6264705882352941
static agent disposition,pathogen vehicle role,0.6277777777777778
static agent disposition,host,0.5571428571428572
static agent disposition,chronic infectious disease course,0.6429824561403508
static agent disposition,asymptomatic infectious agent carrier,0.6795081967213115
static agent disposition,descriptive information content entity,0.6435483870967742
static agent disposition,negative regulation of replication,0.6741379310344828
static agent disposition,sterilizing immunity to infectious agent,0.653125
static agent disposition,establishment of localization in human host,0.658955223880597
static agent disposition,acellular structure,0.5895348837209302
static agent disposition,virulence factor,0.6
static agent disposition,incubation end process boundary,0.6681818181818181
static agent disposition,collective pathogenic disposition,0.7833333333333333
static agent disposition,neurotoxin disposition,0.7760869565217391
static agent disposition,dead-end host role,0.6404761904761905
static agent disposition,molecular entity,0.625
static agent disposition,plan specification,0.6880952380952381
static agent disposition,definitive host role,0.6318181818181818
static agent disposition,latency end temporal region,0.6852941176470588
static agent disposition,innate immunity to infectious agent,0.6533898305084747
static agent disposition,infectious structure,0.609090909090909
static agent disposition,collective disposition,0.7760869565217391
static agent disposition,static agent disposition,0.95
static agent disposition,T cell receptor complex,0.598936170212766
static agent disposition,asymptomatic carrier role,0.6744897959183673
static agent disposition,infectious structure host,0.6132653061224489
static agent disposition,infectious agent population,0.7441176470588234
static agent disposition,respiratory system disease,0.65
static agent disposition,entry into host,0.6551282051282051
static agent disposition,leukocyte-mediated immunity to infectious agent,0.6330985915492958
static agent disposition,adhesion of symbiont to host,0.6230769230769231
static agent disposition,humoral immunity to infectious agent,0.6333333333333333
static agent disposition,infectious disease control strategy,0.6194915254237288
static agent disposition,infectious structure generative stage,0.630327868852459
static agent disposition,immunosuppressive disposition,0.7330188679245283
static agent disposition,pathogenic disposition,0.8195652173913044
static agent disposition,viral disease course,0.6318181818181818
static agent disposition,entry into host through host barriers,0.6139344262295081
static agent disposition,passive immunity to infectious agent,0.65
static agent disposition,infectious disposition,0.7760869565217391
static agent disposition,vaccination against infectious agent,0.6833333333333332
static agent disposition,susceptibility to infectious agent,0.6396551724137931
static agent disposition,bacteriostatic disposition,0.81
static agent disposition,bactericidal disposition,0.8041666666666667
static agent disposition,pathogen host,0.6932432432432433
static agent disposition,invasion disposition,0.7909090909090909
static agent disposition,disease course,0.6078947368421053
static agent disposition,infectious disease course,0.6336734693877552
static agent disposition,viricidal disposition,0.7833333333333333
static agent disposition,acquired immunity to infectious agent,0.6467213114754098
static agent disposition,complex infection,0.6451219512195122
static agent disposition,coronavirus disease course,0.61
static agent disposition,asymptomatic carrier,0.6545454545454545
static agent disposition,biological vehicle role,0.5776595744680851
static agent disposition,symptomatic infectious agent carrier,0.6833333333333332
static agent disposition,intermediate host,0.6451219512195122
static agent disposition,anatomical entity,0.6939024390243902
static agent disposition,disposition,0.7642857142857143
static agent disposition,COVID-19 mortality rate,0.5776595744680851
static agent disposition,negative regulation of life-sustaining process,0.6357142857142857
static agent disposition,place closure control strategy,0.6166666666666667
static agent disposition,geopolitical entity,0.6593023255813953
static agent disposition,adhesion disposition,0.7909090909090909
static agent disposition,symptomatic infectious structure carrier,0.66875
static agent disposition,primary infectious disposition,0.7462962962962962
static agent disposition,pathogen host role,0.6880952380952381
static agent disposition,designative information content entity,0.6435483870967742
static agent disposition,symptomatic carrier role,0.6791666666666666
static agent disposition,object,0.5166666666666666
static agent disposition,intermediate host role,0.6456521739130434
static agent disposition,dead-end host,0.6391891891891892
static agent disposition,pathogen surveillance,0.65
static agent disposition,host role,0.5712121212121213
static agent disposition,establishment of localization in virus host,0.658955223880597
static agent disposition,immunization against infectious agent,0.6795081967213115
static agent disposition,negative regulation of immune response,0.6435483870967742
static agent disposition,immaterial entity,0.6695121951219513
static agent disposition,SARS-COV-2 adhesion disposition,0.7954545454545454
static agent disposition,object aggregate,0.6
static agent disposition,invasive disposition,0.7909090909090909
static agent disposition,infectious agent host,0.7166666666666667
static agent disposition,long-term non-progressing infectious disease course,0.61
static agent disposition,fungicidal disposition,0.7760869565217391
static agent disposition,division of geopolitical entity,0.65
static agent disposition,symptomatic carrier,0.6593023255813953
static agent disposition,negative regulation of viral process,0.6333333333333333
static agent disposition,function,0.60625
static agent disposition,pathogen transporter role,0.6744897959183673
static agent disposition,exotoxin disposition,0.7909090909090909
static agent disposition,infectious agent reservoir,0.69
static agent disposition,immunoglobulin complex,0.558695652173913
static agent disposition,action specification,0.7227272727272727
static agent disposition,infectious disease control objective specification,0.6662162162162162
static agent disposition,symbiont host role,0.6642857142857143
static agent disposition,opportunistic infectious disposition,0.7666666666666666
static agent disposition,negative regulation of biological process,0.6192307692307693
static agent disposition,enterotoxin disposition,0.7904255319148936
static agent disposition,polymerase chain reaction,0.6336734693877552
static agent disposition,COVID-19 disease course,0.598936170212766
static agent disposition,infectious disease incidence rate,0.6429824561403508
static agent disposition,active immunization against infectious agent,0.6705882352941177
static agent disposition,collective resistance disposition,0.7482456140350877
static agent disposition,fungistatic disposition,0.8329787234042553
static agent disposition,infectious agent,0.65
static agent disposition,establishment of a clinically abnormal colony,0.6384057971014493
static agent disposition,adhesion factor,0.6038461538461539
static agent disposition,definitive host,0.6294871794871795
static agent disposition,drug susceptibility of infectious agent,0.6246031746031746
static agent disposition,static agent,0.7833333333333333
disease,virus aggregate,0.6772727272727272
disease,source of infection,0.5653846153846154
disease,virostatic disposition,0.5879310344827586
disease,zoonotic disposition,0.5981481481481481
disease,infectious disease mortality rate,0.625
disease,infection incidence rate profile,0.5525641025641026
disease,communicability end temporal region,0.5452380952380953
disease,subclinical coronavirus infection,0.55
disease,infection end temporal region,0.5611111111111111
disease,infectious disease,0.73
disease,double-stranded DNA virus,0.60625
disease,incubation end temporal region,0.5581081081081081
disease,site of infection,0.575
disease,virulence factor disposition,0.5642857142857143
disease,viral adhesion disposition,0.5712121212121213
disease,parasitostatic disposition,0.5712121212121213
disease,infectious disease incidence,0.65
disease,reverse zoonotic disposition,0.5642857142857143
disease,subclinical SARS-CoV-2 infection,0.5782051282051281
disease,virus translation stage,0.6166666666666667
disease,disease surveillance objective specification,0.5872549019607843
disease,virus release stage,0.6807692307692308
disease,source of infection site,0.5790322580645162
disease,virus,0.6166666666666667
disease,virus replication,0.6166666666666667
disease,B cell receptor complex,0.5166666666666666
disease,systematic infection,0.5981481481481481
disease,infection incidence rate,0.5790322580645162
disease,virus host,0.6264705882352941
disease,double-stranded RNA virus,0.60625
disease,virus transcription stage,0.60625
disease,infectious disease lifetime prevalence,0.6055555555555556
disease,toxin disposition,0.6166666666666667
disease,lower respiratory tract disease,0.6342105263157894
disease,infectious disease incidence proportion,0.6021739130434782
disease,virus generative stage,0.656896551724138
disease,acute infectious disease course,0.6342105263157894
disease,cidal agent disposition,0.5833333333333334
disease,infectious disorder,0.6038461538461539
disease,subclinical infection,0.5571428571428572
disease,appearance of disorder,0.5879310344827586
disease,simple infection,0.5804347826086956
disease,parasiticidal disposition,0.575
disease,infectious disease sporadicity,0.6391891891891892
disease,communicability end process boundary,0.5197674418604651
disease,infection incidence proportion profile,0.5166666666666666
disease,transmissibility disposition,0.5642857142857143
disease,latency end process boundary,0.5357142857142857
disease,infectious disease epidemic,0.6558823529411765
disease,disease transmission model,0.6621212121212122
disease,endotoxin disposition,0.5928571428571429
disease,negative-sense single-stranded RNA virus,0.5563829787234043
disease,cytotoxin disposition,0.5928571428571429
disease,community-acquired infection,0.5357142857142857
disease,chronic infectious disease course,0.625
disease,nursing-home acquired infection,0.5552631578947369
disease,COVID-19 epidemic,0.575
disease,secondary infection,0.6038461538461539
disease,infection start temporal region,0.581578947368421
disease,infection incidence,0.5653846153846154
disease,virus disorder,0.6404761904761905
disease,primary infection,0.575
disease,process of establishing an infection,0.5662790697674418
disease,incubation end process boundary,0.5289473684210526
disease,SARS-CoV-2 disorder,0.6038461538461539
disease,collective pathogenic disposition,0.55
disease,neurotoxin disposition,0.5879310344827586
disease,latency end temporal region,0.5676470588235294
disease,virus adhesion susceptible cell,0.581578947368421
disease,collective disposition,0.5879310344827586
disease,infection,0.575
disease,static agent disposition,0.5790322580645162
disease,T cell receptor complex,0.5166666666666666
disease,respiratory system disease,0.6621212121212122
disease,infectious disease control strategy,0.6166666666666667
disease,infectious disease pandemic,0.6558823529411765
disease,immunosuppressive disposition,0.5888888888888889
disease,pathogenic disposition,0.5879310344827586
disease,viral disease course,0.7092592592592593
disease,intracellular infection,0.5833333333333334
disease,secondary infection role,0.5790322580645162
disease,metastatic infection,0.5981481481481481
disease,infectious disposition,0.5879310344827586
disease,acute infection,0.5409090909090909
disease,bacteriostatic disposition,0.5712121212121213
disease,bactericidal disposition,0.5790322580645162
disease,source of infection role,0.5467741935483871
disease,chronic infection,0.5333333333333333
disease,invasion disposition,0.5981481481481481
disease,disease course,0.7833333333333333
disease,infectious disease course,0.66875
disease,viricidal disposition,0.5928571428571429
disease,complex infection,0.5333333333333333
disease,COVID-19 disease incidence proportion,0.609090909090909
disease,coronavirus disease course,0.6621212121212122
disease,infection incidence proportion,0.5310810810810811
disease,respiratory droplet virus fomite,0.5525641025641026
disease,infectious disease prevalence,0.6444444444444444
disease,disposition,0.6722222222222223
disease,single-stranded DNA virus,0.60625
disease,viral disease,0.8
disease,primary infection role,0.553448275862069
disease,adhesion disposition,0.5981481481481481
disease,infection incidence profile,0.5382352941176471
disease,disease,0.95
disease,primary infectious disposition,0.5581081081081081
disease,infection prevalence,0.5981481481481481
disease,coronavirus disorder,0.5981481481481481
disease,subclinical virus infection,0.5676470588235294
disease,establishment of localization in virus host,0.55
disease,virus attachment stage,0.6224137931034482
disease,virus synthesis stage,0.6285714285714286
disease,SARS-COV-2 adhesion disposition,0.5552631578947369
disease,invasive disposition,0.5981481481481481
disease,long-term non-progressing infectious disease course,0.5706896551724138
disease,viral disease epidemic,0.6913793103448276
disease,fungicidal disposition,0.5879310344827586
disease,viral disease pandemic,0.6913793103448276
disease,virus penetration stage,0.65
disease,acute respiratory distress syndrome,0.5928571428571429
disease,infectious disease endemicity,0.6444444444444444
disease,disorder,0.7166666666666667
disease,extracellular infection,0.55
disease,exotoxin disposition,0.5981481481481481
disease,infection start process boundary,0.5525641025641026
disease,infectious disease control objective specification,0.5728070175438597
disease,opportunistic infectious disposition,0.5430232558139535
disease,process of establishing viral infection,0.558695652173913
disease,enterotoxin disposition,0.5833333333333334
disease,COVID-19 disease course,0.6833333333333332
disease,infectious disease incidence rate,0.625
disease,disordered virus,0.6673913043478261
disease,collective resistance disposition,0.55
disease,fungistatic disposition,0.5833333333333334
disease,virus uncoating stage,0.6285714285714286
disease,local infection,0.5409090909090909
disease,establishment of a clinically abnormal colony,0.5269230769230769
disease,coronavirus disease,0.7192307692307692
disease,positive-sense single-stranded RNA virus,0.5563829787234043
disease,hospital-acquired infection,0.5382352941176471
susceptible organism,extended organism,0.7743243243243243
susceptible organism,information content entity,0.5804347826086956
susceptible organism,immune response,0.6214285714285714
susceptible organism,infectious structure aggregate,0.63
susceptible organism,communicability end temporal region,0.6318181818181818
susceptible organism,geographical entity,0.6294871794871795
susceptible organism,infection end temporal region,0.6336734693877552
susceptible organism,drug-based immunosuppressed organism,0.7
susceptible organism,incubation end temporal region,0.63
susceptible organism,resistant entity,0.6166666666666667
susceptible organism,immunocompetent organism,0.7681818181818181
susceptible organism,virulence factor disposition,0.6166666666666667
susceptible organism,case isolation control strategy,0.6068627450980393
susceptible organism,material entity,0.6214285714285714
susceptible organism,asymptomatic infectious structure carrier,0.5975409836065574
susceptible organism,architectual structure,0.5928571428571429
susceptible organism,B cell receptor complex,0.6127906976744186
susceptible organism,entity,0.5653846153846154
susceptible organism,lower respiratory tract disease,0.6068627450980393
susceptible organism,communicability end process boundary,0.5928571428571429
susceptible organism,directive information content entity,0.6285714285714286
susceptible organism,acellular structure aggregate,0.6336734693877552
susceptible organism,invasion factor,0.5928571428571429
susceptible organism,latency end process boundary,0.5958333333333333
susceptible organism,realizable entity,0.6662162162162162
susceptible organism,pathologically immunosuppressed organism,0.6833333333333332
susceptible organism,infectious structure host role,0.61
susceptible organism,susceptible population,0.8071428571428573
susceptible organism,descriptive information content entity,0.656896551724138
susceptible organism,establishment of localization in human host,0.6246031746031746
susceptible organism,acellular structure,0.5782051282051281
susceptible organism,virulence factor,0.6166666666666667
susceptible organism,incubation end process boundary,0.5872549019607843
susceptible organism,molecular entity,0.5888888888888889
susceptible organism,immunosuppressed organism,0.7388888888888888
susceptible organism,plan specification,0.6078947368421053
susceptible organism,latency end temporal region,0.6202127659574468
susceptible organism,infectious structure,0.575
susceptible organism,virus adhesion susceptible cell,0.6852941176470588
susceptible organism,T cell receptor complex,0.6127906976744186
susceptible organism,infectious structure host,0.6277777777777778
susceptible organism,organism population,0.6551282051282051
susceptible organism,infectious structure generative stage,0.6254385964912281
susceptible organism,innate immune response,0.6166666666666667
susceptible organism,susceptible organism,0.95
susceptible organism,organism substance,0.6605263157894737
susceptible organism,anatomical entity,0.6121621621621621
susceptible organism,geopolitical entity,0.6551282051282051
susceptible organism,symptomatic infectious structure carrier,0.6
susceptible organism,designative information content entity,0.6224137931034482
susceptible organism,humoral immune response,0.6127906976744186
susceptible organism,SARS-COV-2 adhesion susceptible cell,0.6642857142857143
susceptible organism,immunodeficient organism,0.7454545454545455
susceptible organism,infectious human pathogen,0.6055555555555556
susceptible organism,colonization of human,0.6207317073170732
susceptible organism,negative regulation of immune response,0.6396551724137931
susceptible organism,immaterial entity,0.6121621621621621
susceptible organism,blood,0.57
susceptible organism,division of geopolitical entity,0.6264705882352941
susceptible organism,geographical feature,0.6
susceptible organism,herd immunity to infectious organism,0.6821428571428573
susceptible organism,action specification,0.6
susceptible organism,processed material,0.6342105263157894
susceptible organism,immune population,0.6391891891891892
susceptible organism,adaptive immune response,0.6318181818181818
susceptible organism,organism,0.7357142857142857
susceptible organism,establishment of a clinically abnormal colony,0.6192307692307693
susceptible organism,adhesion factor,0.5928571428571429
susceptible organism,material processing,0.6038461538461539
re-emerging pathogen,extended organism,0.6391891891891892
re-emerging pathogen,virus aggregate,0.6214285714285714
re-emerging pathogen,source of infection,0.6294871794871795
re-emerging pathogen,infectious disease mortality rate,0.619811320754717
re-emerging pathogen,infection incidence rate profile,0.6038461538461539
re-emerging pathogen,pathogen generative stage,0.65
re-emerging pathogen,pathogen portal of entry,0.6318181818181818
re-emerging pathogen,subclinical coronavirus infection,0.5820754716981132
re-emerging pathogen,primary pathogen,0.7833333333333333
re-emerging pathogen,infection end temporal region,0.6132653061224489
re-emerging pathogen,drug-based immunosuppressed organism,0.6107142857142857
re-emerging pathogen,infectious disease,0.581578947368421
re-emerging pathogen,double-stranded DNA virus,0.5833333333333334
re-emerging pathogen,site of infection,0.6121621621621621
re-emerging pathogen,immunocompetent organism,0.609090909090909
re-emerging pathogen,pathogen portal of exit,0.636046511627907
re-emerging pathogen,infectious disease incidence,0.5958333333333333
re-emerging pathogen,reservoir of pathogen role,0.7543478260869566
re-emerging pathogen,subclinical SARS-CoV-2 infection,0.5846153846153846
re-emerging pathogen,virus translation stage,0.636046511627907
re-emerging pathogen,disease surveillance objective specification,0.621875
re-emerging pathogen,virus release stage,0.6551282051282051
re-emerging pathogen,infectious agent host role,0.6239130434782608
re-emerging pathogen,source of infection site,0.6318181818181818
re-emerging pathogen,virus replication,0.6391891891891892
re-emerging pathogen,B cell receptor complex,0.6127906976744186
re-emerging pathogen,passive immunization against infectious agent,0.6192307692307693
re-emerging pathogen,systematic infection,0.625
re-emerging pathogen,infection incidence rate,0.609090909090909
re-emerging pathogen,virus host,0.5833333333333334
re-emerging pathogen,double-stranded RNA virus,0.5833333333333334
re-emerging pathogen,pathogen portal of entry role,0.6132653061224489
re-emerging pathogen,virus transcription stage,0.6277777777777778
re-emerging pathogen,infectious disease lifetime prevalence,0.6051724137931035
re-emerging pathogen,pathogen birth temporal region,0.61
re-emerging pathogen,lower respiratory tract disease,0.6068627450980393
re-emerging pathogen,infectious disease incidence proportion,0.6194915254237288
re-emerging pathogen,opportunistic pathogen,0.7119047619047619
re-emerging pathogen,virus generative stage,0.6642857142857143
re-emerging pathogen,acute infectious disease course,0.5872549019607843
re-emerging pathogen,cidal agent disposition,0.6127906976744186
re-emerging pathogen,genetic resistance to pathogen,0.73
re-emerging pathogen,subclinical infection,0.5963414634146341
re-emerging pathogen,simple infection,0.6444444444444444
re-emerging pathogen,droplet pathogen transmission process,0.6429824561403508
re-emerging pathogen,infectious disease sporadicity,0.59
re-emerging pathogen,infection incidence proportion profile,0.6224137931034482
re-emerging pathogen,infectious agent colony,0.6127906976744186
re-emerging pathogen,pathogen transporter,0.65
re-emerging pathogen,infectious disease epidemic,0.5776595744680851
re-emerging pathogen,infectious agent generative stage,0.619811320754717
re-emerging pathogen,disease transmission model,0.6239130434782608
re-emerging pathogen,pathologically immunosuppressed organism,0.5833333333333334
re-emerging pathogen,negative-sense single-stranded RNA virus,0.6166666666666667
re-emerging pathogen,cidal agent,0.6435483870967742
re-emerging pathogen,pathogen vehicle,0.6722222222222223
re-emerging pathogen,community-acquired infection,0.5958333333333333
re-emerging pathogen,pathogen vector,0.6785714285714286
re-emerging pathogen,pathogen vehicle role,0.6451219512195122
re-emerging pathogen,chronic infectious disease course,0.5820754716981132
re-emerging pathogen,asymptomatic infectious agent carrier,0.5903508771929825
re-emerging pathogen,nursing-home acquired infection,0.6460784313725491
re-emerging pathogen,secondary infection,0.6294871794871795
re-emerging pathogen,infection start temporal region,0.6264705882352941
re-emerging pathogen,infection incidence,0.6038461538461539
re-emerging pathogen,virus disorder,0.5676470588235294
re-emerging pathogen,sterilizing immunity to infectious agent,0.6333333333333333
re-emerging pathogen,primary infection,0.6662162162162162
re-emerging pathogen,process of establishing an infection,0.6464285714285714
re-emerging pathogen,pathogen death process boundary,0.6264705882352941
re-emerging pathogen,immunosuppressed organism,0.6055555555555556
re-emerging pathogen,innate immunity to infectious agent,0.6136363636363636
re-emerging pathogen,virus adhesion susceptible cell,0.6068627450980393
re-emerging pathogen,infection,0.6224137931034482
re-emerging pathogen,static agent disposition,0.609090909090909
re-emerging pathogen,T cell receptor complex,0.6127906976744186
re-emerging pathogen,infectious agent population,0.6414893617021277
re-emerging pathogen,respiratory system disease,0.6021739130434782
re-emerging pathogen,leukocyte-mediated immunity to infectious agent,0.6291044776119403
re-emerging pathogen,indirect pathogen transmission process,0.6396551724137931
re-emerging pathogen,organism population,0.6807692307692308
re-emerging pathogen,humoral immunity to infectious agent,0.6285714285714286
re-emerging pathogen,infectious disease control strategy,0.5954545454545455
re-emerging pathogen,parasite,0.5928571428571429
re-emerging pathogen,infectious disease pandemic,0.598936170212766
re-emerging pathogen,antibody reagent,0.6166666666666667
re-emerging pathogen,viral disease course,0.6
re-emerging pathogen,intracellular infection,0.636046511627907
re-emerging pathogen,secondary infection role,0.609090909090909
re-emerging pathogen,metastatic infection,0.625
re-emerging pathogen,passive immunity to infectious agent,0.6107142857142857
re-emerging pathogen,vaccination against infectious agent,0.6107142857142857
re-emerging pathogen,acute infection,0.6214285714285714
re-emerging pathogen,susceptibility to infectious agent,0.5981481481481481
re-emerging pathogen,epitope site,0.60625
re-emerging pathogen,immunity to pathogen,0.725
re-emerging pathogen,source of infection role,0.6318181818181818
re-emerging pathogen,pathogen host,0.6924242424242425
re-emerging pathogen,chronic infection,0.6121621621621621
re-emerging pathogen,disease course,0.5970588235294118
re-emerging pathogen,infectious disease course,0.5833333333333334
re-emerging pathogen,acquired immunity to infectious agent,0.6254385964912281
re-emerging pathogen,complex infection,0.6391891891891892
re-emerging pathogen,COVID-19 disease incidence proportion,0.6254385964912281
re-emerging pathogen,coronavirus disease course,0.5804347826086956
re-emerging pathogen,infection incidence proportion,0.61
re-emerging pathogen,symptomatic infectious agent carrier,0.5928571428571429
re-emerging pathogen,respiratory droplet virus fomite,0.6038461538461539
re-emerging pathogen,susceptible organism,0.6
re-emerging pathogen,parasite role,0.6015151515151516
re-emerging pathogen,pathogen vector role,0.65
re-emerging pathogen,pathogen portal of exit site,0.6166666666666667
re-emerging pathogen,infectious disease prevalence,0.6132653061224489
re-emerging pathogen,organism substance,0.6078947368421053
re-emerging pathogen,single-stranded DNA virus,0.5833333333333334
re-emerging pathogen,viral disease,0.5712121212121213
re-emerging pathogen,primary infection role,0.6404761904761905
re-emerging pathogen,pathogen portal of entry site,0.6132653061224489
re-emerging pathogen,infection incidence profile,0.598936170212766
re-emerging pathogen,disease,0.5611111111111111
re-emerging pathogen,site,0.575
re-emerging pathogen,pathogen host role,0.6605263157894737
re-emerging pathogen,infection prevalence,0.65
re-emerging pathogen,infectious pathogen transmissibility,0.6464285714285714
re-emerging pathogen,pathogen surveillance,0.6451219512195122
re-emerging pathogen,immunodeficient organism,0.6318181818181818
re-emerging pathogen,pathogen,0.7357142857142857
re-emerging pathogen,pathogen birth process boundary,0.6068627450980393
re-emerging pathogen,infectious human pathogen,0.7166666666666667
re-emerging pathogen,subclinical virus infection,0.5776595744680851
re-emerging pathogen,resistance to pathogen,0.7595238095238095
re-emerging pathogen,establishment of localization in virus host,0.5928571428571429
re-emerging pathogen,immunization against infectious agent,0.6254385964912281
re-emerging pathogen,virus attachment stage,0.6404761904761905
re-emerging pathogen,virus synthesis stage,0.6207317073170732
re-emerging pathogen,pathogen portal of exit role,0.6166666666666667
re-emerging pathogen,infectious agent host,0.6207317073170732
re-emerging pathogen,re-emerging pathogen,0.95
re-emerging pathogen,long-term non-progressing infectious disease course,0.6190140845070422
re-emerging pathogen,viral disease epidemic,0.5928571428571429
re-emerging pathogen,viral disease pandemic,0.6166666666666667
re-emerging pathogen,virus penetration stage,0.6825581395348838
re-emerging pathogen,pathogen seroprevalence,0.636046511627907
re-emerging pathogen,infectious disease endemicity,0.5724489795918367
re-emerging pathogen,contact pathogen transmission process,0.6254385964912281
re-emerging pathogen,herd immunity to infectious organism,0.6107142857142857
re-emerging pathogen,extracellular infection,0.636046511627907
re-emerging pathogen,pathogen transporter role,0.6277777777777778
re-emerging pathogen,infectious agent reservoir,0.6021739130434782
re-emerging pathogen,infection start process boundary,0.6230769230769231
re-emerging pathogen,infectious disease control objective specification,0.6071428571428572
re-emerging pathogen,process of establishing viral infection,0.6364406779661017
re-emerging pathogen,COVID-19 disease course,0.5895348837209302
re-emerging pathogen,infectious disease incidence rate,0.619811320754717
re-emerging pathogen,active immunization against infectious agent,0.621875
re-emerging pathogen,disordered virus,0.5611111111111111
re-emerging pathogen,organism,0.5928571428571429
re-emerging pathogen,virus uncoating stage,0.6451219512195122
re-emerging pathogen,local infection,0.5928571428571429
re-emerging pathogen,infectious agent,0.6444444444444444
re-emerging pathogen,establishment of a clinically abnormal colony,0.5884615384615385
re-emerging pathogen,coronavirus disease,0.5782051282051281
re-emerging pathogen,positive-sense single-stranded RNA virus,0.6166666666666667
re-emerging pathogen,horizontal pathogen transmission process,0.65
re-emerging pathogen,hospital-acquired infection,0.598936170212766
re-emerging pathogen,pathogen death temporal region,0.63
re-emerging pathogen,emerging pathogen,0.9094594594594595
re-emerging pathogen,drug susceptibility of infectious agent,0.6025423728813559
re-emerging pathogen,static agent,0.6375
re-emerging pathogen,pathogen transmission process,0.6132653061224489
immunocompetence,T cell receptor complex,0.6038461538461539
immunocompetence,immunocompetence,0.95
material entity,extended organism,0.6375
material entity,information content entity,0.7182926829268292
material entity,infectious disease mortality rate,0.6166666666666667
material entity,infection incidence rate profile,0.598936170212766
material entity,infectious structure aggregate,0.5611111111111111
material entity,communicability end temporal region,0.65
material entity,geographical entity,0.8029411764705883
material entity,primary pathogen,0.6435483870967742
material entity,infection end temporal region,0.6318181818181818
material entity,drug-based immunosuppressed organism,0.5676470588235294
material entity,SARS-CoV-2 incidence rate,0.6
material entity,double-stranded DNA virus,0.6
material entity,incubation end temporal region,0.65
material entity,site of infection,0.6375
material entity,resistant entity,0.7725806451612902
material entity,double-stranded DNA,0.5970588235294118
material entity,immunocompetent organism,0.6294871794871795
material entity,virulence factor disposition,0.6127906976744186
material entity,disease surveillance objective specification,0.6194915254237288
material entity,case isolation control strategy,0.6456521739130434
material entity,material entity,0.95
material entity,asymptomatic infectious structure carrier,0.6107142857142857
material entity,source of infection site,0.6038461538461539
material entity,architectual structure,0.6662162162162162
material entity,B cell receptor complex,0.581578947368421
material entity,infection incidence rate,0.6038461538461539
material entity,entity,0.7357142857142857
material entity,double-stranded RNA virus,0.6
material entity,communicability end process boundary,0.6068627450980393
material entity,directive information content entity,0.6656862745098039
material entity,acellular structure aggregate,0.5863636363636363
material entity,invasion factor,0.5833333333333334
material entity,latency end process boundary,0.6127906976744186
material entity,realizable entity,0.79375
material entity,pathologically immunosuppressed organism,0.6136363636363636
material entity,negative-sense single-stranded RNA virus,0.5954545454545455
material entity,infectious structure host role,0.5611111111111111
material entity,COVID-19 incidence rate,0.581578947368421
material entity,descriptive information content entity,0.6575471698113208
material entity,establishment of localization in human host,0.5879310344827586
material entity,acellular structure,0.6264705882352941
material entity,primary infection,0.66875
material entity,virulence factor,0.6112903225806451
material entity,incubation end process boundary,0.6021739130434782
material entity,molecular entity,0.7725806451612902
material entity,immunosuppressed organism,0.6
material entity,latency end temporal region,0.6642857142857143
material entity,infectious structure,0.5928571428571429
material entity,T cell receptor complex,0.6078947368421053
material entity,infectious structure host,0.575
material entity,respiratory system disease,0.5963414634146341
material entity,organism population,0.5970588235294118
material entity,infectious structure generative stage,0.6038461538461539
material entity,objective specification,0.6078947368421053
material entity,epitope site,0.6351851851851852
material entity,susceptible organism,0.6214285714285714
material entity,pathogen portal of exit site,0.7058139534883722
material entity,organism substance,0.6015151515151516
material entity,anatomical entity,0.825
material entity,single-stranded DNA virus,0.6
material entity,COVID-19 mortality rate,0.6342105263157894
material entity,geopolitical entity,0.7735294117647058
material entity,primary infection role,0.6391891891891892
material entity,primary immunodeficiency,0.6294871794871795
material entity,pathogen portal of entry site,0.7227272727272727
material entity,symptomatic infectious structure carrier,0.6136363636363636
material entity,site,0.5552631578947369
material entity,primary infectious disposition,0.6277777777777778
material entity,designative information content entity,0.6764150943396227
material entity,double-stranded DNA retrovirus,0.6055555555555556
material entity,object,0.5452380952380953
material entity,immunodeficient organism,0.6294871794871795
material entity,infectious human pathogen,0.6
material entity,colonization of human,0.5888888888888889
material entity,immaterial entity,0.91875
material entity,object aggregate,0.5790322580645162
material entity,blood,0.5
material entity,division of geopolitical entity,0.6891304347826087
material entity,geographical feature,0.6785714285714286
material entity,herd immunity to infectious organism,0.5872549019607843
material entity,action specification,0.65
material entity,processed material,0.6924242424242425
material entity,infectious disease control objective specification,0.5884615384615385
material entity,quality,0.6772727272727272
material entity,infectious disease incidence rate,0.5958333333333333
material entity,single-stranded RNA retrovirus,0.6277777777777778
material entity,organism,0.6239130434782608
material entity,establishment of a clinically abnormal colony,0.5833333333333334
material entity,positive-sense single-stranded RNA virus,0.5772727272727273
material entity,adhesion factor,0.6166666666666667
material entity,material processing,0.7735294117647058
colonized host,virostatic disposition,0.6166666666666667
colonized host,zoonotic disposition,0.6852941176470588
colonized host,infectious disease mortality rate,0.598936170212766
colonized host,infection incidence rate profile,0.6021739130434782
colonized host,SARS-CoV-2 incidence rate,0.6294871794871795
colonized host,virulence factor disposition,0.6166666666666667
colonized host,viral adhesion disposition,0.625
colonized host,parasitostatic disposition,0.6
colonized host,reverse zoonotic disposition,0.6404761904761905
colonized host,establishment of localization in host,0.6460784313725491
colonized host,infectious agent host role,0.65
colonized host,B cell receptor complex,0.5851351351351352
colonized host,infection incidence rate,0.6342105263157894
colonized host,colonized host,0.95
colonized host,virus host,0.7
colonized host,toxin disposition,0.6435483870967742
colonized host,cidal agent disposition,0.6391891891891892
colonized host,parasiticidal disposition,0.6294871794871795
colonized host,transmissibility disposition,0.5928571428571429
colonized host,colonization of host,0.8029411764705883
colonized host,endotoxin disposition,0.65
colonized host,infectious structure host role,0.6318181818181818
colonized host,COVID-19 incidence rate,0.6391891891891892
colonized host,cytotoxin disposition,0.6785714285714286
colonized host,host,0.6722222222222223
colonized host,establishment of localization in human host,0.6254385964912281
colonized host,collective pathogenic disposition,0.6627659574468084
colonized host,neurotoxin disposition,0.6444444444444444
colonized host,dead-end host role,0.66875
colonized host,plan specification,0.60625
colonized host,definitive host role,0.6852941176470588
colonized host,collective disposition,0.7
colonized host,static agent disposition,0.6078947368421053
colonized host,T cell receptor complex,0.5851351351351352
colonized host,infectious structure host,0.6551282051282051
colonized host,entry into host,0.6913793103448276
colonized host,adhesion of symbiont to host,0.6404761904761905
colonized host,immunosuppressive disposition,0.6127906976744186
colonized host,pathogenic disposition,0.6444444444444444
colonized host,entry into host through host barriers,0.5872549019607843
colonized host,infectious disposition,0.6166666666666667
colonized host,bacteriostatic disposition,0.625
colonized host,bactericidal disposition,0.6342105263157894
colonized host,pathogen host,0.7092592592592593
colonized host,invasion disposition,0.6264705882352941
colonized host,viricidal disposition,0.65
colonized host,intermediate host,0.7080645161290323
colonized host,disposition,0.61
colonized host,COVID-19 mortality rate,0.6391891891891892
colonized host,adhesion disposition,0.6264705882352941
colonized host,primary infectious disposition,0.5863636363636363
colonized host,pathogen host role,0.66875
colonized host,intermediate host role,0.6722222222222223
colonized host,dead-end host,0.7092592592592593
colonized host,host role,0.6239130434782608
colonized host,establishment of localization in virus host,0.6254385964912281
colonized host,SARS-COV-2 adhesion disposition,0.6277777777777778
colonized host,invasive disposition,0.6558823529411765
colonized host,infectious agent host,0.6785714285714286
colonized host,fungicidal disposition,0.6444444444444444
colonized host,division of geopolitical entity,0.5611111111111111
colonized host,exotoxin disposition,0.6558823529411765
colonized host,symbiont host role,0.66875
colonized host,opportunistic infectious disposition,0.63
colonized host,enterotoxin disposition,0.6391891891891892
colonized host,infectious disease incidence rate,0.598936170212766
colonized host,collective resistance disposition,0.6414893617021277
colonized host,fungistatic disposition,0.6121621621621621
colonized host,establishment of a clinically abnormal colony,0.5516949152542373
colonized host,definitive host,0.7258620689655172
infectious agent host,virostatic disposition,0.6593023255813953
infectious agent host,information content entity,0.7053191489361703
infectious agent host,zoonotic disposition,0.6207317073170732
infectious agent host,infectious disease mortality rate,0.7462962962962962
infectious agent host,infection incidence rate profile,0.7141509433962264
infectious agent host,infectious structure aggregate,0.7441176470588234
infectious agent host,communicability end temporal region,0.6107142857142857
infectious agent host,infection end temporal region,0.73
infectious agent host,infectious disease,0.7833333333333333
infectious agent host,SARS-CoV-2 incidence rate,0.6239130434782608
infectious agent host,incubation end temporal region,0.6852941176470588
infectious agent host,virulence factor disposition,0.6540816326530612
infectious agent host,viral adhesion disposition,0.6414893617021277
infectious agent host,parasitostatic disposition,0.6627659574468084
infectious agent host,infectious disease incidence,0.7357142857142857
infectious agent host,reverse zoonotic disposition,0.6336734693877552
infectious agent host,establishment of localization in host,0.6913793103448276
infectious agent host,disease surveillance objective specification,0.6038461538461539
infectious agent host,infectious agent host role,0.8968085106382978
infectious agent host,asymptomatic infectious structure carrier,0.6596774193548387
infectious agent host,B cell receptor complex,0.5863636363636363
infectious agent host,passive immunization against infectious agent,0.6924242424242425
infectious agent host,infection incidence rate,0.7388888888888888
infectious agent host,colonized host,0.6785714285714286
infectious agent host,virus host,0.7080645161290323
infectious agent host,infectious disease lifetime prevalence,0.7042372881355932
infectious agent host,toxin disposition,0.6342105263157894
infectious agent host,lower respiratory tract disease,0.6038461538461539
infectious agent host,infectious disease incidence proportion,0.7333333333333333
infectious agent host,acute infectious disease course,0.7576923076923078
infectious agent host,cidal agent disposition,0.7227272727272727
infectious agent host,infectious disorder,0.75
infectious agent host,biological vehicle,0.5782051282051281
infectious agent host,parasiticidal disposition,0.6239130434782608
infectious agent host,infectious disease sporadicity,0.7637254901960785
infectious agent host,communicability end process boundary,0.6078947368421053
infectious agent host,directive information content entity,0.6605263157894737
infectious agent host,infectious agent colony,0.859090909090909
infectious agent host,pathogen transporter,0.6451219512195122
infectious agent host,invasion factor,0.6722222222222223
infectious agent host,transmissibility disposition,0.6132653061224489
infectious agent host,latency end process boundary,0.6132653061224489
infectious agent host,colonization of host,0.6939024390243902
infectious agent host,infectious disease epidemic,0.7416666666666667
infectious agent host,infectious agent generative stage,0.8018518518518519
infectious agent host,disease transmission model,0.6202127659574468
infectious agent host,endotoxin disposition,0.6404761904761905
infectious agent host,cidal agent,0.7
infectious agent host,infectious structure host role,0.7833333333333333
infectious agent host,pathogen vehicle,0.6391891891891892
infectious agent host,COVID-19 incidence rate,0.6318181818181818
infectious agent host,cytotoxin disposition,0.6404761904761905
infectious agent host,pathogen vehicle role,0.6404761904761905
infectious agent host,host,0.61
infectious agent host,chronic infectious disease course,0.7462962962962962
infectious agent host,asymptomatic infectious agent carrier,0.743103448275862
infectious agent host,descriptive information content entity,0.6533898305084747
infectious agent host,COVID-19 epidemic,0.5552631578947369
infectious agent host,sterilizing immunity to infectious agent,0.7122950819672131
infectious agent host,establishment of localization in human host,0.684375
infectious agent host,diseased population,0.625
infectious agent host,virulence factor,0.6391891891891892
infectious agent host,incubation end process boundary,0.6807692307692308
infectious agent host,collective pathogenic disposition,0.6907407407407408
infectious agent host,neurotoxin disposition,0.6593023255813953
infectious agent host,dead-end host role,0.6807692307692308
infectious agent host,definitive host role,0.6939024390243902
infectious agent host,latency end temporal region,0.6166666666666667
infectious agent host,innate immunity to infectious agent,0.7357142857142857
infectious agent host,infectious structure,0.7670731707317073
infectious agent host,collective disposition,0.6593023255813953
infectious agent host,static agent disposition,0.7166666666666667
infectious agent host,T cell receptor complex,0.5863636363636363
infectious agent host,asymptomatic carrier role,0.6021739130434782
infectious agent host,infectious structure host,0.8195652173913044
infectious agent host,infectious agent population,0.8458333333333333
infectious agent host,respiratory system disease,0.598936170212766
infectious agent host,entry into host,0.7277777777777777
infectious agent host,leukocyte-mediated immunity to infectious agent,0.6852941176470588
infectious agent host,adhesion of symbiont to host,0.6948979591836735
infectious agent host,humoral immunity to infectious agent,0.730701754385965
infectious agent host,infectious disease control strategy,0.7714285714285714
infectious agent host,infectious disease pandemic,0.7416666666666667
infectious agent host,infectious structure generative stage,0.760344827586207
infectious agent host,immunosuppressive disposition,0.65
infectious agent host,pathogenic disposition,0.6593023255813953
infectious agent host,viral disease course,0.6451219512195122
infectious agent host,entry into host through host barriers,0.656896551724138
infectious agent host,passive immunity to infectious agent,0.730701754385965
infectious agent host,infectious disposition,0.7755813953488372
infectious agent host,vaccination against infectious agent,0.730701754385965
infectious agent host,susceptibility to infectious agent,0.740909090909091
infectious agent host,bacteriostatic disposition,0.6840425531914894
infectious agent host,bactericidal disposition,0.6277777777777778
infectious agent host,pathogen host,0.7441176470588234
infectious agent host,invasion disposition,0.6695121951219513
infectious agent host,disease course,0.65
infectious agent host,infectious disease course,0.7978260869565217
infectious agent host,viricidal disposition,0.6404761904761905
infectious agent host,acquired immunity to infectious agent,0.7258620689655172
infectious agent host,COVID-19 disease incidence proportion,0.6051724137931035
infectious agent host,coronavirus disease course,0.6627659574468084
infectious agent host,asymptomatic carrier,0.5719512195121951
infectious agent host,biological vehicle role,0.5863636363636363
infectious agent host,symptomatic infectious agent carrier,0.7482456140350877
infectious agent host,intermediate host,0.7394736842105263
infectious agent host,infectious disease prevalence,0.73
infectious agent host,disposition,0.60625
infectious agent host,infected population,0.725
infectious agent host,COVID-19 mortality rate,0.609090909090909
infectious agent host,viral disease,0.5970588235294118
infectious agent host,adhesion disposition,0.6451219512195122
infectious agent host,disease,0.5928571428571429
infectious agent host,symptomatic infectious structure carrier,0.6631147540983606
infectious agent host,primary infectious disposition,0.7245098039215686
infectious agent host,pathogen host role,0.7064102564102563
infectious agent host,designative information content entity,0.6533898305084747
infectious agent host,symptomatic carrier role,0.6055555555555556
infectious agent host,infectious pathogen transmissibility,0.7657894736842106
infectious agent host,intermediate host role,0.7058139534883722
infectious agent host,dead-end host,0.7147058823529412
infectious agent host,host role,0.6166666666666667
infectious agent host,infectious human pathogen,0.7978260869565217
infectious agent host,establishment of localization in virus host,0.66875
infectious agent host,immunization against infectious agent,0.7258620689655172
infectious agent host,SARS-COV-2 adhesion disposition,0.6423076923076922
infectious agent host,invasive disposition,0.6451219512195122
infectious agent host,infectious agent host,0.95
infectious agent host,long-term non-progressing infectious disease course,0.6722222222222223
infectious agent host,viral disease epidemic,0.5895348837209302
infectious agent host,fungicidal disposition,0.636046511627907
infectious agent host,viral disease pandemic,0.5895348837209302
infectious agent host,division of geopolitical entity,0.6615384615384616
infectious agent host,symptomatic carrier,0.575
infectious agent host,infectious disease endemicity,0.75
infectious agent host,function,0.656896551724138
infectious agent host,herd immunity to infectious organism,0.6956140350877194
infectious agent host,pathogen transporter role,0.6239130434782608
infectious agent host,exotoxin disposition,0.6451219512195122
infectious agent host,infectious agent reservoir,0.8329787234042553
infectious agent host,COVID-19 pandemic,0.581578947368421
infectious agent host,action specification,0.6451219512195122
infectious agent host,infectious disease control objective specification,0.717605633802817
infectious agent host,symbiont host role,0.6807692307692308
infectious agent host,opportunistic infectious disposition,0.6956140350877194
infectious agent host,enterotoxin disposition,0.6545454545454545
infectious agent host,polymerase chain reaction,0.6239130434782608
infectious agent host,COVID-19 disease course,0.6318181818181818
infectious agent host,infectious disease incidence rate,0.7462962962962962
infectious agent host,active immunization against infectious agent,0.6961538461538461
infectious agent host,collective resistance disposition,0.6537037037037037
infectious agent host,fungistatic disposition,0.6545454545454545
infectious agent host,infectious agent,0.8824324324324324
infectious agent host,establishment of a clinically abnormal colony,0.6015151515151516
infectious agent host,coronavirus disease,0.625
infectious agent host,adhesion factor,0.6444444444444444
infectious agent host,definitive host,0.7277777777777777
infectious agent host,drug susceptibility of infectious agent,0.7166666666666667
infectious agent host,static agent,0.6924242424242425
macromolecular complex,virostatic disposition,0.5636363636363636
macromolecular complex,zoonotic disposition,0.569047619047619
macromolecular complex,infectious disease mortality rate,0.5954545454545455
macromolecular complex,infection incidence rate profile,0.6166666666666667
macromolecular complex,infectious structure aggregate,0.5846153846153846
macromolecular complex,communicability end temporal region,0.6254385964912281
macromolecular complex,infection end temporal region,0.6068627450980393
macromolecular complex,SARS-CoV-2 incidence rate,0.598936170212766
macromolecular complex,incubation end temporal region,0.6038461538461539
macromolecular complex,site of infection,0.5525641025641026
macromolecular complex,virulence factor disposition,0.61
macromolecular complex,viral adhesion disposition,0.5541666666666667
macromolecular complex,parasitostatic disposition,0.575
macromolecular complex,reverse zoonotic disposition,0.57
macromolecular complex,macromolecular complex,0.95
macromolecular complex,asymptomatic infectious structure carrier,0.6087301587301588
macromolecular complex,source of infection site,0.6021739130434782
macromolecular complex,architectual structure,0.6545454545454545
macromolecular complex,B cell receptor complex,0.7388888888888888
macromolecular complex,infection incidence rate,0.5804347826086956
macromolecular complex,toxin disposition,0.5269230769230769
macromolecular complex,lower respiratory tract disease,0.5820754716981132
macromolecular complex,cidal agent disposition,0.5611111111111111
macromolecular complex,infectious disorder,0.5963414634146341
macromolecular complex,appearance of disorder,0.609090909090909
macromolecular complex,parasiticidal disposition,0.5776595744680851
macromolecular complex,communicability end process boundary,0.6051724137931035
macromolecular complex,acellular structure aggregate,0.6460784313725491
macromolecular complex,transmissibility disposition,0.55
macromolecular complex,latency end process boundary,0.61
macromolecular complex,endotoxin disposition,0.5430232558139535
macromolecular complex,infectious structure host role,0.6230769230769231
macromolecular complex,COVID-19 incidence rate,0.5833333333333334
macromolecular complex,cytotoxin disposition,0.5662790697674418
macromolecular complex,virus disorder,0.5888888888888889
macromolecular complex,acellular structure,0.6939024390243902
macromolecular complex,incubation end process boundary,0.5820754716981132
macromolecular complex,SARS-CoV-2 disorder,0.5963414634146341
macromolecular complex,collective pathogenic disposition,0.5954545454545455
macromolecular complex,neurotoxin disposition,0.5636363636363636
macromolecular complex,molecular entity,0.7394736842105263
macromolecular complex,latency end temporal region,0.6132653061224489
macromolecular complex,infectious structure,0.5928571428571429
macromolecular complex,virus adhesion susceptible cell,0.6009433962264151
macromolecular complex,collective disposition,0.609090909090909
macromolecular complex,static agent disposition,0.558695652173913
macromolecular complex,T cell receptor complex,0.7388888888888888
macromolecular complex,infectious structure host,0.598936170212766
macromolecular complex,respiratory system disease,0.5958333333333333
macromolecular complex,infectious structure generative stage,0.5686440677966101
macromolecular complex,immunosuppressive disposition,0.5872549019607843
macromolecular complex,disordered prion,0.581578947368421
macromolecular complex,pathogenic disposition,0.5863636363636363
macromolecular complex,cell,0.6038461538461539
macromolecular complex,infectious disposition,0.5636363636363636
macromolecular complex,bacteriostatic disposition,0.5958333333333333
macromolecular complex,epitope site,0.5676470588235294
macromolecular complex,bactericidal disposition,0.6021739130434782
macromolecular complex,invasion disposition,0.5452380952380953
macromolecular complex,viricidal disposition,0.5662790697674418
macromolecular complex,complex infection,0.6551282051282051
macromolecular complex,pathogen portal of exit site,0.61
macromolecular complex,disposition,0.5106060606060606
macromolecular complex,COVID-19 mortality rate,0.6055555555555556
macromolecular complex,adhesion disposition,0.5452380952380953
macromolecular complex,pathogen portal of entry site,0.6068627450980393
macromolecular complex,symptomatic infectious structure carrier,0.6112903225806451
macromolecular complex,primary infectious disposition,0.6038461538461539
macromolecular complex,coronavirus disorder,0.6404761904761905
macromolecular complex,SARS-COV-2 adhesion susceptible cell,0.6051724137931035
macromolecular complex,virus synthesis stage,0.5430232558139535
macromolecular complex,SARS-COV-2 adhesion disposition,0.5632075471698114
macromolecular complex,invasive disposition,0.5452380952380953
macromolecular complex,fungicidal disposition,0.5409090909090909
macromolecular complex,acute respiratory distress syndrome,0.6254385964912281
macromolecular complex,disorder,0.55
macromolecular complex,exotoxin disposition,0.5452380952380953
macromolecular complex,immunoglobulin complex,0.7681818181818181
macromolecular complex,action specification,0.6166666666666667
macromolecular complex,SARS-CoV-2 synthesis stage,0.575
macromolecular complex,opportunistic infectious disposition,0.5706896551724138
macromolecular complex,quality,0.553448275862069
macromolecular complex,enterotoxin disposition,0.5611111111111111
macromolecular complex,polymerase chain reaction,0.6202127659574468
macromolecular complex,infectious disease incidence rate,0.5772727272727273
macromolecular complex,disordered virus,0.5552631578947369
macromolecular complex,collective resistance disposition,0.5954545454545455
macromolecular complex,fungistatic disposition,0.5388888888888889
macromolecular complex,establishment of a clinically abnormal colony,0.6291044776119403
macromolecular complex,cell space,0.6375
production,communicability end temporal region,0.6055555555555556
production,infection end temporal region,0.6038461538461539
production,incubation end temporal region,0.6
production,negative regulation of production,0.6825581395348838
production,B cell receptor complex,0.5712121212121213
production,lower respiratory tract disease,0.5963414634146341
production,communicability end process boundary,0.5804347826086956
production,latency end process boundary,0.6078947368421053
production,PCR product,0.7833333333333333
production,incubation end process boundary,0.5963414634146341
production,latency end temporal region,0.5851351351351352
production,T cell receptor complex,0.5712121212121213
production,production,0.95
production,action specification,0.65
production,establishment of a clinically abnormal colony,0.5409090909090909
biological role,biological regulation,0.8111111111111111
biological role,primary pathogen,0.6112903225806451
biological role,reservoir of pathogen role,0.6695121951219513
biological role,infectious agent host role,0.6451219512195122
biological role,B cell receptor complex,0.6605263157894737
biological role,pathogen portal of entry role,0.6545454545454545
biological role,lower respiratory tract disease,0.6021739130434782
biological role,acute infectious disease course,0.6021739130434782
biological role,role,0.6605263157894737
biological role,appearance of disorder,0.5581081081081081
biological role,biological vehicle,0.8439393939393939
biological role,mutualist role,0.6913793103448276
biological role,infectious structure host role,0.6277777777777778
biological role,pathogen vehicle role,0.7277777777777777
biological role,chronic infectious disease course,0.5958333333333333
biological role,mechanical vector role,0.6932432432432433
biological role,primary infection,0.575
biological role,dead-end host role,0.6318181818181818
biological role,definitive host role,0.65
biological role,innate immunity to infectious agent,0.57
biological role,virus adhesion susceptible cell,0.5804347826086956
biological role,anatomical space,0.6758064516129032
biological role,T cell receptor complex,0.6342105263157894
biological role,asymptomatic carrier role,0.675
biological role,biological vector,0.825
biological role,innate immune response,0.6121621621621621
biological role,viral disease course,0.65
biological role,secondary infection role,0.6551282051282051
biological role,cell,0.6078947368421053
biological role,source of infection role,0.6807692307692308
biological role,disease course,0.6224137931034482
biological role,infectious disease course,0.625
biological role,coronavirus disease course,0.6207317073170732
biological role,biological vehicle role,0.8447368421052631
biological role,symbiont role,0.7357142857142857
biological role,parasite role,0.6642857142857143
biological role,pathogen vector role,0.6785714285714286
biological role,anatomical entity,0.66875
biological role,primary infection role,0.6662162162162162
biological role,primary immunodeficiency,0.5782051282051281
biological role,biological role,0.95
biological role,biological process,0.8742424242424243
biological role,biological vector role,0.8554054054054054
biological role,primary infectious disposition,0.5611111111111111
biological role,pathogen host role,0.6621212121212122
biological role,symptomatic carrier role,0.6807692307692308
biological role,SARS-COV-2 adhesion susceptible cell,0.5676470588235294
biological role,intermediate host role,0.6662162162162162
biological role,host role,0.7
biological role,pathogen portal of exit role,0.6593023255813953
biological role,long-term non-progressing infectious disease course,0.5863636363636363
biological role,commensal role,0.7258620689655172
biological role,epitope role,0.7092592592592593
biological role,function,0.5369565217391304
biological role,pathogen transporter role,0.65
biological role,antigen role,0.7092592592592593
biological role,action specification,0.6214285714285714
biological role,symbiont host role,0.7227272727272727
biological role,fomite role,0.7192307692307692
biological role,negative regulation of biological process,0.7
biological role,COVID-19 disease course,0.6078947368421053
biological role,reagent role,0.6722222222222223
biological role,viral load,0.65
biological role,establishment of a clinically abnormal colony,0.65
biological role,cell space,0.61
intracellular infection,virus aggregate,0.6342105263157894
intracellular infection,source of infection,0.7595238095238095
intracellular infection,virostatic disposition,0.6722222222222223
intracellular infection,zoonotic disposition,0.6593023255813953
intracellular infection,infectious disease mortality rate,0.6107142857142857
intracellular infection,infection incidence rate profile,0.6318181818181818
intracellular infection,communicability end temporal region,0.6396551724137931
intracellular infection,subclinical coronavirus infection,0.7357142857142857
intracellular infection,infection end temporal region,0.6615384615384616
intracellular infection,infectious disease,0.6451219512195122
intracellular infection,double-stranded DNA virus,0.5958333333333333
intracellular infection,incubation end temporal region,0.6764150943396227
intracellular infection,site of infection,0.775
intracellular infection,virulence factor disposition,0.6852941176470588
intracellular infection,viral adhesion disposition,0.6744897959183673
intracellular infection,parasitostatic disposition,0.6540816326530612
intracellular infection,infectious disease incidence,0.6656862745098039
intracellular infection,reverse zoonotic disposition,0.6460784313725491
intracellular infection,subclinical SARS-CoV-2 infection,0.740909090909091
intracellular infection,virus translation stage,0.6673913043478261
intracellular infection,disease surveillance objective specification,0.658955223880597
intracellular infection,virus release stage,0.6166666666666667
intracellular infection,source of infection site,0.7265957446808511
intracellular infection,virus,0.5571428571428572
intracellular infection,virus replication,0.7
intracellular infection,B cell receptor complex,0.6456521739130434
intracellular infection,systematic infection,0.7523255813953489
intracellular infection,infection incidence rate,0.6414893617021277
intracellular infection,virus host,0.6015151515151516
intracellular infection,double-stranded RNA virus,0.5958333333333333
intracellular infection,virus transcription stage,0.6791666666666666
intracellular infection,infectious disease lifetime prevalence,0.6467213114754098
intracellular infection,toxin disposition,0.65
intracellular infection,lower respiratory tract disease,0.5981481481481481
intracellular infection,infectious disease incidence proportion,0.6758064516129032
intracellular infection,virus generative stage,0.6277777777777778
intracellular infection,acute infectious disease course,0.6722222222222223
intracellular infection,cidal agent disposition,0.6673913043478261
intracellular infection,infectious disorder,0.6404761904761905
intracellular infection,subclinical infection,0.7681818181818181
intracellular infection,appearance of disorder,0.6277777777777778
intracellular infection,simple infection,0.7576923076923078
intracellular infection,parasiticidal disposition,0.6583333333333334
intracellular infection,infectious disease sporadicity,0.619811320754717
intracellular infection,communicability end process boundary,0.5855932203389831
intracellular infection,acellular structure aggregate,0.6807692307692308
intracellular infection,infection incidence proportion profile,0.6467213114754098
intracellular infection,transmissibility disposition,0.6460784313725491
intracellular infection,latency end process boundary,0.5872549019607843
intracellular infection,infectious disease epidemic,0.63
intracellular infection,disease transmission model,0.6132653061224489
intracellular infection,endotoxin disposition,0.6318181818181818
intracellular infection,negative-sense single-stranded RNA virus,0.5928571428571429
intracellular infection,cytotoxin disposition,0.6318181818181818
intracellular infection,community-acquired infection,0.7637254901960785
intracellular infection,chronic infectious disease course,0.6464285714285714
intracellular infection,nursing-home acquired infection,0.7462962962962962
intracellular infection,COVID-19 epidemic,0.575
intracellular infection,secondary infection,0.7595238095238095
intracellular infection,infection start temporal region,0.6537037037037037
intracellular infection,infection incidence,0.6642857142857143
intracellular infection,virus disorder,0.6121621621621621
intracellular infection,acellular structure,0.7357142857142857
intracellular infection,primary infection,0.775
intracellular infection,process of establishing an infection,0.7042372881355932
intracellular infection,incubation end process boundary,0.6537037037037037
intracellular infection,SARS-CoV-2 disorder,0.569047619047619
intracellular infection,collective pathogenic disposition,0.6285714285714286
intracellular infection,neurotoxin disposition,0.6722222222222223
intracellular infection,latency end temporal region,0.65
intracellular infection,virus adhesion susceptible cell,0.6166666666666667
intracellular infection,collective disposition,0.65
intracellular infection,infection,0.73125
intracellular infection,static agent disposition,0.6627659574468084
intracellular infection,T cell receptor complex,0.6673913043478261
intracellular infection,respiratory system disease,0.5928571428571429
intracellular infection,communicability interval,0.598936170212766
intracellular infection,infectious disease control strategy,0.6224137931034482
intracellular infection,infectious disease pandemic,0.63
intracellular infection,immunosuppressive disposition,0.6423076923076922
intracellular infection,pathogenic disposition,0.6277777777777778
intracellular infection,viral disease course,0.6593023255813953
intracellular infection,intracellular infection,0.95
intracellular infection,secondary infection role,0.7265957446808511
intracellular infection,metastatic infection,0.7523255813953489
intracellular infection,cell,0.5981481481481481
intracellular infection,infectious disposition,0.6722222222222223
intracellular infection,acute infection,0.7921052631578948
intracellular infection,bacteriostatic disposition,0.6540816326530612
intracellular infection,bactericidal disposition,0.6627659574468084
intracellular infection,source of infection role,0.7265957446808511
intracellular infection,chronic infection,0.75
intracellular infection,invasion disposition,0.6593023255813953
intracellular infection,disease course,0.6121621621621621
intracellular infection,infectious disease course,0.6375
intracellular infection,viricidal disposition,0.6772727272727272
intracellular infection,complex infection,0.75
intracellular infection,COVID-19 disease incidence proportion,0.65
intracellular infection,coronavirus disease course,0.6132653061224489
intracellular infection,infection incidence proportion,0.6764150943396227
intracellular infection,respiratory droplet virus fomite,0.6136363636363636
intracellular infection,infectious disease prevalence,0.6230769230769231
intracellular infection,disposition,0.6264705882352941
intracellular infection,single-stranded DNA virus,0.6375
intracellular infection,viral disease,0.6444444444444444
intracellular infection,primary infection role,0.7388888888888888
intracellular infection,adhesion disposition,0.636046511627907
intracellular infection,infection incidence profile,0.63
intracellular infection,contagiousness,0.6121621621621621
intracellular infection,disease,0.5833333333333334
intracellular infection,primary infectious disposition,0.6952830188679244
intracellular infection,infection prevalence,0.6593023255813953
intracellular infection,coronavirus disorder,0.5895348837209302
intracellular infection,SARS-COV-2 adhesion susceptible cell,0.5855932203389831
intracellular infection,subclinical virus infection,0.75
intracellular infection,establishment of localization in virus host,0.6166666666666667
intracellular infection,virus attachment stage,0.6055555555555556
intracellular infection,virus synthesis stage,0.609090909090909
intracellular infection,SARS-COV-2 adhesion disposition,0.6166666666666667
intracellular infection,invasive disposition,0.6825581395348838
intracellular infection,long-term non-progressing infectious disease course,0.6256756756756756
intracellular infection,viral disease epidemic,0.65
intracellular infection,communicability start temporal region,0.6166666666666667
intracellular infection,fungicidal disposition,0.65
intracellular infection,viral disease pandemic,0.65
intracellular infection,virus penetration stage,0.6673913043478261
intracellular infection,acute respiratory distress syndrome,0.6051724137931035
intracellular infection,infectious disease endemicity,0.6423076923076922
intracellular infection,disorder,0.5790322580645162
intracellular infection,communicability,0.581578947368421
intracellular infection,extracellular infection,0.9065217391304347
intracellular infection,exotoxin disposition,0.636046511627907
intracellular infection,infection start process boundary,0.6136363636363636
intracellular infection,action specification,0.6825581395348838
intracellular infection,infectious disease control objective specification,0.6417808219178082
intracellular infection,opportunistic infectious disposition,0.6703389830508475
intracellular infection,process of establishing viral infection,0.6919354838709677
intracellular infection,enterotoxin disposition,0.6673913043478261
intracellular infection,COVID-19 disease course,0.5804347826086956
intracellular infection,infectious disease incidence rate,0.6464285714285714
intracellular infection,communicability start process boundary,0.5975409836065574
intracellular infection,disordered virus,0.6038461538461539
intracellular infection,collective resistance disposition,0.6464285714285714
intracellular infection,fungistatic disposition,0.6673913043478261
intracellular infection,virus uncoating stage,0.6545454545454545
intracellular infection,local infection,0.7657894736842106
intracellular infection,establishment of a clinically abnormal colony,0.6558823529411765
intracellular infection,coronavirus disease,0.5928571428571429
intracellular infection,positive-sense single-stranded RNA virus,0.5928571428571429
intracellular infection,hospital-acquired infection,0.77
intracellular infection,cell space,0.6318181818181818
temporal region,communicability end temporal region,0.75
temporal region,infection end temporal region,0.7909090909090909
temporal region,incubation end temporal region,0.7833333333333333
temporal region,two-dimensional spatial region,0.7166666666666667
temporal region,one-dimensional temporal region,0.7760869565217391
temporal region,temporal region,0.95
temporal region,disease surveillance objective specification,0.5855932203389831
temporal region,material entity,0.7166666666666667
temporal region,B cell receptor complex,0.6078947368421053
temporal region,double-stranded RNA virus,0.6
temporal region,pathogen birth temporal region,0.7833333333333333
temporal region,lower respiratory tract disease,0.6021739130434782
temporal region,infectious disease incidence proportion,0.5981481481481481
temporal region,acute infectious disease course,0.6021739130434782
temporal region,communicability end process boundary,0.6068627450980393
temporal region,infection incidence proportion profile,0.6009433962264151
temporal region,SARS-CoV-2 incidence proportion,0.6021739130434782
temporal region,spatiotemporal region,0.8666666666666667
temporal region,latency end process boundary,0.6127906976744186
temporal region,negative-sense single-stranded RNA virus,0.5772727272727273
temporal region,zero-dimensional spatial region,0.7108695652173913
temporal region,zero-dimensional temporal region,0.7691489361702127
temporal region,chronic infectious disease course,0.575
temporal region,infection start temporal region,0.7760869565217391
temporal region,establishment of localization in human host,0.5879310344827586
temporal region,incubation end process boundary,0.6021739130434782
temporal region,geographical region,0.8029411764705883
temporal region,latency end temporal region,0.8071428571428573
temporal region,T cell receptor complex,0.6342105263157894
temporal region,viral disease course,0.6214285714285714
temporal region,three-dimensional spatial region,0.7265957446808511
temporal region,objective specification,0.6342105263157894
temporal region,country,0.5409090909090909
temporal region,disease course,0.6224137931034482
temporal region,infectious disease course,0.6
temporal region,COVID-19 disease incidence proportion,0.5846153846153846
temporal region,coronavirus disease course,0.5963414634146341
temporal region,infection incidence proportion,0.6277777777777778
temporal region,place closure control strategy,0.6277777777777778
temporal region,object,0.5452380952380953
temporal region,infectious human pathogen,0.6
temporal region,colonization of human,0.5888888888888889
temporal region,object aggregate,0.6112903225806451
temporal region,long-term non-progressing infectious disease course,0.6015151515151516
temporal region,communicability start temporal region,0.7384615384615384
temporal region,geospatial region,0.79375
temporal region,division of geopolitical entity,0.6239130434782608
temporal region,processed material,0.6015151515151516
temporal region,infectious disease control objective specification,0.6038461538461539
temporal region,COVID-19 disease course,0.581578947368421
temporal region,single-stranded RNA retrovirus,0.6277777777777778
temporal region,local infection,0.7166666666666667
temporal region,establishment of a clinically abnormal colony,0.6
temporal region,positive-sense single-stranded RNA virus,0.5772727272727273
temporal region,one-dimensional spatial region,0.7166666666666667
temporal region,spatial region,0.7948275862068965
temporal region,pathogen death temporal region,0.7833333333333333
temporal region,material processing,0.7441176470588234
resistant entity,extended organism,0.6318181818181818
resistant entity,information content entity,0.7357142857142857
resistant entity,immune response,0.6112903225806451
resistant entity,infectious disease mortality rate,0.6540816326530612
resistant entity,infection incidence rate profile,0.6166666666666667
resistant entity,infectious structure aggregate,0.6239130434782608
resistant entity,communicability end temporal region,0.6068627450980393
resistant entity,geographical entity,0.7357142857142857
resistant entity,infection end temporal region,0.6277777777777778
resistant entity,drug-based immunosuppressed organism,0.5846153846153846
resistant entity,SARS-CoV-2 incidence rate,0.6207317073170732
resistant entity,incubation end temporal region,0.6239130434782608
resistant entity,resistant entity,0.95
resistant entity,immunocompetent organism,0.625
resistant entity,virulence factor disposition,0.609090909090909
resistant entity,case isolation control strategy,0.6627659574468084
resistant entity,material entity,0.7725806451612902
resistant entity,asymptomatic infectious structure carrier,0.6078947368421053
resistant entity,architectual structure,0.6342105263157894
resistant entity,B cell receptor complex,0.5782051282051281
resistant entity,infection incidence rate,0.625
resistant entity,entity,0.7227272727272727
resistant entity,double-stranded RNA virus,0.6451219512195122
resistant entity,communicability end process boundary,0.5846153846153846
resistant entity,directive information content entity,0.7
resistant entity,acellular structure aggregate,0.6055555555555556
resistant entity,invasion factor,0.6112903225806451
resistant entity,latency end process boundary,0.609090909090909
resistant entity,realizable entity,0.7833333333333333
resistant entity,pathologically immunosuppressed organism,0.575
resistant entity,negative-sense single-stranded RNA virus,0.6285714285714286
resistant entity,infectious structure host role,0.6021739130434782
resistant entity,susceptible population,0.6078947368421053
resistant entity,COVID-19 incidence rate,0.5782051282051281
resistant entity,descriptive information content entity,0.7092592592592593
resistant entity,establishment of localization in human host,0.6194915254237288
resistant entity,acellular structure,0.5928571428571429
resistant entity,virulence factor,0.60625
resistant entity,incubation end process boundary,0.598936170212766
resistant entity,molecular entity,0.73125
resistant entity,immunosuppressed organism,0.6207317073170732
resistant entity,latency end temporal region,0.6127906976744186
resistant entity,infectious structure,0.6166666666666667
resistant entity,virus adhesion susceptible cell,0.6414893617021277
resistant entity,T cell receptor complex,0.5782051282051281
resistant entity,infectious structure host,0.6207317073170732
resistant entity,respiratory system disease,0.6642857142857143
resistant entity,organism population,0.6214285714285714
resistant entity,infectious structure generative stage,0.6575471698113208
resistant entity,innate immune response,0.6078947368421053
resistant entity,susceptible organism,0.6166666666666667
resistant entity,organism substance,0.6558823529411765
resistant entity,anatomical entity,0.7530303030303032
resistant entity,COVID-19 mortality rate,0.6038461538461539
resistant entity,geopolitical entity,0.7642857142857143
resistant entity,symptomatic infectious structure carrier,0.6107142857142857
resistant entity,designative information content entity,0.7092592592592593
resistant entity,humoral immune response,0.6038461538461539
resistant entity,SARS-COV-2 adhesion susceptible cell,0.6230769230769231
resistant entity,object,0.5409090909090909
resistant entity,immunodeficient organism,0.625
resistant entity,infectious human pathogen,0.6451219512195122
resistant entity,colonization of human,0.5851351351351352
resistant entity,negative regulation of immune response,0.5796296296296296
resistant entity,immaterial entity,0.7530303030303032
resistant entity,object aggregate,0.60625
resistant entity,division of geopolitical entity,0.6840425531914894
resistant entity,geographical feature,0.6166666666666667
resistant entity,herd immunity to infectious organism,0.6038461538461539
resistant entity,action specification,0.6166666666666667
resistant entity,processed material,0.6852941176470588
resistant entity,immune population,0.6015151515151516
resistant entity,quality,0.6239130434782608
resistant entity,infectious disease incidence rate,0.6336734693877552
resistant entity,single-stranded RNA retrovirus,0.6673913043478261
resistant entity,adaptive immune response,0.6
resistant entity,organism,0.6166666666666667
resistant entity,establishment of a clinically abnormal colony,0.6139344262295081
resistant entity,positive-sense single-stranded RNA virus,0.6285714285714286
resistant entity,adhesion factor,0.6435483870967742
resistant entity,material processing,0.6214285714285714
infectious disease incidence rate,virus aggregate,0.6375
infectious disease incidence rate,source of infection,0.6230769230769231
infectious disease incidence rate,virostatic disposition,0.65
infectious disease incidence rate,zoonotic disposition,0.6575471698113208
infectious disease incidence rate,infectious disease mortality rate,0.8287878787878787
infectious disease incidence rate,infection incidence rate profile,0.8038461538461539
infectious disease incidence rate,infectious structure aggregate,0.7515873015873015
infectious disease incidence rate,communicability end temporal region,0.6411764705882353
infectious disease incidence rate,subclinical coronavirus infection,0.6318181818181818
infectious disease incidence rate,infection end temporal region,0.7080645161290323
infectious disease incidence rate,infectious disease,0.8029411764705883
infectious disease incidence rate,SARS-CoV-2 incidence rate,0.760344827586207
infectious disease incidence rate,double-stranded DNA virus,0.6224137931034482
infectious disease incidence rate,incubation end temporal region,0.6722222222222223
infectious disease incidence rate,site of infection,0.63
infectious disease incidence rate,virulence factor disposition,0.6795081967213115
infectious disease incidence rate,viral adhesion disposition,0.6533898305084747
infectious disease incidence rate,parasitostatic disposition,0.6533898305084747
infectious disease incidence rate,infectious disease incidence,0.909016393442623
infectious disease incidence rate,reverse zoonotic disposition,0.630327868852459
infectious disease incidence rate,subclinical SARS-CoV-2 infection,0.65
infectious disease incidence rate,virus translation stage,0.6464285714285714
infectious disease incidence rate,disease surveillance objective specification,0.6707792207792208
infectious disease incidence rate,virus release stage,0.6615384615384616
infectious disease incidence rate,infectious agent host role,0.738135593220339
infectious disease incidence rate,material entity,0.5958333333333333
infectious disease incidence rate,asymptomatic infectious structure carrier,0.6932432432432433
infectious disease incidence rate,source of infection site,0.6780701754385965
infectious disease incidence rate,virus,0.5289473684210526
infectious disease incidence rate,virus replication,0.63
infectious disease incidence rate,B cell receptor complex,0.5928571428571429
infectious disease incidence rate,passive immunization against infectious agent,0.6551282051282051
infectious disease incidence rate,systematic infection,0.6386792452830189
infectious disease incidence rate,infection incidence rate,0.8535087719298246
infectious disease incidence rate,virus host,0.5895348837209302
infectious disease incidence rate,double-stranded RNA virus,0.6224137931034482
infectious disease incidence rate,virus transcription stage,0.656896551724138
infectious disease incidence rate,infectious disease lifetime prevalence,0.8161971830985917
infectious disease incidence rate,toxin disposition,0.65
infectious disease incidence rate,serology assay,0.5776595744680851
infectious disease incidence rate,lower respiratory tract disease,0.621875
infectious disease incidence rate,infectious disease incidence proportion,0.8805555555555555
infectious disease incidence rate,virus generative stage,0.65
infectious disease incidence rate,acute infectious disease course,0.79375
infectious disease incidence rate,cidal agent disposition,0.6464285714285714
infectious disease incidence rate,infectious disorder,0.7769230769230769
infectious disease incidence rate,subclinical infection,0.6351851851851852
infectious disease incidence rate,appearance of disorder,0.6318181818181818
infectious disease incidence rate,simple infection,0.6336734693877552
infectious disease incidence rate,parasiticidal disposition,0.6396551724137931
infectious disease incidence rate,infectious disease sporadicity,0.8150793650793651
infectious disease incidence rate,communicability end process boundary,0.6384057971014493
infectious disease incidence rate,infection incidence proportion profile,0.7598591549295775
infectious disease incidence rate,infectious agent colony,0.7357142857142857
infectious disease incidence rate,SARS-CoV-2 incidence proportion,0.7
infectious disease incidence rate,transmissibility disposition,0.630327868852459
infectious disease incidence rate,latency end process boundary,0.6139344262295081
infectious disease incidence rate,infectious disease epidemic,0.8333333333333335
infectious disease incidence rate,infectious agent generative stage,0.7681818181818181
infectious disease incidence rate,disease transmission model,0.6703389830508475
infectious disease incidence rate,endotoxin disposition,0.6537037037037037
infectious disease incidence rate,negative-sense single-stranded RNA virus,0.682876712328767
infectious disease incidence rate,infectious structure host role,0.7198412698412698
infectious disease incidence rate,COVID-19 incidence rate,0.7714285714285714
infectious disease incidence rate,viral plaque assay,0.5676470588235294
infectious disease incidence rate,cytotoxin disposition,0.6537037037037037
infectious disease incidence rate,community-acquired infection,0.6467213114754098
infectious disease incidence rate,chronic infectious disease course,0.7833333333333333
infectious disease incidence rate,asymptomatic infectious agent carrier,0.7071428571428571
infectious disease incidence rate,nursing-home acquired infection,0.653125
infectious disease incidence rate,COVID-19 epidemic,0.61
infectious disease incidence rate,secondary infection,0.6615384615384616
infectious disease incidence rate,infection start temporal region,0.7
infectious disease incidence rate,infection incidence,0.7961538461538461
infectious disease incidence rate,virus disorder,0.6627659574468084
infectious disease incidence rate,sterilizing immunity to infectious agent,0.6554794520547945
infectious disease incidence rate,diseased population,0.6615384615384616
infectious disease incidence rate,primary infection,0.63
infectious disease incidence rate,process of establishing an infection,0.6384057971014493
infectious disease incidence rate,incubation end process boundary,0.66875
infectious disease incidence rate,SARS-CoV-2 disorder,0.6230769230769231
infectious disease incidence rate,collective pathogenic disposition,0.6469696969696969
infectious disease incidence rate,neurotoxin disposition,0.6681818181818181
infectious disease incidence rate,COVID-19 incidence,0.7049019607843137
infectious disease incidence rate,latency end temporal region,0.6166666666666667
infectious disease incidence rate,innate immunity to infectious agent,0.6705882352941177
infectious disease incidence rate,infectious structure,0.7330188679245283
infectious disease incidence rate,virus adhesion susceptible cell,0.66875
infectious disease incidence rate,collective disposition,0.6681818181818181
infectious disease incidence rate,infection,0.6642857142857143
infectious disease incidence rate,static agent disposition,0.6429824561403508
infectious disease incidence rate,T cell receptor complex,0.6107142857142857
infectious disease incidence rate,infectious structure host,0.7258620689655172
infectious disease incidence rate,infectious agent population,0.7333333333333333
infectious disease incidence rate,respiratory system disease,0.6533898305084747
infectious disease incidence rate,leukocyte-mediated immunity to infectious agent,0.65
infectious disease incidence rate,humoral immunity to infectious agent,0.6673913043478261
infectious disease incidence rate,infectious disease control strategy,0.8323529411764706
infectious disease incidence rate,infectious disease pandemic,0.8333333333333335
infectious disease incidence rate,infectious structure generative stage,0.75
infectious disease incidence rate,immunosuppressive disposition,0.6596774193548387
infectious disease incidence rate,pathogenic disposition,0.6318181818181818
infectious disease incidence rate,viral disease course,0.6952830188679244
infectious disease incidence rate,intracellular infection,0.6464285714285714
infectious disease incidence rate,secondary infection role,0.6956140350877194
infectious disease incidence rate,metastatic infection,0.6386792452830189
infectious disease incidence rate,passive immunity to infectious agent,0.6673913043478261
infectious disease incidence rate,infectious disposition,0.7772727272727272
infectious disease incidence rate,vaccination against infectious agent,0.6818840579710145
infectious disease incidence rate,acute infection,0.6375
infectious disease incidence rate,susceptibility to infectious agent,0.6738805970149254
infectious disease incidence rate,bacteriostatic disposition,0.6703389830508475
infectious disease incidence rate,bactericidal disposition,0.6429824561403508
infectious disease incidence rate,source of infection role,0.6605263157894737
infectious disease incidence rate,chronic infection,0.63
infectious disease incidence rate,invasion disposition,0.6764150943396227
infectious disease incidence rate,disease course,0.6840425531914894
infectious disease incidence rate,infectious disease course,0.8293103448275861
infectious disease incidence rate,viricidal disposition,0.6537037037037037
infectious disease incidence rate,acquired immunity to infectious agent,0.6642857142857143
infectious disease incidence rate,complex infection,0.63
infectious disease incidence rate,COVID-19 disease incidence proportion,0.7785714285714286
infectious disease incidence rate,coronavirus disease course,0.7211864406779661
infectious disease incidence rate,infection incidence proportion,0.7833333333333333
infectious disease incidence rate,symptomatic infectious agent carrier,0.7108695652173913
infectious disease incidence rate,respiratory droplet virus fomite,0.6192307692307693
infectious disease incidence rate,infectious disease prevalence,0.8209677419354838
infectious disease incidence rate,disposition,0.609090909090909
infectious disease incidence rate,single-stranded DNA virus,0.6396551724137931
infectious disease incidence rate,infected population,0.6615384615384616
infectious disease incidence rate,COVID-19 mortality rate,0.6285714285714286
infectious disease incidence rate,viral disease,0.6456521739130434
infectious disease incidence rate,primary infection role,0.6681818181818181
infectious disease incidence rate,adhesion disposition,0.6575471698113208
infectious disease incidence rate,infection incidence profile,0.8
infectious disease incidence rate,disease,0.625
infectious disease incidence rate,symptomatic infectious structure carrier,0.6965753424657534
infectious disease incidence rate,primary infectious disposition,0.7357142857142857
infectious disease incidence rate,infection prevalence,0.7330188679245283
infectious disease incidence rate,coronavirus disorder,0.6575471698113208
infectious disease incidence rate,infectious pathogen transmissibility,0.7108695652173913
infectious disease incidence rate,SARS-CoV-2 incidence,0.6952830188679244
infectious disease incidence rate,infectious human pathogen,0.743103448275862
infectious disease incidence rate,subclinical virus infection,0.65
infectious disease incidence rate,establishment of localization in virus host,0.6342105263157894
infectious disease incidence rate,immunization against infectious agent,0.6785714285714286
infectious disease incidence rate,virus attachment stage,0.65
infectious disease incidence rate,assay,0.5289473684210526
infectious disease incidence rate,virus synthesis stage,0.6537037037037037
infectious disease incidence rate,SARS-COV-2 adhesion disposition,0.621875
infectious disease incidence rate,invasive disposition,0.6575471698113208
infectious disease incidence rate,infectious agent host,0.7462962962962962
infectious disease incidence rate,long-term non-progressing infectious disease course,0.7119047619047619
infectious disease incidence rate,viral disease epidemic,0.7045454545454546
infectious disease incidence rate,fungicidal disposition,0.65
infectious disease incidence rate,viral disease pandemic,0.7045454545454546
infectious disease incidence rate,virus penetration stage,0.6464285714285714
infectious disease incidence rate,acute respiratory distress syndrome,0.6705882352941177
infectious disease incidence rate,infectious disease endemicity,0.8370967741935484
infectious disease incidence rate,disorder,0.5963414634146341
infectious disease incidence rate,herd immunity to infectious organism,0.6528985507246376
infectious disease incidence rate,extracellular infection,0.6285714285714286
infectious disease incidence rate,exotoxin disposition,0.6575471698113208
infectious disease incidence rate,infectious agent reservoir,0.738135593220339
infectious disease incidence rate,COVID-19 pandemic,0.61
infectious disease incidence rate,infection start process boundary,0.6961538461538461
infectious disease incidence rate,action specification,0.6764150943396227
infectious disease incidence rate,processed material,0.6264705882352941
infectious disease incidence rate,infectious disease control objective specification,0.7632530120481928
infectious disease incidence rate,COVID-19 lifetime prevalence,0.6467213114754098
infectious disease incidence rate,opportunistic infectious disposition,0.7108695652173913
infectious disease incidence rate,process of establishing viral infection,0.6444444444444444
infectious disease incidence rate,enterotoxin disposition,0.6642857142857143
infectious disease incidence rate,COVID-19 disease course,0.7
infectious disease incidence rate,infectious disease incidence rate,0.95
infectious disease incidence rate,COVID-19 prevalence,0.6230769230769231
infectious disease incidence rate,active immunization against infectious agent,0.6577922077922078
infectious disease incidence rate,SARS-COV-2 prevalence,0.6166666666666667
infectious disease incidence rate,disordered virus,0.6132653061224489
infectious disease incidence rate,collective resistance disposition,0.6469696969696969
infectious disease incidence rate,fungistatic disposition,0.6464285714285714
infectious disease incidence rate,virus uncoating stage,0.6537037037037037
infectious disease incidence rate,local infection,0.6375
infectious disease incidence rate,infectious agent,0.7561224489795919
infectious disease incidence rate,establishment of a clinically abnormal colony,0.6294871794871795
infectious disease incidence rate,coronavirus disease,0.6807692307692308
infectious disease incidence rate,positive-sense single-stranded RNA virus,0.6691780821917809
infectious disease incidence rate,hospital-acquired infection,0.6333333333333333
infectious disease incidence rate,drug susceptibility of infectious agent,0.6583333333333334
infectious disease incidence rate,material processing,0.5846153846153846
spatiotemporal region,communicability end temporal region,0.7535714285714286
spatiotemporal region,infection end temporal region,0.81
spatiotemporal region,incubation end temporal region,0.8225490196078431
spatiotemporal region,two-dimensional spatial region,0.7245098039215686
spatiotemporal region,one-dimensional temporal region,0.7961538461538461
spatiotemporal region,temporal region,0.8666666666666667
spatiotemporal region,disease surveillance objective specification,0.6192307692307693
spatiotemporal region,B cell receptor complex,0.609090909090909
spatiotemporal region,pathogen birth temporal region,0.8225490196078431
spatiotemporal region,lower respiratory tract disease,0.6423076923076922
spatiotemporal region,infectious disease incidence proportion,0.6166666666666667
spatiotemporal region,acute infectious disease course,0.6230769230769231
spatiotemporal region,communicability end process boundary,0.6078947368421053
spatiotemporal region,infection incidence proportion profile,0.6194915254237288
spatiotemporal region,SARS-CoV-2 incidence proportion,0.6423076923076922
spatiotemporal region,spatiotemporal region,0.95
spatiotemporal region,latency end process boundary,0.6132653061224489
spatiotemporal region,zero-dimensional spatial region,0.7192307692307692
spatiotemporal region,zero-dimensional temporal region,0.789622641509434
spatiotemporal region,chronic infectious disease course,0.5981481481481481
spatiotemporal region,infection start temporal region,0.7961538461538461
spatiotemporal region,incubation end process boundary,0.6423076923076922
spatiotemporal region,geographical region,0.75
spatiotemporal region,latency end temporal region,0.8041666666666667
spatiotemporal region,T cell receptor complex,0.609090909090909
spatiotemporal region,viral disease course,0.6207317073170732
spatiotemporal region,three-dimensional spatial region,0.7141509433962264
spatiotemporal region,objective specification,0.6318181818181818
spatiotemporal region,country,0.5571428571428572
spatiotemporal region,disease course,0.6214285714285714
spatiotemporal region,infectious disease course,0.6239130434782608
spatiotemporal region,COVID-19 disease incidence proportion,0.6224137931034482
spatiotemporal region,coronavirus disease course,0.598936170212766
spatiotemporal region,infection incidence proportion,0.6460784313725491
spatiotemporal region,place closure control strategy,0.6656862745098039
spatiotemporal region,object,0.524074074074074
spatiotemporal region,object aggregate,0.6121621621621621
spatiotemporal region,long-term non-progressing infectious disease course,0.6027777777777777
spatiotemporal region,communicability start temporal region,0.760344827586207
spatiotemporal region,geospatial region,0.8184210526315789
spatiotemporal region,division of geopolitical entity,0.6615384615384616
spatiotemporal region,infectious disease control objective specification,0.6190140845070422
spatiotemporal region,COVID-19 disease course,0.5863636363636363
spatiotemporal region,local infection,0.6722222222222223
spatiotemporal region,establishment of a clinically abnormal colony,0.6166666666666667
spatiotemporal region,one-dimensional spatial region,0.7245098039215686
spatiotemporal region,spatial region,0.85
spatiotemporal region,pathogen death temporal region,0.8225490196078431
pathogen vehicle role,extended organism,0.6078947368421053
pathogen vehicle role,virus aggregate,0.5888888888888889
pathogen vehicle role,source of infection,0.6
pathogen vehicle role,infectious disease mortality rate,0.6166666666666667
pathogen vehicle role,infection incidence rate profile,0.6764150943396227
pathogen vehicle role,pathogen generative stage,0.7543478260869566
pathogen vehicle role,pathogen portal of entry,0.7388888888888888
pathogen vehicle role,subclinical coronavirus infection,0.5981481481481481
pathogen vehicle role,primary pathogen,0.6662162162162162
pathogen vehicle role,infection end temporal region,0.65
pathogen vehicle role,drug-based immunosuppressed organism,0.5728070175438597
pathogen vehicle role,vector control strategy,0.6318181818181818
pathogen vehicle role,infectious disease,0.6038461538461539
pathogen vehicle role,SARS-CoV-2 incidence rate,0.6456521739130434
pathogen vehicle role,double-stranded DNA virus,0.6021739130434782
pathogen vehicle role,site of infection,0.6078947368421053
pathogen vehicle role,immunocompetent organism,0.5833333333333334
pathogen vehicle role,virulence factor disposition,0.5928571428571429
pathogen vehicle role,pathogen portal of exit,0.7454545454545455
pathogen vehicle role,infectious disease incidence,0.6132653061224489
pathogen vehicle role,reservoir of pathogen role,0.7265957446808511
pathogen vehicle role,subclinical SARS-CoV-2 infection,0.6009433962264151
pathogen vehicle role,virus translation stage,0.5863636363636363
pathogen vehicle role,disease surveillance objective specification,0.6192307692307693
pathogen vehicle role,virus release stage,0.6
pathogen vehicle role,infectious agent host role,0.7053191489361703
pathogen vehicle role,asymptomatic infectious structure carrier,0.6274193548387097
pathogen vehicle role,source of infection site,0.6055555555555556
pathogen vehicle role,virus,0.5653846153846154
pathogen vehicle role,virus replication,0.581578947368421
pathogen vehicle role,B cell receptor complex,0.6545454545454545
pathogen vehicle role,passive immunization against infectious agent,0.6166666666666667
pathogen vehicle role,systematic infection,0.5963414634146341
pathogen vehicle role,infection incidence rate,0.6722222222222223
pathogen vehicle role,virus host,0.5790322580645162
pathogen vehicle role,double-stranded RNA virus,0.6021739130434782
pathogen vehicle role,mechanical vector,0.6342105263157894
pathogen vehicle role,pathogen portal of entry role,0.77
pathogen vehicle role,virus transcription stage,0.5804347826086956
pathogen vehicle role,infectious disease lifetime prevalence,0.6364406779661017
pathogen vehicle role,pathogen birth temporal region,0.7245098039215686
pathogen vehicle role,lower respiratory tract disease,0.6038461538461539
pathogen vehicle role,infectious disease incidence proportion,0.6166666666666667
pathogen vehicle role,opportunistic pathogen,0.636046511627907
pathogen vehicle role,virus generative stage,0.636046511627907
pathogen vehicle role,acute infectious disease course,0.6423076923076922
pathogen vehicle role,cidal agent disposition,0.609090909090909
pathogen vehicle role,role,0.61
pathogen vehicle role,genetic resistance to pathogen,0.6656862745098039
pathogen vehicle role,subclinical infection,0.5928571428571429
pathogen vehicle role,appearance of disorder,0.636046511627907
pathogen vehicle role,simple infection,0.6121621621621621
pathogen vehicle role,biological vehicle,0.7064102564102563
pathogen vehicle role,droplet pathogen transmission process,0.6913793103448276
pathogen vehicle role,infectious disease sporadicity,0.5872549019607843
pathogen vehicle role,mutualist role,0.65
pathogen vehicle role,infection incidence proportion profile,0.6533898305084747
pathogen vehicle role,infectious agent colony,0.6545454545454545
pathogen vehicle role,pathogen transporter,0.7426829268292683
pathogen vehicle role,invasion factor,0.6166666666666667
pathogen vehicle role,infectious disease epidemic,0.5958333333333333
pathogen vehicle role,infectious agent generative stage,0.6537037037037037
pathogen vehicle role,disease transmission model,0.598936170212766
pathogen vehicle role,vector surveillance,0.675
pathogen vehicle role,pathologically immunosuppressed organism,0.6467213114754098
pathogen vehicle role,negative-sense single-stranded RNA virus,0.6139344262295081
pathogen vehicle role,cidal agent,0.575
pathogen vehicle role,infectious structure host role,0.6460784313725491
pathogen vehicle role,pathogen vehicle,0.8824324324324324
pathogen vehicle role,COVID-19 incidence rate,0.6318181818181818
pathogen vehicle role,community-acquired infection,0.5928571428571429
pathogen vehicle role,pathogen vector,0.8111111111111111
pathogen vehicle role,pathogen vehicle role,0.95
pathogen vehicle role,chronic infectious disease course,0.6351851851851852
pathogen vehicle role,asymptomatic infectious agent carrier,0.6396551724137931
pathogen vehicle role,nursing-home acquired infection,0.6038461538461539
pathogen vehicle role,secondary infection,0.6
pathogen vehicle role,mechanical vector role,0.7058139534883722
pathogen vehicle role,infection start temporal region,0.6230769230769231
pathogen vehicle role,infection incidence,0.65
pathogen vehicle role,virus disorder,0.5928571428571429
pathogen vehicle role,sterilizing immunity to infectious agent,0.5811475409836065
pathogen vehicle role,primary infection,0.6078947368421053
pathogen vehicle role,virulence factor,0.6121621621621621
pathogen vehicle role,process of establishing an infection,0.6078947368421053
pathogen vehicle role,dead-end host role,0.7064102564102563
pathogen vehicle role,pathogen death process boundary,0.7384615384615384
pathogen vehicle role,immunosuppressed organism,0.558695652173913
pathogen vehicle role,definitive host role,0.6939024390243902
pathogen vehicle role,innate immunity to infectious agent,0.6107142857142857
pathogen vehicle role,virus adhesion susceptible cell,0.6615384615384616
pathogen vehicle role,infection,0.5833333333333334
pathogen vehicle role,static agent disposition,0.6277777777777778
pathogen vehicle role,T cell receptor complex,0.6772727272727272
pathogen vehicle role,asymptomatic carrier role,0.6891304347826087
pathogen vehicle role,infectious agent population,0.6166666666666667
pathogen vehicle role,respiratory system disease,0.6414893617021277
pathogen vehicle role,biological vector,0.6342105263157894
pathogen vehicle role,leukocyte-mediated immunity to infectious agent,0.5823529411764706
pathogen vehicle role,indirect pathogen transmission process,0.6872881355932203
pathogen vehicle role,organism population,0.625
pathogen vehicle role,humoral immunity to infectious agent,0.5903508771929825
pathogen vehicle role,infectious disease control strategy,0.6285714285714286
pathogen vehicle role,parasite,0.5879310344827586
pathogen vehicle role,infectious disease pandemic,0.5958333333333333
pathogen vehicle role,antibody reagent,0.6121621621621621
pathogen vehicle role,viral disease course,0.6207317073170732
pathogen vehicle role,intracellular infection,0.5863636363636363
pathogen vehicle role,secondary infection role,0.6722222222222223
pathogen vehicle role,metastatic infection,0.5963414634146341
pathogen vehicle role,passive immunity to infectious agent,0.6078947368421053
pathogen vehicle role,vaccination against infectious agent,0.6254385964912281
pathogen vehicle role,acute infection,0.6444444444444444
pathogen vehicle role,susceptibility to infectious agent,0.5954545454545455
pathogen vehicle role,epitope site,0.6621212121212122
pathogen vehicle role,immunity to pathogen,0.6451219512195122
pathogen vehicle role,source of infection role,0.6722222222222223
pathogen vehicle role,pathogen host,0.7735294117647058
pathogen vehicle role,chronic infection,0.6342105263157894
pathogen vehicle role,disease course,0.6214285714285714
pathogen vehicle role,infectious disease course,0.6239130434782608
pathogen vehicle role,acquired immunity to infectious agent,0.5879310344827586
pathogen vehicle role,complex infection,0.6078947368421053
pathogen vehicle role,COVID-19 disease incidence proportion,0.6051724137931035
pathogen vehicle role,coronavirus disease course,0.6202127659574468
pathogen vehicle role,asymptomatic carrier,0.6451219512195122
pathogen vehicle role,biological vehicle role,0.7909090909090909
pathogen vehicle role,infection incidence proportion,0.6460784313725491
pathogen vehicle role,symptomatic infectious agent carrier,0.6429824561403508
pathogen vehicle role,respiratory droplet virus fomite,0.6575471698113208
pathogen vehicle role,symbiont role,0.6558823529411765
pathogen vehicle role,susceptible organism,0.6207317073170732
pathogen vehicle role,parasite role,0.7147058823529412
pathogen vehicle role,pathogen vector role,0.8646341463414635
pathogen vehicle role,pathogen portal of exit site,0.7153061224489795
pathogen vehicle role,infectious disease prevalence,0.63
pathogen vehicle role,organism substance,0.6038461538461539
pathogen vehicle role,single-stranded DNA virus,0.6021739130434782
pathogen vehicle role,COVID-19 mortality rate,0.609090909090909
pathogen vehicle role,viral disease,0.5970588235294118
pathogen vehicle role,primary infection role,0.6825581395348838
pathogen vehicle role,intervention,0.6318181818181818
pathogen vehicle role,biological role,0.7277777777777777
pathogen vehicle role,pathogen portal of entry site,0.71
pathogen vehicle role,infection incidence profile,0.7
pathogen vehicle role,disease,0.5571428571428572
pathogen vehicle role,symptomatic infectious structure carrier,0.630327868852459
pathogen vehicle role,biological vector role,0.7058139534883722
pathogen vehicle role,site,0.53
pathogen vehicle role,pathogen host role,0.8346153846153846
pathogen vehicle role,infection prevalence,0.6451219512195122
pathogen vehicle role,symptomatic carrier role,0.6944444444444444
pathogen vehicle role,infectious pathogen transmissibility,0.6429824561403508
pathogen vehicle role,intermediate host role,0.6825581395348838
pathogen vehicle role,pathogen surveillance,0.8071428571428573
pathogen vehicle role,immunodeficient organism,0.6055555555555556
pathogen vehicle role,host role,0.6833333333333332
pathogen vehicle role,pathogen,0.7258620689655172
pathogen vehicle role,pathogen birth process boundary,0.7192307692307692
pathogen vehicle role,infectious human pathogen,0.6239130434782608
pathogen vehicle role,subclinical virus infection,0.5958333333333333
pathogen vehicle role,resistance to pathogen,0.636046511627907
pathogen vehicle role,establishment of localization in virus host,0.60625
pathogen vehicle role,immunization against infectious agent,0.6224137931034482
pathogen vehicle role,virus attachment stage,0.6127906976744186
pathogen vehicle role,virus synthesis stage,0.5928571428571429
pathogen vehicle role,pathogen portal of exit role,0.7765306122448979
pathogen vehicle role,infectious agent host,0.6404761904761905
pathogen vehicle role,re-emerging pathogen,0.6451219512195122
pathogen vehicle role,long-term non-progressing infectious disease course,0.6166666666666667
pathogen vehicle role,viral disease epidemic,0.5895348837209302
pathogen vehicle role,commensal role,0.7071428571428571
pathogen vehicle role,epitope role,0.7227272727272727
pathogen vehicle role,viral disease pandemic,0.5895348837209302
pathogen vehicle role,virus penetration stage,0.609090909090909
pathogen vehicle role,pathogen seroprevalence,0.7681818181818181
pathogen vehicle role,symptomatic carrier,0.65
pathogen vehicle role,infectious disease endemicity,0.59
pathogen vehicle role,contact pathogen transmission process,0.6913793103448276
pathogen vehicle role,function,0.553448275862069
pathogen vehicle role,herd immunity to infectious organism,0.5903508771929825
pathogen vehicle role,extracellular infection,0.5863636363636363
pathogen vehicle role,pathogen transporter role,0.7760869565217391
pathogen vehicle role,infectious agent reservoir,0.6627659574468084
pathogen vehicle role,antigen role,0.7530303030303032
pathogen vehicle role,infection start process boundary,0.6009433962264151
pathogen vehicle role,action specification,0.6695121951219513
pathogen vehicle role,infectious disease control objective specification,0.5908450704225352
pathogen vehicle role,symbiont host role,0.6807692307692308
pathogen vehicle role,fomite role,0.7
pathogen vehicle role,process of establishing viral infection,0.6333333333333333
pathogen vehicle role,COVID-19 disease course,0.609090909090909
pathogen vehicle role,infectious disease incidence rate,0.6351851851851852
pathogen vehicle role,active immunization against infectious agent,0.6038461538461539
pathogen vehicle role,disordered virus,0.6121621621621621
pathogen vehicle role,reagent role,0.7227272727272727
pathogen vehicle role,viral load,0.6112903225806451
pathogen vehicle role,organism,0.5879310344827586
pathogen vehicle role,virus uncoating stage,0.569047619047619
pathogen vehicle role,local infection,0.5888888888888889
pathogen vehicle role,infectious agent,0.5851351351351352
pathogen vehicle role,establishment of a clinically abnormal colony,0.6318181818181818
pathogen vehicle role,coronavirus disease,0.6
pathogen vehicle role,positive-sense single-stranded RNA virus,0.6139344262295081
pathogen vehicle role,adhesion factor,0.6444444444444444
pathogen vehicle role,horizontal pathogen transmission process,0.6795081967213115
pathogen vehicle role,hospital-acquired infection,0.5958333333333333
pathogen vehicle role,pathogen death temporal region,0.7441176470588234
pathogen vehicle role,emerging pathogen,0.6605263157894737
pathogen vehicle role,drug susceptibility of infectious agent,0.5833333333333334
pathogen vehicle role,static agent,0.6318181818181818
pathogen vehicle role,pathogen transmission process,0.73
PCR product,virus aggregate,0.6038461538461539
PCR product,infectious structure aggregate,0.5963414634146341
PCR product,communicability end temporal region,0.558695652173913
PCR product,infection end temporal region,0.575
PCR product,incubation end temporal region,0.5719512195121951
PCR product,negative regulation of production,0.6545454545454545
PCR product,material entity,0.5653846153846154
PCR product,SARS-CoV-2 aggregate,0.5790322580645162
PCR product,B cell receptor complex,0.5970588235294118
PCR product,communicability end process boundary,0.5776595744680851
PCR product,acellular structure aggregate,0.625
PCR product,latency end process boundary,0.6038461538461539
PCR product,PCR product,0.95
PCR product,incubation end process boundary,0.5928571428571429
PCR product,plan specification,0.6224137931034482
PCR product,latency end temporal region,0.581578947368421
PCR product,coronavirus aggregate,0.60625
PCR product,T cell receptor complex,0.5970588235294118
PCR product,prion aggregate,0.6423076923076922
PCR product,production,0.7833333333333333
PCR product,reverse transcribed PCR,0.5970588235294118
PCR product,viroid aggregate,0.5981481481481481
PCR product,object,0.6264705882352941
PCR product,object aggregate,0.5981481481481481
PCR product,processed material,0.6224137931034482
PCR product,establishment of a clinically abnormal colony,0.5214285714285714
PCR product,material processing,0.65
droplet pathogen transmission process,extended organism,0.6351851851851852
droplet pathogen transmission process,virus aggregate,0.5846153846153846
droplet pathogen transmission process,source of infection,0.6107142857142857
droplet pathogen transmission process,immune response,0.5846153846153846
droplet pathogen transmission process,infectious disease mortality rate,0.6214285714285714
droplet pathogen transmission process,infection incidence rate profile,0.6384057971014493
droplet pathogen transmission process,communicability end temporal region,0.6305555555555555
droplet pathogen transmission process,pathogen generative stage,0.6758064516129032
droplet pathogen transmission process,pathogen portal of entry,0.6795081967213115
droplet pathogen transmission process,subclinical coronavirus infection,0.5928571428571429
droplet pathogen transmission process,primary pathogen,0.6386792452830189
droplet pathogen transmission process,surveillance process,0.6605263157894737
droplet pathogen transmission process,infection end temporal region,0.6318181818181818
droplet pathogen transmission process,drug-based immunosuppressed organism,0.6143835616438357
droplet pathogen transmission process,infectious disease,0.5954545454545455
droplet pathogen transmission process,SARS-CoV-2 incidence rate,0.5951612903225807
droplet pathogen transmission process,double-stranded DNA virus,0.6435483870967742
droplet pathogen transmission process,incubation end temporal region,0.6291044776119403
droplet pathogen transmission process,site of infection,0.5981481481481481
droplet pathogen transmission process,immunocompetent organism,0.6467213114754098
droplet pathogen transmission process,pathogen portal of exit,0.6833333333333332
droplet pathogen transmission process,infectious disease incidence,0.6192307692307693
droplet pathogen transmission process,reservoir of pathogen role,0.6880952380952381
droplet pathogen transmission process,subclinical SARS-CoV-2 infection,0.5804347826086956
droplet pathogen transmission process,virus translation stage,0.65
droplet pathogen transmission process,disease surveillance objective specification,0.6104938271604938
droplet pathogen transmission process,case isolation control strategy,0.6411764705882353
droplet pathogen transmission process,virus release stage,0.6107142857142857
droplet pathogen transmission process,infectious agent host role,0.6563492063492063
droplet pathogen transmission process,source of infection site,0.630327868852459
droplet pathogen transmission process,virus,0.5214285714285714
droplet pathogen transmission process,respiratory droplet,0.6464285714285714
droplet pathogen transmission process,virus replication,0.5981481481481481
droplet pathogen transmission process,B cell receptor complex,0.6
droplet pathogen transmission process,passive immunization against infectious agent,0.6451219512195122
droplet pathogen transmission process,systematic infection,0.5903508771929825
droplet pathogen transmission process,infection incidence rate,0.630327868852459
droplet pathogen transmission process,virus host,0.5563829787234043
droplet pathogen transmission process,double-stranded RNA virus,0.6596774193548387
droplet pathogen transmission process,pathogen portal of entry role,0.7075757575757575
droplet pathogen transmission process,virus transcription stage,0.6596774193548387
droplet pathogen transmission process,infectious disease lifetime prevalence,0.6233333333333334
droplet pathogen transmission process,pathogen birth temporal region,0.6738805970149254
droplet pathogen transmission process,respiratory droplet coronavirus fomite,0.6633333333333334
droplet pathogen transmission process,lower respiratory tract disease,0.6705882352941177
droplet pathogen transmission process,infectious disease incidence proportion,0.6210526315789474
droplet pathogen transmission process,opportunistic pathogen,0.6703389830508475
droplet pathogen transmission process,virus generative stage,0.6194915254237288
droplet pathogen transmission process,acute infectious disease course,0.6264705882352941
droplet pathogen transmission process,cidal agent disposition,0.6833333333333332
droplet pathogen transmission process,genetic resistance to pathogen,0.6440298507462687
droplet pathogen transmission process,subclinical infection,0.5706896551724138
droplet pathogen transmission process,process,0.609090909090909
droplet pathogen transmission process,simple infection,0.619811320754717
droplet pathogen transmission process,droplet pathogen transmission process,0.95
droplet pathogen transmission process,infectious disease sporadicity,0.6141791044776119
droplet pathogen transmission process,communicability end process boundary,0.6417808219178082
droplet pathogen transmission process,infection incidence proportion profile,0.65
droplet pathogen transmission process,infectious agent colony,0.6166666666666667
droplet pathogen transmission process,pathogen transporter,0.7482456140350877
droplet pathogen transmission process,latency end process boundary,0.6807692307692308
droplet pathogen transmission process,infectious disease epidemic,0.60625
droplet pathogen transmission process,infectious agent generative stage,0.6357142857142857
droplet pathogen transmission process,disease transmission model,0.7674603174603175
droplet pathogen transmission process,pathologically immunosuppressed organism,0.6318181818181818
droplet pathogen transmission process,negative-sense single-stranded RNA virus,0.6318181818181818
droplet pathogen transmission process,cidal agent,0.6166666666666667
droplet pathogen transmission process,pathogen vehicle,0.6764150943396227
droplet pathogen transmission process,COVID-19 incidence rate,0.5833333333333334
droplet pathogen transmission process,community-acquired infection,0.5884615384615385
droplet pathogen transmission process,respiratory droplet SARS-CoV-2 fomite,0.6527027027027027
droplet pathogen transmission process,pathogen vector,0.6807692307692308
droplet pathogen transmission process,negative regulation of developmental process,0.6722222222222223
droplet pathogen transmission process,pathogen vehicle role,0.6913793103448276
droplet pathogen transmission process,chronic infectious disease course,0.6214285714285714
droplet pathogen transmission process,asymptomatic infectious agent carrier,0.6121621621621621
droplet pathogen transmission process,nursing-home acquired infection,0.6117647058823529
droplet pathogen transmission process,secondary infection,0.5928571428571429
droplet pathogen transmission process,infection start temporal region,0.6264705882352941
droplet pathogen transmission process,infection incidence,0.6285714285714286
droplet pathogen transmission process,virus disorder,0.5872549019607843
droplet pathogen transmission process,sterilizing immunity to infectious agent,0.6058441558441559
droplet pathogen transmission process,primary infection,0.5796296296296296
droplet pathogen transmission process,process of establishing an infection,0.6417808219178082
droplet pathogen transmission process,incubation end process boundary,0.6558823529411765
droplet pathogen transmission process,SARS-CoV-2 uncoating stage,0.6087301587301588
droplet pathogen transmission process,pathogen death process boundary,0.7147058823529412
droplet pathogen transmission process,immunosuppressed organism,0.6112903225806451
droplet pathogen transmission process,plan specification,0.6318181818181818
droplet pathogen transmission process,latency end temporal region,0.6375
droplet pathogen transmission process,innate immunity to infectious agent,0.6027777777777777
droplet pathogen transmission process,SARS-CoV-2 penetration stage,0.6653846153846155
droplet pathogen transmission process,virus adhesion susceptible cell,0.6411764705882353
droplet pathogen transmission process,infection,0.558695652173913
droplet pathogen transmission process,static agent disposition,0.6631147540983606
droplet pathogen transmission process,T cell receptor complex,0.6
droplet pathogen transmission process,infectious agent population,0.6375
droplet pathogen transmission process,respiratory system disease,0.6563492063492063
droplet pathogen transmission process,leukocyte-mediated immunity to infectious agent,0.6166666666666667
droplet pathogen transmission process,indirect pathogen transmission process,0.9033333333333333
droplet pathogen transmission process,organism population,0.6107142857142857
droplet pathogen transmission process,planned process,0.7
droplet pathogen transmission process,generative stage,0.6009433962264151
droplet pathogen transmission process,humoral immunity to infectious agent,0.6143835616438357
droplet pathogen transmission process,infectious disease control strategy,0.6166666666666667
droplet pathogen transmission process,SARS-CoV-2 attachment stage,0.6375
droplet pathogen transmission process,parasite,0.6055555555555556
droplet pathogen transmission process,infectious disease pandemic,0.621875
droplet pathogen transmission process,antibody reagent,0.6009433962264151
droplet pathogen transmission process,infectious structure generative stage,0.6121621621621621
droplet pathogen transmission process,innate immune response,0.6364406779661017
droplet pathogen transmission process,viral disease course,0.6078947368421053
droplet pathogen transmission process,intracellular infection,0.5833333333333334
droplet pathogen transmission process,secondary infection role,0.6467213114754098
droplet pathogen transmission process,metastatic infection,0.6078947368421053
droplet pathogen transmission process,passive immunity to infectious agent,0.6143835616438357
droplet pathogen transmission process,vaccination against infectious agent,0.6280821917808219
droplet pathogen transmission process,acute infection,0.6038461538461539
droplet pathogen transmission process,susceptibility to infectious agent,0.6190140845070422
droplet pathogen transmission process,epitope site,0.6336734693877552
droplet pathogen transmission process,immunity to pathogen,0.6254385964912281
droplet pathogen transmission process,source of infection role,0.6631147540983606
droplet pathogen transmission process,pathogen host,0.67
droplet pathogen transmission process,chronic infection,0.5981481481481481
droplet pathogen transmission process,disease course,0.6068627450980393
droplet pathogen transmission process,infectious disease course,0.6112903225806451
droplet pathogen transmission process,acquired immunity to infectious agent,0.6121621621621621
droplet pathogen transmission process,complex infection,0.6351851851851852
droplet pathogen transmission process,COVID-19 disease incidence proportion,0.6121621621621621
droplet pathogen transmission process,coronavirus disease course,0.6246031746031746
droplet pathogen transmission process,infection incidence proportion,0.6291044776119403
droplet pathogen transmission process,symptomatic infectious agent carrier,0.6143835616438357
droplet pathogen transmission process,respiratory droplet virus fomite,0.6384057971014493
droplet pathogen transmission process,susceptible organism,0.6254385964912281
droplet pathogen transmission process,parasite role,0.65
droplet pathogen transmission process,pathogen vector role,0.7131578947368421
droplet pathogen transmission process,pathogen portal of exit site,0.6807692307692308
droplet pathogen transmission process,infectious disease prevalence,0.6318181818181818
droplet pathogen transmission process,organism substance,0.65
droplet pathogen transmission process,respiratory droplet fomite,0.6404761904761905
droplet pathogen transmission process,SARS-CoV-2 genome replication stage,0.6444444444444444
droplet pathogen transmission process,single-stranded DNA virus,0.6112903225806451
droplet pathogen transmission process,COVID-19 mortality rate,0.6
droplet pathogen transmission process,contact tracing,0.6423076923076922
droplet pathogen transmission process,process profile,0.6423076923076922
droplet pathogen transmission process,negative regulation of life-sustaining process,0.7030120481927711
droplet pathogen transmission process,viral disease,0.59
droplet pathogen transmission process,primary infection role,0.6364406779661017
droplet pathogen transmission process,pathogen portal of entry site,0.6772727272727272
droplet pathogen transmission process,developmental process,0.7086206896551723
droplet pathogen transmission process,infection incidence profile,0.653125
droplet pathogen transmission process,disease,0.5636363636363636
droplet pathogen transmission process,biological process,0.6863636363636364
droplet pathogen transmission process,site,0.523170731707317
droplet pathogen transmission process,pathogen host role,0.7045454545454546
droplet pathogen transmission process,infection prevalence,0.6254385964912281
droplet pathogen transmission process,humoral immune response,0.6333333333333333
droplet pathogen transmission process,infectious pathogen transmissibility,0.7513698630136986
droplet pathogen transmission process,incubation start process boundary,0.6642857142857143
droplet pathogen transmission process,pathogen surveillance,0.6913793103448276
droplet pathogen transmission process,immunodeficient organism,0.6139344262295081
droplet pathogen transmission process,pathogen,0.6277777777777778
droplet pathogen transmission process,pathogen birth process boundary,0.7147058823529412
droplet pathogen transmission process,infectious human pathogen,0.6274193548387097
droplet pathogen transmission process,subclinical virus infection,0.590625
droplet pathogen transmission process,resistance to pathogen,0.6533898305084747
droplet pathogen transmission process,establishment of localization in virus host,0.65
droplet pathogen transmission process,immunization against infectious agent,0.6256756756756756
droplet pathogen transmission process,virus attachment stage,0.6364406779661017
droplet pathogen transmission process,negative regulation of immune response,0.65
droplet pathogen transmission process,SARS-CoV-2 transcription stage,0.658955223880597
droplet pathogen transmission process,virus synthesis stage,0.6224137931034482
droplet pathogen transmission process,pathogen portal of exit role,0.6961538461538461
droplet pathogen transmission process,infectious agent host,0.6396551724137931
droplet pathogen transmission process,re-emerging pathogen,0.6429824561403508
droplet pathogen transmission process,long-term non-progressing infectious disease course,0.6431818181818181
droplet pathogen transmission process,viral disease epidemic,0.6025423728813559
droplet pathogen transmission process,viral disease pandemic,0.6364406779661017
droplet pathogen transmission process,virus penetration stage,0.6666666666666667
droplet pathogen transmission process,algorithm,0.5369565217391304
droplet pathogen transmission process,pathogen seroprevalence,0.7
droplet pathogen transmission process,division of geopolitical entity,0.6117647058823529
droplet pathogen transmission process,infectious disease endemicity,0.6015151515151516
droplet pathogen transmission process,negative regulation of viral process,0.6965753424657534
droplet pathogen transmission process,contact pathogen transmission process,0.8824324324324324
droplet pathogen transmission process,function,0.5611111111111111
droplet pathogen transmission process,herd immunity to infectious organism,0.6143835616438357
droplet pathogen transmission process,extracellular infection,0.6
droplet pathogen transmission process,pathogen transporter role,0.7564516129032257
droplet pathogen transmission process,symbiotic process,0.6722222222222223
droplet pathogen transmission process,transmission interval,0.6913793103448276
droplet pathogen transmission process,infectious agent reservoir,0.6404761904761905
droplet pathogen transmission process,infection start process boundary,0.6673913043478261
droplet pathogen transmission process,action specification,0.6254385964912281
droplet pathogen transmission process,SARS-CoV-2 synthesis stage,0.6246031746031746
droplet pathogen transmission process,latency start process boundary,0.6888059701492537
droplet pathogen transmission process,infectious disease control objective specification,0.610919540229885
droplet pathogen transmission process,process of establishing viral infection,0.6473684210526315
droplet pathogen transmission process,negative regulation of biological process,0.6807692307692308
droplet pathogen transmission process,polymerase chain reaction,0.6435483870967742
droplet pathogen transmission process,COVID-19 disease course,0.5833333333333334
droplet pathogen transmission process,infectious disease incidence rate,0.6214285714285714
droplet pathogen transmission process,communicability start process boundary,0.6366666666666667
droplet pathogen transmission process,process that results in death,0.6621212121212122
droplet pathogen transmission process,active immunization against infectious agent,0.6351851851851852
droplet pathogen transmission process,disordered virus,0.6009433962264151
droplet pathogen transmission process,adaptive immune response,0.6467213114754098
droplet pathogen transmission process,organism,0.5833333333333334
droplet pathogen transmission process,virus uncoating stage,0.6051724137931035
droplet pathogen transmission process,local infection,0.6038461538461539
droplet pathogen transmission process,infectious agent,0.6009433962264151
droplet pathogen transmission process,establishment of a clinically abnormal colony,0.6085365853658536
droplet pathogen transmission process,process boundary,0.6009433962264151
droplet pathogen transmission process,coronavirus disease,0.6107142857142857
droplet pathogen transmission process,positive-sense single-stranded RNA virus,0.6188311688311688
droplet pathogen transmission process,horizontal pathogen transmission process,0.8785714285714286
droplet pathogen transmission process,hospital-acquired infection,0.60625
droplet pathogen transmission process,pathogen death temporal region,0.6738805970149254
droplet pathogen transmission process,emerging pathogen,0.6351851851851852
droplet pathogen transmission process,drug susceptibility of infectious agent,0.6210526315789474
droplet pathogen transmission process,SARS-CoV-2 release stage,0.6139344262295081
droplet pathogen transmission process,static agent,0.5928571428571429
droplet pathogen transmission process,pathogen transmission process,0.8893939393939394
exotoxin,toxin disposition,0.65
exotoxin,T cell receptor complex,0.5790322580645162
exotoxin,toxin,0.8346153846153846
exotoxin,exotoxin,0.95
exotoxin,exotoxin disposition,0.7357142857142857
infectious agent,information content entity,0.6880952380952381
infectious agent,infectious disease mortality rate,0.7357142857142857
infectious agent,infection incidence rate profile,0.7
infectious agent,infectious structure aggregate,0.7760869565217391
infectious agent,communicability end temporal region,0.5872549019607843
infectious agent,infection end temporal region,0.7166666666666667
infectious agent,infectious disease,0.8323529411764706
infectious agent,SARS-CoV-2 incidence rate,0.6207317073170732
infectious agent,incubation end temporal region,0.6673913043478261
infectious agent,virulence factor disposition,0.6545454545454545
infectious agent,infectious disease incidence,0.7681818181818181
infectious agent,disease surveillance objective specification,0.6
infectious agent,infectious agent host role,0.830952380952381
infectious agent,asymptomatic infectious structure carrier,0.6780701754385965
infectious agent,B cell receptor complex,0.6038461538461539
infectious agent,passive immunization against infectious agent,0.7122950819672131
infectious agent,infection incidence rate,0.75
infectious agent,infectious disease lifetime prevalence,0.7092592592592593
infectious agent,lower respiratory tract disease,0.598936170212766
infectious agent,infectious disease incidence proportion,0.7227272727272727
infectious agent,acute infectious disease course,0.7265957446808511
infectious agent,cidal agent disposition,0.6551282051282051
infectious agent,infectious disorder,0.7928571428571428
infectious agent,biological vehicle,0.5676470588235294
infectious agent,infectious disease sporadicity,0.7543478260869566
infectious agent,communicability end process boundary,0.5846153846153846
infectious agent,directive information content entity,0.6423076923076922
infectious agent,infectious agent colony,0.8602564102564102
infectious agent,pathogen transporter,0.6166666666666667
infectious agent,invasion factor,0.6758064516129032
infectious agent,latency end process boundary,0.5863636363636363
infectious agent,infectious disease epidemic,0.7523255813953489
infectious agent,infectious agent generative stage,0.7765306122448979
infectious agent,disease transmission model,0.6166666666666667
infectious agent,cidal agent,0.7462962962962962
infectious agent,infectious structure host role,0.7326086956521739
infectious agent,pathogen vehicle,0.60625
infectious agent,COVID-19 incidence rate,0.6294871794871795
infectious agent,pathogen vehicle role,0.5851351351351352
infectious agent,chronic infectious disease course,0.7153061224489795
infectious agent,asymptomatic infectious agent carrier,0.7518867924528303
infectious agent,descriptive information content entity,0.6351851851851852
infectious agent,COVID-19 epidemic,0.5712121212121213
infectious agent,sterilizing immunity to infectious agent,0.7357142857142857
infectious agent,diseased population,0.6214285714285714
infectious agent,virulence factor,0.6375
infectious agent,incubation end process boundary,0.6414893617021277
infectious agent,latency end temporal region,0.6127906976744186
infectious agent,innate immunity to infectious agent,0.7637254901960785
infectious agent,infectious structure,0.7833333333333333
infectious agent,static agent disposition,0.65
infectious agent,T cell receptor complex,0.6038461538461539
infectious agent,asymptomatic carrier role,0.5719512195121951
infectious agent,infectious structure host,0.7670731707317073
infectious agent,infectious agent population,0.822093023255814
infectious agent,respiratory system disease,0.6166666666666667
infectious agent,leukocyte-mediated immunity to infectious agent,0.7039682539682539
infectious agent,humoral immunity to infectious agent,0.7576923076923078
infectious agent,infectious disease control strategy,0.7441176470588234
infectious agent,infectious disease pandemic,0.7755813953488372
infectious agent,infectious structure generative stage,0.7330188679245283
infectious agent,viral disease course,0.6444444444444444
infectious agent,passive immunity to infectious agent,0.7576923076923078
infectious agent,infectious disposition,0.7657894736842106
infectious agent,vaccination against infectious agent,0.7576923076923078
infectious agent,susceptibility to infectious agent,0.77
infectious agent,disease course,0.6833333333333332
infectious agent,infectious disease course,0.7670731707317073
infectious agent,acquired immunity to infectious agent,0.7518867924528303
infectious agent,COVID-19 disease incidence proportion,0.6009433962264151
infectious agent,coronavirus disease course,0.6166666666666667
infectious agent,asymptomatic carrier,0.5888888888888889
infectious agent,biological vehicle role,0.5782051282051281
infectious agent,symptomatic infectious agent carrier,0.7576923076923078
infectious agent,intermediate host,0.6621212121212122
infectious agent,infectious disease prevalence,0.7611111111111112
infectious agent,infected population,0.7357142857142857
infectious agent,COVID-19 mortality rate,0.6038461538461539
infectious agent,viral disease,0.6224137931034482
infectious agent,disease,0.6239130434782608
infectious agent,symptomatic infectious structure carrier,0.6821428571428573
infectious agent,primary infectious disposition,0.7108695652173913
infectious agent,designative information content entity,0.6351851851851852
infectious agent,symptomatic carrier role,0.575
infectious agent,infectious pathogen transmissibility,0.7576923076923078
infectious agent,intermediate host role,0.6605263157894737
infectious agent,infectious human pathogen,0.8158536585365854
infectious agent,immunization against infectious agent,0.7518867924528303
infectious agent,infectious agent host,0.8824324324324324
infectious agent,long-term non-progressing infectious disease course,0.6440298507462687
infectious agent,viral disease epidemic,0.581578947368421
infectious agent,viral disease pandemic,0.6078947368421053
infectious agent,symptomatic carrier,0.5928571428571429
infectious agent,infectious disease endemicity,0.7833333333333333
infectious agent,function,0.7
infectious agent,herd immunity to infectious organism,0.7
infectious agent,pathogen transporter role,0.5963414634146341
infectious agent,infectious agent reservoir,0.830952380952381
infectious agent,COVID-19 pandemic,0.6015151515151516
infectious agent,action specification,0.6722222222222223
infectious agent,infectious disease control objective specification,0.6772727272727272
infectious agent,opportunistic infectious disposition,0.6807692307692308
infectious agent,polymerase chain reaction,0.6451219512195122
infectious agent,COVID-19 disease course,0.6294871794871795
infectious agent,infectious disease incidence rate,0.7561224489795919
infectious agent,active immunization against infectious agent,0.7166666666666667
infectious agent,infectious agent,0.95
infectious agent,establishment of a clinically abnormal colony,0.5811475409836065
infectious agent,coronavirus disease,0.65
infectious agent,adhesion factor,0.6435483870967742
infectious agent,drug susceptibility of infectious agent,0.740909090909091
infectious agent,static agent,0.7357142857142857
innate immune response,immune response,0.8554054054054054
innate immune response,infectious disease mortality rate,0.6318181818181818
innate immune response,infection incidence rate profile,0.6907407407407408
innate immune response,communicability end temporal region,0.6429824561403508
innate immune response,primary pathogen,0.6078947368421053
innate immune response,surveillance process,0.6642857142857143
innate immune response,infection end temporal region,0.6656862745098039
innate immune response,SARS-CoV-2 incidence rate,0.6202127659574468
innate immune response,incubation end temporal region,0.6807692307692308
innate immune response,resistant entity,0.6078947368421053
innate immune response,normal resident microbiota population,0.6194915254237288
innate immune response,virus release stage,0.6451219512195122
innate immune response,material entity,0.6391891891891892
innate immune response,B cell receptor complex,0.6277777777777778
innate immune response,passive immunization against infectious agent,0.6440298507462687
innate immune response,infection incidence rate,0.6673913043478261
innate immune response,double-stranded RNA virus,0.598936170212766
innate immune response,lower respiratory tract disease,0.619811320754717
innate immune response,genetic resistance to pathogen,0.6423076923076922
innate immune response,process,0.5879310344827586
innate immune response,droplet pathogen transmission process,0.6364406779661017
innate immune response,communicability end process boundary,0.6396551724137931
innate immune response,latency end process boundary,0.67
innate immune response,negative-sense single-stranded RNA virus,0.6435483870967742
innate immune response,susceptible population,0.609090909090909
innate immune response,COVID-19 incidence rate,0.6277777777777778
innate immune response,negative regulation of developmental process,0.6469696969696969
innate immune response,antibiotic resistance,0.6593023255813953
innate immune response,nursing-home acquired infection,0.6386792452830189
innate immune response,resistance to drug,0.6
innate immune response,primary infection,0.6551282051282051
innate immune response,process of establishing an infection,0.6051724137931035
innate immune response,incubation end process boundary,0.6952830188679244
innate immune response,pathogen death process boundary,0.6575471698113208
innate immune response,plan specification,0.625
innate immune response,latency end temporal region,0.6744897959183673
innate immune response,innate immunity to infectious agent,0.7482456140350877
innate immune response,virus adhesion susceptible cell,0.619811320754717
innate immune response,T cell receptor complex,0.65
innate immune response,indirect pathogen transmission process,0.6666666666666667
innate immune response,planned process,0.6662162162162162
innate immune response,innate immune response,0.95
innate immune response,passive immunity to infectious agent,0.6741379310344828
innate immune response,acquired immunodeficiency,0.6840425531914894
innate immune response,acquired immunity to infectious agent,0.6703389830508475
innate immune response,symptomatic infectious agent carrier,0.6224137931034482
innate immune response,susceptible organism,0.6166666666666667
innate immune response,COVID-19 mortality rate,0.5833333333333334
innate immune response,process profile,0.6121621621621621
innate immune response,negative regulation of life-sustaining process,0.6411764705882353
innate immune response,place closure control strategy,0.6423076923076922
innate immune response,primary infection role,0.6772727272727272
innate immune response,primary immunodeficiency,0.6891304347826087
innate immune response,developmental process,0.636046511627907
innate immune response,biological process,0.625
innate immune response,symptomatic infectious structure carrier,0.6112903225806451
innate immune response,primary infectious disposition,0.6615384615384616
innate immune response,symptomatic carrier role,0.6456521739130434
innate immune response,humoral immune response,0.8277777777777777
innate immune response,SARS-COV-2 adhesion susceptible cell,0.5879310344827586
innate immune response,incubation start process boundary,0.6681818181818181
innate immune response,pathogen birth process boundary,0.6575471698113208
innate immune response,resistance to pathogen,0.6318181818181818
innate immune response,negative regulation of immune response,0.7833333333333333
innate immune response,symptomatic carrier,0.5963414634146341
innate immune response,negative regulation of viral process,0.656896551724138
innate immune response,contact pathogen transmission process,0.6533898305084747
innate immune response,function,0.6166666666666667
innate immune response,symbiotic process,0.6551282051282051
innate immune response,infection start process boundary,0.6537037037037037
innate immune response,action specification,0.6642857142857143
innate immune response,protective resistance,0.6825581395348838
innate immune response,processed material,0.575
innate immune response,latency start process boundary,0.6423076923076922
innate immune response,immune population,0.7064102564102563
innate immune response,process of establishing viral infection,0.5975409836065574
innate immune response,negative regulation of biological process,0.6404761904761905
innate immune response,polymerase chain reaction,0.6627659574468084
innate immune response,infectious disease incidence rate,0.65
innate immune response,communicability start process boundary,0.6166666666666667
innate immune response,process that results in death,0.6068627450980393
innate immune response,single-stranded RNA retrovirus,0.6615384615384616
innate immune response,collective resistance disposition,0.65
innate immune response,symptom,0.553448275862069
innate immune response,adaptive immune response,0.8630434782608696
innate immune response,local infection,0.6391891891891892
innate immune response,establishment of a clinically abnormal colony,0.5992537313432835
innate immune response,process boundary,0.581578947368421
innate immune response,positive-sense single-stranded RNA virus,0.6274193548387097
innate immune response,horizontal pathogen transmission process,0.6596774193548387
innate immune response,SARS-CoV-2 release stage,0.6021739130434782
innate immune response,pathogen transmission process,0.6656862745098039
innate immune response,material processing,0.6695121951219513
infection incidence proportion,virus aggregate,0.5388888888888889
infection incidence proportion,source of infection,0.6744897959183673
infection incidence proportion,virostatic disposition,0.6615384615384616
infection incidence proportion,zoonotic disposition,0.67
infection incidence proportion,infectious disease mortality rate,0.7198412698412698
infection incidence proportion,infection incidence rate profile,0.8370967741935484
infection incidence proportion,communicability end temporal region,0.6807692307692308
infection incidence proportion,subclinical coronavirus infection,0.6722222222222223
infection incidence proportion,infection end temporal region,0.7720338983050847
infection incidence proportion,infectious disease,0.7
infection incidence proportion,SARS-CoV-2 incidence rate,0.7227272727272727
infection incidence proportion,double-stranded DNA virus,0.5954545454545455
infection incidence proportion,incubation end temporal region,0.7333333333333333
infection incidence proportion,site of infection,0.7053191489361703
infection incidence proportion,virulence factor disposition,0.6913793103448276
infection incidence proportion,viral adhesion disposition,0.6821428571428573
infection incidence proportion,parasitostatic disposition,0.6642857142857143
infection incidence proportion,infectious disease incidence,0.760344827586207
infection incidence proportion,reverse zoonotic disposition,0.656896551724138
infection incidence proportion,subclinical SARS-CoV-2 infection,0.6596774193548387
infection incidence proportion,virus translation stage,0.6009433962264151
infection incidence proportion,disease surveillance objective specification,0.6527027027027027
infection incidence proportion,virus release stage,0.5724489795918367
infection incidence proportion,material entity,0.6055555555555556
infection incidence proportion,source of infection site,0.6722222222222223
infection incidence proportion,virus,0.5071428571428571
infection incidence proportion,virus replication,0.6202127659574468
infection incidence proportion,B cell receptor complex,0.619811320754717
infection incidence proportion,systematic infection,0.69
infection incidence proportion,infection incidence rate,0.8574074074074073
infection incidence proportion,virus host,0.55
infection incidence proportion,double-stranded RNA virus,0.5954545454545455
infection incidence proportion,virus transcription stage,0.6318181818181818
infection incidence proportion,infectious disease lifetime prevalence,0.7
infection incidence proportion,toxin disposition,0.6840425531914894
infection incidence proportion,lower respiratory tract disease,0.5975409836065574
infection incidence proportion,infectious disease incidence proportion,0.8702898550724637
infection incidence proportion,virus generative stage,0.6038461538461539
infection incidence proportion,acute infectious disease course,0.6959016393442623
infection incidence proportion,cidal agent disposition,0.6764150943396227
infection incidence proportion,infectious disorder,0.7153061224489795
infection incidence proportion,subclinical infection,0.6852941176470588
infection incidence proportion,appearance of disorder,0.6038461538461539
infection incidence proportion,simple infection,0.6891304347826087
infection incidence proportion,parasiticidal disposition,0.6863636363636364
infection incidence proportion,infectious disease sporadicity,0.7333333333333333
infection incidence proportion,communicability end process boundary,0.6621212121212122
infection incidence proportion,infection incidence proportion profile,0.8911764705882353
infection incidence proportion,SARS-CoV-2 incidence proportion,0.8270491803278688
infection incidence proportion,transmissibility disposition,0.6396551724137931
infection incidence proportion,latency end process boundary,0.6396551724137931
infection incidence proportion,infectious disease epidemic,0.7131578947368421
infection incidence proportion,disease transmission model,0.6107142857142857
infection incidence proportion,endotoxin disposition,0.6852941176470588
infection incidence proportion,negative-sense single-stranded RNA virus,0.65
infection incidence proportion,COVID-19 incidence rate,0.7330188679245283
infection incidence proportion,cytotoxin disposition,0.6852941176470588
infection incidence proportion,community-acquired infection,0.6741379310344828
infection incidence proportion,chronic infectious disease course,0.6880952380952381
infection incidence proportion,nursing-home acquired infection,0.6795081967213115
infection incidence proportion,COVID-19 epidemic,0.598936170212766
infection incidence proportion,secondary infection,0.7153061224489795
infection incidence proportion,infection start temporal region,0.728688524590164
infection incidence proportion,infection incidence,0.8377551020408163
infection incidence proportion,virus disorder,0.5863636363636363
infection incidence proportion,primary infection,0.6627659574468084
infection incidence proportion,process of establishing an infection,0.6621212121212122
infection incidence proportion,incubation end process boundary,0.7122950819672131
infection incidence proportion,SARS-CoV-2 disorder,0.5928571428571429
infection incidence proportion,collective pathogenic disposition,0.6880952380952381
infection incidence proportion,neurotoxin disposition,0.7
infection incidence proportion,COVID-19 incidence,0.7
infection incidence proportion,latency end temporal region,0.6605263157894737
infection incidence proportion,virus adhesion susceptible cell,0.630327868852459
infection incidence proportion,collective disposition,0.6807692307692308
infection incidence proportion,infection,0.6807692307692308
infection incidence proportion,static agent disposition,0.6722222222222223
infection incidence proportion,T cell receptor complex,0.6386792452830189
infection incidence proportion,respiratory system disease,0.575
infection incidence proportion,communicability interval,0.6166666666666667
infection incidence proportion,infectious disease control strategy,0.7115384615384616
infection incidence proportion,infectious disease pandemic,0.7131578947368421
infection incidence proportion,immunosuppressive disposition,0.6533898305084747
infection incidence proportion,pathogenic disposition,0.6807692307692308
infection incidence proportion,viral disease course,0.61
infection incidence proportion,intracellular infection,0.6764150943396227
infection incidence proportion,secondary infection role,0.6907407407407408
infection incidence proportion,metastatic infection,0.69
infection incidence proportion,infectious disposition,0.7576923076923078
infection incidence proportion,acute infection,0.6944444444444444
infection incidence proportion,bacteriostatic disposition,0.6821428571428573
infection incidence proportion,bactericidal disposition,0.6907407407407408
infection incidence proportion,source of infection role,0.6722222222222223
infection incidence proportion,chronic infection,0.7053191489361703
infection incidence proportion,invasion disposition,0.71
infection incidence proportion,disease course,0.5863636363636363
infection incidence proportion,infectious disease course,0.7227272727272727
infection incidence proportion,viricidal disposition,0.6852941176470588
infection incidence proportion,complex infection,0.6840425531914894
infection incidence proportion,COVID-19 disease incidence proportion,0.7932835820895522
infection incidence proportion,coronavirus disease course,0.6285714285714286
infection incidence proportion,infection incidence proportion,0.95
infection incidence proportion,respiratory droplet virus fomite,0.6274193548387097
infection incidence proportion,infectious disease prevalence,0.7211864406779661
infection incidence proportion,disposition,0.6207317073170732
infection incidence proportion,single-stranded DNA virus,0.6318181818181818
infection incidence proportion,COVID-19 mortality rate,0.619811320754717
infection incidence proportion,viral disease,0.5662790697674418
infection incidence proportion,primary infection role,0.6807692307692308
infection incidence proportion,adhesion disposition,0.69
infection incidence proportion,infection incidence profile,0.8710526315789474
infection incidence proportion,contagiousness,0.609090909090909
infection incidence proportion,disease,0.5310810810810811
infection incidence proportion,primary infectious disposition,0.7166666666666667
infection incidence proportion,infection prevalence,0.73
infection incidence proportion,coronavirus disorder,0.61
infection incidence proportion,SARS-CoV-2 incidence,0.69
infection incidence proportion,subclinical virus infection,0.6780701754385965
infection incidence proportion,establishment of localization in virus host,0.6554794520547945
infection incidence proportion,virus attachment stage,0.5846153846153846
infection incidence proportion,virus synthesis stage,0.5676470588235294
infection incidence proportion,SARS-COV-2 adhesion disposition,0.6631147540983606
infection incidence proportion,invasive disposition,0.67
infection incidence proportion,long-term non-progressing infectious disease course,0.6351851851851852
infection incidence proportion,viral disease epidemic,0.6038461538461539
infection incidence proportion,communicability start temporal region,0.658955223880597
infection incidence proportion,fungicidal disposition,0.7
infection incidence proportion,viral disease pandemic,0.6038461538461539
infection incidence proportion,virus penetration stage,0.6386792452830189
infection incidence proportion,acute respiratory distress syndrome,0.6038461538461539
infection incidence proportion,division of geopolitical entity,0.6467213114754098
infection incidence proportion,infectious disease endemicity,0.7042372881355932
infection incidence proportion,disorder,0.581578947368421
infection incidence proportion,communicability,0.6055555555555556
infection incidence proportion,extracellular infection,0.6575471698113208
infection incidence proportion,exotoxin disposition,0.69
infection incidence proportion,infection start process boundary,0.7080645161290323
infection incidence proportion,action specification,0.71
infection incidence proportion,processed material,0.5958333333333333
infection incidence proportion,infectious disease control objective specification,0.7
infection incidence proportion,COVID-19 lifetime prevalence,0.6224137931034482
infection incidence proportion,opportunistic infectious disposition,0.6924242424242425
infection incidence proportion,process of establishing viral infection,0.6528985507246376
infection incidence proportion,enterotoxin disposition,0.6952830188679244
infection incidence proportion,COVID-19 disease course,0.619811320754717
infection incidence proportion,infectious disease incidence rate,0.7833333333333333
infection incidence proportion,communicability start process boundary,0.6264705882352941
infection incidence proportion,COVID-19 prevalence,0.6132653061224489
infection incidence proportion,SARS-COV-2 prevalence,0.5872549019607843
infection incidence proportion,disordered virus,0.6021739130434782
infection incidence proportion,collective resistance disposition,0.7039682539682539
infection incidence proportion,fungistatic disposition,0.6764150943396227
infection incidence proportion,virus uncoating stage,0.6068627450980393
infection incidence proportion,local infection,0.6722222222222223
infection incidence proportion,establishment of a clinically abnormal colony,0.6366666666666667
infection incidence proportion,coronavirus disease,0.5928571428571429
infection incidence proportion,positive-sense single-stranded RNA virus,0.6357142857142857
infection incidence proportion,hospital-acquired infection,0.6605263157894737
infection incidence proportion,material processing,0.6132653061224489
infection incidence rate,virus aggregate,0.6038461538461539
infection incidence rate,source of infection,0.6593023255813953
infection incidence rate,virostatic disposition,0.6021739130434782
infection incidence rate,zoonotic disposition,0.609090909090909
infection incidence rate,infectious disease mortality rate,0.7482456140350877
infection incidence rate,infection incidence rate profile,0.8785714285714286
infection incidence rate,communicability end temporal region,0.6533898305084747
infection incidence rate,subclinical coronavirus infection,0.6429824561403508
infection incidence rate,infection end temporal region,0.7518867924528303
infection incidence rate,infectious disease,0.7595238095238095
infection incidence rate,SARS-CoV-2 incidence rate,0.7969387755102041
infection incidence rate,double-stranded DNA virus,0.6132653061224489
infection incidence rate,incubation end temporal region,0.7092592592592593
infection incidence rate,site of infection,0.6695121951219513
infection incidence rate,virulence factor disposition,0.6423076923076922
infection incidence rate,viral adhesion disposition,0.63
infection incidence rate,parasitostatic disposition,0.59
infection incidence rate,infectious disease incidence,0.7961538461538461
infection incidence rate,reverse zoonotic disposition,0.5846153846153846
infection incidence rate,subclinical SARS-CoV-2 infection,0.6285714285714286
infection incidence rate,virus translation stage,0.6414893617021277
infection incidence rate,disease surveillance objective specification,0.6264705882352941
infection incidence rate,virus release stage,0.6127906976744186
infection incidence rate,material entity,0.6038461538461539
infection incidence rate,source of infection site,0.7208333333333333
infection incidence rate,virus,0.5189655172413793
infection incidence rate,virus replication,0.6207317073170732
infection incidence rate,B cell receptor complex,0.598936170212766
infection incidence rate,systematic infection,0.6545454545454545
infection incidence rate,infection incidence rate,0.95
infection incidence rate,virus host,0.5382352941176471
infection incidence rate,double-stranded RNA virus,0.6132653061224489
infection incidence rate,virus transcription stage,0.6540816326530612
infection incidence rate,infectious disease lifetime prevalence,0.7241935483870968
infection incidence rate,toxin disposition,0.6207317073170732
infection incidence rate,serology assay,0.5552631578947369
infection incidence rate,lower respiratory tract disease,0.6136363636363636
infection incidence rate,infectious disease incidence proportion,0.7833333333333333
infection incidence rate,virus generative stage,0.6456521739130434
infection incidence rate,acute infectious disease course,0.7227272727272727
infection incidence rate,cidal agent disposition,0.6202127659574468
infection incidence rate,infectious disorder,0.7523255813953489
infection incidence rate,subclinical infection,0.65
infection incidence rate,appearance of disorder,0.6239130434782608
infection incidence rate,simple infection,0.675
infection incidence rate,parasiticidal disposition,0.6132653061224489
infection incidence rate,infectious disease sporadicity,0.7462962962962962
infection incidence rate,communicability end process boundary,0.65
infection incidence rate,infection incidence proportion profile,0.8209677419354838
infection incidence rate,SARS-CoV-2 incidence proportion,0.7227272727272727
infection incidence rate,transmissibility disposition,0.5846153846153846
infection incidence rate,latency end process boundary,0.6230769230769231
infection incidence rate,infectious disease epidemic,0.7245098039215686
infection incidence rate,disease transmission model,0.63
infection incidence rate,endotoxin disposition,0.6277777777777778
infection incidence rate,negative-sense single-stranded RNA virus,0.66875
infection incidence rate,COVID-19 incidence rate,0.8117021276595744
infection incidence rate,viral plaque assay,0.569047619047619
infection incidence rate,cytotoxin disposition,0.6277777777777778
infection incidence rate,community-acquired infection,0.6423076923076922
infection incidence rate,chronic infectious disease course,0.7131578947368421
infection incidence rate,nursing-home acquired infection,0.65
infection incidence rate,COVID-19 epidemic,0.6207317073170732
infection incidence rate,secondary infection,0.6825581395348838
infection incidence rate,infection start temporal region,0.7045454545454546
infection incidence rate,infection incidence,0.891860465116279
infection incidence rate,virus disorder,0.6078947368421053
infection incidence rate,primary infection,0.6695121951219513
infection incidence rate,process of establishing an infection,0.6333333333333333
infection incidence rate,incubation end process boundary,0.7045454545454546
infection incidence rate,SARS-CoV-2 disorder,0.6127906976744186
infection incidence rate,collective pathogenic disposition,0.6254385964912281
infection incidence rate,neurotoxin disposition,0.6456521739130434
infection incidence rate,COVID-19 incidence,0.7357142857142857
infection incidence rate,latency end temporal region,0.6264705882352941
infection incidence rate,virus adhesion susceptible cell,0.65
infection incidence rate,collective disposition,0.6239130434782608
infection incidence rate,infection,0.7227272727272727
infection incidence rate,static agent disposition,0.6166666666666667
infection incidence rate,T cell receptor complex,0.6202127659574468
infection incidence rate,respiratory system disease,0.61
infection incidence rate,communicability interval,0.6583333333333334
infection incidence rate,infectious disease control strategy,0.738135593220339
infection incidence rate,infectious disease pandemic,0.7441176470588234
infection incidence rate,immunosuppressive disposition,0.6009433962264151
infection incidence rate,pathogenic disposition,0.6021739130434782
infection incidence rate,viral disease course,0.6318181818181818
infection incidence rate,intracellular infection,0.6414893617021277
infection incidence rate,secondary infection role,0.7208333333333333
infection incidence rate,metastatic infection,0.6545454545454545
infection incidence rate,infectious disposition,0.7108695652173913
infection incidence rate,acute infection,0.6807692307692308
infection incidence rate,bacteriostatic disposition,0.61
infection incidence rate,bactericidal disposition,0.6166666666666667
infection incidence rate,source of infection role,0.7
infection incidence rate,chronic infection,0.6695121951219513
infection incidence rate,invasion disposition,0.6545454545454545
infection incidence rate,disease course,0.6078947368421053
infection incidence rate,infectious disease course,0.7561224489795919
infection incidence rate,viricidal disposition,0.6055555555555556
infection incidence rate,complex infection,0.6695121951219513
infection incidence rate,COVID-19 disease incidence proportion,0.6959016393442623
infection incidence rate,coronavirus disease course,0.65
infection incidence rate,infection incidence proportion,0.8574074074074073
infection incidence rate,respiratory droplet virus fomite,0.6285714285714286
infection incidence rate,infectious disease prevalence,0.7518867924528303
infection incidence rate,disposition,0.5928571428571429
infection incidence rate,single-stranded DNA virus,0.6540816326530612
infection incidence rate,COVID-19 mortality rate,0.6414893617021277
infection incidence rate,viral disease,0.6121621621621621
infection incidence rate,primary infection role,0.7108695652173913
infection incidence rate,adhesion disposition,0.6318181818181818
infection incidence rate,infection incidence profile,0.8813725490196078
infection incidence rate,contagiousness,0.6078947368421053
infection incidence rate,disease,0.5790322580645162
infection incidence rate,primary infectious disposition,0.6722222222222223
infection incidence rate,infection prevalence,0.7681818181818181
infection incidence rate,coronavirus disorder,0.6318181818181818
infection incidence rate,SARS-CoV-2 incidence,0.7227272727272727
infection incidence rate,subclinical virus infection,0.6460784313725491
infection incidence rate,establishment of localization in virus host,0.658955223880597
infection incidence rate,virus attachment stage,0.6239130434782608
infection incidence rate,virus synthesis stage,0.6055555555555556
infection incidence rate,SARS-COV-2 adhesion disposition,0.5954545454545455
infection incidence rate,invasive disposition,0.6318181818181818
infection incidence rate,long-term non-progressing infectious disease course,0.65
infection incidence rate,viral disease epidemic,0.6021739130434782
infection incidence rate,communicability start temporal region,0.6139344262295081
infection incidence rate,fungicidal disposition,0.6239130434782608
infection incidence rate,viral disease pandemic,0.6239130434782608
infection incidence rate,virus penetration stage,0.6627659574468084
infection incidence rate,acute respiratory distress syndrome,0.6194915254237288
infection incidence rate,infectious disease endemicity,0.7330188679245283
infection incidence rate,disorder,0.60625
infection incidence rate,communicability,0.6294871794871795
infection incidence rate,extracellular infection,0.6414893617021277
infection incidence rate,exotoxin disposition,0.6318181818181818
infection incidence rate,infection start process boundary,0.7
infection incidence rate,action specification,0.7
infection incidence rate,processed material,0.6404761904761905
infection incidence rate,infectious disease control objective specification,0.6797297297297297
infection incidence rate,COVID-19 lifetime prevalence,0.6423076923076922
infection incidence rate,opportunistic infectious disposition,0.65
infection incidence rate,process of establishing viral infection,0.6246031746031746
infection incidence rate,enterotoxin disposition,0.6414893617021277
infection incidence rate,COVID-19 disease course,0.6414893617021277
infection incidence rate,infectious disease incidence rate,0.8535087719298246
infection incidence rate,communicability start process boundary,0.6112903225806451
infection incidence rate,COVID-19 prevalence,0.636046511627907
infection incidence rate,SARS-COV-2 prevalence,0.6055555555555556
infection incidence rate,disordered virus,0.625
infection incidence rate,collective resistance disposition,0.6429824561403508
infection incidence rate,fungistatic disposition,0.598936170212766
infection incidence rate,virus uncoating stage,0.65
infection incidence rate,local infection,0.6807692307692308
infection incidence rate,establishment of a clinically abnormal colony,0.6239130434782608
infection incidence rate,coronavirus disease,0.636046511627907
infection incidence rate,positive-sense single-stranded RNA virus,0.653125
infection incidence rate,hospital-acquired infection,0.6264705882352941
infection incidence rate,material processing,0.5895348837209302
host,virostatic disposition,0.5653846153846154
host,zoonotic disposition,0.575
host,virulence factor disposition,0.54375
host,viral adhesion disposition,0.5833333333333334
host,parasitostatic disposition,0.55
host,reverse zoonotic disposition,0.54375
host,establishment of localization in host,0.5475609756097561
host,infectious agent host role,0.5833333333333334
host,colonized host,0.6722222222222223
host,virus host,0.7357142857142857
host,toxin disposition,0.5928571428571429
host,cidal agent disposition,0.5611111111111111
host,parasiticidal disposition,0.553448275862069
host,transmissibility disposition,0.54375
host,colonization of host,0.6166666666666667
host,endotoxin disposition,0.57
host,infectious structure host role,0.5676470588235294
host,cytotoxin disposition,0.57
host,host,0.95
host,establishment of localization in human host,0.5351063829787234
host,collective pathogenic disposition,0.5581081081081081
host,neurotoxin disposition,0.5653846153846154
host,dead-end host role,0.6318181818181818
host,definitive host role,0.6166666666666667
host,collective disposition,0.5653846153846154
host,static agent disposition,0.5571428571428572
host,infectious structure host,0.5879310344827586
host,entry into host,0.6605263157894737
host,adhesion of symbiont to host,0.575
host,immunosuppressive disposition,0.5409090909090909
host,pathogenic disposition,0.6038461538461539
host,entry into host through host barriers,0.5475609756097561
host,infectious disposition,0.5653846153846154
host,bacteriostatic disposition,0.55
host,bactericidal disposition,0.5571428571428572
host,pathogen host,0.6852941176470588
host,invasion disposition,0.575
host,viricidal disposition,0.57
host,intermediate host,0.6404761904761905
host,disposition,0.65
host,adhesion disposition,0.6166666666666667
host,primary infectious disposition,0.5382352941176471
host,pathogen host role,0.6318181818181818
host,intermediate host role,0.6038461538461539
host,dead-end host,0.6852941176470588
host,host role,0.7576923076923078
host,establishment of localization in virus host,0.5351063829787234
host,SARS-COV-2 adhesion disposition,0.5642857142857143
host,invasive disposition,0.575
host,infectious agent host,0.61
host,fungicidal disposition,0.5653846153846154
host,division of geopolitical entity,0.5071428571428571
host,exotoxin disposition,0.575
host,symbiont host role,0.6318181818181818
host,opportunistic infectious disposition,0.525
host,enterotoxin disposition,0.5611111111111111
host,collective resistance disposition,0.5310810810810811
host,fungistatic disposition,0.5611111111111111
host,definitive host,0.6605263157894737
source of infection role,virus aggregate,0.5782051282051281
source of infection role,source of infection,0.891860465116279
source of infection role,virostatic disposition,0.6456521739130434
source of infection role,zoonotic disposition,0.6545454545454545
source of infection role,infectious disease mortality rate,0.6605263157894737
source of infection role,infection incidence rate profile,0.7
source of infection role,infectious structure aggregate,0.6537037037037037
source of infection role,communicability end temporal region,0.6364406779661017
source of infection role,subclinical coronavirus infection,0.7131578947368421
source of infection role,primary pathogen,0.575
source of infection role,infection end temporal region,0.6952830188679244
source of infection role,infectious disease,0.6880952380952381
source of infection role,double-stranded DNA virus,0.6132653061224489
source of infection role,incubation end temporal region,0.6537037037037037
source of infection role,site of infection,0.8158536585365854
source of infection role,virulence factor disposition,0.6615384615384616
source of infection role,viral adhesion disposition,0.63
source of infection role,parasitostatic disposition,0.65
source of infection role,infectious disease incidence,0.6423076923076922
source of infection role,reservoir of pathogen role,0.75
source of infection role,reverse zoonotic disposition,0.6423076923076922
source of infection role,subclinical SARS-CoV-2 infection,0.7178571428571427
source of infection role,virus translation stage,0.6414893617021277
source of infection role,disease surveillance objective specification,0.6705882352941177
source of infection role,virus release stage,0.5895348837209302
source of infection role,infectious agent host role,0.73
source of infection role,asymptomatic infectious structure carrier,0.6807692307692308
source of infection role,source of infection site,0.8875
source of infection role,architectual structure,0.6456521739130434
source of infection role,virus,0.5189655172413793
source of infection role,virus replication,0.6695121951219513
source of infection role,B cell receptor complex,0.6840425531914894
source of infection role,systematic infection,0.7227272727272727
source of infection role,infection incidence rate,0.7
source of infection role,virus host,0.5676470588235294
source of infection role,double-stranded RNA virus,0.6132653061224489
source of infection role,pathogen portal of entry role,0.6952830188679244
source of infection role,virus transcription stage,0.6540816326530612
source of infection role,infectious disease lifetime prevalence,0.6596774193548387
source of infection role,toxin disposition,0.6451219512195122
source of infection role,pathogen birth temporal region,0.6166666666666667
source of infection role,lower respiratory tract disease,0.6136363636363636
source of infection role,infectious disease incidence proportion,0.6404761904761905
source of infection role,virus generative stage,0.6239130434782608
source of infection role,acute infectious disease course,0.7045454545454546
source of infection role,cidal agent disposition,0.6414893617021277
source of infection role,infectious disorder,0.7058139534883722
source of infection role,role,0.5928571428571429
source of infection role,subclinical infection,0.7388888888888888
source of infection role,appearance of disorder,0.6891304347826087
source of infection role,simple infection,0.75
source of infection role,parasiticidal disposition,0.6336734693877552
source of infection role,infectious disease sporadicity,0.6351851851851852
source of infection role,mutualist role,0.6605263157894737
source of infection role,communicability end process boundary,0.6166666666666667
source of infection role,acellular structure aggregate,0.6009433962264151
source of infection role,infection incidence proportion profile,0.7080645161290323
source of infection role,transmissibility disposition,0.6038461538461539
source of infection role,latency end process boundary,0.6038461538461539
source of infection role,infectious disease epidemic,0.6460784313725491
source of infection role,disease transmission model,0.65
source of infection role,endotoxin disposition,0.6277777777777778
source of infection role,negative-sense single-stranded RNA virus,0.60625
source of infection role,infectious structure host role,0.6907407407407408
source of infection role,cytotoxin disposition,0.6277777777777778
source of infection role,community-acquired infection,0.7192307692307692
source of infection role,pathogen vehicle role,0.6722222222222223
source of infection role,chronic infectious disease course,0.6956140350877194
source of infection role,nursing-home acquired infection,0.7227272727272727
source of infection role,COVID-19 epidemic,0.5963414634146341
source of infection role,secondary infection,0.7523255813953489
source of infection role,mechanical vector role,0.6891304347826087
source of infection role,infection start temporal region,0.7045454545454546
source of infection role,infection incidence,0.7058139534883722
source of infection role,virus disorder,0.6078947368421053
source of infection role,acellular structure,0.6127906976744186
source of infection role,primary infection,0.7182926829268292
source of infection role,process of establishing an infection,0.7166666666666667
source of infection role,incubation end process boundary,0.65
source of infection role,SARS-CoV-2 disorder,0.6593023255813953
source of infection role,collective pathogenic disposition,0.6429824561403508
source of infection role,neurotoxin disposition,0.6456521739130434
source of infection role,dead-end host role,0.6642857142857143
source of infection role,plan specification,0.6642857142857143
source of infection role,definitive host role,0.7227272727272727
source of infection role,latency end temporal region,0.6264705882352941
source of infection role,infectious structure,0.7
source of infection role,virus adhesion susceptible cell,0.6136363636363636
source of infection role,collective disposition,0.6673913043478261
source of infection role,infection,0.7227272727272727
source of infection role,static agent disposition,0.6583333333333334
source of infection role,T cell receptor complex,0.6840425531914894
source of infection role,asymptomatic carrier role,0.6744897959183673
source of infection role,infectious structure host,0.6744897959183673
source of infection role,respiratory system disease,0.61
source of infection role,communicability interval,0.6375
source of infection role,infectious disease control strategy,0.6703389830508475
source of infection role,infectious disease pandemic,0.6460784313725491
source of infection role,infectious structure generative stage,0.6467213114754098
source of infection role,immunosuppressive disposition,0.6575471698113208
source of infection role,pathogenic disposition,0.6456521739130434
source of infection role,viral disease course,0.6318181818181818
source of infection role,intracellular infection,0.7265957446808511
source of infection role,secondary infection role,0.825
source of infection role,metastatic infection,0.7227272727272727
source of infection role,infectious disposition,0.6673913043478261
source of infection role,acute infection,0.7576923076923078
source of infection role,bacteriostatic disposition,0.63
source of infection role,bactericidal disposition,0.6375
source of infection role,source of infection role,0.95
source of infection role,chronic infection,0.7426829268292683
source of infection role,invasion disposition,0.6545454545454545
source of infection role,disease course,0.6342105263157894
source of infection role,infectious disease course,0.6744897959183673
source of infection role,viricidal disposition,0.65
source of infection role,complex infection,0.7426829268292683
source of infection role,COVID-19 disease incidence proportion,0.630327868852459
source of infection role,coronavirus disease course,0.65
source of infection role,biological vehicle role,0.6627659574468084
source of infection role,infection incidence proportion,0.6722222222222223
source of infection role,respiratory droplet virus fomite,0.6464285714285714
source of infection role,symbiont role,0.6932432432432433
source of infection role,parasite role,0.6662162162162162
source of infection role,pathogen vector role,0.7227272727272727
source of infection role,infectious disease prevalence,0.6764150943396227
source of infection role,disposition,0.65
source of infection role,single-stranded DNA virus,0.6132653061224489
source of infection role,place closure control strategy,0.6722222222222223
source of infection role,viral disease,0.5851351351351352
source of infection role,primary infection role,0.7978260869565217
source of infection role,primary immunodeficiency,0.6166666666666667
source of infection role,biological role,0.6807692307692308
source of infection role,adhesion disposition,0.6545454545454545
source of infection role,infection incidence profile,0.7245098039215686
source of infection role,contagiousness,0.6605263157894737
source of infection role,disease,0.5467741935483871
source of infection role,symptomatic infectious structure carrier,0.684375
source of infection role,biological vector role,0.7108695652173913
source of infection role,primary infectious disposition,0.6722222222222223
source of infection role,pathogen host role,0.6880952380952381
source of infection role,infection prevalence,0.7454545454545455
source of infection role,symptomatic carrier role,0.6791666666666666
source of infection role,coronavirus disorder,0.6318181818181818
source of infection role,incubation start process boundary,0.6429824561403508
source of infection role,intermediate host role,0.6673913043478261
source of infection role,host role,0.6621212121212122
source of infection role,pathogen birth process boundary,0.6136363636363636
source of infection role,subclinical virus infection,0.7245098039215686
source of infection role,establishment of localization in virus host,0.658955223880597
source of infection role,virus attachment stage,0.6021739130434782
source of infection role,virus synthesis stage,0.6055555555555556
source of infection role,SARS-COV-2 adhesion disposition,0.65
source of infection role,pathogen portal of exit role,0.7
source of infection role,invasive disposition,0.6545454545454545
source of infection role,long-term non-progressing infectious disease course,0.6633333333333334
source of infection role,viral disease epidemic,0.5804347826086956
source of infection role,commensal role,0.6868421052631578
source of infection role,communicability start temporal region,0.6139344262295081
source of infection role,epitope role,0.7
source of infection role,fungicidal disposition,0.6456521739130434
source of infection role,blood,0.5189655172413793
source of infection role,viral disease pandemic,0.5804347826086956
source of infection role,virus penetration stage,0.6627659574468084
source of infection role,acute respiratory distress syndrome,0.6364406779661017
source of infection role,infectious disease endemicity,0.6386792452830189
source of infection role,disorder,0.60625
source of infection role,function,0.66875
source of infection role,communicability,0.6038461538461539
source of infection role,extracellular infection,0.7265957446808511
source of infection role,pathogen transporter role,0.6540816326530612
source of infection role,exotoxin disposition,0.6318181818181818
source of infection role,antigen role,0.7
source of infection role,infection start process boundary,0.6821428571428573
source of infection role,action specification,0.6772727272727272
source of infection role,latency start process boundary,0.5981481481481481
source of infection role,infectious disease control objective specification,0.6256756756756756
source of infection role,symbiont host role,0.6880952380952381
source of infection role,opportunistic infectious disposition,0.6833333333333332
source of infection role,fomite role,0.6785714285714286
source of infection role,process of establishing viral infection,0.7039682539682539
source of infection role,enterotoxin disposition,0.6202127659574468
source of infection role,COVID-19 disease course,0.6414893617021277
source of infection role,infectious disease incidence rate,0.6605263157894737
source of infection role,communicability start process boundary,0.5951612903225807
source of infection role,disordered virus,0.625
source of infection role,collective resistance disposition,0.6429824561403508
source of infection role,reagent role,0.7
source of infection role,viral load,0.5382352941176471
source of infection role,fungistatic disposition,0.6414893617021277
source of infection role,virus uncoating stage,0.65
source of infection role,local infection,0.7576923076923078
source of infection role,establishment of a clinically abnormal colony,0.6384057971014493
source of infection role,coronavirus disease,0.6127906976744186
source of infection role,positive-sense single-stranded RNA virus,0.60625
source of infection role,hospital-acquired infection,0.7245098039215686
pathogen death temporal region,extended organism,0.6627659574468084
pathogen death temporal region,virus aggregate,0.5833333333333334
pathogen death temporal region,source of infection,0.6336734693877552
pathogen death temporal region,infectious disease mortality rate,0.6880952380952381
pathogen death temporal region,infection incidence rate profile,0.6596774193548387
pathogen death temporal region,communicability end temporal region,0.7730769230769231
pathogen death temporal region,pathogen generative stage,0.740909090909091
pathogen death temporal region,pathogen portal of entry,0.7648148148148148
pathogen death temporal region,subclinical coronavirus infection,0.6246031746031746
pathogen death temporal region,primary pathogen,0.6456521739130434
pathogen death temporal region,infection end temporal region,0.8059322033898306
pathogen death temporal region,drug-based immunosuppressed organism,0.6166666666666667
pathogen death temporal region,infectious disease,0.5958333333333333
pathogen death temporal region,double-stranded DNA virus,0.6136363636363636
pathogen death temporal region,incubation end temporal region,0.8166666666666665
pathogen death temporal region,site of infection,0.6414893617021277
pathogen death temporal region,two-dimensional spatial region,0.7166666666666667
pathogen death temporal region,one-dimensional temporal region,0.7942622950819671
pathogen death temporal region,immunocompetent organism,0.6351851851851852
pathogen death temporal region,pathogen portal of exit,0.7707547169811321
pathogen death temporal region,temporal region,0.7833333333333333
pathogen death temporal region,infectious disease incidence,0.6224137931034482
pathogen death temporal region,reservoir of pathogen role,0.6642857142857143
pathogen death temporal region,subclinical SARS-CoV-2 infection,0.5951612903225807
pathogen death temporal region,virus translation stage,0.6009433962264151
pathogen death temporal region,disease surveillance objective specification,0.6256756756756756
pathogen death temporal region,virus release stage,0.5928571428571429
pathogen death temporal region,infectious agent host role,0.6464285714285714
pathogen death temporal region,material entity,0.65
pathogen death temporal region,source of infection site,0.6166666666666667
pathogen death temporal region,virus replication,0.598936170212766
pathogen death temporal region,B cell receptor complex,0.619811320754717
pathogen death temporal region,passive immunization against infectious agent,0.6366666666666667
pathogen death temporal region,systematic infection,0.63
pathogen death temporal region,infection incidence rate,0.6351851851851852
pathogen death temporal region,virus host,0.525
pathogen death temporal region,double-stranded RNA virus,0.6318181818181818
pathogen death temporal region,pathogen portal of entry role,0.738135593220339
pathogen death temporal region,virus transcription stage,0.5954545454545455
pathogen death temporal region,infectious disease lifetime prevalence,0.6705882352941177
pathogen death temporal region,pathogen birth temporal region,0.9
pathogen death temporal region,lower respiratory tract disease,0.6467213114754098
pathogen death temporal region,infectious disease incidence proportion,0.6528985507246376
pathogen death temporal region,opportunistic pathogen,0.6423076923076922
pathogen death temporal region,virus generative stage,0.6423076923076922
pathogen death temporal region,acute infectious disease course,0.6467213114754098
pathogen death temporal region,cidal agent disposition,0.6575471698113208
pathogen death temporal region,genetic resistance to pathogen,0.65
pathogen death temporal region,subclinical infection,0.6068627450980393
pathogen death temporal region,simple infection,0.6239130434782608
pathogen death temporal region,droplet pathogen transmission process,0.6738805970149254
pathogen death temporal region,infectious disease sporadicity,0.65
pathogen death temporal region,communicability end process boundary,0.6166666666666667
pathogen death temporal region,infection incidence proportion profile,0.6411764705882353
pathogen death temporal region,infectious agent colony,0.6575471698113208
pathogen death temporal region,SARS-CoV-2 incidence proportion,0.6467213114754098
pathogen death temporal region,spatiotemporal region,0.8225490196078431
pathogen death temporal region,pathogen transporter,0.73
pathogen death temporal region,latency end process boundary,0.656896551724138
pathogen death temporal region,infectious disease epidemic,0.6429824561403508
pathogen death temporal region,infectious agent generative stage,0.6563492063492063
pathogen death temporal region,disease transmission model,0.6285714285714286
pathogen death temporal region,pathologically immunosuppressed organism,0.6642857142857143
pathogen death temporal region,negative-sense single-stranded RNA virus,0.6214285714285714
pathogen death temporal region,cidal agent,0.5963414634146341
pathogen death temporal region,pathogen vehicle,0.7326086956521739
pathogen death temporal region,community-acquired infection,0.6051724137931035
pathogen death temporal region,pathogen vector,0.7388888888888888
pathogen death temporal region,pathogen vehicle role,0.7441176470588234
pathogen death temporal region,zero-dimensional spatial region,0.6959016393442623
pathogen death temporal region,zero-dimensional temporal region,0.7725806451612902
pathogen death temporal region,chronic infectious disease course,0.6404761904761905
pathogen death temporal region,asymptomatic infectious agent carrier,0.6291044776119403
pathogen death temporal region,nursing-home acquired infection,0.630327868852459
pathogen death temporal region,secondary infection,0.6540816326530612
pathogen death temporal region,infection start temporal region,0.810655737704918
pathogen death temporal region,infection incidence,0.5928571428571429
pathogen death temporal region,virus disorder,0.5636363636363636
pathogen death temporal region,sterilizing immunity to infectious agent,0.6357142857142857
pathogen death temporal region,establishment of localization in human host,0.6143835616438357
pathogen death temporal region,primary infection,0.6202127659574468
pathogen death temporal region,process of establishing an infection,0.6621212121212122
pathogen death temporal region,incubation end process boundary,0.6467213114754098
pathogen death temporal region,pathogen death process boundary,0.7778688524590163
pathogen death temporal region,geographical region,0.7153061224489795
pathogen death temporal region,immunosuppressed organism,0.5954545454545455
pathogen death temporal region,latency end temporal region,0.8359649122807017
pathogen death temporal region,innate immunity to infectious agent,0.65
pathogen death temporal region,virus adhesion susceptible cell,0.6139344262295081
pathogen death temporal region,infection,0.6038461538461539
pathogen death temporal region,static agent disposition,0.6722222222222223
pathogen death temporal region,T cell receptor complex,0.6386792452830189
pathogen death temporal region,infectious agent population,0.6780701754385965
pathogen death temporal region,respiratory system disease,0.6285714285714286
pathogen death temporal region,leukocyte-mediated immunity to infectious agent,0.6188311688311688
pathogen death temporal region,indirect pathogen transmission process,0.6705882352941177
pathogen death temporal region,organism population,0.6540816326530612
pathogen death temporal region,humoral immunity to infectious agent,0.6318181818181818
pathogen death temporal region,infectious disease control strategy,0.6653846153846155
pathogen death temporal region,parasite,0.581578947368421
pathogen death temporal region,infectious disease pandemic,0.6429824561403508
pathogen death temporal region,antibody reagent,0.6456521739130434
pathogen death temporal region,viral disease course,0.63
pathogen death temporal region,intracellular infection,0.6386792452830189
pathogen death temporal region,secondary infection role,0.6351851851851852
pathogen death temporal region,metastatic infection,0.63
pathogen death temporal region,three-dimensional spatial region,0.7241935483870968
pathogen death temporal region,passive immunity to infectious agent,0.6469696969696969
pathogen death temporal region,vaccination against infectious agent,0.6469696969696969
pathogen death temporal region,objective specification,0.619811320754717
pathogen death temporal region,acute infection,0.65
pathogen death temporal region,susceptibility to infectious agent,0.621875
pathogen death temporal region,epitope site,0.6166666666666667
pathogen death temporal region,immunity to pathogen,0.63
pathogen death temporal region,country,0.5581081081081081
pathogen death temporal region,source of infection role,0.6166666666666667
pathogen death temporal region,pathogen host,0.7058139534883722
pathogen death temporal region,chronic infection,0.6414893617021277
pathogen death temporal region,disease course,0.609090909090909
pathogen death temporal region,infectious disease course,0.6318181818181818
pathogen death temporal region,acquired immunity to infectious agent,0.6291044776119403
pathogen death temporal region,complex infection,0.6414893617021277
pathogen death temporal region,COVID-19 disease incidence proportion,0.6440298507462687
pathogen death temporal region,coronavirus disease course,0.6285714285714286
pathogen death temporal region,infection incidence proportion,0.6666666666666667
pathogen death temporal region,symptomatic infectious agent carrier,0.6318181818181818
pathogen death temporal region,respiratory droplet virus fomite,0.6435483870967742
pathogen death temporal region,susceptible organism,0.61
pathogen death temporal region,parasite role,0.636046511627907
pathogen death temporal region,pathogen vector role,0.77
pathogen death temporal region,pathogen portal of exit site,0.743103448275862
pathogen death temporal region,infectious disease prevalence,0.6703389830508475
pathogen death temporal region,organism substance,0.5958333333333333
pathogen death temporal region,single-stranded DNA virus,0.6136363636363636
pathogen death temporal region,COVID-19 mortality rate,0.6575471698113208
pathogen death temporal region,place closure control strategy,0.6666666666666667
pathogen death temporal region,viral disease,0.5895348837209302
pathogen death temporal region,primary infection role,0.6230769230769231
pathogen death temporal region,pathogen portal of entry site,0.738135593220339
pathogen death temporal region,infection incidence profile,0.6429824561403508
pathogen death temporal region,disease,0.5581081081081081
pathogen death temporal region,site,0.5088235294117647
pathogen death temporal region,pathogen host role,0.7416666666666667
pathogen death temporal region,infection prevalence,0.65
pathogen death temporal region,infectious pathogen transmissibility,0.6621212121212122
pathogen death temporal region,object,0.5333333333333333
pathogen death temporal region,pathogen surveillance,0.7049019607843137
pathogen death temporal region,immunodeficient organism,0.6166666666666667
pathogen death temporal region,pathogen,0.6605263157894737
pathogen death temporal region,pathogen birth process boundary,0.728688524590164
pathogen death temporal region,infectious human pathogen,0.6318181818181818
pathogen death temporal region,subclinical virus infection,0.6078947368421053
pathogen death temporal region,resistance to pathogen,0.6423076923076922
pathogen death temporal region,colonization of human,0.6264705882352941
pathogen death temporal region,establishment of localization in virus host,0.6143835616438357
pathogen death temporal region,immunization against infectious agent,0.6440298507462687
pathogen death temporal region,virus attachment stage,0.6423076923076922
pathogen death temporal region,virus synthesis stage,0.5872549019607843
pathogen death temporal region,object aggregate,0.6239130434782608
pathogen death temporal region,pathogen portal of exit role,0.760344827586207
pathogen death temporal region,infectious agent host,0.6068627450980393
pathogen death temporal region,re-emerging pathogen,0.63
pathogen death temporal region,long-term non-progressing infectious disease course,0.6228395061728395
pathogen death temporal region,viral disease epidemic,0.6423076923076922
pathogen death temporal region,communicability start temporal region,0.7634328358208955
pathogen death temporal region,viral disease pandemic,0.6423076923076922
pathogen death temporal region,virus penetration stage,0.6386792452830189
pathogen death temporal region,pathogen seroprevalence,0.7518867924528303
pathogen death temporal region,geospatial region,0.7265957446808511
pathogen death temporal region,division of geopolitical entity,0.6467213114754098
pathogen death temporal region,infectious disease endemicity,0.6194915254237288
pathogen death temporal region,contact pathogen transmission process,0.6738805970149254
pathogen death temporal region,herd immunity to infectious organism,0.6318181818181818
pathogen death temporal region,extracellular infection,0.6386792452830189
pathogen death temporal region,pathogen transporter role,0.740909090909091
pathogen death temporal region,infectious agent reservoir,0.6285714285714286
pathogen death temporal region,infection start process boundary,0.6435483870967742
pathogen death temporal region,processed material,0.6583333333333334
pathogen death temporal region,infectious disease control objective specification,0.6375
pathogen death temporal region,process of establishing viral infection,0.6818840579710145
pathogen death temporal region,COVID-19 disease course,0.619811320754717
pathogen death temporal region,infectious disease incidence rate,0.6246031746031746
pathogen death temporal region,process that results in death,0.6533898305084747
pathogen death temporal region,single-stranded RNA retrovirus,0.65
pathogen death temporal region,active immunization against infectious agent,0.6256756756756756
pathogen death temporal region,disordered virus,0.5804347826086956
pathogen death temporal region,organism,0.5552631578947369
pathogen death temporal region,virus uncoating stage,0.5872549019607843
pathogen death temporal region,local infection,0.6277777777777778
pathogen death temporal region,infectious agent,0.6021739130434782
pathogen death temporal region,establishment of a clinically abnormal colony,0.6366666666666667
pathogen death temporal region,coronavirus disease,0.5928571428571429
pathogen death temporal region,positive-sense single-stranded RNA virus,0.6214285714285714
pathogen death temporal region,horizontal pathogen transmission process,0.6642857142857143
pathogen death temporal region,one-dimensional spatial region,0.7166666666666667
pathogen death temporal region,hospital-acquired infection,0.6254385964912281
pathogen death temporal region,spatial region,0.7227272727272727
pathogen death temporal region,pathogen death temporal region,0.95
pathogen death temporal region,emerging pathogen,0.6414893617021277
pathogen death temporal region,drug susceptibility of infectious agent,0.6094202898550725
pathogen death temporal region,SARS-CoV-2 release stage,0.6166666666666667
pathogen death temporal region,static agent,0.6166666666666667
pathogen death temporal region,pathogen transmission process,0.7042372881355932
pathogen death temporal region,material processing,0.6744897959183673
prion,prion replication,0.6772727272727272
prion,disordered prion,0.6880952380952381
prion,prion aggregate,0.7
prion,prion,0.95
pathogen transporter,extended organism,0.6662162162162162
pathogen transporter,virus aggregate,0.6214285714285714
pathogen transporter,source of infection,0.5782051282051281
pathogen transporter,infectious disease mortality rate,0.619811320754717
pathogen transporter,infection incidence rate profile,0.6423076923076922
pathogen transporter,pathogen generative stage,0.7611111111111112
pathogen transporter,pathogen portal of entry,0.7909090909090909
pathogen transporter,subclinical coronavirus infection,0.5632075471698114
pathogen transporter,primary pathogen,0.6722222222222223
pathogen transporter,infection end temporal region,0.6540816326530612
pathogen transporter,drug-based immunosuppressed organism,0.6107142857142857
pathogen transporter,infectious disease,0.6078947368421053
pathogen transporter,double-stranded DNA virus,0.6277777777777778
pathogen transporter,site of infection,0.5851351351351352
pathogen transporter,immunocompetent organism,0.6545454545454545
pathogen transporter,pathogen portal of exit,0.7755813953488372
pathogen transporter,infectious disease incidence,0.575
pathogen transporter,reservoir of pathogen role,0.7108695652173913
pathogen transporter,subclinical SARS-CoV-2 infection,0.5653846153846154
pathogen transporter,virus translation stage,0.6593023255813953
pathogen transporter,disease surveillance objective specification,0.590625
pathogen transporter,virus release stage,0.6038461538461539
pathogen transporter,infectious agent host role,0.6673913043478261
pathogen transporter,asymptomatic infectious structure carrier,0.630327868852459
pathogen transporter,source of infection site,0.6318181818181818
pathogen transporter,virus,0.53
pathogen transporter,virus replication,0.5851351351351352
pathogen transporter,B cell receptor complex,0.6127906976744186
pathogen transporter,passive immunization against infectious agent,0.6192307692307693
pathogen transporter,systematic infection,0.575
pathogen transporter,infection incidence rate,0.6545454545454545
pathogen transporter,virus host,0.5833333333333334
pathogen transporter,double-stranded RNA virus,0.6277777777777778
pathogen transporter,pathogen portal of entry role,0.7561224489795919
pathogen transporter,virus transcription stage,0.6722222222222223
pathogen transporter,infectious disease lifetime prevalence,0.6051724137931035
pathogen transporter,pathogen birth temporal region,0.73
pathogen transporter,lower respiratory tract disease,0.6460784313725491
pathogen transporter,infectious disease incidence proportion,0.6194915254237288
pathogen transporter,opportunistic pathogen,0.6404761904761905
pathogen transporter,virus generative stage,0.6404761904761905
pathogen transporter,acute infectious disease course,0.6460784313725491
pathogen transporter,cidal agent disposition,0.6593023255813953
pathogen transporter,genetic resistance to pathogen,0.65
pathogen transporter,subclinical infection,0.5475609756097561
pathogen transporter,simple infection,0.5888888888888889
pathogen transporter,droplet pathogen transmission process,0.7482456140350877
pathogen transporter,infectious disease sporadicity,0.63
pathogen transporter,infection incidence proportion profile,0.6396551724137931
pathogen transporter,infectious agent colony,0.6127906976744186
pathogen transporter,pathogen transporter,0.95
pathogen transporter,infectious disease epidemic,0.598936170212766
pathogen transporter,infectious agent generative stage,0.6575471698113208
pathogen transporter,disease transmission model,0.6673913043478261
pathogen transporter,pathologically immunosuppressed organism,0.6666666666666667
pathogen transporter,negative-sense single-stranded RNA virus,0.6333333333333333
pathogen transporter,cidal agent,0.6112903225806451
pathogen transporter,pathogen vehicle,0.7277777777777777
pathogen transporter,community-acquired infection,0.575
pathogen transporter,pathogen vector,0.7928571428571428
pathogen transporter,pathogen vehicle role,0.7426829268292683
pathogen transporter,chronic infectious disease course,0.6386792452830189
pathogen transporter,asymptomatic infectious agent carrier,0.6605263157894737
pathogen transporter,nursing-home acquired infection,0.5872549019607843
pathogen transporter,secondary infection,0.5782051282051281
pathogen transporter,infection start temporal region,0.6460784313725491
pathogen transporter,infection incidence,0.6038461538461539
pathogen transporter,virus disorder,0.6264705882352941
pathogen transporter,sterilizing immunity to infectious agent,0.5833333333333334
pathogen transporter,primary infection,0.5851351351351352
pathogen transporter,process of establishing an infection,0.5928571428571429
pathogen transporter,pathogen death process boundary,0.7245098039215686
pathogen transporter,immunosuppressed organism,0.6055555555555556
pathogen transporter,innate immunity to infectious agent,0.6136363636363636
pathogen transporter,virus adhesion susceptible cell,0.6264705882352941
pathogen transporter,infection,0.553448275862069
pathogen transporter,static agent disposition,0.6772727272727272
pathogen transporter,T cell receptor complex,0.636046511627907
pathogen transporter,asymptomatic carrier role,0.6277777777777778
pathogen transporter,infectious agent population,0.6414893617021277
pathogen transporter,respiratory system disease,0.6456521739130434
pathogen transporter,leukocyte-mediated immunity to infectious agent,0.5843283582089552
pathogen transporter,indirect pathogen transmission process,0.743103448275862
pathogen transporter,organism population,0.6551282051282051
pathogen transporter,humoral immunity to infectious agent,0.5928571428571429
pathogen transporter,infectious disease control strategy,0.6318181818181818
pathogen transporter,parasite,0.7
pathogen transporter,infectious disease pandemic,0.598936170212766
pathogen transporter,antibody reagent,0.6722222222222223
pathogen transporter,viral disease course,0.625
pathogen transporter,intracellular infection,0.5895348837209302
pathogen transporter,secondary infection role,0.6318181818181818
pathogen transporter,metastatic infection,0.6
pathogen transporter,passive immunity to infectious agent,0.6107142857142857
pathogen transporter,vaccination against infectious agent,0.6285714285714286
pathogen transporter,acute infection,0.6214285714285714
pathogen transporter,susceptibility to infectious agent,0.5981481481481481
pathogen transporter,epitope site,0.7
pathogen transporter,immunity to pathogen,0.65
pathogen transporter,source of infection role,0.609090909090909
pathogen transporter,pathogen host,0.7833333333333333
pathogen transporter,chronic infection,0.6121621621621621
pathogen transporter,disease course,0.6264705882352941
pathogen transporter,infectious disease course,0.6277777777777778
pathogen transporter,acquired immunity to infectious agent,0.5903508771929825
pathogen transporter,complex infection,0.5851351351351352
pathogen transporter,COVID-19 disease incidence proportion,0.6078947368421053
pathogen transporter,coronavirus disease course,0.6239130434782608
pathogen transporter,asymptomatic carrier,0.65
pathogen transporter,infection incidence proportion,0.65
pathogen transporter,symptomatic infectious agent carrier,0.6642857142857143
pathogen transporter,respiratory droplet virus fomite,0.6615384615384616
pathogen transporter,susceptible organism,0.65
pathogen transporter,parasite role,0.6924242424242425
pathogen transporter,pathogen vector role,0.775
pathogen transporter,pathogen portal of exit site,0.7416666666666667
pathogen transporter,infectious disease prevalence,0.6132653061224489
pathogen transporter,organism substance,0.6605263157894737
pathogen transporter,single-stranded DNA virus,0.6277777777777778
pathogen transporter,viral disease,0.6015151515151516
pathogen transporter,primary infection role,0.6642857142857143
pathogen transporter,pathogen portal of entry site,0.7561224489795919
pathogen transporter,infection incidence profile,0.6202127659574468
pathogen transporter,disease,0.5981481481481481
pathogen transporter,symptomatic infectious structure carrier,0.6333333333333333
pathogen transporter,site,0.575
pathogen transporter,pathogen host role,0.7921052631578948
pathogen transporter,infection prevalence,0.65
pathogen transporter,symptomatic carrier role,0.6318181818181818
pathogen transporter,infectious pathogen transmissibility,0.7178571428571427
pathogen transporter,pathogen surveillance,0.7670731707317073
pathogen transporter,immunodeficient organism,0.6318181818181818
pathogen transporter,pathogen,0.7357142857142857
pathogen transporter,pathogen birth process boundary,0.7245098039215686
pathogen transporter,infectious human pathogen,0.6277777777777778
pathogen transporter,subclinical virus infection,0.5563829787234043
pathogen transporter,resistance to pathogen,0.6404761904761905
pathogen transporter,establishment of localization in virus host,0.6087301587301588
pathogen transporter,immunization against infectious agent,0.6254385964912281
pathogen transporter,virus attachment stage,0.6642857142857143
pathogen transporter,virus synthesis stage,0.6207317073170732
pathogen transporter,pathogen portal of exit role,0.7625
pathogen transporter,infectious agent host,0.6451219512195122
pathogen transporter,re-emerging pathogen,0.65
pathogen transporter,long-term non-progressing infectious disease course,0.6190140845070422
pathogen transporter,viral disease epidemic,0.5928571428571429
pathogen transporter,viral disease pandemic,0.5928571428571429
pathogen transporter,virus penetration stage,0.6825581395348838
pathogen transporter,pathogen seroprevalence,0.7523255813953489
pathogen transporter,symptomatic carrier,0.6551282051282051
pathogen transporter,infectious disease endemicity,0.5724489795918367
pathogen transporter,contact pathogen transmission process,0.7482456140350877
pathogen transporter,herd immunity to infectious organism,0.6107142857142857
pathogen transporter,extracellular infection,0.5895348837209302
pathogen transporter,pathogen transporter role,0.8944444444444444
pathogen transporter,infectious agent reservoir,0.6673913043478261
pathogen transporter,infection start process boundary,0.6423076923076922
pathogen transporter,infectious disease control objective specification,0.5785714285714285
pathogen transporter,process of establishing viral infection,0.6025423728813559
pathogen transporter,COVID-19 disease course,0.6127906976744186
pathogen transporter,infectious disease incidence rate,0.619811320754717
pathogen transporter,active immunization against infectious agent,0.60625
pathogen transporter,disordered virus,0.5888888888888889
pathogen transporter,organism,0.6285714285714286
pathogen transporter,virus uncoating stage,0.6207317073170732
pathogen transporter,local infection,0.5642857142857143
pathogen transporter,infectious agent,0.6166666666666667
pathogen transporter,establishment of a clinically abnormal colony,0.5884615384615385
pathogen transporter,coronavirus disease,0.6038461538461539
pathogen transporter,positive-sense single-stranded RNA virus,0.6333333333333333
pathogen transporter,horizontal pathogen transmission process,0.7333333333333333
pathogen transporter,hospital-acquired infection,0.5776595744680851
pathogen transporter,pathogen death temporal region,0.73
pathogen transporter,emerging pathogen,0.6662162162162162
pathogen transporter,drug susceptibility of infectious agent,0.5855932203389831
pathogen transporter,static agent,0.6375
pathogen transporter,pathogen transmission process,0.7969387755102041
infection incidence proportion profile,virus aggregate,0.5443396226415094
infection incidence proportion profile,source of infection,0.6429824561403508
infection incidence proportion profile,virostatic disposition,0.6333333333333333
infection incidence proportion profile,information content entity,0.66875
infection incidence proportion profile,zoonotic disposition,0.6396551724137931
infection incidence proportion profile,infectious disease mortality rate,0.7316901408450704
infection incidence proportion profile,infection incidence rate profile,0.8785714285714286
infection incidence proportion profile,communicability end temporal region,0.6554794520547945
infection incidence proportion profile,subclinical coronavirus infection,0.6471830985915493
infection incidence proportion profile,infection end temporal region,0.7335820895522389
infection incidence proportion profile,infectious disease,0.6642857142857143
infection incidence proportion profile,SARS-CoV-2 incidence rate,0.7039682539682539
infection incidence proportion profile,double-stranded DNA virus,0.5928571428571429
infection incidence proportion profile,incubation end temporal region,0.7
infection incidence proportion profile,site of infection,0.6681818181818181
infection incidence proportion profile,virulence factor disposition,0.6621212121212122
infection incidence proportion profile,viral adhesion disposition,0.653125
infection incidence proportion profile,parasitostatic disposition,0.6375
infection incidence proportion profile,infectious disease incidence,0.7227272727272727
infection incidence proportion profile,reverse zoonotic disposition,0.6318181818181818
infection incidence proportion profile,subclinical SARS-CoV-2 infection,0.6357142857142857
infection incidence proportion profile,virus translation stage,0.5975409836065574
infection incidence proportion profile,disease surveillance objective specification,0.6329268292682927
infection incidence proportion profile,virus release stage,0.5728070175438597
infection incidence proportion profile,material entity,0.5820754716981132
infection incidence proportion profile,source of infection site,0.6758064516129032
infection incidence proportion profile,virus replication,0.5954545454545455
infection incidence proportion profile,B cell receptor complex,0.6467213114754098
infection incidence proportion profile,systematic infection,0.656896551724138
infection incidence proportion profile,infection incidence rate,0.8209677419354838
infection incidence proportion profile,virus host,0.5333333333333333
infection incidence proportion profile,double-stranded RNA virus,0.6087301587301588
infection incidence proportion profile,virus transcription stage,0.6404761904761905
infection incidence proportion profile,infectious disease lifetime prevalence,0.7131578947368421
infection incidence proportion profile,toxin disposition,0.65
infection incidence proportion profile,lower respiratory tract disease,0.6239130434782608
infection incidence proportion profile,infectious disease incidence proportion,0.8266233766233766
infection incidence proportion profile,virus generative stage,0.6166666666666667
infection incidence proportion profile,acute infectious disease course,0.6818840579710145
infection incidence proportion profile,cidal agent disposition,0.6467213114754098
infection incidence proportion profile,infectious disorder,0.6956140350877194
infection incidence proportion profile,subclinical infection,0.6533898305084747
infection incidence proportion profile,appearance of disorder,0.6166666666666667
infection incidence proportion profile,simple infection,0.6537037037037037
infection incidence proportion profile,parasiticidal disposition,0.6563492063492063
infection incidence proportion profile,infectious disease sporadicity,0.7147058823529412
infection incidence proportion profile,communicability end process boundary,0.6527027027027027
infection incidence proportion profile,directive information content entity,0.6797297297297297
infection incidence proportion profile,infection incidence proportion profile,0.95
infection incidence proportion profile,SARS-CoV-2 incidence proportion,0.7833333333333333
infection incidence proportion profile,transmissibility disposition,0.6166666666666667
infection incidence proportion profile,latency end process boundary,0.6318181818181818
infection incidence proportion profile,infectious disease epidemic,0.6961538461538461
infection incidence proportion profile,disease transmission model,0.621875
infection incidence proportion profile,endotoxin disposition,0.6533898305084747
infection incidence proportion profile,negative-sense single-stranded RNA virus,0.6551282051282051
infection incidence proportion profile,COVID-19 incidence rate,0.7122950819672131
infection incidence proportion profile,cytotoxin disposition,0.6533898305084747
infection incidence proportion profile,community-acquired infection,0.6469696969696969
infection incidence proportion profile,chronic infectious disease course,0.6753521126760563
infection incidence proportion profile,nursing-home acquired infection,0.6528985507246376
infection incidence proportion profile,descriptive information content entity,0.6605263157894737
infection incidence proportion profile,COVID-19 epidemic,0.5954545454545455
infection incidence proportion profile,secondary infection,0.6780701754385965
infection incidence proportion profile,infection start temporal region,0.696376811594203
infection incidence proportion profile,infection incidence,0.7833333333333333
infection incidence proportion profile,virus disorder,0.5846153846153846
infection incidence proportion profile,primary infection,0.6318181818181818
infection incidence proportion profile,process of establishing an infection,0.6391891891891892
infection incidence proportion profile,incubation end process boundary,0.696376811594203
infection incidence proportion profile,SARS-CoV-2 disorder,0.5903508771929825
infection incidence proportion profile,collective pathogenic disposition,0.6612676056338028
infection incidence proportion profile,neurotoxin disposition,0.6666666666666667
infection incidence proportion profile,COVID-19 incidence,0.6642857142857143
infection incidence proportion profile,latency end temporal region,0.6346153846153847
infection incidence proportion profile,virus adhesion susceptible cell,0.6384057971014493
infection incidence proportion profile,collective disposition,0.65
infection incidence proportion profile,infection,0.6414893617021277
infection incidence proportion profile,static agent disposition,0.6435483870967742
infection incidence proportion profile,T cell receptor complex,0.6631147540983606
infection incidence proportion profile,respiratory system disease,0.590625
infection incidence proportion profile,communicability interval,0.6274193548387097
infection incidence proportion profile,infectious disease control strategy,0.7102739726027397
infection incidence proportion profile,infectious disease pandemic,0.6961538461538461
infection incidence proportion profile,immunosuppressive disposition,0.6291044776119403
infection incidence proportion profile,pathogenic disposition,0.65
infection incidence proportion profile,viral disease course,0.6051724137931035
infection incidence proportion profile,intracellular infection,0.6467213114754098
infection incidence proportion profile,secondary infection role,0.7403225806451613
infection incidence proportion profile,metastatic infection,0.656896551724138
infection incidence proportion profile,infectious disposition,0.7166666666666667
infection incidence proportion profile,acute infection,0.6575471698113208
infection incidence proportion profile,bacteriostatic disposition,0.653125
infection incidence proportion profile,bactericidal disposition,0.6596774193548387
infection incidence proportion profile,source of infection role,0.7080645161290323
infection incidence proportion profile,chronic infection,0.6681818181818181
infection incidence proportion profile,invasion disposition,0.6741379310344828
infection incidence proportion profile,disease course,0.5846153846153846
infection incidence proportion profile,infectious disease course,0.7039682539682539
infection incidence proportion profile,viricidal disposition,0.6533898305084747
infection incidence proportion profile,complex infection,0.65
infection incidence proportion profile,COVID-19 disease incidence proportion,0.7566666666666666
infection incidence proportion profile,coronavirus disease course,0.621875
infection incidence proportion profile,infection incidence proportion,0.8911764705882353
infection incidence proportion profile,respiratory droplet virus fomite,0.65
infection incidence proportion profile,infectious disease prevalence,0.703731343283582
infection incidence proportion profile,disposition,0.5928571428571429
infection incidence proportion profile,single-stranded DNA virus,0.6246031746031746
infection incidence proportion profile,COVID-19 mortality rate,0.6467213114754098
infection incidence proportion profile,process profile,0.6575471698113208
infection incidence proportion profile,viral disease,0.5480392156862746
infection incidence proportion profile,primary infection role,0.7
infection incidence proportion profile,adhesion disposition,0.656896551724138
infection incidence proportion profile,infection incidence profile,0.8653846153846154
infection incidence proportion profile,contagiousness,0.6038461538461539
infection incidence proportion profile,disease,0.5166666666666666
infection incidence proportion profile,primary infectious disposition,0.6852941176470588
infection incidence proportion profile,infection prevalence,0.6913793103448276
infection incidence proportion profile,designative information content entity,0.6605263157894737
infection incidence proportion profile,coronavirus disorder,0.6051724137931035
infection incidence proportion profile,SARS-CoV-2 incidence,0.656896551724138
infection incidence proportion profile,subclinical virus infection,0.65
infection incidence proportion profile,establishment of localization in virus host,0.6351851851851852
infection incidence proportion profile,virus attachment stage,0.5833333333333334
infection incidence proportion profile,virus synthesis stage,0.5686440677966101
infection incidence proportion profile,SARS-COV-2 adhesion disposition,0.6384057971014493
infection incidence proportion profile,invasive disposition,0.6396551724137931
infection incidence proportion profile,long-term non-progressing infectious disease course,0.6297752808988765
infection incidence proportion profile,viral disease epidemic,0.6
infection incidence proportion profile,communicability start temporal region,0.6366666666666667
infection incidence proportion profile,fungicidal disposition,0.6666666666666667
infection incidence proportion profile,viral disease pandemic,0.6
infection incidence proportion profile,virus penetration stage,0.6467213114754098
infection incidence proportion profile,acute respiratory distress syndrome,0.6280821917808219
infection incidence proportion profile,division of geopolitical entity,0.6384057971014493
infection incidence proportion profile,geographical feature,0.5879310344827586
infection incidence proportion profile,infectious disease endemicity,0.6738805970149254
infection incidence proportion profile,disorder,0.558695652173913
infection incidence proportion profile,history,0.5388888888888889
infection incidence proportion profile,communicability,0.5820754716981132
infection incidence proportion profile,extracellular infection,0.630327868852459
infection incidence proportion profile,exotoxin disposition,0.656896551724138
infection incidence proportion profile,infection start process boundary,0.6928571428571427
infection incidence proportion profile,action specification,0.6741379310344828
infection incidence proportion profile,processed material,0.6107142857142857
infection incidence proportion profile,infectious disease control objective specification,0.7
infection incidence proportion profile,COVID-19 lifetime prevalence,0.6318181818181818
infection incidence proportion profile,opportunistic infectious disposition,0.6662162162162162
infection incidence proportion profile,process of establishing viral infection,0.6318181818181818
infection incidence proportion profile,enterotoxin disposition,0.6631147540983606
infection incidence proportion profile,COVID-19 disease course,0.6139344262295081
infection incidence proportion profile,infectious disease incidence rate,0.7598591549295775
infection incidence proportion profile,communicability start process boundary,0.6342105263157894
infection incidence proportion profile,COVID-19 prevalence,0.6078947368421053
infection incidence proportion profile,single-stranded RNA retrovirus,0.6558823529411765
infection incidence proportion profile,SARS-COV-2 prevalence,0.5686440677966101
infection incidence proportion profile,disordered virus,0.5981481481481481
infection incidence proportion profile,collective resistance disposition,0.6753521126760563
infection incidence proportion profile,fungistatic disposition,0.6467213114754098
infection incidence proportion profile,virus uncoating stage,0.6194915254237288
infection incidence proportion profile,local infection,0.6386792452830189
infection incidence proportion profile,establishment of a clinically abnormal colony,0.6307228915662652
infection incidence proportion profile,coronavirus disease,0.5903508771929825
infection incidence proportion profile,positive-sense single-stranded RNA virus,0.6423076923076922
infection incidence proportion profile,hospital-acquired infection,0.6346153846153847
infection incidence proportion profile,material processing,0.6078947368421053
antigen,immune response,0.5863636363636363
antigen,virulence factor disposition,0.5642857142857143
antigen,negative regulation of production,0.575
antigen,B cell receptor complex,0.5166666666666666
antigen,toxin disposition,0.6166666666666667
antigen,invasion factor,0.5863636363636363
antigen,negative regulation of establishment of localization,0.5516949152542373
antigen,negative regulation of developmental process,0.5676470588235294
antigen,negative regulation of replication,0.5963414634146341
antigen,virulence factor,0.5804347826086956
antigen,T cell receptor complex,0.5166666666666666
antigen,antibody reagent,0.7543478260869566
antigen,innate immune response,0.6224137931034482
antigen,toxin,0.7
antigen,organism substance,0.61
antigen,negative regulation of life-sustaining process,0.5632075471698114
antigen,humoral immune response,0.5833333333333334
antigen,negative regulation of immune response,0.5833333333333334
antigen,negative regulation of viral process,0.5662790697674418
antigen,antigen,0.95
antigen,antigen role,0.8184210526315789
antigen,immune population,0.6166666666666667
antigen,negative regulation of biological process,0.5541666666666667
antigen,adaptive immune response,0.6112903225806451
antigen,establishment of a clinically abnormal colony,0.5461538461538461
antigen,adhesion factor,0.5863636363636363
respiratory droplet virus fomite,extended organism,0.6132653061224489
respiratory droplet virus fomite,virus aggregate,0.6202127659574468
respiratory droplet virus fomite,source of infection,0.6264705882352941
respiratory droplet virus fomite,virostatic disposition,0.6537037037037037
respiratory droplet virus fomite,zoonotic disposition,0.6230769230769231
respiratory droplet virus fomite,immune response,0.598936170212766
respiratory droplet virus fomite,infectious disease mortality rate,0.6346153846153847
respiratory droplet virus fomite,infection incidence rate profile,0.6375
respiratory droplet virus fomite,communicability end temporal region,0.6141791044776119
respiratory droplet virus fomite,pathogen generative stage,0.6429824561403508
respiratory droplet virus fomite,pathogen portal of entry,0.6285714285714286
respiratory droplet virus fomite,subclinical coronavirus infection,0.6653846153846155
respiratory droplet virus fomite,primary pathogen,0.6583333333333334
respiratory droplet virus fomite,infection end temporal region,0.6139344262295081
respiratory droplet virus fomite,drug-based immunosuppressed organism,0.5970588235294118
respiratory droplet virus fomite,infectious disease,0.63
respiratory droplet virus fomite,double-stranded DNA virus,0.6605263157894737
respiratory droplet virus fomite,incubation end temporal region,0.6274193548387097
respiratory droplet virus fomite,site of infection,0.6336734693877552
respiratory droplet virus fomite,immunocompetent organism,0.6285714285714286
respiratory droplet virus fomite,virulence factor disposition,0.6666666666666667
respiratory droplet virus fomite,pathogen portal of exit,0.65
respiratory droplet virus fomite,viral adhesion disposition,0.656896551724138
respiratory droplet virus fomite,parasitostatic disposition,0.656896551724138
respiratory droplet virus fomite,infectious disease incidence,0.6166666666666667
respiratory droplet virus fomite,reservoir of pathogen role,0.6913793103448276
respiratory droplet virus fomite,reverse zoonotic disposition,0.65
respiratory droplet virus fomite,subclinical SARS-CoV-2 infection,0.60625
respiratory droplet virus fomite,virus translation stage,0.6318181818181818
respiratory droplet virus fomite,disease surveillance objective specification,0.6210526315789474
respiratory droplet virus fomite,virus release stage,0.6460784313725491
respiratory droplet virus fomite,source of infection site,0.6642857142857143
respiratory droplet virus fomite,virus,0.5851351351351352
respiratory droplet virus fomite,respiratory droplet,0.8225490196078431
respiratory droplet virus fomite,virus replication,0.6336734693877552
respiratory droplet virus fomite,B cell receptor complex,0.65
respiratory droplet virus fomite,systematic infection,0.6038461538461539
respiratory droplet virus fomite,infection incidence rate,0.6285714285714286
respiratory droplet virus fomite,virus host,0.6404761904761905
respiratory droplet virus fomite,double-stranded RNA virus,0.6605263157894737
respiratory droplet virus fomite,pathogen portal of entry role,0.6631147540983606
respiratory droplet virus fomite,virus transcription stage,0.6429824561403508
respiratory droplet virus fomite,infectious disease lifetime prevalence,0.6071428571428572
respiratory droplet virus fomite,toxin disposition,0.6336734693877552
respiratory droplet virus fomite,pathogen birth temporal region,0.6274193548387097
respiratory droplet virus fomite,respiratory droplet coronavirus fomite,0.9071428571428573
respiratory droplet virus fomite,lower respiratory tract disease,0.7357142857142857
respiratory droplet virus fomite,infectious disease incidence proportion,0.6190140845070422
respiratory droplet virus fomite,opportunistic pathogen,0.6166666666666667
respiratory droplet virus fomite,virus generative stage,0.6351851851851852
respiratory droplet virus fomite,acute infectious disease course,0.6246031746031746
respiratory droplet virus fomite,cidal agent disposition,0.65
respiratory droplet virus fomite,infectious disorder,0.6264705882352941
respiratory droplet virus fomite,genetic resistance to pathogen,0.6435483870967742
respiratory droplet virus fomite,subclinical infection,0.6009433962264151
respiratory droplet virus fomite,appearance of disorder,0.6351851851851852
respiratory droplet virus fomite,simple infection,0.6375
respiratory droplet virus fomite,droplet pathogen transmission process,0.6384057971014493
respiratory droplet virus fomite,parasiticidal disposition,0.6605263157894737
respiratory droplet virus fomite,infectious disease sporadicity,0.6274193548387097
respiratory droplet virus fomite,communicability end process boundary,0.6264705882352941
respiratory droplet virus fomite,infection incidence proportion profile,0.65
respiratory droplet virus fomite,pathogen transporter,0.6615384615384616
respiratory droplet virus fomite,transmissibility disposition,0.65
respiratory droplet virus fomite,latency end process boundary,0.6333333333333333
respiratory droplet virus fomite,infectious disease epidemic,0.6194915254237288
respiratory droplet virus fomite,disease transmission model,0.6051724137931035
respiratory droplet virus fomite,endotoxin disposition,0.6386792452830189
respiratory droplet virus fomite,pathologically immunosuppressed organism,0.6305555555555555
respiratory droplet virus fomite,negative-sense single-stranded RNA virus,0.6305555555555555
respiratory droplet virus fomite,pathogen vehicle,0.6375
respiratory droplet virus fomite,cytotoxin disposition,0.619811320754717
respiratory droplet virus fomite,community-acquired infection,0.6
respiratory droplet virus fomite,respiratory droplet SARS-CoV-2 fomite,0.8702898550724637
respiratory droplet virus fomite,pathogen vector,0.6202127659574468
respiratory droplet virus fomite,pathogen vehicle role,0.6575471698113208
respiratory droplet virus fomite,fomite,0.6078947368421053
respiratory droplet virus fomite,chronic infectious disease course,0.6192307692307693
respiratory droplet virus fomite,nursing-home acquired infection,0.6246031746031746
respiratory droplet virus fomite,COVID-19 epidemic,0.5928571428571429
respiratory droplet virus fomite,secondary infection,0.6264705882352941
respiratory droplet virus fomite,infection start temporal region,0.6246031746031746
respiratory droplet virus fomite,infection incidence,0.5872549019607843
respiratory droplet virus fomite,virus disorder,0.6239130434782608
respiratory droplet virus fomite,primary infection,0.6540816326530612
respiratory droplet virus fomite,process of establishing an infection,0.6264705882352941
respiratory droplet virus fomite,incubation end process boundary,0.6404761904761905
respiratory droplet virus fomite,SARS-CoV-2 disorder,0.6264705882352941
respiratory droplet virus fomite,collective pathogenic disposition,0.6346153846153847
respiratory droplet virus fomite,neurotoxin disposition,0.6537037037037037
respiratory droplet virus fomite,pathogen death process boundary,0.6563492063492063
respiratory droplet virus fomite,immunosuppressed organism,0.5903508771929825
respiratory droplet virus fomite,latency end temporal region,0.6194915254237288
respiratory droplet virus fomite,virus adhesion susceptible cell,0.6246031746031746
respiratory droplet virus fomite,collective disposition,0.6351851851851852
respiratory droplet virus fomite,infection,0.5719512195121951
respiratory droplet virus fomite,static agent disposition,0.6642857142857143
respiratory droplet virus fomite,T cell receptor complex,0.65
respiratory droplet virus fomite,respiratory system disease,0.743103448275862
respiratory droplet virus fomite,indirect pathogen transmission process,0.6357142857142857
respiratory droplet virus fomite,organism population,0.6264705882352941
respiratory droplet virus fomite,infectious disease control strategy,0.6291044776119403
respiratory droplet virus fomite,infectious disease pandemic,0.6194915254237288
respiratory droplet virus fomite,immunosuppressive disposition,0.630327868852459
respiratory droplet virus fomite,innate immune response,0.6351851851851852
respiratory droplet virus fomite,pathogenic disposition,0.6537037037037037
respiratory droplet virus fomite,viral disease course,0.6423076923076922
respiratory droplet virus fomite,intracellular infection,0.6136363636363636
respiratory droplet virus fomite,secondary infection role,0.6464285714285714
respiratory droplet virus fomite,metastatic infection,0.6230769230769231
respiratory droplet virus fomite,respiratory secretion,0.7707547169811321
respiratory droplet virus fomite,infectious disposition,0.6351851851851852
respiratory droplet virus fomite,acute infection,0.598936170212766
respiratory droplet virus fomite,bacteriostatic disposition,0.6396551724137931
respiratory droplet virus fomite,immunity to pathogen,0.6230769230769231
respiratory droplet virus fomite,bactericidal disposition,0.6464285714285714
respiratory droplet virus fomite,source of infection role,0.6464285714285714
respiratory droplet virus fomite,pathogen host,0.6277777777777778
respiratory droplet virus fomite,acquired immunodeficiency,0.6078947368421053
respiratory droplet virus fomite,chronic infection,0.5928571428571429
respiratory droplet virus fomite,invasion disposition,0.6423076923076922
respiratory droplet virus fomite,disease course,0.6021739130434782
respiratory droplet virus fomite,infectious disease course,0.6254385964912281
respiratory droplet virus fomite,viricidal disposition,0.6386792452830189
respiratory droplet virus fomite,acquired immunity to infectious agent,0.6528985507246376
respiratory droplet virus fomite,complex infection,0.6132653061224489
respiratory droplet virus fomite,COVID-19 disease incidence proportion,0.5949275362318841
respiratory droplet virus fomite,coronavirus disease course,0.6396551724137931
respiratory droplet virus fomite,infection incidence proportion,0.6274193548387097
respiratory droplet virus fomite,respiratory droplet virus fomite,0.95
respiratory droplet virus fomite,susceptible organism,0.6230769230769231
respiratory droplet virus fomite,pathogen vector role,0.6615384615384616
respiratory droplet virus fomite,pathogen portal of exit site,0.6833333333333332
respiratory droplet virus fomite,infectious disease prevalence,0.5975409836065574
respiratory droplet virus fomite,organism substance,0.59
respiratory droplet virus fomite,respiratory droplet fomite,0.8982758620689656
respiratory droplet virus fomite,disposition,0.5895348837209302
respiratory droplet virus fomite,single-stranded DNA virus,0.6605263157894737
respiratory droplet virus fomite,viral disease,0.6277777777777778
respiratory droplet virus fomite,primary infection role,0.6722222222222223
respiratory droplet virus fomite,adhesion disposition,0.6615384615384616
respiratory droplet virus fomite,pathogen portal of entry site,0.6795081967213115
respiratory droplet virus fomite,infection incidence profile,0.6364406779661017
respiratory droplet virus fomite,disease,0.5525641025641026
respiratory droplet virus fomite,primary infectious disposition,0.6919354838709677
respiratory droplet virus fomite,pathogen host role,0.67
respiratory droplet virus fomite,infection prevalence,0.6038461538461539
respiratory droplet virus fomite,humoral immune response,0.6136363636363636
respiratory droplet virus fomite,coronavirus disorder,0.6615384615384616
respiratory droplet virus fomite,infectious pathogen transmissibility,0.6411764705882353
respiratory droplet virus fomite,pathogen surveillance,0.619811320754717
respiratory droplet virus fomite,immunodeficient organism,0.6107142857142857
respiratory droplet virus fomite,pathogen,0.575
respiratory droplet virus fomite,pathogen birth process boundary,0.6404761904761905
respiratory droplet virus fomite,infectious human pathogen,0.6254385964912281
respiratory droplet virus fomite,subclinical virus infection,0.6703389830508475
respiratory droplet virus fomite,resistance to pathogen,0.6722222222222223
respiratory droplet virus fomite,establishment of localization in virus host,0.69
respiratory droplet virus fomite,virus attachment stage,0.6351851851851852
respiratory droplet virus fomite,negative regulation of immune response,0.65
respiratory droplet virus fomite,virus synthesis stage,0.619811320754717
respiratory droplet virus fomite,SARS-COV-2 adhesion disposition,0.6404761904761905
respiratory droplet virus fomite,pathogen portal of exit role,0.6666666666666667
respiratory droplet virus fomite,invasive disposition,0.6230769230769231
respiratory droplet virus fomite,re-emerging pathogen,0.6038461538461539
respiratory droplet virus fomite,long-term non-progressing infectious disease course,0.6186746987951807
respiratory droplet virus fomite,viral disease epidemic,0.6351851851851852
respiratory droplet virus fomite,fungicidal disposition,0.6166666666666667
respiratory droplet virus fomite,viral disease pandemic,0.6351851851851852
respiratory droplet virus fomite,virus penetration stage,0.65
respiratory droplet virus fomite,pathogen seroprevalence,0.65
respiratory droplet virus fomite,acute respiratory distress syndrome,0.7485074626865671
respiratory droplet virus fomite,division of geopolitical entity,0.6404761904761905
respiratory droplet virus fomite,infectious disease endemicity,0.630327868852459
respiratory droplet virus fomite,contact pathogen transmission process,0.6094202898550725
respiratory droplet virus fomite,disorder,0.6
respiratory droplet virus fomite,herd immunity to infectious organism,0.6558823529411765
respiratory droplet virus fomite,extracellular infection,0.6136363636363636
respiratory droplet virus fomite,pathogen transporter role,0.6605263157894737
respiratory droplet virus fomite,transmission interval,0.6009433962264151
respiratory droplet virus fomite,exotoxin disposition,0.6423076923076922
respiratory droplet virus fomite,infection start process boundary,0.621875
respiratory droplet virus fomite,action specification,0.6423076923076922
respiratory droplet virus fomite,infectious disease control objective specification,0.6329268292682927
respiratory droplet virus fomite,immune population,0.6132653061224489
respiratory droplet virus fomite,opportunistic infectious disposition,0.6411764705882353
respiratory droplet virus fomite,fomite role,0.6127906976744186
respiratory droplet virus fomite,process of establishing viral infection,0.6471830985915493
respiratory droplet virus fomite,enterotoxin disposition,0.65
respiratory droplet virus fomite,COVID-19 disease course,0.5954545454545455
respiratory droplet virus fomite,infectious disease incidence rate,0.6192307692307693
respiratory droplet virus fomite,disordered virus,0.7
respiratory droplet virus fomite,collective resistance disposition,0.6346153846153847
respiratory droplet virus fomite,adaptive immune response,0.6285714285714286
respiratory droplet virus fomite,fungistatic disposition,0.6318181818181818
respiratory droplet virus fomite,organism,0.575
respiratory droplet virus fomite,virus uncoating stage,0.6386792452830189
respiratory droplet virus fomite,local infection,0.5776595744680851
respiratory droplet virus fomite,establishment of a clinically abnormal colony,0.5928571428571429
respiratory droplet virus fomite,coronavirus disease,0.6656862745098039
respiratory droplet virus fomite,positive-sense single-stranded RNA virus,0.6305555555555555
respiratory droplet virus fomite,horizontal pathogen transmission process,0.6166666666666667
respiratory droplet virus fomite,hospital-acquired infection,0.6194915254237288
respiratory droplet virus fomite,pathogen death temporal region,0.6435483870967742
respiratory droplet virus fomite,emerging pathogen,0.5928571428571429
respiratory droplet virus fomite,pathogen transmission process,0.630327868852459
drug susceptibility,ribonucleic acid,0.6214285714285714
drug susceptibility,communicability end temporal region,0.5981481481481481
drug susceptibility,infection end temporal region,0.575
drug susceptibility,deoxyribonucleic acid,0.625
drug susceptibility,incubation end temporal region,0.5724489795918367
drug susceptibility,infectious agent host role,0.5833333333333334
drug susceptibility,B cell receptor complex,0.5928571428571429
drug susceptibility,passive immunization against infectious agent,0.575
drug susceptibility,drug susceptibility,0.95
drug susceptibility,lower respiratory tract disease,0.59
drug susceptibility,cidal agent disposition,0.6166666666666667
drug susceptibility,communicability end process boundary,0.5954545454545455
drug susceptibility,infectious agent colony,0.5928571428571429
drug susceptibility,latency end process boundary,0.5776595744680851
drug susceptibility,infectious agent generative stage,0.5846153846153846
drug susceptibility,cidal agent,0.5833333333333334
drug susceptibility,asymptomatic infectious agent carrier,0.575
drug susceptibility,nucleic acid,0.6112903225806451
drug susceptibility,resistance to drug,0.6121621621621621
drug susceptibility,sterilizing immunity to infectious agent,0.5855932203389831
drug susceptibility,incubation end process boundary,0.57
drug susceptibility,latency end temporal region,0.5804347826086956
drug susceptibility,innate immunity to infectious agent,0.5611111111111111
drug susceptibility,static agent disposition,0.6127906976744186
drug susceptibility,T cell receptor complex,0.5928571428571429
drug susceptibility,infectious agent population,0.5804347826086956
drug susceptibility,leukocyte-mediated immunity to infectious agent,0.5712121212121213
drug susceptibility,humoral immunity to infectious agent,0.5772727272727273
drug susceptibility,SARS-CoV-2 attachment stage,0.5804347826086956
drug susceptibility,passive immunity to infectious agent,0.5772727272727273
drug susceptibility,vaccination against infectious agent,0.5590909090909091
drug susceptibility,susceptibility,0.8742424242424243
drug susceptibility,susceptibility to infectious agent,0.7141509433962264
drug susceptibility,acquired immunity to infectious agent,0.575
drug susceptibility,symptomatic infectious agent carrier,0.5772727272727273
drug susceptibility,organism substance,0.6662162162162162
drug susceptibility,place closure control strategy,0.6132653061224489
drug susceptibility,immunization against infectious agent,0.575
drug susceptibility,virus attachment stage,0.6207317073170732
drug susceptibility,infectious agent host,0.575
drug susceptibility,infectious agent reservoir,0.5833333333333334
drug susceptibility,action specification,0.6038461538461539
drug susceptibility,polymerase chain reaction,0.5863636363636363
drug susceptibility,active immunization against infectious agent,0.5611111111111111
drug susceptibility,infectious agent,0.5642857142857143
drug susceptibility,establishment of a clinically abnormal colony,0.575
drug susceptibility,drug susceptibility of infectious agent,0.7775862068965518
drug susceptibility,static agent,0.5790322580645162
geographical feature,communicability end temporal region,0.6318181818181818
geographical feature,geographical entity,0.8346153846153846
geographical feature,infection end temporal region,0.6132653061224489
geographical feature,incubation end temporal region,0.61
geographical feature,two-dimensional spatial region,0.65
geographical feature,one-dimensional temporal region,0.6264705882352941
geographical feature,virulence factor disposition,0.5958333333333333
geographical feature,temporal region,0.6785714285714286
geographical feature,B cell receptor complex,0.6127906976744186
geographical feature,double-stranded RNA virus,0.5833333333333334
geographical feature,pathogen birth temporal region,0.63
geographical feature,communicability end process boundary,0.6107142857142857
geographical feature,spatiotemporal region,0.6451219512195122
geographical feature,invasion factor,0.65
geographical feature,latency end process boundary,0.575
geographical feature,negative-sense single-stranded RNA virus,0.6
geographical feature,zero-dimensional spatial region,0.6460784313725491
geographical feature,zero-dimensional temporal region,0.6423076923076922
geographical feature,infection start temporal region,0.6264705882352941
geographical feature,virulence factor,0.6444444444444444
geographical feature,incubation end process boundary,0.5872549019607843
geographical feature,geographical region,0.8346153846153846
geographical feature,latency end temporal region,0.6202127659574468
geographical feature,T cell receptor complex,0.6127906976744186
geographical feature,three-dimensional spatial region,0.6423076923076922
geographical feature,communicability start temporal region,0.6254385964912281
geographical feature,geospatial region,0.7202702702702704
geographical feature,division of geopolitical entity,0.6656862745098039
geographical feature,geographical feature,0.95
geographical feature,quality,0.5611111111111111
geographical feature,single-stranded RNA retrovirus,0.63
geographical feature,establishment of a clinically abnormal colony,0.6038461538461539
geographical feature,positive-sense single-stranded RNA virus,0.5666666666666667
geographical feature,adhesion factor,0.6785714285714286
geographical feature,one-dimensional spatial region,0.65
geographical feature,spatial region,0.6558823529411765
geographical feature,pathogen death temporal region,0.63
viroid aggregate,virus aggregate,0.8693548387096774
viroid aggregate,infectious disease mortality rate,0.6336734693877552
viroid aggregate,infection incidence rate profile,0.6375
viroid aggregate,infectious structure aggregate,0.7108695652173913
viroid aggregate,SARS-CoV-2 incidence rate,0.6695121951219513
viroid aggregate,site of infection,0.6015151515151516
viroid aggregate,SARS-CoV-2 aggregate,0.7833333333333333
viroid aggregate,source of infection site,0.6
viroid aggregate,B cell receptor complex,0.5782051282051281
viroid aggregate,infection incidence rate,0.675
viroid aggregate,acellular structure aggregate,0.6944444444444444
viroid aggregate,COVID-19 incidence rate,0.6807692307692308
viroid aggregate,collective pathogenic disposition,0.5928571428571429
viroid aggregate,coronavirus aggregate,0.8013513513513513
viroid aggregate,collective disposition,0.581578947368421
viroid aggregate,T cell receptor complex,0.5782051282051281
viroid aggregate,epitope site,0.6285714285714286
viroid aggregate,prion aggregate,0.8370967741935484
viroid aggregate,pathogen portal of exit site,0.5863636363636363
viroid aggregate,COVID-19 mortality rate,0.6807692307692308
viroid aggregate,pathogen portal of entry site,0.5833333333333334
viroid aggregate,viroid aggregate,0.95
viroid aggregate,site,0.6
viroid aggregate,object aggregate,0.79375
viroid aggregate,infectious disease incidence rate,0.6336734693877552
viroid aggregate,collective resistance disposition,0.5928571428571429
viroid aggregate,viral load,0.6423076923076922
viroid aggregate,establishment of a clinically abnormal colony,0.5647540983606557
pathogen vector,extended organism,0.6375
pathogen vector,virus aggregate,0.5833333333333334
pathogen vector,source of infection,0.6558823529411765
pathogen vector,infectious disease mortality rate,0.575
pathogen vector,infection incidence rate profile,0.6202127659574468
pathogen vector,pathogen generative stage,0.75
pathogen vector,pathogen portal of entry,0.7576923076923078
pathogen vector,subclinical coronavirus infection,0.6166666666666667
pathogen vector,primary pathogen,0.7080645161290323
pathogen vector,infection end temporal region,0.6318181818181818
pathogen vector,drug-based immunosuppressed organism,0.5676470588235294
pathogen vector,vector control strategy,0.6342105263157894
pathogen vector,infectious disease,0.6015151515151516
pathogen vector,double-stranded DNA virus,0.6
pathogen vector,site of infection,0.66875
pathogen vector,immunocompetent organism,0.6294871794871795
pathogen vector,pathogen portal of exit,0.7394736842105263
pathogen vector,infectious disease incidence,0.5895348837209302
pathogen vector,reservoir of pathogen role,0.6939024390243902
pathogen vector,subclinical SARS-CoV-2 infection,0.598936170212766
pathogen vector,virus translation stage,0.6078947368421053
pathogen vector,disease surveillance objective specification,0.6025423728813559
pathogen vector,virus release stage,0.5676470588235294
pathogen vector,infectious agent host role,0.6451219512195122
pathogen vector,source of infection site,0.6294871794871795
pathogen vector,virus,0.55
pathogen vector,virus replication,0.60625
pathogen vector,B cell receptor complex,0.6342105263157894
pathogen vector,passive immunization against infectious agent,0.6333333333333333
pathogen vector,systematic infection,0.65
pathogen vector,infection incidence rate,0.6294871794871795
pathogen vector,virus host,0.57
pathogen vector,double-stranded RNA virus,0.6
pathogen vector,mechanical vector,0.73125
pathogen vector,pathogen portal of entry role,0.7227272727272727
pathogen vector,virus transcription stage,0.6
pathogen vector,infectious disease lifetime prevalence,0.5820754716981132
pathogen vector,pathogen birth temporal region,0.7166666666666667
pathogen vector,lower respiratory tract disease,0.6021739130434782
pathogen vector,infectious disease incidence proportion,0.5981481481481481
pathogen vector,opportunistic pathogen,0.6662162162162162
pathogen vector,virus generative stage,0.6121621621621621
pathogen vector,acute infectious disease course,0.6456521739130434
pathogen vector,cidal agent disposition,0.6342105263157894
pathogen vector,genetic resistance to pathogen,0.6277777777777778
pathogen vector,subclinical infection,0.6166666666666667
pathogen vector,simple infection,0.6758064516129032
pathogen vector,droplet pathogen transmission process,0.6807692307692308
pathogen vector,infectious disease sporadicity,0.5833333333333334
pathogen vector,infection incidence proportion profile,0.619811320754717
pathogen vector,infectious agent colony,0.6605263157894737
pathogen vector,pathogen transporter,0.7928571428571428
pathogen vector,infectious disease epidemic,0.5928571428571429
pathogen vector,infectious agent generative stage,0.6375
pathogen vector,disease transmission model,0.5963414634146341
pathogen vector,vector surveillance,0.6264705882352941
pathogen vector,pathologically immunosuppressed organism,0.6318181818181818
pathogen vector,negative-sense single-stranded RNA virus,0.5954545454545455
pathogen vector,cidal agent,0.6423076923076922
pathogen vector,pathogen vehicle,0.8370967741935484
pathogen vector,community-acquired infection,0.6127906976744186
pathogen vector,pathogen vector,0.95
pathogen vector,pathogen vehicle role,0.8111111111111111
pathogen vector,chronic infectious disease course,0.6375
pathogen vector,asymptomatic infectious agent carrier,0.6423076923076922
pathogen vector,nursing-home acquired infection,0.6239130434782608
pathogen vector,secondary infection,0.6558823529411765
pathogen vector,mechanical vector role,0.6932432432432433
pathogen vector,infection start temporal region,0.6021739130434782
pathogen vector,infection incidence,0.6264705882352941
pathogen vector,virus disorder,0.553448275862069
pathogen vector,sterilizing immunity to infectious agent,0.5954545454545455
pathogen vector,primary infection,0.66875
pathogen vector,process of establishing an infection,0.6460784313725491
pathogen vector,pathogen death process boundary,0.7326086956521739
pathogen vector,immunosuppressed organism,0.575
pathogen vector,innate immunity to infectious agent,0.63
pathogen vector,virus adhesion susceptible cell,0.6021739130434782
pathogen vector,infection,0.6583333333333334
pathogen vector,static agent disposition,0.6551282051282051
pathogen vector,T cell receptor complex,0.6605263157894737
pathogen vector,infectious agent population,0.6404761904761905
pathogen vector,respiratory system disease,0.6207317073170732
pathogen vector,biological vector,0.73125
pathogen vector,leukocyte-mediated immunity to infectious agent,0.5951612903225807
pathogen vector,indirect pathogen transmission process,0.6764150943396227
pathogen vector,organism population,0.6264705882352941
pathogen vector,humoral immunity to infectious agent,0.6068627450980393
pathogen vector,infectious disease control strategy,0.61
pathogen vector,parasite,0.6239130434782608
pathogen vector,infectious disease pandemic,0.5928571428571429
pathogen vector,antibody reagent,0.6758064516129032
pathogen vector,viral disease course,0.6214285714285714
pathogen vector,intracellular infection,0.6342105263157894
pathogen vector,secondary infection role,0.6551282051282051
pathogen vector,metastatic infection,0.65
pathogen vector,passive immunity to infectious agent,0.6264705882352941
pathogen vector,vaccination against infectious agent,0.6460784313725491
pathogen vector,acute infection,0.7166666666666667
pathogen vector,susceptibility to infectious agent,0.6132653061224489
pathogen vector,epitope site,0.6722222222222223
pathogen vector,immunity to pathogen,0.6785714285714286
pathogen vector,source of infection role,0.6551282051282051
pathogen vector,pathogen host,0.8071428571428573
pathogen vector,chronic infection,0.7
pathogen vector,disease course,0.656896551724138
pathogen vector,infectious disease course,0.625
pathogen vector,acquired immunity to infectious agent,0.6038461538461539
pathogen vector,complex infection,0.66875
pathogen vector,COVID-19 disease incidence proportion,0.5846153846153846
pathogen vector,coronavirus disease course,0.6207317073170732
pathogen vector,infection incidence proportion,0.6277777777777778
pathogen vector,symptomatic infectious agent carrier,0.6460784313725491
pathogen vector,respiratory droplet virus fomite,0.6202127659574468
pathogen vector,susceptible organism,0.6214285714285714
pathogen vector,parasite role,0.6642857142857143
pathogen vector,pathogen vector role,0.8785714285714286
pathogen vector,pathogen portal of exit site,0.7058139534883722
pathogen vector,infectious disease prevalence,0.609090909090909
pathogen vector,organism substance,0.6015151515151516
pathogen vector,single-stranded DNA virus,0.6
pathogen vector,viral disease,0.5571428571428572
pathogen vector,primary infection role,0.6662162162162162
pathogen vector,pathogen portal of entry site,0.7227272727272727
pathogen vector,infection incidence profile,0.6166666666666667
pathogen vector,disease,0.5409090909090909
pathogen vector,biological vector role,0.6932432432432433
pathogen vector,site,0.5552631578947369
pathogen vector,pathogen host role,0.7833333333333333
pathogen vector,infection prevalence,0.65
pathogen vector,infectious pathogen transmissibility,0.6656862745098039
pathogen vector,pathogen surveillance,0.7833333333333333
pathogen vector,immunodeficient organism,0.6038461538461539
pathogen vector,pathogen,0.7978260869565217
pathogen vector,pathogen birth process boundary,0.7108695652173913
pathogen vector,infectious human pathogen,0.65
pathogen vector,subclinical virus infection,0.6166666666666667
pathogen vector,resistance to pathogen,0.6662162162162162
pathogen vector,establishment of localization in virus host,0.6051724137931035
pathogen vector,immunization against infectious agent,0.6423076923076922
pathogen vector,virus attachment stage,0.6391891891891892
pathogen vector,virus synthesis stage,0.5888888888888889
pathogen vector,pathogen portal of exit role,0.7290697674418604
pathogen vector,infectious agent host,0.6444444444444444
pathogen vector,re-emerging pathogen,0.6785714285714286
pathogen vector,long-term non-progressing infectious disease course,0.6166666666666667
pathogen vector,viral disease epidemic,0.5851351351351352
pathogen vector,viral disease pandemic,0.5851351351351352
pathogen vector,virus penetration stage,0.6342105263157894
pathogen vector,pathogen seroprevalence,0.7657894736842106
pathogen vector,infectious disease endemicity,0.609090909090909
pathogen vector,contact pathogen transmission process,0.6807692307692308
pathogen vector,herd immunity to infectious organism,0.6264705882352941
pathogen vector,extracellular infection,0.6342105263157894
pathogen vector,pathogen transporter role,0.75
pathogen vector,infectious agent reservoir,0.6695121951219513
pathogen vector,infection start process boundary,0.598936170212766
pathogen vector,infectious disease control objective specification,0.6038461538461539
pathogen vector,process of establishing viral infection,0.6351851851851852
pathogen vector,COVID-19 disease course,0.6078947368421053
pathogen vector,infectious disease incidence rate,0.5958333333333333
pathogen vector,active immunization against infectious agent,0.6194915254237288
pathogen vector,disordered virus,0.6112903225806451
pathogen vector,organism,0.5804347826086956
pathogen vector,virus uncoating stage,0.5888888888888889
pathogen vector,local infection,0.65
pathogen vector,infectious agent,0.6435483870967742
pathogen vector,establishment of a clinically abnormal colony,0.5833333333333334
pathogen vector,coronavirus disease,0.5676470588235294
pathogen vector,positive-sense single-stranded RNA virus,0.5954545454545455
pathogen vector,horizontal pathogen transmission process,0.6681818181818181
pathogen vector,hospital-acquired infection,0.6404761904761905
pathogen vector,pathogen death temporal region,0.7388888888888888
pathogen vector,emerging pathogen,0.7
pathogen vector,drug susceptibility of infectious agent,0.5981481481481481
pathogen vector,static agent,0.6722222222222223
pathogen vector,pathogen transmission process,0.7227272727272727
virus generative stage,extended organism,0.6294871794871795
virus generative stage,virus aggregate,0.7472972972972972
virus generative stage,source of infection,0.5963414634146341
virus generative stage,virostatic disposition,0.6772727272727272
virus generative stage,zoonotic disposition,0.5928571428571429
virus generative stage,immune response,0.6662162162162162
virus generative stage,infectious disease mortality rate,0.6681818181818181
virus generative stage,infection incidence rate profile,0.6537037037037037
virus generative stage,communicability end temporal region,0.6078947368421053
virus generative stage,pathogen generative stage,0.8117021276595744
virus generative stage,pathogen portal of entry,0.6021739130434782
virus generative stage,subclinical coronavirus infection,0.6318181818181818
virus generative stage,primary pathogen,0.6342105263157894
virus generative stage,infection end temporal region,0.6460784313725491
virus generative stage,drug-based immunosuppressed organism,0.6224137931034482
virus generative stage,infectious disease,0.675
virus generative stage,SARS-CoV-2 incidence rate,0.6627659574468084
virus generative stage,double-stranded DNA virus,0.598936170212766
virus generative stage,incubation end temporal region,0.6423076923076922
virus generative stage,site of infection,0.6038461538461539
virus generative stage,immunocompetent organism,0.6239130434782608
virus generative stage,virulence factor disposition,0.69
virus generative stage,pathogen portal of exit,0.6055555555555556
virus generative stage,viral adhesion disposition,0.6375
virus generative stage,parasitostatic disposition,0.6166666666666667
virus generative stage,infectious disease incidence,0.63
virus generative stage,reservoir of pathogen role,0.6375
virus generative stage,reverse zoonotic disposition,0.65
virus generative stage,subclinical SARS-CoV-2 infection,0.5981481481481481
virus generative stage,virus translation stage,0.8055555555555556
virus generative stage,disease surveillance objective specification,0.6469696969696969
virus generative stage,virus release stage,0.8402439024390245
virus generative stage,source of infection site,0.6673913043478261
virus generative stage,virus,0.6351851851851852
virus generative stage,virus replication,0.7064102564102563
virus generative stage,B cell receptor complex,0.5833333333333334
virus generative stage,systematic infection,0.6166666666666667
virus generative stage,infection incidence rate,0.6456521739130434
virus generative stage,virus host,0.7
virus generative stage,double-stranded RNA virus,0.6202127659574468
virus generative stage,pathogen portal of entry role,0.6068627450980393
virus generative stage,virus transcription stage,0.7904255319148936
virus generative stage,infectious disease lifetime prevalence,0.65
virus generative stage,toxin disposition,0.5782051282051281
virus generative stage,pathogen birth temporal region,0.6230769230769231
virus generative stage,lower respiratory tract disease,0.6386792452830189
virus generative stage,infectious disease incidence proportion,0.6139344262295081
virus generative stage,opportunistic pathogen,0.6545454545454545
virus generative stage,virus generative stage,0.95
virus generative stage,acute infectious disease course,0.6386792452830189
virus generative stage,cidal agent disposition,0.65
virus generative stage,infectious disorder,0.6451219512195122
virus generative stage,genetic resistance to pathogen,0.6807692307692308
virus generative stage,subclinical infection,0.5895348837209302
virus generative stage,appearance of disorder,0.609090909090909
virus generative stage,simple infection,0.6078947368421053
virus generative stage,biological vehicle,0.6
virus generative stage,droplet pathogen transmission process,0.6194915254237288
virus generative stage,parasiticidal disposition,0.598936170212766
virus generative stage,infectious disease sporadicity,0.6423076923076922
virus generative stage,communicability end process boundary,0.5879310344827586
virus generative stage,infection incidence proportion profile,0.6166666666666667
virus generative stage,pathogen transporter,0.6404761904761905
virus generative stage,transmissibility disposition,0.57
virus generative stage,latency end process boundary,0.59
virus generative stage,infectious disease epidemic,0.6336734693877552
virus generative stage,infectious agent generative stage,0.8136363636363637
virus generative stage,disease transmission model,0.6375
virus generative stage,endotoxin disposition,0.6127906976744186
virus generative stage,pathologically immunosuppressed organism,0.5951612903225807
virus generative stage,negative-sense single-stranded RNA virus,0.6435483870967742
virus generative stage,pathogen vehicle,0.6078947368421053
virus generative stage,COVID-19 incidence rate,0.6722222222222223
virus generative stage,cytotoxin disposition,0.5662790697674418
virus generative stage,community-acquired infection,0.59
virus generative stage,pathogen vector,0.6121621621621621
virus generative stage,negative regulation of developmental process,0.6166666666666667
virus generative stage,pathogen vehicle role,0.636046511627907
virus generative stage,chronic infectious disease course,0.6318181818181818
virus generative stage,nursing-home acquired infection,0.619811320754717
virus generative stage,COVID-19 epidemic,0.6038461538461539
virus generative stage,PCR product,0.5712121212121213
virus generative stage,secondary infection,0.6207317073170732
virus generative stage,infection start temporal region,0.6386792452830189
virus generative stage,infection incidence,0.6207317073170732
virus generative stage,virus disorder,0.7
virus generative stage,primary infection,0.6294871794871795
virus generative stage,process of establishing an infection,0.6051724137931035
virus generative stage,incubation end process boundary,0.619811320754717
virus generative stage,SARS-CoV-2 disorder,0.5963414634146341
virus generative stage,collective pathogenic disposition,0.6136363636363636
virus generative stage,neurotoxin disposition,0.6318181818181818
virus generative stage,SARS-CoV-2 uncoating stage,0.7208333333333333
virus generative stage,pathogen death process boundary,0.619811320754717
virus generative stage,immunosuppressed organism,0.6414893617021277
virus generative stage,plan specification,0.575
virus generative stage,latency end temporal region,0.6132653061224489
virus generative stage,SARS-CoV-2 penetration stage,0.77
virus generative stage,virus adhesion susceptible cell,0.7141509433962264
virus generative stage,collective disposition,0.6318181818181818
virus generative stage,infection,0.6112903225806451
virus generative stage,static agent disposition,0.6456521739130434
virus generative stage,T cell receptor complex,0.5833333333333334
virus generative stage,respiratory system disease,0.6583333333333334
virus generative stage,indirect pathogen transmission process,0.6333333333333333
virus generative stage,organism population,0.5963414634146341
virus generative stage,generative stage,0.8710526315789474
virus generative stage,infectious disease control strategy,0.6605263157894737
virus generative stage,SARS-CoV-2 attachment stage,0.6948979591836735
virus generative stage,infectious disease pandemic,0.6540816326530612
virus generative stage,infectious structure generative stage,0.7889830508474576
virus generative stage,immunosuppressive disposition,0.6460784313725491
virus generative stage,innate immune response,0.6545454545454545
virus generative stage,pathogenic disposition,0.609090909090909
virus generative stage,viral disease course,0.6880952380952381
virus generative stage,intracellular infection,0.6277777777777778
virus generative stage,secondary infection role,0.6239130434782608
virus generative stage,metastatic infection,0.5928571428571429
virus generative stage,infectious disposition,0.6318181818181818
virus generative stage,acute infection,0.6121621621621621
virus generative stage,bacteriostatic disposition,0.6166666666666667
virus generative stage,immunity to pathogen,0.6642857142857143
virus generative stage,bactericidal disposition,0.5804347826086956
virus generative stage,source of infection role,0.6239130434782608
virus generative stage,pathogen host,0.6214285714285714
virus generative stage,acquired immunodeficiency,0.598936170212766
virus generative stage,chronic infection,0.6038461538461539
virus generative stage,invasion disposition,0.6166666666666667
virus generative stage,disease course,0.6722222222222223
virus generative stage,infectious disease course,0.6627659574468084
virus generative stage,viricidal disposition,0.6127906976744186
virus generative stage,acquired immunity to infectious agent,0.6533898305084747
virus generative stage,complex infection,0.5782051282051281
virus generative stage,COVID-19 disease incidence proportion,0.6194915254237288
virus generative stage,coronavirus disease course,0.7
virus generative stage,biological vehicle role,0.6055555555555556
virus generative stage,infection incidence proportion,0.6038461538461539
virus generative stage,respiratory droplet virus fomite,0.6351851851851852
virus generative stage,susceptible organism,0.6404761904761905
virus generative stage,pathogen vector role,0.6166666666666667
virus generative stage,pathogen portal of exit site,0.65
virus generative stage,infectious disease prevalence,0.6460784313725491
virus generative stage,organism substance,0.675
virus generative stage,SARS-CoV-2 genome replication stage,0.7482456140350877
virus generative stage,disposition,0.5712121212121213
virus generative stage,single-stranded DNA virus,0.6202127659574468
virus generative stage,COVID-19 mortality rate,0.65
virus generative stage,viral disease,0.6785714285714286
virus generative stage,primary infection role,0.6545454545454545
virus generative stage,adhesion disposition,0.569047619047619
virus generative stage,pathogen portal of entry site,0.6460784313725491
virus generative stage,developmental process,0.5895348837209302
virus generative stage,infection incidence profile,0.6132653061224489
virus generative stage,disease,0.656896551724138
virus generative stage,primary infectious disposition,0.6423076923076922
virus generative stage,pathogen host role,0.625
virus generative stage,infection prevalence,0.6404761904761905
virus generative stage,humoral immune response,0.6277777777777778
virus generative stage,coronavirus disorder,0.6642857142857143
virus generative stage,infectious pathogen transmissibility,0.656896551724138
virus generative stage,pathogen surveillance,0.636046511627907
virus generative stage,immunodeficient organism,0.6239130434782608
virus generative stage,pathogen,0.5833333333333334
virus generative stage,pathogen birth process boundary,0.6009433962264151
virus generative stage,infectious human pathogen,0.6414893617021277
virus generative stage,subclinical virus infection,0.6540816326530612
virus generative stage,resistance to pathogen,0.6545454545454545
virus generative stage,establishment of localization in virus host,0.6192307692307693
virus generative stage,virus attachment stage,0.7909090909090909
virus generative stage,negative regulation of immune response,0.6166666666666667
virus generative stage,SARS-CoV-2 transcription stage,0.7
virus generative stage,virus synthesis stage,0.7988372093023256
virus generative stage,SARS-COV-2 adhesion disposition,0.6009433962264151
virus generative stage,pathogen portal of exit role,0.61
virus generative stage,invasive disposition,0.6642857142857143
virus generative stage,re-emerging pathogen,0.6642857142857143
virus generative stage,long-term non-progressing infectious disease course,0.6143835616438357
virus generative stage,viral disease epidemic,0.6545454545454545
virus generative stage,fungicidal disposition,0.5863636363636363
virus generative stage,viral disease pandemic,0.6772727272727272
virus generative stage,virus penetration stage,0.8722222222222222
virus generative stage,pathogen seroprevalence,0.6277777777777778
virus generative stage,acute respiratory distress syndrome,0.6429824561403508
virus generative stage,division of geopolitical entity,0.6386792452830189
virus generative stage,infectious disease endemicity,0.6264705882352941
virus generative stage,contact pathogen transmission process,0.6025423728813559
virus generative stage,disorder,0.5833333333333334
virus generative stage,herd immunity to infectious organism,0.6051724137931035
virus generative stage,extracellular infection,0.6055555555555556
virus generative stage,pathogen transporter role,0.6414893617021277
virus generative stage,transmission interval,0.636046511627907
virus generative stage,exotoxin disposition,0.5928571428571429
virus generative stage,infection start process boundary,0.6351851851851852
virus generative stage,SARS-CoV-2 synthesis stage,0.7
virus generative stage,infectious disease control objective specification,0.6444444444444444
virus generative stage,immune population,0.6294871794871795
virus generative stage,opportunistic infectious disposition,0.6396551724137931
virus generative stage,process of establishing viral infection,0.6139344262295081
virus generative stage,enterotoxin disposition,0.65
virus generative stage,COVID-19 disease course,0.65
virus generative stage,infectious disease incidence rate,0.65
virus generative stage,single-stranded RNA retrovirus,0.6423076923076922
virus generative stage,disordered virus,0.6342105263157894
virus generative stage,collective resistance disposition,0.6318181818181818
virus generative stage,adaptive immune response,0.6456521739130434
virus generative stage,fungistatic disposition,0.6277777777777778
virus generative stage,organism,0.6166666666666667
virus generative stage,virus uncoating stage,0.822093023255814
virus generative stage,local infection,0.5851351351351352
virus generative stage,establishment of a clinically abnormal colony,0.5694029850746268
virus generative stage,coronavirus disease,0.6939024390243902
virus generative stage,positive-sense single-stranded RNA virus,0.6274193548387097
virus generative stage,horizontal pathogen transmission process,0.6112903225806451
virus generative stage,hospital-acquired infection,0.5928571428571429
virus generative stage,pathogen death temporal region,0.6423076923076922
virus generative stage,emerging pathogen,0.6551282051282051
virus generative stage,SARS-CoV-2 release stage,0.7326086956521739
virus generative stage,pathogen transmission process,0.6068627450980393
negative regulation of immune response,virostatic disposition,0.6333333333333333
negative regulation of immune response,zoonotic disposition,0.6051724137931035
negative regulation of immune response,immune response,0.7330188679245283
negative regulation of immune response,infectious disease mortality rate,0.6330985915492958
negative regulation of immune response,infection incidence rate profile,0.6785714285714286
negative regulation of immune response,communicability end temporal region,0.6280821917808219
negative regulation of immune response,biological regulation,0.6703389830508475
negative regulation of immune response,surveillance process,0.6396551724137931
negative regulation of immune response,infection end temporal region,0.658955223880597
negative regulation of immune response,geospatial location,0.6429824561403508
negative regulation of immune response,vector control strategy,0.630327868852459
negative regulation of immune response,SARS-CoV-2 incidence rate,0.6246031746031746
negative regulation of immune response,incubation end temporal region,0.6705882352941177
negative regulation of immune response,site of infection,0.65
negative regulation of immune response,resistant entity,0.5796296296296296
negative regulation of immune response,virulence factor disposition,0.6469696969696969
negative regulation of immune response,viral adhesion disposition,0.653125
negative regulation of immune response,parasitostatic disposition,0.621875
negative regulation of immune response,negative regulation of production,0.8161971830985917
negative regulation of immune response,reverse zoonotic disposition,0.6621212121212122
negative regulation of immune response,disease surveillance objective specification,0.6695121951219513
negative regulation of immune response,case isolation control strategy,0.6818840579710145
negative regulation of immune response,virus release stage,0.6254385964912281
negative regulation of immune response,source of infection site,0.6596774193548387
negative regulation of immune response,quarantine control strategy,0.65
negative regulation of immune response,B cell receptor complex,0.630327868852459
negative regulation of immune response,passive immunization against infectious agent,0.6789156626506024
negative regulation of immune response,infection incidence rate,0.6596774193548387
negative regulation of immune response,double-stranded RNA virus,0.6087301587301588
negative regulation of immune response,toxin disposition,0.6136363636363636
negative regulation of immune response,lower respiratory tract disease,0.6384057971014493
negative regulation of immune response,cidal agent disposition,0.6139344262295081
negative regulation of immune response,genetic resistance to pathogen,0.6705882352941177
negative regulation of immune response,process,0.5611111111111111
negative regulation of immune response,droplet pathogen transmission process,0.65
negative regulation of immune response,parasiticidal disposition,0.6246031746031746
negative regulation of immune response,communicability end process boundary,0.6256756756756756
negative regulation of immune response,transmissibility disposition,0.6015151515151516
negative regulation of immune response,latency end process boundary,0.6318181818181818
negative regulation of immune response,endotoxin disposition,0.6194915254237288
negative regulation of immune response,vector surveillance,0.6254385964912281
negative regulation of immune response,negative regulation of establishment of localization,0.7722222222222223
negative regulation of immune response,negative-sense single-stranded RNA virus,0.6807692307692308
negative regulation of immune response,susceptible population,0.65
negative regulation of immune response,COVID-19 incidence rate,0.6139344262295081
negative regulation of immune response,cytotoxin disposition,0.6194915254237288
negative regulation of immune response,negative regulation of developmental process,0.8158536585365854
negative regulation of immune response,antibiotic resistance,0.6533898305084747
negative regulation of immune response,negative regulation of replication,0.8388888888888889
negative regulation of immune response,resistance to drug,0.5928571428571429
negative regulation of immune response,process of establishing an infection,0.6256756756756756
negative regulation of immune response,incubation end process boundary,0.6673913043478261
negative regulation of immune response,collective pathogenic disposition,0.6753521126760563
negative regulation of immune response,neurotoxin disposition,0.65
negative regulation of immune response,pathogen death process boundary,0.6384057971014493
negative regulation of immune response,plan specification,0.5928571428571429
negative regulation of immune response,latency end temporal region,0.65
negative regulation of immune response,virus adhesion susceptible cell,0.6239130434782608
negative regulation of immune response,collective disposition,0.6333333333333333
negative regulation of immune response,static agent disposition,0.6435483870967742
negative regulation of immune response,T cell receptor complex,0.6467213114754098
negative regulation of immune response,respiratory system disease,0.6375
negative regulation of immune response,indirect pathogen transmission process,0.6605263157894737
negative regulation of immune response,planned process,0.6386792452830189
negative regulation of immune response,infectious disease control strategy,0.6417808219178082
negative regulation of immune response,immunosuppressive disposition,0.6141791044776119
negative regulation of immune response,innate immune response,0.7833333333333333
negative regulation of immune response,pathogenic disposition,0.6166666666666667
negative regulation of immune response,passive immunity to infectious agent,0.6662162162162162
negative regulation of immune response,infectious disposition,0.6333333333333333
negative regulation of immune response,bacteriostatic disposition,0.653125
negative regulation of immune response,epitope site,0.61
negative regulation of immune response,bactericidal disposition,0.6274193548387097
negative regulation of immune response,invasion disposition,0.656896551724138
negative regulation of immune response,viricidal disposition,0.6025423728813559
negative regulation of immune response,susceptible organism,0.6396551724137931
negative regulation of immune response,pathogen portal of exit site,0.6621212121212122
negative regulation of immune response,disposition,0.5520408163265306
negative regulation of immune response,COVID-19 mortality rate,0.5811475409836065
negative regulation of immune response,process profile,0.5820754716981132
negative regulation of immune response,negative regulation of life-sustaining process,0.819047619047619
negative regulation of immune response,place closure control strategy,0.6264705882352941
negative regulation of immune response,adhesion disposition,0.6396551724137931
negative regulation of immune response,pathogen portal of entry site,0.658955223880597
negative regulation of immune response,developmental process,0.6533898305084747
negative regulation of immune response,biological process,0.6107142857142857
negative regulation of immune response,site,0.5214285714285714
negative regulation of immune response,primary infectious disposition,0.6264705882352941
negative regulation of immune response,humoral immune response,0.7450819672131148
negative regulation of immune response,SARS-COV-2 adhesion susceptible cell,0.6121621621621621
negative regulation of immune response,incubation start process boundary,0.6471830985915493
negative regulation of immune response,pathogen surveillance,0.6194915254237288
negative regulation of immune response,pathogen birth process boundary,0.6239130434782608
negative regulation of immune response,resistance to pathogen,0.6166666666666667
negative regulation of immune response,negative regulation of immune response,0.95
negative regulation of immune response,SARS-COV-2 adhesion disposition,0.6384057971014493
negative regulation of immune response,invasive disposition,0.6396551724137931
negative regulation of immune response,fungicidal disposition,0.6166666666666667
negative regulation of immune response,division of geopolitical entity,0.6384057971014493
negative regulation of immune response,negative regulation of viral process,0.841891891891892
negative regulation of immune response,contact pathogen transmission process,0.6633333333333334
negative regulation of immune response,function,0.558695652173913
negative regulation of immune response,symbiotic process,0.5954545454545455
negative regulation of immune response,exotoxin disposition,0.6224137931034482
negative regulation of immune response,infection start process boundary,0.6357142857142857
negative regulation of immune response,action specification,0.6224137931034482
negative regulation of immune response,protective resistance,0.6533898305084747
negative regulation of immune response,latency start process boundary,0.6264705882352941
negative regulation of immune response,infectious disease control objective specification,0.6545454545454545
negative regulation of immune response,immune population,0.6318181818181818
negative regulation of immune response,opportunistic infectious disposition,0.6391891891891892
negative regulation of immune response,process of establishing viral infection,0.6188311688311688
negative regulation of immune response,negative regulation of biological process,0.8170886075949367
negative regulation of immune response,enterotoxin disposition,0.6631147540983606
negative regulation of immune response,polymerase chain reaction,0.6404761904761905
negative regulation of immune response,infectious disease incidence rate,0.6612676056338028
negative regulation of immune response,communicability start process boundary,0.6078947368421053
negative regulation of immune response,process that results in death,0.658955223880597
negative regulation of immune response,single-stranded RNA retrovirus,0.6411764705882353
negative regulation of immune response,active immunization against infectious agent,0.6939024390243902
negative regulation of immune response,collective resistance disposition,0.6753521126760563
negative regulation of immune response,adaptive immune response,0.7887096774193548
negative regulation of immune response,fungistatic disposition,0.6467213114754098
negative regulation of immune response,establishment of a clinically abnormal colony,0.6307228915662652
negative regulation of immune response,process boundary,0.5796296296296296
negative regulation of immune response,positive-sense single-stranded RNA virus,0.6294871794871795
negative regulation of immune response,horizontal pathogen transmission process,0.6423076923076922
negative regulation of immune response,SARS-CoV-2 release stage,0.6274193548387097
negative regulation of immune response,pathogen transmission process,0.658955223880597
pathogen surveillance,extended organism,0.6342105263157894
pathogen surveillance,virus aggregate,0.6166666666666667
pathogen surveillance,source of infection,0.625
pathogen surveillance,virostatic disposition,0.5895348837209302
pathogen surveillance,zoonotic disposition,0.5963414634146341
pathogen surveillance,infectious disease mortality rate,0.5981481481481481
pathogen surveillance,infection incidence rate profile,0.6386792452830189
pathogen surveillance,communicability end temporal region,0.6107142857142857
pathogen surveillance,pathogen generative stage,0.7543478260869566
pathogen surveillance,pathogen portal of entry,0.7166666666666667
pathogen surveillance,biological regulation,0.6404761904761905
pathogen surveillance,subclinical coronavirus infection,0.5796296296296296
pathogen surveillance,primary pathogen,0.6662162162162162
pathogen surveillance,surveillance process,0.7426829268292683
pathogen surveillance,infection end temporal region,0.63
pathogen surveillance,drug-based immunosuppressed organism,0.6078947368421053
pathogen surveillance,vector control strategy,0.6318181818181818
pathogen surveillance,infectious disease,0.6294871794871795
pathogen surveillance,SARS-CoV-2 incidence rate,0.6239130434782608
pathogen surveillance,double-stranded DNA virus,0.6021739130434782
pathogen surveillance,incubation end temporal region,0.6460784313725491
pathogen surveillance,site of infection,0.6078947368421053
pathogen surveillance,immunocompetent organism,0.6277777777777778
pathogen surveillance,virulence factor disposition,0.5928571428571429
pathogen surveillance,pathogen portal of exit,0.7227272727272727
pathogen surveillance,viral adhesion disposition,0.6202127659574468
pathogen surveillance,parasitostatic disposition,0.6202127659574468
pathogen surveillance,infectious disease incidence,0.6336734693877552
pathogen surveillance,reservoir of pathogen role,0.7053191489361703
pathogen surveillance,negative regulation of production,0.6351851851851852
pathogen surveillance,reverse zoonotic disposition,0.5724489795918367
pathogen surveillance,subclinical SARS-CoV-2 infection,0.6009433962264151
pathogen surveillance,virus translation stage,0.6318181818181818
pathogen surveillance,disease surveillance objective specification,0.6807692307692308
pathogen surveillance,case isolation control strategy,0.6230769230769231
pathogen surveillance,virus release stage,0.6
pathogen surveillance,infectious agent host role,0.6627659574468084
pathogen surveillance,source of infection site,0.6277777777777778
pathogen surveillance,virus,0.5269230769230769
pathogen surveillance,quarantine control strategy,0.6375
pathogen surveillance,virus replication,0.6078947368421053
pathogen surveillance,B cell receptor complex,0.5863636363636363
pathogen surveillance,passive immunization against infectious agent,0.6166666666666667
pathogen surveillance,systematic infection,0.5963414634146341
pathogen surveillance,infection incidence rate,0.6277777777777778
pathogen surveillance,virus host,0.5467741935483871
pathogen surveillance,double-stranded RNA virus,0.6021739130434782
pathogen surveillance,pathogen portal of entry role,0.71
pathogen surveillance,virus transcription stage,0.6239130434782608
pathogen surveillance,infectious disease lifetime prevalence,0.6194915254237288
pathogen surveillance,toxin disposition,0.6342105263157894
pathogen surveillance,pathogen birth temporal region,0.7049019607843137
pathogen surveillance,lower respiratory tract disease,0.6230769230769231
pathogen surveillance,infectious disease incidence proportion,0.6
pathogen surveillance,opportunistic pathogen,0.636046511627907
pathogen surveillance,virus generative stage,0.636046511627907
pathogen surveillance,acute infectious disease course,0.6423076923076922
pathogen surveillance,cidal agent disposition,0.6318181818181818
pathogen surveillance,genetic resistance to pathogen,0.6656862745098039
pathogen surveillance,subclinical infection,0.5928571428571429
pathogen surveillance,simple infection,0.6121621621621621
pathogen surveillance,droplet pathogen transmission process,0.6913793103448276
pathogen surveillance,parasiticidal disposition,0.6021739130434782
pathogen surveillance,infectious disease sporadicity,0.6068627450980393
pathogen surveillance,communicability end process boundary,0.5903508771929825
pathogen surveillance,infection incidence proportion profile,0.6025423728813559
pathogen surveillance,infectious agent colony,0.6318181818181818
pathogen surveillance,pathogen transporter,0.7670731707317073
pathogen surveillance,transmissibility disposition,0.5724489795918367
pathogen surveillance,latency end process boundary,0.6336734693877552
pathogen surveillance,infectious disease epidemic,0.5958333333333333
pathogen surveillance,infectious agent generative stage,0.6537037037037037
pathogen surveillance,disease transmission model,0.598936170212766
pathogen surveillance,endotoxin disposition,0.6166666666666667
pathogen surveillance,vector surveillance,0.825
pathogen surveillance,negative regulation of establishment of localization,0.6006849315068493
pathogen surveillance,pathologically immunosuppressed organism,0.6631147540983606
pathogen surveillance,negative-sense single-stranded RNA virus,0.630327868852459
pathogen surveillance,cidal agent,0.575
pathogen surveillance,pathogen vehicle,0.8283783783783784
pathogen surveillance,COVID-19 incidence rate,0.609090909090909
pathogen surveillance,cytotoxin disposition,0.6166666666666667
pathogen surveillance,community-acquired infection,0.6132653061224489
pathogen surveillance,pathogen vector,0.7833333333333333
pathogen surveillance,negative regulation of developmental process,0.6192307692307693
pathogen surveillance,pathogen vehicle role,0.8071428571428573
pathogen surveillance,chronic infectious disease course,0.6166666666666667
pathogen surveillance,asymptomatic infectious agent carrier,0.6396551724137931
pathogen surveillance,nursing-home acquired infection,0.6423076923076922
pathogen surveillance,negative regulation of replication,0.6318181818181818
pathogen surveillance,secondary infection,0.6
pathogen surveillance,infection start temporal region,0.6230769230769231
pathogen surveillance,infection incidence,0.65
pathogen surveillance,virus disorder,0.5642857142857143
pathogen surveillance,sterilizing immunity to infectious agent,0.5975409836065574
pathogen surveillance,primary infection,0.6078947368421053
pathogen surveillance,process of establishing an infection,0.6078947368421053
pathogen surveillance,incubation end process boundary,0.6230769230769231
pathogen surveillance,collective pathogenic disposition,0.6722222222222223
pathogen surveillance,neurotoxin disposition,0.6127906976744186
pathogen surveillance,pathogen death process boundary,0.7
pathogen surveillance,immunosuppressed organism,0.6021739130434782
pathogen surveillance,latency end temporal region,0.6375
pathogen surveillance,innate immunity to infectious agent,0.6107142857142857
pathogen surveillance,virus adhesion susceptible cell,0.6807692307692308
pathogen surveillance,collective disposition,0.5895348837209302
pathogen surveillance,infection,0.5833333333333334
pathogen surveillance,static agent disposition,0.65
pathogen surveillance,T cell receptor complex,0.609090909090909
pathogen surveillance,infectious agent population,0.6583333333333334
pathogen surveillance,respiratory system disease,0.6627659574468084
pathogen surveillance,entry into host,0.5888888888888889
pathogen surveillance,leukocyte-mediated immunity to infectious agent,0.5823529411764706
pathogen surveillance,indirect pathogen transmission process,0.6872881355932203
pathogen surveillance,organism population,0.65
pathogen surveillance,humoral immunity to infectious agent,0.5903508771929825
pathogen surveillance,infectious disease control strategy,0.6107142857142857
pathogen surveillance,parasite,0.6224137931034482
pathogen surveillance,infectious disease pandemic,0.6166666666666667
pathogen surveillance,antibody reagent,0.6662162162162162
pathogen surveillance,immunosuppressive disposition,0.61
pathogen surveillance,pathogenic disposition,0.7290697674418604
pathogen surveillance,viral disease course,0.6207317073170732
pathogen surveillance,entry into host through host barriers,0.6051724137931035
pathogen surveillance,intracellular infection,0.6318181818181818
pathogen surveillance,secondary infection role,0.6277777777777778
pathogen surveillance,metastatic infection,0.5963414634146341
pathogen surveillance,passive immunity to infectious agent,0.6078947368421053
pathogen surveillance,infectious disposition,0.5895348837209302
pathogen surveillance,vaccination against infectious agent,0.6254385964912281
pathogen surveillance,acute infection,0.6444444444444444
pathogen surveillance,susceptibility to infectious agent,0.5954545454545455
pathogen surveillance,bacteriostatic disposition,0.598936170212766
pathogen surveillance,epitope site,0.6924242424242425
pathogen surveillance,immunity to pathogen,0.6451219512195122
pathogen surveillance,bactericidal disposition,0.6055555555555556
pathogen surveillance,source of infection role,0.6277777777777778
pathogen surveillance,pathogen host,0.7441176470588234
pathogen surveillance,chronic infection,0.6342105263157894
pathogen surveillance,invasion disposition,0.6207317073170732
pathogen surveillance,disease course,0.6214285714285714
pathogen surveillance,infectious disease course,0.6239130434782608
pathogen surveillance,viricidal disposition,0.569047619047619
pathogen surveillance,acquired immunity to infectious agent,0.5879310344827586
pathogen surveillance,complex infection,0.6078947368421053
pathogen surveillance,COVID-19 disease incidence proportion,0.5879310344827586
pathogen surveillance,coronavirus disease course,0.6202127659574468
pathogen surveillance,infection incidence proportion,0.6068627450980393
pathogen surveillance,symptomatic infectious agent carrier,0.6429824561403508
pathogen surveillance,respiratory droplet virus fomite,0.619811320754717
pathogen surveillance,susceptible organism,0.6207317073170732
pathogen surveillance,parasite role,0.6852941176470588
pathogen surveillance,pathogen vector role,0.7670731707317073
pathogen surveillance,pathogen portal of exit site,0.7153061224489795
pathogen surveillance,infectious disease prevalence,0.65
pathogen surveillance,organism substance,0.7064102564102563
pathogen surveillance,disposition,0.60625
pathogen surveillance,single-stranded DNA virus,0.6021739130434782
pathogen surveillance,COVID-19 mortality rate,0.5863636363636363
pathogen surveillance,negative regulation of life-sustaining process,0.6291044776119403
pathogen surveillance,place closure control strategy,0.6656862745098039
pathogen surveillance,viral disease,0.6264705882352941
pathogen surveillance,primary infection role,0.6593023255813953
pathogen surveillance,adhesion disposition,0.6451219512195122
pathogen surveillance,pathogen portal of entry site,0.71
pathogen surveillance,infection incidence profile,0.6375
pathogen surveillance,disease,0.5928571428571429
pathogen surveillance,site,0.57
pathogen surveillance,primary infectious disposition,0.6068627450980393
pathogen surveillance,pathogen host role,0.7833333333333333
pathogen surveillance,infection prevalence,0.6939024390243902
pathogen surveillance,infectious pathogen transmissibility,0.6605263157894737
pathogen surveillance,pathogen surveillance,0.95
pathogen surveillance,immunodeficient organism,0.6055555555555556
pathogen surveillance,pathogen,0.7258620689655172
pathogen surveillance,pathogen birth process boundary,0.6807692307692308
pathogen surveillance,infectious human pathogen,0.6239130434782608
pathogen surveillance,subclinical virus infection,0.575
pathogen surveillance,resistance to pathogen,0.636046511627907
pathogen surveillance,establishment of localization in virus host,0.590625
pathogen surveillance,immunization against infectious agent,0.6224137931034482
pathogen surveillance,virus attachment stage,0.6593023255813953
pathogen surveillance,negative regulation of immune response,0.6194915254237288
pathogen surveillance,virus synthesis stage,0.6166666666666667
pathogen surveillance,SARS-COV-2 adhesion disposition,0.6038461538461539
pathogen surveillance,pathogen portal of exit role,0.7357142857142857
pathogen surveillance,invasive disposition,0.5963414634146341
pathogen surveillance,infectious agent host,0.6166666666666667
pathogen surveillance,re-emerging pathogen,0.6451219512195122
pathogen surveillance,long-term non-progressing infectious disease course,0.6027777777777777
pathogen surveillance,viral disease epidemic,0.5895348837209302
pathogen surveillance,fungicidal disposition,0.5662790697674418
pathogen surveillance,viral disease pandemic,0.6127906976744186
pathogen surveillance,virus penetration stage,0.6545454545454545
pathogen surveillance,pathogen seroprevalence,0.8136363636363637
pathogen surveillance,infectious disease endemicity,0.61
pathogen surveillance,negative regulation of viral process,0.6429824561403508
pathogen surveillance,contact pathogen transmission process,0.6913793103448276
pathogen surveillance,herd immunity to infectious organism,0.5903508771929825
pathogen surveillance,extracellular infection,0.6318181818181818
pathogen surveillance,pathogen transporter role,0.7543478260869566
pathogen surveillance,exotoxin disposition,0.6207317073170732
pathogen surveillance,infectious agent reservoir,0.6627659574468084
pathogen surveillance,infection start process boundary,0.6009433962264151
pathogen surveillance,infectious disease control objective specification,0.5908450704225352
pathogen surveillance,opportunistic infectious disposition,0.5728070175438597
pathogen surveillance,process of establishing viral infection,0.6166666666666667
pathogen surveillance,negative regulation of biological process,0.6274193548387097
pathogen surveillance,enterotoxin disposition,0.609090909090909
pathogen surveillance,COVID-19 disease course,0.609090909090909
pathogen surveillance,infectious disease incidence rate,0.6166666666666667
pathogen surveillance,active immunization against infectious agent,0.6038461538461539
pathogen surveillance,disordered virus,0.5851351351351352
pathogen surveillance,collective resistance disposition,0.6351851851851852
pathogen surveillance,fungistatic disposition,0.5863636363636363
pathogen surveillance,organism,0.5879310344827586
pathogen surveillance,virus uncoating stage,0.6166666666666667
pathogen surveillance,local infection,0.5888888888888889
pathogen surveillance,infectious agent,0.5851351351351352
pathogen surveillance,establishment of a clinically abnormal colony,0.6166666666666667
pathogen surveillance,coronavirus disease,0.625
pathogen surveillance,positive-sense single-stranded RNA virus,0.630327868852459
pathogen surveillance,horizontal pathogen transmission process,0.6795081967213115
pathogen surveillance,hospital-acquired infection,0.6375
pathogen surveillance,pathogen death temporal region,0.7049019607843137
pathogen surveillance,emerging pathogen,0.6605263157894737
pathogen surveillance,drug susceptibility of infectious agent,0.6166666666666667
pathogen surveillance,static agent,0.6015151515151516
pathogen surveillance,pathogen transmission process,0.73
infectious disease,virus aggregate,0.6621212121212122
infectious disease,source of infection,0.6662162162162162
infectious disease,virostatic disposition,0.65
infectious disease,zoonotic disposition,0.6605263157894737
infectious disease,infectious disease mortality rate,0.8029411764705883
infectious disease,infection incidence rate profile,0.71
infectious disease,infectious structure aggregate,0.7625
infectious disease,communicability end temporal region,0.6009433962264151
infectious disease,subclinical coronavirus infection,0.6264705882352941
infectious disease,infection end temporal region,0.7265957446808511
infectious disease,infectious disease,0.95
infectious disease,double-stranded DNA virus,0.6127906976744186
infectious disease,incubation end temporal region,0.6791666666666666
infectious disease,site of infection,0.6785714285714286
infectious disease,virulence factor disposition,0.6891304347826087
infectious disease,viral adhesion disposition,0.6545454545454545
infectious disease,parasitostatic disposition,0.6545454545454545
infectious disease,infectious disease incidence,0.8413043478260869
infectious disease,reverse zoonotic disposition,0.6239130434782608
infectious disease,subclinical SARS-CoV-2 infection,0.61
infectious disease,virus translation stage,0.6695121951219513
infectious disease,disease surveillance objective specification,0.6112903225806451
infectious disease,virus release stage,0.6662162162162162
infectious disease,infectious agent host role,0.7681818181818181
infectious disease,asymptomatic infectious structure carrier,0.7042372881355932
infectious disease,source of infection site,0.7119047619047619
infectious disease,virus,0.5804347826086956
infectious disease,virus replication,0.6214285714285714
infectious disease,B cell receptor complex,0.5963414634146341
infectious disease,passive immunization against infectious agent,0.6563492063492063
infectious disease,systematic infection,0.6605263157894737
infectious disease,infection incidence rate,0.7595238095238095
infectious disease,virus host,0.6285714285714286
infectious disease,double-stranded RNA virus,0.6127906976744186
infectious disease,virus transcription stage,0.6825581395348838
infectious disease,infectious disease lifetime prevalence,0.7714285714285714
infectious disease,toxin disposition,0.65
infectious disease,lower respiratory tract disease,0.6744897959183673
infectious disease,infectious disease incidence proportion,0.7657894736842106
infectious disease,virus generative stage,0.675
infectious disease,acute infectious disease course,0.8173469387755102
infectious disease,cidal agent disposition,0.6451219512195122
infectious disease,infectious disorder,0.8554054054054054
infectious disease,subclinical infection,0.6551282051282051
infectious disease,appearance of disorder,0.65
infectious disease,simple infection,0.6852941176470588
infectious disease,parasiticidal disposition,0.636046511627907
infectious disease,infectious disease sporadicity,0.825
infectious disease,communicability end process boundary,0.5981481481481481
infectious disease,infection incidence proportion profile,0.6642857142857143
infectious disease,infectious agent colony,0.7670731707317073
infectious disease,transmissibility disposition,0.6239130434782608
infectious disease,latency end process boundary,0.6021739130434782
infectious disease,infectious disease epidemic,0.85
infectious disease,infectious agent generative stage,0.7441176470588234
infectious disease,disease transmission model,0.6318181818181818
infectious disease,endotoxin disposition,0.6551282051282051
infectious disease,negative-sense single-stranded RNA virus,0.6396551724137931
infectious disease,infectious structure host role,0.7625
infectious disease,cytotoxin disposition,0.6551282051282051
infectious disease,community-acquired infection,0.6239130434782608
infectious disease,chronic infectious disease course,0.8029411764705883
infectious disease,asymptomatic infectious agent carrier,0.7045454545454546
infectious disease,nursing-home acquired infection,0.6132653061224489
infectious disease,COVID-19 epidemic,0.5928571428571429
infectious disease,secondary infection,0.6662162162162162
infectious disease,infection start temporal region,0.7153061224489795
infectious disease,infection incidence,0.7743243243243243
infectious disease,virus disorder,0.7
infectious disease,sterilizing immunity to infectious agent,0.6741379310344828
infectious disease,diseased population,0.6391891891891892
infectious disease,primary infection,0.6785714285714286
infectious disease,process of establishing an infection,0.5981481481481481
infectious disease,incubation end process boundary,0.6540816326530612
infectious disease,SARS-CoV-2 disorder,0.6391891891891892
infectious disease,collective pathogenic disposition,0.6460784313725491
infectious disease,neurotoxin disposition,0.675
infectious disease,latency end temporal region,0.6055555555555556
infectious disease,innate immunity to infectious agent,0.6952830188679244
infectious disease,infectious structure,0.7921052631578948
infectious disease,virus adhesion susceptible cell,0.6336734693877552
infectious disease,collective disposition,0.675
infectious disease,infection,0.7462962962962962
infectious disease,static agent disposition,0.6404761904761905
infectious disease,T cell receptor complex,0.5963414634146341
infectious disease,infectious structure host,0.7755813953488372
infectious disease,infectious agent population,0.7388888888888888
infectious disease,respiratory system disease,0.7227272727272727
infectious disease,leukocyte-mediated immunity to infectious agent,0.65
infectious disease,humoral immunity to infectious agent,0.6907407407407408
infectious disease,infectious disease control strategy,0.789622641509434
infectious disease,infectious disease pandemic,0.85
infectious disease,infectious structure generative stage,0.740909090909091
infectious disease,immunosuppressive disposition,0.6627659574468084
infectious disease,pathogenic disposition,0.625
infectious disease,viral disease course,0.6868421052631578
infectious disease,intracellular infection,0.6451219512195122
infectious disease,secondary infection role,0.6880952380952381
infectious disease,metastatic infection,0.6605263157894737
infectious disease,passive immunity to infectious agent,0.6907407407407408
infectious disease,infectious disposition,0.825
infectious disease,vaccination against infectious agent,0.6907407407407408
infectious disease,acute infection,0.6924242424242425
infectious disease,susceptibility to infectious agent,0.7
infectious disease,bacteriostatic disposition,0.6772727272727272
infectious disease,bactericidal disposition,0.6404761904761905
infectious disease,source of infection role,0.6880952380952381
infectious disease,chronic infection,0.6785714285714286
infectious disease,invasion disposition,0.6868421052631578
infectious disease,disease course,0.66875
infectious disease,infectious disease course,0.8686046511627907
infectious disease,viricidal disposition,0.6551282051282051
infectious disease,acquired immunity to infectious agent,0.6863636363636364
infectious disease,complex infection,0.6785714285714286
infectious disease,COVID-19 disease incidence proportion,0.6318181818181818
infectious disease,coronavirus disease course,0.7227272727272727
infectious disease,infection incidence proportion,0.7
infectious disease,symptomatic infectious agent carrier,0.7092592592592593
infectious disease,respiratory droplet virus fomite,0.63
infectious disease,infectious disease prevalence,0.8329787234042553
infectious disease,disposition,0.5879310344827586
infectious disease,single-stranded DNA virus,0.636046511627907
infectious disease,infected population,0.6932432432432433
infectious disease,viral disease,0.7403225806451613
infectious disease,primary infection role,0.7
infectious disease,adhesion disposition,0.6605263157894737
infectious disease,infection incidence profile,0.7166666666666667
infectious disease,disease,0.73
infectious disease,symptomatic infectious structure carrier,0.7086206896551723
infectious disease,primary infectious disposition,0.7625
infectious disease,infection prevalence,0.7657894736842106
infectious disease,coronavirus disorder,0.6868421052631578
infectious disease,infectious pathogen transmissibility,0.7092592592592593
infectious disease,infectious human pathogen,0.7523255813953489
infectious disease,subclinical virus infection,0.65
infectious disease,establishment of localization in virus host,0.630327868852459
infectious disease,immunization against infectious agent,0.6863636363636364
infectious disease,virus attachment stage,0.625
infectious disease,virus synthesis stage,0.6807692307692308
infectious disease,SARS-COV-2 adhesion disposition,0.6132653061224489
infectious disease,invasive disposition,0.6605263157894737
infectious disease,infectious agent host,0.7833333333333333
infectious disease,long-term non-progressing infectious disease course,0.7108695652173913
infectious disease,viral disease epidemic,0.675
infectious disease,fungicidal disposition,0.65
infectious disease,viral disease pandemic,0.675
infectious disease,virus penetration stage,0.6939024390243902
infectious disease,acute respiratory distress syndrome,0.6575471698113208
infectious disease,infectious disease endemicity,0.8329787234042553
infectious disease,disorder,0.6038461538461539
infectious disease,herd immunity to infectious organism,0.6907407407407408
infectious disease,extracellular infection,0.6451219512195122
infectious disease,exotoxin disposition,0.6605263157894737
infectious disease,infectious agent reservoir,0.7681818181818181
infectious disease,COVID-19 pandemic,0.5928571428571429
infectious disease,infection start process boundary,0.69
infectious disease,infectious disease control objective specification,0.7147058823529412
infectious disease,opportunistic infectious disposition,0.7277777777777777
infectious disease,process of establishing viral infection,0.6078947368421053
infectious disease,enterotoxin disposition,0.6695121951219513
infectious disease,COVID-19 disease course,0.6939024390243902
infectious disease,infectious disease incidence rate,0.8029411764705883
infectious disease,active immunization against infectious agent,0.6596774193548387
infectious disease,disordered virus,0.5970588235294118
infectious disease,collective resistance disposition,0.6460784313725491
infectious disease,fungistatic disposition,0.6451219512195122
infectious disease,virus uncoating stage,0.6807692307692308
infectious disease,local infection,0.6924242424242425
infectious disease,infectious agent,0.8323529411764706
infectious disease,establishment of a clinically abnormal colony,0.5611111111111111
infectious disease,coronavirus disease,0.7743243243243243
infectious disease,positive-sense single-stranded RNA virus,0.6224137931034482
infectious disease,hospital-acquired infection,0.6277777777777778
infectious disease,drug susceptibility of infectious agent,0.6780701754385965
viral disease course,virus aggregate,0.65
viral disease course,source of infection,0.6038461538461539
viral disease course,virostatic disposition,0.6880952380952381
viral disease course,zoonotic disposition,0.625
viral disease course,infectious disease mortality rate,0.6952830188679244
viral disease course,infection incidence rate profile,0.6230769230769231
viral disease course,communicability end temporal region,0.6318181818181818
viral disease course,pathogen portal of entry,0.5863636363636363
viral disease course,subclinical coronavirus infection,0.619811320754717
viral disease course,infection end temporal region,0.6132653061224489
viral disease course,infectious disease,0.6868421052631578
viral disease course,double-stranded DNA virus,0.6277777777777778
viral disease course,incubation end temporal region,0.63
viral disease course,site of infection,0.6121621621621621
viral disease course,virulence factor disposition,0.6791666666666666
viral disease course,viral adhesion disposition,0.7108695652173913
viral disease course,parasitostatic disposition,0.6239130434782608
viral disease course,infectious disease incidence,0.7
viral disease course,reverse zoonotic disposition,0.6166666666666667
viral disease course,subclinical SARS-CoV-2 infection,0.6423076923076922
viral disease course,virus translation stage,0.6593023255813953
viral disease course,disease surveillance objective specification,0.6375
viral disease course,virus release stage,0.732051282051282
viral disease course,source of infection site,0.6318181818181818
viral disease course,virus,0.65
viral disease course,virus replication,0.6391891891891892
viral disease course,B cell receptor complex,0.636046511627907
viral disease course,systematic infection,0.6
viral disease course,infection incidence rate,0.6318181818181818
viral disease course,virus host,0.6833333333333332
viral disease course,double-stranded RNA virus,0.6277777777777778
viral disease course,pathogen portal of entry role,0.6132653061224489
viral disease course,virus transcription stage,0.6722222222222223
viral disease course,infectious disease lifetime prevalence,0.656896551724138
viral disease course,toxin disposition,0.6391891891891892
viral disease course,lower respiratory tract disease,0.6656862745098039
viral disease course,infectious disease incidence proportion,0.6703389830508475
viral disease course,virus generative stage,0.6880952380952381
viral disease course,acute infectious disease course,0.7637254901960785
viral disease course,cidal agent disposition,0.6593023255813953
viral disease course,infectious disorder,0.6551282051282051
viral disease course,subclinical infection,0.6451219512195122
viral disease course,appearance of disorder,0.6642857142857143
viral disease course,simple infection,0.6444444444444444
viral disease course,parasiticidal disposition,0.65
viral disease course,infectious disease sporadicity,0.69
viral disease course,communicability end process boundary,0.6464285714285714
viral disease course,infection incidence proportion profile,0.6051724137931035
viral disease course,transmissibility disposition,0.6375
viral disease course,latency end process boundary,0.6375
viral disease course,infectious disease epidemic,0.6840425531914894
viral disease course,disease transmission model,0.6891304347826087
viral disease course,endotoxin disposition,0.6207317073170732
viral disease course,negative-sense single-stranded RNA virus,0.6166666666666667
viral disease course,viral plaque assay,0.7131578947368421
viral disease course,cytotoxin disposition,0.6207317073170732
viral disease course,community-acquired infection,0.5958333333333333
viral disease course,chronic infectious disease course,0.7518867924528303
viral disease course,nursing-home acquired infection,0.6068627450980393
viral disease course,COVID-19 epidemic,0.6121621621621621
viral disease course,secondary infection,0.6038461538461539
viral disease course,infection start temporal region,0.6068627450980393
viral disease course,infection incidence,0.6038461538461539
viral disease course,virus disorder,0.7441176470588234
viral disease course,primary infection,0.6391891891891892
viral disease course,process of establishing an infection,0.6107142857142857
viral disease course,incubation end process boundary,0.6460784313725491
viral disease course,SARS-CoV-2 disorder,0.6551282051282051
viral disease course,collective pathogenic disposition,0.6009433962264151
viral disease course,neurotoxin disposition,0.6166666666666667
viral disease course,plan specification,0.6078947368421053
viral disease course,latency end temporal region,0.6202127659574468
viral disease course,virus adhesion susceptible cell,0.6852941176470588
viral disease course,collective disposition,0.6166666666666667
viral disease course,infection,0.5879310344827586
viral disease course,static agent disposition,0.6318181818181818
viral disease course,T cell receptor complex,0.636046511627907
viral disease course,respiratory system disease,0.6891304347826087
viral disease course,entry into host,0.6214285714285714
viral disease course,infectious disease control strategy,0.7227272727272727
viral disease course,infectious disease pandemic,0.6840425531914894
viral disease course,immunosuppressive disposition,0.6132653061224489
viral disease course,pathogenic disposition,0.6166666666666667
viral disease course,viral disease course,0.95
viral disease course,entry into host through host barriers,0.6078947368421053
viral disease course,intracellular infection,0.6593023255813953
viral disease course,secondary infection role,0.6318181818181818
viral disease course,metastatic infection,0.6
viral disease course,viral envelope,0.7441176470588234
viral disease course,infectious disposition,0.6166666666666667
viral disease course,objective specification,0.5895348837209302
viral disease course,acute infection,0.6214285714285714
viral disease course,bacteriostatic disposition,0.6239130434782608
viral disease course,bactericidal disposition,0.6545454545454545
viral disease course,source of infection role,0.6318181818181818
viral disease course,chronic infection,0.6121621621621621
viral disease course,invasion disposition,0.65
viral disease course,disease course,0.8617647058823529
viral disease course,infectious disease course,0.8055555555555556
viral disease course,viricidal disposition,0.7182926829268292
viral disease course,complex infection,0.6121621621621621
viral disease course,COVID-19 disease incidence proportion,0.6956140350877194
viral disease course,coronavirus disease course,0.8413043478260869
viral disease course,infection incidence proportion,0.61
viral disease course,viral capsid,0.7
viral disease course,respiratory droplet virus fomite,0.6423076923076922
viral disease course,infectious disease prevalence,0.6948979591836735
viral disease course,disposition,0.6112903225806451
viral disease course,single-stranded DNA virus,0.65
viral disease course,contact tracing,0.5642857142857143
viral disease course,viral disease,0.8439393939393939
viral disease course,primary infection role,0.6642857142857143
viral disease course,adhesion disposition,0.625
viral disease course,pathogen portal of entry site,0.6132653061224489
viral disease course,infection incidence profile,0.6202127659574468
viral disease course,disease,0.7092592592592593
viral disease course,primary infectious disposition,0.63
viral disease course,infection prevalence,0.625
viral disease course,coronavirus disorder,0.7
viral disease course,object,0.5269230769230769
viral disease course,subclinical virus infection,0.6414893617021277
viral disease course,establishment of localization in virus host,0.6087301587301588
viral disease course,virus attachment stage,0.6642857142857143
viral disease course,virus synthesis stage,0.6939024390243902
viral disease course,SARS-COV-2 adhesion disposition,0.6068627450980393
viral disease course,object aggregate,0.5611111111111111
viral disease course,invasive disposition,0.65
viral disease course,long-term non-progressing infectious disease course,0.6753521126760563
viral disease course,viral disease epidemic,0.8071428571428573
viral disease course,fungicidal disposition,0.6642857142857143
viral disease course,viral disease pandemic,0.8071428571428573
viral disease course,virus penetration stage,0.6593023255813953
viral disease course,acute respiratory distress syndrome,0.6681818181818181
viral disease course,infectious disease endemicity,0.6744897959183673
viral disease course,negative regulation of viral process,0.6107142857142857
viral disease course,contact pathogen transmission process,0.5903508771929825
viral disease course,disorder,0.6642857142857143
viral disease course,extracellular infection,0.636046511627907
viral disease course,exotoxin disposition,0.625
viral disease course,infection start process boundary,0.6230769230769231
viral disease course,infectious disease control objective specification,0.6642857142857143
viral disease course,opportunistic infectious disposition,0.5928571428571429
viral disease course,process of establishing viral infection,0.6194915254237288
viral disease course,enterotoxin disposition,0.6127906976744186
viral disease course,polymerase chain reaction,0.65
viral disease course,COVID-19 disease course,0.8453488372093022
viral disease course,infectious disease incidence rate,0.6952830188679244
viral disease course,disordered virus,0.6722222222222223
viral disease course,collective resistance disposition,0.619811320754717
viral disease course,viral load,0.6833333333333332
viral disease course,fungistatic disposition,0.636046511627907
viral disease course,virus uncoating stage,0.6695121951219513
viral disease course,local infection,0.65
viral disease course,establishment of a clinically abnormal colony,0.6038461538461539
viral disease course,coronavirus disease,0.732051282051282
viral disease course,positive-sense single-stranded RNA virus,0.6166666666666667
viral disease course,hospital-acquired infection,0.6202127659574468
viral disease course,viral pathogenesis,0.6868421052631578
reagent role,reservoir of pathogen role,0.7394736842105263
reagent role,infectious agent host role,0.7394736842105263
reagent role,B cell receptor complex,0.6785714285714286
reagent role,passive immunization against infectious agent,0.5903508771929825
reagent role,pathogen portal of entry role,0.6939024390243902
reagent role,lower respiratory tract disease,0.6127906976744186
reagent role,acute infectious disease course,0.6127906976744186
reagent role,cidal agent disposition,0.65
reagent role,role,0.7
reagent role,appearance of disorder,0.6264705882352941
reagent role,mutualist role,0.7192307692307692
reagent role,infectious agent colony,0.7071428571428571
reagent role,infectious agent generative stage,0.65
reagent role,cidal agent,0.6673913043478261
reagent role,infectious structure host role,0.6404761904761905
reagent role,pathogen vehicle role,0.7227272727272727
reagent role,chronic infectious disease course,0.6055555555555556
reagent role,asymptomatic infectious agent carrier,0.6336734693877552
reagent role,mechanical vector role,0.7147058823529412
reagent role,sterilizing immunity to infectious agent,0.5846153846153846
reagent role,dead-end host role,0.7833333333333333
reagent role,definitive host role,0.7
reagent role,innate immunity to infectious agent,0.598936170212766
reagent role,static agent disposition,0.6444444444444444
reagent role,T cell receptor complex,0.6785714285714286
reagent role,asymptomatic carrier role,0.6391891891891892
reagent role,infectious agent population,0.6807692307692308
reagent role,leukocyte-mediated immunity to infectious agent,0.5855932203389831
reagent role,humoral immunity to infectious agent,0.5958333333333333
reagent role,antibody reagent,0.7
reagent role,viral disease course,0.66875
reagent role,secondary infection role,0.7
reagent role,passive immunity to infectious agent,0.5958333333333333
reagent role,vaccination against infectious agent,0.5958333333333333
reagent role,susceptibility to infectious agent,0.5804347826086956
reagent role,source of infection role,0.7
reagent role,disease course,0.6807692307692308
reagent role,infectious disease course,0.6121621621621621
reagent role,acquired immunity to infectious agent,0.5928571428571429
reagent role,coronavirus disease course,0.6342105263157894
reagent role,biological vehicle role,0.65
reagent role,symptomatic infectious agent carrier,0.6375
reagent role,symbiont role,0.73
reagent role,parasite role,0.77
reagent role,pathogen vector role,0.7625
reagent role,primary infection role,0.7147058823529412
reagent role,biological role,0.6722222222222223
reagent role,reagent,0.8184210526315789
reagent role,biological vector role,0.6852941176470588
reagent role,pathogen host role,0.7833333333333333
reagent role,symptomatic carrier role,0.6444444444444444
reagent role,intermediate host role,0.7441176470588234
reagent role,host role,0.7357142857142857
reagent role,immunization against infectious agent,0.5928571428571429
reagent role,pathogen portal of exit role,0.7
reagent role,infectious agent host,0.6924242424242425
reagent role,long-term non-progressing infectious disease course,0.5769841269841269
reagent role,commensal role,0.7192307692307692
reagent role,epitope role,0.7416666666666667
reagent role,function,0.6
reagent role,pathogen transporter role,0.7202702702702704
reagent role,infectious agent reservoir,0.6868421052631578
reagent role,antigen role,0.825
reagent role,action specification,0.575
reagent role,symbiont host role,0.6833333333333332
reagent role,fomite role,0.7108695652173913
reagent role,COVID-19 disease course,0.6214285714285714
reagent role,active immunization against infectious agent,0.5928571428571429
reagent role,reagent role,0.95
reagent role,viral load,0.6318181818181818
reagent role,infectious agent,0.6642857142857143
reagent role,establishment of a clinically abnormal colony,0.6078947368421053
reagent role,drug susceptibility of infectious agent,0.5872549019607843
reagent role,static agent,0.6583333333333334
eclipse interval,infectious disease mortality rate,0.6540816326530612
eclipse interval,infection incidence rate profile,0.6583333333333334
eclipse interval,communicability end temporal region,0.6460784313725491
eclipse interval,infection end temporal region,0.6722222222222223
eclipse interval,SARS-CoV-2 incidence rate,0.6207317073170732
eclipse interval,incubation end temporal region,0.6456521739130434
eclipse interval,B cell receptor complex,0.6038461538461539
eclipse interval,infection incidence rate,0.675
eclipse interval,infectious disease lifetime prevalence,0.6907407407407408
eclipse interval,communicability end process boundary,0.6038461538461539
eclipse interval,latency end process boundary,0.609090909090909
eclipse interval,COVID-19 incidence rate,0.6551282051282051
eclipse interval,latency interval,0.79375
eclipse interval,incubation end process boundary,0.598936170212766
eclipse interval,latency end temporal region,0.6593023255813953
eclipse interval,anatomical space,0.575
eclipse interval,T cell receptor complex,0.6038461538461539
eclipse interval,communicability interval,0.75
eclipse interval,incubation interval,0.7642857142857143
eclipse interval,COVID-19 mortality rate,0.6294871794871795
eclipse interval,eclipse interval,0.95
eclipse interval,transmission interval,0.7472972972972972
eclipse interval,COVID-19 lifetime prevalence,0.6772727272727272
eclipse interval,infectious disease incidence rate,0.6744897959183673
eclipse interval,establishment of a clinically abnormal colony,0.630327868852459
eclipse interval,cell space,0.6038461538461539
site,geospatial location,0.5804347826086956
site,site of infection,0.6404761904761905
site,source of infection site,0.5928571428571429
site,B cell receptor complex,0.524074074074074
site,double-stranded RNA virus,0.553448275862069
site,negative-sense single-stranded RNA virus,0.5409090909090909
site,infection start temporal region,0.5357142857142857
site,anatomical space,0.55
site,T cell receptor complex,0.524074074074074
site,epitope site,0.7
site,pathogen portal of exit site,0.575
site,place closure control strategy,0.5382352941176471
site,pathogen portal of entry site,0.5712121212121213
site,site,0.95
site,incubation start process boundary,0.5310810810810811
site,communicability start temporal region,0.523170731707317
site,infection start process boundary,0.5333333333333333
site,latency start process boundary,0.5382352941176471
site,communicability start process boundary,0.5214285714285714
site,single-stranded RNA retrovirus,0.5676470588235294
site,local infection,0.5552631578947369
site,establishment of a clinically abnormal colony,0.5112244897959184
site,positive-sense single-stranded RNA virus,0.5409090909090909
site,cell space,0.5928571428571429
pathogen death process boundary,extended organism,0.6166666666666667
pathogen death process boundary,virus aggregate,0.5804347826086956
pathogen death process boundary,source of infection,0.59
pathogen death process boundary,immune response,0.6239130434782608
pathogen death process boundary,infectious disease mortality rate,0.621875
pathogen death process boundary,infection incidence rate profile,0.6563492063492063
pathogen death process boundary,communicability end temporal region,0.6318181818181818
pathogen death process boundary,pathogen generative stage,0.7178571428571427
pathogen death process boundary,pathogen portal of entry,0.740909090909091
pathogen death process boundary,subclinical coronavirus infection,0.590625
pathogen death process boundary,primary pathogen,0.6414893617021277
pathogen death process boundary,surveillance process,0.6656862745098039
pathogen death process boundary,infection end temporal region,0.65
pathogen death process boundary,drug-based immunosuppressed organism,0.6291044776119403
pathogen death process boundary,infectious disease,0.6132653061224489
pathogen death process boundary,SARS-CoV-2 incidence rate,0.6107142857142857
pathogen death process boundary,double-stranded DNA virus,0.6107142857142857
pathogen death process boundary,incubation end temporal region,0.6631147540983606
pathogen death process boundary,site of infection,0.5958333333333333
pathogen death process boundary,immunocompetent organism,0.5954545454545455
pathogen death process boundary,pathogen portal of exit,0.6907407407407408
pathogen death process boundary,infectious disease incidence,0.6194915254237288
pathogen death process boundary,reservoir of pathogen role,0.6605263157894737
pathogen death process boundary,subclinical SARS-CoV-2 infection,0.5769841269841269
pathogen death process boundary,virus translation stage,0.5796296296296296
pathogen death process boundary,disease surveillance objective specification,0.61
pathogen death process boundary,case isolation control strategy,0.6274193548387097
pathogen death process boundary,virus release stage,0.57
pathogen death process boundary,infectious agent host role,0.6429824561403508
pathogen death process boundary,source of infection site,0.5772727272727273
pathogen death process boundary,virus,0.5055555555555555
pathogen death process boundary,virus replication,0.575
pathogen death process boundary,B cell receptor complex,0.5981481481481481
pathogen death process boundary,passive immunization against infectious agent,0.6210526315789474
pathogen death process boundary,systematic infection,0.6068627450980393
pathogen death process boundary,infection incidence rate,0.6318181818181818
pathogen death process boundary,virus host,0.5475609756097561
pathogen death process boundary,double-stranded RNA virus,0.6285714285714286
pathogen death process boundary,pathogen portal of entry role,0.7166666666666667
pathogen death process boundary,virus transcription stage,0.575
pathogen death process boundary,infectious disease lifetime prevalence,0.6239130434782608
pathogen death process boundary,pathogen birth temporal region,0.728688524590164
pathogen death process boundary,lower respiratory tract disease,0.6435483870967742
pathogen death process boundary,infectious disease incidence proportion,0.6214285714285714
pathogen death process boundary,opportunistic pathogen,0.6386792452830189
pathogen death process boundary,virus generative stage,0.619811320754717
pathogen death process boundary,acute infectious disease course,0.6596774193548387
pathogen death process boundary,cidal agent disposition,0.6537037037037037
pathogen death process boundary,genetic resistance to pathogen,0.6631147540983606
pathogen death process boundary,subclinical infection,0.5653846153846154
pathogen death process boundary,process,0.6342105263157894
pathogen death process boundary,simple infection,0.598936170212766
pathogen death process boundary,droplet pathogen transmission process,0.7147058823529412
pathogen death process boundary,infectious disease sporadicity,0.630327868852459
pathogen death process boundary,communicability end process boundary,0.7783582089552239
pathogen death process boundary,infection incidence proportion profile,0.6384057971014493
pathogen death process boundary,infectious agent colony,0.6537037037037037
pathogen death process boundary,pathogen transporter,0.7245098039215686
pathogen death process boundary,latency end process boundary,0.8398305084745763
pathogen death process boundary,infectious disease epidemic,0.6051724137931035
pathogen death process boundary,infectious agent generative stage,0.6375
pathogen death process boundary,disease transmission model,0.6254385964912281
pathogen death process boundary,pathologically immunosuppressed organism,0.6753521126760563
pathogen death process boundary,negative-sense single-stranded RNA virus,0.6330985915492958
pathogen death process boundary,cidal agent,0.569047619047619
pathogen death process boundary,pathogen vehicle,0.7265957446808511
pathogen death process boundary,COVID-19 incidence rate,0.5981481481481481
pathogen death process boundary,community-acquired infection,0.5855932203389831
pathogen death process boundary,pathogen vector,0.7326086956521739
pathogen death process boundary,negative regulation of developmental process,0.6633333333333334
pathogen death process boundary,pathogen vehicle role,0.7384615384615384
pathogen death process boundary,chronic infectious disease course,0.653125
pathogen death process boundary,asymptomatic infectious agent carrier,0.6264705882352941
pathogen death process boundary,nursing-home acquired infection,0.6112903225806451
pathogen death process boundary,secondary infection,0.61
pathogen death process boundary,infection start temporal region,0.6435483870967742
pathogen death process boundary,infection incidence,0.61
pathogen death process boundary,virus disorder,0.5833333333333334
pathogen death process boundary,sterilizing immunity to infectious agent,0.6049295774647887
pathogen death process boundary,primary infection,0.5958333333333333
pathogen death process boundary,process of establishing an infection,0.6141791044776119
pathogen death process boundary,incubation end process boundary,0.8209677419354838
pathogen death process boundary,SARS-CoV-2 uncoating stage,0.5903508771929825
pathogen death process boundary,pathogen death process boundary,0.95
pathogen death process boundary,immunosuppressed organism,0.6107142857142857
pathogen death process boundary,plan specification,0.6336734693877552
pathogen death process boundary,latency end temporal region,0.6741379310344828
pathogen death process boundary,innate immunity to infectious agent,0.6166666666666667
pathogen death process boundary,SARS-CoV-2 penetration stage,0.6194915254237288
pathogen death process boundary,virus adhesion susceptible cell,0.6112903225806451
pathogen death process boundary,anatomical space,0.6202127659574468
pathogen death process boundary,infection,0.575
pathogen death process boundary,static agent disposition,0.6681818181818181
pathogen death process boundary,T cell receptor complex,0.6166666666666667
pathogen death process boundary,infectious agent population,0.6396551724137931
pathogen death process boundary,respiratory system disease,0.6254385964912281
pathogen death process boundary,leukocyte-mediated immunity to infectious agent,0.591025641025641
pathogen death process boundary,indirect pathogen transmission process,0.7108695652173913
pathogen death process boundary,organism population,0.61
pathogen death process boundary,planned process,0.7108695652173913
pathogen death process boundary,generative stage,0.6414893617021277
pathogen death process boundary,humoral immunity to infectious agent,0.5992537313432835
pathogen death process boundary,infectious disease control strategy,0.6318181818181818
pathogen death process boundary,SARS-CoV-2 attachment stage,0.6051724137931035
pathogen death process boundary,parasite,0.5782051282051281
pathogen death process boundary,infectious disease pandemic,0.6224137931034482
pathogen death process boundary,antibody reagent,0.6202127659574468
pathogen death process boundary,infectious structure generative stage,0.6117647058823529
pathogen death process boundary,innate immune response,0.6575471698113208
pathogen death process boundary,viral disease course,0.6460784313725491
pathogen death process boundary,intracellular infection,0.5981481481481481
pathogen death process boundary,secondary infection role,0.6136363636363636
pathogen death process boundary,metastatic infection,0.6068627450980393
pathogen death process boundary,passive immunity to infectious agent,0.6141791044776119
pathogen death process boundary,vaccination against infectious agent,0.6291044776119403
pathogen death process boundary,acute infection,0.6239130434782608
pathogen death process boundary,susceptibility to infectious agent,0.6038461538461539
pathogen death process boundary,epitope site,0.6127906976744186
pathogen death process boundary,immunity to pathogen,0.6264705882352941
pathogen death process boundary,source of infection role,0.6136363636363636
pathogen death process boundary,pathogen host,0.7227272727272727
pathogen death process boundary,chronic infection,0.6166666666666667
pathogen death process boundary,disease course,0.6277777777777778
pathogen death process boundary,infectious disease course,0.6464285714285714
pathogen death process boundary,acquired immunity to infectious agent,0.5970588235294118
pathogen death process boundary,complex infection,0.5958333333333333
pathogen death process boundary,COVID-19 disease incidence proportion,0.6117647058823529
pathogen death process boundary,coronavirus disease course,0.6429824561403508
pathogen death process boundary,infection incidence proportion,0.6467213114754098
pathogen death process boundary,symptomatic infectious agent carrier,0.6291044776119403
pathogen death process boundary,respiratory droplet virus fomite,0.6563492063492063
pathogen death process boundary,susceptible organism,0.5676470588235294
pathogen death process boundary,parasite role,0.6318181818181818
pathogen death process boundary,pathogen vector role,0.7441176470588234
pathogen death process boundary,pathogen portal of exit site,0.6872881355932203
pathogen death process boundary,infectious disease prevalence,0.6333333333333333
pathogen death process boundary,organism substance,0.5928571428571429
pathogen death process boundary,SARS-CoV-2 genome replication stage,0.6318181818181818
pathogen death process boundary,single-stranded DNA virus,0.6107142857142857
pathogen death process boundary,COVID-19 mortality rate,0.5796296296296296
pathogen death process boundary,process profile,0.6456521739130434
pathogen death process boundary,negative regulation of life-sustaining process,0.6448051948051949
pathogen death process boundary,place closure control strategy,0.630327868852459
pathogen death process boundary,viral disease,0.5863636363636363
pathogen death process boundary,primary infection role,0.619811320754717
pathogen death process boundary,pathogen portal of entry site,0.7166666666666667
pathogen death process boundary,developmental process,0.6807692307692308
pathogen death process boundary,infection incidence profile,0.6396551724137931
pathogen death process boundary,disease,0.5552631578947369
pathogen death process boundary,biological process,0.6744897959183673
pathogen death process boundary,site,0.5071428571428571
pathogen death process boundary,pathogen host role,0.7357142857142857
pathogen death process boundary,infection prevalence,0.6068627450980393
pathogen death process boundary,humoral immune response,0.6351851851851852
pathogen death process boundary,infectious pathogen transmissibility,0.6738805970149254
pathogen death process boundary,incubation start process boundary,0.825
pathogen death process boundary,pathogen surveillance,0.7
pathogen death process boundary,immunodeficient organism,0.5954545454545455
pathogen death process boundary,pathogen,0.6551282051282051
pathogen death process boundary,pathogen birth process boundary,0.9016129032258065
pathogen death process boundary,infectious human pathogen,0.6285714285714286
pathogen death process boundary,subclinical virus infection,0.5879310344827586
pathogen death process boundary,resistance to pathogen,0.6386792452830189
pathogen death process boundary,establishment of localization in virus host,0.6121621621621621
pathogen death process boundary,immunization against infectious agent,0.6264705882352941
pathogen death process boundary,virus attachment stage,0.619811320754717
pathogen death process boundary,negative regulation of immune response,0.6384057971014493
pathogen death process boundary,SARS-CoV-2 transcription stage,0.5975409836065574
pathogen death process boundary,virus synthesis stage,0.6038461538461539
pathogen death process boundary,pathogen portal of exit role,0.7042372881355932
pathogen death process boundary,infectious agent host,0.6230769230769231
pathogen death process boundary,re-emerging pathogen,0.6264705882352941
pathogen death process boundary,long-term non-progressing infectious disease course,0.6451219512195122
pathogen death process boundary,viral disease epidemic,0.6009433962264151
pathogen death process boundary,viral disease pandemic,0.619811320754717
pathogen death process boundary,virus penetration stage,0.6166666666666667
pathogen death process boundary,algorithm,0.55
pathogen death process boundary,pathogen seroprevalence,0.7092592592592593
pathogen death process boundary,infectious disease endemicity,0.6333333333333333
pathogen death process boundary,negative regulation of viral process,0.6738805970149254
pathogen death process boundary,contact pathogen transmission process,0.7147058823529412
pathogen death process boundary,function,0.5525641025641026
pathogen death process boundary,herd immunity to infectious organism,0.6141791044776119
pathogen death process boundary,extracellular infection,0.5981481481481481
pathogen death process boundary,pathogen transporter role,0.7178571428571427
pathogen death process boundary,symbiotic process,0.6583333333333334
pathogen death process boundary,infectious agent reservoir,0.6605263157894737
pathogen death process boundary,infection start process boundary,0.8150793650793651
pathogen death process boundary,action specification,0.6460784313725491
pathogen death process boundary,SARS-CoV-2 synthesis stage,0.6254385964912281
pathogen death process boundary,latency start process boundary,0.8434426229508196
pathogen death process boundary,infectious disease control objective specification,0.6228395061728395
pathogen death process boundary,process of establishing viral infection,0.6214285714285714
pathogen death process boundary,negative regulation of biological process,0.6583333333333334
pathogen death process boundary,polymerase chain reaction,0.6285714285714286
pathogen death process boundary,COVID-19 disease course,0.6351851851851852
pathogen death process boundary,infectious disease incidence rate,0.621875
pathogen death process boundary,communicability start process boundary,0.7688405797101449
pathogen death process boundary,process that results in death,0.7
pathogen death process boundary,single-stranded RNA retrovirus,0.630327868852459
pathogen death process boundary,active immunization against infectious agent,0.61
pathogen death process boundary,disordered virus,0.598936170212766
pathogen death process boundary,adaptive immune response,0.65
pathogen death process boundary,organism,0.5525641025641026
pathogen death process boundary,virus uncoating stage,0.5653846153846154
pathogen death process boundary,local infection,0.5804347826086956
pathogen death process boundary,infectious agent,0.598936170212766
pathogen death process boundary,establishment of a clinically abnormal colony,0.6210526315789474
pathogen death process boundary,process boundary,0.7904255319148936
pathogen death process boundary,coronavirus disease,0.61
pathogen death process boundary,positive-sense single-stranded RNA virus,0.6330985915492958
pathogen death process boundary,horizontal pathogen transmission process,0.7035211267605633
pathogen death process boundary,hospital-acquired infection,0.5879310344827586
pathogen death process boundary,pathogen death temporal region,0.7778688524590163
pathogen death process boundary,emerging pathogen,0.6375
pathogen death process boundary,drug susceptibility of infectious agent,0.5928571428571429
pathogen death process boundary,SARS-CoV-2 release stage,0.5954545454545455
pathogen death process boundary,static agent,0.5895348837209302
pathogen death process boundary,pathogen transmission process,0.75
pathogen death process boundary,cell space,0.5719512195121951
indirect pathogen transmission process,extended organism,0.6318181818181818
indirect pathogen transmission process,virus aggregate,0.6009433962264151
indirect pathogen transmission process,source of infection,0.6078947368421053
indirect pathogen transmission process,immune response,0.619811320754717
indirect pathogen transmission process,infectious disease mortality rate,0.6612676056338028
indirect pathogen transmission process,infection incidence rate profile,0.6785714285714286
indirect pathogen transmission process,communicability end temporal region,0.6417808219178082
indirect pathogen transmission process,pathogen generative stage,0.6722222222222223
indirect pathogen transmission process,pathogen portal of entry,0.6758064516129032
indirect pathogen transmission process,subclinical coronavirus infection,0.6330985915492958
indirect pathogen transmission process,primary pathogen,0.6537037037037037
indirect pathogen transmission process,surveillance process,0.656896551724138
indirect pathogen transmission process,infection end temporal region,0.6738805970149254
indirect pathogen transmission process,drug-based immunosuppressed organism,0.6121621621621621
indirect pathogen transmission process,infectious disease,0.6464285714285714
indirect pathogen transmission process,SARS-CoV-2 incidence rate,0.6087301587301588
indirect pathogen transmission process,double-stranded DNA virus,0.6246031746031746
indirect pathogen transmission process,incubation end temporal region,0.6705882352941177
indirect pathogen transmission process,site of infection,0.6136363636363636
indirect pathogen transmission process,immunocompetent organism,0.6596774193548387
indirect pathogen transmission process,pathogen portal of exit,0.6795081967213115
indirect pathogen transmission process,infectious disease incidence,0.6621212121212122
indirect pathogen transmission process,reservoir of pathogen role,0.684375
indirect pathogen transmission process,subclinical SARS-CoV-2 infection,0.6214285714285714
indirect pathogen transmission process,virus translation stage,0.6631147540983606
indirect pathogen transmission process,disease surveillance objective specification,0.6207317073170732
indirect pathogen transmission process,case isolation control strategy,0.6384057971014493
indirect pathogen transmission process,virus release stage,0.6078947368421053
indirect pathogen transmission process,infectious agent host role,0.7
indirect pathogen transmission process,source of infection site,0.6274193548387097
indirect pathogen transmission process,virus,0.5197674418604651
indirect pathogen transmission process,virus replication,0.6136363636363636
indirect pathogen transmission process,B cell receptor complex,0.6139344262295081
indirect pathogen transmission process,passive immunization against infectious agent,0.6427710843373494
indirect pathogen transmission process,systematic infection,0.5879310344827586
indirect pathogen transmission process,infection incidence rate,0.6758064516129032
indirect pathogen transmission process,virus host,0.575
indirect pathogen transmission process,double-stranded RNA virus,0.6246031746031746
indirect pathogen transmission process,pathogen portal of entry role,0.703731343283582
indirect pathogen transmission process,virus transcription stage,0.6722222222222223
indirect pathogen transmission process,infectious disease lifetime prevalence,0.6605263157894737
indirect pathogen transmission process,pathogen birth temporal region,0.6705882352941177
indirect pathogen transmission process,lower respiratory tract disease,0.6528985507246376
indirect pathogen transmission process,infectious disease incidence proportion,0.6577922077922078
indirect pathogen transmission process,opportunistic pathogen,0.65
indirect pathogen transmission process,virus generative stage,0.6333333333333333
indirect pathogen transmission process,acute infectious disease course,0.6384057971014493
indirect pathogen transmission process,cidal agent disposition,0.6795081967213115
indirect pathogen transmission process,genetic resistance to pathogen,0.6705882352941177
indirect pathogen transmission process,subclinical infection,0.6194915254237288
indirect pathogen transmission process,process,0.6055555555555556
indirect pathogen transmission process,simple infection,0.5981481481481481
indirect pathogen transmission process,droplet pathogen transmission process,0.9033333333333333
indirect pathogen transmission process,infectious disease sporadicity,0.6558823529411765
indirect pathogen transmission process,communicability end process boundary,0.6527027027027027
indirect pathogen transmission process,infection incidence proportion profile,0.6868421052631578
indirect pathogen transmission process,infectious agent colony,0.6631147540983606
indirect pathogen transmission process,pathogen transporter,0.743103448275862
indirect pathogen transmission process,latency end process boundary,0.6621212121212122
indirect pathogen transmission process,infectious disease epidemic,0.65
indirect pathogen transmission process,infectious agent generative stage,0.6753521126760563
indirect pathogen transmission process,disease transmission model,0.778125
indirect pathogen transmission process,pathologically immunosuppressed organism,0.6294871794871795
indirect pathogen transmission process,negative-sense single-stranded RNA virus,0.6423076923076922
indirect pathogen transmission process,cidal agent,0.6132653061224489
indirect pathogen transmission process,pathogen vehicle,0.6722222222222223
indirect pathogen transmission process,COVID-19 incidence rate,0.6139344262295081
indirect pathogen transmission process,community-acquired infection,0.6015151515151516
indirect pathogen transmission process,pathogen vector,0.6764150943396227
indirect pathogen transmission process,negative regulation of developmental process,0.6817073170731708
indirect pathogen transmission process,pathogen vehicle role,0.6872881355932203
indirect pathogen transmission process,chronic infectious disease course,0.6330985915492958
indirect pathogen transmission process,asymptomatic infectious agent carrier,0.6366666666666667
indirect pathogen transmission process,nursing-home acquired infection,0.6094202898550725
indirect pathogen transmission process,secondary infection,0.6078947368421053
indirect pathogen transmission process,infection start temporal region,0.6673913043478261
indirect pathogen transmission process,infection incidence,0.6780701754385965
indirect pathogen transmission process,virus disorder,0.6038461538461539
indirect pathogen transmission process,sterilizing immunity to infectious agent,0.6166666666666667
indirect pathogen transmission process,primary infection,0.5954545454545455
indirect pathogen transmission process,process of establishing an infection,0.6256756756756756
indirect pathogen transmission process,incubation end process boundary,0.696376811594203
indirect pathogen transmission process,SARS-CoV-2 uncoating stage,0.60625
indirect pathogen transmission process,pathogen death process boundary,0.7108695652173913
indirect pathogen transmission process,immunosuppressed organism,0.6246031746031746
indirect pathogen transmission process,plan specification,0.6107142857142857
indirect pathogen transmission process,latency end temporal region,0.6346153846153847
indirect pathogen transmission process,innate immunity to infectious agent,0.6280821917808219
indirect pathogen transmission process,SARS-CoV-2 penetration stage,0.6621212121212122
indirect pathogen transmission process,virus adhesion susceptible cell,0.6528985507246376
indirect pathogen transmission process,infection,0.6202127659574468
indirect pathogen transmission process,static agent disposition,0.6758064516129032
indirect pathogen transmission process,T cell receptor complex,0.6139344262295081
indirect pathogen transmission process,infectious agent population,0.6807692307692308
indirect pathogen transmission process,respiratory system disease,0.653125
indirect pathogen transmission process,leukocyte-mediated immunity to infectious agent,0.6147058823529412
indirect pathogen transmission process,indirect pathogen transmission process,0.95
indirect pathogen transmission process,organism population,0.6078947368421053
indirect pathogen transmission process,planned process,0.6764150943396227
indirect pathogen transmission process,generative stage,0.6166666666666667
indirect pathogen transmission process,humoral immunity to infectious agent,0.6256756756756756
indirect pathogen transmission process,infectious disease control strategy,0.6554794520547945
indirect pathogen transmission process,SARS-CoV-2 attachment stage,0.6346153846153847
indirect pathogen transmission process,parasite,0.6021739130434782
indirect pathogen transmission process,infectious disease pandemic,0.6653846153846155
indirect pathogen transmission process,antibody reagent,0.6166666666666667
indirect pathogen transmission process,infectious structure generative stage,0.65
indirect pathogen transmission process,innate immune response,0.6666666666666667
indirect pathogen transmission process,viral disease course,0.6224137931034482
indirect pathogen transmission process,intracellular infection,0.6139344262295081
indirect pathogen transmission process,secondary infection role,0.6596774193548387
indirect pathogen transmission process,metastatic infection,0.6051724137931035
indirect pathogen transmission process,passive immunity to infectious agent,0.6256756756756756
indirect pathogen transmission process,vaccination against infectious agent,0.6527027027027027
indirect pathogen transmission process,acute infection,0.6009433962264151
indirect pathogen transmission process,susceptibility to infectious agent,0.6166666666666667
indirect pathogen transmission process,epitope site,0.63
indirect pathogen transmission process,immunity to pathogen,0.6741379310344828
indirect pathogen transmission process,source of infection role,0.6596774193548387
indirect pathogen transmission process,pathogen host,0.6656862745098039
indirect pathogen transmission process,chronic infection,0.6136363636363636
indirect pathogen transmission process,disease course,0.6230769230769231
indirect pathogen transmission process,infectious disease course,0.6563492063492063
indirect pathogen transmission process,acquired immunity to infectious agent,0.6233333333333334
indirect pathogen transmission process,complex infection,0.5954545454545455
indirect pathogen transmission process,COVID-19 disease incidence proportion,0.6366666666666667
indirect pathogen transmission process,coronavirus disease course,0.621875
indirect pathogen transmission process,infection incidence proportion,0.6705882352941177
indirect pathogen transmission process,symptomatic infectious agent carrier,0.6391891891891892
indirect pathogen transmission process,respiratory droplet virus fomite,0.6357142857142857
indirect pathogen transmission process,susceptible organism,0.6224137931034482
indirect pathogen transmission process,parasite role,0.6460784313725491
indirect pathogen transmission process,pathogen vector role,0.7086206896551723
indirect pathogen transmission process,pathogen portal of exit site,0.6772727272727272
indirect pathogen transmission process,infectious disease prevalence,0.6738805970149254
indirect pathogen transmission process,organism substance,0.6464285714285714
indirect pathogen transmission process,SARS-CoV-2 genome replication stage,0.6417808219178082
indirect pathogen transmission process,single-stranded DNA virus,0.6404761904761905
indirect pathogen transmission process,COVID-19 mortality rate,0.6139344262295081
indirect pathogen transmission process,contact tracing,0.6386792452830189
indirect pathogen transmission process,process profile,0.6386792452830189
indirect pathogen transmission process,negative regulation of life-sustaining process,0.7119047619047619
indirect pathogen transmission process,viral disease,0.6068627450980393
indirect pathogen transmission process,primary infection role,0.65
indirect pathogen transmission process,pathogen portal of entry site,0.6738805970149254
indirect pathogen transmission process,developmental process,0.7042372881355932
indirect pathogen transmission process,infection incidence profile,0.6961538461538461
indirect pathogen transmission process,disease,0.5833333333333334
indirect pathogen transmission process,biological process,0.6642857142857143
indirect pathogen transmission process,site,0.5214285714285714
indirect pathogen transmission process,pathogen host role,0.7
indirect pathogen transmission process,infection prevalence,0.6741379310344828
indirect pathogen transmission process,humoral immune response,0.630327868852459
indirect pathogen transmission process,infectious pathogen transmissibility,0.7878378378378378
indirect pathogen transmission process,incubation start process boundary,0.7035211267605633
indirect pathogen transmission process,pathogen surveillance,0.6872881355932203
indirect pathogen transmission process,immunodeficient organism,0.6596774193548387
indirect pathogen transmission process,pathogen,0.6239130434782608
indirect pathogen transmission process,pathogen birth process boundary,0.7108695652173913
indirect pathogen transmission process,infectious human pathogen,0.6722222222222223
indirect pathogen transmission process,subclinical virus infection,0.6346153846153847
indirect pathogen transmission process,resistance to pathogen,0.6666666666666667
indirect pathogen transmission process,establishment of localization in virus host,0.6475308641975309
indirect pathogen transmission process,immunization against infectious agent,0.6633333333333334
indirect pathogen transmission process,virus attachment stage,0.65
indirect pathogen transmission process,negative regulation of immune response,0.6605263157894737
indirect pathogen transmission process,SARS-CoV-2 transcription stage,0.6705882352941177
indirect pathogen transmission process,virus synthesis stage,0.6364406779661017
indirect pathogen transmission process,pathogen portal of exit role,0.6924242424242425
indirect pathogen transmission process,infectious agent host,0.6872881355932203
indirect pathogen transmission process,re-emerging pathogen,0.6396551724137931
indirect pathogen transmission process,long-term non-progressing infectious disease course,0.6410112359550562
indirect pathogen transmission process,viral disease epidemic,0.6166666666666667
indirect pathogen transmission process,viral disease pandemic,0.65
indirect pathogen transmission process,virus penetration stage,0.6795081967213115
indirect pathogen transmission process,algorithm,0.5351063829787234
indirect pathogen transmission process,pathogen seroprevalence,0.6959016393442623
indirect pathogen transmission process,infectious disease endemicity,0.6440298507462687
indirect pathogen transmission process,negative regulation of viral process,0.7067567567567568
indirect pathogen transmission process,contact pathogen transmission process,0.89
indirect pathogen transmission process,function,0.5804347826086956
indirect pathogen transmission process,herd immunity to infectious organism,0.6391891891891892
indirect pathogen transmission process,extracellular infection,0.5975409836065574
indirect pathogen transmission process,pathogen transporter role,0.7515873015873015
indirect pathogen transmission process,symbiotic process,0.6681818181818181
indirect pathogen transmission process,transmission interval,0.6872881355932203
indirect pathogen transmission process,infectious agent reservoir,0.684375
indirect pathogen transmission process,infection start process boundary,0.7071428571428571
indirect pathogen transmission process,action specification,0.6224137931034482
indirect pathogen transmission process,SARS-CoV-2 synthesis stage,0.621875
indirect pathogen transmission process,latency start process boundary,0.6705882352941177
indirect pathogen transmission process,infectious disease control objective specification,0.6431818181818181
indirect pathogen transmission process,process of establishing viral infection,0.6318181818181818
indirect pathogen transmission process,negative regulation of biological process,0.690506329113924
indirect pathogen transmission process,polymerase chain reaction,0.6246031746031746
indirect pathogen transmission process,COVID-19 disease course,0.6139344262295081
indirect pathogen transmission process,infectious disease incidence rate,0.6612676056338028
indirect pathogen transmission process,communicability start process boundary,0.6605263157894737
indirect pathogen transmission process,process that results in death,0.6440298507462687
indirect pathogen transmission process,active immunization against infectious agent,0.6451219512195122
indirect pathogen transmission process,disordered virus,0.6166666666666667
indirect pathogen transmission process,adaptive immune response,0.6435483870967742
indirect pathogen transmission process,organism,0.5804347826086956
indirect pathogen transmission process,virus uncoating stage,0.6194915254237288
indirect pathogen transmission process,local infection,0.6009433962264151
indirect pathogen transmission process,infectious agent,0.6537037037037037
indirect pathogen transmission process,establishment of a clinically abnormal colony,0.6066265060240964
indirect pathogen transmission process,process boundary,0.5981481481481481
indirect pathogen transmission process,coronavirus disease,0.6078947368421053
indirect pathogen transmission process,positive-sense single-stranded RNA virus,0.6294871794871795
indirect pathogen transmission process,horizontal pathogen transmission process,0.8730769230769231
indirect pathogen transmission process,hospital-acquired infection,0.6038461538461539
indirect pathogen transmission process,pathogen death temporal region,0.6705882352941177
indirect pathogen transmission process,emerging pathogen,0.65
indirect pathogen transmission process,drug susceptibility of infectious agent,0.6058441558441559
indirect pathogen transmission process,SARS-CoV-2 release stage,0.5951612903225807
indirect pathogen transmission process,static agent,0.61
indirect pathogen transmission process,pathogen transmission process,0.8828358208955223
variolation,variolation,0.95
variolation,T cell receptor complex,0.5382352941176471
variolation,establishment of a clinically abnormal colony,0.575
intermediate host,virostatic disposition,0.6551282051282051
intermediate host,zoonotic disposition,0.6391891891891892
intermediate host,infectious disease mortality rate,0.65
intermediate host,infection incidence rate profile,0.6540816326530612
intermediate host,primary pathogen,0.6318181818181818
intermediate host,SARS-CoV-2 incidence rate,0.6166666666666667
intermediate host,virulence factor disposition,0.65
intermediate host,viral adhesion disposition,0.636046511627907
intermediate host,parasitostatic disposition,0.636046511627907
intermediate host,reverse zoonotic disposition,0.6277777777777778
intermediate host,establishment of localization in host,0.6537037037037037
intermediate host,infectious agent host role,0.7058139534883722
intermediate host,B cell receptor complex,0.6
intermediate host,passive immunization against infectious agent,0.6112903225806451
intermediate host,infection incidence rate,0.6451219512195122
intermediate host,colonized host,0.7080645161290323
intermediate host,virus host,0.7092592592592593
intermediate host,double-stranded RNA virus,0.6166666666666667
intermediate host,toxin disposition,0.6558823529411765
intermediate host,cidal agent disposition,0.65
intermediate host,parasiticidal disposition,0.6404761904761905
intermediate host,infectious agent colony,0.65
intermediate host,invasion factor,0.6375
intermediate host,transmissibility disposition,0.65
intermediate host,colonization of host,0.6932432432432433
intermediate host,infectious agent generative stage,0.67
intermediate host,endotoxin disposition,0.6342105263157894
intermediate host,negative-sense single-stranded RNA virus,0.6078947368421053
intermediate host,cidal agent,0.6285714285714286
intermediate host,infectious structure host role,0.6840425531914894
intermediate host,COVID-19 incidence rate,0.625
intermediate host,cytotoxin disposition,0.6342105263157894
intermediate host,host,0.6404761904761905
intermediate host,asymptomatic infectious agent carrier,0.5981481481481481
intermediate host,sterilizing immunity to infectious agent,0.6254385964912281
intermediate host,establishment of localization in human host,0.6333333333333333
intermediate host,primary infection,0.5970588235294118
intermediate host,virulence factor,0.6318181818181818
intermediate host,collective pathogenic disposition,0.63
intermediate host,neurotoxin disposition,0.6551282051282051
intermediate host,dead-end host role,0.6785714285714286
intermediate host,definitive host role,0.7202702702702704
intermediate host,innate immunity to infectious agent,0.6615384615384616
intermediate host,collective disposition,0.6294871794871795
intermediate host,static agent disposition,0.6451219512195122
intermediate host,T cell receptor complex,0.625
intermediate host,infectious structure host,0.7119047619047619
intermediate host,infectious agent population,0.6545454545454545
intermediate host,entry into host,0.7625
intermediate host,leukocyte-mediated immunity to infectious agent,0.653125
intermediate host,adhesion of symbiont to host,0.6722222222222223
intermediate host,humoral immunity to infectious agent,0.6009433962264151
intermediate host,immunosuppressive disposition,0.6673913043478261
intermediate host,pathogenic disposition,0.6294871794871795
intermediate host,entry into host through host barriers,0.6351851851851852
intermediate host,passive immunity to infectious agent,0.619811320754717
intermediate host,infectious disposition,0.6551282051282051
intermediate host,vaccination against infectious agent,0.6386792452830189
intermediate host,susceptibility to infectious agent,0.5872549019607843
intermediate host,bacteriostatic disposition,0.6825581395348838
intermediate host,bactericidal disposition,0.6695121951219513
intermediate host,pathogen host,0.7166666666666667
intermediate host,invasion disposition,0.6391891891891892
intermediate host,viricidal disposition,0.6605263157894737
intermediate host,acquired immunity to infectious agent,0.6351851851851852
intermediate host,symptomatic infectious agent carrier,0.6009433962264151
intermediate host,intermediate host,0.95
intermediate host,disposition,0.6285714285714286
intermediate host,COVID-19 mortality rate,0.6
intermediate host,place closure control strategy,0.598936170212766
intermediate host,primary infection role,0.6038461538461539
intermediate host,primary immunodeficiency,0.5963414634146341
intermediate host,adhesion disposition,0.6391891891891892
intermediate host,primary infectious disposition,0.6202127659574468
intermediate host,pathogen host role,0.6785714285714286
intermediate host,intermediate host role,0.8858974358974359
intermediate host,dead-end host,0.7166666666666667
intermediate host,host role,0.6038461538461539
intermediate host,establishment of localization in virus host,0.6333333333333333
intermediate host,immunization against infectious agent,0.6351851851851852
intermediate host,SARS-COV-2 adhesion disposition,0.5958333333333333
intermediate host,invasive disposition,0.6662162162162162
intermediate host,infectious agent host,0.7394736842105263
intermediate host,fungicidal disposition,0.6294871794871795
intermediate host,division of geopolitical entity,0.5958333333333333
intermediate host,exotoxin disposition,0.6391891891891892
intermediate host,infectious agent reservoir,0.636046511627907
intermediate host,symbiont host role,0.6785714285714286
intermediate host,opportunistic infectious disposition,0.6009433962264151
intermediate host,enterotoxin disposition,0.675
intermediate host,infectious disease incidence rate,0.63
intermediate host,single-stranded RNA retrovirus,0.6627659574468084
intermediate host,active immunization against infectious agent,0.6139344262295081
intermediate host,collective resistance disposition,0.67
intermediate host,fungistatic disposition,0.65
intermediate host,infectious agent,0.6621212121212122
intermediate host,establishment of a clinically abnormal colony,0.5790322580645162
intermediate host,positive-sense single-stranded RNA virus,0.6078947368421053
intermediate host,adhesion factor,0.60625
intermediate host,definitive host,0.7625
intermediate host,drug susceptibility of infectious agent,0.5928571428571429
intermediate host,static agent,0.6224137931034482
colonization of human,extended organism,0.6078947368421053
colonization of human,information content entity,0.6627659574468084
colonization of human,infectious disease mortality rate,0.5981481481481481
colonization of human,infection incidence rate profile,0.619811320754717
colonization of human,geographical entity,0.575
colonization of human,drug-based immunosuppressed organism,0.5728070175438597
colonization of human,geospatial location,0.65
colonization of human,SARS-CoV-2 incidence rate,0.6021739130434782
colonization of human,resistant entity,0.5851351351351352
colonization of human,normal resident microbiota population,0.6396551724137931
colonization of human,immunocompetent organism,0.6277777777777778
colonization of human,establishment of localization in host,0.6741379310344828
colonization of human,material entity,0.5888888888888889
colonization of human,B cell receptor complex,0.609090909090909
colonization of human,infection incidence rate,0.6277777777777778
colonization of human,entity,0.5611111111111111
colonization of human,double-stranded RNA virus,0.6021739130434782
colonization of human,directive information content entity,0.6429824561403508
colonization of human,infectious agent colony,0.6318181818181818
colonization of human,colonization of host,0.8646341463414635
colonization of human,realizable entity,0.6078947368421053
colonization of human,negative regulation of establishment of localization,0.6554794520547945
colonization of human,pathologically immunosuppressed organism,0.630327868852459
colonization of human,negative-sense single-stranded RNA virus,0.5811475409836065
colonization of human,establishment of localization,0.65
colonization of human,COVID-19 incidence rate,0.609090909090909
colonization of human,descriptive information content entity,0.6364406779661017
colonization of human,establishment of localization in human host,0.715625
colonization of human,molecular entity,0.5851351351351352
colonization of human,immunosuppressed organism,0.5804347826086956
colonization of human,plan specification,0.6551282051282051
colonization of human,colony,0.6351851851851852
colonization of human,T cell receptor complex,0.609090909090909
colonization of human,organism population,0.65
colonization of human,susceptible organism,0.6207317073170732
colonization of human,organism substance,0.6294871794871795
colonization of human,anatomical entity,0.6342105263157894
colonization of human,COVID-19 mortality rate,0.609090909090909
colonization of human,place closure control strategy,0.6068627450980393
colonization of human,geopolitical entity,0.625
colonization of human,homo sapiens,0.6015151515151516
colonization of human,designative information content entity,0.6364406779661017
colonization of human,immunodeficient organism,0.6277777777777778
colonization of human,infectious human pathogen,0.6673913043478261
colonization of human,colonization of human,0.95
colonization of human,establishment of localization in virus host,0.653125
colonization of human,immaterial entity,0.6078947368421053
colonization of human,division of geopolitical entity,0.6423076923076922
colonization of human,herd immunity to infectious organism,0.6078947368421053
colonization of human,processed material,0.5782051282051281
colonization of human,infectious disease incidence rate,0.5981481481481481
colonization of human,single-stranded RNA retrovirus,0.5676470588235294
colonization of human,organism,0.5879310344827586
colonization of human,establishment of a clinically abnormal colony,0.6015151515151516
colonization of human,positive-sense single-stranded RNA virus,0.5811475409836065
colonization of human,material processing,0.6
virus adhesion susceptible cell,extended organism,0.5541666666666667
virus adhesion susceptible cell,virus aggregate,0.6673913043478261
virus adhesion susceptible cell,source of infection,0.61
virus adhesion susceptible cell,virostatic disposition,0.6575471698113208
virus adhesion susceptible cell,zoonotic disposition,0.6068627450980393
virus adhesion susceptible cell,immune response,0.6456521739130434
virus adhesion susceptible cell,infectious disease mortality rate,0.653125
virus adhesion susceptible cell,infection incidence rate profile,0.6404761904761905
virus adhesion susceptible cell,communicability end temporal region,0.6015151515151516
virus adhesion susceptible cell,pathogen generative stage,0.6464285714285714
virus adhesion susceptible cell,pathogen portal of entry,0.6318181818181818
virus adhesion susceptible cell,subclinical coronavirus infection,0.621875
virus adhesion susceptible cell,primary pathogen,0.598936170212766
virus adhesion susceptible cell,infection end temporal region,0.6333333333333333
virus adhesion susceptible cell,drug-based immunosuppressed organism,0.6141791044776119
virus adhesion susceptible cell,infectious disease,0.6336734693877552
virus adhesion susceptible cell,SARS-CoV-2 incidence rate,0.6285714285714286
virus adhesion susceptible cell,double-stranded DNA virus,0.6107142857142857
virus adhesion susceptible cell,incubation end temporal region,0.6467213114754098
virus adhesion susceptible cell,site of infection,0.5958333333333333
virus adhesion susceptible cell,resistant entity,0.6414893617021277
virus adhesion susceptible cell,immunocompetent organism,0.5954545454545455
virus adhesion susceptible cell,virulence factor disposition,0.6533898305084747
virus adhesion susceptible cell,pathogen portal of exit,0.6351851851851852
virus adhesion susceptible cell,viral adhesion disposition,0.7482456140350877
virus adhesion susceptible cell,parasitostatic disposition,0.6254385964912281
virus adhesion susceptible cell,infectious disease incidence,0.6872881355932203
virus adhesion susceptible cell,reservoir of pathogen role,0.6429824561403508
virus adhesion susceptible cell,reverse zoonotic disposition,0.6364406779661017
virus adhesion susceptible cell,subclinical SARS-CoV-2 infection,0.6087301587301588
virus adhesion susceptible cell,virus translation stage,0.7277777777777777
virus adhesion susceptible cell,disease surveillance objective specification,0.6366666666666667
virus adhesion susceptible cell,case isolation control strategy,0.6435483870967742
virus adhesion susceptible cell,virus release stage,0.69
virus adhesion susceptible cell,source of infection site,0.6318181818181818
virus adhesion susceptible cell,virus,0.5888888888888889
virus adhesion susceptible cell,virus replication,0.6791666666666666
virus adhesion susceptible cell,B cell receptor complex,0.6351851851851852
virus adhesion susceptible cell,systematic infection,0.5872549019607843
virus adhesion susceptible cell,infection incidence rate,0.65
virus adhesion susceptible cell,virus host,0.6939024390243902
virus adhesion susceptible cell,double-stranded RNA virus,0.6107142857142857
virus adhesion susceptible cell,pathogen portal of entry role,0.6333333333333333
virus adhesion susceptible cell,virus transcription stage,0.7178571428571427
virus adhesion susceptible cell,infectious disease lifetime prevalence,0.6673913043478261
virus adhesion susceptible cell,toxin disposition,0.6166666666666667
virus adhesion susceptible cell,pathogen birth temporal region,0.6139344262295081
virus adhesion susceptible cell,lower respiratory tract disease,0.6435483870967742
virus adhesion susceptible cell,infectious disease incidence proportion,0.65
virus adhesion susceptible cell,opportunistic pathogen,0.6009433962264151
virus adhesion susceptible cell,virus generative stage,0.7141509433962264
virus adhesion susceptible cell,acute infectious disease course,0.6435483870967742
virus adhesion susceptible cell,cidal agent disposition,0.6351851851851852
virus adhesion susceptible cell,infectious disorder,0.61
virus adhesion susceptible cell,genetic resistance to pathogen,0.630327868852459
virus adhesion susceptible cell,subclinical infection,0.5846153846153846
virus adhesion susceptible cell,appearance of disorder,0.5820754716981132
virus adhesion susceptible cell,simple infection,0.598936170212766
virus adhesion susceptible cell,droplet pathogen transmission process,0.6411764705882353
virus adhesion susceptible cell,parasiticidal disposition,0.6107142857142857
virus adhesion susceptible cell,infectious disease sporadicity,0.6467213114754098
virus adhesion susceptible cell,communicability end process boundary,0.5843283582089552
virus adhesion susceptible cell,infection incidence proportion profile,0.6384057971014493
virus adhesion susceptible cell,pathogen transporter,0.6264705882352941
virus adhesion susceptible cell,transmissibility disposition,0.6194915254237288
virus adhesion susceptible cell,latency end process boundary,0.5855932203389831
virus adhesion susceptible cell,infectious disease epidemic,0.6741379310344828
virus adhesion susceptible cell,disease transmission model,0.6605263157894737
virus adhesion susceptible cell,endotoxin disposition,0.6038461538461539
virus adhesion susceptible cell,pathologically immunosuppressed organism,0.5767605633802817
virus adhesion susceptible cell,negative-sense single-stranded RNA virus,0.5908450704225352
virus adhesion susceptible cell,pathogen vehicle,0.6414893617021277
virus adhesion susceptible cell,susceptible population,0.6952830188679244
virus adhesion susceptible cell,COVID-19 incidence rate,0.6351851851851852
virus adhesion susceptible cell,cytotoxin disposition,0.6038461538461539
virus adhesion susceptible cell,community-acquired infection,0.5855932203389831
virus adhesion susceptible cell,pathogen vector,0.6021739130434782
virus adhesion susceptible cell,pathogen vehicle role,0.6615384615384616
virus adhesion susceptible cell,chronic infectious disease course,0.6375
virus adhesion susceptible cell,nursing-home acquired infection,0.6112903225806451
virus adhesion susceptible cell,COVID-19 epidemic,0.6375
virus adhesion susceptible cell,secondary infection,0.61
virus adhesion susceptible cell,infection start temporal region,0.6435483870967742
virus adhesion susceptible cell,infection incidence,0.67
virus adhesion susceptible cell,virus disorder,0.6722222222222223
virus adhesion susceptible cell,primary infection,0.6166666666666667
virus adhesion susceptible cell,process of establishing an infection,0.6141791044776119
virus adhesion susceptible cell,incubation end process boundary,0.6274193548387097
virus adhesion susceptible cell,SARS-CoV-2 disorder,0.59
virus adhesion susceptible cell,collective pathogenic disposition,0.621875
virus adhesion susceptible cell,neurotoxin disposition,0.6009433962264151
virus adhesion susceptible cell,pathogen death process boundary,0.6112903225806451
virus adhesion susceptible cell,immunosuppressed organism,0.5928571428571429
virus adhesion susceptible cell,latency end temporal region,0.6051724137931035
virus adhesion susceptible cell,virus adhesion susceptible cell,0.95
virus adhesion susceptible cell,collective disposition,0.6009433962264151
virus adhesion susceptible cell,infection,0.575
virus adhesion susceptible cell,static agent disposition,0.6318181818181818
virus adhesion susceptible cell,T cell receptor complex,0.6351851851851852
virus adhesion susceptible cell,respiratory system disease,0.6605263157894737
virus adhesion susceptible cell,indirect pathogen transmission process,0.6528985507246376
virus adhesion susceptible cell,adhesion of symbiont to host,0.6533898305084747
virus adhesion susceptible cell,organism population,0.59
virus adhesion susceptible cell,infectious disease control strategy,0.6469696969696969
virus adhesion susceptible cell,SARS-CoV-2 attachment stage,0.6396551724137931
virus adhesion susceptible cell,infectious disease pandemic,0.656896551724138
virus adhesion susceptible cell,immunosuppressive disposition,0.6333333333333333
virus adhesion susceptible cell,innate immune response,0.619811320754717
virus adhesion susceptible cell,pathogenic disposition,0.619811320754717
virus adhesion susceptible cell,viral disease course,0.6852941176470588
virus adhesion susceptible cell,intracellular infection,0.6166666666666667
virus adhesion susceptible cell,secondary infection role,0.6318181818181818
virus adhesion susceptible cell,metastatic infection,0.5872549019607843
virus adhesion susceptible cell,cell,0.5642857142857143
virus adhesion susceptible cell,infectious disposition,0.6386792452830189
virus adhesion susceptible cell,acute infection,0.6021739130434782
virus adhesion susceptible cell,bacteriostatic disposition,0.6078947368421053
virus adhesion susceptible cell,immunity to pathogen,0.6068627450980393
virus adhesion susceptible cell,bactericidal disposition,0.5954545454545455
virus adhesion susceptible cell,source of infection role,0.6136363636363636
virus adhesion susceptible cell,pathogen host,0.609090909090909
virus adhesion susceptible cell,acquired immunodeficiency,0.6285714285714286
virus adhesion susceptible cell,chronic infection,0.5958333333333333
virus adhesion susceptible cell,invasion disposition,0.6656862745098039
virus adhesion susceptible cell,disease course,0.6277777777777778
virus adhesion susceptible cell,infectious disease course,0.6642857142857143
virus adhesion susceptible cell,viricidal disposition,0.6423076923076922
virus adhesion susceptible cell,acquired immunity to infectious agent,0.6117647058823529
virus adhesion susceptible cell,complex infection,0.575
virus adhesion susceptible cell,COVID-19 disease incidence proportion,0.6411764705882353
virus adhesion susceptible cell,coronavirus disease course,0.6956140350877194
virus adhesion susceptible cell,infection incidence proportion,0.630327868852459
virus adhesion susceptible cell,respiratory droplet virus fomite,0.6246031746031746
virus adhesion susceptible cell,susceptible organism,0.6852941176470588
virus adhesion susceptible cell,pathogen vector role,0.6264705882352941
virus adhesion susceptible cell,pathogen portal of exit site,0.6364406779661017
virus adhesion susceptible cell,infectious disease prevalence,0.6833333333333332
virus adhesion susceptible cell,organism substance,0.6540816326530612
virus adhesion susceptible cell,disposition,0.5928571428571429
virus adhesion susceptible cell,single-stranded DNA virus,0.6107142857142857
virus adhesion susceptible cell,COVID-19 mortality rate,0.5981481481481481
virus adhesion susceptible cell,place closure control strategy,0.6139344262295081
virus adhesion susceptible cell,viral disease,0.6545454545454545
virus adhesion susceptible cell,primary infection role,0.6386792452830189
virus adhesion susceptible cell,adhesion disposition,0.7049019607843137
virus adhesion susceptible cell,pathogen portal of entry site,0.6333333333333333
virus adhesion susceptible cell,infection incidence profile,0.656896551724138
virus adhesion susceptible cell,disease,0.581578947368421
virus adhesion susceptible cell,primary infectious disposition,0.630327868852459
virus adhesion susceptible cell,pathogen host role,0.6336734693877552
virus adhesion susceptible cell,infection prevalence,0.6656862745098039
virus adhesion susceptible cell,humoral immune response,0.6166666666666667
virus adhesion susceptible cell,coronavirus disorder,0.6460784313725491
virus adhesion susceptible cell,SARS-COV-2 adhesion susceptible cell,0.8679104477611941
virus adhesion susceptible cell,infectious pathogen transmissibility,0.658955223880597
virus adhesion susceptible cell,pathogen surveillance,0.6807692307692308
virus adhesion susceptible cell,immunodeficient organism,0.6136363636363636
virus adhesion susceptible cell,pathogen,0.5525641025641026
virus adhesion susceptible cell,pathogen birth process boundary,0.5951612903225807
virus adhesion susceptible cell,infectious human pathogen,0.6285714285714286
virus adhesion susceptible cell,subclinical virus infection,0.6396551724137931
virus adhesion susceptible cell,resistance to pathogen,0.6386792452830189
virus adhesion susceptible cell,establishment of localization in virus host,0.5986486486486486
virus adhesion susceptible cell,virus attachment stage,0.7141509433962264
virus adhesion susceptible cell,negative regulation of immune response,0.6239130434782608
virus adhesion susceptible cell,virus synthesis stage,0.7192307692307692
virus adhesion susceptible cell,SARS-COV-2 adhesion disposition,0.7080645161290323
virus adhesion susceptible cell,pathogen portal of exit role,0.6364406779661017
virus adhesion susceptible cell,invasive disposition,0.6264705882352941
virus adhesion susceptible cell,re-emerging pathogen,0.6068627450980393
virus adhesion susceptible cell,long-term non-progressing infectious disease course,0.6207317073170732
virus adhesion susceptible cell,viral disease epidemic,0.6952830188679244
virus adhesion susceptible cell,fungicidal disposition,0.6009433962264151
virus adhesion susceptible cell,viral disease pandemic,0.6764150943396227
virus adhesion susceptible cell,virus penetration stage,0.7092592592592593
virus adhesion susceptible cell,pathogen seroprevalence,0.6722222222222223
virus adhesion susceptible cell,acute respiratory distress syndrome,0.6318181818181818
virus adhesion susceptible cell,division of geopolitical entity,0.6758064516129032
virus adhesion susceptible cell,infectious disease endemicity,0.6333333333333333
virus adhesion susceptible cell,contact pathogen transmission process,0.6264705882352941
virus adhesion susceptible cell,disorder,0.5525641025641026
virus adhesion susceptible cell,herd immunity to infectious organism,0.5843283582089552
virus adhesion susceptible cell,extracellular infection,0.5981481481481481
virus adhesion susceptible cell,pathogen transporter role,0.6464285714285714
virus adhesion susceptible cell,transmission interval,0.6423076923076922
virus adhesion susceptible cell,exotoxin disposition,0.6068627450980393
virus adhesion susceptible cell,infection start process boundary,0.6246031746031746
virus adhesion susceptible cell,action specification,0.6264705882352941
virus adhesion susceptible cell,infectious disease control objective specification,0.6475308641975309
virus adhesion susceptible cell,immune population,0.5958333333333333
virus adhesion susceptible cell,opportunistic infectious disposition,0.6291044776119403
virus adhesion susceptible cell,process of establishing viral infection,0.6214285714285714
virus adhesion susceptible cell,enterotoxin disposition,0.5981481481481481
virus adhesion susceptible cell,COVID-19 disease course,0.6537037037037037
virus adhesion susceptible cell,infectious disease incidence rate,0.66875
virus adhesion susceptible cell,disordered virus,0.598936170212766
virus adhesion susceptible cell,collective resistance disposition,0.621875
virus adhesion susceptible cell,adaptive immune response,0.6318181818181818
virus adhesion susceptible cell,fungistatic disposition,0.6166666666666667
virus adhesion susceptible cell,organism,0.5525641025641026
virus adhesion susceptible cell,virus uncoating stage,0.7
virus adhesion susceptible cell,local infection,0.5804347826086956
virus adhesion susceptible cell,establishment of a clinically abnormal colony,0.6210526315789474
virus adhesion susceptible cell,coronavirus disease,0.67
virus adhesion susceptible cell,positive-sense single-stranded RNA virus,0.5908450704225352
virus adhesion susceptible cell,adhesion factor,0.6891304347826087
virus adhesion susceptible cell,horizontal pathogen transmission process,0.6330985915492958
virus adhesion susceptible cell,hospital-acquired infection,0.6051724137931035
virus adhesion susceptible cell,pathogen death temporal region,0.6139344262295081
virus adhesion susceptible cell,emerging pathogen,0.5958333333333333
virus adhesion susceptible cell,pathogen transmission process,0.6333333333333333
virus adhesion susceptible cell,cell space,0.5963414634146341
passive immunization against infectious agent,information content entity,0.6753521126760563
passive immunization against infectious agent,infectious disease mortality rate,0.6294871794871795
passive immunization against infectious agent,infection incidence rate profile,0.6448051948051949
passive immunization against infectious agent,infectious structure aggregate,0.6633333333333334
passive immunization against infectious agent,communicability end temporal region,0.65
passive immunization against infectious agent,infection end temporal region,0.6391891891891892
passive immunization against infectious agent,infectious disease,0.6563492063492063
passive immunization against infectious agent,SARS-CoV-2 incidence rate,0.6214285714285714
passive immunization against infectious agent,incubation end temporal region,0.65
passive immunization against infectious agent,resistant entity,0.630327868852459
passive immunization against infectious agent,virulence factor disposition,0.6554794520547945
passive immunization against infectious agent,infectious disease incidence,0.6554794520547945
passive immunization against infectious agent,disease surveillance objective specification,0.652247191011236
passive immunization against infectious agent,infectious agent host role,0.6753521126760563
passive immunization against infectious agent,asymptomatic infectious structure carrier,0.6941860465116279
passive immunization against infectious agent,B cell receptor complex,0.5676470588235294
passive immunization against infectious agent,passive immunization against infectious agent,0.95
passive immunization against infectious agent,infection incidence rate,0.6673913043478261
passive immunization against infectious agent,double-stranded RNA virus,0.5785714285714285
passive immunization against infectious agent,infectious disease lifetime prevalence,0.6668674698795181
passive immunization against infectious agent,lower respiratory tract disease,0.6342105263157894
passive immunization against infectious agent,infectious disease incidence proportion,0.6523809523809524
passive immunization against infectious agent,acute infectious disease course,0.6736842105263158
passive immunization against infectious agent,cidal agent disposition,0.6411764705882353
passive immunization against infectious agent,infectious disorder,0.6375
passive immunization against infectious agent,biological vehicle,0.5769841269841269
passive immunization against infectious agent,infectious disease sporadicity,0.6366666666666667
passive immunization against infectious agent,communicability end process boundary,0.6351851851851852
passive immunization against infectious agent,directive information content entity,0.6969135802469135
passive immunization against infectious agent,infectious agent colony,0.6852941176470588
passive immunization against infectious agent,pathogen transporter,0.6192307692307693
passive immunization against infectious agent,invasion factor,0.6333333333333333
passive immunization against infectious agent,latency end process boundary,0.5869863013698631
passive immunization against infectious agent,infectious disease epidemic,0.6305555555555555
passive immunization against infectious agent,infectious agent generative stage,0.6935897435897437
passive immunization against infectious agent,disease transmission model,0.6330985915492958
passive immunization against infectious agent,negative-sense single-stranded RNA virus,0.6264705882352941
passive immunization against infectious agent,cidal agent,0.5928571428571429
passive immunization against infectious agent,infectious structure host role,0.6366666666666667
passive immunization against infectious agent,pathogen vehicle,0.6139344262295081
passive immunization against infectious agent,COVID-19 incidence rate,0.6117647058823529
passive immunization against infectious agent,pathogen vehicle role,0.6166666666666667
passive immunization against infectious agent,chronic infectious disease course,0.6679487179487179
passive immunization against infectious agent,asymptomatic infectious agent carrier,0.7426829268292683
passive immunization against infectious agent,descriptive information content entity,0.7030120481927711
passive immunization against infectious agent,COVID-19 epidemic,0.5467741935483871
passive immunization against infectious agent,sterilizing immunity to infectious agent,0.7911764705882354
passive immunization against infectious agent,diseased population,0.60625
passive immunization against infectious agent,virulence factor,0.5975409836065574
passive immunization against infectious agent,incubation end process boundary,0.6342105263157894
passive immunization against infectious agent,latency end temporal region,0.6166666666666667
passive immunization against infectious agent,innate immunity to infectious agent,0.8125
passive immunization against infectious agent,infectious structure,0.6346153846153847
passive immunization against infectious agent,static agent disposition,0.6673913043478261
passive immunization against infectious agent,T cell receptor complex,0.5823529411764706
passive immunization against infectious agent,asymptomatic carrier role,0.6357142857142857
passive immunization against infectious agent,infectious structure host,0.6357142857142857
passive immunization against infectious agent,infectious agent population,0.6722222222222223
passive immunization against infectious agent,respiratory system disease,0.6330985915492958
passive immunization against infectious agent,leukocyte-mediated immunity to infectious agent,0.7652173913043478
passive immunization against infectious agent,humoral immunity to infectious agent,0.795679012345679
passive immunization against infectious agent,infectious disease control strategy,0.6375
passive immunization against infectious agent,infectious disease pandemic,0.6444444444444444
passive immunization against infectious agent,infectious structure generative stage,0.6573170731707317
passive immunization against infectious agent,viral disease course,0.6346153846153847
passive immunization against infectious agent,passive immunity to infectious agent,0.869753086419753
passive immunization against infectious agent,infectious disposition,0.6440298507462687
passive immunization against infectious agent,vaccination against infectious agent,0.8574074074074073
passive immunization against infectious agent,susceptibility to infectious agent,0.7664556962025317
passive immunization against infectious agent,disease course,0.6194915254237288
passive immunization against infectious agent,infectious disease course,0.65
passive immunization against infectious agent,acquired immunity to infectious agent,0.8158536585365854
passive immunization against infectious agent,COVID-19 disease incidence proportion,0.6207317073170732
passive immunization against infectious agent,coronavirus disease course,0.6330985915492958
passive immunization against infectious agent,asymptomatic carrier,0.6346153846153847
passive immunization against infectious agent,biological vehicle role,0.5823529411764706
passive immunization against infectious agent,symptomatic infectious agent carrier,0.7339506172839506
passive immunization against infectious agent,intermediate host,0.6112903225806451
passive immunization against infectious agent,infectious disease prevalence,0.6391891891891892
passive immunization against infectious agent,infected population,0.60625
passive immunization against infectious agent,COVID-19 mortality rate,0.5970588235294118
passive immunization against infectious agent,viral disease,0.6051724137931035
passive immunization against infectious agent,disease,0.5461538461538461
passive immunization against infectious agent,symptomatic infectious structure carrier,0.6852941176470588
passive immunization against infectious agent,primary infectious disposition,0.6766666666666665
passive immunization against infectious agent,designative information content entity,0.7030120481927711
passive immunization against infectious agent,symptomatic carrier role,0.6239130434782608
passive immunization against infectious agent,infectious pathogen transmissibility,0.6475308641975309
passive immunization against infectious agent,intermediate host role,0.6291044776119403
passive immunization against infectious agent,infectious human pathogen,0.6642857142857143
passive immunization against infectious agent,immunization against infectious agent,0.901219512195122
passive immunization against infectious agent,infectious agent host,0.6924242424242425
passive immunization against infectious agent,long-term non-progressing infectious disease course,0.6791666666666666
passive immunization against infectious agent,viral disease epidemic,0.5992537313432835
passive immunization against infectious agent,viral disease pandemic,0.6141791044776119
passive immunization against infectious agent,symptomatic carrier,0.621875
passive immunization against infectious agent,infectious disease endemicity,0.6527027027027027
passive immunization against infectious agent,function,0.5820754716981132
passive immunization against infectious agent,herd immunity to infectious organism,0.7586419753086421
passive immunization against infectious agent,pathogen transporter role,0.6357142857142857
passive immunization against infectious agent,infectious agent reservoir,0.6753521126760563
passive immunization against infectious agent,COVID-19 pandemic,0.5629032258064516
passive immunization against infectious agent,action specification,0.6653846153846155
passive immunization against infectious agent,infectious disease control objective specification,0.6394736842105263
passive immunization against infectious agent,opportunistic infectious disposition,0.6845679012345678
passive immunization against infectious agent,polymerase chain reaction,0.6642857142857143
passive immunization against infectious agent,COVID-19 disease course,0.6117647058823529
passive immunization against infectious agent,infectious disease incidence rate,0.6551282051282051
passive immunization against infectious agent,single-stranded RNA retrovirus,0.6233333333333334
passive immunization against infectious agent,active immunization against infectious agent,0.9219101123595504
passive immunization against infectious agent,infectious agent,0.7122950819672131
passive immunization against infectious agent,establishment of a clinically abnormal colony,0.6166666666666667
passive immunization against infectious agent,coronavirus disease,0.60625
passive immunization against infectious agent,positive-sense single-stranded RNA virus,0.6382352941176471
passive immunization against infectious agent,adhesion factor,0.6166666666666667
passive immunization against infectious agent,drug susceptibility of infectious agent,0.7357142857142857
passive immunization against infectious agent,static agent,0.6605263157894737
susceptibility to infectious agent,information content entity,0.6333333333333333
susceptibility to infectious agent,infectious disease mortality rate,0.658955223880597
susceptibility to infectious agent,infection incidence rate profile,0.6318181818181818
susceptibility to infectious agent,infectious structure aggregate,0.684375
susceptibility to infectious agent,communicability end temporal region,0.6818840579710145
susceptibility to infectious agent,infection end temporal region,0.6404761904761905
susceptibility to infectious agent,infectious disease,0.7
susceptibility to infectious agent,SARS-CoV-2 incidence rate,0.6533898305084747
susceptibility to infectious agent,incubation end temporal region,0.621875
susceptibility to infectious agent,virulence factor disposition,0.6435483870967742
susceptibility to infectious agent,infectious disease incidence,0.6758064516129032
susceptibility to infectious agent,disease surveillance objective specification,0.6423076923076922
susceptibility to infectious agent,infectious agent host role,0.7166666666666667
susceptibility to infectious agent,asymptomatic infectious structure carrier,0.69
susceptibility to infectious agent,B cell receptor complex,0.6254385964912281
susceptibility to infectious agent,passive immunization against infectious agent,0.7664556962025317
susceptibility to infectious agent,infection incidence rate,0.656896551724138
susceptibility to infectious agent,drug susceptibility,0.7141509433962264
susceptibility to infectious agent,infectious disease lifetime prevalence,0.6444444444444444
susceptibility to infectious agent,lower respiratory tract disease,0.65
susceptibility to infectious agent,infectious disease incidence proportion,0.6554794520547945
susceptibility to infectious agent,acute infectious disease course,0.6961538461538461
susceptibility to infectious agent,cidal agent disposition,0.6429824561403508
susceptibility to infectious agent,infectious disorder,0.6764150943396227
susceptibility to infectious agent,biological vehicle,0.6038461538461539
susceptibility to infectious agent,infectious disease sporadicity,0.66875
susceptibility to infectious agent,communicability end process boundary,0.65
susceptibility to infectious agent,directive information content entity,0.65
susceptibility to infectious agent,infectious agent colony,0.730701754385965
susceptibility to infectious agent,pathogen transporter,0.5981481481481481
susceptibility to infectious agent,invasion factor,0.6132653061224489
susceptibility to infectious agent,latency end process boundary,0.5951612903225807
susceptibility to infectious agent,infectious disease epidemic,0.6631147540983606
susceptibility to infectious agent,infectious agent generative stage,0.6888059701492537
susceptibility to infectious agent,disease transmission model,0.6166666666666667
susceptibility to infectious agent,cidal agent,0.65
susceptibility to infectious agent,infectious structure host role,0.653125
susceptibility to infectious agent,pathogen vehicle,0.59
susceptibility to infectious agent,COVID-19 incidence rate,0.6254385964912281
susceptibility to infectious agent,pathogen vehicle role,0.5954545454545455
susceptibility to infectious agent,chronic infectious disease course,0.6888059701492537
susceptibility to infectious agent,asymptomatic infectious agent carrier,0.7457746478873238
susceptibility to infectious agent,descriptive information content entity,0.6722222222222223
susceptibility to infectious agent,COVID-19 epidemic,0.5676470588235294
susceptibility to infectious agent,sterilizing immunity to infectious agent,0.8148648648648649
susceptibility to infectious agent,diseased population,0.619811320754717
susceptibility to infectious agent,virulence factor,0.61
susceptibility to infectious agent,incubation end process boundary,0.6038461538461539
susceptibility to infectious agent,latency end temporal region,0.630327868852459
susceptibility to infectious agent,innate immunity to infectious agent,0.8123188405797102
susceptibility to infectious agent,infectious structure,0.6722222222222223
susceptibility to infectious agent,static agent disposition,0.6396551724137931
susceptibility to infectious agent,T cell receptor complex,0.6254385964912281
susceptibility to infectious agent,asymptomatic carrier role,0.6025423728813559
susceptibility to infectious agent,infectious structure host,0.6703389830508475
susceptibility to infectious agent,infectious agent population,0.7122950819672131
susceptibility to infectious agent,respiratory system disease,0.65
susceptibility to infectious agent,leukocyte-mediated immunity to infectious agent,0.795679012345679
susceptibility to infectious agent,humoral immunity to infectious agent,0.8071428571428573
susceptibility to infectious agent,infectious disease control strategy,0.6673913043478261
susceptibility to infectious agent,SARS-CoV-2 attachment stage,0.630327868852459
susceptibility to infectious agent,infectious disease pandemic,0.6795081967213115
susceptibility to infectious agent,infectious structure generative stage,0.6612676056338028
susceptibility to infectious agent,viral disease course,0.6351851851851852
susceptibility to infectious agent,passive immunity to infectious agent,0.8357142857142859
susceptibility to infectious agent,infectious disposition,0.6642857142857143
susceptibility to infectious agent,vaccination against infectious agent,0.7642857142857143
susceptibility to infectious agent,susceptibility,0.7416666666666667
susceptibility to infectious agent,susceptibility to infectious agent,0.95
susceptibility to infectious agent,disease course,0.6375
susceptibility to infectious agent,infectious disease course,0.6703389830508475
susceptibility to infectious agent,acquired immunity to infectious agent,0.8161971830985917
susceptibility to infectious agent,COVID-19 disease incidence proportion,0.6190140845070422
susceptibility to infectious agent,coronavirus disease course,0.6166666666666667
susceptibility to infectious agent,asymptomatic carrier,0.6166666666666667
susceptibility to infectious agent,biological vehicle role,0.6078947368421053
susceptibility to infectious agent,symptomatic infectious agent carrier,0.75
susceptibility to infectious agent,intermediate host,0.5872549019607843
susceptibility to infectious agent,infectious disease prevalence,0.6722222222222223
susceptibility to infectious agent,infected population,0.6386792452830189
susceptibility to infectious agent,COVID-19 mortality rate,0.6078947368421053
susceptibility to infectious agent,place closure control strategy,0.621875
susceptibility to infectious agent,viral disease,0.598936170212766
susceptibility to infectious agent,disease,0.5475609756097561
susceptibility to infectious agent,symptomatic infectious structure carrier,0.6932432432432433
susceptibility to infectious agent,primary infectious disposition,0.7
susceptibility to infectious agent,designative information content entity,0.6444444444444444
susceptibility to infectious agent,symptomatic carrier role,0.6051724137931035
susceptibility to infectious agent,infectious pathogen transmissibility,0.6785714285714286
susceptibility to infectious agent,intermediate host role,0.5928571428571429
susceptibility to infectious agent,infectious human pathogen,0.7042372881355932
susceptibility to infectious agent,immunization against infectious agent,0.7598591549295775
susceptibility to infectious agent,virus attachment stage,0.6285714285714286
susceptibility to infectious agent,infectious agent host,0.740909090909091
susceptibility to infectious agent,long-term non-progressing infectious disease course,0.6617647058823529
susceptibility to infectious agent,viral disease epidemic,0.5928571428571429
susceptibility to infectious agent,viral disease pandemic,0.6107142857142857
susceptibility to infectious agent,symptomatic carrier,0.619811320754717
susceptibility to infectious agent,infectious disease endemicity,0.6880952380952381
susceptibility to infectious agent,function,0.6166666666666667
susceptibility to infectious agent,herd immunity to infectious organism,0.7642857142857143
susceptibility to infectious agent,pathogen transporter role,0.5855932203389831
susceptibility to infectious agent,infectious agent reservoir,0.7166666666666667
susceptibility to infectious agent,COVID-19 pandemic,0.5676470588235294
susceptibility to infectious agent,action specification,0.6722222222222223
susceptibility to infectious agent,infectious disease control objective specification,0.6285714285714286
susceptibility to infectious agent,opportunistic infectious disposition,0.6928571428571427
susceptibility to infectious agent,polymerase chain reaction,0.6533898305084747
susceptibility to infectious agent,COVID-19 disease course,0.6254385964912281
susceptibility to infectious agent,infectious disease incidence rate,0.6738805970149254
susceptibility to infectious agent,active immunization against infectious agent,0.7705128205128204
susceptibility to infectious agent,infectious agent,0.77
susceptibility to infectious agent,establishment of a clinically abnormal colony,0.639873417721519
susceptibility to infectious agent,coronavirus disease,0.619811320754717
susceptibility to infectious agent,adhesion factor,0.6132653061224489
susceptibility to infectious agent,drug susceptibility of infectious agent,0.9020547945205479
susceptibility to infectious agent,static agent,0.6891304347826087
quality,communicability end temporal region,0.5928571428571429
quality,infection end temporal region,0.5333333333333333
quality,incubation end temporal region,0.5581081081081081
quality,virulence factor disposition,0.5642857142857143
quality,B cell receptor complex,0.5166666666666666
quality,appearance of disorder,0.5189655172413793
quality,communicability end process boundary,0.5895348837209302
quality,invasion factor,0.5863636363636363
quality,latency end process boundary,0.5357142857142857
quality,virulence factor,0.5804347826086956
quality,incubation end process boundary,0.5552631578947369
quality,latency end temporal region,0.5382352941176471
quality,virus adhesion susceptible cell,0.5552631578947369
quality,anatomical space,0.5369565217391304
quality,T cell receptor complex,0.5166666666666666
quality,facility,0.7833333333333333
quality,healthcare facility,0.6423076923076922
quality,cell,0.5409090909090909
quality,hospital facility,0.6583333333333334
quality,place closure control strategy,0.5581081081081081
quality,SARS-COV-2 adhesion susceptible cell,0.5197674418604651
quality,quality,0.95
quality,local infection,0.6318181818181818
quality,establishment of a clinically abnormal colony,0.5461538461538461
quality,adhesion factor,0.5863636363636363
quality,cell space,0.5088235294117647
virophage,virophage,0.95
virophage,establishment of a clinically abnormal colony,0.5055555555555555
latency end temporal region,infectious disease mortality rate,0.6666666666666667
latency end temporal region,infection incidence rate profile,0.6533898305084747
latency end temporal region,communicability end temporal region,0.8209677419354838
latency end temporal region,infection end temporal region,0.8428571428571427
latency end temporal region,SARS-CoV-2 incidence rate,0.6230769230769231
latency end temporal region,incubation end temporal region,0.8535087719298246
latency end temporal region,two-dimensional spatial region,0.7131578947368421
latency end temporal region,one-dimensional temporal region,0.7775862068965518
latency end temporal region,temporal region,0.8071428571428573
latency end temporal region,disease surveillance objective specification,0.6330985915492958
latency end temporal region,material entity,0.6642857142857143
latency end temporal region,B cell receptor complex,0.63
latency end temporal region,infection incidence rate,0.6264705882352941
latency end temporal region,double-stranded RNA virus,0.6423076923076922
latency end temporal region,pathogen birth temporal region,0.8184210526315789
latency end temporal region,lower respiratory tract disease,0.6224137931034482
latency end temporal region,infectious disease incidence proportion,0.6469696969696969
latency end temporal region,acute infectious disease course,0.656896551724138
latency end temporal region,communicability end process boundary,0.6563492063492063
latency end temporal region,infection incidence proportion profile,0.6346153846153847
latency end temporal region,SARS-CoV-2 incidence proportion,0.656896551724138
latency end temporal region,spatiotemporal region,0.8041666666666667
latency end temporal region,latency end process boundary,0.759090909090909
latency end temporal region,negative-sense single-stranded RNA virus,0.6440298507462687
latency end temporal region,COVID-19 incidence rate,0.61
latency end temporal region,zero-dimensional spatial region,0.6913793103448276
latency end temporal region,zero-dimensional temporal region,0.7720338983050847
latency end temporal region,chronic infectious disease course,0.6166666666666667
latency end temporal region,latency interval,0.7755813953488372
latency end temporal region,infection start temporal region,0.7775862068965518
latency end temporal region,establishment of localization in human host,0.6071428571428572
latency end temporal region,incubation end process boundary,0.6741379310344828
latency end temporal region,pathogen death process boundary,0.6741379310344828
latency end temporal region,geographical region,0.7108695652173913
latency end temporal region,latency end temporal region,0.95
latency end temporal region,virus adhesion susceptible cell,0.6051724137931035
latency end temporal region,T cell receptor complex,0.65
latency end temporal region,communicability interval,0.6460784313725491
latency end temporal region,viral disease course,0.6202127659574468
latency end temporal region,three-dimensional spatial region,0.7042372881355932
latency end temporal region,cell,0.5467741935483871
latency end temporal region,objective specification,0.63
latency end temporal region,country,0.5676470588235294
latency end temporal region,disease course,0.5963414634146341
latency end temporal region,infectious disease course,0.6230769230769231
latency end temporal region,COVID-19 disease incidence proportion,0.653125
latency end temporal region,coronavirus disease course,0.6009433962264151
latency end temporal region,infection incidence proportion,0.6605263157894737
latency end temporal region,incubation interval,0.6673913043478261
latency end temporal region,COVID-19 mortality rate,0.67
latency end temporal region,place closure control strategy,0.6780701754385965
latency end temporal region,SARS-COV-2 adhesion susceptible cell,0.6246031746031746
latency end temporal region,eclipse interval,0.6593023255813953
latency end temporal region,incubation start process boundary,0.6333333333333333
latency end temporal region,object,0.5409090909090909
latency end temporal region,pathogen birth process boundary,0.6396551724137931
latency end temporal region,infectious human pathogen,0.6230769230769231
latency end temporal region,colonization of human,0.6375
latency end temporal region,object aggregate,0.6127906976744186
latency end temporal region,long-term non-progressing infectious disease course,0.6166666666666667
latency end temporal region,communicability start temporal region,0.7625
latency end temporal region,geospatial region,0.7
latency end temporal region,division of geopolitical entity,0.6396551724137931
latency end temporal region,transmission interval,0.6375
latency end temporal region,infection start process boundary,0.6364406779661017
latency end temporal region,action specification,0.6414893617021277
latency end temporal region,processed material,0.65
latency end temporal region,latency start process boundary,0.7131578947368421
latency end temporal region,infectious disease control objective specification,0.6188311688311688
latency end temporal region,COVID-19 disease course,0.61
latency end temporal region,infectious disease incidence rate,0.6166666666666667
latency end temporal region,communicability start process boundary,0.6192307692307693
latency end temporal region,process that results in death,0.6285714285714286
latency end temporal region,single-stranded RNA retrovirus,0.6605263157894737
latency end temporal region,local infection,0.6642857142857143
latency end temporal region,establishment of a clinically abnormal colony,0.6444444444444444
latency end temporal region,process boundary,0.5895348837209302
latency end temporal region,positive-sense single-stranded RNA virus,0.6291044776119403
latency end temporal region,one-dimensional spatial region,0.6956140350877194
latency end temporal region,spatial region,0.7182926829268292
latency end temporal region,pathogen death temporal region,0.8359649122807017
latency end temporal region,cell space,0.6121621621621621
latency end temporal region,material processing,0.6891304347826087
planned process,immune response,0.6833333333333332
planned process,infectious disease mortality rate,0.575
planned process,infection incidence rate profile,0.6202127659574468
planned process,communicability end temporal region,0.59
planned process,pathogen generative stage,0.65
planned process,surveillance process,0.7928571428571428
planned process,infection end temporal region,0.6318181818181818
planned process,SARS-CoV-2 incidence rate,0.625
planned process,incubation end temporal region,0.6277777777777778
planned process,virus translation stage,0.581578947368421
planned process,case isolation control strategy,0.6021739130434782
planned process,virus release stage,0.5970588235294118
planned process,B cell receptor complex,0.6078947368421053
planned process,infection incidence rate,0.6038461538461539
planned process,virus transcription stage,0.575
planned process,virus generative stage,0.5851351351351352
planned process,acute infectious disease course,0.6021739130434782
planned process,process,0.7681818181818181
planned process,droplet pathogen transmission process,0.7
planned process,communicability end process boundary,0.6656862745098039
planned process,latency end process boundary,0.7523255813953489
planned process,infectious agent generative stage,0.5958333333333333
planned process,COVID-19 incidence rate,0.6078947368421053
planned process,negative regulation of developmental process,0.6533898305084747
planned process,chronic infectious disease course,0.5958333333333333
planned process,process of establishing an infection,0.5872549019607843
planned process,incubation end process boundary,0.7108695652173913
planned process,SARS-CoV-2 uncoating stage,0.5719512195121951
planned process,pathogen death process boundary,0.7108695652173913
planned process,plan specification,0.6621212121212122
planned process,definitive host role,0.6214285714285714
planned process,latency end temporal region,0.6642857142857143
planned process,SARS-CoV-2 penetration stage,0.5895348837209302
planned process,T cell receptor complex,0.6078947368421053
planned process,respiratory system disease,0.6207317073170732
planned process,indirect pathogen transmission process,0.6764150943396227
planned process,planned process,0.95
planned process,generative stage,0.6112903225806451
planned process,SARS-CoV-2 attachment stage,0.5928571428571429
planned process,infectious structure generative stage,0.5846153846153846
planned process,innate immune response,0.6662162162162162
planned process,viral disease course,0.6214285714285714
planned process,disease course,0.6224137931034482
planned process,infectious disease course,0.6
planned process,coronavirus disease course,0.5719512195121951
planned process,SARS-CoV-2 genome replication stage,0.59
planned process,COVID-19 mortality rate,0.5552631578947369
planned process,process profile,0.6833333333333332
planned process,negative regulation of life-sustaining process,0.6467213114754098
planned process,developmental process,0.7277777777777777
planned process,biological process,0.7530303030303032
planned process,humoral immune response,0.6605263157894737
planned process,incubation start process boundary,0.6583333333333334
planned process,pathogen birth process boundary,0.6891304347826087
planned process,virus attachment stage,0.5581081081081081
planned process,negative regulation of immune response,0.6386792452830189
planned process,SARS-CoV-2 transcription stage,0.5611111111111111
planned process,virus synthesis stage,0.5611111111111111
planned process,long-term non-progressing infectious disease course,0.6166666666666667
planned process,blood,0.55
planned process,virus penetration stage,0.6078947368421053
planned process,algorithm,0.5333333333333333
planned process,negative regulation of viral process,0.6656862745098039
planned process,contact pathogen transmission process,0.6807692307692308
planned process,function,0.5369565217391304
planned process,symbiotic process,0.7
planned process,infection start process boundary,0.6627659574468084
planned process,action specification,0.5928571428571429
planned process,SARS-CoV-2 synthesis stage,0.5963414634146341
planned process,latency start process boundary,0.6944444444444444
planned process,process of establishing viral infection,0.5796296296296296
planned process,negative regulation of biological process,0.6464285714285714
planned process,polymerase chain reaction,0.625
planned process,COVID-19 disease course,0.581578947368421
planned process,infectious disease incidence rate,0.5958333333333333
planned process,communicability start process boundary,0.6386792452830189
planned process,process that results in death,0.609090909090909
planned process,adaptive immune response,0.6551282051282051
planned process,virus uncoating stage,0.5611111111111111
planned process,establishment of a clinically abnormal colony,0.55
planned process,process boundary,0.6758064516129032
planned process,definitive host,0.6166666666666667
planned process,horizontal pathogen transmission process,0.6681818181818181
planned process,SARS-CoV-2 release stage,0.6038461538461539
planned process,pathogen transmission process,0.7227272727272727
single-stranded DNA virus,extended organism,0.6880952380952381
single-stranded DNA virus,ribonucleic acid,0.6207317073170732
single-stranded DNA virus,virus aggregate,0.575
single-stranded DNA virus,source of infection,0.5863636363636363
single-stranded DNA virus,virostatic disposition,0.6202127659574468
single-stranded DNA virus,zoonotic disposition,0.5833333333333334
single-stranded DNA virus,immune response,0.625
single-stranded DNA virus,infectious disease mortality rate,0.6224137931034482
single-stranded DNA virus,infection incidence rate profile,0.6429824561403508
single-stranded DNA virus,communicability end temporal region,0.6
single-stranded DNA virus,pathogen generative stage,0.61
single-stranded DNA virus,pathogen portal of entry,0.5928571428571429
single-stranded DNA virus,subclinical coronavirus infection,0.656896551724138
single-stranded DNA virus,primary pathogen,0.5719512195121951
single-stranded DNA virus,infection end temporal region,0.6537037037037037
single-stranded DNA virus,deoxyribonucleic acid,0.6021739130434782
single-stranded DNA virus,drug-based immunosuppressed organism,0.630327868852459
single-stranded DNA virus,infectious disease,0.636046511627907
single-stranded DNA virus,double-stranded DNA virus,0.87
single-stranded DNA virus,incubation end temporal region,0.6318181818181818
single-stranded DNA virus,site of infection,0.6166666666666667
single-stranded DNA virus,double-stranded DNA,0.7909090909090909
single-stranded DNA virus,immunocompetent organism,0.6336734693877552
single-stranded DNA virus,virulence factor disposition,0.6386792452830189
single-stranded DNA virus,pathogen portal of exit,0.5958333333333333
single-stranded DNA virus,viral adhesion disposition,0.6264705882352941
single-stranded DNA virus,parasitostatic disposition,0.6264705882352941
single-stranded DNA virus,infectious disease incidence,0.619811320754717
single-stranded DNA virus,reservoir of pathogen role,0.6068627450980393
single-stranded DNA virus,reverse zoonotic disposition,0.6009433962264151
single-stranded DNA virus,subclinical SARS-CoV-2 infection,0.6078947368421053
single-stranded DNA virus,virus translation stage,0.6375
single-stranded DNA virus,disease surveillance objective specification,0.5949275362318841
single-stranded DNA virus,virus release stage,0.609090909090909
single-stranded DNA virus,source of infection site,0.6132653061224489
single-stranded DNA virus,virus,0.6166666666666667
single-stranded DNA virus,virus replication,0.5928571428571429
single-stranded DNA virus,B cell receptor complex,0.5541666666666667
single-stranded DNA virus,systematic infection,0.6055555555555556
single-stranded DNA virus,infection incidence rate,0.6540816326530612
single-stranded DNA virus,virus host,0.5928571428571429
single-stranded DNA virus,double-stranded RNA virus,0.85
single-stranded DNA virus,pathogen portal of entry role,0.5981481481481481
single-stranded DNA virus,virus transcription stage,0.63
single-stranded DNA virus,infectious disease lifetime prevalence,0.6087301587301588
single-stranded DNA virus,toxin disposition,0.5928571428571429
single-stranded DNA virus,pathogen birth temporal region,0.5772727272727273
single-stranded DNA virus,lower respiratory tract disease,0.6285714285714286
single-stranded DNA virus,infectious disease incidence proportion,0.621875
single-stranded DNA virus,opportunistic pathogen,0.5776595744680851
single-stranded DNA virus,virus generative stage,0.6202127659574468
single-stranded DNA virus,acute infectious disease course,0.6285714285714286
single-stranded DNA virus,cidal agent disposition,0.6166666666666667
single-stranded DNA virus,infectious disorder,0.6318181818181818
single-stranded DNA virus,genetic resistance to pathogen,0.6136363636363636
single-stranded DNA virus,subclinical infection,0.6021739130434782
single-stranded DNA virus,appearance of disorder,0.6414893617021277
single-stranded DNA virus,simple infection,0.6207317073170732
single-stranded DNA virus,droplet pathogen transmission process,0.6112903225806451
single-stranded DNA virus,parasiticidal disposition,0.61
single-stranded DNA virus,infectious disease sporadicity,0.6136363636363636
single-stranded DNA virus,communicability end process boundary,0.6139344262295081
single-stranded DNA virus,infection incidence proportion profile,0.6246031746031746
single-stranded DNA virus,pathogen transporter,0.6277777777777778
single-stranded DNA virus,transmissibility disposition,0.6009433962264151
single-stranded DNA virus,latency end process boundary,0.619811320754717
single-stranded DNA virus,infectious disease epidemic,0.6230769230769231
single-stranded DNA virus,disease transmission model,0.6264705882352941
single-stranded DNA virus,endotoxin disposition,0.6021739130434782
single-stranded DNA virus,pathologically immunosuppressed organism,0.6038461538461539
single-stranded DNA virus,negative-sense single-stranded RNA virus,0.8192307692307693
single-stranded DNA virus,pathogen vehicle,0.5963414634146341
single-stranded DNA virus,cytotoxin disposition,0.5804347826086956
single-stranded DNA virus,community-acquired infection,0.6009433962264151
single-stranded DNA virus,pathogen vector,0.6
single-stranded DNA virus,pathogen vehicle role,0.6021739130434782
single-stranded DNA virus,chronic infectious disease course,0.6224137931034482
single-stranded DNA virus,nursing-home acquired infection,0.6464285714285714
single-stranded DNA virus,COVID-19 epidemic,0.569047619047619
single-stranded DNA virus,secondary infection,0.609090909090909
single-stranded DNA virus,nucleic acid,0.6121621621621621
single-stranded DNA virus,infection start temporal region,0.6285714285714286
single-stranded DNA virus,infection incidence,0.6318181818181818
single-stranded DNA virus,virus disorder,0.6294871794871795
single-stranded DNA virus,primary infection,0.569047619047619
single-stranded DNA virus,process of establishing an infection,0.6139344262295081
single-stranded DNA virus,incubation end process boundary,0.6285714285714286
single-stranded DNA virus,SARS-CoV-2 disorder,0.609090909090909
single-stranded DNA virus,collective pathogenic disposition,0.6051724137931035
single-stranded DNA virus,neurotoxin disposition,0.6202127659574468
single-stranded DNA virus,pathogen death process boundary,0.6107142857142857
single-stranded DNA virus,immunosuppressed organism,0.65
single-stranded DNA virus,latency end temporal region,0.6230769230769231
single-stranded DNA virus,virus adhesion susceptible cell,0.6107142857142857
single-stranded DNA virus,collective disposition,0.6202127659574468
single-stranded DNA virus,infection,0.5970588235294118
single-stranded DNA virus,static agent disposition,0.6336734693877552
single-stranded DNA virus,T cell receptor complex,0.5541666666666667
single-stranded DNA virus,respiratory system disease,0.6264705882352941
single-stranded DNA virus,indirect pathogen transmission process,0.6404761904761905
single-stranded DNA virus,organism population,0.5863636363636363
single-stranded DNA virus,infectious disease control strategy,0.6166666666666667
single-stranded DNA virus,infectious disease pandemic,0.6230769230769231
single-stranded DNA virus,immunosuppressive disposition,0.6166666666666667
single-stranded DNA virus,innate immune response,0.6414893617021277
single-stranded DNA virus,pathogenic disposition,0.598936170212766
single-stranded DNA virus,viral disease course,0.65
single-stranded DNA virus,intracellular infection,0.6375
single-stranded DNA virus,secondary infection role,0.6132653061224489
single-stranded DNA virus,metastatic infection,0.6055555555555556
single-stranded DNA virus,infectious disposition,0.6202127659574468
single-stranded DNA virus,acute infection,0.575
single-stranded DNA virus,bacteriostatic disposition,0.6068627450980393
single-stranded DNA virus,immunity to pathogen,0.5833333333333334
single-stranded DNA virus,bactericidal disposition,0.5928571428571429
single-stranded DNA virus,source of infection role,0.6132653061224489
single-stranded DNA virus,pathogen host,0.581578947368421
single-stranded DNA virus,acquired immunodeficiency,0.59
single-stranded DNA virus,chronic infection,0.569047619047619
single-stranded DNA virus,invasion disposition,0.6277777777777778
single-stranded DNA virus,disease course,0.6294871794871795
single-stranded DNA virus,infectious disease course,0.65
single-stranded DNA virus,viricidal disposition,0.6021739130434782
single-stranded DNA virus,acquired immunity to infectious agent,0.6112903225806451
single-stranded DNA virus,complex infection,0.569047619047619
single-stranded DNA virus,COVID-19 disease incidence proportion,0.6112903225806451
single-stranded DNA virus,coronavirus disease course,0.6068627450980393
single-stranded DNA virus,infection incidence proportion,0.6318181818181818
single-stranded DNA virus,respiratory droplet virus fomite,0.6605263157894737
single-stranded DNA virus,susceptible organism,0.65
single-stranded DNA virus,pathogen vector role,0.5833333333333334
single-stranded DNA virus,pathogen portal of exit site,0.6009433962264151
single-stranded DNA virus,infectious disease prevalence,0.6166666666666667
single-stranded DNA virus,organism substance,0.5895348837209302
single-stranded DNA virus,disposition,0.5611111111111111
single-stranded DNA virus,single-stranded DNA virus,0.95
single-stranded DNA virus,viral disease,0.6342105263157894
single-stranded DNA virus,primary infection role,0.598936170212766
single-stranded DNA virus,adhesion disposition,0.6055555555555556
single-stranded DNA virus,pathogen portal of entry site,0.5981481481481481
single-stranded DNA virus,infection incidence profile,0.6423076923076922
single-stranded DNA virus,disease,0.60625
single-stranded DNA virus,primary infectious disposition,0.5954545454545455
single-stranded DNA virus,pathogen host role,0.5895348837209302
single-stranded DNA virus,infection prevalence,0.6277777777777778
single-stranded DNA virus,double-stranded DNA retrovirus,0.8318181818181819
single-stranded DNA virus,humoral immune response,0.5958333333333333
single-stranded DNA virus,coronavirus disorder,0.6277777777777778
single-stranded DNA virus,infectious pathogen transmissibility,0.6139344262295081
single-stranded DNA virus,pathogen surveillance,0.6021739130434782
single-stranded DNA virus,immunodeficient organism,0.6336734693877552
single-stranded DNA virus,pathogen,0.5409090909090909
single-stranded DNA virus,pathogen birth process boundary,0.6107142857142857
single-stranded DNA virus,infectious human pathogen,0.61
single-stranded DNA virus,subclinical virus infection,0.6423076923076922
single-stranded DNA virus,resistance to pathogen,0.6414893617021277
single-stranded DNA virus,establishment of localization in virus host,0.6558823529411765
single-stranded DNA virus,virus attachment stage,0.6202127659574468
single-stranded DNA virus,negative regulation of immune response,0.6246031746031746
single-stranded DNA virus,virus synthesis stage,0.6021739130434782
single-stranded DNA virus,SARS-COV-2 adhesion disposition,0.6107142857142857
single-stranded DNA virus,pathogen portal of exit role,0.6009433962264151
single-stranded DNA virus,invasive disposition,0.6277777777777778
single-stranded DNA virus,re-emerging pathogen,0.5833333333333334
single-stranded DNA virus,long-term non-progressing infectious disease course,0.6210526315789474
single-stranded DNA virus,viral disease epidemic,0.6202127659574468
single-stranded DNA virus,fungicidal disposition,0.598936170212766
single-stranded DNA virus,viral disease pandemic,0.6414893617021277
single-stranded DNA virus,virus penetration stage,0.6375
single-stranded DNA virus,pathogen seroprevalence,0.5958333333333333
single-stranded DNA virus,acute respiratory distress syndrome,0.6
single-stranded DNA virus,infectious disease endemicity,0.6166666666666667
single-stranded DNA virus,contact pathogen transmission process,0.6274193548387097
single-stranded DNA virus,disorder,0.6318181818181818
single-stranded DNA virus,herd immunity to infectious organism,0.5975409836065574
single-stranded DNA virus,extracellular infection,0.6166666666666667
single-stranded DNA virus,pathogen transporter role,0.63
single-stranded DNA virus,transmission interval,0.6239130434782608
single-stranded DNA virus,exotoxin disposition,0.6055555555555556
single-stranded DNA virus,infection start process boundary,0.6429824561403508
single-stranded DNA virus,infectious disease control objective specification,0.5966666666666667
single-stranded DNA virus,immune population,0.5928571428571429
single-stranded DNA virus,opportunistic infectious disposition,0.5975409836065574
single-stranded DNA virus,process of establishing viral infection,0.60625
single-stranded DNA virus,enterotoxin disposition,0.6166666666666667
single-stranded DNA virus,COVID-19 disease course,0.6166666666666667
single-stranded DNA virus,infectious disease incidence rate,0.6396551724137931
single-stranded DNA virus,single-stranded RNA retrovirus,0.8863636363636362
single-stranded DNA virus,disordered virus,0.7426829268292683
single-stranded DNA virus,collective resistance disposition,0.6396551724137931
single-stranded DNA virus,adaptive immune response,0.6132653061224489
single-stranded DNA virus,fungistatic disposition,0.6375
single-stranded DNA virus,organism,0.6015151515151516
single-stranded DNA virus,virus uncoating stage,0.6239130434782608
single-stranded DNA virus,local infection,0.575
single-stranded DNA virus,establishment of a clinically abnormal colony,0.5928571428571429
single-stranded DNA virus,coronavirus disease,0.6318181818181818
single-stranded DNA virus,positive-sense single-stranded RNA virus,0.8192307692307693
single-stranded DNA virus,horizontal pathogen transmission process,0.6346153846153847
single-stranded DNA virus,hospital-acquired infection,0.6423076923076922
single-stranded DNA virus,pathogen death temporal region,0.6136363636363636
single-stranded DNA virus,emerging pathogen,0.5928571428571429
single-stranded DNA virus,pathogen transmission process,0.6351851851851852
disorder,virostatic disposition,0.5833333333333334
disorder,zoonotic disposition,0.5928571428571429
disorder,infectious disease mortality rate,0.5963414634146341
disorder,infectious disease,0.6038461538461539
disorder,virulence factor disposition,0.5611111111111111
disorder,viral adhesion disposition,0.5676470588235294
disorder,parasitostatic disposition,0.5676470588235294
disorder,infectious disease incidence,0.5888888888888889
disorder,reverse zoonotic disposition,0.5611111111111111
disorder,establishment of localization in host,0.5166666666666666
disorder,disease surveillance objective specification,0.5461538461538461
disorder,infectious agent host role,0.5970588235294118
disorder,B cell receptor complex,0.5467741935483871
disorder,colonized host,0.5409090909090909
disorder,virus host,0.6166666666666667
disorder,infectious disease lifetime prevalence,0.558695652173913
disorder,toxin disposition,0.61
disorder,lower respiratory tract disease,0.5782051282051281
disorder,infectious disease incidence proportion,0.5776595744680851
disorder,acute infectious disease course,0.6038461538461539
disorder,cidal agent disposition,0.5790322580645162
disorder,infectious disorder,0.7462962962962962
disorder,appearance of disorder,0.7166666666666667
disorder,parasiticidal disposition,0.5712121212121213
disorder,infectious disease sporadicity,0.6078947368421053
disorder,transmissibility disposition,0.5611111111111111
disorder,colonization of host,0.5214285714285714
disorder,infectious disease epidemic,0.5928571428571429
disorder,disease transmission model,0.6264705882352941
disorder,endotoxin disposition,0.5879310344827586
disorder,infectious structure host role,0.581578947368421
disorder,cytotoxin disposition,0.5879310344827586
disorder,host,0.5333333333333333
disorder,chronic infectious disease course,0.5963414634146341
disorder,virus disorder,0.8136363636363637
disorder,establishment of localization in human host,0.5088235294117647
disorder,diseased population,0.5981481481481481
disorder,SARS-CoV-2 disorder,0.7462962962962962
disorder,collective pathogenic disposition,0.5475609756097561
disorder,neurotoxin disposition,0.5833333333333334
disorder,dead-end host role,0.6038461538461539
disorder,definitive host role,0.6285714285714286
disorder,collective disposition,0.5833333333333334
disorder,static agent disposition,0.575
disorder,T cell receptor complex,0.5467741935483871
disorder,infectious structure host,0.5712121212121213
disorder,respiratory system disease,0.5970588235294118
disorder,entry into host,0.5369565217391304
disorder,adhesion of symbiont to host,0.5611111111111111
disorder,infectious disease control strategy,0.5895348837209302
disorder,infectious disease pandemic,0.5928571428571429
disorder,immunosuppressive disposition,0.5581081081081081
disorder,pathogenic disposition,0.5833333333333334
disorder,viral disease course,0.6642857142857143
disorder,entry into host through host barriers,0.5833333333333334
disorder,infectious disposition,0.5833333333333334
disorder,bacteriostatic disposition,0.5676470588235294
disorder,bactericidal disposition,0.575
disorder,pathogen host,0.5452380952380953
disorder,invasion disposition,0.5928571428571429
disorder,disease course,0.7227272727272727
disorder,infectious disease course,0.6318181818181818
disorder,viricidal disposition,0.5879310344827586
disorder,COVID-19 disease incidence proportion,0.5833333333333334
disorder,coronavirus disease course,0.6264705882352941
disorder,intermediate host,0.61
disorder,infectious disease prevalence,0.5851351351351352
disorder,disposition,0.6605263157894737
disorder,viral disease,0.6404761904761905
disorder,adhesion disposition,0.5928571428571429
disorder,disease,0.7166666666666667
disorder,primary infectious disposition,0.5552631578947369
disorder,pathogen host role,0.5653846153846154
disorder,coronavirus disorder,0.7357142857142857
disorder,intermediate host role,0.6166666666666667
disorder,dead-end host,0.5928571428571429
disorder,host role,0.6264705882352941
disorder,establishment of localization in virus host,0.5284313725490196
disorder,SARS-COV-2 adhesion disposition,0.5525641025641026
disorder,invasive disposition,0.5928571428571429
disorder,infectious agent host,0.553448275862069
disorder,long-term non-progressing infectious disease course,0.5516949152542373
disorder,viral disease epidemic,0.6166666666666667
disorder,fungicidal disposition,0.5833333333333334
disorder,viral disease pandemic,0.6166666666666667
disorder,acute respiratory distress syndrome,0.5895348837209302
disorder,infectious disease endemicity,0.5851351351351352
disorder,disorder,0.95
disorder,exotoxin disposition,0.5928571428571429
disorder,infectious disease control objective specification,0.553448275862069
disorder,symbiont host role,0.6038461538461539
disorder,opportunistic infectious disposition,0.5409090909090909
disorder,enterotoxin disposition,0.5790322580645162
disorder,COVID-19 disease course,0.6435483870967742
disorder,infectious disease incidence rate,0.5963414634146341
disorder,collective resistance disposition,0.5475609756097561
disorder,fungistatic disposition,0.5790322580645162
disorder,establishment of a clinically abnormal colony,0.5254716981132076
disorder,coronavirus disease,0.5981481481481481
disorder,definitive host,0.5804347826086956
disorder,static agent,0.55
cell space,extended organism,0.5611111111111111
cell space,infectious disease mortality rate,0.5895348837209302
cell space,infection incidence rate profile,0.569047619047619
cell space,drug-based immunosuppressed organism,0.558695652173913
cell space,geospatial location,0.6224137931034482
cell space,SARS-CoV-2 incidence rate,0.5928571428571429
cell space,immunocompetent organism,0.5676470588235294
cell space,case isolation control strategy,0.6451219512195122
cell space,B cell receptor complex,0.6924242424242425
cell space,infection incidence rate,0.5970588235294118
cell space,lower respiratory tract disease,0.6207317073170732
cell space,communicability end process boundary,0.5804347826086956
cell space,latency end process boundary,0.6078947368421053
cell space,pathologically immunosuppressed organism,0.59
cell space,COVID-19 incidence rate,0.6015151515151516
cell space,latency interval,0.6038461538461539
cell space,incubation end process boundary,0.5963414634146341
cell space,pathogen death process boundary,0.5719512195121951
cell space,immunosuppressed organism,0.5357142857142857
cell space,virus adhesion susceptible cell,0.5963414634146341
cell space,anatomical space,0.7576923076923078
cell space,T cell receptor complex,0.6924242424242425
cell space,organism population,0.553448275862069
cell space,communicability interval,0.5676470588235294
cell space,cell,0.7357142857142857
cell space,susceptible organism,0.6166666666666667
cell space,organism substance,0.6285714285714286
cell space,incubation interval,0.553448275862069
cell space,COVID-19 mortality rate,0.6015151515151516
cell space,place closure control strategy,0.65
cell space,SARS-COV-2 adhesion susceptible cell,0.6021739130434782
cell space,eclipse interval,0.6038461538461539
cell space,incubation start process boundary,0.5895348837209302
cell space,immunodeficient organism,0.5676470588235294
cell space,pathogen birth process boundary,0.5719512195121951
cell space,division of geopolitical entity,0.5719512195121951
cell space,herd immunity to infectious organism,0.5369565217391304
cell space,transmission interval,0.5145161290322581
cell space,infection start process boundary,0.5928571428571429
cell space,latency start process boundary,0.6
cell space,quality,0.5088235294117647
cell space,infectious disease incidence rate,0.5895348837209302
cell space,communicability start process boundary,0.5958333333333333
cell space,organism,0.5055555555555555
cell space,local infection,0.61
cell space,establishment of a clinically abnormal colony,0.5590909090909091
cell space,process boundary,0.6038461538461539
cell space,cell space,0.95
function,infectious disease mortality rate,0.5719512195121951
function,infection incidence rate profile,0.6
function,SARS-CoV-2 incidence rate,0.5712121212121213
function,site of infection,0.73
function,reservoir of pathogen role,0.5676470588235294
function,disease surveillance objective specification,0.5846153846153846
function,infectious agent host role,0.6264705882352941
function,source of infection site,0.66875
function,B cell receptor complex,0.5467741935483871
function,infection incidence rate,0.6375
function,pathogen portal of entry role,0.5581081081081081
function,role,0.5333333333333333
function,appearance of disorder,0.5833333333333334
function,mutualist role,0.6318181818181818
function,infectious structure host role,0.581578947368421
function,COVID-19 incidence rate,0.5790322580645162
function,pathogen vehicle role,0.553448275862069
function,mechanical vector role,0.5833333333333334
function,dead-end host role,0.5653846153846154
function,definitive host role,0.6285714285714286
function,T cell receptor complex,0.5467741935483871
function,asymptomatic carrier role,0.5409090909090909
function,secondary infection role,0.6375
function,objective specification,0.6435483870967742
function,epitope site,0.55
function,source of infection role,0.66875
function,biological vehicle role,0.5467741935483871
function,symbiont role,0.5928571428571429
function,parasite role,0.5452380952380953
function,pathogen vector role,0.5928571428571429
function,pathogen portal of exit site,0.5333333333333333
function,COVID-19 mortality rate,0.5467741935483871
function,primary infection role,0.65
function,biological role,0.5369565217391304
function,pathogen portal of entry site,0.5581081081081081
function,biological vector role,0.55
function,site,0.5333333333333333
function,pathogen host role,0.5653846153846154
function,symptomatic carrier role,0.54375
function,object,0.5928571428571429
function,intermediate host role,0.5833333333333334
function,host role,0.5676470588235294
function,object aggregate,0.5333333333333333
function,pathogen portal of exit role,0.5611111111111111
function,commensal role,0.5863636363636363
function,epitope role,0.55
function,function,0.95
function,pathogen transporter role,0.5409090909090909
function,antigen role,0.65
function,action specification,0.6642857142857143
function,infectious disease control objective specification,0.5879310344827586
function,symbiont host role,0.5653846153846154
function,fomite role,0.6078947368421053
function,infectious disease incidence rate,0.5963414634146341
function,reagent role,0.6
function,establishment of a clinically abnormal colony,0.5443396226415094
asymptomatic infectious structure carrier,virostatic disposition,0.6404761904761905
asymptomatic infectious structure carrier,zoonotic disposition,0.6139344262295081
asymptomatic infectious structure carrier,infectious disease mortality rate,0.6797297297297297
asymptomatic infectious structure carrier,infection incidence rate profile,0.6691780821917809
asymptomatic infectious structure carrier,infectious structure aggregate,0.7880281690140845
asymptomatic infectious structure carrier,communicability end temporal region,0.6078947368421053
asymptomatic infectious structure carrier,infection end temporal region,0.65
asymptomatic infectious structure carrier,infectious disease,0.7042372881355932
asymptomatic infectious structure carrier,SARS-CoV-2 incidence rate,0.6469696969696969
asymptomatic infectious structure carrier,incubation end temporal region,0.6190140845070422
asymptomatic infectious structure carrier,virulence factor disposition,0.6094202898550725
asymptomatic infectious structure carrier,viral adhesion disposition,0.5843283582089552
asymptomatic infectious structure carrier,parasitostatic disposition,0.658955223880597
asymptomatic infectious structure carrier,infectious disease incidence,0.696376811594203
asymptomatic infectious structure carrier,reverse zoonotic disposition,0.6094202898550725
asymptomatic infectious structure carrier,disease surveillance objective specification,0.6264705882352941
asymptomatic infectious structure carrier,infectious agent host role,0.6888059701492537
asymptomatic infectious structure carrier,macromolecular complex,0.6087301587301588
asymptomatic infectious structure carrier,asymptomatic infectious structure carrier,0.95
asymptomatic infectious structure carrier,architectual structure,0.7198412698412698
asymptomatic infectious structure carrier,B cell receptor complex,0.60625
asymptomatic infectious structure carrier,passive immunization against infectious agent,0.6941860465116279
asymptomatic infectious structure carrier,infection incidence rate,0.6653846153846155
asymptomatic infectious structure carrier,infectious disease lifetime prevalence,0.6651898734177215
asymptomatic infectious structure carrier,toxin disposition,0.6051724137931035
asymptomatic infectious structure carrier,lower respiratory tract disease,0.6305555555555555
asymptomatic infectious structure carrier,infectious disease incidence proportion,0.675
asymptomatic infectious structure carrier,acute infectious disease course,0.7277777777777777
asymptomatic infectious structure carrier,cidal agent disposition,0.590625
asymptomatic infectious structure carrier,infectious disorder,0.7
asymptomatic infectious structure carrier,parasiticidal disposition,0.6166666666666667
asymptomatic infectious structure carrier,infectious disease sporadicity,0.6753521126760563
asymptomatic infectious structure carrier,communicability end process boundary,0.6188311688311688
asymptomatic infectious structure carrier,acellular structure aggregate,0.7071428571428571
asymptomatic infectious structure carrier,infectious agent colony,0.66875
asymptomatic infectious structure carrier,pathogen transporter,0.630327868852459
asymptomatic infectious structure carrier,transmissibility disposition,0.6094202898550725
asymptomatic infectious structure carrier,latency end process boundary,0.6239130434782608
asymptomatic infectious structure carrier,infectious disease epidemic,0.6852941176470588
asymptomatic infectious structure carrier,infectious agent generative stage,0.6932432432432433
asymptomatic infectious structure carrier,disease transmission model,0.5992537313432835
asymptomatic infectious structure carrier,endotoxin disposition,0.5951612903225807
asymptomatic infectious structure carrier,cidal agent,0.5461538461538461
asymptomatic infectious structure carrier,infectious structure host role,0.7739436619718311
asymptomatic infectious structure carrier,COVID-19 incidence rate,0.6375
asymptomatic infectious structure carrier,cytotoxin disposition,0.6274193548387097
asymptomatic infectious structure carrier,chronic infectious disease course,0.7337837837837838
asymptomatic infectious structure carrier,asymptomatic infectious agent carrier,0.8730769230769231
asymptomatic infectious structure carrier,COVID-19 epidemic,0.5706896551724138
asymptomatic infectious structure carrier,sterilizing immunity to infectious agent,0.6722222222222223
asymptomatic infectious structure carrier,diseased population,0.5833333333333334
asymptomatic infectious structure carrier,acellular structure,0.6833333333333332
asymptomatic infectious structure carrier,incubation end process boundary,0.6305555555555555
asymptomatic infectious structure carrier,collective pathogenic disposition,0.5986486486486486
asymptomatic infectious structure carrier,neurotoxin disposition,0.5928571428571429
asymptomatic infectious structure carrier,latency end temporal region,0.6117647058823529
asymptomatic infectious structure carrier,innate immunity to infectious agent,0.6868421052631578
asymptomatic infectious structure carrier,infectious structure,0.7778688524590163
asymptomatic infectious structure carrier,collective disposition,0.5928571428571429
asymptomatic infectious structure carrier,static agent disposition,0.6653846153846155
asymptomatic infectious structure carrier,T cell receptor complex,0.621875
asymptomatic infectious structure carrier,asymptomatic carrier role,0.7530303030303032
asymptomatic infectious structure carrier,infectious structure host,0.7681818181818181
asymptomatic infectious structure carrier,infectious agent population,0.6705882352941177
asymptomatic infectious structure carrier,respiratory system disease,0.6291044776119403
asymptomatic infectious structure carrier,leukocyte-mediated immunity to infectious agent,0.6772727272727272
asymptomatic infectious structure carrier,humoral immunity to infectious agent,0.6837662337662337
asymptomatic infectious structure carrier,infectious disease control strategy,0.6868421052631578
asymptomatic infectious structure carrier,infectious disease pandemic,0.6852941176470588
asymptomatic infectious structure carrier,infectious structure generative stage,0.7576923076923078
asymptomatic infectious structure carrier,immunosuppressive disposition,0.5928571428571429
asymptomatic infectious structure carrier,pathogenic disposition,0.6246031746031746
asymptomatic infectious structure carrier,viral disease course,0.6139344262295081
asymptomatic infectious structure carrier,passive immunity to infectious agent,0.6967532467532468
asymptomatic infectious structure carrier,infectious disposition,0.6722222222222223
asymptomatic infectious structure carrier,vaccination against infectious agent,0.6967532467532468
asymptomatic infectious structure carrier,susceptibility to infectious agent,0.69
asymptomatic infectious structure carrier,bacteriostatic disposition,0.6440298507462687
asymptomatic infectious structure carrier,bactericidal disposition,0.6038461538461539
asymptomatic infectious structure carrier,invasion disposition,0.5975409836065574
asymptomatic infectious structure carrier,disease course,0.5954545454545455
asymptomatic infectious structure carrier,infectious disease course,0.7075757575757575
asymptomatic infectious structure carrier,viricidal disposition,0.5790322580645162
asymptomatic infectious structure carrier,acquired immunity to infectious agent,0.6807692307692308
asymptomatic infectious structure carrier,complex infection,0.6396551724137931
asymptomatic infectious structure carrier,COVID-19 disease incidence proportion,0.6166666666666667
asymptomatic infectious structure carrier,coronavirus disease course,0.6291044776119403
asymptomatic infectious structure carrier,asymptomatic carrier,0.7778688524590163
asymptomatic infectious structure carrier,symptomatic infectious agent carrier,0.8655844155844156
asymptomatic infectious structure carrier,infectious disease prevalence,0.6785714285714286
asymptomatic infectious structure carrier,disposition,0.5846153846153846
asymptomatic infectious structure carrier,infected population,0.6166666666666667
asymptomatic infectious structure carrier,COVID-19 mortality rate,0.590625
asymptomatic infectious structure carrier,viral disease,0.5796296296296296
asymptomatic infectious structure carrier,adhesion disposition,0.5975409836065574
asymptomatic infectious structure carrier,disease,0.5541666666666667
asymptomatic infectious structure carrier,symptomatic infectious structure carrier,0.9438271604938271
asymptomatic infectious structure carrier,primary infectious disposition,0.7035211267605633
asymptomatic infectious structure carrier,symptomatic carrier role,0.7423076923076922
asymptomatic infectious structure carrier,infectious pathogen transmissibility,0.6577922077922078
asymptomatic infectious structure carrier,infectious human pathogen,0.6772727272727272
asymptomatic infectious structure carrier,immunization against infectious agent,0.6935897435897437
asymptomatic infectious structure carrier,virus synthesis stage,0.6274193548387097
asymptomatic infectious structure carrier,SARS-COV-2 adhesion disposition,0.6027777777777777
asymptomatic infectious structure carrier,invasive disposition,0.5975409836065574
asymptomatic infectious structure carrier,infectious agent host,0.6596774193548387
asymptomatic infectious structure carrier,long-term non-progressing infectious disease course,0.6891304347826087
asymptomatic infectious structure carrier,viral disease epidemic,0.5928571428571429
asymptomatic infectious structure carrier,fungicidal disposition,0.5769841269841269
asymptomatic infectious structure carrier,viral disease pandemic,0.5928571428571429
asymptomatic infectious structure carrier,acute respiratory distress syndrome,0.6342105263157894
asymptomatic infectious structure carrier,symptomatic carrier,0.7666666666666666
asymptomatic infectious structure carrier,infectious disease endemicity,0.6785714285714286
asymptomatic infectious structure carrier,herd immunity to infectious organism,0.6837662337662337
asymptomatic infectious structure carrier,pathogen transporter role,0.6318181818181818
asymptomatic infectious structure carrier,exotoxin disposition,0.5975409836065574
asymptomatic infectious structure carrier,infectious agent reservoir,0.703731343283582
asymptomatic infectious structure carrier,immunoglobulin complex,0.5769841269841269
asymptomatic infectious structure carrier,COVID-19 pandemic,0.5706896551724138
asymptomatic infectious structure carrier,SARS-CoV-2 synthesis stage,0.6440298507462687
asymptomatic infectious structure carrier,infectious disease control objective specification,0.6807692307692308
asymptomatic infectious structure carrier,opportunistic infectious disposition,0.7097402597402598
asymptomatic infectious structure carrier,enterotoxin disposition,0.60625
asymptomatic infectious structure carrier,polymerase chain reaction,0.6318181818181818
asymptomatic infectious structure carrier,COVID-19 disease course,0.621875
asymptomatic infectious structure carrier,infectious disease incidence rate,0.6932432432432433
asymptomatic infectious structure carrier,active immunization against infectious agent,0.6852941176470588
asymptomatic infectious structure carrier,collective resistance disposition,0.6121621621621621
asymptomatic infectious structure carrier,symptom,0.5958333333333333
asymptomatic infectious structure carrier,fungistatic disposition,0.6375
asymptomatic infectious structure carrier,infectious agent,0.6780701754385965
asymptomatic infectious structure carrier,establishment of a clinically abnormal colony,0.6127906976744186
asymptomatic infectious structure carrier,coronavirus disease,0.6166666666666667
asymptomatic infectious structure carrier,drug susceptibility of infectious agent,0.675
asymptomatic infectious structure carrier,static agent,0.619811320754717
toxin disposition,virus aggregate,0.54375
toxin disposition,source of infection,0.6722222222222223
toxin disposition,virostatic disposition,0.808974358974359
toxin disposition,information content entity,0.6127906976744186
toxin disposition,zoonotic disposition,0.8283783783783784
toxin disposition,infectious disease mortality rate,0.63
toxin disposition,infection incidence rate profile,0.6132653061224489
toxin disposition,infectious structure aggregate,0.5776595744680851
toxin disposition,communicability end temporal region,0.6230769230769231
toxin disposition,geographical entity,0.5888888888888889
toxin disposition,biological regulation,0.6342105263157894
toxin disposition,subclinical coronavirus infection,0.65
toxin disposition,surveillance process,0.6121621621621621
toxin disposition,infection end temporal region,0.6673913043478261
toxin disposition,vector control strategy,0.6
toxin disposition,SARS-CoV-2 incidence rate,0.569047619047619
toxin disposition,double-stranded DNA virus,0.5928571428571429
toxin disposition,incubation end temporal region,0.6627659574468084
toxin disposition,site of infection,0.6852941176470588
toxin disposition,resistant entity,0.6015151515151516
toxin disposition,virulence factor disposition,0.7611111111111112
toxin disposition,viral adhesion disposition,0.7755813953488372
toxin disposition,parasitostatic disposition,0.7988372093023256
toxin disposition,negative regulation of production,0.65
toxin disposition,reverse zoonotic disposition,0.7611111111111112
toxin disposition,subclinical SARS-CoV-2 infection,0.6540816326530612
toxin disposition,establishment of localization in host,0.6351851851851852
toxin disposition,virus translation stage,0.625
toxin disposition,disease surveillance objective specification,0.630327868852459
toxin disposition,case isolation control strategy,0.6166666666666667
toxin disposition,virus release stage,0.5888888888888889
toxin disposition,infectious agent host role,0.636046511627907
toxin disposition,macromolecular complex,0.5269230769230769
toxin disposition,material entity,0.60625
toxin disposition,asymptomatic infectious structure carrier,0.6051724137931035
toxin disposition,source of infection site,0.6451219512195122
toxin disposition,architectual structure,0.5525641025641026
toxin disposition,virus,0.5409090909090909
toxin disposition,quarantine control strategy,0.609090909090909
toxin disposition,virus replication,0.6852941176470588
toxin disposition,B cell receptor complex,0.55
toxin disposition,systematic infection,0.6662162162162162
toxin disposition,infection incidence rate,0.6207317073170732
toxin disposition,colonized host,0.6435483870967742
toxin disposition,virus host,0.6351851851851852
toxin disposition,entity,0.5804347826086956
toxin disposition,double-stranded RNA virus,0.569047619047619
toxin disposition,virus transcription stage,0.6404761904761905
toxin disposition,toxin disposition,0.95
toxin disposition,virus generative stage,0.5782051282051281
toxin disposition,cidal agent disposition,0.8
toxin disposition,subclinical infection,0.6605263157894737
toxin disposition,simple infection,0.6621212121212122
toxin disposition,parasiticidal disposition,0.7833333333333333
toxin disposition,communicability end process boundary,0.619811320754717
toxin disposition,directive information content entity,0.619811320754717
toxin disposition,acellular structure aggregate,0.5152173913043478
toxin disposition,infection incidence proportion profile,0.65
toxin disposition,transmissibility disposition,0.7611111111111112
toxin disposition,latency end process boundary,0.65
toxin disposition,colonization of host,0.6391891891891892
toxin disposition,realizable entity,0.5676470588235294
toxin disposition,endotoxin disposition,0.8973684210526315
toxin disposition,vector surveillance,0.6166666666666667
toxin disposition,negative regulation of establishment of localization,0.6239130434782608
toxin disposition,negative-sense single-stranded RNA virus,0.5903508771929825
toxin disposition,infectious structure host role,0.6202127659574468
toxin disposition,COVID-19 incidence rate,0.6
toxin disposition,cytotoxin disposition,0.8973684210526315
toxin disposition,community-acquired infection,0.6277777777777778
toxin disposition,negative regulation of developmental process,0.5811475409836065
toxin disposition,host,0.5928571428571429
toxin disposition,nursing-home acquired infection,0.6375
toxin disposition,descriptive information content entity,0.6136363636363636
toxin disposition,negative regulation of replication,0.6460784313725491
toxin disposition,secondary infection,0.6722222222222223
toxin disposition,infection start temporal region,0.6583333333333334
toxin disposition,infection incidence,0.6444444444444444
toxin disposition,virus disorder,0.6435483870967742
toxin disposition,establishment of localization in human host,0.6166666666666667
toxin disposition,acellular structure,0.5333333333333333
toxin disposition,primary infection,0.6558823529411765
toxin disposition,process of establishing an infection,0.619811320754717
toxin disposition,incubation end process boundary,0.6583333333333334
toxin disposition,collective pathogenic disposition,0.75
toxin disposition,neurotoxin disposition,0.8858974358974359
toxin disposition,dead-end host role,0.6214285714285714
toxin disposition,molecular entity,0.5712121212121213
toxin disposition,plan specification,0.7071428571428571
toxin disposition,definitive host role,0.6391891891891892
toxin disposition,latency end temporal region,0.6545454545454545
toxin disposition,infectious structure,0.6121621621621621
toxin disposition,virus adhesion susceptible cell,0.6166666666666667
toxin disposition,collective disposition,0.808974358974359
toxin disposition,infection,0.6807692307692308
toxin disposition,static agent disposition,0.8158536585365854
toxin disposition,T cell receptor complex,0.575
toxin disposition,infectious structure host,0.6166666666666667
toxin disposition,respiratory system disease,0.6127906976744186
toxin disposition,entry into host,0.66875
toxin disposition,adhesion of symbiont to host,0.6277777777777778
toxin disposition,infectious disease control strategy,0.6230769230769231
toxin disposition,infectious structure generative stage,0.5796296296296296
toxin disposition,immunosuppressive disposition,0.7543478260869566
toxin disposition,pathogenic disposition,0.8346153846153846
toxin disposition,toxin,0.6772727272727272
toxin disposition,entry into host through host barriers,0.6166666666666667
toxin disposition,intracellular infection,0.65
toxin disposition,secondary infection role,0.6451219512195122
toxin disposition,metastatic infection,0.6662162162162162
toxin disposition,infectious disposition,0.808974358974359
toxin disposition,acute infection,0.66875
toxin disposition,bacteriostatic disposition,0.7988372093023256
toxin disposition,bactericidal disposition,0.7914634146341464
toxin disposition,source of infection role,0.6451219512195122
toxin disposition,pathogen host,0.6833333333333332
toxin disposition,chronic infection,0.6852941176470588
toxin disposition,invasion disposition,0.8283783783783784
toxin disposition,viricidal disposition,0.7921052631578948
toxin disposition,complex infection,0.6852941176470588
toxin disposition,infection incidence proportion,0.6840425531914894
toxin disposition,respiratory droplet virus fomite,0.6336734693877552
toxin disposition,intermediate host,0.6558823529411765
toxin disposition,organism substance,0.65
toxin disposition,anatomical entity,0.6264705882352941
toxin disposition,disposition,0.8428571428571427
toxin disposition,single-stranded DNA virus,0.5928571428571429
toxin disposition,COVID-19 mortality rate,0.6
toxin disposition,negative regulation of life-sustaining process,0.6087301587301588
toxin disposition,place closure control strategy,0.5563829787234043
toxin disposition,geopolitical entity,0.6444444444444444
toxin disposition,primary infection role,0.6294871794871795
toxin disposition,adhesion disposition,0.8283783783783784
toxin disposition,infection incidence profile,0.6318181818181818
toxin disposition,symptomatic infectious structure carrier,0.6078947368421053
toxin disposition,primary infectious disposition,0.747872340425532
toxin disposition,pathogen host role,0.6785714285714286
toxin disposition,infection prevalence,0.6121621621621621
toxin disposition,designative information content entity,0.6136363636363636
toxin disposition,intermediate host role,0.6551282051282051
toxin disposition,dead-end host,0.6166666666666667
toxin disposition,pathogen surveillance,0.6342105263157894
toxin disposition,host role,0.6038461538461539
toxin disposition,subclinical virus infection,0.6772727272727272
toxin disposition,establishment of localization in virus host,0.6166666666666667
toxin disposition,virus attachment stage,0.5782051282051281
toxin disposition,negative regulation of immune response,0.6136363636363636
toxin disposition,virus synthesis stage,0.6078947368421053
toxin disposition,immaterial entity,0.5970588235294118
toxin disposition,SARS-COV-2 adhesion disposition,0.7625
toxin disposition,invasive disposition,0.8283783783783784
toxin disposition,infectious agent host,0.6342105263157894
toxin disposition,fungicidal disposition,0.7833333333333333
toxin disposition,virus penetration stage,0.625
toxin disposition,division of geopolitical entity,0.6375
toxin disposition,negative regulation of viral process,0.6009433962264151
toxin disposition,extracellular infection,0.625
toxin disposition,exotoxin disposition,0.9094594594594595
toxin disposition,immunoglobulin complex,0.5782051282051281
toxin disposition,infection start process boundary,0.6540816326530612
toxin disposition,infectious disease control objective specification,0.6440298507462687
toxin disposition,symbiont host role,0.65
toxin disposition,opportunistic infectious disposition,0.7330188679245283
toxin disposition,process of establishing viral infection,0.6285714285714286
toxin disposition,negative regulation of biological process,0.5879310344827586
toxin disposition,enterotoxin disposition,0.875
toxin disposition,infectious disease incidence rate,0.65
toxin disposition,disordered virus,0.6015151515151516
toxin disposition,collective resistance disposition,0.75
toxin disposition,fungistatic disposition,0.8
toxin disposition,virus uncoating stage,0.6078947368421053
toxin disposition,local infection,0.66875
toxin disposition,establishment of a clinically abnormal colony,0.5951612903225807
toxin disposition,positive-sense single-stranded RNA virus,0.5903508771929825
toxin disposition,definitive host,0.6375
toxin disposition,hospital-acquired infection,0.6318181818181818
toxin disposition,bacteria,0.53
secondary infection role,virus aggregate,0.6038461538461539
secondary infection role,source of infection,0.7523255813953489
secondary infection role,virostatic disposition,0.6239130434782608
secondary infection role,zoonotic disposition,0.6318181818181818
secondary infection role,infectious disease mortality rate,0.6605263157894737
secondary infection role,infection incidence rate profile,0.7178571428571427
secondary infection role,communicability end temporal region,0.6533898305084747
secondary infection role,subclinical coronavirus infection,0.730701754385965
secondary infection role,infection end temporal region,0.6952830188679244
secondary infection role,infectious disease,0.6880952380952381
secondary infection role,SARS-CoV-2 incidence rate,0.6948979591836735
secondary infection role,double-stranded DNA virus,0.5928571428571429
secondary infection role,incubation end temporal region,0.6537037037037037
secondary infection role,site of infection,0.7670731707317073
secondary infection role,virulence factor disposition,0.6423076923076922
secondary infection role,viral adhesion disposition,0.63
secondary infection role,parasitostatic disposition,0.63
secondary infection role,infectious disease incidence,0.6807692307692308
secondary infection role,reservoir of pathogen role,0.73
secondary infection role,reverse zoonotic disposition,0.6423076923076922
secondary infection role,subclinical SARS-CoV-2 infection,0.7178571428571427
secondary infection role,virus translation stage,0.6414893617021277
secondary infection role,disease surveillance objective specification,0.6264705882352941
secondary infection role,virus release stage,0.5895348837209302
secondary infection role,infectious agent host role,0.73
secondary infection role,source of infection site,0.7625
secondary infection role,virus,0.5189655172413793
secondary infection role,virus replication,0.6451219512195122
secondary infection role,B cell receptor complex,0.6627659574468084
secondary infection role,systematic infection,0.7454545454545455
secondary infection role,infection incidence rate,0.7208333333333333
secondary infection role,virus host,0.5382352941176471
secondary infection role,double-stranded RNA virus,0.5928571428571429
secondary infection role,pathogen portal of entry role,0.6764150943396227
secondary infection role,virus transcription stage,0.6540816326530612
secondary infection role,infectious disease lifetime prevalence,0.6919354838709677
secondary infection role,toxin disposition,0.6451219512195122
secondary infection role,lower respiratory tract disease,0.6136363636363636
secondary infection role,infectious disease incidence proportion,0.6722222222222223
secondary infection role,virus generative stage,0.6239130434782608
secondary infection role,acute infectious disease course,0.6863636363636364
secondary infection role,cidal agent disposition,0.6414893617021277
secondary infection role,infectious disorder,0.7058139534883722
secondary infection role,role,0.5928571428571429
secondary infection role,subclinical infection,0.7611111111111112
secondary infection role,appearance of disorder,0.6456521739130434
secondary infection role,simple infection,0.75
secondary infection role,parasiticidal disposition,0.6540816326530612
secondary infection role,infectious disease sporadicity,0.6351851851851852
secondary infection role,mutualist role,0.6605263157894737
secondary infection role,communicability end process boundary,0.65
secondary infection role,infection incidence proportion profile,0.7403225806451613
secondary infection role,transmissibility disposition,0.6038461538461539
secondary infection role,latency end process boundary,0.6423076923076922
secondary infection role,infectious disease epidemic,0.6460784313725491
secondary infection role,disease transmission model,0.67
secondary infection role,endotoxin disposition,0.65
secondary infection role,negative-sense single-stranded RNA virus,0.621875
secondary infection role,infectious structure host role,0.6907407407407408
secondary infection role,COVID-19 incidence rate,0.7053191489361703
secondary infection role,cytotoxin disposition,0.65
secondary infection role,community-acquired infection,0.7384615384615384
secondary infection role,pathogen vehicle role,0.6722222222222223
secondary infection role,chronic infectious disease course,0.7131578947368421
secondary infection role,nursing-home acquired infection,0.7045454545454546
secondary infection role,COVID-19 epidemic,0.6207317073170732
secondary infection role,secondary infection,0.891860465116279
secondary infection role,mechanical vector role,0.7543478260869566
secondary infection role,infection start temporal region,0.7045454545454546
secondary infection role,infection incidence,0.7058139534883722
secondary infection role,virus disorder,0.6078947368421053
secondary infection role,primary infection,0.7670731707317073
secondary infection role,process of establishing an infection,0.6833333333333332
secondary infection role,incubation end process boundary,0.65
secondary infection role,SARS-CoV-2 disorder,0.636046511627907
secondary infection role,collective pathogenic disposition,0.6254385964912281
secondary infection role,neurotoxin disposition,0.6456521739130434
secondary infection role,dead-end host role,0.6880952380952381
secondary infection role,definitive host role,0.7
secondary infection role,latency end temporal region,0.6460784313725491
secondary infection role,virus adhesion susceptible cell,0.6318181818181818
secondary infection role,collective disposition,0.6239130434782608
secondary infection role,infection,0.7227272727272727
secondary infection role,static agent disposition,0.6375
secondary infection role,T cell receptor complex,0.6627659574468084
secondary infection role,asymptomatic carrier role,0.6744897959183673
secondary infection role,respiratory system disease,0.61
secondary infection role,indirect pathogen transmission process,0.6596774193548387
secondary infection role,communicability interval,0.6791666666666666
secondary infection role,infectious disease control strategy,0.6703389830508475
secondary infection role,infectious disease pandemic,0.6460784313725491
secondary infection role,immunosuppressive disposition,0.6009433962264151
secondary infection role,pathogenic disposition,0.6239130434782608
secondary infection role,viral disease course,0.6318181818181818
secondary infection role,intracellular infection,0.7265957446808511
secondary infection role,secondary infection role,0.95
secondary infection role,metastatic infection,0.7227272727272727
secondary infection role,infectious disposition,0.6673913043478261
secondary infection role,acute infection,0.732051282051282
secondary infection role,bacteriostatic disposition,0.63
secondary infection role,bactericidal disposition,0.6583333333333334
secondary infection role,source of infection role,0.825
secondary infection role,acquired immunodeficiency,0.6336734693877552
secondary infection role,chronic infection,0.7670731707317073
secondary infection role,invasion disposition,0.6545454545454545
secondary infection role,disease course,0.6605263157894737
secondary infection role,infectious disease course,0.6744897959183673
secondary infection role,viricidal disposition,0.65
secondary infection role,acquired immunity to infectious agent,0.6795081967213115
secondary infection role,complex infection,0.7426829268292683
secondary infection role,COVID-19 disease incidence proportion,0.6631147540983606
secondary infection role,coronavirus disease course,0.69
secondary infection role,biological vehicle role,0.6627659574468084
secondary infection role,infection incidence proportion,0.6907407407407408
secondary infection role,respiratory droplet virus fomite,0.6464285714285714
secondary infection role,symbiont role,0.7202702702702704
secondary infection role,parasite role,0.6932432432432433
secondary infection role,pathogen vector role,0.7227272727272727
secondary infection role,generically dependent continuant,0.6464285714285714
secondary infection role,infectious disease prevalence,0.6764150943396227
secondary infection role,disposition,0.65
secondary infection role,single-stranded DNA virus,0.6132653061224489
secondary infection role,COVID-19 mortality rate,0.6414893617021277
secondary infection role,viral disease,0.5851351351351352
secondary infection role,primary infection role,0.8413043478260869
secondary infection role,biological role,0.6551282051282051
secondary infection role,adhesion disposition,0.6545454545454545
secondary infection role,infection incidence profile,0.7441176470588234
secondary infection role,contagiousness,0.6605263157894737
secondary infection role,disease,0.5790322580645162
secondary infection role,biological vector role,0.7108695652173913
secondary infection role,primary infectious disposition,0.7092592592592593
secondary infection role,pathogen host role,0.6642857142857143
secondary infection role,infection prevalence,0.7454545454545455
secondary infection role,symptomatic carrier role,0.6791666666666666
secondary infection role,coronavirus disorder,0.6772727272727272
secondary infection role,intermediate host role,0.6673913043478261
secondary infection role,host role,0.6621212121212122
secondary infection role,subclinical virus infection,0.7441176470588234
secondary infection role,establishment of localization in virus host,0.6440298507462687
secondary infection role,virus attachment stage,0.5804347826086956
secondary infection role,specifically dependent continuant,0.6605263157894737
secondary infection role,virus synthesis stage,0.6055555555555556
secondary infection role,SARS-COV-2 adhesion disposition,0.6318181818181818
secondary infection role,pathogen portal of exit role,0.6807692307692308
secondary infection role,invasive disposition,0.6318181818181818
secondary infection role,long-term non-progressing infectious disease course,0.6633333333333334
secondary infection role,viral disease epidemic,0.6021739130434782
secondary infection role,commensal role,0.6868421052631578
secondary infection role,communicability start temporal region,0.630327868852459
secondary infection role,epitope role,0.7
secondary infection role,fungicidal disposition,0.6456521739130434
secondary infection role,viral disease pandemic,0.6021739130434782
secondary infection role,virus penetration stage,0.6627659574468084
secondary infection role,acute respiratory distress syndrome,0.6364406779661017
secondary infection role,infectious disease endemicity,0.6386792452830189
secondary infection role,disorder,0.60625
secondary infection role,function,0.6375
secondary infection role,communicability,0.6294871794871795
secondary infection role,extracellular infection,0.747872340425532
secondary infection role,pathogen transporter role,0.6540816326530612
secondary infection role,exotoxin disposition,0.6545454545454545
secondary infection role,antigen role,0.7277777777777777
secondary infection role,infection start process boundary,0.6821428571428573
secondary infection role,action specification,0.7
secondary infection role,infectious disease control objective specification,0.6391891891891892
secondary infection role,symbiont host role,0.7119047619047619
secondary infection role,opportunistic infectious disposition,0.6666666666666667
secondary infection role,fomite role,0.6785714285714286
secondary infection role,process of establishing viral infection,0.6722222222222223
secondary infection role,enterotoxin disposition,0.6414893617021277
secondary infection role,COVID-19 disease course,0.6627659574468084
secondary infection role,infectious disease incidence rate,0.6956140350877194
secondary infection role,communicability start process boundary,0.6274193548387097
secondary infection role,single-stranded RNA retrovirus,0.6351851851851852
secondary infection role,disordered virus,0.625
secondary infection role,collective resistance disposition,0.6254385964912281
secondary infection role,reagent role,0.7
secondary infection role,viral load,0.5382352941176471
secondary infection role,fungistatic disposition,0.6202127659574468
secondary infection role,virus uncoating stage,0.65
secondary infection role,local infection,0.7576923076923078
secondary infection role,establishment of a clinically abnormal colony,0.6239130434782608
secondary infection role,coronavirus disease,0.6593023255813953
secondary infection role,positive-sense single-stranded RNA virus,0.621875
secondary infection role,hospital-acquired infection,0.7049019607843137
pathogen portal of exit,extended organism,0.65
pathogen portal of exit,virus aggregate,0.581578947368421
pathogen portal of exit,source of infection,0.6404761904761905
pathogen portal of exit,infectious disease mortality rate,0.6464285714285714
pathogen portal of exit,infection incidence rate profile,0.65
pathogen portal of exit,communicability end temporal region,0.6741379310344828
pathogen portal of exit,pathogen generative stage,0.7208333333333333
pathogen portal of exit,pathogen portal of entry,0.8968085106382978
pathogen portal of exit,subclinical coronavirus infection,0.6107142857142857
pathogen portal of exit,primary pathogen,0.6551282051282051
pathogen portal of exit,infection end temporal region,0.7
pathogen portal of exit,drug-based immunosuppressed organism,0.5855932203389831
pathogen portal of exit,infectious disease,0.5719512195121951
pathogen portal of exit,double-stranded DNA virus,0.5958333333333333
pathogen portal of exit,incubation end temporal region,0.7141509433962264
pathogen portal of exit,site of infection,0.65
pathogen portal of exit,immunocompetent organism,0.6414893617021277
pathogen portal of exit,pathogen portal of exit,0.95
pathogen portal of exit,infectious disease incidence,0.5676470588235294
pathogen portal of exit,reservoir of pathogen role,0.6948979591836735
pathogen portal of exit,subclinical SARS-CoV-2 infection,0.5954545454545455
pathogen portal of exit,virus translation stage,0.6239130434782608
pathogen portal of exit,disease surveillance objective specification,0.6141791044776119
pathogen portal of exit,case isolation control strategy,0.6351851851851852
pathogen portal of exit,virus release stage,0.5928571428571429
pathogen portal of exit,infectious agent host role,0.6744897959183673
pathogen portal of exit,source of infection site,0.6414893617021277
pathogen portal of exit,virus replication,0.575
pathogen portal of exit,B cell receptor complex,0.6456521739130434
pathogen portal of exit,passive immunization against infectious agent,0.6264705882352941
pathogen portal of exit,systematic infection,0.6127906976744186
pathogen portal of exit,infection incidence rate,0.6202127659574468
pathogen portal of exit,virus host,0.5712121212121213
pathogen portal of exit,double-stranded RNA virus,0.6166666666666667
pathogen portal of exit,pathogen portal of entry role,0.8538461538461539
pathogen portal of exit,virus transcription stage,0.6166666666666667
pathogen portal of exit,infectious disease lifetime prevalence,0.5975409836065574
pathogen portal of exit,pathogen birth temporal region,0.7707547169811321
pathogen portal of exit,lower respiratory tract disease,0.6351851851851852
pathogen portal of exit,infectious disease incidence proportion,0.6112903225806451
pathogen portal of exit,opportunistic pathogen,0.6277777777777778
pathogen portal of exit,virus generative stage,0.6055555555555556
pathogen portal of exit,acute infectious disease course,0.6166666666666667
pathogen portal of exit,cidal agent disposition,0.6456521739130434
pathogen portal of exit,genetic resistance to pathogen,0.6575471698113208
pathogen portal of exit,subclinical infection,0.609090909090909
pathogen portal of exit,simple infection,0.6038461538461539
pathogen portal of exit,droplet pathogen transmission process,0.6833333333333332
pathogen portal of exit,infectious disease sporadicity,0.6386792452830189
pathogen portal of exit,communicability end process boundary,0.6025423728813559
pathogen portal of exit,infection incidence proportion profile,0.6631147540983606
pathogen portal of exit,infectious agent colony,0.6456521739130434
pathogen portal of exit,pathogen transporter,0.7755813953488372
pathogen portal of exit,latency end process boundary,0.6264705882352941
pathogen portal of exit,infectious disease epidemic,0.59
pathogen portal of exit,infectious agent generative stage,0.6285714285714286
pathogen portal of exit,disease transmission model,0.6132653061224489
pathogen portal of exit,pathologically immunosuppressed organism,0.6404761904761905
pathogen portal of exit,negative-sense single-stranded RNA virus,0.6087301587301588
pathogen portal of exit,cidal agent,0.5970588235294118
pathogen portal of exit,pathogen vehicle,0.732051282051282
pathogen portal of exit,community-acquired infection,0.6068627450980393
pathogen portal of exit,pathogen vector,0.7394736842105263
pathogen portal of exit,pathogen vehicle role,0.7454545454545455
pathogen portal of exit,chronic infectious disease course,0.6107142857142857
pathogen portal of exit,asymptomatic infectious agent carrier,0.6166666666666667
pathogen portal of exit,nursing-home acquired infection,0.6166666666666667
pathogen portal of exit,secondary infection,0.6166666666666667
pathogen portal of exit,infection start temporal region,0.6722222222222223
pathogen portal of exit,infection incidence,0.569047619047619
pathogen portal of exit,virus disorder,0.5581081081081081
pathogen portal of exit,sterilizing immunity to infectious agent,0.6246031746031746
pathogen portal of exit,primary infection,0.625
pathogen portal of exit,process of establishing an infection,0.6533898305084747
pathogen portal of exit,incubation end process boundary,0.6351851851851852
pathogen portal of exit,pathogen death process boundary,0.6907407407407408
pathogen portal of exit,immunosuppressed organism,0.5958333333333333
pathogen portal of exit,latency end temporal region,0.71
pathogen portal of exit,innate immunity to infectious agent,0.6396551724137931
pathogen portal of exit,virus adhesion susceptible cell,0.6351851851851852
pathogen portal of exit,infection,0.575
pathogen portal of exit,static agent disposition,0.6627659574468084
pathogen portal of exit,T cell receptor complex,0.6673913043478261
pathogen portal of exit,infectious agent population,0.65
pathogen portal of exit,respiratory system disease,0.6132653061224489
pathogen portal of exit,entry into host,0.6342105263157894
pathogen portal of exit,leukocyte-mediated immunity to infectious agent,0.6071428571428572
pathogen portal of exit,indirect pathogen transmission process,0.6795081967213115
pathogen portal of exit,organism population,0.6404761904761905
pathogen portal of exit,humoral immunity to infectious agent,0.6364406779661017
pathogen portal of exit,infectious disease control strategy,0.6051724137931035
pathogen portal of exit,parasite,0.6435483870967742
pathogen portal of exit,infectious disease pandemic,0.61
pathogen portal of exit,antibody reagent,0.6551282051282051
pathogen portal of exit,viral disease course,0.5895348837209302
pathogen portal of exit,entry into host through host barriers,0.6
pathogen portal of exit,intracellular infection,0.6239130434782608
pathogen portal of exit,secondary infection role,0.6202127659574468
pathogen portal of exit,metastatic infection,0.6127906976744186
pathogen portal of exit,passive immunity to infectious agent,0.6364406779661017
pathogen portal of exit,vaccination against infectious agent,0.6364406779661017
pathogen portal of exit,acute infection,0.6342105263157894
pathogen portal of exit,susceptibility to infectious agent,0.6254385964912281
pathogen portal of exit,epitope site,0.65
pathogen portal of exit,immunity to pathogen,0.636046511627907
pathogen portal of exit,source of infection role,0.6202127659574468
pathogen portal of exit,pathogen host,0.7555555555555555
pathogen portal of exit,chronic infection,0.625
pathogen portal of exit,disease course,0.6121621621621621
pathogen portal of exit,infectious disease course,0.5958333333333333
pathogen portal of exit,acquired immunity to infectious agent,0.6166666666666667
pathogen portal of exit,complex infection,0.625
pathogen portal of exit,COVID-19 disease incidence proportion,0.6
pathogen portal of exit,coronavirus disease course,0.5928571428571429
pathogen portal of exit,infection incidence proportion,0.6386792452830189
pathogen portal of exit,symptomatic infectious agent carrier,0.6194915254237288
pathogen portal of exit,respiratory droplet virus fomite,0.65
pathogen portal of exit,susceptible organism,0.636046511627907
pathogen portal of exit,parasite role,0.6722222222222223
pathogen portal of exit,pathogen vector role,0.7755813953488372
pathogen portal of exit,pathogen portal of exit site,0.9009803921568627
pathogen portal of exit,infectious disease prevalence,0.6230769230769231
pathogen portal of exit,organism substance,0.6207317073170732
pathogen portal of exit,single-stranded DNA virus,0.5958333333333333
pathogen portal of exit,COVID-19 mortality rate,0.6456521739130434
pathogen portal of exit,viral disease,0.5888888888888889
pathogen portal of exit,primary infection role,0.65
pathogen portal of exit,pathogen portal of entry site,0.8730769230769231
pathogen portal of exit,infection incidence profile,0.65
pathogen portal of exit,disease,0.55
pathogen portal of exit,site,0.524074074074074
pathogen portal of exit,pathogen host role,0.7914634146341464
pathogen portal of exit,infection prevalence,0.6593023255813953
pathogen portal of exit,infectious pathogen transmissibility,0.6872881355932203
pathogen portal of exit,incubation start process boundary,0.6285714285714286
pathogen portal of exit,pathogen surveillance,0.7227272727272727
pathogen portal of exit,immunodeficient organism,0.6202127659574468
pathogen portal of exit,pathogen,0.7080645161290323
pathogen portal of exit,pathogen birth process boundary,0.7092592592592593
pathogen portal of exit,infectious human pathogen,0.6166666666666667
pathogen portal of exit,subclinical virus infection,0.59
pathogen portal of exit,resistance to pathogen,0.6277777777777778
pathogen portal of exit,establishment of localization in virus host,0.6318181818181818
pathogen portal of exit,immunization against infectious agent,0.6333333333333333
pathogen portal of exit,virus attachment stage,0.65
pathogen portal of exit,virus synthesis stage,0.609090909090909
pathogen portal of exit,pathogen portal of exit role,0.9009803921568627
pathogen portal of exit,infectious agent host,0.6545454545454545
pathogen portal of exit,re-emerging pathogen,0.636046511627907
pathogen portal of exit,long-term non-progressing infectious disease course,0.6121621621621621
pathogen portal of exit,viral disease epidemic,0.6055555555555556
pathogen portal of exit,viral disease pandemic,0.6055555555555556
pathogen portal of exit,virus penetration stage,0.6456521739130434
pathogen portal of exit,pathogen seroprevalence,0.7543478260869566
pathogen portal of exit,infectious disease endemicity,0.6038461538461539
pathogen portal of exit,contact pathogen transmission process,0.6833333333333332
pathogen portal of exit,herd immunity to infectious organism,0.6025423728813559
pathogen portal of exit,extracellular infection,0.6239130434782608
pathogen portal of exit,pathogen transporter role,0.7833333333333333
pathogen portal of exit,infectious agent reservoir,0.6336734693877552
pathogen portal of exit,infection start process boundary,0.6136363636363636
pathogen portal of exit,latency start process boundary,0.6386792452830189
pathogen portal of exit,infectious disease control objective specification,0.6280821917808219
pathogen portal of exit,process of establishing viral infection,0.6435483870967742
pathogen portal of exit,COVID-19 disease course,0.5804347826086956
pathogen portal of exit,infectious disease incidence rate,0.5928571428571429
pathogen portal of exit,communicability start process boundary,0.5811475409836065
pathogen portal of exit,process that results in death,0.6615384615384616
pathogen portal of exit,single-stranded RNA retrovirus,0.619811320754717
pathogen portal of exit,active immunization against infectious agent,0.6141791044776119
pathogen portal of exit,disordered virus,0.5782051282051281
pathogen portal of exit,organism,0.5790322580645162
pathogen portal of exit,virus uncoating stage,0.609090909090909
pathogen portal of exit,local infection,0.6342105263157894
pathogen portal of exit,infectious agent,0.6038461538461539
pathogen portal of exit,establishment of a clinically abnormal colony,0.6117647058823529
pathogen portal of exit,process boundary,0.6038461538461539
pathogen portal of exit,coronavirus disease,0.569047619047619
pathogen portal of exit,positive-sense single-stranded RNA virus,0.6087301587301588
pathogen portal of exit,horizontal pathogen transmission process,0.6722222222222223
pathogen portal of exit,hospital-acquired infection,0.65
pathogen portal of exit,pathogen death temporal region,0.7707547169811321
pathogen portal of exit,emerging pathogen,0.65
pathogen portal of exit,drug susceptibility of infectious agent,0.6435483870967742
pathogen portal of exit,SARS-CoV-2 release stage,0.598936170212766
pathogen portal of exit,static agent,0.6214285714285714
pathogen portal of exit,pathogen transmission process,0.7192307692307692
history,B cell receptor complex,0.55
history,double-stranded RNA virus,0.54375
history,negative-sense single-stranded RNA virus,0.5351063829787234
history,chronic infectious disease course,0.575
history,plan specification,0.57
history,T cell receptor complex,0.55
history,chronic infection,0.6166666666666667
history,history,0.95
history,action specification,0.5981481481481481
history,single-stranded RNA retrovirus,0.5851351351351352
history,establishment of a clinically abnormal colony,0.5653846153846154
history,positive-sense single-stranded RNA virus,0.5351063829787234
transmissibility disposition,virostatic disposition,0.75
transmissibility disposition,information content entity,0.5796296296296296
transmissibility disposition,zoonotic disposition,0.7416666666666667
transmissibility disposition,infectious disease mortality rate,0.630327868852459
transmissibility disposition,infection incidence rate profile,0.6
transmissibility disposition,infectious structure aggregate,0.5706896551724138
transmissibility disposition,communicability end temporal region,0.6880952380952381
transmissibility disposition,geographical entity,0.598936170212766
transmissibility disposition,biological regulation,0.6336734693877552
transmissibility disposition,surveillance process,0.5958333333333333
transmissibility disposition,infection end temporal region,0.6078947368421053
transmissibility disposition,vector control strategy,0.5872549019607843
transmissibility disposition,SARS-CoV-2 incidence rate,0.5632075471698114
transmissibility disposition,incubation end temporal region,0.6224137931034482
transmissibility disposition,resistant entity,0.6318181818181818
transmissibility disposition,virulence factor disposition,0.7178571428571427
transmissibility disposition,viral adhesion disposition,0.7462962962962962
transmissibility disposition,parasitostatic disposition,0.7833333333333333
transmissibility disposition,negative regulation of production,0.630327868852459
transmissibility disposition,reverse zoonotic disposition,0.7178571428571427
transmissibility disposition,establishment of localization in host,0.65
transmissibility disposition,disease surveillance objective specification,0.6444444444444444
transmissibility disposition,case isolation control strategy,0.6194915254237288
transmissibility disposition,infectious agent host role,0.6166666666666667
transmissibility disposition,macromolecular complex,0.55
transmissibility disposition,material entity,0.6127906976744186
transmissibility disposition,asymptomatic infectious structure carrier,0.6094202898550725
transmissibility disposition,architectual structure,0.57
transmissibility disposition,quarantine control strategy,0.5954545454545455
transmissibility disposition,B cell receptor complex,0.5676470588235294
transmissibility disposition,infection incidence rate,0.5846153846153846
transmissibility disposition,colonized host,0.5928571428571429
transmissibility disposition,virus host,0.6078947368421053
transmissibility disposition,entity,0.5676470588235294
transmissibility disposition,toxin disposition,0.7611111111111112
transmissibility disposition,cidal agent disposition,0.7441176470588234
transmissibility disposition,parasiticidal disposition,0.808490566037736
transmissibility disposition,communicability end process boundary,0.684375
transmissibility disposition,directive information content entity,0.590625
transmissibility disposition,acellular structure aggregate,0.537719298245614
transmissibility disposition,transmissibility disposition,0.95
transmissibility disposition,latency end process boundary,0.6285714285714286
transmissibility disposition,colonization of host,0.5958333333333333
transmissibility disposition,realizable entity,0.6277777777777778
transmissibility disposition,endotoxin disposition,0.7357142857142857
transmissibility disposition,vector surveillance,0.5776595744680851
transmissibility disposition,negative regulation of establishment of localization,0.65
transmissibility disposition,infectious structure host role,0.6224137931034482
transmissibility disposition,COVID-19 incidence rate,0.5480392156862746
transmissibility disposition,cytotoxin disposition,0.7357142857142857
transmissibility disposition,negative regulation of developmental process,0.5888888888888889
transmissibility disposition,host,0.54375
transmissibility disposition,descriptive information content entity,0.6015151515151516
transmissibility disposition,negative regulation of replication,0.6274193548387097
transmissibility disposition,establishment of localization in human host,0.6330985915492958
transmissibility disposition,acellular structure,0.5563829787234043
transmissibility disposition,incubation end process boundary,0.6194915254237288
transmissibility disposition,collective pathogenic disposition,0.7122950819672131
transmissibility disposition,neurotoxin disposition,0.73
transmissibility disposition,dead-end host role,0.6021739130434782
transmissibility disposition,molecular entity,0.5636363636363636
transmissibility disposition,plan specification,0.6673913043478261
transmissibility disposition,definitive host role,0.6166666666666667
transmissibility disposition,latency end temporal region,0.6318181818181818
transmissibility disposition,infectious structure,0.575
transmissibility disposition,collective disposition,0.73
transmissibility disposition,static agent disposition,0.7576923076923078
transmissibility disposition,T cell receptor complex,0.5676470588235294
transmissibility disposition,infectious structure host,0.619811320754717
transmissibility disposition,respiratory system disease,0.6537037037037037
transmissibility disposition,entry into host,0.636046511627907
transmissibility disposition,adhesion of symbiont to host,0.6464285714285714
transmissibility disposition,infectious disease control strategy,0.6087301587301588
transmissibility disposition,infectious structure generative stage,0.5884615384615385
transmissibility disposition,immunosuppressive disposition,0.7482456140350877
transmissibility disposition,pathogenic disposition,0.75
transmissibility disposition,entry into host through host barriers,0.6038461538461539
transmissibility disposition,infectious disposition,0.75
transmissibility disposition,bacteriostatic disposition,0.7648148148148148
transmissibility disposition,bactericidal disposition,0.7769230769230769
transmissibility disposition,pathogen host,0.5963414634146341
transmissibility disposition,invasion disposition,0.7625
transmissibility disposition,viricidal disposition,0.7765306122448979
transmissibility disposition,complex infection,0.6277777777777778
transmissibility disposition,intermediate host,0.65
transmissibility disposition,SARS-CoV-2 transmissibility,0.740909090909091
transmissibility disposition,anatomical entity,0.6277777777777778
transmissibility disposition,disposition,0.732051282051282
transmissibility disposition,COVID-19 mortality rate,0.6068627450980393
transmissibility disposition,negative regulation of life-sustaining process,0.6256756756756756
transmissibility disposition,place closure control strategy,0.553448275862069
transmissibility disposition,geopolitical entity,0.5776595744680851
transmissibility disposition,adhesion disposition,0.7625
transmissibility disposition,symptomatic infectious structure carrier,0.5970588235294118
transmissibility disposition,primary infectious disposition,0.743103448275862
transmissibility disposition,pathogen host role,0.6021739130434782
transmissibility disposition,designative information content entity,0.6015151515151516
transmissibility disposition,infectious pathogen transmissibility,0.7
transmissibility disposition,intermediate host role,0.65
transmissibility disposition,dead-end host,0.5963414634146341
transmissibility disposition,pathogen surveillance,0.5724489795918367
transmissibility disposition,host role,0.5581081081081081
transmissibility disposition,establishment of localization in virus host,0.6330985915492958
transmissibility disposition,negative regulation of immune response,0.6015151515151516
transmissibility disposition,immaterial entity,0.6055555555555556
transmissibility disposition,SARS-COV-2 adhesion disposition,0.7211864406779661
transmissibility disposition,invasive disposition,0.7625
transmissibility disposition,infectious agent host,0.6132653061224489
transmissibility disposition,fungicidal disposition,0.77
transmissibility disposition,division of geopolitical entity,0.6194915254237288
transmissibility disposition,negative regulation of viral process,0.60625
transmissibility disposition,exotoxin disposition,0.7416666666666667
transmissibility disposition,immunoglobulin complex,0.57
transmissibility disposition,infectious disease control objective specification,0.6423076923076922
transmissibility disposition,symbiont host role,0.6673913043478261
transmissibility disposition,opportunistic infectious disposition,0.746875
transmissibility disposition,negative regulation of biological process,0.6239130434782608
transmissibility disposition,enterotoxin disposition,0.7441176470588234
transmissibility disposition,infectious disease incidence rate,0.630327868852459
transmissibility disposition,collective resistance disposition,0.7450819672131148
transmissibility disposition,fungistatic disposition,0.7637254901960785
transmissibility disposition,establishment of a clinically abnormal colony,0.6143835616438357
transmissibility disposition,definitive host,0.6127906976744186
pathologic immunosuppression,physiologic immunosuppression,0.9061403508771929
pathologic immunosuppression,T cell receptor complex,0.5872549019607843
pathologic immunosuppression,immunosuppression,0.8277777777777777
pathologic immunosuppression,pathologic immunosuppression,0.95
pathologic immunosuppression,establishment of a clinically abnormal colony,0.6143835616438357
cidal agent,information content entity,0.6121621621621621
cidal agent,infectious disease mortality rate,0.6318181818181818
cidal agent,infection incidence rate profile,0.5895348837209302
cidal agent,communicability end temporal region,0.6239130434782608
cidal agent,infection end temporal region,0.65
cidal agent,SARS-CoV-2 incidence rate,0.6166666666666667
cidal agent,incubation end temporal region,0.6451219512195122
cidal agent,virulence factor disposition,0.5782051282051281
cidal agent,infectious agent host role,0.6662162162162162
cidal agent,asymptomatic infectious structure carrier,0.5461538461538461
cidal agent,B cell receptor complex,0.5970588235294118
cidal agent,passive immunization against infectious agent,0.5928571428571429
cidal agent,infection incidence rate,0.6214285714285714
cidal agent,acute infectious disease course,0.5928571428571429
cidal agent,cidal agent disposition,0.7735294117647058
cidal agent,biological vehicle,0.6224137931034482
cidal agent,communicability end process boundary,0.598936170212766
cidal agent,directive information content entity,0.598936170212766
cidal agent,infectious agent colony,0.6852941176470588
cidal agent,pathogen transporter,0.6112903225806451
cidal agent,invasion factor,0.6423076923076922
cidal agent,latency end process boundary,0.5782051282051281
cidal agent,infectious agent generative stage,0.6318181818181818
cidal agent,cidal agent,0.95
cidal agent,pathogen vehicle,0.5981481481481481
cidal agent,COVID-19 incidence rate,0.6558823529411765
cidal agent,pathogen vehicle role,0.575
cidal agent,chronic infectious disease course,0.5863636363636363
cidal agent,asymptomatic infectious agent carrier,0.6166666666666667
cidal agent,descriptive information content entity,0.5928571428571429
cidal agent,sterilizing immunity to infectious agent,0.6068627450980393
cidal agent,virulence factor,0.6351851851851852
cidal agent,incubation end process boundary,0.5928571428571429
cidal agent,latency end temporal region,0.6342105263157894
cidal agent,innate immunity to infectious agent,0.6239130434782608
cidal agent,static agent disposition,0.65
cidal agent,T cell receptor complex,0.5970588235294118
cidal agent,asymptomatic carrier role,0.5611111111111111
cidal agent,infectious agent population,0.6605263157894737
cidal agent,leukocyte-mediated immunity to infectious agent,0.6051724137931035
cidal agent,humoral immunity to infectious agent,0.6202127659574468
cidal agent,viral disease course,0.6435483870967742
cidal agent,passive immunity to infectious agent,0.6202127659574468
cidal agent,vaccination against infectious agent,0.6414893617021277
cidal agent,susceptibility to infectious agent,0.65
cidal agent,disease course,0.61
cidal agent,infectious disease course,0.6166666666666667
cidal agent,acquired immunity to infectious agent,0.6375
cidal agent,coronavirus disease course,0.6121621621621621
cidal agent,asymptomatic carrier,0.5790322580645162
cidal agent,biological vehicle role,0.5970588235294118
cidal agent,symptomatic infectious agent carrier,0.6202127659574468
cidal agent,intermediate host,0.6285714285714286
cidal agent,COVID-19 mortality rate,0.6852941176470588
cidal agent,symptomatic infectious structure carrier,0.5480392156862746
cidal agent,designative information content entity,0.5928571428571429
cidal agent,symptomatic carrier role,0.5642857142857143
cidal agent,intermediate host role,0.6015151515151516
cidal agent,immunization against infectious agent,0.6166666666666667
cidal agent,infectious agent host,0.7
cidal agent,long-term non-progressing infectious disease course,0.5467741935483871
cidal agent,symptomatic carrier,0.5833333333333334
cidal agent,function,0.6078947368421053
cidal agent,pathogen transporter role,0.5888888888888889
cidal agent,infectious agent reservoir,0.6662162162162162
cidal agent,action specification,0.6112903225806451
cidal agent,polymerase chain reaction,0.5888888888888889
cidal agent,COVID-19 disease course,0.6264705882352941
cidal agent,infectious disease incidence rate,0.6318181818181818
cidal agent,active immunization against infectious agent,0.6136363636363636
cidal agent,infectious agent,0.7462962962962962
cidal agent,establishment of a clinically abnormal colony,0.575
cidal agent,adhesion factor,0.6038461538461539
cidal agent,drug susceptibility of infectious agent,0.63
cidal agent,static agent,0.7543478260869566
pathogen portal of entry role,extended organism,0.6239130434782608
pathogen portal of entry role,virus aggregate,0.5863636363636363
pathogen portal of entry role,source of infection,0.6375
pathogen portal of entry role,infectious disease mortality rate,0.6758064516129032
pathogen portal of entry role,infection incidence rate profile,0.6631147540983606
pathogen portal of entry role,communicability end temporal region,0.653125
pathogen portal of entry role,pathogen generative stage,0.7092592592592593
pathogen portal of entry role,pathogen portal of entry,0.9028301886792454
pathogen portal of entry role,subclinical coronavirus infection,0.6112903225806451
pathogen portal of entry role,primary pathogen,0.6277777777777778
pathogen portal of entry role,infection end temporal region,0.6741379310344828
pathogen portal of entry role,drug-based immunosuppressed organism,0.573076923076923
pathogen portal of entry role,infectious disease,0.5776595744680851
pathogen portal of entry role,double-stranded DNA virus,0.5981481481481481
pathogen portal of entry role,incubation end temporal region,0.6872881355932203
pathogen portal of entry role,site of infection,0.6456521739130434
pathogen portal of entry role,immunocompetent organism,0.619811320754717
pathogen portal of entry role,pathogen portal of exit,0.8538461538461539
pathogen portal of entry role,infectious disease incidence,0.5903508771929825
pathogen portal of entry role,reservoir of pathogen role,0.7045454545454546
pathogen portal of entry role,subclinical SARS-CoV-2 infection,0.5975409836065574
pathogen portal of entry role,virus translation stage,0.6038461538461539
pathogen portal of entry role,disease surveillance objective specification,0.6006849315068493
pathogen portal of entry role,case isolation control strategy,0.6666666666666667
pathogen portal of entry role,virus release stage,0.575
pathogen portal of entry role,infectious agent host role,0.7045454545454546
pathogen portal of entry role,source of infection site,0.6386792452830189
pathogen portal of entry role,virus replication,0.558695652173913
pathogen portal of entry role,B cell receptor complex,0.6423076923076922
pathogen portal of entry role,passive immunization against infectious agent,0.6256756756756756
pathogen portal of entry role,systematic infection,0.6132653061224489
pathogen portal of entry role,infection incidence rate,0.619811320754717
pathogen portal of entry role,virus host,0.5525641025641026
pathogen portal of entry role,double-stranded RNA virus,0.5981481481481481
pathogen portal of entry role,pathogen portal of entry role,0.95
pathogen portal of entry role,virus transcription stage,0.5981481481481481
pathogen portal of entry role,infectious disease lifetime prevalence,0.6291044776119403
pathogen portal of entry role,pathogen birth temporal region,0.738135593220339
pathogen portal of entry role,lower respiratory tract disease,0.65
pathogen portal of entry role,infectious disease incidence proportion,0.6117647058823529
pathogen portal of entry role,opportunistic pathogen,0.6460784313725491
pathogen portal of entry role,virus generative stage,0.6068627450980393
pathogen portal of entry role,acute infectious disease course,0.6333333333333333
pathogen portal of entry role,cidal agent disposition,0.6423076923076922
pathogen portal of entry role,role,0.5712121212121213
pathogen portal of entry role,genetic resistance to pathogen,0.6703389830508475
pathogen portal of entry role,subclinical infection,0.61
pathogen portal of entry role,appearance of disorder,0.6460784313725491
pathogen portal of entry role,simple infection,0.6055555555555556
pathogen portal of entry role,droplet pathogen transmission process,0.7075757575757575
pathogen portal of entry role,infectious disease sporadicity,0.6194915254237288
pathogen portal of entry role,mutualist role,0.6593023255813953
pathogen portal of entry role,communicability end process boundary,0.6346153846153847
pathogen portal of entry role,infection incidence proportion profile,0.6888059701492537
pathogen portal of entry role,infectious agent colony,0.6615384615384616
pathogen portal of entry role,pathogen transporter,0.7561224489795919
pathogen portal of entry role,latency end process boundary,0.6605263157894737
pathogen portal of entry role,infectious disease epidemic,0.575
pathogen portal of entry role,infectious agent generative stage,0.6435483870967742
pathogen portal of entry role,disease transmission model,0.6318181818181818
pathogen portal of entry role,pathologically immunosuppressed organism,0.6384057971014493
pathogen portal of entry role,negative-sense single-stranded RNA virus,0.6094202898550725
pathogen portal of entry role,cidal agent,0.6
pathogen portal of entry role,infectious structure host role,0.6703389830508475
pathogen portal of entry role,pathogen vehicle,0.7166666666666667
pathogen portal of entry role,community-acquired infection,0.6078947368421053
pathogen portal of entry role,pathogen vector,0.7227272727272727
pathogen portal of entry role,pathogen vehicle role,0.77
pathogen portal of entry role,chronic infectious disease course,0.6274193548387097
pathogen portal of entry role,asymptomatic infectious agent carrier,0.6469696969696969
pathogen portal of entry role,nursing-home acquired infection,0.6166666666666667
pathogen portal of entry role,secondary infection,0.6166666666666667
pathogen portal of entry role,mechanical vector role,0.7049019607843137
pathogen portal of entry role,infection start temporal region,0.65
pathogen portal of entry role,infection incidence,0.5958333333333333
pathogen portal of entry role,virus disorder,0.5662790697674418
pathogen portal of entry role,sterilizing immunity to infectious agent,0.6239130434782608
pathogen portal of entry role,primary infection,0.6239130434782608
pathogen portal of entry role,process of establishing an infection,0.65
pathogen portal of entry role,incubation end process boundary,0.6666666666666667
pathogen portal of entry role,dead-end host role,0.6840425531914894
pathogen portal of entry role,pathogen death process boundary,0.7166666666666667
pathogen portal of entry role,immunosuppressed organism,0.5796296296296296
pathogen portal of entry role,definitive host role,0.6744897959183673
pathogen portal of entry role,latency end temporal region,0.6821428571428573
pathogen portal of entry role,innate immunity to infectious agent,0.6375
pathogen portal of entry role,virus adhesion susceptible cell,0.6333333333333333
pathogen portal of entry role,infection,0.581578947368421
pathogen portal of entry role,static agent disposition,0.6575471698113208
pathogen portal of entry role,T cell receptor complex,0.6615384615384616
pathogen portal of entry role,asymptomatic carrier role,0.6722222222222223
pathogen portal of entry role,infectious agent population,0.6464285714285714
pathogen portal of entry role,respiratory system disease,0.6136363636363636
pathogen portal of entry role,entry into host,0.6318181818181818
pathogen portal of entry role,leukocyte-mediated immunity to infectious agent,0.6078947368421053
pathogen portal of entry role,indirect pathogen transmission process,0.703731343283582
pathogen portal of entry role,organism population,0.6375
pathogen portal of entry role,humoral immunity to infectious agent,0.6346153846153847
pathogen portal of entry role,infectious disease control strategy,0.6375
pathogen portal of entry role,parasite,0.6121621621621621
pathogen portal of entry role,infectious disease pandemic,0.5928571428571429
pathogen portal of entry role,antibody reagent,0.65
pathogen portal of entry role,viral disease course,0.6132653061224489
pathogen portal of entry role,entry into host through host barriers,0.6318181818181818
pathogen portal of entry role,intracellular infection,0.6230769230769231
pathogen portal of entry role,secondary infection role,0.6764150943396227
pathogen portal of entry role,metastatic infection,0.6132653061224489
pathogen portal of entry role,passive immunity to infectious agent,0.6346153846153847
pathogen portal of entry role,vaccination against infectious agent,0.6346153846153847
pathogen portal of entry role,acute infection,0.6318181818181818
pathogen portal of entry role,susceptibility to infectious agent,0.6246031746031746
pathogen portal of entry role,epitope site,0.6207317073170732
pathogen portal of entry role,immunity to pathogen,0.6132653061224489
pathogen portal of entry role,source of infection role,0.6952830188679244
pathogen portal of entry role,pathogen host,0.7119047619047619
pathogen portal of entry role,chronic infection,0.6239130434782608
pathogen portal of entry role,disease course,0.5895348837209302
pathogen portal of entry role,infectious disease course,0.5981481481481481
pathogen portal of entry role,acquired immunity to infectious agent,0.6166666666666667
pathogen portal of entry role,complex infection,0.6239130434782608
pathogen portal of entry role,COVID-19 disease incidence proportion,0.6015151515151516
pathogen portal of entry role,coronavirus disease course,0.5954545454545455
pathogen portal of entry role,biological vehicle role,0.6615384615384616
pathogen portal of entry role,infection incidence proportion,0.6364406779661017
pathogen portal of entry role,symptomatic infectious agent carrier,0.65
pathogen portal of entry role,respiratory droplet virus fomite,0.6631147540983606
pathogen portal of entry role,symbiont role,0.6404761904761905
pathogen portal of entry role,susceptible organism,0.6132653061224489
pathogen portal of entry role,parasite role,0.6880952380952381
pathogen portal of entry role,pathogen vector role,0.7969387755102041
pathogen portal of entry role,pathogen portal of exit site,0.8535087719298246
pathogen portal of entry role,infectious disease prevalence,0.6396551724137931
pathogen portal of entry role,organism substance,0.6202127659574468
pathogen portal of entry role,single-stranded DNA virus,0.5981481481481481
pathogen portal of entry role,contact tracing,0.609090909090909
pathogen portal of entry role,viral disease,0.5928571428571429
pathogen portal of entry role,primary infection role,0.6852941176470588
pathogen portal of entry role,biological role,0.6545454545454545
pathogen portal of entry role,pathogen portal of entry site,0.8982758620689656
pathogen portal of entry role,infection incidence profile,0.6464285714285714
pathogen portal of entry role,disease,0.5333333333333333
pathogen portal of entry role,biological vector role,0.7049019607843137
pathogen portal of entry role,site,0.5106060606060606
pathogen portal of entry role,pathogen host role,0.7904255319148936
pathogen portal of entry role,infection prevalence,0.6744897959183673
pathogen portal of entry role,symptomatic carrier role,0.6764150943396227
pathogen portal of entry role,infectious pathogen transmissibility,0.6653846153846155
pathogen portal of entry role,incubation start process boundary,0.6596774193548387
pathogen portal of entry role,intermediate host role,0.6852941176470588
pathogen portal of entry role,pathogen surveillance,0.71
pathogen portal of entry role,immunodeficient organism,0.6009433962264151
pathogen portal of entry role,host role,0.6605263157894737
pathogen portal of entry role,pathogen,0.6662162162162162
pathogen portal of entry role,pathogen birth process boundary,0.7333333333333333
pathogen portal of entry role,infectious human pathogen,0.6166666666666667
pathogen portal of entry role,subclinical virus infection,0.5928571428571429
pathogen portal of entry role,resistance to pathogen,0.6264705882352941
pathogen portal of entry role,establishment of localization in virus host,0.6444444444444444
pathogen portal of entry role,immunization against infectious agent,0.6318181818181818
pathogen portal of entry role,virus attachment stage,0.6264705882352941
pathogen portal of entry role,virus synthesis stage,0.59
pathogen portal of entry role,pathogen portal of exit role,0.9061403508771929
pathogen portal of entry role,infectious agent host,0.63
pathogen portal of entry role,re-emerging pathogen,0.6132653061224489
pathogen portal of entry role,long-term non-progressing infectious disease course,0.625
pathogen portal of entry role,viral disease epidemic,0.5872549019607843
pathogen portal of entry role,commensal role,0.6825581395348838
pathogen portal of entry role,epitope role,0.6939024390243902
pathogen portal of entry role,viral disease pandemic,0.5872549019607843
pathogen portal of entry role,virus penetration stage,0.6230769230769231
pathogen portal of entry role,pathogen seroprevalence,0.7576923076923078
pathogen portal of entry role,infectious disease endemicity,0.6051724137931035
pathogen portal of entry role,contact pathogen transmission process,0.7075757575757575
pathogen portal of entry role,function,0.5581081081081081
pathogen portal of entry role,herd immunity to infectious organism,0.6192307692307693
pathogen portal of entry role,extracellular infection,0.6230769230769231
pathogen portal of entry role,pathogen transporter role,0.8203703703703704
pathogen portal of entry role,infectious agent reservoir,0.6318181818181818
pathogen portal of entry role,antigen role,0.6939024390243902
pathogen portal of entry role,infection start process boundary,0.6467213114754098
pathogen portal of entry role,action specification,0.6336734693877552
pathogen portal of entry role,latency start process boundary,0.6703389830508475
pathogen portal of entry role,infectious disease control objective specification,0.6145569620253164
pathogen portal of entry role,symbiont host role,0.6840425531914894
pathogen portal of entry role,fomite role,0.65
pathogen portal of entry role,process of establishing viral infection,0.6411764705882353
pathogen portal of entry role,COVID-19 disease course,0.5846153846153846
pathogen portal of entry role,infectious disease incidence rate,0.6112903225806451
pathogen portal of entry role,communicability start process boundary,0.6141791044776119
pathogen portal of entry role,active immunization against infectious agent,0.6143835616438357
pathogen portal of entry role,disordered virus,0.5833333333333334
pathogen portal of entry role,reagent role,0.6939024390243902
pathogen portal of entry role,viral load,0.5782051282051281
pathogen portal of entry role,organism,0.5581081081081081
pathogen portal of entry role,virus uncoating stage,0.59
pathogen portal of entry role,local infection,0.6318181818181818
pathogen portal of entry role,infectious agent,0.6055555555555556
pathogen portal of entry role,establishment of a clinically abnormal colony,0.6527027027027027
pathogen portal of entry role,process boundary,0.6277777777777778
pathogen portal of entry role,coronavirus disease,0.5958333333333333
pathogen portal of entry role,positive-sense single-stranded RNA virus,0.6094202898550725
pathogen portal of entry role,horizontal pathogen transmission process,0.696376811594203
pathogen portal of entry role,hospital-acquired infection,0.6464285714285714
pathogen portal of entry role,pathogen death temporal region,0.738135593220339
pathogen portal of entry role,emerging pathogen,0.6239130434782608
pathogen portal of entry role,drug susceptibility of infectious agent,0.6411764705882353
pathogen portal of entry role,static agent,0.6207317073170732
pathogen portal of entry role,pathogen transmission process,0.743103448275862
process boundary,immune response,0.6112903225806451
process boundary,infectious disease mortality rate,0.5928571428571429
process boundary,infection incidence rate profile,0.575
process boundary,communicability end temporal region,0.5872549019607843
process boundary,pathogen generative stage,0.5963414634146341
process boundary,surveillance process,0.6444444444444444
process boundary,infection end temporal region,0.5833333333333334
process boundary,SARS-CoV-2 incidence rate,0.5963414634146341
process boundary,incubation end temporal region,0.6021739130434782
process boundary,virus translation stage,0.6038461538461539
process boundary,case isolation control strategy,0.6202127659574468
process boundary,virus release stage,0.5928571428571429
process boundary,B cell receptor complex,0.5782051282051281
process boundary,infection incidence rate,0.575
process boundary,virus transcription stage,0.5963414634146341
process boundary,virus generative stage,0.581578947368421
process boundary,acute infectious disease course,0.6202127659574468
process boundary,process,0.7543478260869566
process boundary,droplet pathogen transmission process,0.6009433962264151
process boundary,communicability end process boundary,0.7576923076923078
process boundary,latency end process boundary,0.8136363636363637
process boundary,infectious agent generative stage,0.5520408163265306
process boundary,COVID-19 incidence rate,0.5782051282051281
process boundary,negative regulation of developmental process,0.5666666666666667
process boundary,chronic infectious disease course,0.6540816326530612
process boundary,process of establishing an infection,0.6615384615384616
process boundary,incubation end process boundary,0.7904255319148936
process boundary,SARS-CoV-2 uncoating stage,0.5928571428571429
process boundary,pathogen death process boundary,0.7904255319148936
process boundary,plan specification,0.5676470588235294
process boundary,latency end temporal region,0.5895348837209302
process boundary,SARS-CoV-2 penetration stage,0.5863636363636363
process boundary,anatomical space,0.575
process boundary,T cell receptor complex,0.5782051282051281
process boundary,respiratory system disease,0.6404761904761905
process boundary,indirect pathogen transmission process,0.5981481481481481
process boundary,planned process,0.6758064516129032
process boundary,generative stage,0.575
process boundary,SARS-CoV-2 attachment stage,0.5895348837209302
process boundary,infectious structure generative stage,0.5632075471698114
process boundary,innate immune response,0.581578947368421
process boundary,viral disease course,0.6444444444444444
process boundary,disease course,0.65
process boundary,infectious disease course,0.6207317073170732
process boundary,coronavirus disease course,0.6404761904761905
process boundary,SARS-CoV-2 genome replication stage,0.5872549019607843
process boundary,COVID-19 mortality rate,0.5782051282051281
process boundary,process profile,0.7403225806451613
process boundary,negative regulation of life-sustaining process,0.5629032258064516
process boundary,place closure control strategy,0.6456521739130434
process boundary,developmental process,0.6391891891891892
process boundary,biological process,0.6558823529411765
process boundary,humoral immune response,0.5782051282051281
process boundary,incubation start process boundary,0.7765306122448979
process boundary,pathogen birth process boundary,0.7904255319148936
process boundary,virus attachment stage,0.581578947368421
process boundary,negative regulation of immune response,0.5796296296296296
process boundary,SARS-CoV-2 transcription stage,0.5804347826086956
process boundary,virus synthesis stage,0.6121621621621621
process boundary,long-term non-progressing infectious disease course,0.6291044776119403
process boundary,virus penetration stage,0.6038461538461539
process boundary,algorithm,0.53
process boundary,negative regulation of viral process,0.5846153846153846
process boundary,contact pathogen transmission process,0.6009433962264151
process boundary,function,0.575
process boundary,symbiotic process,0.6621212121212122
process boundary,infection start process boundary,0.7833333333333333
process boundary,action specification,0.5611111111111111
process boundary,SARS-CoV-2 synthesis stage,0.6166666666666667
process boundary,latency start process boundary,0.7978260869565217
process boundary,process of establishing viral infection,0.65
process boundary,negative regulation of biological process,0.5728070175438597
process boundary,polymerase chain reaction,0.6207317073170732
process boundary,COVID-19 disease course,0.6294871794871795
process boundary,infectious disease incidence rate,0.5928571428571429
process boundary,communicability start process boundary,0.7462962962962962
process boundary,process that results in death,0.7166666666666667
process boundary,adaptive immune response,0.6
process boundary,virus uncoating stage,0.6121621621621621
process boundary,establishment of a clinically abnormal colony,0.5975409836065574
process boundary,process boundary,0.95
process boundary,horizontal pathogen transmission process,0.5928571428571429
process boundary,SARS-CoV-2 release stage,0.6
process boundary,pathogen transmission process,0.6277777777777778
process boundary,cell space,0.6038461538461539
primary infection role,virus aggregate,0.6121621621621621
primary infection role,source of infection,0.7182926829268292
primary infection role,virostatic disposition,0.6318181818181818
primary infection role,zoonotic disposition,0.6166666666666667
primary infection role,infectious disease mortality rate,0.6681818181818181
primary infection role,infection incidence rate profile,0.7092592592592593
primary infection role,communicability end temporal region,0.6254385964912281
primary infection role,subclinical coronavirus infection,0.6863636363636364
primary infection role,primary pathogen,0.7394736842105263
primary infection role,infection end temporal region,0.7049019607843137
primary infection role,vector control strategy,0.65
primary infection role,infectious disease,0.7
primary infection role,double-stranded DNA virus,0.598936170212766
primary infection role,incubation end temporal region,0.6615384615384616
primary infection role,site of infection,0.732051282051282
primary infection role,virulence factor disposition,0.63
primary infection role,viral adhesion disposition,0.6375
primary infection role,parasitostatic disposition,0.6583333333333334
primary infection role,infectious disease incidence,0.65
primary infection role,reservoir of pathogen role,0.7208333333333333
primary infection role,reverse zoonotic disposition,0.63
primary infection role,subclinical SARS-CoV-2 infection,0.6907407407407408
primary infection role,virus translation stage,0.6722222222222223
primary infection role,disease surveillance objective specification,0.6166666666666667
primary infection role,case isolation control strategy,0.6764150943396227
primary infection role,virus release stage,0.5963414634146341
primary infection role,infectious agent host role,0.7416666666666667
primary infection role,source of infection site,0.7326086956521739
primary infection role,virus,0.524074074074074
primary infection role,quarantine control strategy,0.6948979591836735
primary infection role,virus replication,0.6807692307692308
primary infection role,B cell receptor complex,0.65
primary infection role,systematic infection,0.7357142857142857
primary infection role,infection incidence rate,0.7108695652173913
primary infection role,virus host,0.575
primary infection role,double-stranded RNA virus,0.598936170212766
primary infection role,pathogen portal of entry role,0.6852941176470588
primary infection role,virus transcription stage,0.6840425531914894
primary infection role,infectious disease lifetime prevalence,0.65
primary infection role,toxin disposition,0.6294871794871795
primary infection role,lower respiratory tract disease,0.6386792452830189
primary infection role,infectious disease incidence proportion,0.6467213114754098
primary infection role,virus generative stage,0.6545454545454545
primary infection role,acute infectious disease course,0.6952830188679244
primary infection role,cidal agent disposition,0.6277777777777778
primary infection role,infectious disorder,0.7182926829268292
primary infection role,role,0.6038461538461539
primary infection role,subclinical infection,0.7290697674418604
primary infection role,appearance of disorder,0.6545454545454545
primary infection role,simple infection,0.7657894736842106
primary infection role,parasiticidal disposition,0.6627659574468084
primary infection role,infectious disease sporadicity,0.6423076923076922
primary infection role,mutualist role,0.7
primary infection role,communicability end process boundary,0.6224137931034482
primary infection role,infection incidence proportion profile,0.7
primary infection role,transmissibility disposition,0.63
primary infection role,latency end process boundary,0.63
primary infection role,infectious disease epidemic,0.6540816326530612
primary infection role,disease transmission model,0.6583333333333334
primary infection role,endotoxin disposition,0.6127906976744186
primary infection role,negative-sense single-stranded RNA virus,0.5951612903225807
primary infection role,infectious structure host role,0.7
primary infection role,cytotoxin disposition,0.6127906976744186
primary infection role,community-acquired infection,0.71
primary infection role,pathogen vehicle role,0.6825581395348838
primary infection role,chronic infectious disease course,0.7045454545454546
primary infection role,nursing-home acquired infection,0.7330188679245283
primary infection role,COVID-19 epidemic,0.5782051282051281
primary infection role,secondary infection,0.7670731707317073
primary infection role,mechanical vector role,0.7227272727272727
primary infection role,infection start temporal region,0.7141509433962264
primary infection role,infection incidence,0.7182926829268292
primary infection role,virus disorder,0.6444444444444444
primary infection role,primary infection,0.8858974358974359
primary infection role,process of establishing an infection,0.6913793103448276
primary infection role,incubation end process boundary,0.6575471698113208
primary infection role,SARS-CoV-2 disorder,0.6207317073170732
primary infection role,collective pathogenic disposition,0.5954545454545455
primary infection role,neurotoxin disposition,0.6318181818181818
primary infection role,dead-end host role,0.65
primary infection role,definitive host role,0.6880952380952381
primary infection role,latency end temporal region,0.6336734693877552
primary infection role,virus adhesion susceptible cell,0.6386792452830189
primary infection role,collective disposition,0.609090909090909
primary infection role,infection,0.7403225806451613
primary infection role,static agent disposition,0.6239130434782608
primary infection role,T cell receptor complex,0.65
primary infection role,asymptomatic carrier role,0.6840425531914894
primary infection role,respiratory system disease,0.6375
primary infection role,communicability interval,0.6456521739130434
primary infection role,infectious disease control strategy,0.6780701754385965
primary infection role,infectious disease pandemic,0.6540816326530612
primary infection role,immunosuppressive disposition,0.6264705882352941
primary infection role,pathogenic disposition,0.6318181818181818
primary infection role,viral disease course,0.6642857142857143
primary infection role,intracellular infection,0.7388888888888888
primary infection role,secondary infection role,0.8413043478260869
primary infection role,metastatic infection,0.7357142857142857
primary infection role,infectious disposition,0.6772727272727272
primary infection role,acute infection,0.7472972972972972
primary infection role,bacteriostatic disposition,0.6375
primary infection role,bactericidal disposition,0.6456521739130434
primary infection role,source of infection role,0.7978260869565217
primary infection role,chronic infection,0.7576923076923078
primary infection role,invasion disposition,0.6404761904761905
primary infection role,disease course,0.6444444444444444
primary infection role,infectious disease course,0.6840425531914894
primary infection role,viricidal disposition,0.6593023255813953
primary infection role,complex infection,0.732051282051282
primary infection role,COVID-19 disease incidence proportion,0.6364406779661017
primary infection role,coronavirus disease course,0.6583333333333334
primary infection role,biological vehicle role,0.6722222222222223
primary infection role,infection incidence proportion,0.6807692307692308
primary infection role,respiratory droplet virus fomite,0.6722222222222223
primary infection role,symbiont role,0.7071428571428571
primary infection role,parasite role,0.7357142857142857
primary infection role,pathogen vector role,0.7357142857142857
primary infection role,infectious disease prevalence,0.6852941176470588
primary infection role,disposition,0.6318181818181818
primary infection role,single-stranded DNA virus,0.598936170212766
primary infection role,place closure control strategy,0.6615384615384616
primary infection role,viral disease,0.6214285714285714
primary infection role,primary infection role,0.95
primary infection role,primary immunodeficiency,0.7543478260869566
primary infection role,biological role,0.6662162162162162
primary infection role,adhesion disposition,0.6166666666666667
primary infection role,infection incidence profile,0.7357142857142857
primary infection role,contagiousness,0.6166666666666667
primary infection role,disease,0.553448275862069
primary infection role,biological vector role,0.7227272727272727
primary infection role,primary infectious disposition,0.7961538461538461
primary infection role,pathogen host role,0.7
primary infection role,infection prevalence,0.7595238095238095
primary infection role,symptomatic carrier role,0.6891304347826087
primary infection role,coronavirus disorder,0.6404761904761905
primary infection role,intermediate host role,0.6772727272727272
primary infection role,host role,0.6435483870967742
primary infection role,subclinical virus infection,0.7153061224489795
primary infection role,establishment of localization in virus host,0.6346153846153847
primary infection role,virus attachment stage,0.609090909090909
primary infection role,virus synthesis stage,0.636046511627907
primary infection role,SARS-COV-2 adhesion disposition,0.619811320754717
primary infection role,pathogen portal of exit role,0.69
primary infection role,invasive disposition,0.6404761904761905
primary infection role,long-term non-progressing infectious disease course,0.6554794520547945
primary infection role,viral disease epidemic,0.609090909090909
primary infection role,commensal role,0.6722222222222223
primary infection role,communicability start temporal region,0.6025423728813559
primary infection role,epitope role,0.7147058823529412
primary infection role,fungicidal disposition,0.6318181818181818
primary infection role,viral disease pandemic,0.609090909090909
primary infection role,virus penetration stage,0.6944444444444444
primary infection role,acute respiratory distress syndrome,0.6605263157894737
primary infection role,infectious disease endemicity,0.6460784313725491
primary infection role,disorder,0.5833333333333334
primary infection role,function,0.65
primary infection role,communicability,0.5851351351351352
primary infection role,extracellular infection,0.7388888888888888
primary infection role,pathogen transporter role,0.6627659574468084
primary infection role,exotoxin disposition,0.6166666666666667
primary infection role,antigen role,0.7441176470588234
primary infection role,infection start process boundary,0.6907407407407408
primary infection role,action specification,0.6642857142857143
primary infection role,infectious disease control objective specification,0.6305555555555555
primary infection role,symbiont host role,0.7
primary infection role,opportunistic infectious disposition,0.6913793103448276
primary infection role,fomite role,0.6924242424242425
primary infection role,process of establishing viral infection,0.6795081967213115
primary infection role,enterotoxin disposition,0.6277777777777778
primary infection role,COVID-19 disease course,0.6277777777777778
primary infection role,infectious disease incidence rate,0.6681818181818181
primary infection role,communicability start process boundary,0.6
primary infection role,disordered virus,0.581578947368421
primary infection role,collective resistance disposition,0.6136363636363636
primary infection role,reagent role,0.7147058823529412
primary infection role,viral load,0.575
primary infection role,fungistatic disposition,0.6277777777777778
primary infection role,virus uncoating stage,0.6825581395348838
primary infection role,local infection,0.7472972972972972
primary infection role,establishment of a clinically abnormal colony,0.6141791044776119
primary infection role,coronavirus disease,0.6207317073170732
primary infection role,positive-sense single-stranded RNA virus,0.6112903225806451
primary infection role,hospital-acquired infection,0.7357142857142857
disordered virus,extended organism,0.6318181818181818
disordered virus,virus aggregate,0.6112903225806451
disordered virus,source of infection,0.6214285714285714
disordered virus,virostatic disposition,0.581578947368421
disordered virus,zoonotic disposition,0.5888888888888889
disordered virus,immune response,0.6112903225806451
disordered virus,infectious disease mortality rate,0.6132653061224489
disordered virus,infection incidence rate profile,0.6166666666666667
disordered virus,communicability end temporal region,0.5676470588235294
disordered virus,pathogen generative stage,0.5963414634146341
disordered virus,pathogen portal of entry,0.575
disordered virus,subclinical coronavirus infection,0.6132653061224489
disordered virus,primary pathogen,0.54375
disordered virus,infection end temporal region,0.6055555555555556
disordered virus,drug-based immunosuppressed organism,0.6423076923076922
disordered virus,vector control strategy,0.5782051282051281
disordered virus,infectious disease,0.5970588235294118
disordered virus,double-stranded DNA virus,0.7426829268292683
disordered virus,incubation end temporal region,0.6021739130434782
disordered virus,site of infection,0.5712121212121213
disordered virus,immunocompetent organism,0.625
disordered virus,virulence factor disposition,0.609090909090909
disordered virus,pathogen portal of exit,0.5782051282051281
disordered virus,viral adhesion disposition,0.6166666666666667
disordered virus,parasitostatic disposition,0.569047619047619
disordered virus,infectious disease incidence,0.609090909090909
disordered virus,reservoir of pathogen role,0.5928571428571429
disordered virus,reverse zoonotic disposition,0.609090909090909
disordered virus,subclinical SARS-CoV-2 infection,0.5541666666666667
disordered virus,virus translation stage,0.5782051282051281
disordered virus,disease surveillance objective specification,0.6
disordered virus,case isolation control strategy,0.5776595744680851
disordered virus,virus release stage,0.65
disordered virus,source of infection site,0.625
disordered virus,virus,0.6880952380952381
disordered virus,quarantine control strategy,0.5662790697674418
disordered virus,virus replication,0.6015151515151516
disordered virus,B cell receptor complex,0.5525641025641026
disordered virus,systematic infection,0.5611111111111111
disordered virus,infection incidence rate,0.625
disordered virus,virus host,0.6423076923076922
disordered virus,double-stranded RNA virus,0.7426829268292683
disordered virus,pathogen portal of entry role,0.5833333333333334
disordered virus,virus transcription stage,0.5963414634146341
disordered virus,infectious disease lifetime prevalence,0.5981481481481481
disordered virus,toxin disposition,0.6015151515151516
disordered virus,pathogen birth temporal region,0.5804347826086956
disordered virus,lower respiratory tract disease,0.598936170212766
disordered virus,infectious disease incidence proportion,0.5954545454545455
disordered virus,opportunistic pathogen,0.5552631578947369
disordered virus,virus generative stage,0.6342105263157894
disordered virus,acute infectious disease course,0.6202127659574468
disordered virus,cidal agent disposition,0.6038461538461539
disordered virus,infectious disorder,0.6785714285714286
disordered virus,genetic resistance to pathogen,0.558695652173913
disordered virus,subclinical infection,0.5310810810810811
disordered virus,appearance of disorder,0.6605263157894737
disordered virus,simple infection,0.575
disordered virus,droplet pathogen transmission process,0.6009433962264151
disordered virus,parasiticidal disposition,0.5719512195121951
disordered virus,infectious disease sporadicity,0.6021739130434782
disordered virus,communicability end process boundary,0.5653846153846154
disordered virus,infection incidence proportion profile,0.5981481481481481
disordered virus,pathogen transporter,0.5888888888888889
disordered virus,transmissibility disposition,0.5636363636363636
disordered virus,latency end process boundary,0.5863636363636363
disordered virus,infectious disease epidemic,0.6127906976744186
disordered virus,disease transmission model,0.6404761904761905
disordered virus,endotoxin disposition,0.5851351351351352
disordered virus,pathologically immunosuppressed organism,0.6107142857142857
disordered virus,negative-sense single-stranded RNA virus,0.6642857142857143
disordered virus,pathogen vehicle,0.60625
disordered virus,cytotoxin disposition,0.5851351351351352
disordered virus,community-acquired infection,0.5863636363636363
disordered virus,pathogen vector,0.6112903225806451
disordered virus,pathogen vehicle role,0.6121621621621621
disordered virus,chronic infectious disease course,0.6132653061224489
disordered virus,nursing-home acquired infection,0.6202127659574468
disordered virus,COVID-19 epidemic,0.6015151515151516
disordered virus,secondary infection,0.6214285714285714
disordered virus,infection start temporal region,0.598936170212766
disordered virus,infection incidence,0.5928571428571429
disordered virus,virus disorder,0.7166666666666667
disordered virus,primary infection,0.5712121212121213
disordered virus,process of establishing an infection,0.5461538461538461
disordered virus,incubation end process boundary,0.598936170212766
disordered virus,SARS-CoV-2 disorder,0.6785714285714286
disordered virus,collective pathogenic disposition,0.5724489795918367
disordered virus,neurotoxin disposition,0.581578947368421
disordered virus,pathogen death process boundary,0.598936170212766
disordered virus,immunosuppressed organism,0.6695121951219513
disordered virus,latency end temporal region,0.5895348837209302
disordered virus,virus adhesion susceptible cell,0.598936170212766
disordered virus,collective disposition,0.6078947368421053
disordered virus,infection,0.57
disordered virus,static agent disposition,0.575
disordered virus,T cell receptor complex,0.5525641025641026
disordered virus,respiratory system disease,0.6166666666666667
disordered virus,indirect pathogen transmission process,0.6166666666666667
disordered virus,organism population,0.5642857142857143
disordered virus,infectious disease control strategy,0.6068627450980393
disordered virus,infectious disease pandemic,0.6127906976744186
disordered virus,immunosuppressive disposition,0.6277777777777778
disordered virus,disordered prion,0.825
disordered virus,innate immune response,0.6078947368421053
disordered virus,pathogenic disposition,0.581578947368421
disordered virus,viral disease course,0.6722222222222223
disordered virus,intracellular infection,0.6038461538461539
disordered virus,secondary infection role,0.625
disordered virus,metastatic infection,0.5333333333333333
disordered virus,infectious disposition,0.581578947368421
disordered virus,acute infection,0.5467741935483871
disordered virus,bacteriostatic disposition,0.569047619047619
disordered virus,immunity to pathogen,0.5333333333333333
disordered virus,bactericidal disposition,0.6
disordered virus,source of infection role,0.625
disordered virus,pathogen host,0.5879310344827586
disordered virus,acquired immunodeficiency,0.6207317073170732
disordered virus,chronic infection,0.5409090909090909
disordered virus,invasion disposition,0.6166666666666667
disordered virus,disease course,0.7166666666666667
disordered virus,infectious disease course,0.6451219512195122
disordered virus,viricidal disposition,0.6121621621621621
disordered virus,acquired immunity to infectious agent,0.6009433962264151
disordered virus,complex infection,0.5712121212121213
disordered virus,COVID-19 disease incidence proportion,0.6009433962264151
disordered virus,coronavirus disease course,0.6404761904761905
disordered virus,infection incidence proportion,0.6021739130434782
disordered virus,respiratory droplet virus fomite,0.7
disordered virus,susceptible organism,0.6166666666666667
disordered virus,pathogen vector role,0.5888888888888889
disordered virus,pathogen portal of exit site,0.5863636363636363
disordered virus,infectious disease prevalence,0.6055555555555556
disordered virus,organism substance,0.5970588235294118
disordered virus,disposition,0.6351851851851852
disordered virus,single-stranded DNA virus,0.7426829268292683
disordered virus,place closure control strategy,0.5804347826086956
disordered virus,viral disease,0.6224137931034482
disordered virus,primary infection role,0.581578947368421
disordered virus,adhesion disposition,0.6166666666666667
disordered virus,pathogen portal of entry site,0.5833333333333334
disordered virus,infection incidence profile,0.6127906976744186
disordered virus,disease,0.6673913043478261
disordered virus,primary infectious disposition,0.5804347826086956
disordered virus,pathogen host role,0.5676470588235294
disordered virus,infection prevalence,0.5888888888888889
disordered virus,humoral immune response,0.6038461538461539
disordered virus,coronavirus disorder,0.6722222222222223
disordered virus,infectious pathogen transmissibility,0.5846153846153846
disordered virus,pathogen surveillance,0.5851351351351352
disordered virus,immunodeficient organism,0.65
disordered virus,pathogen,0.5333333333333333
disordered virus,pathogen birth process boundary,0.5776595744680851
disordered virus,infectious human pathogen,0.5719512195121951
disordered virus,subclinical virus infection,0.6127906976744186
disordered virus,resistance to pathogen,0.5552631578947369
disordered virus,establishment of localization in virus host,0.6025423728813559
disordered virus,virus attachment stage,0.581578947368421
disordered virus,negative regulation of immune response,0.5981481481481481
disordered virus,virus synthesis stage,0.5851351351351352
disordered virus,SARS-COV-2 adhesion disposition,0.598936170212766
disordered virus,pathogen portal of exit role,0.5863636363636363
disordered virus,invasive disposition,0.6166666666666667
disordered virus,re-emerging pathogen,0.5611111111111111
disordered virus,long-term non-progressing infectious disease course,0.5694029850746268
disordered virus,viral disease epidemic,0.6342105263157894
disordered virus,fungicidal disposition,0.581578947368421
disordered virus,viral disease pandemic,0.6342105263157894
disordered virus,virus penetration stage,0.6038461538461539
disordered virus,pathogen seroprevalence,0.5782051282051281
disordered virus,acute respiratory distress syndrome,0.6068627450980393
disordered virus,infectious disease endemicity,0.6055555555555556
disordered virus,contact pathogen transmission process,0.5632075471698114
disordered virus,disorder,0.7833333333333333
disordered virus,herd immunity to infectious organism,0.5846153846153846
disordered virus,extracellular infection,0.5782051282051281
disordered virus,pathogen transporter role,0.6207317073170732
disordered virus,transmission interval,0.6121621621621621
disordered virus,exotoxin disposition,0.5888888888888889
disordered virus,infection start process boundary,0.5958333333333333
disordered virus,infectious disease control objective specification,0.5863636363636363
disordered virus,immune population,0.5712121212121213
disordered virus,opportunistic infectious disposition,0.5653846153846154
disordered virus,process of establishing viral infection,0.5772727272727273
disordered virus,enterotoxin disposition,0.5782051282051281
disordered virus,COVID-19 disease course,0.6551282051282051
disordered virus,infectious disease incidence rate,0.6132653061224489
disordered virus,disordered virus,0.95
disordered virus,collective resistance disposition,0.5928571428571429
disordered virus,adaptive immune response,0.625
disordered virus,fungistatic disposition,0.5782051282051281
disordered virus,organism,0.6166666666666667
disordered virus,virus uncoating stage,0.5851351351351352
disordered virus,local infection,0.5467741935483871
disordered virus,establishment of a clinically abnormal colony,0.5483606557377049
disordered virus,coronavirus disease,0.65
disordered virus,positive-sense single-stranded RNA virus,0.6642857142857143
disordered virus,horizontal pathogen transmission process,0.575
disordered virus,hospital-acquired infection,0.5895348837209302
disordered virus,pathogen death temporal region,0.5804347826086956
disordered virus,emerging pathogen,0.5409090909090909
disordered virus,pathogen transmission process,0.5833333333333334
asymptomatic carrier role,reservoir of pathogen role,0.6656862745098039
asymptomatic carrier role,infectious agent host role,0.6460784313725491
asymptomatic carrier role,asymptomatic infectious structure carrier,0.7530303030303032
asymptomatic carrier role,B cell receptor complex,0.6375
asymptomatic carrier role,passive immunization against infectious agent,0.6357142857142857
asymptomatic carrier role,pathogen portal of entry role,0.6722222222222223
asymptomatic carrier role,lower respiratory tract disease,0.6285714285714286
asymptomatic carrier role,acute infectious disease course,0.6285714285714286
asymptomatic carrier role,cidal agent disposition,0.5958333333333333
asymptomatic carrier role,role,0.5879310344827586
asymptomatic carrier role,appearance of disorder,0.6202127659574468
asymptomatic carrier role,mutualist role,0.6807692307692308
asymptomatic carrier role,infectious agent colony,0.6166666666666667
asymptomatic carrier role,pathogen transporter,0.6277777777777778
asymptomatic carrier role,infectious agent generative stage,0.6224137931034482
asymptomatic carrier role,cidal agent,0.5611111111111111
asymptomatic carrier role,infectious structure host role,0.65
asymptomatic carrier role,pathogen vehicle role,0.6891304347826087
asymptomatic carrier role,chronic infectious disease course,0.6224137931034482
asymptomatic carrier role,asymptomatic infectious agent carrier,0.7725806451612902
asymptomatic carrier role,mechanical vector role,0.7053191489361703
asymptomatic carrier role,sterilizing immunity to infectious agent,0.5884615384615385
asymptomatic carrier role,dead-end host role,0.636046511627907
asymptomatic carrier role,definitive host role,0.6277777777777778
asymptomatic carrier role,innate immunity to infectious agent,0.6
asymptomatic carrier role,static agent disposition,0.6744897959183673
asymptomatic carrier role,T cell receptor complex,0.6583333333333334
asymptomatic carrier role,asymptomatic carrier role,0.95
asymptomatic carrier role,infectious agent population,0.6038461538461539
asymptomatic carrier role,leukocyte-mediated immunity to infectious agent,0.6027777777777777
asymptomatic carrier role,humoral immunity to infectious agent,0.5975409836065574
asymptomatic carrier role,viral disease course,0.6055555555555556
asymptomatic carrier role,secondary infection role,0.6744897959183673
asymptomatic carrier role,passive immunity to infectious agent,0.6139344262295081
asymptomatic carrier role,vaccination against infectious agent,0.6139344262295081
asymptomatic carrier role,susceptibility to infectious agent,0.6025423728813559
asymptomatic carrier role,source of infection role,0.6744897959183673
asymptomatic carrier role,disease course,0.6038461538461539
asymptomatic carrier role,infectious disease course,0.61
asymptomatic carrier role,acquired immunity to infectious agent,0.5951612903225807
asymptomatic carrier role,coronavirus disease course,0.6264705882352941
asymptomatic carrier role,asymptomatic carrier,0.8944444444444444
asymptomatic carrier role,biological vehicle role,0.6791666666666666
asymptomatic carrier role,symptomatic infectious agent carrier,0.7614754098360657
asymptomatic carrier role,symbiont role,0.7131578947368421
asymptomatic carrier role,parasite role,0.7131578947368421
asymptomatic carrier role,pathogen vector role,0.6944444444444444
asymptomatic carrier role,primary infection role,0.6840425531914894
asymptomatic carrier role,biological role,0.675
asymptomatic carrier role,symptomatic infectious structure carrier,0.7423076923076922
asymptomatic carrier role,biological vector role,0.6840425531914894
asymptomatic carrier role,pathogen host role,0.6593023255813953
asymptomatic carrier role,symptomatic carrier role,0.939795918367347
asymptomatic carrier role,intermediate host role,0.6627659574468084
asymptomatic carrier role,host role,0.6558823529411765
asymptomatic carrier role,immunization against infectious agent,0.6274193548387097
asymptomatic carrier role,pathogen portal of exit role,0.6575471698113208
asymptomatic carrier role,infectious agent host,0.6021739130434782
asymptomatic carrier role,long-term non-progressing infectious disease course,0.5947368421052631
asymptomatic carrier role,commensal role,0.6551282051282051
asymptomatic carrier role,epitope role,0.6932432432432433
asymptomatic carrier role,symptomatic carrier,0.8818181818181818
asymptomatic carrier role,function,0.5409090909090909
asymptomatic carrier role,pathogen transporter role,0.71
asymptomatic carrier role,infectious agent reservoir,0.6264705882352941
asymptomatic carrier role,antigen role,0.6932432432432433
asymptomatic carrier role,action specification,0.6277777777777778
asymptomatic carrier role,symbiont host role,0.7058139534883722
asymptomatic carrier role,fomite role,0.7
asymptomatic carrier role,COVID-19 disease course,0.6166666666666667
asymptomatic carrier role,active immunization against infectious agent,0.6239130434782608
asymptomatic carrier role,symptom,0.66875
asymptomatic carrier role,reagent role,0.6391891891891892
asymptomatic carrier role,viral load,0.5642857142857143
asymptomatic carrier role,infectious agent,0.5719512195121951
asymptomatic carrier role,establishment of a clinically abnormal colony,0.65
asymptomatic carrier role,drug susceptibility of infectious agent,0.590625
asymptomatic carrier role,static agent,0.6932432432432433
subclinical virus infection,extended organism,0.5636363636363636
subclinical virus infection,virus aggregate,0.6404761904761905
subclinical virus infection,source of infection,0.7543478260869566
subclinical virus infection,virostatic disposition,0.6744897959183673
subclinical virus infection,zoonotic disposition,0.6840425531914894
subclinical virus infection,immune response,0.6166666666666667
subclinical virus infection,infectious disease mortality rate,0.6333333333333333
subclinical virus infection,infection incidence rate profile,0.6364406779661017
subclinical virus infection,communicability end temporal region,0.6596774193548387
subclinical virus infection,pathogen generative stage,0.5653846153846154
subclinical virus infection,pathogen portal of entry,0.5872549019607843
subclinical virus infection,subclinical coronavirus infection,0.9
subclinical virus infection,primary pathogen,0.6127906976744186
subclinical virus infection,infection end temporal region,0.6464285714285714
subclinical virus infection,drug-based immunosuppressed organism,0.6087301587301588
subclinical virus infection,infectious disease,0.65
subclinical virus infection,double-stranded DNA virus,0.6615384615384616
subclinical virus infection,incubation end temporal region,0.6605263157894737
subclinical virus infection,site of infection,0.7454545454545455
subclinical virus infection,immunocompetent organism,0.5872549019607843
subclinical virus infection,virulence factor disposition,0.6863636363636364
subclinical virus infection,pathogen portal of exit,0.59
subclinical virus infection,viral adhesion disposition,0.6575471698113208
subclinical virus infection,parasitostatic disposition,0.6764150943396227
subclinical virus infection,infectious disease incidence,0.6681818181818181
subclinical virus infection,reservoir of pathogen role,0.619811320754717
subclinical virus infection,reverse zoonotic disposition,0.6681818181818181
subclinical virus infection,subclinical SARS-CoV-2 infection,0.8567796610169492
subclinical virus infection,virus translation stage,0.67
subclinical virus infection,disease surveillance objective specification,0.6612676056338028
subclinical virus infection,virus release stage,0.6239130434782608
subclinical virus infection,source of infection site,0.7245098039215686
subclinical virus infection,virus,0.60625
subclinical virus infection,virus replication,0.7227272727272727
subclinical virus infection,B cell receptor complex,0.65
subclinical virus infection,systematic infection,0.7265957446808511
subclinical virus infection,infection incidence rate,0.6460784313725491
subclinical virus infection,virus host,0.6391891891891892
subclinical virus infection,double-stranded RNA virus,0.6615384615384616
subclinical virus infection,pathogen portal of entry role,0.5928571428571429
subclinical virus infection,virus transcription stage,0.6807692307692308
subclinical virus infection,infectious disease lifetime prevalence,0.65
subclinical virus infection,toxin disposition,0.6772727272727272
subclinical virus infection,pathogen birth temporal region,0.6254385964912281
subclinical virus infection,lower respiratory tract disease,0.5879310344827586
subclinical virus infection,infectious disease incidence proportion,0.6772727272727272
subclinical virus infection,opportunistic pathogen,0.6336734693877552
subclinical virus infection,virus generative stage,0.6540816326530612
subclinical virus infection,acute infectious disease course,0.656896551724138
subclinical virus infection,cidal agent disposition,0.69
subclinical virus infection,infectious disorder,0.6456521739130434
subclinical virus infection,genetic resistance to pathogen,0.6605263157894737
subclinical virus infection,subclinical infection,0.8875
subclinical virus infection,appearance of disorder,0.5724489795918367
subclinical virus infection,simple infection,0.7523255813953489
subclinical virus infection,droplet pathogen transmission process,0.590625
subclinical virus infection,parasiticidal disposition,0.7192307692307692
subclinical virus infection,infectious disease sporadicity,0.6429824561403508
subclinical virus infection,communicability end process boundary,0.6404761904761905
subclinical virus infection,infection incidence proportion profile,0.65
subclinical virus infection,pathogen transporter,0.5563829787234043
subclinical virus infection,transmissibility disposition,0.6681818181818181
subclinical virus infection,latency end process boundary,0.6136363636363636
subclinical virus infection,infectious disease epidemic,0.6351851851851852
subclinical virus infection,disease transmission model,0.619811320754717
subclinical virus infection,endotoxin disposition,0.6583333333333334
subclinical virus infection,pathologically immunosuppressed organism,0.6291044776119403
subclinical virus infection,negative-sense single-stranded RNA virus,0.5992537313432835
subclinical virus infection,pathogen vehicle,0.5662790697674418
subclinical virus infection,cytotoxin disposition,0.6791666666666666
subclinical virus infection,community-acquired infection,0.740909090909091
subclinical virus infection,pathogen vector,0.6166666666666667
subclinical virus infection,pathogen vehicle role,0.5958333333333333
subclinical virus infection,chronic infectious disease course,0.6666666666666667
subclinical virus infection,nursing-home acquired infection,0.7258620689655172
subclinical virus infection,COVID-19 epidemic,0.609090909090909
subclinical virus infection,secondary infection,0.7760869565217391
subclinical virus infection,infection start temporal region,0.6396551724137931
subclinical virus infection,infection incidence,0.6673913043478261
subclinical virus infection,virus disorder,0.6451219512195122
subclinical virus infection,primary infection,0.7454545454545455
subclinical virus infection,process of establishing an infection,0.7039682539682539
subclinical virus infection,incubation end process boundary,0.6224137931034482
subclinical virus infection,SARS-CoV-2 disorder,0.6021739130434782
subclinical virus infection,collective pathogenic disposition,0.6833333333333332
subclinical virus infection,neurotoxin disposition,0.6744897959183673
subclinical virus infection,pathogen death process boundary,0.5879310344827586
subclinical virus infection,immunosuppressed organism,0.5846153846153846
subclinical virus infection,latency end temporal region,0.6537037037037037
subclinical virus infection,virus adhesion susceptible cell,0.6396551724137931
subclinical virus infection,collective disposition,0.6744897959183673
subclinical virus infection,infection,0.7
subclinical virus infection,static agent disposition,0.6852941176470588
subclinical virus infection,T cell receptor complex,0.63
subclinical virus infection,respiratory system disease,0.6009433962264151
subclinical virus infection,indirect pathogen transmission process,0.6346153846153847
subclinical virus infection,organism population,0.6239130434782608
subclinical virus infection,communicability interval,0.6656862745098039
subclinical virus infection,infectious disease control strategy,0.6435483870967742
subclinical virus infection,infectious disease pandemic,0.6537037037037037
subclinical virus infection,immunosuppressive disposition,0.6464285714285714
subclinical virus infection,innate immune response,0.6540816326530612
subclinical virus infection,pathogenic disposition,0.6744897959183673
subclinical virus infection,viral disease course,0.6414893617021277
subclinical virus infection,intracellular infection,0.75
subclinical virus infection,secondary infection role,0.7441176470588234
subclinical virus infection,metastatic infection,0.7265957446808511
subclinical virus infection,infectious disposition,0.6948979591836735
subclinical virus infection,acute infection,0.7357142857142857
subclinical virus infection,bacteriostatic disposition,0.6952830188679244
subclinical virus infection,immunity to pathogen,0.6202127659574468
subclinical virus infection,bactericidal disposition,0.7245098039215686
subclinical virus infection,source of infection role,0.7245098039215686
subclinical virus infection,pathogen host,0.55
subclinical virus infection,acquired immunodeficiency,0.6423076923076922
subclinical virus infection,chronic infection,0.7681818181818181
subclinical virus infection,invasion disposition,0.6840425531914894
subclinical virus infection,disease course,0.5963414634146341
subclinical virus infection,infectious disease course,0.6615384615384616
subclinical virus infection,viricidal disposition,0.7208333333333333
subclinical virus infection,acquired immunity to infectious agent,0.684375
subclinical virus infection,complex infection,0.7227272727272727
subclinical virus infection,COVID-19 disease incidence proportion,0.66875
subclinical virus infection,coronavirus disease course,0.6952830188679244
subclinical virus infection,infection incidence proportion,0.6780701754385965
subclinical virus infection,respiratory droplet virus fomite,0.6703389830508475
subclinical virus infection,susceptible organism,0.6414893617021277
subclinical virus infection,pathogen vector role,0.598936170212766
subclinical virus infection,pathogen portal of exit site,0.5954545454545455
subclinical virus infection,infectious disease prevalence,0.6285714285714286
subclinical virus infection,organism substance,0.6055555555555556
subclinical virus infection,disposition,0.6342105263157894
subclinical virus infection,single-stranded DNA virus,0.6423076923076922
subclinical virus infection,viral disease,0.625
subclinical virus infection,primary infection role,0.7153061224489795
subclinical virus infection,adhesion disposition,0.6840425531914894
subclinical virus infection,pathogen portal of entry site,0.5928571428571429
subclinical virus infection,infection incidence profile,0.6351851851851852
subclinical virus infection,contagiousness,0.6451219512195122
subclinical virus infection,disease,0.5676470588235294
subclinical virus infection,primary infectious disposition,0.6780701754385965
subclinical virus infection,pathogen host role,0.5611111111111111
subclinical virus infection,infection prevalence,0.6414893617021277
subclinical virus infection,humoral immune response,0.65
subclinical virus infection,coronavirus disorder,0.6840425531914894
subclinical virus infection,infectious pathogen transmissibility,0.6087301587301588
subclinical virus infection,pathogen surveillance,0.575
subclinical virus infection,immunodeficient organism,0.6264705882352941
subclinical virus infection,pathogen,0.5642857142857143
subclinical virus infection,pathogen birth process boundary,0.5879310344827586
subclinical virus infection,infectious human pathogen,0.6615384615384616
subclinical virus infection,subclinical virus infection,0.95
subclinical virus infection,resistance to pathogen,0.6336734693877552
subclinical virus infection,establishment of localization in virus host,0.6785714285714286
subclinical virus infection,virus attachment stage,0.6132653061224489
subclinical virus infection,negative regulation of immune response,0.6192307692307693
subclinical virus infection,virus synthesis stage,0.6375
subclinical virus infection,SARS-COV-2 adhesion disposition,0.656896551724138
subclinical virus infection,pathogen portal of exit role,0.5954545454545455
subclinical virus infection,invasive disposition,0.6840425531914894
subclinical virus infection,re-emerging pathogen,0.5776595744680851
subclinical virus infection,long-term non-progressing infectious disease course,0.6294871794871795
subclinical virus infection,viral disease epidemic,0.6540816326530612
subclinical virus infection,communicability start temporal region,0.653125
subclinical virus infection,fungicidal disposition,0.7357142857142857
subclinical virus infection,viral disease pandemic,0.6540816326530612
subclinical virus infection,virus penetration stage,0.69
subclinical virus infection,pathogen seroprevalence,0.57
subclinical virus infection,acute respiratory distress syndrome,0.6112903225806451
subclinical virus infection,infectious disease endemicity,0.6642857142857143
subclinical virus infection,contact pathogen transmission process,0.621875
subclinical virus infection,disorder,0.5357142857142857
subclinical virus infection,herd immunity to infectious organism,0.6722222222222223
subclinical virus infection,communicability,0.6404761904761905
subclinical virus infection,extracellular infection,0.73
subclinical virus infection,pathogen transporter role,0.5653846153846154
subclinical virus infection,transmission interval,0.5958333333333333
subclinical virus infection,exotoxin disposition,0.6627659574468084
subclinical virus infection,infection start process boundary,0.6194915254237288
subclinical virus infection,action specification,0.7053191489361703
subclinical virus infection,infectious disease control objective specification,0.6448051948051949
subclinical virus infection,immune population,0.6318181818181818
subclinical virus infection,opportunistic infectious disposition,0.6722222222222223
subclinical virus infection,process of establishing viral infection,0.7378787878787878
subclinical virus infection,enterotoxin disposition,0.65
subclinical virus infection,COVID-19 disease course,0.61
subclinical virus infection,infectious disease incidence rate,0.65
subclinical virus infection,communicability start process boundary,0.6346153846153847
subclinical virus infection,disordered virus,0.6127906976744186
subclinical virus infection,collective resistance disposition,0.6666666666666667
subclinical virus infection,adaptive immune response,0.6068627450980393
subclinical virus infection,fungistatic disposition,0.69
subclinical virus infection,organism,0.5357142857142857
subclinical virus infection,virus uncoating stage,0.6791666666666666
subclinical virus infection,local infection,0.7833333333333333
subclinical virus infection,establishment of a clinically abnormal colony,0.6722222222222223
subclinical virus infection,coronavirus disease,0.6891304347826087
subclinical virus infection,positive-sense single-stranded RNA virus,0.6141791044776119
subclinical virus infection,horizontal pathogen transmission process,0.6141791044776119
subclinical virus infection,hospital-acquired infection,0.7462962962962962
subclinical virus infection,pathogen death temporal region,0.6078947368421053
subclinical virus infection,emerging pathogen,0.5863636363636363
subclinical virus infection,pathogen transmission process,0.5928571428571429
primary infection,virus aggregate,0.60625
primary infection,source of infection,0.7555555555555555
primary infection,virostatic disposition,0.6551282051282051
primary infection,zoonotic disposition,0.6391891891891892
primary infection,infectious disease mortality rate,0.61
primary infection,infection incidence rate profile,0.6336734693877552
primary infection,communicability end temporal region,0.6230769230769231
primary infection,subclinical coronavirus infection,0.71
primary infection,primary pathogen,0.7833333333333333
primary infection,infection end temporal region,0.6456521739130434
primary infection,vector control strategy,0.575
primary infection,infectious disease,0.6785714285714286
primary infection,double-stranded DNA virus,0.569047619047619
primary infection,incubation end temporal region,0.6414893617021277
primary infection,site of infection,0.7735294117647058
primary infection,virulence factor disposition,0.65
primary infection,viral adhesion disposition,0.6593023255813953
primary infection,parasitostatic disposition,0.6825581395348838
primary infection,infectious disease incidence,0.65
primary infection,reverse zoonotic disposition,0.65
primary infection,subclinical SARS-CoV-2 infection,0.7153061224489795
primary infection,virus translation stage,0.65
primary infection,disease surveillance objective specification,0.630327868852459
primary infection,case isolation control strategy,0.5958333333333333
primary infection,virus release stage,0.5888888888888889
primary infection,source of infection site,0.7182926829268292
primary infection,virus,0.5409090909090909
primary infection,quarantine control strategy,0.6318181818181818
primary infection,virus replication,0.7147058823529412
primary infection,B cell receptor complex,0.575
primary infection,systematic infection,0.7743243243243243
primary infection,infection incidence rate,0.6695121951219513
primary infection,virus host,0.5981481481481481
primary infection,double-stranded RNA virus,0.569047619047619
primary infection,virus transcription stage,0.6642857142857143
primary infection,infectious disease lifetime prevalence,0.6136363636363636
primary infection,toxin disposition,0.6558823529411765
primary infection,lower respiratory tract disease,0.6375
primary infection,infectious disease incidence proportion,0.6464285714285714
primary infection,virus generative stage,0.6294871794871795
primary infection,acute infectious disease course,0.6583333333333334
primary infection,cidal agent disposition,0.65
primary infection,infectious disorder,0.6722222222222223
primary infection,subclinical infection,0.7657894736842106
primary infection,appearance of disorder,0.6294871794871795
primary infection,simple infection,0.8136363636363637
primary infection,parasiticidal disposition,0.6880952380952381
primary infection,infectious disease sporadicity,0.6202127659574468
primary infection,communicability end process boundary,0.6009433962264151
primary infection,infection incidence proportion profile,0.6318181818181818
primary infection,transmissibility disposition,0.65
primary infection,latency end process boundary,0.6055555555555556
primary infection,infectious disease epidemic,0.6318181818181818
primary infection,disease transmission model,0.6127906976744186
primary infection,endotoxin disposition,0.6342105263157894
primary infection,negative-sense single-stranded RNA virus,0.5728070175438597
primary infection,cytotoxin disposition,0.6342105263157894
primary infection,community-acquired infection,0.7388888888888888
primary infection,chronic infectious disease course,0.67
primary infection,nursing-home acquired infection,0.7625
primary infection,COVID-19 epidemic,0.5970588235294118
primary infection,secondary infection,0.8111111111111111
primary infection,infection start temporal region,0.6375
primary infection,infection incidence,0.7
primary infection,virus disorder,0.6112903225806451
primary infection,primary infection,0.95
primary infection,process of establishing an infection,0.7141509433962264
primary infection,incubation end process boundary,0.6166666666666667
primary infection,SARS-CoV-2 disorder,0.5888888888888889
primary infection,collective pathogenic disposition,0.61
primary infection,neurotoxin disposition,0.6551282051282051
primary infection,latency end temporal region,0.6318181818181818
primary infection,virus adhesion susceptible cell,0.6166666666666667
primary infection,collective disposition,0.6294871794871795
primary infection,infection,0.7961538461538461
primary infection,static agent disposition,0.6451219512195122
primary infection,T cell receptor complex,0.575
primary infection,respiratory system disease,0.636046511627907
primary infection,communicability interval,0.6207317073170732
primary infection,infectious disease control strategy,0.6230769230769231
primary infection,infectious disease pandemic,0.6545454545454545
primary infection,immunosuppressive disposition,0.6456521739130434
primary infection,pathogenic disposition,0.6551282051282051
primary infection,viral disease course,0.6391891891891892
primary infection,intracellular infection,0.775
primary infection,secondary infection role,0.7670731707317073
primary infection,metastatic infection,0.7743243243243243
primary infection,infectious disposition,0.6807692307692308
primary infection,acute infection,0.79375
primary infection,bacteriostatic disposition,0.6593023255813953
primary infection,bactericidal disposition,0.6695121951219513
primary infection,source of infection role,0.7182926829268292
primary infection,chronic infection,0.8029411764705883
primary infection,invasion disposition,0.6662162162162162
primary infection,disease course,0.6112903225806451
primary infection,infectious disease course,0.6404761904761905
primary infection,viricidal disposition,0.6868421052631578
primary infection,complex infection,0.7735294117647058
primary infection,COVID-19 disease incidence proportion,0.6537037037037037
primary infection,coronavirus disease course,0.636046511627907
primary infection,infection incidence proportion,0.6627659574468084
primary infection,respiratory droplet virus fomite,0.6540816326530612
primary infection,infectious disease prevalence,0.6456521739130434
primary infection,disposition,0.6642857142857143
primary infection,single-stranded DNA virus,0.569047619047619
primary infection,place closure control strategy,0.598936170212766
primary infection,viral disease,0.6166666666666667
primary infection,primary infection role,0.8858974358974359
primary infection,primary immunodeficiency,0.7914634146341464
primary infection,adhesion disposition,0.6391891891891892
primary infection,infection incidence profile,0.6545454545454545
primary infection,contagiousness,0.6112903225806451
primary infection,disease,0.575
primary infection,primary infectious disposition,0.8117021276595744
primary infection,infection prevalence,0.6932432432432433
primary infection,coronavirus disorder,0.6121621621621621
primary infection,subclinical virus infection,0.7454545454545455
primary infection,establishment of localization in virus host,0.6
primary infection,virus attachment stage,0.5782051282051281
primary infection,virus synthesis stage,0.6078947368421053
primary infection,SARS-COV-2 adhesion disposition,0.6375
primary infection,invasive disposition,0.6662162162162162
primary infection,long-term non-progressing infectious disease course,0.6264705882352941
primary infection,viral disease epidemic,0.6294871794871795
primary infection,communicability start temporal region,0.5981481481481481
primary infection,fungicidal disposition,0.6551282051282051
primary infection,viral disease pandemic,0.6294871794871795
primary infection,virus penetration stage,0.675
primary infection,acute respiratory distress syndrome,0.6230769230769231
primary infection,infectious disease endemicity,0.6456521739130434
primary infection,disorder,0.57
primary infection,communicability,0.575
primary infection,extracellular infection,0.775
primary infection,exotoxin disposition,0.6391891891891892
primary infection,infection start process boundary,0.6336734693877552
primary infection,action specification,0.6932432432432433
primary infection,infectious disease control objective specification,0.6141791044776119
primary infection,opportunistic infectious disposition,0.6952830188679244
primary infection,process of establishing viral infection,0.7
primary infection,enterotoxin disposition,0.65
primary infection,COVID-19 disease course,0.6
primary infection,infectious disease incidence rate,0.63
primary infection,communicability start process boundary,0.5772727272727273
primary infection,disordered virus,0.5712121212121213
primary infection,collective resistance disposition,0.63
primary infection,fungistatic disposition,0.65
primary infection,virus uncoating stage,0.6605263157894737
primary infection,local infection,0.79375
primary infection,establishment of a clinically abnormal colony,0.5951612903225807
primary infection,coronavirus disease,0.6166666666666667
primary infection,positive-sense single-stranded RNA virus,0.5903508771929825
primary infection,hospital-acquired infection,0.7681818181818181
definitive host role,virostatic disposition,0.6404761904761905
definitive host role,zoonotic disposition,0.65
definitive host role,infectious disease mortality rate,0.6575471698113208
definitive host role,infection incidence rate profile,0.7
definitive host role,communicability end temporal region,0.6136363636363636
definitive host role,infection end temporal region,0.6540816326530612
definitive host role,SARS-CoV-2 incidence rate,0.6055555555555556
definitive host role,incubation end temporal region,0.65
definitive host role,virulence factor disposition,0.6166666666666667
definitive host role,viral adhesion disposition,0.6456521739130434
definitive host role,parasitostatic disposition,0.6239130434782608
definitive host role,reservoir of pathogen role,0.6673913043478261
definitive host role,reverse zoonotic disposition,0.6375
definitive host role,establishment of localization in host,0.6429824561403508
definitive host role,infectious agent host role,0.7760869565217391
definitive host role,B cell receptor complex,0.6127906976744186
definitive host role,infection incidence rate,0.6545454545454545
definitive host role,colonized host,0.6852941176470588
definitive host role,virus host,0.65
definitive host role,pathogen portal of entry role,0.6744897959183673
definitive host role,toxin disposition,0.6391891891891892
definitive host role,lower respiratory tract disease,0.5872549019607843
definitive host role,acute infectious disease course,0.6460784313725491
definitive host role,cidal agent disposition,0.6593023255813953
definitive host role,role,0.6166666666666667
definitive host role,appearance of disorder,0.6404761904761905
definitive host role,parasiticidal disposition,0.6277777777777778
definitive host role,mutualist role,0.7147058823529412
definitive host role,communicability end process boundary,0.6107142857142857
definitive host role,transmissibility disposition,0.6166666666666667
definitive host role,latency end process boundary,0.6166666666666667
definitive host role,colonization of host,0.675
definitive host role,endotoxin disposition,0.6695121951219513
definitive host role,infectious structure host role,0.75
definitive host role,COVID-19 incidence rate,0.636046511627907
definitive host role,cytotoxin disposition,0.6207317073170732
definitive host role,pathogen vehicle role,0.6939024390243902
definitive host role,host,0.6166666666666667
definitive host role,chronic infectious disease course,0.619811320754717
definitive host role,mechanical vector role,0.7119047619047619
definitive host role,establishment of localization in human host,0.6246031746031746
definitive host role,incubation end process boundary,0.6460784313725491
definitive host role,collective pathogenic disposition,0.6575471698113208
definitive host role,neurotoxin disposition,0.6404761904761905
definitive host role,dead-end host role,0.7921052631578948
definitive host role,definitive host role,0.95
definitive host role,latency end temporal region,0.6202127659574468
definitive host role,virus adhesion susceptible cell,0.6264705882352941
definitive host role,collective disposition,0.6880952380952381
definitive host role,static agent disposition,0.6318181818181818
definitive host role,T cell receptor complex,0.636046511627907
definitive host role,asymptomatic carrier role,0.6277777777777778
definitive host role,infectious structure host,0.6722222222222223
definitive host role,entry into host,0.7071428571428571
definitive host role,adhesion of symbiont to host,0.6791666666666666
definitive host role,immunosuppressive disposition,0.6540816326530612
definitive host role,pathogenic disposition,0.6404761904761905
definitive host role,viral disease course,0.625
definitive host role,entry into host through host barriers,0.6780701754385965
definitive host role,secondary infection role,0.7
definitive host role,cell,0.5333333333333333
definitive host role,infectious disposition,0.6642857142857143
definitive host role,bacteriostatic disposition,0.6456521739130434
definitive host role,bactericidal disposition,0.6318181818181818
definitive host role,source of infection role,0.7227272727272727
definitive host role,pathogen host,0.6621212121212122
definitive host role,invasion disposition,0.65
definitive host role,disease course,0.6558823529411765
definitive host role,infectious disease course,0.65
definitive host role,viricidal disposition,0.6451219512195122
definitive host role,coronavirus disease course,0.6239130434782608
definitive host role,biological vehicle role,0.6825581395348838
definitive host role,symbiont role,0.6924242424242425
definitive host role,parasite role,0.6924242424242425
definitive host role,intermediate host,0.7202702702702704
definitive host role,pathogen vector role,0.7
definitive host role,disposition,0.6435483870967742
definitive host role,COVID-19 mortality rate,0.6127906976744186
definitive host role,primary infection role,0.6880952380952381
definitive host role,biological role,0.65
definitive host role,adhesion disposition,0.675
definitive host role,biological vector role,0.6880952380952381
definitive host role,primary infectious disposition,0.63
definitive host role,pathogen host role,0.7657894736842106
definitive host role,symptomatic carrier role,0.6318181818181818
definitive host role,SARS-COV-2 adhesion susceptible cell,0.6107142857142857
definitive host role,intermediate host role,0.8071428571428573
definitive host role,dead-end host,0.6924242424242425
definitive host role,host role,0.760344827586207
definitive host role,establishment of localization in virus host,0.6404761904761905
definitive host role,SARS-COV-2 adhesion disposition,0.6264705882352941
definitive host role,pathogen portal of exit role,0.6791666666666666
definitive host role,invasive disposition,0.7
definitive host role,infectious agent host,0.6939024390243902
definitive host role,long-term non-progressing infectious disease course,0.6049295774647887
definitive host role,commensal role,0.6852941176470588
definitive host role,epitope role,0.73125
definitive host role,fungicidal disposition,0.6642857142857143
definitive host role,division of geopolitical entity,0.6460784313725491
definitive host role,function,0.6285714285714286
definitive host role,pathogen transporter role,0.6722222222222223
definitive host role,exotoxin disposition,0.65
definitive host role,antigen role,0.73125
definitive host role,action specification,0.6
definitive host role,symbiont host role,0.7921052631578948
definitive host role,opportunistic infectious disposition,0.6285714285714286
definitive host role,fomite role,0.7403225806451613
definitive host role,enterotoxin disposition,0.6593023255813953
definitive host role,COVID-19 disease course,0.6127906976744186
definitive host role,infectious disease incidence rate,0.619811320754717
definitive host role,collective resistance disposition,0.6386792452830189
definitive host role,reagent role,0.7
definitive host role,viral load,0.55
definitive host role,fungistatic disposition,0.6825581395348838
definitive host role,establishment of a clinically abnormal colony,0.6038461538461539
definitive host role,definitive host,0.8785714285714286
definitive host role,cell space,0.5833333333333334
occurrent,occurrent,0.95
occurrent,T cell receptor complex,0.575
susceptibility,communicability end temporal region,0.6132653061224489
susceptibility,infection end temporal region,0.5662790697674418
susceptibility,incubation end temporal region,0.5636363636363636
susceptibility,B cell receptor complex,0.5851351351351352
susceptibility,drug susceptibility,0.8742424242424243
susceptibility,communicability end process boundary,0.61
susceptibility,latency end process boundary,0.569047619047619
susceptibility,incubation end process boundary,0.5611111111111111
susceptibility,latency end temporal region,0.5719512195121951
susceptibility,T cell receptor complex,0.5851351351351352
susceptibility,SARS-CoV-2 attachment stage,0.5963414634146341
susceptibility,susceptibility,0.95
susceptibility,susceptibility to infectious agent,0.7416666666666667
susceptibility,place closure control strategy,0.609090909090909
susceptibility,virus attachment stage,0.6166666666666667
susceptibility,action specification,0.6264705882352941
susceptibility,polymerase chain reaction,0.5782051282051281
susceptibility,establishment of a clinically abnormal colony,0.5855932203389831
susceptibility,drug susceptibility of infectious agent,0.7141509433962264
objective specification,communicability end temporal region,0.6224137931034482
objective specification,infection end temporal region,0.6615384615384616
objective specification,geospatial location,0.6880952380952381
objective specification,incubation end temporal region,0.6386792452830189
objective specification,disease surveillance objective specification,0.7932835820895522
objective specification,B cell receptor complex,0.6239130434782608
objective specification,acute infectious disease course,0.6351851851851852
objective specification,communicability end process boundary,0.6025423728813559
objective specification,latency end process boundary,0.6068627450980393
objective specification,chronic infectious disease course,0.6285714285714286
objective specification,incubation end process boundary,0.6166666666666667
objective specification,plan specification,0.7914634146341464
objective specification,latency end temporal region,0.63
objective specification,T cell receptor complex,0.6021739130434782
objective specification,viral disease course,0.5895348837209302
objective specification,objective specification,0.95
objective specification,disease course,0.6121621621621621
objective specification,infectious disease course,0.6375
objective specification,coronavirus disease course,0.5928571428571429
objective specification,object,0.656896551724138
objective specification,object aggregate,0.7064102564102563
objective specification,long-term non-progressing infectious disease course,0.6121621621621621
objective specification,action specification,0.8453488372093022
objective specification,infectious disease control objective specification,0.7650684931506849
objective specification,COVID-19 disease course,0.6021739130434782
objective specification,establishment of a clinically abnormal colony,0.6264705882352941
object aggregate,virus aggregate,0.7725806451612902
object aggregate,information content entity,0.5928571428571429
object aggregate,infectious disease mortality rate,0.6336734693877552
object aggregate,infection incidence rate profile,0.6166666666666667
object aggregate,infectious structure aggregate,0.7326086956521739
object aggregate,communicability end temporal region,0.6068627450980393
object aggregate,geographical entity,0.5928571428571429
object aggregate,infection end temporal region,0.6277777777777778
object aggregate,SARS-CoV-2 incidence rate,0.6451219512195122
object aggregate,incubation end temporal region,0.6021739130434782
object aggregate,site of infection,0.5712121212121213
object aggregate,resistant entity,0.60625
object aggregate,disease surveillance objective specification,0.6166666666666667
object aggregate,material entity,0.5790322580645162
object aggregate,SARS-CoV-2 aggregate,0.7555555555555555
object aggregate,source of infection site,0.625
object aggregate,B cell receptor complex,0.6294871794871795
object aggregate,infection incidence rate,0.65
object aggregate,entity,0.5863636363636363
object aggregate,acute infectious disease course,0.598936170212766
object aggregate,communicability end process boundary,0.5846153846153846
object aggregate,directive information content entity,0.6038461538461539
object aggregate,acellular structure aggregate,0.7388888888888888
object aggregate,latency end process boundary,0.5863636363636363
object aggregate,realizable entity,0.6015151515151516
object aggregate,COVID-19 incidence rate,0.6551282051282051
object aggregate,chronic infectious disease course,0.6132653061224489
object aggregate,descriptive information content entity,0.5981481481481481
object aggregate,incubation end process boundary,0.5776595744680851
object aggregate,collective pathogenic disposition,0.6336734693877552
object aggregate,molecular entity,0.66875
object aggregate,plan specification,0.5676470588235294
object aggregate,latency end temporal region,0.6127906976744186
object aggregate,coronavirus aggregate,0.7472972972972972
object aggregate,collective disposition,0.6078947368421053
object aggregate,T cell receptor complex,0.6038461538461539
object aggregate,viral disease course,0.5611111111111111
object aggregate,objective specification,0.7064102564102563
object aggregate,epitope site,0.6285714285714286
object aggregate,disease course,0.5833333333333334
object aggregate,infectious disease course,0.6207317073170732
object aggregate,prion aggregate,0.8048387096774193
object aggregate,coronavirus disease course,0.5928571428571429
object aggregate,pathogen portal of exit site,0.609090909090909
object aggregate,organism substance,0.6264705882352941
object aggregate,anatomical entity,0.6015151515151516
object aggregate,COVID-19 mortality rate,0.6294871794871795
object aggregate,geopolitical entity,0.5928571428571429
object aggregate,pathogen portal of entry site,0.6055555555555556
object aggregate,viroid aggregate,0.79375
object aggregate,site,0.55
object aggregate,designative information content entity,0.5796296296296296
object aggregate,object,0.7227272727272727
object aggregate,immaterial entity,0.5712121212121213
object aggregate,object aggregate,0.95
object aggregate,long-term non-progressing infectious disease course,0.5843283582089552
object aggregate,division of geopolitical entity,0.5776595744680851
object aggregate,function,0.5333333333333333
object aggregate,infectious disease control objective specification,0.6015151515151516
object aggregate,COVID-19 disease course,0.5782051282051281
object aggregate,infectious disease incidence rate,0.6336734693877552
object aggregate,collective resistance disposition,0.6336734693877552
object aggregate,viral load,0.5269230769230769
object aggregate,establishment of a clinically abnormal colony,0.5647540983606557
symptom,virostatic disposition,0.5879310344827586
symptom,information content entity,0.5409090909090909
symptom,zoonotic disposition,0.5981481481481481
symptom,communicability end temporal region,0.5452380952380953
symptom,infection end temporal region,0.5333333333333333
symptom,incubation end temporal region,0.5310810810810811
symptom,virulence factor disposition,0.5642857142857143
symptom,viral adhesion disposition,0.5712121212121213
symptom,parasitostatic disposition,0.5712121212121213
symptom,reverse zoonotic disposition,0.5642857142857143
symptom,macromolecular complex,0.553448275862069
symptom,B cell receptor complex,0.5833333333333334
symptom,toxin disposition,0.6166666666666667
symptom,cidal agent disposition,0.5833333333333334
symptom,parasiticidal disposition,0.575
symptom,communicability end process boundary,0.5197674418604651
symptom,directive information content entity,0.5197674418604651
symptom,transmissibility disposition,0.5928571428571429
symptom,latency end process boundary,0.5357142857142857
symptom,disease transmission model,0.5712121212121213
symptom,endotoxin disposition,0.5928571428571429
symptom,cytotoxin disposition,0.5928571428571429
symptom,descriptive information content entity,0.5611111111111111
symptom,incubation end process boundary,0.5026315789473684
symptom,collective pathogenic disposition,0.55
symptom,neurotoxin disposition,0.5879310344827586
symptom,latency end temporal region,0.5676470588235294
symptom,collective disposition,0.5879310344827586
symptom,static agent disposition,0.5790322580645162
symptom,T cell receptor complex,0.5833333333333334
symptom,immunosuppressive disposition,0.5611111111111111
symptom,pathogenic disposition,0.5879310344827586
symptom,infectious disposition,0.5879310344827586
symptom,bacteriostatic disposition,0.5712121212121213
symptom,bactericidal disposition,0.5790322580645162
symptom,invasion disposition,0.5981481481481481
symptom,viricidal disposition,0.5928571428571429
symptom,complex infection,0.6166666666666667
symptom,disposition,0.6722222222222223
symptom,adhesion disposition,0.5981481481481481
symptom,primary infectious disposition,0.5581081081081081
symptom,designative information content entity,0.5388888888888889
symptom,SARS-COV-2 adhesion disposition,0.5552631578947369
symptom,invasive disposition,0.5981481481481481
symptom,fungicidal disposition,0.5879310344827586
symptom,acute respiratory distress syndrome,0.569047619047619
symptom,exotoxin disposition,0.5981481481481481
symptom,immunoglobulin complex,0.553448275862069
symptom,opportunistic infectious disposition,0.5430232558139535
symptom,quality,0.5214285714285714
symptom,enterotoxin disposition,0.5833333333333334
symptom,collective resistance disposition,0.55
symptom,symptom,0.95
symptom,fungistatic disposition,0.5833333333333334
symptom,establishment of a clinically abnormal colony,0.5461538461538461
subclinical infection,virus aggregate,0.5611111111111111
subclinical infection,source of infection,0.775
subclinical infection,virostatic disposition,0.6593023255813953
subclinical infection,zoonotic disposition,0.6695121951219513
subclinical infection,infectious disease mortality rate,0.5981481481481481
subclinical infection,infection incidence rate profile,0.6386792452830189
subclinical infection,communicability end temporal region,0.6642857142857143
subclinical infection,subclinical coronavirus infection,0.8388888888888889
subclinical infection,infection end temporal region,0.65
subclinical infection,infectious disease,0.6551282051282051
subclinical infection,double-stranded DNA virus,0.6021739130434782
subclinical infection,incubation end temporal region,0.6656862745098039
subclinical infection,site of infection,0.7657894736842106
subclinical infection,virulence factor disposition,0.6744897959183673
subclinical infection,viral adhesion disposition,0.6627659574468084
subclinical infection,parasitostatic disposition,0.6627659574468084
subclinical infection,infectious disease incidence,0.6540816326530612
subclinical infection,reverse zoonotic disposition,0.6540816326530612
subclinical infection,subclinical SARS-CoV-2 infection,0.8462264150943396
subclinical infection,virus translation stage,0.609090909090909
subclinical infection,disease surveillance objective specification,0.65
subclinical infection,virus release stage,0.575
subclinical infection,source of infection site,0.7388888888888888
subclinical infection,virus replication,0.6868421052631578
subclinical infection,B cell receptor complex,0.6545454545454545
subclinical infection,systematic infection,0.7670731707317073
subclinical infection,infection incidence rate,0.65
subclinical infection,virus host,0.5467741935483871
subclinical infection,double-stranded RNA virus,0.6021739130434782
subclinical infection,virus transcription stage,0.6239130434782608
subclinical infection,infectious disease lifetime prevalence,0.6364406779661017
subclinical infection,toxin disposition,0.6605263157894737
subclinical infection,lower respiratory tract disease,0.5846153846153846
subclinical infection,infectious disease incidence proportion,0.6666666666666667
subclinical infection,virus generative stage,0.5895348837209302
subclinical infection,acute infectious disease course,0.6423076923076922
subclinical infection,cidal agent disposition,0.6772727272727272
subclinical infection,infectious disorder,0.65
subclinical infection,subclinical infection,0.95
subclinical infection,appearance of disorder,0.5895348837209302
subclinical infection,simple infection,0.8013513513513513
subclinical infection,parasiticidal disposition,0.7108695652173913
subclinical infection,infectious disease sporadicity,0.6068627450980393
subclinical infection,communicability end process boundary,0.6429824561403508
subclinical infection,infection incidence proportion profile,0.6533898305084747
subclinical infection,transmissibility disposition,0.6540816326530612
subclinical infection,latency end process boundary,0.6132653061224489
subclinical infection,infectious disease epidemic,0.6166666666666667
subclinical infection,disease transmission model,0.598936170212766
subclinical infection,endotoxin disposition,0.6404761904761905
subclinical infection,negative-sense single-stranded RNA virus,0.5811475409836065
subclinical infection,cytotoxin disposition,0.6642857142857143
subclinical infection,community-acquired infection,0.7357142857142857
subclinical infection,chronic infectious disease course,0.6907407407407408
subclinical infection,nursing-home acquired infection,0.7192307692307692
subclinical infection,COVID-19 epidemic,0.6078947368421053
subclinical infection,secondary infection,0.8
subclinical infection,infection start temporal region,0.6423076923076922
subclinical infection,infection incidence,0.675
subclinical infection,virus disorder,0.5642857142857143
subclinical infection,primary infection,0.7657894736842106
subclinical infection,process of establishing an infection,0.730701754385965
subclinical infection,incubation end process boundary,0.6423076923076922
subclinical infection,SARS-CoV-2 disorder,0.575
subclinical infection,collective pathogenic disposition,0.6722222222222223
subclinical infection,neurotoxin disposition,0.6593023255813953
subclinical infection,latency end temporal region,0.6583333333333334
subclinical infection,virus adhesion susceptible cell,0.5846153846153846
subclinical infection,collective disposition,0.6593023255813953
subclinical infection,infection,0.75
subclinical infection,static agent disposition,0.6722222222222223
subclinical infection,T cell receptor complex,0.6318181818181818
subclinical infection,respiratory system disease,0.5776595744680851
subclinical infection,communicability interval,0.6722222222222223
subclinical infection,infectious disease control strategy,0.6107142857142857
subclinical infection,infectious disease pandemic,0.6375
subclinical infection,immunosuppressive disposition,0.63
subclinical infection,pathogenic disposition,0.6593023255813953
subclinical infection,viral disease course,0.6451219512195122
subclinical infection,intracellular infection,0.7681818181818181
subclinical infection,secondary infection role,0.7611111111111112
subclinical infection,metastatic infection,0.7670731707317073
subclinical infection,infectious disposition,0.6593023255813953
subclinical infection,acute infection,0.7555555555555555
subclinical infection,bacteriostatic disposition,0.6840425531914894
subclinical infection,bactericidal disposition,0.7166666666666667
subclinical infection,source of infection role,0.7388888888888888
subclinical infection,chronic infection,0.8184210526315789
subclinical infection,invasion disposition,0.6695121951219513
subclinical infection,disease course,0.5928571428571429
subclinical infection,infectious disease course,0.6239130434782608
subclinical infection,viricidal disposition,0.7119047619047619
subclinical infection,complex infection,0.7657894736842106
subclinical infection,COVID-19 disease incidence proportion,0.6741379310344828
subclinical infection,coronavirus disease course,0.6202127659574468
subclinical infection,infection incidence proportion,0.6852941176470588
subclinical infection,respiratory droplet virus fomite,0.6009433962264151
subclinical infection,infectious disease prevalence,0.63
subclinical infection,disposition,0.6375
subclinical infection,single-stranded DNA virus,0.6021739130434782
subclinical infection,viral disease,0.6264705882352941
subclinical infection,primary infection role,0.7290697674418604
subclinical infection,adhesion disposition,0.6695121951219513
subclinical infection,infection incidence profile,0.6375
subclinical infection,contagiousness,0.6214285714285714
subclinical infection,disease,0.5571428571428572
subclinical infection,primary infectious disposition,0.6852941176470588
subclinical infection,infection prevalence,0.6695121951219513
subclinical infection,coronavirus disorder,0.5963414634146341
subclinical infection,subclinical virus infection,0.8875
subclinical infection,establishment of localization in virus host,0.653125
subclinical infection,virus attachment stage,0.5662790697674418
subclinical infection,virus synthesis stage,0.569047619047619
subclinical infection,SARS-COV-2 adhesion disposition,0.6423076923076922
subclinical infection,invasive disposition,0.6695121951219513
subclinical infection,long-term non-progressing infectious disease course,0.6166666666666667
subclinical infection,viral disease epidemic,0.6127906976744186
subclinical infection,communicability start temporal region,0.6396551724137931
subclinical infection,fungicidal disposition,0.7290697674418604
subclinical infection,viral disease pandemic,0.636046511627907
subclinical infection,virus penetration stage,0.6318181818181818
subclinical infection,acute respiratory distress syndrome,0.575
subclinical infection,infectious disease endemicity,0.63
subclinical infection,disorder,0.5189655172413793
subclinical infection,communicability,0.6722222222222223
subclinical infection,extracellular infection,0.7454545454545455
subclinical infection,exotoxin disposition,0.6451219512195122
subclinical infection,infection start process boundary,0.619811320754717
subclinical infection,action specification,0.7182926829268292
subclinical infection,infectious disease control objective specification,0.6330985915492958
subclinical infection,opportunistic infectious disposition,0.6956140350877194
subclinical infection,process of establishing viral infection,0.75
subclinical infection,enterotoxin disposition,0.6318181818181818
subclinical infection,COVID-19 disease course,0.609090909090909
subclinical infection,infectious disease incidence rate,0.6351851851851852
subclinical infection,communicability start process boundary,0.6194915254237288
subclinical infection,disordered virus,0.5310810810810811
subclinical infection,collective resistance disposition,0.6537037037037037
subclinical infection,fungistatic disposition,0.6772727272727272
subclinical infection,virus uncoating stage,0.6404761904761905
subclinical infection,local infection,0.8388888888888889
subclinical infection,establishment of a clinically abnormal colony,0.6772727272727272
subclinical infection,coronavirus disease,0.6
subclinical infection,positive-sense single-stranded RNA virus,0.5975409836065574
subclinical infection,hospital-acquired infection,0.7416666666666667
communicability start process boundary,virus aggregate,0.5632075471698114
communicability start process boundary,source of infection,0.5903508771929825
communicability start process boundary,immune response,0.6386792452830189
communicability start process boundary,infectious disease mortality rate,0.6330985915492958
communicability start process boundary,infection incidence rate profile,0.65
communicability start process boundary,communicability end temporal region,0.7650684931506849
communicability start process boundary,pathogen generative stage,0.5928571428571429
communicability start process boundary,surveillance process,0.656896551724138
communicability start process boundary,infection end temporal region,0.6141791044776119
communicability start process boundary,infectious disease,0.5928571428571429
communicability start process boundary,SARS-CoV-2 incidence rate,0.5928571428571429
communicability start process boundary,double-stranded DNA virus,0.6404761904761905
communicability start process boundary,incubation end temporal region,0.6264705882352941
communicability start process boundary,pathogen portal of exit,0.5811475409836065
communicability start process boundary,infectious disease incidence,0.6015151515151516
communicability start process boundary,virus translation stage,0.5975409836065574
communicability start process boundary,disease surveillance objective specification,0.5963414634146341
communicability start process boundary,case isolation control strategy,0.6384057971014493
communicability start process boundary,virus release stage,0.5903508771929825
communicability start process boundary,source of infection site,0.5951612903225807
communicability start process boundary,virus,0.5197674418604651
communicability start process boundary,virus replication,0.5772727272727273
communicability start process boundary,B cell receptor complex,0.5811475409836065
communicability start process boundary,infection incidence rate,0.6112903225806451
communicability start process boundary,virus host,0.5541666666666667
communicability start process boundary,double-stranded RNA virus,0.6404761904761905
communicability start process boundary,virus transcription stage,0.6087301587301588
communicability start process boundary,infectious disease lifetime prevalence,0.6210526315789474
communicability start process boundary,pathogen birth temporal region,0.6411764705882353
communicability start process boundary,lower respiratory tract disease,0.6239130434782608
communicability start process boundary,infectious disease incidence proportion,0.6188311688311688
communicability start process boundary,virus generative stage,0.6
communicability start process boundary,acute infectious disease course,0.6384057971014493
communicability start process boundary,process,0.6055555555555556
communicability start process boundary,droplet pathogen transmission process,0.6366666666666667
communicability start process boundary,infectious disease sporadicity,0.6117647058823529
communicability start process boundary,communicability end process boundary,0.895945945945946
communicability start process boundary,latency end process boundary,0.7681818181818181
communicability start process boundary,infectious disease epidemic,0.5884615384615385
communicability start process boundary,infectious agent generative stage,0.6049295774647887
communicability start process boundary,disease transmission model,0.60625
communicability start process boundary,negative-sense single-stranded RNA virus,0.6038461538461539
communicability start process boundary,COVID-19 incidence rate,0.5975409836065574
communicability start process boundary,negative regulation of developmental process,0.6451219512195122
communicability start process boundary,chronic infectious disease course,0.6612676056338028
communicability start process boundary,COVID-19 epidemic,0.5590909090909091
communicability start process boundary,infection start temporal region,0.6673913043478261
communicability start process boundary,virus disorder,0.5846153846153846
communicability start process boundary,process of establishing an infection,0.6121621621621621
communicability start process boundary,incubation end process boundary,0.7688405797101449
communicability start process boundary,SARS-CoV-2 uncoating stage,0.6375
communicability start process boundary,pathogen death process boundary,0.7688405797101449
communicability start process boundary,plan specification,0.5928571428571429
communicability start process boundary,latency end temporal region,0.6192307692307693
communicability start process boundary,SARS-CoV-2 penetration stage,0.6015151515151516
communicability start process boundary,virus adhesion susceptible cell,0.5804347826086956
communicability start process boundary,anatomical space,0.6537037037037037
communicability start process boundary,T cell receptor complex,0.5811475409836065
communicability start process boundary,respiratory system disease,0.621875
communicability start process boundary,indirect pathogen transmission process,0.6605263157894737
communicability start process boundary,planned process,0.6386792452830189
communicability start process boundary,generative stage,0.5981481481481481
communicability start process boundary,communicability interval,0.7564516129032257
communicability start process boundary,infectious disease control strategy,0.6280821917808219
communicability start process boundary,SARS-CoV-2 attachment stage,0.6038461538461539
communicability start process boundary,infectious disease pandemic,0.6038461538461539
communicability start process boundary,infectious structure generative stage,0.6233333333333334
communicability start process boundary,innate immune response,0.6166666666666667
communicability start process boundary,viral disease course,0.6396551724137931
communicability start process boundary,source of infection role,0.5951612903225807
communicability start process boundary,disease course,0.6038461538461539
communicability start process boundary,infectious disease course,0.6246031746031746
communicability start process boundary,COVID-19 disease incidence proportion,0.61
communicability start process boundary,coronavirus disease course,0.653125
communicability start process boundary,respiratory droplet virus fomite,0.6214285714285714
communicability start process boundary,pathogen portal of exit site,0.6015151515151516
communicability start process boundary,infectious disease prevalence,0.6141791044776119
communicability start process boundary,SARS-CoV-2 genome replication stage,0.6143835616438357
communicability start process boundary,single-stranded DNA virus,0.6087301587301588
communicability start process boundary,COVID-19 mortality rate,0.6467213114754098
communicability start process boundary,process profile,0.619811320754717
communicability start process boundary,negative regulation of life-sustaining process,0.6523809523809524
communicability start process boundary,place closure control strategy,0.6264705882352941
communicability start process boundary,viral disease,0.5872549019607843
communicability start process boundary,developmental process,0.6703389830508475
communicability start process boundary,contagiousness,0.6230769230769231
communicability start process boundary,disease,0.5388888888888889
communicability start process boundary,biological process,0.6821428571428573
communicability start process boundary,humoral immune response,0.630327868852459
communicability start process boundary,incubation start process boundary,0.8302816901408451
communicability start process boundary,pathogen birth process boundary,0.7833333333333333
communicability start process boundary,subclinical virus infection,0.6346153846153847
communicability start process boundary,establishment of localization in virus host,0.6104938271604938
communicability start process boundary,virus attachment stage,0.6
communicability start process boundary,negative regulation of immune response,0.6078947368421053
communicability start process boundary,SARS-CoV-2 transcription stage,0.6117647058823529
communicability start process boundary,virus synthesis stage,0.6025423728813559
communicability start process boundary,pathogen portal of exit role,0.6015151515151516
communicability start process boundary,long-term non-progressing infectious disease course,0.6410112359550562
communicability start process boundary,viral disease epidemic,0.6
communicability start process boundary,communicability start temporal region,0.81
communicability start process boundary,viral disease pandemic,0.6166666666666667
communicability start process boundary,virus penetration stage,0.5975409836065574
communicability start process boundary,algorithm,0.5351063829787234
communicability start process boundary,infectious disease endemicity,0.6141791044776119
communicability start process boundary,negative regulation of viral process,0.6527027027027027
communicability start process boundary,contact pathogen transmission process,0.6766666666666665
communicability start process boundary,function,0.5804347826086956
communicability start process boundary,communicability,0.7330188679245283
communicability start process boundary,symbiotic process,0.6681818181818181
communicability start process boundary,infection start process boundary,0.8214285714285714
communicability start process boundary,action specification,0.6224137931034482
communicability start process boundary,SARS-CoV-2 synthesis stage,0.60625
communicability start process boundary,latency start process boundary,0.8323529411764706
communicability start process boundary,infectious disease control objective specification,0.6204545454545455
communicability start process boundary,process of establishing viral infection,0.6058441558441559
communicability start process boundary,negative regulation of biological process,0.6525316455696202
communicability start process boundary,polymerase chain reaction,0.6087301587301588
communicability start process boundary,COVID-19 disease course,0.630327868852459
communicability start process boundary,infectious disease incidence rate,0.6049295774647887
communicability start process boundary,communicability start process boundary,0.95
communicability start process boundary,process that results in death,0.6738805970149254
communicability start process boundary,disordered virus,0.5796296296296296
communicability start process boundary,adaptive immune response,0.6112903225806451
communicability start process boundary,virus uncoating stage,0.6194915254237288
communicability start process boundary,establishment of a clinically abnormal colony,0.6307228915662652
communicability start process boundary,process boundary,0.7462962962962962
communicability start process boundary,coronavirus disease,0.6254385964912281
communicability start process boundary,positive-sense single-stranded RNA virus,0.6038461538461539
communicability start process boundary,horizontal pathogen transmission process,0.6551282051282051
communicability start process boundary,SARS-CoV-2 release stage,0.5951612903225807
communicability start process boundary,pathogen transmission process,0.6440298507462687
communicability start process boundary,cell space,0.5958333333333333
innate immunity to infectious agent,information content entity,0.6959016393442623
innate immunity to infectious agent,infectious disease mortality rate,0.6558823529411765
innate immunity to infectious agent,infection incidence rate profile,0.6440298507462687
innate immunity to infectious agent,infectious structure aggregate,0.6807692307692308
innate immunity to infectious agent,communicability end temporal region,0.6642857142857143
innate immunity to infectious agent,primary pathogen,0.6264705882352941
innate immunity to infectious agent,infection end temporal region,0.653125
innate immunity to infectious agent,infectious disease,0.6952830188679244
innate immunity to infectious agent,SARS-CoV-2 incidence rate,0.6166666666666667
innate immunity to infectious agent,incubation end temporal region,0.6653846153846155
innate immunity to infectious agent,normal resident microbiota population,0.6444444444444444
innate immunity to infectious agent,virulence factor disposition,0.6404761904761905
innate immunity to infectious agent,infectious disease incidence,0.6722222222222223
innate immunity to infectious agent,disease surveillance objective specification,0.6525316455696202
innate immunity to infectious agent,virus release stage,0.6166666666666667
innate immunity to infectious agent,infectious agent host role,0.7122950819672131
innate immunity to infectious agent,material entity,0.63
innate immunity to infectious agent,asymptomatic infectious structure carrier,0.6868421052631578
innate immunity to infectious agent,B cell receptor complex,0.5879310344827586
innate immunity to infectious agent,passive immunization against infectious agent,0.8125
innate immunity to infectious agent,infection incidence rate,0.6703389830508475
innate immunity to infectious agent,double-stranded RNA virus,0.5833333333333334
innate immunity to infectious agent,infectious disease lifetime prevalence,0.6691780821917809
innate immunity to infectious agent,lower respiratory tract disease,0.6469696969696969
innate immunity to infectious agent,infectious disease incidence proportion,0.6527027027027027
innate immunity to infectious agent,acute infectious disease course,0.7075757575757575
innate immunity to infectious agent,cidal agent disposition,0.656896551724138
innate immunity to infectious agent,infectious disorder,0.6722222222222223
innate immunity to infectious agent,genetic resistance to pathogen,0.6653846153846155
innate immunity to infectious agent,biological vehicle,0.5632075471698114
innate immunity to infectious agent,infectious disease sporadicity,0.6653846153846155
innate immunity to infectious agent,communicability end process boundary,0.6330985915492958
innate immunity to infectious agent,directive information content entity,0.6753521126760563
innate immunity to infectious agent,infectious agent colony,0.7258620689655172
innate immunity to infectious agent,pathogen transporter,0.6136363636363636
innate immunity to infectious agent,invasion factor,0.65
innate immunity to infectious agent,latency end process boundary,0.6246031746031746
innate immunity to infectious agent,infectious disease epidemic,0.6596774193548387
innate immunity to infectious agent,infectious agent generative stage,0.6852941176470588
innate immunity to infectious agent,disease transmission model,0.6139344262295081
innate immunity to infectious agent,negative-sense single-stranded RNA virus,0.6233333333333334
innate immunity to infectious agent,cidal agent,0.6239130434782608
innate immunity to infectious agent,infectious structure host role,0.65
innate immunity to infectious agent,pathogen vehicle,0.6068627450980393
innate immunity to infectious agent,COVID-19 incidence rate,0.6224137931034482
innate immunity to infectious agent,antibiotic resistance,0.6464285714285714
innate immunity to infectious agent,pathogen vehicle role,0.6107142857142857
innate immunity to infectious agent,chronic infectious disease course,0.6852941176470588
innate immunity to infectious agent,asymptomatic infectious agent carrier,0.7416666666666667
innate immunity to infectious agent,nursing-home acquired infection,0.6924242424242425
innate immunity to infectious agent,descriptive information content entity,0.6691780821917809
innate immunity to infectious agent,COVID-19 epidemic,0.5653846153846154
innate immunity to infectious agent,resistance to drug,0.619811320754717
innate immunity to infectious agent,sterilizing immunity to infectious agent,0.8633333333333334
innate immunity to infectious agent,diseased population,0.6166666666666667
innate immunity to infectious agent,primary infection,0.7
innate immunity to infectious agent,virulence factor,0.6068627450980393
innate immunity to infectious agent,incubation end process boundary,0.6318181818181818
innate immunity to infectious agent,latency end temporal region,0.6596774193548387
innate immunity to infectious agent,innate immunity to infectious agent,0.95
innate immunity to infectious agent,infectious structure,0.6681818181818181
innate immunity to infectious agent,static agent disposition,0.6533898305084747
innate immunity to infectious agent,T cell receptor complex,0.6051724137931035
innate immunity to infectious agent,asymptomatic carrier role,0.6
innate immunity to infectious agent,infectious structure host,0.6666666666666667
innate immunity to infectious agent,infectious agent population,0.7080645161290323
innate immunity to infectious agent,respiratory system disease,0.630327868852459
innate immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.852439024390244
innate immunity to infectious agent,humoral immunity to infectious agent,0.8725352112676056
innate immunity to infectious agent,infectious disease control strategy,0.6642857142857143
innate immunity to infectious agent,infectious disease pandemic,0.6758064516129032
innate immunity to infectious agent,infectious structure generative stage,0.6722222222222223
innate immunity to infectious agent,innate immune response,0.7482456140350877
innate immunity to infectious agent,viral disease course,0.6318181818181818
innate immunity to infectious agent,passive immunity to infectious agent,0.8866197183098592
innate immunity to infectious agent,infectious disposition,0.6605263157894737
innate immunity to infectious agent,vaccination against infectious agent,0.802112676056338
innate immunity to infectious agent,susceptibility to infectious agent,0.8123188405797102
innate immunity to infectious agent,immunity to pathogen,0.759090909090909
innate immunity to infectious agent,acquired immunodeficiency,0.6833333333333332
innate immunity to infectious agent,disease course,0.6336734693877552
innate immunity to infectious agent,infectious disease course,0.6666666666666667
innate immunity to infectious agent,acquired immunity to infectious agent,0.8805555555555555
innate immunity to infectious agent,COVID-19 disease incidence proportion,0.6305555555555555
innate immunity to infectious agent,coronavirus disease course,0.6467213114754098
innate immunity to infectious agent,asymptomatic carrier,0.6136363636363636
innate immunity to infectious agent,biological vehicle role,0.5706896551724138
innate immunity to infectious agent,symptomatic infectious agent carrier,0.7316901408450704
innate immunity to infectious agent,intermediate host,0.6615384615384616
innate immunity to infectious agent,infectious disease prevalence,0.66875
innate immunity to infectious agent,infected population,0.6351851851851852
innate immunity to infectious agent,COVID-19 mortality rate,0.6051724137931035
innate immunity to infectious agent,viral disease,0.5958333333333333
innate immunity to infectious agent,primary infection role,0.6956140350877194
innate immunity to infectious agent,primary immunodeficiency,0.6872881355932203
innate immunity to infectious agent,leukocyte mediated immunity,0.6596774193548387
innate immunity to infectious agent,disease,0.5452380952380953
innate immunity to infectious agent,symptomatic infectious structure carrier,0.6766666666666665
innate immunity to infectious agent,primary infectious disposition,0.6961538461538461
innate immunity to infectious agent,designative information content entity,0.6965753424657534
innate immunity to infectious agent,symptomatic carrier role,0.5855932203389831
innate immunity to infectious agent,infectious pathogen transmissibility,0.6753521126760563
innate immunity to infectious agent,intermediate host role,0.6605263157894737
innate immunity to infectious agent,infectious human pathogen,0.7
innate immunity to infectious agent,resistance to pathogen,0.6605263157894737
innate immunity to infectious agent,immunization against infectious agent,0.8111111111111111
innate immunity to infectious agent,infectious agent host,0.7357142857142857
innate immunity to infectious agent,long-term non-progressing infectious disease course,0.6825581395348838
innate immunity to infectious agent,viral disease epidemic,0.5903508771929825
innate immunity to infectious agent,viral disease pandemic,0.6078947368421053
innate immunity to infectious agent,symptomatic carrier,0.5981481481481481
innate immunity to infectious agent,infectious disease endemicity,0.684375
innate immunity to infectious agent,function,0.6127906976744186
innate immunity to infectious agent,herd immunity to infectious organism,0.8302816901408451
innate immunity to infectious agent,pathogen transporter role,0.6166666666666667
innate immunity to infectious agent,infectious agent reservoir,0.7122950819672131
innate immunity to infectious agent,COVID-19 pandemic,0.5653846153846154
innate immunity to infectious agent,action specification,0.6681818181818181
innate immunity to infectious agent,protective resistance,0.6107142857142857
innate immunity to infectious agent,processed material,0.5820754716981132
innate immunity to infectious agent,infectious disease control objective specification,0.65
innate immunity to infectious agent,opportunistic infectious disposition,0.7035211267605633
innate immunity to infectious agent,polymerase chain reaction,0.65
innate immunity to infectious agent,COVID-19 disease course,0.6051724137931035
innate immunity to infectious agent,infectious disease incidence rate,0.6705882352941177
innate immunity to infectious agent,single-stranded RNA retrovirus,0.6346153846153847
innate immunity to infectious agent,active immunization against infectious agent,0.829746835443038
innate immunity to infectious agent,collective resistance disposition,0.6264705882352941
innate immunity to infectious agent,symptom,0.5214285714285714
innate immunity to infectious agent,local infection,0.67
innate immunity to infectious agent,infectious agent,0.7637254901960785
innate immunity to infectious agent,establishment of a clinically abnormal colony,0.625
innate immunity to infectious agent,coronavirus disease,0.6166666666666667
innate immunity to infectious agent,positive-sense single-stranded RNA virus,0.61
innate immunity to infectious agent,adhesion factor,0.63
innate immunity to infectious agent,drug susceptibility of infectious agent,0.7743243243243243
innate immunity to infectious agent,SARS-CoV-2 release stage,0.6025423728813559
innate immunity to infectious agent,static agent,0.6627659574468084
innate immunity to infectious agent,material processing,0.6166666666666667
site of infection,virus aggregate,0.575
site of infection,source of infection,0.8666666666666667
site of infection,virostatic disposition,0.6807692307692308
site of infection,zoonotic disposition,0.6662162162162162
site of infection,infectious disease mortality rate,0.61
site of infection,infection incidence rate profile,0.6540816326530612
site of infection,communicability end temporal region,0.6423076923076922
site of infection,subclinical coronavirus infection,0.73
site of infection,infection end temporal region,0.6673913043478261
site of infection,geospatial location,0.7
site of infection,infectious disease,0.6785714285714286
site of infection,double-stranded DNA virus,0.5928571428571429
site of infection,incubation end temporal region,0.6627659574468084
site of infection,site of infection,0.95
site of infection,virulence factor disposition,0.6722222222222223
site of infection,viral adhesion disposition,0.6593023255813953
site of infection,parasitostatic disposition,0.6825581395348838
site of infection,infectious disease incidence,0.65
site of infection,reverse zoonotic disposition,0.6722222222222223
site of infection,subclinical SARS-CoV-2 infection,0.7357142857142857
site of infection,virus translation stage,0.625
site of infection,disease surveillance objective specification,0.6631147540983606
site of infection,virus release stage,0.5611111111111111
site of infection,source of infection site,0.8158536585365854
site of infection,virus replication,0.6852941176470588
site of infection,B cell receptor complex,0.6
site of infection,systematic infection,0.8013513513513513
site of infection,infection incidence rate,0.6695121951219513
site of infection,virus host,0.5981481481481481
site of infection,double-stranded RNA virus,0.5928571428571429
site of infection,virus transcription stage,0.6404761904761905
site of infection,infectious disease lifetime prevalence,0.6318181818181818
site of infection,toxin disposition,0.6852941176470588
site of infection,lower respiratory tract disease,0.6166666666666667
site of infection,infectious disease incidence proportion,0.6642857142857143
site of infection,virus generative stage,0.6038461538461539
site of infection,acute infectious disease course,0.6791666666666666
site of infection,cidal agent disposition,0.675
site of infection,infectious disorder,0.6722222222222223
site of infection,subclinical infection,0.7657894736842106
site of infection,appearance of disorder,0.6294871794871795
site of infection,simple infection,0.8439393939393939
site of infection,parasiticidal disposition,0.6880952380952381
site of infection,infectious disease sporadicity,0.6202127659574468
site of infection,communicability end process boundary,0.6009433962264151
site of infection,infection incidence proportion profile,0.6681818181818181
site of infection,transmissibility disposition,0.6722222222222223
site of infection,latency end process boundary,0.6055555555555556
site of infection,infectious disease epidemic,0.6318181818181818
site of infection,disease transmission model,0.6127906976744186
site of infection,endotoxin disposition,0.6605263157894737
site of infection,negative-sense single-stranded RNA virus,0.5903508771929825
site of infection,cytotoxin disposition,0.6605263157894737
site of infection,community-acquired infection,0.7388888888888888
site of infection,chronic infectious disease course,0.65
site of infection,nursing-home acquired infection,0.7416666666666667
site of infection,COVID-19 epidemic,0.5970588235294118
site of infection,secondary infection,0.8111111111111111
site of infection,infection start temporal region,0.6375
site of infection,infection incidence,0.7
site of infection,virus disorder,0.5790322580645162
site of infection,primary infection,0.7735294117647058
site of infection,process of establishing an infection,0.7141509433962264
site of infection,incubation end process boundary,0.6166666666666667
site of infection,SARS-CoV-2 disorder,0.5888888888888889
site of infection,collective pathogenic disposition,0.65
site of infection,neurotoxin disposition,0.6551282051282051
site of infection,latency end temporal region,0.6545454545454545
site of infection,virus adhesion susceptible cell,0.5958333333333333
site of infection,anatomical space,0.5712121212121213
site of infection,collective disposition,0.6807692307692308
site of infection,infection,0.7961538461538461
site of infection,static agent disposition,0.6939024390243902
site of infection,T cell receptor complex,0.625
site of infection,respiratory system disease,0.6127906976744186
site of infection,communicability interval,0.5963414634146341
site of infection,infectious disease control strategy,0.6230769230769231
site of infection,infectious disease pandemic,0.6545454545454545
site of infection,immunosuppressive disposition,0.6673913043478261
site of infection,pathogenic disposition,0.6807692307692308
site of infection,viral disease course,0.6121621621621621
site of infection,intracellular infection,0.775
site of infection,secondary infection role,0.7670731707317073
site of infection,metastatic infection,0.7743243243243243
site of infection,infectious disposition,0.6807692307692308
site of infection,acute infection,0.825
site of infection,bacteriostatic disposition,0.6593023255813953
site of infection,epitope site,0.656896551724138
site of infection,bactericidal disposition,0.6695121951219513
site of infection,source of infection role,0.8158536585365854
site of infection,chronic infection,0.7735294117647058
site of infection,invasion disposition,0.6932432432432433
site of infection,disease course,0.6112903225806451
site of infection,infectious disease course,0.6404761904761905
site of infection,viricidal disposition,0.6605263157894737
site of infection,complex infection,0.7735294117647058
site of infection,COVID-19 disease incidence proportion,0.6537037037037037
site of infection,coronavirus disease course,0.5895348837209302
site of infection,infection incidence proportion,0.7053191489361703
site of infection,respiratory droplet virus fomite,0.6336734693877552
site of infection,pathogen portal of exit site,0.65
site of infection,infectious disease prevalence,0.6456521739130434
site of infection,disposition,0.7
site of infection,single-stranded DNA virus,0.6166666666666667
site of infection,place closure control strategy,0.598936170212766
site of infection,viral disease,0.5833333333333334
site of infection,primary infection role,0.732051282051282
site of infection,adhesion disposition,0.6932432432432433
site of infection,pathogen portal of entry site,0.6456521739130434
site of infection,infection incidence profile,0.6545454545454545
site of infection,contagiousness,0.6435483870967742
site of infection,disease,0.575
site of infection,site,0.6404761904761905
site of infection,primary infectious disposition,0.6840425531914894
site of infection,infection prevalence,0.6932432432432433
site of infection,coronavirus disorder,0.5581081081081081
site of infection,incubation start process boundary,0.59
site of infection,subclinical virus infection,0.7454545454545455
site of infection,establishment of localization in virus host,0.65
site of infection,virus attachment stage,0.5782051282051281
site of infection,virus synthesis stage,0.581578947368421
site of infection,SARS-COV-2 adhesion disposition,0.6375
site of infection,invasive disposition,0.7202702702702704
site of infection,long-term non-progressing infectious disease course,0.6411764705882353
site of infection,viral disease epidemic,0.6038461538461539
site of infection,communicability start temporal region,0.6166666666666667
site of infection,fungicidal disposition,0.6551282051282051
site of infection,viral disease pandemic,0.6038461538461539
site of infection,virus penetration stage,0.65
site of infection,acute respiratory distress syndrome,0.6038461538461539
site of infection,infectious disease endemicity,0.6456521739130434
site of infection,disorder,0.57
site of infection,communicability,0.575
site of infection,extracellular infection,0.75
site of infection,exotoxin disposition,0.6662162162162162
site of infection,infection start process boundary,0.6336734693877552
site of infection,action specification,0.7202702702702704
site of infection,latency start process boundary,0.598936170212766
site of infection,infectious disease control objective specification,0.6440298507462687
site of infection,opportunistic infectious disposition,0.6764150943396227
site of infection,process of establishing viral infection,0.7
site of infection,enterotoxin disposition,0.675
site of infection,COVID-19 disease course,0.6
site of infection,infectious disease incidence rate,0.63
site of infection,communicability start process boundary,0.5772727272727273
site of infection,single-stranded RNA retrovirus,0.6414893617021277
site of infection,disordered virus,0.5712121212121213
site of infection,collective resistance disposition,0.67
site of infection,fungistatic disposition,0.675
site of infection,virus uncoating stage,0.6342105263157894
site of infection,local infection,0.79375
site of infection,establishment of a clinically abnormal colony,0.6435483870967742
site of infection,coronavirus disease,0.5611111111111111
site of infection,positive-sense single-stranded RNA virus,0.6254385964912281
site of infection,hospital-acquired infection,0.7681818181818181
site of infection,cell space,0.5611111111111111
negative regulation of production,virostatic disposition,0.6681818181818181
negative regulation of production,zoonotic disposition,0.6575471698113208
negative regulation of production,infectious disease mortality rate,0.6318181818181818
negative regulation of production,infection incidence rate profile,0.6653846153846155
negative regulation of production,communicability end temporal region,0.6411764705882353
negative regulation of production,biological regulation,0.6907407407407408
negative regulation of production,surveillance process,0.6386792452830189
negative regulation of production,infection end temporal region,0.6758064516129032
negative regulation of production,geospatial location,0.6807692307692308
negative regulation of production,vector control strategy,0.6107142857142857
negative regulation of production,SARS-CoV-2 incidence rate,0.5879310344827586
negative regulation of production,incubation end temporal region,0.6722222222222223
negative regulation of production,site of infection,0.67
negative regulation of production,virulence factor disposition,0.6795081967213115
negative regulation of production,viral adhesion disposition,0.6872881355932203
negative regulation of production,parasitostatic disposition,0.6533898305084747
negative regulation of production,negative regulation of production,0.95
negative regulation of production,reverse zoonotic disposition,0.6959016393442623
negative regulation of production,disease surveillance objective specification,0.6837662337662337
negative regulation of production,case isolation control strategy,0.66875
negative regulation of production,source of infection site,0.6429824561403508
negative regulation of production,quarantine control strategy,0.6333333333333333
negative regulation of production,B cell receptor complex,0.6107142857142857
negative regulation of production,infection incidence rate,0.6254385964912281
negative regulation of production,double-stranded RNA virus,0.6051724137931035
negative regulation of production,toxin disposition,0.65
negative regulation of production,lower respiratory tract disease,0.6375
negative regulation of production,cidal agent disposition,0.6464285714285714
negative regulation of production,parasiticidal disposition,0.656896551724138
negative regulation of production,communicability end process boundary,0.6384057971014493
negative regulation of production,transmissibility disposition,0.630327868852459
negative regulation of production,latency end process boundary,0.6631147540983606
negative regulation of production,endotoxin disposition,0.6537037037037037
negative regulation of production,vector surveillance,0.6230769230769231
negative regulation of production,negative regulation of establishment of localization,0.7911764705882354
negative regulation of production,negative-sense single-stranded RNA virus,0.682876712328767
negative regulation of production,COVID-19 incidence rate,0.575
negative regulation of production,cytotoxin disposition,0.6537037037037037
negative regulation of production,negative regulation of developmental process,0.8006493506493507
negative regulation of production,negative regulation of replication,0.8828358208955223
negative regulation of production,PCR product,0.6545454545454545
negative regulation of production,incubation end process boundary,0.684375
negative regulation of production,collective pathogenic disposition,0.7075757575757575
negative regulation of production,neurotoxin disposition,0.6863636363636364
negative regulation of production,latency end temporal region,0.6666666666666667
negative regulation of production,collective disposition,0.6863636363636364
negative regulation of production,static agent disposition,0.6780701754385965
negative regulation of production,T cell receptor complex,0.6285714285714286
negative regulation of production,respiratory system disease,0.6194915254237288
negative regulation of production,infectious disease control strategy,0.6411764705882353
negative regulation of production,immunosuppressive disposition,0.6596774193548387
negative regulation of production,pathogenic disposition,0.65
negative regulation of production,infectious disposition,0.6681818181818181
negative regulation of production,bacteriostatic disposition,0.6872881355932203
negative regulation of production,epitope site,0.5833333333333334
negative regulation of production,bactericidal disposition,0.6605263157894737
negative regulation of production,invasion disposition,0.6952830188679244
negative regulation of production,viricidal disposition,0.6351851851851852
negative regulation of production,pathogen portal of exit site,0.6467213114754098
negative regulation of production,production,0.6825581395348838
negative regulation of production,disposition,0.609090909090909
negative regulation of production,COVID-19 mortality rate,0.5928571428571429
negative regulation of production,negative regulation of life-sustaining process,0.7917721518987341
negative regulation of production,place closure control strategy,0.6246031746031746
negative regulation of production,adhesion disposition,0.6764150943396227
negative regulation of production,pathogen portal of entry site,0.6435483870967742
negative regulation of production,site,0.504054054054054
negative regulation of production,primary infectious disposition,0.6563492063492063
negative regulation of production,pathogen surveillance,0.6351851851851852
negative regulation of production,negative regulation of immune response,0.8161971830985917
negative regulation of production,SARS-COV-2 adhesion disposition,0.66875
negative regulation of production,invasive disposition,0.6952830188679244
negative regulation of production,fungicidal disposition,0.65
negative regulation of production,division of geopolitical entity,0.66875
negative regulation of production,negative regulation of viral process,0.8413043478260869
negative regulation of production,exotoxin disposition,0.6575471698113208
negative regulation of production,action specification,0.6764150943396227
negative regulation of production,infectious disease control objective specification,0.6668674698795181
negative regulation of production,opportunistic infectious disposition,0.6673913043478261
negative regulation of production,negative regulation of biological process,0.8148648648648649
negative regulation of production,enterotoxin disposition,0.7
negative regulation of production,infectious disease incidence rate,0.6318181818181818
negative regulation of production,single-stranded RNA retrovirus,0.6246031746031746
negative regulation of production,active immunization against infectious agent,0.6967532467532468
negative regulation of production,collective resistance disposition,0.7075757575757575
negative regulation of production,fungistatic disposition,0.6821428571428573
negative regulation of production,establishment of a clinically abnormal colony,0.6294871794871795
negative regulation of production,positive-sense single-stranded RNA virus,0.6280821917808219
replication,infectious disease mortality rate,0.5636363636363636
replication,infection incidence rate profile,0.5895348837209302
replication,coronavirus replication,0.7735294117647058
replication,SARS-CoV-2 incidence rate,0.5888888888888889
replication,prion replication,0.8428571428571427
replication,negative regulation of production,0.6545454545454545
replication,virus replication,0.8428571428571427
replication,B cell receptor complex,0.5970588235294118
replication,infection incidence rate,0.6214285714285714
replication,virus transcription stage,0.6166666666666667
replication,appearance of disorder,0.5712121212121213
replication,disease transmission model,0.6121621621621621
replication,COVID-19 incidence rate,0.5676470588235294
replication,negative regulation of replication,0.6944444444444444
replication,PCR product,0.6318181818181818
replication,T cell receptor complex,0.5970588235294118
replication,SARS-CoV-2 replication,0.7833333333333333
replication,SARS-CoV-2 genome replication stage,0.6891304347826087
replication,production,0.7357142857142857
replication,COVID-19 mortality rate,0.5970588235294118
replication,contact tracing,0.6423076923076922
replication,replication,0.95
replication,SARS-CoV-2 transcription stage,0.6207317073170732
replication,infectious disease incidence rate,0.5863636363636363
replication,establishment of a clinically abnormal colony,0.575
colony,infectious disease mortality rate,0.5525641025641026
colony,infection incidence rate profile,0.5289473684210526
colony,communicability end temporal region,0.5719512195121951
colony,infection end temporal region,0.5928571428571429
colony,SARS-CoV-2 incidence rate,0.5467741935483871
colony,incubation end temporal region,0.5888888888888889
colony,normal resident microbiota population,0.5662790697674418
colony,establishment of localization in host,0.5430232558139535
colony,infectious agent host role,0.54375
colony,B cell receptor complex,0.553448275862069
colony,infection incidence rate,0.55
colony,colonized host,0.7
colony,virus host,0.5125
colony,communicability end process boundary,0.5928571428571429
colony,infectious agent colony,0.656896551724138
colony,latency end process boundary,0.5970588235294118
colony,colonization of host,0.6423076923076922
colony,infectious structure host role,0.5333333333333333
colony,COVID-19 incidence rate,0.553448275862069
colony,host,0.55
colony,establishment of localization in human host,0.5316326530612244
colony,incubation end process boundary,0.5851351351351352
colony,dead-end host role,0.5333333333333333
colony,definitive host role,0.5269230769230769
colony,latency end temporal region,0.6015151515151516
colony,colony,0.95
colony,T cell receptor complex,0.553448275862069
colony,infectious structure host,0.5467741935483871
colony,entry into host,0.5452380952380953
colony,adhesion of symbiont to host,0.5382352941176471
colony,pathogen host,0.5552631578947369
colony,COVID-19 mortality rate,0.5879310344827586
colony,pathogen host role,0.5333333333333333
colony,intermediate host role,0.5214285714285714
colony,dead-end host,0.5026315789473684
colony,host role,0.5833333333333334
colony,establishment of localization in virus host,0.5316326530612244
colony,infectious agent host,0.5611111111111111
colony,herd immunity to infectious organism,0.5452380952380953
colony,symbiont host role,0.5333333333333333
colony,infectious disease incidence rate,0.5269230769230769
colony,local infection,0.6404761904761905
colony,establishment of a clinically abnormal colony,0.5676470588235294
infectious disposition,virostatic disposition,0.7909090909090909
infectious disposition,information content entity,0.6583333333333334
infectious disposition,zoonotic disposition,0.8071428571428573
infectious disposition,infectious disease mortality rate,0.759090909090909
infectious disposition,infection incidence rate profile,0.6907407407407408
infectious disposition,infectious structure aggregate,0.7
infectious disposition,communicability end temporal region,0.6254385964912281
infectious disposition,geographical entity,0.5963414634146341
infectious disposition,biological regulation,0.636046511627907
infectious disposition,surveillance process,0.6166666666666667
infectious disposition,infection end temporal region,0.7441176470588234
infectious disposition,vector control strategy,0.6277777777777778
infectious disposition,infectious disease,0.825
infectious disposition,SARS-CoV-2 incidence rate,0.5776595744680851
infectious disposition,incubation end temporal region,0.7
infectious disposition,resistant entity,0.6078947368421053
infectious disposition,virulence factor disposition,0.81
infectious disposition,viral adhesion disposition,0.7833333333333333
infectious disposition,parasitostatic disposition,0.7833333333333333
infectious disposition,infectious disease incidence,0.81
infectious disposition,negative regulation of production,0.6681818181818181
infectious disposition,reverse zoonotic disposition,0.75
infectious disposition,establishment of localization in host,0.6533898305084747
infectious disposition,disease surveillance objective specification,0.6621212121212122
infectious disposition,case isolation control strategy,0.6386792452830189
infectious disposition,infectious agent host role,0.7625
infectious disposition,macromolecular complex,0.5636363636363636
infectious disposition,material entity,0.5851351351351352
infectious disposition,asymptomatic infectious structure carrier,0.6722222222222223
infectious disposition,architectual structure,0.6318181818181818
infectious disposition,quarantine control strategy,0.6336734693877552
infectious disposition,B cell receptor complex,0.5833333333333334
infectious disposition,passive immunization against infectious agent,0.6440298507462687
infectious disposition,infection incidence rate,0.7108695652173913
infectious disposition,colonized host,0.6166666666666667
infectious disposition,virus host,0.66875
infectious disposition,entity,0.5928571428571429
infectious disposition,infectious disease lifetime prevalence,0.7666666666666666
infectious disposition,toxin disposition,0.808974358974359
infectious disposition,lower respiratory tract disease,0.6009433962264151
infectious disposition,infectious disease incidence proportion,0.7778688524590163
infectious disposition,acute infectious disease course,0.7518867924528303
infectious disposition,cidal agent disposition,0.7833333333333333
infectious disposition,infectious disorder,0.8158536585365854
infectious disposition,parasiticidal disposition,0.7691489361702127
infectious disposition,infectious disease sporadicity,0.7961538461538461
infectious disposition,communicability end process boundary,0.6224137931034482
infectious disposition,directive information content entity,0.656896551724138
infectious disposition,acellular structure aggregate,0.5676470588235294
infectious disposition,infectious agent colony,0.7611111111111112
infectious disposition,transmissibility disposition,0.75
infectious disposition,latency end process boundary,0.63
infectious disposition,colonization of host,0.6404761904761905
infectious disposition,infectious disease epidemic,0.7969387755102041
infectious disposition,infectious agent generative stage,0.7045454545454546
infectious disposition,disease transmission model,0.6583333333333334
infectious disposition,realizable entity,0.5782051282051281
infectious disposition,endotoxin disposition,0.7988372093023256
infectious disposition,vector surveillance,0.6451219512195122
infectious disposition,negative regulation of establishment of localization,0.6391891891891892
infectious disposition,infectious structure host role,0.7576923076923078
infectious disposition,COVID-19 incidence rate,0.5833333333333334
infectious disposition,cytotoxin disposition,0.7988372093023256
infectious disposition,negative regulation of developmental process,0.6015151515151516
infectious disposition,host,0.5653846153846154
infectious disposition,chronic infectious disease course,0.740909090909091
infectious disposition,asymptomatic infectious agent carrier,0.6703389830508475
infectious disposition,descriptive information content entity,0.6333333333333333
infectious disposition,COVID-19 epidemic,0.6038461538461539
infectious disposition,negative regulation of replication,0.6642857142857143
infectious disposition,sterilizing immunity to infectious agent,0.6435483870967742
infectious disposition,establishment of localization in human host,0.6346153846153847
infectious disposition,diseased population,0.6939024390243902
infectious disposition,acellular structure,0.5719512195121951
infectious disposition,incubation end process boundary,0.6952830188679244
infectious disposition,collective pathogenic disposition,0.759090909090909
infectious disposition,neurotoxin disposition,0.8136363636363637
infectious disposition,dead-end host role,0.6
infectious disposition,molecular entity,0.6078947368421053
infectious disposition,plan specification,0.675
infectious disposition,definitive host role,0.6642857142857143
infectious disposition,latency end temporal region,0.6336734693877552
infectious disposition,innate immunity to infectious agent,0.6605263157894737
infectious disposition,infectious structure,0.7595238095238095
infectious disposition,collective disposition,0.8136363636363637
infectious disposition,static agent disposition,0.7760869565217391
infectious disposition,T cell receptor complex,0.5833333333333334
infectious disposition,infectious structure host,0.7691489361702127
infectious disposition,infectious agent population,0.7969387755102041
infectious disposition,respiratory system disease,0.6375
infectious disposition,entry into host,0.6662162162162162
infectious disposition,leukocyte-mediated immunity to infectious agent,0.6239130434782608
infectious disposition,adhesion of symbiont to host,0.63
infectious disposition,humoral immunity to infectious agent,0.656896551724138
infectious disposition,infectious disease control strategy,0.7482456140350877
infectious disposition,infectious disease pandemic,0.7765306122448979
infectious disposition,infectious structure generative stage,0.6872881355932203
infectious disposition,immunosuppressive disposition,0.7833333333333333
infectious disposition,pathogenic disposition,0.7681818181818181
infectious disposition,viral disease course,0.6166666666666667
infectious disposition,entry into host through host barriers,0.6194915254237288
infectious disposition,passive immunity to infectious agent,0.656896551724138
infectious disposition,infectious disposition,0.95
infectious disposition,vaccination against infectious agent,0.6741379310344828
infectious disposition,susceptibility to infectious agent,0.6642857142857143
infectious disposition,bacteriostatic disposition,0.8041666666666667
infectious disposition,bactericidal disposition,0.7760869565217391
infectious disposition,pathogen host,0.6214285714285714
infectious disposition,invasion disposition,0.830952380952381
infectious disposition,disease course,0.6166666666666667
infectious disposition,infectious disease course,0.7904255319148936
infectious disposition,viricidal disposition,0.7988372093023256
infectious disposition,acquired immunity to infectious agent,0.6533898305084747
infectious disposition,complex infection,0.6807692307692308
infectious disposition,COVID-19 disease incidence proportion,0.6533898305084747
infectious disposition,coronavirus disease course,0.6583333333333334
infectious disposition,symptomatic infectious agent carrier,0.6741379310344828
infectious disposition,intermediate host,0.6551282051282051
infectious disposition,infectious disease prevalence,0.7637254901960785
infectious disposition,anatomical entity,0.6038461538461539
infectious disposition,disposition,0.7833333333333333
infectious disposition,infected population,0.7670731707317073
infectious disposition,COVID-19 mortality rate,0.5833333333333334
infectious disposition,negative regulation of life-sustaining process,0.6264705882352941
infectious disposition,place closure control strategy,0.6038461538461539
infectious disposition,geopolitical entity,0.6451219512195122
infectious disposition,viral disease,0.6214285714285714
infectious disposition,adhesion disposition,0.8071428571428573
infectious disposition,disease,0.5879310344827586
infectious disposition,symptomatic infectious structure carrier,0.6758064516129032
infectious disposition,primary infectious disposition,0.8730769230769231
infectious disposition,pathogen host role,0.625
infectious disposition,designative information content entity,0.6333333333333333
infectious disposition,infectious pathogen transmissibility,0.7258620689655172
infectious disposition,intermediate host role,0.6545454545454545
infectious disposition,dead-end host,0.5928571428571429
infectious disposition,pathogen surveillance,0.5895348837209302
infectious disposition,host role,0.5790322580645162
infectious disposition,infectious human pathogen,0.7691489361702127
infectious disposition,establishment of localization in virus host,0.65
infectious disposition,immunization against infectious agent,0.6703389830508475
infectious disposition,negative regulation of immune response,0.6333333333333333
infectious disposition,immaterial entity,0.6038461538461539
infectious disposition,SARS-COV-2 adhesion disposition,0.7330188679245283
infectious disposition,invasive disposition,0.8071428571428573
infectious disposition,infectious agent host,0.7755813953488372
infectious disposition,long-term non-progressing infectious disease course,0.6691780821917809
infectious disposition,viral disease epidemic,0.6318181818181818
infectious disposition,fungicidal disposition,0.7909090909090909
infectious disposition,viral disease pandemic,0.609090909090909
infectious disposition,division of geopolitical entity,0.6575471698113208
infectious disposition,infectious disease endemicity,0.7833333333333333
infectious disposition,negative regulation of viral process,0.6224137931034482
infectious disposition,herd immunity to infectious organism,0.6741379310344828
infectious disposition,exotoxin disposition,0.8071428571428573
infectious disposition,infectious agent reservoir,0.7416666666666667
infectious disposition,immunoglobulin complex,0.5863636363636363
infectious disposition,COVID-19 pandemic,0.5782051282051281
infectious disposition,infectious disease control objective specification,0.7416666666666667
infectious disposition,symbiont host role,0.65
infectious disposition,opportunistic infectious disposition,0.8293103448275861
infectious disposition,negative regulation of biological process,0.6087301587301588
infectious disposition,enterotoxin disposition,0.8055555555555556
infectious disposition,COVID-19 disease course,0.6277777777777778
infectious disposition,infectious disease incidence rate,0.7772727272727272
infectious disposition,active immunization against infectious agent,0.6469696969696969
infectious disposition,collective resistance disposition,0.759090909090909
infectious disposition,fungistatic disposition,0.7833333333333333
infectious disposition,infectious agent,0.7657894736842106
infectious disposition,establishment of a clinically abnormal colony,0.5992537313432835
infectious disposition,coronavirus disease,0.6695121951219513
infectious disposition,definitive host,0.6662162162162162
infectious disposition,drug susceptibility of infectious agent,0.6467213114754098
disease surveillance objective specification,virus aggregate,0.5855932203389831
disease surveillance objective specification,source of infection,0.6880952380952381
disease surveillance objective specification,virostatic disposition,0.6621212121212122
disease surveillance objective specification,zoonotic disposition,0.6375
disease surveillance objective specification,infectious disease mortality rate,0.6448051948051949
disease surveillance objective specification,infection incidence rate profile,0.6342105263157894
disease surveillance objective specification,communicability end temporal region,0.6145569620253164
disease surveillance objective specification,pathogen portal of entry,0.5970588235294118
disease surveillance objective specification,biological regulation,0.6192307692307693
disease surveillance objective specification,subclinical coronavirus infection,0.6577922077922078
disease surveillance objective specification,surveillance process,0.715625
disease surveillance objective specification,infection end temporal region,0.6280821917808219
disease surveillance objective specification,geospatial location,0.6404761904761905
disease surveillance objective specification,vector control strategy,0.5992537313432835
disease surveillance objective specification,infectious disease,0.6112903225806451
disease surveillance objective specification,SARS-CoV-2 incidence rate,0.6384057971014493
disease surveillance objective specification,double-stranded DNA virus,0.5949275362318841
disease surveillance objective specification,incubation end temporal region,0.6256756756756756
disease surveillance objective specification,site of infection,0.6631147540983606
disease surveillance objective specification,virulence factor disposition,0.6861111111111111
disease surveillance objective specification,viral adhesion disposition,0.6642857142857143
disease surveillance objective specification,parasitostatic disposition,0.65
disease surveillance objective specification,infectious disease incidence,0.6444444444444444
disease surveillance objective specification,negative regulation of production,0.6837662337662337
disease surveillance objective specification,reverse zoonotic disposition,0.6722222222222223
disease surveillance objective specification,subclinical SARS-CoV-2 infection,0.6605263157894737
disease surveillance objective specification,virus translation stage,0.6291044776119403
disease surveillance objective specification,disease surveillance objective specification,0.95
disease surveillance objective specification,case isolation control strategy,0.65
disease surveillance objective specification,virus release stage,0.6246031746031746
disease surveillance objective specification,source of infection site,0.6705882352941177
disease surveillance objective specification,virus,0.5112244897959184
disease surveillance objective specification,quarantine control strategy,0.6190140845070422
disease surveillance objective specification,virus replication,0.6631147540983606
disease surveillance objective specification,B cell receptor complex,0.6141791044776119
disease surveillance objective specification,systematic infection,0.66875
disease surveillance objective specification,infection incidence rate,0.6264705882352941
disease surveillance objective specification,virus host,0.5611111111111111
disease surveillance objective specification,double-stranded RNA virus,0.5949275362318841
disease surveillance objective specification,pathogen portal of entry role,0.6006849315068493
disease surveillance objective specification,virus transcription stage,0.6384057971014493
disease surveillance objective specification,infectious disease lifetime prevalence,0.6695121951219513
disease surveillance objective specification,toxin disposition,0.630327868852459
disease surveillance objective specification,lower respiratory tract disease,0.6233333333333334
disease surveillance objective specification,infectious disease incidence proportion,0.6909638554216868
disease surveillance objective specification,virus generative stage,0.6469696969696969
disease surveillance objective specification,acute infectious disease course,0.6366666666666667
disease surveillance objective specification,cidal agent disposition,0.658955223880597
disease surveillance objective specification,infectious disorder,0.5928571428571429
disease surveillance objective specification,subclinical infection,0.65
disease surveillance objective specification,appearance of disorder,0.6318181818181818
disease surveillance objective specification,simple infection,0.65
disease surveillance objective specification,parasiticidal disposition,0.6384057971014493
disease surveillance objective specification,infectious disease sporadicity,0.6527027027027027
disease surveillance objective specification,communicability end process boundary,0.6
disease surveillance objective specification,infection incidence proportion profile,0.6329268292682927
disease surveillance objective specification,transmissibility disposition,0.6444444444444444
disease surveillance objective specification,latency end process boundary,0.6166666666666667
disease surveillance objective specification,infectious disease epidemic,0.6471830985915493
disease surveillance objective specification,disease transmission model,0.6785714285714286
disease surveillance objective specification,endotoxin disposition,0.65
disease surveillance objective specification,vector surveillance,0.6722222222222223
disease surveillance objective specification,negative regulation of establishment of localization,0.6895833333333334
disease surveillance objective specification,negative-sense single-stranded RNA virus,0.6285714285714286
disease surveillance objective specification,COVID-19 incidence rate,0.6141791044776119
disease surveillance objective specification,cytotoxin disposition,0.6346153846153847
disease surveillance objective specification,community-acquired infection,0.6444444444444444
disease surveillance objective specification,negative regulation of developmental process,0.6545454545454545
disease surveillance objective specification,chronic infectious disease course,0.6188311688311688
disease surveillance objective specification,nursing-home acquired infection,0.6766666666666665
disease surveillance objective specification,COVID-19 epidemic,0.5811475409836065
disease surveillance objective specification,negative regulation of replication,0.7064102564102563
disease surveillance objective specification,secondary infection,0.6404761904761905
disease surveillance objective specification,infection start temporal region,0.6233333333333334
disease surveillance objective specification,infection incidence,0.6246031746031746
disease surveillance objective specification,virus disorder,0.553448275862069
disease surveillance objective specification,primary infection,0.630327868852459
disease surveillance objective specification,process of establishing an infection,0.65
disease surveillance objective specification,incubation end process boundary,0.61
disease surveillance objective specification,SARS-CoV-2 disorder,0.5928571428571429
disease surveillance objective specification,collective pathogenic disposition,0.6837662337662337
disease surveillance objective specification,neurotoxin disposition,0.6621212121212122
disease surveillance objective specification,plan specification,0.7241935483870968
disease surveillance objective specification,latency end temporal region,0.6330985915492958
disease surveillance objective specification,virus adhesion susceptible cell,0.6366666666666667
disease surveillance objective specification,collective disposition,0.6924242424242425
disease surveillance objective specification,infection,0.6009433962264151
disease surveillance objective specification,static agent disposition,0.6705882352941177
disease surveillance objective specification,T cell receptor complex,0.6141791044776119
disease surveillance objective specification,respiratory system disease,0.6071428571428572
disease surveillance objective specification,entry into host,0.5855932203389831
disease surveillance objective specification,infectious disease control strategy,0.639873417721519
disease surveillance objective specification,infectious disease pandemic,0.6330985915492958
disease surveillance objective specification,immunosuppressive disposition,0.6691780821917809
disease surveillance objective specification,pathogenic disposition,0.6469696969696969
disease surveillance objective specification,viral disease course,0.6375
disease surveillance objective specification,entry into host through host barriers,0.5858024691358025
disease surveillance objective specification,intracellular infection,0.658955223880597
disease surveillance objective specification,secondary infection role,0.6264705882352941
disease surveillance objective specification,metastatic infection,0.66875
disease surveillance objective specification,infectious disposition,0.6621212121212122
disease surveillance objective specification,objective specification,0.7932835820895522
disease surveillance objective specification,acute infection,0.6533898305084747
disease surveillance objective specification,bacteriostatic disposition,0.6642857142857143
disease surveillance objective specification,bactericidal disposition,0.6558823529411765
disease surveillance objective specification,source of infection role,0.6705882352941177
disease surveillance objective specification,chronic infection,0.630327868852459
disease surveillance objective specification,invasion disposition,0.66875
disease surveillance objective specification,disease course,0.656896551724138
disease surveillance objective specification,infectious disease course,0.6239130434782608
disease surveillance objective specification,viricidal disposition,0.65
disease surveillance objective specification,complex infection,0.630327868852459
disease surveillance objective specification,COVID-19 disease incidence proportion,0.6969135802469135
disease surveillance objective specification,coronavirus disease course,0.6214285714285714
disease surveillance objective specification,infection incidence proportion,0.6527027027027027
disease surveillance objective specification,respiratory droplet virus fomite,0.6210526315789474
disease surveillance objective specification,infectious disease prevalence,0.6417808219178082
disease surveillance objective specification,disposition,0.6318181818181818
disease surveillance objective specification,single-stranded DNA virus,0.5949275362318841
disease surveillance objective specification,COVID-19 mortality rate,0.5843283582089552
disease surveillance objective specification,negative regulation of life-sustaining process,0.6388888888888888
disease surveillance objective specification,place closure control strategy,0.6391891891891892
disease surveillance objective specification,viral disease,0.5903508771929825
disease surveillance objective specification,primary infection role,0.6166666666666667
disease surveillance objective specification,adhesion disposition,0.66875
disease surveillance objective specification,pathogen portal of entry site,0.6280821917808219
disease surveillance objective specification,infection incidence profile,0.6330985915492958
disease surveillance objective specification,disease,0.5872549019607843
disease surveillance objective specification,primary infectious disposition,0.6797297297297297
disease surveillance objective specification,infection prevalence,0.621875
disease surveillance objective specification,coronavirus disorder,0.559375
disease surveillance objective specification,object,0.57
disease surveillance objective specification,pathogen surveillance,0.6807692307692308
disease surveillance objective specification,subclinical virus infection,0.6612676056338028
disease surveillance objective specification,establishment of localization in virus host,0.6224137931034482
disease surveillance objective specification,virus attachment stage,0.6015151515151516
disease surveillance objective specification,negative regulation of immune response,0.6695121951219513
disease surveillance objective specification,virus synthesis stage,0.6038461538461539
disease surveillance objective specification,SARS-COV-2 adhesion disposition,0.6633333333333334
disease surveillance objective specification,object aggregate,0.6166666666666667
disease surveillance objective specification,invasive disposition,0.66875
disease surveillance objective specification,long-term non-progressing infectious disease course,0.6184210526315789
disease surveillance objective specification,viral disease epidemic,0.6469696969696969
disease surveillance objective specification,fungicidal disposition,0.6318181818181818
disease surveillance objective specification,viral disease pandemic,0.6469696969696969
disease surveillance objective specification,virus penetration stage,0.6291044776119403
disease surveillance objective specification,acute respiratory distress syndrome,0.6145569620253164
disease surveillance objective specification,infectious disease endemicity,0.6554794520547945
disease surveillance objective specification,negative regulation of viral process,0.6375
disease surveillance objective specification,disorder,0.5461538461538461
disease surveillance objective specification,extracellular infection,0.658955223880597
disease surveillance objective specification,exotoxin disposition,0.6375
disease surveillance objective specification,infection start process boundary,0.6078947368421053
disease surveillance objective specification,action specification,0.73125
disease surveillance objective specification,infectious disease control objective specification,0.8117021276595744
disease surveillance objective specification,opportunistic infectious disposition,0.6625
disease surveillance objective specification,process of establishing viral infection,0.6548192771084337
disease surveillance objective specification,negative regulation of biological process,0.65
disease surveillance objective specification,enterotoxin disposition,0.658955223880597
disease surveillance objective specification,COVID-19 disease course,0.6291044776119403
disease surveillance objective specification,infectious disease incidence rate,0.6707792207792208
disease surveillance objective specification,disordered virus,0.6
disease surveillance objective specification,collective resistance disposition,0.6967532467532468
disease surveillance objective specification,fungistatic disposition,0.658955223880597
disease surveillance objective specification,virus uncoating stage,0.6346153846153847
disease surveillance objective specification,local infection,0.6364406779661017
disease surveillance objective specification,establishment of a clinically abnormal colony,0.6185393258426967
disease surveillance objective specification,coronavirus disease,0.5769841269841269
disease surveillance objective specification,positive-sense single-stranded RNA virus,0.6285714285714286
disease surveillance objective specification,hospital-acquired infection,0.6612676056338028
acellular structure,virostatic disposition,0.5719512195121951
acellular structure,zoonotic disposition,0.5525641025641026
acellular structure,infectious disease mortality rate,0.6038461538461539
acellular structure,infection incidence rate profile,0.5872549019607843
acellular structure,infectious structure aggregate,0.6948979591836735
acellular structure,SARS-CoV-2 incidence rate,0.609090909090909
acellular structure,virulence factor disposition,0.598936170212766
acellular structure,viral adhesion disposition,0.5833333333333334
acellular structure,parasitostatic disposition,0.5833333333333334
acellular structure,reverse zoonotic disposition,0.5776595744680851
acellular structure,macromolecular complex,0.6939024390243902
acellular structure,asymptomatic infectious structure carrier,0.6833333333333332
acellular structure,architectual structure,0.8158536585365854
acellular structure,B cell receptor complex,0.6880952380952381
acellular structure,infection incidence rate,0.5895348837209302
acellular structure,toxin disposition,0.5333333333333333
acellular structure,cidal agent disposition,0.5928571428571429
acellular structure,parasiticidal disposition,0.5863636363636363
acellular structure,acellular structure aggregate,0.8458333333333333
acellular structure,transmissibility disposition,0.5563829787234043
acellular structure,endotoxin disposition,0.55
acellular structure,infectious structure host role,0.6948979591836735
acellular structure,COVID-19 incidence rate,0.5928571428571429
acellular structure,cytotoxin disposition,0.55
acellular structure,acellular structure,0.95
acellular structure,collective pathogenic disposition,0.5846153846153846
acellular structure,neurotoxin disposition,0.5963414634146341
acellular structure,infectious structure,0.7576923076923078
acellular structure,virus adhesion susceptible cell,0.61
acellular structure,collective disposition,0.5963414634146341
acellular structure,static agent disposition,0.5895348837209302
acellular structure,T cell receptor complex,0.6880952380952381
acellular structure,infectious structure host,0.7227272727272727
acellular structure,respiratory system disease,0.6055555555555556
acellular structure,infectious structure generative stage,0.6642857142857143
acellular structure,immunosuppressive disposition,0.5541666666666667
acellular structure,pathogenic disposition,0.5719512195121951
acellular structure,cell,0.6239130434782608
acellular structure,infectious disposition,0.5719512195121951
acellular structure,bacteriostatic disposition,0.6277777777777778
acellular structure,bactericidal disposition,0.6127906976744186
acellular structure,invasion disposition,0.5525641025641026
acellular structure,viricidal disposition,0.575
acellular structure,complex infection,0.5888888888888889
acellular structure,disposition,0.5166666666666666
acellular structure,COVID-19 mortality rate,0.5928571428571429
acellular structure,adhesion disposition,0.5782051282051281
acellular structure,symptomatic infectious structure carrier,0.6872881355932203
acellular structure,primary infectious disposition,0.5724489795918367
acellular structure,SARS-COV-2 adhesion susceptible cell,0.6136363636363636
acellular structure,virus synthesis stage,0.6
acellular structure,SARS-COV-2 adhesion disposition,0.57
acellular structure,invasive disposition,0.5782051282051281
acellular structure,fungicidal disposition,0.5719512195121951
acellular structure,acute respiratory distress syndrome,0.6537037037037037
acellular structure,exotoxin disposition,0.5525641025641026
acellular structure,immunoglobulin complex,0.5963414634146341
acellular structure,SARS-CoV-2 synthesis stage,0.6055555555555556
acellular structure,opportunistic infectious disposition,0.5590909090909091
acellular structure,enterotoxin disposition,0.569047619047619
acellular structure,polymerase chain reaction,0.609090909090909
acellular structure,infectious disease incidence rate,0.5846153846153846
acellular structure,collective resistance disposition,0.6038461538461539
acellular structure,fungistatic disposition,0.569047619047619
acellular structure,establishment of a clinically abnormal colony,0.590625
acellular structure,cell space,0.7258620689655172
nursing-home acquired infection,virus aggregate,0.6021739130434782
nursing-home acquired infection,source of infection,0.75
nursing-home acquired infection,virostatic disposition,0.6386792452830189
nursing-home acquired infection,zoonotic disposition,0.6264705882352941
nursing-home acquired infection,infectious disease mortality rate,0.60625
nursing-home acquired infection,infection incidence rate profile,0.6404761904761905
nursing-home acquired infection,communicability end temporal region,0.6166666666666667
nursing-home acquired infection,subclinical coronavirus infection,0.715625
nursing-home acquired infection,infection end temporal region,0.65
nursing-home acquired infection,infectious disease,0.6132653061224489
nursing-home acquired infection,double-stranded DNA virus,0.5928571428571429
nursing-home acquired infection,incubation end temporal region,0.6467213114754098
nursing-home acquired infection,site of infection,0.7416666666666667
nursing-home acquired infection,virulence factor disposition,0.6703389830508475
nursing-home acquired infection,viral adhesion disposition,0.6429824561403508
nursing-home acquired infection,parasitostatic disposition,0.6605263157894737
nursing-home acquired infection,infectious disease incidence,0.6703389830508475
nursing-home acquired infection,reverse zoonotic disposition,0.6364406779661017
nursing-home acquired infection,subclinical SARS-CoV-2 infection,0.7039682539682539
nursing-home acquired infection,virus translation stage,0.6166666666666667
nursing-home acquired infection,disease surveillance objective specification,0.6766666666666665
nursing-home acquired infection,virus release stage,0.59
nursing-home acquired infection,source of infection site,0.7227272727272727
nursing-home acquired infection,virus,0.5055555555555555
nursing-home acquired infection,virus replication,0.6791666666666666
nursing-home acquired infection,B cell receptor complex,0.5981481481481481
nursing-home acquired infection,systematic infection,0.7245098039215686
nursing-home acquired infection,infection incidence rate,0.65
nursing-home acquired infection,virus host,0.5719512195121951
nursing-home acquired infection,double-stranded RNA virus,0.5928571428571429
nursing-home acquired infection,virus transcription stage,0.6464285714285714
nursing-home acquired infection,infectious disease lifetime prevalence,0.6528985507246376
nursing-home acquired infection,toxin disposition,0.6375
nursing-home acquired infection,lower respiratory tract disease,0.6112903225806451
nursing-home acquired infection,infectious disease incidence proportion,0.6785714285714286
nursing-home acquired infection,virus generative stage,0.619811320754717
nursing-home acquired infection,acute infectious disease course,0.6596774193548387
nursing-home acquired infection,cidal agent disposition,0.6351851851851852
nursing-home acquired infection,infectious disorder,0.63
nursing-home acquired infection,subclinical infection,0.7192307692307692
nursing-home acquired infection,appearance of disorder,0.6009433962264151
nursing-home acquired infection,simple infection,0.747872340425532
nursing-home acquired infection,parasiticidal disposition,0.6642857142857143
nursing-home acquired infection,infectious disease sporadicity,0.630327868852459
nursing-home acquired infection,communicability end process boundary,0.5992537313432835
nursing-home acquired infection,infection incidence proportion profile,0.6528985507246376
nursing-home acquired infection,transmissibility disposition,0.6194915254237288
nursing-home acquired infection,latency end process boundary,0.5855932203389831
nursing-home acquired infection,infectious disease epidemic,0.6396551724137931
nursing-home acquired infection,disease transmission model,0.6078947368421053
nursing-home acquired infection,endotoxin disposition,0.6423076923076922
nursing-home acquired infection,negative-sense single-stranded RNA virus,0.6190140845070422
nursing-home acquired infection,cytotoxin disposition,0.6230769230769231
nursing-home acquired infection,community-acquired infection,0.8059322033898306
nursing-home acquired infection,chronic infectious disease course,0.6375
nursing-home acquired infection,nursing-home acquired infection,0.95
nursing-home acquired infection,COVID-19 epidemic,0.5958333333333333
nursing-home acquired infection,secondary infection,0.73
nursing-home acquired infection,infection start temporal region,0.6435483870967742
nursing-home acquired infection,infection incidence,0.67
nursing-home acquired infection,virus disorder,0.6055555555555556
nursing-home acquired infection,primary infection,0.7625
nursing-home acquired infection,process of establishing an infection,0.703731343283582
nursing-home acquired infection,incubation end process boundary,0.6274193548387097
nursing-home acquired infection,SARS-CoV-2 disorder,0.63
nursing-home acquired infection,collective pathogenic disposition,0.6375
nursing-home acquired infection,neurotoxin disposition,0.6764150943396227
nursing-home acquired infection,latency end temporal region,0.6051724137931035
nursing-home acquired infection,virus adhesion susceptible cell,0.6112903225806451
nursing-home acquired infection,collective disposition,0.6575471698113208
nursing-home acquired infection,infection,0.675
nursing-home acquired infection,static agent disposition,0.65
nursing-home acquired infection,T cell receptor complex,0.5981481481481481
nursing-home acquired infection,facility,0.5782051282051281
nursing-home acquired infection,respiratory system disease,0.6078947368421053
nursing-home acquired infection,communicability interval,0.5954545454545455
nursing-home acquired infection,infectious disease control strategy,0.6166666666666667
nursing-home acquired infection,infectious disease pandemic,0.6396551724137931
nursing-home acquired infection,immunosuppressive disposition,0.6666666666666667
nursing-home acquired infection,pathogenic disposition,0.6386792452830189
nursing-home acquired infection,viral disease course,0.6068627450980393
nursing-home acquired infection,intracellular infection,0.7462962962962962
nursing-home acquired infection,secondary infection role,0.7045454545454546
nursing-home acquired infection,metastatic infection,0.7245098039215686
nursing-home acquired infection,healthcare facility,0.65
nursing-home acquired infection,infectious disposition,0.6575471698113208
nursing-home acquired infection,acute infection,0.7543478260869566
nursing-home acquired infection,bacteriostatic disposition,0.6429824561403508
nursing-home acquired infection,bactericidal disposition,0.65
nursing-home acquired infection,source of infection role,0.7227272727272727
nursing-home acquired infection,acquired immunodeficiency,0.7178571428571427
nursing-home acquired infection,chronic infection,0.7208333333333333
nursing-home acquired infection,invasion disposition,0.6656862745098039
nursing-home acquired infection,disease course,0.6055555555555556
nursing-home acquired infection,infectious disease course,0.6285714285714286
nursing-home acquired infection,viricidal disposition,0.6615384615384616
nursing-home acquired infection,acquired immunity to infectious agent,0.7147058823529412
nursing-home acquired infection,complex infection,0.7208333333333333
nursing-home acquired infection,COVID-19 disease incidence proportion,0.6558823529411765
nursing-home acquired infection,coronavirus disease course,0.6254385964912281
nursing-home acquired infection,infection incidence proportion,0.6795081967213115
nursing-home acquired infection,respiratory droplet virus fomite,0.6246031746031746
nursing-home acquired infection,infectious disease prevalence,0.6166666666666667
nursing-home acquired infection,disposition,0.6166666666666667
nursing-home acquired infection,single-stranded DNA virus,0.6464285714285714
nursing-home acquired infection,hospital facility,0.6166666666666667
nursing-home acquired infection,viral disease,0.5636363636363636
nursing-home acquired infection,primary infection role,0.7330188679245283
nursing-home acquired infection,adhesion disposition,0.6460784313725491
nursing-home acquired infection,infection incidence profile,0.6396551724137931
nursing-home acquired infection,contagiousness,0.5833333333333334
nursing-home acquired infection,disease,0.5552631578947369
nursing-home acquired infection,primary infectious disposition,0.6959016393442623
nursing-home acquired infection,infection prevalence,0.6264705882352941
nursing-home acquired infection,coronavirus disorder,0.6068627450980393
nursing-home acquired infection,subclinical virus infection,0.7258620689655172
nursing-home acquired infection,establishment of localization in virus host,0.6256756756756756
nursing-home acquired infection,virus attachment stage,0.6009433962264151
nursing-home acquired infection,virus synthesis stage,0.6038461538461539
nursing-home acquired infection,SARS-COV-2 adhesion disposition,0.6596774193548387
nursing-home acquired infection,invasive disposition,0.6656862745098039
nursing-home acquired infection,long-term non-progressing infectious disease course,0.6451219512195122
nursing-home acquired infection,viral disease epidemic,0.619811320754717
nursing-home acquired infection,communicability start temporal region,0.6117647058823529
nursing-home acquired infection,fungicidal disposition,0.6764150943396227
nursing-home acquired infection,viral disease pandemic,0.619811320754717
nursing-home acquired infection,virus penetration stage,0.6351851851851852
nursing-home acquired infection,acute respiratory distress syndrome,0.6318181818181818
nursing-home acquired infection,infectious disease endemicity,0.65
nursing-home acquired infection,disorder,0.5782051282051281
nursing-home acquired infection,communicability,0.5804347826086956
nursing-home acquired infection,extracellular infection,0.7277777777777777
nursing-home acquired infection,exotoxin disposition,0.6264705882352941
nursing-home acquired infection,infection start process boundary,0.6087301587301588
nursing-home acquired infection,action specification,0.6656862745098039
nursing-home acquired infection,infectious disease control objective specification,0.6722222222222223
nursing-home acquired infection,opportunistic infectious disposition,0.658955223880597
nursing-home acquired infection,process of establishing viral infection,0.7071428571428571
nursing-home acquired infection,enterotoxin disposition,0.6537037037037037
nursing-home acquired infection,COVID-19 disease course,0.5981481481481481
nursing-home acquired infection,infectious disease incidence rate,0.653125
nursing-home acquired infection,communicability start process boundary,0.5804347826086956
nursing-home acquired infection,single-stranded RNA retrovirus,0.6631147540983606
nursing-home acquired infection,disordered virus,0.6202127659574468
nursing-home acquired infection,collective resistance disposition,0.653125
nursing-home acquired infection,fungistatic disposition,0.6537037037037037
nursing-home acquired infection,virus uncoating stage,0.6230769230769231
nursing-home acquired infection,local infection,0.7108695652173913
nursing-home acquired infection,establishment of a clinically abnormal colony,0.6342105263157894
nursing-home acquired infection,coronavirus disease,0.61
nursing-home acquired infection,positive-sense single-stranded RNA virus,0.6190140845070422
nursing-home acquired infection,hospital-acquired infection,0.8120689655172413
infectious disease sporadicity,virus aggregate,0.6277777777777778
infectious disease sporadicity,source of infection,0.6132653061224489
infectious disease sporadicity,virostatic disposition,0.6615384615384616
infectious disease sporadicity,zoonotic disposition,0.67
infectious disease sporadicity,infectious disease mortality rate,0.8468253968253968
infectious disease sporadicity,infection incidence rate profile,0.7241935483870968
infectious disease sporadicity,infectious structure aggregate,0.7333333333333333
infectious disease sporadicity,communicability end temporal region,0.6346153846153847
infectious disease sporadicity,subclinical coronavirus infection,0.6246031746031746
infectious disease sporadicity,infection end temporal region,0.7211864406779661
infectious disease sporadicity,infectious disease,0.825
infectious disease sporadicity,double-stranded DNA virus,0.5954545454545455
infectious disease sporadicity,incubation end temporal region,0.6833333333333332
infectious disease sporadicity,site of infection,0.6202127659574468
infectious disease sporadicity,virulence factor disposition,0.6913793103448276
infectious disease sporadicity,viral adhesion disposition,0.6642857142857143
infectious disease sporadicity,parasitostatic disposition,0.6642857142857143
infectious disease sporadicity,infectious disease incidence,0.8293103448275861
infectious disease sporadicity,reverse zoonotic disposition,0.6396551724137931
infectious disease sporadicity,subclinical SARS-CoV-2 infection,0.6274193548387097
infectious disease sporadicity,virus translation stage,0.619811320754717
infectious disease sporadicity,disease surveillance objective specification,0.6527027027027027
infectious disease sporadicity,virus release stage,0.6744897959183673
infectious disease sporadicity,infectious agent host role,0.7357142857142857
infectious disease sporadicity,asymptomatic infectious structure carrier,0.6753521126760563
infectious disease sporadicity,source of infection site,0.6722222222222223
infectious disease sporadicity,virus,0.5357142857142857
infectious disease sporadicity,virus replication,0.6414893617021277
infectious disease sporadicity,B cell receptor complex,0.6009433962264151
infectious disease sporadicity,passive immunization against infectious agent,0.6366666666666667
infectious disease sporadicity,systematic infection,0.61
infectious disease sporadicity,infection incidence rate,0.7462962962962962
infectious disease sporadicity,virus host,0.6
infectious disease sporadicity,double-stranded RNA virus,0.6136363636363636
infectious disease sporadicity,virus transcription stage,0.6318181818181818
infectious disease sporadicity,infectious disease lifetime prevalence,0.7882352941176471
infectious disease sporadicity,toxin disposition,0.6627659574468084
infectious disease sporadicity,lower respiratory tract disease,0.630327868852459
infectious disease sporadicity,infectious disease incidence proportion,0.7833333333333333
infectious disease sporadicity,virus generative stage,0.6423076923076922
infectious disease sporadicity,acute infectious disease course,0.7942622950819671
infectious disease sporadicity,cidal agent disposition,0.6575471698113208
infectious disease sporadicity,infectious disorder,0.7969387755102041
infectious disease sporadicity,subclinical infection,0.6068627450980393
infectious disease sporadicity,appearance of disorder,0.6423076923076922
infectious disease sporadicity,simple infection,0.6239130434782608
infectious disease sporadicity,parasiticidal disposition,0.65
infectious disease sporadicity,infectious disease sporadicity,0.95
infectious disease sporadicity,communicability end process boundary,0.6166666666666667
infectious disease sporadicity,infection incidence proportion profile,0.7147058823529412
infectious disease sporadicity,infectious agent colony,0.7518867924528303
infectious disease sporadicity,transmissibility disposition,0.6396551724137931
infectious disease sporadicity,latency end process boundary,0.6224137931034482
infectious disease sporadicity,infectious disease epidemic,0.8535087719298246
infectious disease sporadicity,infectious agent generative stage,0.7357142857142857
infectious disease sporadicity,disease transmission model,0.6642857142857143
infectious disease sporadicity,endotoxin disposition,0.6656862745098039
infectious disease sporadicity,negative-sense single-stranded RNA virus,0.65
infectious disease sporadicity,infectious structure host role,0.7166666666666667
infectious disease sporadicity,COVID-19 sporadicity,0.75
infectious disease sporadicity,cytotoxin disposition,0.6656862745098039
infectious disease sporadicity,community-acquired infection,0.6224137931034482
infectious disease sporadicity,chronic infectious disease course,0.7833333333333333
infectious disease sporadicity,asymptomatic infectious agent carrier,0.6888059701492537
infectious disease sporadicity,nursing-home acquired infection,0.630327868852459
infectious disease sporadicity,COVID-19 epidemic,0.6202127659574468
infectious disease sporadicity,secondary infection,0.6336734693877552
infectious disease sporadicity,infection start temporal region,0.728688524590164
infectious disease sporadicity,infection incidence,0.6948979591836735
infectious disease sporadicity,virus disorder,0.6772727272727272
infectious disease sporadicity,sterilizing immunity to infectious agent,0.65
infectious disease sporadicity,diseased population,0.6948979591836735
infectious disease sporadicity,primary infection,0.6202127659574468
infectious disease sporadicity,process of establishing an infection,0.6166666666666667
infectious disease sporadicity,incubation end process boundary,0.6795081967213115
infectious disease sporadicity,SARS-CoV-2 disorder,0.6336734693877552
infectious disease sporadicity,collective pathogenic disposition,0.6563492063492063
infectious disease sporadicity,neurotoxin disposition,0.6807692307692308
infectious disease sporadicity,latency end temporal region,0.6254385964912281
infectious disease sporadicity,innate immunity to infectious agent,0.6653846153846155
infectious disease sporadicity,infectious structure,0.75
infectious disease sporadicity,virus adhesion susceptible cell,0.6467213114754098
infectious disease sporadicity,collective disposition,0.6807692307692308
infectious disease sporadicity,infection,0.6551282051282051
infectious disease sporadicity,static agent disposition,0.6537037037037037
infectious disease sporadicity,T cell receptor complex,0.6009433962264151
infectious disease sporadicity,infectious structure host,0.740909090909091
infectious disease sporadicity,infectious agent population,0.7657894736842106
infectious disease sporadicity,respiratory system disease,0.6642857142857143
infectious disease sporadicity,leukocyte-mediated immunity to infectious agent,0.6318181818181818
infectious disease sporadicity,humoral immunity to infectious agent,0.6621212121212122
infectious disease sporadicity,infectious disease control strategy,0.8192307692307693
infectious disease sporadicity,infectious disease pandemic,0.8710526315789474
infectious disease sporadicity,infectious structure generative stage,0.7186567164179104
infectious disease sporadicity,immunosuppressive disposition,0.6703389830508475
infectious disease sporadicity,pathogenic disposition,0.6423076923076922
infectious disease sporadicity,viral disease course,0.69
infectious disease sporadicity,intracellular infection,0.619811320754717
infectious disease sporadicity,secondary infection role,0.6351851851851852
infectious disease sporadicity,metastatic infection,0.63
infectious disease sporadicity,passive immunity to infectious agent,0.6621212121212122
infectious disease sporadicity,infectious disposition,0.7961538461538461
infectious disease sporadicity,vaccination against infectious agent,0.6621212121212122
infectious disease sporadicity,acute infection,0.6277777777777778
infectious disease sporadicity,susceptibility to infectious agent,0.66875
infectious disease sporadicity,bacteriostatic disposition,0.6821428571428573
infectious disease sporadicity,bactericidal disposition,0.6537037037037037
infectious disease sporadicity,source of infection role,0.6351851851851852
infectious disease sporadicity,chronic infection,0.6202127659574468
infectious disease sporadicity,invasion disposition,0.69
infectious disease sporadicity,disease course,0.6772727272727272
infectious disease sporadicity,infectious disease course,0.8318181818181819
infectious disease sporadicity,viricidal disposition,0.6656862745098039
infectious disease sporadicity,acquired immunity to infectious agent,0.658955223880597
infectious disease sporadicity,complex infection,0.6202127659574468
infectious disease sporadicity,COVID-19 disease incidence proportion,0.6738805970149254
infectious disease sporadicity,coronavirus disease course,0.7178571428571427
infectious disease sporadicity,infection incidence proportion,0.7333333333333333
infectious disease sporadicity,symptomatic infectious agent carrier,0.6924242424242425
infectious disease sporadicity,respiratory droplet virus fomite,0.6274193548387097
infectious disease sporadicity,infectious disease prevalence,0.8398305084745763
infectious disease sporadicity,disposition,0.6207317073170732
infectious disease sporadicity,single-stranded DNA virus,0.6136363636363636
infectious disease sporadicity,infected population,0.6948979591836735
infectious disease sporadicity,viral disease,0.6593023255813953
infectious disease sporadicity,primary infection role,0.6423076923076922
infectious disease sporadicity,adhesion disposition,0.67
infectious disease sporadicity,infection incidence profile,0.730701754385965
infectious disease sporadicity,disease,0.6391891891891892
infectious disease sporadicity,symptomatic infectious structure carrier,0.6785714285714286
infectious disease sporadicity,primary infectious disposition,0.75
infectious disease sporadicity,infection prevalence,0.71
infectious disease sporadicity,coronavirus disorder,0.67
infectious disease sporadicity,infectious pathogen transmissibility,0.7530303030303032
infectious disease sporadicity,infectious human pathogen,0.740909090909091
infectious disease sporadicity,subclinical virus infection,0.6429824561403508
infectious disease sporadicity,establishment of localization in virus host,0.6280821917808219
infectious disease sporadicity,immunization against infectious agent,0.658955223880597
infectious disease sporadicity,virus attachment stage,0.6230769230769231
infectious disease sporadicity,virus synthesis stage,0.6460784313725491
infectious disease sporadicity,SARS-COV-2 adhesion disposition,0.6467213114754098
infectious disease sporadicity,invasive disposition,0.67
infectious disease sporadicity,infectious agent host,0.7637254901960785
infectious disease sporadicity,long-term non-progressing infectious disease course,0.7092592592592593
infectious disease sporadicity,viral disease epidemic,0.7192307692307692
infectious disease sporadicity,fungicidal disposition,0.6615384615384616
infectious disease sporadicity,viral disease pandemic,0.7384615384615384
infectious disease sporadicity,virus penetration stage,0.6386792452830189
infectious disease sporadicity,acute respiratory distress syndrome,0.65
infectious disease sporadicity,infectious disease endemicity,0.8737288135593221
infectious disease sporadicity,disorder,0.6078947368421053
infectious disease sporadicity,herd immunity to infectious organism,0.6772727272727272
infectious disease sporadicity,extracellular infection,0.6009433962264151
infectious disease sporadicity,exotoxin disposition,0.67
infectious disease sporadicity,infectious agent reservoir,0.7535714285714286
infectious disease sporadicity,COVID-19 pandemic,0.6414893617021277
infectious disease sporadicity,infection start process boundary,0.7080645161290323
infectious disease sporadicity,infectious disease control objective specification,0.7625
infectious disease sporadicity,opportunistic infectious disposition,0.7227272727272727
infectious disease sporadicity,process of establishing viral infection,0.6239130434782608
infectious disease sporadicity,enterotoxin disposition,0.6764150943396227
infectious disease sporadicity,COVID-19 disease course,0.6952830188679244
infectious disease sporadicity,infectious disease incidence rate,0.8150793650793651
infectious disease sporadicity,active immunization against infectious agent,0.6391891891891892
infectious disease sporadicity,disordered virus,0.6021739130434782
infectious disease sporadicity,collective resistance disposition,0.6880952380952381
infectious disease sporadicity,fungistatic disposition,0.6575471698113208
infectious disease sporadicity,virus uncoating stage,0.6264705882352941
infectious disease sporadicity,local infection,0.6277777777777778
infectious disease sporadicity,infectious agent,0.7543478260869566
infectious disease sporadicity,establishment of a clinically abnormal colony,0.6233333333333334
infectious disease sporadicity,coronavirus disease,0.6948979591836735
infectious disease sporadicity,positive-sense single-stranded RNA virus,0.6357142857142857
infectious disease sporadicity,hospital-acquired infection,0.6078947368421053
infectious disease sporadicity,drug susceptibility of infectious agent,0.6528985507246376
single-stranded RNA retrovirus,ribonucleic acid,0.6021739130434782
single-stranded RNA retrovirus,virus aggregate,0.6055555555555556
single-stranded RNA retrovirus,deoxyribonucleic acid,0.5872549019607843
single-stranded RNA retrovirus,double-stranded DNA virus,0.8136363636363637
single-stranded RNA retrovirus,virus translation stage,0.6386792452830189
single-stranded RNA retrovirus,virus release stage,0.6132653061224489
single-stranded RNA retrovirus,virus,0.5928571428571429
single-stranded RNA retrovirus,virus replication,0.598936170212766
single-stranded RNA retrovirus,virus host,0.575
single-stranded RNA retrovirus,double-stranded RNA virus,0.8318181818181819
single-stranded RNA retrovirus,virus transcription stage,0.6318181818181818
single-stranded RNA retrovirus,virus generative stage,0.6423076923076922
single-stranded RNA retrovirus,genetic resistance to pathogen,0.6333333333333333
single-stranded RNA retrovirus,negative-sense single-stranded RNA virus,0.8071428571428573
single-stranded RNA retrovirus,nucleic acid,0.5928571428571429
single-stranded RNA retrovirus,virus disorder,0.609090909090909
single-stranded RNA retrovirus,virus adhesion susceptible cell,0.6139344262295081
single-stranded RNA retrovirus,T cell receptor complex,0.6009433962264151
single-stranded RNA retrovirus,respiratory droplet virus fomite,0.6758064516129032
single-stranded RNA retrovirus,single-stranded DNA virus,0.8863636363636362
single-stranded RNA retrovirus,double-stranded DNA retrovirus,0.8666666666666667
single-stranded RNA retrovirus,subclinical virus infection,0.6254385964912281
single-stranded RNA retrovirus,establishment of localization in virus host,0.6417808219178082
single-stranded RNA retrovirus,virus attachment stage,0.6038461538461539
single-stranded RNA retrovirus,virus synthesis stage,0.5872549019607843
single-stranded RNA retrovirus,virus penetration stage,0.6386792452830189
single-stranded RNA retrovirus,single-stranded RNA retrovirus,0.95
single-stranded RNA retrovirus,disordered virus,0.7108695652173913
single-stranded RNA retrovirus,virus uncoating stage,0.6068627450980393
single-stranded RNA retrovirus,establishment of a clinically abnormal colony,0.5966666666666667
single-stranded RNA retrovirus,positive-sense single-stranded RNA virus,0.8071428571428573
respiratory droplet,communicability end temporal region,0.6166666666666667
respiratory droplet,infection end temporal region,0.6166666666666667
respiratory droplet,incubation end temporal region,0.6336734693877552
respiratory droplet,respiratory droplet,0.95
respiratory droplet,B cell receptor complex,0.7119047619047619
respiratory droplet,respiratory droplet coronavirus fomite,0.7833333333333333
respiratory droplet,lower respiratory tract disease,0.73
respiratory droplet,droplet pathogen transmission process,0.6464285714285714
respiratory droplet,communicability end process boundary,0.6136363636363636
respiratory droplet,latency end process boundary,0.6202127659574468
respiratory droplet,respiratory droplet SARS-CoV-2 fomite,0.7892857142857143
respiratory droplet,incubation end process boundary,0.63
respiratory droplet,latency end temporal region,0.6239130434782608
respiratory droplet,T cell receptor complex,0.7119047619047619
respiratory droplet,respiratory system disease,0.7611111111111112
respiratory droplet,respiratory secretion,0.825
respiratory droplet,respiratory droplet virus fomite,0.8225490196078431
respiratory droplet,respiratory droplet fomite,0.8722222222222222
respiratory droplet,acute respiratory distress syndrome,0.7462962962962962
respiratory droplet,division of geopolitical entity,0.63
respiratory droplet,action specification,0.6294871794871795
respiratory droplet,establishment of a clinically abnormal colony,0.60625
zoonosis,zoonosis,0.95
zoonosis,reverse zoonosis,0.7833333333333333
vaccination against infectious agent,information content entity,0.7080645161290323
vaccination against infectious agent,infectious disease mortality rate,0.6528985507246376
vaccination against infectious agent,infection incidence rate profile,0.6705882352941177
vaccination against infectious agent,infectious structure aggregate,0.6924242424242425
vaccination against infectious agent,communicability end temporal region,0.6330985915492958
vaccination against infectious agent,infection end temporal region,0.6653846153846155
vaccination against infectious agent,infectious disease,0.6907407407407408
vaccination against infectious agent,SARS-CoV-2 incidence rate,0.6467213114754098
vaccination against infectious agent,incubation end temporal region,0.6772727272727272
vaccination against infectious agent,virulence factor disposition,0.66875
vaccination against infectious agent,infectious disease incidence,0.684375
vaccination against infectious agent,disease surveillance objective specification,0.6375
vaccination against infectious agent,infectious agent host role,0.7080645161290323
vaccination against infectious agent,asymptomatic infectious structure carrier,0.6967532467532468
vaccination against infectious agent,B cell receptor complex,0.5855932203389831
vaccination against infectious agent,passive immunization against infectious agent,0.8574074074074073
vaccination against infectious agent,infection incidence rate,0.7
vaccination against infectious agent,drug susceptibility,0.5590909090909091
vaccination against infectious agent,infectious disease lifetime prevalence,0.6932432432432433
vaccination against infectious agent,toxin disposition,0.6575471698113208
vaccination against infectious agent,lower respiratory tract disease,0.6291044776119403
vaccination against infectious agent,infectious disease incidence proportion,0.6766666666666665
vaccination against infectious agent,acute infectious disease course,0.703731343283582
vaccination against infectious agent,cidal agent disposition,0.6872881355932203
vaccination against infectious agent,infectious disorder,0.6681818181818181
vaccination against infectious agent,biological vehicle,0.5981481481481481
vaccination against infectious agent,infectious disease sporadicity,0.6621212121212122
vaccination against infectious agent,communicability end process boundary,0.6166666666666667
vaccination against infectious agent,directive information content entity,0.6861111111111111
vaccination against infectious agent,infectious agent colony,0.7211864406779661
vaccination against infectious agent,pathogen transporter,0.6285714285714286
vaccination against infectious agent,invasion factor,0.6656862745098039
vaccination against infectious agent,latency end process boundary,0.60625
vaccination against infectious agent,infectious disease epidemic,0.6563492063492063
vaccination against infectious agent,infectious agent generative stage,0.7253623188405797
vaccination against infectious agent,disease transmission model,0.6274193548387097
vaccination against infectious agent,cidal agent,0.6414893617021277
vaccination against infectious agent,infectious structure host role,0.6621212121212122
vaccination against infectious agent,pathogen vehicle,0.6230769230769231
vaccination against infectious agent,COVID-19 incidence rate,0.6364406779661017
vaccination against infectious agent,antibiotic resistance,0.6605263157894737
vaccination against infectious agent,pathogen vehicle role,0.6254385964912281
vaccination against infectious agent,chronic infectious disease course,0.7108695652173913
vaccination against infectious agent,asymptomatic infectious agent carrier,0.7513698630136986
vaccination against infectious agent,descriptive information content entity,0.6797297297297297
vaccination against infectious agent,COVID-19 epidemic,0.5820754716981132
vaccination against infectious agent,resistance to drug,0.6166666666666667
vaccination against infectious agent,sterilizing immunity to infectious agent,0.7657894736842106
vaccination against infectious agent,diseased population,0.5954545454545455
vaccination against infectious agent,virulence factor,0.6038461538461539
vaccination against infectious agent,incubation end process boundary,0.658955223880597
vaccination against infectious agent,latency end temporal region,0.6246031746031746
vaccination against infectious agent,innate immunity to infectious agent,0.802112676056338
vaccination against infectious agent,infectious structure,0.6642857142857143
vaccination against infectious agent,static agent disposition,0.6833333333333332
vaccination against infectious agent,T cell receptor complex,0.6025423728813559
vaccination against infectious agent,asymptomatic carrier role,0.6139344262295081
vaccination against infectious agent,infectious structure host,0.6631147540983606
vaccination against infectious agent,infectious agent population,0.7039682539682539
vaccination against infectious agent,respiratory system disease,0.6435483870967742
vaccination against infectious agent,leukocyte-mediated immunity to infectious agent,0.7512048192771084
vaccination against infectious agent,humoral immunity to infectious agent,0.7694444444444444
vaccination against infectious agent,infectious disease control strategy,0.6612676056338028
vaccination against infectious agent,infectious disease pandemic,0.6722222222222223
vaccination against infectious agent,infectious structure generative stage,0.682876712328767
vaccination against infectious agent,viral disease course,0.6642857142857143
vaccination against infectious agent,toxin,0.5475609756097561
vaccination against infectious agent,passive immunity to infectious agent,0.7694444444444444
vaccination against infectious agent,infectious disposition,0.6741379310344828
vaccination against infectious agent,vaccination against infectious agent,0.95
vaccination against infectious agent,susceptibility to infectious agent,0.7642857142857143
vaccination against infectious agent,disease course,0.63
vaccination against infectious agent,infectious disease course,0.6795081967213115
vaccination against infectious agent,acquired immunity to infectious agent,0.7787671232876713
vaccination against infectious agent,COVID-19 disease incidence proportion,0.6417808219178082
vaccination against infectious agent,coronavirus disease course,0.6758064516129032
vaccination against infectious agent,asymptomatic carrier,0.6285714285714286
vaccination against infectious agent,biological vehicle role,0.6025423728813559
vaccination against infectious agent,symptomatic infectious agent carrier,0.7416666666666667
vaccination against infectious agent,intermediate host,0.6386792452830189
vaccination against infectious agent,infectious disease prevalence,0.6653846153846155
vaccination against infectious agent,infected population,0.6318181818181818
vaccination against infectious agent,COVID-19 mortality rate,0.6025423728813559
vaccination against infectious agent,viral disease,0.6336734693877552
vaccination against infectious agent,disease,0.5662790697674418
vaccination against infectious agent,symptomatic infectious structure carrier,0.6868421052631578
vaccination against infectious agent,primary infectious disposition,0.6772727272727272
vaccination against infectious agent,designative information content entity,0.6797297297297297
vaccination against infectious agent,symptomatic carrier role,0.6
vaccination against infectious agent,infectious pathogen transmissibility,0.6722222222222223
vaccination against infectious agent,intermediate host role,0.6396551724137931
vaccination against infectious agent,infectious human pathogen,0.6959016393442623
vaccination against infectious agent,immunization against infectious agent,0.8883561643835617
vaccination against infectious agent,infectious agent host,0.730701754385965
vaccination against infectious agent,long-term non-progressing infectious disease course,0.6913793103448276
vaccination against infectious agent,viral disease epidemic,0.6224137931034482
vaccination against infectious agent,viral disease pandemic,0.6396551724137931
vaccination against infectious agent,symptomatic carrier,0.6136363636363636
vaccination against infectious agent,infectious disease endemicity,0.6807692307692308
vaccination against infectious agent,function,0.5863636363636363
vaccination against infectious agent,herd immunity to infectious organism,0.7138888888888889
vaccination against infectious agent,pathogen transporter role,0.6467213114754098
vaccination against infectious agent,infectious agent reservoir,0.7080645161290323
vaccination against infectious agent,COVID-19 pandemic,0.5820754716981132
vaccination against infectious agent,action specification,0.7178571428571427
vaccination against infectious agent,infectious disease control objective specification,0.6476744186046511
vaccination against infectious agent,opportunistic infectious disposition,0.7
vaccination against infectious agent,polymerase chain reaction,0.6467213114754098
vaccination against infectious agent,COVID-19 disease course,0.6364406779661017
vaccination against infectious agent,infectious disease incidence rate,0.6818840579710145
vaccination against infectious agent,active immunization against infectious agent,0.875
vaccination against infectious agent,infectious agent,0.7576923076923078
vaccination against infectious agent,establishment of a clinically abnormal colony,0.6228395061728395
vaccination against infectious agent,coronavirus disease,0.65
vaccination against infectious agent,adhesion factor,0.6264705882352941
vaccination against infectious agent,drug susceptibility of infectious agent,0.7433333333333333
vaccination against infectious agent,static agent,0.6791666666666666
virostatic disposition,virostatic disposition,0.95
virostatic disposition,information content entity,0.6375
virostatic disposition,zoonotic disposition,0.830952380952381
virostatic disposition,infectious disease mortality rate,0.6318181818181818
virostatic disposition,infection incidence rate profile,0.5981481481481481
virostatic disposition,infectious structure aggregate,0.5846153846153846
virostatic disposition,communicability end temporal region,0.6254385964912281
virostatic disposition,geographical entity,0.6207317073170732
virostatic disposition,biological regulation,0.6593023255813953
virostatic disposition,surveillance process,0.6404761904761905
virostatic disposition,infection end temporal region,0.6460784313725491
virostatic disposition,vector control strategy,0.6055555555555556
virostatic disposition,SARS-CoV-2 incidence rate,0.598936170212766
virostatic disposition,incubation end temporal region,0.6615384615384616
virostatic disposition,resistant entity,0.6605263157894737
virostatic disposition,virulence factor disposition,0.79
virostatic disposition,viral adhesion disposition,0.8041666666666667
virostatic disposition,parasitostatic disposition,0.8666666666666667
virostatic disposition,negative regulation of production,0.6681818181818181
virostatic disposition,reverse zoonotic disposition,0.81
virostatic disposition,virostatic,0.7625
virostatic disposition,establishment of localization in host,0.6364406779661017
virostatic disposition,disease surveillance objective specification,0.6621212121212122
virostatic disposition,case isolation control strategy,0.619811320754717
virostatic disposition,infectious agent host role,0.6583333333333334
virostatic disposition,macromolecular complex,0.5636363636363636
virostatic disposition,material entity,0.6121621621621621
virostatic disposition,asymptomatic infectious structure carrier,0.6404761904761905
virostatic disposition,architectual structure,0.5863636363636363
virostatic disposition,quarantine control strategy,0.6132653061224489
virostatic disposition,B cell receptor complex,0.5611111111111111
virostatic disposition,infection incidence rate,0.6021739130434782
virostatic disposition,colonized host,0.6166666666666667
virostatic disposition,virus host,0.7
virostatic disposition,entity,0.5571428571428572
virostatic disposition,toxin disposition,0.808974358974359
virostatic disposition,cidal agent disposition,0.7833333333333333
virostatic disposition,parasiticidal disposition,0.8117021276595744
virostatic disposition,communicability end process boundary,0.6224137931034482
virostatic disposition,directive information content entity,0.6396551724137931
virostatic disposition,acellular structure aggregate,0.5676470588235294
virostatic disposition,transmissibility disposition,0.75
virostatic disposition,latency end process boundary,0.65
virostatic disposition,colonization of host,0.6404761904761905
virostatic disposition,realizable entity,0.6038461538461539
virostatic disposition,endotoxin disposition,0.7988372093023256
virostatic disposition,vector surveillance,0.5963414634146341
virostatic disposition,negative regulation of establishment of localization,0.6391891891891892
virostatic disposition,infectious structure host role,0.6423076923076922
virostatic disposition,COVID-19 incidence rate,0.5833333333333334
virostatic disposition,cytotoxin disposition,0.7988372093023256
virostatic disposition,negative regulation of developmental process,0.6015151515151516
virostatic disposition,host,0.5653846153846154
virostatic disposition,descriptive information content entity,0.6166666666666667
virostatic disposition,negative regulation of replication,0.6642857142857143
virostatic disposition,establishment of localization in human host,0.6192307692307693
virostatic disposition,acellular structure,0.5719512195121951
virostatic disposition,incubation end process boundary,0.6575471698113208
virostatic disposition,collective pathogenic disposition,0.7772727272727272
virostatic disposition,neurotoxin disposition,0.8136363636363637
virostatic disposition,dead-end host role,0.6
virostatic disposition,molecular entity,0.581578947368421
virostatic disposition,plan specification,0.675
virostatic disposition,definitive host role,0.6404761904761905
virostatic disposition,latency end temporal region,0.6540816326530612
virostatic disposition,infectious structure,0.5928571428571429
virostatic disposition,collective disposition,0.7909090909090909
virostatic disposition,static agent disposition,0.8413043478260869
virostatic disposition,T cell receptor complex,0.5833333333333334
virostatic disposition,infectious structure host,0.6414893617021277
virostatic disposition,respiratory system disease,0.6583333333333334
virostatic disposition,entry into host,0.6121621621621621
virostatic disposition,adhesion of symbiont to host,0.63
virostatic disposition,infectious disease control strategy,0.6254385964912281
virostatic disposition,infectious structure generative stage,0.6194915254237288
virostatic disposition,immunosuppressive disposition,0.7637254901960785
virostatic disposition,pathogenic disposition,0.8136363636363637
virostatic disposition,entry into host through host barriers,0.6194915254237288
virostatic disposition,infectious disposition,0.7909090909090909
virostatic disposition,bacteriostatic disposition,0.8666666666666667
virostatic disposition,bactericidal disposition,0.7978260869565217
virostatic disposition,pathogen host,0.6214285714285714
virostatic disposition,invasion disposition,0.8071428571428573
virostatic disposition,viricidal disposition,0.8453488372093022
virostatic disposition,complex infection,0.6294871794871795
virostatic disposition,intermediate host,0.6551282051282051
virostatic disposition,anatomical entity,0.6294871794871795
virostatic disposition,disposition,0.7833333333333333
virostatic disposition,COVID-19 mortality rate,0.6277777777777778
virostatic disposition,negative regulation of life-sustaining process,0.6264705882352941
virostatic disposition,place closure control strategy,0.5846153846153846
virostatic disposition,geopolitical entity,0.6207317073170732
virostatic disposition,adhesion disposition,0.7833333333333333
virostatic disposition,symptomatic infectious structure carrier,0.6435483870967742
virostatic disposition,primary infectious disposition,0.7576923076923078
virostatic disposition,pathogen host role,0.625
virostatic disposition,designative information content entity,0.6333333333333333
virostatic disposition,intermediate host role,0.6545454545454545
virostatic disposition,dead-end host,0.5928571428571429
virostatic disposition,pathogen surveillance,0.5895348837209302
virostatic disposition,host role,0.6112903225806451
virostatic disposition,establishment of localization in virus host,0.6346153846153847
virostatic disposition,negative regulation of immune response,0.6333333333333333
virostatic disposition,immaterial entity,0.6294871794871795
virostatic disposition,SARS-COV-2 adhesion disposition,0.7518867924528303
virostatic disposition,invasive disposition,0.8071428571428573
virostatic disposition,infectious agent host,0.6593023255813953
virostatic disposition,fungicidal disposition,0.7681818181818181
virostatic disposition,division of geopolitical entity,0.6575471698113208
virostatic disposition,negative regulation of viral process,0.6224137931034482
virostatic disposition,exotoxin disposition,0.8071428571428573
virostatic disposition,immunoglobulin complex,0.5636363636363636
virostatic disposition,infectious disease control objective specification,0.6444444444444444
virostatic disposition,symbiont host role,0.65
virostatic disposition,opportunistic infectious disposition,0.743103448275862
virostatic disposition,negative regulation of biological process,0.6087301587301588
virostatic disposition,enterotoxin disposition,0.8055555555555556
virostatic disposition,infectious disease incidence rate,0.65
virostatic disposition,collective resistance disposition,0.7772727272727272
virostatic disposition,fungistatic disposition,0.8722222222222222
virostatic disposition,establishment of a clinically abnormal colony,0.5992537313432835
virostatic disposition,definitive host,0.6391891891891892
virostatic disposition,static agent,0.6852941176470588
herd immunity to infectious organism,extended organism,0.6952830188679244
herd immunity to infectious organism,information content entity,0.6274193548387097
herd immunity to infectious organism,infectious disease mortality rate,0.6673913043478261
herd immunity to infectious organism,infectious structure aggregate,0.6621212121212122
herd immunity to infectious organism,communicability end temporal region,0.6612676056338028
herd immunity to infectious organism,geographical entity,0.5772727272727273
herd immunity to infectious organism,infection end temporal region,0.65
herd immunity to infectious organism,drug-based immunosuppressed organism,0.7277777777777777
herd immunity to infectious organism,infectious disease,0.6907407407407408
herd immunity to infectious organism,incubation end temporal region,0.6318181818181818
herd immunity to infectious organism,resistant entity,0.6038461538461539
herd immunity to infectious organism,immunocompetent organism,0.7333333333333333
herd immunity to infectious organism,virulence factor disposition,0.6375
herd immunity to infectious organism,infectious disease incidence,0.66875
herd immunity to infectious organism,disease surveillance objective specification,0.625
herd immunity to infectious organism,case isolation control strategy,0.6291044776119403
herd immunity to infectious organism,virus release stage,0.5772727272727273
herd immunity to infectious organism,infectious agent host role,0.6758064516129032
herd immunity to infectious organism,material entity,0.5872549019607843
herd immunity to infectious organism,asymptomatic infectious structure carrier,0.6837662337662337
herd immunity to infectious organism,architectual structure,0.6051724137931035
herd immunity to infectious organism,B cell receptor complex,0.6025423728813559
herd immunity to infectious organism,passive immunization against infectious agent,0.7586419753086421
herd immunity to infectious organism,entity,0.569047619047619
herd immunity to infectious organism,infectious disease lifetime prevalence,0.6391891891891892
herd immunity to infectious organism,lower respiratory tract disease,0.658955223880597
herd immunity to infectious organism,infectious disease incidence proportion,0.6366666666666667
herd immunity to infectious organism,acute infectious disease course,0.703731343283582
herd immunity to infectious organism,infectious disorder,0.6863636363636364
herd immunity to infectious organism,genetic resistance to pathogen,0.6469696969696969
herd immunity to infectious organism,infectious disease sporadicity,0.6772727272727272
herd immunity to infectious organism,communicability end process boundary,0.6444444444444444
herd immunity to infectious organism,directive information content entity,0.6444444444444444
herd immunity to infectious organism,acellular structure aggregate,0.6192307692307693
herd immunity to infectious organism,infectious agent colony,0.6703389830508475
herd immunity to infectious organism,invasion factor,0.6460784313725491
herd immunity to infectious organism,latency end process boundary,0.60625
herd immunity to infectious organism,infectious disease epidemic,0.6722222222222223
herd immunity to infectious organism,infectious agent generative stage,0.6673913043478261
herd immunity to infectious organism,disease transmission model,0.6274193548387097
herd immunity to infectious organism,realizable entity,0.5632075471698114
herd immunity to infectious organism,pathologically immunosuppressed organism,0.7
herd immunity to infectious organism,infectious structure host role,0.6469696969696969
herd immunity to infectious organism,antibiotic resistance,0.6078947368421053
herd immunity to infectious organism,chronic infectious disease course,0.7253623188405797
herd immunity to infectious organism,asymptomatic infectious agent carrier,0.6965753424657534
herd immunity to infectious organism,descriptive information content entity,0.6527027027027027
herd immunity to infectious organism,COVID-19 epidemic,0.5632075471698114
herd immunity to infectious organism,resistance to drug,0.6351851851851852
herd immunity to infectious organism,sterilizing immunity to infectious agent,0.8184210526315789
herd immunity to infectious organism,establishment of localization in human host,0.6525316455696202
herd immunity to infectious organism,diseased population,0.5954545454545455
herd immunity to infectious organism,acellular structure,0.5954545454545455
herd immunity to infectious organism,virulence factor,0.6230769230769231
herd immunity to infectious organism,incubation end process boundary,0.6141791044776119
herd immunity to infectious organism,molecular entity,0.6038461538461539
herd immunity to infectious organism,immunosuppressed organism,0.728688524590164
herd immunity to infectious organism,plan specification,0.6166666666666667
herd immunity to infectious organism,latency end temporal region,0.6246031746031746
herd immunity to infectious organism,innate immunity to infectious agent,0.8302816901408451
herd immunity to infectious organism,infectious structure,0.6642857142857143
herd immunity to infectious organism,virus adhesion susceptible cell,0.5843283582089552
herd immunity to infectious organism,T cell receptor complex,0.6194915254237288
herd immunity to infectious organism,infectious structure host,0.6631147540983606
herd immunity to infectious organism,infectious agent population,0.6722222222222223
herd immunity to infectious organism,respiratory system disease,0.6274193548387097
herd immunity to infectious organism,leukocyte-mediated immunity to infectious agent,0.7873493975903614
herd immunity to infectious organism,organism population,0.6136363636363636
herd immunity to infectious organism,humoral immunity to infectious agent,0.8388888888888889
herd immunity to infectious organism,infectious disease control strategy,0.6471830985915493
herd immunity to infectious organism,infectious disease pandemic,0.6722222222222223
herd immunity to infectious organism,infectious structure generative stage,0.6691780821917809
herd immunity to infectious organism,viral disease course,0.6107142857142857
herd immunity to infectious organism,passive immunity to infectious agent,0.825
herd immunity to infectious organism,infectious disposition,0.6741379310344828
herd immunity to infectious organism,vaccination against infectious agent,0.7138888888888889
herd immunity to infectious organism,susceptibility to infectious agent,0.7642857142857143
herd immunity to infectious organism,immunity to pathogen,0.7357142857142857
herd immunity to infectious organism,disease course,0.61
herd immunity to infectious organism,infectious disease course,0.6795081967213115
herd immunity to infectious organism,acquired immunity to infectious agent,0.8335616438356164
herd immunity to infectious organism,COVID-19 disease incidence proportion,0.6143835616438357
herd immunity to infectious organism,coronavirus disease course,0.6274193548387097
herd immunity to infectious organism,symptomatic infectious agent carrier,0.7
herd immunity to infectious organism,susceptible organism,0.6821428571428573
herd immunity to infectious organism,infectious disease prevalence,0.6653846153846155
herd immunity to infectious organism,organism substance,0.5981481481481481
herd immunity to infectious organism,anatomical entity,0.6009433962264151
herd immunity to infectious organism,infected population,0.6318181818181818
herd immunity to infectious organism,geopolitical entity,0.5954545454545455
herd immunity to infectious organism,viral disease,0.5724489795918367
herd immunity to infectious organism,leukocyte mediated immunity,0.6246031746031746
herd immunity to infectious organism,disease,0.5662790697674418
herd immunity to infectious organism,symptomatic infectious structure carrier,0.6868421052631578
herd immunity to infectious organism,primary infectious disposition,0.7227272727272727
herd immunity to infectious organism,designative information content entity,0.6527027027027027
herd immunity to infectious organism,SARS-COV-2 adhesion susceptible cell,0.575
herd immunity to infectious organism,infectious pathogen transmissibility,0.6861111111111111
herd immunity to infectious organism,immunodeficient organism,0.75
herd immunity to infectious organism,infectious human pathogen,0.6795081967213115
herd immunity to infectious organism,resistance to pathogen,0.6396551724137931
herd immunity to infectious organism,colonization of human,0.6078947368421053
herd immunity to infectious organism,immunization against infectious agent,0.7650684931506849
herd immunity to infectious organism,immaterial entity,0.619811320754717
herd immunity to infectious organism,infectious agent host,0.6956140350877194
herd immunity to infectious organism,long-term non-progressing infectious disease course,0.6798850574712644
herd immunity to infectious organism,viral disease epidemic,0.5879310344827586
herd immunity to infectious organism,viral disease pandemic,0.6051724137931035
herd immunity to infectious organism,division of geopolitical entity,0.6291044776119403
herd immunity to infectious organism,geographical feature,0.6107142857142857
herd immunity to infectious organism,infectious disease endemicity,0.6653846153846155
herd immunity to infectious organism,herd immunity to infectious organism,0.95
herd immunity to infectious organism,infectious agent reservoir,0.6758064516129032
herd immunity to infectious organism,COVID-19 pandemic,0.5632075471698114
herd immunity to infectious organism,action specification,0.6285714285714286
herd immunity to infectious organism,protective resistance,0.6254385964912281
herd immunity to infectious organism,processed material,0.5981481481481481
herd immunity to infectious organism,infectious disease control objective specification,0.6244186046511628
herd immunity to infectious organism,opportunistic infectious disposition,0.7138888888888889
herd immunity to infectious organism,COVID-19 disease course,0.6025423728813559
herd immunity to infectious organism,infectious disease incidence rate,0.6528985507246376
herd immunity to infectious organism,active immunization against infectious agent,0.7625
herd immunity to infectious organism,collective resistance disposition,0.6094202898550725
herd immunity to infectious organism,organism,0.6318181818181818
herd immunity to infectious organism,infectious agent,0.7
herd immunity to infectious organism,establishment of a clinically abnormal colony,0.6475308641975309
herd immunity to infectious organism,coronavirus disease,0.6136363636363636
herd immunity to infectious organism,adhesion factor,0.6460784313725491
herd immunity to infectious organism,drug susceptibility of infectious agent,0.7433333333333333
herd immunity to infectious organism,SARS-CoV-2 release stage,0.5666666666666667
herd immunity to infectious organism,cell space,0.5369565217391304
herd immunity to infectious organism,material processing,0.5954545454545455
immunodeficiency,immunodeficiency,0.95
immunodeficiency,acquired immunodeficiency,0.8402439024390245
immunodeficiency,primary immunodeficiency,0.85
bacteremia,B cell receptor complex,0.6318181818181818
bacteremia,bacteremia,0.95
bacteremia,T cell receptor complex,0.6015151515151516
bacteremia,establishment of a clinically abnormal colony,0.5590909090909091
source of infection,virus aggregate,0.5676470588235294
source of infection,source of infection,0.95
source of infection,virostatic disposition,0.6695121951219513
source of infection,zoonotic disposition,0.6807692307692308
source of infection,infectious disease mortality rate,0.6038461538461539
source of infection,infection incidence rate profile,0.6264705882352941
source of infection,infectious structure aggregate,0.6132653061224489
source of infection,communicability end temporal region,0.6537037037037037
source of infection,subclinical coronavirus infection,0.7384615384615384
source of infection,primary pathogen,0.5928571428571429
source of infection,infection end temporal region,0.6375
source of infection,infectious disease,0.6662162162162162
source of infection,double-stranded DNA virus,0.609090909090909
source of infection,incubation end temporal region,0.6336734693877552
source of infection,site of infection,0.8666666666666667
source of infection,virulence factor disposition,0.6840425531914894
source of infection,viral adhesion disposition,0.65
source of infection,parasitostatic disposition,0.6722222222222223
source of infection,infectious disease incidence,0.6414893617021277
source of infection,reverse zoonotic disposition,0.6627659574468084
source of infection,subclinical SARS-CoV-2 infection,0.7441176470588234
source of infection,virus translation stage,0.6166666666666667
source of infection,disease surveillance objective specification,0.6880952380952381
source of infection,virus release stage,0.581578947368421
source of infection,asymptomatic infectious structure carrier,0.65
source of infection,source of infection site,0.891860465116279
source of infection,architectual structure,0.5963414634146341
source of infection,virus replication,0.7
source of infection,B cell receptor complex,0.6166666666666667
source of infection,systematic infection,0.7576923076923078
source of infection,infection incidence rate,0.6593023255813953
source of infection,virus host,0.5879310344827586
source of infection,double-stranded RNA virus,0.609090909090909
source of infection,virus transcription stage,0.6318181818181818
source of infection,infectious disease lifetime prevalence,0.6254385964912281
source of infection,toxin disposition,0.6722222222222223
source of infection,pathogen birth temporal region,0.6336734693877552
source of infection,lower respiratory tract disease,0.61
source of infection,infectious disease incidence proportion,0.656896551724138
source of infection,virus generative stage,0.5963414634146341
source of infection,acute infectious disease course,0.67
source of infection,cidal agent disposition,0.6642857142857143
source of infection,infectious disorder,0.6605263157894737
source of infection,subclinical infection,0.775
source of infection,appearance of disorder,0.6695121951219513
source of infection,simple infection,0.7928571428571428
source of infection,parasiticidal disposition,0.6545454545454545
source of infection,infectious disease sporadicity,0.6132653061224489
source of infection,communicability end process boundary,0.6136363636363636
source of infection,acellular structure aggregate,0.5958333333333333
source of infection,infection incidence proportion profile,0.6429824561403508
source of infection,transmissibility disposition,0.6202127659574468
source of infection,latency end process boundary,0.598936170212766
source of infection,infectious disease epidemic,0.6239130434782608
source of infection,disease transmission model,0.6055555555555556
source of infection,endotoxin disposition,0.65
source of infection,negative-sense single-stranded RNA virus,0.5855932203389831
source of infection,infectious structure host role,0.6336734693877552
source of infection,cytotoxin disposition,0.65
source of infection,community-acquired infection,0.747872340425532
source of infection,chronic infectious disease course,0.6615384615384616
source of infection,nursing-home acquired infection,0.75
source of infection,COVID-19 epidemic,0.6166666666666667
source of infection,secondary infection,0.7921052631578948
source of infection,infection start temporal region,0.63
source of infection,infection incidence,0.6868421052631578
source of infection,virus disorder,0.5712121212121213
source of infection,acellular structure,0.581578947368421
source of infection,primary infection,0.7555555555555555
source of infection,process of establishing an infection,0.740909090909091
source of infection,incubation end process boundary,0.59
source of infection,SARS-CoV-2 disorder,0.6342105263157894
source of infection,collective pathogenic disposition,0.6615384615384616
source of infection,neurotoxin disposition,0.6695121951219513
source of infection,plan specification,0.6932432432432433
source of infection,latency end temporal region,0.6456521739130434
source of infection,infectious structure,0.6551282051282051
source of infection,virus adhesion susceptible cell,0.61
source of infection,collective disposition,0.6939024390243902
source of infection,infection,0.7714285714285714
source of infection,static agent disposition,0.6825581395348838
source of infection,T cell receptor complex,0.6166666666666667
source of infection,infectious structure host,0.6318181818181818
source of infection,respiratory system disease,0.6055555555555556
source of infection,communicability interval,0.6127906976744186
source of infection,infectious disease control strategy,0.6166666666666667
source of infection,infectious disease pandemic,0.6456521739130434
source of infection,infectious structure generative stage,0.6285714285714286
source of infection,immunosuppressive disposition,0.6791666666666666
source of infection,pathogenic disposition,0.6695121951219513
source of infection,viral disease course,0.6038461538461539
source of infection,intracellular infection,0.7595238095238095
source of infection,secondary infection role,0.7523255813953489
source of infection,metastatic infection,0.7576923076923078
source of infection,infectious disposition,0.6695121951219513
source of infection,acute infection,0.8029411764705883
source of infection,bacteriostatic disposition,0.65
source of infection,bactericidal disposition,0.6593023255813953
source of infection,source of infection role,0.891860465116279
source of infection,chronic infection,0.7833333333333333
source of infection,invasion disposition,0.6807692307692308
source of infection,disease course,0.6015151515151516
source of infection,infectious disease course,0.6318181818181818
source of infection,viricidal disposition,0.675
source of infection,complex infection,0.7833333333333333
source of infection,COVID-19 disease incidence proportion,0.6464285714285714
source of infection,coronavirus disease course,0.6277777777777778
source of infection,infection incidence proportion,0.6744897959183673
source of infection,respiratory droplet virus fomite,0.6264705882352941
source of infection,infectious disease prevalence,0.6375
source of infection,disposition,0.6833333333333332
source of infection,single-stranded DNA virus,0.5863636363636363
source of infection,place closure control strategy,0.6336734693877552
source of infection,viral disease,0.575
source of infection,primary infection role,0.7182926829268292
source of infection,primary immunodeficiency,0.636046511627907
source of infection,adhesion disposition,0.6807692307692308
source of infection,infection incidence profile,0.6456521739130434
source of infection,contagiousness,0.6621212121212122
source of infection,disease,0.5653846153846154
source of infection,symptomatic infectious structure carrier,0.6533898305084747
source of infection,primary infectious disposition,0.6744897959183673
source of infection,infection prevalence,0.6807692307692308
source of infection,coronavirus disorder,0.6038461538461539
source of infection,incubation start process boundary,0.5846153846153846
source of infection,pathogen birth process boundary,0.59
source of infection,subclinical virus infection,0.7543478260869566
source of infection,establishment of localization in virus host,0.6274193548387097
source of infection,virus attachment stage,0.5719512195121951
source of infection,virus synthesis stage,0.575
source of infection,SARS-COV-2 adhesion disposition,0.67
source of infection,invasive disposition,0.6807692307692308
source of infection,long-term non-progressing infectious disease course,0.6357142857142857
source of infection,viral disease epidemic,0.5963414634146341
source of infection,communicability start temporal region,0.6285714285714286
source of infection,fungicidal disposition,0.6695121951219513
source of infection,blood,0.5333333333333333
source of infection,viral disease pandemic,0.5963414634146341
source of infection,virus penetration stage,0.6404761904761905
source of infection,acute respiratory distress syndrome,0.5981481481481481
source of infection,infectious disease endemicity,0.6375
source of infection,disorder,0.5981481481481481
source of infection,communicability,0.5970588235294118
source of infection,extracellular infection,0.7595238095238095
source of infection,exotoxin disposition,0.6551282051282051
source of infection,infection start process boundary,0.6264705882352941
source of infection,action specification,0.7064102564102563
source of infection,latency start process boundary,0.5928571428571429
source of infection,infectious disease control objective specification,0.6384057971014493
source of infection,opportunistic infectious disposition,0.6863636363636364
source of infection,process of establishing viral infection,0.7258620689655172
source of infection,enterotoxin disposition,0.6404761904761905
source of infection,COVID-19 disease course,0.6166666666666667
source of infection,infectious disease incidence rate,0.6230769230769231
source of infection,communicability start process boundary,0.5903508771929825
source of infection,disordered virus,0.6214285714285714
source of infection,collective resistance disposition,0.6615384615384616
source of infection,fungistatic disposition,0.6642857142857143
source of infection,virus uncoating stage,0.625
source of infection,local infection,0.8029411764705883
source of infection,establishment of a clinically abnormal colony,0.621875
source of infection,coronavirus disease,0.6078947368421053
source of infection,positive-sense single-stranded RNA virus,0.5855932203389831
source of infection,hospital-acquired infection,0.7543478260869566
fomite,respiratory droplet coronavirus fomite,0.5863636363636363
fomite,respiratory droplet SARS-CoV-2 fomite,0.5895348837209302
fomite,fomite,0.95
fomite,T cell receptor complex,0.553448275862069
fomite,respiratory droplet virus fomite,0.6078947368421053
fomite,respiratory droplet fomite,0.6375
fomite,fomite role,0.8029411764705883
process of establishing viral infection,virus aggregate,0.5981481481481481
process of establishing viral infection,source of infection,0.7258620689655172
process of establishing viral infection,virostatic disposition,0.6631147540983606
process of establishing viral infection,zoonotic disposition,0.6364406779661017
process of establishing viral infection,immune response,0.5796296296296296
process of establishing viral infection,infectious disease mortality rate,0.6305555555555555
process of establishing viral infection,infection incidence rate profile,0.6190140845070422
process of establishing viral infection,communicability end temporal region,0.6662162162162162
process of establishing viral infection,pathogen generative stage,0.621875
process of establishing viral infection,subclinical coronavirus infection,0.7138888888888889
process of establishing viral infection,surveillance process,0.5855932203389831
process of establishing viral infection,infection end temporal region,0.6558823529411765
process of establishing viral infection,infectious disease,0.6078947368421053
process of establishing viral infection,SARS-CoV-2 incidence rate,0.621875
process of establishing viral infection,double-stranded DNA virus,0.60625
process of establishing viral infection,incubation end temporal region,0.6528985507246376
process of establishing viral infection,site of infection,0.7
process of establishing viral infection,virulence factor disposition,0.6440298507462687
process of establishing viral infection,viral adhesion disposition,0.65
process of establishing viral infection,parasitostatic disposition,0.6807692307692308
process of establishing viral infection,infectious disease incidence,0.658955223880597
process of establishing viral infection,reverse zoonotic disposition,0.658955223880597
process of establishing viral infection,subclinical SARS-CoV-2 infection,0.7035211267605633
process of establishing viral infection,virus translation stage,0.6274193548387097
process of establishing viral infection,disease surveillance objective specification,0.6548192771084337
process of establishing viral infection,case isolation control strategy,0.6214285714285714
process of establishing viral infection,virus release stage,0.6051724137931035
process of establishing viral infection,source of infection site,0.7039682539682539
process of establishing viral infection,virus,0.5181818181818182
process of establishing viral infection,virus replication,0.6464285714285714
process of establishing viral infection,B cell receptor complex,0.5951612903225807
process of establishing viral infection,systematic infection,0.7042372881355932
process of establishing viral infection,infection incidence rate,0.6246031746031746
process of establishing viral infection,virus host,0.5724489795918367
process of establishing viral infection,double-stranded RNA virus,0.621875
process of establishing viral infection,virus transcription stage,0.6375
process of establishing viral infection,infectious disease lifetime prevalence,0.6448051948051949
process of establishing viral infection,toxin disposition,0.6285714285714286
process of establishing viral infection,lower respiratory tract disease,0.6214285714285714
process of establishing viral infection,infectious disease incidence proportion,0.6679487179487179
process of establishing viral infection,virus generative stage,0.6139344262295081
process of establishing viral infection,acute infectious disease course,0.65
process of establishing viral infection,cidal agent disposition,0.6274193548387097
process of establishing viral infection,infectious disorder,0.6051724137931035
process of establishing viral infection,subclinical infection,0.75
process of establishing viral infection,process,0.6021739130434782
process of establishing viral infection,appearance of disorder,0.6467213114754098
process of establishing viral infection,simple infection,0.6863636363636364
process of establishing viral infection,droplet pathogen transmission process,0.6473684210526315
process of establishing viral infection,parasiticidal disposition,0.66875
process of establishing viral infection,infectious disease sporadicity,0.6239130434782608
process of establishing viral infection,communicability end process boundary,0.61
process of establishing viral infection,infection incidence proportion profile,0.6318181818181818
process of establishing viral infection,transmissibility disposition,0.658955223880597
process of establishing viral infection,latency end process boundary,0.6141791044776119
process of establishing viral infection,infectious disease epidemic,0.6318181818181818
process of establishing viral infection,infectious agent generative stage,0.6166666666666667
process of establishing viral infection,disease transmission model,0.6192307692307693
process of establishing viral infection,endotoxin disposition,0.65
process of establishing viral infection,negative-sense single-stranded RNA virus,0.6272151898734176
process of establishing viral infection,COVID-19 incidence rate,0.6112903225806451
process of establishing viral infection,viral plaque assay,0.5728070175438597
process of establishing viral infection,cytotoxin disposition,0.65
process of establishing viral infection,community-acquired infection,0.6888059701492537
process of establishing viral infection,negative regulation of developmental process,0.6066265060240964
process of establishing viral infection,chronic infectious disease course,0.6583333333333334
process of establishing viral infection,nursing-home acquired infection,0.7071428571428571
process of establishing viral infection,COVID-19 epidemic,0.5928571428571429
process of establishing viral infection,secondary infection,0.6913793103448276
process of establishing viral infection,infection start temporal region,0.6642857142857143
process of establishing viral infection,infection incidence,0.6396551724137931
process of establishing viral infection,virus disorder,0.5820754716981132
process of establishing viral infection,primary infection,0.7
process of establishing viral infection,process of establishing an infection,0.9166666666666665
process of establishing viral infection,incubation end process boundary,0.6071428571428572
process of establishing viral infection,SARS-CoV-2 disorder,0.5879310344827586
process of establishing viral infection,collective pathogenic disposition,0.6444444444444444
process of establishing viral infection,neurotoxin disposition,0.6467213114754098
process of establishing viral infection,SARS-CoV-2 uncoating stage,0.6192307692307693
process of establishing viral infection,pathogen death process boundary,0.6214285714285714
process of establishing viral infection,plan specification,0.6429824561403508
process of establishing viral infection,latency end temporal region,0.6469696969696969
process of establishing viral infection,SARS-CoV-2 penetration stage,0.6291044776119403
process of establishing viral infection,virus adhesion susceptible cell,0.6214285714285714
process of establishing viral infection,collective disposition,0.6467213114754098
process of establishing viral infection,infection,0.6375
process of establishing viral infection,static agent disposition,0.6404761904761905
process of establishing viral infection,T cell receptor complex,0.5951612903225807
process of establishing viral infection,respiratory system disease,0.6192307692307693
process of establishing viral infection,indirect pathogen transmission process,0.6318181818181818
process of establishing viral infection,planned process,0.5796296296296296
process of establishing viral infection,generative stage,0.5954545454545455
process of establishing viral infection,communicability interval,0.6246031746031746
process of establishing viral infection,infectious disease control strategy,0.6121621621621621
process of establishing viral infection,SARS-CoV-2 attachment stage,0.6166666666666667
process of establishing viral infection,infectious disease pandemic,0.6318181818181818
process of establishing viral infection,infectious structure generative stage,0.6078947368421053
process of establishing viral infection,immunosuppressive disposition,0.6411764705882353
process of establishing viral infection,innate immune response,0.5975409836065574
process of establishing viral infection,pathogenic disposition,0.630327868852459
process of establishing viral infection,viral disease course,0.6194915254237288
process of establishing viral infection,intracellular infection,0.6919354838709677
process of establishing viral infection,secondary infection role,0.6722222222222223
process of establishing viral infection,metastatic infection,0.7042372881355932
process of establishing viral infection,viral envelope,0.619811320754717
process of establishing viral infection,infectious disposition,0.6467213114754098
process of establishing viral infection,acute infection,0.6722222222222223
process of establishing viral infection,bacteriostatic disposition,0.6653846153846155
process of establishing viral infection,bactericidal disposition,0.6404761904761905
process of establishing viral infection,source of infection role,0.7039682539682539
process of establishing viral infection,chronic infection,0.7
process of establishing viral infection,invasion disposition,0.6364406779661017
process of establishing viral infection,disease course,0.5820754716981132
process of establishing viral infection,infectious disease course,0.621875
process of establishing viral infection,viricidal disposition,0.6333333333333333
process of establishing viral infection,complex infection,0.6821428571428573
process of establishing viral infection,COVID-19 disease incidence proportion,0.6473684210526315
process of establishing viral infection,coronavirus disease course,0.6192307692307693
process of establishing viral infection,infection incidence proportion,0.6528985507246376
process of establishing viral infection,viral capsid,0.6068627450980393
process of establishing viral infection,respiratory droplet virus fomite,0.6471830985915493
process of establishing viral infection,infectious disease prevalence,0.6264705882352941
process of establishing viral infection,SARS-CoV-2 genome replication stage,0.6527027027027027
process of establishing viral infection,disposition,0.61
process of establishing viral infection,single-stranded DNA virus,0.60625
process of establishing viral infection,COVID-19 mortality rate,0.6274193548387097
process of establishing viral infection,process profile,0.6907407407407408
process of establishing viral infection,negative regulation of life-sustaining process,0.65
process of establishing viral infection,place closure control strategy,0.6239130434782608
process of establishing viral infection,viral disease,0.6038461538461539
process of establishing viral infection,primary infection role,0.6795081967213115
process of establishing viral infection,adhesion disposition,0.6364406779661017
process of establishing viral infection,developmental process,0.6
process of establishing viral infection,infection incidence profile,0.6166666666666667
process of establishing viral infection,contagiousness,0.6009433962264151
process of establishing viral infection,disease,0.558695652173913
process of establishing viral infection,biological process,0.5903508771929825
process of establishing viral infection,primary infectious disposition,0.6673913043478261
process of establishing viral infection,infection prevalence,0.6364406779661017
process of establishing viral infection,humoral immune response,0.6112903225806451
process of establishing viral infection,coronavirus disorder,0.6025423728813559
process of establishing viral infection,incubation start process boundary,0.6027777777777777
process of establishing viral infection,pathogen birth process boundary,0.6214285714285714
process of establishing viral infection,subclinical virus infection,0.7378787878787878
process of establishing viral infection,establishment of localization in virus host,0.6695121951219513
process of establishing viral infection,virus attachment stage,0.6139344262295081
process of establishing viral infection,negative regulation of immune response,0.6188311688311688
process of establishing viral infection,SARS-CoV-2 transcription stage,0.6384057971014493
process of establishing viral infection,virus synthesis stage,0.6166666666666667
process of establishing viral infection,SARS-COV-2 adhesion disposition,0.6642857142857143
process of establishing viral infection,invasive disposition,0.6194915254237288
process of establishing viral infection,long-term non-progressing infectious disease course,0.6611111111111111
process of establishing viral infection,viral disease epidemic,0.6139344262295081
process of establishing viral infection,communicability start temporal region,0.6605263157894737
process of establishing viral infection,fungicidal disposition,0.6467213114754098
process of establishing viral infection,viral disease pandemic,0.6139344262295081
process of establishing viral infection,virus penetration stage,0.6274193548387097
process of establishing viral infection,algorithm,0.575
process of establishing viral infection,acute respiratory distress syndrome,0.6121621621621621
process of establishing viral infection,infectious disease endemicity,0.6411764705882353
process of establishing viral infection,negative regulation of viral process,0.6366666666666667
process of establishing viral infection,contact pathogen transmission process,0.6342105263157894
process of establishing viral infection,disorder,0.5351063829787234
process of establishing viral infection,function,0.598936170212766
process of establishing viral infection,communicability,0.5981481481481481
process of establishing viral infection,extracellular infection,0.6919354838709677
process of establishing viral infection,symbiotic process,0.575
process of establishing viral infection,exotoxin disposition,0.6533898305084747
process of establishing viral infection,infection start process boundary,0.6049295774647887
process of establishing viral infection,action specification,0.6533898305084747
process of establishing viral infection,SARS-CoV-2 synthesis stage,0.6192307692307693
process of establishing viral infection,latency start process boundary,0.6094202898550725
process of establishing viral infection,infectious disease control objective specification,0.652247191011236
process of establishing viral infection,opportunistic infectious disposition,0.6633333333333334
process of establishing viral infection,process of establishing viral infection,0.95
process of establishing viral infection,negative regulation of biological process,0.625
process of establishing viral infection,enterotoxin disposition,0.6435483870967742
process of establishing viral infection,polymerase chain reaction,0.7
process of establishing viral infection,COVID-19 disease course,0.5951612903225807
process of establishing viral infection,infectious disease incidence rate,0.6444444444444444
process of establishing viral infection,communicability start process boundary,0.6058441558441559
process of establishing viral infection,process that results in death,0.7147058823529412
process of establishing viral infection,disordered virus,0.5772727272727273
process of establishing viral infection,collective resistance disposition,0.6722222222222223
process of establishing viral infection,adaptive immune response,0.6087301587301588
process of establishing viral infection,viral load,0.5928571428571429
process of establishing viral infection,fungistatic disposition,0.6435483870967742
process of establishing viral infection,virus uncoating stage,0.6333333333333333
process of establishing viral infection,local infection,0.7092592592592593
process of establishing viral infection,establishment of a clinically abnormal colony,0.6761904761904762
process of establishing viral infection,process boundary,0.65
process of establishing viral infection,coronavirus disease,0.6051724137931035
process of establishing viral infection,positive-sense single-stranded RNA virus,0.6525316455696202
process of establishing viral infection,horizontal pathogen transmission process,0.6272151898734176
process of establishing viral infection,hospital-acquired infection,0.7075757575757575
process of establishing viral infection,viral pathogenesis,0.6078947368421053
process of establishing viral infection,SARS-CoV-2 release stage,0.6087301587301588
process of establishing viral infection,pathogen transmission process,0.6411764705882353
infectious disease mortality rate,virus aggregate,0.6375
infectious disease mortality rate,source of infection,0.6038461538461539
infectious disease mortality rate,virostatic disposition,0.6318181818181818
infectious disease mortality rate,zoonotic disposition,0.6386792452830189
infectious disease mortality rate,infectious disease mortality rate,0.95
infectious disease mortality rate,infection incidence rate profile,0.7423076923076922
infectious disease mortality rate,infectious structure aggregate,0.7515873015873015
infectious disease mortality rate,communicability end temporal region,0.6705882352941177
infectious disease mortality rate,subclinical coronavirus infection,0.6166666666666667
infectious disease mortality rate,infection end temporal region,0.7564516129032257
infectious disease mortality rate,infectious disease,0.8029411764705883
infectious disease mortality rate,SARS-CoV-2 incidence rate,0.656896551724138
infectious disease mortality rate,double-stranded DNA virus,0.6051724137931035
infectious disease mortality rate,virulence,0.5452380952380953
infectious disease mortality rate,incubation end temporal region,0.7198412698412698
infectious disease mortality rate,site of infection,0.61
infectious disease mortality rate,one-dimensional temporal region,0.684375
infectious disease mortality rate,virulence factor disposition,0.6631147540983606
infectious disease mortality rate,pathogen portal of exit,0.6464285714285714
infectious disease mortality rate,viral adhesion disposition,0.6364406779661017
infectious disease mortality rate,parasitostatic disposition,0.6364406779661017
infectious disease mortality rate,temporal region,0.6583333333333334
infectious disease mortality rate,infectious disease incidence,0.7942622950819671
infectious disease mortality rate,reverse zoonotic disposition,0.6139344262295081
infectious disease mortality rate,subclinical SARS-CoV-2 infection,0.6038461538461539
infectious disease mortality rate,virus translation stage,0.6464285714285714
infectious disease mortality rate,disease surveillance objective specification,0.6448051948051949
infectious disease mortality rate,virus release stage,0.6807692307692308
infectious disease mortality rate,infectious agent host role,0.7720338983050847
infectious disease mortality rate,asymptomatic infectious structure carrier,0.6797297297297297
infectious disease mortality rate,source of infection site,0.6780701754385965
infectious disease mortality rate,virus,0.5289473684210526
infectious disease mortality rate,virus replication,0.63
infectious disease mortality rate,B cell receptor complex,0.5928571428571429
infectious disease mortality rate,passive immunization against infectious agent,0.6294871794871795
infectious disease mortality rate,systematic infection,0.6009433962264151
infectious disease mortality rate,infection incidence rate,0.7482456140350877
infectious disease mortality rate,virus host,0.5895348837209302
infectious disease mortality rate,double-stranded RNA virus,0.6224137931034482
infectious disease mortality rate,virus transcription stage,0.656896551724138
infectious disease mortality rate,infectious disease lifetime prevalence,0.8161971830985917
infectious disease mortality rate,toxin disposition,0.63
infectious disease mortality rate,pathogen birth temporal region,0.6563492063492063
infectious disease mortality rate,serology assay,0.598936170212766
infectious disease mortality rate,lower respiratory tract disease,0.653125
infectious disease mortality rate,infectious disease incidence proportion,0.7694444444444444
infectious disease mortality rate,virus generative stage,0.6681818181818181
infectious disease mortality rate,acute infectious disease course,0.79375
infectious disease mortality rate,cidal agent disposition,0.6285714285714286
infectious disease mortality rate,infectious disorder,0.7769230769230769
infectious disease mortality rate,subclinical infection,0.5981481481481481
infectious disease mortality rate,appearance of disorder,0.6318181818181818
infectious disease mortality rate,simple infection,0.6132653061224489
infectious disease mortality rate,parasiticidal disposition,0.6224137931034482
infectious disease mortality rate,infectious disease sporadicity,0.8468253968253968
infectious disease mortality rate,communicability end process boundary,0.6239130434782608
infectious disease mortality rate,infection incidence proportion profile,0.7316901408450704
infectious disease mortality rate,infectious agent colony,0.7535714285714286
infectious disease mortality rate,transmissibility disposition,0.630327868852459
infectious disease mortality rate,latency end process boundary,0.6139344262295081
infectious disease mortality rate,infectious disease epidemic,0.8
infectious disease mortality rate,infectious agent generative stage,0.7530303030303032
infectious disease mortality rate,disease transmission model,0.6703389830508475
infectious disease mortality rate,endotoxin disposition,0.6351851851851852
infectious disease mortality rate,negative-sense single-stranded RNA virus,0.6554794520547945
infectious disease mortality rate,infectious structure host role,0.7515873015873015
infectious disease mortality rate,SARS-CoV-2 virulence,0.5820754716981132
infectious disease mortality rate,COVID-19 incidence rate,0.6642857142857143
infectious disease mortality rate,viral plaque assay,0.5872549019607843
infectious disease mortality rate,cytotoxin disposition,0.6351851851851852
infectious disease mortality rate,community-acquired infection,0.5975409836065574
infectious disease mortality rate,zero-dimensional temporal region,0.6807692307692308
infectious disease mortality rate,chronic infectious disease course,0.7833333333333333
infectious disease mortality rate,asymptomatic infectious agent carrier,0.6928571428571427
infectious disease mortality rate,nursing-home acquired infection,0.60625
infectious disease mortality rate,COVID-19 epidemic,0.59
infectious disease mortality rate,secondary infection,0.6230769230769231
infectious disease mortality rate,infection start temporal region,0.7625
infectious disease mortality rate,infection incidence,0.6807692307692308
infectious disease mortality rate,virus disorder,0.6627659574468084
infectious disease mortality rate,sterilizing immunity to infectious agent,0.6417808219178082
infectious disease mortality rate,establishment of localization in human host,0.6342105263157894
infectious disease mortality rate,diseased population,0.6807692307692308
infectious disease mortality rate,primary infection,0.61
infectious disease mortality rate,virulence factor,0.6132653061224489
infectious disease mortality rate,process of establishing an infection,0.6239130434782608
infectious disease mortality rate,incubation end process boundary,0.66875
infectious disease mortality rate,SARS-CoV-2 disorder,0.6230769230769231
infectious disease mortality rate,collective pathogenic disposition,0.6318181818181818
infectious disease mortality rate,neurotoxin disposition,0.65
infectious disease mortality rate,latency end temporal region,0.6666666666666667
infectious disease mortality rate,innate immunity to infectious agent,0.6558823529411765
infectious disease mortality rate,infectious structure,0.7518867924528303
infectious disease mortality rate,virus adhesion susceptible cell,0.653125
infectious disease mortality rate,collective disposition,0.65
infectious disease mortality rate,infection,0.6404761904761905
infectious disease mortality rate,static agent disposition,0.6254385964912281
infectious disease mortality rate,T cell receptor complex,0.5928571428571429
infectious disease mortality rate,infectious structure host,0.7258620689655172
infectious disease mortality rate,infectious agent population,0.75
infectious disease mortality rate,respiratory system disease,0.6533898305084747
infectious disease mortality rate,leukocyte-mediated immunity to infectious agent,0.6375
infectious disease mortality rate,humoral immunity to infectious agent,0.6528985507246376
infectious disease mortality rate,infectious disease control strategy,0.8470588235294118
infectious disease mortality rate,infectious disease pandemic,0.8
infectious disease mortality rate,infectious structure generative stage,0.7357142857142857
infectious disease mortality rate,immunosuppressive disposition,0.6435483870967742
infectious disease mortality rate,pathogenic disposition,0.6136363636363636
infectious disease mortality rate,viral disease course,0.6952830188679244
infectious disease mortality rate,intracellular infection,0.6107142857142857
infectious disease mortality rate,secondary infection role,0.6605263157894737
infectious disease mortality rate,metastatic infection,0.619811320754717
infectious disease mortality rate,passive immunity to infectious agent,0.6528985507246376
infectious disease mortality rate,infectious disposition,0.759090909090909
infectious disease mortality rate,vaccination against infectious agent,0.6528985507246376
infectious disease mortality rate,acute infection,0.6166666666666667
infectious disease mortality rate,susceptibility to infectious agent,0.658955223880597
infectious disease mortality rate,bacteriostatic disposition,0.6533898305084747
infectious disease mortality rate,bactericidal disposition,0.6254385964912281
infectious disease mortality rate,source of infection role,0.6605263157894737
infectious disease mortality rate,chronic infection,0.61
infectious disease mortality rate,invasion disposition,0.6575471698113208
infectious disease mortality rate,disease course,0.6840425531914894
infectious disease mortality rate,infectious disease course,0.8293103448275861
infectious disease mortality rate,viricidal disposition,0.6351851851851852
infectious disease mortality rate,acquired immunity to infectious agent,0.65
infectious disease mortality rate,complex infection,0.61
infectious disease mortality rate,COVID-19 disease incidence proportion,0.6642857142857143
infectious disease mortality rate,coronavirus disease course,0.7211864406779661
infectious disease mortality rate,infection incidence proportion,0.7198412698412698
infectious disease mortality rate,symptomatic infectious agent carrier,0.696376811594203
infectious disease mortality rate,respiratory droplet virus fomite,0.6346153846153847
infectious disease mortality rate,pathogen portal of exit site,0.6795081967213115
infectious disease mortality rate,infectious disease prevalence,0.8209677419354838
infectious disease mortality rate,disposition,0.5863636363636363
infectious disease mortality rate,single-stranded DNA virus,0.6224137931034482
infectious disease mortality rate,infected population,0.6807692307692308
infectious disease mortality rate,COVID-19 mortality rate,0.7714285714285714
infectious disease mortality rate,viral disease,0.6456521739130434
infectious disease mortality rate,primary infection role,0.6681818181818181
infectious disease mortality rate,adhesion disposition,0.6386792452830189
infectious disease mortality rate,infection incidence profile,0.7166666666666667
infectious disease mortality rate,disease,0.625
infectious disease mortality rate,symptomatic infectious structure carrier,0.682876712328767
infectious disease mortality rate,homo sapiens,0.5833333333333334
infectious disease mortality rate,primary infectious disposition,0.7198412698412698
infectious disease mortality rate,infection prevalence,0.6952830188679244
infectious disease mortality rate,coronavirus disorder,0.6575471698113208
infectious disease mortality rate,infectious pathogen transmissibility,0.7398550724637681
infectious disease mortality rate,infectious human pathogen,0.743103448275862
infectious disease mortality rate,subclinical virus infection,0.6333333333333333
infectious disease mortality rate,colonization of human,0.5981481481481481
infectious disease mortality rate,establishment of localization in virus host,0.6342105263157894
infectious disease mortality rate,immunization against infectious agent,0.65
infectious disease mortality rate,virus attachment stage,0.65
infectious disease mortality rate,assay,0.5552631578947369
infectious disease mortality rate,virus synthesis stage,0.6537037037037037
infectious disease mortality rate,SARS-COV-2 adhesion disposition,0.60625
infectious disease mortality rate,pathogen portal of exit role,0.6795081967213115
infectious disease mortality rate,invasive disposition,0.6386792452830189
infectious disease mortality rate,infectious agent host,0.7462962962962962
infectious disease mortality rate,long-term non-progressing infectious disease course,0.7119047619047619
infectious disease mortality rate,viral disease epidemic,0.6681818181818181
infectious disease mortality rate,communicability start temporal region,0.6642857142857143
infectious disease mortality rate,fungicidal disposition,0.6318181818181818
infectious disease mortality rate,blood,0.5026315789473684
infectious disease mortality rate,viral disease pandemic,0.6681818181818181
infectious disease mortality rate,virus penetration stage,0.6642857142857143
infectious disease mortality rate,acute respiratory distress syndrome,0.6558823529411765
infectious disease mortality rate,infectious disease endemicity,0.8209677419354838
infectious disease mortality rate,disorder,0.5963414634146341
infectious disease mortality rate,herd immunity to infectious organism,0.6673913043478261
infectious disease mortality rate,extracellular infection,0.5928571428571429
infectious disease mortality rate,exotoxin disposition,0.6386792452830189
infectious disease mortality rate,infectious agent reservoir,0.738135593220339
infectious disease mortality rate,COVID-19 pandemic,0.59
infectious disease mortality rate,infection start process boundary,0.6961538461538461
infectious disease mortality rate,infectious disease control objective specification,0.7632530120481928
infectious disease mortality rate,opportunistic infectious disposition,0.696376811594203
infectious disease mortality rate,process of establishing viral infection,0.6305555555555555
infectious disease mortality rate,enterotoxin disposition,0.6464285714285714
infectious disease mortality rate,COVID-19 disease course,0.7
infectious disease mortality rate,infectious disease incidence rate,0.8287878787878787
infectious disease mortality rate,single-stranded RNA retrovirus,0.6404761904761905
infectious disease mortality rate,active immunization against infectious agent,0.6318181818181818
infectious disease mortality rate,disordered virus,0.6132653061224489
infectious disease mortality rate,collective resistance disposition,0.6469696969696969
infectious disease mortality rate,fungistatic disposition,0.6285714285714286
infectious disease mortality rate,virus uncoating stage,0.6351851851851852
infectious disease mortality rate,local infection,0.6166666666666667
infectious disease mortality rate,infectious agent,0.7357142857142857
infectious disease mortality rate,establishment of a clinically abnormal colony,0.6294871794871795
infectious disease mortality rate,coronavirus disease,0.6807692307692308
infectious disease mortality rate,positive-sense single-stranded RNA virus,0.6417808219178082
infectious disease mortality rate,hospital-acquired infection,0.6
infectious disease mortality rate,pathogen death temporal region,0.6880952380952381
infectious disease mortality rate,drug susceptibility of infectious agent,0.6444444444444444
infectious disease mortality rate,SARS-CoV-2 release stage,0.6429824561403508
bacteria,extended organism,0.61
bacteria,virus aggregate,0.5804347826086956
bacteria,angiotensin-converting enzyme 2,0.5782051282051281
bacteria,source of infection,0.5611111111111111
bacteria,infection incidence rate profile,0.575
bacteria,pathogen generative stage,0.6318181818181818
bacteria,pathogen portal of entry,0.60625
bacteria,subclinical coronavirus infection,0.5719512195121951
bacteria,primary pathogen,0.575
bacteria,infection end temporal region,0.5851351351351352
bacteria,drug-based immunosuppressed organism,0.5636363636363636
bacteria,double-stranded DNA virus,0.5712121212121213
bacteria,site of infection,0.57
bacteria,immunocompetent organism,0.60625
bacteria,pathogen portal of exit,0.6112903225806451
bacteria,reservoir of pathogen role,0.5676470588235294
bacteria,subclinical SARS-CoV-2 infection,0.575
bacteria,virus translation stage,0.5790322580645162
bacteria,virus release stage,0.5611111111111111
bacteria,infectious agent host role,0.5676470588235294
bacteria,source of infection site,0.54375
bacteria,virus,0.5269230769230769
bacteria,virus replication,0.57
bacteria,B cell receptor complex,0.5790322580645162
bacteria,passive immunization against infectious agent,0.5443396226415094
bacteria,systematic infection,0.5928571428571429
bacteria,infection incidence rate,0.60625
bacteria,virus host,0.5055555555555555
bacteria,double-stranded RNA virus,0.6015151515151516
bacteria,pathogen portal of entry role,0.5851351351351352
bacteria,virus transcription stage,0.6015151515151516
bacteria,toxin disposition,0.53
bacteria,pathogen birth temporal region,0.581578947368421
bacteria,opportunistic pathogen,0.55
bacteria,virus generative stage,0.5833333333333334
bacteria,cidal agent disposition,0.5467741935483871
bacteria,genetic resistance to pathogen,0.5552631578947369
bacteria,subclinical infection,0.6224137931034482
bacteria,simple infection,0.575
bacteria,droplet pathogen transmission process,0.5611111111111111
bacteria,infection incidence proportion profile,0.558695652173913
bacteria,infectious agent colony,0.5790322580645162
bacteria,pathogen transporter,0.6285714285714286
bacteria,infectious agent generative stage,0.5963414634146341
bacteria,pathologically immunosuppressed organism,0.5541666666666667
bacteria,negative-sense single-stranded RNA virus,0.5541666666666667
bacteria,cidal agent,0.6078947368421053
bacteria,pathogen vehicle,0.6166666666666667
bacteria,community-acquired infection,0.5611111111111111
bacteria,pathogen vector,0.6239130434782608
bacteria,pathogen vehicle role,0.5879310344827586
bacteria,asymptomatic infectious agent carrier,0.5833333333333334
bacteria,nursing-home acquired infection,0.5525641025641026
bacteria,secondary infection,0.5981481481481481
bacteria,infection start temporal region,0.5782051282051281
bacteria,infection incidence,0.5611111111111111
bacteria,virus disorder,0.5409090909090909
bacteria,sterilizing immunity to infectious agent,0.5541666666666667
bacteria,primary infection,0.61
bacteria,process of establishing an infection,0.5636363636363636
bacteria,pathogen death process boundary,0.5782051282051281
bacteria,immunosuppressed organism,0.5409090909090909
bacteria,innate immunity to infectious agent,0.5662790697674418
bacteria,virus adhesion susceptible cell,0.5525641025641026
bacteria,infection,0.6264705882352941
bacteria,static agent disposition,0.575
bacteria,T cell receptor complex,0.5467741935483871
bacteria,infectious agent population,0.5642857142857143
bacteria,leukocyte-mediated immunity to infectious agent,0.5409090909090909
bacteria,indirect pathogen transmission process,0.558695652173913
bacteria,organism population,0.5611111111111111
bacteria,humoral immunity to infectious agent,0.5636363636363636
bacteria,toxin,0.6038461538461539
bacteria,intracellular infection,0.6112903225806451
bacteria,secondary infection role,0.575
bacteria,metastatic infection,0.5928571428571429
bacteria,passive immunity to infectious agent,0.5636363636363636
bacteria,vaccination against infectious agent,0.5863636363636363
bacteria,acute infection,0.6673913043478261
bacteria,susceptibility to infectious agent,0.569047619047619
bacteria,immunity to pathogen,0.5571428571428572
bacteria,source of infection role,0.54375
bacteria,pathogen host,0.5928571428571429
bacteria,chronic infection,0.57
bacteria,acquired immunity to infectious agent,0.5833333333333334
bacteria,complex infection,0.57
bacteria,infection incidence proportion,0.581578947368421
bacteria,symptomatic infectious agent carrier,0.5863636363636363
bacteria,respiratory droplet virus fomite,0.575
bacteria,susceptible organism,0.6285714285714286
bacteria,pathogen vector role,0.5928571428571429
bacteria,pathogen portal of exit site,0.5888888888888889
bacteria,organism substance,0.6038461538461539
bacteria,single-stranded DNA virus,0.5409090909090909
bacteria,primary infection role,0.5833333333333334
bacteria,pathogen portal of entry site,0.5851351351351352
bacteria,infection incidence profile,0.5928571428571429
bacteria,pathogen host role,0.6038461538461539
bacteria,infection prevalence,0.5928571428571429
bacteria,infectious pathogen transmissibility,0.5636363636363636
bacteria,pathogen surveillance,0.656896551724138
bacteria,immunodeficient organism,0.575
bacteria,pathogen,0.6375
bacteria,pathogen birth process boundary,0.5782051282051281
bacteria,infectious human pathogen,0.5712121212121213
bacteria,subclinical virus infection,0.5928571428571429
bacteria,resistance to pathogen,0.5833333333333334
bacteria,establishment of localization in virus host,0.5284313725490196
bacteria,immunization against infectious agent,0.5611111111111111
bacteria,virus attachment stage,0.5833333333333334
bacteria,virus synthesis stage,0.5879310344827586
bacteria,pathogen portal of exit role,0.5888888888888889
bacteria,infectious agent host,0.5879310344827586
bacteria,re-emerging pathogen,0.5928571428571429
bacteria,virus penetration stage,0.5790322580645162
bacteria,pathogen seroprevalence,0.6112903225806451
bacteria,contact pathogen transmission process,0.5833333333333334
bacteria,herd immunity to infectious organism,0.5409090909090909
bacteria,extracellular infection,0.6112903225806451
bacteria,pathogen transporter role,0.6015151515151516
bacteria,infectious agent reservoir,0.5970588235294118
bacteria,infection start process boundary,0.55
bacteria,process of establishing viral infection,0.5563829787234043
bacteria,active immunization against infectious agent,0.5653846153846154
bacteria,disordered virus,0.575
bacteria,organism,0.575
bacteria,virus uncoating stage,0.5879310344827586
bacteria,local infection,0.6239130434782608
bacteria,infectious agent,0.6166666666666667
bacteria,establishment of a clinically abnormal colony,0.5443396226415094
bacteria,positive-sense single-stranded RNA virus,0.5333333333333333
bacteria,horizontal pathogen transmission process,0.5541666666666667
bacteria,hospital-acquired infection,0.5642857142857143
bacteria,bacteria,0.95
bacteria,pathogen death temporal region,0.581578947368421
bacteria,emerging pathogen,0.61
bacteria,drug susceptibility of infectious agent,0.5563829787234043
bacteria,static agent,0.65
bacteria,pathogen transmission process,0.5851351351351352
entity,extended organism,0.5804347826086956
entity,information content entity,0.6375
entity,infectious disease mortality rate,0.5782051282051281
entity,infection incidence rate profile,0.5552631578947369
entity,infectious structure aggregate,0.5611111111111111
entity,communicability end temporal region,0.5475609756097561
entity,geographical entity,0.69
entity,infection end temporal region,0.5642857142857143
entity,drug-based immunosuppressed organism,0.5214285714285714
entity,SARS-CoV-2 incidence rate,0.5467741935483871
entity,incubation end temporal region,0.5611111111111111
entity,resistant entity,0.7227272727272727
entity,immunocompetent organism,0.5833333333333334
entity,virulence factor disposition,0.5970588235294118
entity,case isolation control strategy,0.5851351351351352
entity,material entity,0.7357142857142857
entity,asymptomatic infectious structure carrier,0.5351063829787234
entity,architectual structure,0.5571428571428572
entity,B cell receptor complex,0.5189655172413793
entity,infection incidence rate,0.5833333333333334
entity,entity,0.95
entity,communicability end process boundary,0.5452380952380953
entity,directive information content entity,0.5928571428571429
entity,acellular structure aggregate,0.5357142857142857
entity,invasion factor,0.5928571428571429
entity,latency end process boundary,0.5382352941176471
entity,realizable entity,0.7108695652173913
entity,pathologically immunosuppressed organism,0.5152173913043478
entity,infectious structure host role,0.5611111111111111
entity,COVID-19 incidence rate,0.553448275862069
entity,descriptive information content entity,0.5863636363636363
entity,establishment of localization in human host,0.5520408163265306
entity,acellular structure,0.57
entity,virulence factor,0.5863636363636363
entity,incubation end process boundary,0.5581081081081081
entity,molecular entity,0.7227272727272727
entity,immunosuppressed organism,0.5467741935483871
entity,latency end temporal region,0.5712121212121213
entity,infectious structure,0.6038461538461539
entity,T cell receptor complex,0.5189655172413793
entity,infectious structure host,0.5790322580645162
entity,respiratory system disease,0.575
entity,organism population,0.57
entity,infectious structure generative stage,0.5662790697674418
entity,susceptible organism,0.5653846153846154
entity,organism substance,0.575
entity,anatomical entity,0.7108695652173913
entity,COVID-19 mortality rate,0.5879310344827586
entity,geopolitical entity,0.69
entity,symptomatic infectious structure carrier,0.5369565217391304
entity,designative information content entity,0.5863636363636363
entity,immunodeficient organism,0.5833333333333334
entity,infectious human pathogen,0.5790322580645162
entity,colonization of human,0.5611111111111111
entity,immaterial entity,0.7108695652173913
entity,division of geopolitical entity,0.6121621621621621
entity,geographical feature,0.5653846153846154
entity,herd immunity to infectious organism,0.569047619047619
entity,action specification,0.5653846153846154
entity,processed material,0.575
entity,quality,0.6807692307692308
entity,infectious disease incidence rate,0.5525641025641026
entity,organism,0.5928571428571429
entity,establishment of a clinically abnormal colony,0.5480392156862746
entity,adhesion factor,0.5928571428571429
entity,material processing,0.53
virus uncoating stage,extended organism,0.581578947368421
virus uncoating stage,virus aggregate,0.7277777777777777
virus uncoating stage,source of infection,0.625
virus uncoating stage,virostatic disposition,0.6825581395348838
virus uncoating stage,zoonotic disposition,0.6207317073170732
virus uncoating stage,immune response,0.6444444444444444
virus uncoating stage,infectious disease mortality rate,0.6351851851851852
virus uncoating stage,infection incidence rate profile,0.619811320754717
virus uncoating stage,communicability end temporal region,0.6285714285714286
virus uncoating stage,pathogen generative stage,0.6891304347826087
virus uncoating stage,pathogen portal of entry,0.6055555555555556
virus uncoating stage,subclinical coronavirus infection,0.6537037037037037
virus uncoating stage,primary pathogen,0.6391891891891892
virus uncoating stage,infection end temporal region,0.65
virus uncoating stage,drug-based immunosuppressed organism,0.6254385964912281
virus uncoating stage,infectious disease,0.6807692307692308
virus uncoating stage,SARS-CoV-2 incidence rate,0.6673913043478261
virus uncoating stage,double-stranded DNA virus,0.6021739130434782
virus uncoating stage,incubation end temporal region,0.6656862745098039
virus uncoating stage,site of infection,0.6342105263157894
virus uncoating stage,immunocompetent organism,0.65
virus uncoating stage,virulence factor disposition,0.6744897959183673
virus uncoating stage,pathogen portal of exit,0.609090909090909
virus uncoating stage,viral adhesion disposition,0.6627659574468084
virus uncoating stage,parasitostatic disposition,0.6414893617021277
virus uncoating stage,infectious disease incidence,0.6336734693877552
virus uncoating stage,reservoir of pathogen role,0.6627659574468084
virus uncoating stage,reverse zoonotic disposition,0.6744897959183673
virus uncoating stage,subclinical SARS-CoV-2 infection,0.619811320754717
virus uncoating stage,virus translation stage,0.8363636363636363
virus uncoating stage,disease surveillance objective specification,0.6346153846153847
virus uncoating stage,virus release stage,0.775
virus uncoating stage,source of infection site,0.6944444444444444
virus uncoating stage,virus,0.6423076923076922
virus uncoating stage,virus replication,0.7394736842105263
virus uncoating stage,B cell receptor complex,0.5636363636363636
virus uncoating stage,systematic infection,0.6207317073170732
virus uncoating stage,infection incidence rate,0.65
virus uncoating stage,virus host,0.7403225806451613
virus uncoating stage,double-stranded RNA virus,0.6021739130434782
virus uncoating stage,pathogen portal of entry role,0.59
virus uncoating stage,virus transcription stage,0.8195652173913044
virus uncoating stage,infectious disease lifetime prevalence,0.6194915254237288
virus uncoating stage,toxin disposition,0.6078947368421053
virus uncoating stage,pathogen birth temporal region,0.5872549019607843
virus uncoating stage,lower respiratory tract disease,0.6230769230769231
virus uncoating stage,infectious disease incidence proportion,0.6166666666666667
virus uncoating stage,opportunistic pathogen,0.6593023255813953
virus uncoating stage,virus generative stage,0.822093023255814
virus uncoating stage,acute infectious disease course,0.6423076923076922
virus uncoating stage,cidal agent disposition,0.609090909090909
virus uncoating stage,infectious disorder,0.65
virus uncoating stage,genetic resistance to pathogen,0.6460784313725491
virus uncoating stage,subclinical infection,0.6404761904761905
virus uncoating stage,appearance of disorder,0.6127906976744186
virus uncoating stage,simple infection,0.6391891891891892
virus uncoating stage,biological vehicle,0.5782051282051281
virus uncoating stage,droplet pathogen transmission process,0.6051724137931035
virus uncoating stage,parasiticidal disposition,0.6021739130434782
virus uncoating stage,infectious disease sporadicity,0.6264705882352941
virus uncoating stage,communicability end process boundary,0.6078947368421053
virus uncoating stage,infection incidence proportion profile,0.6194915254237288
virus uncoating stage,pathogen transporter,0.6207317073170732
virus uncoating stage,transmissibility disposition,0.5928571428571429
virus uncoating stage,latency end process boundary,0.5724489795918367
virus uncoating stage,infectious disease epidemic,0.6375
virus uncoating stage,infectious agent generative stage,0.7092592592592593
virus uncoating stage,disease transmission model,0.6202127659574468
virus uncoating stage,endotoxin disposition,0.6404761904761905
virus uncoating stage,pathologically immunosuppressed organism,0.5811475409836065
virus uncoating stage,negative-sense single-stranded RNA virus,0.6139344262295081
virus uncoating stage,pathogen vehicle,0.5851351351351352
virus uncoating stage,COVID-19 incidence rate,0.6772727272727272
virus uncoating stage,cytotoxin disposition,0.6404761904761905
virus uncoating stage,community-acquired infection,0.6132653061224489
virus uncoating stage,pathogen vector,0.5888888888888889
virus uncoating stage,pathogen vehicle role,0.569047619047619
virus uncoating stage,chronic infectious disease course,0.6351851851851852
virus uncoating stage,nursing-home acquired infection,0.6230769230769231
virus uncoating stage,COVID-19 epidemic,0.581578947368421
virus uncoating stage,secondary infection,0.625
virus uncoating stage,infection start temporal region,0.6615384615384616
virus uncoating stage,infection incidence,0.65
virus uncoating stage,virus disorder,0.7071428571428571
virus uncoating stage,primary infection,0.6605263157894737
virus uncoating stage,process of establishing an infection,0.6429824561403508
virus uncoating stage,incubation end process boundary,0.6423076923076922
virus uncoating stage,SARS-CoV-2 disorder,0.625
virus uncoating stage,collective pathogenic disposition,0.5981481481481481
virus uncoating stage,neurotoxin disposition,0.636046511627907
virus uncoating stage,SARS-CoV-2 uncoating stage,0.8329787234042553
virus uncoating stage,pathogen death process boundary,0.5653846153846154
virus uncoating stage,immunosuppressed organism,0.6239130434782608
virus uncoating stage,plan specification,0.6038461538461539
virus uncoating stage,latency end temporal region,0.5958333333333333
virus uncoating stage,SARS-CoV-2 penetration stage,0.7357142857142857
virus uncoating stage,virus adhesion susceptible cell,0.7
virus uncoating stage,collective disposition,0.6127906976744186
virus uncoating stage,infection,0.65
virus uncoating stage,static agent disposition,0.6277777777777778
virus uncoating stage,T cell receptor complex,0.5636363636363636
virus uncoating stage,respiratory system disease,0.6414893617021277
virus uncoating stage,indirect pathogen transmission process,0.6194915254237288
virus uncoating stage,organism population,0.65
virus uncoating stage,generative stage,0.7202702702702704
virus uncoating stage,infectious disease control strategy,0.6642857142857143
virus uncoating stage,SARS-CoV-2 attachment stage,0.7208333333333333
virus uncoating stage,infectious disease pandemic,0.6375
virus uncoating stage,infectious structure generative stage,0.7086206896551723
virus uncoating stage,immunosuppressive disposition,0.61
virus uncoating stage,innate immune response,0.6593023255813953
virus uncoating stage,pathogenic disposition,0.5895348837209302
virus uncoating stage,viral disease course,0.6695121951219513
virus uncoating stage,intracellular infection,0.6545454545454545
virus uncoating stage,secondary infection role,0.65
virus uncoating stage,metastatic infection,0.6207317073170732
virus uncoating stage,infectious disposition,0.636046511627907
virus uncoating stage,acute infection,0.6444444444444444
virus uncoating stage,bacteriostatic disposition,0.6202127659574468
virus uncoating stage,immunity to pathogen,0.6695121951219513
virus uncoating stage,bactericidal disposition,0.5833333333333334
virus uncoating stage,source of infection role,0.65
virus uncoating stage,pathogen host,0.6264705882352941
virus uncoating stage,acquired immunodeficiency,0.6239130434782608
virus uncoating stage,chronic infection,0.6342105263157894
virus uncoating stage,invasion disposition,0.6451219512195122
virus uncoating stage,disease course,0.65
virus uncoating stage,infectious disease course,0.6456521739130434
virus uncoating stage,viricidal disposition,0.6404761904761905
virus uncoating stage,acquired immunity to infectious agent,0.656896551724138
virus uncoating stage,complex infection,0.6078947368421053
virus uncoating stage,COVID-19 disease incidence proportion,0.6224137931034482
virus uncoating stage,coronavirus disease course,0.6627659574468084
virus uncoating stage,biological vehicle role,0.5863636363636363
virus uncoating stage,infection incidence proportion,0.6068627450980393
virus uncoating stage,respiratory droplet virus fomite,0.6386792452830189
virus uncoating stage,susceptible organism,0.6207317073170732
virus uncoating stage,pathogen vector role,0.5963414634146341
virus uncoating stage,pathogen portal of exit site,0.6132653061224489
virus uncoating stage,infectious disease prevalence,0.63
virus uncoating stage,organism substance,0.6551282051282051
virus uncoating stage,SARS-CoV-2 genome replication stage,0.7178571428571427
virus uncoating stage,disposition,0.6375
virus uncoating stage,single-stranded DNA virus,0.6239130434782608
virus uncoating stage,COVID-19 mortality rate,0.6545454545454545
virus uncoating stage,viral disease,0.6852941176470588
virus uncoating stage,primary infection role,0.6825581395348838
virus uncoating stage,adhesion disposition,0.5963414634146341
virus uncoating stage,pathogen portal of entry site,0.61
virus uncoating stage,infection incidence profile,0.6166666666666667
virus uncoating stage,disease,0.6285714285714286
virus uncoating stage,primary infectious disposition,0.6460784313725491
virus uncoating stage,pathogen host role,0.6294871794871795
virus uncoating stage,infection prevalence,0.6695121951219513
virus uncoating stage,humoral immune response,0.6318181818181818
virus uncoating stage,coronavirus disorder,0.6695121951219513
virus uncoating stage,infectious pathogen transmissibility,0.6254385964912281
virus uncoating stage,pathogen surveillance,0.6166666666666667
virus uncoating stage,immunodeficient organism,0.6277777777777778
virus uncoating stage,pathogen,0.5879310344827586
virus uncoating stage,pathogen birth process boundary,0.5846153846153846
virus uncoating stage,infectious human pathogen,0.6891304347826087
virus uncoating stage,subclinical virus infection,0.6791666666666666
virus uncoating stage,resistance to pathogen,0.6593023255813953
virus uncoating stage,establishment of localization in virus host,0.621875
virus uncoating stage,virus attachment stage,0.7988372093023256
virus uncoating stage,negative regulation of immune response,0.6194915254237288
virus uncoating stage,SARS-CoV-2 transcription stage,0.7245098039215686
virus uncoating stage,virus synthesis stage,0.8071428571428573
virus uncoating stage,SARS-COV-2 adhesion disposition,0.6423076923076922
virus uncoating stage,pathogen portal of exit role,0.5928571428571429
virus uncoating stage,invasive disposition,0.6207317073170732
virus uncoating stage,re-emerging pathogen,0.6451219512195122
virus uncoating stage,long-term non-progressing infectious disease course,0.6027777777777777
virus uncoating stage,viral disease epidemic,0.636046511627907
virus uncoating stage,fungicidal disposition,0.6127906976744186
virus uncoating stage,viral disease pandemic,0.636046511627907
virus uncoating stage,virus penetration stage,0.8363636363636363
virus uncoating stage,pathogen seroprevalence,0.609090909090909
virus uncoating stage,acute respiratory distress syndrome,0.5928571428571429
virus uncoating stage,division of geopolitical entity,0.6230769230769231
virus uncoating stage,infectious disease endemicity,0.63
virus uncoating stage,contact pathogen transmission process,0.6051724137931035
virus uncoating stage,disorder,0.5879310344827586
virus uncoating stage,herd immunity to infectious organism,0.6078947368421053
virus uncoating stage,extracellular infection,0.6318181818181818
virus uncoating stage,pathogen transporter role,0.6021739130434782
virus uncoating stage,transmission interval,0.6166666666666667
virus uncoating stage,exotoxin disposition,0.6207317073170732
virus uncoating stage,infection start process boundary,0.6575471698113208
virus uncoating stage,SARS-CoV-2 synthesis stage,0.7053191489361703
virus uncoating stage,infectious disease control objective specification,0.6049295774647887
virus uncoating stage,immune population,0.6605263157894737
virus uncoating stage,opportunistic infectious disposition,0.6429824561403508
virus uncoating stage,process of establishing viral infection,0.6333333333333333
virus uncoating stage,enterotoxin disposition,0.6318181818181818
virus uncoating stage,COVID-19 disease course,0.6318181818181818
virus uncoating stage,infectious disease incidence rate,0.6537037037037037
virus uncoating stage,disordered virus,0.5851351351351352
virus uncoating stage,collective resistance disposition,0.6166666666666667
virus uncoating stage,adaptive immune response,0.6277777777777778
virus uncoating stage,fungistatic disposition,0.6318181818181818
virus uncoating stage,organism,0.5879310344827586
virus uncoating stage,virus uncoating stage,0.95
virus uncoating stage,local infection,0.6166666666666667
virus uncoating stage,establishment of a clinically abnormal colony,0.5863636363636363
virus uncoating stage,coronavirus disease,0.7
virus uncoating stage,positive-sense single-stranded RNA virus,0.6139344262295081
virus uncoating stage,horizontal pathogen transmission process,0.5975409836065574
virus uncoating stage,hospital-acquired infection,0.6166666666666667
virus uncoating stage,pathogen death temporal region,0.5872549019607843
virus uncoating stage,emerging pathogen,0.6605263157894737
virus uncoating stage,SARS-CoV-2 release stage,0.6944444444444444
virus uncoating stage,pathogen transmission process,0.59
acute infection,virus aggregate,0.5833333333333334
acute infection,source of infection,0.8029411764705883
acute infection,virostatic disposition,0.6662162162162162
acute infection,zoonotic disposition,0.65
acute infection,infectious disease mortality rate,0.6166666666666667
acute infection,infection incidence rate profile,0.6414893617021277
acute infection,communicability end temporal region,0.63
acute infection,subclinical coronavirus infection,0.7208333333333333
acute infection,infection end temporal region,0.6545454545454545
acute infection,infectious disease,0.6924242424242425
acute infection,SARS-CoV-2 incidence rate,0.65
acute infection,double-stranded DNA virus,0.6
acute infection,incubation end temporal region,0.6722222222222223
acute infection,site of infection,0.825
acute infection,virulence factor disposition,0.6593023255813953
acute infection,viral adhesion disposition,0.6451219512195122
acute infection,parasitostatic disposition,0.6451219512195122
acute infection,infectious disease incidence,0.6593023255813953
acute infection,reverse zoonotic disposition,0.636046511627907
acute infection,subclinical SARS-CoV-2 infection,0.7053191489361703
acute infection,virus translation stage,0.6342105263157894
acute infection,disease surveillance objective specification,0.6533898305084747
acute infection,virus release stage,0.5676470588235294
acute infection,source of infection site,0.7576923076923078
acute infection,virus,0.5
acute infection,virus replication,0.7
acute infection,B cell receptor complex,0.6342105263157894
acute infection,systematic infection,0.7928571428571428
acute infection,infection incidence rate,0.6807692307692308
acute infection,virus host,0.57
acute infection,double-stranded RNA virus,0.6
acute infection,virus transcription stage,0.65
acute infection,infectious disease lifetime prevalence,0.6386792452830189
acute infection,toxin disposition,0.66875
acute infection,lower respiratory tract disease,0.5804347826086956
acute infection,infectious disease incidence proportion,0.6722222222222223
acute infection,virus generative stage,0.6121621621621621
acute infection,acute infectious disease course,0.7543478260869566
acute infection,cidal agent disposition,0.6605263157894737
acute infection,infectious disorder,0.6852941176470588
acute infection,subclinical infection,0.7555555555555555
acute infection,appearance of disorder,0.6391891891891892
acute infection,simple infection,0.8048387096774193
acute infection,parasiticidal disposition,0.65
acute infection,infectious disease sporadicity,0.6277777777777778
acute infection,communicability end process boundary,0.6068627450980393
acute infection,infection incidence proportion profile,0.6575471698113208
acute infection,transmissibility disposition,0.636046511627907
acute infection,latency end process boundary,0.636046511627907
acute infection,infectious disease epidemic,0.6404761904761905
acute infection,disease transmission model,0.6207317073170732
acute infection,endotoxin disposition,0.6444444444444444
acute infection,negative-sense single-stranded RNA virus,0.6136363636363636
acute infection,COVID-19 incidence rate,0.6342105263157894
acute infection,cytotoxin disposition,0.6722222222222223
acute infection,community-acquired infection,0.7755813953488372
acute infection,chronic infectious disease course,0.6583333333333334
acute infection,nursing-home acquired infection,0.7543478260869566
acute infection,COVID-19 epidemic,0.60625
acute infection,secondary infection,0.7735294117647058
acute infection,infection start temporal region,0.6456521739130434
acute infection,infection incidence,0.7147058823529412
acute infection,virus disorder,0.5879310344827586
acute infection,primary infection,0.79375
acute infection,process of establishing an infection,0.6852941176470588
acute infection,incubation end process boundary,0.6456521739130434
acute infection,SARS-CoV-2 disorder,0.5970588235294118
acute infection,collective pathogenic disposition,0.6583333333333334
acute infection,neurotoxin disposition,0.6662162162162162
acute infection,SARS-CoV-2 spike glycoprotein,0.6545454545454545
acute infection,latency end temporal region,0.6642857142857143
acute infection,virus adhesion susceptible cell,0.6021739130434782
acute infection,collective disposition,0.6932432432432433
acute infection,infection,0.825
acute infection,static agent disposition,0.6807692307692308
acute infection,T cell receptor complex,0.6342105263157894
acute infection,respiratory system disease,0.5963414634146341
acute infection,communicability interval,0.6294871794871795
acute infection,infectious disease control strategy,0.63
acute infection,infectious disease pandemic,0.6642857142857143
acute infection,immunosuppressive disposition,0.6318181818181818
acute infection,pathogenic disposition,0.6932432432432433
acute infection,viral disease course,0.6214285714285714
acute infection,intracellular infection,0.7921052631578948
acute infection,secondary infection role,0.732051282051282
acute infection,metastatic infection,0.7928571428571428
acute infection,infectious disposition,0.6932432432432433
acute infection,acute infection,0.95
acute infection,bacteriostatic disposition,0.6939024390243902
acute infection,epitope site,0.6351851851851852
acute infection,bactericidal disposition,0.7064102564102563
acute infection,source of infection role,0.7576923076923078
acute infection,chronic infection,0.79375
acute infection,invasion disposition,0.65
acute infection,disease course,0.6224137931034482
acute infection,infectious disease course,0.65
acute infection,viricidal disposition,0.6444444444444444
acute infection,complex infection,0.825
acute infection,COVID-19 disease incidence proportion,0.6615384615384616
acute infection,coronavirus disease course,0.6207317073170732
acute infection,infection incidence proportion,0.6944444444444444
acute infection,respiratory droplet virus fomite,0.598936170212766
acute infection,pathogen portal of exit site,0.636046511627907
acute infection,infectious disease prevalence,0.6545454545454545
acute infection,disposition,0.6423076923076922
acute infection,single-stranded DNA virus,0.575
acute infection,COVID-19 mortality rate,0.5552631578947369
acute infection,viral disease,0.5928571428571429
acute infection,primary infection role,0.7472972972972972
acute infection,adhesion disposition,0.6785714285714286
acute infection,pathogen portal of entry site,0.6318181818181818
acute infection,infection incidence profile,0.6642857142857143
acute infection,contagiousness,0.656896551724138
acute infection,disease,0.5409090909090909
acute infection,site,0.5552631578947369
acute infection,primary infectious disposition,0.6944444444444444
acute infection,infection prevalence,0.7071428571428571
acute infection,coronavirus disorder,0.5928571428571429
acute infection,subclinical virus infection,0.7357142857142857
acute infection,establishment of localization in virus host,0.6051724137931035
acute infection,virus attachment stage,0.5851351351351352
acute infection,virus synthesis stage,0.5888888888888889
acute infection,SARS-COV-2 adhesion disposition,0.6456521739130434
acute infection,invasive disposition,0.6785714285714286
acute infection,long-term non-progressing infectious disease course,0.6166666666666667
acute infection,viral disease epidemic,0.6121621621621621
acute infection,communicability start temporal region,0.6230769230769231
acute infection,fungicidal disposition,0.6391891891891892
acute infection,viral disease pandemic,0.6121621621621621
acute infection,virus penetration stage,0.6605263157894737
acute infection,acute respiratory distress syndrome,0.65
acute infection,infectious disease endemicity,0.6545454545454545
acute infection,disorder,0.5369565217391304
acute infection,communicability,0.6166666666666667
acute infection,extracellular infection,0.7921052631578948
acute infection,exotoxin disposition,0.65
acute infection,infection start process boundary,0.6414893617021277
acute infection,action specification,0.7642857142857143
acute infection,infectious disease control objective specification,0.6346153846153847
acute infection,opportunistic infectious disposition,0.6852941176470588
acute infection,process of establishing viral infection,0.6722222222222223
acute infection,enterotoxin disposition,0.6605263157894737
acute infection,COVID-19 disease course,0.6078947368421053
acute infection,infectious disease incidence rate,0.6375
acute infection,communicability start process boundary,0.5820754716981132
acute infection,active immunization against infectious agent,0.6872881355932203
acute infection,disordered virus,0.5467741935483871
acute infection,collective resistance disposition,0.6791666666666666
acute infection,fungistatic disposition,0.6605263157894737
acute infection,virus uncoating stage,0.6444444444444444
acute infection,local infection,0.8166666666666665
acute infection,establishment of a clinically abnormal colony,0.5833333333333334
acute infection,coronavirus disease,0.5970588235294118
acute infection,positive-sense single-stranded RNA virus,0.5954545454545455
acute infection,hospital-acquired infection,0.7833333333333333
leukocyte-mediated immunity to infectious agent,information content entity,0.6554794520547945
leukocyte-mediated immunity to infectious agent,infectious disease mortality rate,0.6375
leukocyte-mediated immunity to infectious agent,infection incidence rate profile,0.6272151898734176
leukocyte-mediated immunity to infectious agent,infectious structure aggregate,0.6448051948051949
leukocyte-mediated immunity to infectious agent,communicability end temporal region,0.6451219512195122
leukocyte-mediated immunity to infectious agent,infection end temporal region,0.6342105263157894
leukocyte-mediated immunity to infectious agent,infectious disease,0.65
leukocyte-mediated immunity to infectious agent,SARS-CoV-2 incidence rate,0.6027777777777777
leukocyte-mediated immunity to infectious agent,incubation end temporal region,0.6188311688311688
leukocyte-mediated immunity to infectious agent,virulence factor disposition,0.6366666666666667
leukocyte-mediated immunity to infectious agent,infectious disease incidence,0.6366666666666667
leukocyte-mediated immunity to infectious agent,disease surveillance objective specification,0.6368131868131869
leukocyte-mediated immunity to infectious agent,virus release stage,0.6015151515151516
leukocyte-mediated immunity to infectious agent,infectious agent host role,0.6691780821917809
leukocyte-mediated immunity to infectious agent,asymptomatic infectious structure carrier,0.6772727272727272
leukocyte-mediated immunity to infectious agent,B cell receptor complex,0.5928571428571429
leukocyte-mediated immunity to infectious agent,passive immunization against infectious agent,0.7652173913043478
leukocyte-mediated immunity to infectious agent,infection incidence rate,0.6330985915492958
leukocyte-mediated immunity to infectious agent,infectious disease lifetime prevalence,0.65
leukocyte-mediated immunity to infectious agent,lower respiratory tract disease,0.6551282051282051
leukocyte-mediated immunity to infectious agent,infectious disease incidence proportion,0.6476744186046511
leukocyte-mediated immunity to infectious agent,acute infectious disease course,0.6679487179487179
leukocyte-mediated immunity to infectious agent,cidal agent disposition,0.6357142857142857
leukocyte-mediated immunity to infectious agent,infectious disorder,0.6318181818181818
leukocyte-mediated immunity to infectious agent,genetic resistance to pathogen,0.6448051948051949
leukocyte-mediated immunity to infectious agent,biological vehicle,0.573076923076923
leukocyte-mediated immunity to infectious agent,infectious disease sporadicity,0.6318181818181818
leukocyte-mediated immunity to infectious agent,communicability end process boundary,0.6186746987951807
leukocyte-mediated immunity to infectious agent,directive information content entity,0.6668674698795181
leukocyte-mediated immunity to infectious agent,infectious agent colony,0.6785714285714286
leukocyte-mediated immunity to infectious agent,pathogen transporter,0.5843283582089552
leukocyte-mediated immunity to infectious agent,invasion factor,0.5951612903225807
leukocyte-mediated immunity to infectious agent,latency end process boundary,0.61
leukocyte-mediated immunity to infectious agent,infectious disease epidemic,0.6256756756756756
leukocyte-mediated immunity to infectious agent,infectious agent generative stage,0.6625
leukocyte-mediated immunity to infectious agent,disease transmission model,0.6006849315068493
leukocyte-mediated immunity to infectious agent,cidal agent,0.6051724137931035
leukocyte-mediated immunity to infectious agent,infectious structure host role,0.6188311688311688
leukocyte-mediated immunity to infectious agent,pathogen vehicle,0.5769841269841269
leukocyte-mediated immunity to infectious agent,COVID-19 incidence rate,0.6214285714285714
leukocyte-mediated immunity to infectious agent,antibiotic resistance,0.6117647058823529
leukocyte-mediated immunity to infectious agent,pathogen vehicle role,0.5823529411764706
leukocyte-mediated immunity to infectious agent,chronic infectious disease course,0.6625
leukocyte-mediated immunity to infectious agent,asymptomatic infectious agent carrier,0.7238095238095238
leukocyte-mediated immunity to infectious agent,descriptive information content entity,0.6617647058823529
leukocyte-mediated immunity to infectious agent,COVID-19 epidemic,0.575
leukocyte-mediated immunity to infectious agent,resistance to drug,0.6038461538461539
leukocyte-mediated immunity to infectious agent,sterilizing immunity to infectious agent,0.8178160919540229
leukocyte-mediated immunity to infectious agent,diseased population,0.6166666666666667
leukocyte-mediated immunity to infectious agent,virulence factor,0.5928571428571429
leukocyte-mediated immunity to infectious agent,incubation end process boundary,0.591025641025641
leukocyte-mediated immunity to infectious agent,latency end temporal region,0.6527027027027027
leukocyte-mediated immunity to infectious agent,innate immunity to infectious agent,0.852439024390244
leukocyte-mediated immunity to infectious agent,infectious structure,0.6291044776119403
leukocyte-mediated immunity to infectious agent,static agent disposition,0.6330985915492958
leukocyte-mediated immunity to infectious agent,T cell receptor complex,0.5928571428571429
leukocyte-mediated immunity to infectious agent,asymptomatic carrier role,0.6027777777777777
leukocyte-mediated immunity to infectious agent,infectious structure host,0.6305555555555555
leukocyte-mediated immunity to infectious agent,infectious agent population,0.6662162162162162
leukocyte-mediated immunity to infectious agent,respiratory system disease,0.6143835616438357
leukocyte-mediated immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.95
leukocyte-mediated immunity to infectious agent,humoral immunity to infectious agent,0.8355421686746988
leukocyte-mediated immunity to infectious agent,infectious disease control strategy,0.6329268292682927
leukocyte-mediated immunity to infectious agent,infectious disease pandemic,0.6391891891891892
leukocyte-mediated immunity to infectious agent,infectious structure generative stage,0.6404761904761905
leukocyte-mediated immunity to infectious agent,viral disease course,0.6141791044776119
leukocyte-mediated immunity to infectious agent,passive immunity to infectious agent,0.8234939759036144
leukocyte-mediated immunity to infectious agent,infectious disposition,0.6239130434782608
leukocyte-mediated immunity to infectious agent,vaccination against infectious agent,0.7512048192771084
leukocyte-mediated immunity to infectious agent,susceptibility to infectious agent,0.795679012345679
leukocyte-mediated immunity to infectious agent,immunity to pathogen,0.703731343283582
leukocyte-mediated immunity to infectious agent,disease course,0.6139344262295081
leukocyte-mediated immunity to infectious agent,infectious disease course,0.6305555555555555
leukocyte-mediated immunity to infectious agent,acquired immunity to infectious agent,0.8428571428571427
leukocyte-mediated immunity to infectious agent,COVID-19 disease incidence proportion,0.6404761904761905
leukocyte-mediated immunity to infectious agent,coronavirus disease course,0.6143835616438357
leukocyte-mediated immunity to infectious agent,asymptomatic carrier,0.5992537313432835
leukocyte-mediated immunity to infectious agent,biological vehicle role,0.5785714285714285
leukocyte-mediated immunity to infectious agent,symptomatic infectious agent carrier,0.7271084337349397
leukocyte-mediated immunity to infectious agent,intermediate host,0.653125
leukocyte-mediated immunity to infectious agent,infectious disease prevalence,0.6342105263157894
leukocyte-mediated immunity to infectious agent,infected population,0.6166666666666667
leukocyte-mediated immunity to infectious agent,COVID-19 mortality rate,0.6071428571428572
leukocyte-mediated immunity to infectious agent,viral disease,0.5666666666666667
leukocyte-mediated immunity to infectious agent,leukocyte mediated immunity,0.8013513513513513
leukocyte-mediated immunity to infectious agent,disease,0.5425925925925926
leukocyte-mediated immunity to infectious agent,symptomatic infectious structure carrier,0.6798850574712644
leukocyte-mediated immunity to infectious agent,primary infectious disposition,0.6577922077922078
leukocyte-mediated immunity to infectious agent,designative information content entity,0.6617647058823529
leukocyte-mediated immunity to infectious agent,symptomatic carrier role,0.6049295774647887
leukocyte-mediated immunity to infectious agent,infectious pathogen transmissibility,0.6427710843373494
leukocyte-mediated immunity to infectious agent,intermediate host role,0.6528985507246376
leukocyte-mediated immunity to infectious agent,infectious human pathogen,0.6583333333333334
leukocyte-mediated immunity to infectious agent,resistance to pathogen,0.6384057971014493
leukocyte-mediated immunity to infectious agent,immunization against infectious agent,0.7595238095238095
leukocyte-mediated immunity to infectious agent,infectious agent host,0.6852941176470588
leukocyte-mediated immunity to infectious agent,long-term non-progressing infectious disease course,0.6744897959183673
leukocyte-mediated immunity to infectious agent,viral disease epidemic,0.5949275362318841
leukocyte-mediated immunity to infectious agent,viral disease pandemic,0.5804347826086956
leukocyte-mediated immunity to infectious agent,symptomatic carrier,0.6015151515151516
leukocyte-mediated immunity to infectious agent,infectious disease endemicity,0.6473684210526315
leukocyte-mediated immunity to infectious agent,function,0.5772727272727273
leukocyte-mediated immunity to infectious agent,herd immunity to infectious organism,0.7873493975903614
leukocyte-mediated immunity to infectious agent,pathogen transporter role,0.5888888888888889
leukocyte-mediated immunity to infectious agent,infectious agent reservoir,0.6691780821917809
leukocyte-mediated immunity to infectious agent,COVID-19 pandemic,0.559375
leukocyte-mediated immunity to infectious agent,action specification,0.6291044776119403
leukocyte-mediated immunity to infectious agent,protective resistance,0.6117647058823529
leukocyte-mediated immunity to infectious agent,infectious disease control objective specification,0.6561855670103093
leukocyte-mediated immunity to infectious agent,opportunistic infectious disposition,0.6789156626506024
leukocyte-mediated immunity to infectious agent,polymerase chain reaction,0.6722222222222223
leukocyte-mediated immunity to infectious agent,COVID-19 disease course,0.6214285714285714
leukocyte-mediated immunity to infectious agent,infectious disease incidence rate,0.65
leukocyte-mediated immunity to infectious agent,active immunization against infectious agent,0.7906593406593407
leukocyte-mediated immunity to infectious agent,collective resistance disposition,0.6625
leukocyte-mediated immunity to infectious agent,infectious agent,0.7039682539682539
leukocyte-mediated immunity to infectious agent,establishment of a clinically abnormal colony,0.6239130434782608
leukocyte-mediated immunity to infectious agent,coronavirus disease,0.5863636363636363
leukocyte-mediated immunity to infectious agent,adhesion factor,0.5951612903225807
leukocyte-mediated immunity to infectious agent,drug susceptibility of infectious agent,0.763953488372093
leukocyte-mediated immunity to infectious agent,SARS-CoV-2 release stage,0.5908450704225352
leukocyte-mediated immunity to infectious agent,static agent,0.6364406779661017
infection incidence profile,virus aggregate,0.5452380952380953
infection incidence profile,source of infection,0.6456521739130434
infection incidence profile,virostatic disposition,0.6132653061224489
infection incidence profile,information content entity,0.6952830188679244
infection incidence profile,zoonotic disposition,0.6202127659574468
infection incidence profile,infectious disease mortality rate,0.7166666666666667
infection incidence profile,infection incidence rate profile,0.9076271186440679
infection incidence profile,communicability end temporal region,0.6596774193548387
infection incidence profile,subclinical coronavirus infection,0.6333333333333333
infection incidence profile,infection end temporal region,0.7535714285714286
infection incidence profile,infectious disease,0.7166666666666667
infection incidence profile,SARS-CoV-2 incidence rate,0.7384615384615384
infection incidence profile,double-stranded DNA virus,0.6038461538461539
infection incidence profile,incubation end temporal region,0.7131578947368421
infection incidence profile,site of infection,0.6545454545454545
infection incidence profile,virulence factor disposition,0.65
infection incidence profile,viral adhesion disposition,0.6386792452830189
infection incidence profile,parasitostatic disposition,0.619811320754717
infection incidence profile,infectious disease incidence,0.7772727272727272
infection incidence profile,reverse zoonotic disposition,0.6136363636363636
infection incidence profile,subclinical SARS-CoV-2 infection,0.6194915254237288
infection incidence profile,virus translation stage,0.61
infection incidence profile,disease surveillance objective specification,0.6330985915492958
infection incidence profile,virus release stage,0.5804347826086956
infection incidence profile,material entity,0.5928571428571429
infection incidence profile,source of infection site,0.6852941176470588
infection incidence profile,virus,0.5125
infection incidence profile,virus replication,0.609090909090909
infection incidence profile,B cell receptor complex,0.65
infection incidence profile,systematic infection,0.6414893617021277
infection incidence profile,infection incidence rate,0.8813725490196078
infection incidence profile,virus host,0.5310810810810811
infection incidence profile,double-stranded RNA virus,0.6038461538461539
infection incidence profile,virus transcription stage,0.6230769230769231
infection incidence profile,infectious disease lifetime prevalence,0.7269230769230769
infection incidence profile,toxin disposition,0.6318181818181818
infection incidence profile,lower respiratory tract disease,0.5879310344827586
infection incidence profile,infectious disease incidence proportion,0.7984848484848485
infection incidence profile,virus generative stage,0.6132653061224489
infection incidence profile,acute infectious disease course,0.7086206896551723
infection incidence profile,cidal agent disposition,0.63
infection incidence profile,infectious disorder,0.7326086956521739
infection incidence profile,subclinical infection,0.6375
infection incidence profile,appearance of disorder,0.6336734693877552
infection incidence profile,simple infection,0.6593023255813953
infection incidence profile,parasiticidal disposition,0.6423076923076922
infection incidence profile,infectious disease sporadicity,0.730701754385965
infection incidence profile,communicability end process boundary,0.6563492063492063
infection incidence profile,directive information content entity,0.6722222222222223
infection incidence profile,infection incidence proportion profile,0.8653846153846154
infection incidence profile,SARS-CoV-2 incidence proportion,0.743103448275862
infection incidence profile,transmissibility disposition,0.5954545454545455
infection incidence profile,latency end process boundary,0.6318181818181818
infection incidence profile,infectious disease epidemic,0.7462962962962962
infection incidence profile,disease transmission model,0.6386792452830189
infection incidence profile,endotoxin disposition,0.6375
infection incidence profile,negative-sense single-stranded RNA virus,0.658955223880597
infection incidence profile,COVID-19 incidence rate,0.75
infection incidence profile,cytotoxin disposition,0.6375
infection incidence profile,community-acquired infection,0.6318181818181818
infection incidence profile,chronic infectious disease course,0.7
infection incidence profile,nursing-home acquired infection,0.6396551724137931
infection incidence profile,descriptive information content entity,0.65
infection incidence profile,COVID-19 epidemic,0.6318181818181818
infection incidence profile,secondary infection,0.6673913043478261
infection incidence profile,infection start temporal region,0.7086206896551723
infection incidence profile,infection incidence,0.8630434782608696
infection incidence profile,virus disorder,0.5963414634146341
infection incidence profile,primary infection,0.6545454545454545
infection incidence profile,process of establishing an infection,0.6246031746031746
infection incidence profile,incubation end process boundary,0.7086206896551723
infection incidence profile,SARS-CoV-2 disorder,0.6021739130434782
infection incidence profile,collective pathogenic disposition,0.65
infection incidence profile,neurotoxin disposition,0.6540816326530612
infection incidence profile,COVID-19 incidence,0.7166666666666667
infection incidence profile,latency end temporal region,0.6351851851851852
infection incidence profile,virus adhesion susceptible cell,0.656896551724138
infection incidence profile,collective disposition,0.6336734693877552
infection incidence profile,infection,0.7
infection incidence profile,static agent disposition,0.6264705882352941
infection incidence profile,T cell receptor complex,0.67
infection incidence profile,respiratory system disease,0.6009433962264151
infection incidence profile,communicability interval,0.6460784313725491
infection incidence profile,infectious disease control strategy,0.7241935483870968
infection incidence profile,infectious disease pandemic,0.7277777777777777
infection incidence profile,immunosuppressive disposition,0.6107142857142857
infection incidence profile,pathogenic disposition,0.6336734693877552
infection incidence profile,viral disease course,0.6202127659574468
infection incidence profile,intracellular infection,0.63
infection incidence profile,secondary infection role,0.7441176470588234
infection incidence profile,metastatic infection,0.6414893617021277
infection incidence profile,infectious disposition,0.7153061224489795
infection incidence profile,acute infection,0.6642857142857143
infection incidence profile,bacteriostatic disposition,0.6386792452830189
infection incidence profile,bactericidal disposition,0.6460784313725491
infection incidence profile,source of infection role,0.7245098039215686
infection incidence profile,chronic infection,0.6545454545454545
infection incidence profile,invasion disposition,0.6627659574468084
infection incidence profile,disease course,0.5963414634146341
infection incidence profile,infectious disease course,0.7384615384615384
infection incidence profile,viricidal disposition,0.6375
infection incidence profile,complex infection,0.6545454545454545
infection incidence profile,COVID-19 disease incidence proportion,0.715625
infection incidence profile,coronavirus disease course,0.6386792452830189
infection incidence profile,infection incidence proportion,0.8710526315789474
infection incidence profile,respiratory droplet virus fomite,0.6364406779661017
infection incidence profile,infectious disease prevalence,0.7535714285714286
infection incidence profile,disposition,0.581578947368421
infection incidence profile,single-stranded DNA virus,0.6423076923076922
infection incidence profile,COVID-19 mortality rate,0.61
infection incidence profile,process profile,0.7119047619047619
infection incidence profile,viral disease,0.575
infection incidence profile,primary infection role,0.7357142857142857
infection incidence profile,adhesion disposition,0.6414893617021277
infection incidence profile,infection incidence profile,0.95
infection incidence profile,contagiousness,0.5963414634146341
infection incidence profile,disease,0.5382352941176471
infection incidence profile,primary infectious disposition,0.6780701754385965
infection incidence profile,infection prevalence,0.747872340425532
infection incidence profile,designative information content entity,0.65
infection incidence profile,coronavirus disorder,0.6202127659574468
infection incidence profile,SARS-CoV-2 incidence,0.7053191489361703
infection incidence profile,subclinical virus infection,0.6351851851851852
infection incidence profile,establishment of localization in virus host,0.65
infection incidence profile,virus attachment stage,0.5928571428571429
infection incidence profile,virus synthesis stage,0.575
infection incidence profile,SARS-COV-2 adhesion disposition,0.6224137931034482
infection incidence profile,invasive disposition,0.6202127659574468
infection incidence profile,long-term non-progressing infectious disease course,0.6423076923076922
infection incidence profile,viral disease epidemic,0.6336734693877552
infection incidence profile,communicability start temporal region,0.621875
infection incidence profile,fungicidal disposition,0.6540816326530612
infection incidence profile,viral disease pandemic,0.6132653061224489
infection incidence profile,virus penetration stage,0.63
infection incidence profile,acute respiratory distress syndrome,0.6274193548387097
infection incidence profile,geographical feature,0.598936170212766
infection incidence profile,infectious disease endemicity,0.7178571428571427
infection incidence profile,disorder,0.5928571428571429
infection incidence profile,history,0.5676470588235294
infection incidence profile,communicability,0.6166666666666667
infection incidence profile,extracellular infection,0.63
infection incidence profile,exotoxin disposition,0.6414893617021277
infection incidence profile,infection start process boundary,0.7042372881355932
infection incidence profile,action specification,0.6627659574468084
infection incidence profile,processed material,0.6277777777777778
infection incidence profile,infectious disease control objective specification,0.6837662337662337
infection incidence profile,COVID-19 lifetime prevalence,0.65
infection incidence profile,opportunistic infectious disposition,0.6563492063492063
infection incidence profile,process of establishing viral infection,0.6166666666666667
infection incidence profile,enterotoxin disposition,0.65
infection incidence profile,COVID-19 disease course,0.63
infection incidence profile,infectious disease incidence rate,0.8
infection incidence profile,communicability start process boundary,0.6192307692307693
infection incidence profile,COVID-19 prevalence,0.6456521739130434
infection incidence profile,single-stranded RNA retrovirus,0.6605263157894737
infection incidence profile,SARS-COV-2 prevalence,0.5958333333333333
infection incidence profile,disordered virus,0.6127906976744186
infection incidence profile,collective resistance disposition,0.6666666666666667
infection incidence profile,fungistatic disposition,0.63
infection incidence profile,virus uncoating stage,0.6166666666666667
infection incidence profile,local infection,0.6642857142857143
infection incidence profile,establishment of a clinically abnormal colony,0.6305555555555555
infection incidence profile,coronavirus disease,0.6021739130434782
infection incidence profile,positive-sense single-stranded RNA virus,0.6440298507462687
infection incidence profile,hospital-acquired infection,0.6166666666666667
infection incidence profile,material processing,0.6021739130434782
pathogen generative stage,extended organism,0.6404761904761905
pathogen generative stage,virus aggregate,0.625
pathogen generative stage,source of infection,0.609090909090909
pathogen generative stage,infectious disease mortality rate,0.6396551724137931
pathogen generative stage,infection incidence rate profile,0.6780701754385965
pathogen generative stage,pathogen generative stage,0.95
pathogen generative stage,pathogen portal of entry,0.7153061224489795
pathogen generative stage,subclinical coronavirus infection,0.5879310344827586
pathogen generative stage,primary pathogen,0.6451219512195122
pathogen generative stage,infection end temporal region,0.6537037037037037
pathogen generative stage,drug-based immunosuppressed organism,0.5975409836065574
pathogen generative stage,infectious disease,0.636046511627907
pathogen generative stage,SARS-CoV-2 incidence rate,0.65
pathogen generative stage,double-stranded DNA virus,0.61
pathogen generative stage,site of infection,0.6166666666666667
pathogen generative stage,immunocompetent organism,0.6336734693877552
pathogen generative stage,pathogen portal of exit,0.7208333333333333
pathogen generative stage,infectious disease incidence,0.6009433962264151
pathogen generative stage,reservoir of pathogen role,0.6656862745098039
pathogen generative stage,subclinical SARS-CoV-2 infection,0.5728070175438597
pathogen generative stage,virus translation stage,0.6791666666666666
pathogen generative stage,disease surveillance objective specification,0.6384057971014493
pathogen generative stage,virus release stage,0.7
pathogen generative stage,infectious agent host role,0.6656862745098039
pathogen generative stage,source of infection site,0.6744897959183673
pathogen generative stage,virus,0.5166666666666666
pathogen generative stage,virus replication,0.569047619047619
pathogen generative stage,B cell receptor complex,0.5958333333333333
pathogen generative stage,passive immunization against infectious agent,0.6642857142857143
pathogen generative stage,systematic infection,0.6055555555555556
pathogen generative stage,infection incidence rate,0.6744897959183673
pathogen generative stage,virus host,0.5642857142857143
pathogen generative stage,double-stranded RNA virus,0.61
pathogen generative stage,pathogen portal of entry role,0.7092592592592593
pathogen generative stage,virus transcription stage,0.67
pathogen generative stage,infectious disease lifetime prevalence,0.6246031746031746
pathogen generative stage,pathogen birth temporal region,0.7227272727272727
pathogen generative stage,lower respiratory tract disease,0.6642857142857143
pathogen generative stage,infectious disease incidence proportion,0.60625
pathogen generative stage,opportunistic pathogen,0.6627659574468084
pathogen generative stage,virus generative stage,0.8117021276595744
pathogen generative stage,acute infectious disease course,0.6642857142857143
pathogen generative stage,cidal agent disposition,0.6375
pathogen generative stage,genetic resistance to pathogen,0.6681818181818181
pathogen generative stage,subclinical infection,0.5804347826086956
pathogen generative stage,simple infection,0.6207317073170732
pathogen generative stage,biological vehicle,0.5895348837209302
pathogen generative stage,droplet pathogen transmission process,0.6758064516129032
pathogen generative stage,infectious disease sporadicity,0.6136363636363636
pathogen generative stage,infection incidence proportion profile,0.6404761904761905
pathogen generative stage,infectious agent colony,0.6166666666666667
pathogen generative stage,pathogen transporter,0.7611111111111112
pathogen generative stage,infectious disease epidemic,0.6038461538461539
pathogen generative stage,infectious agent generative stage,0.8293103448275861
pathogen generative stage,disease transmission model,0.6068627450980393
pathogen generative stage,pathologically immunosuppressed organism,0.65
pathogen generative stage,negative-sense single-stranded RNA virus,0.65
pathogen generative stage,cidal agent,0.6166666666666667
pathogen generative stage,pathogen vehicle,0.7426829268292683
pathogen generative stage,COVID-19 incidence rate,0.6375
pathogen generative stage,community-acquired infection,0.5820754716981132
pathogen generative stage,pathogen vector,0.75
pathogen generative stage,negative regulation of developmental process,0.6384057971014493
pathogen generative stage,pathogen vehicle role,0.7543478260869566
pathogen generative stage,chronic infectious disease course,0.656896551724138
pathogen generative stage,asymptomatic infectious agent carrier,0.6435483870967742
pathogen generative stage,nursing-home acquired infection,0.6107142857142857
pathogen generative stage,PCR product,0.5611111111111111
pathogen generative stage,secondary infection,0.609090909090909
pathogen generative stage,infection start temporal region,0.6285714285714286
pathogen generative stage,infection incidence,0.6318181818181818
pathogen generative stage,virus disorder,0.5525641025641026
pathogen generative stage,sterilizing immunity to infectious agent,0.6346153846153847
pathogen generative stage,primary infection,0.6166666666666667
pathogen generative stage,process of establishing an infection,0.6139344262295081
pathogen generative stage,SARS-CoV-2 uncoating stage,0.7049019607843137
pathogen generative stage,pathogen death process boundary,0.7178571428571427
pathogen generative stage,immunosuppressed organism,0.59
pathogen generative stage,plan specification,0.636046511627907
pathogen generative stage,innate immunity to infectious agent,0.6666666666666667
pathogen generative stage,SARS-CoV-2 penetration stage,0.7518867924528303
pathogen generative stage,virus adhesion susceptible cell,0.6464285714285714
pathogen generative stage,infection,0.5676470588235294
pathogen generative stage,static agent disposition,0.6540816326530612
pathogen generative stage,T cell receptor complex,0.6166666666666667
pathogen generative stage,infectious agent population,0.6230769230769231
pathogen generative stage,respiratory system disease,0.6656862745098039
pathogen generative stage,leukocyte-mediated immunity to infectious agent,0.6305555555555555
pathogen generative stage,indirect pathogen transmission process,0.6722222222222223
pathogen generative stage,organism population,0.609090909090909
pathogen generative stage,generative stage,0.8402439024390245
pathogen generative stage,humoral immunity to infectious agent,0.6467213114754098
pathogen generative stage,infectious disease control strategy,0.6333333333333333
pathogen generative stage,SARS-CoV-2 attachment stage,0.6807692307692308
pathogen generative stage,parasite,0.6621212121212122
pathogen generative stage,infectious disease pandemic,0.6230769230769231
pathogen generative stage,antibody reagent,0.6695121951219513
pathogen generative stage,infectious structure generative stage,0.7725806451612902
pathogen generative stage,viral disease course,0.6277777777777778
pathogen generative stage,intracellular infection,0.5958333333333333
pathogen generative stage,secondary infection role,0.6336734693877552
pathogen generative stage,metastatic infection,0.6055555555555556
pathogen generative stage,passive immunity to infectious agent,0.6631147540983606
pathogen generative stage,vaccination against infectious agent,0.6795081967213115
pathogen generative stage,acute infection,0.65
pathogen generative stage,susceptibility to infectious agent,0.6533898305084747
pathogen generative stage,epitope site,0.6662162162162162
pathogen generative stage,immunity to pathogen,0.6277777777777778
pathogen generative stage,source of infection role,0.6336734693877552
pathogen generative stage,pathogen host,0.7394736842105263
pathogen generative stage,chronic infection,0.6404761904761905
pathogen generative stage,disease course,0.6038461538461539
pathogen generative stage,infectious disease course,0.63
pathogen generative stage,acquired immunity to infectious agent,0.6435483870967742
pathogen generative stage,complex infection,0.6166666666666667
pathogen generative stage,COVID-19 disease incidence proportion,0.5951612903225807
pathogen generative stage,coronavirus disease course,0.6264705882352941
pathogen generative stage,biological vehicle role,0.6166666666666667
pathogen generative stage,infection incidence proportion,0.6318181818181818
pathogen generative stage,symptomatic infectious agent carrier,0.6467213114754098
pathogen generative stage,respiratory droplet virus fomite,0.6429824561403508
pathogen generative stage,susceptible organism,0.6277777777777778
pathogen generative stage,parasite role,0.6605263157894737
pathogen generative stage,pathogen vector role,0.7388888888888888
pathogen generative stage,pathogen portal of exit site,0.7518867924528303
pathogen generative stage,infectious disease prevalence,0.6166666666666667
pathogen generative stage,organism substance,0.6593023255813953
pathogen generative stage,SARS-CoV-2 genome replication stage,0.7333333333333333
pathogen generative stage,single-stranded DNA virus,0.61
pathogen generative stage,COVID-19 mortality rate,0.6166666666666667
pathogen generative stage,viral disease,0.6078947368421053
pathogen generative stage,primary infection role,0.6414893617021277
pathogen generative stage,pathogen portal of entry site,0.7462962962962962
pathogen generative stage,developmental process,0.6021739130434782
pathogen generative stage,infection incidence profile,0.6423076923076922
pathogen generative stage,disease,0.575
pathogen generative stage,site,0.553448275862069
pathogen generative stage,pathogen host role,0.7290697674418604
pathogen generative stage,infection prevalence,0.6277777777777778
pathogen generative stage,infectious pathogen transmissibility,0.6795081967213115
pathogen generative stage,pathogen surveillance,0.7543478260869566
pathogen generative stage,immunodeficient organism,0.6132653061224489
pathogen generative stage,pathogen,0.6924242424242425
pathogen generative stage,pathogen birth process boundary,0.7
pathogen generative stage,infectious human pathogen,0.61
pathogen generative stage,subclinical virus infection,0.5653846153846154
pathogen generative stage,resistance to pathogen,0.6202127659574468
pathogen generative stage,establishment of localization in virus host,0.6264705882352941
pathogen generative stage,immunization against infectious agent,0.6758064516129032
pathogen generative stage,virus attachment stage,0.7053191489361703
pathogen generative stage,SARS-CoV-2 transcription stage,0.6863636363636364
pathogen generative stage,virus synthesis stage,0.6673913043478261
pathogen generative stage,pathogen portal of exit role,0.7141509433962264
pathogen generative stage,infectious agent host,0.6673913043478261
pathogen generative stage,re-emerging pathogen,0.65
pathogen generative stage,long-term non-progressing infectious disease course,0.6342105263157894
pathogen generative stage,viral disease epidemic,0.598936170212766
pathogen generative stage,viral disease pandemic,0.6202127659574468
pathogen generative stage,virus penetration stage,0.7416666666666667
pathogen generative stage,pathogen seroprevalence,0.7416666666666667
pathogen generative stage,division of geopolitical entity,0.6107142857142857
pathogen generative stage,infectious disease endemicity,0.6166666666666667
pathogen generative stage,contact pathogen transmission process,0.6758064516129032
pathogen generative stage,herd immunity to infectious organism,0.6139344262295081
pathogen generative stage,extracellular infection,0.5958333333333333
pathogen generative stage,pathogen transporter role,0.75
pathogen generative stage,infectious agent reservoir,0.6460784313725491
pathogen generative stage,infection start process boundary,0.6078947368421053
pathogen generative stage,SARS-CoV-2 synthesis stage,0.6852941176470588
pathogen generative stage,infectious disease control objective specification,0.6233333333333334
pathogen generative stage,process of establishing viral infection,0.621875
pathogen generative stage,COVID-19 disease course,0.6166666666666667
pathogen generative stage,infectious disease incidence rate,0.6396551724137931
pathogen generative stage,single-stranded RNA retrovirus,0.6318181818181818
pathogen generative stage,active immunization against infectious agent,0.6528985507246376
pathogen generative stage,disordered virus,0.5963414634146341
pathogen generative stage,organism,0.6015151515151516
pathogen generative stage,virus uncoating stage,0.6891304347826087
pathogen generative stage,local infection,0.6
pathogen generative stage,infectious agent,0.6451219512195122
pathogen generative stage,establishment of a clinically abnormal colony,0.5785714285714285
pathogen generative stage,coronavirus disease,0.6318181818181818
pathogen generative stage,positive-sense single-stranded RNA virus,0.65
pathogen generative stage,horizontal pathogen transmission process,0.6653846153846155
pathogen generative stage,hospital-acquired infection,0.6038461538461539
pathogen generative stage,pathogen death temporal region,0.740909090909091
pathogen generative stage,emerging pathogen,0.6404761904761905
pathogen generative stage,drug susceptibility of infectious agent,0.6375
pathogen generative stage,SARS-CoV-2 release stage,0.7153061224489795
pathogen generative stage,static agent,0.6662162162162162
pathogen generative stage,pathogen transmission process,0.7092592592592593
geographical region,communicability end temporal region,0.6722222222222223
geographical region,geographical entity,0.8447368421052631
geographical region,infection end temporal region,0.7
geographical region,incubation end temporal region,0.6948979591836735
geographical region,two-dimensional spatial region,0.7357142857142857
geographical region,one-dimensional temporal region,0.71
geographical region,temporal region,0.8029411764705883
geographical region,disease surveillance objective specification,0.6087301587301588
geographical region,B cell receptor complex,0.5928571428571429
geographical region,double-stranded RNA virus,0.5863636363636363
geographical region,pathogen birth temporal region,0.7153061224489795
geographical region,lower respiratory tract disease,0.61
geographical region,infectious disease incidence proportion,0.6224137931034482
geographical region,acute infectious disease course,0.59
geographical region,communicability end process boundary,0.6318181818181818
geographical region,infection incidence proportion profile,0.6078947368421053
geographical region,SARS-CoV-2 incidence proportion,0.61
geographical region,spatiotemporal region,0.75
geographical region,latency end process boundary,0.598936170212766
geographical region,negative-sense single-stranded RNA virus,0.5855932203389831
geographical region,zero-dimensional spatial region,0.73
geographical region,zero-dimensional temporal region,0.7049019607843137
geographical region,chronic infectious disease course,0.5846153846153846
geographical region,infection start temporal region,0.71
geographical region,incubation end process boundary,0.61
geographical region,geographical region,0.95
geographical region,latency end temporal region,0.7108695652173913
geographical region,T cell receptor complex,0.5928571428571429
geographical region,viral disease course,0.6294871794871795
geographical region,three-dimensional spatial region,0.7245098039215686
geographical region,objective specification,0.6404761904761905
geographical region,country,0.5653846153846154
geographical region,disease course,0.6015151515151516
geographical region,infectious disease course,0.609090909090909
geographical region,COVID-19 disease incidence proportion,0.6107142857142857
geographical region,coronavirus disease course,0.6277777777777778
geographical region,infection incidence proportion,0.6336734693877552
geographical region,place closure control strategy,0.6336734693877552
geographical region,object,0.53
geographical region,object aggregate,0.6214285714285714
geographical region,long-term non-progressing infectious disease course,0.6071428571428572
geographical region,communicability start temporal region,0.6642857142857143
geographical region,geospatial region,0.8388888888888889
geographical region,division of geopolitical entity,0.67
geographical region,geographical feature,0.8346153846153846
geographical region,infectious disease control objective specification,0.5949275362318841
geographical region,COVID-19 disease course,0.5928571428571429
geographical region,single-stranded RNA retrovirus,0.6336734693877552
geographical region,local infection,0.7147058823529412
geographical region,establishment of a clinically abnormal colony,0.621875
geographical region,positive-sense single-stranded RNA virus,0.5686440677966101
geographical region,one-dimensional spatial region,0.7357142857142857
geographical region,spatial region,0.7833333333333333
geographical region,pathogen death temporal region,0.7153061224489795
infectious disease prevalence,virus aggregate,0.6545454545454545
infectious disease prevalence,source of infection,0.6375
infectious disease prevalence,virostatic disposition,0.6264705882352941
infectious disease prevalence,zoonotic disposition,0.6336734693877552
infectious disease prevalence,infectious disease mortality rate,0.8209677419354838
infectious disease prevalence,infection incidence rate profile,0.7450819672131148
infectious disease prevalence,infectious structure aggregate,0.7550847457627118
infectious disease prevalence,communicability end temporal region,0.653125
infectious disease prevalence,subclinical coronavirus infection,0.6112903225806451
infectious disease prevalence,infection end temporal region,0.743103448275862
infectious disease prevalence,vector control strategy,0.6230769230769231
infectious disease prevalence,infectious disease,0.8329787234042553
infectious disease prevalence,double-stranded DNA virus,0.5981481481481481
infectious disease prevalence,incubation end temporal region,0.7042372881355932
infectious disease prevalence,site of infection,0.6456521739130434
infectious disease prevalence,virulence factor disposition,0.6605263157894737
infectious disease prevalence,viral adhesion disposition,0.6318181818181818
infectious disease prevalence,parasitostatic disposition,0.6318181818181818
infectious disease prevalence,infectious disease incidence,0.8535087719298246
infectious disease prevalence,reverse zoonotic disposition,0.6078947368421053
infectious disease prevalence,subclinical SARS-CoV-2 infection,0.6139344262295081
infectious disease prevalence,virus translation stage,0.6230769230769231
infectious disease prevalence,disease surveillance objective specification,0.6417808219178082
infectious disease prevalence,case isolation control strategy,0.6166666666666667
infectious disease prevalence,virus release stage,0.6791666666666666
infectious disease prevalence,infectious agent host role,0.759090909090909
infectious disease prevalence,asymptomatic infectious structure carrier,0.6785714285714286
infectious disease prevalence,source of infection site,0.6575471698113208
infectious disease prevalence,virus,0.5382352941176471
infectious disease prevalence,quarantine control strategy,0.6464285714285714
infectious disease prevalence,virus replication,0.6239130434782608
infectious disease prevalence,B cell receptor complex,0.6038461538461539
infectious disease prevalence,passive immunization against infectious agent,0.6391891891891892
infectious disease prevalence,systematic infection,0.6336734693877552
infectious disease prevalence,infection incidence rate,0.7518867924528303
infectious disease prevalence,virus host,0.5782051282051281
infectious disease prevalence,double-stranded RNA virus,0.5981481481481481
infectious disease prevalence,virus transcription stage,0.6351851851851852
infectious disease prevalence,infectious disease lifetime prevalence,0.8828358208955223
infectious disease prevalence,toxin disposition,0.6239130434782608
infectious disease prevalence,lower respiratory tract disease,0.6333333333333333
infectious disease prevalence,infectious disease incidence proportion,0.7882352941176471
infectious disease prevalence,virus generative stage,0.6460784313725491
infectious disease prevalence,acute infectious disease course,0.8
infectious disease prevalence,cidal agent disposition,0.6230769230769231
infectious disease prevalence,infectious disorder,0.7833333333333333
infectious disease prevalence,subclinical infection,0.63
infectious disease prevalence,appearance of disorder,0.6264705882352941
infectious disease prevalence,simple infection,0.65
infectious disease prevalence,parasiticidal disposition,0.6166666666666667
infectious disease prevalence,infectious disease sporadicity,0.8398305084745763
infectious disease prevalence,communicability end process boundary,0.6192307692307693
infectious disease prevalence,infection incidence proportion profile,0.703731343283582
infectious disease prevalence,infectious agent colony,0.7576923076923078
infectious disease prevalence,transmissibility disposition,0.6078947368421053
infectious disease prevalence,latency end process boundary,0.6078947368421053
infectious disease prevalence,infectious disease epidemic,0.8428571428571427
infectious disease prevalence,infectious agent generative stage,0.7403225806451613
infectious disease prevalence,disease transmission model,0.6681818181818181
infectious disease prevalence,endotoxin disposition,0.63
infectious disease prevalence,negative-sense single-stranded RNA virus,0.6384057971014493
infectious disease prevalence,infectious structure host role,0.7550847457627118
infectious disease prevalence,cytotoxin disposition,0.63
infectious disease prevalence,community-acquired infection,0.6078947368421053
infectious disease prevalence,chronic infectious disease course,0.7887096774193548
infectious disease prevalence,asymptomatic infectious agent carrier,0.6924242424242425
infectious disease prevalence,nursing-home acquired infection,0.6166666666666667
infectious disease prevalence,COVID-19 epidemic,0.6021739130434782
infectious disease prevalence,secondary infection,0.6375
infectious disease prevalence,infection start temporal region,0.75
infectious disease prevalence,infection incidence,0.7416666666666667
infectious disease prevalence,virus disorder,0.6593023255813953
infectious disease prevalence,sterilizing immunity to infectious agent,0.6528985507246376
infectious disease prevalence,diseased population,0.6791666666666666
infectious disease prevalence,primary infection,0.6456521739130434
infectious disease prevalence,process of establishing an infection,0.6038461538461539
infectious disease prevalence,incubation end process boundary,0.6666666666666667
infectious disease prevalence,SARS-CoV-2 disorder,0.6166666666666667
infectious disease prevalence,collective pathogenic disposition,0.6274193548387097
infectious disease prevalence,neurotoxin disposition,0.6460784313725491
infectious disease prevalence,latency end temporal region,0.6464285714285714
infectious disease prevalence,innate immunity to infectious agent,0.66875
infectious disease prevalence,infectious structure,0.7561224489795919
infectious disease prevalence,virus adhesion susceptible cell,0.6833333333333332
infectious disease prevalence,collective disposition,0.6460784313725491
infectious disease prevalence,infection,0.6868421052631578
infectious disease prevalence,static agent disposition,0.619811320754717
infectious disease prevalence,T cell receptor complex,0.6230769230769231
infectious disease prevalence,infectious structure host,0.7277777777777777
infectious disease prevalence,infectious agent population,0.7535714285714286
infectious disease prevalence,respiratory system disease,0.6681818181818181
infectious disease prevalence,leukocyte-mediated immunity to infectious agent,0.6342105263157894
infectious disease prevalence,humoral immunity to infectious agent,0.6653846153846155
infectious disease prevalence,infectious disease control strategy,0.79375
infectious disease prevalence,infectious disease pandemic,0.8607142857142857
infectious disease prevalence,infectious structure generative stage,0.7227272727272727
infectious disease prevalence,immunosuppressive disposition,0.6396551724137931
infectious disease prevalence,pathogenic disposition,0.6068627450980393
infectious disease prevalence,viral disease course,0.6948979591836735
infectious disease prevalence,intracellular infection,0.6230769230769231
infectious disease prevalence,secondary infection role,0.6764150943396227
infectious disease prevalence,metastatic infection,0.6336734693877552
infectious disease prevalence,passive immunity to infectious agent,0.6653846153846155
infectious disease prevalence,infectious disposition,0.7637254901960785
infectious disease prevalence,vaccination against infectious agent,0.6653846153846155
infectious disease prevalence,acute infection,0.6545454545454545
infectious disease prevalence,susceptibility to infectious agent,0.6722222222222223
infectious disease prevalence,bacteriostatic disposition,0.65
infectious disease prevalence,bactericidal disposition,0.619811320754717
infectious disease prevalence,source of infection role,0.6764150943396227
infectious disease prevalence,chronic infection,0.6456521739130434
infectious disease prevalence,invasion disposition,0.6540816326530612
infectious disease prevalence,disease course,0.6825581395348838
infectious disease prevalence,infectious disease course,0.8388888888888889
infectious disease prevalence,viricidal disposition,0.63
infectious disease prevalence,acquired immunity to infectious agent,0.6621212121212122
infectious disease prevalence,complex infection,0.6456521739130434
infectious disease prevalence,COVID-19 disease incidence proportion,0.6772727272727272
infectious disease prevalence,coronavirus disease course,0.7227272727272727
infectious disease prevalence,infection incidence proportion,0.7211864406779661
infectious disease prevalence,symptomatic infectious agent carrier,0.6961538461538461
infectious disease prevalence,respiratory droplet virus fomite,0.5975409836065574
infectious disease prevalence,infectious disease prevalence,0.95
infectious disease prevalence,disposition,0.575
infectious disease prevalence,single-stranded DNA virus,0.6166666666666667
infectious disease prevalence,infected population,0.6791666666666666
infectious disease prevalence,place closure control strategy,0.6025423728813559
infectious disease prevalence,viral disease,0.6642857142857143
infectious disease prevalence,primary infection role,0.6852941176470588
infectious disease prevalence,adhesion disposition,0.6336734693877552
infectious disease prevalence,infection incidence profile,0.7535714285714286
infectious disease prevalence,disease,0.6444444444444444
infectious disease prevalence,symptomatic infectious structure carrier,0.6818840579710145
infectious disease prevalence,primary infectious disposition,0.7211864406779661
infectious disease prevalence,infection prevalence,0.8377551020408163
infectious disease prevalence,coronavirus disorder,0.6540816326530612
infectious disease prevalence,infectious pathogen transmissibility,0.7115384615384616
infectious disease prevalence,incubation start process boundary,0.6758064516129032
infectious disease prevalence,infectious human pathogen,0.7648148148148148
infectious disease prevalence,subclinical virus infection,0.6285714285714286
infectious disease prevalence,establishment of localization in virus host,0.6027777777777777
infectious disease prevalence,immunization against infectious agent,0.6621212121212122
infectious disease prevalence,virus attachment stage,0.6264705882352941
infectious disease prevalence,virus synthesis stage,0.65
infectious disease prevalence,SARS-COV-2 adhesion disposition,0.6
infectious disease prevalence,invasive disposition,0.6336734693877552
infectious disease prevalence,infectious agent host,0.73
infectious disease prevalence,long-term non-progressing infectious disease course,0.7125
infectious disease prevalence,viral disease epidemic,0.7049019607843137
infectious disease prevalence,communicability start temporal region,0.6469696969696969
infectious disease prevalence,fungicidal disposition,0.6264705882352941
infectious disease prevalence,viral disease pandemic,0.7245098039215686
infectious disease prevalence,virus penetration stage,0.6423076923076922
infectious disease prevalence,acute respiratory distress syndrome,0.653125
infectious disease prevalence,infectious disease endemicity,0.8293103448275861
infectious disease prevalence,disorder,0.5851351351351352
infectious disease prevalence,herd immunity to infectious organism,0.6653846153846155
infectious disease prevalence,extracellular infection,0.6230769230769231
infectious disease prevalence,exotoxin disposition,0.6336734693877552
infectious disease prevalence,infectious agent reservoir,0.759090909090909
infectious disease prevalence,COVID-19 pandemic,0.6239130434782608
infectious disease prevalence,infection start process boundary,0.7122950819672131
infectious disease prevalence,latency start process boundary,0.6194915254237288
infectious disease prevalence,infectious disease control objective specification,0.7537974683544304
infectious disease prevalence,COVID-19 lifetime prevalence,0.7482456140350877
infectious disease prevalence,opportunistic infectious disposition,0.6961538461538461
infectious disease prevalence,process of establishing viral infection,0.6264705882352941
infectious disease prevalence,enterotoxin disposition,0.6423076923076922
infectious disease prevalence,COVID-19 disease course,0.7
infectious disease prevalence,infectious disease incidence rate,0.8209677419354838
infectious disease prevalence,communicability start process boundary,0.6141791044776119
infectious disease prevalence,COVID-19 prevalence,0.7416666666666667
infectious disease prevalence,active immunization against infectious agent,0.6417808219178082
infectious disease prevalence,SARS-COV-2 prevalence,0.73
infectious disease prevalence,disordered virus,0.6055555555555556
infectious disease prevalence,collective resistance disposition,0.6435483870967742
infectious disease prevalence,fungistatic disposition,0.6230769230769231
infectious disease prevalence,virus uncoating stage,0.63
infectious disease prevalence,local infection,0.6545454545454545
infectious disease prevalence,infectious agent,0.7611111111111112
infectious disease prevalence,establishment of a clinically abnormal colony,0.6121621621621621
infectious disease prevalence,coronavirus disease,0.7
infectious disease prevalence,positive-sense single-stranded RNA virus,0.6239130434782608
infectious disease prevalence,hospital-acquired infection,0.6107142857142857
infectious disease prevalence,drug susceptibility of infectious agent,0.6558823529411765
cell,infectious disease mortality rate,0.5310810810810811
cell,infection incidence rate profile,0.5333333333333333
cell,SARS-CoV-2 incidence rate,0.5189655172413793
cell,immunocompetent organism,0.5214285714285714
cell,case isolation control strategy,0.5642857142857143
cell,B cell receptor complex,0.5981481481481481
cell,infection incidence rate,0.5214285714285714
cell,pathologically immunosuppressed organism,0.5181818181818182
cell,COVID-19 incidence rate,0.524074074074074
cell,virus adhesion susceptible cell,0.5642857142857143
cell,T cell receptor complex,0.5981481481481481
cell,cell,0.95
cell,susceptible organism,0.575
cell,organism substance,0.5409090909090909
cell,COVID-19 mortality rate,0.524074074074074
cell,place closure control strategy,0.5676470588235294
cell,SARS-COV-2 adhesion susceptible cell,0.55
cell,immunodeficient organism,0.5214285714285714
cell,division of geopolitical entity,0.5357142857142857
cell,infectious disease incidence rate,0.504054054054054
cell,establishment of a clinically abnormal colony,0.5112244897959184
cell,cell space,0.7357142857142857
prion replication,infectious disease mortality rate,0.61
prion replication,infection incidence rate profile,0.6336734693877552
prion replication,coronavirus replication,0.825
prion replication,SARS-CoV-2 incidence rate,0.6166666666666667
prion replication,prion replication,0.95
prion replication,negative regulation of production,0.67
prion replication,virus replication,0.8323529411764706
prion replication,B cell receptor complex,0.6
prion replication,infection incidence rate,0.6451219512195122
prion replication,virus transcription stage,0.6404761904761905
prion replication,appearance of disorder,0.6038461538461539
prion replication,disease transmission model,0.6127906976744186
prion replication,COVID-19 incidence rate,0.6
prion replication,negative regulation of replication,0.7637254901960785
prion replication,PCR product,0.6642857142857143
prion replication,T cell receptor complex,0.6
prion replication,SARS-CoV-2 replication,0.808974358974359
prion replication,disordered prion,0.6924242424242425
prion replication,prion aggregate,0.7625
prion replication,SARS-CoV-2 genome replication stage,0.7384615384615384
prion replication,production,0.7462962962962962
prion replication,COVID-19 mortality rate,0.625
prion replication,contact tracing,0.66875
prion replication,replication,0.8428571428571427
prion replication,SARS-CoV-2 transcription stage,0.6414893617021277
prion replication,infectious disease incidence rate,0.61
prion replication,establishment of a clinically abnormal colony,0.5951612903225807
prion replication,prion,0.6772727272727272
exotoxin disposition,virostatic disposition,0.8071428571428573
exotoxin disposition,information content entity,0.6239130434782608
exotoxin disposition,zoonotic disposition,0.825
exotoxin disposition,infectious disease mortality rate,0.6386792452830189
exotoxin disposition,infection incidence rate profile,0.6230769230769231
exotoxin disposition,infectious structure aggregate,0.57
exotoxin disposition,communicability end temporal region,0.6136363636363636
exotoxin disposition,geographical entity,0.6038461538461539
exotoxin disposition,biological regulation,0.6451219512195122
exotoxin disposition,surveillance process,0.625
exotoxin disposition,infection end temporal region,0.6744897959183673
exotoxin disposition,vector control strategy,0.6127906976744186
exotoxin disposition,SARS-CoV-2 incidence rate,0.5611111111111111
exotoxin disposition,incubation end temporal region,0.65
exotoxin disposition,resistant entity,0.6166666666666667
exotoxin disposition,virulence factor disposition,0.7625
exotoxin disposition,viral adhesion disposition,0.7760869565217391
exotoxin disposition,parasitostatic disposition,0.7760869565217391
exotoxin disposition,negative regulation of production,0.6575471698113208
exotoxin disposition,reverse zoonotic disposition,0.7833333333333333
exotoxin disposition,establishment of localization in host,0.6429824561403508
exotoxin disposition,disease surveillance objective specification,0.6375
exotoxin disposition,case isolation control strategy,0.6264705882352941
exotoxin disposition,infectious agent host role,0.6456521739130434
exotoxin disposition,macromolecular complex,0.5452380952380953
exotoxin disposition,material entity,0.5928571428571429
exotoxin disposition,asymptomatic infectious structure carrier,0.5975409836065574
exotoxin disposition,architectual structure,0.569047619047619
exotoxin disposition,quarantine control strategy,0.598936170212766
exotoxin disposition,B cell receptor complex,0.5662790697674418
exotoxin disposition,infection incidence rate,0.6318181818181818
exotoxin disposition,colonized host,0.6558823529411765
exotoxin disposition,virus host,0.6166666666666667
exotoxin disposition,entity,0.6038461538461539
exotoxin disposition,toxin disposition,0.9094594594594595
exotoxin disposition,cidal agent disposition,0.7755813953488372
exotoxin disposition,parasiticidal disposition,0.7611111111111112
exotoxin disposition,communicability end process boundary,0.6107142857142857
exotoxin disposition,directive information content entity,0.6285714285714286
exotoxin disposition,acellular structure aggregate,0.5316326530612244
exotoxin disposition,transmissibility disposition,0.7416666666666667
exotoxin disposition,latency end process boundary,0.6375
exotoxin disposition,colonization of host,0.65
exotoxin disposition,realizable entity,0.5851351351351352
exotoxin disposition,endotoxin disposition,0.9134146341463415
exotoxin disposition,vector surveillance,0.6294871794871795
exotoxin disposition,negative regulation of establishment of localization,0.6305555555555555
exotoxin disposition,infectious structure host role,0.63
exotoxin disposition,COVID-19 incidence rate,0.5895348837209302
exotoxin disposition,cytotoxin disposition,0.8890243902439025
exotoxin disposition,negative regulation of developmental process,0.590625
exotoxin disposition,host,0.575
exotoxin disposition,descriptive information content entity,0.6224137931034482
exotoxin disposition,negative regulation of replication,0.6537037037037037
exotoxin disposition,establishment of localization in human host,0.6246031746031746
exotoxin disposition,acellular structure,0.5525641025641026
exotoxin disposition,incubation end process boundary,0.6460784313725491
exotoxin disposition,collective pathogenic disposition,0.7518867924528303
exotoxin disposition,neurotoxin disposition,0.9023809523809524
exotoxin disposition,dead-end host role,0.6342105263157894
exotoxin disposition,molecular entity,0.5611111111111111
exotoxin disposition,plan specification,0.6868421052631578
exotoxin disposition,definitive host role,0.65
exotoxin disposition,latency end temporal region,0.6414893617021277
exotoxin disposition,infectious structure,0.6
exotoxin disposition,collective disposition,0.8071428571428573
exotoxin disposition,static agent disposition,0.7909090909090909
exotoxin disposition,T cell receptor complex,0.5662790697674418
exotoxin disposition,infectious structure host,0.6277777777777778
exotoxin disposition,respiratory system disease,0.6239130434782608
exotoxin disposition,entry into host,0.6785714285714286
exotoxin disposition,adhesion of symbiont to host,0.6375
exotoxin disposition,infectious disease control strategy,0.6318181818181818
exotoxin disposition,infectious structure generative stage,0.5728070175438597
exotoxin disposition,immunosuppressive disposition,0.7357142857142857
exotoxin disposition,pathogenic disposition,0.8071428571428573
exotoxin disposition,toxin,0.65
exotoxin disposition,entry into host through host barriers,0.6254385964912281
exotoxin disposition,infectious disposition,0.8071428571428573
exotoxin disposition,bacteriostatic disposition,0.7978260869565217
exotoxin disposition,bactericidal disposition,0.7681818181818181
exotoxin disposition,pathogen host,0.6621212121212122
exotoxin disposition,invasion disposition,0.8
exotoxin disposition,viricidal disposition,0.7670731707317073
exotoxin disposition,complex infection,0.6662162162162162
exotoxin disposition,intermediate host,0.6391891891891892
exotoxin disposition,anatomical entity,0.6121621621621621
exotoxin disposition,disposition,0.8048387096774193
exotoxin disposition,COVID-19 mortality rate,0.5895348837209302
exotoxin disposition,negative regulation of life-sustaining process,0.6166666666666667
exotoxin disposition,place closure control strategy,0.59
exotoxin disposition,geopolitical entity,0.6551282051282051
exotoxin disposition,adhesion disposition,0.825
exotoxin disposition,symptomatic infectious structure carrier,0.6
exotoxin disposition,primary infectious disposition,0.75
exotoxin disposition,pathogen host role,0.6605263157894737
exotoxin disposition,designative information content entity,0.6224137931034482
exotoxin disposition,intermediate host role,0.6404761904761905
exotoxin disposition,dead-end host,0.6318181818181818
exotoxin disposition,pathogen surveillance,0.6207317073170732
exotoxin disposition,host role,0.5879310344827586
exotoxin disposition,establishment of localization in virus host,0.6404761904761905
exotoxin disposition,negative regulation of immune response,0.6224137931034482
exotoxin disposition,immaterial entity,0.5851351351351352
exotoxin disposition,SARS-COV-2 adhesion disposition,0.7441176470588234
exotoxin disposition,invasive disposition,0.8
exotoxin disposition,infectious agent host,0.6451219512195122
exotoxin disposition,exotoxin,0.7357142857142857
exotoxin disposition,fungicidal disposition,0.7595238095238095
exotoxin disposition,division of geopolitical entity,0.6264705882352941
exotoxin disposition,negative regulation of viral process,0.6107142857142857
exotoxin disposition,exotoxin disposition,0.95
exotoxin disposition,immunoglobulin complex,0.5928571428571429
exotoxin disposition,infectious disease control objective specification,0.65
exotoxin disposition,symbiont host role,0.6342105263157894
exotoxin disposition,opportunistic infectious disposition,0.7357142857142857
exotoxin disposition,negative regulation of biological process,0.5975409836065574
exotoxin disposition,enterotoxin disposition,0.891860465116279
exotoxin disposition,infectious disease incidence rate,0.6575471698113208
exotoxin disposition,collective resistance disposition,0.7518867924528303
exotoxin disposition,fungistatic disposition,0.7755813953488372
exotoxin disposition,establishment of a clinically abnormal colony,0.6038461538461539
exotoxin disposition,definitive host,0.65
entry into host through host barriers,virostatic disposition,0.6194915254237288
entry into host through host barriers,zoonotic disposition,0.6078947368421053
entry into host through host barriers,pathogen portal of entry,0.6139344262295081
entry into host through host barriers,virulence factor disposition,0.6192307692307693
entry into host through host barriers,pathogen portal of exit,0.6
entry into host through host barriers,viral adhesion disposition,0.6087301587301588
entry into host through host barriers,parasitostatic disposition,0.6404761904761905
entry into host through host barriers,reverse zoonotic disposition,0.6192307692307693
entry into host through host barriers,establishment of localization in host,0.6527027027027027
entry into host through host barriers,infectious agent host role,0.6880952380952381
entry into host through host barriers,B cell receptor complex,0.5833333333333334
entry into host through host barriers,colonized host,0.5872549019607843
entry into host through host barriers,virus host,0.6202127659574468
entry into host through host barriers,pathogen portal of entry role,0.6318181818181818
entry into host through host barriers,toxin disposition,0.6166666666666667
entry into host through host barriers,acute infectious disease course,0.6411764705882353
entry into host through host barriers,cidal agent disposition,0.6166666666666667
entry into host through host barriers,appearance of disorder,0.6194915254237288
entry into host through host barriers,parasiticidal disposition,0.5951612903225807
entry into host through host barriers,communicability end process boundary,0.6280821917808219
entry into host through host barriers,transmissibility disposition,0.6038461538461539
entry into host through host barriers,latency end process boundary,0.65
entry into host through host barriers,colonization of host,0.6429824561403508
entry into host through host barriers,endotoxin disposition,0.6396551724137931
entry into host through host barriers,infectious structure host role,0.703731343283582
entry into host through host barriers,cytotoxin disposition,0.6224137931034482
entry into host through host barriers,host,0.5475609756097561
entry into host through host barriers,chronic infectious disease course,0.6357142857142857
entry into host through host barriers,establishment of localization in human host,0.6625
entry into host through host barriers,incubation end process boundary,0.6411764705882353
entry into host through host barriers,collective pathogenic disposition,0.6357142857142857
entry into host through host barriers,neurotoxin disposition,0.6194915254237288
entry into host through host barriers,dead-end host role,0.65
entry into host through host barriers,pathogen death process boundary,0.6411764705882353
entry into host through host barriers,definitive host role,0.6780701754385965
entry into host through host barriers,collective disposition,0.6025423728813559
entry into host through host barriers,static agent disposition,0.6139344262295081
entry into host through host barriers,T cell receptor complex,0.5833333333333334
entry into host through host barriers,infectious structure host,0.6758064516129032
entry into host through host barriers,entry into host,0.7384615384615384
entry into host through host barriers,adhesion of symbiont to host,0.6807692307692308
entry into host through host barriers,immunosuppressive disposition,0.6015151515151516
entry into host through host barriers,pathogenic disposition,0.6025423728813559
entry into host through host barriers,viral disease course,0.6078947368421053
entry into host through host barriers,entry into host through host barriers,0.95
entry into host through host barriers,infectious disposition,0.6194915254237288
entry into host through host barriers,bacteriostatic disposition,0.6404761904761905
entry into host through host barriers,bactericidal disposition,0.5975409836065574
entry into host through host barriers,pathogen host,0.63
entry into host through host barriers,invasion disposition,0.6078947368421053
entry into host through host barriers,disease course,0.5872549019607843
entry into host through host barriers,infectious disease course,0.6274193548387097
entry into host through host barriers,viricidal disposition,0.5879310344827586
entry into host through host barriers,coronavirus disease course,0.6087301587301588
entry into host through host barriers,intermediate host,0.6351851851851852
entry into host through host barriers,pathogen portal of exit site,0.6346153846153847
entry into host through host barriers,disposition,0.575
entry into host through host barriers,contact tracing,0.6038461538461539
entry into host through host barriers,place closure control strategy,0.6440298507462687
entry into host through host barriers,adhesion disposition,0.6078947368421053
entry into host through host barriers,pathogen portal of entry site,0.6469696969696969
entry into host through host barriers,primary infectious disposition,0.6440298507462687
entry into host through host barriers,pathogen host role,0.6681818181818181
entry into host through host barriers,incubation start process boundary,0.6642857142857143
entry into host through host barriers,intermediate host role,0.6872881355932203
entry into host through host barriers,dead-end host,0.59
entry into host through host barriers,host role,0.6239130434782608
entry into host through host barriers,pathogen birth process boundary,0.6558823529411765
entry into host through host barriers,establishment of localization in virus host,0.6625
entry into host through host barriers,SARS-COV-2 adhesion disposition,0.6117647058823529
entry into host through host barriers,pathogen portal of exit role,0.6346153846153847
entry into host through host barriers,invasive disposition,0.5903508771929825
entry into host through host barriers,infectious agent host,0.656896551724138
entry into host through host barriers,long-term non-progressing infectious disease course,0.6545454545454545
entry into host through host barriers,fungicidal disposition,0.5855932203389831
entry into host through host barriers,division of geopolitical entity,0.5970588235294118
entry into host through host barriers,contact pathogen transmission process,0.6391891891891892
entry into host through host barriers,exotoxin disposition,0.6254385964912281
entry into host through host barriers,infection start process boundary,0.6673913043478261
entry into host through host barriers,latency start process boundary,0.658955223880597
entry into host through host barriers,symbiont host role,0.6863636363636364
entry into host through host barriers,opportunistic infectious disposition,0.6280821917808219
entry into host through host barriers,enterotoxin disposition,0.65
entry into host through host barriers,COVID-19 disease course,0.5833333333333334
entry into host through host barriers,communicability start process boundary,0.6366666666666667
entry into host through host barriers,collective resistance disposition,0.6071428571428572
entry into host through host barriers,fungistatic disposition,0.6166666666666667
entry into host through host barriers,establishment of a clinically abnormal colony,0.5963414634146341
entry into host through host barriers,process boundary,0.6009433962264151
entry into host through host barriers,definitive host,0.6230769230769231
infectious agent reservoir,source of infection,0.65
infectious agent reservoir,information content entity,0.7
infectious agent reservoir,infectious disease mortality rate,0.738135593220339
infectious agent reservoir,infection incidence rate profile,0.743103448275862
infectious agent reservoir,infectious structure aggregate,0.7357142857142857
infectious agent reservoir,communicability end temporal region,0.630327868852459
infectious agent reservoir,infection end temporal region,0.740909090909091
infectious agent reservoir,infectious disease,0.7681818181818181
infectious agent reservoir,SARS-CoV-2 incidence rate,0.6264705882352941
infectious agent reservoir,incubation end temporal region,0.7
infectious agent reservoir,virulence factor disposition,0.6351851851851852
infectious agent reservoir,infectious disease incidence,0.7462962962962962
infectious agent reservoir,reservoir of pathogen role,0.6615384615384616
infectious agent reservoir,disease surveillance objective specification,0.6071428571428572
infectious agent reservoir,infectious agent host role,0.8346153846153846
infectious agent reservoir,asymptomatic infectious structure carrier,0.703731343283582
infectious agent reservoir,source of infection site,0.69
infectious agent reservoir,B cell receptor complex,0.6132653061224489
infectious agent reservoir,passive immunization against infectious agent,0.6753521126760563
infectious agent reservoir,infection incidence rate,0.73
infectious agent reservoir,infectious disease lifetime prevalence,0.73125
infectious agent reservoir,lower respiratory tract disease,0.6254385964912281
infectious agent reservoir,infectious disease incidence proportion,0.7423076923076922
infectious agent reservoir,acute infectious disease course,0.7482456140350877
infectious agent reservoir,cidal agent disposition,0.6948979591836735
infectious agent reservoir,infectious disorder,0.7611111111111112
infectious agent reservoir,biological vehicle,0.5863636363636363
infectious agent reservoir,infectious disease sporadicity,0.7535714285714286
infectious agent reservoir,communicability end process boundary,0.6435483870967742
infectious agent reservoir,directive information content entity,0.6596774193548387
infectious agent reservoir,infectious agent colony,0.8173469387755102
infectious agent reservoir,pathogen transporter,0.6673913043478261
infectious agent reservoir,invasion factor,0.6695121951219513
infectious agent reservoir,latency end process boundary,0.6537037037037037
infectious agent reservoir,infectious disease epidemic,0.7707547169811321
infectious agent reservoir,infectious agent generative stage,0.8059322033898306
infectious agent reservoir,disease transmission model,0.6038461538461539
infectious agent reservoir,cidal agent,0.6662162162162162
infectious agent reservoir,infectious structure host role,0.7535714285714286
infectious agent reservoir,pathogen vehicle,0.6404761904761905
infectious agent reservoir,COVID-19 incidence rate,0.6336734693877552
infectious agent reservoir,pathogen vehicle role,0.6627659574468084
infectious agent reservoir,chronic infectious disease course,0.738135593220339
infectious agent reservoir,asymptomatic infectious agent carrier,0.7833333333333333
infectious agent reservoir,descriptive information content entity,0.653125
infectious agent reservoir,COVID-19 epidemic,0.5895348837209302
infectious agent reservoir,sterilizing immunity to infectious agent,0.6924242424242425
infectious agent reservoir,diseased population,0.6055555555555556
infectious agent reservoir,virulence factor,0.6404761904761905
infectious agent reservoir,incubation end process boundary,0.7131578947368421
infectious agent reservoir,latency end temporal region,0.6386792452830189
infectious agent reservoir,innate immunity to infectious agent,0.7122950819672131
infectious agent reservoir,infectious structure,0.7543478260869566
infectious agent reservoir,static agent disposition,0.69
infectious agent reservoir,T cell receptor complex,0.6336734693877552
infectious agent reservoir,asymptomatic carrier role,0.6264705882352941
infectious agent reservoir,infectious structure host,0.7441176470588234
infectious agent reservoir,infectious agent population,0.808490566037736
infectious agent reservoir,respiratory system disease,0.6230769230769231
infectious agent reservoir,leukocyte-mediated immunity to infectious agent,0.6691780821917809
infectious agent reservoir,humoral immunity to infectious agent,0.7080645161290323
infectious agent reservoir,infectious disease control strategy,0.7450819672131148
infectious agent reservoir,infectious disease pandemic,0.7518867924528303
infectious agent reservoir,infectious structure generative stage,0.7357142857142857
infectious agent reservoir,viral disease course,0.6456521739130434
infectious agent reservoir,passive immunity to infectious agent,0.7080645161290323
infectious agent reservoir,infectious disposition,0.7416666666666667
infectious agent reservoir,vaccination against infectious agent,0.7080645161290323
infectious agent reservoir,susceptibility to infectious agent,0.7166666666666667
infectious agent reservoir,source of infection role,0.69
infectious agent reservoir,disease course,0.65
infectious agent reservoir,infectious disease course,0.7833333333333333
infectious agent reservoir,acquired immunity to infectious agent,0.7039682539682539
infectious agent reservoir,COVID-19 disease incidence proportion,0.6246031746031746
infectious agent reservoir,coronavirus disease course,0.6615384615384616
infectious agent reservoir,asymptomatic carrier,0.6456521739130434
infectious agent reservoir,biological vehicle role,0.6132653061224489
infectious agent reservoir,symptomatic infectious agent carrier,0.7887096774193548
infectious agent reservoir,intermediate host,0.636046511627907
infectious agent reservoir,infectious disease prevalence,0.759090909090909
infectious agent reservoir,infected population,0.6944444444444444
infectious agent reservoir,COVID-19 mortality rate,0.6132653061224489
infectious agent reservoir,viral disease,0.6038461538461539
infectious agent reservoir,disease,0.6015151515151516
infectious agent reservoir,symptomatic infectious structure carrier,0.7075757575757575
infectious agent reservoir,primary infectious disposition,0.7
infectious agent reservoir,designative information content entity,0.653125
infectious agent reservoir,symptomatic carrier role,0.63
infectious agent reservoir,infectious pathogen transmissibility,0.7564516129032257
infectious agent reservoir,intermediate host role,0.6583333333333334
infectious agent reservoir,infectious human pathogen,0.7441176470588234
infectious agent reservoir,immunization against infectious agent,0.7039682539682539
infectious agent reservoir,infectious agent host,0.8329787234042553
infectious agent reservoir,long-term non-progressing infectious disease course,0.6707792207792208
infectious agent reservoir,viral disease epidemic,0.6375
infectious agent reservoir,viral disease pandemic,0.6166666666666667
infectious agent reservoir,symptomatic carrier,0.65
infectious agent reservoir,infectious disease endemicity,0.759090909090909
infectious agent reservoir,function,0.6264705882352941
infectious agent reservoir,herd immunity to infectious organism,0.6758064516129032
infectious agent reservoir,pathogen transporter role,0.6656862745098039
infectious agent reservoir,infectious agent reservoir,0.95
infectious agent reservoir,COVID-19 pandemic,0.6127906976744186
infectious agent reservoir,action specification,0.6456521739130434
infectious agent reservoir,infectious disease control objective specification,0.7131578947368421
infectious agent reservoir,opportunistic infectious disposition,0.6758064516129032
infectious agent reservoir,polymerase chain reaction,0.6264705882352941
infectious agent reservoir,COVID-19 disease course,0.6336734693877552
infectious agent reservoir,infectious disease incidence rate,0.738135593220339
infectious agent reservoir,active immunization against infectious agent,0.6785714285714286
infectious agent reservoir,infectious agent,0.830952380952381
infectious agent reservoir,establishment of a clinically abnormal colony,0.6049295774647887
infectious agent reservoir,coronavirus disease,0.6277777777777778
infectious agent reservoir,adhesion factor,0.6451219512195122
infectious agent reservoir,drug susceptibility of infectious agent,0.6961538461538461
infectious agent reservoir,static agent,0.6605263157894737
virus replication,extended organism,0.5676470588235294
virus replication,virus aggregate,0.7625
virus replication,source of infection,0.7
virus replication,virostatic disposition,0.732051282051282
virus replication,zoonotic disposition,0.6662162162162162
virus replication,immune response,0.7
virus replication,infectious disease mortality rate,0.63
virus replication,infection incidence rate profile,0.5928571428571429
virus replication,communicability end temporal region,0.6038461538461539
virus replication,pathogen generative stage,0.569047619047619
virus replication,pathogen portal of entry,0.5719512195121951
virus replication,subclinical coronavirus infection,0.69
virus replication,primary pathogen,0.6924242424242425
virus replication,infection end temporal region,0.6239130434782608
virus replication,drug-based immunosuppressed organism,0.6009433962264151
virus replication,coronavirus replication,0.875
virus replication,infectious disease,0.6214285714285714
virus replication,SARS-CoV-2 incidence rate,0.6166666666666667
virus replication,double-stranded DNA virus,0.5928571428571429
virus replication,incubation end temporal region,0.6414893617021277
virus replication,site of infection,0.6852941176470588
virus replication,immunocompetent organism,0.5963414634146341
virus replication,virulence factor disposition,0.7166666666666667
virus replication,pathogen portal of exit,0.575
virus replication,viral adhesion disposition,0.7058139534883722
virus replication,parasitostatic disposition,0.6593023255813953
virus replication,infectious disease incidence,0.65
virus replication,prion replication,0.8323529411764706
virus replication,reservoir of pathogen role,0.6593023255813953
virus replication,negative regulation of production,0.67
virus replication,reverse zoonotic disposition,0.6722222222222223
virus replication,subclinical SARS-CoV-2 infection,0.6540816326530612
virus replication,virus translation stage,0.775
virus replication,disease surveillance objective specification,0.6631147540983606
virus replication,virus release stage,0.7555555555555555
virus replication,source of infection site,0.6695121951219513
virus replication,virus,0.6772727272727272
virus replication,virus replication,0.95
virus replication,B cell receptor complex,0.6
virus replication,systematic infection,0.6662162162162162
virus replication,infection incidence rate,0.6207317073170732
virus replication,virus host,0.7092592592592593
virus replication,double-stranded RNA virus,0.5928571428571429
virus replication,pathogen portal of entry role,0.558695652173913
virus replication,virus transcription stage,0.7357142857142857
virus replication,infectious disease lifetime prevalence,0.6318181818181818
virus replication,toxin disposition,0.6852941176470588
virus replication,pathogen birth temporal region,0.6414893617021277
virus replication,lower respiratory tract disease,0.6375
virus replication,infectious disease incidence proportion,0.6464285714285714
virus replication,opportunistic pathogen,0.6807692307692308
virus replication,virus generative stage,0.7064102564102563
virus replication,acute infectious disease course,0.5958333333333333
virus replication,cidal agent disposition,0.675
virus replication,infectious disorder,0.6166666666666667
virus replication,genetic resistance to pathogen,0.6627659574468084
virus replication,subclinical infection,0.6868421052631578
virus replication,appearance of disorder,0.5525641025641026
virus replication,simple infection,0.7227272727272727
virus replication,droplet pathogen transmission process,0.5981481481481481
virus replication,parasiticidal disposition,0.6642857142857143
virus replication,infectious disease sporadicity,0.6414893617021277
virus replication,communicability end process boundary,0.5820754716981132
virus replication,infection incidence proportion profile,0.5954545454545455
virus replication,pathogen transporter,0.5851351351351352
virus replication,transmissibility disposition,0.65
virus replication,latency end process boundary,0.5833333333333334
virus replication,infectious disease epidemic,0.6318181818181818
virus replication,disease transmission model,0.636046511627907
virus replication,endotoxin disposition,0.6605263157894737
virus replication,pathologically immunosuppressed organism,0.5903508771929825
virus replication,negative-sense single-stranded RNA virus,0.5728070175438597
virus replication,pathogen vehicle,0.6015151515151516
virus replication,COVID-19 incidence rate,0.625
virus replication,cytotoxin disposition,0.6605263157894737
virus replication,community-acquired infection,0.6722222222222223
virus replication,pathogen vector,0.60625
virus replication,pathogen vehicle role,0.581578947368421
virus replication,chronic infectious disease course,0.59
virus replication,nursing-home acquired infection,0.6791666666666666
virus replication,COVID-19 epidemic,0.6558823529411765
virus replication,negative regulation of replication,0.7441176470588234
virus replication,PCR product,0.6285714285714286
virus replication,secondary infection,0.6722222222222223
virus replication,infection start temporal region,0.6375
virus replication,infection incidence,0.6444444444444444
virus replication,virus disorder,0.7080645161290323
virus replication,primary infection,0.7147058823529412
virus replication,process of establishing an infection,0.6575471698113208
virus replication,incubation end process boundary,0.6166666666666667
virus replication,SARS-CoV-2 disorder,0.5888888888888889
virus replication,collective pathogenic disposition,0.63
virus replication,neurotoxin disposition,0.6551282051282051
virus replication,pathogen death process boundary,0.575
virus replication,immunosuppressed organism,0.6166666666666667
virus replication,latency end temporal region,0.609090909090909
virus replication,virus adhesion susceptible cell,0.6791666666666666
virus replication,collective disposition,0.6807692307692308
virus replication,infection,0.7192307692307692
virus replication,static agent disposition,0.6695121951219513
virus replication,T cell receptor complex,0.6
virus replication,respiratory system disease,0.6127906976744186
virus replication,indirect pathogen transmission process,0.6136363636363636
virus replication,organism population,0.7277777777777777
virus replication,infectious disease control strategy,0.6038461538461539
virus replication,infectious disease pandemic,0.6318181818181818
virus replication,immunosuppressive disposition,0.6891304347826087
virus replication,SARS-CoV-2 replication,0.808974358974359
virus replication,innate immune response,0.6551282051282051
virus replication,pathogenic disposition,0.6551282051282051
virus replication,viral disease course,0.6391891891891892
virus replication,intracellular infection,0.7
virus replication,secondary infection role,0.6451219512195122
virus replication,metastatic infection,0.6662162162162162
virus replication,infectious disposition,0.7064102564102563
virus replication,acute infection,0.7
virus replication,bacteriostatic disposition,0.6593023255813953
virus replication,immunity to pathogen,0.6662162162162162
virus replication,bactericidal disposition,0.6451219512195122
virus replication,source of infection role,0.6695121951219513
virus replication,pathogen host,0.6166666666666667
virus replication,acquired immunodeficiency,0.6404761904761905
virus replication,chronic infection,0.6852941176470588
virus replication,invasion disposition,0.6932432432432433
virus replication,disease course,0.6112903225806451
virus replication,infectious disease course,0.6166666666666667
virus replication,viricidal disposition,0.7131578947368421
virus replication,acquired immunity to infectious agent,0.6351851851851852
virus replication,complex infection,0.6852941176470588
virus replication,COVID-19 disease incidence proportion,0.6351851851851852
virus replication,coronavirus disease course,0.6593023255813953
virus replication,infection incidence proportion,0.6202127659574468
virus replication,respiratory droplet virus fomite,0.6336734693877552
virus replication,susceptible organism,0.6662162162162162
virus replication,pathogen vector role,0.5851351351351352
virus replication,pathogen portal of exit site,0.5833333333333334
virus replication,infectious disease prevalence,0.6239130434782608
virus replication,organism substance,0.5928571428571429
virus replication,SARS-CoV-2 genome replication stage,0.7192307692307692
virus replication,production,0.7092592592592593
virus replication,disposition,0.7357142857142857
virus replication,single-stranded DNA virus,0.5928571428571429
virus replication,COVID-19 mortality rate,0.65
virus replication,contact tracing,0.60625
virus replication,viral disease,0.65
virus replication,primary infection role,0.6807692307692308
virus replication,adhesion disposition,0.6662162162162162
virus replication,pathogen portal of entry site,0.558695652173913
virus replication,infection incidence profile,0.609090909090909
virus replication,disease,0.6166666666666667
virus replication,primary infectious disposition,0.6840425531914894
virus replication,pathogen host role,0.5928571428571429
virus replication,infection prevalence,0.6391891891891892
virus replication,replication,0.8428571428571427
virus replication,humoral immune response,0.65
virus replication,coronavirus disorder,0.6662162162162162
virus replication,infectious pathogen transmissibility,0.619811320754717
virus replication,pathogen surveillance,0.6078947368421053
virus replication,immunodeficient organism,0.6451219512195122
virus replication,pathogen,0.65
virus replication,pathogen birth process boundary,0.5958333333333333
virus replication,infectious human pathogen,0.6642857142857143
virus replication,subclinical virus infection,0.7227272727272727
virus replication,resistance to pathogen,0.6551282051282051
virus replication,establishment of localization in virus host,0.6166666666666667
virus replication,virus attachment stage,0.6807692307692308
virus replication,negative regulation of immune response,0.6318181818181818
virus replication,SARS-CoV-2 transcription stage,0.6414893617021277
virus replication,virus synthesis stage,0.6868421052631578
virus replication,SARS-COV-2 adhesion disposition,0.6583333333333334
virus replication,pathogen portal of exit role,0.5833333333333334
virus replication,invasive disposition,0.6932432432432433
virus replication,re-emerging pathogen,0.6391891891891892
virus replication,long-term non-progressing infectious disease course,0.5823529411764706
virus replication,viral disease epidemic,0.6807692307692308
virus replication,fungicidal disposition,0.6551282051282051
virus replication,viral disease pandemic,0.6551282051282051
virus replication,virus penetration stage,0.75
virus replication,pathogen seroprevalence,0.575
virus replication,acute respiratory distress syndrome,0.6423076923076922
virus replication,infectious disease endemicity,0.6239130434782608
virus replication,contact pathogen transmission process,0.5796296296296296
virus replication,disorder,0.61
virus replication,herd immunity to infectious organism,0.619811320754717
virus replication,extracellular infection,0.675
virus replication,pathogen transporter role,0.569047619047619
virus replication,transmission interval,0.6078947368421053
virus replication,exotoxin disposition,0.6662162162162162
virus replication,infection start process boundary,0.5928571428571429
virus replication,infectious disease control objective specification,0.658955223880597
virus replication,immune population,0.7441176470588234
virus replication,opportunistic infectious disposition,0.6575471698113208
virus replication,process of establishing viral infection,0.6464285714285714
virus replication,enterotoxin disposition,0.65
virus replication,COVID-19 disease course,0.6
virus replication,infectious disease incidence rate,0.63
virus replication,disordered virus,0.6015151515151516
virus replication,collective resistance disposition,0.65
virus replication,adaptive immune response,0.6695121951219513
virus replication,fungistatic disposition,0.675
virus replication,organism,0.57
virus replication,virus uncoating stage,0.7394736842105263
virus replication,local infection,0.66875
virus replication,establishment of a clinically abnormal colony,0.5951612903225807
virus replication,coronavirus disease,0.6722222222222223
virus replication,positive-sense single-stranded RNA virus,0.5728070175438597
virus replication,horizontal pathogen transmission process,0.5903508771929825
virus replication,hospital-acquired infection,0.6772727272727272
virus replication,pathogen death temporal region,0.598936170212766
virus replication,emerging pathogen,0.6558823529411765
virus replication,pathogen transmission process,0.5804347826086956
zero-dimensional temporal region,communicability end temporal region,0.7783582089552239
zero-dimensional temporal region,infection end temporal region,0.7942622950819671
zero-dimensional temporal region,incubation end temporal region,0.7887096774193548
zero-dimensional temporal region,two-dimensional spatial region,0.8370967741935484
zero-dimensional temporal region,one-dimensional temporal region,0.9103174603174602
zero-dimensional temporal region,temporal region,0.7691489361702127
zero-dimensional temporal region,disease surveillance objective specification,0.6342105263157894
zero-dimensional temporal region,material entity,0.6627659574468084
zero-dimensional temporal region,B cell receptor complex,0.6136363636363636
zero-dimensional temporal region,double-stranded RNA virus,0.6078947368421053
zero-dimensional temporal region,pathogen birth temporal region,0.7725806451612902
zero-dimensional temporal region,lower respiratory tract disease,0.6404761904761905
zero-dimensional temporal region,infectious disease incidence proportion,0.6612676056338028
zero-dimensional temporal region,acute infectious disease course,0.6246031746031746
zero-dimensional temporal region,communicability end process boundary,0.6411764705882353
zero-dimensional temporal region,infection incidence proportion profile,0.6357142857142857
zero-dimensional temporal region,SARS-CoV-2 incidence proportion,0.6722222222222223
zero-dimensional temporal region,spatiotemporal region,0.789622641509434
zero-dimensional temporal region,latency end process boundary,0.6
zero-dimensional temporal region,negative-sense single-stranded RNA virus,0.6444444444444444
zero-dimensional temporal region,zero-dimensional spatial region,0.8785714285714286
zero-dimensional temporal region,zero-dimensional temporal region,0.95
zero-dimensional temporal region,chronic infectious disease course,0.6346153846153847
zero-dimensional temporal region,infection start temporal region,0.7992063492063491
zero-dimensional temporal region,establishment of localization in human host,0.6233333333333334
zero-dimensional temporal region,incubation end process boundary,0.6404761904761905
zero-dimensional temporal region,geographical region,0.7049019607843137
zero-dimensional temporal region,latency end temporal region,0.7720338983050847
zero-dimensional temporal region,T cell receptor complex,0.6136363636363636
zero-dimensional temporal region,viral disease course,0.6230769230769231
zero-dimensional temporal region,three-dimensional spatial region,0.825
zero-dimensional temporal region,objective specification,0.6318181818181818
zero-dimensional temporal region,country,0.5525641025641026
zero-dimensional temporal region,disease course,0.6239130434782608
zero-dimensional temporal region,infectious disease course,0.6254385964912281
zero-dimensional temporal region,COVID-19 disease incidence proportion,0.6673913043478261
zero-dimensional temporal region,coronavirus disease course,0.6224137931034482
zero-dimensional temporal region,infection incidence proportion,0.6596774193548387
zero-dimensional temporal region,place closure control strategy,0.6435483870967742
zero-dimensional temporal region,object,0.5289473684210526
zero-dimensional temporal region,infectious human pathogen,0.6254385964912281
zero-dimensional temporal region,colonization of human,0.619811320754717
zero-dimensional temporal region,object aggregate,0.5958333333333333
zero-dimensional temporal region,long-term non-progressing infectious disease course,0.6307228915662652
zero-dimensional temporal region,communicability start temporal region,0.7688405797101449
zero-dimensional temporal region,geospatial region,0.7357142857142857
zero-dimensional temporal region,division of geopolitical entity,0.6880952380952381
zero-dimensional temporal region,processed material,0.65
zero-dimensional temporal region,infectious disease control objective specification,0.6573170731707317
zero-dimensional temporal region,COVID-19 disease course,0.6318181818181818
zero-dimensional temporal region,single-stranded RNA retrovirus,0.6435483870967742
zero-dimensional temporal region,local infection,0.6414893617021277
zero-dimensional temporal region,establishment of a clinically abnormal colony,0.6707792207792208
zero-dimensional temporal region,positive-sense single-stranded RNA virus,0.6444444444444444
zero-dimensional temporal region,one-dimensional spatial region,0.8370967741935484
zero-dimensional temporal region,spatial region,0.7108695652173913
zero-dimensional temporal region,pathogen death temporal region,0.7725806451612902
zero-dimensional temporal region,material processing,0.6852941176470588
organism population,extended organism,0.6722222222222223
organism population,angiotensin-converting enzyme 2,0.61
organism population,information content entity,0.6277777777777778
organism population,infectious disease mortality rate,0.6038461538461539
organism population,infection incidence rate profile,0.5872549019607843
organism population,infectious structure aggregate,0.5928571428571429
organism population,geographical entity,0.6342105263157894
organism population,drug-based immunosuppressed organism,0.6136363636363636
organism population,SARS-CoV-2 incidence rate,0.5863636363636363
organism population,resistant entity,0.6214285714285714
organism population,normal resident microbiota population,0.7357142857142857
organism population,immunocompetent organism,0.636046511627907
organism population,virulence factor disposition,0.6627659574468084
organism population,reservoir of pathogen role,0.65
organism population,case isolation control strategy,0.65
organism population,infectious agent host role,0.6055555555555556
organism population,material entity,0.5970588235294118
organism population,asymptomatic infectious structure carrier,0.6
organism population,architectual structure,0.5719512195121951
organism population,B cell receptor complex,0.5928571428571429
organism population,infection incidence rate,0.5895348837209302
organism population,entity,0.57
organism population,pathogen portal of entry role,0.6375
organism population,lower respiratory tract disease,0.61
organism population,role,0.5804347826086956
organism population,mutualist role,0.6318181818181818
organism population,directive information content entity,0.6136363636363636
organism population,acellular structure aggregate,0.5541666666666667
organism population,invasion factor,0.6264705882352941
organism population,realizable entity,0.6166666666666667
organism population,pathologically immunosuppressed organism,0.6025423728813559
organism population,infectious structure host role,0.5928571428571429
organism population,susceptible population,0.7426829268292683
organism population,COVID-19 incidence rate,0.5928571428571429
organism population,pathogen vehicle role,0.625
organism population,descriptive information content entity,0.6078947368421053
organism population,mechanical vector role,0.5963414634146341
organism population,establishment of localization in human host,0.6435483870967742
organism population,diseased population,0.7921052631578948
organism population,acellular structure,0.581578947368421
organism population,virulence factor,0.6214285714285714
organism population,dead-end host role,0.6121621621621621
organism population,molecular entity,0.65
organism population,immunosuppressed organism,0.6318181818181818
organism population,plan specification,0.6932432432432433
organism population,definitive host role,0.6038461538461539
organism population,infectious structure,0.6038461538461539
organism population,T cell receptor complex,0.5928571428571429
organism population,asymptomatic carrier role,0.6545454545454545
organism population,infectious structure host,0.609090909090909
organism population,infectious agent population,0.7543478260869566
organism population,organism population,0.95
organism population,infectious structure generative stage,0.5928571428571429
organism population,secondary infection role,0.6127906976744186
organism population,country,0.5653846153846154
organism population,source of infection role,0.636046511627907
organism population,biological vehicle role,0.6166666666666667
organism population,symbiont role,0.60625
organism population,susceptible organism,0.6551282051282051
organism population,parasite role,0.6375
organism population,pathogen vector role,0.6038461538461539
organism population,organism substance,0.7743243243243243
organism population,anatomical entity,0.6166666666666667
organism population,infected population,0.7657894736842106
organism population,COVID-19 mortality rate,0.6166666666666667
organism population,geopolitical entity,0.6342105263157894
organism population,primary infection role,0.6451219512195122
organism population,biological role,0.6264705882352941
organism population,symptomatic infectious structure carrier,0.6025423728813559
organism population,biological vector role,0.5963414634146341
organism population,pathogen host role,0.6391891891891892
organism population,designative information content entity,0.6254385964912281
organism population,symptomatic carrier role,0.636046511627907
organism population,intermediate host role,0.5963414634146341
organism population,immunodeficient organism,0.636046511627907
organism population,host role,0.6285714285714286
organism population,infectious human pathogen,0.6772727272727272
organism population,colonization of human,0.65
organism population,immaterial entity,0.6166666666666667
organism population,pathogen portal of exit role,0.6414893617021277
organism population,commensal role,0.6318181818181818
organism population,epitope role,0.5790322580645162
organism population,blood,0.5333333333333333
organism population,division of geopolitical entity,0.63
organism population,geographical feature,0.6294871794871795
organism population,herd immunity to infectious organism,0.6136363636363636
organism population,pathogen transporter role,0.6545454545454545
organism population,antigen role,0.6435483870967742
organism population,action specification,0.6807692307692308
organism population,processed material,0.6121621621621621
organism population,symbiont host role,0.6121621621621621
organism population,immune population,0.8111111111111111
organism population,fomite role,0.6166666666666667
organism population,infectious disease incidence rate,0.5846153846153846
organism population,reagent role,0.6435483870967742
organism population,organism,0.7462962962962962
organism population,establishment of a clinically abnormal colony,0.60625
organism population,adhesion factor,0.6264705882352941
organism population,material processing,0.6342105263157894
blood,angiotensin-converting enzyme 2,0.5055555555555555
blood,source of infection,0.5333333333333333
blood,communicability end temporal region,0.55
blood,biological regulation,0.6038461538461539
blood,infection end temporal region,0.5088235294117647
blood,incubation end temporal region,0.5357142857142857
blood,source of infection site,0.5189655172413793
blood,B cell receptor complex,0.5928571428571429
blood,pathogen birth temporal region,0.5357142857142857
blood,lower respiratory tract disease,0.5611111111111111
blood,genetic resistance to pathogen,0.5071428571428571
blood,biological vehicle,0.5804347826086956
blood,communicability end process boundary,0.5719512195121951
blood,latency end process boundary,0.5712121212121213
blood,incubation end process boundary,0.5611111111111111
blood,latency end temporal region,0.54375
blood,T cell receptor complex,0.5571428571428572
blood,biological vector,0.6318181818181818
blood,source of infection role,0.5189655172413793
blood,biological vehicle role,0.5928571428571429
blood,biological role,0.65
blood,biological process,0.6239130434782608
blood,biological vector role,0.5981481481481481
blood,pathogen birth process boundary,0.5611111111111111
blood,blood,0.95
blood,action specification,0.53
blood,negative regulation of biological process,0.5369565217391304
blood,establishment of a clinically abnormal colony,0.53
immune response,immune response,0.95
immune response,infectious disease mortality rate,0.6166666666666667
immune response,infection incidence rate profile,0.6414893617021277
immune response,communicability end temporal region,0.65
immune response,surveillance process,0.6785714285714286
immune response,infection end temporal region,0.6318181818181818
immune response,SARS-CoV-2 incidence rate,0.6
immune response,incubation end temporal region,0.65
immune response,resistant entity,0.6112903225806451
immune response,virus release stage,0.6852941176470588
immune response,B cell receptor complex,0.6342105263157894
immune response,passive immunization against infectious agent,0.6166666666666667
immune response,infection incidence rate,0.6294871794871795
immune response,lower respiratory tract disease,0.6456521739130434
immune response,genetic resistance to pathogen,0.65
immune response,process,0.6318181818181818
immune response,droplet pathogen transmission process,0.5846153846153846
immune response,communicability end process boundary,0.6656862745098039
immune response,latency end process boundary,0.636046511627907
immune response,susceptible population,0.6121621621621621
immune response,COVID-19 incidence rate,0.6078947368421053
immune response,negative regulation of developmental process,0.6025423728813559
immune response,antibiotic resistance,0.6444444444444444
immune response,resistance to drug,0.6015151515151516
immune response,process of establishing an infection,0.5676470588235294
immune response,incubation end process boundary,0.6673913043478261
immune response,pathogen death process boundary,0.6239130434782608
immune response,plan specification,0.6318181818181818
immune response,latency end temporal region,0.6166666666666667
immune response,virus adhesion susceptible cell,0.6456521739130434
immune response,T cell receptor complex,0.6342105263157894
immune response,indirect pathogen transmission process,0.619811320754717
immune response,planned process,0.6833333333333332
immune response,innate immune response,0.8554054054054054
immune response,passive immunity to infectious agent,0.6460784313725491
immune response,susceptible organism,0.6214285714285714
immune response,COVID-19 mortality rate,0.581578947368421
immune response,process profile,0.65
immune response,negative regulation of life-sustaining process,0.5975409836065574
immune response,place closure control strategy,0.6277777777777778
immune response,developmental process,0.6444444444444444
immune response,biological process,0.6318181818181818
immune response,humoral immune response,0.8447368421052631
immune response,SARS-COV-2 adhesion susceptible cell,0.5872549019607843
immune response,incubation start process boundary,0.6375
immune response,pathogen birth process boundary,0.6021739130434782
immune response,resistance to pathogen,0.6391891891891892
immune response,negative regulation of immune response,0.7330188679245283
immune response,negative regulation of viral process,0.6068627450980393
immune response,contact pathogen transmission process,0.6038461538461539
immune response,function,0.6239130434782608
immune response,symbiotic process,0.6375
immune response,infection start process boundary,0.6414893617021277
immune response,action specification,0.65
immune response,protective resistance,0.6722222222222223
immune response,latency start process boundary,0.6055555555555556
immune response,immune population,0.7625
immune response,process of establishing viral infection,0.5796296296296296
immune response,negative regulation of biological process,0.5928571428571429
immune response,polymerase chain reaction,0.625
immune response,infectious disease incidence rate,0.6166666666666667
immune response,communicability start process boundary,0.6386792452830189
immune response,process that results in death,0.609090909090909
immune response,collective resistance disposition,0.6375
immune response,adaptive immune response,0.8346153846153846
immune response,establishment of a clinically abnormal colony,0.5666666666666667
immune response,process boundary,0.6112903225806451
immune response,horizontal pathogen transmission process,0.6136363636363636
immune response,SARS-CoV-2 release stage,0.6038461538461539
immune response,pathogen transmission process,0.609090909090909
pathogen,extended organism,0.61
pathogen,virus aggregate,0.5804347826086956
pathogen,source of infection,0.5611111111111111
pathogen,infectious disease mortality rate,0.523170731707317
pathogen,infection incidence rate profile,0.55
pathogen,pathogen generative stage,0.6924242424242425
pathogen,pathogen portal of entry,0.7
pathogen,subclinical coronavirus infection,0.5475609756097561
pathogen,primary pathogen,0.7833333333333333
pathogen,infection end temporal region,0.5581081081081081
pathogen,drug-based immunosuppressed organism,0.5409090909090909
pathogen,infectious disease,0.5653846153846154
pathogen,double-stranded DNA virus,0.5409090909090909
pathogen,site of infection,0.61
pathogen,immunocompetent organism,0.60625
pathogen,pathogen portal of exit,0.7080645161290323
pathogen,infectious disease incidence,0.5611111111111111
pathogen,reservoir of pathogen role,0.6852941176470588
pathogen,subclinical SARS-CoV-2 infection,0.55
pathogen,virus translation stage,0.6112903225806451
pathogen,disease surveillance objective specification,0.5461538461538461
pathogen,virus release stage,0.5981481481481481
pathogen,infectious agent host role,0.5970588235294118
pathogen,source of infection site,0.54375
pathogen,virus replication,0.65
pathogen,B cell receptor complex,0.5790322580645162
pathogen,passive immunization against infectious agent,0.5820754716981132
pathogen,systematic infection,0.5928571428571429
pathogen,infection incidence rate,0.575
pathogen,virus host,0.5611111111111111
pathogen,double-stranded RNA virus,0.5409090909090909
pathogen,pathogen portal of entry role,0.6662162162162162
pathogen,virus transcription stage,0.6015151515151516
pathogen,infectious disease lifetime prevalence,0.5369565217391304
pathogen,pathogen birth temporal region,0.6605263157894737
pathogen,lower respiratory tract disease,0.5782051282051281
pathogen,infectious disease incidence proportion,0.5351063829787234
pathogen,opportunistic pathogen,0.7166666666666667
pathogen,virus generative stage,0.5833333333333334
pathogen,acute infectious disease course,0.5525641025641026
pathogen,cidal agent disposition,0.5790322580645162
pathogen,genetic resistance to pathogen,0.6605263157894737
pathogen,subclinical infection,0.5879310344827586
pathogen,simple infection,0.6166666666666667
pathogen,droplet pathogen transmission process,0.6277777777777778
pathogen,infectious disease sporadicity,0.5289473684210526
pathogen,infection incidence proportion profile,0.5369565217391304
pathogen,infectious agent colony,0.6112903225806451
pathogen,pathogen transporter,0.7357142857142857
pathogen,infectious disease epidemic,0.5357142857142857
pathogen,infectious agent generative stage,0.5719512195121951
pathogen,disease transmission model,0.5676470588235294
pathogen,pathologically immunosuppressed organism,0.6166666666666667
pathogen,negative-sense single-stranded RNA virus,0.5541666666666667
pathogen,cidal agent,0.6605263157894737
pathogen,pathogen vehicle,0.7833333333333333
pathogen,community-acquired infection,0.5611111111111111
pathogen,pathogen vector,0.7978260869565217
pathogen,pathogen vehicle role,0.7258620689655172
pathogen,chronic infectious disease course,0.523170731707317
pathogen,asymptomatic infectious agent carrier,0.6055555555555556
pathogen,nursing-home acquired infection,0.5525641025641026
pathogen,secondary infection,0.5981481481481481
pathogen,infection start temporal region,0.5782051282051281
pathogen,infection incidence,0.5981481481481481
pathogen,virus disorder,0.5409090909090909
pathogen,sterilizing immunity to infectious agent,0.5541666666666667
pathogen,primary infection,0.65
pathogen,process of establishing an infection,0.5863636363636363
pathogen,pathogen death process boundary,0.6551282051282051
pathogen,immunosuppressed organism,0.5712121212121213
pathogen,innate immunity to infectious agent,0.5895348837209302
pathogen,virus adhesion susceptible cell,0.5525641025641026
pathogen,infection,0.6264705882352941
pathogen,static agent disposition,0.60625
pathogen,T cell receptor complex,0.5790322580645162
pathogen,infectious agent population,0.5928571428571429
pathogen,respiratory system disease,0.5970588235294118
pathogen,leukocyte-mediated immunity to infectious agent,0.5590909090909091
pathogen,indirect pathogen transmission process,0.6239130434782608
pathogen,organism population,0.6351851851851852
pathogen,humoral immunity to infectious agent,0.5863636363636363
pathogen,infectious disease control strategy,0.5430232558139535
pathogen,parasite,0.7
pathogen,infectious disease pandemic,0.5642857142857143
pathogen,antibody reagent,0.7
pathogen,viral disease course,0.5571428571428572
pathogen,intracellular infection,0.5790322580645162
pathogen,secondary infection role,0.575
pathogen,metastatic infection,0.5928571428571429
pathogen,passive immunity to infectious agent,0.609090909090909
pathogen,vaccination against infectious agent,0.5863636363636363
pathogen,acute infection,0.6239130434782608
pathogen,susceptibility to infectious agent,0.5928571428571429
pathogen,epitope site,0.65
pathogen,immunity to pathogen,0.7357142857142857
pathogen,source of infection role,0.54375
pathogen,pathogen host,0.830952380952381
pathogen,chronic infection,0.61
pathogen,disease course,0.5863636363636363
pathogen,infectious disease course,0.5409090909090909
pathogen,acquired immunity to infectious agent,0.5833333333333334
pathogen,complex infection,0.61
pathogen,COVID-19 disease incidence proportion,0.5388888888888889
pathogen,coronavirus disease course,0.5382352941176471
pathogen,infection incidence proportion,0.5552631578947369
pathogen,symptomatic infectious agent carrier,0.609090909090909
pathogen,respiratory droplet virus fomite,0.575
pathogen,susceptible organism,0.6285714285714286
pathogen,parasite role,0.6880952380952381
pathogen,pathogen vector role,0.7357142857142857
pathogen,pathogen portal of exit site,0.6722222222222223
pathogen,infectious disease prevalence,0.5581081081081081
pathogen,organism substance,0.5653846153846154
pathogen,single-stranded DNA virus,0.5409090909090909
pathogen,viral disease,0.5452380952380953
pathogen,primary infection role,0.6166666666666667
pathogen,pathogen portal of entry site,0.6662162162162162
pathogen,infection incidence profile,0.5642857142857143
pathogen,disease,0.5833333333333334
pathogen,site,0.6166666666666667
pathogen,pathogen host role,0.7576923076923078
pathogen,infection prevalence,0.5928571428571429
pathogen,infectious pathogen transmissibility,0.6318181818181818
pathogen,pathogen surveillance,0.7258620689655172
pathogen,immunodeficient organism,0.575
pathogen,pathogen,0.95
pathogen,pathogen birth process boundary,0.6551282051282051
pathogen,infectious human pathogen,0.6924242424242425
pathogen,subclinical virus infection,0.5642857142857143
pathogen,resistance to pathogen,0.7166666666666667
pathogen,establishment of localization in virus host,0.5284313725490196
pathogen,immunization against infectious agent,0.5833333333333334
pathogen,virus attachment stage,0.6166666666666667
pathogen,virus synthesis stage,0.5879310344827586
pathogen,pathogen portal of exit role,0.6722222222222223
pathogen,infectious agent host,0.6224137931034482
pathogen,re-emerging pathogen,0.7357142857142857
pathogen,long-term non-progressing infectious disease course,0.5347457627118644
pathogen,viral disease epidemic,0.5166666666666666
pathogen,viral disease pandemic,0.55
pathogen,virus penetration stage,0.6435483870967742
pathogen,pathogen seroprevalence,0.7080645161290323
pathogen,infectious disease endemicity,0.5581081081081081
pathogen,contact pathogen transmission process,0.6277777777777778
pathogen,herd immunity to infectious organism,0.5409090909090909
pathogen,extracellular infection,0.5790322580645162
pathogen,pathogen transporter role,0.6924242424242425
pathogen,infectious agent reservoir,0.5970588235294118
pathogen,infection start process boundary,0.575
pathogen,infectious disease control objective specification,0.5362068965517242
pathogen,process of establishing viral infection,0.5776595744680851
pathogen,COVID-19 disease course,0.5467741935483871
pathogen,infectious disease incidence rate,0.5475609756097561
pathogen,active immunization against infectious agent,0.5653846153846154
pathogen,disordered virus,0.5333333333333333
pathogen,organism,0.6375
pathogen,virus uncoating stage,0.5879310344827586
pathogen,local infection,0.6239130434782608
pathogen,infectious agent,0.6583333333333334
pathogen,establishment of a clinically abnormal colony,0.5254716981132076
pathogen,coronavirus disease,0.524074074074074
pathogen,positive-sense single-stranded RNA virus,0.5541666666666667
pathogen,horizontal pathogen transmission process,0.6166666666666667
pathogen,hospital-acquired infection,0.5928571428571429
pathogen,pathogen death temporal region,0.6605263157894737
pathogen,emerging pathogen,0.77
pathogen,drug susceptibility of infectious agent,0.5776595744680851
pathogen,static agent,0.7
pathogen,pathogen transmission process,0.6662162162162162
anatomical space,biological regulation,0.6391891891891892
anatomical space,primary pathogen,0.6375
anatomical space,geospatial location,0.65
anatomical space,disease surveillance objective specification,0.5833333333333334
anatomical space,physiologic immunosuppression,0.6055555555555556
anatomical space,material entity,0.6758064516129032
anatomical space,B cell receptor complex,0.6038461538461539
anatomical space,double-stranded RNA virus,0.5719512195121951
anatomical space,lower respiratory tract disease,0.6202127659574468
anatomical space,biological vehicle,0.6852941176470588
anatomical space,communicability end process boundary,0.6423076923076922
anatomical space,latency end process boundary,0.609090909090909
anatomical space,negative-sense single-stranded RNA virus,0.5928571428571429
anatomical space,latency interval,0.60625
anatomical space,establishment of localization in human host,0.6025423728813559
anatomical space,primary infection,0.5712121212121213
anatomical space,incubation end process boundary,0.6202127659574468
anatomical space,pathogen death process boundary,0.6202127659574468
anatomical space,innate immunity to infectious agent,0.6264705882352941
anatomical space,virus adhesion susceptible cell,0.6202127659574468
anatomical space,anatomical space,0.95
anatomical space,T cell receptor complex,0.6294871794871795
anatomical space,biological vector,0.6621212121212122
anatomical space,communicability interval,0.65
anatomical space,innate immune response,0.6605263157894737
anatomical space,cell,0.55
anatomical space,objective specification,0.6038461538461539
anatomical space,biological vehicle role,0.6551282051282051
anatomical space,incubation interval,0.65
anatomical space,anatomical entity,0.8136363636363637
anatomical space,place closure control strategy,0.6456521739130434
anatomical space,primary infection role,0.6078947368421053
anatomical space,primary immunodeficiency,0.6
anatomical space,biological role,0.6758064516129032
anatomical space,biological process,0.7147058823529412
anatomical space,biological vector role,0.6605263157894737
anatomical space,primary infectious disposition,0.6021739130434782
anatomical space,SARS-COV-2 adhesion susceptible cell,0.6038461538461539
anatomical space,eclipse interval,0.575
anatomical space,incubation start process boundary,0.6336734693877552
anatomical space,object,0.5409090909090909
anatomical space,pathogen birth process boundary,0.6202127659574468
anatomical space,infectious human pathogen,0.6695121951219513
anatomical space,colonization of human,0.6121621621621621
anatomical space,object aggregate,0.60625
anatomical space,transmission interval,0.6121621621621621
anatomical space,infection start process boundary,0.6166666666666667
anatomical space,processed material,0.5970588235294118
anatomical space,latency start process boundary,0.6239130434782608
anatomical space,infectious disease control objective specification,0.6015151515151516
anatomical space,quality,0.5369565217391304
anatomical space,negative regulation of biological process,0.6605263157894737
anatomical space,communicability start process boundary,0.6537037037037037
anatomical space,single-stranded RNA retrovirus,0.6021739130434782
anatomical space,local infection,0.6435483870967742
anatomical space,establishment of a clinically abnormal colony,0.630327868852459
anatomical space,process boundary,0.575
anatomical space,positive-sense single-stranded RNA virus,0.5571428571428572
anatomical space,cell space,0.7576923076923078
anatomical space,material processing,0.7071428571428571
viricidal disposition,virostatic disposition,0.8453488372093022
viricidal disposition,information content entity,0.598936170212766
viricidal disposition,zoonotic disposition,0.7914634146341464
viricidal disposition,infectious disease mortality rate,0.6351851851851852
viricidal disposition,infection incidence rate profile,0.6386792452830189
viricidal disposition,infectious structure aggregate,0.5676470588235294
viricidal disposition,communicability end temporal region,0.6464285714285714
viricidal disposition,geographical entity,0.65
viricidal disposition,biological regulation,0.6880952380952381
viricidal disposition,surveillance process,0.6207317073170732
viricidal disposition,infection end temporal region,0.65
viricidal disposition,vector control strategy,0.609090909090909
viricidal disposition,SARS-CoV-2 incidence rate,0.6021739130434782
viricidal disposition,incubation end temporal region,0.6460784313725491
viricidal disposition,resistant entity,0.6121621621621621
viricidal disposition,virulence factor disposition,0.7969387755102041
viricidal disposition,viral adhesion disposition,0.8117021276595744
viricidal disposition,parasitostatic disposition,0.7691489361702127
viricidal disposition,negative regulation of production,0.6351851851851852
viricidal disposition,reverse zoonotic disposition,0.7765306122448979
viricidal disposition,establishment of localization in host,0.6224137931034482
viricidal disposition,disease surveillance objective specification,0.65
viricidal disposition,case isolation control strategy,0.6423076923076922
viricidal disposition,infectious agent host role,0.6414893617021277
viricidal disposition,macromolecular complex,0.5662790697674418
viricidal disposition,material entity,0.6444444444444444
viricidal disposition,asymptomatic infectious structure carrier,0.5790322580645162
viricidal disposition,architectual structure,0.636046511627907
viricidal disposition,quarantine control strategy,0.5958333333333333
viricidal disposition,B cell receptor complex,0.5863636363636363
viricidal disposition,infection incidence rate,0.6055555555555556
viricidal disposition,colonized host,0.65
viricidal disposition,virus host,0.6758064516129032
viricidal disposition,entity,0.524074074074074
viricidal disposition,toxin disposition,0.7921052631578948
viricidal disposition,cidal agent disposition,0.8363636363636363
viricidal disposition,parasiticidal disposition,0.8630434782608696
viricidal disposition,communicability end process boundary,0.6429824561403508
viricidal disposition,directive information content entity,0.6429824561403508
viricidal disposition,acellular structure aggregate,0.55
viricidal disposition,transmissibility disposition,0.7765306122448979
viricidal disposition,latency end process boundary,0.6132653061224489
viricidal disposition,colonization of host,0.6451219512195122
viricidal disposition,realizable entity,0.6342105263157894
viricidal disposition,endotoxin disposition,0.7595238095238095
viricidal disposition,vector surveillance,0.6
viricidal disposition,negative regulation of establishment of localization,0.6280821917808219
viricidal disposition,cidal agent,0.66875
viricidal disposition,infectious structure host role,0.6264705882352941
viricidal disposition,COVID-19 incidence rate,0.6318181818181818
viricidal disposition,cytotoxin disposition,0.7833333333333333
viricidal disposition,negative regulation of developmental process,0.6038461538461539
viricidal disposition,host,0.57
viricidal disposition,descriptive information content entity,0.6194915254237288
viricidal disposition,negative regulation of replication,0.6318181818181818
viricidal disposition,establishment of localization in human host,0.60625
viricidal disposition,acellular structure,0.575
viricidal disposition,incubation end process boundary,0.6423076923076922
viricidal disposition,collective pathogenic disposition,0.7277777777777777
viricidal disposition,neurotoxin disposition,0.7755813953488372
viricidal disposition,dead-end host role,0.6294871794871795
viricidal disposition,molecular entity,0.5851351351351352
viricidal disposition,plan specification,0.6807692307692308
viricidal disposition,definitive host role,0.6451219512195122
viricidal disposition,latency end temporal region,0.6166666666666667
viricidal disposition,infectious structure,0.5963414634146341
viricidal disposition,collective disposition,0.7755813953488372
viricidal disposition,static agent disposition,0.7833333333333333
viricidal disposition,T cell receptor complex,0.5863636363636363
viricidal disposition,infectious structure host,0.6239130434782608
viricidal disposition,respiratory system disease,0.6202127659574468
viricidal disposition,entry into host,0.6166666666666667
viricidal disposition,adhesion of symbiont to host,0.6132653061224489
viricidal disposition,infectious disease control strategy,0.6285714285714286
viricidal disposition,infectious structure generative stage,0.5706896551724138
viricidal disposition,immunosuppressive disposition,0.75
viricidal disposition,pathogenic disposition,0.7755813953488372
viricidal disposition,entry into host through host barriers,0.5879310344827586
viricidal disposition,infectious disposition,0.7988372093023256
viricidal disposition,bacteriostatic disposition,0.7691489361702127
viricidal disposition,bactericidal disposition,0.8722222222222222
viricidal disposition,pathogen host,0.5970588235294118
viricidal disposition,invasion disposition,0.7914634146341464
viricidal disposition,viricidal disposition,0.95
viricidal disposition,complex infection,0.6605263157894737
viricidal disposition,intermediate host,0.6605263157894737
viricidal disposition,anatomical entity,0.6342105263157894
viricidal disposition,disposition,0.79375
viricidal disposition,COVID-19 mortality rate,0.609090909090909
viricidal disposition,negative regulation of life-sustaining process,0.5992537313432835
viricidal disposition,place closure control strategy,0.5676470588235294
viricidal disposition,geopolitical entity,0.65
viricidal disposition,adhesion disposition,0.7670731707317073
viricidal disposition,symptomatic infectious structure carrier,0.5811475409836065
viricidal disposition,primary infectious disposition,0.7833333333333333
viricidal disposition,pathogen host role,0.6038461538461539
viricidal disposition,designative information content entity,0.6025423728813559
viricidal disposition,intermediate host role,0.6593023255813953
viricidal disposition,dead-end host,0.6264705882352941
viricidal disposition,pathogen surveillance,0.569047619047619
viricidal disposition,host role,0.5833333333333334
viricidal disposition,establishment of localization in virus host,0.60625
viricidal disposition,negative regulation of immune response,0.6025423728813559
viricidal disposition,immaterial entity,0.6605263157894737
viricidal disposition,SARS-COV-2 adhesion disposition,0.7384615384615384
viricidal disposition,invasive disposition,0.7914634146341464
viricidal disposition,infectious agent host,0.6404761904761905
viricidal disposition,fungicidal disposition,0.8686046511627907
viricidal disposition,division of geopolitical entity,0.6423076923076922
viricidal disposition,negative regulation of viral process,0.6254385964912281
viricidal disposition,exotoxin disposition,0.7670731707317073
viricidal disposition,immunoglobulin complex,0.5662790697674418
viricidal disposition,infectious disease control objective specification,0.6612676056338028
viricidal disposition,symbiont host role,0.6038461538461539
viricidal disposition,opportunistic infectious disposition,0.730701754385965
viricidal disposition,negative regulation of biological process,0.6112903225806451
viricidal disposition,enterotoxin disposition,0.7681818181818181
viricidal disposition,infectious disease incidence rate,0.6537037037037037
viricidal disposition,collective resistance disposition,0.7462962962962962
viricidal disposition,fungistatic disposition,0.7909090909090909
viricidal disposition,establishment of a clinically abnormal colony,0.5863636363636363
viricidal disposition,definitive host,0.6444444444444444
communicability,virus aggregate,0.55
communicability,infectious disease mortality rate,0.6375
communicability,communicability end temporal region,0.75
communicability,infectious disease,0.6015151515151516
communicability,double-stranded DNA virus,0.575
communicability,infectious disease incidence,0.6127906976744186
communicability,virus translation stage,0.581578947368421
communicability,disease surveillance objective specification,0.5686440677966101
communicability,virus release stage,0.5382352941176471
communicability,virus,0.5
communicability,virus replication,0.60625
communicability,B cell receptor complex,0.5552631578947369
communicability,virus host,0.53
communicability,double-stranded RNA virus,0.575
communicability,virus transcription stage,0.6
communicability,infectious disease lifetime prevalence,0.6009433962264151
communicability,lower respiratory tract disease,0.558695652173913
communicability,infectious disease incidence proportion,0.5981481481481481
communicability,virus generative stage,0.5851351351351352
communicability,acute infectious disease course,0.5804347826086956
communicability,infectious disease sporadicity,0.65
communicability,communicability end process boundary,0.7441176470588234
communicability,infectious disease epidemic,0.6166666666666667
communicability,disease transmission model,0.5475609756097561
communicability,negative-sense single-stranded RNA virus,0.5409090909090909
communicability,chronic infectious disease course,0.5958333333333333
communicability,COVID-19 epidemic,0.60625
communicability,virus disorder,0.5189655172413793
communicability,virus adhesion susceptible cell,0.558695652173913
communicability,T cell receptor complex,0.5552631578947369
communicability,respiratory system disease,0.5475609756097561
communicability,communicability interval,0.8346153846153846
communicability,infectious disease control strategy,0.61
communicability,infectious disease pandemic,0.5928571428571429
communicability,viral disease course,0.5642857142857143
communicability,disease course,0.553448275862069
communicability,infectious disease course,0.575
communicability,COVID-19 disease incidence proportion,0.5846153846153846
communicability,coronavirus disease course,0.5963414634146341
communicability,respiratory droplet virus fomite,0.5563829787234043
communicability,infectious disease prevalence,0.5863636363636363
communicability,single-stranded DNA virus,0.525
communicability,viral disease,0.5928571428571429
communicability,contagiousness,0.6224137931034482
communicability,disease,0.5409090909090909
communicability,subclinical virus infection,0.6404761904761905
communicability,establishment of localization in virus host,0.5706896551724138
communicability,virus attachment stage,0.5581081081081081
communicability,virus synthesis stage,0.5611111111111111
communicability,long-term non-progressing infectious disease course,0.5560606060606061
communicability,viral disease epidemic,0.5581081081081081
communicability,communicability start temporal region,0.7384615384615384
communicability,viral disease pandemic,0.5581081081081081
communicability,virus penetration stage,0.581578947368421
communicability,infectious disease endemicity,0.6545454545454545
communicability,communicability,0.95
communicability,infectious disease control objective specification,0.5884615384615385
communicability,COVID-19 disease course,0.5552631578947369
communicability,infectious disease incidence rate,0.6166666666666667
communicability,communicability start process boundary,0.7330188679245283
communicability,disordered virus,0.5145161290322581
communicability,virus uncoating stage,0.6166666666666667
communicability,establishment of a clinically abnormal colony,0.5833333333333334
communicability,coronavirus disease,0.6264705882352941
communicability,positive-sense single-stranded RNA virus,0.5409090909090909
directive information content entity,extended organism,0.619811320754717
directive information content entity,information content entity,0.8693548387096774
directive information content entity,infectious disease mortality rate,0.6528985507246376
directive information content entity,infection incidence rate profile,0.6705882352941177
directive information content entity,infectious structure aggregate,0.6469696969696969
directive information content entity,communicability end temporal region,0.6190140845070422
directive information content entity,geographical entity,0.6863636363636364
directive information content entity,biological regulation,0.6078947368421053
directive information content entity,infection end temporal region,0.6653846153846155
directive information content entity,drug-based immunosuppressed organism,0.6166666666666667
directive information content entity,vector control strategy,0.6872881355932203
directive information content entity,SARS-CoV-2 incidence rate,0.6467213114754098
directive information content entity,incubation end temporal region,0.6621212121212122
directive information content entity,resistant entity,0.7
directive information content entity,immunocompetent organism,0.65
directive information content entity,virulence factor disposition,0.66875
directive information content entity,negative regulation of production,0.696376811594203
directive information content entity,virus translation stage,0.6533898305084747
directive information content entity,disease surveillance objective specification,0.6625
directive information content entity,case isolation control strategy,0.7335820895522389
directive information content entity,material entity,0.6656862745098039
directive information content entity,asymptomatic infectious structure carrier,0.6448051948051949
directive information content entity,architectual structure,0.6051724137931035
directive information content entity,quarantine control strategy,0.6722222222222223
directive information content entity,B cell receptor complex,0.6194915254237288
directive information content entity,infection incidence rate,0.6833333333333332
directive information content entity,entity,0.5928571428571429
directive information content entity,communicability end process boundary,0.6166666666666667
directive information content entity,directive information content entity,0.95
directive information content entity,acellular structure aggregate,0.6038461538461539
directive information content entity,invasion factor,0.6264705882352941
directive information content entity,latency end process boundary,0.621875
directive information content entity,realizable entity,0.6764150943396227
directive information content entity,negative regulation of establishment of localization,0.6886363636363636
directive information content entity,pathologically immunosuppressed organism,0.5947368421052631
directive information content entity,infectious structure host role,0.6469696969696969
directive information content entity,COVID-19 incidence rate,0.6364406779661017
directive information content entity,negative regulation of developmental process,0.6875
directive information content entity,descriptive information content entity,0.9094594594594595
directive information content entity,negative regulation of replication,0.7071428571428571
directive information content entity,establishment of localization in human host,0.6651898734177215
directive information content entity,acellular structure,0.5772727272727273
directive information content entity,virulence factor,0.6423076923076922
directive information content entity,incubation end process boundary,0.658955223880597
directive information content entity,molecular entity,0.6423076923076922
directive information content entity,immunosuppressed organism,0.6139344262295081
directive information content entity,plan specification,0.6166666666666667
directive information content entity,latency end temporal region,0.6087301587301588
directive information content entity,infectious structure,0.6285714285714286
directive information content entity,T cell receptor complex,0.6194915254237288
directive information content entity,infectious structure host,0.6467213114754098
directive information content entity,respiratory system disease,0.6435483870967742
directive information content entity,organism population,0.6136363636363636
directive information content entity,infectious disease control strategy,0.6894366197183097
directive information content entity,infectious structure generative stage,0.6691780821917809
directive information content entity,objective specification,0.6872881355932203
directive information content entity,susceptible organism,0.6285714285714286
directive information content entity,organism substance,0.5981481481481481
directive information content entity,anatomical entity,0.6764150943396227
directive information content entity,COVID-19 mortality rate,0.6194915254237288
directive information content entity,negative regulation of life-sustaining process,0.6695121951219513
directive information content entity,place closure control strategy,0.6621212121212122
directive information content entity,geopolitical entity,0.6681818181818181
directive information content entity,symptomatic infectious structure carrier,0.6473684210526315
directive information content entity,designative information content entity,0.895945945945946
directive information content entity,immunodeficient organism,0.6333333333333333
directive information content entity,infectious human pathogen,0.6631147540983606
directive information content entity,colonization of human,0.6429824561403508
directive information content entity,negative regulation of immune response,0.7067567567567568
directive information content entity,immaterial entity,0.6764150943396227
directive information content entity,division of geopolitical entity,0.7186567164179104
directive information content entity,geographical feature,0.6107142857142857
directive information content entity,negative regulation of viral process,0.6722222222222223
directive information content entity,herd immunity to infectious organism,0.6444444444444444
directive information content entity,action specification,0.6464285714285714
directive information content entity,processed material,0.6166666666666667
directive information content entity,infectious disease control objective specification,0.6709302325581397
directive information content entity,quality,0.5430232558139535
directive information content entity,negative regulation of biological process,0.6577922077922078
directive information content entity,infectious disease incidence rate,0.6673913043478261
directive information content entity,viral load,0.5804347826086956
directive information content entity,organism,0.5636363636363636
directive information content entity,establishment of a clinically abnormal colony,0.6475308641975309
directive information content entity,adhesion factor,0.6068627450980393
directive information content entity,material processing,0.5954545454545455
vector control strategy,virostatic disposition,0.6055555555555556
vector control strategy,zoonotic disposition,0.6127906976744186
vector control strategy,infectious disease mortality rate,0.6821428571428573
vector control strategy,infection incidence rate profile,0.6681818181818181
vector control strategy,communicability end temporal region,0.6396551724137931
vector control strategy,biological regulation,0.609090909090909
vector control strategy,surveillance process,0.6127906976744186
vector control strategy,infection end temporal region,0.7
vector control strategy,vector control strategy,0.95
vector control strategy,SARS-CoV-2 incidence rate,0.6583333333333334
vector control strategy,incubation end temporal region,0.6764150943396227
vector control strategy,virulence factor disposition,0.6460784313725491
vector control strategy,viral adhesion disposition,0.6132653061224489
vector control strategy,parasitostatic disposition,0.5928571428571429
vector control strategy,negative regulation of production,0.6107142857142857
vector control strategy,reverse zoonotic disposition,0.6460784313725491
vector control strategy,disease surveillance objective specification,0.5992537313432835
vector control strategy,case isolation control strategy,0.8203703703703704
vector control strategy,infectious agent host role,0.6948979591836735
vector control strategy,quarantine control strategy,0.81
vector control strategy,B cell receptor complex,0.6673913043478261
vector control strategy,passive immunization against infectious agent,0.6117647058823529
vector control strategy,infection incidence rate,0.7053191489361703
vector control strategy,mechanical vector,0.625
vector control strategy,infectious disease lifetime prevalence,0.6139344262295081
vector control strategy,toxin disposition,0.6
vector control strategy,acute infectious disease course,0.6351851851851852
vector control strategy,cidal agent disposition,0.6021739130434782
vector control strategy,parasiticidal disposition,0.575
vector control strategy,communicability end process boundary,0.6025423728813559
vector control strategy,infectious agent colony,0.6673913043478261
vector control strategy,transmissibility disposition,0.5872549019607843
vector control strategy,latency end process boundary,0.6264705882352941
vector control strategy,infectious agent generative stage,0.6821428571428573
vector control strategy,endotoxin disposition,0.609090909090909
vector control strategy,vector surveillance,0.7119047619047619
vector control strategy,negative regulation of establishment of localization,0.61
vector control strategy,cidal agent,0.5970588235294118
vector control strategy,COVID-19 incidence rate,0.6673913043478261
vector control strategy,cytotoxin disposition,0.6318181818181818
vector control strategy,pathogen vector,0.6342105263157894
vector control strategy,negative regulation of developmental process,0.6291044776119403
vector control strategy,chronic infectious disease course,0.6285714285714286
vector control strategy,asymptomatic infectious agent carrier,0.6166666666666667
vector control strategy,negative regulation of replication,0.6254385964912281
vector control strategy,mechanical vector role,0.6944444444444444
vector control strategy,sterilizing immunity to infectious agent,0.6087301587301588
vector control strategy,incubation end process boundary,0.6351851851851852
vector control strategy,collective pathogenic disposition,0.6107142857142857
vector control strategy,neurotoxin disposition,0.6277777777777778
vector control strategy,plan specification,0.5719512195121951
vector control strategy,latency end temporal region,0.67
vector control strategy,innate immunity to infectious agent,0.6224137931034482
vector control strategy,collective disposition,0.6055555555555556
vector control strategy,static agent disposition,0.598936170212766
vector control strategy,T cell receptor complex,0.6673913043478261
vector control strategy,infectious agent population,0.67
vector control strategy,respiratory system disease,0.6540816326530612
vector control strategy,biological vector,0.6
vector control strategy,leukocyte-mediated immunity to infectious agent,0.6071428571428572
vector control strategy,humoral immunity to infectious agent,0.6194915254237288
vector control strategy,infectious disease control strategy,0.8120689655172413
vector control strategy,immunosuppressive disposition,0.5653846153846154
vector control strategy,pathogenic disposition,0.5833333333333334
vector control strategy,viral disease course,0.636046511627907
vector control strategy,passive immunity to infectious agent,0.6364406779661017
vector control strategy,infectious disposition,0.6277777777777778
vector control strategy,vaccination against infectious agent,0.6364406779661017
vector control strategy,susceptibility to infectious agent,0.6254385964912281
vector control strategy,bacteriostatic disposition,0.6132653061224489
vector control strategy,bactericidal disposition,0.6202127659574468
vector control strategy,invasion disposition,0.5895348837209302
vector control strategy,disease course,0.6391891891891892
vector control strategy,infectious disease course,0.6583333333333334
vector control strategy,viricidal disposition,0.609090909090909
vector control strategy,acquired immunity to infectious agent,0.6166666666666667
vector control strategy,coronavirus disease course,0.6540816326530612
vector control strategy,symptomatic infectious agent carrier,0.6194915254237288
vector control strategy,pathogen vector role,0.7058139534883722
vector control strategy,infectious disease prevalence,0.6230769230769231
vector control strategy,disposition,0.5382352941176471
vector control strategy,COVID-19 mortality rate,0.6891304347826087
vector control strategy,negative regulation of life-sustaining process,0.6094202898550725
vector control strategy,place closure control strategy,0.8462264150943396
vector control strategy,adhesion disposition,0.5895348837209302
vector control strategy,biological vector role,0.6944444444444444
vector control strategy,primary infectious disposition,0.6009433962264151
vector control strategy,infection prevalence,0.6593023255813953
vector control strategy,pathogen surveillance,0.6318181818181818
vector control strategy,immunization against infectious agent,0.6
vector control strategy,negative regulation of immune response,0.630327868852459
vector control strategy,SARS-COV-2 adhesion disposition,0.5981481481481481
vector control strategy,invasive disposition,0.5895348837209302
vector control strategy,infectious agent host,0.6772727272727272
vector control strategy,long-term non-progressing infectious disease course,0.5986486486486486
vector control strategy,fungicidal disposition,0.5611111111111111
vector control strategy,negative regulation of viral process,0.6364406779661017
vector control strategy,herd immunity to infectious organism,0.6194915254237288
vector control strategy,exotoxin disposition,0.6127906976744186
vector control strategy,infectious agent reservoir,0.6540816326530612
vector control strategy,action specification,0.636046511627907
vector control strategy,infectious disease control objective specification,0.6691780821917809
vector control strategy,COVID-19 lifetime prevalence,0.6068627450980393
vector control strategy,opportunistic infectious disposition,0.6025423728813559
vector control strategy,negative regulation of biological process,0.621875
vector control strategy,enterotoxin disposition,0.6456521739130434
vector control strategy,COVID-19 disease course,0.6239130434782608
vector control strategy,infectious disease incidence rate,0.6642857142857143
vector control strategy,COVID-19 prevalence,0.5928571428571429
vector control strategy,active immunization against infectious agent,0.6141791044776119
vector control strategy,SARS-COV-2 prevalence,0.609090909090909
vector control strategy,collective resistance disposition,0.6107142857142857
vector control strategy,fungistatic disposition,0.558695652173913
vector control strategy,infectious agent,0.6294871794871795
vector control strategy,establishment of a clinically abnormal colony,0.6117647058823529
vector control strategy,drug susceptibility of infectious agent,0.6112903225806451
vector control strategy,static agent,0.5928571428571429
immunoassay,serology assay,0.69
immunoassay,viral plaque assay,0.6913793103448276
immunoassay,immunoassay,0.95
immunoassay,assay,0.7625
immunoassay,establishment of a clinically abnormal colony,0.575
virus,extended organism,0.5409090909090909
virus,virus aggregate,0.7
virus,virostatic disposition,0.5981481481481481
virus,zoonotic disposition,0.53
virus,immune response,0.6
virus,infectious disease mortality rate,0.5289473684210526
virus,infection incidence rate profile,0.504054054054054
virus,communicability end temporal region,0.5
virus,pathogen generative stage,0.5166666666666666
virus,subclinical coronavirus infection,0.581578947368421
virus,primary pathogen,0.5452380952380953
virus,infection end temporal region,0.5088235294117647
virus,drug-based immunosuppressed organism,0.523170731707317
virus,infectious disease,0.5804347826086956
virus,double-stranded DNA virus,0.6166666666666667
virus,incubation end temporal region,0.5071428571428571
virus,immunocompetent organism,0.553448275862069
virus,virulence factor disposition,0.6015151515151516
virus,viral adhesion disposition,0.5790322580645162
virus,parasitostatic disposition,0.5145161290322581
virus,infectious disease incidence,0.5409090909090909
virus,reservoir of pathogen role,0.5467741935483871
virus,reverse zoonotic disposition,0.5409090909090909
virus,subclinical SARS-CoV-2 infection,0.5310810810810811
virus,virus translation stage,0.6285714285714286
virus,disease surveillance objective specification,0.5112244897959184
virus,virus release stage,0.6583333333333334
virus,source of infection site,0.5189655172413793
virus,virus,0.95
virus,virus replication,0.6772727272727272
virus,infection incidence rate,0.5189655172413793
virus,virus host,0.7833333333333333
virus,double-stranded RNA virus,0.6166666666666667
virus,virus transcription stage,0.6166666666666667
virus,infectious disease lifetime prevalence,0.5197674418604651
virus,toxin disposition,0.5409090909090909
virus,pathogen birth temporal region,0.5071428571428571
virus,lower respiratory tract disease,0.5333333333333333
virus,infectious disease incidence proportion,0.5181818181818182
virus,opportunistic pathogen,0.5611111111111111
virus,virus generative stage,0.6351851851851852
virus,acute infectious disease course,0.5333333333333333
virus,cidal agent disposition,0.5214285714285714
virus,infectious disorder,0.575
virus,genetic resistance to pathogen,0.5357142857142857
virus,appearance of disorder,0.524074074074074
virus,droplet pathogen transmission process,0.5214285714285714
virus,parasiticidal disposition,0.5166666666666666
virus,infectious disease sporadicity,0.5357142857142857
virus,communicability end process boundary,0.523170731707317
virus,pathogen transporter,0.53
virus,transmissibility disposition,0.5106060606060606
virus,latency end process boundary,0.5106060606060606
virus,infectious disease epidemic,0.54375
virus,disease transmission model,0.5467741935483871
virus,endotoxin disposition,0.5269230769230769
virus,pathologically immunosuppressed organism,0.5166666666666666
virus,negative-sense single-stranded RNA virus,0.5611111111111111
virus,pathogen vehicle,0.5452380952380953
virus,cytotoxin disposition,0.5269230769230769
virus,community-acquired infection,0.5106060606060606
virus,pathogen vector,0.55
virus,pathogen vehicle role,0.5653846153846154
virus,chronic infectious disease course,0.5289473684210526
virus,nursing-home acquired infection,0.5055555555555555
virus,COVID-19 epidemic,0.5409090909090909
virus,infection start temporal region,0.5055555555555555
virus,virus disorder,0.7131578947368421
virus,primary infection,0.5409090909090909
virus,incubation end process boundary,0.5333333333333333
virus,SARS-CoV-2 disorder,0.575
virus,collective pathogenic disposition,0.5289473684210526
virus,neurotoxin disposition,0.524074074074074
virus,pathogen death process boundary,0.5055555555555555
virus,immunosuppressed organism,0.55
virus,virus adhesion susceptible cell,0.5888888888888889
virus,collective disposition,0.5611111111111111
virus,infection,0.5214285714285714
virus,static agent disposition,0.5189655172413793
virus,respiratory system disease,0.5467741935483871
virus,indirect pathogen transmission process,0.5197674418604651
virus,organism population,0.5333333333333333
virus,infectious disease control strategy,0.525
virus,infectious disease pandemic,0.54375
virus,immunosuppressive disposition,0.5382352941176471
virus,innate immune response,0.5611111111111111
virus,pathogenic disposition,0.524074074074074
virus,viral disease course,0.65
virus,intracellular infection,0.5571428571428572
virus,secondary infection role,0.5189655172413793
virus,infectious disposition,0.5611111111111111
virus,acute infection,0.5
virus,bacteriostatic disposition,0.5145161290322581
virus,immunity to pathogen,0.53
virus,bactericidal disposition,0.5189655172413793
virus,source of infection role,0.5189655172413793
virus,pathogen host,0.5055555555555555
virus,acquired immunodeficiency,0.55
virus,invasion disposition,0.57
virus,disease course,0.6078947368421053
virus,infectious disease course,0.55
virus,viricidal disposition,0.6038461538461539
virus,acquired immunity to infectious agent,0.5452380952380953
virus,COVID-19 disease incidence proportion,0.5214285714285714
virus,coronavirus disease course,0.6112903225806451
virus,infection incidence proportion,0.5071428571428571
virus,respiratory droplet virus fomite,0.5851351351351352
virus,susceptible organism,0.57
virus,pathogen vector role,0.53
virus,pathogen portal of exit site,0.5106060606060606
virus,infectious disease prevalence,0.5382352941176471
virus,organism substance,0.5804347826086956
virus,disposition,0.575
virus,single-stranded DNA virus,0.6166666666666667
virus,viral disease,0.6722222222222223
virus,primary infection role,0.524074074074074
virus,adhesion disposition,0.53
virus,pathogen portal of entry site,0.5088235294117647
virus,infection incidence profile,0.5125
virus,disease,0.6166666666666667
virus,primary infectious disposition,0.5642857142857143
virus,infection prevalence,0.53
virus,humoral immune response,0.5571428571428572
virus,coronavirus disorder,0.65
virus,infectious pathogen transmissibility,0.523170731707317
virus,pathogen surveillance,0.5269230769230769
virus,immunodeficient organism,0.553448275862069
virus,pathogen birth process boundary,0.5333333333333333
virus,infectious human pathogen,0.55
virus,subclinical virus infection,0.60625
virus,resistance to pathogen,0.524074074074074
virus,establishment of localization in virus host,0.5541666666666667
virus,virus attachment stage,0.6351851851851852
virus,negative regulation of immune response,0.5430232558139535
virus,virus synthesis stage,0.6423076923076922
virus,SARS-COV-2 adhesion disposition,0.5333333333333333
virus,pathogen portal of exit role,0.5106060606060606
virus,invasive disposition,0.57
virus,long-term non-progressing infectious disease course,0.5035714285714286
virus,viral disease epidemic,0.5981481481481481
virus,fungicidal disposition,0.524074074074074
virus,viral disease pandemic,0.5981481481481481
virus,virus penetration stage,0.6285714285714286
virus,acute respiratory distress syndrome,0.525
virus,infectious disease endemicity,0.5382352941176471
virus,contact pathogen transmission process,0.5214285714285714
virus,disorder,0.6038461538461539
virus,herd immunity to infectious organism,0.523170731707317
virus,extracellular infection,0.5214285714285714
virus,pathogen transporter role,0.5166666666666666
virus,transmission interval,0.5269230769230769
virus,exotoxin disposition,0.53
virus,infection start process boundary,0.5310810810810811
virus,infectious disease control objective specification,0.5045454545454545
virus,immune population,0.5409090909090909
virus,opportunistic infectious disposition,0.523170731707317
virus,process of establishing viral infection,0.5181818181818182
virus,enterotoxin disposition,0.5214285714285714
virus,COVID-19 disease course,0.5928571428571429
virus,infectious disease incidence rate,0.5289473684210526
virus,disordered virus,0.6880952380952381
virus,collective resistance disposition,0.5289473684210526
virus,adaptive immune response,0.5879310344827586
virus,fungistatic disposition,0.5214285714285714
virus,organism,0.6038461538461539
virus,virus uncoating stage,0.6423076923076922
virus,local infection,0.5
virus,coronavirus disease,0.6583333333333334
virus,positive-sense single-stranded RNA virus,0.5611111111111111
virus,horizontal pathogen transmission process,0.5166666666666666
virus,hospital-acquired infection,0.5125
virus,pathogen transmission process,0.5382352941176471
establishment of localization,infectious structure aggregate,0.6025423728813559
establishment of localization,communicability end temporal region,0.653125
establishment of localization,infection end temporal region,0.656896551724138
establishment of localization,incubation end temporal region,0.6364406779661017
establishment of localization,virulence factor disposition,0.6605263157894737
establishment of localization,establishment of localization in host,0.8893939393939394
establishment of localization,asymptomatic infectious structure carrier,0.6071428571428572
establishment of localization,architectual structure,0.6068627450980393
establishment of localization,B cell receptor complex,0.6038461538461539
establishment of localization,communicability end process boundary,0.6192307692307693
establishment of localization,acellular structure aggregate,0.5879310344827586
establishment of localization,invasion factor,0.6318181818181818
establishment of localization,latency end process boundary,0.6078947368421053
establishment of localization,negative regulation of establishment of localization,0.8080246913580247
establishment of localization,infectious structure host role,0.6194915254237288
establishment of localization,establishment of localization,0.95
establishment of localization,establishment of localization in human host,0.8527777777777777
establishment of localization,acellular structure,0.575
establishment of localization,virulence factor,0.6277777777777778
establishment of localization,incubation end process boundary,0.6
establishment of localization,plan specification,0.6627659574468084
establishment of localization,latency end temporal region,0.6464285714285714
establishment of localization,infectious structure,0.5928571428571429
establishment of localization,T cell receptor complex,0.6038461538461539
establishment of localization,infectious structure host,0.5981481481481481
establishment of localization,respiratory system disease,0.5954545454545455
establishment of localization,infectious structure generative stage,0.5863636363636363
establishment of localization,place closure control strategy,0.6194915254237288
establishment of localization,symptomatic infectious structure carrier,0.6094202898550725
establishment of localization,establishment of localization in virus host,0.8527777777777777
establishment of localization,local infection,0.6772727272727272
establishment of localization,establishment of a clinically abnormal colony,0.7743243243243243
establishment of localization,adhesion factor,0.6545454545454545
infection start temporal region,virus aggregate,0.6021739130434782
infection start temporal region,source of infection,0.63
infection start temporal region,virostatic disposition,0.6764150943396227
infection start temporal region,zoonotic disposition,0.6460784313725491
infection start temporal region,infectious disease mortality rate,0.7625
infection start temporal region,infection incidence rate profile,0.7198412698412698
infection start temporal region,communicability end temporal region,0.7681818181818181
infection start temporal region,subclinical coronavirus infection,0.653125
infection start temporal region,infection end temporal region,0.8833333333333334
infection start temporal region,infectious disease,0.7153061224489795
infection start temporal region,SARS-CoV-2 incidence rate,0.6107142857142857
infection start temporal region,double-stranded DNA virus,0.5928571428571429
infection start temporal region,incubation end temporal region,0.8434426229508196
infection start temporal region,site of infection,0.6375
infection start temporal region,two-dimensional spatial region,0.7450819672131148
infection start temporal region,one-dimensional temporal region,0.8048387096774193
infection start temporal region,virulence factor disposition,0.6703389830508475
infection start temporal region,pathogen portal of exit,0.6722222222222223
infection start temporal region,viral adhesion disposition,0.6605263157894737
infection start temporal region,parasitostatic disposition,0.6780701754385965
infection start temporal region,temporal region,0.7760869565217391
infection start temporal region,infectious disease incidence,0.7042372881355932
infection start temporal region,reverse zoonotic disposition,0.6194915254237288
infection start temporal region,subclinical SARS-CoV-2 infection,0.6563492063492063
infection start temporal region,virus translation stage,0.6537037037037037
infection start temporal region,disease surveillance objective specification,0.6233333333333334
infection start temporal region,virus release stage,0.59
infection start temporal region,material entity,0.6456521739130434
infection start temporal region,source of infection site,0.6863636363636364
infection start temporal region,virus,0.5055555555555555
infection start temporal region,virus replication,0.6375
infection start temporal region,B cell receptor complex,0.6351851851851852
infection start temporal region,systematic infection,0.6460784313725491
infection start temporal region,infection incidence rate,0.7045454545454546
infection start temporal region,virus host,0.5475609756097561
infection start temporal region,double-stranded RNA virus,0.6107142857142857
infection start temporal region,virus transcription stage,0.6642857142857143
infection start temporal region,infectious disease lifetime prevalence,0.7398550724637681
infection start temporal region,toxin disposition,0.6583333333333334
infection start temporal region,pathogen birth temporal region,0.810655737704918
infection start temporal region,lower respiratory tract disease,0.6274193548387097
infection start temporal region,infectious disease incidence proportion,0.7214285714285714
infection start temporal region,virus generative stage,0.6386792452830189
infection start temporal region,acute infectious disease course,0.6919354838709677
infection start temporal region,cidal agent disposition,0.6537037037037037
infection start temporal region,infectious disorder,0.71
infection start temporal region,subclinical infection,0.6423076923076922
infection start temporal region,appearance of disorder,0.6009433962264151
infection start temporal region,simple infection,0.6414893617021277
infection start temporal region,parasiticidal disposition,0.6285714285714286
infection start temporal region,infectious disease sporadicity,0.728688524590164
infection start temporal region,communicability end process boundary,0.6291044776119403
infection start temporal region,infection incidence proportion profile,0.696376811594203
infection start temporal region,SARS-CoV-2 incidence proportion,0.6596774193548387
infection start temporal region,spatiotemporal region,0.7961538461538461
infection start temporal region,transmissibility disposition,0.6194915254237288
infection start temporal region,latency end process boundary,0.6025423728813559
infection start temporal region,infectious disease epidemic,0.7258620689655172
infection start temporal region,disease transmission model,0.6254385964912281
infection start temporal region,endotoxin disposition,0.6615384615384616
infection start temporal region,negative-sense single-stranded RNA virus,0.6471830985915493
infection start temporal region,COVID-19 incidence rate,0.6166666666666667
infection start temporal region,cytotoxin disposition,0.6615384615384616
infection start temporal region,community-acquired infection,0.6533898305084747
infection start temporal region,zero-dimensional spatial region,0.7403225806451613
infection start temporal region,zero-dimensional temporal region,0.7992063492063491
infection start temporal region,chronic infectious disease course,0.684375
infection start temporal region,nursing-home acquired infection,0.6435483870967742
infection start temporal region,COVID-19 epidemic,0.5958333333333333
infection start temporal region,secondary infection,0.67
infection start temporal region,infection start temporal region,0.95
infection start temporal region,infection incidence,0.69
infection start temporal region,virus disorder,0.5833333333333334
infection start temporal region,establishment of localization in human host,0.6391891891891892
infection start temporal region,primary infection,0.6375
infection start temporal region,process of establishing an infection,0.6440298507462687
infection start temporal region,incubation end process boundary,0.6758064516129032
infection start temporal region,SARS-CoV-2 disorder,0.59
infection start temporal region,collective pathogenic disposition,0.653125
infection start temporal region,neurotoxin disposition,0.6764150943396227
infection start temporal region,geographical region,0.71
infection start temporal region,latency end temporal region,0.7775862068965518
infection start temporal region,virus adhesion susceptible cell,0.6435483870967742
infection start temporal region,collective disposition,0.6575471698113208
infection start temporal region,infection,0.675
infection start temporal region,static agent disposition,0.65
infection start temporal region,T cell receptor complex,0.6351851851851852
infection start temporal region,respiratory system disease,0.6254385964912281
infection start temporal region,communicability interval,0.65
infection start temporal region,infectious disease control strategy,0.7378787878787878
infection start temporal region,infectious disease pandemic,0.7258620689655172
infection start temporal region,immunosuppressive disposition,0.6333333333333333
infection start temporal region,pathogenic disposition,0.6386792452830189
infection start temporal region,viral disease course,0.6068627450980393
infection start temporal region,intracellular infection,0.6537037037037037
infection start temporal region,secondary infection role,0.7045454545454546
infection start temporal region,metastatic infection,0.6656862745098039
infection start temporal region,three-dimensional spatial region,0.7357142857142857
infection start temporal region,infectious disposition,0.7330188679245283
infection start temporal region,objective specification,0.6537037037037037
infection start temporal region,acute infection,0.6456521739130434
infection start temporal region,bacteriostatic disposition,0.6956140350877194
infection start temporal region,bactericidal disposition,0.6318181818181818
infection start temporal region,country,0.581578947368421
infection start temporal region,source of infection role,0.7045454545454546
infection start temporal region,chronic infection,0.6375
infection start temporal region,invasion disposition,0.6852941176470588
infection start temporal region,disease course,0.6055555555555556
infection start temporal region,infectious disease course,0.7178571428571427
infection start temporal region,viricidal disposition,0.6423076923076922
infection start temporal region,complex infection,0.6583333333333334
infection start temporal region,COVID-19 disease incidence proportion,0.6411764705882353
infection start temporal region,coronavirus disease course,0.6429824561403508
infection start temporal region,infection incidence proportion,0.728688524590164
infection start temporal region,respiratory droplet virus fomite,0.6246031746031746
infection start temporal region,pathogen portal of exit site,0.6533898305084747
infection start temporal region,infectious disease prevalence,0.75
infection start temporal region,disposition,0.6166666666666667
infection start temporal region,single-stranded DNA virus,0.6285714285714286
infection start temporal region,COVID-19 mortality rate,0.6537037037037037
infection start temporal region,place closure control strategy,0.6631147540983606
infection start temporal region,viral disease,0.5863636363636363
infection start temporal region,primary infection role,0.7141509433962264
infection start temporal region,adhesion disposition,0.6656862745098039
infection start temporal region,infection incidence profile,0.7086206896551723
infection start temporal region,contagiousness,0.65
infection start temporal region,disease,0.581578947368421
infection start temporal region,primary infectious disposition,0.6959016393442623
infection start temporal region,infection prevalence,0.7637254901960785
infection start temporal region,coronavirus disorder,0.6264705882352941
infection start temporal region,incubation start process boundary,0.746875
infection start temporal region,object,0.5310810810810811
infection start temporal region,pathogen birth process boundary,0.6435483870967742
infection start temporal region,infectious human pathogen,0.7178571428571427
infection start temporal region,subclinical virus infection,0.6396551724137931
infection start temporal region,colonization of human,0.6423076923076922
infection start temporal region,establishment of localization in virus host,0.6256756756756756
infection start temporal region,virus attachment stage,0.619811320754717
infection start temporal region,virus synthesis stage,0.6230769230769231
infection start temporal region,SARS-COV-2 adhesion disposition,0.6274193548387097
infection start temporal region,object aggregate,0.6414893617021277
infection start temporal region,pathogen portal of exit role,0.6703389830508475
infection start temporal region,invasive disposition,0.6460784313725491
infection start temporal region,long-term non-progressing infectious disease course,0.6329268292682927
infection start temporal region,viral disease epidemic,0.619811320754717
infection start temporal region,communicability start temporal region,0.8176470588235294
infection start temporal region,fungicidal disposition,0.6386792452830189
infection start temporal region,viral disease pandemic,0.619811320754717
infection start temporal region,virus penetration stage,0.6722222222222223
infection start temporal region,acute respiratory distress syndrome,0.6318181818181818
infection start temporal region,geospatial region,0.7416666666666667
infection start temporal region,division of geopolitical entity,0.6758064516129032
infection start temporal region,infectious disease endemicity,0.7
infection start temporal region,disorder,0.5782051282051281
infection start temporal region,communicability,0.5804347826086956
infection start temporal region,extracellular infection,0.6351851851851852
infection start temporal region,exotoxin disposition,0.6656862745098039
infection start temporal region,infection start process boundary,0.7833333333333333
infection start temporal region,action specification,0.6852941176470588
infection start temporal region,processed material,0.6132653061224489
infection start temporal region,latency start process boundary,0.6795081967213115
infection start temporal region,infectious disease control objective specification,0.6969135802469135
infection start temporal region,opportunistic infectious disposition,0.6738805970149254
infection start temporal region,process of establishing viral infection,0.6642857142857143
infection start temporal region,enterotoxin disposition,0.6722222222222223
infection start temporal region,COVID-19 disease course,0.6166666666666667
infection start temporal region,infectious disease incidence rate,0.7
infection start temporal region,communicability start process boundary,0.6673913043478261
infection start temporal region,single-stranded RNA retrovirus,0.6631147540983606
infection start temporal region,disordered virus,0.598936170212766
infection start temporal region,collective resistance disposition,0.66875
infection start temporal region,fungistatic disposition,0.6722222222222223
infection start temporal region,virus uncoating stage,0.6615384615384616
infection start temporal region,local infection,0.6456521739130434
infection start temporal region,establishment of a clinically abnormal colony,0.6473684210526315
infection start temporal region,coronavirus disease,0.63
infection start temporal region,positive-sense single-stranded RNA virus,0.6330985915492958
infection start temporal region,one-dimensional spatial region,0.7450819672131148
infection start temporal region,hospital-acquired infection,0.6396551724137931
infection start temporal region,spatial region,0.7166666666666667
infection start temporal region,pathogen death temporal region,0.810655737704918
infection start temporal region,material processing,0.67
diseased population,angiotensin-converting enzyme 2,0.59
diseased population,infectious disease mortality rate,0.6807692307692308
diseased population,infection incidence rate profile,0.6068627450980393
diseased population,infectious structure aggregate,0.5928571428571429
diseased population,infectious disease,0.6391891891891892
diseased population,SARS-CoV-2 incidence rate,0.609090909090909
diseased population,normal resident microbiota population,0.7
diseased population,infectious disease incidence,0.6627659574468084
diseased population,reservoir of pathogen role,0.6722222222222223
diseased population,disease surveillance objective specification,0.6880952380952381
diseased population,infectious agent host role,0.6277777777777778
diseased population,asymptomatic infectious structure carrier,0.5833333333333334
diseased population,B cell receptor complex,0.5928571428571429
diseased population,passive immunization against infectious agent,0.60625
diseased population,infection incidence rate,0.5895348837209302
diseased population,pathogen portal of entry role,0.6166666666666667
diseased population,infectious disease lifetime prevalence,0.6605263157894737
diseased population,lower respiratory tract disease,0.59
diseased population,infectious disease incidence proportion,0.7258620689655172
diseased population,acute infectious disease course,0.65
diseased population,infectious disorder,0.6078947368421053
diseased population,role,0.5369565217391304
diseased population,infectious disease sporadicity,0.6948979591836735
diseased population,mutualist role,0.6015151515151516
diseased population,infectious agent colony,0.6642857142857143
diseased population,infectious disease epidemic,0.6673913043478261
diseased population,infectious agent generative stage,0.6038461538461539
diseased population,disease transmission model,0.7166666666666667
diseased population,infectious structure host role,0.6132653061224489
diseased population,susceptible population,0.7914634146341464
diseased population,COVID-19 incidence rate,0.6166666666666667
diseased population,pathogen vehicle role,0.575
diseased population,chronic infectious disease course,0.6423076923076922
diseased population,asymptomatic infectious agent carrier,0.6107142857142857
diseased population,COVID-19 epidemic,0.5888888888888889
diseased population,mechanical vector role,0.5963414634146341
diseased population,sterilizing immunity to infectious agent,0.5855932203389831
diseased population,establishment of localization in human host,0.6435483870967742
diseased population,diseased population,0.95
diseased population,dead-end host role,0.6932432432432433
diseased population,definitive host role,0.6294871794871795
diseased population,innate immunity to infectious agent,0.6166666666666667
diseased population,infectious structure,0.6038461538461539
diseased population,T cell receptor complex,0.5928571428571429
diseased population,asymptomatic carrier role,0.6318181818181818
diseased population,infectious structure host,0.609090909090909
diseased population,infectious agent population,0.7760869565217391
diseased population,respiratory system disease,0.6055555555555556
diseased population,leukocyte-mediated immunity to infectious agent,0.6166666666666667
diseased population,organism population,0.7921052631578948
diseased population,humoral immunity to infectious agent,0.5772727272727273
diseased population,infectious disease control strategy,0.6722222222222223
diseased population,infectious disease pandemic,0.6891304347826087
diseased population,infectious structure generative stage,0.5928571428571429
diseased population,viral disease course,0.7064102564102563
diseased population,secondary infection role,0.636046511627907
diseased population,passive immunity to infectious agent,0.6136363636363636
diseased population,infectious disposition,0.6939024390243902
diseased population,vaccination against infectious agent,0.5954545454545455
diseased population,susceptibility to infectious agent,0.619811320754717
diseased population,country,0.5653846153846154
diseased population,source of infection role,0.636046511627907
diseased population,disease course,0.7530303030303032
diseased population,infectious disease course,0.6772727272727272
diseased population,acquired immunity to infectious agent,0.6107142857142857
diseased population,COVID-19 disease incidence proportion,0.7357142857142857
diseased population,coronavirus disease course,0.6722222222222223
diseased population,biological vehicle role,0.5928571428571429
diseased population,symptomatic infectious agent carrier,0.5954545454545455
diseased population,symbiont role,0.575
diseased population,parasite role,0.6375
diseased population,pathogen vector role,0.5782051282051281
diseased population,infectious disease prevalence,0.6791666666666666
diseased population,infected population,0.8447368421052631
diseased population,COVID-19 mortality rate,0.6166666666666667
diseased population,viral disease,0.66875
diseased population,primary infection role,0.6207317073170732
diseased population,biological role,0.5970588235294118
diseased population,disease,0.7192307692307692
diseased population,symptomatic infectious structure carrier,0.5686440677966101
diseased population,biological vector role,0.5963414634146341
diseased population,primary infectious disposition,0.6540816326530612
diseased population,pathogen host role,0.6121621621621621
diseased population,symptomatic carrier role,0.6127906976744186
diseased population,infectious pathogen transmissibility,0.6136363636363636
diseased population,intermediate host role,0.6451219512195122
diseased population,host role,0.5928571428571429
diseased population,infectious human pathogen,0.6545454545454545
diseased population,colonization of human,0.625
diseased population,immunization against infectious agent,0.5928571428571429
diseased population,pathogen portal of exit role,0.6202127659574468
diseased population,infectious agent host,0.625
diseased population,long-term non-progressing infectious disease course,0.5928571428571429
diseased population,viral disease epidemic,0.6939024390243902
diseased population,commensal role,0.6015151515151516
diseased population,epitope role,0.6112903225806451
diseased population,viral disease pandemic,0.7182926829268292
diseased population,infectious disease endemicity,0.6375
diseased population,herd immunity to infectious organism,0.5954545454545455
diseased population,pathogen transporter role,0.609090909090909
diseased population,infectious agent reservoir,0.6055555555555556
diseased population,antigen role,0.6112903225806451
diseased population,infectious disease control objective specification,0.6673913043478261
diseased population,symbiont host role,0.5851351351351352
diseased population,immune population,0.8111111111111111
diseased population,opportunistic infectious disposition,0.65
diseased population,fomite role,0.6166666666666667
diseased population,COVID-19 disease course,0.6880952380952381
diseased population,infectious disease incidence rate,0.6615384615384616
diseased population,active immunization against infectious agent,0.5928571428571429
diseased population,reagent role,0.6435483870967742
diseased population,infectious agent,0.6214285714285714
diseased population,establishment of a clinically abnormal colony,0.60625
diseased population,coronavirus disease,0.6342105263157894
diseased population,drug susceptibility of infectious agent,0.6224137931034482
symptomatic carrier,communicability end temporal region,0.5981481481481481
symptomatic carrier,infection end temporal region,0.5958333333333333
symptomatic carrier,incubation end temporal region,0.5928571428571429
symptomatic carrier,normal resident microbiota population,0.6107142857142857
symptomatic carrier,infectious agent host role,0.6055555555555556
symptomatic carrier,asymptomatic infectious structure carrier,0.7666666666666666
symptomatic carrier,B cell receptor complex,0.5928571428571429
symptomatic carrier,passive immunization against infectious agent,0.621875
symptomatic carrier,acute infectious disease course,0.61
symptomatic carrier,cidal agent disposition,0.569047619047619
symptomatic carrier,communicability end process boundary,0.5954545454545455
symptomatic carrier,infectious agent colony,0.5928571428571429
symptomatic carrier,pathogen transporter,0.6551282051282051
symptomatic carrier,latency end process boundary,0.598936170212766
symptomatic carrier,infectious agent generative stage,0.6038461538461539
symptomatic carrier,cidal agent,0.5833333333333334
symptomatic carrier,chronic infectious disease course,0.6038461538461539
symptomatic carrier,asymptomatic infectious agent carrier,0.7892857142857143
symptomatic carrier,sterilizing immunity to infectious agent,0.6025423728813559
symptomatic carrier,incubation end process boundary,0.59
symptomatic carrier,plan specification,0.6121621621621621
symptomatic carrier,latency end temporal region,0.6239130434782608
symptomatic carrier,innate immunity to infectious agent,0.5981481481481481
symptomatic carrier,static agent disposition,0.6593023255813953
symptomatic carrier,T cell receptor complex,0.5928571428571429
symptomatic carrier,asymptomatic carrier role,0.8818181818181818
symptomatic carrier,infectious agent population,0.6021739130434782
symptomatic carrier,leukocyte-mediated immunity to infectious agent,0.6015151515151516
symptomatic carrier,humoral immunity to infectious agent,0.6136363636363636
symptomatic carrier,innate immune response,0.5963414634146341
symptomatic carrier,viral disease course,0.6038461538461539
symptomatic carrier,passive immunity to infectious agent,0.6136363636363636
symptomatic carrier,vaccination against infectious agent,0.6136363636363636
symptomatic carrier,susceptibility to infectious agent,0.619811320754717
symptomatic carrier,disease course,0.6318181818181818
symptomatic carrier,infectious disease course,0.609090909090909
symptomatic carrier,acquired immunity to infectious agent,0.5928571428571429
symptomatic carrier,coronavirus disease course,0.6055555555555556
symptomatic carrier,asymptomatic carrier,0.9371794871794872
symptomatic carrier,symptomatic infectious agent carrier,0.7954545454545454
symptomatic carrier,symptomatic infectious structure carrier,0.7720338983050847
symptomatic carrier,designative information content entity,0.6254385964912281
symptomatic carrier,symptomatic carrier role,0.891860465116279
symptomatic carrier,immunization against infectious agent,0.6285714285714286
symptomatic carrier,infectious agent host,0.575
symptomatic carrier,long-term non-progressing infectious disease course,0.5785714285714285
symptomatic carrier,symptomatic carrier,0.95
symptomatic carrier,pathogen transporter role,0.6318181818181818
symptomatic carrier,infectious agent reservoir,0.65
symptomatic carrier,COVID-19 disease course,0.5928571428571429
symptomatic carrier,active immunization against infectious agent,0.6087301587301588
symptomatic carrier,symptom,0.7192307692307692
symptomatic carrier,local infection,0.5970588235294118
symptomatic carrier,infectious agent,0.5928571428571429
symptomatic carrier,establishment of a clinically abnormal colony,0.60625
symptomatic carrier,drug susceptibility of infectious agent,0.6051724137931035
symptomatic carrier,static agent,0.7403225806451613
passive immunity to infectious agent,information content entity,0.6435483870967742
passive immunity to infectious agent,infectious disease mortality rate,0.6528985507246376
passive immunity to infectious agent,infection incidence rate profile,0.6264705882352941
passive immunity to infectious agent,infectious structure aggregate,0.6772727272727272
passive immunity to infectious agent,communicability end temporal region,0.6612676056338028
passive immunity to infectious agent,infection end temporal region,0.6346153846153847
passive immunity to infectious agent,infectious disease,0.6907407407407408
passive immunity to infectious agent,SARS-CoV-2 incidence rate,0.6467213114754098
passive immunity to infectious agent,incubation end temporal region,0.6318181818181818
passive immunity to infectious agent,resistant entity,0.6230769230769231
passive immunity to infectious agent,virulence factor disposition,0.653125
passive immunity to infectious agent,infectious disease incidence,0.66875
passive immunity to infectious agent,disease surveillance objective specification,0.6625
passive immunity to infectious agent,virus release stage,0.6318181818181818
passive immunity to infectious agent,infectious agent host role,0.7080645161290323
passive immunity to infectious agent,asymptomatic infectious structure carrier,0.6967532467532468
passive immunity to infectious agent,B cell receptor complex,0.5855932203389831
passive immunity to infectious agent,passive immunization against infectious agent,0.869753086419753
passive immunity to infectious agent,infection incidence rate,0.65
passive immunity to infectious agent,double-stranded RNA virus,0.5811475409836065
passive immunity to infectious agent,infectious disease lifetime prevalence,0.6527027027027027
passive immunity to infectious agent,lower respiratory tract disease,0.6440298507462687
passive immunity to infectious agent,infectious disease incidence proportion,0.65
passive immunity to infectious agent,acute infectious disease course,0.703731343283582
passive immunity to infectious agent,cidal agent disposition,0.6364406779661017
passive immunity to infectious agent,infectious disorder,0.6681818181818181
passive immunity to infectious agent,genetic resistance to pathogen,0.6621212121212122
passive immunity to infectious agent,biological vehicle,0.5611111111111111
passive immunity to infectious agent,infectious disease sporadicity,0.6621212121212122
passive immunity to infectious agent,communicability end process boundary,0.6305555555555555
passive immunity to infectious agent,directive information content entity,0.6722222222222223
passive immunity to infectious agent,infectious agent colony,0.7211864406779661
passive immunity to infectious agent,pathogen transporter,0.6107142857142857
passive immunity to infectious agent,invasion factor,0.6264705882352941
passive immunity to infectious agent,latency end process boundary,0.60625
passive immunity to infectious agent,infectious disease epidemic,0.6563492063492063
passive immunity to infectious agent,infectious agent generative stage,0.6818840579710145
passive immunity to infectious agent,disease transmission model,0.6112903225806451
passive immunity to infectious agent,negative-sense single-stranded RNA virus,0.6210526315789474
passive immunity to infectious agent,cidal agent,0.6202127659574468
passive immunity to infectious agent,infectious structure host role,0.6469696969696969
passive immunity to infectious agent,pathogen vehicle,0.6038461538461539
passive immunity to infectious agent,COVID-19 incidence rate,0.6194915254237288
passive immunity to infectious agent,antibiotic resistance,0.6254385964912281
passive immunity to infectious agent,pathogen vehicle role,0.6078947368421053
passive immunity to infectious agent,chronic infectious disease course,0.6818840579710145
passive immunity to infectious agent,asymptomatic infectious agent carrier,0.7513698630136986
passive immunity to infectious agent,descriptive information content entity,0.6797297297297297
passive immunity to infectious agent,COVID-19 epidemic,0.5632075471698114
passive immunity to infectious agent,resistance to drug,0.6166666666666667
passive immunity to infectious agent,sterilizing immunity to infectious agent,0.8578947368421052
passive immunity to infectious agent,diseased population,0.6136363636363636
passive immunity to infectious agent,virulence factor,0.6230769230769231
passive immunity to infectious agent,incubation end process boundary,0.5992537313432835
passive immunity to infectious agent,latency end temporal region,0.6404761904761905
passive immunity to infectious agent,innate immunity to infectious agent,0.8866197183098592
passive immunity to infectious agent,infectious structure,0.6642857142857143
passive immunity to infectious agent,static agent disposition,0.65
passive immunity to infectious agent,T cell receptor complex,0.6025423728813559
passive immunity to infectious agent,asymptomatic carrier role,0.6139344262295081
passive immunity to infectious agent,infectious structure host,0.6631147540983606
passive immunity to infectious agent,infectious agent population,0.7039682539682539
passive immunity to infectious agent,respiratory system disease,0.6274193548387097
passive immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.8234939759036144
passive immunity to infectious agent,humoral immunity to infectious agent,0.8666666666666667
passive immunity to infectious agent,infectious disease control strategy,0.6612676056338028
passive immunity to infectious agent,infectious disease pandemic,0.6722222222222223
passive immunity to infectious agent,infectious structure generative stage,0.6554794520547945
passive immunity to infectious agent,viral disease course,0.6285714285714286
passive immunity to infectious agent,passive immunity to infectious agent,0.95
passive immunity to infectious agent,infectious disposition,0.656896551724138
passive immunity to infectious agent,vaccination against infectious agent,0.7694444444444444
passive immunity to infectious agent,susceptibility to infectious agent,0.8357142857142859
passive immunity to infectious agent,immunity to pathogen,0.7535714285714286
passive immunity to infectious agent,disease course,0.63
passive immunity to infectious agent,infectious disease course,0.6631147540983606
passive immunity to infectious agent,acquired immunity to infectious agent,0.8883561643835617
passive immunity to infectious agent,COVID-19 disease incidence proportion,0.6280821917808219
passive immunity to infectious agent,coronavirus disease course,0.6435483870967742
passive immunity to infectious agent,asymptomatic carrier,0.6285714285714286
passive immunity to infectious agent,biological vehicle role,0.5686440677966101
passive immunity to infectious agent,symptomatic infectious agent carrier,0.7416666666666667
passive immunity to infectious agent,intermediate host,0.619811320754717
passive immunity to infectious agent,infectious disease prevalence,0.6653846153846155
passive immunity to infectious agent,infected population,0.6318181818181818
passive immunity to infectious agent,COVID-19 mortality rate,0.6025423728813559
passive immunity to infectious agent,viral disease,0.5928571428571429
passive immunity to infectious agent,leukocyte mediated immunity,0.6246031746031746
passive immunity to infectious agent,disease,0.5430232558139535
passive immunity to infectious agent,symptomatic infectious structure carrier,0.6868421052631578
passive immunity to infectious agent,primary infectious disposition,0.7075757575757575
passive immunity to infectious agent,designative information content entity,0.6797297297297297
passive immunity to infectious agent,symptomatic carrier role,0.6
passive immunity to infectious agent,infectious pathogen transmissibility,0.6722222222222223
passive immunity to infectious agent,intermediate host role,0.6224137931034482
passive immunity to infectious agent,infectious human pathogen,0.6959016393442623
passive immunity to infectious agent,resistance to pathogen,0.656896551724138
passive immunity to infectious agent,immunization against infectious agent,0.8061643835616438
passive immunity to infectious agent,infectious agent host,0.730701754385965
passive immunity to infectious agent,long-term non-progressing infectious disease course,0.6683908045977012
passive immunity to infectious agent,viral disease epidemic,0.6051724137931035
passive immunity to infectious agent,viral disease pandemic,0.6051724137931035
passive immunity to infectious agent,symptomatic carrier,0.6136363636363636
passive immunity to infectious agent,infectious disease endemicity,0.6807692307692308
passive immunity to infectious agent,function,0.609090909090909
passive immunity to infectious agent,herd immunity to infectious organism,0.825
passive immunity to infectious agent,pathogen transporter role,0.6139344262295081
passive immunity to infectious agent,infectious agent reservoir,0.7080645161290323
passive immunity to infectious agent,COVID-19 pandemic,0.5632075471698114
passive immunity to infectious agent,action specification,0.6464285714285714
passive immunity to infectious agent,protective resistance,0.6254385964912281
passive immunity to infectious agent,infectious disease control objective specification,0.636046511627907
passive immunity to infectious agent,opportunistic infectious disposition,0.7
passive immunity to infectious agent,polymerase chain reaction,0.6795081967213115
passive immunity to infectious agent,COVID-19 disease course,0.6194915254237288
passive immunity to infectious agent,infectious disease incidence rate,0.6673913043478261
passive immunity to infectious agent,single-stranded RNA retrovirus,0.6166666666666667
passive immunity to infectious agent,active immunization against infectious agent,0.8375
passive immunity to infectious agent,collective resistance disposition,0.6384057971014493
passive immunity to infectious agent,infectious agent,0.7576923076923078
passive immunity to infectious agent,establishment of a clinically abnormal colony,0.6228395061728395
passive immunity to infectious agent,coronavirus disease,0.6136363636363636
passive immunity to infectious agent,positive-sense single-stranded RNA virus,0.6342105263157894
passive immunity to infectious agent,adhesion factor,0.6264705882352941
passive immunity to infectious agent,drug susceptibility of infectious agent,0.7966666666666667
passive immunity to infectious agent,SARS-CoV-2 release stage,0.6166666666666667
passive immunity to infectious agent,static agent,0.6791666666666666
organism substance,extended organism,0.6785714285714286
organism substance,source of infection,0.5851351351351352
organism substance,information content entity,0.6318181818181818
organism substance,infectious structure aggregate,0.6375
organism substance,geographical entity,0.6121621621621621
organism substance,drug-based immunosuppressed organism,0.6351851851851852
organism substance,resistant entity,0.6558823529411765
organism substance,immunocompetent organism,0.6404761904761905
organism substance,virulence factor disposition,0.6021739130434782
organism substance,case isolation control strategy,0.6132653061224489
organism substance,material entity,0.6015151515151516
organism substance,asymptomatic infectious structure carrier,0.6364406779661017
organism substance,source of infection site,0.6404761904761905
organism substance,architectual structure,0.625
organism substance,B cell receptor complex,0.5719512195121951
organism substance,entity,0.575
organism substance,directive information content entity,0.5981481481481481
organism substance,acellular structure aggregate,0.598936170212766
organism substance,invasion factor,0.6015151515151516
organism substance,realizable entity,0.5928571428571429
organism substance,pathologically immunosuppressed organism,0.6224137931034482
organism substance,infectious structure host role,0.6375
organism substance,descriptive information content entity,0.5928571428571429
organism substance,establishment of localization in human host,0.5811475409836065
organism substance,acellular structure,0.6121621621621621
organism substance,virulence factor,0.5970588235294118
organism substance,molecular entity,0.5970588235294118
organism substance,immunosuppressed organism,0.636046511627907
organism substance,plan specification,0.6166666666666667
organism substance,infectious structure,0.6605263157894737
organism substance,T cell receptor complex,0.5719512195121951
organism substance,infectious structure host,0.636046511627907
organism substance,organism population,0.7743243243243243
organism substance,infectious structure generative stage,0.6318181818181818
organism substance,source of infection role,0.5928571428571429
organism substance,susceptible organism,0.6605263157894737
organism substance,organism substance,0.95
organism substance,anatomical entity,0.5928571428571429
organism substance,geopolitical entity,0.5851351351351352
organism substance,symptomatic infectious structure carrier,0.6396551724137931
organism substance,designative information content entity,0.5928571428571429
organism substance,object,0.575
organism substance,immunodeficient organism,0.6404761904761905
organism substance,infectious human pathogen,0.636046511627907
organism substance,colonization of human,0.6294871794871795
organism substance,immaterial entity,0.5928571428571429
organism substance,object aggregate,0.6264705882352941
organism substance,division of geopolitical entity,0.5724489795918367
organism substance,geographical feature,0.6342105263157894
organism substance,herd immunity to infectious organism,0.5981481481481481
organism substance,action specification,0.6078947368421053
organism substance,processed material,0.5888888888888889
organism substance,organism,0.7576923076923078
organism substance,establishment of a clinically abnormal colony,0.5769841269841269
organism substance,adhesion factor,0.6015151515151516
organism substance,material processing,0.6121621621621621
homo sapiens,homo sapiens,0.95
homo sapiens,establishment of a clinically abnormal colony,0.5728070175438597
infectious disease epidemic,virus aggregate,0.6166666666666667
infectious disease epidemic,source of infection,0.6239130434782608
infectious disease epidemic,virostatic disposition,0.6540816326530612
infectious disease epidemic,zoonotic disposition,0.6627659574468084
infectious disease epidemic,infectious disease mortality rate,0.8
infectious disease epidemic,infection incidence rate profile,0.738135593220339
infectious disease epidemic,infectious structure aggregate,0.730701754385965
infectious disease epidemic,communicability end temporal region,0.6274193548387097
infectious disease epidemic,subclinical coronavirus infection,0.6166666666666667
infectious disease epidemic,infection end temporal region,0.7178571428571427
infectious disease epidemic,infectious disease,0.85
infectious disease epidemic,double-stranded DNA virus,0.6038461538461539
infectious disease epidemic,incubation end temporal region,0.6780701754385965
infectious disease epidemic,site of infection,0.6318181818181818
infectious disease epidemic,virulence factor disposition,0.6863636363636364
infectious disease epidemic,viral adhesion disposition,0.6575471698113208
infectious disease epidemic,parasitostatic disposition,0.6575471698113208
infectious disease epidemic,infectious disease incidence,0.8681818181818182
infectious disease epidemic,reverse zoonotic disposition,0.6318181818181818
infectious disease epidemic,subclinical SARS-CoV-2 infection,0.6364406779661017
infectious disease epidemic,virus translation stage,0.63
infectious disease epidemic,disease surveillance objective specification,0.6471830985915493
infectious disease epidemic,virus release stage,0.6673913043478261
infectious disease epidemic,infectious agent host role,0.7330188679245283
infectious disease epidemic,asymptomatic infectious structure carrier,0.6852941176470588
infectious disease epidemic,source of infection site,0.6852941176470588
infectious disease epidemic,virus,0.54375
infectious disease epidemic,virus replication,0.6318181818181818
infectious disease epidemic,B cell receptor complex,0.59
infectious disease epidemic,passive immunization against infectious agent,0.6305555555555555
infectious disease epidemic,systematic infection,0.6202127659574468
infectious disease epidemic,infection incidence rate,0.7245098039215686
infectious disease epidemic,virus host,0.5851351351351352
infectious disease epidemic,double-stranded RNA virus,0.6038461538461539
infectious disease epidemic,virus transcription stage,0.6423076923076922
infectious disease epidemic,infectious disease lifetime prevalence,0.8038461538461539
infectious disease epidemic,toxin disposition,0.6545454545454545
infectious disease epidemic,lower respiratory tract disease,0.6396551724137931
infectious disease epidemic,infectious disease incidence proportion,0.7984848484848485
infectious disease epidemic,virus generative stage,0.6336734693877552
infectious disease epidemic,acute infectious disease course,0.7948275862068965
infectious disease epidemic,cidal agent disposition,0.65
infectious disease epidemic,infectious disorder,0.7978260869565217
infectious disease epidemic,subclinical infection,0.6166666666666667
infectious disease epidemic,appearance of disorder,0.6336734693877552
infectious disease epidemic,simple infection,0.636046511627907
infectious disease epidemic,parasiticidal disposition,0.6423076923076922
infectious disease epidemic,infectious disease sporadicity,0.8535087719298246
infectious disease epidemic,communicability end process boundary,0.5928571428571429
infectious disease epidemic,infection incidence proportion profile,0.6961538461538461
infectious disease epidemic,infectious agent colony,0.75
infectious disease epidemic,transmissibility disposition,0.6318181818181818
infectious disease epidemic,latency end process boundary,0.5954545454545455
infectious disease epidemic,infectious disease epidemic,0.95
infectious disease epidemic,infectious agent generative stage,0.7333333333333333
infectious disease epidemic,disease transmission model,0.6575471698113208
infectious disease epidemic,endotoxin disposition,0.6583333333333334
infectious disease epidemic,negative-sense single-stranded RNA virus,0.6440298507462687
infectious disease epidemic,infectious structure host role,0.730701754385965
infectious disease epidemic,cytotoxin disposition,0.6583333333333334
infectious disease epidemic,community-acquired infection,0.6318181818181818
infectious disease epidemic,chronic infectious disease course,0.7833333333333333
infectious disease epidemic,asymptomatic infectious agent carrier,0.7
infectious disease epidemic,nursing-home acquired infection,0.6396551724137931
infectious disease epidemic,COVID-19 epidemic,0.7227272727272727
infectious disease epidemic,secondary infection,0.6456521739130434
infectious disease epidemic,infection start temporal region,0.7258620689655172
infectious disease epidemic,infection incidence,0.7543478260869566
infectious disease epidemic,virus disorder,0.6695121951219513
infectious disease epidemic,sterilizing immunity to infectious agent,0.6440298507462687
infectious disease epidemic,diseased population,0.6673913043478261
infectious disease epidemic,primary infection,0.6318181818181818
infectious disease epidemic,process of establishing an infection,0.6246031746031746
infectious disease epidemic,incubation end process boundary,0.656896551724138
infectious disease epidemic,SARS-CoV-2 disorder,0.6239130434782608
infectious disease epidemic,collective pathogenic disposition,0.65
infectious disease epidemic,neurotoxin disposition,0.6744897959183673
infectious disease epidemic,latency end temporal region,0.6166666666666667
infectious disease epidemic,innate immunity to infectious agent,0.6596774193548387
infectious disease epidemic,infectious structure,0.7265957446808511
infectious disease epidemic,virus adhesion susceptible cell,0.6741379310344828
infectious disease epidemic,collective disposition,0.6744897959183673
infectious disease epidemic,infection,0.6722222222222223
infectious disease epidemic,static agent disposition,0.6460784313725491
infectious disease epidemic,T cell receptor complex,0.59
infectious disease epidemic,infectious structure host,0.7192307692307692
infectious disease epidemic,infectious agent population,0.7462962962962962
infectious disease epidemic,respiratory system disease,0.6764150943396227
infectious disease epidemic,leukocyte-mediated immunity to infectious agent,0.6256756756756756
infectious disease epidemic,humoral immunity to infectious agent,0.6563492063492063
infectious disease epidemic,infectious disease control strategy,0.7725806451612902
infectious disease epidemic,infectious disease pandemic,0.9129629629629631
infectious disease epidemic,infectious structure generative stage,0.715625
infectious disease epidemic,immunosuppressive disposition,0.6642857142857143
infectious disease epidemic,pathogenic disposition,0.6336734693877552
infectious disease epidemic,viral disease course,0.6840425531914894
infectious disease epidemic,intracellular infection,0.63
infectious disease epidemic,secondary infection role,0.6460784313725491
infectious disease epidemic,metastatic infection,0.6202127659574468
infectious disease epidemic,passive immunity to infectious agent,0.6563492063492063
infectious disease epidemic,infectious disposition,0.7969387755102041
infectious disease epidemic,vaccination against infectious agent,0.6563492063492063
infectious disease epidemic,acute infection,0.6404761904761905
infectious disease epidemic,susceptibility to infectious agent,0.6631147540983606
infectious disease epidemic,bacteriostatic disposition,0.6764150943396227
infectious disease epidemic,bactericidal disposition,0.6460784313725491
infectious disease epidemic,source of infection role,0.6460784313725491
infectious disease epidemic,chronic infection,0.6318181818181818
infectious disease epidemic,invasion disposition,0.6840425531914894
infectious disease epidemic,disease course,0.6695121951219513
infectious disease epidemic,infectious disease course,0.8346153846153846
infectious disease epidemic,viricidal disposition,0.6583333333333334
infectious disease epidemic,acquired immunity to infectious agent,0.653125
infectious disease epidemic,complex infection,0.6318181818181818
infectious disease epidemic,COVID-19 disease incidence proportion,0.684375
infectious disease epidemic,coronavirus disease course,0.7141509433962264
infectious disease epidemic,infection incidence proportion,0.7131578947368421
infectious disease epidemic,symptomatic infectious agent carrier,0.7039682539682539
infectious disease epidemic,respiratory droplet virus fomite,0.6194915254237288
infectious disease epidemic,infectious disease prevalence,0.8428571428571427
infectious disease epidemic,disposition,0.6078947368421053
infectious disease epidemic,single-stranded DNA virus,0.6230769230769231
infectious disease epidemic,infected population,0.6673913043478261
infectious disease epidemic,viral disease,0.675
infectious disease epidemic,primary infection role,0.6540816326530612
infectious disease epidemic,adhesion disposition,0.6627659574468084
infectious disease epidemic,infection incidence profile,0.7462962962962962
infectious disease epidemic,disease,0.6558823529411765
infectious disease epidemic,symptomatic infectious structure carrier,0.6888059701492537
infectious disease epidemic,primary infectious disposition,0.7482456140350877
infectious disease epidemic,infection prevalence,0.7265957446808511
infectious disease epidemic,coronavirus disorder,0.6627659574468084
infectious disease epidemic,infectious pathogen transmissibility,0.7039682539682539
infectious disease epidemic,infectious human pathogen,0.7384615384615384
infectious disease epidemic,subclinical virus infection,0.6351851851851852
infectious disease epidemic,establishment of localization in virus host,0.6071428571428572
infectious disease epidemic,immunization against infectious agent,0.653125
infectious disease epidemic,virus attachment stage,0.6132653061224489
infectious disease epidemic,virus synthesis stage,0.6375
infectious disease epidemic,SARS-COV-2 adhesion disposition,0.6224137931034482
infectious disease epidemic,invasive disposition,0.6627659574468084
infectious disease epidemic,infectious agent host,0.7416666666666667
infectious disease epidemic,long-term non-progressing infectious disease course,0.7064102564102563
infectious disease epidemic,viral disease epidemic,0.8173469387755102
infectious disease epidemic,fungicidal disposition,0.6540816326530612
infectious disease epidemic,viral disease pandemic,0.7765306122448979
infectious disease epidemic,virus penetration stage,0.65
infectious disease epidemic,acute respiratory distress syndrome,0.6596774193548387
infectious disease epidemic,infectious disease endemicity,0.8964285714285714
infectious disease epidemic,disorder,0.5928571428571429
infectious disease epidemic,herd immunity to infectious organism,0.6722222222222223
infectious disease epidemic,extracellular infection,0.61
infectious disease epidemic,exotoxin disposition,0.6627659574468084
infectious disease epidemic,infectious agent reservoir,0.7707547169811321
infectious disease epidemic,COVID-19 pandemic,0.6772727272727272
infectious disease epidemic,infection start process boundary,0.6872881355932203
infectious disease epidemic,infectious disease control objective specification,0.7616883116883116
infectious disease epidemic,opportunistic infectious disposition,0.7198412698412698
infectious disease epidemic,process of establishing viral infection,0.6318181818181818
infectious disease epidemic,enterotoxin disposition,0.67
infectious disease epidemic,COVID-19 disease course,0.69
infectious disease epidemic,infectious disease incidence rate,0.8333333333333335
infectious disease epidemic,active immunization against infectious agent,0.6330985915492958
infectious disease epidemic,disordered virus,0.6127906976744186
infectious disease epidemic,collective resistance disposition,0.6666666666666667
infectious disease epidemic,fungistatic disposition,0.65
infectious disease epidemic,virus uncoating stage,0.6375
infectious disease epidemic,local infection,0.6404761904761905
infectious disease epidemic,infectious agent,0.7523255813953489
infectious disease epidemic,establishment of a clinically abnormal colony,0.5888888888888889
infectious disease epidemic,coronavirus disease,0.7108695652173913
infectious disease epidemic,positive-sense single-stranded RNA virus,0.6291044776119403
infectious disease epidemic,hospital-acquired infection,0.6166666666666667
infectious disease epidemic,drug susceptibility of infectious agent,0.6469696969696969
biological process,immune response,0.6318181818181818
biological process,infectious disease mortality rate,0.6068627450980393
biological process,infection incidence rate profile,0.65
biological process,communicability end temporal region,0.619811320754717
biological process,pathogen generative stage,0.5895348837209302
biological process,biological regulation,0.7833333333333333
biological process,primary pathogen,0.6264705882352941
biological process,surveillance process,0.7394736842105263
biological process,infection end temporal region,0.6202127659574468
biological process,SARS-CoV-2 incidence rate,0.5895348837209302
biological process,incubation end temporal region,0.6375
biological process,virus translation stage,0.5719512195121951
biological process,case isolation control strategy,0.6336734693877552
biological process,virus release stage,0.6121621621621621
biological process,B cell receptor complex,0.6451219512195122
biological process,infection incidence rate,0.6166666666666667
biological process,virus transcription stage,0.5662790697674418
biological process,virus generative stage,0.575
biological process,acute infectious disease course,0.5928571428571429
biological process,process,0.73
biological process,biological vehicle,0.8111111111111111
biological process,droplet pathogen transmission process,0.6863636363636364
biological process,communicability end process boundary,0.6907407407407408
biological process,latency end process boundary,0.6673913043478261
biological process,infectious agent generative stage,0.5872549019607843
biological process,COVID-19 incidence rate,0.5963414634146341
biological process,negative regulation of developmental process,0.6758064516129032
biological process,chronic infectious disease course,0.6068627450980393
biological process,primary infection,0.5642857142857143
biological process,process of establishing an infection,0.5796296296296296
biological process,incubation end process boundary,0.6744897959183673
biological process,SARS-CoV-2 uncoating stage,0.5636363636363636
biological process,pathogen death process boundary,0.6744897959183673
biological process,plan specification,0.5888888888888889
biological process,latency end temporal region,0.6055555555555556
biological process,innate immunity to infectious agent,0.5632075471698114
biological process,SARS-CoV-2 penetration stage,0.5804347826086956
biological process,virus adhesion susceptible cell,0.5928571428571429
biological process,anatomical space,0.7147058823529412
biological process,T cell receptor complex,0.6207317073170732
biological process,respiratory system disease,0.5863636363636363
biological process,biological vector,0.7928571428571428
biological process,indirect pathogen transmission process,0.6642857142857143
biological process,planned process,0.7530303030303032
biological process,generative stage,0.5676470588235294
biological process,SARS-CoV-2 attachment stage,0.5833333333333334
biological process,infectious structure generative stage,0.5772727272727273
biological process,innate immune response,0.625
biological process,viral disease course,0.6342105263157894
biological process,cell,0.5409090909090909
biological process,disease course,0.60625
biological process,infectious disease course,0.6127906976744186
biological process,coronavirus disease course,0.609090909090909
biological process,biological vehicle role,0.7914634146341464
biological process,anatomical entity,0.65
biological process,SARS-CoV-2 genome replication stage,0.5820754716981132
biological process,COVID-19 mortality rate,0.6207317073170732
biological process,process profile,0.6621212121212122
biological process,negative regulation of life-sustaining process,0.653125
biological process,primary infection role,0.625
biological process,primary immunodeficiency,0.5928571428571429
biological process,biological role,0.8742424242424243
biological process,developmental process,0.7576923076923078
biological process,biological process,0.95
biological process,biological vector role,0.8
biological process,primary infectious disposition,0.5958333333333333
biological process,humoral immune response,0.6451219512195122
biological process,SARS-COV-2 adhesion susceptible cell,0.5796296296296296
biological process,incubation start process boundary,0.6852941176470588
biological process,pathogen birth process boundary,0.6744897959183673
biological process,virus attachment stage,0.575
biological process,negative regulation of immune response,0.6107142857142857
biological process,SARS-CoV-2 transcription stage,0.5541666666666667
biological process,virus synthesis stage,0.5782051282051281
biological process,long-term non-progressing infectious disease course,0.6094202898550725
biological process,virus penetration stage,0.5963414634146341
biological process,algorithm,0.5611111111111111
biological process,negative regulation of viral process,0.7092592592592593
biological process,contact pathogen transmission process,0.6681818181818181
biological process,function,0.5269230769230769
biological process,symbiotic process,0.8214285714285714
biological process,infection start process boundary,0.67
biological process,action specification,0.6078947368421053
biological process,SARS-CoV-2 synthesis stage,0.5863636363636363
biological process,latency start process boundary,0.6791666666666666
biological process,process of establishing viral infection,0.5903508771929825
biological process,negative regulation of biological process,0.7550847457627118
biological process,polymerase chain reaction,0.6127906976744186
biological process,COVID-19 disease course,0.5963414634146341
biological process,infectious disease incidence rate,0.5872549019607843
biological process,communicability start process boundary,0.6821428571428573
biological process,process that results in death,0.6202127659574468
biological process,adaptive immune response,0.6166666666666667
biological process,virus uncoating stage,0.5782051282051281
biological process,establishment of a clinically abnormal colony,0.6246031746031746
biological process,process boundary,0.6558823529411765
biological process,horizontal pathogen transmission process,0.6913793103448276
biological process,SARS-CoV-2 release stage,0.5928571428571429
biological process,pathogen transmission process,0.6840425531914894
biological process,cell space,0.6642857142857143
invasive disposition,virostatic disposition,0.8071428571428573
invasive disposition,information content entity,0.6239130434782608
invasive disposition,zoonotic disposition,0.8
invasive disposition,infectious disease mortality rate,0.6386792452830189
invasive disposition,infection incidence rate profile,0.6038461538461539
invasive disposition,infectious structure aggregate,0.59
invasive disposition,communicability end temporal region,0.6318181818181818
invasive disposition,geographical entity,0.5782051282051281
invasive disposition,biological regulation,0.6207317073170732
invasive disposition,surveillance process,0.625
invasive disposition,infection end temporal region,0.6540816326530612
invasive disposition,vector control strategy,0.5895348837209302
invasive disposition,SARS-CoV-2 incidence rate,0.6055555555555556
invasive disposition,incubation end temporal region,0.67
invasive disposition,resistant entity,0.5888888888888889
invasive disposition,virulence factor disposition,0.7625
invasive disposition,viral adhesion disposition,0.7978260869565217
invasive disposition,parasitostatic disposition,0.7760869565217391
invasive disposition,negative regulation of production,0.6952830188679244
invasive disposition,reverse zoonotic disposition,0.7625
invasive disposition,establishment of localization in host,0.6254385964912281
invasive disposition,disease surveillance objective specification,0.66875
invasive disposition,case isolation control strategy,0.6656862745098039
invasive disposition,infectious agent host role,0.6456521739130434
invasive disposition,macromolecular complex,0.5452380952380953
invasive disposition,material entity,0.5928571428571429
invasive disposition,asymptomatic infectious structure carrier,0.5975409836065574
invasive disposition,architectual structure,0.5928571428571429
invasive disposition,quarantine control strategy,0.598936170212766
invasive disposition,B cell receptor complex,0.5662790697674418
invasive disposition,infection incidence rate,0.6318181818181818
invasive disposition,colonized host,0.6558823529411765
invasive disposition,virus host,0.65
invasive disposition,entity,0.5653846153846154
invasive disposition,toxin disposition,0.8283783783783784
invasive disposition,cidal agent disposition,0.7988372093023256
invasive disposition,parasiticidal disposition,0.7833333333333333
invasive disposition,communicability end process boundary,0.6285714285714286
invasive disposition,directive information content entity,0.6464285714285714
invasive disposition,acellular structure aggregate,0.5520408163265306
invasive disposition,transmissibility disposition,0.7625
invasive disposition,latency end process boundary,0.6375
invasive disposition,colonization of host,0.625
invasive disposition,realizable entity,0.6121621621621621
invasive disposition,endotoxin disposition,0.7914634146341464
invasive disposition,vector surveillance,0.6038461538461539
invasive disposition,negative regulation of establishment of localization,0.6444444444444444
invasive disposition,infectious structure host role,0.63
invasive disposition,COVID-19 incidence rate,0.5895348837209302
invasive disposition,cytotoxin disposition,0.7914634146341464
invasive disposition,negative regulation of developmental process,0.60625
invasive disposition,host,0.575
invasive disposition,descriptive information content entity,0.6396551724137931
invasive disposition,negative regulation of replication,0.6907407407407408
invasive disposition,establishment of localization in human host,0.6087301587301588
invasive disposition,acellular structure,0.5782051282051281
invasive disposition,incubation end process boundary,0.6656862745098039
invasive disposition,collective pathogenic disposition,0.7518867924528303
invasive disposition,neurotoxin disposition,0.7833333333333333
invasive disposition,dead-end host role,0.6342105263157894
invasive disposition,molecular entity,0.5611111111111111
invasive disposition,plan specification,0.6868421052631578
invasive disposition,definitive host role,0.7
invasive disposition,latency end temporal region,0.6414893617021277
invasive disposition,infectious structure,0.625
invasive disposition,collective disposition,0.8071428571428573
invasive disposition,static agent disposition,0.7909090909090909
invasive disposition,T cell receptor complex,0.5662790697674418
invasive disposition,infectious structure host,0.6277777777777778
invasive disposition,respiratory system disease,0.6456521739130434
invasive disposition,entry into host,0.6214285714285714
invasive disposition,adhesion of symbiont to host,0.6375
invasive disposition,infectious disease control strategy,0.6318181818181818
invasive disposition,infectious structure generative stage,0.6078947368421053
invasive disposition,immunosuppressive disposition,0.8173469387755102
invasive disposition,pathogenic disposition,0.7833333333333333
invasive disposition,entry into host through host barriers,0.5903508771929825
invasive disposition,infectious disposition,0.8071428571428573
invasive disposition,bacteriostatic disposition,0.7760869565217391
invasive disposition,bactericidal disposition,0.7681818181818181
invasive disposition,pathogen host,0.6318181818181818
invasive disposition,invasion disposition,0.9
invasive disposition,viricidal disposition,0.7914634146341464
invasive disposition,complex infection,0.6391891891891892
invasive disposition,intermediate host,0.6662162162162162
invasive disposition,anatomical entity,0.6121621621621621
invasive disposition,disposition,0.8048387096774193
invasive disposition,COVID-19 mortality rate,0.5895348837209302
invasive disposition,negative regulation of life-sustaining process,0.6318181818181818
invasive disposition,place closure control strategy,0.59
invasive disposition,geopolitical entity,0.6294871794871795
invasive disposition,adhesion disposition,0.825
invasive disposition,symptomatic infectious structure carrier,0.5833333333333334
invasive disposition,primary infectious disposition,0.77
invasive disposition,pathogen host role,0.6342105263157894
invasive disposition,designative information content entity,0.6741379310344828
invasive disposition,intermediate host role,0.6642857142857143
invasive disposition,dead-end host,0.6318181818181818
invasive disposition,pathogen surveillance,0.5963414634146341
invasive disposition,host role,0.5879310344827586
invasive disposition,establishment of localization in virus host,0.6087301587301588
invasive disposition,negative regulation of immune response,0.6396551724137931
invasive disposition,immaterial entity,0.6121621621621621
invasive disposition,SARS-COV-2 adhesion disposition,0.7637254901960785
invasive disposition,invasive disposition,0.95
invasive disposition,infectious agent host,0.6451219512195122
invasive disposition,fungicidal disposition,0.7833333333333333
invasive disposition,division of geopolitical entity,0.6656862745098039
invasive disposition,negative regulation of viral process,0.6285714285714286
invasive disposition,exotoxin disposition,0.8
invasive disposition,immunoglobulin complex,0.569047619047619
invasive disposition,infectious disease control objective specification,0.6642857142857143
invasive disposition,symbiont host role,0.6342105263157894
invasive disposition,opportunistic infectious disposition,0.7357142857142857
invasive disposition,negative regulation of biological process,0.630327868852459
invasive disposition,enterotoxin disposition,0.7755813953488372
invasive disposition,infectious disease incidence rate,0.6575471698113208
invasive disposition,collective resistance disposition,0.7707547169811321
invasive disposition,fungistatic disposition,0.7988372093023256
invasive disposition,establishment of a clinically abnormal colony,0.5884615384615385
invasive disposition,definitive host,0.7071428571428571
primary immunodeficiency,communicability end temporal region,0.6025423728813559
primary immunodeficiency,primary pathogen,0.725
primary immunodeficiency,infection end temporal region,0.5820754716981132
primary immunodeficiency,vector control strategy,0.5776595744680851
primary immunodeficiency,incubation end temporal region,0.5981481481481481
primary immunodeficiency,case isolation control strategy,0.5954545454545455
primary immunodeficiency,quarantine control strategy,0.6068627450980393
primary immunodeficiency,B cell receptor complex,0.5563829787234043
primary immunodeficiency,lower respiratory tract disease,0.6136363636363636
primary immunodeficiency,simple infection,0.675
primary immunodeficiency,communicability end process boundary,0.6333333333333333
primary immunodeficiency,latency end process boundary,0.6230769230769231
primary immunodeficiency,primary infection,0.7914634146341464
primary immunodeficiency,incubation end process boundary,0.6136363636363636
primary immunodeficiency,immunodeficiency,0.85
primary immunodeficiency,latency end temporal region,0.6068627450980393
primary immunodeficiency,T cell receptor complex,0.5563829787234043
primary immunodeficiency,infectious disease control strategy,0.5855932203389831
primary immunodeficiency,acquired immunodeficiency,0.8377551020408163
primary immunodeficiency,place closure control strategy,0.5981481481481481
primary immunodeficiency,primary infection role,0.7543478260869566
primary immunodeficiency,primary immunodeficiency,0.95
primary immunodeficiency,primary infectious disposition,0.7277777777777777
primary immunodeficiency,infectious disease control objective specification,0.5986486486486486
primary immunodeficiency,establishment of a clinically abnormal colony,0.6094202898550725
epitope,epitope,0.95
epitope,T cell receptor complex,0.65
epitope,epitope site,0.8184210526315789
epitope,epitope role,0.8184210526315789
viremia,viremia,0.95
viremia,establishment of a clinically abnormal colony,0.5269230769230769
source of infection site,virus aggregate,0.5782051282051281
source of infection site,source of infection,0.891860465116279
source of infection site,virostatic disposition,0.6456521739130434
source of infection site,zoonotic disposition,0.6545454545454545
source of infection site,infectious disease mortality rate,0.6780701754385965
source of infection site,infection incidence rate profile,0.6821428571428573
source of infection site,infectious structure aggregate,0.6722222222222223
source of infection site,communicability end temporal region,0.6364406779661017
source of infection site,subclinical coronavirus infection,0.7131578947368421
source of infection site,primary pathogen,0.575
source of infection site,infection end temporal region,0.6764150943396227
source of infection site,geospatial location,0.636046511627907
source of infection site,infectious disease,0.7119047619047619
source of infection site,double-stranded DNA virus,0.6132653061224489
source of infection site,incubation end temporal region,0.6351851851851852
source of infection site,site of infection,0.8158536585365854
source of infection site,virulence factor disposition,0.6807692307692308
source of infection site,viral adhesion disposition,0.65
source of infection site,parasitostatic disposition,0.65
source of infection site,infectious disease incidence,0.6807692307692308
source of infection site,reverse zoonotic disposition,0.6615384615384616
source of infection site,subclinical SARS-CoV-2 infection,0.7178571428571427
source of infection site,virus translation stage,0.6840425531914894
source of infection site,disease surveillance objective specification,0.6705882352941177
source of infection site,virus release stage,0.636046511627907
source of infection site,asymptomatic infectious structure carrier,0.6961538461538461
source of infection site,source of infection site,0.95
source of infection site,architectual structure,0.6673913043478261
source of infection site,virus,0.5189655172413793
source of infection site,virus replication,0.6695121951219513
source of infection site,B cell receptor complex,0.6414893617021277
source of infection site,systematic infection,0.7227272727272727
source of infection site,infection incidence rate,0.7208333333333333
source of infection site,virus host,0.5970588235294118
source of infection site,double-stranded RNA virus,0.6132653061224489
source of infection site,virus transcription stage,0.6948979591836735
source of infection site,infectious disease lifetime prevalence,0.6596774193548387
source of infection site,toxin disposition,0.6451219512195122
source of infection site,pathogen birth temporal region,0.6166666666666667
source of infection site,lower respiratory tract disease,0.6318181818181818
source of infection site,infectious disease incidence proportion,0.6404761904761905
source of infection site,virus generative stage,0.6673913043478261
source of infection site,acute infectious disease course,0.7045454545454546
source of infection site,cidal agent disposition,0.6414893617021277
source of infection site,infectious disorder,0.7058139534883722
source of infection site,subclinical infection,0.7388888888888888
source of infection site,appearance of disorder,0.6673913043478261
source of infection site,simple infection,0.75
source of infection site,parasiticidal disposition,0.6336734693877552
source of infection site,infectious disease sporadicity,0.6722222222222223
source of infection site,communicability end process boundary,0.6
source of infection site,acellular structure aggregate,0.6009433962264151
source of infection site,infection incidence proportion profile,0.6758064516129032
source of infection site,transmissibility disposition,0.6038461538461539
source of infection site,latency end process boundary,0.5846153846153846
source of infection site,infectious disease epidemic,0.6852941176470588
source of infection site,disease transmission model,0.63
source of infection site,endotoxin disposition,0.65
source of infection site,negative-sense single-stranded RNA virus,0.60625
source of infection site,infectious structure host role,0.6722222222222223
source of infection site,cytotoxin disposition,0.65
source of infection site,community-acquired infection,0.7192307692307692
source of infection site,chronic infectious disease course,0.6956140350877194
source of infection site,nursing-home acquired infection,0.7227272727272727
source of infection site,COVID-19 epidemic,0.5963414634146341
source of infection site,secondary infection,0.7523255813953489
source of infection site,infection start temporal region,0.6863636363636364
source of infection site,infection incidence,0.7290697674418604
source of infection site,virus disorder,0.581578947368421
source of infection site,acellular structure,0.5895348837209302
source of infection site,primary infection,0.7182926829268292
source of infection site,process of establishing an infection,0.7166666666666667
source of infection site,incubation end process boundary,0.6136363636363636
source of infection site,SARS-CoV-2 disorder,0.636046511627907
source of infection site,collective pathogenic disposition,0.6605263157894737
source of infection site,neurotoxin disposition,0.6673913043478261
source of infection site,plan specification,0.6642857142857143
source of infection site,latency end temporal region,0.6264705882352941
source of infection site,infectious structure,0.7227272727272727
source of infection site,virus adhesion susceptible cell,0.6318181818181818
source of infection site,anatomical space,0.6
source of infection site,collective disposition,0.6673913043478261
source of infection site,infection,0.7227272727272727
source of infection site,static agent disposition,0.6583333333333334
source of infection site,T cell receptor complex,0.6414893617021277
source of infection site,infectious structure host,0.6948979591836735
source of infection site,respiratory system disease,0.63
source of infection site,communicability interval,0.6375
source of infection site,infectious disease control strategy,0.6703389830508475
source of infection site,infectious disease pandemic,0.6656862745098039
source of infection site,infectious structure generative stage,0.6795081967213115
source of infection site,immunosuppressive disposition,0.6575471698113208
source of infection site,pathogenic disposition,0.6456521739130434
source of infection site,viral disease course,0.6318181818181818
source of infection site,intracellular infection,0.7265957446808511
source of infection site,secondary infection role,0.7625
source of infection site,metastatic infection,0.7227272727272727
source of infection site,infectious disposition,0.7108695652173913
source of infection site,acute infection,0.7576923076923078
source of infection site,bacteriostatic disposition,0.65
source of infection site,epitope site,0.7
source of infection site,bactericidal disposition,0.6375
source of infection site,source of infection role,0.8875
source of infection site,chronic infection,0.7426829268292683
source of infection site,invasion disposition,0.6545454545454545
source of infection site,disease course,0.6342105263157894
source of infection site,infectious disease course,0.6744897959183673
source of infection site,viricidal disposition,0.65
source of infection site,complex infection,0.7426829268292683
source of infection site,COVID-19 disease incidence proportion,0.630327868852459
source of infection site,coronavirus disease course,0.65
source of infection site,infection incidence proportion,0.6722222222222223
source of infection site,respiratory droplet virus fomite,0.6642857142857143
source of infection site,pathogen portal of exit site,0.7
source of infection site,infectious disease prevalence,0.6575471698113208
source of infection site,disposition,0.65
source of infection site,single-stranded DNA virus,0.6132653061224489
source of infection site,place closure control strategy,0.6907407407407408
source of infection site,viral disease,0.6121621621621621
source of infection site,primary infection role,0.7326086956521739
source of infection site,primary immunodeficiency,0.6166666666666667
source of infection site,adhesion disposition,0.6545454545454545
source of infection site,pathogen portal of entry site,0.6952830188679244
source of infection site,infection incidence profile,0.6852941176470588
source of infection site,contagiousness,0.6605263157894737
source of infection site,disease,0.5790322580645162
source of infection site,symptomatic infectious structure carrier,0.7
source of infection site,site,0.5928571428571429
source of infection site,primary infectious disposition,0.7092592592592593
source of infection site,infection prevalence,0.7
source of infection site,coronavirus disorder,0.6318181818181818
source of infection site,incubation start process boundary,0.6429824561403508
source of infection site,pathogen birth process boundary,0.5772727272727273
source of infection site,subclinical virus infection,0.7245098039215686
source of infection site,establishment of localization in virus host,0.658955223880597
source of infection site,virus attachment stage,0.6456521739130434
source of infection site,virus synthesis stage,0.65
source of infection site,SARS-COV-2 adhesion disposition,0.6863636363636364
source of infection site,invasive disposition,0.6545454545454545
source of infection site,long-term non-progressing infectious disease course,0.6633333333333334
source of infection site,viral disease epidemic,0.6021739130434782
source of infection site,communicability start temporal region,0.6139344262295081
source of infection site,fungicidal disposition,0.6456521739130434
source of infection site,blood,0.5189655172413793
source of infection site,viral disease pandemic,0.5804347826086956
source of infection site,virus penetration stage,0.7053191489361703
source of infection site,acute respiratory distress syndrome,0.6194915254237288
source of infection site,infectious disease endemicity,0.6764150943396227
source of infection site,disorder,0.575
source of infection site,communicability,0.6294871794871795
source of infection site,extracellular infection,0.7265957446808511
source of infection site,exotoxin disposition,0.6545454545454545
source of infection site,infection start process boundary,0.6821428571428573
source of infection site,action specification,0.6772727272727272
source of infection site,latency start process boundary,0.5796296296296296
source of infection site,infectious disease control objective specification,0.6391891891891892
source of infection site,opportunistic infectious disposition,0.7166666666666667
source of infection site,process of establishing viral infection,0.7039682539682539
source of infection site,enterotoxin disposition,0.6627659574468084
source of infection site,COVID-19 disease course,0.6414893617021277
source of infection site,infectious disease incidence rate,0.6780701754385965
source of infection site,communicability start process boundary,0.5951612903225807
source of infection site,single-stranded RNA retrovirus,0.6166666666666667
source of infection site,disordered virus,0.625
source of infection site,collective resistance disposition,0.6605263157894737
source of infection site,fungistatic disposition,0.6414893617021277
source of infection site,virus uncoating stage,0.6944444444444444
source of infection site,local infection,0.7576923076923078
source of infection site,establishment of a clinically abnormal colony,0.6094202898550725
source of infection site,coronavirus disease,0.636046511627907
source of infection site,positive-sense single-stranded RNA virus,0.60625
source of infection site,hospital-acquired infection,0.7245098039215686
source of infection site,cell space,0.5970588235294118
metastatic infection,virus aggregate,0.5642857142857143
metastatic infection,source of infection,0.7576923076923078
metastatic infection,virostatic disposition,0.7357142857142857
metastatic infection,zoonotic disposition,0.675
metastatic infection,infectious disease mortality rate,0.619811320754717
metastatic infection,infection incidence rate profile,0.6423076923076922
metastatic infection,communicability end temporal region,0.6136363636363636
metastatic infection,subclinical coronavirus infection,0.6952830188679244
metastatic infection,infection end temporal region,0.6336734693877552
metastatic infection,infectious disease,0.6605263157894737
metastatic infection,double-stranded DNA virus,0.6055555555555556
metastatic infection,incubation end temporal region,0.63
metastatic infection,site of infection,0.7743243243243243
metastatic infection,virulence factor disposition,0.6375
metastatic infection,viral adhesion disposition,0.6456521739130434
metastatic infection,parasitostatic disposition,0.7326086956521739
metastatic infection,infectious disease incidence,0.6583333333333334
metastatic infection,reverse zoonotic disposition,0.6791666666666666
metastatic infection,subclinical SARS-CoV-2 infection,0.7192307692307692
metastatic infection,virus translation stage,0.636046511627907
metastatic infection,disease surveillance objective specification,0.66875
metastatic infection,virus release stage,0.6038461538461539
metastatic infection,source of infection site,0.7227272727272727
metastatic infection,virus replication,0.6662162162162162
metastatic infection,B cell receptor complex,0.5895348837209302
metastatic infection,systematic infection,0.85
metastatic infection,infection incidence rate,0.6545454545454545
metastatic infection,virus host,0.55
metastatic infection,double-stranded RNA virus,0.6055555555555556
metastatic infection,virus transcription stage,0.65
metastatic infection,infectious disease lifetime prevalence,0.6396551724137931
metastatic infection,toxin disposition,0.6662162162162162
metastatic infection,lower respiratory tract disease,0.6068627450980393
metastatic infection,infectious disease incidence proportion,0.6703389830508475
metastatic infection,virus generative stage,0.5928571428571429
metastatic infection,acute infectious disease course,0.6656862745098039
metastatic infection,cidal agent disposition,0.6593023255813953
metastatic infection,infectious disorder,0.6551282051282051
metastatic infection,subclinical infection,0.7670731707317073
metastatic infection,appearance of disorder,0.6404761904761905
metastatic infection,simple infection,0.7833333333333333
metastatic infection,parasiticidal disposition,0.6944444444444444
metastatic infection,infectious disease sporadicity,0.63
metastatic infection,communicability end process boundary,0.5928571428571429
metastatic infection,infection incidence proportion profile,0.656896551724138
metastatic infection,transmissibility disposition,0.6583333333333334
metastatic infection,latency end process boundary,0.6166666666666667
metastatic infection,infectious disease epidemic,0.6202127659574468
metastatic infection,disease transmission model,0.6456521739130434
metastatic infection,endotoxin disposition,0.6695121951219513
metastatic infection,negative-sense single-stranded RNA virus,0.6166666666666667
metastatic infection,cytotoxin disposition,0.6695121951219513
metastatic infection,community-acquired infection,0.7416666666666667
metastatic infection,chronic infectious disease course,0.6575471698113208
metastatic infection,nursing-home acquired infection,0.7245098039215686
metastatic infection,COVID-19 epidemic,0.5851351351351352
metastatic infection,secondary infection,0.7576923076923078
metastatic infection,infection start temporal region,0.6656862745098039
metastatic infection,infection incidence,0.6807692307692308
metastatic infection,virus disorder,0.5676470588235294
metastatic infection,primary infection,0.7743243243243243
metastatic infection,process of establishing an infection,0.7178571428571427
metastatic infection,incubation end process boundary,0.6068627450980393
metastatic infection,SARS-CoV-2 disorder,0.6038461538461539
metastatic infection,collective pathogenic disposition,0.6764150943396227
metastatic infection,neurotoxin disposition,0.6642857142857143
metastatic infection,latency end temporal region,0.6414893617021277
metastatic infection,virus adhesion susceptible cell,0.5872549019607843
metastatic infection,collective disposition,0.6642857142857143
metastatic infection,infection,0.760344827586207
metastatic infection,static agent disposition,0.7227272727272727
metastatic infection,T cell receptor complex,0.6127906976744186
metastatic infection,respiratory system disease,0.6021739130434782
metastatic infection,communicability interval,0.609090909090909
metastatic infection,infectious disease control strategy,0.6136363636363636
metastatic infection,infectious disease pandemic,0.6414893617021277
metastatic infection,immunosuppressive disposition,0.6540816326530612
metastatic infection,pathogenic disposition,0.6880952380952381
metastatic infection,viral disease course,0.6
metastatic infection,intracellular infection,0.7523255813953489
metastatic infection,secondary infection role,0.7227272727272727
metastatic infection,metastatic infection,0.95
metastatic infection,infectious disposition,0.6642857142857143
metastatic infection,acute infection,0.7928571428571428
metastatic infection,bacteriostatic disposition,0.7326086956521739
metastatic infection,bactericidal disposition,0.6772727272727272
metastatic infection,source of infection role,0.7227272727272727
metastatic infection,chronic infection,0.7743243243243243
metastatic infection,invasion disposition,0.675
metastatic infection,disease course,0.6264705882352941
metastatic infection,infectious disease course,0.6277777777777778
metastatic infection,viricidal disposition,0.6451219512195122
metastatic infection,complex infection,0.7743243243243243
metastatic infection,COVID-19 disease incidence proportion,0.6605263157894737
metastatic infection,coronavirus disease course,0.6021739130434782
metastatic infection,infection incidence proportion,0.69
metastatic infection,respiratory droplet virus fomite,0.6230769230769231
metastatic infection,infectious disease prevalence,0.6336734693877552
metastatic infection,disposition,0.6435483870967742
metastatic infection,single-stranded DNA virus,0.6055555555555556
metastatic infection,viral disease,0.5712121212121213
metastatic infection,primary infection role,0.7357142857142857
metastatic infection,adhesion disposition,0.675
metastatic infection,infection incidence profile,0.6414893617021277
metastatic infection,contagiousness,0.6264705882352941
metastatic infection,disease,0.5981481481481481
metastatic infection,primary infectious disposition,0.69
metastatic infection,infection prevalence,0.675
metastatic infection,coronavirus disorder,0.575
metastatic infection,subclinical virus infection,0.7265957446808511
metastatic infection,establishment of localization in virus host,0.6563492063492063
metastatic infection,virus attachment stage,0.6166666666666667
metastatic infection,virus synthesis stage,0.5719512195121951
metastatic infection,SARS-COV-2 adhesion disposition,0.6460784313725491
metastatic infection,invasive disposition,0.675
metastatic infection,long-term non-progressing infectious disease course,0.6330985915492958
metastatic infection,viral disease epidemic,0.6166666666666667
metastatic infection,communicability start temporal region,0.6429824561403508
metastatic infection,fungicidal disposition,0.6404761904761905
metastatic infection,viral disease pandemic,0.6166666666666667
metastatic infection,virus penetration stage,0.636046511627907
metastatic infection,acute respiratory distress syndrome,0.5954545454545455
metastatic infection,infectious disease endemicity,0.6336734693877552
metastatic infection,disorder,0.5214285714285714
metastatic infection,communicability,0.5928571428571429
metastatic infection,extracellular infection,0.7755813953488372
metastatic infection,exotoxin disposition,0.675
metastatic infection,infection start process boundary,0.6423076923076922
metastatic infection,action specification,0.725
metastatic infection,infectious disease control objective specification,0.6642857142857143
metastatic infection,opportunistic infectious disposition,0.7178571428571427
metastatic infection,process of establishing viral infection,0.7042372881355932
metastatic infection,enterotoxin disposition,0.6825581395348838
metastatic infection,COVID-19 disease course,0.5895348837209302
metastatic infection,infectious disease incidence rate,0.6386792452830189
metastatic infection,communicability start process boundary,0.6224137931034482
metastatic infection,disordered virus,0.5333333333333333
metastatic infection,collective resistance disposition,0.6764150943396227
metastatic infection,fungistatic disposition,0.7290697674418604
metastatic infection,virus uncoating stage,0.6207317073170732
metastatic infection,local infection,0.7642857142857143
metastatic infection,establishment of a clinically abnormal colony,0.65
metastatic infection,coronavirus disease,0.5782051282051281
metastatic infection,positive-sense single-stranded RNA virus,0.6
metastatic infection,hospital-acquired infection,0.747872340425532
metastatic infection,static agent,0.73125
acute infectious disease course,virus aggregate,0.6021739130434782
acute infectious disease course,source of infection,0.67
acute infectious disease course,virostatic disposition,0.6386792452830189
acute infectious disease course,zoonotic disposition,0.6264705882352941
acute infectious disease course,infectious disease mortality rate,0.79375
acute infectious disease course,infection incidence rate profile,0.7039682539682539
acute infectious disease course,infectious structure aggregate,0.7122950819672131
acute infectious disease course,communicability end temporal region,0.6318181818181818
acute infectious disease course,pathogen portal of entry,0.6136363636363636
acute infectious disease course,subclinical coronavirus infection,0.6375
acute infectious disease course,infection end temporal region,0.7
acute infectious disease course,infectious disease,0.8173469387755102
acute infectious disease course,SARS-CoV-2 incidence rate,0.6821428571428573
acute infectious disease course,double-stranded DNA virus,0.6285714285714286
acute infectious disease course,incubation end temporal region,0.6631147540983606
acute infectious disease course,site of infection,0.6791666666666666
acute infectious disease course,virulence factor disposition,0.6703389830508475
acute infectious disease course,viral adhesion disposition,0.6429824561403508
acute infectious disease course,parasitostatic disposition,0.6429824561403508
acute infectious disease course,infectious disease incidence,0.8059322033898306
acute infectious disease course,reverse zoonotic disposition,0.6364406779661017
acute infectious disease course,subclinical SARS-CoV-2 infection,0.6246031746031746
acute infectious disease course,virus translation stage,0.6351851851851852
acute infectious disease course,disease surveillance objective specification,0.6366666666666667
acute infectious disease course,virus release stage,0.67
acute infectious disease course,infectious agent host role,0.7482456140350877
acute infectious disease course,asymptomatic infectious structure carrier,0.7277777777777777
acute infectious disease course,source of infection site,0.7045454545454546
acute infectious disease course,virus,0.5333333333333333
acute infectious disease course,virus replication,0.5958333333333333
acute infectious disease course,B cell receptor complex,0.6537037037037037
acute infectious disease course,passive immunization against infectious agent,0.6736842105263158
acute infectious disease course,systematic infection,0.6656862745098039
acute infectious disease course,infection incidence rate,0.7227272727272727
acute infectious disease course,virus host,0.5963414634146341
acute infectious disease course,double-stranded RNA virus,0.6107142857142857
acute infectious disease course,pathogen portal of entry role,0.6333333333333333
acute infectious disease course,virus transcription stage,0.6464285714285714
acute infectious disease course,infectious disease lifetime prevalence,0.7543478260869566
acute infectious disease course,toxin disposition,0.6375
acute infectious disease course,lower respiratory tract disease,0.6596774193548387
acute infectious disease course,infectious disease incidence proportion,0.7642857142857143
acute infectious disease course,virus generative stage,0.6386792452830189
acute infectious disease course,acute infectious disease course,0.95
acute infectious disease course,cidal agent disposition,0.6351851851851852
acute infectious disease course,infectious disorder,0.79
acute infectious disease course,subclinical infection,0.6423076923076922
acute infectious disease course,appearance of disorder,0.6764150943396227
acute infectious disease course,simple infection,0.6627659574468084
acute infectious disease course,parasiticidal disposition,0.6464285714285714
acute infectious disease course,infectious disease sporadicity,0.7942622950819671
acute infectious disease course,communicability end process boundary,0.6440298507462687
acute infectious disease course,infection incidence proportion profile,0.6818840579710145
acute infectious disease course,infectious agent colony,0.7462962962962962
acute infectious disease course,transmissibility disposition,0.6194915254237288
acute infectious disease course,latency end process boundary,0.6703389830508475
acute infectious disease course,infectious disease epidemic,0.7948275862068965
acute infectious disease course,infectious agent generative stage,0.715625
acute infectious disease course,disease transmission model,0.6429824561403508
acute infectious disease course,endotoxin disposition,0.6423076923076922
acute infectious disease course,negative-sense single-stranded RNA virus,0.6471830985915493
acute infectious disease course,infectious structure host role,0.728688524590164
acute infectious disease course,COVID-19 incidence rate,0.6722222222222223
acute infectious disease course,cytotoxin disposition,0.6423076923076922
acute infectious disease course,community-acquired infection,0.6703389830508475
acute infectious disease course,chronic infectious disease course,0.871875
acute infectious disease course,asymptomatic infectious agent carrier,0.7441176470588234
acute infectious disease course,nursing-home acquired infection,0.6596774193548387
acute infectious disease course,COVID-19 epidemic,0.5958333333333333
acute infectious disease course,secondary infection,0.65
acute infectious disease course,infection start temporal region,0.6919354838709677
acute infectious disease course,infection incidence,0.71
acute infectious disease course,virus disorder,0.6722222222222223
acute infectious disease course,sterilizing immunity to infectious agent,0.6753521126760563
acute infectious disease course,diseased population,0.65
acute infectious disease course,primary infection,0.6583333333333334
acute infectious disease course,process of establishing an infection,0.6440298507462687
acute infectious disease course,incubation end process boundary,0.6758064516129032
acute infectious disease course,SARS-CoV-2 disorder,0.65
acute infectious disease course,collective pathogenic disposition,0.6375
acute infectious disease course,neurotoxin disposition,0.6386792452830189
acute infectious disease course,plan specification,0.6132653061224489
acute infectious disease course,SARS-CoV-2 spike glycoprotein,0.6333333333333333
acute infectious disease course,latency end temporal region,0.656896551724138
acute infectious disease course,innate immunity to infectious agent,0.7075757575757575
acute infectious disease course,infectious structure,0.7637254901960785
acute infectious disease course,virus adhesion susceptible cell,0.6435483870967742
acute infectious disease course,collective disposition,0.6575471698113208
acute infectious disease course,infection,0.65
acute infectious disease course,static agent disposition,0.65
acute infectious disease course,T cell receptor complex,0.6537037037037037
acute infectious disease course,infectious structure host,0.7357142857142857
acute infectious disease course,infectious agent population,0.7258620689655172
acute infectious disease course,respiratory system disease,0.6780701754385965
acute infectious disease course,entry into host,0.6456521739130434
acute infectious disease course,leukocyte-mediated immunity to infectious agent,0.6679487179487179
acute infectious disease course,humoral immunity to infectious agent,0.703731343283582
acute infectious disease course,infectious disease control strategy,0.8136363636363637
acute infectious disease course,infectious disease pandemic,0.7948275862068965
acute infectious disease course,infectious structure generative stage,0.7147058823529412
acute infectious disease course,immunosuppressive disposition,0.6333333333333333
acute infectious disease course,pathogenic disposition,0.6575471698113208
acute infectious disease course,viral disease course,0.7637254901960785
acute infectious disease course,entry into host through host barriers,0.6411764705882353
acute infectious disease course,intracellular infection,0.6722222222222223
acute infectious disease course,secondary infection role,0.6863636363636364
acute infectious disease course,metastatic infection,0.6656862745098039
acute infectious disease course,passive immunity to infectious agent,0.703731343283582
acute infectious disease course,infectious disposition,0.7518867924528303
acute infectious disease course,vaccination against infectious agent,0.703731343283582
acute infectious disease course,objective specification,0.6351851851851852
acute infectious disease course,acute infection,0.7543478260869566
acute infectious disease course,susceptibility to infectious agent,0.6961538461538461
acute infectious disease course,bacteriostatic disposition,0.6780701754385965
acute infectious disease course,epitope site,0.636046511627907
acute infectious disease course,bactericidal disposition,0.6863636363636364
acute infectious disease course,source of infection role,0.7045454545454546
acute infectious disease course,chronic infection,0.6583333333333334
acute infectious disease course,invasion disposition,0.6460784313725491
acute infectious disease course,disease course,0.7611111111111112
acute infectious disease course,infectious disease course,0.8964285714285714
acute infectious disease course,viricidal disposition,0.6230769230769231
acute infectious disease course,acquired immunity to infectious agent,0.7147058823529412
acute infectious disease course,complex infection,0.6791666666666666
acute infectious disease course,COVID-19 disease incidence proportion,0.6558823529411765
acute infectious disease course,coronavirus disease course,0.8008771929824562
acute infectious disease course,infection incidence proportion,0.6959016393442623
acute infectious disease course,symptomatic infectious agent carrier,0.7485074626865671
acute infectious disease course,respiratory droplet virus fomite,0.6246031746031746
acute infectious disease course,pathogen portal of exit site,0.6364406779661017
acute infectious disease course,infectious disease prevalence,0.8
acute infectious disease course,disposition,0.569047619047619
acute infectious disease course,single-stranded DNA virus,0.6285714285714286
acute infectious disease course,infected population,0.65
acute infectious disease course,COVID-19 mortality rate,0.5796296296296296
acute infectious disease course,contact tracing,0.6021739130434782
acute infectious disease course,viral disease,0.6545454545454545
acute infectious disease course,primary infection role,0.6952830188679244
acute infectious disease course,adhesion disposition,0.6460784313725491
acute infectious disease course,pathogen portal of entry site,0.6333333333333333
acute infectious disease course,infection incidence profile,0.7086206896551723
acute infectious disease course,disease,0.6342105263157894
acute infectious disease course,symptomatic infectious structure carrier,0.7316901408450704
acute infectious disease course,site,0.5357142857142857
acute infectious disease course,primary infectious disposition,0.7450819672131148
acute infectious disease course,infection prevalence,0.7245098039215686
acute infectious disease course,coronavirus disorder,0.6852941176470588
acute infectious disease course,infectious pathogen transmissibility,0.6888059701492537
acute infectious disease course,object,0.5310810810810811
acute infectious disease course,infectious human pathogen,0.7178571428571427
acute infectious disease course,subclinical virus infection,0.656896551724138
acute infectious disease course,establishment of localization in virus host,0.6391891891891892
acute infectious disease course,immunization against infectious agent,0.6852941176470588
acute infectious disease course,virus attachment stage,0.619811320754717
acute infectious disease course,virus synthesis stage,0.6423076923076922
acute infectious disease course,SARS-COV-2 adhesion disposition,0.6435483870967742
acute infectious disease course,object aggregate,0.598936170212766
acute infectious disease course,invasive disposition,0.6264705882352941
acute infectious disease course,infectious agent host,0.7576923076923078
acute infectious disease course,long-term non-progressing infectious disease course,0.7914634146341464
acute infectious disease course,viral disease epidemic,0.6575471698113208
acute infectious disease course,fungicidal disposition,0.6386792452830189
acute infectious disease course,viral disease pandemic,0.6575471698113208
acute infectious disease course,virus penetration stage,0.6537037037037037
acute infectious disease course,acute respiratory distress syndrome,0.7227272727272727
acute infectious disease course,infectious disease endemicity,0.7833333333333333
acute infectious disease course,contact pathogen transmission process,0.6411764705882353
acute infectious disease course,disorder,0.6038461538461539
acute infectious disease course,herd immunity to infectious organism,0.703731343283582
acute infectious disease course,extracellular infection,0.6722222222222223
acute infectious disease course,exotoxin disposition,0.6264705882352941
acute infectious disease course,infectious agent reservoir,0.7482456140350877
acute infectious disease course,COVID-19 pandemic,0.575
acute infectious disease course,infection start process boundary,0.7039682539682539
acute infectious disease course,infectious disease control objective specification,0.7462962962962962
acute infectious disease course,opportunistic infectious disposition,0.7335820895522389
acute infectious disease course,process of establishing viral infection,0.65
acute infectious disease course,enterotoxin disposition,0.6537037037037037
acute infectious disease course,polymerase chain reaction,0.6285714285714286
acute infectious disease course,COVID-19 disease course,0.7648148148148148
acute infectious disease course,infectious disease incidence rate,0.79375
acute infectious disease course,active immunization against infectious agent,0.7033333333333335
acute infectious disease course,disordered virus,0.6202127659574468
acute infectious disease course,collective resistance disposition,0.653125
acute infectious disease course,fungistatic disposition,0.6351851851851852
acute infectious disease course,virus uncoating stage,0.6423076923076922
acute infectious disease course,local infection,0.6673913043478261
acute infectious disease course,infectious agent,0.7265957446808511
acute infectious disease course,establishment of a clinically abnormal colony,0.5947368421052631
acute infectious disease course,coronavirus disease,0.71
acute infectious disease course,positive-sense single-stranded RNA virus,0.6330985915492958
acute infectious disease course,hospital-acquired infection,0.6741379310344828
acute infectious disease course,drug susceptibility of infectious agent,0.6785714285714286
cidal agent disposition,virostatic disposition,0.7833333333333333
cidal agent disposition,information content entity,0.6336734693877552
cidal agent disposition,zoonotic disposition,0.7755813953488372
cidal agent disposition,infectious disease mortality rate,0.6285714285714286
cidal agent disposition,infection incidence rate profile,0.6318181818181818
cidal agent disposition,infectious structure aggregate,0.5820754716981132
cidal agent disposition,communicability end temporal region,0.6741379310344828
cidal agent disposition,geographical entity,0.6642857142857143
cidal agent disposition,biological regulation,0.6545454545454545
cidal agent disposition,surveillance process,0.636046511627907
cidal agent disposition,infection end temporal region,0.6615384615384616
cidal agent disposition,vector control strategy,0.6021739130434782
cidal agent disposition,SARS-CoV-2 incidence rate,0.5958333333333333
cidal agent disposition,incubation end temporal region,0.6575471698113208
cidal agent disposition,resistant entity,0.6551282051282051
cidal agent disposition,virulence factor disposition,0.7833333333333333
cidal agent disposition,viral adhesion disposition,0.8377551020408163
cidal agent disposition,parasitostatic disposition,0.7561224489795919
cidal agent disposition,negative regulation of production,0.6464285714285714
cidal agent disposition,reverse zoonotic disposition,0.7441176470588234
cidal agent disposition,establishment of localization in host,0.65
cidal agent disposition,disease surveillance objective specification,0.658955223880597
cidal agent disposition,case isolation control strategy,0.6537037037037037
cidal agent disposition,infectious agent host role,0.7153061224489795
cidal agent disposition,macromolecular complex,0.5611111111111111
cidal agent disposition,material entity,0.6868421052631578
cidal agent disposition,asymptomatic infectious structure carrier,0.590625
cidal agent disposition,architectual structure,0.6055555555555556
cidal agent disposition,quarantine control strategy,0.61
cidal agent disposition,B cell receptor complex,0.6021739130434782
cidal agent disposition,passive immunization against infectious agent,0.6411764705882353
cidal agent disposition,infection incidence rate,0.6202127659574468
cidal agent disposition,colonized host,0.6391891891891892
cidal agent disposition,virus host,0.6015151515151516
cidal agent disposition,entity,0.6224137931034482
cidal agent disposition,toxin disposition,0.8
cidal agent disposition,acute infectious disease course,0.6351851851851852
cidal agent disposition,cidal agent disposition,0.95
cidal agent disposition,biological vehicle,0.5963414634146341
cidal agent disposition,parasiticidal disposition,0.8041666666666667
cidal agent disposition,communicability end process boundary,0.6703389830508475
cidal agent disposition,directive information content entity,0.6194915254237288
cidal agent disposition,acellular structure aggregate,0.5846153846153846
cidal agent disposition,infectious agent colony,0.7108695652173913
cidal agent disposition,pathogen transporter,0.6593023255813953
cidal agent disposition,invasion factor,0.6078947368421053
cidal agent disposition,transmissibility disposition,0.7441176470588234
cidal agent disposition,latency end process boundary,0.6656862745098039
cidal agent disposition,colonization of host,0.636046511627907
cidal agent disposition,infectious agent generative stage,0.6642857142857143
cidal agent disposition,realizable entity,0.675
cidal agent disposition,endotoxin disposition,0.7909090909090909
cidal agent disposition,vector surveillance,0.5928571428571429
cidal agent disposition,negative regulation of establishment of localization,0.6366666666666667
cidal agent disposition,cidal agent,0.7735294117647058
cidal agent disposition,infectious structure host role,0.619811320754717
cidal agent disposition,pathogen vehicle,0.6038461538461539
cidal agent disposition,COVID-19 incidence rate,0.6239130434782608
cidal agent disposition,cytotoxin disposition,0.7909090909090909
cidal agent disposition,negative regulation of developmental process,0.5992537313432835
cidal agent disposition,pathogen vehicle role,0.609090909090909
cidal agent disposition,host,0.5611111111111111
cidal agent disposition,chronic infectious disease course,0.6464285714285714
cidal agent disposition,asymptomatic infectious agent carrier,0.6166666666666667
cidal agent disposition,descriptive information content entity,0.6139344262295081
cidal agent disposition,negative regulation of replication,0.6429824561403508
cidal agent disposition,sterilizing immunity to infectious agent,0.6404761904761905
cidal agent disposition,establishment of localization in human host,0.6318181818181818
cidal agent disposition,acellular structure,0.5928571428571429
cidal agent disposition,virulence factor,0.6294871794871795
cidal agent disposition,incubation end process boundary,0.6537037037037037
cidal agent disposition,collective pathogenic disposition,0.7892857142857143
cidal agent disposition,neurotoxin disposition,0.7611111111111112
cidal agent disposition,dead-end host role,0.6695121951219513
cidal agent disposition,molecular entity,0.6551282051282051
cidal agent disposition,plan specification,0.7182926829268292
cidal agent disposition,definitive host role,0.6593023255813953
cidal agent disposition,latency end temporal region,0.67
cidal agent disposition,innate immunity to infectious agent,0.656896551724138
cidal agent disposition,infectious structure,0.6127906976744186
cidal agent disposition,collective disposition,0.8055555555555556
cidal agent disposition,static agent disposition,0.8542553191489362
cidal agent disposition,T cell receptor complex,0.6021739130434782
cidal agent disposition,asymptomatic carrier role,0.5958333333333333
cidal agent disposition,infectious structure host,0.6166666666666667
cidal agent disposition,infectious agent population,0.75
cidal agent disposition,respiratory system disease,0.6336734693877552
cidal agent disposition,entry into host,0.6605263157894737
cidal agent disposition,leukocyte-mediated immunity to infectious agent,0.6357142857142857
cidal agent disposition,adhesion of symbiont to host,0.6264705882352941
cidal agent disposition,humoral immunity to infectious agent,0.6533898305084747
cidal agent disposition,infectious disease control strategy,0.6224137931034482
cidal agent disposition,infectious structure generative stage,0.6166666666666667
cidal agent disposition,immunosuppressive disposition,0.7192307692307692
cidal agent disposition,pathogenic disposition,0.8055555555555556
cidal agent disposition,viral disease course,0.6593023255813953
cidal agent disposition,entry into host through host barriers,0.6166666666666667
cidal agent disposition,passive immunity to infectious agent,0.6364406779661017
cidal agent disposition,infectious disposition,0.7833333333333333
cidal agent disposition,vaccination against infectious agent,0.6872881355932203
cidal agent disposition,susceptibility to infectious agent,0.6429824561403508
cidal agent disposition,bacteriostatic disposition,0.7765306122448979
cidal agent disposition,bactericidal disposition,0.8117021276595744
cidal agent disposition,pathogen host,0.6722222222222223
cidal agent disposition,invasion disposition,0.7988372093023256
cidal agent disposition,disease course,0.6121621621621621
cidal agent disposition,infectious disease course,0.6375
cidal agent disposition,viricidal disposition,0.8363636363636363
cidal agent disposition,acquired immunity to infectious agent,0.6666666666666667
cidal agent disposition,complex infection,0.675
cidal agent disposition,coronavirus disease course,0.6132653061224489
cidal agent disposition,asymptomatic carrier,0.5895348837209302
cidal agent disposition,biological vehicle role,0.6021739130434782
cidal agent disposition,symptomatic infectious agent carrier,0.6194915254237288
cidal agent disposition,intermediate host,0.65
cidal agent disposition,anatomical entity,0.675
cidal agent disposition,disposition,0.7735294117647058
cidal agent disposition,COVID-19 mortality rate,0.6239130434782608
cidal agent disposition,negative regulation of life-sustaining process,0.6094202898550725
cidal agent disposition,place closure control strategy,0.6009433962264151
cidal agent disposition,geopolitical entity,0.6642857142857143
cidal agent disposition,adhesion disposition,0.7988372093023256
cidal agent disposition,symptomatic infectious structure carrier,0.5928571428571429
cidal agent disposition,primary infectious disposition,0.7707547169811321
cidal agent disposition,pathogen host role,0.6695121951219513
cidal agent disposition,designative information content entity,0.630327868852459
cidal agent disposition,symptomatic carrier role,0.5776595744680851
cidal agent disposition,intermediate host role,0.65
cidal agent disposition,dead-end host,0.6722222222222223
cidal agent disposition,pathogen surveillance,0.6318181818181818
cidal agent disposition,host role,0.575
cidal agent disposition,establishment of localization in virus host,0.6318181818181818
cidal agent disposition,immunization against infectious agent,0.6666666666666667
cidal agent disposition,negative regulation of immune response,0.6139344262295081
cidal agent disposition,immaterial entity,0.675
cidal agent disposition,SARS-COV-2 adhesion disposition,0.7648148148148148
cidal agent disposition,invasive disposition,0.7988372093023256
cidal agent disposition,infectious agent host,0.7227272727272727
cidal agent disposition,long-term non-progressing infectious disease course,0.6121621621621621
cidal agent disposition,fungicidal disposition,0.8277777777777777
cidal agent disposition,division of geopolitical entity,0.6351851851851852
cidal agent disposition,symptomatic carrier,0.569047619047619
cidal agent disposition,negative regulation of viral process,0.6025423728813559
cidal agent disposition,function,0.6112903225806451
cidal agent disposition,pathogen transporter role,0.6583333333333334
cidal agent disposition,exotoxin disposition,0.7755813953488372
cidal agent disposition,infectious agent reservoir,0.6948979591836735
cidal agent disposition,immunoglobulin complex,0.5611111111111111
cidal agent disposition,action specification,0.7058139534883722
cidal agent disposition,infectious disease control objective specification,0.6691780821917809
cidal agent disposition,symbiont host role,0.6451219512195122
cidal agent disposition,opportunistic infectious disposition,0.7211864406779661
cidal agent disposition,negative regulation of biological process,0.590625
cidal agent disposition,enterotoxin disposition,0.7760869565217391
cidal agent disposition,polymerase chain reaction,0.6375
cidal agent disposition,COVID-19 disease course,0.6456521739130434
cidal agent disposition,infectious disease incidence rate,0.6464285714285714
cidal agent disposition,active immunization against infectious agent,0.658955223880597
cidal agent disposition,collective resistance disposition,0.7535714285714286
cidal agent disposition,fungistatic disposition,0.7760869565217391
cidal agent disposition,infectious agent,0.6551282051282051
cidal agent disposition,establishment of a clinically abnormal colony,0.6117647058823529
cidal agent disposition,adhesion factor,0.6078947368421053
cidal agent disposition,definitive host,0.6605263157894737
cidal agent disposition,drug susceptibility of infectious agent,0.6274193548387097
cidal agent disposition,static agent,0.65
quarantine control strategy,virostatic disposition,0.6132653061224489
quarantine control strategy,zoonotic disposition,0.598936170212766
quarantine control strategy,infectious disease mortality rate,0.6666666666666667
quarantine control strategy,infection incidence rate profile,0.6533898305084747
quarantine control strategy,communicability end temporal region,0.6435483870967742
quarantine control strategy,biological regulation,0.6166666666666667
quarantine control strategy,surveillance process,0.6414893617021277
quarantine control strategy,infection end temporal region,0.6821428571428573
quarantine control strategy,vector control strategy,0.81
quarantine control strategy,SARS-CoV-2 incidence rate,0.6615384615384616
quarantine control strategy,incubation end temporal region,0.6956140350877194
quarantine control strategy,virulence factor disposition,0.6318181818181818
quarantine control strategy,viral adhesion disposition,0.6009433962264151
quarantine control strategy,parasitostatic disposition,0.6386792452830189
quarantine control strategy,negative regulation of production,0.6333333333333333
quarantine control strategy,reverse zoonotic disposition,0.6136363636363636
quarantine control strategy,disease surveillance objective specification,0.6190140845070422
quarantine control strategy,case isolation control strategy,0.8293103448275861
quarantine control strategy,quarantine control strategy,0.95
quarantine control strategy,B cell receptor complex,0.61
quarantine control strategy,infection incidence rate,0.6852941176470588
quarantine control strategy,infectious disease lifetime prevalence,0.6346153846153847
quarantine control strategy,toxin disposition,0.609090909090909
quarantine control strategy,lower respiratory tract disease,0.6396551724137931
quarantine control strategy,cidal agent disposition,0.61
quarantine control strategy,parasiticidal disposition,0.6423076923076922
quarantine control strategy,communicability end process boundary,0.6087301587301588
quarantine control strategy,transmissibility disposition,0.5954545454545455
quarantine control strategy,latency end process boundary,0.6318181818181818
quarantine control strategy,endotoxin disposition,0.6166666666666667
quarantine control strategy,vector surveillance,0.6456521739130434
quarantine control strategy,negative regulation of establishment of localization,0.6272151898734176
quarantine control strategy,COVID-19 incidence rate,0.63
quarantine control strategy,cytotoxin disposition,0.5958333333333333
quarantine control strategy,negative regulation of developmental process,0.6471830985915493
quarantine control strategy,negative regulation of replication,0.6467213114754098
quarantine control strategy,incubation end process boundary,0.656896551724138
quarantine control strategy,collective pathogenic disposition,0.6
quarantine control strategy,neurotoxin disposition,0.6336734693877552
quarantine control strategy,plan specification,0.5833333333333334
quarantine control strategy,latency end temporal region,0.6722222222222223
quarantine control strategy,collective disposition,0.5928571428571429
quarantine control strategy,static agent disposition,0.6264705882352941
quarantine control strategy,T cell receptor complex,0.63
quarantine control strategy,respiratory system disease,0.6386792452830189
quarantine control strategy,infectious disease control strategy,0.7887096774193548
quarantine control strategy,immunosuppressive disposition,0.5928571428571429
quarantine control strategy,pathogenic disposition,0.5928571428571429
quarantine control strategy,infectious disposition,0.6336734693877552
quarantine control strategy,bacteriostatic disposition,0.619811320754717
quarantine control strategy,bactericidal disposition,0.6068627450980393
quarantine control strategy,invasion disposition,0.598936170212766
quarantine control strategy,viricidal disposition,0.5958333333333333
quarantine control strategy,infectious disease prevalence,0.6464285714285714
quarantine control strategy,disposition,0.5552631578947369
quarantine control strategy,COVID-19 mortality rate,0.65
quarantine control strategy,negative regulation of life-sustaining process,0.6280821917808219
quarantine control strategy,place closure control strategy,0.8008771929824562
quarantine control strategy,adhesion disposition,0.598936170212766
quarantine control strategy,primary infectious disposition,0.6429824561403508
quarantine control strategy,infection prevalence,0.6627659574468084
quarantine control strategy,pathogen surveillance,0.6375
quarantine control strategy,negative regulation of immune response,0.65
quarantine control strategy,SARS-COV-2 adhesion disposition,0.6051724137931035
quarantine control strategy,invasive disposition,0.598936170212766
quarantine control strategy,fungicidal disposition,0.6132653061224489
quarantine control strategy,negative regulation of viral process,0.6563492063492063
quarantine control strategy,herd immunity to infectious organism,0.6404761904761905
quarantine control strategy,exotoxin disposition,0.598936170212766
quarantine control strategy,action specification,0.6414893617021277
quarantine control strategy,infectious disease control objective specification,0.6577922077922078
quarantine control strategy,COVID-19 lifetime prevalence,0.5772727272727273
quarantine control strategy,opportunistic infectious disposition,0.6404761904761905
quarantine control strategy,negative regulation of biological process,0.6411764705882353
quarantine control strategy,enterotoxin disposition,0.63
quarantine control strategy,infectious disease incidence rate,0.65
quarantine control strategy,COVID-19 prevalence,0.5804347826086956
quarantine control strategy,SARS-COV-2 prevalence,0.6166666666666667
quarantine control strategy,collective resistance disposition,0.6
quarantine control strategy,fungistatic disposition,0.61
quarantine control strategy,establishment of a clinically abnormal colony,0.6027777777777777
disease transmission model,virus aggregate,0.5963414634146341
disease transmission model,source of infection,0.6055555555555556
disease transmission model,virostatic disposition,0.6583333333333334
disease transmission model,zoonotic disposition,0.6239130434782608
disease transmission model,infectious disease mortality rate,0.6703389830508475
disease transmission model,infection incidence rate profile,0.6224137931034482
disease transmission model,communicability end temporal region,0.6139344262295081
disease transmission model,subclinical coronavirus infection,0.6194915254237288
disease transmission model,infection end temporal region,0.6318181818181818
disease transmission model,infectious disease,0.6318181818181818
disease transmission model,double-stranded DNA virus,0.6264705882352941
disease transmission model,incubation end temporal region,0.6285714285714286
disease transmission model,site of infection,0.6127906976744186
disease transmission model,virulence factor disposition,0.6722222222222223
disease transmission model,viral adhesion disposition,0.6615384615384616
disease transmission model,parasitostatic disposition,0.6423076923076922
disease transmission model,infectious disease incidence,0.6722222222222223
disease transmission model,reservoir of pathogen role,0.6423076923076922
disease transmission model,reverse zoonotic disposition,0.6537037037037037
disease transmission model,subclinical SARS-CoV-2 infection,0.6051724137931035
disease transmission model,virus translation stage,0.7153061224489795
disease transmission model,disease surveillance objective specification,0.6785714285714286
disease transmission model,virus release stage,0.6722222222222223
disease transmission model,infectious agent host role,0.6423076923076922
disease transmission model,source of infection site,0.63
disease transmission model,virus,0.5467741935483871
disease transmission model,virus replication,0.636046511627907
disease transmission model,B cell receptor complex,0.5928571428571429
disease transmission model,systematic infection,0.6239130434782608
disease transmission model,infection incidence rate,0.63
disease transmission model,virus host,0.5888888888888889
disease transmission model,double-stranded RNA virus,0.6264705882352941
disease transmission model,pathogen portal of entry role,0.6318181818181818
disease transmission model,virus transcription stage,0.7245098039215686
disease transmission model,infectious disease lifetime prevalence,0.653125
disease transmission model,toxin disposition,0.636046511627907
disease transmission model,lower respiratory tract disease,0.6254385964912281
disease transmission model,infectious disease incidence proportion,0.65
disease transmission model,virus generative stage,0.6375
disease transmission model,acute infectious disease course,0.6429824561403508
disease transmission model,cidal agent disposition,0.6744897959183673
disease transmission model,infectious disorder,0.65
disease transmission model,role,0.55
disease transmission model,subclinical infection,0.598936170212766
disease transmission model,appearance of disorder,0.6583333333333334
disease transmission model,simple infection,0.6166666666666667
disease transmission model,droplet pathogen transmission process,0.7674603174603175
disease transmission model,parasiticidal disposition,0.6460784313725491
disease transmission model,infectious disease sporadicity,0.6642857142857143
disease transmission model,mutualist role,0.625
disease transmission model,communicability end process boundary,0.6112903225806451
disease transmission model,infection incidence proportion profile,0.621875
disease transmission model,transmissibility disposition,0.6722222222222223
disease transmission model,latency end process boundary,0.6166666666666667
disease transmission model,infectious disease epidemic,0.6575471698113208
disease transmission model,disease transmission model,0.95
disease transmission model,endotoxin disposition,0.6414893617021277
disease transmission model,negative-sense single-stranded RNA virus,0.6318181818181818
disease transmission model,infectious structure host role,0.6285714285714286
disease transmission model,cytotoxin disposition,0.6202127659574468
disease transmission model,community-acquired infection,0.5981481481481481
disease transmission model,pathogen vehicle role,0.598936170212766
disease transmission model,chronic infectious disease course,0.6364406779661017
disease transmission model,nursing-home acquired infection,0.6078947368421053
disease transmission model,COVID-19 epidemic,0.5662790697674418
disease transmission model,secondary infection,0.6277777777777778
disease transmission model,mechanical vector role,0.6166666666666667
disease transmission model,infection start temporal region,0.6254385964912281
disease transmission model,infection incidence,0.65
disease transmission model,virus disorder,0.65
disease transmission model,primary infection,0.6127906976744186
disease transmission model,process of establishing an infection,0.6274193548387097
disease transmission model,incubation end process boundary,0.6254385964912281
disease transmission model,SARS-CoV-2 disorder,0.65
disease transmission model,collective pathogenic disposition,0.6364406779661017
disease transmission model,neurotoxin disposition,0.6375
disease transmission model,dead-end host role,0.6545454545454545
disease transmission model,plan specification,0.609090909090909
disease transmission model,definitive host role,0.6456521739130434
disease transmission model,latency end temporal region,0.619811320754717
disease transmission model,virus adhesion susceptible cell,0.6605263157894737
disease transmission model,collective disposition,0.6375
disease transmission model,infection,0.6214285714285714
disease transmission model,static agent disposition,0.67
disease transmission model,T cell receptor complex,0.5928571428571429
disease transmission model,asymptomatic carrier role,0.6264705882352941
disease transmission model,respiratory system disease,0.6423076923076922
disease transmission model,indirect pathogen transmission process,0.778125
disease transmission model,infectious disease control strategy,0.6631147540983606
disease transmission model,infectious disease pandemic,0.6764150943396227
disease transmission model,immunosuppressive disposition,0.6681818181818181
disease transmission model,pathogenic disposition,0.6375
disease transmission model,viral disease course,0.6891304347826087
disease transmission model,intracellular infection,0.6132653061224489
disease transmission model,secondary infection role,0.67
disease transmission model,metastatic infection,0.6456521739130434
disease transmission model,infectious disposition,0.6583333333333334
disease transmission model,acute infection,0.6207317073170732
disease transmission model,bacteriostatic disposition,0.6423076923076922
disease transmission model,bactericidal disposition,0.65
disease transmission model,source of infection role,0.65
disease transmission model,chronic infection,0.5895348837209302
disease transmission model,invasion disposition,0.6673913043478261
disease transmission model,disease course,0.725
disease transmission model,infectious disease course,0.6656862745098039
disease transmission model,viricidal disposition,0.6414893617021277
disease transmission model,complex infection,0.5895348837209302
disease transmission model,COVID-19 disease incidence proportion,0.6563492063492063
disease transmission model,coronavirus disease course,0.6615384615384616
disease transmission model,biological vehicle role,0.5928571428571429
disease transmission model,infection incidence proportion,0.6107142857142857
disease transmission model,respiratory droplet virus fomite,0.6051724137931035
disease transmission model,symbiont role,0.6551282051282051
disease transmission model,parasite role,0.6551282051282051
disease transmission model,pathogen vector role,0.6239130434782608
disease transmission model,infectious disease prevalence,0.6681818181818181
disease transmission model,disposition,0.6662162162162162
disease transmission model,single-stranded DNA virus,0.6264705882352941
disease transmission model,contact tracing,0.6207317073170732
disease transmission model,viral disease,0.6294871794871795
disease transmission model,primary infection role,0.6583333333333334
disease transmission model,biological role,0.5963414634146341
disease transmission model,adhesion disposition,0.6673913043478261
disease transmission model,infection incidence profile,0.6386792452830189
disease transmission model,disease,0.6621212121212122
disease transmission model,biological vector role,0.6166666666666667
disease transmission model,primary infectious disposition,0.6464285714285714
disease transmission model,pathogen host role,0.609090909090909
disease transmission model,infection prevalence,0.6456521739130434
disease transmission model,symptomatic carrier role,0.61
disease transmission model,coronavirus disorder,0.6239130434782608
disease transmission model,intermediate host role,0.6375
disease transmission model,host role,0.5928571428571429
disease transmission model,subclinical virus infection,0.619811320754717
disease transmission model,establishment of localization in virus host,0.6239130434782608
disease transmission model,virus attachment stage,0.6375
disease transmission model,virus synthesis stage,0.6414893617021277
disease transmission model,SARS-COV-2 adhesion disposition,0.6605263157894737
disease transmission model,pathogen portal of exit role,0.6166666666666667
disease transmission model,invasive disposition,0.6891304347826087
disease transmission model,long-term non-progressing infectious disease course,0.5928571428571429
disease transmission model,viral disease epidemic,0.6791666666666666
disease transmission model,commensal role,0.6
disease transmission model,epitope role,0.6078947368421053
disease transmission model,fungicidal disposition,0.6375
disease transmission model,viral disease pandemic,0.7
disease transmission model,virus penetration stage,0.6948979591836735
disease transmission model,acute respiratory distress syndrome,0.630327868852459
disease transmission model,infectious disease endemicity,0.6681818181818181
disease transmission model,contact pathogen transmission process,0.7357142857142857
disease transmission model,disorder,0.6264705882352941
disease transmission model,extracellular infection,0.6132653061224489
disease transmission model,pathogen transporter role,0.6852941176470588
disease transmission model,transmission interval,0.7691489361702127
disease transmission model,exotoxin disposition,0.6456521739130434
disease transmission model,antigen role,0.6342105263157894
disease transmission model,infection start process boundary,0.6224137931034482
disease transmission model,infectious disease control objective specification,0.6473684210526315
disease transmission model,symbiont host role,0.6318181818181818
disease transmission model,opportunistic infectious disposition,0.6274193548387097
disease transmission model,fomite role,0.6121621621621621
disease transmission model,process of establishing viral infection,0.6192307692307693
disease transmission model,enterotoxin disposition,0.6540816326530612
disease transmission model,COVID-19 disease course,0.6744897959183673
disease transmission model,infectious disease incidence rate,0.6703389830508475
disease transmission model,active immunization against infectious agent,0.6214285714285714
disease transmission model,disordered virus,0.6404761904761905
disease transmission model,collective resistance disposition,0.6533898305084747
disease transmission model,reagent role,0.6342105263157894
disease transmission model,fungistatic disposition,0.6540816326530612
disease transmission model,virus uncoating stage,0.6202127659574468
disease transmission model,local infection,0.5963414634146341
disease transmission model,establishment of a clinically abnormal colony,0.6190140845070422
disease transmission model,coronavirus disease,0.6055555555555556
disease transmission model,positive-sense single-stranded RNA virus,0.6318181818181818
disease transmission model,horizontal pathogen transmission process,0.7378787878787878
disease transmission model,hospital-acquired infection,0.6009433962264151
disease transmission model,pathogen transmission process,0.7772727272727272
chronic infectious disease course,virus aggregate,0.5958333333333333
chronic infectious disease course,source of infection,0.6615384615384616
chronic infectious disease course,virostatic disposition,0.6318181818181818
chronic infectious disease course,zoonotic disposition,0.6386792452830189
chronic infectious disease course,infectious disease mortality rate,0.7833333333333333
chronic infectious disease course,infection incidence rate profile,0.6961538461538461
chronic infectious disease course,infectious structure aggregate,0.7039682539682539
chronic infectious disease course,communicability end temporal region,0.6558823529411765
chronic infectious disease course,pathogen portal of entry,0.6078947368421053
chronic infectious disease course,biological regulation,0.5981481481481481
chronic infectious disease course,subclinical coronavirus infection,0.6621212121212122
chronic infectious disease course,infection end temporal region,0.6919354838709677
chronic infectious disease course,infectious disease,0.8029411764705883
chronic infectious disease course,SARS-CoV-2 incidence rate,0.6741379310344828
chronic infectious disease course,double-stranded DNA virus,0.6051724137931035
chronic infectious disease course,incubation end temporal region,0.6563492063492063
chronic infectious disease course,site of infection,0.65
chronic infectious disease course,normal resident microbiota population,0.6214285714285714
chronic infectious disease course,virulence factor disposition,0.6795081967213115
chronic infectious disease course,viral adhesion disposition,0.6364406779661017
chronic infectious disease course,parasitostatic disposition,0.6364406779661017
chronic infectious disease course,infectious disease incidence,0.7942622950819671
chronic infectious disease course,negative regulation of production,0.6166666666666667
chronic infectious disease course,reverse zoonotic disposition,0.630327868852459
chronic infectious disease course,subclinical SARS-CoV-2 infection,0.65
chronic infectious disease course,virus translation stage,0.6285714285714286
chronic infectious disease course,disease surveillance objective specification,0.6188311688311688
chronic infectious disease course,virus release stage,0.6615384615384616
chronic infectious disease course,infectious agent host role,0.738135593220339
chronic infectious disease course,asymptomatic infectious structure carrier,0.7337837837837838
chronic infectious disease course,source of infection site,0.6956140350877194
chronic infectious disease course,virus,0.5289473684210526
chronic infectious disease course,virus replication,0.59
chronic infectious disease course,B cell receptor complex,0.6285714285714286
chronic infectious disease course,passive immunization against infectious agent,0.6679487179487179
chronic infectious disease course,systematic infection,0.6575471698113208
chronic infectious disease course,infection incidence rate,0.7131578947368421
chronic infectious disease course,virus host,0.5895348837209302
chronic infectious disease course,double-stranded RNA virus,0.6051724137931035
chronic infectious disease course,pathogen portal of entry role,0.6274193548387097
chronic infectious disease course,virus transcription stage,0.6396551724137931
chronic infectious disease course,infectious disease lifetime prevalence,0.7457746478873238
chronic infectious disease course,toxin disposition,0.63
chronic infectious disease course,lower respiratory tract disease,0.653125
chronic infectious disease course,infectious disease incidence proportion,0.7555555555555555
chronic infectious disease course,virus generative stage,0.6318181818181818
chronic infectious disease course,acute infectious disease course,0.871875
chronic infectious disease course,cidal agent disposition,0.6464285714285714
chronic infectious disease course,infectious disorder,0.7769230769230769
chronic infectious disease course,subclinical infection,0.6907407407407408
chronic infectious disease course,appearance of disorder,0.6681818181818181
chronic infectious disease course,simple infection,0.6540816326530612
chronic infectious disease course,parasiticidal disposition,0.6396551724137931
chronic infectious disease course,infectious disease sporadicity,0.7833333333333333
chronic infectious disease course,communicability end process boundary,0.6673913043478261
chronic infectious disease course,infection incidence proportion profile,0.6753521126760563
chronic infectious disease course,infectious agent colony,0.7357142857142857
chronic infectious disease course,transmissibility disposition,0.630327868852459
chronic infectious disease course,latency end process boundary,0.630327868852459
chronic infectious disease course,infectious disease epidemic,0.7833333333333333
chronic infectious disease course,infectious agent generative stage,0.7075757575757575
chronic infectious disease course,disease transmission model,0.6364406779661017
chronic infectious disease course,endotoxin disposition,0.6166666666666667
chronic infectious disease course,negative regulation of establishment of localization,0.6264705882352941
chronic infectious disease course,negative-sense single-stranded RNA virus,0.6280821917808219
chronic infectious disease course,infectious structure host role,0.7198412698412698
chronic infectious disease course,COVID-19 incidence rate,0.7
chronic infectious disease course,cytotoxin disposition,0.6351851851851852
chronic infectious disease course,community-acquired infection,0.6795081967213115
chronic infectious disease course,negative regulation of developmental process,0.6318181818181818
chronic infectious disease course,chronic infectious disease course,0.95
chronic infectious disease course,asymptomatic infectious agent carrier,0.75
chronic infectious disease course,nursing-home acquired infection,0.6375
chronic infectious disease course,COVID-19 epidemic,0.63
chronic infectious disease course,negative regulation of replication,0.6141791044776119
chronic infectious disease course,secondary infection,0.6807692307692308
chronic infectious disease course,infection start temporal region,0.684375
chronic infectious disease course,infection incidence,0.7
chronic infectious disease course,virus disorder,0.6627659574468084
chronic infectious disease course,sterilizing immunity to infectious agent,0.682876712328767
chronic infectious disease course,diseased population,0.6423076923076922
chronic infectious disease course,primary infection,0.67
chronic infectious disease course,process of establishing an infection,0.6528985507246376
chronic infectious disease course,incubation end process boundary,0.66875
chronic infectious disease course,SARS-CoV-2 disorder,0.6423076923076922
chronic infectious disease course,collective pathogenic disposition,0.6469696969696969
chronic infectious disease course,neurotoxin disposition,0.6318181818181818
chronic infectious disease course,plan specification,0.6068627450980393
chronic infectious disease course,latency end temporal region,0.6166666666666667
chronic infectious disease course,innate immunity to infectious agent,0.6852941176470588
chronic infectious disease course,infectious structure,0.7518867924528303
chronic infectious disease course,virus adhesion susceptible cell,0.6375
chronic infectious disease course,collective disposition,0.6681818181818181
chronic infectious disease course,infection,0.6404761904761905
chronic infectious disease course,static agent disposition,0.6429824561403508
chronic infectious disease course,T cell receptor complex,0.6285714285714286
chronic infectious disease course,infectious structure host,0.7258620689655172
chronic infectious disease course,infectious agent population,0.7166666666666667
chronic infectious disease course,respiratory system disease,0.6703389830508475
chronic infectious disease course,entry into host,0.6375
chronic infectious disease course,leukocyte-mediated immunity to infectious agent,0.6625
chronic infectious disease course,humoral immunity to infectious agent,0.7108695652173913
chronic infectious disease course,infectious disease control strategy,0.8029411764705883
chronic infectious disease course,infectious disease pandemic,0.7833333333333333
chronic infectious disease course,infectious structure generative stage,0.7071428571428571
chronic infectious disease course,immunosuppressive disposition,0.6274193548387097
chronic infectious disease course,pathogenic disposition,0.65
chronic infectious disease course,viral disease course,0.7518867924528303
chronic infectious disease course,entry into host through host barriers,0.6357142857142857
chronic infectious disease course,intracellular infection,0.6464285714285714
chronic infectious disease course,secondary infection role,0.7131578947368421
chronic infectious disease course,metastatic infection,0.6575471698113208
chronic infectious disease course,passive immunity to infectious agent,0.6818840579710145
chronic infectious disease course,infectious disposition,0.740909090909091
chronic infectious disease course,vaccination against infectious agent,0.7108695652173913
chronic infectious disease course,objective specification,0.6285714285714286
chronic infectious disease course,acute infection,0.6583333333333334
chronic infectious disease course,susceptibility to infectious agent,0.6888059701492537
chronic infectious disease course,bacteriostatic disposition,0.6364406779661017
chronic infectious disease course,bactericidal disposition,0.6429824561403508
chronic infectious disease course,source of infection role,0.6956140350877194
chronic infectious disease course,chronic infection,0.77
chronic infectious disease course,invasion disposition,0.6386792452830189
chronic infectious disease course,disease course,0.747872340425532
chronic infectious disease course,infectious disease course,0.8810344827586206
chronic infectious disease course,viricidal disposition,0.6351851851851852
chronic infectious disease course,acquired immunity to infectious agent,0.7071428571428571
chronic infectious disease course,complex infection,0.67
chronic infectious disease course,COVID-19 disease incidence proportion,0.6642857142857143
chronic infectious disease course,coronavirus disease course,0.8228813559322035
chronic infectious disease course,infection incidence proportion,0.6880952380952381
chronic infectious disease course,symptomatic infectious agent carrier,0.7543478260869566
chronic infectious disease course,respiratory droplet virus fomite,0.6192307692307693
chronic infectious disease course,infectious disease prevalence,0.7887096774193548
chronic infectious disease course,disposition,0.5636363636363636
chronic infectious disease course,single-stranded DNA virus,0.6224137931034482
chronic infectious disease course,infected population,0.6423076923076922
chronic infectious disease course,COVID-19 mortality rate,0.6107142857142857
chronic infectious disease course,contact tracing,0.6166666666666667
chronic infectious disease course,negative regulation of life-sustaining process,0.6272151898734176
chronic infectious disease course,viral disease,0.6456521739130434
chronic infectious disease course,primary infection role,0.7045454545454546
chronic infectious disease course,adhesion disposition,0.6386792452830189
chronic infectious disease course,pathogen portal of entry site,0.6274193548387097
chronic infectious disease course,infection incidence profile,0.7
chronic infectious disease course,disease,0.625
chronic infectious disease course,symptomatic infectious structure carrier,0.7376712328767124
chronic infectious disease course,primary infectious disposition,0.7515873015873015
chronic infectious disease course,infection prevalence,0.7141509433962264
chronic infectious disease course,coronavirus disorder,0.7141509433962264
chronic infectious disease course,infectious pathogen transmissibility,0.6818840579710145
chronic infectious disease course,object,0.5525641025641026
chronic infectious disease course,infectious human pathogen,0.7086206896551723
chronic infectious disease course,subclinical virus infection,0.6666666666666667
chronic infectious disease course,establishment of localization in virus host,0.6342105263157894
chronic infectious disease course,immunization against infectious agent,0.6928571428571427
chronic infectious disease course,virus attachment stage,0.6136363636363636
chronic infectious disease course,negative regulation of immune response,0.6471830985915493
chronic infectious disease course,virus synthesis stage,0.6351851851851852
chronic infectious disease course,SARS-COV-2 adhesion disposition,0.6375
chronic infectious disease course,object aggregate,0.6132653061224489
chronic infectious disease course,invasive disposition,0.619811320754717
chronic infectious disease course,infectious agent host,0.7462962962962962
chronic infectious disease course,long-term non-progressing infectious disease course,0.8071428571428573
chronic infectious disease course,viral disease epidemic,0.65
chronic infectious disease course,fungicidal disposition,0.6318181818181818
chronic infectious disease course,viral disease pandemic,0.65
chronic infectious disease course,virus penetration stage,0.6464285714285714
chronic infectious disease course,acute respiratory distress syndrome,0.6558823529411765
chronic infectious disease course,infectious disease endemicity,0.7725806451612902
chronic infectious disease course,negative regulation of viral process,0.6384057971014493
chronic infectious disease course,contact pathogen transmission process,0.65
chronic infectious disease course,disorder,0.5963414634146341
chronic infectious disease course,herd immunity to infectious organism,0.7253623188405797
chronic infectious disease course,extracellular infection,0.6464285714285714
chronic infectious disease course,exotoxin disposition,0.619811320754717
chronic infectious disease course,infectious agent reservoir,0.738135593220339
chronic infectious disease course,COVID-19 pandemic,0.61
chronic infectious disease course,infection start process boundary,0.6961538461538461
chronic infectious disease course,infectious disease control objective specification,0.739156626506024
chronic infectious disease course,opportunistic infectious disposition,0.7543478260869566
chronic infectious disease course,process of establishing viral infection,0.6583333333333334
chronic infectious disease course,negative regulation of biological process,0.6256756756756756
chronic infectious disease course,enterotoxin disposition,0.6285714285714286
chronic infectious disease course,polymerase chain reaction,0.6051724137931035
chronic infectious disease course,COVID-19 disease course,0.7714285714285714
chronic infectious disease course,infectious disease incidence rate,0.7833333333333333
chronic infectious disease course,single-stranded RNA retrovirus,0.6246031746031746
chronic infectious disease course,active immunization against infectious agent,0.6837662337662337
chronic infectious disease course,disordered virus,0.6132653061224489
chronic infectious disease course,collective resistance disposition,0.6621212121212122
chronic infectious disease course,fungistatic disposition,0.6285714285714286
chronic infectious disease course,virus uncoating stage,0.6351851851851852
chronic infectious disease course,local infection,0.6791666666666666
chronic infectious disease course,infectious agent,0.7153061224489795
chronic infectious disease course,establishment of a clinically abnormal colony,0.6038461538461539
chronic infectious disease course,coronavirus disease,0.7384615384615384
chronic infectious disease course,positive-sense single-stranded RNA virus,0.6280821917808219
chronic infectious disease course,hospital-acquired infection,0.6666666666666667
chronic infectious disease course,drug susceptibility of infectious agent,0.6722222222222223
respiratory droplet fomite,communicability end temporal region,0.6139344262295081
respiratory droplet fomite,infection end temporal region,0.6136363636363636
respiratory droplet fomite,incubation end temporal region,0.6285714285714286
respiratory droplet fomite,respiratory droplet,0.8722222222222222
respiratory droplet fomite,B cell receptor complex,0.6744897959183673
respiratory droplet fomite,respiratory droplet coronavirus fomite,0.85625
respiratory droplet fomite,lower respiratory tract disease,0.7482456140350877
respiratory droplet fomite,droplet pathogen transmission process,0.6404761904761905
respiratory droplet fomite,communicability end process boundary,0.6274193548387097
respiratory droplet fomite,latency end process boundary,0.6351851851851852
respiratory droplet fomite,respiratory droplet SARS-CoV-2 fomite,0.8626984126984126
respiratory droplet fomite,fomite,0.6375
respiratory droplet fomite,incubation end process boundary,0.6429824561403508
respiratory droplet fomite,latency end temporal region,0.619811320754717
respiratory droplet fomite,T cell receptor complex,0.6744897959183673
respiratory droplet fomite,respiratory system disease,0.7576923076923078
respiratory droplet fomite,respiratory secretion,0.7904255319148936
respiratory droplet fomite,respiratory droplet virus fomite,0.8982758620689656
respiratory droplet fomite,respiratory droplet fomite,0.95
respiratory droplet fomite,acute respiratory distress syndrome,0.7614754098360657
respiratory droplet fomite,division of geopolitical entity,0.6429824561403508
respiratory droplet fomite,action specification,0.6456521739130434
respiratory droplet fomite,fomite role,0.6391891891891892
respiratory droplet fomite,establishment of a clinically abnormal colony,0.6049295774647887
double-stranded DNA retrovirus,ribonucleic acid,0.6021739130434782
double-stranded DNA retrovirus,virus aggregate,0.6055555555555556
double-stranded DNA retrovirus,deoxyribonucleic acid,0.6068627450980393
double-stranded DNA retrovirus,double-stranded DNA virus,0.9045454545454545
double-stranded DNA retrovirus,double-stranded DNA,0.8377551020408163
double-stranded DNA retrovirus,virus translation stage,0.6386792452830189
double-stranded DNA retrovirus,virus release stage,0.6132653061224489
double-stranded DNA retrovirus,virus,0.5928571428571429
double-stranded DNA retrovirus,virus replication,0.598936170212766
double-stranded DNA retrovirus,B cell receptor complex,0.6009433962264151
double-stranded DNA retrovirus,virus host,0.575
double-stranded DNA retrovirus,double-stranded RNA virus,0.8863636363636362
double-stranded DNA retrovirus,virus transcription stage,0.6318181818181818
double-stranded DNA retrovirus,virus generative stage,0.6038461538461539
double-stranded DNA retrovirus,genetic resistance to pathogen,0.6166666666666667
double-stranded DNA retrovirus,negative-sense single-stranded RNA virus,0.7357142857142857
double-stranded DNA retrovirus,nucleic acid,0.5928571428571429
double-stranded DNA retrovirus,virus disorder,0.609090909090909
double-stranded DNA retrovirus,virus adhesion susceptible cell,0.6139344262295081
double-stranded DNA retrovirus,T cell receptor complex,0.6009433962264151
double-stranded DNA retrovirus,respiratory droplet virus fomite,0.6758064516129032
double-stranded DNA retrovirus,single-stranded DNA virus,0.8318181818181819
double-stranded DNA retrovirus,double-stranded DNA retrovirus,0.95
double-stranded DNA retrovirus,subclinical virus infection,0.6429824561403508
double-stranded DNA retrovirus,establishment of localization in virus host,0.6417808219178082
double-stranded DNA retrovirus,virus attachment stage,0.6038461538461539
double-stranded DNA retrovirus,virus synthesis stage,0.5872549019607843
double-stranded DNA retrovirus,virus penetration stage,0.619811320754717
double-stranded DNA retrovirus,single-stranded RNA retrovirus,0.8666666666666667
double-stranded DNA retrovirus,disordered virus,0.7108695652173913
double-stranded DNA retrovirus,virus uncoating stage,0.6068627450980393
double-stranded DNA retrovirus,establishment of a clinically abnormal colony,0.5966666666666667
double-stranded DNA retrovirus,positive-sense single-stranded RNA virus,0.75
pathogen portal of entry site,extended organism,0.6456521739130434
pathogen portal of entry site,virus aggregate,0.5863636363636363
pathogen portal of entry site,source of infection,0.6375
pathogen portal of entry site,infectious disease mortality rate,0.6758064516129032
pathogen portal of entry site,infection incidence rate profile,0.6467213114754098
pathogen portal of entry site,communicability end temporal region,0.653125
pathogen portal of entry site,pathogen generative stage,0.7462962962962962
pathogen portal of entry site,pathogen portal of entry,0.9028301886792454
pathogen portal of entry site,subclinical coronavirus infection,0.6112903225806451
pathogen portal of entry site,primary pathogen,0.6277777777777778
pathogen portal of entry site,infection end temporal region,0.6741379310344828
pathogen portal of entry site,drug-based immunosuppressed organism,0.5884615384615385
pathogen portal of entry site,geospatial location,0.6583333333333334
pathogen portal of entry site,infectious disease,0.598936170212766
pathogen portal of entry site,double-stranded DNA virus,0.5981481481481481
pathogen portal of entry site,incubation end temporal region,0.6872881355932203
pathogen portal of entry site,site of infection,0.6456521739130434
pathogen portal of entry site,immunocompetent organism,0.6386792452830189
pathogen portal of entry site,pathogen portal of exit,0.8730769230769231
pathogen portal of entry site,infectious disease incidence,0.5903508771929825
pathogen portal of entry site,reservoir of pathogen role,0.6681818181818181
pathogen portal of entry site,subclinical SARS-CoV-2 infection,0.5975409836065574
pathogen portal of entry site,virus translation stage,0.6423076923076922
pathogen portal of entry site,disease surveillance objective specification,0.6280821917808219
pathogen portal of entry site,case isolation control strategy,0.6833333333333332
pathogen portal of entry site,virus release stage,0.6166666666666667
pathogen portal of entry site,infectious agent host role,0.65
pathogen portal of entry site,source of infection site,0.6952830188679244
pathogen portal of entry site,virus,0.5088235294117647
pathogen portal of entry site,virus replication,0.558695652173913
pathogen portal of entry site,B cell receptor complex,0.6038461538461539
pathogen portal of entry site,passive immunization against infectious agent,0.6256756756756756
pathogen portal of entry site,systematic infection,0.6132653061224489
pathogen portal of entry site,infection incidence rate,0.619811320754717
pathogen portal of entry site,virus host,0.5782051282051281
pathogen portal of entry site,double-stranded RNA virus,0.6166666666666667
pathogen portal of entry site,pathogen portal of entry role,0.8982758620689656
pathogen portal of entry site,virus transcription stage,0.6351851851851852
pathogen portal of entry site,infectious disease lifetime prevalence,0.6141791044776119
pathogen portal of entry site,pathogen birth temporal region,0.738135593220339
pathogen portal of entry site,lower respiratory tract disease,0.6666666666666667
pathogen portal of entry site,infectious disease incidence proportion,0.6117647058823529
pathogen portal of entry site,opportunistic pathogen,0.6460784313725491
pathogen portal of entry site,virus generative stage,0.6460784313725491
pathogen portal of entry site,acute infectious disease course,0.6333333333333333
pathogen portal of entry site,cidal agent disposition,0.6423076923076922
pathogen portal of entry site,genetic resistance to pathogen,0.6533898305084747
pathogen portal of entry site,subclinical infection,0.61
pathogen portal of entry site,appearance of disorder,0.6460784313725491
pathogen portal of entry site,simple infection,0.6055555555555556
pathogen portal of entry site,droplet pathogen transmission process,0.6772727272727272
pathogen portal of entry site,infectious disease sporadicity,0.6194915254237288
pathogen portal of entry site,communicability end process boundary,0.6346153846153847
pathogen portal of entry site,infection incidence proportion profile,0.658955223880597
pathogen portal of entry site,infectious agent colony,0.6615384615384616
pathogen portal of entry site,pathogen transporter,0.7561224489795919
pathogen portal of entry site,latency end process boundary,0.6605263157894737
pathogen portal of entry site,infectious disease epidemic,0.5928571428571429
pathogen portal of entry site,infectious agent generative stage,0.6758064516129032
pathogen portal of entry site,disease transmission model,0.6136363636363636
pathogen portal of entry site,pathologically immunosuppressed organism,0.6384057971014493
pathogen portal of entry site,negative-sense single-stranded RNA virus,0.6094202898550725
pathogen portal of entry site,cidal agent,0.6
pathogen portal of entry site,pathogen vehicle,0.7166666666666667
pathogen portal of entry site,community-acquired infection,0.6078947368421053
pathogen portal of entry site,pathogen vector,0.7227272727272727
pathogen portal of entry site,pathogen vehicle role,0.71
pathogen portal of entry site,chronic infectious disease course,0.6274193548387097
pathogen portal of entry site,asymptomatic infectious agent carrier,0.6469696969696969
pathogen portal of entry site,nursing-home acquired infection,0.6166666666666667
pathogen portal of entry site,secondary infection,0.6166666666666667
pathogen portal of entry site,infection start temporal region,0.65
pathogen portal of entry site,infection incidence,0.5958333333333333
pathogen portal of entry site,virus disorder,0.5662790697674418
pathogen portal of entry site,sterilizing immunity to infectious agent,0.6239130434782608
pathogen portal of entry site,primary infection,0.6239130434782608
pathogen portal of entry site,process of establishing an infection,0.65
pathogen portal of entry site,incubation end process boundary,0.6666666666666667
pathogen portal of entry site,pathogen death process boundary,0.7166666666666667
pathogen portal of entry site,immunosuppressed organism,0.5981481481481481
pathogen portal of entry site,latency end temporal region,0.6821428571428573
pathogen portal of entry site,innate immunity to infectious agent,0.6375
pathogen portal of entry site,virus adhesion susceptible cell,0.6333333333333333
pathogen portal of entry site,anatomical space,0.6277777777777778
pathogen portal of entry site,infection,0.581578947368421
pathogen portal of entry site,static agent disposition,0.6575471698113208
pathogen portal of entry site,T cell receptor complex,0.6230769230769231
pathogen portal of entry site,infectious agent population,0.6464285714285714
pathogen portal of entry site,respiratory system disease,0.65
pathogen portal of entry site,entry into host,0.6545454545454545
pathogen portal of entry site,leukocyte-mediated immunity to infectious agent,0.6078947368421053
pathogen portal of entry site,indirect pathogen transmission process,0.6738805970149254
pathogen portal of entry site,organism population,0.6375
pathogen portal of entry site,humoral immunity to infectious agent,0.65
pathogen portal of entry site,infectious disease control strategy,0.653125
pathogen portal of entry site,parasite,0.6662162162162162
pathogen portal of entry site,infectious disease pandemic,0.5928571428571429
pathogen portal of entry site,antibody reagent,0.65
pathogen portal of entry site,viral disease course,0.6132653061224489
pathogen portal of entry site,entry into host through host barriers,0.6469696969696969
pathogen portal of entry site,intracellular infection,0.6230769230769231
pathogen portal of entry site,secondary infection role,0.619811320754717
pathogen portal of entry site,metastatic infection,0.6132653061224489
pathogen portal of entry site,passive immunity to infectious agent,0.6346153846153847
pathogen portal of entry site,vaccination against infectious agent,0.6346153846153847
pathogen portal of entry site,acute infection,0.6318181818181818
pathogen portal of entry site,susceptibility to infectious agent,0.6246031746031746
pathogen portal of entry site,epitope site,0.6939024390243902
pathogen portal of entry site,immunity to pathogen,0.6132653061224489
pathogen portal of entry site,source of infection role,0.6386792452830189
pathogen portal of entry site,pathogen host,0.7357142857142857
pathogen portal of entry site,chronic infection,0.6239130434782608
pathogen portal of entry site,disease course,0.6127906976744186
pathogen portal of entry site,infectious disease course,0.6166666666666667
pathogen portal of entry site,acquired immunity to infectious agent,0.6166666666666667
pathogen portal of entry site,complex infection,0.6239130434782608
pathogen portal of entry site,COVID-19 disease incidence proportion,0.6015151515151516
pathogen portal of entry site,coronavirus disease course,0.6136363636363636
pathogen portal of entry site,infection incidence proportion,0.6364406779661017
pathogen portal of entry site,symptomatic infectious agent carrier,0.65
pathogen portal of entry site,respiratory droplet virus fomite,0.6795081967213115
pathogen portal of entry site,susceptible organism,0.6336734693877552
pathogen portal of entry site,parasite role,0.6404761904761905
pathogen portal of entry site,pathogen vector role,0.7357142857142857
pathogen portal of entry site,pathogen portal of exit site,0.9061403508771929
pathogen portal of entry site,infectious disease prevalence,0.6396551724137931
pathogen portal of entry site,organism substance,0.6202127659574468
pathogen portal of entry site,single-stranded DNA virus,0.5981481481481481
pathogen portal of entry site,contact tracing,0.6318181818181818
pathogen portal of entry site,place closure control strategy,0.7042372881355932
pathogen portal of entry site,viral disease,0.6166666666666667
pathogen portal of entry site,primary infection role,0.6264705882352941
pathogen portal of entry site,pathogen portal of entry site,0.95
pathogen portal of entry site,infection incidence profile,0.6464285714285714
pathogen portal of entry site,disease,0.5611111111111111
pathogen portal of entry site,site,0.5712121212121213
pathogen portal of entry site,pathogen host role,0.747872340425532
pathogen portal of entry site,infection prevalence,0.6744897959183673
pathogen portal of entry site,infectious pathogen transmissibility,0.6807692307692308
pathogen portal of entry site,incubation start process boundary,0.6596774193548387
pathogen portal of entry site,pathogen surveillance,0.71
pathogen portal of entry site,immunodeficient organism,0.619811320754717
pathogen portal of entry site,pathogen,0.6662162162162162
pathogen portal of entry site,pathogen birth process boundary,0.7333333333333333
pathogen portal of entry site,infectious human pathogen,0.6166666666666667
pathogen portal of entry site,subclinical virus infection,0.5928571428571429
pathogen portal of entry site,resistance to pathogen,0.6264705882352941
pathogen portal of entry site,establishment of localization in virus host,0.6583333333333334
pathogen portal of entry site,immunization against infectious agent,0.6318181818181818
pathogen portal of entry site,virus attachment stage,0.6656862745098039
pathogen portal of entry site,virus synthesis stage,0.61
pathogen portal of entry site,pathogen portal of exit role,0.8535087719298246
pathogen portal of entry site,infectious agent host,0.65
pathogen portal of entry site,re-emerging pathogen,0.6132653061224489
pathogen portal of entry site,long-term non-progressing infectious disease course,0.625
pathogen portal of entry site,viral disease epidemic,0.6068627450980393
pathogen portal of entry site,communicability start temporal region,0.6166666666666667
pathogen portal of entry site,viral disease pandemic,0.5872549019607843
pathogen portal of entry site,virus penetration stage,0.6615384615384616
pathogen portal of entry site,pathogen seroprevalence,0.7576923076923078
pathogen portal of entry site,infectious disease endemicity,0.6051724137931035
pathogen portal of entry site,contact pathogen transmission process,0.6772727272727272
pathogen portal of entry site,herd immunity to infectious organism,0.6192307692307693
pathogen portal of entry site,extracellular infection,0.6230769230769231
pathogen portal of entry site,pathogen transporter role,0.7648148148148148
pathogen portal of entry site,infectious agent reservoir,0.6318181818181818
pathogen portal of entry site,infection start process boundary,0.6467213114754098
pathogen portal of entry site,latency start process boundary,0.6703389830508475
pathogen portal of entry site,infectious disease control objective specification,0.639873417721519
pathogen portal of entry site,process of establishing viral infection,0.6411764705882353
pathogen portal of entry site,COVID-19 disease course,0.6038461538461539
pathogen portal of entry site,infectious disease incidence rate,0.6112903225806451
pathogen portal of entry site,communicability start process boundary,0.6141791044776119
pathogen portal of entry site,single-stranded RNA retrovirus,0.6364406779661017
pathogen portal of entry site,active immunization against infectious agent,0.6280821917808219
pathogen portal of entry site,disordered virus,0.5833333333333334
pathogen portal of entry site,organism,0.5851351351351352
pathogen portal of entry site,virus uncoating stage,0.61
pathogen portal of entry site,local infection,0.6318181818181818
pathogen portal of entry site,infectious agent,0.6055555555555556
pathogen portal of entry site,establishment of a clinically abnormal colony,0.6256756756756756
pathogen portal of entry site,process boundary,0.6277777777777778
pathogen portal of entry site,coronavirus disease,0.6166666666666667
pathogen portal of entry site,positive-sense single-stranded RNA virus,0.6094202898550725
pathogen portal of entry site,horizontal pathogen transmission process,0.6673913043478261
pathogen portal of entry site,hospital-acquired infection,0.6464285714285714
pathogen portal of entry site,pathogen death temporal region,0.738135593220339
pathogen portal of entry site,emerging pathogen,0.6239130434782608
pathogen portal of entry site,drug susceptibility of infectious agent,0.6411764705882353
pathogen portal of entry site,static agent,0.6207317073170732
pathogen portal of entry site,pathogen transmission process,0.7086206896551723
pathogen portal of entry site,cell space,0.5782051282051281
pathogen portal of exit role,extended organism,0.6277777777777778
pathogen portal of exit role,virus aggregate,0.5895348837209302
pathogen portal of exit role,source of infection,0.6414893617021277
pathogen portal of exit role,infectious disease mortality rate,0.6795081967213115
pathogen portal of exit role,infection incidence rate profile,0.6666666666666667
pathogen portal of exit role,communicability end temporal region,0.6722222222222223
pathogen portal of exit role,pathogen generative stage,0.7141509433962264
pathogen portal of exit role,pathogen portal of entry,0.8730769230769231
pathogen portal of exit role,subclinical coronavirus infection,0.6139344262295081
pathogen portal of exit role,primary pathogen,0.6318181818181818
pathogen portal of exit role,infection end temporal region,0.6956140350877194
pathogen portal of exit role,drug-based immunosuppressed organism,0.575
pathogen portal of exit role,infectious disease,0.5804347826086956
pathogen portal of exit role,double-stranded DNA virus,0.6009433962264151
pathogen portal of exit role,incubation end temporal region,0.7086206896551723
pathogen portal of exit role,site of infection,0.65
pathogen portal of exit role,immunocompetent organism,0.6230769230769231
pathogen portal of exit role,pathogen portal of exit,0.9009803921568627
pathogen portal of exit role,infectious disease incidence,0.575
pathogen portal of exit role,reservoir of pathogen role,0.6907407407407408
pathogen portal of exit role,subclinical SARS-CoV-2 infection,0.6
pathogen portal of exit role,virus translation stage,0.6068627450980393
pathogen portal of exit role,disease surveillance objective specification,0.6166666666666667
pathogen portal of exit role,case isolation control strategy,0.6533898305084747
pathogen portal of exit role,virus release stage,0.5776595744680851
pathogen portal of exit role,infectious agent host role,0.7092592592592593
pathogen portal of exit role,source of infection site,0.6423076923076922
pathogen portal of exit role,virus,0.5106060606060606
pathogen portal of exit role,virus replication,0.5833333333333334
pathogen portal of exit role,B cell receptor complex,0.6264705882352941
pathogen portal of exit role,passive immunization against infectious agent,0.6280821917808219
pathogen portal of exit role,systematic infection,0.6166666666666667
pathogen portal of exit role,infection incidence rate,0.6230769230769231
pathogen portal of exit role,virus host,0.5552631578947369
pathogen portal of exit role,double-stranded RNA virus,0.619811320754717
pathogen portal of exit role,pathogen portal of entry role,0.9061403508771929
pathogen portal of exit role,virus transcription stage,0.6009433962264151
pathogen portal of exit role,infectious disease lifetime prevalence,0.6318181818181818
pathogen portal of exit role,pathogen birth temporal region,0.760344827586207
pathogen portal of exit role,lower respiratory tract disease,0.6364406779661017
pathogen portal of exit role,infectious disease incidence proportion,0.6141791044776119
pathogen portal of exit role,opportunistic pathogen,0.65
pathogen portal of exit role,virus generative stage,0.61
pathogen portal of exit role,acute infectious disease course,0.6364406779661017
pathogen portal of exit role,cidal agent disposition,0.6460784313725491
pathogen portal of exit role,role,0.575
pathogen portal of exit role,genetic resistance to pathogen,0.6741379310344828
pathogen portal of exit role,subclinical infection,0.6132653061224489
pathogen portal of exit role,appearance of disorder,0.67
pathogen portal of exit role,simple infection,0.609090909090909
pathogen portal of exit role,droplet pathogen transmission process,0.6961538461538461
pathogen portal of exit role,infectious disease sporadicity,0.6224137931034482
pathogen portal of exit role,mutualist role,0.6880952380952381
pathogen portal of exit role,communicability end process boundary,0.621875
pathogen portal of exit role,infection incidence proportion profile,0.6772727272727272
pathogen portal of exit role,infectious agent colony,0.6264705882352941
pathogen portal of exit role,pathogen transporter,0.7625
pathogen portal of exit role,latency end process boundary,0.6464285714285714
pathogen portal of exit role,infectious disease epidemic,0.5954545454545455
pathogen portal of exit role,infectious agent generative stage,0.630327868852459
pathogen portal of exit role,disease transmission model,0.6166666666666667
pathogen portal of exit role,pathologically immunosuppressed organism,0.6411764705882353
pathogen portal of exit role,negative-sense single-stranded RNA virus,0.6117647058823529
pathogen portal of exit role,cidal agent,0.5782051282051281
pathogen portal of exit role,infectious structure host role,0.6741379310344828
pathogen portal of exit role,pathogen vehicle,0.7454545454545455
pathogen portal of exit role,community-acquired infection,0.6107142857142857
pathogen portal of exit role,pathogen vector,0.7290697674418604
pathogen portal of exit role,pathogen vehicle role,0.7765306122448979
pathogen portal of exit role,chronic infectious disease course,0.630327868852459
pathogen portal of exit role,asymptomatic infectious agent carrier,0.6346153846153847
pathogen portal of exit role,nursing-home acquired infection,0.6194915254237288
pathogen portal of exit role,secondary infection,0.6202127659574468
pathogen portal of exit role,mechanical vector role,0.69
pathogen portal of exit role,infection start temporal region,0.6703389830508475
pathogen portal of exit role,infection incidence,0.5776595744680851
pathogen portal of exit role,virus disorder,0.569047619047619
pathogen portal of exit role,sterilizing immunity to infectious agent,0.6264705882352941
pathogen portal of exit role,primary infection,0.6277777777777778
pathogen portal of exit role,process of establishing an infection,0.653125
pathogen portal of exit role,incubation end process boundary,0.6533898305084747
pathogen portal of exit role,dead-end host role,0.6891304347826087
pathogen portal of exit role,pathogen death process boundary,0.7042372881355932
pathogen portal of exit role,immunosuppressed organism,0.5820754716981132
pathogen portal of exit role,definitive host role,0.6791666666666666
pathogen portal of exit role,latency end temporal region,0.7045454545454546
pathogen portal of exit role,innate immunity to infectious agent,0.6404761904761905
pathogen portal of exit role,virus adhesion susceptible cell,0.6364406779661017
pathogen portal of exit role,infection,0.5851351351351352
pathogen portal of exit role,static agent disposition,0.6615384615384616
pathogen portal of exit role,T cell receptor complex,0.6460784313725491
pathogen portal of exit role,asymptomatic carrier role,0.6575471698113208
pathogen portal of exit role,infectious agent population,0.65
pathogen portal of exit role,respiratory system disease,0.6166666666666667
pathogen portal of exit role,entry into host,0.636046511627907
pathogen portal of exit role,leukocyte-mediated immunity to infectious agent,0.61
pathogen portal of exit role,indirect pathogen transmission process,0.6924242424242425
pathogen portal of exit role,organism population,0.6414893617021277
pathogen portal of exit role,humoral immunity to infectious agent,0.6375
pathogen portal of exit role,infectious disease control strategy,0.6246031746031746
pathogen portal of exit role,parasite,0.6444444444444444
pathogen portal of exit role,infectious disease pandemic,0.5954545454545455
pathogen portal of exit role,antibody reagent,0.6318181818181818
pathogen portal of exit role,viral disease course,0.6166666666666667
pathogen portal of exit role,entry into host through host barriers,0.6346153846153847
pathogen portal of exit role,intracellular infection,0.6264705882352941
pathogen portal of exit role,secondary infection role,0.6807692307692308
pathogen portal of exit role,metastatic infection,0.6166666666666667
pathogen portal of exit role,passive immunity to infectious agent,0.6375
pathogen portal of exit role,vaccination against infectious agent,0.6375
pathogen portal of exit role,acute infection,0.636046511627907
pathogen portal of exit role,susceptibility to infectious agent,0.6274193548387097
pathogen portal of exit role,epitope site,0.65
pathogen portal of exit role,immunity to pathogen,0.6166666666666667
pathogen portal of exit role,source of infection role,0.7
pathogen portal of exit role,pathogen host,0.7182926829268292
pathogen portal of exit role,chronic infection,0.6277777777777778
pathogen portal of exit role,disease course,0.5928571428571429
pathogen portal of exit role,infectious disease course,0.6009433962264151
pathogen portal of exit role,acquired immunity to infectious agent,0.6192307692307693
pathogen portal of exit role,complex infection,0.6277777777777778
pathogen portal of exit role,COVID-19 disease incidence proportion,0.6038461538461539
pathogen portal of exit role,coronavirus disease course,0.5981481481481481
pathogen portal of exit role,biological vehicle role,0.6852941176470588
pathogen portal of exit role,infection incidence proportion,0.6396551724137931
pathogen portal of exit role,symptomatic infectious agent carrier,0.6375
pathogen portal of exit role,respiratory droplet virus fomite,0.6666666666666667
pathogen portal of exit role,symbiont role,0.6451219512195122
pathogen portal of exit role,susceptible organism,0.6166666666666667
pathogen portal of exit role,parasite role,0.7182926829268292
pathogen portal of exit role,pathogen vector role,0.7833333333333333
pathogen portal of exit role,pathogen portal of exit site,0.8964285714285714
pathogen portal of exit role,infectious disease prevalence,0.6254385964912281
pathogen portal of exit role,organism substance,0.6021739130434782
pathogen portal of exit role,single-stranded DNA virus,0.6009433962264151
pathogen portal of exit role,COVID-19 mortality rate,0.6852941176470588
pathogen portal of exit role,viral disease,0.5963414634146341
pathogen portal of exit role,primary infection role,0.69
pathogen portal of exit role,biological role,0.6593023255813953
pathogen portal of exit role,pathogen portal of entry site,0.8535087719298246
pathogen portal of exit role,infection incidence profile,0.6681818181818181
pathogen portal of exit role,disease,0.5357142857142857
pathogen portal of exit role,biological vector role,0.69
pathogen portal of exit role,site,0.54375
pathogen portal of exit role,pathogen host role,0.7978260869565217
pathogen portal of exit role,infection prevalence,0.6583333333333334
pathogen portal of exit role,symptomatic carrier role,0.6615384615384616
pathogen portal of exit role,infectious pathogen transmissibility,0.66875
pathogen portal of exit role,incubation start process boundary,0.6467213114754098
pathogen portal of exit role,intermediate host role,0.69
pathogen portal of exit role,pathogen surveillance,0.7357142857142857
pathogen portal of exit role,immunodeficient organism,0.6038461538461539
pathogen portal of exit role,host role,0.6662162162162162
pathogen portal of exit role,pathogen,0.6722222222222223
pathogen portal of exit role,pathogen birth process boundary,0.7211864406779661
pathogen portal of exit role,infectious human pathogen,0.619811320754717
pathogen portal of exit role,subclinical virus infection,0.5954545454545455
pathogen portal of exit role,resistance to pathogen,0.63
pathogen portal of exit role,establishment of localization in virus host,0.6471830985915493
pathogen portal of exit role,immunization against infectious agent,0.6346153846153847
pathogen portal of exit role,virus attachment stage,0.63
pathogen portal of exit role,virus synthesis stage,0.5928571428571429
pathogen portal of exit role,pathogen portal of exit role,0.95
pathogen portal of exit role,infectious agent host,0.6336734693877552
pathogen portal of exit role,re-emerging pathogen,0.6166666666666667
pathogen portal of exit role,long-term non-progressing infectious disease course,0.6272151898734176
pathogen portal of exit role,viral disease epidemic,0.61
pathogen portal of exit role,commensal role,0.6880952380952381
pathogen portal of exit role,epitope role,0.7
pathogen portal of exit role,viral disease pandemic,0.59
pathogen portal of exit role,virus penetration stage,0.6264705882352941
pathogen portal of exit role,pathogen seroprevalence,0.7441176470588234
pathogen portal of exit role,infectious disease endemicity,0.5903508771929825
pathogen portal of exit role,contact pathogen transmission process,0.6961538461538461
pathogen portal of exit role,function,0.5611111111111111
pathogen portal of exit role,herd immunity to infectious organism,0.621875
pathogen portal of exit role,extracellular infection,0.6264705882352941
pathogen portal of exit role,pathogen transporter role,0.808490566037736
pathogen portal of exit role,infectious agent reservoir,0.6351851851851852
pathogen portal of exit role,antigen role,0.7
pathogen portal of exit role,infection start process boundary,0.6333333333333333
pathogen portal of exit role,action specification,0.6583333333333334
pathogen portal of exit role,latency start process boundary,0.656896551724138
pathogen portal of exit role,infectious disease control objective specification,0.6294871794871795
pathogen portal of exit role,symbiont host role,0.6891304347826087
pathogen portal of exit role,fomite role,0.6551282051282051
pathogen portal of exit role,process of establishing viral infection,0.6440298507462687
pathogen portal of exit role,COVID-19 disease course,0.5872549019607843
pathogen portal of exit role,infectious disease incidence rate,0.5975409836065574
pathogen portal of exit role,communicability start process boundary,0.6015151515151516
pathogen portal of exit role,process that results in death,0.6429824561403508
pathogen portal of exit role,single-stranded RNA retrovirus,0.6396551724137931
pathogen portal of exit role,active immunization against infectious agent,0.6166666666666667
pathogen portal of exit role,disordered virus,0.5863636363636363
pathogen portal of exit role,reagent role,0.7
pathogen portal of exit role,viral load,0.581578947368421
pathogen portal of exit role,organism,0.5611111111111111
pathogen portal of exit role,virus uncoating stage,0.5928571428571429
pathogen portal of exit role,local infection,0.636046511627907
pathogen portal of exit role,infectious agent,0.5863636363636363
pathogen portal of exit role,establishment of a clinically abnormal colony,0.6417808219178082
pathogen portal of exit role,process boundary,0.609090909090909
pathogen portal of exit role,coronavirus disease,0.5776595744680851
pathogen portal of exit role,positive-sense single-stranded RNA virus,0.6117647058823529
pathogen portal of exit role,horizontal pathogen transmission process,0.6852941176470588
pathogen portal of exit role,hospital-acquired infection,0.65
pathogen portal of exit role,pathogen death temporal region,0.760344827586207
pathogen portal of exit role,emerging pathogen,0.6277777777777778
pathogen portal of exit role,drug susceptibility of infectious agent,0.6440298507462687
pathogen portal of exit role,SARS-CoV-2 release stage,0.6038461538461539
pathogen portal of exit role,static agent,0.6
pathogen portal of exit role,pathogen transmission process,0.730701754385965
adhesion of symbiont to host,virostatic disposition,0.63
adhesion of symbiont to host,zoonotic disposition,0.6166666666666667
adhesion of symbiont to host,communicability end temporal region,0.6087301587301588
adhesion of symbiont to host,infection end temporal region,0.6429824561403508
adhesion of symbiont to host,incubation end temporal region,0.6396551724137931
adhesion of symbiont to host,virulence factor disposition,0.6285714285714286
adhesion of symbiont to host,viral adhesion disposition,0.7092592592592593
adhesion of symbiont to host,parasitostatic disposition,0.6537037037037037
adhesion of symbiont to host,reverse zoonotic disposition,0.6464285714285714
adhesion of symbiont to host,establishment of localization in host,0.7115384615384616
adhesion of symbiont to host,infectious agent host role,0.6722222222222223
adhesion of symbiont to host,B cell receptor complex,0.5676470588235294
adhesion of symbiont to host,colonized host,0.6404761904761905
adhesion of symbiont to host,virus host,0.6342105263157894
adhesion of symbiont to host,toxin disposition,0.6277777777777778
adhesion of symbiont to host,lower respiratory tract disease,0.6025423728813559
adhesion of symbiont to host,cidal agent disposition,0.6264705882352941
adhesion of symbiont to host,parasiticidal disposition,0.619811320754717
adhesion of symbiont to host,communicability end process boundary,0.590625
adhesion of symbiont to host,transmissibility disposition,0.6464285714285714
adhesion of symbiont to host,latency end process boundary,0.6107142857142857
adhesion of symbiont to host,colonization of host,0.7
adhesion of symbiont to host,endotoxin disposition,0.6336734693877552
adhesion of symbiont to host,infectious structure host role,0.656896551724138
adhesion of symbiont to host,cytotoxin disposition,0.6132653061224489
adhesion of symbiont to host,host,0.575
adhesion of symbiont to host,establishment of localization in human host,0.6894366197183097
adhesion of symbiont to host,incubation end process boundary,0.6194915254237288
adhesion of symbiont to host,collective pathogenic disposition,0.6139344262295081
adhesion of symbiont to host,neurotoxin disposition,0.63
adhesion of symbiont to host,dead-end host role,0.6673913043478261
adhesion of symbiont to host,definitive host role,0.6791666666666666
adhesion of symbiont to host,latency end temporal region,0.6318181818181818
adhesion of symbiont to host,virus adhesion susceptible cell,0.6533898305084747
adhesion of symbiont to host,collective disposition,0.61
adhesion of symbiont to host,static agent disposition,0.6230769230769231
adhesion of symbiont to host,T cell receptor complex,0.5676470588235294
adhesion of symbiont to host,infectious structure host,0.6764150943396227
adhesion of symbiont to host,entry into host,0.7290697674418604
adhesion of symbiont to host,adhesion of symbiont to host,0.95
adhesion of symbiont to host,SARS-CoV-2 attachment stage,0.6318181818181818
adhesion of symbiont to host,immunosuppressive disposition,0.6078947368421053
adhesion of symbiont to host,pathogenic disposition,0.65
adhesion of symbiont to host,entry into host through host barriers,0.6807692307692308
adhesion of symbiont to host,infectious disposition,0.63
adhesion of symbiont to host,bacteriostatic disposition,0.6537037037037037
adhesion of symbiont to host,bactericidal disposition,0.6230769230769231
adhesion of symbiont to host,pathogen host,0.6695121951219513
adhesion of symbiont to host,invasion disposition,0.6791666666666666
adhesion of symbiont to host,viricidal disposition,0.6132653061224489
adhesion of symbiont to host,symbiont role,0.6939024390243902
adhesion of symbiont to host,intermediate host,0.6722222222222223
adhesion of symbiont to host,disposition,0.6294871794871795
adhesion of symbiont to host,adhesion disposition,0.7416666666666667
adhesion of symbiont to host,primary infectious disposition,0.6224137931034482
adhesion of symbiont to host,pathogen host role,0.6673913043478261
adhesion of symbiont to host,SARS-COV-2 adhesion susceptible cell,0.6375
adhesion of symbiont to host,intermediate host role,0.65
adhesion of symbiont to host,dead-end host,0.6695121951219513
adhesion of symbiont to host,host role,0.6121621621621621
adhesion of symbiont to host,establishment of localization in virus host,0.6894366197183097
adhesion of symbiont to host,virus attachment stage,0.61
adhesion of symbiont to host,SARS-COV-2 adhesion disposition,0.6872881355932203
adhesion of symbiont to host,invasive disposition,0.6375
adhesion of symbiont to host,infectious agent host,0.6948979591836735
adhesion of symbiont to host,obligatory symbiont,0.6840425531914894
adhesion of symbiont to host,fungicidal disposition,0.61
adhesion of symbiont to host,division of geopolitical entity,0.6872881355932203
adhesion of symbiont to host,exotoxin disposition,0.6375
adhesion of symbiont to host,action specification,0.6375
adhesion of symbiont to host,symbiont host role,0.7326086956521739
adhesion of symbiont to host,opportunistic infectious disposition,0.621875
adhesion of symbiont to host,symbiont,0.6722222222222223
adhesion of symbiont to host,enterotoxin disposition,0.6264705882352941
adhesion of symbiont to host,collective resistance disposition,0.6139344262295081
adhesion of symbiont to host,fungistatic disposition,0.6068627450980393
adhesion of symbiont to host,establishment of a clinically abnormal colony,0.6417808219178082
adhesion of symbiont to host,adhesion factor,0.7290697674418604
adhesion of symbiont to host,definitive host,0.7058139534883722
infectious structure aggregate,virus aggregate,0.7388888888888888
infectious structure aggregate,virostatic disposition,0.5846153846153846
infectious structure aggregate,zoonotic disposition,0.57
infectious structure aggregate,infectious disease mortality rate,0.7515873015873015
infectious structure aggregate,infection incidence rate profile,0.7080645161290323
infectious structure aggregate,infectious structure aggregate,0.95
infectious structure aggregate,communicability end temporal region,0.6192307692307693
infectious structure aggregate,infection end temporal region,0.7042372881355932
infectious structure aggregate,infectious disease,0.7625
infectious structure aggregate,SARS-CoV-2 incidence rate,0.65
infectious structure aggregate,incubation end temporal region,0.6666666666666667
infectious structure aggregate,site of infection,0.6202127659574468
infectious structure aggregate,virulence factor disposition,0.6051724137931035
infectious structure aggregate,viral adhesion disposition,0.575
infectious structure aggregate,parasitostatic disposition,0.5928571428571429
infectious structure aggregate,infectious disease incidence,0.7258620689655172
infectious structure aggregate,reverse zoonotic disposition,0.5706896551724138
infectious structure aggregate,disease surveillance objective specification,0.6256756756756756
infectious structure aggregate,infectious agent host role,0.7357142857142857
infectious structure aggregate,macromolecular complex,0.5846153846153846
infectious structure aggregate,SARS-CoV-2 aggregate,0.71
infectious structure aggregate,asymptomatic infectious structure carrier,0.7880281690140845
infectious structure aggregate,source of infection site,0.6722222222222223
infectious structure aggregate,architectual structure,0.7384615384615384
infectious structure aggregate,B cell receptor complex,0.6009433962264151
infectious structure aggregate,passive immunization against infectious agent,0.6633333333333334
infectious structure aggregate,infection incidence rate,0.7462962962962962
infectious structure aggregate,infectious disease lifetime prevalence,0.7294117647058823
infectious structure aggregate,toxin disposition,0.5776595744680851
infectious structure aggregate,lower respiratory tract disease,0.6467213114754098
infectious structure aggregate,infectious disease incidence proportion,0.696376811594203
infectious structure aggregate,acute infectious disease course,0.7122950819672131
infectious structure aggregate,cidal agent disposition,0.5820754716981132
infectious structure aggregate,infectious disorder,0.7561224489795919
infectious structure aggregate,parasiticidal disposition,0.5590909090909091
infectious structure aggregate,infectious disease sporadicity,0.7333333333333333
infectious structure aggregate,communicability end process boundary,0.6015151515151516
infectious structure aggregate,acellular structure aggregate,0.8228813559322035
infectious structure aggregate,infectious agent colony,0.7330188679245283
infectious structure aggregate,transmissibility disposition,0.5706896551724138
infectious structure aggregate,latency end process boundary,0.6051724137931035
infectious structure aggregate,infectious disease epidemic,0.730701754385965
infectious structure aggregate,infectious agent generative stage,0.7515873015873015
infectious structure aggregate,disease transmission model,0.5928571428571429
infectious structure aggregate,endotoxin disposition,0.5676470588235294
infectious structure aggregate,infectious structure host role,0.8333333333333335
infectious structure aggregate,COVID-19 incidence rate,0.6575471698113208
infectious structure aggregate,cytotoxin disposition,0.5676470588235294
infectious structure aggregate,chronic infectious disease course,0.7039682539682539
infectious structure aggregate,asymptomatic infectious agent carrier,0.6888059701492537
infectious structure aggregate,COVID-19 epidemic,0.5563829787234043
infectious structure aggregate,sterilizing immunity to infectious agent,0.6642857142857143
infectious structure aggregate,diseased population,0.5928571428571429
infectious structure aggregate,acellular structure,0.6948979591836735
infectious structure aggregate,incubation end process boundary,0.6631147540983606
infectious structure aggregate,collective pathogenic disposition,0.6087301587301588
infectious structure aggregate,neurotoxin disposition,0.5846153846153846
infectious structure aggregate,latency end temporal region,0.6078947368421053
infectious structure aggregate,coronavirus aggregate,0.7245098039215686
infectious structure aggregate,innate immunity to infectious agent,0.6807692307692308
infectious structure aggregate,infectious structure,0.85
infectious structure aggregate,collective disposition,0.5846153846153846
infectious structure aggregate,static agent disposition,0.5981481481481481
infectious structure aggregate,T cell receptor complex,0.619811320754717
infectious structure aggregate,infectious structure host,0.85
infectious structure aggregate,infectious agent population,0.730701754385965
infectious structure aggregate,respiratory system disease,0.6464285714285714
infectious structure aggregate,leukocyte-mediated immunity to infectious agent,0.6448051948051949
infectious structure aggregate,humoral immunity to infectious agent,0.6772727272727272
infectious structure aggregate,infectious disease control strategy,0.7576923076923078
infectious structure aggregate,infectious disease pandemic,0.7482456140350877
infectious structure aggregate,infectious structure generative stage,0.8380597014925374
infectious structure aggregate,immunosuppressive disposition,0.6025423728813559
infectious structure aggregate,pathogenic disposition,0.5653846153846154
infectious structure aggregate,viral disease course,0.61
infectious structure aggregate,passive immunity to infectious agent,0.6772727272727272
infectious structure aggregate,infectious disposition,0.7
infectious structure aggregate,vaccination against infectious agent,0.6924242424242425
infectious structure aggregate,susceptibility to infectious agent,0.684375
infectious structure aggregate,bacteriostatic disposition,0.6107142857142857
infectious structure aggregate,epitope site,0.6166666666666667
infectious structure aggregate,bactericidal disposition,0.5611111111111111
infectious structure aggregate,invasion disposition,0.59
infectious structure aggregate,disease course,0.6318181818181818
infectious structure aggregate,infectious disease course,0.740909090909091
infectious structure aggregate,viricidal disposition,0.5676470588235294
infectious structure aggregate,acquired immunity to infectious agent,0.6738805970149254
infectious structure aggregate,complex infection,0.6202127659574468
infectious structure aggregate,prion aggregate,0.7166666666666667
infectious structure aggregate,COVID-19 disease incidence proportion,0.5843283582089552
infectious structure aggregate,coronavirus disease course,0.6285714285714286
infectious structure aggregate,symptomatic infectious agent carrier,0.6924242424242425
infectious structure aggregate,pathogen portal of exit site,0.6051724137931035
infectious structure aggregate,infectious disease prevalence,0.7550847457627118
infectious structure aggregate,disposition,0.5475609756097561
infectious structure aggregate,infected population,0.6540816326530612
infectious structure aggregate,COVID-19 mortality rate,0.6386792452830189
infectious structure aggregate,viral disease,0.5895348837209302
infectious structure aggregate,adhesion disposition,0.57
infectious structure aggregate,pathogen portal of entry site,0.6025423728813559
infectious structure aggregate,viroid aggregate,0.7108695652173913
infectious structure aggregate,disease,0.5851351351351352
infectious structure aggregate,symptomatic infectious structure carrier,0.7928571428571428
infectious structure aggregate,site,0.5382352941176471
infectious structure aggregate,primary infectious disposition,0.6666666666666667
infectious structure aggregate,infectious pathogen transmissibility,0.7075757575757575
infectious structure aggregate,infectious human pathogen,0.740909090909091
infectious structure aggregate,immunization against infectious agent,0.6888059701492537
infectious structure aggregate,virus synthesis stage,0.6656862745098039
infectious structure aggregate,SARS-COV-2 adhesion disposition,0.5647540983606557
infectious structure aggregate,object aggregate,0.7326086956521739
infectious structure aggregate,invasive disposition,0.59
infectious structure aggregate,infectious agent host,0.7441176470588234
infectious structure aggregate,long-term non-progressing infectious disease course,0.6475308641975309
infectious structure aggregate,viral disease epidemic,0.6038461538461539
infectious structure aggregate,fungicidal disposition,0.5653846153846154
infectious structure aggregate,viral disease pandemic,0.6038461538461539
infectious structure aggregate,acute respiratory distress syndrome,0.6346153846153847
infectious structure aggregate,infectious disease endemicity,0.7211864406779661
infectious structure aggregate,herd immunity to infectious organism,0.6621212121212122
infectious structure aggregate,exotoxin disposition,0.57
infectious structure aggregate,infectious agent reservoir,0.7357142857142857
infectious structure aggregate,immunoglobulin complex,0.5846153846153846
infectious structure aggregate,COVID-19 pandemic,0.5563829787234043
infectious structure aggregate,SARS-CoV-2 synthesis stage,0.6285714285714286
infectious structure aggregate,infectious disease control objective specification,0.7125
infectious structure aggregate,opportunistic infectious disposition,0.6469696969696969
infectious structure aggregate,enterotoxin disposition,0.5820754716981132
infectious structure aggregate,polymerase chain reaction,0.6136363636363636
infectious structure aggregate,COVID-19 disease course,0.6009433962264151
infectious structure aggregate,infectious disease incidence rate,0.7515873015873015
infectious structure aggregate,active immunization against infectious agent,0.6662162162162162
infectious structure aggregate,collective resistance disposition,0.6246031746031746
infectious structure aggregate,viral load,0.55
infectious structure aggregate,fungistatic disposition,0.5820754716981132
infectious structure aggregate,infectious agent,0.7760869565217391
infectious structure aggregate,establishment of a clinically abnormal colony,0.5833333333333334
infectious structure aggregate,coronavirus disease,0.6336734693877552
infectious structure aggregate,drug susceptibility of infectious agent,0.6673913043478261
pathogen portal of entry,extended organism,0.6451219512195122
pathogen portal of entry,virus aggregate,0.5782051282051281
pathogen portal of entry,source of infection,0.636046511627907
pathogen portal of entry,infectious disease mortality rate,0.6429824561403508
pathogen portal of entry,infection incidence rate profile,0.6464285714285714
pathogen portal of entry,communicability end temporal region,0.6703389830508475
pathogen portal of entry,pathogen generative stage,0.7153061224489795
pathogen portal of entry,pathogen portal of entry,0.95
pathogen portal of entry,subclinical coronavirus infection,0.6078947368421053
pathogen portal of entry,primary pathogen,0.65
pathogen portal of entry,infection end temporal region,0.6952830188679244
pathogen portal of entry,drug-based immunosuppressed organism,0.5833333333333334
pathogen portal of entry,infectious disease,0.569047619047619
pathogen portal of entry,double-stranded DNA virus,0.5928571428571429
pathogen portal of entry,incubation end temporal region,0.7092592592592593
pathogen portal of entry,site of infection,0.6451219512195122
pathogen portal of entry,immunocompetent organism,0.6375
pathogen portal of entry,pathogen portal of exit,0.8968085106382978
pathogen portal of entry,infectious disease incidence,0.5846153846153846
pathogen portal of entry,reservoir of pathogen role,0.69
pathogen portal of entry,subclinical SARS-CoV-2 infection,0.5928571428571429
pathogen portal of entry,virus translation stage,0.6202127659574468
pathogen portal of entry,disease surveillance objective specification,0.5970588235294118
pathogen portal of entry,case isolation control strategy,0.6681818181818181
pathogen portal of entry,virus release stage,0.5895348837209302
pathogen portal of entry,infectious agent host role,0.67
pathogen portal of entry,source of infection site,0.6375
pathogen portal of entry,virus replication,0.5719512195121951
pathogen portal of entry,B cell receptor complex,0.6202127659574468
pathogen portal of entry,passive immunization against infectious agent,0.6384057971014493
pathogen portal of entry,systematic infection,0.609090909090909
pathogen portal of entry,infection incidence rate,0.6166666666666667
pathogen portal of entry,virus host,0.5676470588235294
pathogen portal of entry,double-stranded RNA virus,0.6132653061224489
pathogen portal of entry,pathogen portal of entry role,0.9028301886792454
pathogen portal of entry,virus transcription stage,0.6132653061224489
pathogen portal of entry,infectious disease lifetime prevalence,0.6112903225806451
pathogen portal of entry,pathogen birth temporal region,0.7648148148148148
pathogen portal of entry,lower respiratory tract disease,0.6318181818181818
pathogen portal of entry,infectious disease incidence proportion,0.6246031746031746
pathogen portal of entry,opportunistic pathogen,0.6456521739130434
pathogen portal of entry,virus generative stage,0.6021739130434782
pathogen portal of entry,acute infectious disease course,0.6136363636363636
pathogen portal of entry,cidal agent disposition,0.6627659574468084
pathogen portal of entry,genetic resistance to pathogen,0.6722222222222223
pathogen portal of entry,subclinical infection,0.6055555555555556
pathogen portal of entry,appearance of disorder,0.6673913043478261
pathogen portal of entry,simple infection,0.6
pathogen portal of entry,droplet pathogen transmission process,0.6795081967213115
pathogen portal of entry,infectious disease sporadicity,0.6351851851851852
pathogen portal of entry,communicability end process boundary,0.65
pathogen portal of entry,infection incidence proportion profile,0.6596774193548387
pathogen portal of entry,infectious agent colony,0.6840425531914894
pathogen portal of entry,pathogen transporter,0.7909090909090909
pathogen portal of entry,latency end process boundary,0.6807692307692308
pathogen portal of entry,infectious disease epidemic,0.5676470588235294
pathogen portal of entry,infectious agent generative stage,0.6254385964912281
pathogen portal of entry,disease transmission model,0.61
pathogen portal of entry,pathologically immunosuppressed organism,0.6375
pathogen portal of entry,negative-sense single-stranded RNA virus,0.60625
pathogen portal of entry,cidal agent,0.6214285714285714
pathogen portal of entry,pathogen vehicle,0.725
pathogen portal of entry,community-acquired infection,0.6038461538461539
pathogen portal of entry,pathogen vector,0.7576923076923078
pathogen portal of entry,pathogen vehicle role,0.7388888888888888
pathogen portal of entry,chronic infectious disease course,0.6078947368421053
pathogen portal of entry,asymptomatic infectious agent carrier,0.630327868852459
pathogen portal of entry,nursing-home acquired infection,0.6136363636363636
pathogen portal of entry,secondary infection,0.6127906976744186
pathogen portal of entry,infection start temporal region,0.6681818181818181
pathogen portal of entry,infection incidence,0.5895348837209302
pathogen portal of entry,virus disorder,0.581578947368421
pathogen portal of entry,sterilizing immunity to infectious agent,0.6375
pathogen portal of entry,primary infection,0.6207317073170732
pathogen portal of entry,process of establishing an infection,0.65
pathogen portal of entry,incubation end process boundary,0.6863636363636364
pathogen portal of entry,pathogen death process boundary,0.740909090909091
pathogen portal of entry,immunosuppressed organism,0.5928571428571429
pathogen portal of entry,latency end temporal region,0.7049019607843137
pathogen portal of entry,innate immunity to infectious agent,0.6533898305084747
pathogen portal of entry,virus adhesion susceptible cell,0.6318181818181818
pathogen portal of entry,infection,0.5712121212121213
pathogen portal of entry,static agent disposition,0.6791666666666666
pathogen portal of entry,T cell receptor complex,0.6414893617021277
pathogen portal of entry,infectious agent population,0.6656862745098039
pathogen portal of entry,respiratory system disease,0.61
pathogen portal of entry,entry into host,0.6294871794871795
pathogen portal of entry,leukocyte-mediated immunity to infectious agent,0.6190140845070422
pathogen portal of entry,indirect pathogen transmission process,0.6758064516129032
pathogen portal of entry,organism population,0.6593023255813953
pathogen portal of entry,humoral immunity to infectious agent,0.65
pathogen portal of entry,infectious disease control strategy,0.6364406779661017
pathogen portal of entry,parasite,0.60625
pathogen portal of entry,infectious disease pandemic,0.5872549019607843
pathogen portal of entry,antibody reagent,0.675
pathogen portal of entry,viral disease course,0.5863636363636363
pathogen portal of entry,entry into host through host barriers,0.6139344262295081
pathogen portal of entry,intracellular infection,0.6202127659574468
pathogen portal of entry,secondary infection role,0.6166666666666667
pathogen portal of entry,metastatic infection,0.609090909090909
pathogen portal of entry,passive immunity to infectious agent,0.65
pathogen portal of entry,vaccination against infectious agent,0.65
pathogen portal of entry,acute infection,0.6294871794871795
pathogen portal of entry,susceptibility to infectious agent,0.6396551724137931
pathogen portal of entry,epitope site,0.6444444444444444
pathogen portal of entry,immunity to pathogen,0.6318181818181818
pathogen portal of entry,source of infection role,0.6375
pathogen portal of entry,pathogen host,0.7472972972972972
pathogen portal of entry,chronic infection,0.6207317073170732
pathogen portal of entry,disease course,0.6078947368421053
pathogen portal of entry,infectious disease course,0.5928571428571429
pathogen portal of entry,acquired immunity to infectious agent,0.630327868852459
pathogen portal of entry,complex infection,0.6207317073170732
pathogen portal of entry,COVID-19 disease incidence proportion,0.6139344262295081
pathogen portal of entry,coronavirus disease course,0.59
pathogen portal of entry,infection incidence proportion,0.6537037037037037
pathogen portal of entry,symptomatic infectious agent carrier,0.6333333333333333
pathogen portal of entry,respiratory droplet virus fomite,0.6285714285714286
pathogen portal of entry,susceptible organism,0.6318181818181818
pathogen portal of entry,parasite role,0.6662162162162162
pathogen portal of entry,pathogen vector role,0.7681818181818181
pathogen portal of entry,pathogen portal of exit site,0.8538461538461539
pathogen portal of entry,infectious disease prevalence,0.6386792452830189
pathogen portal of entry,organism substance,0.6166666666666667
pathogen portal of entry,single-stranded DNA virus,0.5928571428571429
pathogen portal of entry,contact tracing,0.6294871794871795
pathogen portal of entry,viral disease,0.5851351351351352
pathogen portal of entry,primary infection role,0.6456521739130434
pathogen portal of entry,pathogen portal of entry site,0.9028301886792454
pathogen portal of entry,infection incidence profile,0.6460784313725491
pathogen portal of entry,disease,0.5467741935483871
pathogen portal of entry,site,0.5214285714285714
pathogen portal of entry,pathogen host role,0.7833333333333333
pathogen portal of entry,infection prevalence,0.6772727272727272
pathogen portal of entry,infectious pathogen transmissibility,0.6833333333333332
pathogen portal of entry,incubation start process boundary,0.6780701754385965
pathogen portal of entry,pathogen surveillance,0.7166666666666667
pathogen portal of entry,immunodeficient organism,0.6166666666666667
pathogen portal of entry,pathogen,0.7
pathogen portal of entry,pathogen birth process boundary,0.759090909090909
pathogen portal of entry,infectious human pathogen,0.6336734693877552
pathogen portal of entry,subclinical virus infection,0.5872549019607843
pathogen portal of entry,resistance to pathogen,0.6456521739130434
pathogen portal of entry,establishment of localization in virus host,0.6291044776119403
pathogen portal of entry,immunization against infectious agent,0.6467213114754098
pathogen portal of entry,virus attachment stage,0.6456521739130434
pathogen portal of entry,virus synthesis stage,0.6055555555555556
pathogen portal of entry,pathogen portal of exit role,0.8730769230769231
pathogen portal of entry,infectious agent host,0.65
pathogen portal of entry,re-emerging pathogen,0.6318181818181818
pathogen portal of entry,long-term non-progressing infectious disease course,0.61
pathogen portal of entry,viral disease epidemic,0.5804347826086956
pathogen portal of entry,viral disease pandemic,0.5804347826086956
pathogen portal of entry,virus penetration stage,0.6414893617021277
pathogen portal of entry,pathogen seroprevalence,0.7691489361702127
pathogen portal of entry,infectious disease endemicity,0.619811320754717
pathogen portal of entry,contact pathogen transmission process,0.6795081967213115
pathogen portal of entry,herd immunity to infectious organism,0.6166666666666667
pathogen portal of entry,extracellular infection,0.6202127659574468
pathogen portal of entry,pathogen transporter role,0.7765306122448979
pathogen portal of entry,infectious agent reservoir,0.63
pathogen portal of entry,infection start process boundary,0.6642857142857143
pathogen portal of entry,latency start process boundary,0.6907407407407408
pathogen portal of entry,infectious disease control objective specification,0.6121621621621621
pathogen portal of entry,process of establishing viral infection,0.6404761904761905
pathogen portal of entry,COVID-19 disease course,0.5776595744680851
pathogen portal of entry,infectious disease incidence rate,0.5903508771929825
pathogen portal of entry,communicability start process boundary,0.6274193548387097
pathogen portal of entry,active immunization against infectious agent,0.6264705882352941
pathogen portal of entry,disordered virus,0.575
pathogen portal of entry,organism,0.575
pathogen portal of entry,virus uncoating stage,0.6055555555555556
pathogen portal of entry,local infection,0.6294871794871795
pathogen portal of entry,infectious agent,0.625
pathogen portal of entry,establishment of a clinically abnormal colony,0.6384057971014493
pathogen portal of entry,process boundary,0.65
pathogen portal of entry,coronavirus disease,0.5662790697674418
pathogen portal of entry,positive-sense single-stranded RNA virus,0.60625
pathogen portal of entry,horizontal pathogen transmission process,0.66875
pathogen portal of entry,hospital-acquired infection,0.6460784313725491
pathogen portal of entry,pathogen death temporal region,0.7648148148148148
pathogen portal of entry,emerging pathogen,0.6451219512195122
pathogen portal of entry,drug susceptibility of infectious agent,0.6404761904761905
pathogen portal of entry,static agent,0.6444444444444444
pathogen portal of entry,pathogen transmission process,0.7141509433962264
viral disease,virus aggregate,0.7
viral disease,source of infection,0.575
viral disease,virostatic disposition,0.7071428571428571
viral disease,zoonotic disposition,0.6318181818181818
viral disease,infectious disease mortality rate,0.6456521739130434
viral disease,infection incidence rate profile,0.5833333333333334
viral disease,communicability end temporal region,0.6166666666666667
viral disease,subclinical coronavirus infection,0.6021739130434782
viral disease,infection end temporal region,0.5928571428571429
viral disease,infectious disease,0.7403225806451613
viral disease,double-stranded DNA virus,0.6078947368421053
viral disease,incubation end temporal region,0.6127906976744186
viral disease,site of infection,0.5833333333333334
viral disease,virulence factor disposition,0.6695121951219513
viral disease,viral adhesion disposition,0.7064102564102563
viral disease,parasitostatic disposition,0.6294871794871795
viral disease,infectious disease incidence,0.6695121951219513
viral disease,reverse zoonotic disposition,0.6207317073170732
viral disease,subclinical SARS-CoV-2 infection,0.6277777777777778
viral disease,virus translation stage,0.7
viral disease,disease surveillance objective specification,0.5903508771929825
viral disease,virus release stage,0.7
viral disease,source of infection site,0.6121621621621621
viral disease,virus,0.6722222222222223
viral disease,virus replication,0.65
viral disease,B cell receptor complex,0.5611111111111111
viral disease,systematic infection,0.5712121212121213
viral disease,infection incidence rate,0.6121621621621621
viral disease,virus host,0.6673913043478261
viral disease,double-stranded RNA virus,0.6078947368421053
viral disease,virus transcription stage,0.6605263157894737
viral disease,infectious disease lifetime prevalence,0.6264705882352941
viral disease,toxin disposition,0.65
viral disease,lower respiratory tract disease,0.7
viral disease,infectious disease incidence proportion,0.6230769230769231
viral disease,virus generative stage,0.6785714285714286
viral disease,acute infectious disease course,0.6545454545454545
viral disease,cidal agent disposition,0.6722222222222223
viral disease,infectious disorder,0.6375
viral disease,subclinical infection,0.6264705882352941
viral disease,appearance of disorder,0.65
viral disease,simple infection,0.6224137931034482
viral disease,parasiticidal disposition,0.6605263157894737
viral disease,infectious disease sporadicity,0.6593023255813953
viral disease,communicability end process boundary,0.5928571428571429
viral disease,infection incidence proportion profile,0.5480392156862746
viral disease,transmissibility disposition,0.6451219512195122
viral disease,latency end process boundary,0.5719512195121951
viral disease,infectious disease epidemic,0.675
viral disease,disease transmission model,0.6294871794871795
viral disease,endotoxin disposition,0.6264705882352941
viral disease,negative-sense single-stranded RNA virus,0.6009433962264151
viral disease,viral plaque assay,0.7403225806451613
viral disease,cytotoxin disposition,0.6264705882352941
viral disease,community-acquired infection,0.5719512195121951
viral disease,chronic infectious disease course,0.6456521739130434
viral disease,nursing-home acquired infection,0.5636363636363636
viral disease,COVID-19 epidemic,0.6166666666666667
viral disease,secondary infection,0.575
viral disease,infection start temporal region,0.5863636363636363
viral disease,infection incidence,0.60625
viral disease,virus disorder,0.7462962962962962
viral disease,primary infection,0.6166666666666667
viral disease,process of establishing an infection,0.5928571428571429
viral disease,incubation end process boundary,0.5863636363636363
viral disease,SARS-CoV-2 disorder,0.6375
viral disease,collective pathogenic disposition,0.6021739130434782
viral disease,neurotoxin disposition,0.6214285714285714
viral disease,latency end temporal region,0.6
viral disease,virus adhesion susceptible cell,0.6545454545454545
viral disease,collective disposition,0.6214285714285714
viral disease,infection,0.5409090909090909
viral disease,static agent disposition,0.6391891891891892
viral disease,T cell receptor complex,0.5611111111111111
viral disease,respiratory system disease,0.732051282051282
viral disease,infectious disease control strategy,0.6375
viral disease,infectious disease pandemic,0.675
viral disease,immunosuppressive disposition,0.6166666666666667
viral disease,pathogenic disposition,0.6214285714285714
viral disease,viral disease course,0.8439393939393939
viral disease,intracellular infection,0.6444444444444444
viral disease,secondary infection role,0.5851351351351352
viral disease,metastatic infection,0.5712121212121213
viral disease,viral envelope,0.7462962962962962
viral disease,infectious disposition,0.6214285714285714
viral disease,acute infection,0.5928571428571429
viral disease,bacteriostatic disposition,0.6294871794871795
viral disease,bactericidal disposition,0.6662162162162162
viral disease,source of infection role,0.5851351351351352
viral disease,chronic infection,0.5833333333333334
viral disease,invasion disposition,0.6621212121212122
viral disease,disease course,0.7092592592592593
viral disease,infectious disease course,0.6868421052631578
viral disease,viricidal disposition,0.7441176470588234
viral disease,complex infection,0.5833333333333334
viral disease,COVID-19 disease incidence proportion,0.65
viral disease,coronavirus disease course,0.732051282051282
viral disease,infection incidence proportion,0.5662790697674418
viral disease,viral capsid,0.77
viral disease,respiratory droplet virus fomite,0.6277777777777778
viral disease,infectious disease prevalence,0.6642857142857143
viral disease,disposition,0.6166666666666667
viral disease,single-stranded DNA virus,0.6342105263157894
viral disease,viral disease,0.95
viral disease,primary infection role,0.6214285714285714
viral disease,adhesion disposition,0.6318181818181818
viral disease,infection incidence profile,0.575
viral disease,disease,0.8
viral disease,primary infectious disposition,0.6127906976744186
viral disease,infection prevalence,0.6318181818181818
viral disease,coronavirus disorder,0.6924242424242425
viral disease,subclinical virus infection,0.625
viral disease,establishment of localization in virus host,0.575
viral disease,virus attachment stage,0.6785714285714286
viral disease,virus synthesis stage,0.6852941176470588
viral disease,SARS-COV-2 adhesion disposition,0.609090909090909
viral disease,invasive disposition,0.6621212121212122
viral disease,long-term non-progressing infectious disease course,0.590625
viral disease,viral disease epidemic,0.8214285714285714
viral disease,fungicidal disposition,0.6785714285714286
viral disease,viral disease pandemic,0.8214285714285714
viral disease,virus penetration stage,0.6722222222222223
viral disease,acute respiratory distress syndrome,0.6583333333333334
viral disease,infectious disease endemicity,0.6642857142857143
viral disease,negative regulation of viral process,0.6132653061224489
viral disease,disorder,0.6404761904761905
viral disease,extracellular infection,0.6166666666666667
viral disease,exotoxin disposition,0.6318181818181818
viral disease,infection start process boundary,0.5611111111111111
viral disease,infectious disease control objective specification,0.5928571428571429
viral disease,opportunistic infectious disposition,0.5724489795918367
viral disease,process of establishing viral infection,0.6038461538461539
viral disease,enterotoxin disposition,0.6166666666666667
viral disease,COVID-19 disease course,0.7277777777777777
viral disease,infectious disease incidence rate,0.6456521739130434
viral disease,disordered virus,0.6224137931034482
viral disease,collective resistance disposition,0.6239130434782608
viral disease,viral load,0.7543478260869566
viral disease,fungistatic disposition,0.6444444444444444
viral disease,virus uncoating stage,0.6852941176470588
viral disease,local infection,0.6285714285714286
viral disease,establishment of a clinically abnormal colony,0.553448275862069
viral disease,coronavirus disease,0.79375
viral disease,positive-sense single-stranded RNA virus,0.6009433962264151
viral disease,hospital-acquired infection,0.6
viral disease,viral pathogenesis,0.7080645161290323
opportunistic pathogen,extended organism,0.6038461538461539
opportunistic pathogen,virus aggregate,0.6391891891891892
opportunistic pathogen,source of infection,0.6207317073170732
opportunistic pathogen,infectious disease mortality rate,0.6318181818181818
opportunistic pathogen,infection incidence rate profile,0.6351851851851852
opportunistic pathogen,pathogen generative stage,0.6627659574468084
opportunistic pathogen,pathogen portal of entry,0.6456521739130434
opportunistic pathogen,subclinical coronavirus infection,0.6318181818181818
opportunistic pathogen,primary pathogen,0.7657894736842106
opportunistic pathogen,infection end temporal region,0.6068627450980393
opportunistic pathogen,drug-based immunosuppressed organism,0.6051724137931035
opportunistic pathogen,infectious disease,0.6
opportunistic pathogen,SARS-CoV-2 incidence rate,0.6202127659574468
opportunistic pathogen,double-stranded DNA virus,0.598936170212766
opportunistic pathogen,site of infection,0.6294871794871795
opportunistic pathogen,immunocompetent organism,0.6456521739130434
opportunistic pathogen,pathogen portal of exit,0.6277777777777778
opportunistic pathogen,infectious disease incidence,0.61
opportunistic pathogen,reservoir of pathogen role,0.7
opportunistic pathogen,subclinical SARS-CoV-2 infection,0.6166666666666667
opportunistic pathogen,virus translation stage,0.6722222222222223
opportunistic pathogen,disease surveillance objective specification,0.6015151515151516
opportunistic pathogen,virus release stage,0.6451219512195122
opportunistic pathogen,infectious agent host role,0.6375
opportunistic pathogen,source of infection site,0.6239130434782608
opportunistic pathogen,virus,0.5611111111111111
opportunistic pathogen,virus replication,0.6807692307692308
opportunistic pathogen,B cell receptor complex,0.5833333333333334
opportunistic pathogen,passive immunization against infectious agent,0.6440298507462687
opportunistic pathogen,systematic infection,0.6404761904761905
opportunistic pathogen,infection incidence rate,0.6456521739130434
opportunistic pathogen,virus host,0.6375
opportunistic pathogen,double-stranded RNA virus,0.598936170212766
opportunistic pathogen,pathogen portal of entry role,0.6460784313725491
opportunistic pathogen,virus transcription stage,0.6627659574468084
opportunistic pathogen,infectious disease lifetime prevalence,0.6333333333333333
opportunistic pathogen,pathogen birth temporal region,0.6423076923076922
opportunistic pathogen,lower respiratory tract disease,0.619811320754717
opportunistic pathogen,infectious disease incidence proportion,0.630327868852459
opportunistic pathogen,opportunistic pathogen,0.95
opportunistic pathogen,virus generative stage,0.6545454545454545
opportunistic pathogen,acute infectious disease course,0.6009433962264151
opportunistic pathogen,cidal agent disposition,0.6055555555555556
opportunistic pathogen,genetic resistance to pathogen,0.7192307692307692
opportunistic pathogen,subclinical infection,0.636046511627907
opportunistic pathogen,simple infection,0.6078947368421053
opportunistic pathogen,droplet pathogen transmission process,0.6703389830508475
opportunistic pathogen,infectious disease sporadicity,0.6038461538461539
opportunistic pathogen,infection incidence proportion profile,0.6333333333333333
opportunistic pathogen,infectious agent colony,0.6277777777777778
opportunistic pathogen,pathogen transporter,0.6404761904761905
opportunistic pathogen,infectious disease epidemic,0.5928571428571429
opportunistic pathogen,infectious agent generative stage,0.6136363636363636
opportunistic pathogen,disease transmission model,0.6166666666666667
opportunistic pathogen,pathologically immunosuppressed organism,0.5951612903225807
opportunistic pathogen,negative-sense single-stranded RNA virus,0.5790322580645162
opportunistic pathogen,cidal agent,0.6318181818181818
opportunistic pathogen,pathogen vehicle,0.6605263157894737
opportunistic pathogen,COVID-19 incidence rate,0.6277777777777778
opportunistic pathogen,community-acquired infection,0.65
opportunistic pathogen,pathogen vector,0.6662162162162162
opportunistic pathogen,pathogen vehicle role,0.636046511627907
opportunistic pathogen,chronic infectious disease course,0.6136363636363636
opportunistic pathogen,asymptomatic infectious agent carrier,0.6364406779661017
opportunistic pathogen,nursing-home acquired infection,0.6009433962264151
opportunistic pathogen,secondary infection,0.6207317073170732
opportunistic pathogen,infection start temporal region,0.619811320754717
opportunistic pathogen,infection incidence,0.5963414634146341
opportunistic pathogen,virus disorder,0.6166666666666667
opportunistic pathogen,sterilizing immunity to infectious agent,0.6435483870967742
opportunistic pathogen,primary infection,0.6551282051282051
opportunistic pathogen,process of establishing an infection,0.6396551724137931
opportunistic pathogen,pathogen death process boundary,0.6386792452830189
opportunistic pathogen,immunosuppressed organism,0.6414893617021277
opportunistic pathogen,innate immunity to infectious agent,0.6605263157894737
opportunistic pathogen,virus adhesion susceptible cell,0.6009433962264151
opportunistic pathogen,infection,0.6112903225806451
opportunistic pathogen,static agent disposition,0.6456521739130434
opportunistic pathogen,T cell receptor complex,0.6055555555555556
opportunistic pathogen,infectious agent population,0.6540816326530612
opportunistic pathogen,respiratory system disease,0.6166666666666667
opportunistic pathogen,leukocyte-mediated immunity to infectious agent,0.6384057971014493
opportunistic pathogen,indirect pathogen transmission process,0.65
opportunistic pathogen,organism population,0.7182926829268292
opportunistic pathogen,humoral immunity to infectious agent,0.6741379310344828
opportunistic pathogen,infectious disease control strategy,0.6078947368421053
opportunistic pathogen,parasite,0.65
opportunistic pathogen,infectious disease pandemic,0.6132653061224489
opportunistic pathogen,antibody reagent,0.6605263157894737
opportunistic pathogen,viral disease course,0.5928571428571429
opportunistic pathogen,intracellular infection,0.6055555555555556
opportunistic pathogen,secondary infection role,0.6239130434782608
opportunistic pathogen,metastatic infection,0.6642857142857143
opportunistic pathogen,passive immunity to infectious agent,0.656896551724138
opportunistic pathogen,vaccination against infectious agent,0.656896551724138
opportunistic pathogen,acute infection,0.6391891891891892
opportunistic pathogen,susceptibility to infectious agent,0.6464285714285714
opportunistic pathogen,epitope site,0.6264705882352941
opportunistic pathogen,immunity to pathogen,0.7595238095238095
opportunistic pathogen,source of infection role,0.6239130434782608
opportunistic pathogen,pathogen host,0.6785714285714286
opportunistic pathogen,chronic infection,0.6551282051282051
opportunistic pathogen,disease course,0.5888888888888889
opportunistic pathogen,infectious disease course,0.598936170212766
opportunistic pathogen,acquired immunity to infectious agent,0.6533898305084747
opportunistic pathogen,complex infection,0.6294871794871795
opportunistic pathogen,COVID-19 disease incidence proportion,0.6194915254237288
opportunistic pathogen,coronavirus disease course,0.6375
opportunistic pathogen,infection incidence proportion,0.6423076923076922
opportunistic pathogen,symptomatic infectious agent carrier,0.6396551724137931
opportunistic pathogen,respiratory droplet virus fomite,0.6166666666666667
opportunistic pathogen,susceptible organism,0.6404761904761905
opportunistic pathogen,parasite role,0.65
opportunistic pathogen,pathogen vector role,0.6404761904761905
opportunistic pathogen,pathogen portal of exit site,0.65
opportunistic pathogen,infectious disease prevalence,0.6264705882352941
opportunistic pathogen,organism substance,0.65
opportunistic pathogen,single-stranded DNA virus,0.5776595744680851
opportunistic pathogen,COVID-19 mortality rate,0.6722222222222223
opportunistic pathogen,viral disease,0.5928571428571429
opportunistic pathogen,primary infection role,0.6318181818181818
opportunistic pathogen,pathogen portal of entry site,0.6460784313725491
opportunistic pathogen,infection incidence profile,0.6336734693877552
opportunistic pathogen,disease,0.5879310344827586
opportunistic pathogen,site,0.6038461538461539
opportunistic pathogen,pathogen host role,0.65
opportunistic pathogen,infection prevalence,0.6404761904761905
opportunistic pathogen,infectious pathogen transmissibility,0.656896551724138
opportunistic pathogen,pathogen surveillance,0.636046511627907
opportunistic pathogen,immunodeficient organism,0.6239130434782608
opportunistic pathogen,pathogen,0.7166666666666667
opportunistic pathogen,pathogen birth process boundary,0.6386792452830189
opportunistic pathogen,infectious human pathogen,0.7053191489361703
opportunistic pathogen,subclinical virus infection,0.6336734693877552
opportunistic pathogen,resistance to pathogen,0.7681818181818181
opportunistic pathogen,establishment of localization in virus host,0.5884615384615385
opportunistic pathogen,immunization against infectious agent,0.6533898305084747
opportunistic pathogen,virus attachment stage,0.6545454545454545
opportunistic pathogen,virus synthesis stage,0.6593023255813953
opportunistic pathogen,pathogen portal of exit role,0.65
opportunistic pathogen,infectious agent host,0.636046511627907
opportunistic pathogen,re-emerging pathogen,0.7119047619047619
opportunistic pathogen,long-term non-progressing infectious disease course,0.6143835616438357
opportunistic pathogen,viral disease epidemic,0.5863636363636363
opportunistic pathogen,viral disease pandemic,0.609090909090909
opportunistic pathogen,virus penetration stage,0.6722222222222223
opportunistic pathogen,pathogen seroprevalence,0.6277777777777778
opportunistic pathogen,infectious disease endemicity,0.5872549019607843
opportunistic pathogen,contact pathogen transmission process,0.6703389830508475
opportunistic pathogen,herd immunity to infectious organism,0.6396551724137931
opportunistic pathogen,extracellular infection,0.6055555555555556
opportunistic pathogen,pathogen transporter role,0.6414893617021277
opportunistic pathogen,infectious agent reservoir,0.6166666666666667
opportunistic pathogen,infection start process boundary,0.6166666666666667
opportunistic pathogen,infectious disease control objective specification,0.6166666666666667
opportunistic pathogen,opportunistic infectious disposition,0.760344827586207
opportunistic pathogen,process of establishing viral infection,0.630327868852459
opportunistic pathogen,COVID-19 disease course,0.5833333333333334
opportunistic pathogen,infectious disease incidence rate,0.6318181818181818
opportunistic pathogen,active immunization against infectious agent,0.6469696969696969
opportunistic pathogen,disordered virus,0.5552631578947369
opportunistic pathogen,organism,0.6166666666666667
opportunistic pathogen,virus uncoating stage,0.6593023255813953
opportunistic pathogen,local infection,0.6121621621621621
opportunistic pathogen,infectious agent,0.6605263157894737
opportunistic pathogen,establishment of a clinically abnormal colony,0.5992537313432835
opportunistic pathogen,coronavirus disease,0.6451219512195122
opportunistic pathogen,positive-sense single-stranded RNA virus,0.6112903225806451
opportunistic pathogen,horizontal pathogen transmission process,0.6596774193548387
opportunistic pathogen,hospital-acquired infection,0.6540816326530612
opportunistic pathogen,pathogen death temporal region,0.6423076923076922
opportunistic pathogen,emerging pathogen,0.732051282051282
opportunistic pathogen,drug susceptibility of infectious agent,0.630327868852459
opportunistic pathogen,static agent,0.7147058823529412
opportunistic pathogen,pathogen transmission process,0.6656862745098039
cytotoxin disposition,virostatic disposition,0.7988372093023256
cytotoxin disposition,information content entity,0.6202127659574468
cytotoxin disposition,zoonotic disposition,0.8158536585365854
cytotoxin disposition,infectious disease mortality rate,0.6351851851851852
cytotoxin disposition,infection incidence rate profile,0.619811320754717
cytotoxin disposition,infectious structure aggregate,0.5676470588235294
cytotoxin disposition,communicability end temporal region,0.6285714285714286
cytotoxin disposition,geographical entity,0.575
cytotoxin disposition,biological regulation,0.6404761904761905
cytotoxin disposition,surveillance process,0.5963414634146341
cytotoxin disposition,infection end temporal region,0.67
cytotoxin disposition,vector control strategy,0.6318181818181818
cytotoxin disposition,SARS-CoV-2 incidence rate,0.5804347826086956
cytotoxin disposition,incubation end temporal region,0.6656862745098039
cytotoxin disposition,resistant entity,0.5851351351351352
cytotoxin disposition,virulence factor disposition,0.7561224489795919
cytotoxin disposition,viral adhesion disposition,0.747872340425532
cytotoxin disposition,parasitostatic disposition,0.7904255319148936
cytotoxin disposition,negative regulation of production,0.6537037037037037
cytotoxin disposition,reverse zoonotic disposition,0.7561224489795919
cytotoxin disposition,establishment of localization in host,0.6224137931034482
cytotoxin disposition,disease surveillance objective specification,0.6346153846153847
cytotoxin disposition,case isolation control strategy,0.6230769230769231
cytotoxin disposition,infectious agent host role,0.6414893617021277
cytotoxin disposition,macromolecular complex,0.5662790697674418
cytotoxin disposition,material entity,0.5888888888888889
cytotoxin disposition,asymptomatic infectious structure carrier,0.6274193548387097
cytotoxin disposition,architectual structure,0.5895348837209302
cytotoxin disposition,quarantine control strategy,0.5958333333333333
cytotoxin disposition,B cell receptor complex,0.5636363636363636
cytotoxin disposition,infection incidence rate,0.6277777777777778
cytotoxin disposition,colonized host,0.6785714285714286
cytotoxin disposition,virus host,0.6112903225806451
cytotoxin disposition,entity,0.5611111111111111
cytotoxin disposition,toxin disposition,0.8973684210526315
cytotoxin disposition,cidal agent disposition,0.7909090909090909
cytotoxin disposition,parasiticidal disposition,0.7543478260869566
cytotoxin disposition,communicability end process boundary,0.6254385964912281
cytotoxin disposition,directive information content entity,0.6254385964912281
cytotoxin disposition,acellular structure aggregate,0.55
cytotoxin disposition,transmissibility disposition,0.7357142857142857
cytotoxin disposition,latency end process boundary,0.6336734693877552
cytotoxin disposition,colonization of host,0.6695121951219513
cytotoxin disposition,realizable entity,0.5552631578947369
cytotoxin disposition,endotoxin disposition,0.8785714285714286
cytotoxin disposition,vector surveillance,0.625
cytotoxin disposition,negative regulation of establishment of localization,0.6280821917808219
cytotoxin disposition,infectious structure host role,0.6264705882352941
cytotoxin disposition,COVID-19 incidence rate,0.609090909090909
cytotoxin disposition,cytotoxin disposition,0.95
cytotoxin disposition,negative regulation of developmental process,0.5884615384615385
cytotoxin disposition,host,0.57
cytotoxin disposition,descriptive information content entity,0.6194915254237288
cytotoxin disposition,negative regulation of replication,0.65
cytotoxin disposition,establishment of localization in human host,0.60625
cytotoxin disposition,acellular structure,0.55
cytotoxin disposition,incubation end process boundary,0.6615384615384616
cytotoxin disposition,collective pathogenic disposition,0.7648148148148148
cytotoxin disposition,neurotoxin disposition,0.8686046511627907
cytotoxin disposition,dead-end host role,0.6038461538461539
cytotoxin disposition,molecular entity,0.5581081081081081
cytotoxin disposition,plan specification,0.6807692307692308
cytotoxin disposition,definitive host role,0.6207317073170732
cytotoxin disposition,latency end temporal region,0.6375
cytotoxin disposition,infectious structure,0.5963414634146341
cytotoxin disposition,collective disposition,0.822093023255814
cytotoxin disposition,static agent disposition,0.8055555555555556
cytotoxin disposition,T cell receptor complex,0.5636363636363636
cytotoxin disposition,infectious structure host,0.6239130434782608
cytotoxin disposition,respiratory system disease,0.6202127659574468
cytotoxin disposition,entry into host,0.6444444444444444
cytotoxin disposition,adhesion of symbiont to host,0.6132653061224489
cytotoxin disposition,infectious disease control strategy,0.6285714285714286
cytotoxin disposition,infectious structure generative stage,0.5879310344827586
cytotoxin disposition,immunosuppressive disposition,0.73
cytotoxin disposition,pathogenic disposition,0.7988372093023256
cytotoxin disposition,toxin,0.6423076923076922
cytotoxin disposition,entry into host through host barriers,0.6224137931034482
cytotoxin disposition,infectious disposition,0.7988372093023256
cytotoxin disposition,bacteriostatic disposition,0.8117021276595744
cytotoxin disposition,bactericidal disposition,0.7833333333333333
cytotoxin disposition,pathogen host,0.6558823529411765
cytotoxin disposition,invasion disposition,0.7914634146341464
cytotoxin disposition,viricidal disposition,0.7833333333333333
cytotoxin disposition,complex infection,0.6868421052631578
cytotoxin disposition,intermediate host,0.6342105263157894
cytotoxin disposition,anatomical entity,0.6078947368421053
cytotoxin disposition,disposition,0.79375
cytotoxin disposition,COVID-19 mortality rate,0.609090909090909
cytotoxin disposition,negative regulation of life-sustaining process,0.6141791044776119
cytotoxin disposition,place closure control strategy,0.5872549019607843
cytotoxin disposition,geopolitical entity,0.625
cytotoxin disposition,adhesion disposition,0.7914634146341464
cytotoxin disposition,symptomatic infectious structure carrier,0.630327868852459
cytotoxin disposition,primary infectious disposition,0.7441176470588234
cytotoxin disposition,pathogen host role,0.6551282051282051
cytotoxin disposition,designative information content entity,0.6025423728813559
cytotoxin disposition,intermediate host role,0.636046511627907
cytotoxin disposition,dead-end host,0.5970588235294118
cytotoxin disposition,pathogen surveillance,0.6166666666666667
cytotoxin disposition,host role,0.5833333333333334
cytotoxin disposition,establishment of localization in virus host,0.6375
cytotoxin disposition,negative regulation of immune response,0.6194915254237288
cytotoxin disposition,immaterial entity,0.581578947368421
cytotoxin disposition,SARS-COV-2 adhesion disposition,0.7576923076923078
cytotoxin disposition,invasive disposition,0.7914634146341464
cytotoxin disposition,infectious agent host,0.6404761904761905
cytotoxin disposition,fungicidal disposition,0.7755813953488372
cytotoxin disposition,division of geopolitical entity,0.6230769230769231
cytotoxin disposition,cytotoxin,0.75
cytotoxin disposition,negative regulation of viral process,0.6078947368421053
cytotoxin disposition,exotoxin disposition,0.8890243902439025
cytotoxin disposition,immunoglobulin complex,0.5895348837209302
cytotoxin disposition,infectious disease control objective specification,0.6471830985915493
cytotoxin disposition,symbiont host role,0.6551282051282051
cytotoxin disposition,opportunistic infectious disposition,0.730701754385965
cytotoxin disposition,negative regulation of biological process,0.5951612903225807
cytotoxin disposition,enterotoxin disposition,0.8818181818181818
cytotoxin disposition,infectious disease incidence rate,0.6537037037037037
cytotoxin disposition,collective resistance disposition,0.7648148148148148
cytotoxin disposition,fungistatic disposition,0.7909090909090909
cytotoxin disposition,establishment of a clinically abnormal colony,0.5863636363636363
cytotoxin disposition,definitive host,0.6166666666666667
incubation end process boundary,immune response,0.6673913043478261
incubation end process boundary,infectious disease mortality rate,0.66875
incubation end process boundary,infection incidence rate profile,0.6880952380952381
incubation end process boundary,infectious structure aggregate,0.6631147540983606
incubation end process boundary,communicability end temporal region,0.6621212121212122
incubation end process boundary,pathogen generative stage,0.6464285714285714
incubation end process boundary,surveillance process,0.6852941176470588
incubation end process boundary,infection end temporal region,0.7333333333333333
incubation end process boundary,SARS-CoV-2 incidence rate,0.6285714285714286
incubation end process boundary,incubation end temporal region,0.7778688524590163
incubation end process boundary,negative regulation of production,0.684375
incubation end process boundary,establishment of localization in host,0.6411764705882353
incubation end process boundary,virus translation stage,0.6351851851851852
incubation end process boundary,disease surveillance objective specification,0.61
incubation end process boundary,case isolation control strategy,0.6596774193548387
incubation end process boundary,virus release stage,0.61
incubation end process boundary,asymptomatic infectious structure carrier,0.6305555555555555
incubation end process boundary,architectual structure,0.619811320754717
incubation end process boundary,B cell receptor complex,0.6166666666666667
incubation end process boundary,infection incidence rate,0.7045454545454546
incubation end process boundary,virus transcription stage,0.6285714285714286
incubation end process boundary,lower respiratory tract disease,0.6112903225806451
incubation end process boundary,virus generative stage,0.619811320754717
incubation end process boundary,acute infectious disease course,0.6758064516129032
incubation end process boundary,process,0.6342105263157894
incubation end process boundary,droplet pathogen transmission process,0.6558823529411765
incubation end process boundary,communicability end process boundary,0.8231343283582089
incubation end process boundary,acellular structure aggregate,0.6166666666666667
incubation end process boundary,latency end process boundary,0.8567796610169492
incubation end process boundary,infectious agent generative stage,0.66875
incubation end process boundary,negative regulation of establishment of localization,0.6307228915662652
incubation end process boundary,infectious structure host role,0.6631147540983606
incubation end process boundary,establishment of localization,0.6
incubation end process boundary,COVID-19 incidence rate,0.6351851851851852
incubation end process boundary,negative regulation of developmental process,0.69
incubation end process boundary,chronic infectious disease course,0.66875
incubation end process boundary,PCR product,0.5928571428571429
incubation end process boundary,establishment of localization in human host,0.6256756756756756
incubation end process boundary,acellular structure,0.61
incubation end process boundary,process of establishing an infection,0.6141791044776119
incubation end process boundary,incubation end process boundary,0.95
incubation end process boundary,SARS-CoV-2 uncoating stage,0.6078947368421053
incubation end process boundary,pathogen death process boundary,0.8209677419354838
incubation end process boundary,plan specification,0.5928571428571429
incubation end process boundary,latency end temporal region,0.6741379310344828
incubation end process boundary,SARS-CoV-2 penetration stage,0.6025423728813559
incubation end process boundary,infectious structure,0.6656862745098039
incubation end process boundary,virus adhesion susceptible cell,0.6274193548387097
incubation end process boundary,anatomical space,0.6202127659574468
incubation end process boundary,T cell receptor complex,0.6166666666666667
incubation end process boundary,infectious structure host,0.6642857142857143
incubation end process boundary,respiratory system disease,0.6254385964912281
incubation end process boundary,indirect pathogen transmission process,0.696376811594203
incubation end process boundary,planned process,0.7108695652173913
incubation end process boundary,generative stage,0.6202127659574468
incubation end process boundary,SARS-CoV-2 attachment stage,0.5879310344827586
incubation end process boundary,infectious structure generative stage,0.6411764705882353
incubation end process boundary,innate immune response,0.6952830188679244
incubation end process boundary,viral disease course,0.6460784313725491
incubation end process boundary,cell,0.5071428571428571
incubation end process boundary,objective specification,0.6166666666666667
incubation end process boundary,disease course,0.6277777777777778
incubation end process boundary,infectious disease course,0.7
incubation end process boundary,coronavirus disease course,0.6429824561403508
incubation end process boundary,incubation interval,0.73
incubation end process boundary,SARS-CoV-2 genome replication stage,0.6166666666666667
incubation end process boundary,production,0.5963414634146341
incubation end process boundary,COVID-19 mortality rate,0.5796296296296296
incubation end process boundary,process profile,0.6456521739130434
incubation end process boundary,negative regulation of life-sustaining process,0.6837662337662337
incubation end process boundary,place closure control strategy,0.6139344262295081
incubation end process boundary,developmental process,0.6615384615384616
incubation end process boundary,biological process,0.6744897959183673
incubation end process boundary,symptomatic infectious structure carrier,0.6330985915492958
incubation end process boundary,humoral immune response,0.6537037037037037
incubation end process boundary,SARS-COV-2 adhesion susceptible cell,0.5992537313432835
incubation end process boundary,incubation start process boundary,0.8875
incubation end process boundary,object,0.5310810810810811
incubation end process boundary,pathogen birth process boundary,0.8048387096774193
incubation end process boundary,establishment of localization in virus host,0.6527027027027027
incubation end process boundary,virus attachment stage,0.619811320754717
incubation end process boundary,negative regulation of immune response,0.6673913043478261
incubation end process boundary,SARS-CoV-2 transcription stage,0.5975409836065574
incubation end process boundary,virus synthesis stage,0.6230769230769231
incubation end process boundary,object aggregate,0.5776595744680851
incubation end process boundary,long-term non-progressing infectious disease course,0.6451219512195122
incubation end process boundary,virus penetration stage,0.6351851851851852
incubation end process boundary,algorithm,0.525
incubation end process boundary,negative regulation of viral process,0.6888059701492537
incubation end process boundary,contact pathogen transmission process,0.6852941176470588
incubation end process boundary,function,0.6038461538461539
incubation end process boundary,symbiotic process,0.6791666666666666
incubation end process boundary,infection start process boundary,0.8468253968253968
incubation end process boundary,action specification,0.6460784313725491
incubation end process boundary,SARS-CoV-2 synthesis stage,0.6078947368421053
incubation end process boundary,latency start process boundary,0.7942622950819671
incubation end process boundary,infectious disease control objective specification,0.6475308641975309
incubation end process boundary,process of establishing viral infection,0.6071428571428572
incubation end process boundary,negative regulation of biological process,0.6722222222222223
incubation end process boundary,polymerase chain reaction,0.6107142857142857
incubation end process boundary,COVID-19 disease course,0.6351851851851852
incubation end process boundary,infectious disease incidence rate,0.66875
incubation end process boundary,communicability start process boundary,0.7688405797101449
incubation end process boundary,process that results in death,0.65
incubation end process boundary,adaptive immune response,0.65
incubation end process boundary,virus uncoating stage,0.6423076923076922
incubation end process boundary,establishment of a clinically abnormal colony,0.6078947368421053
incubation end process boundary,process boundary,0.7904255319148936
incubation end process boundary,horizontal pathogen transmission process,0.6753521126760563
incubation end process boundary,pathogen death temporal region,0.6467213114754098
incubation end process boundary,SARS-CoV-2 release stage,0.5954545454545455
incubation end process boundary,pathogen transmission process,0.6833333333333332
incubation end process boundary,cell space,0.5963414634146341
contact tracing,communicability end temporal region,0.67
contact tracing,pathogen portal of entry,0.6294871794871795
contact tracing,infection end temporal region,0.6545454545454545
contact tracing,coronavirus replication,0.6868421052631578
contact tracing,incubation end temporal region,0.65
contact tracing,prion replication,0.66875
contact tracing,negative regulation of production,0.6375
contact tracing,virus replication,0.60625
contact tracing,B cell receptor complex,0.581578947368421
contact tracing,pathogen portal of entry role,0.609090909090909
contact tracing,virus transcription stage,0.65
contact tracing,acute infectious disease course,0.6021739130434782
contact tracing,communicability end process boundary,0.6264705882352941
contact tracing,latency end process boundary,0.5895348837209302
contact tracing,disease transmission model,0.6207317073170732
contact tracing,chronic infectious disease course,0.6166666666666667
contact tracing,negative regulation of replication,0.6336734693877552
contact tracing,PCR product,0.6038461538461539
contact tracing,incubation end process boundary,0.6021739130434782
contact tracing,plan specification,0.6015151515151516
contact tracing,latency end temporal region,0.6404761904761905
contact tracing,T cell receptor complex,0.6078947368421053
contact tracing,entry into host,0.6166666666666667
contact tracing,SARS-CoV-2 replication,0.6391891891891892
contact tracing,viral disease course,0.5642857142857143
contact tracing,entry into host through host barriers,0.6038461538461539
contact tracing,disease course,0.553448275862069
contact tracing,infectious disease course,0.6
contact tracing,coronavirus disease course,0.6207317073170732
contact tracing,SARS-CoV-2 genome replication stage,0.63
contact tracing,production,0.65
contact tracing,contact tracing,0.95
contact tracing,pathogen portal of entry site,0.6318181818181818
contact tracing,replication,0.6423076923076922
contact tracing,SARS-CoV-2 transcription stage,0.6722222222222223
contact tracing,long-term non-progressing infectious disease course,0.5712121212121213
contact tracing,contact pathogen transmission process,0.7
contact tracing,action specification,0.65
contact tracing,COVID-19 disease course,0.581578947368421
contact tracing,establishment of a clinically abnormal colony,0.6
realizable entity,extended organism,0.5970588235294118
realizable entity,information content entity,0.7058139534883722
realizable entity,infectious disease mortality rate,0.63
realizable entity,infection incidence rate profile,0.5928571428571429
realizable entity,infectious structure aggregate,0.5776595744680851
realizable entity,communicability end temporal region,0.6230769230769231
realizable entity,geographical entity,0.7833333333333333
realizable entity,infection end temporal region,0.6021739130434782
realizable entity,drug-based immunosuppressed organism,0.5820754716981132
realizable entity,SARS-CoV-2 incidence rate,0.569047619047619
realizable entity,incubation end temporal region,0.598936170212766
realizable entity,resistant entity,0.7833333333333333
realizable entity,immunocompetent organism,0.5963414634146341
realizable entity,virulence factor disposition,0.6055555555555556
realizable entity,case isolation control strategy,0.6166666666666667
realizable entity,material entity,0.79375
realizable entity,asymptomatic infectious structure carrier,0.5706896551724138
realizable entity,architectual structure,0.6294871794871795
realizable entity,B cell receptor complex,0.6
realizable entity,infection incidence rate,0.5963414634146341
realizable entity,entity,0.7108695652173913
realizable entity,simple infection,0.6621212121212122
realizable entity,communicability end process boundary,0.619811320754717
realizable entity,directive information content entity,0.6764150943396227
realizable entity,acellular structure aggregate,0.6021739130434782
realizable entity,invasion factor,0.575
realizable entity,latency end process boundary,0.6055555555555556
realizable entity,realizable entity,0.95
realizable entity,pathologically immunosuppressed organism,0.6078947368421053
realizable entity,infectious structure host role,0.5563829787234043
realizable entity,COVID-19 incidence rate,0.575
realizable entity,descriptive information content entity,0.6681818181818181
realizable entity,establishment of localization in human host,0.6
realizable entity,acellular structure,0.6166666666666667
realizable entity,virulence factor,0.6015151515151516
realizable entity,incubation end process boundary,0.5958333333333333
realizable entity,molecular entity,0.7530303030303032
realizable entity,immunosuppressed organism,0.5928571428571429
realizable entity,latency end temporal region,0.6318181818181818
realizable entity,infectious structure,0.5851351351351352
realizable entity,T cell receptor complex,0.6
realizable entity,infectious structure host,0.569047619047619
realizable entity,respiratory system disease,0.6127906976744186
realizable entity,organism population,0.6166666666666667
realizable entity,infectious structure generative stage,0.6166666666666667
realizable entity,susceptible organism,0.6662162162162162
realizable entity,generically dependent continuant,0.6540816326530612
realizable entity,organism substance,0.5928571428571429
realizable entity,anatomical entity,0.7735294117647058
realizable entity,COVID-19 mortality rate,0.6
realizable entity,geopolitical entity,0.7833333333333333
realizable entity,symptomatic infectious structure carrier,0.5728070175438597
realizable entity,designative information content entity,0.6681818181818181
realizable entity,immunodeficient organism,0.5963414634146341
realizable entity,infectious human pathogen,0.5928571428571429
realizable entity,colonization of human,0.6078947368421053
realizable entity,specifically dependent continuant,0.65
realizable entity,immaterial entity,0.7735294117647058
realizable entity,blood,0.5409090909090909
realizable entity,division of geopolitical entity,0.7
realizable entity,geographical feature,0.6662162162162162
realizable entity,herd immunity to infectious organism,0.5632075471698114
realizable entity,action specification,0.6121621621621621
realizable entity,processed material,0.6214285714285714
realizable entity,quality,0.6583333333333334
realizable entity,infectious disease incidence rate,0.61
realizable entity,organism,0.61
realizable entity,establishment of a clinically abnormal colony,0.6112903225806451
realizable entity,adhesion factor,0.575
realizable entity,material processing,0.6444444444444444
pathogen birth temporal region,extended organism,0.6202127659574468
pathogen birth temporal region,virus aggregate,0.6055555555555556
pathogen birth temporal region,source of infection,0.6336734693877552
pathogen birth temporal region,infectious disease mortality rate,0.6563492063492063
pathogen birth temporal region,infection incidence rate profile,0.6435483870967742
pathogen birth temporal region,communicability end temporal region,0.7730769230769231
pathogen birth temporal region,pathogen generative stage,0.7227272727272727
pathogen birth temporal region,pathogen portal of entry,0.7648148148148148
pathogen birth temporal region,subclinical coronavirus infection,0.6246031746031746
pathogen birth temporal region,primary pathogen,0.6239130434782608
pathogen birth temporal region,infection end temporal region,0.7889830508474576
pathogen birth temporal region,drug-based immunosuppressed organism,0.6166666666666667
pathogen birth temporal region,infectious disease,0.5958333333333333
pathogen birth temporal region,double-stranded DNA virus,0.5772727272727273
pathogen birth temporal region,incubation end temporal region,0.8
pathogen birth temporal region,site of infection,0.6414893617021277
pathogen birth temporal region,two-dimensional spatial region,0.7166666666666667
pathogen birth temporal region,one-dimensional temporal region,0.7778688524590163
pathogen birth temporal region,immunocompetent organism,0.6351851851851852
pathogen birth temporal region,pathogen portal of exit,0.7707547169811321
pathogen birth temporal region,temporal region,0.7833333333333333
pathogen birth temporal region,infectious disease incidence,0.6051724137931035
pathogen birth temporal region,reservoir of pathogen role,0.6821428571428573
pathogen birth temporal region,subclinical SARS-CoV-2 infection,0.6112903225806451
pathogen birth temporal region,virus translation stage,0.6386792452830189
pathogen birth temporal region,disease surveillance objective specification,0.6121621621621621
pathogen birth temporal region,virus release stage,0.5928571428571429
pathogen birth temporal region,infectious agent host role,0.6464285714285714
pathogen birth temporal region,material entity,0.65
pathogen birth temporal region,source of infection site,0.6166666666666667
pathogen birth temporal region,virus,0.5071428571428571
pathogen birth temporal region,virus replication,0.6414893617021277
pathogen birth temporal region,B cell receptor complex,0.619811320754717
pathogen birth temporal region,passive immunization against infectious agent,0.6366666666666667
pathogen birth temporal region,systematic infection,0.63
pathogen birth temporal region,infection incidence rate,0.6166666666666667
pathogen birth temporal region,virus host,0.55
pathogen birth temporal region,double-stranded RNA virus,0.5954545454545455
pathogen birth temporal region,pathogen portal of entry role,0.738135593220339
pathogen birth temporal region,virus transcription stage,0.6318181818181818
pathogen birth temporal region,infectious disease lifetime prevalence,0.6411764705882353
pathogen birth temporal region,pathogen birth temporal region,0.95
pathogen birth temporal region,lower respiratory tract disease,0.6467213114754098
pathogen birth temporal region,infectious disease incidence proportion,0.6239130434782608
pathogen birth temporal region,opportunistic pathogen,0.6423076923076922
pathogen birth temporal region,virus generative stage,0.6230769230769231
pathogen birth temporal region,acute infectious disease course,0.6467213114754098
pathogen birth temporal region,cidal agent disposition,0.6575471698113208
pathogen birth temporal region,genetic resistance to pathogen,0.65
pathogen birth temporal region,subclinical infection,0.6264705882352941
pathogen birth temporal region,simple infection,0.6456521739130434
pathogen birth temporal region,droplet pathogen transmission process,0.6738805970149254
pathogen birth temporal region,infectious disease sporadicity,0.6166666666666667
pathogen birth temporal region,communicability end process boundary,0.6318181818181818
pathogen birth temporal region,infection incidence proportion profile,0.6264705882352941
pathogen birth temporal region,infectious agent colony,0.6575471698113208
pathogen birth temporal region,SARS-CoV-2 incidence proportion,0.6467213114754098
pathogen birth temporal region,spatiotemporal region,0.8225490196078431
pathogen birth temporal region,pathogen transporter,0.73
pathogen birth temporal region,latency end process boundary,0.6396551724137931
pathogen birth temporal region,infectious disease epidemic,0.6078947368421053
pathogen birth temporal region,infectious agent generative stage,0.6404761904761905
pathogen birth temporal region,disease transmission model,0.6107142857142857
pathogen birth temporal region,pathologically immunosuppressed organism,0.6642857142857143
pathogen birth temporal region,negative-sense single-stranded RNA virus,0.6214285714285714
pathogen birth temporal region,cidal agent,0.5963414634146341
pathogen birth temporal region,pathogen vehicle,0.7108695652173913
pathogen birth temporal region,community-acquired infection,0.6224137931034482
pathogen birth temporal region,pathogen vector,0.7166666666666667
pathogen birth temporal region,pathogen vehicle role,0.7245098039215686
pathogen birth temporal region,zero-dimensional spatial region,0.6959016393442623
pathogen birth temporal region,zero-dimensional temporal region,0.7725806451612902
pathogen birth temporal region,chronic infectious disease course,0.6404761904761905
pathogen birth temporal region,asymptomatic infectious agent carrier,0.6291044776119403
pathogen birth temporal region,nursing-home acquired infection,0.6467213114754098
pathogen birth temporal region,secondary infection,0.6132653061224489
pathogen birth temporal region,infection start temporal region,0.810655737704918
pathogen birth temporal region,infection incidence,0.5928571428571429
pathogen birth temporal region,virus disorder,0.5863636363636363
pathogen birth temporal region,sterilizing immunity to infectious agent,0.65
pathogen birth temporal region,establishment of localization in human host,0.6143835616438357
pathogen birth temporal region,primary infection,0.6414893617021277
pathogen birth temporal region,process of establishing an infection,0.6621212121212122
pathogen birth temporal region,incubation end process boundary,0.630327868852459
pathogen birth temporal region,pathogen death process boundary,0.728688524590164
pathogen birth temporal region,geographical region,0.7153061224489795
pathogen birth temporal region,immunosuppressed organism,0.5954545454545455
pathogen birth temporal region,latency end temporal region,0.8184210526315789
pathogen birth temporal region,innate immunity to infectious agent,0.6653846153846155
pathogen birth temporal region,virus adhesion susceptible cell,0.6139344262295081
pathogen birth temporal region,infection,0.5782051282051281
pathogen birth temporal region,static agent disposition,0.6722222222222223
pathogen birth temporal region,T cell receptor complex,0.6386792452830189
pathogen birth temporal region,infectious agent population,0.6780701754385965
pathogen birth temporal region,respiratory system disease,0.6464285714285714
pathogen birth temporal region,leukocyte-mediated immunity to infectious agent,0.6318181818181818
pathogen birth temporal region,indirect pathogen transmission process,0.6705882352941177
pathogen birth temporal region,organism population,0.6744897959183673
pathogen birth temporal region,humoral immunity to infectious agent,0.6469696969696969
pathogen birth temporal region,infectious disease control strategy,0.6346153846153847
pathogen birth temporal region,parasite,0.581578947368421
pathogen birth temporal region,infectious disease pandemic,0.6078947368421053
pathogen birth temporal region,antibody reagent,0.6456521739130434
pathogen birth temporal region,viral disease course,0.61
pathogen birth temporal region,intracellular infection,0.6386792452830189
pathogen birth temporal region,secondary infection role,0.6166666666666667
pathogen birth temporal region,metastatic infection,0.63
pathogen birth temporal region,three-dimensional spatial region,0.7080645161290323
pathogen birth temporal region,passive immunity to infectious agent,0.6621212121212122
pathogen birth temporal region,vaccination against infectious agent,0.6469696969696969
pathogen birth temporal region,objective specification,0.619811320754717
pathogen birth temporal region,acute infection,0.65
pathogen birth temporal region,susceptibility to infectious agent,0.653125
pathogen birth temporal region,epitope site,0.6404761904761905
pathogen birth temporal region,immunity to pathogen,0.63
pathogen birth temporal region,country,0.5581081081081081
pathogen birth temporal region,source of infection role,0.6166666666666667
pathogen birth temporal region,pathogen host,0.7058139534883722
pathogen birth temporal region,chronic infection,0.6414893617021277
pathogen birth temporal region,disease course,0.5863636363636363
pathogen birth temporal region,infectious disease course,0.6136363636363636
pathogen birth temporal region,acquired immunity to infectious agent,0.6440298507462687
pathogen birth temporal region,complex infection,0.6414893617021277
pathogen birth temporal region,COVID-19 disease incidence proportion,0.6141791044776119
pathogen birth temporal region,coronavirus disease course,0.6285714285714286
pathogen birth temporal region,infection incidence proportion,0.65
pathogen birth temporal region,symptomatic infectious agent carrier,0.6318181818181818
pathogen birth temporal region,respiratory droplet virus fomite,0.6274193548387097
pathogen birth temporal region,susceptible organism,0.61
pathogen birth temporal region,parasite role,0.6593023255813953
pathogen birth temporal region,pathogen vector role,0.75
pathogen birth temporal region,pathogen portal of exit site,0.743103448275862
pathogen birth temporal region,infectious disease prevalence,0.6364406779661017
pathogen birth temporal region,organism substance,0.6166666666666667
pathogen birth temporal region,single-stranded DNA virus,0.5772727272727273
pathogen birth temporal region,place closure control strategy,0.6666666666666667
pathogen birth temporal region,viral disease,0.5895348837209302
pathogen birth temporal region,primary infection role,0.6423076923076922
pathogen birth temporal region,pathogen portal of entry site,0.738135593220339
pathogen birth temporal region,infection incidence profile,0.6254385964912281
pathogen birth temporal region,disease,0.5581081081081081
pathogen birth temporal region,site,0.5382352941176471
pathogen birth temporal region,pathogen host role,0.7416666666666667
pathogen birth temporal region,infection prevalence,0.65
pathogen birth temporal region,infectious pathogen transmissibility,0.6621212121212122
pathogen birth temporal region,incubation start process boundary,0.6563492063492063
pathogen birth temporal region,object,0.5333333333333333
pathogen birth temporal region,pathogen surveillance,0.7049019607843137
pathogen birth temporal region,immunodeficient organism,0.6166666666666667
pathogen birth temporal region,pathogen,0.6605263157894737
pathogen birth temporal region,pathogen birth process boundary,0.7778688524590163
pathogen birth temporal region,infectious human pathogen,0.6136363636363636
pathogen birth temporal region,subclinical virus infection,0.6254385964912281
pathogen birth temporal region,resistance to pathogen,0.6230769230769231
pathogen birth temporal region,colonization of human,0.6264705882352941
pathogen birth temporal region,establishment of localization in virus host,0.6143835616438357
pathogen birth temporal region,immunization against infectious agent,0.6440298507462687
pathogen birth temporal region,virus attachment stage,0.6423076923076922
pathogen birth temporal region,virus synthesis stage,0.6068627450980393
pathogen birth temporal region,object aggregate,0.6239130434782608
pathogen birth temporal region,pathogen portal of exit role,0.760344827586207
pathogen birth temporal region,infectious agent host,0.6068627450980393
pathogen birth temporal region,re-emerging pathogen,0.61
pathogen birth temporal region,long-term non-progressing infectious disease course,0.6228395061728395
pathogen birth temporal region,viral disease epidemic,0.6038461538461539
pathogen birth temporal region,communicability start temporal region,0.7783582089552239
pathogen birth temporal region,blood,0.5357142857142857
pathogen birth temporal region,viral disease pandemic,0.6038461538461539
pathogen birth temporal region,virus penetration stage,0.619811320754717
pathogen birth temporal region,pathogen seroprevalence,0.7518867924528303
pathogen birth temporal region,geospatial region,0.7265957446808511
pathogen birth temporal region,division of geopolitical entity,0.6467213114754098
pathogen birth temporal region,infectious disease endemicity,0.6025423728813559
pathogen birth temporal region,contact pathogen transmission process,0.6738805970149254
pathogen birth temporal region,herd immunity to infectious organism,0.6469696969696969
pathogen birth temporal region,extracellular infection,0.6386792452830189
pathogen birth temporal region,pathogen transporter role,0.740909090909091
pathogen birth temporal region,infectious agent reservoir,0.6285714285714286
pathogen birth temporal region,infection start process boundary,0.6435483870967742
pathogen birth temporal region,action specification,0.65
pathogen birth temporal region,processed material,0.6375
pathogen birth temporal region,latency start process boundary,0.6666666666666667
pathogen birth temporal region,infectious disease control objective specification,0.6125
pathogen birth temporal region,process of establishing viral infection,0.6818840579710145
pathogen birth temporal region,COVID-19 disease course,0.6009433962264151
pathogen birth temporal region,infectious disease incidence rate,0.5928571428571429
pathogen birth temporal region,communicability start process boundary,0.6411764705882353
pathogen birth temporal region,single-stranded RNA retrovirus,0.6166666666666667
pathogen birth temporal region,active immunization against infectious agent,0.6256756756756756
pathogen birth temporal region,disordered virus,0.5804347826086956
pathogen birth temporal region,organism,0.581578947368421
pathogen birth temporal region,virus uncoating stage,0.5872549019607843
pathogen birth temporal region,local infection,0.6277777777777778
pathogen birth temporal region,infectious agent,0.5804347826086956
pathogen birth temporal region,establishment of a clinically abnormal colony,0.6366666666666667
pathogen birth temporal region,coronavirus disease,0.6132653061224489
pathogen birth temporal region,positive-sense single-stranded RNA virus,0.6214285714285714
pathogen birth temporal region,horizontal pathogen transmission process,0.6642857142857143
pathogen birth temporal region,one-dimensional spatial region,0.7
pathogen birth temporal region,hospital-acquired infection,0.6429824561403508
pathogen birth temporal region,spatial region,0.7454545454545455
pathogen birth temporal region,pathogen death temporal region,0.9
pathogen birth temporal region,emerging pathogen,0.6202127659574468
pathogen birth temporal region,drug susceptibility of infectious agent,0.6239130434782608
pathogen birth temporal region,static agent,0.6166666666666667
pathogen birth temporal region,pathogen transmission process,0.7042372881355932
pathogen birth temporal region,material processing,0.6744897959183673
infection start process boundary,virus aggregate,0.5776595744680851
infection start process boundary,source of infection,0.6264705882352941
infection start process boundary,virostatic disposition,0.6722222222222223
infection start process boundary,zoonotic disposition,0.6423076923076922
infection start process boundary,immune response,0.6414893617021277
infection start process boundary,infectious disease mortality rate,0.6961538461538461
infection start process boundary,infection incidence rate profile,0.715625
infection start process boundary,communicability end temporal region,0.6291044776119403
infection start process boundary,pathogen generative stage,0.6078947368421053
infection start process boundary,subclinical coronavirus infection,0.6192307692307693
infection start process boundary,surveillance process,0.6615384615384616
infection start process boundary,infection end temporal region,0.728688524590164
infection start process boundary,infectious disease,0.69
infection start process boundary,SARS-CoV-2 incidence rate,0.6078947368421053
infection start process boundary,double-stranded DNA virus,0.6078947368421053
infection start process boundary,incubation end temporal region,0.6919354838709677
infection start process boundary,site of infection,0.6336734693877552
infection start process boundary,virulence factor disposition,0.6666666666666667
infection start process boundary,pathogen portal of exit,0.6136363636363636
infection start process boundary,viral adhesion disposition,0.656896551724138
infection start process boundary,parasitostatic disposition,0.6741379310344828
infection start process boundary,infectious disease incidence,0.7
infection start process boundary,reverse zoonotic disposition,0.6166666666666667
infection start process boundary,subclinical SARS-CoV-2 infection,0.621875
infection start process boundary,virus translation stage,0.65
infection start process boundary,disease surveillance objective specification,0.6078947368421053
infection start process boundary,case isolation control strategy,0.6404761904761905
infection start process boundary,virus release stage,0.6068627450980393
infection start process boundary,source of infection site,0.6821428571428573
infection start process boundary,virus,0.5310810810810811
infection start process boundary,virus replication,0.5928571428571429
infection start process boundary,B cell receptor complex,0.5954545454545455
infection start process boundary,systematic infection,0.6230769230769231
infection start process boundary,infection incidence rate,0.7
infection start process boundary,virus host,0.569047619047619
infection start process boundary,double-stranded RNA virus,0.6078947368421053
infection start process boundary,virus transcription stage,0.6605263157894737
infection start process boundary,infectious disease lifetime prevalence,0.6928571428571427
infection start process boundary,toxin disposition,0.6540816326530612
infection start process boundary,pathogen birth temporal region,0.6435483870967742
infection start process boundary,lower respiratory tract disease,0.6246031746031746
infection start process boundary,infectious disease incidence proportion,0.6894366197183097
infection start process boundary,virus generative stage,0.6351851851851852
infection start process boundary,acute infectious disease course,0.7039682539682539
infection start process boundary,cidal agent disposition,0.65
infection start process boundary,infectious disorder,0.7245098039215686
infection start process boundary,subclinical infection,0.619811320754717
infection start process boundary,process,0.6294871794871795
infection start process boundary,appearance of disorder,0.6166666666666667
infection start process boundary,simple infection,0.6375
infection start process boundary,droplet pathogen transmission process,0.6673913043478261
infection start process boundary,parasiticidal disposition,0.6254385964912281
infection start process boundary,infectious disease sporadicity,0.7080645161290323
infection start process boundary,communicability end process boundary,0.7735294117647058
infection start process boundary,infection incidence proportion profile,0.6928571428571427
infection start process boundary,transmissibility disposition,0.6166666666666667
infection start process boundary,latency end process boundary,0.7833333333333333
infection start process boundary,infectious disease epidemic,0.6872881355932203
infection start process boundary,infectious agent generative stage,0.6961538461538461
infection start process boundary,disease transmission model,0.6224137931034482
infection start process boundary,endotoxin disposition,0.6575471698113208
infection start process boundary,negative-sense single-stranded RNA virus,0.6444444444444444
infection start process boundary,COVID-19 incidence rate,0.6136363636363636
infection start process boundary,cytotoxin disposition,0.6575471698113208
infection start process boundary,community-acquired infection,0.6166666666666667
infection start process boundary,negative regulation of developmental process,0.6736842105263158
infection start process boundary,chronic infectious disease course,0.6961538461538461
infection start process boundary,nursing-home acquired infection,0.6087301587301588
infection start process boundary,COVID-19 epidemic,0.5520408163265306
infection start process boundary,secondary infection,0.6460784313725491
infection start process boundary,infection start temporal region,0.7833333333333333
infection start process boundary,infection incidence,0.7049019607843137
infection start process boundary,virus disorder,0.6021739130434782
infection start process boundary,primary infection,0.6336734693877552
infection start process boundary,process of establishing an infection,0.6117647058823529
infection start process boundary,incubation end process boundary,0.8468253968253968
infection start process boundary,SARS-CoV-2 disorder,0.6068627450980393
infection start process boundary,collective pathogenic disposition,0.65
infection start process boundary,neurotoxin disposition,0.6722222222222223
infection start process boundary,SARS-CoV-2 uncoating stage,0.6224137931034482
infection start process boundary,pathogen death process boundary,0.8150793650793651
infection start process boundary,plan specification,0.61
infection start process boundary,latency end temporal region,0.6364406779661017
infection start process boundary,SARS-CoV-2 penetration stage,0.6333333333333333
infection start process boundary,virus adhesion susceptible cell,0.6246031746031746
infection start process boundary,anatomical space,0.6166666666666667
infection start process boundary,collective disposition,0.6537037037037037
infection start process boundary,infection,0.6695121951219513
infection start process boundary,static agent disposition,0.6464285714285714
infection start process boundary,T cell receptor complex,0.5954545454545455
infection start process boundary,respiratory system disease,0.6224137931034482
infection start process boundary,indirect pathogen transmission process,0.7071428571428571
infection start process boundary,planned process,0.6627659574468084
infection start process boundary,generative stage,0.6375
infection start process boundary,communicability interval,0.5928571428571429
infection start process boundary,infectious disease control strategy,0.703731343283582
infection start process boundary,SARS-CoV-2 attachment stage,0.6025423728813559
infection start process boundary,infectious disease pandemic,0.7042372881355932
infection start process boundary,infectious structure generative stage,0.7108695652173913
infection start process boundary,immunosuppressive disposition,0.6467213114754098
infection start process boundary,innate immune response,0.6537037037037037
infection start process boundary,pathogenic disposition,0.6351851851851852
infection start process boundary,viral disease course,0.6230769230769231
infection start process boundary,intracellular infection,0.6136363636363636
infection start process boundary,secondary infection role,0.6821428571428573
infection start process boundary,metastatic infection,0.6423076923076922
infection start process boundary,infectious disposition,0.7277777777777777
infection start process boundary,acute infection,0.6414893617021277
infection start process boundary,bacteriostatic disposition,0.6913793103448276
infection start process boundary,bactericidal disposition,0.6285714285714286
infection start process boundary,source of infection role,0.6821428571428573
infection start process boundary,chronic infection,0.6336734693877552
infection start process boundary,invasion disposition,0.6807692307692308
infection start process boundary,disease course,0.6239130434782608
infection start process boundary,infectious disease course,0.730701754385965
infection start process boundary,viricidal disposition,0.6386792452830189
infection start process boundary,complex infection,0.6336734693877552
infection start process boundary,COVID-19 disease incidence proportion,0.6094202898550725
infection start process boundary,coronavirus disease course,0.656896551724138
infection start process boundary,infection incidence proportion,0.7080645161290323
infection start process boundary,respiratory droplet virus fomite,0.621875
infection start process boundary,pathogen portal of exit site,0.6166666666666667
infection start process boundary,infectious disease prevalence,0.7122950819672131
infection start process boundary,SARS-CoV-2 genome replication stage,0.6291044776119403
infection start process boundary,disposition,0.6127906976744186
infection start process boundary,single-stranded DNA virus,0.6429824561403508
infection start process boundary,COVID-19 mortality rate,0.6136363636363636
infection start process boundary,process profile,0.6414893617021277
infection start process boundary,negative regulation of life-sustaining process,0.6807692307692308
infection start process boundary,place closure control strategy,0.6274193548387097
infection start process boundary,viral disease,0.5611111111111111
infection start process boundary,primary infection role,0.6907407407407408
infection start process boundary,adhesion disposition,0.6615384615384616
infection start process boundary,developmental process,0.6952830188679244
infection start process boundary,infection incidence profile,0.7042372881355932
infection start process boundary,contagiousness,0.6456521739130434
infection start process boundary,disease,0.5525641025641026
infection start process boundary,biological process,0.67
infection start process boundary,primary infectious disposition,0.6919354838709677
infection start process boundary,infection prevalence,0.7192307692307692
infection start process boundary,humoral immune response,0.6136363636363636
infection start process boundary,coronavirus disorder,0.6423076923076922
infection start process boundary,incubation start process boundary,0.9115384615384616
infection start process boundary,pathogen birth process boundary,0.8150793650793651
infection start process boundary,subclinical virus infection,0.6194915254237288
infection start process boundary,establishment of localization in virus host,0.6366666666666667
infection start process boundary,virus attachment stage,0.5981481481481481
infection start process boundary,negative regulation of immune response,0.6357142857142857
infection start process boundary,SARS-CoV-2 transcription stage,0.6274193548387097
infection start process boundary,virus synthesis stage,0.619811320754717
infection start process boundary,SARS-COV-2 adhesion disposition,0.6246031746031746
infection start process boundary,pathogen portal of exit role,0.6333333333333333
infection start process boundary,invasive disposition,0.6423076923076922
infection start process boundary,long-term non-progressing infectious disease course,0.6548192771084337
infection start process boundary,viral disease epidemic,0.5796296296296296
infection start process boundary,communicability start temporal region,0.6673913043478261
infection start process boundary,fungicidal disposition,0.6351851851851852
infection start process boundary,viral disease pandemic,0.5981481481481481
infection start process boundary,virus penetration stage,0.6681818181818181
infection start process boundary,algorithm,0.523170731707317
infection start process boundary,acute respiratory distress syndrome,0.6738805970149254
infection start process boundary,infectious disease endemicity,0.7122950819672131
infection start process boundary,negative regulation of viral process,0.6852941176470588
infection start process boundary,contact pathogen transmission process,0.6818840579710145
infection start process boundary,disorder,0.575
infection start process boundary,function,0.6
infection start process boundary,communicability,0.5776595744680851
infection start process boundary,extracellular infection,0.6136363636363636
infection start process boundary,symbiotic process,0.6744897959183673
infection start process boundary,exotoxin disposition,0.6615384615384616
infection start process boundary,infection start process boundary,0.95
infection start process boundary,action specification,0.6615384615384616
infection start process boundary,SARS-CoV-2 synthesis stage,0.6224137931034482
infection start process boundary,latency start process boundary,0.8532258064516128
infection start process boundary,infectious disease control objective specification,0.6817073170731708
infection start process boundary,opportunistic infectious disposition,0.6705882352941177
infection start process boundary,process of establishing viral infection,0.6049295774647887
infection start process boundary,negative regulation of biological process,0.6691780821917809
infection start process boundary,enterotoxin disposition,0.6681818181818181
infection start process boundary,polymerase chain reaction,0.6078947368421053
infection start process boundary,COVID-19 disease course,0.6318181818181818
infection start process boundary,infectious disease incidence rate,0.6961538461538461
infection start process boundary,communicability start process boundary,0.8214285714285714
infection start process boundary,process that results in death,0.6795081967213115
infection start process boundary,disordered virus,0.5958333333333333
infection start process boundary,collective resistance disposition,0.6653846153846155
infection start process boundary,adaptive immune response,0.6285714285714286
infection start process boundary,fungistatic disposition,0.6681818181818181
infection start process boundary,virus uncoating stage,0.6575471698113208
infection start process boundary,local infection,0.6414893617021277
infection start process boundary,establishment of a clinically abnormal colony,0.6318181818181818
infection start process boundary,process boundary,0.7833333333333333
infection start process boundary,coronavirus disease,0.6264705882352941
infection start process boundary,positive-sense single-stranded RNA virus,0.6305555555555555
infection start process boundary,horizontal pathogen transmission process,0.6722222222222223
infection start process boundary,hospital-acquired infection,0.6025423728813559
infection start process boundary,SARS-CoV-2 release stage,0.6107142857142857
infection start process boundary,pathogen transmission process,0.6795081967213115
infection start process boundary,cell space,0.5928571428571429
obligatory symbiont,site of infection,0.6444444444444444
obligatory symbiont,source of infection site,0.636046511627907
obligatory symbiont,B cell receptor complex,0.6166666666666667
obligatory symbiont,T cell receptor complex,0.5928571428571429
obligatory symbiont,adhesion of symbiont to host,0.6840425531914894
obligatory symbiont,epitope site,0.6758064516129032
obligatory symbiont,symbiont role,0.7
obligatory symbiont,pathogen portal of exit site,0.6202127659574468
obligatory symbiont,pathogen portal of entry site,0.6583333333333334
obligatory symbiont,site,0.5804347826086956
obligatory symbiont,obligatory symbiont,0.95
obligatory symbiont,symbiont host role,0.6662162162162162
obligatory symbiont,symbiont,0.7462962962962962
obligatory symbiont,establishment of a clinically abnormal colony,0.60625
three-dimensional spatial region,communicability end temporal region,0.6888059701492537
three-dimensional spatial region,geographical entity,0.6460784313725491
three-dimensional spatial region,infection end temporal region,0.7122950819672131
three-dimensional spatial region,incubation end temporal region,0.7080645161290323
three-dimensional spatial region,two-dimensional spatial region,0.9016129032258065
three-dimensional spatial region,one-dimensional temporal region,0.830952380952381
three-dimensional spatial region,temporal region,0.7265957446808511
three-dimensional spatial region,disease surveillance objective specification,0.6342105263157894
three-dimensional spatial region,B cell receptor complex,0.5954545454545455
three-dimensional spatial region,pathogen birth temporal region,0.7080645161290323
three-dimensional spatial region,lower respiratory tract disease,0.6246031746031746
three-dimensional spatial region,infectious disease incidence proportion,0.6330985915492958
three-dimensional spatial region,acute infectious disease course,0.6404761904761905
three-dimensional spatial region,communicability end process boundary,0.6117647058823529
three-dimensional spatial region,infection incidence proportion profile,0.6214285714285714
three-dimensional spatial region,SARS-CoV-2 incidence proportion,0.6404761904761905
three-dimensional spatial region,spatiotemporal region,0.7141509433962264
three-dimensional spatial region,latency end process boundary,0.6166666666666667
three-dimensional spatial region,zero-dimensional spatial region,0.8944444444444444
three-dimensional spatial region,zero-dimensional temporal region,0.825
three-dimensional spatial region,chronic infectious disease course,0.6346153846153847
three-dimensional spatial region,infection start temporal region,0.7357142857142857
three-dimensional spatial region,incubation end process boundary,0.6246031746031746
three-dimensional spatial region,geographical region,0.7245098039215686
three-dimensional spatial region,latency end temporal region,0.7042372881355932
three-dimensional spatial region,T cell receptor complex,0.6136363636363636
three-dimensional spatial region,viral disease course,0.6230769230769231
three-dimensional spatial region,three-dimensional spatial region,0.95
three-dimensional spatial region,objective specification,0.65
three-dimensional spatial region,country,0.5525641025641026
three-dimensional spatial region,disease course,0.6239130434782608
three-dimensional spatial region,infectious disease course,0.6254385964912281
three-dimensional spatial region,COVID-19 disease incidence proportion,0.6384057971014493
three-dimensional spatial region,coronavirus disease course,0.6224137931034482
three-dimensional spatial region,infection incidence proportion,0.6435483870967742
three-dimensional spatial region,place closure control strategy,0.6274193548387097
three-dimensional spatial region,object,0.5026315789473684
three-dimensional spatial region,object aggregate,0.575
three-dimensional spatial region,long-term non-progressing infectious disease course,0.6186746987951807
three-dimensional spatial region,communicability start temporal region,0.7108695652173913
three-dimensional spatial region,geospatial region,0.7765306122448979
three-dimensional spatial region,division of geopolitical entity,0.6880952380952381
three-dimensional spatial region,geographical feature,0.6423076923076922
three-dimensional spatial region,infectious disease control objective specification,0.6451219512195122
three-dimensional spatial region,COVID-19 disease course,0.6136363636363636
three-dimensional spatial region,local infection,0.6414893617021277
three-dimensional spatial region,establishment of a clinically abnormal colony,0.6577922077922078
three-dimensional spatial region,one-dimensional spatial region,0.9016129032258065
three-dimensional spatial region,spatial region,0.7543478260869566
three-dimensional spatial region,pathogen death temporal region,0.7241935483870968
symbiont role,reservoir of pathogen role,0.6807692307692308
symbiont role,infectious agent host role,0.6807692307692308
symbiont role,B cell receptor complex,0.6166666666666667
symbiont role,pathogen portal of entry role,0.6404761904761905
symbiont role,lower respiratory tract disease,0.5863636363636363
symbiont role,acute infectious disease course,0.5863636363636363
symbiont role,role,0.6852941176470588
symbiont role,appearance of disorder,0.5642857142857143
symbiont role,mutualist role,0.7462962962962962
symbiont role,infectious structure host role,0.636046511627907
symbiont role,pathogen vehicle role,0.6558823529411765
symbiont role,chronic infectious disease course,0.5804347826086956
symbiont role,mechanical vector role,0.6785714285714286
symbiont role,dead-end host role,0.6758064516129032
symbiont role,definitive host role,0.6924242424242425
symbiont role,T cell receptor complex,0.6166666666666667
symbiont role,asymptomatic carrier role,0.7131578947368421
symbiont role,adhesion of symbiont to host,0.6939024390243902
symbiont role,viral disease course,0.5712121212121213
symbiont role,secondary infection role,0.7202702702702704
symbiont role,source of infection role,0.6932432432432433
symbiont role,disease course,0.5981481481481481
symbiont role,infectious disease course,0.6078947368421053
symbiont role,coronavirus disease course,0.5782051282051281
symbiont role,biological vehicle role,0.6722222222222223
symbiont role,symbiont role,0.95
symbiont role,parasite role,0.7576923076923078
symbiont role,pathogen vector role,0.6924242424242425
symbiont role,primary infection role,0.7071428571428571
symbiont role,biological role,0.7357142857142857
symbiont role,biological vector role,0.7071428571428571
symbiont role,pathogen host role,0.7080645161290323
symbiont role,symptomatic carrier role,0.7202702702702704
symbiont role,intermediate host role,0.7071428571428571
symbiont role,host role,0.7681818181818181
symbiont role,pathogen portal of exit role,0.6451219512195122
symbiont role,obligatory symbiont,0.7
symbiont role,long-term non-progressing infectious disease course,0.559375
symbiont role,commensal role,0.7092592592592593
symbiont role,epitope role,0.73
symbiont role,function,0.5928571428571429
symbiont role,pathogen transporter role,0.6605263157894737
symbiont role,antigen role,0.73
symbiont role,action specification,0.6015151515151516
symbiont role,symbiont host role,0.8693548387096774
symbiont role,fomite role,0.7833333333333333
symbiont role,symbiont,0.830952380952381
symbiont role,COVID-19 disease course,0.5611111111111111
symbiont role,reagent role,0.73
symbiont role,viral load,0.5804347826086956
symbiont role,establishment of a clinically abnormal colony,0.6051724137931035
parasite role,communicability end temporal region,0.6166666666666667
parasite role,infection end temporal region,0.6166666666666667
parasite role,incubation end temporal region,0.6127906976744186
parasite role,site of infection,0.6833333333333332
parasite role,reservoir of pathogen role,0.7064102564102563
parasite role,infectious agent host role,0.6551282051282051
parasite role,source of infection site,0.5851351351351352
parasite role,B cell receptor complex,0.6166666666666667
parasite role,double-stranded RNA virus,0.581578947368421
parasite role,pathogen portal of entry role,0.6880952380952381
parasite role,lower respiratory tract disease,0.609090909090909
parasite role,acute infectious disease course,0.609090909090909
parasite role,role,0.6852941176470588
parasite role,appearance of disorder,0.6785714285714286
parasite role,mutualist role,0.7462962962962962
parasite role,communicability end process boundary,0.6132653061224489
parasite role,latency end process boundary,0.6207317073170732
parasite role,negative-sense single-stranded RNA virus,0.5820754716981132
parasite role,infectious structure host role,0.636046511627907
parasite role,pathogen vehicle role,0.7147058823529412
parasite role,chronic infectious disease course,0.6021739130434782
parasite role,mechanical vector role,0.6785714285714286
parasite role,incubation end process boundary,0.609090909090909
parasite role,dead-end host role,0.7080645161290323
parasite role,definitive host role,0.6924242424242425
parasite role,latency end temporal region,0.625
parasite role,T cell receptor complex,0.6444444444444444
parasite role,asymptomatic carrier role,0.7131578947368421
parasite role,parasite,0.830952380952381
parasite role,viral disease course,0.6621212121212122
parasite role,secondary infection role,0.6932432432432433
parasite role,epitope site,0.69
parasite role,source of infection role,0.6662162162162162
parasite role,disease course,0.6722222222222223
parasite role,infectious disease course,0.6078947368421053
parasite role,coronavirus disease course,0.6551282051282051
parasite role,biological vehicle role,0.6722222222222223
parasite role,symbiont role,0.7576923076923078
parasite role,parasite role,0.95
parasite role,pathogen vector role,0.7227272727272727
parasite role,generically dependent continuant,0.5611111111111111
parasite role,pathogen portal of exit site,0.6451219512195122
parasite role,primary infection role,0.7357142857142857
parasite role,biological role,0.6642857142857143
parasite role,pathogen portal of entry site,0.6404761904761905
parasite role,biological vector role,0.65
parasite role,site,0.6852941176470588
parasite role,pathogen host role,0.7403225806451613
parasite role,symptomatic carrier role,0.7202702702702704
parasite role,intermediate host role,0.7071428571428571
parasite role,host role,0.7681818181818181
parasite role,specifically dependent continuant,0.558695652173913
parasite role,pathogen portal of exit role,0.7182926829268292
parasite role,long-term non-progressing infectious disease course,0.590625
parasite role,commensal role,0.6722222222222223
parasite role,epitope role,0.81
parasite role,blood,0.5055555555555555
parasite role,function,0.5452380952380953
parasite role,pathogen transporter role,0.7657894736842106
parasite role,antigen role,0.77
parasite role,action specification,0.6015151515151516
parasite role,symbiont host role,0.7080645161290323
parasite role,fomite role,0.7833333333333333
parasite role,COVID-19 disease course,0.6166666666666667
parasite role,single-stranded RNA retrovirus,0.6127906976744186
parasite role,reagent role,0.77
parasite role,viral load,0.6239130434782608
parasite role,establishment of a clinically abnormal colony,0.5706896551724138
parasite role,positive-sense single-stranded RNA virus,0.6009433962264151
acquired immunity to infectious agent,information content entity,0.6563492063492063
acquired immunity to infectious agent,infectious disease mortality rate,0.65
acquired immunity to infectious agent,infection incidence rate profile,0.6239130434782608
acquired immunity to infectious agent,infectious structure aggregate,0.6738805970149254
acquired immunity to infectious agent,communicability end temporal region,0.6722222222222223
acquired immunity to infectious agent,infection end temporal region,0.6318181818181818
acquired immunity to infectious agent,infectious disease,0.6863636363636364
acquired immunity to infectious agent,SARS-CoV-2 incidence rate,0.6274193548387097
acquired immunity to infectious agent,incubation end temporal region,0.6440298507462687
acquired immunity to infectious agent,virulence factor disposition,0.65
acquired immunity to infectious agent,infectious disease incidence,0.6653846153846155
acquired immunity to infectious agent,disease surveillance objective specification,0.6475308641975309
acquired immunity to infectious agent,virus release stage,0.6285714285714286
acquired immunity to infectious agent,infectious agent host role,0.7039682539682539
acquired immunity to infectious agent,asymptomatic infectious structure carrier,0.6807692307692308
acquired immunity to infectious agent,B cell receptor complex,0.6
acquired immunity to infectious agent,passive immunization against infectious agent,0.8158536585365854
acquired immunity to infectious agent,infection incidence rate,0.6467213114754098
acquired immunity to infectious agent,double-stranded RNA virus,0.6112903225806451
acquired immunity to infectious agent,infectious disease lifetime prevalence,0.65
acquired immunity to infectious agent,lower respiratory tract disease,0.6411764705882353
acquired immunity to infectious agent,infectious disease incidence proportion,0.6473684210526315
acquired immunity to infectious agent,acute infectious disease course,0.7147058823529412
acquired immunity to infectious agent,cidal agent disposition,0.6666666666666667
acquired immunity to infectious agent,infectious disorder,0.6642857142857143
acquired immunity to infectious agent,genetic resistance to pathogen,0.658955223880597
acquired immunity to infectious agent,biological vehicle,0.5590909090909091
acquired immunity to infectious agent,infectious disease sporadicity,0.658955223880597
acquired immunity to infectious agent,communicability end process boundary,0.6417808219178082
acquired immunity to infectious agent,directive information content entity,0.6691780821917809
acquired immunity to infectious agent,infectious agent colony,0.7166666666666667
acquired immunity to infectious agent,pathogen transporter,0.5903508771929825
acquired immunity to infectious agent,invasion factor,0.6230769230769231
acquired immunity to infectious agent,latency end process boundary,0.6038461538461539
acquired immunity to infectious agent,infectious disease epidemic,0.653125
acquired immunity to infectious agent,infectious agent generative stage,0.6785714285714286
acquired immunity to infectious agent,disease transmission model,0.5928571428571429
acquired immunity to infectious agent,negative-sense single-stranded RNA virus,0.6058441558441559
acquired immunity to infectious agent,cidal agent,0.6375
acquired immunity to infectious agent,infectious structure host role,0.6440298507462687
acquired immunity to infectious agent,pathogen vehicle,0.5820754716981132
acquired immunity to infectious agent,COVID-19 incidence rate,0.65
acquired immunity to infectious agent,antibiotic resistance,0.6224137931034482
acquired immunity to infectious agent,pathogen vehicle role,0.5879310344827586
acquired immunity to infectious agent,chronic infectious disease course,0.7071428571428571
acquired immunity to infectious agent,asymptomatic infectious agent carrier,0.7337837837837838
acquired immunity to infectious agent,nursing-home acquired infection,0.7147058823529412
acquired immunity to infectious agent,descriptive information content entity,0.6633333333333334
acquired immunity to infectious agent,COVID-19 epidemic,0.5981481481481481
acquired immunity to infectious agent,secondary infection,0.6821428571428573
acquired immunity to infectious agent,resistance to drug,0.6318181818181818
acquired immunity to infectious agent,sterilizing immunity to infectious agent,0.8396103896103897
acquired immunity to infectious agent,diseased population,0.6107142857142857
acquired immunity to infectious agent,virulence factor,0.619811320754717
acquired immunity to infectious agent,incubation end process boundary,0.6117647058823529
acquired immunity to infectious agent,latency end temporal region,0.6375
acquired immunity to infectious agent,innate immunity to infectious agent,0.8805555555555555
acquired immunity to infectious agent,infectious structure,0.6605263157894737
acquired immunity to infectious agent,static agent disposition,0.6467213114754098
acquired immunity to infectious agent,T cell receptor complex,0.6
acquired immunity to infectious agent,asymptomatic carrier role,0.5951612903225807
acquired immunity to infectious agent,infectious structure host,0.6596774193548387
acquired immunity to infectious agent,infectious agent population,0.7
acquired immunity to infectious agent,respiratory system disease,0.6404761904761905
acquired immunity to infectious agent,leukocyte-mediated immunity to infectious agent,0.8428571428571427
acquired immunity to infectious agent,humoral immunity to infectious agent,0.8746575342465753
acquired immunity to infectious agent,infectious disease control strategy,0.6583333333333334
acquired immunity to infectious agent,infectious disease pandemic,0.66875
acquired immunity to infectious agent,infectious structure generative stage,0.6527027027027027
acquired immunity to infectious agent,viral disease course,0.6254385964912281
acquired immunity to infectious agent,secondary infection role,0.6795081967213115
acquired immunity to infectious agent,passive immunity to infectious agent,0.8883561643835617
acquired immunity to infectious agent,infectious disposition,0.6533898305084747
acquired immunity to infectious agent,vaccination against infectious agent,0.7787671232876713
acquired immunity to infectious agent,susceptibility to infectious agent,0.8161971830985917
acquired immunity to infectious agent,immunity to pathogen,0.7482456140350877
acquired immunity to infectious agent,acquired immunodeficiency,0.7725806451612902
acquired immunity to infectious agent,disease course,0.6068627450980393
acquired immunity to infectious agent,infectious disease course,0.6596774193548387
acquired immunity to infectious agent,acquired immunity to infectious agent,0.95
acquired immunity to infectious agent,COVID-19 disease incidence proportion,0.6391891891891892
acquired immunity to infectious agent,coronavirus disease course,0.6404761904761905
acquired immunity to infectious agent,asymptomatic carrier,0.6078947368421053
acquired immunity to infectious agent,biological vehicle role,0.5666666666666667
acquired immunity to infectious agent,symptomatic infectious agent carrier,0.7239726027397261
acquired immunity to infectious agent,intermediate host,0.6351851851851852
acquired immunity to infectious agent,infectious disease prevalence,0.6621212121212122
acquired immunity to infectious agent,infected population,0.6285714285714286
acquired immunity to infectious agent,COVID-19 mortality rate,0.6333333333333333
acquired immunity to infectious agent,viral disease,0.59
acquired immunity to infectious agent,leukocyte mediated immunity,0.653125
acquired immunity to infectious agent,disease,0.5636363636363636
acquired immunity to infectious agent,symptomatic infectious structure carrier,0.6707792207792208
acquired immunity to infectious agent,primary infectious disposition,0.703731343283582
acquired immunity to infectious agent,designative information content entity,0.6633333333333334
acquired immunity to infectious agent,symptomatic carrier role,0.5811475409836065
acquired immunity to infectious agent,infectious pathogen transmissibility,0.6691780821917809
acquired immunity to infectious agent,intermediate host role,0.6364406779661017
acquired immunity to infectious agent,infectious human pathogen,0.6919354838709677
acquired immunity to infectious agent,resistance to pathogen,0.6703389830508475
acquired immunity to infectious agent,immunization against infectious agent,0.8013513513513513
acquired immunity to infectious agent,infectious agent host,0.7258620689655172
acquired immunity to infectious agent,long-term non-progressing infectious disease course,0.6545454545454545
acquired immunity to infectious agent,viral disease epidemic,0.5855932203389831
acquired immunity to infectious agent,viral disease pandemic,0.6025423728813559
acquired immunity to infectious agent,symptomatic carrier,0.5928571428571429
acquired immunity to infectious agent,infectious disease endemicity,0.6772727272727272
acquired immunity to infectious agent,function,0.6055555555555556
acquired immunity to infectious agent,herd immunity to infectious organism,0.8335616438356164
acquired immunity to infectious agent,pathogen transporter role,0.5951612903225807
acquired immunity to infectious agent,infectious agent reservoir,0.7039682539682539
acquired immunity to infectious agent,COVID-19 pandemic,0.5796296296296296
acquired immunity to infectious agent,action specification,0.6605263157894737
acquired immunity to infectious agent,protective resistance,0.6051724137931035
acquired immunity to infectious agent,infectious disease control objective specification,0.6454022988505748
acquired immunity to infectious agent,opportunistic infectious disposition,0.6965753424657534
acquired immunity to infectious agent,polymerase chain reaction,0.6435483870967742
acquired immunity to infectious agent,COVID-19 disease course,0.6333333333333333
acquired immunity to infectious agent,infectious disease incidence rate,0.6642857142857143
acquired immunity to infectious agent,single-stranded RNA retrovirus,0.6291044776119403
acquired immunity to infectious agent,active immunization against infectious agent,0.8327160493827159
acquired immunity to infectious agent,collective resistance disposition,0.6357142857142857
acquired immunity to infectious agent,infectious agent,0.7518867924528303
acquired immunity to infectious agent,establishment of a clinically abnormal colony,0.6207317073170732
acquired immunity to infectious agent,coronavirus disease,0.6285714285714286
acquired immunity to infectious agent,positive-sense single-stranded RNA virus,0.5928571428571429
acquired immunity to infectious agent,adhesion factor,0.6230769230769231
acquired immunity to infectious agent,drug susceptibility of infectious agent,0.7789473684210526
acquired immunity to infectious agent,SARS-CoV-2 release stage,0.6139344262295081
acquired immunity to infectious agent,static agent,0.6540816326530612
double-stranded DNA virus,extended organism,0.6880952380952381
double-stranded DNA virus,ribonucleic acid,0.6207317073170732
double-stranded DNA virus,virus aggregate,0.575
double-stranded DNA virus,source of infection,0.609090909090909
double-stranded DNA virus,virostatic disposition,0.6202127659574468
double-stranded DNA virus,zoonotic disposition,0.5833333333333334
double-stranded DNA virus,immune response,0.6
double-stranded DNA virus,infectious disease mortality rate,0.6051724137931035
double-stranded DNA virus,infection incidence rate profile,0.6078947368421053
double-stranded DNA virus,communicability end temporal region,0.6333333333333333
double-stranded DNA virus,pathogen generative stage,0.61
double-stranded DNA virus,pathogen portal of entry,0.5928571428571429
double-stranded DNA virus,subclinical coronavirus infection,0.656896551724138
double-stranded DNA virus,primary pathogen,0.5475609756097561
double-stranded DNA virus,infection end temporal region,0.6166666666666667
double-stranded DNA virus,deoxyribonucleic acid,0.6239130434782608
double-stranded DNA virus,drug-based immunosuppressed organism,0.6467213114754098
double-stranded DNA virus,infectious disease,0.6127906976744186
double-stranded DNA virus,double-stranded DNA virus,0.95
double-stranded DNA virus,incubation end temporal region,0.6318181818181818
double-stranded DNA virus,site of infection,0.5928571428571429
double-stranded DNA virus,double-stranded DNA,0.8818181818181818
double-stranded DNA virus,immunocompetent organism,0.6132653061224489
double-stranded DNA virus,virulence factor disposition,0.6386792452830189
double-stranded DNA virus,pathogen portal of exit,0.5958333333333333
double-stranded DNA virus,viral adhesion disposition,0.6068627450980393
double-stranded DNA virus,parasitostatic disposition,0.6068627450980393
double-stranded DNA virus,infectious disease incidence,0.6009433962264151
double-stranded DNA virus,reservoir of pathogen role,0.6068627450980393
double-stranded DNA virus,reverse zoonotic disposition,0.6009433962264151
double-stranded DNA virus,subclinical SARS-CoV-2 infection,0.5903508771929825
double-stranded DNA virus,virus translation stage,0.6375
double-stranded DNA virus,disease surveillance objective specification,0.5949275362318841
double-stranded DNA virus,virus release stage,0.609090909090909
double-stranded DNA virus,source of infection site,0.6132653061224489
double-stranded DNA virus,virus,0.6166666666666667
double-stranded DNA virus,virus replication,0.5928571428571429
double-stranded DNA virus,B cell receptor complex,0.575
double-stranded DNA virus,systematic infection,0.5833333333333334
double-stranded DNA virus,infection incidence rate,0.6132653061224489
double-stranded DNA virus,virus host,0.5928571428571429
double-stranded DNA virus,double-stranded RNA virus,0.93
double-stranded DNA virus,pathogen portal of entry role,0.5981481481481481
double-stranded DNA virus,virus transcription stage,0.63
double-stranded DNA virus,infectious disease lifetime prevalence,0.5928571428571429
double-stranded DNA virus,toxin disposition,0.5928571428571429
double-stranded DNA virus,pathogen birth temporal region,0.5772727272727273
double-stranded DNA virus,lower respiratory tract disease,0.6285714285714286
double-stranded DNA virus,infectious disease incidence proportion,0.60625
double-stranded DNA virus,opportunistic pathogen,0.598936170212766
double-stranded DNA virus,virus generative stage,0.598936170212766
double-stranded DNA virus,acute infectious disease course,0.6285714285714286
double-stranded DNA virus,cidal agent disposition,0.6166666666666667
double-stranded DNA virus,infectious disorder,0.609090909090909
double-stranded DNA virus,genetic resistance to pathogen,0.5954545454545455
double-stranded DNA virus,subclinical infection,0.6021739130434782
double-stranded DNA virus,appearance of disorder,0.6414893617021277
double-stranded DNA virus,simple infection,0.5719512195121951
double-stranded DNA virus,droplet pathogen transmission process,0.6435483870967742
double-stranded DNA virus,parasiticidal disposition,0.59
double-stranded DNA virus,infectious disease sporadicity,0.5954545454545455
double-stranded DNA virus,communicability end process boundary,0.6467213114754098
double-stranded DNA virus,infection incidence proportion profile,0.5928571428571429
double-stranded DNA virus,pathogen transporter,0.6277777777777778
double-stranded DNA virus,transmissibility disposition,0.6009433962264151
double-stranded DNA virus,latency end process boundary,0.619811320754717
double-stranded DNA virus,infectious disease epidemic,0.6038461538461539
double-stranded DNA virus,disease transmission model,0.6264705882352941
double-stranded DNA virus,endotoxin disposition,0.6239130434782608
double-stranded DNA virus,pathologically immunosuppressed organism,0.6038461538461539
double-stranded DNA virus,negative-sense single-stranded RNA virus,0.7576923076923078
double-stranded DNA virus,pathogen vehicle,0.5963414634146341
double-stranded DNA virus,cytotoxin disposition,0.6021739130434782
double-stranded DNA virus,community-acquired infection,0.619811320754717
double-stranded DNA virus,pathogen vector,0.6
double-stranded DNA virus,pathogen vehicle role,0.6021739130434782
double-stranded DNA virus,chronic infectious disease course,0.6051724137931035
double-stranded DNA virus,nursing-home acquired infection,0.5928571428571429
double-stranded DNA virus,COVID-19 epidemic,0.569047619047619
double-stranded DNA virus,secondary infection,0.5863636363636363
double-stranded DNA virus,nucleic acid,0.6121621621621621
double-stranded DNA virus,infection start temporal region,0.5928571428571429
double-stranded DNA virus,infection incidence,0.5863636363636363
double-stranded DNA virus,virus disorder,0.6038461538461539
double-stranded DNA virus,primary infection,0.569047619047619
double-stranded DNA virus,process of establishing an infection,0.6139344262295081
double-stranded DNA virus,incubation end process boundary,0.6285714285714286
double-stranded DNA virus,SARS-CoV-2 disorder,0.609090909090909
double-stranded DNA virus,collective pathogenic disposition,0.6224137931034482
double-stranded DNA virus,neurotoxin disposition,0.598936170212766
double-stranded DNA virus,pathogen death process boundary,0.6107142857142857
double-stranded DNA virus,immunosuppressed organism,0.65
double-stranded DNA virus,latency end temporal region,0.6230769230769231
double-stranded DNA virus,virus adhesion susceptible cell,0.6107142857142857
double-stranded DNA virus,collective disposition,0.6414893617021277
double-stranded DNA virus,infection,0.5382352941176471
double-stranded DNA virus,static agent disposition,0.6132653061224489
double-stranded DNA virus,T cell receptor complex,0.5541666666666667
double-stranded DNA virus,respiratory system disease,0.6264705882352941
double-stranded DNA virus,indirect pathogen transmission process,0.6246031746031746
double-stranded DNA virus,organism population,0.609090909090909
double-stranded DNA virus,infectious disease control strategy,0.6
double-stranded DNA virus,infectious disease pandemic,0.6230769230769231
double-stranded DNA virus,immunosuppressive disposition,0.6166666666666667
double-stranded DNA virus,innate immune response,0.598936170212766
double-stranded DNA virus,pathogenic disposition,0.598936170212766
double-stranded DNA virus,viral disease course,0.6277777777777778
double-stranded DNA virus,intracellular infection,0.5958333333333333
double-stranded DNA virus,secondary infection role,0.5928571428571429
double-stranded DNA virus,metastatic infection,0.6055555555555556
double-stranded DNA virus,infectious disposition,0.598936170212766
double-stranded DNA virus,acute infection,0.6
double-stranded DNA virus,bacteriostatic disposition,0.6264705882352941
double-stranded DNA virus,immunity to pathogen,0.5611111111111111
double-stranded DNA virus,bactericidal disposition,0.6132653061224489
double-stranded DNA virus,source of infection role,0.6132653061224489
double-stranded DNA virus,pathogen host,0.581578947368421
double-stranded DNA virus,acquired immunodeficiency,0.59
double-stranded DNA virus,chronic infection,0.569047619047619
double-stranded DNA virus,invasion disposition,0.5833333333333334
double-stranded DNA virus,disease course,0.6294871794871795
double-stranded DNA virus,infectious disease course,0.63
double-stranded DNA virus,viricidal disposition,0.5804347826086956
double-stranded DNA virus,acquired immunity to infectious agent,0.6112903225806451
double-stranded DNA virus,complex infection,0.5928571428571429
double-stranded DNA virus,COVID-19 disease incidence proportion,0.6112903225806451
double-stranded DNA virus,coronavirus disease course,0.6264705882352941
double-stranded DNA virus,infection incidence proportion,0.5954545454545455
double-stranded DNA virus,respiratory droplet virus fomite,0.6605263157894737
double-stranded DNA virus,susceptible organism,0.65
double-stranded DNA virus,pathogen vector role,0.5833333333333334
double-stranded DNA virus,pathogen portal of exit site,0.6009433962264151
double-stranded DNA virus,infectious disease prevalence,0.5981481481481481
double-stranded DNA virus,organism substance,0.636046511627907
double-stranded DNA virus,disposition,0.5888888888888889
double-stranded DNA virus,single-stranded DNA virus,0.87
double-stranded DNA virus,viral disease,0.6078947368421053
double-stranded DNA virus,primary infection role,0.598936170212766
double-stranded DNA virus,adhesion disposition,0.6277777777777778
double-stranded DNA virus,pathogen portal of entry site,0.5981481481481481
double-stranded DNA virus,infection incidence profile,0.6038461538461539
double-stranded DNA virus,disease,0.60625
double-stranded DNA virus,primary infectious disposition,0.5954545454545455
double-stranded DNA virus,pathogen host role,0.5895348837209302
double-stranded DNA virus,infection prevalence,0.5833333333333334
double-stranded DNA virus,double-stranded DNA retrovirus,0.9045454545454545
double-stranded DNA virus,humoral immune response,0.6166666666666667
double-stranded DNA virus,coronavirus disorder,0.65
double-stranded DNA virus,infectious pathogen transmissibility,0.5975409836065574
double-stranded DNA virus,pathogen surveillance,0.6021739130434782
double-stranded DNA virus,immunodeficient organism,0.6132653061224489
double-stranded DNA virus,pathogen,0.5409090909090909
double-stranded DNA virus,pathogen birth process boundary,0.6107142857142857
double-stranded DNA virus,infectious human pathogen,0.59
double-stranded DNA virus,subclinical virus infection,0.6615384615384616
double-stranded DNA virus,resistance to pathogen,0.6202127659574468
double-stranded DNA virus,establishment of localization in virus host,0.6558823529411765
double-stranded DNA virus,virus attachment stage,0.6202127659574468
double-stranded DNA virus,negative regulation of immune response,0.6087301587301588
double-stranded DNA virus,virus synthesis stage,0.5804347826086956
double-stranded DNA virus,SARS-COV-2 adhesion disposition,0.6107142857142857
double-stranded DNA virus,pathogen portal of exit role,0.6009433962264151
double-stranded DNA virus,invasive disposition,0.5833333333333334
double-stranded DNA virus,re-emerging pathogen,0.5833333333333334
double-stranded DNA virus,long-term non-progressing infectious disease course,0.6078947368421053
double-stranded DNA virus,viral disease epidemic,0.598936170212766
double-stranded DNA virus,fungicidal disposition,0.598936170212766
double-stranded DNA virus,viral disease pandemic,0.6202127659574468
double-stranded DNA virus,virus penetration stage,0.6166666666666667
double-stranded DNA virus,pathogen seroprevalence,0.5958333333333333
double-stranded DNA virus,acute respiratory distress syndrome,0.6166666666666667
double-stranded DNA virus,infectious disease endemicity,0.5981481481481481
double-stranded DNA virus,contact pathogen transmission process,0.6112903225806451
double-stranded DNA virus,disorder,0.6318181818181818
double-stranded DNA virus,herd immunity to infectious organism,0.5975409836065574
double-stranded DNA virus,extracellular infection,0.6166666666666667
double-stranded DNA virus,pathogen transporter role,0.63
double-stranded DNA virus,transmission interval,0.6239130434782608
double-stranded DNA virus,exotoxin disposition,0.6055555555555556
double-stranded DNA virus,infection start process boundary,0.6078947368421053
double-stranded DNA virus,infectious disease control objective specification,0.5833333333333334
double-stranded DNA virus,immune population,0.5928571428571429
double-stranded DNA virus,opportunistic infectious disposition,0.6139344262295081
double-stranded DNA virus,process of establishing viral infection,0.60625
double-stranded DNA virus,enterotoxin disposition,0.6166666666666667
double-stranded DNA virus,COVID-19 disease course,0.6166666666666667
double-stranded DNA virus,infectious disease incidence rate,0.6224137931034482
double-stranded DNA virus,disordered virus,0.7426829268292683
double-stranded DNA virus,collective resistance disposition,0.656896551724138
double-stranded DNA virus,adaptive immune response,0.6132653061224489
double-stranded DNA virus,fungistatic disposition,0.6166666666666667
double-stranded DNA virus,organism,0.6318181818181818
double-stranded DNA virus,virus uncoating stage,0.6021739130434782
double-stranded DNA virus,local infection,0.575
double-stranded DNA virus,establishment of a clinically abnormal colony,0.5928571428571429
double-stranded DNA virus,coronavirus disease,0.6545454545454545
double-stranded DNA virus,positive-sense single-stranded RNA virus,0.7730769230769231
double-stranded DNA virus,horizontal pathogen transmission process,0.6192307692307693
double-stranded DNA virus,hospital-acquired infection,0.6230769230769231
double-stranded DNA virus,pathogen death temporal region,0.6136363636363636
double-stranded DNA virus,emerging pathogen,0.569047619047619
double-stranded DNA virus,pathogen transmission process,0.6351851851851852
transmission interval,communicability end temporal region,0.6285714285714286
transmission interval,infection end temporal region,0.67
transmission interval,incubation end temporal region,0.6656862745098039
transmission interval,B cell receptor complex,0.5409090909090909
transmission interval,infectious disease lifetime prevalence,0.6703389830508475
transmission interval,acute infectious disease course,0.6038461538461539
transmission interval,droplet pathogen transmission process,0.6913793103448276
transmission interval,communicability end process boundary,0.5903508771929825
transmission interval,latency end process boundary,0.5928571428571429
transmission interval,disease transmission model,0.7691489361702127
transmission interval,chronic infectious disease course,0.6166666666666667
transmission interval,latency interval,0.7472972972972972
transmission interval,incubation end process boundary,0.6038461538461539
transmission interval,latency end temporal region,0.6375
transmission interval,anatomical space,0.6121621621621621
transmission interval,T cell receptor complex,0.5636363636363636
transmission interval,indirect pathogen transmission process,0.6872881355932203
transmission interval,communicability interval,0.7166666666666667
transmission interval,viral disease course,0.6207317073170732
transmission interval,disease course,0.5928571428571429
transmission interval,infectious disease course,0.6021739130434782
transmission interval,coronavirus disease course,0.6202127659574468
transmission interval,incubation interval,0.775
transmission interval,contact tracing,0.6166666666666667
transmission interval,eclipse interval,0.7472972972972972
transmission interval,long-term non-progressing infectious disease course,0.6305555555555555
transmission interval,contact pathogen transmission process,0.6913793103448276
transmission interval,transmission interval,0.95
transmission interval,COVID-19 lifetime prevalence,0.6336734693877552
transmission interval,COVID-19 disease course,0.5636363636363636
transmission interval,establishment of a clinically abnormal colony,0.6166666666666667
transmission interval,horizontal pathogen transmission process,0.6795081967213115
transmission interval,pathogen transmission process,0.73
transmission interval,cell space,0.5145161290322581
complex infection,virus aggregate,0.54375
complex infection,source of infection,0.7833333333333333
complex infection,virostatic disposition,0.6294871794871795
complex infection,zoonotic disposition,0.6391891891891892
complex infection,infectious disease mortality rate,0.61
complex infection,infection incidence rate profile,0.6336734693877552
complex infection,infectious structure aggregate,0.6202127659574468
complex infection,communicability end temporal region,0.6423076923076922
complex infection,subclinical coronavirus infection,0.69
complex infection,infection end temporal region,0.6673913043478261
complex infection,infectious disease,0.6785714285714286
complex infection,SARS-CoV-2 incidence rate,0.6404761904761905
complex infection,double-stranded DNA virus,0.5928571428571429
complex infection,incubation end temporal region,0.6627659574468084
complex infection,site of infection,0.7735294117647058
complex infection,virulence factor disposition,0.65
complex infection,viral adhesion disposition,0.636046511627907
complex infection,parasitostatic disposition,0.6127906976744186
complex infection,infectious disease incidence,0.65
complex infection,reverse zoonotic disposition,0.6277777777777778
complex infection,subclinical SARS-CoV-2 infection,0.6948979591836735
complex infection,virus translation stage,0.6
complex infection,disease surveillance objective specification,0.630327868852459
complex infection,virus release stage,0.5611111111111111
complex infection,macromolecular complex,0.6551282051282051
complex infection,asymptomatic infectious structure carrier,0.6396551724137931
complex infection,source of infection site,0.7426829268292683
complex infection,architectual structure,0.5782051282051281
complex infection,virus replication,0.6852941176470588
complex infection,B cell receptor complex,0.625
complex infection,systematic infection,0.7472972972972972
complex infection,infection incidence rate,0.6695121951219513
complex infection,virus host,0.524074074074074
complex infection,double-stranded RNA virus,0.5928571428571429
complex infection,virus transcription stage,0.6166666666666667
complex infection,infectious disease lifetime prevalence,0.6318181818181818
complex infection,toxin disposition,0.6852941176470588
complex infection,lower respiratory tract disease,0.5958333333333333
complex infection,infectious disease incidence proportion,0.6642857142857143
complex infection,virus generative stage,0.5782051282051281
complex infection,acute infectious disease course,0.6791666666666666
complex infection,cidal agent disposition,0.675
complex infection,infectious disorder,0.6722222222222223
complex infection,subclinical infection,0.7657894736842106
complex infection,appearance of disorder,0.6038461538461539
complex infection,simple infection,0.8742424242424243
complex infection,parasiticidal disposition,0.6404761904761905
complex infection,infectious disease sporadicity,0.6202127659574468
complex infection,communicability end process boundary,0.619811320754717
complex infection,acellular structure aggregate,0.5804347826086956
complex infection,infection incidence proportion profile,0.65
complex infection,transmissibility disposition,0.6277777777777778
complex infection,latency end process boundary,0.6055555555555556
complex infection,infectious disease epidemic,0.6318181818181818
complex infection,disease transmission model,0.5895348837209302
complex infection,endotoxin disposition,0.6605263157894737
complex infection,negative-sense single-stranded RNA virus,0.5728070175438597
complex infection,infectious structure host role,0.6202127659574468
complex infection,COVID-19 incidence rate,0.65
complex infection,cytotoxin disposition,0.6868421052631578
complex infection,community-acquired infection,0.7611111111111112
complex infection,chronic infectious disease course,0.67
complex infection,nursing-home acquired infection,0.7208333333333333
complex infection,COVID-19 epidemic,0.6264705882352941
complex infection,secondary infection,0.7833333333333333
complex infection,infection start temporal region,0.6583333333333334
complex infection,infection incidence,0.7
complex infection,virus disorder,0.5467741935483871
complex infection,acellular structure,0.5888888888888889
complex infection,primary infection,0.7735294117647058
complex infection,process of establishing an infection,0.6952830188679244
complex infection,incubation end process boundary,0.5958333333333333
complex infection,SARS-CoV-2 disorder,0.5888888888888889
complex infection,collective pathogenic disposition,0.67
complex infection,neurotoxin disposition,0.6551282051282051
complex infection,latency end temporal region,0.6545454545454545
complex infection,infectious structure,0.6662162162162162
complex infection,virus adhesion susceptible cell,0.575
complex infection,collective disposition,0.7064102564102563
complex infection,infection,0.7961538461538461
complex infection,static agent disposition,0.6451219512195122
complex infection,T cell receptor complex,0.625
complex infection,infectious structure host,0.6404761904761905
complex infection,respiratory system disease,0.5662790697674418
complex infection,communicability interval,0.6451219512195122
complex infection,infectious disease control strategy,0.6230769230769231
complex infection,infectious disease pandemic,0.6545454545454545
complex infection,infectious structure generative stage,0.6166666666666667
complex infection,immunosuppressive disposition,0.6456521739130434
complex infection,disordered prion,0.6318181818181818
complex infection,pathogenic disposition,0.6551282051282051
complex infection,viral disease course,0.6121621621621621
complex infection,intracellular infection,0.75
complex infection,secondary infection role,0.7426829268292683
complex infection,metastatic infection,0.7743243243243243
complex infection,cell,0.5452380952380953
complex infection,infectious disposition,0.6807692307692308
complex infection,acute infection,0.825
complex infection,bacteriostatic disposition,0.636046511627907
complex infection,epitope site,0.656896551724138
complex infection,bactericidal disposition,0.6451219512195122
complex infection,source of infection role,0.7426829268292683
complex infection,chronic infection,0.8029411764705883
complex infection,invasion disposition,0.6391891891891892
complex infection,disease course,0.5790322580645162
complex infection,infectious disease course,0.6404761904761905
complex infection,viricidal disposition,0.6605263157894737
complex infection,complex infection,0.95
complex infection,COVID-19 disease incidence proportion,0.6722222222222223
complex infection,coronavirus disease course,0.6127906976744186
complex infection,infection incidence proportion,0.6840425531914894
complex infection,respiratory droplet virus fomite,0.6132653061224489
complex infection,pathogen portal of exit site,0.6277777777777778
complex infection,infectious disease prevalence,0.6456521739130434
complex infection,disposition,0.6642857142857143
complex infection,single-stranded DNA virus,0.569047619047619
complex infection,COVID-19 mortality rate,0.6
complex infection,viral disease,0.5833333333333334
complex infection,primary infection role,0.732051282051282
complex infection,adhesion disposition,0.6391891891891892
complex infection,pathogen portal of entry site,0.6239130434782608
complex infection,infection incidence profile,0.6545454545454545
complex infection,contagiousness,0.6758064516129032
complex infection,disease,0.5333333333333333
complex infection,symptomatic infectious structure carrier,0.6429824561403508
complex infection,site,0.5452380952380953
complex infection,primary infectious disposition,0.6840425531914894
complex infection,infection prevalence,0.6932432432432433
complex infection,coronavirus disorder,0.5851351351351352
complex infection,SARS-COV-2 adhesion susceptible cell,0.6009433962264151
complex infection,subclinical virus infection,0.7227272727272727
complex infection,establishment of localization in virus host,0.6
complex infection,virus attachment stage,0.5782051282051281
complex infection,virus synthesis stage,0.5552631578947369
complex infection,SARS-COV-2 adhesion disposition,0.6375
complex infection,invasive disposition,0.6391891891891892
complex infection,long-term non-progressing infectious disease course,0.6411764705882353
complex infection,viral disease epidemic,0.6038461538461539
complex infection,communicability start temporal region,0.6351851851851852
complex infection,fungicidal disposition,0.6551282051282051
complex infection,viral disease pandemic,0.6038461538461539
complex infection,virus penetration stage,0.65
complex infection,acute respiratory distress syndrome,0.5846153846153846
complex infection,infectious disease endemicity,0.6456521739130434
complex infection,disorder,0.53
complex infection,communicability,0.6375
complex infection,extracellular infection,0.75
complex infection,exotoxin disposition,0.6662162162162162
complex infection,immunoglobulin complex,0.6294871794871795
complex infection,infection start process boundary,0.6336734693877552
complex infection,action specification,0.7472972972972972
complex infection,SARS-CoV-2 synthesis stage,0.5895348837209302
complex infection,infectious disease control objective specification,0.6291044776119403
complex infection,opportunistic infectious disposition,0.6764150943396227
complex infection,quality,0.575
complex infection,process of establishing viral infection,0.6821428571428573
complex infection,enterotoxin disposition,0.65
complex infection,polymerase chain reaction,0.7357142857142857
complex infection,COVID-19 disease course,0.625
complex infection,infectious disease incidence rate,0.63
complex infection,communicability start process boundary,0.5954545454545455
complex infection,disordered virus,0.5712121212121213
complex infection,collective resistance disposition,0.69
complex infection,fungistatic disposition,0.625
complex infection,virus uncoating stage,0.6078947368421053
complex infection,local infection,0.825
complex infection,establishment of a clinically abnormal colony,0.5790322580645162
complex infection,coronavirus disease,0.5888888888888889
complex infection,positive-sense single-stranded RNA virus,0.5903508771929825
complex infection,hospital-acquired infection,0.7681818181818181
complex infection,cell space,0.5981481481481481
infected population,angiotensin-converting enzyme 2,0.59
infected population,infectious disease mortality rate,0.6807692307692308
infected population,infection incidence rate profile,0.6656862745098039
infected population,infectious structure aggregate,0.6540816326530612
infected population,communicability end temporal region,0.6722222222222223
infected population,infection end temporal region,0.7625
infected population,infectious disease,0.6932432432432433
infected population,SARS-CoV-2 incidence rate,0.6318181818181818
infected population,incubation end temporal region,0.7153061224489795
infected population,normal resident microbiota population,0.7178571428571427
infected population,infectious disease incidence,0.6840425531914894
infected population,reservoir of pathogen role,0.65
infected population,disease surveillance objective specification,0.6563492063492063
infected population,infectious agent host role,0.6944444444444444
infected population,asymptomatic infectious structure carrier,0.6166666666666667
infected population,B cell receptor complex,0.6166666666666667
infected population,passive immunization against infectious agent,0.60625
infected population,infection incidence rate,0.6825581395348838
infected population,double-stranded RNA virus,0.609090909090909
infected population,pathogen portal of entry role,0.6166666666666667
infected population,infectious disease lifetime prevalence,0.6605263157894737
infected population,lower respiratory tract disease,0.59
infected population,infectious disease incidence proportion,0.7258620689655172
infected population,acute infectious disease course,0.65
infected population,infectious disorder,0.7131578947368421
infected population,role,0.5369565217391304
infected population,appearance of disorder,0.6207317073170732
infected population,infectious disease sporadicity,0.6948979591836735
infected population,mutualist role,0.6015151515151516
infected population,communicability end process boundary,0.6318181818181818
infected population,infectious agent colony,0.7357142857142857
infected population,latency end process boundary,0.6414893617021277
infected population,infectious disease epidemic,0.6673913043478261
infected population,infectious agent generative stage,0.6615384615384616
infected population,disease transmission model,0.6277777777777778
infected population,negative-sense single-stranded RNA virus,0.6025423728813559
infected population,infectious structure host role,0.6744897959183673
infected population,susceptible population,0.7914634146341464
infected population,COVID-19 incidence rate,0.6404761904761905
infected population,pathogen vehicle role,0.625
infected population,chronic infectious disease course,0.6423076923076922
infected population,asymptomatic infectious agent carrier,0.6464285714285714
infected population,mechanical vector role,0.6207317073170732
infected population,virus disorder,0.5712121212121213
infected population,sterilizing immunity to infectious agent,0.6194915254237288
infected population,establishment of localization in human host,0.6274193548387097
infected population,diseased population,0.8447368421052631
infected population,incubation end process boundary,0.67
infected population,SARS-CoV-2 disorder,0.5552631578947369
infected population,dead-end host role,0.6391891891891892
infected population,definitive host role,0.6551282051282051
infected population,latency end temporal region,0.6891304347826087
infected population,innate immunity to infectious agent,0.6351851851851852
infected population,infectious structure,0.6807692307692308
infected population,T cell receptor complex,0.6166666666666667
infected population,asymptomatic carrier role,0.5863636363636363
infected population,infectious structure host,0.6772727272727272
infected population,infectious agent population,0.8413043478260869
infected population,respiratory system disease,0.5611111111111111
infected population,leukocyte-mediated immunity to infectious agent,0.6166666666666667
infected population,organism population,0.7657894736842106
infected population,humoral immunity to infectious agent,0.6318181818181818
infected population,infectious disease control strategy,0.6722222222222223
infected population,infectious disease pandemic,0.6891304347826087
infected population,infectious structure generative stage,0.6464285714285714
infected population,disordered prion,0.7071428571428571
infected population,viral disease course,0.6038461538461539
infected population,secondary infection role,0.6593023255813953
infected population,passive immunity to infectious agent,0.6318181818181818
infected population,infectious disposition,0.7670731707317073
infected population,vaccination against infectious agent,0.6318181818181818
infected population,susceptibility to infectious agent,0.6386792452830189
infected population,country,0.6038461538461539
infected population,source of infection role,0.6593023255813953
infected population,disease course,0.6318181818181818
infected population,infectious disease course,0.6772727272727272
infected population,acquired immunity to infectious agent,0.6285714285714286
infected population,COVID-19 disease incidence proportion,0.6821428571428573
infected population,coronavirus disease course,0.5833333333333334
infected population,biological vehicle role,0.6166666666666667
infected population,symptomatic infectious agent carrier,0.65
infected population,symbiont role,0.6375
infected population,parasite role,0.6375
infected population,pathogen vector role,0.6294871794871795
infected population,infectious disease prevalence,0.6791666666666666
infected population,infected population,0.95
infected population,COVID-19 mortality rate,0.6166666666666667
infected population,hospital facility,0.5888888888888889
infected population,viral disease,0.54375
infected population,primary infection role,0.6695121951219513
infected population,biological role,0.5970588235294118
infected population,disease,0.5653846153846154
infected population,symptomatic infectious structure carrier,0.6194915254237288
infected population,biological vector role,0.6207317073170732
infected population,primary infectious disposition,0.7153061224489795
infected population,pathogen host role,0.6121621621621621
infected population,symptomatic carrier role,0.5895348837209302
infected population,coronavirus disorder,0.5782051282051281
infected population,infectious pathogen transmissibility,0.6681818181818181
infected population,intermediate host role,0.6695121951219513
infected population,host role,0.5928571428571429
infected population,infectious human pathogen,0.7227272727272727
infected population,colonization of human,0.65
infected population,immunization against infectious agent,0.6285714285714286
infected population,pathogen portal of exit role,0.6202127659574468
infected population,infectious agent host,0.725
infected population,long-term non-progressing infectious disease course,0.5928571428571429
infected population,viral disease epidemic,0.5963414634146341
infected population,commensal role,0.6015151515151516
infected population,epitope role,0.6435483870967742
infected population,blood,0.5333333333333333
infected population,viral disease pandemic,0.6207317073170732
infected population,infectious disease endemicity,0.6583333333333334
infected population,disorder,0.5611111111111111
infected population,herd immunity to infectious organism,0.6318181818181818
infected population,pathogen transporter role,0.609090909090909
infected population,infectious agent reservoir,0.6944444444444444
infected population,antigen role,0.6435483870967742
infected population,infectious disease control objective specification,0.6673913043478261
infected population,symbiont host role,0.6391891891891892
infected population,immune population,0.8388888888888889
infected population,opportunistic infectious disposition,0.6863636363636364
infected population,fomite role,0.65
infected population,COVID-19 disease course,0.5928571428571429
infected population,infectious disease incidence rate,0.6615384615384616
infected population,single-stranded RNA retrovirus,0.6540816326530612
infected population,active immunization against infectious agent,0.6087301587301588
infected population,disordered virus,0.6214285714285714
infected population,reagent role,0.6112903225806451
infected population,infectious agent,0.7357142857142857
infected population,establishment of a clinically abnormal colony,0.590625
infected population,coronavirus disease,0.5552631578947369
infected population,positive-sense single-stranded RNA virus,0.6025423728813559
infected population,drug susceptibility of infectious agent,0.6224137931034482
primary pathogen,extended organism,0.5712121212121213
primary pathogen,virus aggregate,0.6435483870967742
primary pathogen,source of infection,0.5928571428571429
primary pathogen,infectious disease mortality rate,0.6132653061224489
primary pathogen,infection incidence rate profile,0.575
primary pathogen,communicability end temporal region,0.6068627450980393
primary pathogen,pathogen generative stage,0.6451219512195122
primary pathogen,pathogen portal of entry,0.65
primary pathogen,subclinical coronavirus infection,0.5928571428571429
primary pathogen,primary pathogen,0.95
primary pathogen,infection end temporal region,0.5833333333333334
primary pathogen,drug-based immunosuppressed organism,0.6038461538461539
primary pathogen,vector control strategy,0.6038461538461539
primary pathogen,infectious disease,0.5676470588235294
primary pathogen,double-stranded DNA virus,0.5475609756097561
primary pathogen,incubation end temporal region,0.6021739130434782
primary pathogen,site of infection,0.6015151515151516
primary pathogen,immunocompetent organism,0.625
primary pathogen,pathogen portal of exit,0.6551282051282051
primary pathogen,infectious disease incidence,0.5636363636363636
primary pathogen,reservoir of pathogen role,0.7357142857142857
primary pathogen,subclinical SARS-CoV-2 infection,0.5958333333333333
primary pathogen,virus translation stage,0.6551282051282051
primary pathogen,disease surveillance objective specification,0.6
primary pathogen,case isolation control strategy,0.598936170212766
primary pathogen,virus release stage,0.65
primary pathogen,infectious agent host role,0.6166666666666667
primary pathogen,source of infection site,0.575
primary pathogen,virus,0.5452380952380953
primary pathogen,quarantine control strategy,0.6127906976744186
primary pathogen,virus replication,0.6924242424242425
primary pathogen,B cell receptor complex,0.5782051282051281
primary pathogen,passive immunization against infectious agent,0.630327868852459
primary pathogen,systematic infection,0.6166666666666667
primary pathogen,infection incidence rate,0.575
primary pathogen,virus host,0.6423076923076922
primary pathogen,double-stranded RNA virus,0.5475609756097561
primary pathogen,pathogen portal of entry role,0.6277777777777778
primary pathogen,virus transcription stage,0.6451219512195122
primary pathogen,infectious disease lifetime prevalence,0.5796296296296296
primary pathogen,pathogen birth temporal region,0.6239130434782608
primary pathogen,lower respiratory tract disease,0.6414893617021277
primary pathogen,infectious disease incidence proportion,0.5772727272727273
primary pathogen,opportunistic pathogen,0.7657894736842106
primary pathogen,virus generative stage,0.6342105263157894
primary pathogen,acute infectious disease course,0.5563829787234043
primary pathogen,cidal agent disposition,0.6294871794871795
primary pathogen,genetic resistance to pathogen,0.7108695652173913
primary pathogen,subclinical infection,0.6121621621621621
primary pathogen,simple infection,0.6375
primary pathogen,droplet pathogen transmission process,0.6386792452830189
primary pathogen,infectious disease sporadicity,0.5804347826086956
primary pathogen,communicability end process boundary,0.6038461538461539
primary pathogen,infection incidence proportion profile,0.5796296296296296
primary pathogen,infectious agent colony,0.6038461538461539
primary pathogen,pathogen transporter,0.6722222222222223
primary pathogen,latency end process boundary,0.609090909090909
primary pathogen,infectious disease epidemic,0.5662790697674418
primary pathogen,infectious agent generative stage,0.5928571428571429
primary pathogen,disease transmission model,0.5928571428571429
primary pathogen,pathologically immunosuppressed organism,0.6107142857142857
primary pathogen,negative-sense single-stranded RNA virus,0.5392857142857143
primary pathogen,cidal agent,0.7092592592592593
primary pathogen,pathogen vehicle,0.7
primary pathogen,community-acquired infection,0.609090909090909
primary pathogen,pathogen vector,0.7080645161290323
primary pathogen,pathogen vehicle role,0.6662162162162162
primary pathogen,chronic infectious disease course,0.5724489795918367
primary pathogen,asymptomatic infectious agent carrier,0.619811320754717
primary pathogen,nursing-home acquired infection,0.6414893617021277
primary pathogen,secondary infection,0.65
primary pathogen,infection start temporal region,0.6202127659574468
primary pathogen,infection incidence,0.5928571428571429
primary pathogen,virus disorder,0.6166666666666667
primary pathogen,sterilizing immunity to infectious agent,0.6285714285714286
primary pathogen,primary infection,0.7833333333333333
primary pathogen,process of establishing an infection,0.6038461538461539
primary pathogen,incubation end process boundary,0.598936170212766
primary pathogen,pathogen death process boundary,0.6414893617021277
primary pathogen,immunosuppressed organism,0.6207317073170732
primary pathogen,latency end temporal region,0.6127906976744186
primary pathogen,innate immunity to infectious agent,0.6264705882352941
primary pathogen,virus adhesion susceptible cell,0.598936170212766
primary pathogen,infection,0.61
primary pathogen,static agent disposition,0.625
primary pathogen,T cell receptor complex,0.5782051282051281
primary pathogen,infectious agent population,0.636046511627907
primary pathogen,respiratory system disease,0.6404761904761905
primary pathogen,leukocyte-mediated immunity to infectious agent,0.5928571428571429
primary pathogen,indirect pathogen transmission process,0.6537037037037037
primary pathogen,organism population,0.7071428571428571
primary pathogen,humoral immunity to infectious agent,0.6423076923076922
primary pathogen,infectious disease control strategy,0.5872549019607843
primary pathogen,parasite,0.7
primary pathogen,infectious disease pandemic,0.5895348837209302
primary pathogen,antibody reagent,0.66875
primary pathogen,viral disease course,0.6166666666666667
primary pathogen,intracellular infection,0.6294871794871795
primary pathogen,secondary infection role,0.625
primary pathogen,metastatic infection,0.6166666666666667
primary pathogen,passive immunity to infectious agent,0.6423076923076922
primary pathogen,vaccination against infectious agent,0.6230769230769231
primary pathogen,acute infection,0.6112903225806451
primary pathogen,susceptibility to infectious agent,0.63
primary pathogen,epitope site,0.6285714285714286
primary pathogen,immunity to pathogen,0.7833333333333333
primary pathogen,source of infection role,0.575
primary pathogen,pathogen host,0.7258620689655172
primary pathogen,chronic infection,0.6318181818181818
primary pathogen,disease course,0.6166666666666667
primary pathogen,infectious disease course,0.5719512195121951
primary pathogen,acquired immunity to infectious agent,0.6386792452830189
primary pathogen,complex infection,0.6015151515151516
primary pathogen,COVID-19 disease incidence proportion,0.5820754716981132
primary pathogen,coronavirus disease course,0.6166666666666667
primary pathogen,infection incidence proportion,0.5804347826086956
primary pathogen,symptomatic infectious agent carrier,0.6230769230769231
primary pathogen,respiratory droplet virus fomite,0.6583333333333334
primary pathogen,susceptible organism,0.6166666666666667
primary pathogen,parasite role,0.6913793103448276
primary pathogen,pathogen vector role,0.6722222222222223
primary pathogen,pathogen portal of exit site,0.6318181818181818
primary pathogen,infectious disease prevalence,0.6055555555555556
primary pathogen,organism substance,0.6264705882352941
primary pathogen,single-stranded DNA virus,0.5719512195121951
primary pathogen,place closure control strategy,0.6021739130434782
primary pathogen,viral disease,0.6224137931034482
primary pathogen,primary infection role,0.7394736842105263
primary pathogen,primary immunodeficiency,0.725
primary pathogen,pathogen portal of entry site,0.6277777777777778
primary pathogen,infection incidence profile,0.5662790697674418
primary pathogen,disease,0.5804347826086956
primary pathogen,site,0.6
primary pathogen,primary infectious disposition,0.7108695652173913
primary pathogen,pathogen host role,0.6852941176470588
primary pathogen,infection prevalence,0.6166666666666667
primary pathogen,infectious pathogen transmissibility,0.6423076923076922
primary pathogen,pathogen surveillance,0.6662162162162162
primary pathogen,immunodeficient organism,0.6
primary pathogen,pathogen,0.7833333333333333
primary pathogen,pathogen birth process boundary,0.6202127659574468
primary pathogen,infectious human pathogen,0.7426829268292683
primary pathogen,subclinical virus infection,0.6127906976744186
primary pathogen,resistance to pathogen,0.7657894736842106
primary pathogen,establishment of localization in virus host,0.5686440677966101
primary pathogen,immunization against infectious agent,0.6386792452830189
primary pathogen,virus attachment stage,0.6605263157894737
primary pathogen,virus synthesis stage,0.6391891891891892
primary pathogen,pathogen portal of exit role,0.6318181818181818
primary pathogen,infectious agent host,0.6121621621621621
primary pathogen,re-emerging pathogen,0.7833333333333333
primary pathogen,long-term non-progressing infectious disease course,0.5694029850746268
primary pathogen,viral disease epidemic,0.6078947368421053
primary pathogen,viral disease pandemic,0.6342105263157894
primary pathogen,virus penetration stage,0.6807692307692308
primary pathogen,pathogen seroprevalence,0.6551282051282051
primary pathogen,infectious disease endemicity,0.5611111111111111
primary pathogen,contact pathogen transmission process,0.6386792452830189
primary pathogen,herd immunity to infectious organism,0.6230769230769231
primary pathogen,extracellular infection,0.6294871794871795
primary pathogen,pathogen transporter role,0.6451219512195122
primary pathogen,infectious agent reservoir,0.5928571428571429
primary pathogen,infection start process boundary,0.6166666666666667
primary pathogen,infectious disease control objective specification,0.5863636363636363
primary pathogen,process of establishing viral infection,0.5954545454545455
primary pathogen,COVID-19 disease course,0.5782051282051281
primary pathogen,infectious disease incidence rate,0.5724489795918367
primary pathogen,active immunization against infectious agent,0.6166666666666667
primary pathogen,disordered virus,0.54375
primary pathogen,organism,0.575
primary pathogen,virus uncoating stage,0.6391891891891892
primary pathogen,local infection,0.6112903225806451
primary pathogen,infectious agent,0.6375
primary pathogen,establishment of a clinically abnormal colony,0.5811475409836065
primary pathogen,coronavirus disease,0.6214285714285714
primary pathogen,positive-sense single-stranded RNA virus,0.5571428571428572
primary pathogen,horizontal pathogen transmission process,0.6642857142857143
primary pathogen,hospital-acquired infection,0.636046511627907
primary pathogen,pathogen death temporal region,0.6456521739130434
primary pathogen,emerging pathogen,0.7833333333333333
primary pathogen,drug susceptibility of infectious agent,0.6136363636363636
primary pathogen,static agent,0.6642857142857143
primary pathogen,pathogen transmission process,0.6277777777777778
viral load,information content entity,0.5888888888888889
viral load,viral adhesion disposition,0.6722222222222223
viral load,B cell receptor complex,0.5409090909090909
viral load,directive information content entity,0.5804347826086956
viral load,viral plaque assay,0.7357142857142857
viral load,descriptive information content entity,0.575
viral load,T cell receptor complex,0.5409090909090909
viral load,viral disease course,0.6833333333333332
viral load,viral envelope,0.7833333333333333
viral load,viral capsid,0.8136363636363637
viral load,place closure control strategy,0.575
viral load,viral disease,0.7543478260869566
viral load,designative information content entity,0.575
viral load,viral disease epidemic,0.7
viral load,viral disease pandemic,0.7
viral load,negative regulation of viral process,0.6021739130434782
viral load,process of establishing viral infection,0.5928571428571429
viral load,viral load,0.95
viral load,establishment of a clinically abnormal colony,0.5772727272727273
viral load,viral pathogenesis,0.7
opportunistic infectious disposition,virostatic disposition,0.743103448275862
opportunistic infectious disposition,information content entity,0.6274193548387097
opportunistic infectious disposition,zoonotic disposition,0.7714285714285714
opportunistic infectious disposition,infectious disease mortality rate,0.696376811594203
opportunistic infectious disposition,infection incidence rate profile,0.6411764705882353
opportunistic infectious disposition,infectious structure aggregate,0.6469696969696969
opportunistic infectious disposition,communicability end temporal region,0.6471830985915493
opportunistic infectious disposition,geographical entity,0.6136363636363636
opportunistic infectious disposition,biological regulation,0.6429824561403508
opportunistic infectious disposition,surveillance process,0.5928571428571429
opportunistic infectious disposition,infection end temporal region,0.6807692307692308
opportunistic infectious disposition,vector control strategy,0.6025423728813559
opportunistic infectious disposition,infectious disease,0.7277777777777777
opportunistic infectious disposition,SARS-CoV-2 incidence rate,0.6139344262295081
opportunistic infectious disposition,incubation end temporal region,0.6469696969696969
opportunistic infectious disposition,resistant entity,0.6230769230769231
opportunistic infectious disposition,virulence factor disposition,0.778125
opportunistic infectious disposition,viral adhesion disposition,0.7241935483870968
opportunistic infectious disposition,parasitostatic disposition,0.7564516129032257
opportunistic infectious disposition,infectious disease incidence,0.73125
opportunistic infectious disposition,negative regulation of production,0.6673913043478261
opportunistic infectious disposition,reverse zoonotic disposition,0.73125
opportunistic infectious disposition,establishment of localization in host,0.6554794520547945
opportunistic infectious disposition,disease surveillance objective specification,0.6625
opportunistic infectious disposition,case isolation control strategy,0.6141791044776119
opportunistic infectious disposition,infectious agent host role,0.6919354838709677
opportunistic infectious disposition,macromolecular complex,0.5706896551724138
opportunistic infectious disposition,material entity,0.5872549019607843
opportunistic infectious disposition,asymptomatic infectious structure carrier,0.7097402597402598
opportunistic infectious disposition,architectual structure,0.6224137931034482
opportunistic infectious disposition,quarantine control strategy,0.6404761904761905
opportunistic infectious disposition,B cell receptor complex,0.5855932203389831
opportunistic infectious disposition,passive immunization against infectious agent,0.6845679012345678
opportunistic infectious disposition,infection incidence rate,0.65
opportunistic infectious disposition,colonized host,0.63
opportunistic infectious disposition,virus host,0.6021739130434782
opportunistic infectious disposition,entity,0.5452380952380953
opportunistic infectious disposition,infectious disease lifetime prevalence,0.7067567567567568
opportunistic infectious disposition,toxin disposition,0.7330188679245283
opportunistic infectious disposition,lower respiratory tract disease,0.6291044776119403
opportunistic infectious disposition,infectious disease incidence proportion,0.7166666666666667
opportunistic infectious disposition,opportunistic pathogen,0.760344827586207
opportunistic infectious disposition,acute infectious disease course,0.7335820895522389
opportunistic infectious disposition,cidal agent disposition,0.7211864406779661
opportunistic infectious disposition,infectious disorder,0.7227272727272727
opportunistic infectious disposition,parasiticidal disposition,0.7614754098360657
opportunistic infectious disposition,infectious disease sporadicity,0.7227272727272727
opportunistic infectious disposition,communicability end process boundary,0.6444444444444444
opportunistic infectious disposition,directive information content entity,0.6444444444444444
opportunistic infectious disposition,acellular structure aggregate,0.573076923076923
opportunistic infectious disposition,infectious agent colony,0.6872881355932203
opportunistic infectious disposition,transmissibility disposition,0.746875
opportunistic infectious disposition,latency end process boundary,0.621875
opportunistic infectious disposition,colonization of host,0.6642857142857143
opportunistic infectious disposition,infectious disease epidemic,0.7198412698412698
opportunistic infectious disposition,infectious agent generative stage,0.6528985507246376
opportunistic infectious disposition,disease transmission model,0.6274193548387097
opportunistic infectious disposition,realizable entity,0.5820754716981132
opportunistic infectious disposition,endotoxin disposition,0.730701754385965
opportunistic infectious disposition,vector surveillance,0.5954545454545455
opportunistic infectious disposition,negative regulation of establishment of localization,0.6545454545454545
opportunistic infectious disposition,infectious structure host role,0.6924242424242425
opportunistic infectious disposition,COVID-19 incidence rate,0.6025423728813559
opportunistic infectious disposition,cytotoxin disposition,0.730701754385965
opportunistic infectious disposition,negative regulation of developmental process,0.6125
opportunistic infectious disposition,host,0.525
opportunistic infectious disposition,chronic infectious disease course,0.7543478260869566
opportunistic infectious disposition,asymptomatic infectious agent carrier,0.7102739726027397
opportunistic infectious disposition,descriptive information content entity,0.6527027027027027
opportunistic infectious disposition,COVID-19 epidemic,0.5820754716981132
opportunistic infectious disposition,negative regulation of replication,0.6642857142857143
opportunistic infectious disposition,sterilizing immunity to infectious agent,0.6868421052631578
opportunistic infectious disposition,establishment of localization in human host,0.639873417721519
opportunistic infectious disposition,diseased population,0.65
opportunistic infectious disposition,acellular structure,0.5590909090909091
opportunistic infectious disposition,incubation end process boundary,0.6440298507462687
opportunistic infectious disposition,collective pathogenic disposition,0.7108695652173913
opportunistic infectious disposition,neurotoxin disposition,0.7258620689655172
opportunistic infectious disposition,dead-end host role,0.5611111111111111
opportunistic infectious disposition,molecular entity,0.5846153846153846
opportunistic infectious disposition,plan specification,0.6537037037037037
opportunistic infectious disposition,definitive host role,0.6285714285714286
opportunistic infectious disposition,latency end temporal region,0.6246031746031746
opportunistic infectious disposition,innate immunity to infectious agent,0.7035211267605633
opportunistic infectious disposition,infectious structure,0.6821428571428573
opportunistic infectious disposition,collective disposition,0.743103448275862
opportunistic infectious disposition,static agent disposition,0.7666666666666666
opportunistic infectious disposition,T cell receptor complex,0.6025423728813559
opportunistic infectious disposition,infectious structure host,0.6959016393442623
opportunistic infectious disposition,infectious agent population,0.7198412698412698
opportunistic infectious disposition,respiratory system disease,0.6274193548387097
opportunistic infectious disposition,entry into host,0.6656862745098039
opportunistic infectious disposition,leukocyte-mediated immunity to infectious agent,0.6789156626506024
opportunistic infectious disposition,adhesion of symbiont to host,0.621875
opportunistic infectious disposition,humoral immunity to infectious agent,0.7138888888888889
opportunistic infectious disposition,infectious disease control strategy,0.6894366197183097
opportunistic infectious disposition,infectious disease pandemic,0.7039682539682539
opportunistic infectious disposition,infectious structure generative stage,0.6417808219178082
opportunistic infectious disposition,immunosuppressive disposition,0.7423076923076922
opportunistic infectious disposition,pathogenic disposition,0.743103448275862
opportunistic infectious disposition,viral disease course,0.5928571428571429
opportunistic infectious disposition,entry into host through host barriers,0.6280821917808219
opportunistic infectious disposition,passive immunity to infectious agent,0.7
opportunistic infectious disposition,infectious disposition,0.8293103448275861
opportunistic infectious disposition,vaccination against infectious agent,0.7
opportunistic infectious disposition,susceptibility to infectious agent,0.6928571428571427
opportunistic infectious disposition,bacteriostatic disposition,0.7403225806451613
opportunistic infectious disposition,bactericidal disposition,0.7166666666666667
opportunistic infectious disposition,pathogen host,0.5928571428571429
opportunistic infectious disposition,invasion disposition,0.7357142857142857
opportunistic infectious disposition,disease course,0.59
opportunistic infectious disposition,infectious disease course,0.7122950819672131
opportunistic infectious disposition,viricidal disposition,0.730701754385965
opportunistic infectious disposition,acquired immunity to infectious agent,0.6965753424657534
opportunistic infectious disposition,complex infection,0.6764150943396227
opportunistic infectious disposition,COVID-19 disease incidence proportion,0.6554794520547945
opportunistic infectious disposition,coronavirus disease course,0.6435483870967742
opportunistic infectious disposition,symptomatic infectious agent carrier,0.7138888888888889
opportunistic infectious disposition,intermediate host,0.6009433962264151
opportunistic infectious disposition,infectious disease prevalence,0.6961538461538461
opportunistic infectious disposition,anatomical entity,0.619811320754717
opportunistic infectious disposition,disposition,0.6840425531914894
opportunistic infectious disposition,infected population,0.6863636363636364
opportunistic infectious disposition,COVID-19 mortality rate,0.5855932203389831
opportunistic infectious disposition,negative regulation of life-sustaining process,0.6329268292682927
opportunistic infectious disposition,place closure control strategy,0.6015151515151516
opportunistic infectious disposition,geopolitical entity,0.6681818181818181
opportunistic infectious disposition,viral disease,0.5724489795918367
opportunistic infectious disposition,adhesion disposition,0.7178571428571427
opportunistic infectious disposition,disease,0.5430232558139535
opportunistic infectious disposition,symptomatic infectious structure carrier,0.7131578947368421
opportunistic infectious disposition,primary infectious disposition,0.8439393939393939
opportunistic infectious disposition,pathogen host role,0.5981481481481481
opportunistic infectious disposition,designative information content entity,0.6391891891891892
opportunistic infectious disposition,infectious pathogen transmissibility,0.6722222222222223
opportunistic infectious disposition,intermediate host role,0.6051724137931035
opportunistic infectious disposition,dead-end host,0.5520408163265306
opportunistic infectious disposition,pathogen surveillance,0.5728070175438597
opportunistic infectious disposition,host role,0.5611111111111111
opportunistic infectious disposition,infectious human pathogen,0.6959016393442623
opportunistic infectious disposition,establishment of localization in virus host,0.6525316455696202
opportunistic infectious disposition,immunization against infectious agent,0.6965753424657534
opportunistic infectious disposition,negative regulation of immune response,0.6391891891891892
opportunistic infectious disposition,immaterial entity,0.6009433962264151
opportunistic infectious disposition,SARS-COV-2 adhesion disposition,0.7335820895522389
opportunistic infectious disposition,invasive disposition,0.7357142857142857
opportunistic infectious disposition,infectious agent host,0.6956140350877194
opportunistic infectious disposition,long-term non-progressing infectious disease course,0.7143678160919541
opportunistic infectious disposition,viral disease epidemic,0.6051724137931035
opportunistic infectious disposition,fungicidal disposition,0.743103448275862
opportunistic infectious disposition,viral disease pandemic,0.5879310344827586
opportunistic infectious disposition,division of geopolitical entity,0.6440298507462687
opportunistic infectious disposition,infectious disease endemicity,0.7115384615384616
opportunistic infectious disposition,negative regulation of viral process,0.6305555555555555
opportunistic infectious disposition,herd immunity to infectious organism,0.7138888888888889
opportunistic infectious disposition,exotoxin disposition,0.7357142857142857
opportunistic infectious disposition,infectious agent reservoir,0.6758064516129032
opportunistic infectious disposition,immunoglobulin complex,0.5879310344827586
opportunistic infectious disposition,COVID-19 pandemic,0.5632075471698114
opportunistic infectious disposition,infectious disease control objective specification,0.6941860465116279
opportunistic infectious disposition,symbiont host role,0.6166666666666667
opportunistic infectious disposition,opportunistic infectious disposition,0.95
opportunistic infectious disposition,negative regulation of biological process,0.6188311688311688
opportunistic infectious disposition,enterotoxin disposition,0.738135593220339
opportunistic infectious disposition,COVID-19 disease course,0.6025423728813559
opportunistic infectious disposition,infectious disease incidence rate,0.7108695652173913
opportunistic infectious disposition,active immunization against infectious agent,0.6875
opportunistic infectious disposition,collective resistance disposition,0.7253623188405797
opportunistic infectious disposition,fungistatic disposition,0.7720338983050847
opportunistic infectious disposition,infectious agent,0.6807692307692308
opportunistic infectious disposition,establishment of a clinically abnormal colony,0.6104938271604938
opportunistic infectious disposition,coronavirus disease,0.65
opportunistic infectious disposition,definitive host,0.6264705882352941
opportunistic infectious disposition,drug susceptibility of infectious agent,0.69
protective resistance,virostatic disposition,0.6825581395348838
protective resistance,information content entity,0.6414893617021277
protective resistance,zoonotic disposition,0.6451219512195122
protective resistance,immune response,0.6722222222222223
protective resistance,infectious disease mortality rate,0.6537037037037037
protective resistance,infection incidence rate profile,0.6386792452830189
protective resistance,communicability end temporal region,0.6285714285714286
protective resistance,infection end temporal region,0.65
protective resistance,SARS-CoV-2 incidence rate,0.6456521739130434
protective resistance,incubation end temporal region,0.6264705882352941
protective resistance,virulence factor disposition,0.6540816326530612
protective resistance,viral adhesion disposition,0.6202127659574468
protective resistance,parasitostatic disposition,0.6840425531914894
protective resistance,reverse zoonotic disposition,0.6540816326530612
protective resistance,establishment of localization in host,0.6051724137931035
protective resistance,infectious agent host role,0.6414893617021277
protective resistance,B cell receptor complex,0.6318181818181818
protective resistance,infection incidence rate,0.65
protective resistance,colonized host,0.6214285714285714
protective resistance,virus host,0.6112903225806451
protective resistance,double-stranded RNA virus,0.6239130434782608
protective resistance,toxin disposition,0.6342105263157894
protective resistance,cidal agent disposition,0.6318181818181818
protective resistance,genetic resistance to pathogen,0.7245098039215686
protective resistance,parasiticidal disposition,0.6673913043478261
protective resistance,communicability end process boundary,0.6254385964912281
protective resistance,directive information content entity,0.6780701754385965
protective resistance,transmissibility disposition,0.5928571428571429
protective resistance,latency end process boundary,0.6540816326530612
protective resistance,colonization of host,0.5963414634146341
protective resistance,endotoxin disposition,0.6404761904761905
protective resistance,negative-sense single-stranded RNA virus,0.6631147540983606
protective resistance,infectious structure host role,0.6460784313725491
protective resistance,COVID-19 incidence rate,0.6318181818181818
protective resistance,cytotoxin disposition,0.6404761904761905
protective resistance,antibiotic resistance,0.7833333333333333
protective resistance,host,0.57
protective resistance,descriptive information content entity,0.6533898305084747
protective resistance,resistance to drug,0.7064102564102563
protective resistance,sterilizing immunity to infectious agent,0.5975409836065574
protective resistance,establishment of localization in human host,0.590625
protective resistance,incubation end process boundary,0.6423076923076922
protective resistance,collective pathogenic disposition,0.6907407407407408
protective resistance,neurotoxin disposition,0.6593023255813953
protective resistance,dead-end host role,0.6038461538461539
protective resistance,definitive host role,0.6695121951219513
protective resistance,latency end temporal region,0.6583333333333334
protective resistance,innate immunity to infectious agent,0.6107142857142857
protective resistance,collective disposition,0.7290697674418604
protective resistance,static agent disposition,0.65
protective resistance,T cell receptor complex,0.6545454545454545
protective resistance,infectious structure host,0.6456521739130434
protective resistance,entry into host,0.6166666666666667
protective resistance,leukocyte-mediated immunity to infectious agent,0.6117647058823529
protective resistance,adhesion of symbiont to host,0.5928571428571429
protective resistance,humoral immunity to infectious agent,0.6078947368421053
protective resistance,immunosuppressive disposition,0.67
protective resistance,innate immune response,0.6825581395348838
protective resistance,pathogenic disposition,0.6593023255813953
protective resistance,entry into host through host barriers,0.6051724137931035
protective resistance,passive immunity to infectious agent,0.6254385964912281
protective resistance,infectious disposition,0.6593023255813953
protective resistance,bacteriostatic disposition,0.6627659574468084
protective resistance,immunity to pathogen,0.5719512195121951
protective resistance,bactericidal disposition,0.65
protective resistance,pathogen host,0.6264705882352941
protective resistance,invasion disposition,0.6207317073170732
protective resistance,viricidal disposition,0.6404761904761905
protective resistance,acquired immunity to infectious agent,0.6051724137931035
protective resistance,intermediate host,0.6342105263157894
protective resistance,disposition,0.6375
protective resistance,COVID-19 mortality rate,0.6318181818181818
protective resistance,adhesion disposition,0.6207317073170732
protective resistance,leukocyte mediated immunity,0.6375
protective resistance,primary infectious disposition,0.6656862745098039
protective resistance,pathogen host role,0.6294871794871795
protective resistance,designative information content entity,0.6364406779661017
protective resistance,humoral immune response,0.6545454545454545
protective resistance,object,0.5981481481481481
protective resistance,intermediate host role,0.636046511627907
protective resistance,dead-end host,0.5970588235294118
protective resistance,host role,0.6166666666666667
protective resistance,resistance to pathogen,0.6825581395348838
protective resistance,establishment of localization in virus host,0.60625
protective resistance,negative regulation of immune response,0.6533898305084747
protective resistance,SARS-COV-2 adhesion disposition,0.6423076923076922
protective resistance,object aggregate,0.6932432432432433
protective resistance,invasive disposition,0.6451219512195122
protective resistance,infectious agent host,0.6404761904761905
protective resistance,fungicidal disposition,0.6127906976744186
protective resistance,herd immunity to infectious organism,0.6254385964912281
protective resistance,exotoxin disposition,0.6451219512195122
protective resistance,action specification,0.6451219512195122
protective resistance,protective resistance,0.95
protective resistance,symbiont host role,0.6038461538461539
protective resistance,opportunistic infectious disposition,0.6605263157894737
protective resistance,enterotoxin disposition,0.6545454545454545
protective resistance,polymerase chain reaction,0.6673913043478261
protective resistance,infectious disease incidence rate,0.6537037037037037
protective resistance,single-stranded RNA retrovirus,0.6068627450980393
protective resistance,collective resistance disposition,0.7833333333333333
protective resistance,adaptive immune response,0.6944444444444444
protective resistance,fungistatic disposition,0.6318181818181818
protective resistance,establishment of a clinically abnormal colony,0.5863636363636363
protective resistance,positive-sense single-stranded RNA virus,0.6795081967213115
protective resistance,definitive host,0.6722222222222223
humoral immune response,immune response,0.8447368421052631
humoral immune response,infectious disease mortality rate,0.6285714285714286
humoral immune response,infection incidence rate profile,0.65
humoral immune response,communicability end temporal region,0.6396551724137931
humoral immune response,surveillance process,0.6825581395348838
humoral immune response,infection end temporal region,0.6423076923076922
humoral immune response,SARS-CoV-2 incidence rate,0.6166666666666667
humoral immune response,incubation end temporal region,0.6575471698113208
humoral immune response,resistant entity,0.6038461538461539
humoral immune response,virus release stage,0.6404761904761905
humoral immune response,B cell receptor complex,0.6239130434782608
humoral immune response,passive immunization against infectious agent,0.6264705882352941
humoral immune response,infection incidence rate,0.6202127659574468
humoral immune response,lower respiratory tract disease,0.6351851851851852
humoral immune response,genetic resistance to pathogen,0.619811320754717
humoral immune response,process,0.5833333333333334
humoral immune response,droplet pathogen transmission process,0.6333333333333333
humoral immune response,communicability end process boundary,0.6533898305084747
humoral immune response,latency end process boundary,0.6264705882352941
humoral immune response,susceptible population,0.6055555555555556
humoral immune response,COVID-19 incidence rate,0.6239130434782608
humoral immune response,negative regulation of developmental process,0.5992537313432835
humoral immune response,antibiotic resistance,0.6318181818181818
humoral immune response,resistance to drug,0.5963414634146341
humoral immune response,process of establishing an infection,0.6025423728813559
humoral immune response,incubation end process boundary,0.6537037037037037
humoral immune response,pathogen death process boundary,0.6351851851851852
humoral immune response,plan specification,0.6207317073170732
humoral immune response,latency end temporal region,0.65
humoral immune response,virus adhesion susceptible cell,0.6166666666666667
humoral immune response,T cell receptor complex,0.6239130434782608
humoral immune response,indirect pathogen transmission process,0.630327868852459
humoral immune response,planned process,0.6605263157894737
humoral immune response,humoral immunity to infectious agent,0.7550847457627118
humoral immune response,innate immune response,0.8277777777777777
humoral immune response,passive immunity to infectious agent,0.6533898305084747
humoral immune response,susceptible organism,0.6127906976744186
humoral immune response,COVID-19 mortality rate,0.6456521739130434
humoral immune response,process profile,0.6078947368421053
humoral immune response,negative regulation of life-sustaining process,0.6094202898550725
humoral immune response,place closure control strategy,0.619811320754717
humoral immune response,developmental process,0.6318181818181818
humoral immune response,biological process,0.6451219512195122
humoral immune response,humoral immune response,0.95
humoral immune response,SARS-COV-2 adhesion susceptible cell,0.5855932203389831
humoral immune response,incubation start process boundary,0.6285714285714286
humoral immune response,pathogen birth process boundary,0.6351851851851852
humoral immune response,resistance to pathogen,0.6277777777777778
humoral immune response,negative regulation of immune response,0.7450819672131148
humoral immune response,negative regulation of viral process,0.6194915254237288
humoral immune response,contact pathogen transmission process,0.6333333333333333
humoral immune response,function,0.5790322580645162
humoral immune response,symbiotic process,0.65
humoral immune response,infection start process boundary,0.6136363636363636
humoral immune response,action specification,0.636046511627907
humoral immune response,protective resistance,0.6545454545454545
humoral immune response,latency start process boundary,0.6009433962264151
humoral immune response,immune population,0.7
humoral immune response,process of establishing viral infection,0.6112903225806451
humoral immune response,negative regulation of biological process,0.590625
humoral immune response,polymerase chain reaction,0.6791666666666666
humoral immune response,infectious disease incidence rate,0.6107142857142857
humoral immune response,communicability start process boundary,0.630327868852459
humoral immune response,process that results in death,0.6038461538461539
humoral immune response,collective resistance disposition,0.6464285714285714
humoral immune response,adaptive immune response,0.8117021276595744
humoral immune response,establishment of a clinically abnormal colony,0.6117647058823529
humoral immune response,process boundary,0.5782051282051281
humoral immune response,horizontal pathogen transmission process,0.6563492063492063
humoral immune response,SARS-CoV-2 release stage,0.598936170212766
humoral immune response,pathogen transmission process,0.6615384615384616
process profile,information content entity,0.5963414634146341
process profile,immune response,0.65
process profile,infectious disease mortality rate,0.5958333333333333
process profile,infection incidence rate profile,0.6840425531914894
process profile,communicability end temporal region,0.61
process profile,pathogen generative stage,0.625
process profile,surveillance process,0.6785714285714286
process profile,infection end temporal region,0.609090909090909
process profile,SARS-CoV-2 incidence rate,0.625
process profile,incubation end temporal region,0.6055555555555556
process profile,virus translation stage,0.6078947368421053
process profile,case isolation control strategy,0.6239130434782608
process profile,virus release stage,0.6264705882352941
process profile,B cell receptor complex,0.6605263157894737
process profile,infection incidence rate,0.6038461538461539
process profile,double-stranded RNA virus,0.6
process profile,virus transcription stage,0.6
process profile,lower respiratory tract disease,0.6239130434782608
process profile,virus generative stage,0.6121621621621621
process profile,acute infectious disease course,0.6021739130434782
process profile,process,0.7681818181818181
process profile,appearance of disorder,0.6932432432432433
process profile,droplet pathogen transmission process,0.6423076923076922
process profile,communicability end process boundary,0.6264705882352941
process profile,directive information content entity,0.5872549019607843
process profile,infection incidence proportion profile,0.6575471698113208
process profile,latency end process boundary,0.6593023255813953
process profile,infectious agent generative stage,0.575
process profile,disease transmission model,0.5963414634146341
process profile,negative-sense single-stranded RNA virus,0.5772727272727273
process profile,COVID-19 incidence rate,0.6078947368421053
process profile,negative regulation of developmental process,0.5855932203389831
process profile,chronic infectious disease course,0.6375
process profile,descriptive information content entity,0.5820754716981132
process profile,process of establishing an infection,0.6852941176470588
process profile,incubation end process boundary,0.6456521739130434
process profile,SARS-CoV-2 uncoating stage,0.5963414634146341
process profile,pathogen death process boundary,0.6456521739130434
process profile,plan specification,0.6015151515151516
process profile,latency end temporal region,0.6166666666666667
process profile,SARS-CoV-2 penetration stage,0.6127906976744186
process profile,T cell receptor complex,0.6605263157894737
process profile,respiratory system disease,0.6451219512195122
process profile,indirect pathogen transmission process,0.6386792452830189
process profile,planned process,0.6833333333333332
process profile,generative stage,0.5790322580645162
process profile,SARS-CoV-2 attachment stage,0.5928571428571429
process profile,infectious structure generative stage,0.5846153846153846
process profile,innate immune response,0.6121621621621621
process profile,viral disease course,0.6214285714285714
process profile,disease course,0.6224137931034482
process profile,infectious disease course,0.6
process profile,coronavirus disease course,0.6207317073170732
process profile,SARS-CoV-2 genome replication stage,0.59
process profile,COVID-19 mortality rate,0.581578947368421
process profile,process profile,0.95
process profile,negative regulation of life-sustaining process,0.6139344262295081
process profile,developmental process,0.6444444444444444
process profile,infection incidence profile,0.7119047619047619
process profile,biological process,0.6621212121212122
process profile,designative information content entity,0.5632075471698114
process profile,humoral immune response,0.6078947368421053
process profile,incubation start process boundary,0.6375
process profile,pathogen birth process boundary,0.6456521739130434
process profile,virus attachment stage,0.5851351351351352
process profile,negative regulation of immune response,0.5820754716981132
process profile,SARS-CoV-2 transcription stage,0.5833333333333334
process profile,virus synthesis stage,0.6166666666666667
process profile,long-term non-progressing infectious disease course,0.6015151515151516
process profile,virus penetration stage,0.6342105263157894
process profile,algorithm,0.575
process profile,geographical feature,0.5928571428571429
process profile,negative regulation of viral process,0.6068627450980393
process profile,contact pathogen transmission process,0.6423076923076922
process profile,history,0.5409090909090909
process profile,function,0.5369565217391304
process profile,symbiotic process,0.66875
process profile,infection start process boundary,0.6414893617021277
process profile,action specification,0.5928571428571429
process profile,SARS-CoV-2 synthesis stage,0.6207317073170732
process profile,latency start process boundary,0.65
process profile,process of establishing viral infection,0.6907407407407408
process profile,negative regulation of biological process,0.5928571428571429
process profile,polymerase chain reaction,0.625
process profile,COVID-19 disease course,0.6078947368421053
process profile,infectious disease incidence rate,0.575
process profile,communicability start process boundary,0.619811320754717
process profile,process that results in death,0.7
process profile,single-stranded RNA retrovirus,0.5833333333333334
process profile,adaptive immune response,0.6294871794871795
process profile,virus uncoating stage,0.6166666666666667
process profile,establishment of a clinically abnormal colony,0.5833333333333334
process profile,process boundary,0.7403225806451613
process profile,positive-sense single-stranded RNA virus,0.6136363636363636
process profile,horizontal pathogen transmission process,0.6318181818181818
process profile,SARS-CoV-2 release stage,0.6038461538461539
process profile,pathogen transmission process,0.6772727272727272
antibody reagent,extended organism,0.6318181818181818
antibody reagent,virus aggregate,0.6435483870967742
antibody reagent,infectious disease mortality rate,0.6540816326530612
antibody reagent,pathogen generative stage,0.6695121951219513
antibody reagent,pathogen portal of entry,0.675
antibody reagent,primary pathogen,0.66875
antibody reagent,drug-based immunosuppressed organism,0.6038461538461539
antibody reagent,infectious disease,0.6852941176470588
antibody reagent,double-stranded DNA virus,0.5719512195121951
antibody reagent,site of infection,0.6015151515151516
antibody reagent,immunocompetent organism,0.6
antibody reagent,pathogen portal of exit,0.6551282051282051
antibody reagent,infectious disease incidence,0.6545454545454545
antibody reagent,reservoir of pathogen role,0.6166666666666667
antibody reagent,virus translation stage,0.6807692307692308
antibody reagent,disease surveillance objective specification,0.5833333333333334
antibody reagent,virus release stage,0.65
antibody reagent,infectious agent host role,0.6880952380952381
antibody reagent,source of infection site,0.6
antibody reagent,virus,0.5452380952380953
antibody reagent,virus replication,0.6318181818181818
antibody reagent,B cell receptor complex,0.6038461538461539
antibody reagent,passive immunization against infectious agent,0.6467213114754098
antibody reagent,virus host,0.5653846153846154
antibody reagent,double-stranded RNA virus,0.5963414634146341
antibody reagent,pathogen portal of entry role,0.65
antibody reagent,virus transcription stage,0.6695121951219513
antibody reagent,infectious disease lifetime prevalence,0.6537037037037037
antibody reagent,toxin disposition,0.6015151515151516
antibody reagent,pathogen birth temporal region,0.6456521739130434
antibody reagent,lower respiratory tract disease,0.6414893617021277
antibody reagent,infectious disease incidence proportion,0.6318181818181818
antibody reagent,opportunistic pathogen,0.6605263157894737
antibody reagent,virus generative stage,0.6342105263157894
antibody reagent,acute infectious disease course,0.6414893617021277
antibody reagent,cidal agent disposition,0.6551282051282051
antibody reagent,genetic resistance to pathogen,0.6673913043478261
antibody reagent,droplet pathogen transmission process,0.6009433962264151
antibody reagent,infectious disease sporadicity,0.6456521739130434
antibody reagent,infectious agent colony,0.7064102564102563
antibody reagent,pathogen transporter,0.6722222222222223
antibody reagent,infectious disease epidemic,0.636046511627907
antibody reagent,infectious agent generative stage,0.6540816326530612
antibody reagent,disease transmission model,0.5928571428571429
antibody reagent,pathologically immunosuppressed organism,0.6107142857142857
antibody reagent,negative-sense single-stranded RNA virus,0.5928571428571429
antibody reagent,cidal agent,0.7462962962962962
antibody reagent,pathogen vehicle,0.6375
antibody reagent,pathogen vector,0.6758064516129032
antibody reagent,antibiotic resistance,0.7472972972972972
antibody reagent,pathogen vehicle role,0.6121621621621621
antibody reagent,chronic infectious disease course,0.6132653061224489
antibody reagent,asymptomatic infectious agent carrier,0.6575471698113208
antibody reagent,virus disorder,0.5833333333333334
antibody reagent,sterilizing immunity to infectious agent,0.6285714285714286
antibody reagent,pathogen death process boundary,0.6202127659574468
antibody reagent,immunosuppressed organism,0.6207317073170732
antibody reagent,innate immunity to infectious agent,0.6656862745098039
antibody reagent,virus adhesion susceptible cell,0.598936170212766
antibody reagent,static agent disposition,0.675
antibody reagent,T cell receptor complex,0.6038461538461539
antibody reagent,infectious agent population,0.6825581395348838
antibody reagent,respiratory system disease,0.6404761904761905
antibody reagent,leukocyte-mediated immunity to infectious agent,0.6246031746031746
antibody reagent,indirect pathogen transmission process,0.6166666666666667
antibody reagent,organism population,0.6214285714285714
antibody reagent,humoral immunity to infectious agent,0.6615384615384616
antibody reagent,infectious disease control strategy,0.6460784313725491
antibody reagent,parasite,0.6166666666666667
antibody reagent,infectious disease pandemic,0.6593023255813953
antibody reagent,antibody reagent,0.95
antibody reagent,viral disease course,0.5888888888888889
antibody reagent,toxin,0.5928571428571429
antibody reagent,passive immunity to infectious agent,0.6615384615384616
antibody reagent,vaccination against infectious agent,0.6807692307692308
antibody reagent,susceptibility to infectious agent,0.67
antibody reagent,epitope site,0.5928571428571429
antibody reagent,immunity to pathogen,0.6722222222222223
antibody reagent,pathogen host,0.6913793103448276
antibody reagent,disease course,0.5833333333333334
antibody reagent,infectious disease course,0.6451219512195122
antibody reagent,acquired immunity to infectious agent,0.6575471698113208
antibody reagent,COVID-19 disease incidence proportion,0.6009433962264151
antibody reagent,coronavirus disease course,0.5928571428571429
antibody reagent,symptomatic infectious agent carrier,0.6615384615384616
antibody reagent,respiratory droplet virus fomite,0.6166666666666667
antibody reagent,susceptible organism,0.6444444444444444
antibody reagent,parasite role,0.6224137931034482
antibody reagent,pathogen vector role,0.6444444444444444
antibody reagent,pathogen portal of exit site,0.6318181818181818
antibody reagent,infectious disease prevalence,0.6944444444444444
antibody reagent,organism substance,0.6264705882352941
antibody reagent,single-stranded DNA virus,0.5963414634146341
antibody reagent,viral disease,0.6224137931034482
antibody reagent,reagent,0.7543478260869566
antibody reagent,pathogen portal of entry site,0.65
antibody reagent,disease,0.6239130434782608
antibody reagent,site,0.55
antibody reagent,pathogen host role,0.6558823529411765
antibody reagent,infectious pathogen transmissibility,0.6423076923076922
antibody reagent,pathogen surveillance,0.6662162162162162
antibody reagent,immunodeficient organism,0.625
antibody reagent,pathogen,0.7
antibody reagent,pathogen birth process boundary,0.598936170212766
antibody reagent,infectious human pathogen,0.6695121951219513
antibody reagent,subclinical virus infection,0.5895348837209302
antibody reagent,resistance to pathogen,0.6868421052631578
antibody reagent,establishment of localization in virus host,0.5855932203389831
antibody reagent,immunization against infectious agent,0.6575471698113208
antibody reagent,virus attachment stage,0.6342105263157894
antibody reagent,virus synthesis stage,0.6391891891891892
antibody reagent,pathogen portal of exit role,0.6318181818181818
antibody reagent,infectious agent host,0.7202702702702704
antibody reagent,re-emerging pathogen,0.6166666666666667
antibody reagent,long-term non-progressing infectious disease course,0.5694029850746268
antibody reagent,viral disease epidemic,0.581578947368421
antibody reagent,viral disease pandemic,0.6078947368421053
antibody reagent,virus penetration stage,0.6551282051282051
antibody reagent,pathogen seroprevalence,0.6807692307692308
antibody reagent,infectious disease endemicity,0.6722222222222223
antibody reagent,contact pathogen transmission process,0.6009433962264151
antibody reagent,herd immunity to infectious organism,0.6038461538461539
antibody reagent,pathogen transporter role,0.6451219512195122
antibody reagent,antigen,0.7543478260869566
antibody reagent,infectious agent reservoir,0.6880952380952381
antibody reagent,antigen role,0.7
antibody reagent,infectious disease control objective specification,0.6015151515151516
antibody reagent,COVID-19 disease course,0.6038461538461539
antibody reagent,infectious disease incidence rate,0.6540816326530612
antibody reagent,active immunization against infectious agent,0.65
antibody reagent,disordered virus,0.60625
antibody reagent,reagent role,0.7
antibody reagent,organism,0.6166666666666667
antibody reagent,virus uncoating stage,0.6391891891891892
antibody reagent,infectious agent,0.7625
antibody reagent,establishment of a clinically abnormal colony,0.5975409836065574
antibody reagent,coronavirus disease,0.6214285714285714
antibody reagent,positive-sense single-stranded RNA virus,0.575
antibody reagent,horizontal pathogen transmission process,0.5928571428571429
antibody reagent,pathogen death temporal region,0.6456521739130434
antibody reagent,emerging pathogen,0.6318181818181818
antibody reagent,drug susceptibility of infectious agent,0.65
antibody reagent,static agent,0.7714285714285714
antibody reagent,pathogen transmission process,0.6277777777777778
long-term non-progressing infectious disease course,virus aggregate,0.5712121212121213
long-term non-progressing infectious disease course,source of infection,0.6357142857142857
long-term non-progressing infectious disease course,virostatic disposition,0.6006849315068493
long-term non-progressing infectious disease course,zoonotic disposition,0.6190140845070422
long-term non-progressing infectious disease course,infectious disease mortality rate,0.7119047619047619
long-term non-progressing infectious disease course,infection incidence rate profile,0.6427710843373494
long-term non-progressing infectious disease course,infectious structure aggregate,0.6475308641975309
long-term non-progressing infectious disease course,communicability end temporal region,0.6011627906976744
long-term non-progressing infectious disease course,pathogen portal of entry,0.61
long-term non-progressing infectious disease course,subclinical coronavirus infection,0.6523809523809524
long-term non-progressing infectious disease course,infection end temporal region,0.6375
long-term non-progressing infectious disease course,infectious disease,0.7108695652173913
long-term non-progressing infectious disease course,double-stranded DNA virus,0.6078947368421053
long-term non-progressing infectious disease course,incubation end temporal region,0.6104938271604938
long-term non-progressing infectious disease course,site of infection,0.6411764705882353
long-term non-progressing infectious disease course,virulence factor disposition,0.639873417721519
long-term non-progressing infectious disease course,viral adhesion disposition,0.6058441558441559
long-term non-progressing infectious disease course,parasitostatic disposition,0.6188311688311688
long-term non-progressing infectious disease course,infectious disease incidence,0.7158227848101265
long-term non-progressing infectious disease course,reverse zoonotic disposition,0.6272151898734176
long-term non-progressing infectious disease course,subclinical SARS-CoV-2 infection,0.6186746987951807
long-term non-progressing infectious disease course,virus translation stage,0.5986486486486486
long-term non-progressing infectious disease course,disease surveillance objective specification,0.6184210526315789
long-term non-progressing infectious disease course,virus release stage,0.6071428571428572
long-term non-progressing infectious disease course,infectious agent host role,0.6707792207792208
long-term non-progressing infectious disease course,asymptomatic infectious structure carrier,0.6891304347826087
long-term non-progressing infectious disease course,source of infection site,0.6633333333333334
long-term non-progressing infectious disease course,virus,0.5035714285714286
long-term non-progressing infectious disease course,virus replication,0.5823529411764706
long-term non-progressing infectious disease course,B cell receptor complex,0.5986486486486486
long-term non-progressing infectious disease course,passive immunization against infectious agent,0.6791666666666666
long-term non-progressing infectious disease course,systematic infection,0.6330985915492958
long-term non-progressing infectious disease course,infection incidence rate,0.65
long-term non-progressing infectious disease course,virus host,0.5483606557377049
long-term non-progressing infectious disease course,double-stranded RNA virus,0.6078947368421053
long-term non-progressing infectious disease course,pathogen portal of entry role,0.625
long-term non-progressing infectious disease course,virus transcription stage,0.6078947368421053
long-term non-progressing infectious disease course,infectious disease lifetime prevalence,0.6859550561797753
long-term non-progressing infectious disease course,toxin disposition,0.5970588235294118
long-term non-progressing infectious disease course,lower respiratory tract disease,0.6939024390243902
long-term non-progressing infectious disease course,infectious disease incidence proportion,0.6944444444444444
long-term non-progressing infectious disease course,virus generative stage,0.6143835616438357
long-term non-progressing infectious disease course,acute infectious disease course,0.7914634146341464
long-term non-progressing infectious disease course,cidal agent disposition,0.6121621621621621
long-term non-progressing infectious disease course,infectious disorder,0.6928571428571427
long-term non-progressing infectious disease course,subclinical infection,0.6166666666666667
long-term non-progressing infectious disease course,appearance of disorder,0.6280821917808219
long-term non-progressing infectious disease course,simple infection,0.6291044776119403
long-term non-progressing infectious disease course,parasiticidal disposition,0.6210526315789474
long-term non-progressing infectious disease course,infectious disease sporadicity,0.7092592592592593
long-term non-progressing infectious disease course,communicability end process boundary,0.6454022988505748
long-term non-progressing infectious disease course,infection incidence proportion profile,0.6297752808988765
long-term non-progressing infectious disease course,infectious agent colony,0.6662162162162162
long-term non-progressing infectious disease course,transmissibility disposition,0.6272151898734176
long-term non-progressing infectious disease course,latency end process boundary,0.6651898734177215
long-term non-progressing infectious disease course,infectious disease epidemic,0.7064102564102563
long-term non-progressing infectious disease course,infectious agent generative stage,0.6523809523809524
long-term non-progressing infectious disease course,disease transmission model,0.5928571428571429
long-term non-progressing infectious disease course,endotoxin disposition,0.6166666666666667
long-term non-progressing infectious disease course,negative-sense single-stranded RNA virus,0.6587912087912088
long-term non-progressing infectious disease course,infectious structure host role,0.6598765432098764
long-term non-progressing infectious disease course,cytotoxin disposition,0.6027777777777777
long-term non-progressing infectious disease course,community-acquired infection,0.639873417721519
long-term non-progressing infectious disease course,chronic infectious disease course,0.8071428571428573
long-term non-progressing infectious disease course,asymptomatic infectious agent carrier,0.7
long-term non-progressing infectious disease course,nursing-home acquired infection,0.6451219512195122
long-term non-progressing infectious disease course,COVID-19 epidemic,0.5676470588235294
long-term non-progressing infectious disease course,secondary infection,0.6357142857142857
long-term non-progressing infectious disease course,infection start temporal region,0.6329268292682927
long-term non-progressing infectious disease course,infection incidence,0.6357142857142857
long-term non-progressing infectious disease course,virus disorder,0.6038461538461539
long-term non-progressing infectious disease course,sterilizing immunity to infectious agent,0.6807692307692308
long-term non-progressing infectious disease course,diseased population,0.5928571428571429
long-term non-progressing infectious disease course,primary infection,0.6264705882352941
long-term non-progressing infectious disease course,process of establishing an infection,0.6683908045977012
long-term non-progressing infectious disease course,incubation end process boundary,0.6451219512195122
long-term non-progressing infectious disease course,SARS-CoV-2 disorder,0.6071428571428572
long-term non-progressing infectious disease course,collective pathogenic disposition,0.6523809523809524
long-term non-progressing infectious disease course,neurotoxin disposition,0.6280821917808219
long-term non-progressing infectious disease course,plan specification,0.6094202898550725
long-term non-progressing infectious disease course,latency end temporal region,0.6166666666666667
long-term non-progressing infectious disease course,innate immunity to infectious agent,0.6825581395348838
long-term non-progressing infectious disease course,infectious structure,0.6753521126760563
long-term non-progressing infectious disease course,virus adhesion susceptible cell,0.6207317073170732
long-term non-progressing infectious disease course,collective disposition,0.6006849315068493
long-term non-progressing infectious disease course,infection,0.5833333333333334
long-term non-progressing infectious disease course,static agent disposition,0.61
long-term non-progressing infectious disease course,T cell receptor complex,0.6121621621621621
long-term non-progressing infectious disease course,infectious structure host,0.6605263157894737
long-term non-progressing infectious disease course,infectious agent population,0.6551282051282051
long-term non-progressing infectious disease course,respiratory system disease,0.6577922077922078
long-term non-progressing infectious disease course,entry into host,0.6166666666666667
long-term non-progressing infectious disease course,leukocyte-mediated immunity to infectious agent,0.6744897959183673
long-term non-progressing infectious disease course,humoral immunity to infectious agent,0.6683908045977012
long-term non-progressing infectious disease course,infectious disease control strategy,0.7290697674418604
long-term non-progressing infectious disease course,infectious disease pandemic,0.7064102564102563
long-term non-progressing infectious disease course,infectious structure generative stage,0.6545454545454545
long-term non-progressing infectious disease course,immunosuppressive disposition,0.65
long-term non-progressing infectious disease course,pathogenic disposition,0.6280821917808219
long-term non-progressing infectious disease course,viral disease course,0.6753521126760563
long-term non-progressing infectious disease course,entry into host through host barriers,0.6545454545454545
long-term non-progressing infectious disease course,intracellular infection,0.6256756756756756
long-term non-progressing infectious disease course,secondary infection role,0.6633333333333334
long-term non-progressing infectious disease course,metastatic infection,0.6330985915492958
long-term non-progressing infectious disease course,passive immunity to infectious agent,0.6683908045977012
long-term non-progressing infectious disease course,infectious disposition,0.6691780821917809
long-term non-progressing infectious disease course,vaccination against infectious agent,0.6913793103448276
long-term non-progressing infectious disease course,objective specification,0.6121621621621621
long-term non-progressing infectious disease course,acute infection,0.6166666666666667
long-term non-progressing infectious disease course,susceptibility to infectious agent,0.6617647058823529
long-term non-progressing infectious disease course,bacteriostatic disposition,0.6188311688311688
long-term non-progressing infectious disease course,bactericidal disposition,0.61
long-term non-progressing infectious disease course,source of infection role,0.6633333333333334
long-term non-progressing infectious disease course,chronic infection,0.6411764705882353
long-term non-progressing infectious disease course,invasion disposition,0.5908450704225352
long-term non-progressing infectious disease course,disease course,0.6653846153846155
long-term non-progressing infectious disease course,infectious disease course,0.7789473684210526
long-term non-progressing infectious disease course,viricidal disposition,0.5888888888888889
long-term non-progressing infectious disease course,acquired immunity to infectious agent,0.6545454545454545
long-term non-progressing infectious disease course,complex infection,0.6411764705882353
long-term non-progressing infectious disease course,COVID-19 disease incidence proportion,0.6318181818181818
long-term non-progressing infectious disease course,coronavirus disease course,0.7357142857142857
long-term non-progressing infectious disease course,infection incidence proportion,0.6351851851851852
long-term non-progressing infectious disease course,symptomatic infectious agent carrier,0.7028735632183909
long-term non-progressing infectious disease course,respiratory droplet virus fomite,0.6186746987951807
long-term non-progressing infectious disease course,infectious disease prevalence,0.7125
long-term non-progressing infectious disease course,disposition,0.5629032258064516
long-term non-progressing infectious disease course,single-stranded DNA virus,0.6210526315789474
long-term non-progressing infectious disease course,infected population,0.5928571428571429
long-term non-progressing infectious disease course,contact tracing,0.5712121212121213
long-term non-progressing infectious disease course,viral disease,0.590625
long-term non-progressing infectious disease course,primary infection role,0.6554794520547945
long-term non-progressing infectious disease course,adhesion disposition,0.5908450704225352
long-term non-progressing infectious disease course,pathogen portal of entry site,0.625
long-term non-progressing infectious disease course,infection incidence profile,0.6423076923076922
long-term non-progressing infectious disease course,disease,0.5706896551724138
long-term non-progressing infectious disease course,symptomatic infectious structure carrier,0.6917582417582417
long-term non-progressing infectious disease course,primary infectious disposition,0.6969135802469135
long-term non-progressing infectious disease course,infection prevalence,0.6471830985915493
long-term non-progressing infectious disease course,coronavirus disorder,0.6471830985915493
long-term non-progressing infectious disease course,infectious pathogen transmissibility,0.6339080459770114
long-term non-progressing infectious disease course,object,0.5201754385964912
long-term non-progressing infectious disease course,infectious human pathogen,0.6473684210526315
long-term non-progressing infectious disease course,subclinical virus infection,0.6294871794871795
long-term non-progressing infectious disease course,establishment of localization in virus host,0.6308510638297872
long-term non-progressing infectious disease course,immunization against infectious agent,0.6886363636363636
long-term non-progressing infectious disease course,virus attachment stage,0.5732876712328767
long-term non-progressing infectious disease course,virus synthesis stage,0.6027777777777777
long-term non-progressing infectious disease course,SARS-COV-2 adhesion disposition,0.6085365853658536
long-term non-progressing infectious disease course,object aggregate,0.5843283582089552
long-term non-progressing infectious disease course,invasive disposition,0.5908450704225352
long-term non-progressing infectious disease course,infectious agent host,0.6722222222222223
long-term non-progressing infectious disease course,long-term non-progressing infectious disease course,0.95
long-term non-progressing infectious disease course,viral disease epidemic,0.6006849315068493
long-term non-progressing infectious disease course,fungicidal disposition,0.6006849315068493
long-term non-progressing infectious disease course,viral disease pandemic,0.6006849315068493
long-term non-progressing infectious disease course,virus penetration stage,0.6256756756756756
long-term non-progressing infectious disease course,acute respiratory distress syndrome,0.6593023255813953
long-term non-progressing infectious disease course,infectious disease endemicity,0.7
long-term non-progressing infectious disease course,contact pathogen transmission process,0.6545454545454545
long-term non-progressing infectious disease course,disorder,0.5516949152542373
long-term non-progressing infectious disease course,herd immunity to infectious organism,0.6798850574712644
long-term non-progressing infectious disease course,extracellular infection,0.6121621621621621
long-term non-progressing infectious disease course,exotoxin disposition,0.6049295774647887
long-term non-progressing infectious disease course,infectious agent reservoir,0.6707792207792208
long-term non-progressing infectious disease course,COVID-19 pandemic,0.5676470588235294
long-term non-progressing infectious disease course,infection start process boundary,0.6548192771084337
long-term non-progressing infectious disease course,infectious disease control objective specification,0.6876237623762376
long-term non-progressing infectious disease course,opportunistic infectious disposition,0.7143678160919541
long-term non-progressing infectious disease course,process of establishing viral infection,0.6611111111111111
long-term non-progressing infectious disease course,enterotoxin disposition,0.6391891891891892
long-term non-progressing infectious disease course,polymerase chain reaction,0.6078947368421053
long-term non-progressing infectious disease course,COVID-19 disease course,0.6797297297297297
long-term non-progressing infectious disease course,infectious disease incidence rate,0.7119047619047619
long-term non-progressing infectious disease course,single-stranded RNA retrovirus,0.6351851851851852
long-term non-progressing infectious disease course,active immunization against infectious agent,0.6921052631578948
long-term non-progressing infectious disease course,disordered virus,0.5694029850746268
long-term non-progressing infectious disease course,collective resistance disposition,0.6404761904761905
long-term non-progressing infectious disease course,fungistatic disposition,0.5986486486486486
long-term non-progressing infectious disease course,virus uncoating stage,0.6027777777777777
long-term non-progressing infectious disease course,local infection,0.6166666666666667
long-term non-progressing infectious disease course,infectious agent,0.6440298507462687
long-term non-progressing infectious disease course,establishment of a clinically abnormal colony,0.5958333333333333
long-term non-progressing infectious disease course,coronavirus disease,0.6642857142857143
long-term non-progressing infectious disease course,positive-sense single-stranded RNA virus,0.6478021978021978
long-term non-progressing infectious disease course,hospital-acquired infection,0.6294871794871795
long-term non-progressing infectious disease course,drug susceptibility of infectious agent,0.6611111111111111
infection prevalence,virus aggregate,0.6214285714285714
infection prevalence,source of infection,0.6807692307692308
infection prevalence,virostatic disposition,0.5928571428571429
infection prevalence,zoonotic disposition,0.6
infection prevalence,infectious disease mortality rate,0.6952830188679244
infection prevalence,infection incidence rate profile,0.7192307692307692
infection prevalence,communicability end temporal region,0.65
infection prevalence,subclinical coronavirus infection,0.619811320754717
infection prevalence,infection end temporal region,0.7765306122448979
infection prevalence,vector control strategy,0.6593023255813953
infection prevalence,infectious disease,0.7657894736842106
infection prevalence,double-stranded DNA virus,0.5833333333333334
infection prevalence,incubation end temporal region,0.73
infection prevalence,site of infection,0.6932432432432433
infection prevalence,virulence factor disposition,0.6375
infection prevalence,viral adhesion disposition,0.6239130434782608
infection prevalence,parasitostatic disposition,0.5804347826086956
infection prevalence,infectious disease incidence,0.7625
infection prevalence,reverse zoonotic disposition,0.575
infection prevalence,subclinical SARS-CoV-2 infection,0.6230769230769231
infection prevalence,virus translation stage,0.6593023255813953
infection prevalence,disease surveillance objective specification,0.621875
infection prevalence,case isolation control strategy,0.6264705882352941
infection prevalence,virus release stage,0.6294871794871795
infection prevalence,source of infection site,0.7
infection prevalence,virus,0.53
infection prevalence,quarantine control strategy,0.6627659574468084
infection prevalence,virus replication,0.6391891891891892
infection prevalence,B cell receptor complex,0.636046511627907
infection prevalence,systematic infection,0.675
infection prevalence,infection incidence rate,0.7681818181818181
infection prevalence,virus host,0.5166666666666666
infection prevalence,double-stranded RNA virus,0.5833333333333334
infection prevalence,virus transcription stage,0.6722222222222223
infection prevalence,infectious disease lifetime prevalence,0.7775862068965518
infection prevalence,toxin disposition,0.6121621621621621
infection prevalence,lower respiratory tract disease,0.6068627450980393
infection prevalence,infectious disease incidence proportion,0.7042372881355932
infection prevalence,virus generative stage,0.6404761904761905
infection prevalence,acute infectious disease course,0.7245098039215686
infection prevalence,cidal agent disposition,0.5895348837209302
infection prevalence,infectious disorder,0.732051282051282
infection prevalence,subclinical infection,0.6695121951219513
infection prevalence,appearance of disorder,0.5928571428571429
infection prevalence,simple infection,0.7
infection prevalence,parasiticidal disposition,0.5833333333333334
infection prevalence,infectious disease sporadicity,0.71
infection prevalence,communicability end process boundary,0.6107142857142857
infection prevalence,infection incidence proportion profile,0.6913793103448276
infection prevalence,transmissibility disposition,0.5541666666666667
infection prevalence,latency end process boundary,0.6166666666666667
infection prevalence,infectious disease epidemic,0.7265957446808511
infection prevalence,disease transmission model,0.6456521739130434
infection prevalence,endotoxin disposition,0.6207317073170732
infection prevalence,negative-sense single-stranded RNA virus,0.6166666666666667
infection prevalence,cytotoxin disposition,0.6207317073170732
infection prevalence,community-acquired infection,0.6375
infection prevalence,chronic infectious disease course,0.7141509433962264
infection prevalence,nursing-home acquired infection,0.6264705882352941
infection prevalence,COVID-19 epidemic,0.6121621621621621
infection prevalence,secondary infection,0.6807692307692308
infection prevalence,infection start temporal region,0.7637254901960785
infection prevalence,infection incidence,0.808974358974359
infection prevalence,virus disorder,0.5970588235294118
infection prevalence,primary infection,0.6932432432432433
infection prevalence,process of establishing an infection,0.6107142857142857
infection prevalence,incubation end process boundary,0.6852941176470588
infection prevalence,SARS-CoV-2 disorder,0.5782051282051281
infection prevalence,collective pathogenic disposition,0.6386792452830189
infection prevalence,neurotoxin disposition,0.6404761904761905
infection prevalence,latency end temporal region,0.6627659574468084
infection prevalence,virus adhesion susceptible cell,0.6656862745098039
infection prevalence,collective disposition,0.6166666666666667
infection prevalence,infection,0.760344827586207
infection prevalence,static agent disposition,0.5863636363636363
infection prevalence,T cell receptor complex,0.636046511627907
infection prevalence,respiratory system disease,0.6021739130434782
infection prevalence,communicability interval,0.6545454545454545
infection prevalence,infectious disease control strategy,0.7045454545454546
infection prevalence,infectious disease pandemic,0.747872340425532
infection prevalence,immunosuppressive disposition,0.6336734693877552
infection prevalence,pathogenic disposition,0.5928571428571429
infection prevalence,viral disease course,0.625
infection prevalence,intracellular infection,0.6593023255813953
infection prevalence,secondary infection role,0.7454545454545455
infection prevalence,metastatic infection,0.675
infection prevalence,infectious disposition,0.7119047619047619
infection prevalence,acute infection,0.7071428571428571
infection prevalence,bacteriostatic disposition,0.6021739130434782
infection prevalence,bactericidal disposition,0.5863636363636363
infection prevalence,source of infection role,0.7454545454545455
infection prevalence,chronic infection,0.6932432432432433
infection prevalence,invasion disposition,0.65
infection prevalence,disease course,0.6264705882352941
infection prevalence,infectious disease course,0.7611111111111112
infection prevalence,viricidal disposition,0.5963414634146341
infection prevalence,complex infection,0.6932432432432433
infection prevalence,COVID-19 disease incidence proportion,0.6078947368421053
infection prevalence,coronavirus disease course,0.6456521739130434
infection prevalence,infection incidence proportion,0.73
infection prevalence,respiratory droplet virus fomite,0.6038461538461539
infection prevalence,infectious disease prevalence,0.8377551020408163
infection prevalence,disposition,0.6112903225806451
infection prevalence,single-stranded DNA virus,0.6277777777777778
infection prevalence,place closure control strategy,0.61
infection prevalence,viral disease,0.6318181818181818
infection prevalence,primary infection role,0.7595238095238095
infection prevalence,adhesion disposition,0.625
infection prevalence,infection incidence profile,0.747872340425532
infection prevalence,contagiousness,0.6264705882352941
infection prevalence,disease,0.5981481481481481
infection prevalence,primary infectious disposition,0.67
infection prevalence,infection prevalence,0.95
infection prevalence,coronavirus disorder,0.6
infection prevalence,incubation start process boundary,0.6764150943396227
infection prevalence,subclinical virus infection,0.6414893617021277
infection prevalence,establishment of localization in virus host,0.6087301587301588
infection prevalence,virus attachment stage,0.5928571428571429
infection prevalence,virus synthesis stage,0.6207317073170732
infection prevalence,SARS-COV-2 adhesion disposition,0.5872549019607843
infection prevalence,invasive disposition,0.625
infection prevalence,long-term non-progressing infectious disease course,0.6471830985915493
infection prevalence,viral disease epidemic,0.5928571428571429
infection prevalence,communicability start temporal region,0.6254385964912281
infection prevalence,fungicidal disposition,0.5928571428571429
infection prevalence,viral disease pandemic,0.6166666666666667
infection prevalence,virus penetration stage,0.6825581395348838
infection prevalence,acute respiratory distress syndrome,0.6136363636363636
infection prevalence,infectious disease endemicity,0.7357142857142857
infection prevalence,disorder,0.5928571428571429
infection prevalence,communicability,0.5928571428571429
infection prevalence,extracellular infection,0.6593023255813953
infection prevalence,exotoxin disposition,0.625
infection prevalence,infection start process boundary,0.7192307692307692
infection prevalence,action specification,0.7
infection prevalence,latency start process boundary,0.61
infection prevalence,infectious disease control objective specification,0.6642857142857143
infection prevalence,COVID-19 lifetime prevalence,0.7833333333333333
infection prevalence,opportunistic infectious disposition,0.6464285714285714
infection prevalence,process of establishing viral infection,0.6364406779661017
infection prevalence,enterotoxin disposition,0.636046511627907
infection prevalence,COVID-19 disease course,0.636046511627907
infection prevalence,infectious disease incidence rate,0.7330188679245283
infection prevalence,communicability start process boundary,0.5879310344827586
infection prevalence,COVID-19 prevalence,0.7833333333333333
infection prevalence,SARS-COV-2 prevalence,0.7670731707317073
infection prevalence,disordered virus,0.5888888888888889
infection prevalence,collective resistance disposition,0.6575471698113208
infection prevalence,fungistatic disposition,0.5895348837209302
infection prevalence,virus uncoating stage,0.6695121951219513
infection prevalence,local infection,0.7071428571428571
infection prevalence,establishment of a clinically abnormal colony,0.6192307692307693
infection prevalence,coronavirus disease,0.6294871794871795
infection prevalence,positive-sense single-stranded RNA virus,0.6
infection prevalence,hospital-acquired infection,0.6414893617021277
action specification,immune response,0.65
action specification,communicability end temporal region,0.6318181818181818
action specification,surveillance process,0.575
action specification,infection end temporal region,0.6744897959183673
action specification,geospatial location,0.7064102564102563
action specification,incubation end temporal region,0.67
action specification,disease surveillance objective specification,0.73125
action specification,case isolation control strategy,0.6264705882352941
action specification,B cell receptor complex,0.5895348837209302
action specification,process,0.524074074074074
action specification,biological vehicle,0.6078947368421053
action specification,droplet pathogen transmission process,0.6254385964912281
action specification,communicability end process boundary,0.6107142857142857
action specification,latency end process boundary,0.6166666666666667
action specification,pathogen vehicle,0.6722222222222223
action specification,negative regulation of developmental process,0.60625
action specification,pathogen vehicle role,0.6695121951219513
action specification,process of establishing an infection,0.6642857142857143
action specification,incubation end process boundary,0.6460784313725491
action specification,pathogen death process boundary,0.6460784313725491
action specification,plan specification,0.8710526315789474
action specification,latency end temporal region,0.6414893617021277
action specification,T cell receptor complex,0.5895348837209302
action specification,indirect pathogen transmission process,0.6224137931034482
action specification,planned process,0.5928571428571429
action specification,innate immune response,0.6642857142857143
action specification,objective specification,0.8453488372093022
action specification,biological vehicle role,0.6127906976744186
action specification,process profile,0.5928571428571429
action specification,negative regulation of life-sustaining process,0.6166666666666667
action specification,intervention,0.66875
action specification,developmental process,0.5719512195121951
action specification,biological process,0.6078947368421053
action specification,humoral immune response,0.636046511627907
action specification,incubation start process boundary,0.6575471698113208
action specification,pathogen birth process boundary,0.6264705882352941
action specification,negative regulation of immune response,0.6224137931034482
action specification,negative regulation of viral process,0.6285714285714286
action specification,contact pathogen transmission process,0.6429824561403508
action specification,function,0.6642857142857143
action specification,symbiotic process,0.5851351351351352
action specification,infection start process boundary,0.6615384615384616
action specification,action specification,0.95
action specification,latency start process boundary,0.63
action specification,infectious disease control objective specification,0.7214285714285714
action specification,process of establishing viral infection,0.6533898305084747
action specification,negative regulation of biological process,0.630327868852459
action specification,polymerase chain reaction,0.6944444444444444
action specification,communicability start process boundary,0.6224137931034482
action specification,process that results in death,0.6132653061224489
action specification,active immunization against infectious agent,0.684375
action specification,adaptive immune response,0.6545454545454545
action specification,establishment of a clinically abnormal colony,0.6192307692307693
action specification,process boundary,0.5611111111111111
action specification,horizontal pathogen transmission process,0.6166666666666667
action specification,pathogen transmission process,0.6540816326530612
specifically dependent continuant,infectious disease mortality rate,0.6469696969696969
specifically dependent continuant,infection incidence rate profile,0.65
specifically dependent continuant,communicability end temporal region,0.6558823529411765
specifically dependent continuant,infection end temporal region,0.6274193548387097
specifically dependent continuant,vector control strategy,0.6285714285714286
specifically dependent continuant,SARS-CoV-2 incidence rate,0.6396551724137931
specifically dependent continuant,incubation end temporal region,0.6246031746031746
specifically dependent continuant,normal resident microbiota population,0.6642857142857143
specifically dependent continuant,case isolation control strategy,0.6375
specifically dependent continuant,quarantine control strategy,0.6166666666666667
specifically dependent continuant,B cell receptor complex,0.6285714285714286
specifically dependent continuant,infection incidence rate,0.6605263157894737
specifically dependent continuant,lower respiratory tract disease,0.621875
specifically dependent continuant,communicability end process boundary,0.6673913043478261
specifically dependent continuant,latency end process boundary,0.6467213114754098
specifically dependent continuant,susceptible population,0.6318181818181818
specifically dependent continuant,COVID-19 incidence rate,0.6464285714285714
specifically dependent continuant,descriptive information content entity,0.6753521126760563
specifically dependent continuant,secondary infection,0.6807692307692308
specifically dependent continuant,incubation end process boundary,0.6375
specifically dependent continuant,plan specification,0.6852941176470588
specifically dependent continuant,latency end temporal region,0.6333333333333333
specifically dependent continuant,virus adhesion susceptible cell,0.590625
specifically dependent continuant,anatomical space,0.5928571428571429
specifically dependent continuant,T cell receptor complex,0.6285714285714286
specifically dependent continuant,infectious disease control strategy,0.6558823529411765
specifically dependent continuant,secondary infection role,0.6605263157894737
specifically dependent continuant,susceptible organism,0.619811320754717
specifically dependent continuant,generically dependent continuant,0.8807692307692307
specifically dependent continuant,COVID-19 mortality rate,0.6107142857142857
specifically dependent continuant,place closure control strategy,0.6404761904761905
specifically dependent continuant,continuant,0.6825581395348838
specifically dependent continuant,SARS-COV-2 adhesion susceptible cell,0.5949275362318841
specifically dependent continuant,specifically dependent continuant,0.95
specifically dependent continuant,independent continuant,0.8318181818181819
specifically dependent continuant,infectious disease control objective specification,0.6307228915662652
specifically dependent continuant,infectious disease incidence rate,0.6621212121212122
specifically dependent continuant,establishment of a clinically abnormal colony,0.6551282051282051
specifically dependent continuant,cell space,0.5895348837209302
two-dimensional spatial region,communicability end temporal region,0.7115384615384616
two-dimensional spatial region,geographical entity,0.6540816326530612
two-dimensional spatial region,infection end temporal region,0.7211864406779661
two-dimensional spatial region,incubation end temporal region,0.7166666666666667
two-dimensional spatial region,two-dimensional spatial region,0.95
two-dimensional spatial region,one-dimensional temporal region,0.8434426229508196
two-dimensional spatial region,temporal region,0.7166666666666667
two-dimensional spatial region,disease surveillance objective specification,0.6391891891891892
two-dimensional spatial region,B cell receptor complex,0.5820754716981132
two-dimensional spatial region,pathogen birth temporal region,0.7166666666666667
two-dimensional spatial region,lower respiratory tract disease,0.630327868852459
two-dimensional spatial region,infectious disease incidence proportion,0.6528985507246376
two-dimensional spatial region,acute infectious disease course,0.630327868852459
two-dimensional spatial region,communicability end process boundary,0.6318181818181818
two-dimensional spatial region,infection incidence proportion profile,0.6411764705882353
two-dimensional spatial region,SARS-CoV-2 incidence proportion,0.6467213114754098
two-dimensional spatial region,spatiotemporal region,0.7245098039215686
two-dimensional spatial region,latency end process boundary,0.6224137931034482
two-dimensional spatial region,zero-dimensional spatial region,0.909016393442623
two-dimensional spatial region,zero-dimensional temporal region,0.8370967741935484
two-dimensional spatial region,chronic infectious disease course,0.6246031746031746
two-dimensional spatial region,infection start temporal region,0.7450819672131148
two-dimensional spatial region,incubation end process boundary,0.630327868852459
two-dimensional spatial region,geographical region,0.7357142857142857
two-dimensional spatial region,latency end temporal region,0.7131578947368421
two-dimensional spatial region,T cell receptor complex,0.6009433962264151
two-dimensional spatial region,viral disease course,0.63
two-dimensional spatial region,three-dimensional spatial region,0.9016129032258065
two-dimensional spatial region,objective specification,0.6575471698113208
two-dimensional spatial region,country,0.5581081081081081
two-dimensional spatial region,disease course,0.6318181818181818
two-dimensional spatial region,infectious disease course,0.6318181818181818
two-dimensional spatial region,COVID-19 disease incidence proportion,0.658955223880597
two-dimensional spatial region,coronavirus disease course,0.6285714285714286
two-dimensional spatial region,infection incidence proportion,0.65
two-dimensional spatial region,place closure control strategy,0.6333333333333333
two-dimensional spatial region,object,0.5333333333333333
two-dimensional spatial region,object aggregate,0.6021739130434782
two-dimensional spatial region,long-term non-progressing infectious disease course,0.6228395061728395
two-dimensional spatial region,communicability start temporal region,0.7335820895522389
two-dimensional spatial region,geospatial region,0.7904255319148936
two-dimensional spatial region,division of geopolitical entity,0.6959016393442623
two-dimensional spatial region,geographical feature,0.65
two-dimensional spatial region,infectious disease control objective specification,0.6625
two-dimensional spatial region,COVID-19 disease course,0.6386792452830189
two-dimensional spatial region,local infection,0.65
two-dimensional spatial region,establishment of a clinically abnormal colony,0.6633333333333334
two-dimensional spatial region,one-dimensional spatial region,0.9166666666666665
two-dimensional spatial region,spatial region,0.7681818181818181
two-dimensional spatial region,pathogen death temporal region,0.7166666666666667
adhesion factor,infection incidence rate profile,0.6202127659574468
adhesion factor,communicability end temporal region,0.59
adhesion factor,infection end temporal region,0.6318181818181818
adhesion factor,SARS-CoV-2 incidence rate,0.625
adhesion factor,incubation end temporal region,0.6277777777777778
adhesion factor,virulence factor disposition,0.6593023255813953
adhesion factor,pathogen portal of exit,0.6342105263157894
adhesion factor,viral adhesion disposition,0.7182926829268292
adhesion factor,infectious disease incidence,0.5895348837209302
adhesion factor,case isolation control strategy,0.6891304347826087
adhesion factor,infectious agent host role,0.6451219512195122
adhesion factor,macromolecular complex,0.5851351351351352
adhesion factor,B cell receptor complex,0.6078947368421053
adhesion factor,passive immunization against infectious agent,0.6166666666666667
adhesion factor,infection incidence rate,0.6294871794871795
adhesion factor,lower respiratory tract disease,0.6239130434782608
adhesion factor,infectious disease incidence proportion,0.5981481481481481
adhesion factor,cidal agent disposition,0.6078947368421053
adhesion factor,biological vehicle,0.5712121212121213
adhesion factor,communicability end process boundary,0.6068627450980393
adhesion factor,infection incidence proportion profile,0.619811320754717
adhesion factor,infectious agent colony,0.6342105263157894
adhesion factor,SARS-CoV-2 incidence proportion,0.6021739130434782
adhesion factor,invasion factor,0.85
adhesion factor,latency end process boundary,0.636046511627907
adhesion factor,infectious agent generative stage,0.5958333333333333
adhesion factor,cidal agent,0.6038461538461539
adhesion factor,pathogen vehicle,0.6435483870967742
adhesion factor,COVID-19 incidence rate,0.6078947368421053
adhesion factor,pathogen vehicle role,0.6444444444444444
adhesion factor,asymptomatic infectious agent carrier,0.6230769230769231
adhesion factor,infection incidence,0.6264705882352941
adhesion factor,sterilizing immunity to infectious agent,0.5954545454545455
adhesion factor,virulence factor,0.7403225806451613
adhesion factor,incubation end process boundary,0.6239130434782608
adhesion factor,COVID-19 incidence,0.5712121212121213
adhesion factor,latency end temporal region,0.6166666666666667
adhesion factor,innate immunity to infectious agent,0.63
adhesion factor,virus adhesion susceptible cell,0.6891304347826087
adhesion factor,static agent disposition,0.6038461538461539
adhesion factor,T cell receptor complex,0.6078947368421053
adhesion factor,infectious agent population,0.6404761904761905
adhesion factor,leukocyte-mediated immunity to infectious agent,0.5951612903225807
adhesion factor,adhesion of symbiont to host,0.7290697674418604
adhesion factor,humoral immunity to infectious agent,0.6068627450980393
adhesion factor,SARS-CoV-2 attachment stage,0.6166666666666667
adhesion factor,passive immunity to infectious agent,0.6264705882352941
adhesion factor,vaccination against infectious agent,0.6264705882352941
adhesion factor,susceptibility to infectious agent,0.6132653061224489
adhesion factor,acquired immunity to infectious agent,0.6230769230769231
adhesion factor,complex infection,0.66875
adhesion factor,COVID-19 disease incidence proportion,0.6038461538461539
adhesion factor,biological vehicle role,0.581578947368421
adhesion factor,infection incidence proportion,0.6277777777777778
adhesion factor,symptomatic infectious agent carrier,0.6068627450980393
adhesion factor,intermediate host,0.60625
adhesion factor,pathogen portal of exit site,0.6127906976744186
adhesion factor,place closure control strategy,0.6277777777777778
adhesion factor,intervention,0.5981481481481481
adhesion factor,adhesion disposition,0.7642857142857143
adhesion factor,infection incidence profile,0.6166666666666667
adhesion factor,SARS-COV-2 adhesion susceptible cell,0.6656862745098039
adhesion factor,intermediate host role,0.6121621621621621
adhesion factor,SARS-CoV-2 incidence,0.5928571428571429
adhesion factor,immunization against infectious agent,0.6230769230769231
adhesion factor,virus attachment stage,0.6121621621621621
adhesion factor,SARS-COV-2 adhesion disposition,0.6891304347826087
adhesion factor,pathogen portal of exit role,0.636046511627907
adhesion factor,infectious agent host,0.6444444444444444
adhesion factor,geographical feature,0.6785714285714286
adhesion factor,infectious agent reservoir,0.6451219512195122
adhesion factor,immunoglobulin complex,0.6121621621621621
adhesion factor,action specification,0.7071428571428571
adhesion factor,infectious disease incidence rate,0.6166666666666667
adhesion factor,active immunization against infectious agent,0.6194915254237288
adhesion factor,infectious agent,0.6435483870967742
adhesion factor,establishment of a clinically abnormal colony,0.6166666666666667
adhesion factor,adhesion factor,0.95
adhesion factor,drug susceptibility of infectious agent,0.6166666666666667
adhesion factor,static agent,0.6351851851851852
virus transcription stage,extended organism,0.5928571428571429
virus transcription stage,virus aggregate,0.7
virus transcription stage,source of infection,0.6318181818181818
virus transcription stage,virostatic disposition,0.7265957446808511
virus transcription stage,zoonotic disposition,0.6277777777777778
virus transcription stage,immune response,0.7
virus transcription stage,infectious disease mortality rate,0.656896551724138
virus transcription stage,infection incidence rate profile,0.6254385964912281
virus transcription stage,communicability end temporal region,0.6166666666666667
virus transcription stage,pathogen generative stage,0.67
virus transcription stage,pathogen portal of entry,0.6132653061224489
virus transcription stage,subclinical coronavirus infection,0.656896551724138
virus transcription stage,primary pathogen,0.6451219512195122
virus transcription stage,infection end temporal region,0.6537037037037037
virus transcription stage,drug-based immunosuppressed organism,0.6139344262295081
virus transcription stage,coronavirus replication,0.7
virus transcription stage,infectious disease,0.6825581395348838
virus transcription stage,SARS-CoV-2 incidence rate,0.65
virus transcription stage,double-stranded DNA virus,0.63
virus transcription stage,incubation end temporal region,0.65
virus transcription stage,site of infection,0.6404761904761905
virus transcription stage,immunocompetent organism,0.6336734693877552
virus transcription stage,virulence factor disposition,0.7141509433962264
virus transcription stage,pathogen portal of exit,0.6166666666666667
virus transcription stage,viral adhesion disposition,0.6852941176470588
virus transcription stage,parasitostatic disposition,0.6656862745098039
virus transcription stage,infectious disease incidence,0.6386792452830189
virus transcription stage,prion replication,0.6404761904761905
virus transcription stage,reservoir of pathogen role,0.6460784313725491
virus transcription stage,negative regulation of production,0.6224137931034482
virus transcription stage,reverse zoonotic disposition,0.6764150943396227
virus transcription stage,subclinical SARS-CoV-2 infection,0.6254385964912281
virus transcription stage,virus translation stage,0.8875
virus transcription stage,disease surveillance objective specification,0.6384057971014493
virus transcription stage,virus release stage,0.7909090909090909
virus transcription stage,material entity,0.625
virus transcription stage,source of infection site,0.6948979591836735
virus transcription stage,virus,0.6166666666666667
virus transcription stage,virus replication,0.7357142857142857
virus transcription stage,B cell receptor complex,0.6166666666666667
virus transcription stage,systematic infection,0.65
virus transcription stage,infection incidence rate,0.6540816326530612
virus transcription stage,virus host,0.7071428571428571
virus transcription stage,double-stranded RNA virus,0.65
virus transcription stage,pathogen portal of entry role,0.5981481481481481
virus transcription stage,virus transcription stage,0.95
virus transcription stage,infectious disease lifetime prevalence,0.6404761904761905
virus transcription stage,toxin disposition,0.6404761904761905
virus transcription stage,pathogen birth temporal region,0.6318181818181818
virus transcription stage,lower respiratory tract disease,0.6642857142857143
virus transcription stage,infectious disease incidence proportion,0.653125
virus transcription stage,opportunistic pathogen,0.6627659574468084
virus transcription stage,virus generative stage,0.7904255319148936
virus transcription stage,acute infectious disease course,0.6464285714285714
virus transcription stage,cidal agent disposition,0.6583333333333334
virus transcription stage,infectious disorder,0.6545454545454545
virus transcription stage,genetic resistance to pathogen,0.6863636363636364
virus transcription stage,subclinical infection,0.6239130434782608
virus transcription stage,appearance of disorder,0.6202127659574468
virus transcription stage,simple infection,0.6451219512195122
virus transcription stage,biological vehicle,0.5430232558139535
virus transcription stage,droplet pathogen transmission process,0.6596774193548387
virus transcription stage,parasiticidal disposition,0.65
virus transcription stage,infectious disease sporadicity,0.6318181818181818
virus transcription stage,communicability end process boundary,0.5975409836065574
virus transcription stage,infection incidence proportion profile,0.6404761904761905
virus transcription stage,pathogen transporter,0.6722222222222223
virus transcription stage,transmissibility disposition,0.6575471698113208
virus transcription stage,latency end process boundary,0.5820754716981132
virus transcription stage,infectious disease epidemic,0.6423076923076922
virus transcription stage,infectious agent generative stage,0.7086206896551723
virus transcription stage,disease transmission model,0.7245098039215686
virus transcription stage,endotoxin disposition,0.6239130434782608
virus transcription stage,pathologically immunosuppressed organism,0.5884615384615385
virus transcription stage,negative-sense single-stranded RNA virus,0.6192307692307693
virus transcription stage,pathogen vehicle,0.5963414634146341
virus transcription stage,COVID-19 incidence rate,0.6583333333333334
virus transcription stage,cytotoxin disposition,0.6239130434782608
virus transcription stage,community-acquired infection,0.6386792452830189
virus transcription stage,pathogen vector,0.6
virus transcription stage,pathogen vehicle role,0.5804347826086956
virus transcription stage,chronic infectious disease course,0.6396551724137931
virus transcription stage,nursing-home acquired infection,0.6464285714285714
virus transcription stage,COVID-19 epidemic,0.5928571428571429
virus transcription stage,negative regulation of replication,0.6364406779661017
virus transcription stage,PCR product,0.5888888888888889
virus transcription stage,secondary infection,0.6318181818181818
virus transcription stage,infection start temporal region,0.6642857142857143
virus transcription stage,infection incidence,0.6545454545454545
virus transcription stage,virus disorder,0.6807692307692308
virus transcription stage,primary infection,0.6642857142857143
virus transcription stage,process of establishing an infection,0.630327868852459
virus transcription stage,incubation end process boundary,0.6285714285714286
virus transcription stage,SARS-CoV-2 disorder,0.6318181818181818
virus transcription stage,collective pathogenic disposition,0.6396551724137931
virus transcription stage,neurotoxin disposition,0.6414893617021277
virus transcription stage,SARS-CoV-2 uncoating stage,0.7245098039215686
virus transcription stage,pathogen death process boundary,0.575
virus transcription stage,immunosuppressed organism,0.63
virus transcription stage,plan specification,0.6593023255813953
virus transcription stage,latency end temporal region,0.6038461538461539
virus transcription stage,SARS-CoV-2 penetration stage,0.7518867924528303
virus transcription stage,virus adhesion susceptible cell,0.7178571428571427
virus transcription stage,collective disposition,0.6414893617021277
virus transcription stage,infection,0.6558823529411765
virus transcription stage,static agent disposition,0.6540816326530612
virus transcription stage,T cell receptor complex,0.6166666666666667
virus transcription stage,respiratory system disease,0.6656862745098039
virus transcription stage,entry into host,0.65
virus transcription stage,indirect pathogen transmission process,0.6722222222222223
virus transcription stage,organism population,0.6545454545454545
virus transcription stage,generative stage,0.6939024390243902
virus transcription stage,infectious disease control strategy,0.6833333333333332
virus transcription stage,SARS-CoV-2 attachment stage,0.7
virus transcription stage,infectious disease pandemic,0.6423076923076922
virus transcription stage,infectious structure generative stage,0.7080645161290323
virus transcription stage,immunosuppressive disposition,0.6537037037037037
virus transcription stage,SARS-CoV-2 replication,0.6627659574468084
virus transcription stage,innate immune response,0.6627659574468084
virus transcription stage,pathogenic disposition,0.6414893617021277
virus transcription stage,viral disease course,0.6722222222222223
virus transcription stage,entry into host through host barriers,0.6274193548387097
virus transcription stage,intracellular infection,0.6791666666666666
virus transcription stage,secondary infection role,0.6540816326530612
virus transcription stage,metastatic infection,0.65
virus transcription stage,infectious disposition,0.6627659574468084
virus transcription stage,acute infection,0.65
virus transcription stage,bacteriostatic disposition,0.6656862745098039
virus transcription stage,immunity to pathogen,0.6722222222222223
virus transcription stage,bactericidal disposition,0.6336734693877552
virus transcription stage,source of infection role,0.6540816326530612
virus transcription stage,pathogen host,0.6342105263157894
virus transcription stage,acquired immunodeficiency,0.59
virus transcription stage,chronic infection,0.6404761904761905
virus transcription stage,invasion disposition,0.65
virus transcription stage,disease course,0.6551282051282051
virus transcription stage,infectious disease course,0.65
virus transcription stage,viricidal disposition,0.6673913043478261
virus transcription stage,acquired immunity to infectious agent,0.6758064516129032
virus transcription stage,complex infection,0.6166666666666667
virus transcription stage,COVID-19 disease incidence proportion,0.6435483870967742
virus transcription stage,coronavirus disease course,0.6852941176470588
virus transcription stage,biological vehicle role,0.575
virus transcription stage,infection incidence proportion,0.6318181818181818
virus transcription stage,respiratory droplet virus fomite,0.6429824561403508
virus transcription stage,susceptible organism,0.65
virus transcription stage,pathogen vector role,0.6055555555555556
virus transcription stage,pathogen portal of exit site,0.619811320754717
virus transcription stage,infectious disease prevalence,0.6351851851851852
virus transcription stage,organism substance,0.6593023255813953
virus transcription stage,SARS-CoV-2 genome replication stage,0.7166666666666667
virus transcription stage,production,0.65
virus transcription stage,disposition,0.6722222222222223
virus transcription stage,single-stranded DNA virus,0.63
virus transcription stage,COVID-19 mortality rate,0.6583333333333334
virus transcription stage,contact tracing,0.65
virus transcription stage,viral disease,0.6605263157894737
virus transcription stage,primary infection role,0.6840425531914894
virus transcription stage,adhesion disposition,0.6277777777777778
virus transcription stage,pathogen portal of entry site,0.6351851851851852
virus transcription stage,infection incidence profile,0.6230769230769231
virus transcription stage,disease,0.60625
virus transcription stage,primary infectious disposition,0.65
virus transcription stage,pathogen host role,0.636046511627907
virus transcription stage,infection prevalence,0.6722222222222223
virus transcription stage,replication,0.6166666666666667
virus transcription stage,humoral immune response,0.6583333333333334
virus transcription stage,coronavirus disorder,0.65
virus transcription stage,infectious pathogen transmissibility,0.6467213114754098
virus transcription stage,pathogen surveillance,0.6239130434782608
virus transcription stage,immunodeficient organism,0.6336734693877552
virus transcription stage,pathogen,0.6015151515151516
virus transcription stage,pathogen birth process boundary,0.5928571428571429
virus transcription stage,infectious human pathogen,0.67
virus transcription stage,subclinical virus infection,0.6807692307692308
virus transcription stage,resistance to pathogen,0.7053191489361703
virus transcription stage,establishment of localization in virus host,0.6411764705882353
virus transcription stage,virus attachment stage,0.7904255319148936
virus transcription stage,negative regulation of immune response,0.6246031746031746
virus transcription stage,SARS-CoV-2 transcription stage,0.85
virus transcription stage,virus synthesis stage,0.7760869565217391
virus transcription stage,SARS-COV-2 adhesion disposition,0.6464285714285714
virus transcription stage,pathogen portal of exit role,0.6009433962264151
virus transcription stage,invasive disposition,0.65
virus transcription stage,re-emerging pathogen,0.6277777777777778
virus transcription stage,long-term non-progressing infectious disease course,0.6078947368421053
virus transcription stage,viral disease epidemic,0.6414893617021277
virus transcription stage,fungicidal disposition,0.6414893617021277
virus transcription stage,viral disease pandemic,0.6414893617021277
virus transcription stage,virus penetration stage,0.8458333333333333
virus transcription stage,pathogen seroprevalence,0.6166666666666667
virus transcription stage,acute respiratory distress syndrome,0.6333333333333333
virus transcription stage,division of geopolitical entity,0.6285714285714286
virus transcription stage,infectious disease endemicity,0.6351851851851852
virus transcription stage,contact pathogen transmission process,0.6435483870967742
virus transcription stage,disorder,0.5712121212121213
virus transcription stage,history,0.575
virus transcription stage,herd immunity to infectious organism,0.630327868852459
virus transcription stage,extracellular infection,0.6583333333333334
virus transcription stage,pathogen transporter role,0.65
virus transcription stage,transmission interval,0.7108695652173913
virus transcription stage,exotoxin disposition,0.6277777777777778
virus transcription stage,infection start process boundary,0.6605263157894737
virus transcription stage,action specification,0.65
virus transcription stage,SARS-CoV-2 synthesis stage,0.6852941176470588
virus transcription stage,processed material,0.6127906976744186
virus transcription stage,infectious disease control objective specification,0.6366666666666667
virus transcription stage,immune population,0.6404761904761905
virus transcription stage,opportunistic infectious disposition,0.6467213114754098
virus transcription stage,process of establishing viral infection,0.6375
virus transcription stage,enterotoxin disposition,0.6375
virus transcription stage,COVID-19 disease course,0.6375
virus transcription stage,infectious disease incidence rate,0.656896551724138
virus transcription stage,single-stranded RNA retrovirus,0.6318181818181818
virus transcription stage,disordered virus,0.5963414634146341
virus transcription stage,collective resistance disposition,0.6741379310344828
virus transcription stage,adaptive immune response,0.6744897959183673
virus transcription stage,fungistatic disposition,0.6791666666666666
virus transcription stage,organism,0.6015151515151516
virus transcription stage,virus uncoating stage,0.8195652173913044
virus transcription stage,local infection,0.625
virus transcription stage,establishment of a clinically abnormal colony,0.5785714285714285
virus transcription stage,coronavirus disease,0.6772727272727272
virus transcription stage,positive-sense single-stranded RNA virus,0.6192307692307693
virus transcription stage,horizontal pathogen transmission process,0.65
virus transcription stage,hospital-acquired infection,0.6423076923076922
virus transcription stage,pathogen death temporal region,0.5954545454545455
virus transcription stage,emerging pathogen,0.6166666666666667
virus transcription stage,SARS-CoV-2 release stage,0.6948979591836735
virus transcription stage,pathogen transmission process,0.6722222222222223
virus transcription stage,material processing,0.609090909090909
incubation start process boundary,source of infection,0.5846153846153846
incubation start process boundary,immune response,0.6375
incubation start process boundary,infectious disease mortality rate,0.6621212121212122
incubation start process boundary,infection incidence rate profile,0.6807692307692308
incubation start process boundary,infectious structure aggregate,0.7039682539682539
incubation start process boundary,communicability end temporal region,0.6411764705882353
incubation start process boundary,pathogen generative stage,0.6224137931034482
incubation start process boundary,surveillance process,0.6575471698113208
incubation start process boundary,infection end temporal region,0.6919354838709677
incubation start process boundary,SARS-CoV-2 incidence rate,0.6051724137931035
incubation start process boundary,incubation end temporal region,0.7357142857142857
incubation start process boundary,pathogen portal of exit,0.6285714285714286
incubation start process boundary,negative regulation of production,0.6772727272727272
incubation start process boundary,establishment of localization in host,0.6214285714285714
incubation start process boundary,virus translation stage,0.6642857142857143
incubation start process boundary,case isolation control strategy,0.653125
incubation start process boundary,virus release stage,0.6230769230769231
incubation start process boundary,asymptomatic infectious structure carrier,0.6662162162162162
incubation start process boundary,source of infection site,0.6429824561403508
incubation start process boundary,architectual structure,0.65
incubation start process boundary,B cell receptor complex,0.5928571428571429
incubation start process boundary,infection incidence rate,0.6605263157894737
incubation start process boundary,virus transcription stage,0.656896551724138
incubation start process boundary,pathogen birth temporal region,0.6563492063492063
incubation start process boundary,virus generative stage,0.6318181818181818
incubation start process boundary,acute infectious disease course,0.66875
incubation start process boundary,process,0.625
incubation start process boundary,droplet pathogen transmission process,0.6642857142857143
incubation start process boundary,communicability end process boundary,0.7688405797101449
incubation start process boundary,acellular structure aggregate,0.6596774193548387
incubation start process boundary,latency end process boundary,0.7942622950819671
incubation start process boundary,infectious agent generative stage,0.6621212121212122
incubation start process boundary,negative regulation of establishment of localization,0.65
incubation start process boundary,infectious structure host role,0.7039682539682539
incubation start process boundary,establishment of localization,0.5951612903225807
incubation start process boundary,COVID-19 incidence rate,0.6107142857142857
incubation start process boundary,negative regulation of developmental process,0.6837662337662337
incubation start process boundary,chronic infectious disease course,0.6621212121212122
incubation start process boundary,PCR product,0.609090909090909
incubation start process boundary,infection start temporal region,0.746875
incubation start process boundary,establishment of localization in human host,0.6210526315789474
incubation start process boundary,acellular structure,0.6423076923076922
incubation start process boundary,process of establishing an infection,0.6094202898550725
incubation start process boundary,incubation end process boundary,0.8875
incubation start process boundary,SARS-CoV-2 uncoating stage,0.6364406779661017
incubation start process boundary,pathogen death process boundary,0.825
incubation start process boundary,plan specification,0.6068627450980393
incubation start process boundary,latency end temporal region,0.6333333333333333
incubation start process boundary,SARS-CoV-2 penetration stage,0.630327868852459
incubation start process boundary,infectious structure,0.6952830188679244
incubation start process boundary,anatomical space,0.6336734693877552
incubation start process boundary,T cell receptor complex,0.5928571428571429
incubation start process boundary,infectious structure host,0.7086206896551723
incubation start process boundary,respiratory system disease,0.6364406779661017
incubation start process boundary,indirect pathogen transmission process,0.7035211267605633
incubation start process boundary,planned process,0.6583333333333334
incubation start process boundary,generative stage,0.6336734693877552
incubation start process boundary,SARS-CoV-2 attachment stage,0.6
incubation start process boundary,infectious structure generative stage,0.6785714285714286
incubation start process boundary,innate immune response,0.6681818181818181
incubation start process boundary,viral disease course,0.6386792452830189
incubation start process boundary,source of infection role,0.6429824561403508
incubation start process boundary,disease course,0.6202127659574468
incubation start process boundary,infectious disease course,0.6913793103448276
incubation start process boundary,coronavirus disease course,0.6533898305084747
incubation start process boundary,pathogen portal of exit site,0.630327868852459
incubation start process boundary,incubation interval,0.7192307692307692
incubation start process boundary,SARS-CoV-2 genome replication stage,0.6264705882352941
incubation start process boundary,production,0.5895348837209302
incubation start process boundary,COVID-19 mortality rate,0.6107142857142857
incubation start process boundary,process profile,0.6375
incubation start process boundary,negative regulation of life-sustaining process,0.690506329113924
incubation start process boundary,place closure control strategy,0.6246031746031746
incubation start process boundary,developmental process,0.6722222222222223
incubation start process boundary,biological process,0.6852941176470588
incubation start process boundary,symptomatic infectious structure carrier,0.6691780821917809
incubation start process boundary,humoral immune response,0.6285714285714286
incubation start process boundary,incubation start process boundary,0.95
incubation start process boundary,pathogen birth process boundary,0.825
incubation start process boundary,establishment of localization in virus host,0.6342105263157894
incubation start process boundary,virus attachment stage,0.6318181818181818
incubation start process boundary,negative regulation of immune response,0.6471830985915493
incubation start process boundary,SARS-CoV-2 transcription stage,0.6246031746031746
incubation start process boundary,virus synthesis stage,0.6351851851851852
incubation start process boundary,pathogen portal of exit role,0.6467213114754098
incubation start process boundary,long-term non-progressing infectious disease course,0.6523809523809524
incubation start process boundary,communicability start temporal region,0.6785714285714286
incubation start process boundary,virus penetration stage,0.6642857142857143
incubation start process boundary,algorithm,0.5452380952380953
incubation start process boundary,negative regulation of viral process,0.696376811594203
incubation start process boundary,contact pathogen transmission process,0.6928571428571427
incubation start process boundary,function,0.5963414634146341
incubation start process boundary,symbiotic process,0.69
incubation start process boundary,infection start process boundary,0.9115384615384616
incubation start process boundary,action specification,0.6575471698113208
incubation start process boundary,SARS-CoV-2 synthesis stage,0.6194915254237288
incubation start process boundary,latency start process boundary,0.8626984126984126
incubation start process boundary,process of establishing viral infection,0.6027777777777777
incubation start process boundary,negative regulation of biological process,0.6797297297297297
incubation start process boundary,polymerase chain reaction,0.6051724137931035
incubation start process boundary,COVID-19 disease course,0.6285714285714286
incubation start process boundary,infectious disease incidence rate,0.6621212121212122
incubation start process boundary,communicability start process boundary,0.8302816901408451
incubation start process boundary,process that results in death,0.6758064516129032
incubation start process boundary,adaptive immune response,0.6254385964912281
incubation start process boundary,virus uncoating stage,0.6722222222222223
incubation start process boundary,establishment of a clinically abnormal colony,0.6166666666666667
incubation start process boundary,process boundary,0.7765306122448979
incubation start process boundary,horizontal pathogen transmission process,0.682876712328767
incubation start process boundary,SARS-CoV-2 release stage,0.6078947368421053
incubation start process boundary,pathogen transmission process,0.6919354838709677
incubation start process boundary,cell space,0.5895348837209302
viricide,viricide,0.95
symbiotic process,immune response,0.6375
symbiotic process,infectious disease mortality rate,0.61
symbiotic process,infection incidence rate profile,0.6336734693877552
symbiotic process,communicability end temporal region,0.6038461538461539
symbiotic process,pathogen generative stage,0.569047619047619
symbiotic process,surveillance process,0.7472972972972972
symbiotic process,infection end temporal region,0.6021739130434782
symbiotic process,SARS-CoV-2 incidence rate,0.6166666666666667
symbiotic process,incubation end temporal region,0.598936170212766
symbiotic process,virus translation stage,0.575
symbiotic process,case isolation control strategy,0.6375
symbiotic process,virus release stage,0.6166666666666667
symbiotic process,B cell receptor complex,0.625
symbiotic process,infection incidence rate,0.6207317073170732
symbiotic process,virus transcription stage,0.5928571428571429
symbiotic process,virus generative stage,0.5782051282051281
symbiotic process,acute infectious disease course,0.5958333333333333
symbiotic process,process,0.7416666666666667
symbiotic process,droplet pathogen transmission process,0.6722222222222223
symbiotic process,communicability end process boundary,0.6764150943396227
symbiotic process,latency end process boundary,0.6722222222222223
symbiotic process,infectious agent generative stage,0.59
symbiotic process,COVID-19 incidence rate,0.6
symbiotic process,negative regulation of developmental process,0.630327868852459
symbiotic process,chronic infectious disease course,0.61
symbiotic process,PCR product,0.6642857142857143
symbiotic process,process of establishing an infection,0.5820754716981132
symbiotic process,incubation end process boundary,0.6791666666666666
symbiotic process,collective pathogenic disposition,0.63
symbiotic process,SARS-CoV-2 uncoating stage,0.5895348837209302
symbiotic process,pathogen death process boundary,0.6583333333333334
symbiotic process,plan specification,0.5928571428571429
symbiotic process,latency end temporal region,0.5863636363636363
symbiotic process,SARS-CoV-2 penetration stage,0.6055555555555556
symbiotic process,collective disposition,0.6294871794871795
symbiotic process,T cell receptor complex,0.625
symbiotic process,respiratory system disease,0.6127906976744186
symbiotic process,indirect pathogen transmission process,0.6681818181818181
symbiotic process,planned process,0.7
symbiotic process,generative stage,0.5712121212121213
symbiotic process,SARS-CoV-2 attachment stage,0.5863636363636363
symbiotic process,infectious structure generative stage,0.5981481481481481
symbiotic process,innate immune response,0.6551282051282051
symbiotic process,viral disease course,0.5851351351351352
symbiotic process,disease course,0.5790322580645162
symbiotic process,infectious disease course,0.6166666666666667
symbiotic process,coronavirus disease course,0.5895348837209302
symbiotic process,generically dependent continuant,0.5520408163265306
symbiotic process,SARS-CoV-2 genome replication stage,0.5846153846153846
symbiotic process,COVID-19 mortality rate,0.625
symbiotic process,process profile,0.66875
symbiotic process,negative regulation of life-sustaining process,0.6404761904761905
symbiotic process,developmental process,0.7131578947368421
symbiotic process,biological process,0.8214285714285714
symbiotic process,humoral immune response,0.65
symbiotic process,incubation start process boundary,0.69
symbiotic process,pathogen birth process boundary,0.6791666666666666
symbiotic process,virus attachment stage,0.5782051282051281
symbiotic process,negative regulation of immune response,0.5954545454545455
symbiotic process,SARS-CoV-2 transcription stage,0.598936170212766
symbiotic process,specifically dependent continuant,0.59
symbiotic process,virus synthesis stage,0.6078947368421053
symbiotic process,long-term non-progressing infectious disease course,0.5970588235294118
symbiotic process,virus penetration stage,0.6
symbiotic process,algorithm,0.5269230769230769
symbiotic process,negative regulation of viral process,0.6575471698113208
symbiotic process,contact pathogen transmission process,0.6722222222222223
symbiotic process,function,0.57
symbiotic process,symbiotic process,0.95
symbiotic process,infection start process boundary,0.6744897959183673
symbiotic process,action specification,0.5851351351351352
symbiotic process,SARS-CoV-2 synthesis stage,0.5895348837209302
symbiotic process,latency start process boundary,0.6627659574468084
symbiotic process,process of establishing viral infection,0.575
symbiotic process,negative regulation of biological process,0.6741379310344828
symbiotic process,polymerase chain reaction,0.5928571428571429
symbiotic process,COVID-19 disease course,0.6
symbiotic process,infectious disease incidence rate,0.59
symbiotic process,communicability start process boundary,0.6681818181818181
symbiotic process,process that results in death,0.6021739130434782
symbiotic process,active immunization against infectious agent,0.5811475409836065
symbiotic process,collective resistance disposition,0.63
symbiotic process,adaptive immune response,0.6207317073170732
symbiotic process,virus uncoating stage,0.6078947368421053
symbiotic process,establishment of a clinically abnormal colony,0.5951612903225807
symbiotic process,process boundary,0.6621212121212122
symbiotic process,horizontal pathogen transmission process,0.6605263157894737
symbiotic process,SARS-CoV-2 release stage,0.6207317073170732
symbiotic process,pathogen transmission process,0.7108695652173913
negative regulation of viral process,virostatic disposition,0.6224137931034482
negative regulation of viral process,zoonotic disposition,0.5928571428571429
negative regulation of viral process,immune response,0.6068627450980393
negative regulation of viral process,infectious disease mortality rate,0.6673913043478261
negative regulation of viral process,infection incidence rate profile,0.6705882352941177
negative regulation of viral process,communicability end temporal region,0.6471830985915493
negative regulation of viral process,pathogen generative stage,0.630327868852459
negative regulation of viral process,biological regulation,0.6780701754385965
negative regulation of viral process,surveillance process,0.6821428571428573
negative regulation of viral process,infection end temporal region,0.6807692307692308
negative regulation of viral process,geospatial location,0.65
negative regulation of viral process,vector control strategy,0.6364406779661017
negative regulation of viral process,SARS-CoV-2 incidence rate,0.5975409836065574
negative regulation of viral process,incubation end temporal region,0.6772727272727272
negative regulation of viral process,site of infection,0.6009433962264151
negative regulation of viral process,virulence factor disposition,0.6375
negative regulation of viral process,viral adhesion disposition,0.6435483870967742
negative regulation of viral process,parasitostatic disposition,0.6112903225806451
negative regulation of viral process,negative regulation of production,0.8413043478260869
negative regulation of viral process,reverse zoonotic disposition,0.653125
negative regulation of viral process,virus translation stage,0.6533898305084747
negative regulation of viral process,disease surveillance objective specification,0.6375
negative regulation of viral process,case isolation control strategy,0.6888059701492537
negative regulation of viral process,virus release stage,0.6136363636363636
negative regulation of viral process,source of infection site,0.6166666666666667
negative regulation of viral process,quarantine control strategy,0.6563492063492063
negative regulation of viral process,B cell receptor complex,0.6194915254237288
negative regulation of viral process,infection incidence rate,0.6333333333333333
negative regulation of viral process,double-stranded RNA virus,0.630327868852459
negative regulation of viral process,virus transcription stage,0.630327868852459
negative regulation of viral process,toxin disposition,0.6009433962264151
negative regulation of viral process,lower respiratory tract disease,0.6440298507462687
negative regulation of viral process,virus generative stage,0.6396551724137931
negative regulation of viral process,acute infectious disease course,0.658955223880597
negative regulation of viral process,cidal agent disposition,0.6025423728813559
negative regulation of viral process,process,0.6127906976744186
negative regulation of viral process,droplet pathogen transmission process,0.6965753424657534
negative regulation of viral process,parasiticidal disposition,0.6467213114754098
negative regulation of viral process,communicability end process boundary,0.6444444444444444
negative regulation of viral process,transmissibility disposition,0.60625
negative regulation of viral process,latency end process boundary,0.66875
negative regulation of viral process,infectious agent generative stage,0.6384057971014493
negative regulation of viral process,endotoxin disposition,0.6078947368421053
negative regulation of viral process,vector surveillance,0.6318181818181818
negative regulation of viral process,negative regulation of establishment of localization,0.7681818181818181
negative regulation of viral process,negative-sense single-stranded RNA virus,0.7
negative regulation of viral process,COVID-19 incidence rate,0.5855932203389831
negative regulation of viral process,viral plaque assay,0.6351851851851852
negative regulation of viral process,cytotoxin disposition,0.6078947368421053
negative regulation of viral process,negative regulation of developmental process,0.875
negative regulation of viral process,chronic infectious disease course,0.6384057971014493
negative regulation of viral process,negative regulation of replication,0.8214285714285714
negative regulation of viral process,process of establishing an infection,0.5888888888888889
negative regulation of viral process,incubation end process boundary,0.6888059701492537
negative regulation of viral process,collective pathogenic disposition,0.6673913043478261
negative regulation of viral process,neurotoxin disposition,0.6396551724137931
negative regulation of viral process,SARS-CoV-2 uncoating stage,0.6274193548387097
negative regulation of viral process,pathogen death process boundary,0.6738805970149254
negative regulation of viral process,plan specification,0.5981481481481481
negative regulation of viral process,latency end temporal region,0.6722222222222223
negative regulation of viral process,SARS-CoV-2 penetration stage,0.6375
negative regulation of viral process,collective disposition,0.6224137931034482
negative regulation of viral process,static agent disposition,0.6333333333333333
negative regulation of viral process,T cell receptor complex,0.6364406779661017
negative regulation of viral process,respiratory system disease,0.6274193548387097
negative regulation of viral process,indirect pathogen transmission process,0.7067567567567568
negative regulation of viral process,planned process,0.6656862745098039
negative regulation of viral process,generative stage,0.6615384615384616
negative regulation of viral process,infectious disease control strategy,0.6471830985915493
negative regulation of viral process,SARS-CoV-2 attachment stage,0.5928571428571429
negative regulation of viral process,infectious structure generative stage,0.6417808219178082
negative regulation of viral process,immunosuppressive disposition,0.6038461538461539
negative regulation of viral process,innate immune response,0.656896551724138
negative regulation of viral process,pathogenic disposition,0.6051724137931035
negative regulation of viral process,viral disease course,0.6107142857142857
negative regulation of viral process,viral envelope,0.61
negative regulation of viral process,infectious disposition,0.6224137931034482
negative regulation of viral process,bacteriostatic disposition,0.6435483870967742
negative regulation of viral process,epitope site,0.5958333333333333
negative regulation of viral process,bactericidal disposition,0.65
negative regulation of viral process,invasion disposition,0.6464285714285714
negative regulation of viral process,disease course,0.59
negative regulation of viral process,infectious disease course,0.630327868852459
negative regulation of viral process,viricidal disposition,0.6254385964912281
negative regulation of viral process,coronavirus disease course,0.6274193548387097
negative regulation of viral process,viral capsid,0.6166666666666667
negative regulation of viral process,pathogen portal of exit site,0.653125
negative regulation of viral process,SARS-CoV-2 genome replication stage,0.6612676056338028
negative regulation of viral process,disposition,0.5563829787234043
negative regulation of viral process,COVID-19 mortality rate,0.6194915254237288
negative regulation of viral process,process profile,0.6068627450980393
negative regulation of viral process,negative regulation of life-sustaining process,0.852439024390244
negative regulation of viral process,place closure control strategy,0.6318181818181818
negative regulation of viral process,viral disease,0.6132653061224489
negative regulation of viral process,adhesion disposition,0.6285714285714286
negative regulation of viral process,pathogen portal of entry site,0.65
negative regulation of viral process,developmental process,0.730701754385965
negative regulation of viral process,biological process,0.7092592592592593
negative regulation of viral process,site,0.525
negative regulation of viral process,primary infectious disposition,0.6166666666666667
negative regulation of viral process,humoral immune response,0.6194915254237288
negative regulation of viral process,incubation start process boundary,0.696376811594203
negative regulation of viral process,pathogen surveillance,0.6429824561403508
negative regulation of viral process,pathogen birth process boundary,0.6738805970149254
negative regulation of viral process,virus attachment stage,0.6051724137931035
negative regulation of viral process,negative regulation of immune response,0.841891891891892
negative regulation of viral process,SARS-CoV-2 transcription stage,0.6318181818181818
negative regulation of viral process,virus synthesis stage,0.5903508771929825
negative regulation of viral process,SARS-COV-2 adhesion disposition,0.6291044776119403
negative regulation of viral process,invasive disposition,0.6285714285714286
negative regulation of viral process,long-term non-progressing infectious disease course,0.6454022988505748
negative regulation of viral process,viral disease epidemic,0.6051724137931035
negative regulation of viral process,fungicidal disposition,0.6224137931034482
negative regulation of viral process,viral disease pandemic,0.6051724137931035
negative regulation of viral process,virus penetration stage,0.6533898305084747
negative regulation of viral process,algorithm,0.5388888888888889
negative regulation of viral process,division of geopolitical entity,0.658955223880597
negative regulation of viral process,negative regulation of viral process,0.95
negative regulation of viral process,contact pathogen transmission process,0.7102739726027397
negative regulation of viral process,function,0.5636363636363636
negative regulation of viral process,symbiotic process,0.6575471698113208
negative regulation of viral process,exotoxin disposition,0.6107142857142857
negative regulation of viral process,infection start process boundary,0.6852941176470588
negative regulation of viral process,action specification,0.6285714285714286
negative regulation of viral process,SARS-CoV-2 synthesis stage,0.5790322580645162
negative regulation of viral process,latency start process boundary,0.6621212121212122
negative regulation of viral process,infectious disease control objective specification,0.636046511627907
negative regulation of viral process,opportunistic infectious disposition,0.6305555555555555
negative regulation of viral process,process of establishing viral infection,0.6366666666666667
negative regulation of viral process,negative regulation of biological process,0.8915584415584417
negative regulation of viral process,enterotoxin disposition,0.6533898305084747
negative regulation of viral process,polymerase chain reaction,0.630327868852459
negative regulation of viral process,COVID-19 disease course,0.5855932203389831
negative regulation of viral process,infectious disease incidence rate,0.6384057971014493
negative regulation of viral process,communicability start process boundary,0.6527027027027027
negative regulation of viral process,process that results in death,0.65
negative regulation of viral process,single-stranded RNA retrovirus,0.6469696969696969
negative regulation of viral process,active immunization against infectious agent,0.6625
negative regulation of viral process,collective resistance disposition,0.6673913043478261
negative regulation of viral process,adaptive immune response,0.6666666666666667
negative regulation of viral process,viral load,0.6021739130434782
negative regulation of viral process,fungistatic disposition,0.6364406779661017
negative regulation of viral process,virus uncoating stage,0.6254385964912281
negative regulation of viral process,establishment of a clinically abnormal colony,0.6351851851851852
negative regulation of viral process,process boundary,0.5846153846153846
negative regulation of viral process,positive-sense single-stranded RNA virus,0.6473684210526315
negative regulation of viral process,horizontal pathogen transmission process,0.6868421052631578
negative regulation of viral process,viral pathogenesis,0.6537037037037037
negative regulation of viral process,SARS-CoV-2 release stage,0.6166666666666667
negative regulation of viral process,pathogen transmission process,0.7115384615384616
nucleic acid,ribonucleic acid,0.8785714285714286
nucleic acid,infectious disease mortality rate,0.5833333333333334
nucleic acid,infection incidence rate profile,0.609090909090909
nucleic acid,deoxyribonucleic acid,0.8136363636363637
nucleic acid,SARS-CoV-2 incidence rate,0.6121621621621621
nucleic acid,B cell receptor complex,0.6214285714285714
nucleic acid,infection incidence rate,0.6444444444444444
nucleic acid,drug susceptibility,0.6112903225806451
nucleic acid,COVID-19 incidence rate,0.6214285714285714
nucleic acid,nucleic acid,0.95
nucleic acid,resistance to drug,0.6166666666666667
nucleic acid,T cell receptor complex,0.6214285714285714
nucleic acid,COVID-19 mortality rate,0.5928571428571429
nucleic acid,infectious disease incidence rate,0.6277777777777778
nucleic acid,establishment of a clinically abnormal colony,0.5903508771929825
nucleic acid,drug susceptibility of infectious agent,0.5872549019607843
